PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Vitek, JL; Jain, R; Chen, L; Troster, AI; Schrock, LE; House, PA; Giroux, ML; Hebb, AO; Farris, SM; Whiting, DM; Leichliter, TA; Ostrem, JL; San Luciano, M; Galifianakis, N; Metman, LV; Sani, S; Karl, JA; Siddiqui, MS; Tatter, SB; ul Haq, I; Machado, AG; Gostkowski, M; Tagliati, M; Mamelak, AN; Okun, MS; Foote, KD; Moguel-Cobos, G; Ponce, FA; Pahwa, R; Nazzaro, JM; Buetefisch, CM; Gross, RE; Luca, CC; Jagid, JR; Revuelta, GJ; Takacs, I; Pourfar, MH; Mogilner, AY; Duker, AP; Mandybur, GT; Rosenow, JM; Cooper, SE; Park, MC; Khandhar, SM; Sedrak, M; Phibbs, FT; Pilitsis, JG; Uitti, RJ; Starr, PA				Vitek, Jerrold L.; Jain, Roshini; Chen, Lilly; Troster, Alexander I.; Schrock, Lauren E.; House, Paul A.; Giroux, Monique L.; Hebb, Adam O.; Farris, Sierra M.; Whiting, Donald M.; Leichliter, Timothy A.; Ostrem, Jill L.; San Luciano, Marta; Galifianakis, Nicholas; Metman, Leo Verhagen; Sani, Sepehr; Karl, Jessica A.; Siddiqui, Mustafa S.; Tatter, Stephen B.; ul Haq, Ihtsham; Machado, Andre G.; Gostkowski, Michal; Tagliati, Michele; Mamelak, Adam N.; Okun, Michael S.; Foote, Kelly D.; Moguel-Cobos, Guillermo; Ponce, Francisco A.; Pahwa, Rajesh; Nazzaro, Jules M.; Buetefisch, Cathrin M.; Gross, Robert E.; Luca, Corneliu C.; Jagid, Jonathan R.; Revuelta, Gonzalo J.; Takacs, Istvan; Pourfar, Michael H.; Mogilner, Alon Y.; Duker, Andrew P.; Mandybur, George T.; Rosenow, Joshua M.; Cooper, Scott E.; Park, Michael C.; Khandhar, Suketu M.; Sedrak, Mark; Phibbs, Fenna T.; Pilitsis, Julie G.; Uitti, Ryan J.; Starr, Philip A.			Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study	LANCET NEUROLOGY			English	Article							MEDICAL THERAPY; FOLLOW-UP; TRIAL	Background Deep brain stimulation (DBS) of the subthalamic nucleus is an established therapeutic option for managing motor symptoms of Parkinson's disease. We conducted a double-blind, sham-controlled, randomised controlled trial to assess subthalamic nucleus DBS, with a novel multiple independent contact current-controlled (MICC) device, in patients with Parkinson's disease. Methods This trial took place at 23 implanting centres in the USA. Key inclusion criteria were age between 22 and 75 years, a diagnosis of idiopathic Parkinson's disease with over 5 years of motor symptoms, and stable use of anti-parkinsonian medications for 28 days before consent. Patients who passed screening criteria were implanted with the DBS device bilaterally in the subthalamic nucleus. Patients were randomly assigned in a 3:1 ratio to receive either active therapeutic stimulation settings (active group) or subtherapeutic stimulation settings (control group) for the 3-month blinded period. Randomisation took place with a computer-generated data capture system using a pre-generated randomisation table, stratified by site with random permuted blocks. During the 3-month blinded period, both patients and the assessors were masked to the treatment group while the unmasked programmer was responsible for programming and optimisation of device settings. The primary outcome was the difference in mean change from baseline visit to 3 months post-randomisation between the active and control groups in the mean number of waking hours per day with good symptom control and no troublesome dyskinesias, with no increase in anti-parkinsonian medications. Upon completion of the blinded phase, all patients received active treatment in the open-label period for up to 5 years. Primary and secondary outcomes were analysed by intention to treat. All patients who provided informed consent were included in the safety analysis. The open-label phase is ongoing with no new enrolment, and current findings are based on the prespecified interim analysis of the first 160 randomly assigned patients. The study is registered with ClinicalTrials.gov , NCT01839396. Findings Between May 17, 2013, and Nov 30, 2017, 313 patients were enrolled across 23 sites. Of these 313 patients, 196 (63%) received the DBS implant and 191 (61%) were randomly assigned. Of the 160 patients included in the interim analysis, 121 (76%) were randomly assigned to the active group and 39 (24%) to the control group. The difference in mean change from the baseline visit (post-implant) to 3 months post-randomisation in increased ON time without troublesome dyskinesias between the active and control groups was 3.03 h (SD 4.52, 95% CI 1.3-4.7; p<0.0001). 26 serious adverse events in 20 (13%) patients occurred during the 3-month blinded period. Of these, 18 events were reported in the active group and 8 in the control group. One death was reported among the 196 patients before randomisation, which was unrelated to the procedure, device, or stimulation. Interpretation This double-blind, sham-controlled, randomised controlled trial provides class I evidence of the safety and clinical efficacy of subthalamic nucleus DBS with a novel MICC device for the treatment of motor symptoms of Parkinson's disease. Future trials are needed to investigate potential benefits of producing a more defined current field using MICC technology, and its effect on clinical outcomes. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Vitek, Jerrold L.; Schrock, Lauren E.; Cooper, Scott E.] Univ Minnesota, Dept Neurol, Sch Med, Minneapolis, MN 55455 USA; [Park, Michael C.] Univ Minnesota, Dept Neurosurg, Sch Med, Minneapolis, MN 55455 USA; [Jain, Roshini; Chen, Lilly; Farris, Sierra M.] Boston Sci, Div Neuromodulat, Valencia, CA USA; [Troster, Alexander I.] Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA; [Moguel-Cobos, Guillermo] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA; [Ponce, Francisco A.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA; [House, Paul A.] Neurosurg Associates, Murray, UT USA; [Giroux, Monique L.; Farris, Sierra M.] Movement & Neuroperformance Ctr Colorado, Englewood, CO USA; [Hebb, Adam O.] Kaiser Permanente, Dept Neurol Surg, Denver, CO USA; [Whiting, Donald M.] Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; [Leichliter, Timothy A.] Allegheny Gen Hosp, Dept Neurol, Pittsburgh, PA 15212 USA; [Ostrem, Jill L.; San Luciano, Marta; Galifianakis, Nicholas] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA; [Metman, Leo Verhagen; Karl, Jessica A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; [Sani, Sepehr] Rush Univ, Med Ctr, Dept Neurol Surg, Chicago, IL 60612 USA; [Siddiqui, Mustafa S.; ul Haq, Ihtsham] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC 27101 USA; [Tatter, Stephen B.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA; [Machado, Andre G.; Gostkowski, Michal] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44106 USA; [Tagliati, Michele] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA; [Mamelak, Adam N.] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA; [Okun, Michael S.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA; [Foote, Kelly D.] Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL USA; [Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; [Nazzaro, Jules M.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66103 USA; [Buetefisch, Cathrin M.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Gross, Robert E.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA; [Luca, Corneliu C.] Univ Miami, Sch Med, Dept Neurol, Miami, FL USA; [Jagid, Jonathan R.] Univ Miami, Sch Med, Dept Neurosurg, Miami, FL USA; [Revuelta, Gonzalo J.] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA; [Takacs, Istvan] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA; [Pourfar, Michael H.] NYU, Dept Neurol, Med Ctr, New York, NY 10016 USA; [Mogilner, Alon Y.] NYU, Dept Neurosurg, Med Ctr, 550 1St Ave, New York, NY 10016 USA; [Duker, Andrew P.] Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45267 USA; [Mandybur, George T.] Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA; [Rosenow, Joshua M.] Northwestern Univ, Sch Med, Dept Neurosurg, Chicago, IL USA; [Khandhar, Suketu M.] Kaiser Permanente Med Ctr, Dept Neurol, Sacramento, CA USA; [Sedrak, Mark] Kaiser Permanente Med Ctr, Dept Neurosurg, Redwood City, CA USA; [Phibbs, Fenna T.] Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN USA; [Pilitsis, Julie G.] Albany Med Ctr, Dept Neurosurg, Albany, NY USA; [Uitti, Ryan J.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; [Giroux, Monique L.] Clin Res Neurol, Woodcliff Lake, NJ USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Boston Scientific; Barrow Neurological Institute; Barrow Neurological Institute; Barrow Neurological Institute; Kaiser Permanente; Allegheny General Hospital; Allegheny General Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rush University; Rush University; Wake Forest University; Wake Forest University; Cleveland Clinic Foundation; Cedars Sinai Medical Center; Cedars Sinai Medical Center; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Emory University; Emory University; University of Miami; University of Miami; Medical University of South Carolina; Medical University of South Carolina; New York University; New York University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Northwestern University; Kaiser Permanente; Kaiser Permanente; Vanderbilt University; Albany Medical College; Mayo Clinic	Vitek, JL (corresponding author), Univ Minnesota, Dept Neurol, Sch Med, Minneapolis, MN 55455 USA.	vitek004@umn.edu	Siddiqui, Mustafa Saad/L-5495-2013; Tatter, Stephen/AAD-6524-2021; Haq, Ihtsham/AAO-5392-2020	Siddiqui, Mustafa Saad/0000-0003-4794-5119; Tatter, Stephen/0000-0002-1063-0431; Haq, Ihtsham/0000-0002-8001-8440; Luca, Corneliu/0000-0001-8435-222X; Tagliati, Michele/0000-0002-6722-8208; Mogilner, Alon/0000-0003-1493-0463; San Luciano, Marta/0000-0002-9885-704X	Boston Scientific	Boston Scientific(Boston Scientific)	Boston Scientific.	Castrioto A, 2014, LANCET NEUROL, V13, P287, DOI 10.1016/S1474-4422(13)70294-1; Charles PD, 2002, NEUROLOGY, V59, P932, DOI 10.1212/WNL.59.6.932; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Deuschl G, 2020, J NEUROSURG, V132, P1376, DOI 10.3171/2018.12.JNS182042; Dmitrienko A, 2008, BIOMETRICAL J, V50, P667, DOI 10.1002/bimj.200710464; Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083; Hauser RA, 2004, MOVEMENT DISORD, V19, P1409, DOI 10.1002/mds.20248; Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Odekerken VJJ, 2013, LANCET NEUROL, V12, P37, DOI 10.1016/S1474-4422(12)70264-8; Okun MS, 2012, LANCET NEUROL, V11, P140, DOI 10.1016/S1474-4422(11)70308-8; Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158; Seijo FJ, 2007, ACTA NEUROCHIR, V149, P867, DOI 10.1007/s00701-007-1267-1; Sillay KA, 2008, NEUROSURGERY, V62, P360, DOI 10.1227/01.neu.0000316002.03765.33; Timmermann L, 2015, LANCET NEUROL, V14, P693, DOI 10.1016/S1474-4422(15)00087-3; Tir M, 2007, NEUROSURGERY, V61, P297, DOI 10.1227/01.NEU.0000285347.50028.B9; Troster AI, 2017, MOVEMENT DISORD, V32, P433, DOI 10.1002/mds.26827; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929; Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4; Wong J, 2018, TREMOR OTHER HYPERK, V8, DOI 10.7916/D8M62XTC; Zaidel A, 2010, BRAIN, V133, P2007, DOI 10.1093/brain/awq144	22	46	44	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					491	501		10.1016/S1474-4422(20)30108-3	http://dx.doi.org/10.1016/S1474-4422(20)30108-3			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470421				2022-12-18	WOS:000544059200010
J	Ahmadi, M; Laumeier, I; Ihl, T; Steinicke, M; Ferse, C; Endres, M; Grau, A; Hastrup, S; Poppert, H; Palm, F; Schoene, M; Seifert, CL; Kandil, FI; Weber, JE; von Weitzel-Mudersbach, P; Wimmer, MLJ; Algra, A; Amarenco, P; Greving, JP; Busse, O; Kohler, F; Marx, P; Audebert, HJ				Ahmadi, Michael; Laumeier, Inga; Ihl, Thomas; Steinicke, Maureen; Ferse, Caroline; Endres, Matthias; Grau, Armin; Hastrup, Sidsel; Poppert, Holger; Palm, Frederick; Schoene, Martin; Seifert, Christian L.; Kandil, Farid I.; Weber, Joachim E.; von Weitzel-Mudersbach, Paul; Wimmer, Martin L. J.; Algra, Ale; Amarenco, Pierre; Greving, Jacoba P.; Busse, Otto; Kohler, Friedrich; Marx, Peter; Audebert, Heinrich J.			A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial	LANCET NEUROLOGY			English	Article							MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; INTERVENTION; STRATEGIES; MANAGEMENT; IMPLEMENTATION; RECURRENCE; THERAPY; IMPROVE; PROJECT	Background Patients with recent stroke or transient ischaemic attack are at high risk for a further vascular event, possibly leading to permanent disability or death. Although evidence-based treatments for secondary prevention are available, many patients do not achieve recommended behavioural modifications and pharmaceutical prevention targets in the long-term. We aimed to investigate whether a support programme for enhanced secondary prevention can reduce the frequency of recurrent vascular events. Methods INSPiRE-TMS was an open-label, multicentre, international randomised controlled trial done at seven German hospitals with acute stroke units and a Danish stroke centre. Patients with non-disabling stroke or transient ischaemic attack within 2 weeks from study enrolment and at least one modifiable risk factor (ie, arterial hypertension, diabetes, atrial fibrillation, or smoking) were induded. Computerised randomisation was used to allocate patients (1:1) either to the support programme in addition to conventional care or to conventional care alone. The support programme used feedback and motivational interviewing strategies with eight outpatient visits over 2 years aiming to improve adherence to secondary prevention targets. The primary outcome was the composite of major vascular events consisting of stroke, acute coronary syndrome, and vascular death, assessed in the intention-to-treat population (all patients who underwent randomisation, did not withdraw study participation, and had at least one follow-up). Outcomes were assessed at annual follow-ups using time-to-first-event analysis. All-cause death was monitored as a safety outcome. This trial is registered with ClinicalTrials.gov , NCT01586702. Findings From Aug 22, 2011, to Oct 30, 2017, we enrolled 2098 patients. Of those, 1048 (50.0%) were randomly assigned to the support programme group and 1050 (50.0%) patients were assigned to the conventional care group. 1030 (98.3%) patients in the support group and 1042 (99.2%) patients in the conventional care group were included in the intention-to-treat analysis. The mean age of analysed participants was 67.4 years and 700 (34%) were women. After a mean follow-up of 3.6 years, the primary outcome of major vascular events had occurred in 163 (15.8%) of 1030 patients of the support programme group and in 175 (16.8%) of 1042 patients of the conventional care group (hazard ratio [HR] 0.92, 95% CI 0.75-1.14). Total major vascular event numbers were 209 for the support programme group and 225 for the conventional care group (incidence rate ratio 0.93, 95% CI 0.77-1.12; p=0.46) and all-cause death occurred in 73 (7.1%) patients in the support programme group and 85 (8.2%) patients in the conventional care group (HR 0.85, 0-62-1.17). More patients in the support programme group achieved secondary prevention targets (eg, in 1-year-follow-up 52% vs 42% [p<0.0001] for blood pressure, 62% vs 54% [p=0 0010]for LDL, 33% vs 19% [p<0 . 0001] for physical activity, and 51% vs 34% [p=0.0010] for smoking cessation). Interpretation Provision of an intensified secondary prevention programme in patients with non-disabling stroke or transient ischaemic attack was associated with improved achievement of secondary prevention targets but did not lead to a significantly lower rate of major vascular events. Further research is needed to investigate the effects of support programmes in selected patients who do not achieve secondary prevention targets soon after discharge. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Ahmadi, Michael; Laumeier, Inga; Ihl, Thomas; Steinicke, Maureen; Ferse, Caroline; Schoene, Martin; Kandil, Farid I.; Weber, Joachim E.; Marx, Peter; Audebert, Heinrich J.] Charite Univ Med Berlin, Campus Benjamin Franklin, Klin & Hsch Ambulanz Neurol, Berlin, Germany; [Endres, Matthias] Charite Univ Med Berlin, Klin & Hsch Ambulanz Neurol, Berlin, Germany; [Endres, Matthias; Audebert, Heinrich J.] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [Ahmadi, Michael; Endres, Matthias; Weber, Joachim E.] Berlin Inst Hlth, Berlin, Germany; [Endres, Matthias] German Ctr Cardiovasc Res, Berlin, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis, Berlin, Germany; [Grau, Armin; Palm, Frederick] Klinikum Ludwigshafen, Ludwigshafen, Germany; [Hastrup, Sidsel; Seifert, Christian L.; von Weitzel-Mudersbach, Paul] Aarhus Univ Hosp, Danish Stroke Ctr, Neurol, Aarhus, Denmark; [Poppert, Holger; Seifert, Christian L.] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany; [Kandil, Farid I.] Univ Med Ctr Hamburg Eppendorf, Inst Computat Neurosci, Hamburg, Germany; [Wimmer, Martin L. J.] Praxis Neurol & Psychiatrie Prinzregentenplatz Mu, Munich, Germany; [Algra, Ale; Greving, Jacoba P.] Univ Med Ctr, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Algra, Ale; Greving, Jacoba P.] Univ Med Ctr, Ctr Utrecht, Utrecht, Netherlands; [Algra, Ale; Greving, Jacoba P.] Univ Utrecht, Utrecht, Netherlands; [Amarenco, Pierre] Univ Paris Diderot, Dept Neurol, Bichat Hosp, Paris, France; [Amarenco, Pierre] Univ Paris Diderot, Stroke Ctr, Bichat Hosp, Paris, France; [Busse, Otto] German Stroke Soc, Berlin, Germany; [Kohler, Friedrich] Charite Univ Med Berlin, Dept Med, Div Cardiol & Angiol, Campus Charite Mitte,Ctr Cardiovasc Telemed, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; German Centre for Cardiovascular Research; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Ludwigshafen Hospital; Aarhus University; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Audebert, HJ (corresponding author), Charite Univ Med Berlin, Dept Neurol, Ctr Stroke Res, D-12200 Berlin, Germany.	Heinrich.audebert@charite.de	Weber, Joachim/AAL-2799-2020	Weber, Joachim/0000-0002-1666-6021; Kandil, Farid/0000-0003-3071-7902; Koehler, Friedrich/0000-0003-0441-4123; Audebert, Heinrich/0000-0002-4785-0366; Endres, Matthias/0000-0001-6520-3720; Poppert, Holger/0000-0003-2189-7681; Ahmadi, Michael/0000-0001-5792-4704	German Federal Ministry of Education and Research within Center for Stroke Research Berlin; Pfizer; German Stroke Foundation; German Federal Ministry of Education and Research within the grant of the Center for Stroke Research Berlin at the Charite Universitaetsmedizin Berlin	German Federal Ministry of Education and Research within Center for Stroke Research Berlin; Pfizer(Pfizer); German Stroke Foundation; German Federal Ministry of Education and Research within the grant of the Center for Stroke Research Berlin at the Charite Universitaetsmedizin Berlin	We thank the German Federal Ministry of Education and Research within the grant of the Center for Stroke Research Berlin, Pfizer, and the German Stroke Foundation for funding the study. The INSPIRE-TMS trial was funded by the German Federal Ministry of Education and Research within the grant of the Center for Stroke Research Berlin at the Charite Universitaetsmedizin Berlin. To finalise the study after the end of the second funding period (2018), both Pfizer and the German Stroke Foundation provided otherwise unrestricted research grants. We thank Gabriele Nieweler, Sabine Wunderlich, Gabriele May, Katrin Hayens, Katrin Haug, Melanie Heigl, Valentin Watermann, and Ramanan Ganeshan (all Charite Berlin), Kristina Eiskjaer Sorensen, Louise Madsen, Niels Hjort, and Noelia Morales (all Aarhus), Susanne Streib (Klinikum Ludwigshafen), and Manuela Tepper (Klinikum Rechts der Isar, Munich) for their high-quality work as prevention assistants or study nurses as well as Frank Hamilton, Bruno-Marcel Mackert (both Vivantes Auguste-Viktoria-Klinikum Berlin), and Darius Nabavi (Vivantes Klinikum Neukolln, Berlin) for supporting the trial by granting access to patients of their departments. We also thank Ulrike Grittner (Charite Berlin) for reviewing the statistical analyses.	Alberts MJ, 2009, EUR HEART J, V30, P2318, DOI 10.1093/eurheartj/ehp355; Amarenco P, 2018, NEW ENGL J MED, V378, P2182, DOI 10.1056/NEJMoa1802712; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Audebert HJ, 2006, LANCET NEUROL, V5, P742, DOI 10.1016/S1474-4422(06)70527-0; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barker-Collo S, 2015, STROKE, V46, P3451, DOI 10.1161/STROKEAHA.115.011003; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Easton JD, 2012, LANCET NEUROL, V11, P503, DOI 10.1016/S1474-4422(12)70092-3; Endres M, 2015, LEITLINIEN DGN SEKUN; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Giannuzzi P, 2008, ARCH INTERN MED, V168, P2194, DOI 10.1001/archinte.168.20.2194; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Irewall AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139997; Johnson CO, 2019, LANCET NEUROL, V18, P439, DOI [10.1016/S1474-4422(19)30034-1, DOI 10.1016/S1474-4422(20)30308-2]; Kolominsky-Rabas PL, 1998, STROKE, V29, P2501, DOI 10.1161/01.STR.29.12.2501; Kono Y, 2013, CEREBROVASC DIS, V36, P88, DOI 10.1159/000352052; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Kronish IM, 2014, STROKE, V45, P3330, DOI 10.1161/STROKEAHA.114.006623; Leistner S, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-11; Leistner S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049985; McAlister FA, 2014, CAN MED ASSOC J, V186, P577, DOI 10.1503/cmaj.140053; Olaiya MT, 2017, STROKE, V48, P2504, DOI 10.1161/STROKEAHA.117.017499; Peng B, 2014, STROKE, V45, P515, DOI 10.1161/STROKEAHA.113.001424; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Rauch G, 2018, CLIN RES CARDIOL, V107, P437, DOI 10.1007/s00392-018-1205-7; Rothwell PM, 2007, LANCET, V370, P1432, DOI 10.1016/S0140-6736(07)61448-2; Therneau T.M., 2000, STAT BIOL HEALTH; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Wang YL, 2018, JAMA-J AM MED ASSOC, V320, P245, DOI 10.1001/jama.2018.8802; Wolfe CDA, 2010, STROKE, V41, P2470, DOI 10.1161/STROKEAHA.110.588046; Zonneveld TP, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007858.pub2	31	46	46	3	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					49	60		10.1016/S1474-4422(19)30369-2	http://dx.doi.org/10.1016/S1474-4422(19)30369-2			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31708447				2022-12-18	WOS:000502286000028
J	Way, SW; Popko, B				Way, Sharon W.; Popko, Brian			Harnessing the integrated stress response for the treatment of multiple sclerosis	LANCET NEUROLOGY			English	Review							ENDOPLASMIC-RETICULUM-STRESS; UNFOLDED PROTEIN RESPONSE; AUTOIMMUNE-MEDIATED DEMYELINATION; CYTOKINE INTERFERON-GAMMA; APPEARING WHITE-MATTER; CENTRAL-NERVOUS-SYSTEM; ER STRESS; TISSUE-INJURY; ANTISENSE OLIGONUCLEOTIDES; SELECTIVE-INHIBITION	Multiple sclerosis is a chronic demyelinating autoimmune disease of the CNS with no known cure. Although 12 immunomodulatory therapies exist, they have only modest effects on disease progression. The field has therefore focused on the development of alternative treatment strategies, such as enhancement of remyelination and CNS repair. Progress has been made on a third, complementary treatment approach that aims to protect oligodendrocytes- and the myelin they generate and maintain-from inflammation-mediated death by enhancing the integrated stress response. Studies in cells and in mouse models of multiple sclerosis have shown that this innate protective pathway, which maintains proteostasis, can be harnessed effectively to protect oligodendrocytes and myelin during inflammation. With one drug already in clinical development for patients with multiple sclerosis, and several potential therapies under investigation, modulation of the integrated stress response might become an important component of strategies to halt the progression of the disease.	[Way, Sharon W.; Popko, Brian] Univ Chicago, Dept Neurol, Ctr Peripheral Neuropathy, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago	Popko, B (corresponding author), Univ Chicago, Dept Neurol, Ctr Peripheral Neuropathy, 5841 S Maryland Ave, Chicago, IL 60637 USA.	bpopko@neurology.bsd.uchicago.edu		Way, Sharon/0000-0002-9598-2240; Popko, Brian/0000-0001-9948-2553	Myelin Repair Foundation; US National Institutes of Health [NS34939]; National Multiple Sclerosis Society [FG 1998-A-1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034939] Funding Source: NIH RePORTER	Myelin Repair Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Benjamin L Clayton and Gloria Wright for their assistance with the figures, and relevant funding sources for their support. BP has received grants from the Myelin Repair Foundation and the US National Institutes of Health (NS34939). SWW received a postdoctoral fellowship from the National Multiple Sclerosis Society (FG 1998-A-1).	Aboul-Enein F, 2005, ACTA NEUROPATHOL, V109, P49, DOI 10.1007/s00401-004-0954-8; Allen IV, 2001, NEUROL SCI, V22, P141, DOI 10.1007/s100720170012; Baerwald KD, 1998, J NEUROSCI RES, V52, P230, DOI 10.1002/(SICI)1097-4547(19980415)52:2<230::AID-JNR11>3.3.CO;2-P; Baerwald KD, 2000, J NEUROSCI RES, V59, P160, DOI 10.1002/(SICI)1097-4547(20000115)59:2<160::AID-JNR2>3.3.CO;2-B; BAUM T, 1976, EUR J PHARMACOL, V37, P31, DOI 10.1016/0014-2999(76)90005-4; Ben-Hur T, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0397-5; Boettcher M, 2015, MOL CELL, V58, P575, DOI 10.1016/j.molcel.2015.04.028; Bogdan C, 2015, TRENDS IMMUNOL, V36, P161, DOI 10.1016/j.it.2015.01.003; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Ciccarelli O, 2014, LANCET NEUROL, V13, P807, DOI 10.1016/S1474-4422(14)70101-2; Cnop M, 2012, TRENDS MOL MED, V18, P59, DOI 10.1016/j.molmed.2011.07.010; Costello K., 2015, USE DIS MODIFYING TH; Cunnea P, 2011, MULT SCLER J, V17, P808, DOI 10.1177/1352458511399114; Czepiel M, 2015, GLIA, V63, P513, DOI 10.1002/glia.22769; Das I, 2015, SCIENCE, V348, P239, DOI 10.1126/science.aaa4484; Deslauriers AM, 2011, J IMMUNOL, V187, P4788, DOI 10.4049/jimmunol.1004111; DeVos SL, 2013, NEUROTHERAPEUTICS, V10, P486, DOI 10.1007/s13311-013-0194-5; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Dutta R, 2014, CURR OPIN NEUROL, V27, P271, DOI 10.1097/WCO.0000000000000094; Dutta R, 2011, PROG NEUROBIOL, V93, P1, DOI 10.1016/j.pneurobio.2010.09.005; Eizirik DL, 2008, ENDOCR REV, V29, P42, DOI 10.1210/er.2007-0015; Fern RF, 2014, GLIA, V62, P1780, DOI 10.1002/glia.22722; Fhlathartaigh MN, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-37; Franklin RJM, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020594; Franklin RJM, 2012, NAT REV NEUROL, V8, P624, DOI 10.1038/nrneurol.2012.200; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Ghasemi M, 2014, NEUROSCI BIOBEHAV R, V45, P168, DOI 10.1016/j.neubiorev.2014.06.002; Gow A, 2009, CURR OPIN NEUROBIOL, V19, P505, DOI 10.1016/j.conb.2009.08.007; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; Hauser SL, 2013, ANN NEUROL, V74, P317, DOI 10.1002/ana.24009; Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064; Hisahara S, 2000, EMBO J, V19, P341, DOI 10.1093/emboj/19.3.341; Hussien Y, 2014, GLIA, V62, P680, DOI 10.1002/glia.22634; Jm C., 1868, GAZ HOPITAUX, P554; Mansilla MJ, 2012, MOL MED, V18, P1018, DOI 10.2119/molmed.2012.00119; Kang J, 2015, J NEUROIMMUNOL, V279, P25, DOI 10.1016/j.jneuroim.2015.01.001; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Kremer D, 2015, MULT SCLER J, V21, P541, DOI 10.1177/1352458514566419; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Lassmann H, 2003, J NEUROL SCI, V206, P187, DOI 10.1016/S0022-510X(02)00421-5; Law M, 2004, RADIOLOGY, V231, P645, DOI 10.1148/radiol.2313030996; Lin WS, 2008, AM J PATHOL, V173, P1508, DOI 10.2353/ajpath.2008.080449; Lin WS, 2007, J CLIN INVEST, V117, P448, DOI 10.1172/JCI29571; Lin WS, 2013, J NEUROSCI, V33, P5980, DOI 10.1523/JNEUROSCI.1636-12.2013; Lin WS, 2006, BRAIN, V129, P1306, DOI 10.1093/brain/awl044; Lin WS, 2005, J CELL BIOL, V169, P603, DOI 10.1083/jcb.200502086; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Lin YF, 2014, AM J PATHOL, V184, P507, DOI 10.1016/j.ajpath.2013.10.009; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Mc Guire C, 2010, J IMMUNOL, V185, P7646, DOI 10.4049/jimmunol.1000930; McClorey G, 2015, CURR OPIN PHARMACOL, V24, P52, DOI 10.1016/j.coph.2015.07.005; McMahon JM, 2012, MULT SCLER J, V18, P1437, DOI 10.1177/1352458512438455; Mhaille AN, 2008, J NEUROPATH EXP NEUR, V67, P200, DOI 10.1097/NEN.0b013e318165b239; Miller SD, 2010, CURR PROTOC IMMUNOL, V88; Morrison BM, 2013, TRENDS CELL BIOL, V23, P644, DOI 10.1016/j.tcb.2013.07.007; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Noga MJ, 2012, METABOLOMICS, V8, P253, DOI 10.1007/s11306-011-0306-3; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Pender MP, 2011, NEUROSCIENTIST, V17, P351, DOI 10.1177/1073858410381531; Nguyen PH, 2014, ACS CHEM NEUROSCI, V5, P1075, DOI 10.1021/cn5001588; Pierson E, 2012, IMMUNOL REV, V248, P205, DOI 10.1111/j.1600-065X.2012.01126.x; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2007, TRENDS BIOCHEM SCI, V32, P469, DOI 10.1016/j.tibs.2007.09.003; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schuh C, 2014, ACTA NEUROPATHOL, V128, P247, DOI 10.1007/s00401-014-1263-5; Southwood CM, 2002, NEURON, V36, P585, DOI 10.1016/S0896-6273(02)01045-0; Steinman L, 2015, J CLIN INVEST, V125, P1371, DOI 10.1172/JCI74255; Stephenson E, 2014, NAT REV NEUROL, V10, P459, DOI 10.1038/nrneurol.2014.118; Stone S, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00264; Tanner DC, 2015, CELL DEATH DIFFER, V22, P1489, DOI 10.1038/cdd.2014.237; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; TRAUGOTT U, 1988, ANN NEUROL, V24, P243, DOI 10.1002/ana.410240211; Trinh MA, 2014, LEARN MEMORY, V21, P298, DOI 10.1101/lm.032219.113; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Turturici G, 2014, J NEUROPATH EXP NEUR, V73, P1092, DOI 10.1097/NEN.0000000000000136; Virtanen JO, 2012, CNS NEUROL DISORD-DR, V11, P528; Voumvourakis KI, 2011, NEUROCHEM INT, V59, P542, DOI 10.1016/j.neuint.2011.06.004; Watkins TA, 2008, NEURON, V60, P555, DOI 10.1016/j.neuron.2008.09.011; Way SW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7532; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006	90	46	48	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					434	443		10.1016/S1474-4422(15)00381-6	http://dx.doi.org/10.1016/S1474-4422(15)00381-6			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26873788	Green Accepted			2022-12-18	WOS:000371974000022
J	Bonnett, L; Smith, CT; Smith, D; Williamson, P; Chadwick, D; Marson, AG				Bonnett, Laura; Smith, Catrin Tudur; Smith, David; Williamson, Paula; Chadwick, David; Marson, Anthony G.			Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial	LANCET NEUROLOGY			English	Article							FRACTIONAL POLYNOMIALS; SEIZURE RECURRENCE; MODELS; RISK; CARBAMAZEPINE; LAMOTRIGINE; TOPIRAMATE	Background Epilepsy is a heterogeneous disorder, with outcomes ranging from immediate remission after taking a first antiepileptic drug to frequent unremitting seizures with multiple treatment failures. Few prognostic models enable prediction of outcome; we therefore aimed to use data from the SANAD study to predict outcome overall and for patients receiving specific treatments. Methods The SANAD study was a randomised controlled trial in which standard antiepileptic drugs were compared with new treatments. Arm A included patients for whom carbamazepine was considered the first-line treatment, most of whom were newly diagnosed with focal epilepsy. Patients were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Outcomes were time to treatment failure overall, because of inadequate seizure control, and because of adverse events, and time to 12 months of remission from seizures. In this post-hoc study we used regression multivariable modelling to investigate how clinical factors affect the probability of treatment failure and the probability of achieving 12 months of remission. Findings For time to treatment failure, we identified several significant risk factors: sex (male vs female, hazard ratio [HR] 0.86, 95% CI 0.75-0.99), treatment history (taking non-SANAD antiepileptic drugs [other than those listed above] vs treatment naive, 1.27, 1.05-1.53), age (eg, older than 71 years vs 10 years or younger, 0.68, 0.51-0.91), total number of seizures (eg, four toll seizures vs two or fewer, 1.08, 1-05-1.11), electroencephalogram results (epileptiform abnormality vs normal, 1.26, 1.07-1-50), seizure type (eg, secondary generalised vs simple or complex partial only, 0.78, 0.66-0.91), site of onset (not localised vs temporal lobe, 1.25, 1.06-1.47), and treatment (lamotrigine vs carbamazepine, 0.76, 0.61-0.95). Significant factors for time to 12 months of remission were sex (male vs female, 1.19, 1.05-1.35), treatment history (taking a non-SANAD antiepileptic drug vs treatment naive, 0.64, 0.52-0.78), age (eg, older than 71 years vs 10 years or younger, 1.60, 1.26-2.03), time from first seizure (60-239 months vs 2 months, 1.14, 1.01-1.29; >240 months vs <= 2 months, 1.39, 1.04-1.86), neurological insult (presentv absent, 0.75, 0.61-0.93), total number of seizures before randomisation (eg, four to 11 vs two or fewer, 0.87, 0.85-0.90), and treatment (gabapentin vs carbamazepine, 0.71, 0.59-0.86; topiramate vs carbamazepine, 0.81, 0.68-0.98). Interpretation We present a thorough investigation of prognostic factors from a large randomised controlled trial in patients starting antiepileptic monotherapy. If validated, our models could aid in individual patient risk stratification and the design and analysis of epilepsy trials.	[Marson, Anthony G.] Univ Liverpool, Dept Mol & Clin Pharmacol, Clin Sci Ctr Res & Educ, Liverpool L9 7LJ, Merseyside, England; [Bonnett, Laura; Smith, Catrin Tudur; Williamson, Paula] Univ Liverpool, Dept Biostat, Liverpool L9 7LJ, Merseyside, England; [Smith, David; Chadwick, David] Walton Ctr Fdn NHS Trust, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool; Walton Centre	Marson, AG (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Clin Sci Ctr Res & Educ, Liverpool L9 7LJ, Merseyside, England.	a.g.marson@liverpool.ac.uk	Bonnett, Laura/A-2159-2015; Marson, Anthony/AAW-9776-2020; Williamson, Paula R/B-6425-2016	Bonnett, Laura/0000-0002-6981-9212; Marson, Anthony/0000-0002-6861-8806; Williamson, Paula R/0000-0001-9802-6636; Tudur Smith, Catrin/0000-0003-3051-1445	National Institute for Health Research (UK); Health Technology Assessment programme (HTA); National Institute for Health Research (NIHR) [RP-PG-0606-1062]; National Institute for Health Research [RP-PG-0606-1062] Funding Source: researchfish	National Institute for Health Research (UK)(National Institute for Health Research (NIHR)); Health Technology Assessment programme (HTA); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Funding National Institute for Health Research (UK).; The SANAD trial was funded by the Health Technology Assessment programme (HTA). Our Article received financial support from the National Institute for Health Research (NIHR) Programme Grants for Applied Research funding scheme (RP-PG-0606-1062). The views and opinions expressed in this Article do not necessarily represent those of the NHS, the HTA, or the Department of Health.	[Anonymous], STAT SCI, DOI DOI 10.1214/ss/1177013607; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bonnett LJ, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6477; Bonnett LJ, 2011, J NEUROL NEUROSUR PS, V82, P1328, DOI 10.1136/jnnp.2010.222885; CHADWICK D, 1991, LANCET, V337, P1175; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; Collett D., 2003, MODELLING SURVIVAL D; Engel J, 2006, EPILEPSY RES, V70, pS5, DOI 10.1016/j.eplepsyres.2005.11.014; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Harrell F. E., 2001, REGRESSION MODELING; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hosmer D. W., 2000, APPL LOGISTIC REGRES, V2nd; Kim LG, 2006, LANCET NEUROL, V5, P317, DOI 10.1016/S1474-4422(06)70383-0; Kraemer HC, 2004, INT J METH PSYCH RES, V13, P141, DOI 10.1002/mpr.170; MacDonald BK, 2000, ANN NEUROL, V48, P833, DOI 10.1002/1531-8249(200012)48:6<833::AID-ANA3>3.0.CO;2-U; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9; Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Medical Research Council, 1998, GUID GOOD CLIN PRACT; Panayiotopoulos CP, 2007, LANCET, V370, P313, DOI 10.1016/S0140-6736(07)61150-7; Panayiotopoulos CP, 2007, EPILEPSIA, V48, P1268, DOI 10.1111/j.1528-1167.2007.01172.x; Royston P, 2007, COMPUT STAT DATA AN, V51, P4240, DOI 10.1016/j.csda.2006.05.006; Royston P, 2005, METHOD INFORM MED, V44, P561; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Royston P, 2008, MULTIVARIABLE MODEL; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Smith CT, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-34	29	46	47	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2012	11	4					331	340		10.1016/S1474-4422(12)70018-2	http://dx.doi.org/10.1016/S1474-4422(12)70018-2			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	915CD	22377180	hybrid			2022-12-18	WOS:000301999600009
J	Beretta, S; Carri, MT; Beghi, E; Chio, A; Ferrarese, C				Beretta, S; Carri, MT; Beghi, E; Chio, A; Ferrarese, C			The sinister side of Italian soccer	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; DEATH; ALS		Univ Milan, Dept Neurosci, Milan, Italy; Univ Roma Tor Vergata, Dept Biol, Rome, Italy; Ctr Neurobiol Sperimentale Mondino Tor Vergata, Rome, Italy; Univ Turin, Dept Neurosci, Turin, Italy	University of Milan; University of Rome Tor Vergata; University of Turin	Beretta, S (corresponding author), Univ Milan, Dept Neurosci, Milan, Italy.		Chio, Adriano/K-3425-2016; Ferrarese, Carlo/AAC-4903-2022; Beghi, Ettore/AAA-7426-2020; Beretta, Simone/J-6300-2019; Carri, Maria Teresa/K-5480-2016	Chio, Adriano/0000-0001-9579-5341; Beghi, Ettore/0000-0003-2542-0469; Beretta, Simone/0000-0002-9417-2748; Carri, Maria Teresa/0000-0002-1789-1546				Almer G, 2002, NEUROLOGY, V58, P1277, DOI 10.1212/WNL.58.8.1277; Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.3.CO;2-O; Armon C, 2001, NEUROEPIDEMIOLOGY, V20, P2, DOI 10.1159/000054751; CLEMENT A, 2002, AMYOTROPH LATERAL SC, V3, P5; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; FERRI A, 2002, AMYOTROPH LATERAL SC, V3, P25; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; McArdle A, 2001, AM J PHYSIOL-CELL PH, V280, pC621, DOI 10.1152/ajpcell.2001.280.3.C621; Rao SD, 2003, J NEUROSCI, V23, P2627; Scarmeas N, 2002, NEUROLOGY, V59, P773, DOI 10.1212/WNL.59.5.773	11	46	47	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2003	2	11					656	657		10.1016/S1474-4422(03)00579-9	http://dx.doi.org/10.1016/S1474-4422(03)00579-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	734ZN	14572730				2022-12-18	WOS:000186088000011
J	Overeem, S; van Vliet, JA; Lammers, GJ; Zitman, FG; Swaab, DF; Ferrari, MD				Overeem, S; van Vliet, JA; Lammers, GJ; Zitman, FG; Swaab, DF; Ferrari, MD			The hypothalamus in episodic brain disorders	LANCET NEUROLOGY			English	Editorial Material							PRADER-WILLI-SYNDROME; PARAVENTRICULAR NUCLEUS; CLUSTER HEADACHE; SUPRACHIASMATIC NUCLEUS; HYPOCRETIN OREXIN; NERVOUS-SYSTEM; CARDIOVASCULAR REFLEXES; MELATONIN EXCRETION; EXPRESSING NEURONS; GROWTH-HORMONE	Episodic brain disorders (EBD) form an intriguing group of neurological diseases in which at least some of the symptoms occur in attacks. The hypothalamus integrates many brain functions, including endocrine and autonomic control, and governs various body rhythms. It seems a likely site in which the initiation of attacks of EBD can be modulated. Indeed, the hypothalamus has a crucial role in EBD such as narcolepsy and cluster headache. The same may be true for migraine and depression. Here we summarise the evidence supporting an important role for the hypothalamus in the initiation of disease episodes in various EBD. Study of the various pathophysiological concepts of EBD within the context of the hypothalamus may prove a fruitful example of cross-fertilisation between various research areas.	Leiden Univ, Med Ctr, Dept Neurol, Leiden Headache Grp, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Psychiat, NL-2300 RC Leiden, Netherlands; Univ Amsterdam, Amsterdam, Netherlands; Netherlands Inst Brain Res, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Ferrari, MD (corresponding author), Leiden Univ, Med Ctr, Dept Neurol, Leiden Headache Grp, POB 9600, NL-2300 RC Leiden, Netherlands.	M.D.Ferrari@lumc.nl	Zitman, Frans G./E-7705-2010; Ferrari, Michel D./ABE-3758-2021; Overeem, Sebastiaan/D-2139-2010	Ferrari, Michel D./0000-0001-9691-9449; Lammers, Gert Jan/0000-0003-4755-7060; Overeem, Sebastiaan/0000-0002-6445-9836; Swaab, Dick/0000-0002-9665-7845				Abrahamson EE, 2001, NEUROREPORT, V12, P435, DOI 10.1097/00001756-200102120-00048; American Psychiatric Association, 2000, QUICK REF DIAGN CRIT; Ariyasu H, 2001, J CLIN ENDOCR METAB, V86, P4753, DOI 10.1210/jc.86.10.4753; ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X; Armitage R, 1999, PSYCHOL MED, V29, P1435, DOI 10.1017/S0033291799001300; Aston-Jones G, 2001, NAT NEUROSCI, V4, P732, DOI 10.1038/89522; Bahra A, 2002, NEUROLOGY, V58, P354, DOI 10.1212/WNL.58.3.354; Baile CA, 2000, ANNU REV NUTR, V20, P105, DOI 10.1146/annurev.nutr.20.1.105; Bartness TJ, 2001, J BIOL RHYTHM, V16, P196, DOI 10.1177/074873001129001908; BLAU JN, 1984, J NEUROL NEUROSUR PS, V47, P437, DOI 10.1136/jnnp.47.5.437; BOIARDI A, 1988, HEADACHE, V28, P417, DOI 10.1111/j.1526-4610.1988.hed2806417.x; BRAGA PC, 1993, NEUROSCI LETT, V151, P85, DOI 10.1016/0304-3940(93)90052-M; BROUGHTON R, 1986, SLEEP, V9, P205, DOI 10.1093/sleep/9.1.205; BRUN J, 1995, CEPHALALGIA, V15, P136, DOI 10.1046/j.1468-2982.1995.015002136.x; Buijs RM, 2001, NAT REV NEUROSCI, V2, P521, DOI 10.1038/35081582; CHAZOT G, 1984, CEPHALALGIA, V4, P213, DOI 10.1046/j.1468-2982.1984.0404213.x; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; CLAUSTRAT B, 1989, HEADACHE, V29, P242, DOI 10.1111/j.1526-4610.1989.hed22904242.x; Dahmen N, 2001, EUR ARCH PSY CLIN N, V251, P85, DOI 10.1007/s004060170057; DALESSANDRO R, 1986, CEPHALALGIA, V6, P159, DOI 10.1046/j.1468-2982.1986.0603159.x; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dodick DW, 2000, CEPHALALGIA, V20, P787, DOI 10.1046/j.1468-2982.2000.00118.x; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; Eiholzer U, 2000, HORM RES, V53, P44, DOI 10.1159/000023533; EKBOM K, 1968, ARCH NEUROL-CHICAGO, V19, P487, DOI 10.1001/archneur.1968.00480050057005; Elmquist JK, 2001, INT J OBESITY, V25, pS78, DOI 10.1038/sj.ijo.0801918; FACCHINETTI F, 1990, CEPHALALGIA, V10, P51, DOI 10.1046/j.1468-2982.1990.1001051.x; FACCHINETTI F, 1983, CEPHALALGIA, V3, P94, DOI 10.1177/03331024830030S113; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; Fox AW, 1998, HEADACHE, V38, P436, DOI 10.1046/j.1526-4610.1998.3806436.x; Gadoth N, 2001, J SLEEP RES, V10, P337, DOI 10.1046/j.1365-2869.2001.00272.x; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; GOMI S, 1989, CEPHALALGIA, V9, P179, DOI 10.1046/j.1468-2982.1989.0903179.x; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Harmatz MG, 2000, J BIOL RHYTHM, V15, P344, DOI 10.1177/074873000129001350; HEUSER I, 1994, J PSYCHIAT RES, V28, P341, DOI 10.1016/0022-3956(94)90017-5; HOKFELT T, 1977, P NATL ACAD SCI USA, V74, P3081, DOI 10.1073/pnas.74.7.3081; HOLM VA, 1993, PEDIATRICS, V91, P398; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kalsbeek A, 2001, ENDOCRINOLOGY, V142, P2677, DOI 10.1210/en.142.6.2677; Kok SW, 2002, J CLIN ENDOCR METAB, V87, P805, DOI 10.1210/jc.87.2.805; KUDROW L, 1987, CEPHALALGIA, V7, P197, DOI 10.1046/j.1468-2982.1987.0703197.x; Kuzniecky R, 1997, ANN NEUROL, V42, P60, DOI 10.1002/ana.410420111; Lammers GJ, 1996, SLEEP, V19, P75, DOI 10.1093/sleep/19.1.75; LEONE M, 1995, CEPHALALGIA, V15, P224, DOI 10.1046/j.1468-2982.1995.015003224.x; Leone M, 2001, NEW ENGL J MED, V345, P1428, DOI 10.1056/NEJM200111083451915; Leone M, 1998, CEPHALALGIA, V18, P664, DOI 10.1046/j.1468-2982.1998.1810664.x; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; MacGregor A, 2000, REV CONTEMP PHARMACO, V11, P75; MARTIN R, 1992, CEPHALALGIA, V12, P360, DOI 10.1111/j.1468-2982.1992.00360.x; May A, 1999, NAT MED, V5, P836, DOI 10.1038/10561; May A, 1998, LANCET, V352, P275, DOI 10.1016/S0140-6736(98)02470-2; Micieli G, 1989, Funct Neurol, V4, P105; MIDDELKOOP HAM, 1995, PSYCHOPHYSIOLOGY, V32, P286, DOI 10.1111/j.1469-8986.1995.tb02957.x; MIKAMO K, 1989, HEADACHE, V29, P86, DOI 10.1111/j.1526-4610.1989.hed2902086.x; MILLAN MJ, 1982, PHARM BIOCH BEHAV, V18, P901; MIRSKI MA, 1993, AM J NEURORADIOL, V14, P1336; MURIALDO G, 1994, CEPHALALGIA, V14, P205, DOI 10.1046/j.1468-2982.1994.014003205.x; NAGELLEIBY S, 1990, CEPHALALGIA, V10, P317, DOI 10.1046/j.1468-2982.1990.1006317.x; NAPPI A, 1994, HEADACHE CLASSIFICAT, P107; Nemeroff CB, 1996, MOL PSYCHIATR, V1, P336; Nishino S, 2001, ANN NEUROL, V50, P381, DOI 10.1002/ana.1130; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; OGLDSTONE AP, 2002, J CLIN ENDOCR METAB, V87, P927; Overeem S, 2001, J CLIN NEUROPHYSIOL, V18, P78, DOI 10.1097/00004691-200103000-00002; OVEREEM S, IN PRESS SLEED MED; Papacostas SS, 2000, EUR PSYCHIAT, V15, P231, DOI 10.1016/S0924-9338(00)00239-X; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Purba JS, 1996, ARCH GEN PSYCHIAT, V53, P137; RAADSHEER FC, 1995, AM J PSYCHIAT, V152, P1372; RAADSHEER FC, 1994, NEUROENDOCRINOLOGY, V60, P436, DOI 10.1159/000126778; Richardson D E, 1977, Neurosurgery, V1, P199; Ripley B, 2001, NEUROLOGY, V57, P2253, DOI 10.1212/WNL.57.12.2253; RUBIN LS, 1985, HEADACHE, V25, P40, DOI 10.1111/j.1526-4610.1985.hed2501040.x; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Saper C.B., 1990, HUMAN NERVOUS SYSTEM, P389, DOI DOI 10.1016/B978-0-12-547625-6.50020-9; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Seifritz E, 2001, NEUROPSYCHOPHARMACOL, V25, pS85, DOI 10.1016/S0893-133X(01)00319-0; SHAW SWJ, 1977, J NEUROL SCI, V33, P51, DOI 10.1016/0022-510X(77)90181-2; Shechter A, 2002, NEUROLOGY, V58, P422, DOI 10.1212/WNL.58.3.422; SILBERSTEIN SD, 1995, HEADACHE, V35, P387, DOI 10.1111/j.1526-4610.1995.hed3507387.x; SOLOMON GD, 1992, CLEV CLIN J MED, V59, P326, DOI 10.3949/ccjm.59.3.326; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Strittmatter M, 1996, NEUROREPORT, V7, P1229, DOI 10.1097/00001756-199605170-00001; SWAAB DF, 1995, J CLIN ENDOCR METAB, V80, P573, DOI 10.1210/jcem.80.2.7852523; Swaab DF, 2000, PROG BRAIN RES, V126, P369; Swaab DF, 1999, AUTONOMIC NERVOUS  1, P467; SWAAB DF, 1997, PRIAMTE NERVOUS SYST, P39; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; WALDENLIND E, 1987, CEPHALALGIA, V7, P43, DOI 10.1046/j.1468-2982.1987.0701043.x; WEELBAUMGARTEN EM, 2000, J FAM PRACTICE, V49, P1113; Wehr TA, 2001, ARCH GEN PSYCHIAT, V58, P1108, DOI 10.1001/archpsyc.58.12.1108; Wolkowitz OM, 1999, BIOL PSYCHIAT, V45, P1070, DOI 10.1016/S0006-3223(98)00267-4; World Health Organization, 2001, WORLD HLTH REPORT 20; Zhou JN, 2001, ARCH GEN PSYCHIAT, V58, P655, DOI 10.1001/archpsyc.58.7.655; Zobel AW, 2000, J PSYCHIATR RES, V34, P171, DOI 10.1016/S0022-3956(00)00016-9	98	46	49	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					437	444		10.1016/S1474-4422(02)00191-6	http://dx.doi.org/10.1016/S1474-4422(02)00191-6			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC	12849366				2022-12-18	WOS:000178732300021
J	Gorelick, PB				Gorelick, PB			New horizons for stroke prevention: PROGRESS and HOPE	LANCET NEUROLOGY			English	Review							CONVERTING ENZYME-INHIBITORS; CORONARY-HEART-DISEASE; ISOLATED SYSTOLIC HYPERTENSION; HEALTH-CARE PROFESSIONALS; BLOOD-PRESSURE; RISK-FACTORS; CARDIOVASCULAR RISK; PULSE PRESSURE; ISCHEMIC-STROKE; ACE-INHIBITION		Rush Med Coll, Dept Neurol, Chicago, IL 60612 USA	Rush University	Gorelick, PB (corresponding author), Rush Med Coll, Dept Neurol, 1645 W Jackson,Suite 400, Chicago, IL 60612 USA.	Philip_B_Gorelick@rush.edu			NIA NIH HHS [R01 AG17934] Funding Source: Medline; NINDS NIH HHS [R01 NS33430] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017934] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS HP, 1994, CIRCULATION, V90, P1588, DOI 10.1161/01.CIR.90.3.1588; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Blacher J, 2000, ARCH INTERN MED, V160, P1085, DOI 10.1001/archinte.160.8.1085; Blacher J, 1999, HYPERTENSION, V33, P1111, DOI 10.1161/01.HYP.33.5.1111; BONITA R, 2001, STROKE PREVENTION, P259; Brown NJ, 1998, CIRCULATION, V97, P1411, DOI 10.1161/01.CIR.97.14.1411; Brunel P, 1996, CLIN DRUG INVEST, V12, P226, DOI 10.2165/00044011-199612050-00002; Chalmers J, 2001, J HYPERTENS, V19, pS21; Chalmers J, 2000, Heart Dis, V2, pS13; Chaturvedi N, 2001, ANN INTERN MED, V134, P370, DOI 10.7326/0003-4819-134-5-200103060-00009; Cohn J N, 2000, Heart Dis, V2, pS2; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Cohn JN, 1998, J HYPERTENS, V16, P2117; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DZAU VJ, 1993, ARCH INTERN MED, V153, P937, DOI 10.1001/archinte.153.8.937; DZAU VJ, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199322005-00002; Dzau VJ, 1998, EUR HEART J, V19, pJ2; DZAU VJ, 1995, J MYOCARD ISCHEMIA, V7, P6; Elliott WJ, 2002, PREVENTION OF STROKE, P163; Farmer J A, 2001, Curr Atheroscler Rep, V3, P117, DOI 10.1007/s11883-001-0047-2; Francis GS, 2000, NEW ENGL J MED, V342, P201, DOI 10.1056/NEJM200001203420309; Franklin SS, 2001, CIRCULATION, V103, P1245; Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354; Franklin SS, 1997, CIRCULATION, V96, P308; Furberg CD, 2001, J AM COLL CARDIOL, V37, P1456, DOI 10.1016/S0735-1097(01)01161-5; Gerbrandt KR, 1996, PHARMACOECONOMICS, V10, P594, DOI 10.2165/00019053-199610060-00006; Gibbons GH, 1997, AM J CARDIOL, V79, P3, DOI 10.1016/S0002-9149(97)00122-7; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; Glasser SP, 1998, AM HEART J, V135, pS16, DOI 10.1053/hj.1998.v135.86973; Glasser SP, 1996, AM HEART J, V131, P379, DOI 10.1016/S0002-8703(96)90370-1; Goldstein LB, 2001, CIRCULATION, V103, P163; GORELICK PB, 1995, ARCH NEUROL-CHICAGO, V52, P347, DOI 10.1001/archneur.1995.00540280029015; GORELICK PB, 1993, ARCH NEUROL-CHICAGO, V50, P714, DOI 10.1001/archneur.1993.00540070034011; Gorelick PB, 2002, STROKE, V33, P862, DOI 10.1161/hs0302.103657; Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112; Gorelick PB, 1997, NEUROEPIDEMIOLOGY, V16, P163, DOI 10.1159/000109683; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; JOSEPH LN, 1998, P 23 INT C STROK CER; KOPFF BS, 2000, HYPERTENSION, V36, P220; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MacMahon S, 2000, NEW ENGL J MED, V342, P50, DOI 10.1056/NEJM200001063420109; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Millar JA, 2000, HYPERTENSION, V36, P907, DOI 10.1161/01.HYP.36.5.907; Neal B, 2000, LANCET, V356, P1955; Neutel JM, 1998, AM J HYPERTENS, V11, p150S, DOI 10.1016/S0895-7061(98)00192-7; *NIH, 1997, NIH PUBL; Perry HM, 2000, JAMA-J AM MED ASSOC, V284, P465, DOI 10.1001/jama.284.4.465; Piepho RW, 2000, AM J HEALTH-SYST PH, V57, pS3, DOI 10.1093/ajhp/57.suppl_1.S3; Port S, 2000, LANCET, V355, P175, DOI 10.1016/S0140-6736(99)07051-8; *PROGRESS COLL GRO, 2000, LANCET, V358, P1033; Rangoonwala B, 1998, INT J CLIN PRACT, V52, P492; RODGERS A, 1997, NEUROL REV INT, V2, P12; ROSSI GP, 1995, STROKE, V26, P1700, DOI 10.1161/01.STR.26.9.1700; Sacco RL, 1999, NEUROLOGY, V53, pS15; Sacco RL, 2001, STROKE, V32, P1725, DOI 10.1161/01.STR.32.8.1725; Safar ME, 2000, STROKE, V31, P782, DOI 10.1161/01.STR.31.3.782; Seshadri S, 2001, ARCH INTERN MED, V161, P2343, DOI 10.1001/archinte.161.19.2343; *SHEP COOP RES GRO, 1991, JAMA-J AM MED ASSOC, V256, P3255; Sihm Inger, 1995, Blood Pressure, V4, P241, DOI 10.3109/08037059509077602; SOWERS JR, 1993, AM J HYPERTENS, V6, pS260, DOI 10.1093/ajh/6.7.260S; *SPARCL, 2001, STROKE, V32, P589; Staessen JA, 2000, LANCET, V355, P865, DOI 10.1016/S0140-6736(99)07330-4; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Staessen JA, 2001, LANCET, V358, P1026, DOI 10.1016/S0140-6736(01)06226-2; Stephenson J, 1999, JAMA-J AM MED ASSOC, V282, P313, DOI 10.1001/jama.282.4.313; Svensson P, 2001, HYPERTENSION, V38, pE28, DOI 10.1161/hy1101.099502; THYBO NK, 1995, HYPERTENSION, V25, P474, DOI 10.1161/01.HYP.25.4.474; Van Bortel LMAB, 2001, HYPERTENSION, V38, P914, DOI 10.1161/hy1001.095773; Vasan RS, 2002, CIRCULATION, V105, P48, DOI 10.1161/hc0102.101774; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; Verdecchia P, 2001, CIRCULATION, V103, P2579; Walters MR, 2001, STROKE, V32, P473, DOI 10.1161/01.STR.32.2.473; Waugh WJ, 2000, AM J HEALTH-SYST PH, V57, pS26, DOI 10.1093/ajhp/57.suppl_1.S26; Weber KT, 2001, NEW ENGL J MED, V345, P1689, DOI 10.1056/NEJMra000050; White CM, 1998, PHARMACOTHERAPY, V18, P588; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Yusuf S, 2000, NEW ENGL J MED, V342, P145	85	46	49	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					149	156		10.1016/S1474-4422(02)00070-4	http://dx.doi.org/10.1016/S1474-4422(02)00070-4			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB	12849483				2022-12-18	WOS:000177695100016
J	Benkert, P; Meier, S; Schaedelin, S; Manouchehrinia, A; Yaldizli, O; Maceski, A; Oechtering, J; Achtnichts, L; Conen, D; Derfuss, T; Lalive, PH; Mueller, C; Muller, S; Naegelin, Y; Oksenberg, JR; Pot, C; Salmen, A; Willemse, E; Kockum, I; Blennow, K; Zetterberg, H; Gobbi, C; Kappos, L; Wiendl, H; Berger, K; Sormani, MP; Granziera, C; Piehl, F; Leppert, D; Kuhle, J				Benkert, Pascal; Meier, Stephanie; Schaedelin, Sabine; Manouchehrinia, Ali; Yaldizli, Ozgur; Maceski, Aleksandra; Oechtering, Johanna; Achtnichts, Lutz; Conen, David; Derfuss, Tobias; Lalive, Patrice H.; Mueller, Christian; Muller, Stefanie; Naegelin, Yvonne; Oksenberg, Jorge R.; Pot, Caroline; Salmen, Anke; Willemse, Eline; Kockum, Ingrid; Blennow, Kaj; Zetterberg, Henrik; Gobbi, Claudio; Kappos, Ludwig; Wiendl, Heinz; Berger, Klaus; Sormani, Maria Pia; Granziera, Cristina; Piehl, Fredrik; Leppert, David; Kuhle, Jens		NfL Reference Database Swiss Multi	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study	LANCET NEUROLOGY			English	Article							DISABILITY	Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease modifying therapies. Methods For derivation of a reference database of sNfL values, a control group was created, comprising participants with no evidence of CNS disease taking part in four cohort studies in Europe and North America. We modelled the distribution of sNfL concentrations in function of physiological age-related increase and BMI-dependent modulation, to derive percentile and Z score values from this reference database, via a generalised additive model for location, scale, and shape. We tested the reference database in participants with multiple sclerosis in the Swiss Multiple Sclerosis Cohort (SMSC). We compared the association of sNfL Z scores with clinical and MRI characteristics recorded longitudinally to ascertain their respective disease prognostic capacity. We validated these findings in an independent sample of individuals with multiple sclerosis who were followed up in the Swedish Multiple Sclerosis registry. Findings We obtained 10 133 blood samples from 5390 people (median samples per patient 1 [IQR 1-2] in the control group). In the control group, sNfL concentrations rose exponentially with age and at a steeper increased rate after approximately 50 years of age. We obtained 7769 samples from 1313 people (median samples per person 6.0 [IQR 3.0-8.0]). In people with multiple sclerosis from the SMSC, sNfL percentiles and Z scores indicated a gradually increased risk for future acute (eg, relapse and lesion formation) and chronic (disability worsening) disease activity. A sNfL Z score above 1.5 was associated with an increased risk of future clinical or MRI disease activity in all people with multiple sclerosis (odds ratio 3.15, 95% CI 2.35-4.23; p<0.0001) and in people considered stable with no evidence of disease activity (2.66, 1.08-6.55; p=0.034). Increased Z scores outperformed absolute raw sNfL cutoff values for diagnostic accuracy. At the group level, the longitudinal course of sNfL Z score values in people with multiple sclerosis from the SMSC decreased to those seen in the control group with use of monoclonal antibodies (ie, alemtuzumab, natalizumab, ocrelizumab, and rituximab) and, to a lesser extent, oral therapies (ie, dimethyl fumarate, fingolimod, siponimod, and teriflunomide). However, longitudinal sNfL Z scores remained elevated with platform compounds (interferons and glatiramer acetate; p<0.0001 for the interaction term between treatment category and treatment duration). Results were fully supported in the validation cohort (n=4341) from the Swedish Multiple Sclerosis registry. Interpretation The use of sNfL percentiles and Z scores allows for identification of individual people with multiple sclerosis at risk for a detrimental disease course and suboptimal therapy response beyond clinical and MRI measures, specifically in people with disease activity-free status. Additionally, sNfL might be used as an endpoint for comparing effectiveness across drug classes in pragmatic trials. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Benkert, Pascal; Schaedelin, Sabine] Univ Basel, Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland; [Meier, Stephanie; Yaldizli, Ozgur; Maceski, Aleksandra; Oechtering, Johanna; Derfuss, Tobias; Naegelin, Yvonne; Willemse, Eline; Kappos, Ludwig; Granziera, Cristina; Leppert, David; Kuhle, Jens] Univ Basel, Univ Hosp Basel, Neurol Clink & Polidin, MS Ctr, Basel, Switzerland; [Meier, Stephanie; Yaldizli, Ozgur; Maceski, Aleksandra; Oechtering, Johanna; Derfuss, Tobias; Naegelin, Yvonne; Willemse, Eline; Kappos, Ludwig; Granziera, Cristina; Leppert, David; Kuhle, Jens] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel, Basel, Switzerland; [Granziera, Cristina] Univ Basel, Univ Hosp Basel, Dept Med & Biomed Engn, Translat Imaging Neurol Basel, Basel, Switzerland; [Mueller, Christian] Univ Basel, Univ Hosp Basel, Cardiovasc Res Inst Basel, Dept Med,Cardiol Div, Basel, Switzerland; [Manouchehrinia, Ali; Kockum, Ingrid; Piehl, Fredrik] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Stockholm, Sweden; [Piehl, Fredrik] Stockholm Hlth Serv, Acad Specialist Ctr, Ctr Neurol, Stockholm, Sweden; [Achtnichts, Lutz] Cantonal Hosp Aarau, Dept Neurol, Aarau, Switzerland; [Salmen, Anke] Univ Bern, Bern Univ Hosp, Dept Neurol, Bern, Switzerland; [Conen, David] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; [Gobbi, Claudio] Neuroctr Southern Switzerland, Multiple Sclerosis Ctr, Dept Neurol, Lugano, Switzerland; [Pot, Caroline] Univ Lausanne, Lausanne Univ Hosp, Dept Clin Neurosci, Serv Neurol, Lausanne, Switzerland; [Lalive, Patrice H.] Univ Hosp Geneva, Dept Neurosci, Div Neurol, Unit Neuroimmunol & Neuromuscular Dis, Geneva, Switzerland; [Lalive, Patrice H.] Fac Med, Geneva, Switzerland; [Muller, Stefanie] Cantonal Hosp St Gallen, MD Dept Neurol, St Gallen, Switzerland; [Oksenberg, Jorge R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Oksenberg, Jorge R.] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Gobbi, Claudio] Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Neurosci & Physiol, Dept Psychiat & Neurochem,Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [Zetterberg, Henrik] Dementia Res Inst UCL, London, England; [Wiendl, Heinz] Univ Hosp Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany; [Berger, Klaus] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany; [Sormani, Maria Pia] Univ Genoa, Dept Hlth Sci, Genoa, Italy	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; Karolinska Institutet; Karolinska University Hospital; Kantonsspital Aarau AG (KSA); University of Bern; University Hospital of Bern; McMaster University; Population Health Research Institute; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva; Kantonsspital St. Gallen; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universita della Svizzera Italiana; Sahlgrenska University Hospital; University of Gothenburg; University of London; University College London; University of Munster; University of Munster; University of Genoa	Kuhle, J (corresponding author), Univ Basel, Univ Hosp Basel, Multiple Sclerosis Ctr, CH-4031 Basel, Switzerland.; Kuhle, J (corresponding author), Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel, Dept Head Spine & Neuromed,Neurol, CH-4031 Basel, Switzerland.; Kuhle, J (corresponding author), Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel, Dept Biomed & Clin Res,Neurol, CH-4031 Basel, Switzerland.	jens.kuhle@usb.ch	Benkert, Pascal/C-3895-2009; Salmen, Anke/S-9681-2018; Kockum, Ingrid/O-8781-2018	Salmen, Anke/0000-0002-4751-299X; Kockum, Ingrid/0000-0002-0867-4726; Yaldizli, Ozgur/0000-0002-0800-4845; Granziera, Cristina/0000-0002-4917-8761; Gobbi, Claudio/0000-0002-7554-0664; Rahmanzadeh, Reza/0000-0002-5091-0585; Chan, Andrew/0000-0003-3434-7283; Zecca, Chiara/0000-0002-9990-3431	Swiss National Science Foundation; Progressive Multiple Sclerosis Alliance; Biogen; Celgene; Novartis; Roche	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Progressive Multiple Sclerosis Alliance; Biogen(Biogen); Celgene(Bristol-Myers SquibbCelgene Corporation); Novartis(Novartis); Roche(Roche Holding)	Swiss National Science Foundation, Progressive Multiple Sclerosis Alliance, Biogen, Celgene, Novartis, Roche.	Akgun K, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000555; Alping P, 2019, EPIDEMIOLOGY, V30, P230, DOI 10.1097/EDE.0000000000000948; Barro C, 2018, BRAIN, V141, P2382, DOI 10.1093/brain/awy154; Bittner S, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102807; Calabrese P, 2017, MULT SCLER J, V23, P192, DOI 10.1177/1352458517708685; Calabresi PA, 2021, MULT SCLER J, V27, P1497, DOI 10.1177/1352458520972573; Chitnis T, 2018, ANN CLIN TRANSL NEUR, V5, P1478, DOI 10.1002/acn3.638; Cree BAC, 2016, ANN NEUROL, V80, P499, DOI 10.1002/ana.24747; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; Curtis Alexander E, 2016, Aorta (Stamford), V4, P124, DOI 10.12945/j.aorta.2016.16.014; decke D., SJPLOT DATA VISUALIZ; Delcoigne B, 2020, NEUROLOGY, V94, pE1201, DOI 10.1212/WNL.0000000000009097; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Disanto G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152347; Giovannoni G, 2018, BRAIN, V141, P2235, DOI 10.1093/brain/awy200; Gyllensten Hanna, 2018, Mult Scler J Exp Transl Clin, V4, p2055217318783352, DOI 10.1177/2055217318783352; Hakansson I, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1249-7; Hauser SL, 2020, NEW ENGL J MED, V383, P546, DOI 10.1056/NEJMoa1917246; Hauser SL, 2020, AM J MED, V133, P1380, DOI 10.1016/j.amjmed.2020.05.049; Hedstrom AK, 2013, EUR J EPIDEMIOL, V28, P867, DOI 10.1007/s10654-013-9853-4; Holmen C, 2011, MULT SCLER J, V17, P708, DOI 10.1177/1352458510394701; Jens K., SERUM NEUROFILAMENT; Kapoor R, 2019, NEUROLOGY, V92; Kappos L, 2009, LANCET NEUROL, V8, P987, DOI 10.1016/S1474-4422(09)70237-6; Khalil M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14612-6; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Kuhle J, 2018, NEUROFILAMENT LIGHT; Kuhle J, 2019, NEUROLOGY, V92, pE1007, DOI 10.1212/WNL.0000000000007032; Lambertsen KL, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10010056; Leppert D, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000599; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Manouchehrinia A, 2020, NEUROLOGY, V94, pE2457, DOI 10.1212/WNL.0000000000009571; Manouchehrinia A, 2020, ANN CLIN TRANSL NEUR, V7, P139, DOI 10.1002/acn3.50972; Novakova L, 2017, NEUROLOGY, V89, P2230, DOI 10.1212/WNL.0000000000004683; Pittock SJ, 2009, LANCET NEUROL, V8, P970, DOI 10.1016/S1474-4422(09)70258-3; Polymeris AA, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa166; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Rotstein DL, 2015, JAMA NEUROL, V72, P152, DOI 10.1001/jamaneurol.2014.3537; Sormani MP, 2019, ANN CLIN TRANSL NEUR, V6, P1081, DOI 10.1002/acn3.795; Tur C, 2019, NEUROLOGY, V93, P793, DOI 10.1212/WNL.0000000000008319; Ziemssen T, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1674-2	41	45	45	9	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					246	257		10.1016/S1474-4422(22)00009-6	http://dx.doi.org/10.1016/S1474-4422(22)00009-6			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182510	Green Submitted			2022-12-18	WOS:000759721800021
J	Howard, DPJ; Gaziano, L; Rothwell, PM				Howard, Dominic P. J.; Gaziano, Liam; Rothwell, Peter M.		Oxford Vasc Study	Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis	LANCET NEUROLOGY			English	Review							RANDOMIZED CONTROLLED-TRIALS; HEALTH-CARE PROFESSIONALS; OF-NEUROLOGY-AFFIRMS; ARTERY STENOSIS; NATURAL-HISTORY; ENDARTERECTOMY; PREVENTION; GUIDELINES; STATEMENT; LESSONS	Background There is uncertainty around which patients with asymptomatic carotid stenosis should be offered surgical intervention. Although stroke rates were unrelated to the degree of stenosis in the medical-treatment-only groups in previous randomised trials, this could simply reflect recruitment bias and there has been no systematic analysis of a stenosis-risk association in cohort studies. We aimed to establish whether there is any association between the degree of asymptomatic stenosis and ipsilateral stroke risk in patients on contemporary medical treatment. Methods We did a prospective population-based study (Oxford Vascular Study; OxVasc), and a systematic review and meta-analysis. All patients in OxVasc with a recent suspected transient ischaemic attack or stroke, between April 1, 2002, and April 1, 2017, who had asymptomatic carotid stenosis were included in these analyses. We commenced contemporary medical treatment and determined ipsilateral stroke risk in this cohort by face-to-face follow-up (to Oct 1, 2020). We also did a systematic review and meta-analysis of all published studies (from an 1,1980, to Oct 1, 2020) reporting ipsilateral stroke risk in patients with asymptomatic carotid stenosis. We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, and included both observational cohort studies and medical treatment groups of randomised controlled trials if the number of patients exceeded 30, ipsilateral stroke rates (or the raw data to calculate these) were provided, and were published in English. Findings Between April 1,2002, and April 1,2017,2354 patients were consecutively enrolled in OxVasc and 2178 patients underwent carotid imaging, of whom 207 had 50-99% asymptomatic stenosis of at least one carotid bifurcation (mean age at imaging: 77.5 years [SD 10.3]; 88 143%1 women). The 5-year ipsilateral stroke risk increased with the degree of stenosis; patients with 70-99% stenosis had a significantly greater 5-year ipsilateral stroke risk than did those with 50-69% stenosis (six [14.6%; 95% CI 3-5-25.7] of 53 patients vs none of 154; p<0.0001); and patients with 80-99% stenosis had a significantly greater 5-year ipsilateral stroke risk than did those with 50-79% stenosis (five [18.3%; 7.7-29-9] of 34 patients vs one [1.0%; 0.0-2-9] of 173; p<0.0001). Of the 56 studies identified in the systematic review (comprising 13 717 patients), 23 provided data on ipsilateral stroke risk fully stratified by degree of asymptomatic stenosis (in 8419 patients). Stroke risk was linearly associated with degree of ipsilateral stenosis (p<0.0001); there was a higher risk in patients with 70-99% stenosis than in those with 50-69% stenosis (386 of 3778 patients vs 181 of 3806 patients; odds ratio [OR] 2.1 [95% CI 1-7-2.5], p<0.0001; 15 cohort studies, three trials) and a higher risk in patients with 80-99% stenosis than in those with 50-79% stenosis (77 of 727 patients vs 167 of 3272 patients; OR 2.5 [1.8-3-5], p<0.0001; 11 cohort studies). Heterogeneity in stroke risk between studies for patients with severe versus moderate stenosis (P-het<0.0001) was accounted for by highly discrepant results (P-diff<0.0001) in the randomised controlled trials of endarterectomy compared with cohort studies (trials: pooled OR 0.8 [95% CI 0.6-1.2], P-het =0.89; cohorts: 2.9 [2.3-3.7], P-het=0-54). Interpretation Contrary to the assumptions of current guidelines and the findings of subgroup analyses of previous randomised controlled trials, the stroke risk reported in cohort studies was highly dependent on the degree of asymptomatic carotid stenosis, suggesting that the benefit of endarterectomy might be underestimated in patients with severe stenosis. Conversely, the 5-year stroke risk was low for patients with moderate stenosis on contemporary medical treatment, calling into question any benefit from revascularisation. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Howard, Dominic P. J.; Gaziano, Liam; Rothwell, Peter M.] Univ Oxford, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clinkal Neurosci, Oxford OX3 9DU, England; [Howard, Dominic P. J.] Oxford Univ Hosp NHS Trust, Dept Vasc Surg, Oxford, England	University of Oxford; Oxford University Hospitals NHS Foundation Trust	Rothwell, PM (corresponding author), Univ Oxford, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clinkal Neurosci, Oxford OX3 9DU, England.	peter.rothwell@ndcn.ox.ac.uk	Howard, Dominic/AAX-1890-2020	Howard, Dominic/0000-0001-7564-436X	NIHR Oxford Biomedical Research Centre; Wellcome Trust; Wolfson Foundation; British Heart Foundation	NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); Wolfson Foundation; British Heart Foundation(British Heart Foundation)	NIHR Oxford Biomedical Research Centre, Wellcome Trust, Wolfson Foundation, and the British Heart Foundation.	Abbott AL, 2009, STROKE, V40, pE573, DOI 10.1161/STROKEAHA.109.556068; [Anonymous], 1995, J Neurol Sci, V129, P76; Caplan LR, 2006, CEREBROVASC DIS, V21, P145, DOI 10.1159/000090791; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; Cuffe RL, 2006, STROKE, V37, P1785, DOI 10.1161/01.STR.0000227231.85653.ea; de Weerd M, 2009, STROKE, V40, P1105, DOI 10.1161/STROKEAHA.108.532218; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Glousman BN, 2020, J VASC SURG, V71, P518, DOI 10.1016/j.jvs.2019.05.054; Hadar N, 2014, CEREBROVASC DIS, V38, P163, DOI 10.1159/000365206; Halliday A, 2004, LANCET, V363, P1491; Halliday A, 2010, LANCET, V376, P1074, DOI 10.1016/S0140-6736(10)61197-X; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Keyhani S, 2020, JAMA NEUROL, V77, P1110, DOI 10.1001/jamaneurol.2020.1427; Meschia JF, 2014, STROKE, V45, P3754, DOI 10.1161/STR.0000000000000046; Naylor AR, 2018, EUR J VASC ENDOVASC, V55, P3, DOI 10.1016/j.ejvs.2017.06.021; Naylor AR, 2017, CURR OPIN NEUROL, V30, P15, DOI 10.1097/WCO.0000000000000408; Naylor AR, 2011, STROKE, V42, P2080, DOI 10.1161/STROKEAHA.110.597708; NICE, 2008, CG38 NICE; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; Oates CP, 2009, EUR J VASC ENDOVASC, V37, P251, DOI 10.1016/j.ejvs.2008.10.015; OHOLLERAN LW, 1987, AM J SURG, V154, P659, DOI 10.1016/0002-9610(87)90238-8; Otite FO, 2018, JAMA NEUROL, V75, P51, DOI 10.1001/jamaneurol.2017.3496; ROTHWELL PM, 1994, STROKE, V25, P2440, DOI 10.1161/01.STR.25.12.2440; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Rothwell PM, 2000, J NEUROL, V247, P825, DOI 10.1007/s004150070068; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Vikatmaa P, 2012, EUR J VASC ENDOVASC, V44, P11, DOI 10.1016/j.ejvs.2012.04.013; von Reutern GM, 2012, STROKE, V43, P916, DOI 10.1161/STROKEAHA.111.636084	35	45	44	8	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					193	202		10.1016/S1474-4422(20)30484-1	http://dx.doi.org/10.1016/S1474-4422(20)30484-1			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609477	hybrid, Green Published			2022-12-18	WOS:000620258400019
J	AbdelRazek, MA; Venna, N; Stone, JH				AbdelRazek, Mahmoud A.; Venna, Nagagopal; Stone, John H.			IgG4-related disease of the central and peripheral nervous systems	LANCET NEUROLOGY			English	Review							NATIONWIDE EPIDEMIOLOGIC SURVEY; CYTOTOXIC T-LYMPHOCYTES; AUTOIMMUNE PANCREATITIS; OPTIC-NERVE; PACHYMENINGITIS; HYPOPHYSITIS; FEATURES; MANIFESTATION; PREVALENCE; PITUITARY	IgG4-related disease can involve nearly any organ system, including the central and peripheral nervous systems. The pathology findings are consistent from organ to organ, but careful clinicopathological correlation is necessary to establish the diagnosis. Many non-neurological and neurological inflammatory conditions, previously regarded as idiopathic in nature, are now recognised to fall within the spectrum of IgG4-related disease. The condition is highly treatable, but probably remains substantially under-recognised. In this Review, we offer an important and timely update on the current and emerging aspects of this neurological disease. Following a short overview of IgG4-related disease, we describe the current understanding of neurological findings, pathophysiology, approaches to diagnosis, and treatment of IgG4-related disease affecting the central and peripheral nervous systems.	[AbdelRazek, Mahmoud A.; Venna, Nagagopal] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Stone, John H.] Massachusetts Gen Hosp, Rheumatol Clin, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Stone, JH (corresponding author), Massachusetts Gen Hosp, Rheumatol Clin, Boston, MA 02114 USA.	jhstone@mgh.harvard.edu	AbdelRazek, Mahmoud/AAL-3887-2021	AbdelRazek, Mahmoud/0000-0002-2391-3502				Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Aihara Y, 2013, JPN J OPHTHALMOL, V57, P573, DOI 10.1007/s10384-013-0266-4; Alt JA, 2012, ALLERGY RHINOL, V3, pE41, DOI 10.2500/ar.2012.3.0026; Bando H, 2014, EUR J ENDOCRINOL, V170, P161, DOI 10.1530/EJE-13-0642; Behbehani RS, 2015, J NEURO-OPHTHALMOL, V35, P229, DOI 10.1097/WNO.0000000000000227; Caputo C, 2014, PITUITARY, V17, P251, DOI 10.1007/s11102-013-0498-9; Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605; Caturegli P, 2008, AUTOIMMUN REV, V7, P631, DOI 10.1016/j.autrev.2008.04.016; Cheuk W, 2012, SEMIN DIAGN PATHOL, V29, P226, DOI 10.1053/j.semdp.2012.07.001; Cho HK, 2011, CLIN EXP OTORHINOLAR, V4, P52, DOI 10.3342/ceo.2011.4.1.52; Della Torre E, 2014, ALLERGY, V69, P269, DOI 10.1111/all.12320; Della-Torre E, 2014, J NEUROIMMUNOL, V266, P82, DOI 10.1016/j.jneuroim.2013.10.008; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Ezzeldin M, 2014, J NEUROL SCI, V347, P398, DOI 10.1016/j.jns.2014.10.012; Fujii M, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-41; Gu R, 2016, EUR SPINE J, V25, pS147, DOI 10.1007/s00586-015-4251-0; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Hao MJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003785; Hattori Y, 2013, J CLIN ENDOCR METAB, V98, P1808, DOI 10.1210/jc.2013-1088; Hiraga A, 2015, J NEUROL SCI, V357, P338, DOI 10.1016/j.jns.2015.07.048; Huijbers MG, 2015, EUR J NEUROL, V22, P1151, DOI 10.1111/ene.12758; Inoue D, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/401890; Inoue D, 2009, RADIOLOGY, V251, P260, DOI 10.1148/radiol.2511080965; Irani SR, 2012, ANN NEUROL, V72, P241, DOI 10.1002/ana.23577; Kamisawa T, 2003, J GASTROENTEROL, V38, P982, DOI 10.1007/s00535-003-1175-y; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; Kamisawa T, 2010, NAT REV GASTRO HEPAT, V7, P401, DOI 10.1038/nrgastro.2010.81; Kanno A, 2015, PANCREAS, V44, P535, DOI 10.1097/MPA.0000000000000325; Kanno A, 2012, PANCREAS, V41, P835, DOI 10.1097/MPA.0b013e3182480c99; Katsura M, 2012, NEURORADIOLOGY, V54, P873, DOI 10.1007/s00234-012-1012-1; Khosroshahi A, 2015, ARTHRITIS RHEUMATOL, V67, P1688, DOI 10.1002/art.39132; Khosroshahi A, 2013, MEDICINE, V92, P82, DOI 10.1097/MD.0b013e318289610f; Khosroshahi A, 2010, ARTHRITIS RHEUM-US, V62, P1755, DOI 10.1002/art.27435; Kim EH, 2011, J NEUROSURG, V115, P1242, DOI 10.3171/2011.7.JNS1166; Klooster R, 2012, BRAIN, V135, P1081, DOI 10.1093/brain/aws025; Koneczny I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080695; Li LF, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.035; Lindstrom KM, 2010, ACTA NEUROPATHOL, V120, P765, DOI 10.1007/s00401-010-0746-2; Lu LX, 2014, JAMA NEUROL, V71, P785, DOI 10.1001/jamaneurol.2014.243; Lui PCW, 2009, HUM PATHOL, V40, P1611, DOI 10.1016/j.humpath.2009.04.016; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Mattoo H, 2014, J ALLERGY CLIN IMMUN, V134, P679, DOI 10.1016/j.jaci.2014.03.034; Mehta SH, 2014, NEUROLOGY, V82, P540, DOI 10.1212/WNL.0000000000000100; Norikane T, 2012, CLIN NUCL MED, V37, P108, DOI 10.1097/RLU.0b013e31823933c1; Ohshima K, 2012, JPN J OPHTHALMOL, V56, P380, DOI 10.1007/s10384-012-0151-6; Ohyama K, 2015, NEUROLOGY, V85, P1400, DOI 10.1212/WNL.0000000000002039; Ohyama K, 2013, JAMA NEUROL, V70, P502, DOI 10.1001/jamaneurol.2013.658; Perugino CA, 2016, Z RHEUMATOL, V75, P681, DOI 10.1007/s00393-016-0142-y; Plaza JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P421, DOI 10.1001/archophthalmol.2011.16; Querol L, 2014, NEUROLOGY, V82, P879, DOI 10.1212/WNL.0000000000000205; Querol L, 2013, ANN NEUROL, V73, P370, DOI 10.1002/ana.23794; Radotra BD, 2016, J NEUROSURG-SPINE, V25, P790, DOI 10.3171/2016.4.SPINE1674; Regev K, 2014, JAMA NEUROL, V71, P767, DOI 10.1001/jamaneurol.2014.40; Saeki T, 2010, KIDNEY INT, V78, P1016, DOI 10.1038/ki.2010.271; Sato Y, 2008, PATHOL INT, V58, P465, DOI 10.1111/j.1440-1827.2008.02257.x; Shimatsu A, 2009, ENDOCR J, V56, P1033, DOI 10.1507/endocrj.K09E-277; Soussan JB, 2016, EUR RADIOL, V27, P1335; Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Takahashi H, 2014, JOINT BONE SPINE, V81, P331, DOI 10.1016/j.jbspin.2014.01.010; Takahashi M, 2011, AM J MED SCI, V341, P166, DOI 10.1097/MAJ.0b013e3181fbb6f2; Tiegs-Heiden CA, 2014, AM J NEURORADIOL, V35, P1393, DOI 10.3174/ajnr.A3865; Toyoda K, 2012, AM J NEURORADIOL, V33, P2136, DOI 10.3174/ajnr.A3147; Uchida K, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/358371; Wallace ZS, 2015, ARTHRITIS RHEUMATOL, V67, P2466, DOI 10.1002/art.39205; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Wallace ZS, 2014, SEMIN ARTHRITIS RHEU, V43, P806, DOI 10.1016/j.semarthrit.2013.11.008; Wallace ZS, 2013, MEDICINE, V92, P206, DOI 10.1097/MD.0b013e31829cce35; Wick CC, 2016, AM J OTOLARYNG, V37, P567, DOI 10.1016/j.amjoto.2016.08.005; Williams Thomas, 2016, Pract Neurol, V16, P235, DOI 10.1136/practneurol-2015-001275; Wong S, 2007, HUM PATHOL, V38, P1720, DOI 10.1016/j.humpath.2007.06.011; Wu A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0530-4; Yamamoto Motohisa, 2006, Mod Rheumatol, V16, P335; Zwicker J, 2014, CAN J NEUROL SCI, V41, P392, DOI 10.1017/S0317167100017364	76	45	46	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					183	192		10.1016/S1474-4422(17)30471-4	http://dx.doi.org/10.1016/S1474-4422(17)30471-4			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29413316				2022-12-18	WOS:000422828500016
J	McDonagh, DL; Berger, M; Mathew, JP; Graffagnino, C; Milano, CA; Newman, MF				McDonagh, David L.; Berger, Miles; Mathew, Joseph P.; Graffagnino, Carmelo; Milano, Carmelo A.; Newman, Mark F.			Neurological complications of cardiac surgery	LANCET NEUROLOGY			English	Review							CORONARY-ARTERY-BYPASS; POSTOPERATIVE COGNITIVE DYSFUNCTION; NEAR-INFRARED SPECTROSCOPY; ACUTE ISCHEMIC-STROKE; THORACIC EPIDURAL-ANESTHESIA; LEFT ATRIAL APPENDAGE; 5-YEAR FOLLOW-UP; CARDIOPULMONARY BYPASS; GRAFT-SURGERY; OFF-PUMP	As increasing numbers of elderly people undergo cardiac surgery, neurologists are frequently called upon to assess patients with neurological complications from the procedure. Some complications mandate acute intervention, whereas others need longer term observation and management. A large amount of published literature exists about these complications and guidance on best practice is constantly changing. Similarly, despite technological advances in surgical intervention and modifications in surgical technique to make cardiac procedures safer, these advances often create new avenues for neurological injury. Accordingly, rapid and precise neurological assessment and therapeutic intervention rests on a solid understanding of the evidence base and procedural variables.	[McDonagh, David L.; Berger, Miles; Mathew, Joseph P.; Newman, Mark F.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [McDonagh, David L.; Graffagnino, Carmelo] Duke Univ, Med Ctr, Dept Neurol, Durham, NC 27710 USA; [Milano, Carmelo A.] Duke Univ, Med Ctr, Dept Surg, Div Cardiovasc & Thorac Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University	McDonagh, DL (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, DUMC Box 3094, Durham, NC 27710 USA.	david.mcdonagh@duke.edu	Berger, Miles/B-8648-2015	Berger, Miles/0000-0002-2386-5061; Mathew, Joseph/0000-0002-3815-4131	Duke University Department of Anesthesiology; National Institutes of Health (Washington, DC, USA) [HL096978, HL108280, HL109971]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL109971, R21HL108280, R01HL096978] Funding Source: NIH RePORTER	Duke University Department of Anesthesiology; National Institutes of Health (Washington, DC, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the Duke University Department of Anesthesiology and was supported in part by grants HL096978, HL108280, and HL109971 (to JPM) from the National Institutes of Health (Washington, DC, USA). We thank Kathy Gage (Department of Anesthesiology Duke University, NC, USA) for editorial assistance.	Alam M, 2013, AM J CARDIOL, V112, P615, DOI 10.1016/j.amjcard.2013.04.034; Alhan CH, 2012, EUR J CARDIO-THORAC, V41, P1213, DOI 10.1093/ejcts/ezr172; Arenson BG, 2013, J THORAC CARDIOV SUR, V146, P172, DOI 10.1016/j.jtcvs.2012.12.042; Aronson S, 2011, ANESTH ANALG, V113, P19, DOI 10.1213/ANE.0b013e31820f9231; Arsenault KA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003611.pub3; Avidan MS, 2011, J ALZHEIMERS DIS, V24, P201, DOI 10.3233/JAD-2011-101680; Bainbridge D, 2005, SEMIN CARDIOTHORAC V, V9, P105, DOI 10.1177/108925320500900110; Bakker RC, 2012, EUR J CARDIO-THORAC, V41, P544, DOI 10.1093/ejcts/ezr031; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Barreto JA, 2013, JAMA-J AM MED ASSOC, V310, P2078, DOI 10.1001/jama.2013.282437; BEDFORD PD, 1955, LANCET, V2, P259; Bonow Robert O, 2008, Circulation, V118, pe523, DOI 10.1161/CIRCULATIONAHA.108.190748; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Bucerius J, 2003, ANN THORAC SURG, V75, P472, DOI 10.1016/S0003-4975(02)04370-9; Budera P, 2012, EUR HEART J, V33, P2644, DOI 10.1093/eurheartj/ehs290; Buse GALL, 2012, CIRCULATION, V126, P2696, DOI 10.1161/CIRCULATIONAHA.112.126144; Butterworth J, 2005, J THORAC CARDIOV SUR, V130, P1319, DOI 10.1016/j.jtcvs.2005.02.049; Charlson ME, 2007, J CARDIAC SURG, V22, P465, DOI 10.1111/j.1540-8191.2007.00471.x; Collard CD, 2006, J THORAC CARDIOV SUR, V132, P392, DOI 10.1016/j.jtcvs.2006.04.009; Cook DJ, 2007, ANN THORAC SURG, V83, P1389, DOI 10.1016/j.athoracsur.2006.11.089; Cox JL, 2013, J THORAC CARDIOV SUR, V146, P1018, DOI 10.1016/j.jtcvs.2013.07.011; Davis MJ, 2012, ANESTHESIOLOGY, V116, P396, DOI 10.1097/ALN.0b013e318242a5d2; de la Torre JC, 2012, J ALZHEIMERS DIS, V32, P553, DOI 10.3233/JAD-2012-120793; Deb S, 2013, JAMA-J AM MED ASSOC, V310, P2086, DOI 10.1001/jama.2013.281718; Desai CS, 2012, JAMA-J AM MED ASSOC, V308, P573, DOI 10.1001/jama.2012.9427; Duraes AR, 2012, NEW ENGL J MED, V367, pE24, DOI 10.1056/NEJMicm1211164; ElBardissi AW, 2012, J THORAC CARDIOV SUR, V143, P273, DOI 10.1016/j.jtcvs.2011.10.029; Evered L, 2011, ANESTH ANALG, V112, P1179, DOI 10.1213/ANE.0b013e318215217e; Fairbairn TA, 2012, HEART, V98, P18, DOI 10.1136/heartjnl-2011-300065; Farkouh ME, 2012, NEW ENGL J MED, V367, P2375, DOI 10.1056/NEJMoa1211585; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; Finfer S, 2012, NEW ENGL J MED, V367, P1108, DOI 10.1056/NEJMoa1204942; Fontes MT, 2013, ANESTH ANALG, V116, P435, DOI 10.1213/ANE.0b013e318273f37e; Gamberini M, 2009, CRIT CARE MED, V37, P1762, DOI 10.1097/CCM.0b013e31819da780; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Georgiadis D, 2000, J THORAC CARDIOV SUR, V119, P138, DOI 10.1016/S0022-5223(00)70229-7; Gerriets T, 2010, AM J CARDIOL, V105, P1095, DOI 10.1016/j.amjcard.2009.12.009; Ghosh A, 2012, ANESTH ANALG, V115, P1373, DOI 10.1213/ANE.0b013e31826dd6a6; GILMAN S, 1965, NEW ENGL J MED, V272, P489, DOI 10.1056/NEJM196503112721001; Glas KE, 2008, ANESTH ANALG, V106, P1376, DOI 10.1213/ane.0b013e31816a6b4c; GOLD JP, 1995, J THORAC CARDIOV SUR, V110, P1302, DOI 10.1016/S0022-5223(95)70053-6; Gopaldas RR, 2011, ANN THORAC SURG, V91, P1323, DOI 10.1016/j.athoracsur.2011.02.053; Grigore AM, 2009, ANESTH ANALG, V109, P1741, DOI 10.1213/ANE.0b013e3181c04fea; Grigore AM, 2001, ANESTHESIOLOGY, V95, P1110, DOI 10.1097/00000542-200111000-00014; Barrera JG, 2013, J VASC SURG, V57, p58S, DOI 10.1016/j.jvs.2012.06.116; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hakim SM, 2012, ANESTHESIOLOGY, V116, P987, DOI 10.1097/ALN.0b013e31825153cc; Hatano Y, 2013, AM J GERIAT PSYCHIAT, V21, P938, DOI 10.1016/j.jagp.2013.01.061; Hedberg M, 2011, EUR J CARDIO-THORAC, V40, P379, DOI 10.1016/j.ejcts.2010.11.060; Hillis LD, 2011, CIRCULATION, V124, pE652, DOI 10.1161/CIR.0b013e31823c074e; Hipp DM, 2012, NEUROTHERAPEUTICS, V9, P158, DOI 10.1007/s13311-011-0102-9; Hlatky MA, 2009, LANCET, V373, P1190, DOI 10.1016/S0140-6736(09)60552-3; Ho KM, 2011, CARDIOVASC THER, V29, P260, DOI 10.1111/j.1755-5922.2009.00114.x; Holinski S, 2011, ANN THORAC CARDIOVAS, V17, P137, DOI 10.5761/atcs.oa.10.01545; Holzer M, 2002, NEW ENGL J MED, V346, P549; Houlind K, 2012, CIRCULATION, V125, P2431, DOI 10.1161/CIRCULATIONAHA.111.052571; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Karkouti K, 2005, ANN THORAC SURG, V80, P1381, DOI 10.1016/j.athoracsur.2005.03.137; Kennedy ED, 2013, J CARDIOTHOR VASC AN, V27, P253, DOI 10.1053/j.jvca.2012.11.008; Kertai MD, 2012, ANESTH ANALG, V114, P533, DOI 10.1213/ANE.0b013e31823ee030; Knipp SC, 2004, EUR J CARDIO-THORAC, V25, P791, DOI 10.1016/j.ejcts.2004.02.012; Kodali SK, 2012, NEW ENGL J MED, V366, P1686, DOI 10.1056/NEJMoa1200384; Koster S, 2012, ANN THORAC SURG, V93, P705, DOI 10.1016/j.athoracsur.2011.07.006; Kuhn EW, 2014, EUR J CARDIO-THORAC, V45, P17, DOI 10.1093/ejcts/ezt181; Lamy A, 2013, NEW ENGL J MED, V368, P1179, DOI 10.1056/NEJMoa1301228; Lamy A, 2012, NEW ENGL J MED, V366, P1489, DOI 10.1056/NEJMoa1200388; Lazar HL, 2011, ANN SURG, V254, P458, DOI 10.1097/SLA.0b013e31822c5d78; Lee EJ, 2011, J AM COLL CARDIOL, V57, P1811, DOI 10.1016/j.jacc.2010.12.026; Levine GN, 2011, J AM COLL CARDIOL, V58, pE44, DOI 10.1016/j.jacc.2011.08.007; Liakopoulos OJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008493.pub2; Likosky DS, 2003, ANN THORAC SURG, V76, P428, DOI 10.1016/S0003-4975(03)00490-9; Liu YH, 2009, ANESTH ANALG, V109, P1013, DOI 10.1213/ane.0b013e3181aed2bb; Mackensen GB, 2009, J NEUROTRAUM, V26, P341, DOI 10.1089/neu.2008.0596; Mangano DT, 2002, NEW ENGL J MED, V347, P1309; Mariani J, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.005033; Marshall RS, 2012, J ALZHEIMERS DIS, V32, P633, DOI 10.3233/JAD-2012-120949; Mathew JP, 2007, ANESTHESIOLOGY, V107, P577, DOI 10.1097/01.anes.0000281896.07256.71; Mathew JP, 2007, J AM COLL CARDIOL, V49, P1934, DOI 10.1016/j.jacc.2007.01.080; Mathew JP, 2013, STROKE, V44, P3407, DOI 10.1161/STROKEAHA.113.002703; Mathew JP, 2009, STROKE, V40, P880, DOI 10.1161/STROKEAHA.108.531236; Mathew JP, 2006, ANN THORAC SURG, V81, P1644, DOI 10.1016/j.athoracsur.2005.12.070; Mauermann WJ, 2006, ANESTH ANALG, V103, P1018, DOI 10.1213/01.ane.0000237267.75543.59; Medi C, 2013, J AM COLL CARDIOL, V62, P531, DOI 10.1016/j.jacc.2013.03.073; Merino JG, 2013, AM J NEURORADIOL, V34, P518, DOI 10.3174/ajnr.A3251; Messerotti Benvenuti S, 2012, PERFUSION-UK, V27, P486, DOI 10.1177/0267659112453475; Messerotti Benvenuti S, 2012, PSYCHOSOM MED, V74, P73, DOI 10.1097/PSY.0b013e3182383a94; Meybohm P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064743; Mikkelsen ME, 2013, CRIT CARE MED, V41, P1385, DOI 10.1097/CCM.0b013e318287f2c4; Mirow N, 2011, J CARDIOVASC SURG, V52, P117; Moazami N, 2001, ANN THORAC SURG, V72, P1933, DOI 10.1016/S0003-4975(01)03030-2; Mohr FW, 2013, LANCET, V381, P629, DOI 10.1016/S0140-6736(13)60141-5; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Mozaffarian D, 2012, JAMA-J AM MED ASSOC, V308, P2001, DOI 10.1001/jama.2012.28733; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; Nathan HJ, 2007, J THORAC CARDIOV SUR, V133, P1206, DOI 10.1016/j.jtcvs.2006.09.112; Naylor AR, 2011, EUR J VASC ENDOVASC, V41, P607, DOI 10.1016/j.ejvs.2011.02.016; Newman MF, 2012, JAMA-J AM MED ASSOC, V308, P157, DOI 10.1001/jama.2012.7633; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9; Ono M, 2012, BRIT J ANAESTH, V109, P391, DOI 10.1093/bja/aes148; Ono M, 2014, J THORAC CARDIOV SUR, V147, P483, DOI 10.1016/j.jtcvs.2013.07.069; Ono M, 2013, ANESTH ANALG, V116, P198, DOI 10.1213/ANE.0b013e318271fb10; Osse RJ, 2012, J AM GERIATR SOC, V60, P661, DOI 10.1111/j.1532-5415.2011.03885.x; Palotas A, 2010, J ALZHEIMERS DIS, V21, P1153, DOI 10.3233/JAD-2010-100702; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Phillips-Bute B, 2006, PSYCHOSOM MED, V68, P369, DOI 10.1097/01.psy.0000221272.77984.e2; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Prakanrattana U, 2007, ANAESTH INTENS CARE, V35, P714, DOI 10.1177/0310057X0703500509; Puskas F, 2007, ANN THORAC SURG, V84, P1467, DOI 10.1016/j.athoracsur.2007.06.023; Reddy VY, 2013, CIRCULATION, V127, P720, DOI 10.1161/CIRCULATIONAHA.112.114389; Reinsfelt B, 2012, ANN THORAC SURG, V94, P549, DOI 10.1016/j.athoracsur.2012.04.044; Reis HJ, 2011, CURR MED CHEM, V18, P1019; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rudolph JL, 2010, ACTA ANAESTH SCAND, V54, P663, DOI 10.1111/j.1399-6576.2010.02236.x; Rudolph JL, 2008, J GERONTOL A-BIOL, V63, P184, DOI 10.1093/gerona/63.2.184; Rudolph JL, 2009, CIRCULATION, V119, P229, DOI 10.1161/CIRCULATIONAHA.108.795260; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1; Selnes OA, 2012, NEW ENGL J MED, V366, P250, DOI 10.1056/NEJMra1100109; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626; Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783; Shi QY, 2013, NEUROPSYCH DIS TREAT, V9, P1359, DOI 10.2147/NDT.S49520; Shishehbor MH, 2013, J AM COLL CARDIOL, V62, P1948, DOI 10.1016/j.jacc.2013.03.094; Siepe M, 2011, EUR J CARDIO-THORAC, V40, P200, DOI 10.1016/j.ejcts.2010.11.024; Silbert BS, 2008, ANN THORAC SURG, V86, P841, DOI 10.1016/j.athoracsur.2008.04.085; Slater JP, 2009, ANN THORAC SURG, V87, P36, DOI 10.1016/j.athoracsur.2008.08.070; Song SS, 2012, CURR TREAT OPTION NE, V14, P541, DOI 10.1007/s11940-012-0201-x; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Subramaniam B, 2014, ANESTH ANALG, V118, P277, DOI 10.1213/ANE.0000000000000100; Sun XM, 2012, J AM COLL CARDIOL, V60, P791, DOI 10.1016/j.jacc.2012.02.079; Svircevic V, 2011, ANESTHESIOLOGY, V114, P262, DOI 10.1097/ALN.0b013e318201d2de; Svircevic V, 2011, ANESTHESIOLOGY, V114, P271, DOI 10.1097/ALN.0b013e318201d300; Sweet JJ, 2008, ANN THORAC SURG, V85, P1571, DOI 10.1016/j.athoracsur.2008.01.090; Tarakji KG, 2011, JAMA-J AM MED ASSOC, V305, P381, DOI 10.1001/jama.2011.37; Timaran CH, 2008, J VASC SURG, V48, P355, DOI 10.1016/j.jvs.2008.03.031; U.S. Food and Drug Administration, DEV FDA; Vacas S, 2013, BRIT MED BULL, V106, P161, DOI 10.1093/bmb/ldt006; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7; Vollroth M, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-190; Wahrborg P, 2004, CIRCULATION, V110, P3411, DOI 10.1161/01.CIR.0000148366.80443.2B; Webb JG, 2012, CIRCULATION, V126, P1567, DOI 10.1161/CIRCULATIONAHA.112.136796; Weintraub WS, 2012, NEW ENGL J MED, V366, P1467, DOI 10.1056/NEJMoa1110717; Zheng F, 2013, ANESTH ANALG, V116, P663, DOI 10.1213/ANE.0b013e318277a255	146	45	51	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2014	13	5					490	502		10.1016/S1474-4422(14)70004-3	http://dx.doi.org/10.1016/S1474-4422(14)70004-3			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG0LX	24703207	Green Accepted			2022-12-18	WOS:000335108100015
J	[Anonymous]				[Anonymous]			Traumatic brain injury: time to end the silence	LANCET NEUROLOGY			English	Editorial Material																			0	45	46	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					331	331		10.1016/S1474-4422(10)70069-7	http://dx.doi.org/10.1016/S1474-4422(10)70069-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA	20298955				2022-12-18	WOS:000276142000001
J	Barker, RA				Barker, RA			Continuing trials of GDNF in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							NEUROTROPHIC FACTOR; INFUSION; BRAIN		Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge, England; Univ Cambridge, Dept Clin Neurosci, Dept Neurol, Cambridge, England	University of Cambridge; University of Cambridge	Barker, RA (corresponding author), Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge, England.	rab46@cam.ac.uk		Barker, Roger Alistair/0000-0001-8843-7730				Foltynie T, 2004, BRAIN, V127, P550, DOI 10.1093/brain/awh067; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Hurelbrink CB, 2004, EXP NEUROL, V185, P1, DOI 10.1016/j.expneurol.2003.09.018; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Love S, 2005, NAT MED, V11, P703, DOI 10.1038/nm0705-703; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69	6	45	48	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					285	286		10.1016/S1474-4422(06)70386-6	http://dx.doi.org/10.1016/S1474-4422(06)70386-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI	16545740				2022-12-18	WOS:000236535200003
J	Bar-Or, A; Li, R				Bar-Or, Amit; Li, Rui			Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances	LANCET NEUROLOGY			English	Review							INVARIANT T-CELLS; B-CELLS; CRITICAL REGULATORS; TARGET ANTIGENS; TISSUE-REPAIR; MAIT CELLS; ACTIVATION; AUTOIMMUNE; MONOCYTES; SUBSETS	Novel insights from basic and translational studies are reshaping concepts of the immunopathogenesis of multiple sclerosis and understanding of the different inflammatory responses throughout the disease course. Previously, the cellular immunology of relapsing multiple sclerosis was considered to be principally T-cell driven; however, this process is now understood to involve multiple cell types and their functionally distinct subsets. Particularly, relapsing multiple sclerosis appears to involve imbalanced interactions between T cells, myeloid cells, B cells, and their effector and regulatory subpopulations. The major contributors to such imbalances differ across patients. Several emerging techniques enable comprehensive immune cell profiling at the single-cell level, revealing substantial functional heterogeneity and plasticity that could influence disease state and response to treatment. Findings from clinical trials with agents that successfully limit new multiple sclerosis disease activity and trials of agents that inadvertently exacerbate CNS inflammation have helped to elucidate disease mechanisms, better define the relevant modes of action of current immune therapies, and pave the way for new therapeutic strategies.	[Bar-Or, Amit; Li, Rui] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Perelman Sch Med, Dept Neurol,Multiple Sclerosis Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Bar-Or, A (corresponding author), Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Perelman Sch Med, Dept Neurol,Multiple Sclerosis Div, Philadelphia, PA 19104 USA.	amitbar@pennmedidne.upenn.edu	Li, Rui/O-7397-2016; Bar-Or, Amit/AIC-1416-2022	Li, Rui/0000-0002-7210-8358; 				Baecher-Allan C, 2018, NEURON, V97, P742, DOI 10.1016/j.neuron.2018.01.021; Balint B, 2013, NEUROLOGY, V81, P784, DOI 10.1212/WNL.0b013e3182a2ce0e; Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Bar-Or A, 2018, NEUROLOGY, V90, pE1805, DOI 10.1212/WNL.0000000000005516; Bar-Or A, 2010, ANN NEUROL, V67, P452, DOI 10.1002/ana.21939; Baranzini SE, 2017, TRENDS GENET, V33, P960, DOI 10.1016/j.tig.2017.09.004; Barkhof Frederik, 2019, Neurology, V93, pe1778, DOI 10.1212/WNL.0000000000008189; Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675; Bassler K, 2019, ANNU REV IMMUNOL, V37, P269, DOI 10.1146/annurev-immunol-042718-041728; Beltran E, 2019, J CLIN INVEST, V129, P4758, DOI 10.1172/JCI128475; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Brandle SM, 2016, P NATL ACAD SCI USA, V113, P7864, DOI 10.1073/pnas.1522730113; Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035; Cancro MP, 2020, ANNU REV IMMUNOL, V38, P315, DOI 10.1146/annurev-immunol-092419-031130; Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038; Carolan E, 2015, J IMMUNOL, V194, P5775, DOI 10.4049/jimmunol.1402945; Chuluundorj D, 2014, IMMUNOL CELL BIOL, V92, P509, DOI 10.1038/icb.2014.15; Claes N, 2016, J IMMUNOL, V197, P4576, DOI 10.4049/jimmunol.1502448; Dhaeze T, 2015, J IMMUNOL, V195, P832, DOI 10.4049/jimmunol.1500759; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Dong YF, 2019, NAT REV NEUROL, V15, P704, DOI 10.1038/s41582-019-0253-6; Duddy M, 2007, J IMMUNOL, V178, P6092, DOI 10.4049/jimmunol.178.10.6092; Duffy SS, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01107; Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4; Fransen NL, 2020, BRAIN, V143, P1714, DOI 10.1093/brain/awaa117; Galli E, 2019, NAT MED, V25, P1290, DOI 10.1038/s41591-019-0521-4; Gaublomme JT, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.009; Gerdes LA, 2020, P NATL ACAD SCI USA, V117, P21546, DOI 10.1073/pnas.2003339117; Gerhards R, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01086-2; Gjelstrup MC, 2018, IMMUNOL CELL BIOL, V96, P160, DOI 10.1111/imcb.1025; Godfrey DI, 2019, NAT IMMUNOL, V20, P1110, DOI 10.1038/s41590-019-0444-8; Guerrier T, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000431; Guo J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00944; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2020, NEW ENGL J MED, V383, P546, DOI 10.1056/NEJMoa1917246; Held K, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000107; Hinks TSC, 2019, CELL REP, V28, P3249, DOI 10.1016/j.celrep.2019.07.039; Hohlfeld R, 2016, LANCET NEUROL, V15, P317, DOI 10.1016/S1474-4422(15)00313-0; Hohlfeld R, 2016, LANCET NEUROL, V15, P198, DOI 10.1016/S1474-4422(15)00334-8; Hu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01571-8; Ifergan I, 2011, BRAIN, V134, P3557, DOI 10.1093/brain/awr268; Jelcic I, 2018, CELL, V175, P85, DOI 10.1016/j.cell.2018.08.011; Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035; Kim YC, 2018, J AUTOIMMUN, V92, P77, DOI 10.1016/j.jaut.2018.05.003; Klotz L, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aao5563; Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665; Lassmann H, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028936; Leng TQ, 2019, CELL REP, V28, P3077, DOI 10.1016/j.celrep.2019.08.050; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Li R, 2018, NAT IMMUNOL, V19, P696, DOI 10.1038/s41590-018-0135-x; Li R, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a029108; Li R, 2017, J IMMUNOL, V198, P3245, DOI 10.4049/jimmunol.1601572; Li R, 2017, J IMMUNOL, V198, P691, DOI 10.4049/jimmunol.1601649; Li R, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00626; Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176; Lloyd AF, 2019, NAT REV NEUROL, V15, P447, DOI 10.1038/s41582-019-0184-2; Lucca LE, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124427; Machado-Santos J, 2018, BRAIN, V141, P2066, DOI 10.1093/brain/awy151; Madireddy L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09773-y; Martin Elodie, 2020, Brain Plast, V5, P123, DOI 10.3233/BPL-200100; Meng XY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02683-x; Mexhitaj I, 2019, BRAIN, V142, P617, DOI 10.1093/brain/awz017; Michel L, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw0475; Mishra MK, 2016, NAT REV NEUROL, V12, P539, DOI 10.1038/nrneurol.2016.110; Miyazaki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105421; Miyazaki Y, 2011, INT IMMUNOL, V23, P529, DOI 10.1093/intimm/dxr047; Montalban X, 2019, NEW ENGL J MED, V380, P2406, DOI 10.1056/NEJMoa1901981; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Obermeier B, 2008, NAT MED, V14, P688, DOI 10.1038/nm1714; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Peeters LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01160; Planas R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4301; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Rojas OL, 2019, CELL, V177, P492, DOI 10.1016/j.cell.2019.03.037; Sabatino JJ, 2019, P NATL ACAD SCI USA, V116, P25800, DOI 10.1073/pnas.1915309116; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Saligrama N, 2019, NATURE, V572, P481, DOI 10.1038/s41586-019-1467-x; Salou M, 2016, CLIN IMMUNOL, V166, P1, DOI 10.1016/j.clim.2016.03.014; Saxena A, 2008, J IMMUNOL, V181, P1617, DOI 10.4049/jimmunol.181.3.1617; Schneider A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004970; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089; Segal BM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010120; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Sorensen PS, 2020, CURR OPIN NEUROL, V33, P262, DOI 10.1097/WCO.0000000000000811; Steinman L, 2014, ANNU REV IMMUNOL, V32, P257, DOI 10.1146/annurev-immunol-032713-120227; Sumida T, 2018, NAT IMMUNOL, V19, P1391, DOI 10.1038/s41590-018-0236-6; Tintore M, 2019, NAT REV NEUROL, V15, P53, DOI 10.1038/s41582-018-0082-z; van der Poel M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08976-7; van Langelaar J, 2019, ANN NEUROL, V86, P264, DOI 10.1002/ana.25508; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; von Essen MR, 2019, BRAIN, V142, P120, DOI 10.1093/brain/awy301; Wang J, 2020, CELL, V183, P1264, DOI 10.1016/j.cell.2020.09.054; Waschbisch A, 2016, J IMMUNOL, V196, P1558, DOI 10.4049/jimmunol.1501960; Willing A, 2018, J IMMUNOL, V200, P974, DOI 10.4049/jimmunol.1701213; Wing JB, 2019, IMMUNITY, V50, P302, DOI 10.1016/j.immuni.2019.01.020; Zheng YX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00914; Zrzavy T, 2017, BRAIN, V140, P1900, DOI 10.1093/brain/awx113	101	44	44	12	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					470	483		10.1016/S1474-4422(21)00063-6	http://dx.doi.org/10.1016/S1474-4422(21)00063-6		MAY 2021	14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	33930317				2022-12-18	WOS:000653434700017
J	Mazighi, M; Richard, S; Lapergue, B; Sibon, I; Gory, B; Berge, J; Consoli, A; Labreuche, J; Olivot, JM; Broderick, J; Duhamel, A; Touze, E; Qureshi, AI; Yavchitz, A; Escalard, S; Desilles, JP; Redjem, H; Smajda, S; Fahed, R; Hebert, S; Maier, B; Delvoye, F; Boursin, P; Maacha, MB; Obadia, M; Sabben, C; Blanc, R; Savatovsky, J; Piotin, M				Mazighi, Mikael; Richard, Sebastien; Lapergue, Bertrand; Sibon, Igor; Gory, Benjamin; Berge, Jerome; Consoli, Arturo; Labreuche, Julien; Olivot, Jean-Marc; Broderick, Joseph; Duhamel, Alain; Touze, Emmanuel; Qureshi, Adnan, I; Yavchitz, Amelie; Escalard, Simon; Desilles, Jean-Philippe; Redjem, Hocine; Smajda, Stanislas; Fahed, Robert; Hebert, Solene; Maier, Benjamin; Delvoye, Francois; Boursin, Perrine; Maacha, Malek Ben; Obadia, Michael; Sabben, Candice; Blanc, Raphael; Savatovsky, Julien; Piotin, Michel		BP-TARGET Investigators	Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial	LANCET NEUROLOGY			English	Article								Background High systolic blood pressure after successful endovascular therapy for acute ischaemic stroke is associated with increased risk of intraparenchymal haemorrhage. However, no randomised controlled trials are available to guide optimal management. We therefore aimed to assess whether an intensive systolic blood pressure target resulted in reduced rates of intraparenchymal haemorrhage compared with a standard systolic blood pressure target. Methods We did a multicentre, open-label, randomised controlled trial at four academic hospital centres in France. Eligible individuals were adults (aged >= 18 years) with an acute ischaemic stroke due to a large-vessel occlusion that was successfully treated with endovascular therapy. Patients were randomly assigned (1:1) to either an intensive systolic blood pressure target group (100-129 mm Hg) or a standard care systolic blood pressure target group (130-185 mm Hg), by means of a central web-based procedure, stratified by centre and intravenous thrombolysis use before endovascular therapy. In both groups, the target systolic blood pressure had to be achieved within 1 h after randomisation and maintained for 24 h with intravenous blood pressure lowering treatments. The primary outcome was the rate of radiographic intraparenchymal haemorrhage at 24-36 h and the primary safety outcome was the occurrence of hypotension. Analyses were done on an intention-to-treat basis. BP-TARGET is registered with ClinicalTrials.gov, number NCT03160677, and the trial is closed at all participating sites. Findings Between June 21, 2017, and Sept 27, 2019, 324 patients were enrolled in the four participating stroke centres: 162 patients were randomly assigned to the intensive target group and 162 to the standard target group. Four (2%) of 162 patients were excluded from the intensive target group and two (1%) of 162 from the standard target group for withdrawal of consent or legal reasons. The mean systolic blood pressure during the first 24 h after reperfusion was 128 mm Hg (SD 11) in the intensive target group and 138 mm Hg (17) in the standard target group. The primary outcome was observed in 65 (42%) of 154 patients in the intensive target group and 68 (43%) of 157 in the standard target group on brain CT within 24-36 h after reperfusion] (adjusted odds ratio 0.96, 95% CI 0.60-1.51; p=0.84). Hypotensive events were not significantly different between both groups and occurred in 12 (8%) of 158 patients in the intensive target and five (3%) of 160 in the standard target group. Mortality within the first week after randomisation occurred in 11 (7%) of 158 patients in the intensive target group and in seven (4%) of 160 in the standard target group. Interpretation An intensive systolic blood pressure target of 100-129 mm Hg after successful endovascular therapy did not reduce radiographic intraparenchymal haemorrhage rates at 24-36 h as compared with a standard care systolic blood pressure target of 130-185 mm Hg. Notably, these results are applicable to patients with successful reperfusion and systolic blood pressures of more than 130 mm Hg at the end of procedure. Further studies are needed to understand the association between blood pressure and outcomes after reperfusion. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Mazighi, Mikael; Escalard, Simon; Desilles, Jean-Philippe; Redjem, Hocine; Smajda, Stanislas; Hebert, Solene; Maier, Benjamin; Delvoye, Francois; Boursin, Perrine; Blanc, Raphael; Piotin, Michel] Rothschild Fdn Hosp, Dept Intervent Neuroradiol, F-75019 Paris, France; [Yavchitz, Amelie; Maacha, Malek Ben] Rothschild Fdn Hosp, Dept Clin Res, Paris, France; [Obadia, Michael; Sabben, Candice] Rothschild Fdn Hosp, Stroke Unit, Paris, France; [Savatovsky, Julien] Rothschild Fdn Hosp, Diagnost Imaging & Radiol Dept, Paris, France; [Mazighi, Mikael; Desilles, Jean-Philippe; Maier, Benjamin; Blanc, Raphael; Piotin, Michel] INSERM, Lab Vasc Translat Sci, Paris, France; [Fahed, Robert] Univ Ottawa, Ottawa Hosp Res Inst, Div Neurol & Dept Med Imaging, Paris, France; [Fahed, Robert] Univ Ottawa, Ottawa Hosp Res Inst, Dept Med Imaging, Paris, France; [Mazighi, Mikael; Desilles, Jean-Philippe; Maier, Benjamin; Blanc, Raphael] Univ Paris, Paris, France; [Mazighi, Mikael; Desilles, Jean-Philippe; Maier, Benjamin; Blanc, Raphael] FHU NeuroVasc, AP HP, Paris, France; [Richard, Sebastien] Univ Hosp Nancy, Dept Neurol, Stroke Unit, Nancy, Meurthe Moselle, France; [Richard, Sebastien] Univ Lorraine, INSERM, Nancy, Meurthe Moselle, France; [Lapergue, Bertrand] Univ Versailles St Quentin Yvelines, Dept Neurol, Foch Hosp, Suresnes, France; [Consoli, Arturo] Univ Versailles St Quentin Yvelines, Dept Neuroradiol, Foch Hosp, Suresnes, France; [Sibon, Igor] Univ Bordeaux, Stroke Unit, CHU Bordeaux, Bordeaux, France; [Gory, Benjamin] Univ Lorraine, Dept Diagnost & Therapeut Neuroradiol, CHRU Nancy, Nancy, Meurthe Moselle, France; [Gory, Benjamin] Univ Lorraine, INSERM U1254, IADI, Nancy, Meurthe Moselle, France; [Berge, Jerome] Bordeaux Univ Hosp, Intervent & Diagnost Neuroradiol Dept, Bordeaux, France; [Labreuche, Julien; Duhamel, Alain] Univ Lille, Dept Biostat, CHU Lille, Lille, France; [Olivot, Jean-Marc] Toulouse Univ Hosp, Stroke Unit, Toulouse, France; [Broderick, Joseph] Univ Cincinnati, Coll Med, Dept Neurol & Rehabil Med, Cincinnati, OH USA; [Touze, Emmanuel] Univ Caen Normandie, Dept Neurol, CHU Caen Normandie, INSERM U1237, Caen, France; [Qureshi, Adnan, I] Univ Missouri, Womens & Childrens Hosp, Dept Neurol, Columbia, MO USA	Fondation Adolphe de Rothschild; Fondation Adolphe de Rothschild; Fondation Adolphe de Rothschild; Fondation Adolphe de Rothschild; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); CHU de Nancy; Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; CHU de Nancy; Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; CHU Bordeaux; Universite de Lille - ISITE; CHU Lille; Universite de Lille; CHU de Toulouse; University System of Ohio; University of Cincinnati; CHU de Caen NORMANDIE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; University of Missouri System; University of Missouri Columbia	Mazighi, M (corresponding author), Rothschild Fdn Hosp, Dept Intervent Neuroradiol, F-75019 Paris, France.	mmazighi@for.paris	Gory, Benjamin/ABH-1210-2021; SIBON, IGOR/AAJ-2503-2020	SIBON, IGOR/0000-0002-1171-4215	French Health Ministry	French Health Ministry	French Health Ministry.	Ahmed N, 2009, STROKE, V40, P2442, DOI 10.1161/STROKEAHA.109.548602; Anadani M, 2020, J NEUROINTERV SURG, V12, P932, DOI 10.1136/neurintsurg-2019-015561; Anadani M, 2019, STROKE, V50, P2448, DOI 10.1161/STROKEAHA.118.024687; Anderson CS, 2008, LANCET NEUROL, V7, P391, DOI 10.1016/S1474-4422(08)70069-3; Anderson CS, 2019, LANCET, V393, P877, DOI 10.1016/S0140-6736(19)30038-8; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P2, DOI 10.1016/j.jclinepi.2008.11.004; Chang JY, 2019, EUR NEUROL, V81, P216, DOI 10.1159/000502519; Desilles JP, 2017, STROKE, V48, P1932, DOI 10.1161/STROKEAHA.117.017080; Desilles JP, 2013, NEUROLOGY, V80, P844, DOI 10.1212/WNL.0b013e31828406de; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Hao YG, 2019, J NEUROINTERV SURG, V11, P123, DOI 10.1136/neurintsurg-2018-013848; Jeong HG, 2019, STROKE, V50, P2677, DOI 10.1161/STROKEAHA.119.025426; Kim TJ, 2019, ANN NEUROL, V85, P574, DOI 10.1002/ana.25434; Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644; Maier B, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.573382; Maier B, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006484; Matusevicius M, 2020, STROKE, V51, P519, DOI 10.1161/STROKEAHA.119.026914; Mazighi M, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00480; Mistry EA, 2018, J STROKE CEREBROVASC, V27, P2474, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.003; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460; Turc G, 2019, EUR STROKE J, V4, P6, DOI 10.1177/2396987319832140; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Kranendonk KR, 2019, J NEUROINTERV SURG, V11, P464, DOI 10.1136/neurintsurg-2018-014141; Vemmos KN, 2004, J INTERN MED, V255, P257, DOI 10.1046/j.1365-2796.2003.01291.x; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049; Woimant F, 2001, REV NEUROL-FRANCE, V157, P1447	30	44	46	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					265	274		10.1016/S1474-4422(20)30483-X	http://dx.doi.org/10.1016/S1474-4422(20)30483-X		MAR 2021	10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33647246				2022-12-18	WOS:000630325700017
J	Dharmadasa, T; Kiernan, MC				Dharmadasa, Thanuja; Kiernan, Matthew C.			Riluzole, disease stage and survival in ALS	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE		[Dharmadasa, Thanuja; Kiernan, Matthew C.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW 2040, Australia; [Dharmadasa, Thanuja; Kiernan, Matthew C.] Royal Prince Alfred Hosp, Inst Clin Neurosci, Sydney, NSW 2040, Australia	University of Sydney; University of Sydney	Kiernan, MC (corresponding author), Univ Sydney, Brain & Mind Ctr, Sydney, NSW 2040, Australia.; Kiernan, MC (corresponding author), Royal Prince Alfred Hosp, Inst Clin Neurosci, Sydney, NSW 2040, Australia.	matthew.kiernan@sydney.edu.au		Kiernan, Matthew/0000-0001-9054-026X	Forefront; National Health and Medical Research Council of Australia [1037746]	Forefront; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We receive research funding from Forefront, a collaborative research group supported from the National Health and Medical Research Council of Australia program grant (#1037746).	Al-Chalabi A, 2016, LANCET NEUROL, V15, P1182, DOI 10.1016/S1474-4422(16)30199-5; Cheah BC, 2010, CURR MED CHEM, V17, P1942, DOI 10.2174/092986710791163939; Dharmadasa T, 2017, MED J AUSTRALIA, V206, P357, DOI 10.5694/mja16.01063; Fang T, 2018, LANCET NEUROL, V17, P416, DOI 10.1016/S1474-4422(18)30054-1; Geevasinga N, 2016, AMYOTROPH LAT SCL FR, V17, P580, DOI 10.1080/21678421.2016.1188961; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Riviere M, 1998, ARCH NEUROL-CHICAGO, V55, P526, DOI 10.1001/archneur.55.4.526; Traynor BJ, 2003, J NEUROL, V250, P473, DOI 10.1007/s00415-003-1026-z; Turner MR, 2013, LANCET NEUROL, V12, P310, DOI 10.1016/S1474-4422(13)70036-X; Zoing MC, 2006, J CLIN NEUROSCI, V13, P78, DOI 10.1016/j.jocn.2004.04.011	12	44	44	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					385	386		10.1016/S1474-4422(18)30091-7	http://dx.doi.org/10.1016/S1474-4422(18)30091-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29525493	hybrid			2022-12-18	WOS:000429968100003
J	Rabinstein, AA; Yee, AH; Mandrekar, J; Fugate, JE; de Groot, YJ; Kompanje, EJ; Shutter, LA; Freeman, WD; Rubin, MA; Wijdicks, EFM				Rabinstein, Alejandro A.; Yee, Alan H.; Mandrekar, Jay; Fugate, Jennifer E.; de Groot, Yorick J.; Kompanje, Erwin J.; Shutter, Lori A.; Freeman, W. David; Rubin, Michael A.; Wijdicks, Eelco F. M.			Prediction of potential for organ donation after cardiac death in patients in neurocritical state: a prospective observational study	LANCET NEUROLOGY			English	Article							LIFE-SUPPORT; TIME; WITHDRAWAL; DONORS; VALIDATION	Background Successful donation of organs after cardiac death (DCD) requires identification of patients who will die within 60 mm of withdrawal of life-sustaining treatment (WLST). We aimed to validate a straightforward model to predict the likelihood of death within 60 min of WLST in patients with irreversible brain injury. Methods In this multicentre, observational study, we prospectively enrolled consecutive comatose patients with irreversible brain injury undergoing WLST at six medical centres in the USA and the Netherlands. We assessed four clinical characteristics (corneal reflex, cough reflex, best motor response, and oxygenation index) as predictor variables, which were selected on the basis of previous findings. We excluded patients who had brain death or were not intubated. The primary endpoint was death within 60 min of WLST. We used univariate and multivariable logistic regression analyses to assess associations with predictor variables. Points attributed to each variable were summed to create a predictive score for cardiac death in patients in neurocritical state (the DCD-N score). We assessed performance of the score using area under the curve analysis. Findings We included 178 patients, 82 (46%) of whom died within 60 mm of WLST. Absent corneal reflexes (odds ratio [OR] 2.67, 95% CI 1.19-6.01; p=0.0173; 1 point), absent cough reflex (4.16, 1.79-9.70; p=0.0009; 2 points), extensor or absent motor responses (2.99, 1.22-7.34; p=0.0168; 1 point), and an oxygenation index score of more than 3.0 (2.31, 1.10-4.88; p=0.0276; 1 point) were predictive of death within 60 mm of WLST. 59 of 82 patients who died within 60 min of WLST had DCD-N scores of 3 or more (72% sensitivity), and 75 of 96 of those who did not die within this interval had scores of 0-2 (78% specificity); taking into account the prevalence of death within 60 min in this population, a score of 3 or more was translated into a 74% chance of death within 60 mm (positive predictive value) and a score of 0-2 translated into a 77% chance of survival beyond 60 mm (negative predictive value). Interpretation The DCD-N score can be used to predict potential candidates for DCD in patients with non-survivable brain injury. However, this score needs to be tested specifically in a cohort of potential donors participating in DCD protocols.	[Rabinstein, Alejandro A.; Fugate, Jennifer E.; Wijdicks, Eelco F. M.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Mandrekar, Jay] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN USA; [Yee, Alan H.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [de Groot, Yorick J.; Kompanje, Erwin J.] Erasmus MC Univ Med Ctr, Dept Intens Care, Rotterdam, Netherlands; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45221 USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA; [Freeman, W. David] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; [Rubin, Michael A.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco; Erasmus University Rotterdam; Erasmus MC; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Mayo Clinic; Washington University (WUSTL)	Rabinstein, AA (corresponding author), 200 1st St SW,Mayo W8B, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu	Shutter, Lori A/G-2957-2013; Yee, Alan/AAH-4604-2019	Rubin, Michael/0000-0002-3177-133X; Freeman, M.D., William D./0000-0003-2326-0633; Shutter, Lori/0000-0002-1390-0628				Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; Cooke CR, 2010, CHEST, V138, P289, DOI 10.1378/chest.10-0289; D'Alessandro Anthony M, 2004, Ann Transplant, V9, P68; de Groot YJ, 2012, CRIT CARE MED, V40, P233, DOI 10.1097/CCM.0b013e31822f0633; DeVita MA, 2008, AM J TRANSPLANT, V8, P432, DOI 10.1111/j.1600-6143.2007.02087.x; Dominguez-Gil B, 2011, TRANSPL INT, V24, P676, DOI 10.1111/j.1432-2277.2011.01257.x; Fugate JE, 2011, TRANSPLANTATION, V91, P386, DOI 10.1097/TP.0b013e318204ee96; Hosmer D. W., 2000, APPL LOGISTIC REGRES, V2nd; Lewis Jonathan, 2003, Prog Transplant, V13, P265; Manara AR, 2012, BRIT J ANAESTH, V108, pI108, DOI 10.1093/bja/aer357; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Reid AWN, 2011, AM J TRANSPLANT, V11, P995, DOI 10.1111/j.1600-6143.2011.03474.x; Suntharalingam C, 2009, AM J TRANSPLANT, V9, P2157, DOI 10.1111/j.1600-6143.2009.02758.x; Tuttle-Newhall JE, 2009, AM J TRANSPLANT, V9, P879, DOI 10.1111/j.1600-6143.2009.02565.x; Wind J, 2012, CRIT CARE MED, V40, P766, DOI 10.1097/CCM.0b013e318232e2e7; Yee AH, 2010, NEUROLOGY, V74, P1380, DOI 10.1212/WNL.0b013e3181dad5f0	16	44	44	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2012	11	5					414	419		10.1016/S1474-4422(12)70060-1	http://dx.doi.org/10.1016/S1474-4422(12)70060-1			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	930KM	22494955				2022-12-18	WOS:000303138300012
J	Juvela, S				Juvela, Seppo			Prevalence of and risk factors for intracranial aneurysms	LANCET NEUROLOGY			English	Editorial Material							SUBARACHNOID HEMORRHAGE; RUPTURE; SMOKING		Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland	University of Helsinki	Juvela, S (corresponding author), Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland.	seppo.juvela@helsinki.fi		Juvela, Seppo/0000-0003-4944-4983				CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8; JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639; Juvela S, 2003, STROKE, V34, P1852, DOI 10.1161/01.STR.0000080380.56799.DD; Juvela S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485; Juvela S, 2008, J NEUROSURG, V108, P1052, DOI 10.3171/JNS/2008/108/5/1052; Kissela BM, 2002, STROKE, V33, P1321, DOI 10.1161/01.STR.0000014773.57733.3E; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Wermer MJH, 2005, BRAIN, V128, P2421, DOI 10.1093/brain/awh587	11	44	51	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2011	10	7					595	597		10.1016/S1474-4422(11)70125-9	http://dx.doi.org/10.1016/S1474-4422(11)70125-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789BD	21641283				2022-12-18	WOS:000292487400004
J	Kirschner, J; Schessl, J; Schara, U; Reitter, B; Stettner, GM; Hobbiebrunken, E; Wilichowski, E; Bernert, G; Weiss, S; Stehling, F; Wiegand, G; Muller-Felber, W; Thiele, S; Grieben, U; von der Hagen, M; Lutschg, J; Schmoor, C; Ihorst, G; Korinthenberg, R				Kirschner, Janbernd; Schessl, Joachim; Schara, Ulrike; Reitter, Bernd; Stettner, Georg M.; Hobbiebrunken, Elke; Wilichowski, Ekkehard; Bernert, Guenther; Weiss, Simone; Stehling, Florian; Wiegand, Gert; Mueller-Felber, Wolfgang; Thiele, Simone; Grieben, Ulrike; von der Hagen, Maja; Luetschg, Juerg; Schmoor, Claudia; Ihorst, Gabriele; Korinthenberg, Rudolf			Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial	LANCET NEUROLOGY			English	Article							PREDNISONE THERAPY; CHILDREN	Background Duchenne muscular dystrophy is a rare X-linked progressive disease characterised by loss of ambulation at about age 10 years, with death in early adulthood due to respiratory and cardiac insufficiency. Steroids are effective at slowing the progression of muscle weakness; however, their use is limited by side-effects, prompting the search for alternatives. We assessed the effect of ciclosporin A as monotherapy and in combination with intermittent prednisone for the treatment of ambulant patients with this disorder. Methods Our study was a parallel-group, placebo-controlled, double-blind, multicentre trial at trial sites of the German muscular dystrophy network, MD-NET, over 36 months. Ambulant patients with Duchenne muscular dystrophy who were aged 5 years or older were randomly assigned to receive either ciclosporin A (3.5-4.0 mg/kg per day) or matching placebo. Allocation was done centrally with computer-generated random numbers. Patients and investigators were masked to the allocated treatment. After 3 months of treatment, both groups were also given intermittent prednisone for a further 12 months (0.75 mg/kg, alternating 10 days on with 10 days off). All patients who received at least one dose of study drug or placebo were included in the primary analysis. The primary outcome measure was manual muscle strength measured on the Medical Research Council (MRC) scale. This trial is registered with the German clinical trial register DRKS, number DRKS00000445. Findings 77 patients were randomly assigned to the ciclosporin A group and 76 to the placebo group; 73 patients on ciclosporin A and 73 on placebo received at least one dose and were available for efficacy analyses. 3 months of treatment with ciclosporin A alone did not show any significant improvement in primary outcome measures (mean change in the proportion of a possible total MRC score [%MRC] was -2.6 [SD 6.0] for patients on ciclosporin A and -0.8 [4.9] for patients on placebo; adjusted group difference estimate -0.88, 97.5% CI -2.6 to 0.9; p=0.26). The combination of ciclosporin A with intermittent steroids was not better than intermittent steroids alone over 12 months (mean change in %MRC was 0.7 [7.1] for patients on ciclosporin A and -0.3 [7.9] for patients on placebo; adjusted group difference estimate -0.85, -3.6 to 1.9; p=0.48). Numbers of adverse events (75 in patients on ciclosporin A and 74 on placebo) and serious adverse events (four with ciclosporin A and four with placebo) did not differ significantly between groups. Interpretation Ciclosporin A alone or in combination with intermittent prednisone does not improve muscle strength or functional abilities in ambulant boys with Duchenne muscular dystrophy, but is safe and well tolerated.	[Kirschner, Janbernd] Univ Med Ctr Freiburg, Ctr Paediat & Adolescent Med, Div Neuropaediat & Muscle Disorders, D-79106 Freiburg, Germany; [Schara, Ulrike; Stehling, Florian] Univ Essen Gesamthsch, Dept Paediat Neurol, Essen, Germany; [Reitter, Bernd] Johannes Gutenberg Univ Mainz, Childrens Hosp, D-6500 Mainz, Germany; [Stettner, Georg M.; Hobbiebrunken, Elke; Wilichowski, Ekkehard] Univ Gottingen, Dept Paediat & Paediat Neurol, Gottingen, Germany; [Bernert, Guenther; Weiss, Simone] Preyer Childrens Hosp, Vienna, Austria; [Wiegand, Gert] Univ Med Ctr Schleswig Holstein, Dept Neuropaediat, Kiel, Germany; [Schessl, Joachim; Mueller-Felber, Wolfgang; Thiele, Simone] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany; [Grieben, Ulrike] Charite, Dept Neuropaediat, Berlin, Germany; [von der Hagen, Maja] Tech Univ Dresden, Dept Paediat Neurol, Dresden, Germany; [Luetschg, Juerg] Univ Childrens Hosp Basel, Dept Neuropaediat & Dev Neurol, Basel, Switzerland; [Schmoor, Claudia; Ihorst, Gabriele] Univ Med Ctr, Clin Trials Ctr, Freiburg, Germany	University of Freiburg; University of Duisburg Essen; Johannes Gutenberg University of Mainz; University of Gottingen; University of Kiel; Schleswig Holstein University Hospital; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technische Universitat Dresden; University of Basel; University of Freiburg	Kirschner, J (corresponding author), Univ Med Ctr Freiburg, Ctr Paediat & Adolescent Med, Div Neuropaediat & Muscle Disorders, Mathildenstr 1, D-79106 Freiburg, Germany.	janbernd.kirschner@uniklinik-freiburg.de	Ihorst, Gabriele/AAA-7445-2021; Stettner, Georg/J-6989-2019; Kirschner, Janbernd/Q-1493-2019; Korinthenberg, Rudolf/A-9796-2009; Stehling, Florian/AAX-9428-2020; Kirschner, Janbernd/H-7418-2016	Kirschner, Janbernd/0000-0003-1618-7386; Kirschner, Janbernd/0000-0003-1618-7386; Korinthenberg, Rudolf/0000-0002-4638-3460; Stettner, Georg M./0000-0002-0906-8816	German Ministry of Education and Research (BMBF, Bonn, Germany); EU; German Duchenne muscular dystrophy parent project group Aktion Benni and co eV	German Ministry of Education and Research (BMBF, Bonn, Germany)(Federal Ministry of Education & Research (BMBF)); EU(European Commission); German Duchenne muscular dystrophy parent project group Aktion Benni and co eV	Novartis Pharma AG supported the trial through donation of study drugs. This study was done as a research project of the German network on muscular dystrophies (MD-NET) funded by the German Ministry of Education and Research (BMBF, Bonn, Germany). MD-NET is a partner of the EU-funded network of excellence TREAT-NMD. We thank all patients and families for their participation in this trial; German Duchenne muscular dystrophy parent project group Aktion Benni and co eV for their substantial financial support; and Deutsche Gesellschaft fur Muskelkranke eV for providing dynamometers for all sites. Without the dedication of all study personnel and physiotherapists at each site this trial would not have been possible.	Anderson JE, 2000, CELL TRANSPLANT, V9, P551, DOI 10.1177/096368970000900411; Beenakker EAC, 2005, ARCH NEUROL-CHICAGO, V62, P128, DOI 10.1001/archneur.62.1.128; Beenakker EAC, 2001, NEUROMUSCULAR DISORD, V11, P441, DOI 10.1016/S0960-8966(01)00193-6; BROOKE MH, 1983, MUSCLE NERVE, V6, P204, DOI 10.1002/mus.880060307; BROOKE MH, 1981, MUSCLE NERVE, V4, P186, DOI 10.1002/mus.880040304; Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6; De Luca A, 2005, AM J PATHOL, V166, P477, DOI 10.1016/S0002-9440(10)62270-5; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; Fisher I, 2005, FASEB J, V19, P834, DOI 10.1096/fj.04-2511fje; GRIGGS RC, 1991, ARCH NEUROL-CHICAGO, V48, P383, DOI 10.1001/archneur.1991.00530160047012; HECKMATT JZ, 1988, MUSCLE NERVE, V11, P836, DOI 10.1002/mus.880110807; Hussein MR, 2006, INT J EXP PATHOL, V87, P451, DOI 10.1111/j.1365-2613.2006.00470.x; Jacobs SCJM, 1996, J NEUROL, V243, P410, DOI 10.1007/BF00869001; KISSEL JT, 1991, NEUROLOGY, V41, P667, DOI 10.1212/WNL.41.5.667; Magnasco A, 2008, CURR CLIN PHARMACOL, V3, P166, DOI 10.2174/157488408785747674; MANZUR AY, 1992, NEUROMUSCULAR DISORD, V2, P379, DOI 10.1016/S0960-8966(06)80009-X; Manzur AY, 2008, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD14003725.PUB14651853; Medical Research Council, 1943, AIDS INV PER NERV IN; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Miller RG, 1997, MUSCLE NERVE, V20, P469, DOI 10.1002/(SICI)1097-4598(199704)20:4<469::AID-MUS10>3.3.CO;2-1; Ravens-Sieberer U, 1998, QUAL LIFE RES, V7, P399, DOI 10.1023/A:1008853819715; SHARMA KR, 1993, NEUROLOGY, V43, P527, DOI 10.1212/WNL.43.3_Part_1.527; Stupka N, 2004, ACTA NEUROPATHOL, V107, P299, DOI 10.1007/s00401-003-0807-x; Tidball JG, 2005, CURR OPIN RHEUMATOL, V17, P707, DOI 10.1097/01.bor.0000179948.65895.1a	26	44	48	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2010	9	11					1053	1059		10.1016/S1474-4422(10)70196-4	http://dx.doi.org/10.1016/S1474-4422(10)70196-4			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680PL	20801085				2022-12-18	WOS:000284246800013
J	Pollard, JR; French, J				Pollard, John R.; French, Jacqueline			Antiepileptic drugs in development	LANCET NEUROLOGY			English	Review							ANTICONVULSANT RETIGABINE; PARTIAL SEIZURES; IN-VITRO; EPILEPSY; LACOSAMIDE; SAFETY; TRIAL; UCB-34714; EFFICACY; D-23129	Background Despite the success of several new antiepileptic drugs, about one third of patients with epilepsy are not seizure free on medication. Improvement in this situation might lie in drugs that are currently in development. Recent developments Some new antiepileptic drugs are modifications of those already available, referred to in this Rapid Review as evolutionary drugs. These modifications of existing drugs are developed to improve effectiveness, often by increasing tolerability. Other drugs work by new mechanisms and are usually discovered through screening of animal models. Where next? The large number of drugs currently in clinical trials provides a measure of hope for patients whose epilepsy is not controlled with currently available medication. In the future, this range of antiepileptic drugs will probably increase because of the use of new animal models, discovery of new basic mechanisms of epileptogenesis, acceleration of proof of principle studies in people, and development of new methods of drug delivery.	Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	French, J (corresponding author), Univ Penn, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA.	jacqueline.French@uphs.upenn.edu	French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027				Ben-Menachem E, 2005, NEUROLOGY, V64, pA187; Bialer M, 2004, EPILEPSY RES, V61, P1, DOI 10.1016/j.eplepsyres.2004.07.010; Blackburn-Munro G, 2003, EUR J PHARMACOL, V460, P109, DOI 10.1016/S0014-2999(02)02924-2; Chappell AS, 2002, NEUROLOGY, V58, P1680, DOI 10.1212/WNL.58.11.1680; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Duncan GE, 2005, EPILEPSY RES, V67, P81, DOI 10.1016/j.eplepsyres.2005.08.009; Fisher RS, 2002, CNS DRUGS, V16, P579, DOI 10.2165/00023210-200216090-00001; Glauser T, 2005, NEUROLOGY, V64, P1826, DOI 10.1212/WNL.64.10.1826; Hovinga Collin A, 2004, Curr Opin Investig Drugs, V5, P101; Kerrigan J, 2000, YALE J CRIT, V13, P3; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lees G, 2006, NEUROPHARMACOLOGY, V50, P98, DOI 10.1016/j.neuropharm.2005.08.016; LEESE PT, SELETRACETAM UCB 442; Malawska Barbara, 2005, Curr Opin Investig Drugs, V6, P740; Monaghan, 1999, Expert Opin Investig Drugs, V8, P1663, DOI 10.1517/13543784.8.10.1663; Monaghan EP, 1997, EPILEPSIA, V38, P1026, DOI 10.1111/j.1528-1157.1997.tb01486.x; PELLOCK JM, 2002, ANTIEPILEPTIC DRUGS, P301; Plosker GL, 2006, CNS DRUGS, V20, P601, DOI 10.2165/00023210-200620070-00005; Rivera-Arconada I, 2004, NEUROPHARMACOLOGY, V46, P598, DOI 10.1016/j.neuropharm.2003.10.016; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Rogawski MA, 2006, EPILEPSY RES, V69, P273, DOI 10.1016/j.eplepsyres.2006.02.004; Rolan P, 2004, EPILEPSIA, V45, P314; Rostock A, 1996, EPILEPSY RES, V23, P211, DOI 10.1016/0920-1211(95)00101-8; Rundfeldt C, 2000, NEUROSCI LETT, V282, P73, DOI 10.1016/S0304-3940(00)00866-1; Rundfeldt C, 2000, ARZNEIMITTEL-FORSCH, V50, P1063; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Solyom S, 2002, CURR PHARM DESIGN, V8, P913, DOI 10.2174/1381612024607081; Tober C, 1996, EUR J PHARMACOL, V303, P163, DOI 10.1016/0014-2999(96)00073-8; VAZQUEZ BRS, 2000, EPILIPSIA, V37, P255; Zona C, 2004, EPILEPSIA, V45, P146; 2005, DRUGS R D, V6, P249	31	44	48	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					1064	1067		10.1016/S1474-4422(06)70627-5	http://dx.doi.org/10.1016/S1474-4422(06)70627-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	17110287				2022-12-18	WOS:000242266100036
J	Lacey, M				Lacey, M			Nodding disease: mystery of southern Sudan	LANCET NEUROLOGY			English	News Item																			0	44	45	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					714	714		10.1016/S1474-4422(03)00599-4	http://dx.doi.org/10.1016/S1474-4422(03)00599-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14649236				2022-12-18	WOS:000186665800002
J	Wilcock, GK				Wilcock, GK			Memantine for the treatment of dementia	LANCET NEUROLOGY			English	Review							MODERATE VASCULAR DEMENTIA; SEVERE ALZHEIMERS-DISEASE; SEVERE IMPAIRMENT BATTERY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; EFFICACY; MILD	Background The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with mild to moderate Alzheimer's disease (AD) is well established. However, the treatment is only effective in about half of the patients for whom it is prescribed. Vascular dementia may respond, at least to some extent, to these drugs (T Erkinjuntti and colleagues, Lancet 2002; 359: 1283-90). In 2002, the Committee of Proprietary Medicinal Products recommended that memantine-a drug that acts on the glutamatergic system rather than the cholinergic system-be approved by the European Commission for the treatment of moderately severe to severe AD. Clinical trials have shown some effectiveness of memantine in the treatment of vascular dementia, although it has not been approved for use in this disorder. Recent developments The results of a study of the effects of memantine on moderate to severe AD have recently been published (B Reisberg and colleagues, N Engl J Med 2003; 348: 1333-41). Reisberg and colleagues treated their patients for 28 weeks, assessed several outcome variables, and found that memantine reduced clinical deterioration without significant adverse effects. This study is important as memantine is the only treatment licensed for patients with more advanced AD. Where next? Several questions about the use of memantine as a treatment for AD remain to be answered. How beneficial is memantine treatment in routine clinical practice compared with clinical trials? What is the best way to assess treatment effects? How long do the beneficial effects last? Does memantine have neuroprotective, rather than just symptomatic, effects? In addition, we need to know when to switch from cholinesterase inhibitors to memantine or when to co-prescribe memantine with cholinesterase inhibitors. The efficacy of memantine in vascular dementia also requires further investigation.	Univ Bristol, Dept Care Elderly, Bristol, Avon, England	University of Bristol	Wilcock, GK (corresponding author), Univ Bristol, Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England.	gordon.wilcock@bris.ac.uk						AMBROZI L, 1988, PHARMACOPSYCHIATRY, V21, P144, DOI 10.1055/s-2007-1014666; DITZLER K, 1991, ARZNEIMITTEL-FORSCH, V41-2, P773; FARLOW MR, 2003, NEUROLOGY S1, V60; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Galasko DR, 2000, NEUROBIOL AGING S1, V21, pS168; GORTELMEYER R, 1992, ARZNEIMITTEL-FORSCH, V42-2, P904; Guy W, 1976, ECDEU ASSESSMENT MAN, P217; MOHS RC, 1988, PSYCHOPHARMACOL BULL, V24, P627; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; PANISSET M, 1994, ARCH NEUROL-CHICAGO, V51, P41, DOI 10.1001/archneur.1994.00540130067012; Reisberg B, 1997, ALZ DIS ASSOC DIS, V11, P8; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Schmitt FA, 1997, ALZ DIS ASSOC DIS, V11, pS51; Sclan S G, 1992, Int Psychogeriatr, V4 Suppl 1, P55; Wilcock G, 2002, INT CLIN PSYCHOPHARM, V17, P297, DOI 10.1097/00004850-200211000-00005; Wilcock G., 2000, European Neuropsychopharmacology, V10, pS360; Wimo A, 2003, PHARMACOECONOMICS, V21, P327, DOI 10.2165/00019053-200321050-00004; Wimo A., 1998, HLTH EC DEMENTIA, DOI DOI 10.1186/S12913-017-2422-X; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0	20	44	50	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					503	505		10.1016/S1474-4422(03)00486-1	http://dx.doi.org/10.1016/S1474-4422(03)00486-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	12878438				2022-12-18	WOS:000184314700019
J	Szallasi, A; Fowler, CJ				Szallasi, A; Fowler, CJ			After a decade of intravesical vanilloid therapy: still more questions than answers	LANCET NEUROLOGY			English	Review							NERVE GROWTH-FACTOR; CAPSAICIN RECEPTOR; URINARY-BLADDER; VR1 RECEPTORS; ION-CHANNEL; SPINAL-CORD; RESINIFERATOXIN; ANANDAMIDE; EXPRESSION; IMMUNOREACTIVITY	Vanilloid sensitivity is a functional signature of a subset of unmyelinated fibres innervating the urinary bladder. The role that these nerves have in the physiological control of storage and voiding is unclear. However, after the bladder has been disconnected by spinal injury from the pontine micturition centre, vanilloid-sensitive fibres assume a central role in the reflex emptying of the bladder that occurs at low volumes. Intravesical vanilloid (capsaicin or resiniferatoxin) administration is beneficial in this disorder by "desensitising" these nerves. Resiniferatoxin is superior to capsaicin in terms of its tolerability profile. Investigators are moving rapidly to identify the mechanisms by which desensitisation to vanilloids occurs. Vanilloids induce lasting, but fully reversible, changes in gene expression, including downregulation of the vanilloid receptor subtype 1. It is hoped that application of gene chip technologies will address the global profile of vanilloid-induced changes in gene expression and their relative contribution to desensitisation. Drugs that target signalling mechanisms that bring about these changes in gene expression have obvious therapeutic potential.	Washington Univ, Sch Med, Dept Pathol & Immunol, Div Clin Pathol, St Louis, MO 63110 USA; UCL, Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London, England	Washington University (WUSTL); University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Szallasi, A (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Div Clin Pathol, 1 Barnes Pl, St Louis, MO 63110 USA.	aszallasi@path.wustl.edu	Szallasi, Arpad/ABG-5948-2021; Fowler, Clare J/B-2812-2009					Ahluwalia J, 2000, NEUROSCIENCE, V100, P685, DOI 10.1016/S0306-4522(00)00389-4; Appendino G, 1997, LIFE SCI, V60, P681, DOI 10.1016/S0024-3205(96)00567-X; Avelino A, 2002, NEUROSCIENCE, V109, P787, DOI 10.1016/S0306-4522(01)00496-1; Avelino A, 2000, AUTON NEUROSCI-BASIC, V86, P37, DOI 10.1016/S1566-0702(00)00204-6; Birder LA, 2001, P NATL ACAD SCI USA, V98, P13396, DOI 10.1073/pnas.231243698; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Brady CM, 2002, J NEUROL NEUROSUR PS, V72, P139; BRAND L, 1987, DRUG EXP CLIN RES, V13, P259; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chancellor MB, 1999, J UROLOGY, V162, P3, DOI 10.1097/00005392-199907000-00002; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Chuang YC, 2001, J UROLOGY, V165, P975, DOI 10.1016/S0022-5347(05)66587-1; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Cruz F., 1999, Society for Neuroscience Abstracts, V25, P1687; Cruz F, 1997, LANCET, V350, P640, DOI 10.1016/S0140-6736(05)63330-2; Cruz F., 2000, Neurourology and Urodynamics, V19, P456; Cruz F, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P214, DOI 10.1007/BF01901607; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; de Groat WC, 1997, UROLOGY, V50, P36, DOI 10.1016/S0090-4295(97)00587-6; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; De Ridder D, 2000, BJU INT, V86, P172, DOI 10.1046/j.1464-410x.2000.00750.x; DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2000, EUR J PHARMACOL, V406, P363, DOI 10.1016/S0014-2999(00)00687-7; Di Marzo V, 2001, TRENDS PHARMACOL SCI, V22, P346, DOI 10.1016/S0165-6147(00)01712-0; FOWLER CJ, 1992, LANCET, V339, P1239, DOI 10.1016/0140-6736(92)91186-C; Fowler CJ, 2000, UROLOGY, V55, P60, DOI 10.1016/S0090-4295(99)00498-7; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; GOSO C, 1993, NEUROSCI LETT, V162, P197, DOI 10.1016/0304-3940(93)90594-B; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Hayes P, 2000, PAIN, V88, P205, DOI 10.1016/S0304-3959(00)00353-5; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kim DY, 2000, J ENDOUROL, V14, P97, DOI 10.1089/end.2000.14.97; Kim Joon Chul, 2001, Journal of Urology, V165, P34; LOWE E, 1977, BRIT J PHARMACOL, V79, P572; MILLER MS, 1982, BRAIN RES, V250, P193, DOI 10.1016/0006-8993(82)90969-6; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; O'Reilly BA, 2002, J UROLOGY, V167, P157, DOI 10.1016/S0022-5347(05)65403-1; Okragly AJ, 1999, J UROLOGY, V161, P442; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Robbins W, 2000, CLIN J PAIN, V16, pS86, DOI 10.1097/00002508-200006001-00015; Simone DA, 1998, J NEUROSCI, V18, P8947; Sterner O, 1999, TRENDS PHARMACOL SCI, V20, P459, DOI 10.1016/S0165-6147(99)01393-0; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 1996, J Peripher Nerv Syst, V1, P6; Szallasi A, 1999, PHARMACOL REV, V51, P159; Szallasi A, 1992, METHODS NEUROSCIENCE, V8, P368; Szolcsanyi J, 2000, TRENDS PHARMACOL SCI, V21, P41, DOI 10.1016/S0165-6147(99)01436-4; Tominaga M, 2000, JPN J PHARMACOL, V83, P20, DOI 10.1254/jjp.83.20; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Winston J, 2001, PAIN, V89, P181, DOI 10.1016/S0304-3959(00)00370-5; WINTER J, 1995, BRIT J ANAESTH, V75, P157, DOI 10.1093/bja/75.2.157; Wood J, 1993, CAPSAICIN STUDY PAIN; Xue Q, 2001, GENOMICS, V76, P14, DOI 10.1006/geno.2001.6582; Yiangou Y, 2001, LANCET, V357, P1338, DOI 10.1016/S0140-6736(00)04503-7; Yiangou Y, 2001, BJU INT, V87, P774, DOI 10.1046/j.1464-410x.2001.02190.x; Zygmunt PM, 2000, TRENDS PHARMACOL SCI, V21, P43, DOI 10.1016/S0165-6147(99)01430-3	63	44	48	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					167	172		10.1016/S1474-4422(02)00072-8	http://dx.doi.org/10.1016/S1474-4422(02)00072-8			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB	12849485				2022-12-18	WOS:000177695100018
J	Diallo, A; Jacobi, H; Cook, A; Labrum, R; Durr, A; Brice, A; Charles, P; Marelli, C; Mariotti, C; Nanetti, L; Panzeri, M; Rakowicz, M; Sobanska, A; Sulek, A; Schmitz-Hubsch, T; Schols, L; Hengel, H; Melegh, B; Filla, A; Antenora, A; Infante, J; Berciano, J; van de Warrenburg, BP; Timmann, D; Boesch, S; Pandolfo, M; Schulz, JB; Bauer, P; Giunti, P; Kang, JS; Klockgether, T; du Montcel, ST				Diallo, Alhassane; Jacobi, Heike; Cook, Arron; Labrum, Robyn; Durr, Alexandra; Brice, Alexis; Charles, Perrine; Marelli, Cecilia; Mariotti, Caterina; Nanetti, Lorenzo; Panzeri, Marta; Rakowicz, Maria; Sobanska, Anna; Sulek, Anna; Schmitz-Huebsch, Tanja; Schoels, Ludger; Hengel, Holger; Melegh, Bela; Filla, Alessandro; Antenora, Antonella; Infante, Jon; Berciano, Jose; van de Warrenburg, Bart P.; Timmann, Dagmar; Boesch, Sylvia; Pandolfo, Massimo; Schulz, Jorg B.; Bauer, Peter; Giunti, Paola; Kang, Jun-Suk; Klockgether, Thomas; du Montcel, Sophie Tezenas			Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study	LANCET NEUROLOGY			English	Article							PREOPERATIVE NOMOGRAM; NATURAL-HISTORY; PREDICTION; VALIDATION; SEVERITY; MODEL	Background Spinocerebellar ataxias are dominantly inherited progressive ataxia disorders that can lead to premature death. We aimed to study the overall survival of patients with the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6) and to identify the strongest contributing predictors that affect survival. Methods In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, from 17 ataxia referral centres in ten European countries; participants had positive genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias. Survival was defined as the time from enrolment to death for any reason. We used the Cox regression model adjusted for age at baseline to analyse survival. We used prognostic factors with a p value less than 0.05 from a multivariate model to build nomograms and assessed their performance based on discrimination and calibration. The EUROSCA study is registered with ClinicalTrials.gov, number NCT02440763. Findings Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1 (n=117), SCA2 (n=162), SCA3 (n=139), or SCA6 (n=107) were enrolled and followed up. The 10-year survival rate was 57% (95% CI 47-69) for SCA1, 74% (67-81) for SCA2, 73% (65-82) for SCA3, and 87% (80-94) for SCA6. Factors associated with shorter survival were: dysphagia (hazard ratio 4.52, 95% CI 1.83-11.15) and a higher value for the Scale for the Assessment and Rating of Ataxia (SARA) score (1.26, 1.19-1.33) for patients with SCA1; older age at inclusion (1.04, 1.01-1.08), longer CAG repeat length (1.16, 1.03-1.31), and higher SARA score (1.15, 1.10-1.20) for patients with SCA2; older age at inclusion (1.44, 1.20-1.74), dystonia (2.65, 1.21-5.53), higher SARA score (1.26, 1.17-1.35), and negative interaction between CAG and age at inclusion (0.994, 0.991-0.997) for patients with SCA3; and higher SARA score (1.17, 1.08-1.27) for patients with SCA6. The nomogram-predicted probability of 10-year survival showed good discrimination (c index 0.905 [SD 0.027] for SCA1, 0.822 [0.032] for SCA2, 0.891 [0.021] for SCA3, and 0.825 [0.054] for SCA6). Interpretation Our study provides quantitative data on the survival of patients with the most common spinocerebellar ataxias, based on a long follow-up period. These results have implications for the design of future interventional studies of spinocerebellar ataxias; for example, the prognostic survival nomogram could be useful for selection and stratification of patients. Our findings need validation in an external population before they can be used to counsel patients and their families.	[Diallo, Alhassane; du Montcel, Sophie Tezenas] Sorbonne Univ, INSERM, IPLESP, Paris, France; [Durr, Alexandra; Brice, Alexis] Sorbonne Univ, INSERM, Inst Cerveau & Moelle Epiniere ICM, Paris, France; [Charles, Perrine] Pitie Salpetriere Univ, Hosp Paris, Genet Dept, Paris, France; [Durr, Alexandra; Brice, Alexis; du Montcel, Sophie Tezenas] Pitie Salpetriere Univ, Hosp Paris, AP HP, Paris, France; [Jacobi, Heike; Schmitz-Huebsch, Tanja; Klockgether, Thomas] Univ Hosp Heidelberg, Dept Neurol, Heidelberg, Germany; [Jacobi, Heike; Schmitz-Huebsch, Tanja; Hengel, Holger; Klockgether, Thomas] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [Cook, Arron; Giunti, Paola] UCL, Inst Neurol, Dept Mol Neurosci, London, England; [Labrum, Robyn] UCL, Natl Hosp Neurol & Neurosurg, Neurogenet Lab, London, England; [Marelli, Cecilia] CHU Gui De Chauliac, Serv Neurol CMRR, Montpellier, France; [Mariotti, Caterina; Nanetti, Lorenzo; Panzeri, Marta] Fdn IRCCS, Ist Neurol Carlo Besta, SOSD Genet Neurodegenerat & Metab Dis, Milan, Italy; [Rakowicz, Maria; Sobanska, Anna] Inst Psychiat & Neurol, Dept Clin Neurophysiol, Warsaw, Poland; [Sulek, Anna] Inst Psychiat & Neurol, Dept Genet, Warsaw, Poland; [Schmitz-Huebsch, Tanja] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Clin Neuroimmunol Grp, Berlin, Germany; [Schoels, Ludger; Hengel, Holger] Univ Tubingen, Dept Neurodegenerat, Tubingen, Germany; [Schoels, Ludger; Hengel, Holger] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Bauer, Peter] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany; [Schoels, Ludger; Hengel, Holger] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany; [Melegh, Bela] Univ Pecs, Dept Med Genet, Pecs, Hungary; [Melegh, Bela] Univ Pecs, Szentagothai Res Ctr, Pecs, Hungary; [Filla, Alessandro; Antenora, Antonella] Federico II Univ Naples, Dept Neurosci & Reprod & Odontostomatol Sci, Naples, Italy; [Infante, Jon; Berciano, Jose] UC, Univ Hosp Marques Valdecilla IDIVAL, Serv Neurol, Santander, Spain; [Infante, Jon; Berciano, Jose] Ctr Invest Biomed Red Enfermedades Neurodegenrat, Santander, Spain; [van de Warrenburg, Bart P.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands; [Timmann, Dagmar] Univ Duisburg Essen, Essen Univ Hosp, Dept Neurol, Essen, Germany; [Boesch, Sylvia] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Pandolfo, Massimo] ULB, Hop Erasme, Neurol Serv, Lab Expt Neurol, Brussels, Belgium; [Schulz, Jorg B.] Rhein Westfal TH Aachen, Dept Neurol, Aachen, Germany; [Schulz, Jorg B.] Aachen Julich, JARA Translat Brain Med, Aachen, Germany; [Melegh, Bela] Zala Cty Hosp, Dept Neurol, Zalaegerszeg, Hungary; [Kang, Jun-Suk] Goethe Univ Frankfurt, Dept Neurol, Frankfurt, Germany; [Schoels, Ludger; Hengel, Holger; Klockgether, Thomas] Univ Hosp Bonn, Dept Neurol, Bonn, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Hopital Universitaire Sainte-Perine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Hopital Universitaire Sainte-Perine - APHP; UDICE-French Research Universities; Sorbonne Universite; Ruprecht Karls University Heidelberg; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Universite de Montpellier; CHU de Montpellier; IRCCS Istituto Neurologico Besta; Institute of Psychiatry & Neurology; Institute of Psychiatry & Neurology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Pecs; University of Pecs; University of Naples Federico II; Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; CIBERNED; Radboud University Nijmegen; University of Duisburg Essen; Medical University of Innsbruck; Universite Libre de Bruxelles; RWTH Aachen University; Goethe University Frankfurt; University of Bonn	du Montcel, ST (corresponding author), Sorbonne Univ, IPLESP, F-75013 Paris, France.	sophie.tezenas@aphp.fr	van de Warrenburg, Bart PC/D-1935-2010; Rakowicz, Maria/T-7768-2019; brice, alexis/AAE-8275-2019; Tezenas du Montcel, Sophie/A-6207-2012; Rakowicz, Maria/U-9134-2018; nanetti, lorenzo/A-7361-2013; Schöls, Ludger/ABB-2482-2021; Mariotti, Caterina/AAP-9425-2021; Brice, Alexis/A-2170-2009; Schulz, Jorg B./D-9786-2012	van de Warrenburg, Bart PC/0000-0003-4412-1616; brice, alexis/0000-0002-0941-3990; Tezenas du Montcel, Sophie/0000-0002-2866-4330; Rakowicz, Maria/0000-0003-3998-8936; nanetti, lorenzo/0000-0002-1952-4539; Schöls, Ludger/0000-0001-7774-5025; Mariotti, Caterina/0000-0003-2405-3564; Sobanska, Anna/0000-0002-7129-913X; Sulek, Anna/0000-0003-2975-4888; Panzeri, Marta/0000-0002-3359-025X; Boesch, Sylvia/0000-0003-1657-7368; Infante, Jon/0000-0003-4025-4606; Schulz, Jorg B./0000-0002-8903-0593	European Union; German Ministry of Education and Research; Polish Ministry of Scientific Research and Information Technology; Fondation pour la Recherche Medicale	European Union(European Commission); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Polish Ministry of Scientific Research and Information Technology; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	European Union 6th Framework programme, German Ministry of Education and Research, Polish Ministry of Scientific Research and Information Technology, European Union 7th Framework programme, and Fondation pour la Recherche Medicale.	Almaguer-Mederos LE, 2013, CLIN GENET, V83, P293, DOI 10.1111/j.1399-0004.2012.01902.x; Ashizawa T, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-177; Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7; Chalise P., 2016, INT J STAT PROBABILI, V5, P91, DOI [10.5539/ijsp.v5n3p91, DOI 10.5539/IJSP.V5N3P91, DOI 10.5539/ijsp.v5n3p91]; Chalise P, 2013, COMMUN STAT-SIMUL C, V42, P636, DOI 10.1080/03610918.2011.650259; Chalise P, 2012, J STAT COMPUT SIM, V82, P1767, DOI 10.1080/00949655.2011.595010; COX DR, 1957, J AM STAT ASSOC, V52, P543, DOI 10.2307/2281704; Durr A, 2010, LANCET NEUROL, V9, P885, DOI 10.1016/S1474-4422(10)70183-6; Hayashi YK, 2012, EUR J CANCER, V48, P3396, DOI 10.1016/j.ejca.2012.06.020; Jacobi H, 2011, NEUROLOGY, V77, P1035, DOI 10.1212/WNL.0b013e31822e7ca0; Jacobi H, 2015, LANCET NEUROL, V14, P1101, DOI 10.1016/S1474-4422(15)00202-1; Keller JL, 2014, NEUROREHAB NEURAL RE, V28, P770, DOI 10.1177/1545968314522350; Kieling C, 2007, CLIN GENET, V72, P543, DOI 10.1111/j.1399-0004.2007.00910.x; Kim DY, 2014, BRIT J CANCER, V110, P34, DOI 10.1038/bjc.2013.718; Klockgether T, 1998, BRAIN, V121, P589, DOI 10.1093/brain/121.4.589; Lamberink HJ, 2017, LANCET NEUROL, V16, P523, DOI 10.1016/S1474-4422(17)30114-X; Lin NX, 2013, BIOMETRICS, V69, P850, DOI 10.1111/biom.12096; Monin ML, 2015, ANN CLIN TRANSL NEUR, V2, P202, DOI 10.1002/acn3.156; Royston P, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-33; Schmitz-Hubsch T, 2008, NEUROLOGY, V71, P982, DOI 10.1212/01.wnl.0000325057.33666.72; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Synofzik M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/583507; Thompson AM, 2014, THYROID, V24, P675, DOI 10.1089/thy.2013.0224; van Houwelingen HC, 2000, STAT MED, V19, P3401, DOI 10.1002/1097-0258(20001230)19:24<3401::AID-SIM554>3.0.CO;2-2	25	43	44	2	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2018	17	4					327	334		10.1016/S1474-4422(18)30042-5	http://dx.doi.org/10.1016/S1474-4422(18)30042-5			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ3AO	29553382	Green Submitted			2022-12-18	WOS:000427458000016
J	Costerus, JM; Brouwer, MC; van de Beek, D				Costerus, Joost M.; Brouwer, Matthijs C.; van de Beek, Diederik			Technological advances and changing indications for lumbar puncture in neurological disorders	LANCET NEUROLOGY			English	Review							ACUTE BACTERIAL-MENINGITIS; NEUROFILAMENT LIGHT-CHAIN; CEREBROSPINAL-FLUID; DIAGNOSTIC-ACCURACY; ALZHEIMERS-DISEASE; CLINICAL-FEATURES; MASS-SPECTROMETRY; OPENING PRESSURE; GENE-THERAPY; FOLLOW-UP	Technological advances have changed the indications for and the way in which lumbar puncture is done. Suspected CNS infection remains the most common indication for lumbar puncture, but new molecular techniques have broadened CSF analysis indications, such as the determination of neuronal autoantibodies in autoimmune encephalitis. New screening techniques have increased sensitvity for pathogen detection and can be used to identify pathogens that were previously unknown to cause CNS infections. Evidence suggests that potential treatments for neurodegenerative diseases, such as Alzheimer's disease, will rely on early detection of the disease with the use of CSF biomarkers. In addition to being used as a diagnostic tool, lumbar puncture can also be used to administer intrathecal treatments as shown by studies of antisense oligonucleotides in patients with spinal muscular atrophy. Lumbar puncture is generally a safe procedure but complications can occur, ranging from minor (eg, back pain) to potentially devastating (eg, cerebral herniation). Evidence that an atraumatic needle tip design reduces complications of lumbar puncture is compelling, and reinforces the need to change clinical practice.	[Costerus, Joost M.; Brouwer, Matthijs C.; van de Beek, Diederik] Univ Amsterdam, Acad Med Ctr, Dept Neurol, Amsterdam Neurosci, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	van de Beek, D (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Amsterdam Neurosci, NL-1100 DD Amsterdam, Netherlands.	d.vandebeek@amc.uva.nl	van de Beek, Diederik/Y-2713-2019	van de Beek, Diederik/0000-0002-4571-044X; Brouwer, Matthijs/0000-0001-7775-7843	Netherlands Organisation for Health Research and Development (ZonMw, NWO) [917.17.308, 016.116.358]; European Research Council (ERC Starting Grant)	Netherlands Organisation for Health Research and Development (ZonMw, NWO); European Research Council (ERC Starting Grant)(European Research Council (ERC))	MCB is supported by the Netherlands Organisation for Health Research and Development (ZonMw, NWO-Vidi-Grant [917.17.308]). DvdB is funded by the Netherlands Organisation for Health Research and Development (ZonMW, NWO-Vidi-Grant [016.116.358]) and the European Research Council (ERC Starting Grant).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Akiyama M, 2016, CLIN CHIM ACTA, V460, P120, DOI 10.1016/j.cca.2016.06.032; Alcolea D, 2017, NEUROLOGY, V89, P178, DOI 10.1212/WNL.0000000000004088; Amorim JA, 2012, CEPHALALGIA, V32, P916, DOI 10.1177/0333102412453951; Angeletti S, 2017, J MICROBIOL METH, V138, P20, DOI 10.1016/j.mimet.2016.09.003; Arevalo-Rodriguez I, 2016, COCHRANE DB SYST REV, V3; Avery RA, 2010, NEW ENGL J MED, V363, P891, DOI 10.1056/NEJMc1004957; Baer ET, 2006, ANESTHESIOLOGY, V105, P381, DOI 10.1097/00000542-200608000-00022; Basurto Ona X, 2015, COCHRANE DB SYST REV, V7; Beauchesne P, 2010, LANCET ONCOL, V11, P871, DOI 10.1016/S1470-2045(10)70034-6; Beh SC, 2013, NEUROL CLIN, V31, P79, DOI 10.1016/j.ncl.2012.09.008; BOONMAK P, 2010, COCHRANE DB SYST REV, V1; BREUER AC, 1982, CANCER-AM CANCER SOC, V49, P2168, DOI 10.1002/1097-0142(19820515)49:10<2168::AID-CNCR2820491031>3.0.CO;2-O; Brouwer MC, 2014, NEW ENGL J MED, V371, P447, DOI 10.1056/NEJMra1301635; Brouwer MC, 2014, NEUROLOGY, V82, P806, DOI 10.1212/WNL.0000000000000172; Brown Merritt Weaver, 2016, Surg Neurol Int, V7, pS581, DOI 10.4103/2152-7806.189441; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Chang CC, 2016, CURR OPIN INFECT DIS, V29, P539, DOI 10.1097/QCO.0000000000000315; Chong GM, 2016, J CLIN MICROBIOL, V54, P428, DOI 10.1128/JCM.02913-15; Crock C, 2014, ARCH DIS CHILD, V99, P203, DOI 10.1136/archdischild-2013-305145; Davis A, 2014, EUR J NEUROL, V21, P305, DOI 10.1111/ene.12307; de Almeida SM, 2011, HEADACHE, V51, P1503, DOI 10.1111/j.1526-4610.2011.01959.x; de Vries RMV, 2017, JAMA NEUROL, V74, P284, DOI 10.1001/jamaneurol.2016.4997; Duits FH, 2016, ALZHEIMERS DEMENT, V12, P154, DOI 10.1016/j.jalz.2015.08.003; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Edwards C, 2015, NEUROLOGY, V84, pE69, DOI 10.1212/WNL.0000000000001335; Engelborghs Sebastiaan, 2017, Alzheimers Dement (Amst), V8, P111, DOI 10.1016/j.dadm.2017.04.007; Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Finkel RS, 2016, LANCET, V388, P3017, DOI 10.1016/S0140-6736(16)31408-8; Foerster MV, 2015, PEDIATR ANESTH, V25, P206, DOI 10.1111/pan.12527; Gaiani A, 2017, JAMA NEUROL, V74, P525, DOI 10.1001/jamaneurol.2016.5398; Gogarten W, 2010, EUR J ANAESTH, V27, P999, DOI 10.1097/EJA.0b013e32833f6f6f; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Hanson KE, 2016, J CLIN MICROBIOL, V54, P2222, DOI [10.1128/JCM.00730-16, 10.1128/JCM.01255-16]; Hartmeyer GN, 2010, SCAND J INFECT DIS, V42, P716, DOI 10.3109/00365541003754493; Hasnat MJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004552.pub2; Havens MA, 2016, NUCLEIC ACIDS RES, V44, P6549, DOI 10.1093/nar/gkw533; Hegen H, 2016, CLIN CHEM LAB MED, V54, P285, DOI 10.1515/cclm-2015-0253; Heiss JD, 2011, J NEURO-ONCOL, V104, P365, DOI 10.1007/s11060-010-0458-4; Hoang-Xuan K, 2015, LANCET ONCOL, V16, pE322, DOI 10.1016/S1470-2045(15)00076-5; Hoffmann B, 2015, NEW ENGL J MED, V373, P154, DOI 10.1056/NEJMoa1415627; Houldcroft CJ, 2017, NAT REV MICROBIOL, V15, P183, DOI 10.1038/nrmicro.2016.182; Huy NT, 2010, CRIT CARE, V14, DOI 10.1186/cc9268; Hytonen J, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-103; Jabbari E, 2017, J NEUROL NEUROSUR PS, V88, P883, DOI 10.1136/jnnp-2017-315857; Kagiava A, 2016, P NATL ACAD SCI USA, V113, pE2421, DOI 10.1073/pnas.1522202113; Kasanmoentalib ES, 2010, NEUROLOGY, V75, P918, DOI 10.1212/WNL.0b013e3181f11e10; Kate Mahesh P, 2014, F1000Res, V3, P41, DOI 10.12688/f1000research.3-41.v1; Kennedy PGE, 2013, LANCET NEUROL, V12, P186, DOI 10.1016/S1474-4422(12)70296-X; Kerklaan BM, 2016, NEURO-ONCOLOGY, V18, P855, DOI 10.1093/neuonc/nov273; Khatib U, 2017, J INFECTION, V74, P1, DOI 10.1016/j.jinf.2016.09.007; Kleines M, 2014, DIAGN MICR INFEC DIS, V80, P207, DOI 10.1016/j.diagmicrobio.2014.07.010; Koedel U, 2015, NAT REV NEUROL, V11, P446, DOI 10.1038/nrneurol.2015.121; Krishnan P, 2013, ANN INDIAN ACAD NEUR, V16, P440, DOI 10.4103/0972-2327.116935; Kroll H, 2015, AM J ROENTGENOL, V204, P15, DOI 10.2214/AJR.14.12622; Kwong JC, 2015, PATHOLOGY, V47, P199, DOI 10.1097/PAT.0000000000000235; Leber AL, 2016, J CLIN MICROBIOL, V54, P2251, DOI 10.1128/JCM.00730-16; Leen WG, 2013, JAMA NEUROL, V70, P1440, DOI 10.1001/jamaneurol.2013.3090; LEONHARD SE, 2016, MEDICINE, V95; Li DX, 2017, NEUROSCIENCE, V365, P192, DOI 10.1016/j.neuroscience.2017.10.001; Li W, 2017, J CLIN MICROBIOL, V55, P1193, DOI [10.1128/JCM.02018-16, 10.1128/jcm.02018-16]; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7; Magdalinou NK, 2015, J NEUROL NEUROSUR PS, V86, P1240, DOI 10.1136/jnnp-2014-309562; Markey KA, 2016, LANCET NEUROL, V15, P78, DOI 10.1016/S1474-4422(15)00298-7; Marra CM, 2015, NEUROINFECT DIS, V21, P1714, DOI DOI 10.1212/C0N.0000000000000250; Maski K, 2016, LANCET NEUROL, V15, P1170, DOI 10.1016/S1474-4422(16)30204-6; McGill F, 2016, LANCET, V388, P3036, DOI 10.1016/S0140-6736(16)30654-7; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; McLane HC, 2015, NEUROLOGY, V85, P1614, DOI 10.1212/WNL.0000000000002090; Moat S, 2010, MOL GENET METAB, V101, P149, DOI 10.1016/j.ymgme.2010.07.006; Moisset X, 2016, EUR NEUROL, V76, P8, DOI 10.1159/000447452; Mouzaki A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135434; Muayqil T, 2012, NEUROLOGY, V79, P1499, DOI 10.1212/WNL.0b013e31826d5fc3; Nagy K, 2013, CLIN CHEM LAB MED, V51, P2073, DOI 10.1515/cclm-2012-0783; Nath S, 2018, LANCET, V391, P1197, DOI 10.1016/S0140-6736(17)32451-0; O'Bryant SE, 2017, ALZHEIMERS DEMENT, V13, P45, DOI 10.1016/j.jalz.2016.09.014; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314; Petereit HF, 2010, J NEUROL, V257, P1855, DOI 10.1007/s00415-010-5623-3; Poesen K, 2017, NEUROLOGY, V88, P2302, DOI 10.1212/WNL.0000000000004029; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Raza SM, 2016, J NEUROSURG, V124, P621, DOI 10.3171/2014.12.JNS14995; Reiber H, 2016, ARQ NEURO-PSIQUIAT, V74, P501, DOI 10.1590/0004-282X20160066; Reiber H, 2016, ARQ NEURO-PSIQUIAT, V74, P337, DOI 10.1590/0004-282X20160044; Remy MM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0948-9; Rochester L, 2017, NEUROLOGY, V88, P1501, DOI 10.1212/WNL.0000000000003840; Rolfes MA, 2014, CLIN INFECT DIS, V59, P1607, DOI 10.1093/cid/ciu596; Sakushima K, 2011, J INFECTION, V62, P255, DOI 10.1016/j.jinf.2011.02.010; Salvarani C, 2012, LANCET, V380, P767, DOI 10.1016/S0140-6736(12)60069-5; Schmidt C, 2011, NEUROLOGY, V76, P1051, DOI 10.1212/WNL.0b013e318211c39a; Scott BJ, 2013, JAMA NEUROL, V70, P311, DOI 10.1001/jamaneurol.2013.606; Segawa S, 2014, CLIN CHIM ACTA, V435, P59, DOI 10.1016/j.cca.2014.04.024; Steinacker P, 2016, J NEUROL NEUROSUR PS, V87, P12, DOI 10.1136/jnnp-2015-311387; Tan IL, 2012, LANCET NEUROL, V11, P605, DOI 10.1016/S1474-4422(12)70098-4; Tiberti N, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002088; van de Beek D, 2006, NEW ENGL J MED, V354, P44, DOI 10.1056/NEJMra052116; van de Beek D, 2016, CLIN MICROBIOL INFEC, V22, pS37, DOI 10.1016/j.cmi.2016.01.007; Van de Beek D, 2018, LANCET, V391, P1128, DOI 10.1016/S0140-6736(17)32480-7; van de Beek D, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.74; van de Beek D, 2010, NEW ENGL J MED, V362, P146, DOI 10.1056/NEJMra0804573; van Doorn LJCV, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00310; van Kooten F, 2008, J NEUROL NEUROSUR PS, V79, P553, DOI 10.1136/jnnp.2007.122879; van Oosterhout WPJ, 2013, NEUROLOGY, V80, P941, DOI 10.1212/WNL.0b013e3182840bf6; van Veen JJ, 2010, BRIT J HAEMATOL, V148, P15, DOI 10.1111/j.1365-2141.2009.07899.x; Vikse J, 2015, INT J INFECT DIS, V38, P68, DOI 10.1016/j.ijid.2015.07.011; Vincent IM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005140; Whiteley W, 2006, NEUROLOGY, V67, P1690, DOI 10.1212/01.wnl.0000242704.60275.e9; Wikkelso C, 2013, J NEUROL NEUROSUR PS, V84, P562, DOI 10.1136/jnnp-2012-303314; Williams Michael A, 2016, Continuum (Minneap Minn), V22, P579, DOI 10.1212/CON.0000000000000305; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Wolf DA, 2015, EXPERT OPIN DRUG DEL, V12, P283, DOI 10.1517/17425247.2015.966682; Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525	114	43	43	1	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					268	278		10.1016/S1474-4422(18)30033-4	http://dx.doi.org/10.1016/S1474-4422(18)30033-4			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29452686				2022-12-18	WOS:000425090000017
J	Jansen, IE; Bras, JM; Lesage, S; Schulte, C; Gibbs, JR; Nalls, MA; Brice, A; Wood, NW; Morris, H; Hardy, JA; Singleton, AB; Gasser, T; Heutink, P; Sharma, M				Jansen, Iris E.; Bras, Jose M.; Lesage, Suzanne; Schulte, Claudia; Gibbs, J. Raphael; Nalls, Mike A.; Brice, Alexis; Wood, Nicholas W.; Morris, Huw; Hardy, John A.; Singleton, Andrew B.; Gasser, Thomas; Heutink, Peter; Sharma, Manu		IPDGC	CHCHD2 and Parkinson's disease	LANCET NEUROLOGY			English	Letter							GENOME-WIDE ASSOCIATION; LOCI		[Jansen, Iris E.; Heutink, Peter] Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [Jansen, Iris E.; Schulte, Claudia; Gasser, Thomas; Heutink, Peter] German Ctr Neurodegenerat Dis, Tubingen, Germany; [Bras, Jose M.; Wood, Nicholas W.] UCL, Inst Neurol, Dept Mol Neurosci, London, England; [Lesage, Suzanne; Brice, Alexis] Univ Paris 06, Univ Sorbonne, INSERM, CNRS, Paris, France; [Lesage, Suzanne; Brice, Alexis] Inst Cerveau & Moelle Epiniere, Paris, France; [Lesage, Suzanne; Brice, Alexis] Hop La Pitie Salpetriere, AP HP, Dept Genet & Cytogenet, Paris, France; [Schulte, Claudia; Gasser, Thomas; Heutink, Peter; Sharma, Manu] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Tubingen, Germany; [Gibbs, J. Raphael; Nalls, Mike A.; Singleton, Andrew B.] NIA, Neurogenet Lab, Bethesda, MD 20892 USA; [Morris, Huw] UCL, Natl Hosp Neurol & Neurosurg, London, England; [Hardy, John A.] UCL, Rita Lila Weston Inst, London, England; [Sharma, Manu] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Ctr Genet Epidemiol, D-70276 Tubingen, Germany	Vrije Universiteit Amsterdam; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; Eberhard Karls University of Tubingen	Jansen, IE (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.	manu.sharma@uni-tuebingen.de	Brice, Alexis/A-2170-2009; Hardy, John/C-2451-2009; Wood, Nicholas W/C-2505-2009; Sharma, Manu/AAX-2594-2020; Morris, Huw R/B-8527-2008; Gibbs, J. Raphael/A-3984-2010; brice, alexis/AAE-8275-2019; Singleton, Andrew B/C-3010-2009; Liu, Jianjun/AAK-4989-2020; Gasser, Thomas/GNH-5293-2022; Lubbe, Steven/L-8261-2013	Hardy, John/0000-0002-3122-0423; Wood, Nicholas W/0000-0002-9500-3348; Morris, Huw R/0000-0002-5473-3774; Gibbs, J. Raphael/0000-0002-6985-0658; brice, alexis/0000-0002-0941-3990; Liu, Jianjun/0000-0002-3255-3019; Gasser, Thomas/0000-0002-1069-1146; Lubbe, Steven/0000-0002-7103-6671; Bras, Jose/0000-0001-8186-0333; Schulte, Claudia/0000-0003-4006-1265; Heutink, Peter/0000-0001-5218-1737	MRC [G0700943, G1100643] Funding Source: UKRI; Alzheimers Research UK [ARUK-PhD2014-16] Funding Source: researchfish; Medical Research Council [G1100643, G0700943] Funding Source: researchfish; NATIONAL INSTITUTE ON AGING [ZIAAG000958, ZIAAG000949] Funding Source: NIH RePORTER; Medical Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485; Trinh J, 2013, NAT REV NEUROL, V9, P445, DOI 10.1038/nrneurol.2013.132	4	43	43	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					678	679		10.1016/S1474-4422(15)00094-0	http://dx.doi.org/10.1016/S1474-4422(15)00094-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067110				2022-12-18	WOS:000356195900008
J	Ederle, J; Davagnanam, I; van der Worp, HB; Venables, GS; Lyrer, PA; Featherstone, RL; Brown, MM; Jager, HR				Ederle, Joerg; Davagnanam, Indran; van der Worp, H. Bart; Venables, Graham S.; Lyrer, Philippe A.; Featherstone, Roland L.; Brown, Martin M.; Jaeger, H. Rolf		ICSS Investigators	Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial	LANCET NEUROLOGY			English	Article							CEREBRAL-BLOOD-FLOW; LEUKOARAIOSIS; STENOSIS; DISEASE; ANGIOPLASTY; PREDICTS; MARKERS	Background Findings from randomised trials have shown a higher early risk of stroke after carotid artery stenting than after carotid endarterectomy. We assessed whether white-matter lesions affect the perioperative risk of stroke in patients treated with carotid artery stenting versus carotid endarterectomy. Methods Patients with symptomatic carotid artery stenosis induded in the International Carotid Stenting Study (ICSS) were randomly allocated to receive carotid artery stenting or carotid endarterectomy. Copies of baseline brain imaging were analysed by two investigators, who were masked to treatment, for the severity of white-matter lesions using the age-related white-matter changes (ARWMC) score. Randomisation was done with a computer-generated sequence (1:1). Patients were divided into two groups using the median ARWMC. We analysed the risk of stroke within 30 days of revascularisation using a per-protocol analysis. ICSS is registered with controlled-trials.com, number ISRCTN 25337470. Findings 1036 patients (536 randomly allocated to carotid artery stenting, 500 to carotid endarterectomy) had baseline imaging available. Median ARWMC score was 7, and patients were dichotomised into those with a score of 7 or more and those with a score of less than 7. In patients treated with carotid artery stenting, those with an ARWMC score of 7 or more had an increased risk of stroke compared with those with a score of less than 7 (HR for any stroke 2.76, 95% CI 1.17-6.51; p=0.021; HR for non-disabling stroke 3.00, 1.10-8.36; p=0.031), but we did not see a similar association in patients treated with carotid endarterectomy (HR for any stroke 1.18, 0.40-3.55; p=0. 76; HR for disabling or fatal stroke 1.41, 0.38-5.26; p=0 607). Carotid artery stenting was associated with a higher risk of stroke compared with carotid endarterectomy in patients with an ARWMC score of 7 or more (HR for any stroke 2.98, 1.29-6.93; p=0. 011; HR for non-disabling stroke 6.34, 1.45-27. 71; p=0. 014), but there was no risk difference in patients with an ARWMC score of less than 7. Interpretation The presence of white-matter lesions on brain imaging should be taken into account when selecting patients for carotid revascularisation. Carotid artery stenting should be avoided in patients with more extensive white-matter lesions, but might be an acceptable alternative to carotid endarterectomy in patients with less extensive lesions.	[Ederle, Joerg; Featherstone, Roland L.; Brown, Martin M.; Jaeger, H. Rolf] UCL Inst Neurol, Stroke Res Grp, Dept Brain Repair & Rehabil, London WC1N 3BG, England; [Davagnanam, Indran; Jaeger, H. Rolf] UCL Inst Neurol, Lysholm Dept Neuroradiol, London WC1N 3BG, England; [van der Worp, H. Bart] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht Stroke Ctr, Utrecht, Netherlands; [Venables, Graham S.] Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England; [Lyrer, Philippe A.] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland	University of London; University College London; University of London; University College London; Utrecht University; Utrecht University Medical Center; University of Sheffield; University of Basel	Brown, MM (corresponding author), UCL Inst Neurol, Natl Hosp Neurol & Neurosurg, Box 6,Queen Sq, London WC1N 3BG, England.	martin.brown@ucl.ac.uk	Vanhooren, Geert/H-4433-2011; de Leeuw, Frank-Erik/E-4795-2012; Jäger, Hans Rolf/K-1868-2013; Gillgren, Peter/AAB-4724-2020; Blankensteijn, Jan D/Q-9291-2016; Mali, Willem PThM/I-1123-2014; van der Vliet, J. Adam/L-4721-2015; Hirt, Lorenz/G-3553-2010; Kool, L.J. Schultze/H-8088-2014; Bonati, Leo/G-4058-2012; Ijäs, Petra/F-8280-2015; Skjelland, Mona/B-7362-2016	Vanhooren, Geert/0000-0001-6818-9346; Jäger, Hans Rolf/0000-0002-6403-4184; Gillgren, Peter/0000-0003-0538-3496; Blankensteijn, Jan D/0000-0002-2062-8749; Mali, Willem PThM/0000-0003-4391-0904; Hirt, Lorenz/0000-0002-2921-5000; Bonati, Leo/0000-0003-1163-8133; Ijäs, Petra/0000-0002-7292-1971; Bonvin, Christophe/0000-0002-9058-8105; Malmstedt, Jonas/0000-0002-2758-9623; lovblad, karl-olof/0000-0003-2768-9779; Wahlgren, Carl Magnus/0000-0002-9619-3577; Hendriks, Jeroen/0000-0001-9145-3643; Engelter, Stefan/0000-0003-3855-6234; Krohg-Sorensen, Kirsten/0000-0002-5713-809X; Brown, Martin M/0000-0002-3273-1356; Kaste, Markku/0000-0001-6557-6412	Medical Research Council; Stroke Association, Sanofi-Synthelabo; European Union Research Framework Programme 5; MRC [G0300411] Funding Source: UKRI; Medical Research Council [G0300411] Funding Source: researchfish; National Institute for Health Research [PB-PG-0609-19216, NF-SI-0507-10339, 06/301/233] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Stroke Association, Sanofi-Synthelabo; European Union Research Framework Programme 5; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Funding Medical Research Council, the Stroke Association, Sanofi-Synthelabo, the European Union Research Framework Programme 5.	Altaf N, 2006, EUR J VASC ENDOVASC, V31, P8, DOI 10.1016/j.ejvs.2005.08.026; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Arshad Ali, 2009, Perspect Vasc Surg Endovasc Ther, V21, P173, DOI 10.1177/1531003509351095; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Bastos-Leite AJ, 2008, AM J NEURORADIOL, V29, P1296, DOI 10.3174/ajnr.A1091; Black S, 2009, STROKE, V40, pS48, DOI 10.1161/STROKEAHA.108.537704; Bonati LH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000515.pub4; Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Chutinet A, 2012, AM J NEURORADIOL, V33, P1591, DOI 10.3174/ajnr.A3015; Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0; Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Enzinger C, 2007, J NEUROL SCI, V257, P5, DOI 10.1016/j.jns.2007.01.018; Featherstone RL, 2004, CEREBROVASC DIS, V18, P69, DOI 10.1159/000078753; Fu JH, 2005, J NEUROL NEUROSUR PS, V76, P793, DOI 10.1136/jnnp.2003.032771; Grueter BE, 2012, POSTGRAD MED J, V88, P79, DOI 10.1136/postgradmedj-2011-130307; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; Hassan A, 2003, BRAIN, V126, P424, DOI 10.1093/brain/awg040; Jeerakathil T, 2004, STROKE, V35, P1857, DOI 10.1161/01.STR.0000135226.53499.85; Leys D, 1999, EUR NEUROL, V42, P67, DOI 10.1159/000069414; Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9; Nagai M, 2012, AM J HYPERTENS, V25, P1088, DOI 10.1038/ajh.2012.85; O'Sullivan M, 2002, NEUROLOGY, V59, P321, DOI 10.1212/WNL.59.3.321; Pantoni L, 1997, STROKE, V28, P652, DOI 10.1161/01.STR.28.3.652; PANTONI L, 1995, STROKE, V26, P1293, DOI 10.1161/01.STR.26.7.1293; Simoni M, 2010, CEREBROVASC DIS, V29, P300; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P21, DOI 10.1001/archneur.1995.00540250025008; Streifler JY, 2002, STROKE, V33, P1651, DOI 10.1161/01.STR.0000018010.38749.08; TarvonenSchroder S, 1996, J NEUROL NEUROSUR PS, V60, P431, DOI 10.1136/jnnp.60.4.431; Topakian R, 2010, J NEUROL NEUROSUR PS, V81, P192, DOI 10.1136/jnnp.2009.172072; VANSWIETEN JC, 1991, BRAIN, V114, P761; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Wattjes MP, 2009, RADIOLOGY, V253, P174, DOI 10.1148/radiol.2531082262	34	43	47	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					866	872		10.1016/S1474-4422(13)70135-2	http://dx.doi.org/10.1016/S1474-4422(13)70135-2			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210WU	23849948	Green Published, hybrid			2022-12-18	WOS:000323866600015
J	Eiger, CE; Mormann, F				Eiger, Christian E.; Mormann, Florian			Seizure prediction and documentation-two important problems	LANCET NEUROLOGY			English	Editorial Material							EPILEPSY		[Eiger, Christian E.; Mormann, Florian] Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany	University of Bonn	Eiger, CE (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany.	christian.elger@ukb.uni-bonn.de	Mormann, Florian/K-1582-2014	Mormann, Florian/0000-0003-1305-8028				Andrzejak RG, 2009, CLIN NEUROPHYSIOL, V120, P1465, DOI 10.1016/j.clinph.2009.05.019; Cook MJ, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70075-9; Fisher RS, 2012, EPILEPSY BEHAV, V24, P304, DOI 10.1016/j.yebeh.2012.04.128; Hoppe C, 2007, ARCH NEUROL-CHICAGO, V64, P1595, DOI 10.1001/archneur.64.11.1595; Kerling F, 2006, EPILEPSY BEHAV, V9, P281, DOI 10.1016/j.yebeh.2006.05.010; Klatt J, 2012, EPILEPSIA, V53, P1669, DOI 10.1111/j.1528-1167.2012.03564.x; Mormann F, 2005, CLIN NEUROPHYSIOL, V116, P569, DOI 10.1016/j.clinph.2004.08.025; Mormann F., 2008, SCHOLARPEDIA, V3, P5770; Mormann F, 2007, BRAIN, V130, P314, DOI 10.1093/brain/awl241; Park Y, 2011, EPILEPSIA, V52, P1761, DOI 10.1111/j.1528-1167.2011.03138.x; Snyder DE, 2008, J NEURAL ENG, V5, P392, DOI 10.1088/1741-2560/5/4/004	11	43	44	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2013	12	6					531	532		10.1016/S1474-4422(13)70092-9	http://dx.doi.org/10.1016/S1474-4422(13)70092-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161SL	23642341				2022-12-18	WOS:000320213500005
J	Centner, CM; Bateman, KJ; Heckmann, JM				Centner, Chad M.; Bateman, Kathleen J.; Heckmann, Jeannine M.			Manifestations of HIV infection in the peripheral nervous system	LANCET NEUROLOGY			English	Review							INFILTRATIVE LYMPHOCYTOSIS SYNDROME; ACUTE LUMBOSACRAL POLYRADICULOPATHY; ACTIVE ANTIRETROVIRAL THERAPY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; BRACHIAL AMYOTROPHIC DIPLEGIA; DISTAL SENSORY POLYNEUROPATHY; PREDICT NEUROPATHY RISK; GUILLAIN-BARRE-SYNDROME; QUALITY-OF-LIFE; DOUBLE-BLIND	Peripheral nerve disorders are associated with all stages of HIV infection. Distal sensory polyneuropathy is characterised by often-disabling pain that is difficult to treat. It is prevalent in both high-income and low-income settings. In low-income settings, use of potentially neurotoxic antiretrovirals, which are inexpensive and widely available, contributes substantially to incidence. Research has focused on identification of factors that predict risk of distal sensory polyneuropathy and elucidation of the multifactorial mechanisms behind pathogenesis. Sensorimotor polyneuropathies and polyradiculopathies are less frequent than distal sensory polyneuropathy, but still occur in low-income settings and have potentially devastating consequences. However, many of these diseases can be treated successfully with a combination of antiretroviral and immune-modulating therapies. To distinguish between peripheral nerve disorders that have diverse, overlapping, and frequently atypical presentations can be challenging; a framework based on a clinicoanatomical approach might assist in the diagnosis and management of such disorders.	[Centner, Chad M.; Heckmann, Jeannine M.] Univ Cape Town, Groote Schuur Hosp, Neurol Res Grp, ZA-7925 Cape Town, South Africa; [Bateman, Kathleen J.; Heckmann, Jeannine M.] Univ Cape Town, Groote Schuur Hosp, Div Neurol, Dept Med, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Cape Town	Heckmann, JM (corresponding author), Groote Schuur Hosp, Neurol Res Grp, ZA-7925 Cape Town, South Africa.	jeanine.heckmann@uct.ac.za	Heckmann, Jeannine M/K-3972-2019	Heckmann, Jeannine M/0000-0002-8999-718X; Centner, Chad/0000-0001-7289-534X; Bateman, Kathleen/0000-0002-0213-7102	Pfizer; University of Cape Town Neurology Research Fund	Pfizer(Pfizer); University of Cape Town Neurology Research Fund	JMH was a site investigator on a Pfizer-sponsored study of pregabalin for pain in HIV infection. CMC and KJB declare that they have no conflicts of interest.; CMC was supported by the University of Cape Town Neurology Research Fund.	Abad S, 2002, CLIN INFECT DIS, V34, P1162, DOI 10.1086/339756; Acharjee S, 2011, BRAIN, V134, P3209, DOI 10.1093/brain/awr242; Acharjee S, 2010, FASEB J, V24, P4343, DOI 10.1096/fj.10-162313; Affandi JS, 2008, AIDS RES HUM RETROV, V24, P1281, DOI 10.1089/aid.2008.0045; Anziska Y, 2012, J NEUROL SCI, V315, P129, DOI 10.1016/j.jns.2011.11.009; Arenas-Pinto A, 2008, ANTIVIR THER, V13, P289; Babu K, 2009, INDIAN J OPHTHALMOL, V57, P315, DOI 10.4103/0301-4738.53062; Backonja Misha-Miroslav, 2006, Curr Pain Headache Rep, V10, P34, DOI 10.1007/s11916-006-0007-1; Banerjee S, 2011, AIDS, V25, pF1, DOI 10.1097/QAD.0b013e328341dd68; Basu D, 2006, ARTHRIT RHEUM-ARTHR, V55, P466, DOI 10.1002/art.21980; BELEC L, 1989, J NEUROL, V236, P411, DOI 10.1007/BF00314900; Benatar MG, 2000, ARCH NEUROL-CHICAGO, V57, P1034, DOI 10.1001/archneur.57.7.1034; Benatar M, 2006, MUSCLE NERVE, V34, P131, DOI 10.1002/mus.20573; Berger JR, 2005, ARCH NEUROL-CHICAGO, V62, P817, DOI 10.1001/archneur.62.5.817; Bhangoo SK, 2007, BRAIN BEHAV IMMUN, V21, P581, DOI 10.1016/j.bbi.2006.12.003; Biraguma J, 2012, SAHARA J-J SOC ASP H, V9, P88, DOI 10.1080/17290376.2012.683582; Bradley WG, 1996, NEUROLOGY, V47, P1446, DOI 10.1212/WNL.47.6.1446; Brannagan TH, 2003, J NEUROL SCI, V208, P39, DOI 10.1016/S0022-510X(02)00418-5; Brew BJ, 2003, MUSCLE NERVE, V28, P542, DOI 10.1002/mus.10484; Calado S, 2004, J NEUROL NEUROSUR PS, V75, P660, DOI 10.1136/jnnp.2003.023564; Cepeda MS, 2012, PAIN MED, V13, P575, DOI 10.1111/j.1526-4637.2012.01340.x; Cersosimo MG, 2002, CLIN NEUROPHARMACOL, V25, P51, DOI 10.1097/00002826-200201000-00009; Chahin N, 2010, MUSCLE NERVE, V41, P276, DOI 10.1002/mus.21507; Chand V, 1997, CLIN INFECT DIS, V24, P521, DOI 10.1093/clinids/24.3.521; Chen-Plotkin AS, 2007, AIDS, V21, P1663, DOI 10.1097/QAD.0b013e32827038e1; Cherry CL, 2010, NEUROLOGY, V74, P1538, DOI 10.1212/WNL.0b013e3181dd436d; Cherry CL, 2009, NEUROLOGY, V73, P315, DOI 10.1212/WNL.0b013e3181af7a22; Cherry CL, 2005, NEUROLOGY, V65, P1778, DOI 10.1212/01.wnl.0000187119.33075.41; Choi Y, 2011, J NEUROVIROL, V17, P166, DOI 10.1007/s13365-011-0022-9; Clifford DB, 2012, JAIDS-J ACQ IMM DEF, V59, P126, DOI 10.1097/QAI.0b013e31823e31f7; Compostella C, 2008, CLIN AUTON RES, V18, P6, DOI 10.1007/s10286-007-0451-y; Ellis RJ, 2010, ARCH NEUROL-CHICAGO, V67, P552, DOI 10.1001/archneurol.2010.76; Ellis RJ, 2009, NEUROPSYCHOPHARMACOL, V34, P672, DOI 10.1038/npp.2008.120; Ellis RJ, 2008, ANN NEUROL, V64, P566, DOI 10.1002/ana.21484; Estanislao L, 2004, MITOCHONDRION, V4, P131, DOI 10.1016/j.mito.2004.06.007; Estanislao LB, 2005, AIDS, V19, pS135, DOI 10.1097/01.aids.0000192082.41561.49; Evans SR, 2012, J NEUROVIROL, V18, P428, DOI 10.1007/s13365-012-0119-9; Evans SR, 2011, AIDS, V25, P919, DOI 10.1097/QAD.0b013e328345889d; Ferrari LF, 2010, EUR J NEUROSCI, V32, P811, DOI 10.1111/j.1460-9568.2010.07355.x; Finney KA, 2012, INT J STD AIDS, V23, P143, DOI 10.1258/ijsa.2011.011176; Forna F, 2007, JAIDS-J ACQ IMM DEF, V44, P456, DOI 10.1097/QAI.0b013e318033ffa1; FULLER GN, 1993, J NEUROL NEUROSUR PS, V56, P372, DOI 10.1136/jnnp.56.4.372; Golbus Jessica R, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P223, DOI 10.1177/1545109712442798; GOZLAN J, 1995, AIDS, V9, P253, DOI 10.1097/00002030-199509030-00006; GRIFFIN JW, 1994, RES P ARNMD, V72, P159; Hahn K, 2004, J NEUROL, V251, P1260, DOI 10.1007/s00415-004-0529-6; Henning F, 2008, J NEUROL NEUROSUR PS, V79, P1392, DOI 10.1136/jnnp.2008.147272; Hernandez-Albujar S, 2000, CLIN INFECT DIS, V30, P915, DOI 10.1086/313821; HUANG PP, 1993, ARCH NEUROL-CHICAGO, V50, P1328, DOI 10.1001/archneur.1993.00540120041011; ITESCU S, 1994, P NATL ACAD SCI USA, V91, P11472, DOI 10.1073/pnas.91.24.11472; ITESCU S, 1992, RHEUM DIS CLIN N AM, V18, P683; ITESCU S, 1990, ANN INTERN MED, V112, P3, DOI 10.7326/0003-4819-112-1-3; Jones G, 2005, VIROLOGY, V334, P178, DOI 10.1016/j.virol.2005.01.027; Kamerman PR, 2012, CURR PAIN HEADACHE R, V16, P226, DOI 10.1007/s11916-012-0257-z; Kamerman PR, 2012, J PERIPHER NERV SYST, V17, P19, DOI 10.1111/j.1529-8027.2012.00373.x; Kandiah PA, 2010, J NEUROL NEUROSUR PS, V81, P1380, DOI 10.1136/jnnp.2009.183210; Kazi S, 1996, AIDS, V10, P385, DOI 10.1097/00002030-199604000-00006; KEANE JR, 1994, NEUROLOGY, V44, P1198, DOI 10.1212/WNL.44.7.1198; Keltner JR, 2012, PSYCHOSOMATICS, V53, P380, DOI 10.1016/j.psym.2012.05.002; Keswani SC, 2003, ANN NEUROL, V54, P287, DOI 10.1002/ana.10645; Koeppe J, 2012, CLIN J PAIN, V28, P32, DOI 10.1097/AJP.0b013e318220199d; Kumar N, 2007, NEUROL CLIN, V25, P209, DOI 10.1016/j.ncl.2006.11.001; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; Lanternier F, 2007, INT J TUBERC LUNG D, V11, P1203; LEGER JM, 1992, J NEUROL, V239, P132, DOI 10.1007/BF00833911; Lehmann HC, 2011, ANN NEUROL, V69, P100, DOI 10.1002/ana.22150; Lichtenstein KA, 2005, CLIN INFECT DIS, V40, P148, DOI 10.1086/426076; Lichtenstein KA, 2008, JAIDS-J ACQ IMM DEF, V47, P27, DOI 10.1097/QAI.0b013e31815acacc; Lucey BP, 2011, AIDS CARE, V23, P921, DOI 10.1080/09540121.2010.543883; Makela P, 2002, J INFECTION, V44, P47, DOI 10.1053/jinf.2001.0917; Marais S, 2010, TUBERCULOSIS, V90, P367, DOI 10.1016/j.tube.2010.08.006; Maritz J, 2010, MUSCLE NERVE, V41, P599, DOI 10.1002/mus.21535; Marks DJB, 2009, INT J STD AIDS, V20, P339, DOI 10.1258/ijsa.2008.008361; Masjuan J, 1997, J ACQ IMMUN DEF SYND, V15, P175; McArthur CP, 2000, ARCH PATHOL LAB MED, V124, P1773; McArthur JC, 2000, NEUROLOGY, V54, P1080, DOI 10.1212/WNL.54.5.1080; McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053; Mehta SA, 2011, CLIN INFECT DIS, V53, P490, DOI 10.1093/cid/cir432; Mehta SA, 2010, AM J TROP MED HYG, V83, P565, DOI 10.4269/ajtmh.2010.09-0629; Melli G, 2006, BRAIN, V129, P1330, DOI 10.1093/brain/awl058; Miller RF, 1996, J NEUROL NEUROSUR PS, V61, P456, DOI 10.1136/jnnp.61.5.456; MILLER RG, 1988, MUSCLE NERVE, V11, P857, DOI 10.1002/mus.880110810; MILLER RG, 1990, NEUROLOGY, V40, P569, DOI 10.1212/WNL.40.4.569; Moghtaderi A, 2003, INT J TUBERC LUNG D, V7, P1186; MORGELLO S, 1994, MUSCLE NERVE, V17, P176, DOI 10.1002/mus.880170208; Morgello S, 2004, ARCH NEUROL-CHICAGO, V61, P546, DOI 10.1001/archneur.61.4.546; Moulignier A, 1997, ANN NEUROL, V41, P438, DOI 10.1002/ana.410410406; Moulignier A, 2003, J NEUROL, V250, P108, DOI 10.1007/s00415-003-0922-6; Mullin S, 2011, TROP MED INT HEALTH, V16, P1291, DOI 10.1111/j.1365-3156.2011.02825.x; Nakamoto BK, 2004, NEUROLOGY, V63, P2423, DOI 10.1212/01.WNL.0000147263.89255.B8; Nicholas PK, 2010, NURS HEALTH SCI, V12, P119, DOI 10.1111/j.1442-2018.2009.00505.x; Nishio M, 2001, J NEUROL, V248, P233, DOI 10.1007/s004150170233; Oshinaike O, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/961510; Ownby KK, 2007, J PAIN SYMPTOM MANAG, V34, P48, DOI 10.1016/j.jpainsymman.2006.10.013; Pardo CA, 2001, J PERIPHER NERV SYST, V6, P21, DOI 10.1046/j.1529-8027.2001.006001021.x; Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863; Pettersen JA, 2006, ANN NEUROL, V59, P816, DOI 10.1002/ana.20816; Phan V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030647; Phillips TJC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014433; Piliero PJ, 2004, NEUROLOGY, V62, P154, DOI 10.1212/WNL.62.1.154; Piliero PJ, 2003, CLIN INFECT DIS, V36, pE111, DOI 10.1086/368311; Robinson-Papp J, 2010, PAIN, V151, P732, DOI 10.1016/j.pain.2010.08.045; Robinson-Papp J, 2012, J NEUROVIROL, V18, P331, DOI 10.1007/s13365-011-0074-x; Robinson-Papp J, 2012, MUSCLE NERVE, V45, P471, DOI 10.1002/mus.23231; Robinson-Papp J, 2009, MUSCLE NERVE, V40, P1043, DOI 10.1002/mus.21465; Robinson-Papp J, 2009, JAIDS-J ACQ IMM DEF, V51, P569, DOI 10.1097/QAI.0b013e3181adcefa; SAID G, 1991, ANN NEUROL, V29, P139, DOI 10.1002/ana.410290205; Schleicher GK, 2003, CRIT CARE MED, V31, P1848, DOI 10.1097/01.CCM.0000069516.81522.F4; Serrano P, 2007, CLIN INFECT DIS, V44, pE57, DOI 10.1086/511876; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; Silva MTT, 2012, AIDS, V26, P521, DOI 10.1097/QAD.0b013e32834c4a3e; Simpson DM, 2006, NEUROLOGY, V66, P1679, DOI 10.1212/01.wnl.0000218303.48113.5d; Simpson DM, 2010, NEUROLOGY, V74, P413, DOI 10.1212/WNL.0b013e3181ccc6ef; Simpson DM, 2008, NEUROLOGY, V70, P2305, DOI 10.1212/01.wnl.0000314647.35825.9c; Simpson DM, 2003, NEUROLOGY, V60, P1508, DOI 10.1212/01.WNL.0000063304.88470.D9; SIMPSON DM, 1995, J ACQ IMMUN DEF SYND, V9, P153; Smyth K, 2007, HIV MED, V8, P367, DOI 10.1111/j.1468-1293.2007.00478.x; SO YT, 1994, ANN NEUROL, V35, P53, DOI 10.1002/ana.410350109; Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8; Tagliati M, 1999, ARCH NEUROL-CHICAGO, V56, P84, DOI 10.1001/archneur.56.1.84; Teo E C Y, 2007, J HIV Ther, V12, P62; van der Watt JJ, 2011, INT J TUBERC LUNG D, V15, P722, DOI 10.5588/ijtld.10.0284; Van Dyke RB, 2008, J INFECT DIS, V198, P1599, DOI 10.1086/593022; Vidal JE, 2007, ARQ NEURO-PSIQUIAT, V65, P848, DOI 10.1590/S0004-282X2007000500024; WADIA NH, 1969, J NEUROL SCI, V8, P239, DOI 10.1016/0022-510X(69)90112-9; Wadley AL, 2011, J PAIN SYMPTOM MANAG, V41, P700, DOI 10.1016/j.jpainsymman.2010.07.006; Wagner Jeffrey C, 2007, J Clin Neuromuscul Dis, V9, P303; Wallace VCJ, 2007, PAIN, V133, P47, DOI 10.1016/j.pain.2007.02.015; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; WILEY CA, 1987, NEUROLOGY, V37, P1791, DOI 10.1212/WNL.37.11.1791; Winston A, 2005, HIV MED, V6, P191, DOI 10.1111/j.1468-1293.2005.00288.x; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304; WOOLSEY RM, 1988, ARCH NEUROL-CHICAGO, V45, P691, DOI 10.1001/archneur.1988.00520300111030; Wright E, 2008, NEUROLOGY, V71, P50, DOI 10.1212/01.wnl.0000316390.17248.65; Youle M, 2007, HIV MED, V8, P241, DOI 10.1111/j.1468-1293.2007.00467.x; Zehender G, 2002, JAIDS, V31, P440, DOI 10.1097/00126334-200212010-00011	136	43	44	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2013	12	3					295	309		10.1016/S1474-4422(13)70002-4	http://dx.doi.org/10.1016/S1474-4422(13)70002-4			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SW	23415569				2022-12-18	WOS:000318531300015
J	Siccoli, MM; Bassetti, CL; Sandor, PS				Siccoli, MM; Bassetti, CL; Sandor, PS			Facial pain: clinical differential diagnosis	LANCET NEUROLOGY			English	Review							RED EAR SYNDROME; TOLOSA-HUNT-SYNDROME; TRIGEMINAL NEURALGIA; NEUROVASCULAR COMPRESSION; TEMPOROMANDIBULAR DISORDERS; MICROVASCULAR DECOMPRESSION; GLOSSOPHARYNGEAL NEURALGIA; CRANIAL NERVE; OPHTHALMOPLEGIC MIGRAINE; SUPRAORBITAL NEURALGIA	Differential diagnosis of pain in the face as the presenting complaint can be difficult. We propose an approach based on history and neurological examination, which allows a working diagnosis to be made at the bedside, including aetiological hypotheses, leading to a choice of investigations. Neuralgias are characterised by stabs of short lasting, lancinating pain, and, although neuralgias are often primary, imaging may be needed to exclude symptomatic forms. Facial pain with cranial nerve symptoms and signs is almost exclusively of secondary origin and requires urgent examination. Facial pain with focal autonomic signs is mostly primary and belongs to the group of the idiopathic trigeminal autonomic cephalalgias, but can occasionally be secondary. Pure facial pain is most often due to sinusitis and the chewing apparatus, but also a multitude of other causes. The pain can also be idiopathic. Imaging as well as non-neurological specialist assessment is often necessary in these cases.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Inst Neurol, London WC1N 3BG, England	University of Zurich; University Zurich Hospital; University of London; University College London	Sandor, PS (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	peter.sandor@usz.ch	Sandor, Peter/GRJ-5508-2022	Bassetti, Claudio/0000-0002-4535-0245				Abraham PJ, 2003, HEADACHE, V43, P499, DOI 10.1046/j.1526-4610.2003.03097.x; ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; Ahamed SH, 2003, J LARYNGOL OTOL, V117, P437, DOI 10.1258/002221503321892253; Al-Din AS, 2005, CEPHALALGIA, V25, P605, DOI 10.1111/j.1468-2982.2005.00935.x; ALPERT JN, 1977, ARCH NEUROL-CHICAGO, V34, P233, DOI 10.1001/archneur.1977.00500160047008; Aouba A, 2003, REV MED INTERNE, V24, P261, DOI 10.1016/S0248-8663(03)00029-8; Arjona A, 2005, CEPHALALGIA, V25, P479, DOI 10.1111/j.1468-2982.2005.00902.x; Bahra A, 2002, NEUROLOGY, V58, P354, DOI 10.1212/WNL.58.3.354; Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701; BECH RW, 1991, ARCH OPHTHALMOL-CHIC, V109, P1673, DOI 10.1001/archopht.1991.01080120057025; BINDOFF LA, 1988, LANCET, V1, P812; BIOUSSE V, 1994, CEPHALALGIA, V14, P33, DOI 10.1046/j.1468-2982.1994.1401033.x; BIOUSSE V, 1994, NEUROLOGY, V44, P993, DOI 10.1212/WNL.44.6.993; Biousse V, 2000, SEMIN NEUROL, V20, P55, DOI 10.1055/s-2000-6833; Blattler T, 2003, NEUROLOGY, V60, P2012, DOI 10.1212/01.WNL.0000068015.58948.D3; Boecher-Schwarz HG, 1998, NEURORADIOLOGY, V40, P88, DOI 10.1007/s002340050546; BOGOUSSLAVSKY J, 1987, NEUROLOGY, V37, P263, DOI 10.1212/WNL.37.2.263; BRUYN GW, 1984, CEPHALALGIA, V4, P71, DOI 10.1046/j.1468-2982.1984.0401071.x; BRUYN GW, 1983, CEPHALALGIA, V3, P143, DOI 10.1046/j.1468-2982.1983.0303143.x; Bruyn GW, 1986, HEADACHE HDB CLIN NE, V4, P487; BRUYN GW, 1986, HEADACHE HDB CLIN NE, V4, P483; Cady RK, 2002, NEUROLOGY, V58, pS10, DOI 10.1212/WNL.58.9_suppl_6.S10; Caminero AB, 2001, CEPHALALGIA, V21, P216, DOI 10.1046/j.1468-2982.2001.00190.x; Capobianco DJ, 1995, HEADACHE, V35, P581, DOI 10.1111/j.1526-4610.1995.hed3510581.x; CASELLI RJ, 1988, NEUROLOGY, V38, P352, DOI 10.1212/WNL.38.3.352; CHENG TMW, 1993, NEUROLOGY, V43, P2298, DOI 10.1212/WNL.43.11.2298; Ciancaglini R, 2001, J ORAL REHABIL, V28, P842, DOI 10.1046/j.1365-2842.2001.00753.x; Cleary PA, 1997, J NEURO-OPHTHALMOL, V17, P18; Close LG, 1997, SEMIN NEUROL, V17, P351, DOI 10.1055/s-2008-1040948; Crevits L, 2004, GRAEF ARCH CLIN EXP, V242, P181, DOI 10.1007/s00417-003-0807-5; de Arcaya AA, 1999, HEADACHE, V39, P321, DOI 10.1046/j.1526-4610.1999.3905321.x; Doi H, 2003, NEUROLOGY, V60, P521, DOI 10.1212/WNL.60.3.521; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Egermark I, 2001, ACTA ODONTOL SCAND, V59, P40, DOI 10.1080/000163501300035788; Evans RW, 2004, HEADACHE, V44, P835, DOI 10.1111/j.1526-4610.2004.04157.x; FERRANTE L, 1995, NEUROSURGERY, V36, P58, DOI 10.1227/00006123-199501000-00007; Fisher CM, 1968, HDB CLIN NEUROLOGY, V5, P124; Fitzek S, 2001, ANN NEUROL, V49, P493; FROMM GH, 1990, NEUROLOGY, V40, P1493, DOI 10.1212/WNL.40.10.1493; Fukuda H, 2003, SURG NEUROL, V59, P93, DOI 10.1016/S0090-3019(02)00993-X; Galende AV, 2004, HEADACHE, V44, P70, DOI 10.1111/j.1526-4610.2004.04012.x; Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906; Gilden DH, 2004, NEW ENGL J MED, V351, P1323, DOI 10.1056/NEJMcp041120; Giuffrida R, 2005, REV NEUROL-FRANCE, V161, P407, DOI 10.1016/S0035-3787(05)85070-2; Goadsby PJ, 1997, BRAIN, V120, P193, DOI 10.1093/brain/120.1.193; Goadsby PJ, 2002, LANCET NEUROL, V1, P251, DOI 10.1016/S1474-4422(02)00104-7; GOADSBY PJ, 1989, J NEUROL NEUROSUR PS, V52, P1290, DOI 10.1136/jnnp.52.11.1290; Gonzalez-Gay MA, 1998, J RHEUMATOL, V25, P1242; Gouda JJ, 1997, NEUROSURG CLIN N AM, V8, P87; GURALNICK W, 1978, NEW ENGL J MED, V299, P123, DOI 10.1056/NEJM197807202990304; HALMAGYI GM, 1990, NEUROL CLIN, V8, P313, DOI 10.1016/S0733-8619(18)30358-X; Hapak Lesli, 1994, Journal of Orofacial Pain, V8, P357; HARRISON SD, 2002, ASSESSMENT MANAGEMEN, V14, P251; Holland NJ, 2004, BMJ-BRIT MED J, V329, P553, DOI 10.1136/bmj.329.7465.553; HOOGE JP, 1995, NEUROLOGY, V45, P1294, DOI 10.1212/WNL.45.7.1294; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HUNT WE, 1961, NEUROLOGY, V11, P56, DOI 10.1212/WNL.11.1.56; Ito M, 1996, SURG NEUROL, V45, P370, DOI 10.1016/0090-3019(95)00438-6; Jacobs Dina, 2002, Curr Opin Ophthalmol, V13, P347, DOI 10.1097/00055735-200212000-00001; JANNETTA PJ, 1980, ANN SURG, V192, P518, DOI 10.1097/00000658-198010000-00010; Jawahar A, 2001, NEUROSURGERY, V48, P101, DOI 10.1097/00006123-200101000-00018; Kara M, 2004, EUR J CARDIO-THORAC, V26, P456, DOI 10.1016/j.ejcts.2004.04.021; KATO T, 1995, SURG NEUROL, V44, P33, DOI 10.1016/0090-3019(95)00056-9; KATUSIC S, 1990, ANN NEUROL, V27, P89, DOI 10.1002/ana.410270114; Keane JR, 1996, ARCH NEUROL-CHICAGO, V53, P561, DOI 10.1001/archneur.1996.00550060105023; KEANE JR, 1994, NEUROLOGY, V44, P1198, DOI 10.1212/WNL.44.7.1198; Kenny TJ, 2001, OTOLARYNG HEAD NECK, V125, P40, DOI 10.1067/mhn.2001.116779; Kim JS, 1998, NEUROLOGY, V51, P1511, DOI 10.1212/WNL.51.5.1511; Kline LB, 2001, J NEUROL NEUROSUR PS, V71, P577, DOI 10.1136/jnnp.71.5.577; KOROGI Y, 1995, J COMPUT ASSIST TOMO, V19, P879, DOI 10.1097/00004728-199511000-00007; Kumar N, 2004, CEPHALALGIA, V24, P305, DOI 10.1111/j.1468-2982.2004.00666.x; Lacey B, 1999, SURV OPHTHALMOL, V44, P187, DOI 10.1016/S0039-6257(99)00101-0; Lance JW, 2001, CEPHALALGIA, V21, P84, DOI 10.1046/j.1468-2982.2001.00160.x; Lance JW, 1996, NEUROLOGY, V47, P617, DOI 10.1212/WNL.47.3.617; Lee AG, 2004, NEUROL CLIN, V22, P75, DOI 10.1016/S0733-8619(03)00093-8; Lewis J, 1998, HEADACHE, V38, P684, DOI 10.1046/j.1526-4610.1998.3809684.x; Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347; Madland G, 2001, J NEUROL NEUROSUR PS, V71, P716, DOI 10.1136/jnnp.71.6.716; Majoie CBLM, 1998, RADIOLOGY, V209, P557, DOI 10.1148/radiology.209.2.9807589; Majoie CBLM, 1997, RADIOLOGY, V204, P455, DOI 10.1148/radiology.204.2.9240535; Manfredini D, 2003, CRANIO, V21, P279, DOI 10.1080/08869634.2003.11746263; Mark AS, 1998, AM J NEURORADIOL, V19, P1887; MASUR H, 1995, J NEUROL, V242, P93, DOI 10.1007/BF00887823; Matharu MS, 2004, HEADACHE, V44, P747, DOI 10.1111/j.1526-4610.2004.04141.x; Matharu MS, 2002, J NEUROL NEUROSUR PS, V72, P19; Matthies C, 1997, NEUROSURGERY, V40, P1; May A, 1999, ANN NEUROL, V46, P791, DOI 10.1002/1531-8249(199911)46:5<791::AID-ANA18>3.0.CO;2-8; May A, 2003, J NEUROL, V250, P1273, DOI 10.1007/s00415-003-0241-y; May A, 1999, NAT MED, V5, P836, DOI 10.1038/10561; May A, 1998, LANCET, V352, P275, DOI 10.1016/S0140-6736(98)02470-2; McCluskey PJ, 1999, OPHTHALMOLOGY, V106, P2380, DOI 10.1016/S0161-6420(99)90543-2; McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001; MEANEY JFM, 1994, AM J ROENTGENOL, V163, P1447, DOI 10.2214/ajr.163.6.7992745; MEANEY JFM, 1995, J NEUROSURG, V83, P799, DOI 10.3171/jns.1995.83.5.0799; Minagar A, 2000, NEUROLOGY, V54, P1368, DOI 10.1212/WNL.54.6.1368; MITCHELL RG, 1980, BRIT DENT J, V149, P167, DOI 10.1038/sj.bdj.4804480; Mohanty A, 1997, NEUROSURGERY, V40, P24, DOI 10.1097/00006123-199701000-00004; Molina OF, 2000, CRANIO, V18, P205, DOI 10.1080/08869634.2000.11746134; MONTALBETTI L, 1995, CEPHALALGIA, V15, P80, DOI 10.1046/j.1468-2982.1995.015002080.x; NURMIKKO TJ, 1991, ARCH NEUROL-CHICAGO, V48, P523, DOI 10.1001/archneur.1991.00530170087025; OGASAWARA H, 1995, J NEUROSURG, V82, P895, DOI 10.3171/jns.1995.82.5.0895; Patel NK, 2003, BRIT J NEUROSURG, V17, P60, DOI 10.1080/0268869031000093735; PESTRONK A, 1983, NEW ENGL J MED, V308, P226; Pulec Jack L, 2002, Ear Nose Throat J, V81, P30; Purvin VA, 2000, SEMIN NEUROL, V20, P97, DOI 10.1055/s-2000-6836; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003; Raieli V, 2002, HEADACHE, V42, P147, DOI 10.1046/j.1526-4610.2002.02033.x; Randeva HS, 1999, CLIN ENDOCRINOL, V51, P181, DOI 10.1046/j.1365-2265.1999.00754.x; Revuelta R, 2003, CLIN NEUROL NEUROSUR, V106, P19, DOI 10.1016/j.clineuro.2003.07.001; RUSHTON JG, 1981, ARCH NEUROL-CHICAGO, V38, P201, DOI 10.1001/archneur.1981.00510040027002; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206; Scott Ingrid U., 1997, Current Opinion in Rheumatology, V9, P504, DOI 10.1097/00002281-199711000-00005; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2004, NEUROL CLIN, V22, P1, DOI 10.1016/S0733-8619(03)00091-4; Sinay VJ, 2003, CEPHALALGIA, V23, P541, DOI 10.1046/j.1468-2982.2003.00581.x; Sipila K, 2002, CRANIO, V20, P158, DOI 10.1080/08869634.2002.11746206; Sjaastad O, 1997, HEADACHE, V37, P346, DOI 10.1046/j.1526-4610.1997.3706346.x; Sjaastad O, 1999, HEADACHE, V39, P204, DOI 10.1046/j.1526-4610.1999.3903204.x; STEAHLY LP, 1988, SEMIN NEUROL, V8, P315, DOI 10.1055/s-2008-1041395; STURZENEGGER M, 1993, J NEUROL NEUROSUR PS, V56, P1191, DOI 10.1136/jnnp.56.11.1191; Sweeney CJ, 2001, J NEUROL NEUROSUR PS, V71, P149, DOI 10.1136/jnnp.71.2.149; SZAPIRO J, 1985, NEUROSURGERY, V17, P920, DOI 10.1227/00006123-198512000-00009; TOLOSA E, 1954, J NEUROL NEUROSUR PS, V17, P300, DOI 10.1136/jnnp.17.4.300; TRUELOVE EL, 1992, J AM DENT ASSOC, V123, P47, DOI 10.14219/jada.archive.1992.0094; Wasmeier C, 2002, J NEUROL, V249, P1237, DOI 10.1007/s00415-002-0818-x; WATSON CPN, 1988, PAIN, V35, P289, DOI 10.1016/0304-3959(88)90139-X; WEINSTEIN GS, 1983, AM J OPHTHALMOL, V96, P209, DOI 10.1016/S0002-9394(14)77789-X; White JC, 1969, PAIN NEUROSURGEON 40, P123; Yanguela J, 2004, NEUROLOGY, V62, P1134, DOI 10.1212/01.WNL.0000118841.97273.5D; YOSHIMASU F, 1972, NEUROLOGY, V22, P952, DOI 10.1212/WNL.22.9.952; Younis RT, 2002, LARYNGOSCOPE, V112, P224, DOI 10.1097/00005537-200202000-00005; ZAKRZEWSKA J, 2002, ASSESSMENT MANAGEMEN, V14, P367; Zakrzewska JM, 2002, J NEUROL NEUROSUR PS, V72, P27; Zakrzewska JM, 2002, CLIN J PAIN, V18, P14, DOI 10.1097/00002508-200201000-00003; [No title captured]	136	43	50	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2006	5	3					257	267		10.1016/S1474-4422(06)70375-1	http://dx.doi.org/10.1016/S1474-4422(06)70375-1			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016PS	16488381				2022-12-18	WOS:000235632900020
J	Geschwind, DH				Geschwind, DH			DNA microarrays: translation of the genome from laboratory to clinic	LANCET NEUROLOGY			English	Review							SINGLE-NUCLEOTIDE POLYMORPHISMS; GENE-EXPRESSION PROFILES; MULTIPLE-SCLEROSIS; ANALYSIS REVEALS; CDNA MICROARRAYS; OLIGONUCLEOTIDE; SEQUENCE; BRAIN; AMPLIFICATION; PATTERNS	As the complete sequences of human and other mammalian genomes become available we are faced with the challenge of understanding how variation in sequence and gene expression contributes to neurological and psychiatric disorders. DNA microarrays, or DNA chips, provide the means to measure simultaneously where and when thousands of genes are expressed. Microarrays are changing the way that researchers approach work at the bench and have already yielded new insights into brain tumours, multiple sclerosis, acute neurological insults such as stroke and seizures, and schizophrenia. The study of disease-related changes in gene expression is the first step in the long process in translation of genome research to the clinic. Eventually, the changes observed in microarray studies will need to be independently confirmed and we will need to understand how gene expression changes translate into functional effects at the cellular level in the nervous system. Progress in these studies will translate into array-based disease classification schemes and help optimise therapy for individual patients based on gene expression patterns or their genetic background.	Univ Calif Los Angeles, Dept Neurol, Program Neurogenet, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Ctr Neurobehav Genet, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Geschwind, DH (corresponding author), Univ Calif Los Angeles, Dept Neurol, Program Neurogenet, 710 Westwood Plaza, Los Angeles, CA 90024 USA.	dhg@ucla.edu						Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Brown VM, 2002, GENOME RES, V12, P244, DOI 10.1101/gr.204102; Brown VM, 2002, PHYSIOL GENOMICS, V8, P159, DOI 10.1152/physiolgenomics.00090.2001; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Colantuoni C, 2001, NEUROBIOL DIS, V8, P847, DOI 10.1006/nbdi.2001.0428; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; D'Agata V, 2002, NEUROBIOL DIS, V10, P211, DOI 10.1006/nbdi.2002.0506; Datson NA, 2001, HIPPOCAMPUS, V11, P430, DOI 10.1002/hipo.1058; DeRisi J, 1996, NAT GENET, V14, P457; Dong SL, 2001, GENOME RES, V11, P1418, DOI 10.1101/gr.171101; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Evans SJ, 2002, EUR J NEUROSCI, V16, P409, DOI 10.1046/j.1460-9568.2002.02097.x; FRANKEL WN, 1995, TRENDS GENET, V11, P471, DOI 10.1016/S0168-9525(00)89155-6; Garcia CK, 2001, GENOME RES, V11, P1043, DOI 10.1101/gr.172301; Geschwind DH, 2000, P NATL ACAD SCI USA, V97, P10676, DOI 10.1073/pnas.97.20.10676; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Geschwind DH, 2001, NAT REV NEUROSCI, V2, P435, DOI 10.1038/35077576; Geschwind DH, 1998, DEV GENET, V23, P215, DOI 10.1002/(SICI)1520-6408(1998)23:3<215::AID-DVG7>3.0.CO;2-X; Geschwind DH, 2002, CEL MOL NEU; Gilles PN, 1999, NAT BIOTECHNOL, V17, P365, DOI 10.1038/7921; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.3.CO;2-1; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hanzel DK, 1999, NAT BIOTECHNOL, V17, P53, DOI 10.1038/5225; Hardy J, 2001, BIOCHEM SOC SYMP, V67, P51; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Karsten SL, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e4; KARSTEN SL, 2002, CURR PROTOC NEUROSCI; Kohane I. S., 2002, MICROARRAYS INTEGRAT; Lewohl JM, 2000, ALCOHOL CLIN EXP RES, V24, P1873, DOI 10.1111/j.1530-0277.2000.tb01993.x; Lipsitt DR, 1999, GEN HOSP PSYCHIAT, V21, P1; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lord C, 2000, NEURON, V28, P355, DOI 10.1016/S0896-6273(00)00115-X; Lord C, 2002, J AM ACAD CHILD PSY, V41, P1134, DOI 10.1097/00004583-200209000-00015; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Mayfield RD, 2002, J NEUROCHEM, V81, P802, DOI 10.1046/j.1471-4159.2002.00860.x; Merikangas KR, 2002, BIOL PSYCHIAT, V52, P457, DOI 10.1016/S0006-3223(02)01471-3; Middleton FA, 2002, J NEUROSCI, V22, P2718, DOI 10.1523/JNEUROSCI.22-07-02718.2002; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Mirnics K, 2001, MOL PSYCHIATR, V6, P293, DOI 10.1038/sj.mp.4000866; Nadeau JH, 2000, NAT GENET, V25, P381, DOI 10.1038/78051; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Nelson NJ, 2001, J NATL CANCER I, V93, P493, DOI 10.1093/jnci/93.7.493; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Purcell AE, 2001, NEUROLOGY, V57, P1618, DOI 10.1212/WNL.57.9.1618; Rickman DS, 2001, CANCER RES, V61, P6885; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rosenberg RN, 1996, NEW ENGL J MED, V335, P1222, DOI 10.1056/NEJM199610173351609; Sallinen SL, 2000, CANCER RES, V60, P6617; Sandberg R, 2000, P NATL ACAD SCI USA, V97, P11038, DOI 10.1073/pnas.97.20.11038; Santacroce R, 2002, CLIN CHEM, V48, P2124; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Tang Y, 2001, ANN NEUROL, V50, P699, DOI 10.1002/ana.10042; Tanwar MK, 2002, CANCER RES, V62, P4364; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; VANDEERLIN VMD, 2002, CEL MOL NEU, P201; Varis A, 2002, CANCER RES, V62, P2625; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Whitney LW, 1999, ANN NEUROL, V46, P425; Whitney LW, 2001, J NEUROIMMUNOL, V121, P40, DOI 10.1016/S0165-5728(01)00438-6; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zirlinger M, 2001, P NATL ACAD SCI USA, V98, P5270, DOI 10.1073/pnas.091094698	77	43	45	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2003	2	5					275	282		10.1016/S1474-4422(03)00379-X	http://dx.doi.org/10.1016/S1474-4422(03)00379-X			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	669RC	12849181				2022-12-18	WOS:000182363400015
J	Selzer, ME				Selzer, ME			Promotion of axonal regeneration in the injured CNS	LANCET NEUROLOGY			English	Review							RAT SPINAL-CORD; CENTRAL-NERVOUS-SYSTEM; MYELIN-ASSOCIATED GLYCOPROTEIN; RETINAL GANGLION-CELLS; GROWTH-ASSOCIATED PROTEIN; BODY-WEIGHT SUPPORT; ENSHEATHING GLIA TRANSPLANTS; NEUROEPITHELIAL STEM-CELLS; CLARKES NUCLEUS NEURONS; ADULT-RAT	Molecules that are found in the extracellular environment at a CNS lesion site, or that are associated with myelin, inhibit axon growth. In addition, neuronal changes-such as an age-dependent reduction in concentrations of cyclic AMP-render the neuron less able to respond to axotomy by a rapid, forward, actin-dependent movement. An alternative mechanism, based on the protrusive forces generated by microtubule elongation or the anterograde transport of cytoskeletal elements, may underlie a slower form of axon elongation that happens during regeneration in the mature CNS. Therapeutic approaches that restore the extracellular CNS environment or the neuron's characteristics back to a more embryonic state increase axon regeneration and improve functional recovery after injury. These advances in the understanding of regeneration in the CNS have major implications for neurorehabilitation and for the use of axonal regeneration as a therapeutic approach to disorders of the CNS such as spinal-cord injury.	Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	Selzer, ME (corresponding author), Univ Penn, Med Ctr, Dept Neurol, 3400 Spruce St,3W Gates Bldg, Philadelphia, PA 19104 USA.	selzerm@mail.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014837, R01NS038537] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS14837, R01 NS38537] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen LB, 1999, EXP NEUROL, V155, P157, DOI 10.1006/exnr.1998.6903; Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; Barouch R, 2002, FASEB J, V16, P1304, DOI 10.1096/fj.01-0467fje; Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; Becker CG, 1999, J NEUROSCI, V19, P813; Becker T, 1998, J NEUROSCI, V18, P5789; Bentley David, 1994, Current Opinion in Neurobiology, V4, P43, DOI 10.1016/0959-4388(94)90030-2; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; Blesch A, 1999, J NEUROSCI, V19, P3556; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Bonfanti L, 1996, J NEUROSCI, V16, P4186; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRAY GM, 1987, J EXP BIOL, V132, P5; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Brosamle C, 2000, J NEUROSCI, V20, P8061; Buffo A, 1997, J NEUROSCI, V17, P8778; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal S. Ramon, 1928, DEGENERATION REGENER; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CHALASANI SH, IN PRESS J NEUROSCI; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Chierzi S, 1999, J NEUROSCI, V19, P8367; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Dergham P, 2002, J NEUROSCI, V22, P6570; DIETZ V, 1995, ANN NEUROL, V37, P574, DOI 10.1002/ana.410370506; Dobkin BH, 1995, J NEUROL REHABIL, V9, P183; Dobkin BH, 1999, NEUROREHAB NEURAL RE, V13, P157, DOI 10.1177/154596839901300301; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; Falci S, 1997, J NEUROTRAUM, V14, P875, DOI 10.1089/neu.1997.14.875; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; FRANKLIN RJM, 1995, GLIA, V13, P39, DOI 10.1002/glia.440130105; Freeman TB, 2001, ADV NEUROL, V86, P435; FRIEDMAN B, 1985, J NEUROSCI, V5, P1616; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; GAZE RM, 1963, PROC R SOC SER B-BIO, V157, P420, DOI 10.1098/rspb.1963.0020; Giehl KM, 2001, REV NEUROSCIENCE, V12, P79; GOCHT A, 1993, J NEUROCYTOL, V22, P461, DOI 10.1007/BF01181566; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Hall GF, 1997, J NEUROCYTOL, V26, P733, DOI 10.1023/A:1018562331003; Hammang JP, 1997, EXP NEUROL, V147, P84, DOI 10.1006/exnr.1997.6592; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Hauser RA, 2002, NEUROLOGY, V58, P687, DOI 10.1212/WNL.58.5.687; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Himes BT, 2001, J NEUROSCI RES, V65, P549, DOI 10.1002/jnr.1185; HOFFMAN PN, 1989, J NEUROSCI, V9, P893; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Iwaya K, 1999, NEUROSURGERY, V44, P589, DOI 10.1097/00006123-199903000-00085; Jacobs AJ, 1997, J NEUROSCI, V17, P5206; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; KAO CC, 1977, J NEUROPATH EXP NEUR, V36, P140, DOI 10.1097/00005072-197701000-00012; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; LANNERS HN, 1980, J NEUROCYTOL, V9, P733, DOI 10.1007/BF01205016; Lazarov-Spiegler O, 1998, GLIA, V24, P329, DOI 10.1002/(SICI)1098-1136(199811)24:3<329::AID-GLIA7>3.0.CO;2-X; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lindvall O, 1998, MOVEMENT DISORD, V13, P83; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Liu Y, 1999, J NEUROSCI, V19, P4370; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; LURIE DI, 1994, J COMP NEUROL, V344, P559, DOI 10.1002/cne.903440406; MACKLER SA, 1987, J PHYSIOL-LONDON, V388, P183, DOI 10.1113/jphysiol.1987.sp016609; MACKLER SA, 1986, J NEUROSCI, V6, P1814; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; Masato S, 2000, NEUROREHAB NEURAL RE, V14, P319, DOI 10.1177/154596830001400408; Mason MRJ, 2000, EXP NEUROL, V165, P143, DOI 10.1006/exnr.2000.7445; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKERRACHER L, 1990, J NEUROSCI, V10, P641; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MOYA KL, 1988, J NEUROSCI, V8, P4445; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MUMA NA, 1990, EXP NEUROL, V107, P230, DOI 10.1016/0014-4886(90)90140-N; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SASAKI H, 1993, VISION RES, V33, P877, DOI 10.1016/0042-6989(93)90070-D; SCALIA F, 1985, J COMP NEUROL, V231, P323, DOI 10.1002/cne.902310304; SCHMIDT RE, 1985, J NEUROPATH EXP NEUR, V44, P130, DOI 10.1097/00005072-198503000-00002; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwartz M, 1999, J MOL MED, V77, P713, DOI 10.1007/s001099900047; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Shifman MI, 2000, NEUROREHAB NEURAL RE, V14, P49, DOI 10.1177/154596830001400106; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; SKENE JHP, 1981, J NEUROSCI, V1, P419; Sperry RW, 1944, J NEUROPHYSIOL, V7, P57, DOI 10.1152/jn.1944.7.1.57; Strata P, 1999, ARCH ITAL BIOL, V137, P181; Takahashi K, 1999, J COMP NEUROL, V404, P159, DOI 10.1002/(SICI)1096-9861(19990208)404:2<159::AID-CNE2>3.0.CO;2-E; Takami T, 2002, J NEUROSCI, V22, P6670; TESSER P, 1986, J NEUROCHEM, V47, P1235; Tessler A, 1997, Adv Neurol, V72, P291; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Thompson FJ, 2001, J NEUROTRAUM, V18, P931, DOI 10.1089/089771501750451848; Trigueros MA, 2000, J NEUROSCI, V20, P361, DOI 10.1523/JNEUROSCI.20-01-00361.2000; TUSZYNSKI MH, 1995, MOL NEUROBIOL, V10, P151, DOI 10.1007/BF02740673; Tuszynski MH, 2002, J MOL NEUROSCI, V19, P207, DOI 10.1007/s12031-002-0034-2; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; Udvadia AJ, 2001, DEVELOPMENT, V128, P1175; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; Whiteley SJO, 1998, EXP NEUROL, V154, P560, DOI 10.1006/exnr.1998.6959; Wirz M, 2001, J NEUROL NEUROSUR PS, V71, P93, DOI 10.1136/jnnp.71.1.93; Xu Zuoshang, 1994, Current Opinion in Neurobiology, V4, P655, DOI 10.1016/0959-4388(94)90006-X; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; YIN HS, 1983, J NEUROSCI, V3, P1135	140	43	46	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2003	2	3					157	166		10.1016/S1474-4422(03)00322-3	http://dx.doi.org/10.1016/S1474-4422(03)00322-3			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648NV	12849237				2022-12-18	WOS:000181158200014
J	Kullmann, DM; Hanna, MG				Kullmann, DM; Hanna, MG			Neurological disorders caused by inherited ion-channel mutations	LANCET NEUROLOGY			English	Review							HYPOKALEMIC PERIODIC PARALYSIS; FRONTAL-LOBE EPILEPSY; FAMILIAL HEMIPLEGIC MIGRAINE; EPISODIC ATAXIA TYPE-2; INHIBITORY GLYCINE RECEPTOR; ARTHROGRYPOSIS MULTIPLEX CONGENITA; NEURONAL SODIUM-CHANNEL; MYOTONIC MUSCLE-FIBERS; CENTRAL CORE DISEASE; POTASSIUM CHANNEL	Several neurological diseases-including neuromuscular disorders, movement disorders, migraine, and epilepsy-are caused by inherited mutations of ion channels. The list of these "channelopathies" is expanding rapidly, as is the phenotypic range associated with each channel. At present the best understood channelopathies are those that affect muscle-fibre excitability. These channelopathies produce a range of disorders which include: periodic paralysis, myotonias, malignant hyperthermia, and congenital myasthenic syndromes. By contrast, the mechanisms of diseases caused by mutations of ion channels that are expressed in neurons are less well understood. However, as for the muscle channelopathies, a striking feature is that many neuronal channelopathies cause paroxysmal symptoms. This review summarises the clinical features of the known neurological channelopathies, within the context of the functions of the individual ion channels.	UCL, Neurol Inst, London WC1N 3BG, England; Natl Hosp Neurol & Neurosurg, London, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Kullmann, DM (corresponding author), UCL, Neurol Inst, Queen Sq, London WC1N 3BG, England.	d.kullman@ion.ucl.ac.uk	Hanna, Michael G/B-1995-2009; Kullmann, Dimitri M/A-3162-2009	Kullmann, Dimitri M/0000-0001-6696-3545; Hanna, Michael/0000-0003-0825-4075				Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; ADRIAN RH, 1976, J PHYSIOL-LONDON, V258, P125, DOI 10.1113/jphysiol.1976.sp011410; ADRIAN RH, 1974, J PHYSIOL-LONDON, V240, P505, DOI 10.1113/jphysiol.1974.sp010620; Ashcroft FM, 2000, ION CHANNELS DIS; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Beeson D, 1998, ANN NY ACAD SCI, V841, P181, DOI 10.1111/j.1749-6632.1998.tb10924.x; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bertrand S, 1998, BRIT J PHARMACOL, V125, P751, DOI 10.1038/sj.bjp.0702154; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Bretschneider F, 1999, EUR J NEUROSCI, V11, P2403, DOI 10.1046/j.1460-9568.1999.00659.x; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Brownlow S, 2001, J CLIN INVEST, V108, P125, DOI 10.1172/JCI12935; Brune W, 1996, AM J HUM GENET, V58, P989; BUCKWALTER MS, 1994, HUM MOL GENET, V3, P2025, DOI 10.1093/hmg/3.11.2025; Bulman DE, 1999, NEUROLOGY, V53, P1932, DOI 10.1212/WNL.53.9.1932; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chioza B, 2001, NEUROLOGY, V56, P1245, DOI 10.1212/WNL.56.9.1245; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Davies NP, 2001, CURR OPIN NEUROL, V14, P539, DOI 10.1097/00019052-200110000-00001; De Fusco M, 2000, NAT GENET, V26, P275; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; Denier C, 2001, ARCH NEUROL-CHICAGO, V58, P292, DOI 10.1001/archneur.58.2.292; Denier C, 1999, NEUROLOGY, V52, P1816, DOI 10.1212/WNL.52.9.1816; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; ENGEL AG, 1993, ANN NEUROL, V34, P38, DOI 10.1002/ana.410340109; Engel AG, 1999, ARCH NEUROL-CHICAGO, V56, P163, DOI 10.1001/archneur.56.2.163; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Eunson LH, 2000, ANN NEUROL, V48, P647; FLORES CM, 1992, MOL PHARMACOL, V41, P31; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Gomez CM, 1996, ANN NEUROL, V39, P712, DOI 10.1002/ana.410390607; Gomez CM, 1997, J NEUROSCI, V17, P4170; GRIGGS RC, 1995, ANN NEUROL, V37, P285, DOI 10.1002/ana.410370302; Guida S, 2001, AM J HUM GENET, V68, P759, DOI 10.1086/318804; Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P248, DOI 10.1136/jnnp.65.2.248; Hans M, 1999, J NEUROSCI, V19, P1610; HARRISON GG, 1988, BRIT J ANAESTH, V60, P279, DOI 10.1093/bja/60.3.279; Hayward LJ, 1999, NEUROLOGY, V52, P1447, DOI 10.1212/WNL.52.7.1447; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HUDSON AJ, 1995, BRAIN, V118, P547, DOI 10.1093/brain/118.2.547; HUTCHINSON DO, 1993, BRAIN, V116, P633, DOI 10.1093/brain/116.3.633; Jen J, 2001, NEUROLOGY, V57, P1843, DOI 10.1212/WNL.57.10.1843; Jouvenceau A, 2001, LANCET, V358, P801, DOI 10.1016/S0140-6736(01)05971-2; Jurkat-Rott K, 2000, P NATL ACAD SCI USA, V97, P9549, DOI 10.1073/pnas.97.17.9549; JURKATROTT K, 1994, HUM MOL GENET, V3, P1415, DOI 10.1093/hmg/3.8.1415; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; Kubisch C, 1998, HUM MOL GENET, V7, P1753, DOI 10.1093/hmg/7.11.1753; Kullmann DM, 2002, BRAIN, V125, P1177, DOI 10.1093/brain/awf130; Kuryatov A, 1997, J NEUROSCI, V17, P9035; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; Laube G, 1996, MOL BRAIN RES, V42, P51, DOI 10.1016/S0169-328X(96)00120-9; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; LEHMANNHORN F, 1993, NEUROMUSCULAR DISORD, V3, P161, DOI 10.1016/0960-8966(93)90009-9; LEHMANNHORN F, 1995, SOC GEN PHY, V50, P101; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; Matsuyama Z, 1999, J Neurosci, V19, pRC14; MCMANIS PG, 1986, MUSCLE NERVE, V9, P704, DOI 10.1002/mus.880090805; Meisler MH, 2001, ANNU REV GENET, V35, P567, DOI 10.1146/annurev.genet.35.102401.091142; Monnier N, 1997, AM J HUM GENET, V60, P1316, DOI 10.1086/515454; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Phillips HA, 2001, AM J HUM GENET, V68, P225, DOI 10.1086/316946; Piedras-Renteria ES, 2001, J NEUROSCI, V21, P9185, DOI 10.1523/JNEUROSCI.21-23-09185.2001; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1994, CELL, V77, P863; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; Rajendra S, 1997, PHARMACOL THERAPEUT, V73, P121, DOI 10.1016/S0163-7258(96)00163-5; REA R, 1922, J PHYSL, V538, P5; REES MI, 1994, HUM MOL GENET, V3, P2175, DOI 10.1093/hmg/3.12.2175; Restituito S, 2000, J NEUROSCI, V20, P6394, DOI 10.1523/JNEUROSCI.20-17-06394.2000; Rosenberg H, 2002, ANESTHESIOLOGY, V96, P232, DOI 10.1097/00000542-200201000-00036; RUDEL R, 1984, MUSCLE NERVE, V7, P110, DOI 10.1002/mus.880070205; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; SCHEFFER IE, 1994, LANCET, V343, P515, DOI 10.1016/S0140-6736(94)91463-X; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; SHIANG R, 1995, ANN NEUROL, V38, P85, DOI 10.1002/ana.410380115; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; Sugawara T, 2001, P NATL ACAD SCI USA, V98, P6384, DOI 10.1073/pnas.111065098; Tawil R, 2000, ANN NEUROL, V47, P46, DOI 10.1002/1531-8249(200001)47:1<46::AID-ANA9>3.3.CO;2-8; VAJSAR J, 1995, PEDIATR NEUROL, V12, P237, DOI 10.1016/0887-8994(95)00004-Y; Wallace RH, 2001, AM J HUM GENET, V68, P859, DOI 10.1086/319516; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/88259; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Waxman SG, 2001, NAT REV NEUROSCI, V2, P652, DOI 10.1038/35090026; Yue Q, 1997, AM J HUM GENET, V61, P1078, DOI 10.1086/301613; Zerr P, 1998, FEBS LETT, V431, P461, DOI 10.1016/S0014-5793(98)00814-X; Zerr P, 1998, J NEUROSCI, V18, P2842; Zhang CL, 1999, J NEUROSCI, V19, P2852; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; Zhou L, 1998, J NEUROSCI, V18, P7200; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; Zuberi SM, 1999, BRAIN, V122, P817, DOI 10.1093/brain/122.5.817	110	43	47	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					157	166		10.1016/S1474-4422(02)00071-6	http://dx.doi.org/10.1016/S1474-4422(02)00071-6			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB	12849484				2022-12-18	WOS:000177695100017
J	Halfpenny, C; Benn, T; Scolding, N				Halfpenny, C; Benn, T; Scolding, N			Cell transplantation, myelin repair, and multiple sclerosis	LANCET NEUROLOGY			English	Review							CENTRAL-NERVOUS-SYSTEM; RAT SPINAL-CORD; HUMAN SCHWANN-CELLS; OLFACTORY ENSHEATHING CELLS; OLIGODENDROCYTE PROGENITOR CELLS; MARROW STROMAL CELLS; ADULT HUMAN BRAIN; SPONTANEOUS CNS REMYELINATION; RETINAL GANGLION-CELLS; IN-VITRO	A decade ago, therapeutic strategies to remyelinate the CNS in diseases such as multiple sclerosis had much experimental appeal, but translation of laboratory success into clinical treatments appeared to be a long way off. Within the past 12 months, however, the first patients with multiple sclerosis have received intracerebral implants of autologous myelinating cells. Here we review the clinical and biological problems presented by multiple sclerosis disease processes, and the background to the development of myelin-repair strategies. We attempt to highlight those areas where difficulties have yet to be resolved, and draw on various experimental findings to speculate on how remyelinating therapies are likely to develop in the foreseeable future.	Univ Bristol, Inst Clin Neurosci, Dept Neurol, Frenchay Hosp, Bristol BS16 1LE, Avon, England	University of Bristol	Scolding, N (corresponding author), Univ Bristol, Inst Clin Neurosci, Dept Neurol, Frenchay Hosp, Bristol BS16 1LE, Avon, England.	Rachel.Bowles@north-bristol.swest.nhs.uk						ARCHER DR, 1994, EXP NEUROL, V125, P268, DOI 10.1006/exnr.1994.1029; Archer DR, 1997, NAT MED, V3, P54, DOI 10.1038/nm0197-54; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; Asakura K, 1996, J NEUROSCI RES, V43, P273, DOI 10.1002/(SICI)1097-4547(19960201)43:3<273::AID-JNR2>3.0.CO;2-G; AvellanaAdalid V, 1996, J NEUROSCI RES, V45, P558, DOI 10.1002/(SICI)1097-4547(19960901)45:5<558::AID-JNR6>3.0.CO;2-B; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; BARNETT SC, 1993, EUR J NEUROSCI, V5, P1247, DOI 10.1111/j.1460-9568.1993.tb00910.x; BaronVanEvercooren A, 1996, GLIA, V16, P147, DOI 10.1002/(SICI)1098-1136(199602)16:2<147::AID-GLIA7>3.0.CO;2-0; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Berger J, 2001, CURR OPIN NEUROL, V14, P305, DOI 10.1097/00019052-200106000-00007; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bjartmar C, 2000, ANN NEUROL, V48, P893, DOI 10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; Blakemore WF, 1999, J NEUROIMMUNOL, V98, P69, DOI 10.1016/S0165-5728(99)00083-1; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brierley CMH, 2001, CELL TRANSPLANT, V10, P305, DOI 10.3727/000000001783986774; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; BUNGE MB, 1961, J BIOPHYS BIOCHEM CY, V10, P67, DOI 10.1083/jcb.10.1.67; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; CARROLL WM, 1994, BRAIN, V117, P563, DOI 10.1093/brain/117.3.563; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Compston A, 1996, Mult Scler, V1, P388; Confavreux C, 2000, NEW ENGL J MED, V343, P1430, DOI 10.1056/NEJM200011163432001; CRANG AJ, 1991, GLIA, V4, P305, DOI 10.1002/glia.440040308; CUZNER ML, 1994, NEUROPATH APPL NEURO, V20, P200; Davie CA, 1995, BRAIN, V118, P1583, DOI 10.1093/brain/118.6.1583; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Deloire-Grassin MSA, 2000, J NEUROL SCI, V178, P10, DOI 10.1016/S0022-510X(00)00331-2; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; Duncan ID, 1997, J ANAT, V190, P35, DOI 10.1046/j.1469-7580.1997.19010035.x; DUNCAN ID, 1992, DEV NEUROSCI-BASEL, V14, P114, DOI 10.1159/000111655; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Edge ASB, 1998, CELL TRANSPLANT, V7, P525, DOI 10.1016/S0963-6897(98)00043-8; Evercooren ABV, 1997, MULT SCLER J, V3, P157, DOI 10.1177/135245859700300219; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FELTS PA, 1992, BRAIN RES, V574, P178, DOI 10.1016/0006-8993(92)90815-Q; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; FOKSEANG J, 1995, DEV BIOL, V171, P1, DOI 10.1006/dbio.1995.1255; Franklin R J, 2001, Prog Brain Res, V132, P185; Franklin RJM, 2000, NEURON, V28, P15, DOI 10.1016/S0896-6273(00)00080-5; Franklin RJM, 1996, EXP NEUROL, V137, P263, DOI 10.1006/exnr.1996.0025; Franklin RJM, 1999, NEUROREPORT, V10, P3961, DOI 10.1097/00001756-199912160-00043; FRANKLIN RJM, 1993, INT J DEV NEUROSCI, V11, P641, DOI 10.1016/0736-5748(93)90052-F; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; Franklin RJM, 1997, J ANAT, V190, P23, DOI 10.1046/j.1469-7580.1997.19010023.x; Franklin RJM, 1997, J NEUROSCI RES, V50, P337, DOI 10.1002/(SICI)1097-4547(19971015)50:2<337::AID-JNR21>3.0.CO;2-3; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Hale G, 1996, BONE MARROW TRANSPL, V17, P305; HARRISON B, 1985, J NEUROL SCI, V67, P143, DOI 10.1016/0022-510X(85)90111-X; HARRISON BM, 1980, J NEUROL SCI, V46, P63, DOI 10.1016/0022-510X(80)90044-1; Hinks GL, 1999, MOL CELL NEUROSCI, V14, P153, DOI 10.1006/mcne.1999.0771; Hinks GL, 2001, NEUROPATH APPL NEURO, V27, P59, DOI 10.1046/j.0305-1846.2001.00303.x; Hinks GL, 2000, MOL CELL NEUROSCI, V16, P542, DOI 10.1006/mcne.2000.0897; Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962; Honmou O, 1996, J NEUROSCI, V16, P3199; Imaizumi T, 1998, J NEUROSCI, V18, P6176; ITOYAMA Y, 1983, ANN NEUROL, V14, P339, DOI 10.1002/ana.410140313; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jefferson S, 1997, MULT SCLER, V3, P162, DOI 10.1177/135245859700300220; Jeffery ND, 1999, EUR J NEUROSCI, V11, P1508, DOI 10.1046/j.1460-9568.1999.00564.x; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; KENNEDY PGE, 1986, BRAIN, V109, P1261, DOI 10.1093/brain/109.6.1261; KIERNAN BW, 1993, DEVELOPMENT, P219; Kocsis JD, 1999, J NEUROTRAUM, V16, P695, DOI 10.1089/neu.1999.16.695; Kohama I, 2001, J NEUROSCI, V21, P944, DOI 10.1523/JNEUROSCI.21-03-00944.2001; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; KRIVIT W, 1995, J INHERIT METAB DIS, V18, P398, DOI 10.1007/BF00710052; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; LANGFORD LA, 1988, J NEUROCYTOL, V17, P521, DOI 10.1007/BF01189807; Lassmann H, 1997, MULT SCLER J, V3, P133, DOI 10.1177/135245859700300213; Learish RD, 1999, ANN NEUROL, V46, P716, DOI 10.1002/1531-8249(199911)46:5<716::AID-ANA6>3.0.CO;2-M; LEVI ADO, 1994, EXP NEUROL, V130, P41, DOI 10.1006/exnr.1994.1183; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Ludwin S K, 1988, Adv Neurol, V47, P215; Maeda Y, 2001, ANN NEUROL, V49, P776, DOI 10.1002/ana.1015; McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Miller DJ, 1995, J NEUROSCI, V15, P8345; MILLER DJ, 1995, J IMMUNOL, V154, P2460; Milward EA, 2000, GLIA, V32, P264, DOI 10.1002/1098-1136(200012)32:3<264::AID-GLIA60>3.0.CO;2-Z; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; MOREAU T, 1994, LANCET, V344, P298, DOI 10.1016/S0140-6736(94)91339-0; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; Muir DA, 1996, J NEUROSCI RES, V44, P1; Niehaus A, 2000, ANN NEUROL, V48, P362, DOI 10.1002/1531-8249(200009)48:3<362::AID-ANA11>3.0.CO;2-6; Noel F, 1999, NEUROREPORT, V10, P535, DOI 10.1097/00001756-199902250-00017; Noseworthy JH, 2000, NEUROLOGY, V55, P1135, DOI 10.1212/WNL.55.8.1135; OGATA J, 1975, NEUROLOGY, V25, P713, DOI 10.1212/WNL.25.8.713; OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311; PERIER O, 1965, BRAIN, V88, P937, DOI 10.1093/brain/88.5.937; Pouly S, 2001, ACTA NEUROPATHOL, V102, P313; Pouly S, 1999, GLIA, V27, P259, DOI 10.1002/(SICI)1098-1136(199909)27:3<259::AID-GLIA7>3.0.CO;2-8; PRABHAKAR S, 1995, BRAIN RES, V672, P159, DOI 10.1016/0006-8993(94)01377-T; PRINEAS JW, 1979, ANN NEUROL, V5, P22, DOI 10.1002/ana.410050105; PRINEAS JW, 1993, BRAIN, V116, P681, DOI 10.1093/brain/116.3.681; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; PRINEAS JW, 1989, LAB INVEST, V61, P489; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAINE CS, 1989, LAB INVEST, V60, P714; RAINE CS, 1993, J NEUROPATH EXP NEUR, V52, P199, DOI 10.1097/00005072-199305000-00003; RAINE CS, 1981, LAB INVEST, V45, P534; RODRIGUEZ M, 1987, J NEUROPATH EXP NEUR, V46, P84, DOI 10.1097/00005072-198701000-00008; Rogister B, 1999, MOL CELL NEUROSCI, V14, P287, DOI 10.1006/mcne.1999.0790; Rosenbluth J., 1996, P124, DOI 10.1017/CBO9780511570193.014; ROSENBLUTH J, 1993, J NEUROCYTOL, V22, P967, DOI 10.1007/BF01218354; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; RUTKOWSKI JL, 1995, NAT MED, V1, P80, DOI 10.1038/nm0195-80; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Schnadelbach O, 2000, MOL CELL NEUROSCI, V15, P288, DOI 10.1006/mcne.1999.0819; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Scolding N, 1998, LANCET, V352, P340, DOI 10.1016/S0140-6736(05)60463-1; Scolding N, 2001, BRAIN, V124, P2129, DOI 10.1093/brain/124.11.2129; Scolding N, 2001, LANCET, V357, P329, DOI 10.1016/S0140-6736(00)03637-0; Scolding NJ, 1999, NEUROSCIENCE, V89, P1, DOI 10.1016/S0306-4522(98)00548-X; SCOLDING NJ, 1995, NEUROREPORT, V6, P441, DOI 10.1097/00001756-199502000-00009; SCOLDING NJ, 1995, NEUROSCI LETT, V183, P75, DOI 10.1016/0304-3940(94)11118-3; SCOLDING NJ, 1999, CLIN NEUROLOGY INT P, V6, P525; Seilhean D, 1996, ACTA NEUROPATHOL, V91, P82; Skoff RP, 1996, NEUROSCIENTIST, V2, P335, DOI 10.1177/107385849600200611; Smith KJ, 1999, PHILOS T R SOC B, V354, P1649, DOI 10.1098/rstb.1999.0510; Smith PM, 2001, J NEUROIMMUNOL, V119, P261, DOI 10.1016/S0165-5728(01)00396-4; Stangel M, 2000, J NEUROIMMUNOL, V106, P137, DOI 10.1016/S0165-5728(00)00210-1; Stangel M, 1999, J NEUROIMMUNOL, V96, P228, DOI 10.1016/S0165-5728(99)00035-1; Stangel M, 2000, J NEUROIMMUNOL, V103, P195, DOI 10.1016/S0165-5728(99)00241-6; Stangel M, 2000, J NEUROL NEUROSUR PS, V68, P89, DOI 10.1136/jnnp.68.1.89; Strauer BE, 2001, DEUT MED WOCHENSCHR, V126, P932, DOI 10.1055/s-2001-16579-1; Targett MP, 1996, NEUROPATH APPL NEURO, V22, P199; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; UTZSCHNEIDER DA, 1994, P NATL ACAD SCI USA, V91, P53, DOI 10.1073/pnas.91.1.53; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Weiss S, 1996, J NEUROSCI, V16, P7599; Wolswijk G, 2000, BRAIN, V123, P105, DOI 10.1093/brain/123.1.105; Wolswijk G, 1998, J NEUROSCI, V18, P601; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.3.CO;2-3; Woodruff RH, 1999, GLIA, V25, P216, DOI 10.1002/(SICI)1098-1136(19990201)25:3<216::AID-GLIA2>3.0.CO;2-L; Zhang SC, 1998, J NEUROSCI RES, V54, P181, DOI 10.1002/(SICI)1097-4547(19981015)54:2<181::AID-JNR6>3.0.CO;2-A; Zhang SC, 1999, P NATL ACAD SCI USA, V96, P4089, DOI 10.1073/pnas.96.7.4089	152	43	47	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					31	40		10.1016/S1474-4422(02)00004-2	http://dx.doi.org/10.1016/S1474-4422(02)00004-2			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ	12849543				2022-12-18	WOS:000177694100018
J	Donovan, J; Figaji, A; Imran, D; Phu, NH; Rohlwink, U; Thwaites, GE				Donovan, Joseph; Figaji, Anthony; Imran, Darma; Nguyen Hoan Phu; Rohlwink, Ursula; Thwaites, Guy E.			The neurocritical care of tuberculous meningitis	LANCET NEUROLOGY			English	Review							RAISED INTRACRANIAL-PRESSURE; PARADOXICAL REACTION; CEREBRAL INFARCTION; BRAIN-INJURY; SYSTEM; PREDICTORS; FREQUENCY; INFECTIONS; BIOMARKERS; IMPACT	Tuberculous meningitis is the most severe form of tuberculosis and often causes critical illness with high mortality. Two primary management objectives are reducing intracranial pressure, and optimising cerebral perfusion, while killing the bacteria and controlling intracerebral inflammation. However, the evidence base guiding the care of critically ill patients with tuberculous meningitis is poor and many patients do not have access to neurocritical care units. Invasive intracranial pressure monitoring is often unavailable and although new non-invasive monitoring techniques show promise, further evidence for their use is required. Optimal management regimens of neurological complications (eg, hydrocephalus and paradoxical reactions) and of hyponatraemia, which frequently accompanies tuberculous meningitis, remain to be elucidated. Advances in the field of tuberculous meningitis predominantly focus on diagnosis, inflammatory processes, and antituberculosis chemotherapy. However, clinical trials are required to provide robust evidence guiding the most effective supportive, therapeutic, and neurosurgical interventions for tuberculous meningitis that will improve morbidity and mortality.	[Donovan, Joseph; Nguyen Hoan Phu; Thwaites, Guy E.] Oxford Univ Clin Res Unit, Ctr Trop Med, Ho Chi Minh City, Vietnam; [Donovan, Joseph; Thwaites, Guy E.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England; [Figaji, Anthony; Rohlwink, Ursula] Univ Cape Town, Div Neurosurg, Cape Town, South Africa; [Figaji, Anthony; Rohlwink, Ursula] Univ Cape Town, Inst Neurosci, Cape Town, South Africa; [Imran, Darma] Univ Indonesia, Fac Med, Cipto Mangunkusumo Hosp, Jakarta, Indonesia; [Nguyen Hoan Phu] Hosp Trop Dis, Ho Chi Minh City, Vietnam	University of Oxford; University of Cape Town; University of Cape Town; University of Indonesia	Donovan, J (corresponding author), Oxford Univ Clin Res Unit, Ctr Trop Med, Ho Chi Minh City, Vietnam.	jdonovan@oucru.org	Figaji, Anthony/ADH-9410-2022; Rohlwink, Ursula/AAE-2513-2020; Rohlwink, Ursula Karin/U-8917-2019	Figaji, Anthony/0000-0002-3357-6490; Rohlwink, Ursula Karin/0000-0002-4469-4935; Imran, Darma/0000-0002-4109-4192; Thwaites, Guy/0000-0002-2858-2087				Adole PS, 2013, EUR J PHARMACOL, V714, P157, DOI 10.1016/j.ejphar.2013.05.032; Ahmad S, 2016, J RENAL INJ PREV, V5, P53, DOI 10.15171/jrip.2016.12; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Aranha Andrew, 2018, Asian J Neurosurg, V13, P1140, DOI 10.4103/ajns.AJNS_107_18; Bahr N, 2013, CURR INFECT DIS REP, V15, P583, DOI 10.1007/s11908-013-0378-5; Bahr NC, 2018, LANCET INFECT DIS, V18, P68, DOI [10.1016/s1473-3099(17)30474-7, 10.1016/S1473-3099(17)30474-7]; Bertrand A, 2017, MED MALADIES INFECT, V47, P195, DOI 10.1016/j.medmal.2017.01.002; BHIVA, 2018, BHIVA GUID MAN TUB A; Boone Myles Dustin, 2015, Surg Neurol Int, V6, P177, DOI 10.4103/2152-7806.170248; Cantier M, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2140-8; Chiang SS, 2014, LANCET INFECT DIS, V14, P947, DOI 10.1016/S1473-3099(14)70852-7; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; D'Andrea A, 2016, J CARDIOVASC ECHOGR, V26, P28, DOI 10.4103/2211-4122.183746; Daskapan A, 2019, CLIN PHARMACOKINET, V58, P747, DOI 10.1007/s40262-018-0716-8; DeLance AR, 2013, J CLIN NEUROSCI, V20, P1333, DOI 10.1016/j.jocn.2013.01.008; Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents, 2016, GUID US ANT AG AD AD; Desta Z, 2001, ANTIMICROB AGENTS CH, V45, P382, DOI 10.1128/AAC.45.2.382-392.2001; Dittrich S, 2015, AM J TROP MED HYG, V93, P232, DOI 10.4269/ajtmh.15-0119; Donovan Joseph, 2018, Wellcome Open Res, V3, P31, DOI 10.12688/wellcomeopenres.14006.1; Figaji A, 2017, TUBERCULOSIS CENTRAL, P419; Garg RK, 2016, NEUROL INDIA, V64, P219, DOI 10.4103/0028-3886.177608; Garg RK, 2014, J NEUROL SCI, V340, P26, DOI 10.1016/j.jns.2014.03.025; Giancola ML, 2015, J INFECT DEV COUNTR, V9, P536, DOI 10.3855/jidc.5552; Goyal P, 2014, CHILD NERV SYST, V30, P851, DOI 10.1007/s00381-014-2371-1; Granerod J, 2016, CLIN RADIOL, V71, P1050, DOI 10.1016/j.crad.2016.03.015; Gupta R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000404; Hannon MJ, 2014, J CLIN MED, V3, P1084, DOI 10.3390/jcm3041084; Harrichandparsad R, 2019, WORLD NEUROSURG, V123, pE574, DOI 10.1016/j.wneu.2018.11.221; He Y, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2447-0; Heemskerk AD, 2017, CLIN INFECT DIS, V65, P20, DOI 10.1093/cid/cix230; Heemskerk AD, 2016, NEW ENGL J MED, V374, P124, DOI 10.1056/NEJMoa1507062; Imran D, 2018, NEUROL-CLIN PRACT, V8, P379, DOI 10.1212/CPJ.0000000000000517; Jain SK, 2018, NAT IMMUNOL, V19, P521, DOI 10.1038/s41590-018-0119-x; Jawaid A, 2016, JCPSP-J COLL PHYSICI, V26, P716, DOI 2415; Jeon SB, 2014, J STROKE, V16, P146, DOI 10.5853/jos.2014.16.3.146; Kalita J, 2016, TUBERCULOSIS, V98, P1, DOI 10.1016/j.tube.2016.01.004; Kalita J, 2018, J NEURORADIOLOGY, V45, P130, DOI 10.1016/j.neurad.2017.09.005; Karnatovskaia LV, 2014, NEUROHOSPITALIST, V4, P153, DOI 10.1177/1941874413519802; Kukreti V, 2014, J PEDIATR NEUROSCI, V9, P207, DOI 10.4103/1817-1745.147572; Lau VI, 2017, CRIT ULTRASOUND J, V9, DOI 10.1186/s13089-017-0077-9; Thao LTP, 2018, CLIN INFECT DIS, V66, P523, DOI 10.1093/cid/cix849; Lee EK, 2016, KOREAN J RADIOL, V17, P127, DOI 10.3348/kjr.2016.17.1.127; Lopez GA, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-016-0393-6; Mai NTH, 2018, ELIFE, V7, DOI [10.7554/elife.33478, 10.7554/eLife.33478]; Marais BJ, 2017, CLIN INFECT DIS, V64, P501, DOI 10.1093/cid/ciw757; Marais S, 2013, CLIN INFECT DIS, V56, P450, DOI 10.1093/cid/cis899; Marcus HJ, 2015, INSERTION INTRACRANI; Millichap JG, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00013; Misra UK, 2015, J CRIT CARE, V30, P1365, DOI 10.1016/j.jcrc.2015.08.017; Misra UK, 2018, JAMA NEUROL; Misra UK, 2018, EPILEPSY RES, V148, P90, DOI 10.1016/j.eplepsyres.2018.10.005; Misra UK, 2016, J NEUROL SCI, V367, P152, DOI 10.1016/j.jns.2016.06.004; Misra UK, 2014, T ROY SOC TROP MED H, V108, P141, DOI 10.1093/trstmh/tru008; Modi M, 2017, CLIN NEUROL NEUROSUR, V161, P29, DOI 10.1016/j.clineuro.2017.08.006; Morgado TC, 2013, WORLD NEUROSURG, V80, pE255, DOI 10.1016/j.wneu.2012.09.021; Mourvillier B, 2013, JAMA; Narum S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004587; Thuong NTT, 2017, J INFECT DIS, V215, P665, DOI 10.1093/infdis/jiw565; Ojukwu N, 2014, CRIT CARE, V18, P448; Ong CWM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0801-1; Prasad K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002244.pub4; Raut T, 2013, J INFECTION, V66, P330, DOI 10.1016/j.jinf.2012.12.009; Rickard AC, 2014, EMERG MED J, V31, P679, DOI 10.1136/emermed-2013-202679; Rizvi I, 2017, J NEUROL SCI, V375, P255, DOI 10.1016/j.jns.2017.02.008; Rohlwink UK, 2017, CLIN INFECT DIS, V65, P1298, DOI 10.1093/cid/cix540; Rohlwink UK, 2014, CLIN CHEM, V60, P823, DOI 10.1373/clinchem.2013.212472; Ruslami R, 2013, LANCET INFECT DIS, V13, P27, DOI 10.1016/S1473-3099(12)70264-5; Sanfilippo F, 2015, NEUROCRIT CARE, V22, P325, DOI 10.1007/s12028-014-0061-1; Sangani Shruti V, 2015, Indian J Radiol Imaging, V25, P173, DOI 10.4103/0971-3026.155869; Schaller MA, 2019, CLIN NEURORADIOL, V29, P3, DOI 10.1007/s00062-018-0726-9; Senbayrak S, 2015, ANN CLIN MICROB ANTI, V14, DOI 10.1186/s12941-015-0107-z; Sharma RM, 2015, J NEUROSURG, V122, P1087, DOI 10.3171/2014.12.JNS14257; Sharma SK, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7-0013-2016; Singh AK, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1625-9; Sonneville R, 2015, INTENS CARE MED, V41, P192, DOI 10.1007/s00134-014-3577-0; Spasovski G, 2014, EUR J ENDOCRINOL, V170, pG1, DOI 10.1530/EJE-13-1020; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Tai MLS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38802; Tai MLS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164266; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Thuong NTT, 2017, J INFECT DIS, V215, P1020, DOI 10.1093/infdis/jix050; Thwaites G., 2017, MEDICINE, V45, P670, DOI [10.1016/j.mpmed.2017.08.010, DOI 10.1016/J.MPMED.2017.08.010]; Thwaites GE, 2013, LANCET NEUROL, V12, P999, DOI 10.1016/S1474-4422(13)70168-6; Torok ME, 2015, BRIT MED BULL, V113, P117, DOI 10.1093/bmb/ldv003; Vadivelu S, 2013, CLIN PEDIATR, V52, P1135, DOI 10.1177/0009922813493833; van Laarhoven A, 2017, J INFECT DIS, V215, P1029, DOI 10.1093/infdis/jix051; van Toorn R, 2014, CHILD NERV SYST, V30, P1711, DOI 10.1007/s00381-014-2435-2; Wakai A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub5; Wang T, 2016, SCI REP-UK, V6, DOI 10.1038/srep25251; Wasay M, 2018, STROKE, V49, P2288, DOI 10.1161/STROKEAHA.118.021301; Wasay M, 2014, J NEUROL NEUROSUR PS, V85, P1260, DOI 10.1136/jnnp-2013-307178; Wilkinson RJ, 2017, NAT REV NEUROL, V13, P581, DOI 10.1038/nrneurol.2017.120; World Health Organization (WHO), 2021, GLOBAL TUBERCULOSIS; Zhang X, 2017, PHYSIOL MEAS, V38, P143, DOI 10.1088/1361-6579/aa7256	94	42	45	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2019	18	8					771	783		10.1016/S1474-4422(19)30154-1	http://dx.doi.org/10.1016/S1474-4422(19)30154-1			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IH7ZF	31109897	Green Submitted			2022-12-18	WOS:000474722800018
J	Rexach, J; Lee, H; Martinez-Agosto, JA; Nemeth, AH; Fogel, BL				Rexach, Jessica; Lee, Hane; Martinez-Agosto, Julian A.; Nemeth, Andrea H.; Fogel, Brent L.			Clinical application of next-generation sequencing to the practice of neurology	LANCET NEUROLOGY			English	Review							HETEROZYGOUS HTRA1 MUTATIONS; ALZHEIMERS-DISEASE; PRECISION MEDICINE; NEURODEGENERATIVE DISEASES; MOLECULAR DIAGNOSIS; NATIONAL INSTITUTE; GENETIC-BASIS; ENCODE DATA; EXOME; DISORDERS	Next-generation sequencing technologies allow for rapid and inexpensive large-scale genomic analysis, creating unprecedented opportunities to integrate genomic data into the clinical diagnosis and management of neurological disorders. However, the scale and complexity of these data make them difficult to interpret and require the use of sophisticated bioinformatics applied to extensive datasets, including whole exome and genome sequences. Detailed analysis of genetic data has shown that accurate phenotype information is essential for correct interpretation of genetic variants and might necessitate re-evaluation of the patient in some cases. A multidisciplinary approach that incorporates bioinformatics, clinical evaluation, and human genetics can help to address these challenges. However, despite numerous studies that show the efficacy of next-generation sequencing in establishing molecular diagnoses, pathogenic mutations are generally identified in fewer than half of all patients with genetic neurological disorders, exposing considerable gaps in the understanding of the human genome and providing opportunities to focus research on improving the usefulness of genomics in clinical practice. Looking forward, the emergence of precision health in neurological care will increasingly apply genomic data analysis to pharmacogenetics, preventive medicine, and patient-targeted therapies.	[Rexach, Jessica; Fogel, Brent L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, Los Angeles, CA 90095 USA; [Lee, Hane] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Lee, Hane; Martinez-Agosto, Julian A.; Fogel, Brent L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; [Martinez-Agosto, Julian A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Med Genet, Los Angeles, CA 90095 USA; [Fogel, Brent L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Clin Neurogen Res Ctr, Los Angeles, CA 90095 USA; [Nemeth, Andrea H.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Nemeth, Andrea H.] Oxford Univ Hosp Natl Hlth Serv Fdn Trust, Oxford Ctr Genom Med, Oxford, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oxford; Oxford University Hospitals NHS Foundation Trust	Fogel, BL (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.	bfogel@ucla.edu		Nemeth, Andrea/0000-0002-2941-7657	US National Institute for Neurological Disorders and Stroke [R25NS065723, R01NS082094]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R25NS065723, R01NS082094] Funding Source: NIH RePORTER; MRC [MC_UP_1502/3] Funding Source: UKRI	US National Institute for Neurological Disorders and Stroke; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	JR and BLF were supported in part by the US National Institute for Neurological Disorders and Stroke (fellowship training grant R25NS065723 and grant R01NS082094).	Abul-Husn NS, 2016, SCIENCE, V354, DOI 10.1126/science.aaf7000; Acuna-Hidalgo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1110-1; Akbarian S, 2015, NAT NEUROSCI, V18, P1707, DOI 10.1038/nn.4156; Akizu N, 2014, AM J HUM GENET, V94, P80, DOI 10.1016/j.ajhg.2013.11.015; Alfares A, 2018, GENET MED, V20, P1328, DOI 10.1038/gim.2018.41; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Amendola LM, 2016, AM J HUM GENET, V99, P247, DOI 10.1016/j.ajhg.2016.06.001; [Anonymous], 2010, NAT METHODS, V7, P331, DOI 10.1038/nmeth0510-331; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Armaroli A, 2015, EUR J PAEDIATR NEURO, V19, P533, DOI 10.1016/j.ejpn.2015.04.002; Ashley EA, 2015, JAMA-J AM MED ASSOC, V313, P2119, DOI 10.1001/jama.2015.3595; Bahlo Melanie, 2018, F1000Res, V7, DOI 10.12688/f1000research.13980.1; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Belkadi A, 2015, P NATL ACAD SCI USA, V112, P5473, DOI 10.1073/pnas.1418631112; Berm EJJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146262; Berto S, 2016, HUM MOL GENET, V25, P2451, DOI 10.1093/hmg/ddw110; Bowdin SC, 2016, CLIN GENET, V89, P10, DOI 10.1111/cge.12579; Boycott KM, 2017, AM J HUM GENET, V100, P695, DOI 10.1016/j.ajhg.2017.04.003; Boycott KM, 2013, NAT REV GENET, V14, P681, DOI 10.1038/nrg3555; Braverman Genna, 2018, Mayo Clin Proc Innov Qual Outcomes, V2, P81, DOI 10.1016/j.mayocpiqo.2018.03.005; Bunnik EM, 2011, BMC MED ETHICS, V12, DOI 10.1186/1472-6939-12-11; Castellana S, 2013, BRIEF BIOINFORM, V14, P448, DOI 10.1093/bib/bbt013; Cheng CS, 2018, HUM MOL GENET, V27, P4303, DOI 10.1093/hmg/ddy331; Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209; Cummings Jeffrey, 2018, Alzheimers Dement (N Y), V4, P195, DOI 10.1016/j.trci.2018.03.009; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; de la Torre-Ubieta L, 2018, CELL, V172, P289, DOI 10.1016/j.cell.2017.12.014; Delaney SK, 2016, CLIN PHARMACOL THER, V99, P146, DOI 10.1002/cpt.287; Eichler F, 2017, NEW ENGL J MED, V377, P1630, DOI 10.1056/NEJMoa1700554; Ellingford JM, 2016, OPHTHALMOLOGY, V123, P1143, DOI 10.1016/j.ophtha.2016.01.009; Elsaid MF, 2017, ANN NEUROL, V81, P68, DOI 10.1002/ana.24826; Escott-Price V, 2015, BRAIN, V138, P3673, DOI 10.1093/brain/awv268; Ewans LJ, 2018, GENET MED; Fan J, 2018, CEREBELLUM ATAXIAS, V5, P1; Farwell KD, 2015, GENET MED, V17, P578, DOI 10.1038/gim.2014.154; Federico A, 2016, GENEREVIEWS; Fitzgerald TW, 2015, NATURE, V519, P223, DOI 10.1038/nature14135; Fogel BL, 2015, NEUROLOGY CLIN PRACT, P648; Fogel BL, 2018, ANN NEUROL, V83, P1072, DOI 10.1002/ana.25262; Fogel Brent L, 2018, Handb Clin Neurol, V147, P11, DOI 10.1016/B978-0-444-63233-3.00002-6; Fogel BL, 2016, NEUROL-CLIN PRACT, V6, P164, DOI 10.1212/CPJ.0000000000000239; Fogel BL, 2016, ANN NY ACAD SCI, V1366, P49, DOI 10.1111/nyas.12850; Fogel BL, 2014, JAMA NEUROL, V71, P1237, DOI 10.1001/jamaneurol.2014.1944; Fogel Brent L, 2011, Continuum (Minneap Minn), V17, P347, DOI 10.1212/01.CON.0000396975.87637.86; Gagliano SA, 2017, BIOL PSYCHIAT, V81, P478, DOI 10.1016/j.biopsych.2016.08.011; Galatolo D, 2018, NEUROGENETICS, V19, P1, DOI 10.1007/s10048-017-0532-6; Gardiner AR, 2012, NEUROLOGY, V79, P2115, DOI 10.1212/WNL.0b013e3182752c5a; Gavan SP, 2018, EXPERT REV PRECIS ME, V3, P1, DOI 10.1080/23808993.2018.1421858; Ghosh R, 2018, HUM MUTAT, V39, P1525, DOI 10.1002/humu.23642; Ghosh R, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1353-5; Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]; Ginsburg GS, 2018, HEALTH AFFAIR, V37, P694, DOI 10.1377/hlthaff.2017.1624; Goolam S, 2018, MOL VIS, V24, P407; Gray VE, 2012, BIOINFORMATICS, V28, P2093, DOI 10.1093/bioinformatics/bts336; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Hallowell N, 2015, J MED ETHICS, V41, P317, DOI 10.1136/medethics-2013-101996; Haskell GT, 2018, NEUROL-GENET, V4, DOI 10.1212/NXG.0000000000000212; Helbig KL, 2016, GENET MED, V18, P898, DOI 10.1038/gim.2015.186; Iglesias A, 2014, GENET MED, V16, P922, DOI 10.1038/gim.2014.58; Kaye J, 2008, HUM MOL GENET, V17, pR180, DOI 10.1093/hmg/ddn253; Klein CJ, 2014, J NEUROL NEUROSUR PS, V85, P1265, DOI 10.1136/jnnp-2013-306740; Knopman DS, 2018, ALZHEIMERS DEMENT, V14, P563, DOI 10.1016/j.jalz.2018.03.002; Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824; Kuhl JS, 2017, BRAIN, V140, P953, DOI 10.1093/brain/awx016; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Lee YC, 2018, STROKE, V49, P1593, DOI 10.1161/STROKEAHA.118.021283; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lelieveld SH, 2015, HUM MUTAT, V36, P815, DOI 10.1002/humu.22813; Love-Koh J, 2018, PHARMACOECONOMICS, V36, P1439, DOI 10.1007/s40273-018-0686-6; Lupski JR, 2010, NEW ENGL J MED, V362, P1181, DOI 10.1056/NEJMoa0908094; MacArthur DG, 2014, NATURE, V508, P469, DOI 10.1038/nature13127; Makrythanasis P, 2014, HUM MUTAT, V35, P1203, DOI 10.1002/humu.22617; Mandelker D, 2016, GENET MED, V18, P1282, DOI 10.1038/gim.2016.58; Manole A, 2017, BRAIN, V140, P2820, DOI 10.1093/brain/awx231; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Manrai AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMsa1507092; Mcrae JF, 2017, NATURE, V542, P433, DOI 10.1038/nature21062; Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355; Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006; Miller IO, 2014, GENEREVIEWS; Moortgat S., 2018, EUR J MED GENET; Mukerjee G, 2018, NPJ GENOM MED, V3, DOI 10.1038/s41525-018-0065-4; Nambot S, 2018, GENET MED, V20, P645, DOI 10.1038/gim.2017.162; Negi SK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00952-9; Nemeth AH, 2013, BRAIN, V136, P3106, DOI 10.1093/brain/awt236; Ohba C, 2013, NEUROGENETICS, V14, P225, DOI 10.1007/s10048-013-0375-8; Ormondroyd E, 2017, EUR J HUM GENET, V25, P680, DOI 10.1038/ejhg.2017.37; Palmer EE, 2018, MOL GENET GENOM MED, V6, P186, DOI 10.1002/mgg3.355; Pati AR, 2018, NEUROL SCI, V39, P1479, DOI 10.1007/s10072-018-3294-5; Pazin Michael J, 2015, Cold Spring Harb Protoc, V2015, P522, DOI 10.1101/pdb.top084988; Pearson TS, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0342-7; Perlman RL, 2016, EVOL MED PUBLIC HLTH, P170, DOI 10.1093/emph/eow014; Pfeffer G, 2015, NEUROLOGY, V84, P1174, DOI 10.1212/WNL.0000000000001369; Pihlstrom L, 2018, HAND CLINIC, V145, P309, DOI 10.1016/B978-0-12-802395-2.00022-5; Puoti G, 2014, J ALZHEIMERS DIS, V42, P939, DOI 10.3233/JAD-140717; Pyle A, 2015, BRAIN, V138, P276, DOI 10.1093/brain/awu348; Qureshi IA, 2013, JAMA NEUROL, V70, P703, DOI 10.1001/jamaneurol.2013.1443; Retterer K, 2016, GENET MED, V18, P696, DOI 10.1038/gim.2015.148; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Riva P, 2016, CURR ALZHEIMER RES, V13, P1219, DOI 10.2174/1567205013666160622112234; Rossi M, 2017, PEDIATR NEUROL, V70, P34, DOI 10.1016/j.pediatrneurol.2017.01.033; Roxburgh RH, 2013, J NEUROL, V260, P1286, DOI 10.1007/s00415-012-6792-z; Rutten JW, 2016, ANN CLIN TRANSL NEUR, V3, P844, DOI 10.1002/acn3.344; Sawyer SL, 2014, HUM MUTAT, V35, P45, DOI 10.1002/humu.22451; Schabhuttl M, 2014, J NEUROL, V261, P970, DOI 10.1007/s00415-014-7289-8; Schneider VA, 2017, GENOME RES, V27, P849, DOI 10.1101/gr.213611.116; Schnekenberg RP, 2015, BRAIN, V138, P1817, DOI 10.1093/brain/awv117; Schwartz MLB, 2018, AM J HUM GENET, V103, P328, DOI 10.1016/j.ajhg.2018.07.009; Shearer AE, 2014, AM J HUM GENET, V95, P445, DOI 10.1016/j.ajhg.2014.09.001; Shi YW, 2017, NEUROLOGY, V88, P2183, DOI [10.1212/wnl.0000000000004008, 10.1212/WNL.0000000000004008]; Shiraishi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114263; Silvado CE, 2018, PHARMACOGEN PERS MED, V11, P51, DOI 10.2147/PGPM.S108113; Sloan CA, 2016, NUCLEIC ACIDS RES, V44, pD726, DOI 10.1093/nar/gkv1160; Sobreira Nara, 2015, Hum Mutat, V36, P928, DOI 10.1002/humu.22844; Sperling R, 2014, NEURON, V84, P608, DOI 10.1016/j.neuron.2014.10.038; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Srivastava S, 2014, ANN NEUROL, V76, P473, DOI 10.1002/ana.24251; Stenson PD, 2017, HUM GENET, V136, P665, DOI 10.1007/s00439-017-1779-6; Strzelczyk A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00712; Synofzik M, 2018, EUR J HUM GENET, V26, P1623, DOI 10.1038/s41431-018-0206-3; Tandy-Connor S, 2018, GENET MED, V20, P1515, DOI 10.1038/gim.2018.38; Tarailo-Graovac M, 2016, NEW ENGL J MED, V374, P2246, DOI 10.1056/NEJMoa1515792; Tariot Pierre N, 2018, Alzheimers Dement (N Y), V4, P150, DOI 10.1016/j.trci.2018.02.002; Taylor JC, 2015, NAT GENET, V47, P717, DOI 10.1038/ng.3304; Thusberg J, 2011, HUM MUTAT, V32, P358, DOI 10.1002/humu.21445; Turner SA, 2019, GENET MED, V21, P426, DOI 10.1038/s41436-018-0063-z; Vanderver A, 2016, ANN NEUROL, V79, P1031, DOI 10.1002/ana.24650; Verbelen M, 2017, PHARMACOGENOMICS J, V17, P395, DOI 10.1038/tpj.2017.21; Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Vilboux T, 2017, GENET MED, V19, P875, DOI 10.1038/gim.2016.204; Voelkerding KV, 2009, CLIN CHEM, V55, P641, DOI 10.1373/clinchem.2008.112789; Walker S, 2018, NEUROL-GENET, V4, DOI 10.1212/NXG.0000000000000242; Wang D, 2018, GENEREVIEWS; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Watson MS, 2015, GENET MED, V17, DOI [10.1038/gim.2015.94, 10.1038/gim.2014.151]; Wijemanne S, 2015, NAT REV NEUROL, V11, P414, DOI 10.1038/nrneurol.2015.86; Wolf SM, 2017, EXPERT REV MOL DIAGN, V17, P415, DOI 10.1080/14737159.2017.1309976; Won HJ, 2016, NATURE, V538, P523, DOI 10.1038/nature19847; Wright CF, 2018, GENET MED, V20, P1216, DOI 10.1038/gim.2017.246; Wright CF, 2015, LANCET, V385, P1305, DOI 10.1016/S0140-6736(14)61705-0; Wu XW, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176632, 10.1590/1414-431x20176632]; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Zech M, 2017, MOVEMENT DISORD, V32, P549, DOI 10.1002/mds.26808; Zhang DL, 2017, EXP THER MED, V13, P2129, DOI 10.3892/etm.2017.4267; Zhao HK, 2018, J NEURO-ONCOL, V140, P281, DOI 10.1007/s11060-018-2874-9; Zusso M, 2018, J ALZHEIMERS DIS, V64, P671, DOI 10.3233/JAD-180259	149	42	43	3	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2019	18	5					492	503		10.1016/S1474-4422(19)30033-X	http://dx.doi.org/10.1016/S1474-4422(19)30033-X			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HS8SW	30981321	Green Accepted			2022-12-18	WOS:000464140400016
J	Spencer, DD; Gerrard, JL; Zaveri, HP				Spencer, Dennis D.; Gerrard, Jason L.; Zaveri, Hitten P.			The roles of surgery and technology in understanding focal epilepsy and its comorbidities	LANCET NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; DEFAULT MODE NETWORK; ALTERED FUNCTIONAL CONNECTIVITY; SEIZURE ONSET ZONE; EPILEPTOGENIC NETWORKS; ANXIETY DISORDERS; MAJOR DEPRESSION; NEURAL-NETWORKS; BRAIN; EEG	Intracranial electrophysiological recording in patients with refractory focal epilepsy is the gold standard for defining epileptogenic tissue. Although the concordance of intracranial electrophysiology, structural MRI, and pathology can identify brain regions for resection, complete seizure control after surgery is not achieved in all patients with focal epilepsy. Repetitive identical behavioural seizures suggest one onset area, but epileptogenesis might be distributed and connected by functional and structural brain networks outside the seizure onset area, which could explain poor postsurgical outcomes in some patients. Similar networks are postulated in neuropsychiatric disorders, such as depression and anxiety, and seem to overlap with posited epilepsy networks, perhaps explaining the high prevalence of comorbid neuropsychiatric disorders in patients with epilepsy. These networks are difficult to verify with available electrophysiological recording approaches. Advances in intracranial technology are needed to confirm the epilepsy network hypothesis and improve surgical outcomes by providing individualised therapies based on specific network contributions.	[Spencer, Dennis D.; Gerrard, Jason L.] Yale Univ, Dept Neurosurg, New Haven, CT 06520 USA; [Zaveri, Hitten P.] Yale Univ, Dept Neurol, New Haven, CT USA	Yale University; Yale University	Spencer, DD (corresponding author), Yale Univ, Dept Neurosurg, New Haven, CT 06520 USA.	dennis.spencer@yale.edu	Morden, Frances/AAY-4233-2020	Gerrard, Jason/0000-0001-6971-1407				Alomar S, 2016, NEUROSURG CLIN N AM, V27, P83, DOI 10.1016/j.nec.2015.08.003; Barba C, 2016, BRAIN, V139, P444, DOI 10.1093/brain/awv372; Bari AA, 2018, J NEUROL NEUROSURG P; Bartolomei F, 2017, EPILEPSIA, V58, P1131, DOI 10.1111/epi.13791; Basten U, 2011, J COGNITIVE NEUROSCI, V23, P3132, DOI 10.1162/jocn_a_00003; Bettus G, 2008, EPILEPSY RES, V81, P58, DOI 10.1016/j.eplepsyres.2008.04.020; Bialonski S, 2013, CHAOS, V23, DOI 10.1063/1.4821915; Blumenfeld H, 2007, EPILEPSIA, V48, P254, DOI 10.1111/j.1528-1167.2006.00934.x; Blumenfeld H, 2014, ADV EXP MED BIOL, V813, P63, DOI 10.1007/978-94-017-8914-1_5; Bower MR, 2017, EPILEPSIA, V58, P94, DOI 10.1111/epi.13614; Bower MR, 2015, J NEUROSCI, V35, P999, DOI 10.1523/JNEUROSCI.3019-14.2015; Broicher SD, 2012, J NEUROL, V259, P2546, DOI 10.1007/s00415-012-6533-3; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Burns SP, 2014, P NATL ACAD SCI USA, V111, pE5321, DOI 10.1073/pnas.1401752111; Buzsaki G, 2015, HIPPOCAMPUS, V25, P1073, DOI 10.1002/hipo.22488; Cataldi M, 2013, EPILEPSIA, V54, P2048, DOI 10.1111/epi.12400; Cavus I, 2016, ANN NEUROL, V80, P35, DOI 10.1002/ana.24673; Cerullo MA, 2012, BIPOLAR DISORD, V14, P175, DOI 10.1111/j.1399-5618.2012.01002.x; Cohen-Gadol AA, 2005, J NEUROSURG, V102, P902, DOI 10.3171/jns.2005.102.5.0902; Constable RT, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00039; Dickten H, 2016, SCI REP-UK, V6, DOI 10.1038/srep34824; Duncan D, 2013, CLIN NEUROPHYSIOL, V124, P1943, DOI 10.1016/j.clinph.2013.03.028; DURING MJ, 1993, LANCET, V341, P1607; Englot DJ, 2016, EPILEPSIA, V57, P1546, DOI 10.1111/epi.13510; Englot DJ, 2015, BRAIN, V138, P2249, DOI 10.1093/brain/awv130; FEINDEL W, 1991, CAN J NEUROL SCI, V18, P603; Frei MG, 2010, EPILEPSY BEHAV, V19, P4, DOI 10.1016/j.yebeh.2010.06.009; FRIED I, 1995, J NEUROSURG, V83, P60, DOI 10.3171/jns.1995.83.1.0060; Geier C, 2017, INT J NEURAL SYST, V27, DOI 10.1142/S0129065716500337; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Guye M, 2006, BRAIN, V129, P1917, DOI 10.1093/brain/awl151; Haneef Z, 2012, EPILEPSY BEHAV, V25, P350, DOI 10.1016/j.yebeh.2012.07.019; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; HIRSCH LJ, 1991, ANN NEUROL, V30, P347, DOI 10.1002/ana.410300306; Jayakar P, 2016, EPILEPSIA, V57, P1735, DOI 10.1111/epi.13515; Jiruska P, 2013, J PHYSIOL-LONDON, V591, P787, DOI 10.1113/jphysiol.2012.239590; Joshi RB, 2016, CLIN NEUROPHYSIOL, V127, P3485, DOI 10.1016/j.clinph.2016.09.003; Kaiser RH, 2015, JAMA PSYCHIAT, V72, P603, DOI 10.1001/jamapsychiatry.2015.0071; Kang JY, 2016, EPILEPSIA, V57, P325, DOI 10.1111/epi.13284; Khambhati AN, 2016, NEURON, V91, P1170, DOI 10.1016/j.neuron.2016.07.039; King-Stephens D, 2015, EPILEPSIA, V56, P959, DOI 10.1111/epi.13010; Kramer MA, 2012, NEUROSCIENTIST, V18, P360, DOI 10.1177/1073858411422754; Lee HW, 2014, NEUROLOGY, V83, P2269, DOI 10.1212/WNL.0000000000001068; Leistedt SJ, 2013, EUR NEUROPSYCHOPHARM, V23, P55, DOI 10.1016/j.euroneuro.2012.10.011; McIntosh AM, 2012, EPILEPSIA, V53, P970, DOI 10.1111/j.1528-1167.2012.03430.x; Najm I, 2013, EPILEPSIA, V54, P772, DOI 10.1111/epi.12152; Nissen IA, 2017, EPILEPSIA, V58, P137, DOI 10.1111/epi.13622; Omidvarnia A, 2017, HUM BRAIN MAPP, V38, P5356, DOI 10.1002/hbm.23723; Palmigiano A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041799; Pan JW, 2013, EPILEPSIA, V54, P1668, DOI 10.1111/epi.12322; Paz JT, 2013, NAT NEUROSCI, V16, P64, DOI 10.1038/nn.3269; Pittau F, 2012, EPILEPSIA, V53, P1013, DOI 10.1111/j.1528-1167.2012.03464.x; Rayner G, 2017, EPILEPSY CURR, V17, P78, DOI 10.5698/1535-7511.17.2.78; Richardson MP, 2012, J NEUROL NEUROSUR PS, V83, P1238, DOI 10.1136/jnnp-2011-301944; Russell S, 2009, ARTIF INTELL, V3rd; Salanova V, 2004, ACTA NEUROL SCAND; Salanova V, 2015, NEUROLOGY, V84, P1017, DOI 10.1212/WNL.0000000000001334; Sinha N, 2017, BRAIN, V140, P319, DOI 10.1093/brain/aww299; Smith EH, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0701-2; Smith EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11098; Spencer D, 2016, TREATMENT OF EPILEPSY, 4TH EDITION, P733; SPENCER SS, 1994, EPILEPSIA, V35, P721, DOI 10.1111/j.1528-1157.1994.tb02502.x; Spencer SS, 2002, EPILEPSIA, V43, P219, DOI 10.1046/j.1528-1157.2002.26901.x; Sritharan D, 2014, NEURAL COMPUT, V26, P2294, DOI 10.1162/NECO_a_00644; Sylvester CM, 2012, TRENDS NEUROSCI, V35, P527, DOI 10.1016/j.tins.2012.04.012; Terry JR, 2012, EPILEPSIA, V53, pe166, DOI 10.1111/j.1528-1167.2012.03560.x; THADANI VM, 1995, EPILEPSIA, V36, P7, DOI 10.1111/j.1528-1157.1995.tb01658.x; Tomlinson SB, 2017, EPILEPSIA, V58, P402, DOI 10.1111/epi.13657; Ung H, 2016, EPILEPSIA, V57, P1949, DOI 10.1111/epi.13591; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Varotto G, 2012, NEUROIMAGE, V61, P591, DOI 10.1016/j.neuroimage.2012.03.090; Vlooswijk MCG, 2011, EPILEPSIA, V52, P1467, DOI 10.1111/j.1528-1167.2011.03108.x; Wang H, 2017, EPILEPSIA, V58, P824, DOI 10.1111/epi.13731; Warren CP, 2010, J NEUROPHYSIOL, V104, P3530, DOI 10.1152/jn.00368.2010; Wendling F, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00154; Wilke C, 2011, EPILEPSIA, V52, P84, DOI 10.1111/j.1528-1167.2010.02785.x; Yaffe RB, 2015, CLIN NEUROPHYSIOL, V126, P227, DOI 10.1016/j.clinph.2014.09.009; Yue YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075058; Zaveri HP, 2010, CLIN NEUROPHYSIOL, V121, P311, DOI 10.1016/j.clinph.2009.11.081; Zaveri HR, 2009, NEUROREPORT, V20, P891, DOI 10.1097/WNR.0b013e32832c78e0; Zhang ZQ, 2009, NEUROSCI LETT, V458, P97, DOI 10.1016/j.neulet.2009.04.040; Zhao XH, 2007, EUR J RADIOL, V63, P373, DOI 10.1016/j.ejrad.2007.02.006; Zhu XL, 2012, BIOL PSYCHIAT, V71, P611, DOI 10.1016/j.biopsych.2011.10.035	83	42	43	4	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2018	17	4					373	382		10.1016/S1474-4422(18)30031-0	http://dx.doi.org/10.1016/S1474-4422(18)30031-0			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ3AO	29553383				2022-12-18	WOS:000427458000020
J	Gonzalez-Bermejo, J; Morelot-Panzini, C; Tanguy, ML				Gonzalez-Bermejo, J.; Morelot-Panzini, C.; Tanguy, M-L			Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial (vol 15, pg 1217, 2016)	LANCET NEUROLOGY			English	Correction													PRIGENT, HELENE/S-7445-2018; attali, valerie/AAC-4437-2020	attali, valerie/0000-0001-5444-9223; BRUNETEAU, GAELLE/0000-0002-1905-7985; Gonzalez-Bermejo, Jesus/0000-0003-2395-4694; guy, nathalie/0000-0002-1877-8393				Gonzalez-Bermejo J, 2016, LANCET NEUROL, V15, P1301, DOI 10.1016/S1474-4422(16)30233-2	1	42	43	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2016	15	13					1301	1301		10.1016/S1474-4422(16)30233-2	http://dx.doi.org/10.1016/S1474-4422(16)30233-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EB6XV	27751553				2022-12-18	WOS:000387529800005
J	Gonzalez-Bermejo, J; Morelot-Panzini, C; Tanguy, ML; Meininger, V; Pradat, PF; Lenglet, T; Bruneteau, G; Le Forestier, N; Couratier, P; Guy, N; Desnuelle, C; Prigent, H; Perrin, C; Attali, V; Fargeot, C; Nierat, MC; Royer, C; Menegaux, F; Salachas, F; Similowski, T				Gonzalez-Bermejo, Jesus; Morelot-Panzini, Capucine; Tanguy, Marie-Laure; Meininger, Vincent; Pradat, Pierre-Francois; Lenglet, Timothee; Bruneteau, Gaelle; Le Forestier, Nadine; Couratier, Philippe; Guy, Nathalie; Desnuelle, Claude; Prigent, Helene; Perrin, Christophe; Attali, Valerie; Fargeot, Catherine; Nierat, Marie-Cecile; Royer, Catherine; Menegaux, Fabrice; Salachas, Francois; Similowski, Thomas			Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial	LANCET NEUROLOGY			English	Article							NONINVASIVE VENTILATION; PHRENIC-NERVE; MECHANICAL VENTILATION; SURVIVAL; ALS; COHORT; STIMULATION; ELECTRODES; EXPERIENCE; MUSCLE	Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder associated with respiratory muscle weakness and respiratory failure. Non-invasive ventilation alleviates respiratory symptoms and prolongs life, but is a palliative intervention. Slowing the deterioration of diaphragm function before respiratory failure would be desirable. We aimed to assess whether early diaphragm pacing could slow down diaphragm deterioration and would therefore delay the need for non-invasive ventilation. Methods We did a multicentre, randomised, controlled, triple-blind trial in patients with probable or definite ALS in 12 ALS centres in France. The main inclusion criterion was moderate respiratory involvement (forced vital capacity 60-80% predicted). Other key eligibility criteria were age older than 18 years and bilateral responses of the diaphragm to diagnostic phrenic stimulation. All patients were operated laparoscopically and received phrenic stimulators. Clinicians randomly assigned patients (1:1) to receive either active or sham stimulation with a central web-based randomisation system (computer-generated list). Investigators, patients, and an external outcome allocation committee were masked to treatment. The primary outcome was non-invasive ventilation-free survival, analysed in the intention-to-treat population. Safety outcomes were also assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01583088. Findings Between Sept 27, 2012, and July 8, 2015, 74 participants were randomly assigned to receive either active (n=37) or sham (n=37) stimulation. On July 16, 2015, an unplanned masked analysis was done after another trial showed excess mortality with diaphragm pacing in patients with hypoventilation (DiPALS, ISRCTN 53817913). In view of this finding, we analysed mortality in our study and found excess mortality (death from any cause) in our active stimulation group. We therefore terminated the study on July, 16, 2015. Median non-invasive ventilation-free survival was 6.0 months (95% CI 3.6-8.7) in the active stimulation group versus 8.8 months (4.2-not reached) in the control (sham stimulation) group (hazard ratio 1.96 [95% CI 1.08-3.56], p=0.02). Serious adverse events (mainly capnothorax or pneumothorax, acute respiratory failure, venous thromboembolism, and gastrostomy) were frequent (24 [65%] patients in the active stimulation group vs 22 [59%] patients in the control group). No treatment-related death was reported. Interpretation Early diaphragm pacing in patients with ALS and incipient respiratory involvement did not delay noninvasive ventilation and was associated with decreased survival. Diaphragm pacing is not indicated at the early stage of the ALS-related respiratory involvement.	[Gonzalez-Bermejo, Jesus; Morelot-Panzini, Capucine; Attali, Valerie; Nierat, Marie-Cecile] Univ Paris 06, Sorbonne Univ, INSERM, Neurophysiol Resp Expt & Clin UMRS1158, Paris, France; [Gonzalez-Bermejo, Jesus; Morelot-Panzini, Capucine; Similowski, Thomas] Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Serv Pneumol & Reanimat Med, Dept 1235, Paris, France; [Tanguy, Marie-Laure] Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Unite Rech Clin, Paris, France; [Meininger, Vincent; Pradat, Pierre-Francois; Lenglet, Timothee; Bruneteau, Gaelle; Le Forestier, Nadine; Salachas, Francois] Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Ctr Reference Malad Rares SLA, Dept Malad Syst Nerveux, Paris, France; [Pradat, Pierre-Francois] Univ Paris 06, Sorbonne Univ, CNRS, INSERM,Lab Imagerie Biomed, Paris, France; [Bruneteau, Gaelle] Univ Paris 06, Sorbonne Univ, UMR S 1127, Inst Cerveau & Moelle Epiniere,ICM, Paris, France; [Couratier, Philippe] CHU Limoges, Ctr Competence SLA, Limoges, France; [Guy, Nathalie] CHU Gabriel Montpied, Serv Neurol, Clermont Ferrand, France; [Guy, Nathalie] INSERM U1107, Fac Chirurg Dentaire, Neurodol, Douleur Trigeminale & Migraine, Clermont Ferrand, France; [Desnuelle, Claude] Hop Pasteur 2, Ctr Reference SLA, Nice, France; [Prigent, Helene] GHU Paris Ouest, AP HP, Site Raymond Poincare, Serv Physiol & Explorat Fonct, Garches, France; [Perrin, Christophe] CH Cannes, Serv Pneumol, Cannes, France; [Attali, Valerie] Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Serv Pathol Sommeil, Dept R3S, Paris, France; [Fargeot, Catherine] UFDMS, Serv Pharm, Hosp Pitie Salpetriere Charles Foix, Paris, France; [Royer, Catherine] Grp Hosp Pitie Salpetriere Charles Foix, Dept Anesthesie & Reanimat, Paris, France; [Menegaux, Fabrice] Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Serv Chirurg Viscerale, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; CHU Limoges; CHU Clermont Ferrand; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Gonzalez-Bermejo, J (corresponding author), Grp Hosp Pitie Salpetriere, Serv Pneumol & Reanimat Med, Dept R3S, F-75651 Paris 13, France.	jesus.gonzalez@psl.aphp.fr	PRIGENT, HELENE/S-7445-2018; attali, valerie/AAC-4437-2020	attali, valerie/0000-0001-5444-9223; BRUNETEAU, GAELLE/0000-0002-1905-7985; Gonzalez-Bermejo, Jesus/0000-0003-2395-4694; guy, nathalie/0000-0002-1877-8393	Hospital Program for Clinical Research, French Ministry of Health [P110133]; Contrat de Recherche Clinique of the Direction de la Recherche Clinique et du Developpement (DRCD), Assistance Publique-Hopitaux de Paris, Paris, France [CRC15017-R02]; French patients' association for ALS research (Association pour la Rercherche sur la Sclerose Laterale Amyotrophique, ARSLA); Thierry de Latran Foundation for ALS; program Investissement d'Avenir of the French Government [ANR-10-AIHU 06]	Hospital Program for Clinical Research, French Ministry of Health; Contrat de Recherche Clinique of the Direction de la Recherche Clinique et du Developpement (DRCD), Assistance Publique-Hopitaux de Paris, Paris, France; French patients' association for ALS research (Association pour la Rercherche sur la Sclerose Laterale Amyotrophique, ARSLA); Thierry de Latran Foundation for ALS; program Investissement d'Avenir of the French Government	RespiStimALS was funded by the Hospital Program for Clinical Research, French Ministry of Health (grant number P110133) and by a Contrat de Recherche Clinique of the Direction de la Recherche Clinique et du Developpement (DRCD), Assistance Publique-Hopitaux de Paris, Paris, France (grant number CRC15017-R02). It was also funded by the French patients' association for ALS research (Association pour la Rercherche sur la Sclerose Laterale Amyotrophique, ARSLA) and by the Thierry de Latran Foundation for ALS. The study was also supported by the program Investissement d'Avenir ANR-10-AIHU 06 of the French Government.Synapse Biomedical Europe did not contribute to the funding of the study but consented a bulk sale price reduction of 50%. We are grateful to ARSLA for its general support to research in the field of ALS and its respiratory complications, with a particular mention to Yves Tronchon. We thank Lucette Lacomblez, Didier Dreyfuss, and Alain Mallet for their advice regarding the study design, methods, and statistical analysis; Cecile Hoffart-Jourdain and Philippe Lechat from the DRCD of Assistance Publique-Hopitaux de Paris for their invaluable contribution to the logistical and scientific management of the study; Gwenael Le Breton, senior research assistant, for her dedication to the study at the coordinating centre and Anthony Saul for his help with English style and grammar.	Al-Chalabi A, 2013, NAT REV NEUROL, V9, P617, DOI 10.1038/nrneurol.2013.203; Amirjani N, 2012, AMYOTROPH LATERAL SC, V13, P521, DOI 10.3109/17482968.2012.673169; Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Atkeson AD, 2011, NEUROLOGY, V77, P549, DOI 10.1212/WNL.0b013e318228c0fb; Baumann F, 2010, AMYOTROPH LATERAL SC, V11, P194, DOI 10.3109/17482960902991773; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Carreras I, 2010, BRAIN RES, V1313, P192, DOI 10.1016/j.brainres.2009.11.051; Cheah BC, 2009, AMYOTROPH LATERAL SC, V10, P384, DOI 10.3109/17482960903082218; CIESIELSKI TE, 1983, J NEUROSURG, V58, P92, DOI 10.3171/jns.1983.58.1.0092; Corcia P, 2008, AMYOTROPH LATERAL SC, V9, P59, DOI 10.1080/17482960701656940; Cordesse V, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0810-7; DiMarco AF, 2002, AM J RESP CRIT CARE, V166, P1604, DOI 10.1164/rccm.200203-175CR; Dreyer P, 2014, AMYOTROPH LAT SCL FR, V15, P62, DOI 10.3109/21678421.2013.837929; Food and Drug Administration, 2011, NEURRX DPS DIAPHR PA; Gonzalez-Bermejo J, 2013, AMYOTROPH LAT SCL FR, V14, P373, DOI 10.3109/21678421.2013.776086; Gonzalez-Bermejo J, 2012, AMYOTROPH LATERAL SC, V13, P44, DOI 10.3109/17482968.2011.597862; Gordon PH, 2013, NEURODEGENER DIS, V12, P81, DOI 10.1159/000341316; Gordon PH, 2012, J NEUROL, V259, P1788, DOI 10.1007/s00415-011-6403-4; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Hirschfeld S, 2008, SPINAL CORD, V46, P738, DOI 10.1038/sc.2008.43; Jaiswal Manoj Kumar, 2014, Mol Cell Ther, V2, P26, DOI 10.1186/2052-8426-2-26; Lechtzin N, 2007, AMYOTROPH LATERAL SC, V8, P185, DOI 10.1080/17482960701262392; Lepore AC, 2010, NEUROBIOL DIS, V39, P252, DOI 10.1016/j.nbd.2010.03.021; McDermott CJ, 2015, LANCET NEUROL, V14, P883, DOI 10.1016/S1474-4422(15)00152-0; Morelot-Panzini C, 2015, EUR RESPIR J, V45, P1751, DOI 10.1183/09031936.00220614; Onders RP, 2014, AM J SURG, V207, P393, DOI 10.1016/j.amjsurg.2013.08.039; Onders RP, 2009, SURG ENDOSC, V23, P1433, DOI 10.1007/s00464-008-0223-3; Pinto S, 2014, J NEUROL NEUROSUR PS, V85, P643, DOI 10.1136/jnnp-2013-305770; Pupillo E, 2014, ANN NEUROL, V75, P287, DOI 10.1002/ana.24096; Scherer K, 2012, MUSCLE NERVE, V46, P1, DOI 10.1002/mus.23419; Sutherland E Rand, 2007, Proc Am Thorac Soc, V4, P574	34	42	43	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2016	15	12					1217	1225		10.1016/S1474-4422(16)30233-2	http://dx.doi.org/10.1016/S1474-4422(16)30233-2			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA0YO	27751553				2022-12-18	WOS:000386315700017
J	Maski, K; Owens, JA				Maski, Kiran; Owens, Judith A.			Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management	LANCET NEUROLOGY			English	Review							DEFICIT HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS; EYE-MOVEMENT SLEEP; DEPENDENT MEMORY CONSOLIDATION; COGNITIVE-BEHAVIORAL THERAPY; FRONTAL-LOBE EPILEPSY; SCHOOL-AGED CHILDREN; CHILDHOOD NARCOLEPSY; DAYTIME SLEEPINESS; PEDIATRIC NARCOLEPSY	Sleep problems are frequently encountered as presenting complaints in child neurology clinical practice. They can affect the functioning and quality of life of children, particularly those with primary neurological and neurodevelopmental disorders, since coexisting sleep problems can add substantially to neurocognitive and behavioural comorbidities. Additionally, symptoms of some sleep disorders such as parasomnias and narcolepsy can be confused with those of other neurological disorders (eg, epilepsy), posing diagnostic challenges for paediatric neurologists. The understanding of the neurophysiology of sleep disorders such as insomnia, parasomnias, and narcolepsy is still evolving. There is a complex relation between the sleeping brain and its waking function. The interplay among genetic factors, alterations in neurotransmitters, electrophysiological changes, and environmental factors potentially contribute to the genesis of these sleep disorders.	[Maski, Kiran; Owens, Judith A.] Boston Childrens Hosp, Boston, MA 02115 USA; [Maski, Kiran; Owens, Judith A.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Owens, JA (corresponding author), Boston Childrens Hosp, Boston, MA 02115 USA.; Owens, JA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	judith.owens@childrens.harvard.edu			Jazz Pharmaceuticals; Union Chimique Belge	Jazz Pharmaceuticals(Jazz Pharmaceuticals); Union Chimique Belge	KM receives research support from Jazz Pharmaceuticals for her work on the phase 2/3 sodium oxybate clinical trial for children with narcolepsy type 1. JAO is a consultant for and receives research support from Jazz Pharmaceuticals, has received research support from Union Chimique Belge, and has served as a consultant to Transcept, Purdue, Takeda, Pfizer, UCB, Teva, and Rhodes Pharmaceuticals.	American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S; Andlauer O, 2013, JAMA NEUROL, V70, P891, DOI 10.1001/jamaneurol.2013.1589; Andlauer O, 2012, SLEEP, V35, P1247, DOI 10.5665/sleep.2080; Aran A, 2009, SLEEP, V32, P979, DOI 10.1093/sleep/32.8.979; Arii J, 2001, NEUROLOGY, V56, P1775, DOI 10.1212/WNL.56.12.1775; Armstrong JM, 2014, SLEEP, V37, P901, DOI 10.5665/sleep.3656; Attarian JZ, 2013, INT J NEUROSCI, V123, P3; Aurora RN, 2012, SLEEP, V35, P1467, DOI 10.5665/sleep.2190; Baglioni C, 2014, SLEEP, V37, P1907, DOI 10.5665/sleep.4240; Barnett AL, 2012, CHILD CARE HLTH DEV, V38, P403, DOI 10.1111/j.1365-2214.2011.01260.x; Bassetti C, 2000, LANCET, V356, P484, DOI 10.1016/S0140-6736(00)02561-7; Becker SP, 2015, EUR CHILD ADOLES PSY, V24, P897, DOI 10.1007/s00787-014-0636-6; Bjorvatn B, 2010, SLEEP MED, V11, P1031, DOI 10.1016/j.sleep.2010.07.011; Boardman HF, 2005, HEADACHE, V45, P657, DOI 10.1111/j.1526-4610.2005.05133.x; Bourke-Taylor H, 2013, J PAEDIATR CHILD H, V49, P775, DOI 10.1111/jpc.12254; Choi-Kwon S, 2011, INT J STROKE, V6, P328, DOI 10.1111/j.1747-4949.2011.00624.x; Corkum P, 2016, J PEDIATR PSYCHOL, V41, P701, DOI 10.1093/jpepsy/jsw031; Cortesi F, 2012, J SLEEP RES, V21, P700, DOI 10.1111/j.1365-2869.2012.01021.x; de Bruin EJ, 2017, SLEEP MED REV, V32, P45, DOI 10.1016/j.smrv.2016.02.006; de Bruin EJ, 2015, SLEEP, V38, P1913, DOI 10.5665/sleep.5240; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Derry CP, 2009, SLEEP, V32, P1637, DOI 10.1093/sleep/32.12.1637; Dosi C, 2015, SEMIN PEDIATR NEUROL, V22, P105, DOI 10.1016/j.spen.2015.04.005; Drake C, 2003, SLEEP, V26, P455; Ekinci O, 2016, SEIZURE-EUR J EPILEP, V40, P108, DOI 10.1016/j.seizure.2016.06.011; Engelhardt CR, 2013, PEDIATRICS, V132, P1081, DOI 10.1542/peds.2013-2066; Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182; Ferlisi M, 2014, EPILEPSY BEHAV, V33, P101, DOI 10.1016/j.yebeh.2014.02.019; Fernandez-Mendoza J, 2016, SLEEP, V39, P1029, DOI 10.5665/sleep.5746; Fosse R, 2002, SLEEP, V25, P724, DOI 10.1093/sleep/25.7.724; Frank NC, 1997, J PEDIATR PSYCHOL, V22, P345, DOI 10.1093/jpepsy/22.3.345; Gledhill RF, 2004, ARCH NEUROL-CHICAGO, V61, P758, DOI 10.1001/archneur.61.5.758; Goldman SE, 2014, J AUTISM DEV DISORD, V44, P2525, DOI 10.1007/s10803-014-2123-9; Gradisar M, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1486; Grigg-Damberger MM, 2015, CHILD ADOL PSYCH CL, V24, P145, DOI 10.1016/j.chc.2014.09.001; Gujar N, 2011, J NEUROSCI, V31, P4466, DOI 10.1523/JNEUROSCI.3220-10.2011; Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587; Hiscock H, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h68; Honaker SM, 2016, SLEEP MED REV, V25, P31, DOI 10.1016/j.smrv.2015.01.004; Horvath A, 2016, NAT SCI SLEEP; Howell MJ, 2012, NEUROTHERAPEUTICS, V9, P753, DOI 10.1007/s13311-012-0143-8; Hvolby A, 2008, ARCH PEDIAT ADOL MED, V162, P323, DOI 10.1001/archpedi.162.4.323; Iglowstein I, 2003, PEDIATRICS, V111, P302, DOI 10.1542/peds.111.2.302; Ivanenko A, 2003, SLEEP MED, V4, P579, DOI 10.1016/S1389-9457(03)00162-X; Jennum P, 2012, SLEEP MED, V13, P1086, DOI 10.1016/j.sleep.2012.06.006; KANDT RS, 1982, ANN NEUROL, V12, P284, DOI 10.1002/ana.410120313; Kauta SR, 2012, PEDIATR NEUROL, V47, P362, DOI 10.1016/j.pediatrneurol.2012.08.005; Kim LJ, 2015, J CLIN SLEEP MED, V11, P1377, DOI 10.5664/jcsm.5268; Kornum BR, 2015, BRAIN BEHAV IMMUN, V49, P54, DOI 10.1016/j.bbi.2015.03.004; Kotagal S, 2004, SLEEP MED, V5, P147, DOI 10.1016/j.sleep.2003.10.006; Kulman G, 2000, NEUROENDOCRINOL LETT, V21, P31; LeBourgeois MK, 2005, PEDIATRICS; Lecendreux M, 2015, SLEEP, V38, P1285, DOI 10.5665/sleep.4910; Lecendreux M, 2012, SLEEP, V35, P709, DOI 10.5665/sleep.1836; Lee J, 2013, RES DEV DISABIL, V34, P4255, DOI 10.1016/j.ridd.2013.09.008; Licis AK, 2011, NEUROLOGY, V76, P49, DOI 10.1212/WNL.0b013e318203e964; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Liu XC, 2015, PSYCHIAT RES, V228, P797, DOI 10.1016/j.psychres.2015.05.023; Longstreth WT, 2007, SLEEP, V30, P13, DOI 10.1093/sleep/30.1.13; Luc ME, 2006, PEDIATR NEUROL, V34, P7, DOI 10.1016/j.pediatrneurol.2005.06.009; Malik S, 2001, NEUROLOGY, V57, P539, DOI 10.1212/WNL.57.3.539; Malow BA, 2014, J AUTISM DEV DISORD, V44, P216, DOI 10.1007/s10803-013-1866-z; Manni R, 2001, CLIN NEUROPHYSIOL, V112, P800, DOI 10.1016/S1388-2457(01)00483-7; Manni R, 2010, EPILEPSY RES, V90, P171, DOI 10.1016/j.eplepsyres.2010.05.006; Maski K, 2015, SLEEP, V38, P1955, DOI 10.5665/sleep.5248; Maski KP, 2015, SEMIN PEDIATR NEUROL, V22, P130, DOI 10.1016/j.spen.2015.03.008; Maski KP, 2013, INT J PSYCHOPHYSIOL, V89, P259, DOI 10.1016/j.ijpsycho.2013.06.019; Melendres MCS, 2004, PEDIATRICS, V114, P768, DOI 10.1542/peds.2004-0730; Meltzer LJ, 2014, SLEEP MED, V15, P1500, DOI 10.1016/j.sleep.2014.08.010; Meltzer LJ, 2014, J PEDIATR PSYCHOL, V39, P932, DOI 10.1093/jpepsy/jsu041; Miano S, 2013, REV NEUROLOGIA, V56, P257, DOI 10.33588/rn.5605.2013018; Mignot E, 1997, SLEEP, V20, P1012; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Mignot E, 2001, AM J HUM GENET, V68, P686, DOI 10.1086/318799; Moller LR, 2009, J CHILD ADOL PSYCHOP, V19, P197, DOI 10.1089/cap.2008.036; Morin CM, 2006, SLEEP; Morrish E, 2004, SLEEP MED, V5, P37, DOI 10.1016/j.sleep.2003.06.002; Murali H, 2006, SLEEP, V29, P1025, DOI 10.1093/sleep/29.8.1025; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536; Odegard SS, 2010, J HEADACHE PAIN, V11, P197, DOI 10.1007/s10194-010-0201-8; Ohayon MM, 2012, NEUROLOGY, V78, P1583, DOI 10.1212/WNL.0b013e3182563be5; Orsmond GI, 2011, AUTISM, V15, P579, DOI 10.1177/1362361310386503; Owens JA, 2000, SLEEP, V23, P1043; Owens J, 2008, PRIMARY CARE, V35, P533, DOI 10.1016/j.pop.2008.06.003; Owens J, 2013, J ATTEN DISORD, V17, P550, DOI 10.1177/1087054712457992; Owens JA, 2011, PEDIATR CLIN N AM, V58, P555, DOI 10.1016/j.pcl.2011.03.011; Parisi P, 2010, DEV MED CHILD NEUROL, V52, P805, DOI 10.1111/j.1469-8749.2010.03662.x; Partinen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033723; Paruthi S, 2016, J CLIN SLEEP MED, V12, P785, DOI 10.5664/jcsm.5866; Perlis ML, 1997, J SLEEP RES, V6, P179, DOI 10.1046/j.1365-2869.1997.00045.x; Petit D, 2007, PEDIATRICS, V119, pE1016, DOI 10.1542/peds.2006-2132; Petit D, 2015, JAMA PEDIATR, V169, P653, DOI 10.1001/jamapediatrics.2015.127; Peyron C, 1998, J NEUROSCI, V18, P9996; Pizza F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129386; Pizza F, 2013, BRAIN, V136, P3787, DOI 10.1093/brain/awt277; Plazzi G, 2015, NEUROPSYCHOBIOLOGY, V71, P218, DOI 10.1159/000432400; Poli F, 2013, SLEEP, V36, P175, DOI 10.5665/sleep.2366; Prehn-Kristensen A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065098; Prehn-Kristensen A, 2011, SLEEP MED, V12, P672, DOI 10.1016/j.sleep.2010.10.010; Price AM, 2012, PEDIATRICS, V130, P9; Reiter J, 2015, SLEEP, V38, P859, DOI 10.5665/sleep.4728; Richdale AL, 2009, SLEEP MED REV, V13, P403, DOI 10.1016/j.smrv.2009.02.003; Riedner BA, 2016, SLEEP, V39, P801, DOI 10.5665/sleep.5632; Riemann D, 2015, LANCET NEUROL, V14, P547, DOI 10.1016/S1474-4422(15)00021-6; Riemann D, 2010, SLEEP MED REV, V14, P19, DOI 10.1016/j.smrv.2009.04.002; Rodopman-Arman A, 2011, TURKISH J PEDIATR, V53, P397; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Rueda-Sanchez M, 2008, CEPHALALGIA, V28, P216, DOI 10.1111/j.1468-2982.2007.01499.x; Sasai-Sakuma T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136988; Scammell TE, 2001, NEUROLOGY, V56, P1751, DOI 10.1212/WNL.56.12.1751; Serra L, 2008, MOVEMENT DISORD, V23, P858, DOI 10.1002/mds.21965; Silber MH, 2002, SLEEP, V25, P197, DOI 10.1093/sleep/25.2.197; Souders MC, 2009, SLEEP, V32, P1566, DOI 10.1093/sleep/32.12.1566; Spilsbury JC, 2007, J CLIN SLEEP MED, V3, P603; Taibi DM, 2013, J CLIN SLEEP MED, V9, P217, DOI 10.5664/jcsm.2482; Taylor MA, 2012, RES DEV DISABIL, V33, P1408, DOI 10.1016/j.ridd.2012.03.013; Terzano MG, 2000, SLEEP MED REV; Thien TDV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133474; Thorpy MJ, 2014, SLEEP MED, V15, P502, DOI 10.1016/j.sleep.2014.01.015; Tinuper P, 2016, NEUROLOGY, V86, P1834, DOI 10.1212/WNL.0000000000002666; Tordjman S, 2005, BIOL PSYCHIAT, V57, P134, DOI 10.1016/j.biopsych.2004.11.003; Tordjman S, 2014, PSYCHONEUROENDOCRINO, V50, P227, DOI 10.1016/j.psyneuen.2014.08.010; Urbain C, 2016, NEUROIMAGE, V134, P213, DOI 10.1016/j.neuroimage.2016.03.055; van Geijlswijk IM, 2011, PSYCHOPHARMACOLOGY, V216, P111, DOI 10.1007/s00213-011-2202-y; van Golde EGA, 2011, SLEEP MED REV, V15, P357, DOI 10.1016/j.smrv.2011.01.002; Veatch Olivia J, 2015, Curr Sleep Med Rep, V1, P131; Vendrame M, 2013, J CLIN SLEEP MED, V9, P141, DOI 10.5664/jcsm.2410; Venkatraman V, 2011, J NEUROSCI, V31, P3712, DOI 10.1523/JNEUROSCI.4407-10.2011; Vossler DG, 1996, NEUROLOGY, V46, P1258, DOI 10.1212/WNL.46.5.1258; Vriend J, 2015, SLEEP MED CLIN, V10, P107, DOI 10.1016/j.jsmc.2015.02.009; Walker MP, 2009, ANN NY ACAD SCI, V1156, P168, DOI 10.1111/j.1749-6632.2009.04416.x; Wilhelm I, 2008, LEARN MEMORY, V15, P373, DOI 10.1101/lm.803708; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Zhang JH, 2011, SLEEP, V34, P1395, DOI 10.5665/SLEEP.1286	135	42	46	1	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1170	1181		10.1016/S1474-4422(16)30204-6	http://dx.doi.org/10.1016/S1474-4422(16)30204-6			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DX3MJ	27647645				2022-12-18	WOS:000384276900019
J	Barzel, A; Ketels, G; Stark, A; Tetzlaff, B; Daubmann, A; Wegscheider, K; van den Bussche, H; Scherer, M				Barzel, Anne; Ketels, Gesche; Stark, Anne; Tetzlaff, Britta; Daubmann, Anne; Wegscheider, Karl; van den Bussche, Hendrik; Scherer, Martin			Home-based constraint-induced movement therapy for patients with upper limb dysfunction after stroke (HOMECIMT): a cluster-randomised, controlled trial	LANCET NEUROLOGY			English	Article							UPPER EXTREMITY FUNCTION; MOTOR FUNCTION-TEST; ARM; RELIABILITY; REHABILITATION; METAANALYSIS; VALIDITY; CARE	Background Constraint-induced movement therapy (CIMT) is recommended for patients with upper limb dysfunction after stroke, yet evidence to support the implementation of CIMT in ambulatory care is insufficient. We assessed the efficacy of home CIMT, a modified form of CIMT that trains arm use in daily activities within the home environment. Methods In this parallel, cluster-randomised controlled trial, we selected 71 therapy practices in northern Germany that treat adult patients with upper limb dysfunction after stroke. Practices were stratified by region and randomly allocated by an external biometrician (1:1, block size of four) using a computer-generated sequence. 37 practices were randomly assigned to provide 4 weeks of home CIMT and 34 practices to provide 4 weeks of standard therapy. Eligible patients had mild to moderate impairment of arm function at least 6 months after stroke and a friend or family member willing to participate as a non-professional coach. Patients of both groups received 5 h of professional therapist contact in 4 weeks. In the home CIMT group, therapists used the contact time to instruct and supervise patients and coaches in home CIMT. Patients in the standard therapy group received conventional physical or occupational therapy, but additional home training was not obligatory. All assessments were done by masked outcome assessors at baseline, after 4 weeks of intervention, and at 6 month follow-up. The primary outcomes were quality of movement, assessed by the Motor Activity Log (MAL-QOM, assessor-assisted self-reported), and performance time, assessed by the Wolf Motor Function Test (WMFT-PT, assessor-reported). Primary outcomes were tested hierarchically after 4 weeks of intervention and analysed by intention to treat, using mixed linear models. This trial is registered with ClinicalTrials.gov, NCT01343602. Findings Between July 11,2011, and June 4,2013,85 of 156 enrolled patients were assigned home CIMT and 71 patients were assigned standard therapy. 82 (96%) patients in the home CIMT group and 71 (100%) patients in the standard therapy group completed treatment and were assessed at 4 weeks. Patients in both groups improved in quality of movement (MAL-QOM; change from baseline 0.56,95% CI 0.41-0.71, p<0.0001 for home CIMT vs 0.31,0.15-0.46, p=0.0003 for standard therapy). Patients in the home CIMT group improved more than patients in the standard therapy group (between-group difference 0.26,95% CI 0.05-0.46; p=0.0156). Both groups also improved in motor function performance time (WMFT-PT; change from baseline -25.60%, 95% CI -36.75 to -12-49, p=0.0006 for home CIMT vs -27-52%, -38-94 to -13.94, p=0.0004 for standard therapy), but the extent of improvement did not differ between groups (2.65%, -17.94 to 28.40; p=0.8152). Nine adverse events (of which six were serious) were reported in the home CIMT group and ten (of which seven were serious) in the standard therapy group; however, none was deemed related to the study intervention. Interpretation Home-based CIMT can enhance the perceived use of the stroke-affected arm in daily activities more effectively than conventional therapy, but was not superior with respect to motor function. Further research is needed to confirm whether home CIMT leads to clinically significant improvements and if so to identify patients that are most likely to benefit.	[Barzel, Anne; Stark, Anne; Tetzlaff, Britta; van den Bussche, Hendrik; Scherer, Martin] Univ Med Ctr Hamburg Eppendorf, Dept Primary Med Care, D-20246 Hamburg, Germany; [Ketels, Gesche] Univ Med Ctr Hamburg Eppendorf, Dept Physiotherapy, D-20246 Hamburg, Germany; [Daubmann, Anne; Wegscheider, Karl] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Barzel, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Primary Med Care, D-20246 Hamburg, Germany.	a.barzel@uke.de			German Federal Ministry of Education and Research	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	German Federal Ministry of Education and Research.	Barzel A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-334; Barzel A, 2009, RESTOR NEUROL NEUROS, V27, P673, DOI 10.3233/RNN-2009-0524; Brunner IC, 2012, CLIN REHABIL, V26, P1078, DOI 10.1177/0269215512443138; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Corbetta D, 2010, EUR J PHYS REHAB MED, V46, P537; Dahl AE, 2008, CLIN REHABIL, V22, P436, DOI 10.1177/0269215507084581; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gregson JM, 2000, AGE AGEING, V29, P223, DOI 10.1093/ageing/29.3.223; Klasen Bernhard W, 2004, Psychosoc Med, V1, pDoc07; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kurland KS, 2012, GIS TUTORIAL HLTH; Kwakkel G, 2015, LANCET NEUROL, V14, P224, DOI 10.1016/S1474-4422(14)70160-7; Lang CE, 2008, ARCH PHYS MED REHAB, V89, P1693, DOI 10.1016/j.apmr.2008.02.022; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P441, DOI 10.1177/1545968308328719; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P429, DOI 10.1177/1545968308331144; McIntyre A, 2012, TOP STROKE REHABIL, V19, P499, DOI 10.1310/tsr1906-499; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Noorkoiv M, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-144; Peurala SH, 2012, CLIN REHABIL, V26, P209, DOI 10.1177/0269215511420306; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Rieck M, 2005, DISABIL REHABIL, V27, P1425, DOI 10.1080/09638280500330435; Rigler SK, 2002, CLIN REHABIL, V16, P420, DOI 10.1191/0269215502cr515oa; Sawaki L, 2008, NEUROREHAB NEURAL RE, V22, P505, DOI 10.1177/1545968308317531; Senn S, 2000, STAT MED, V19, P861, DOI 10.1002/(SICI)1097-0258(20000330)19:6<861::AID-SIM407>3.0.CO;2-F; Shi YX, 2011, ARCH PHYS MED REHAB, V92, P972, DOI 10.1016/j.apmr.2010.12.036; Sirtori V, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004433.pub2; Smania N, 2012, NEUROREHAB NEURAL RE, V26, P1035, DOI 10.1177/1545968312446003; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Steinmann S., 1999, ZUMA NACHRICHTEN, V23, P7; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; Taub E, 2013, STROKE, V44, P1383, DOI 10.1161/STROKEAHA.111.000559; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; Viana R, 2012, TOP STROKE REHABIL, V19, P104, DOI 10.1310/tsr1902-104; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; World Health Organization, INT CLASS FUNCT DIS	39	42	45	1	58	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2015	14	9					893	902		10.1016/S1474-4422(15)00147-7	http://dx.doi.org/10.1016/S1474-4422(15)00147-7			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CP4YZ	26231624				2022-12-18	WOS:000359889800009
J	Lauer, A; Pfeilschifter, W; Schaffer, CB; Lo, EH; Foerch, C				Lauer, Arne; Pfeilschifter, Waltraud; Schaffer, Chris B.; Lo, Eng H.; Foerch, Christian			Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies	LANCET NEUROLOGY			English	Review							DIRECT THROMBIN INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; RECOMBINANT FACTOR VIIA; FRESH-FROZEN PLASMA; PRIOR ANTIPLATELET THERAPY; REDUCED PLATELET ACTIVITY; BLOOD-CLOT FORMATION; ACTIVATED FACTOR-VII; ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE	Little is known about the pathophysiology of intracerebral haemorrhage that occurs during anticoagulant treatment. In observational studies, investigators have reported larger haematoma volumes and worse functional outcome in these patients than in those with intracerebral haemorrhage and a normal coagulation status. The need to prevent extensive haematoma enlargement by rapid reversal of the anticoagulation seems intuitive, although no evidence is available from randomised clinical trials. New oral anticoagulants, such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban, have been approved recently; however, intracerebral haemorrhage during dabigatran or rivaroxaban anticoagulation has not been characterised, and whether anticoagulation reversal can be beneficial in this scenario is unknown. In a translational approach, new experimental models have been developed to study anticoagulation-associated intracerebral haemorrhage in more detail and to test treatment strategies. Vitamin k antagonists enlarge haematoma volumes and worsen functional outcome in animal models. Rapid reversal of anticoagulation in the experimental setting prevents prolonged haematoma expansion and improves outcome. The new oral anticoagulants increase intracerbral haemorrhage volumes less than does warfarin. Haemostatic approaches that have been used for vitamin k-associated intracerebral haemorrhage also seem to be effective in intracerebral haemorrhage associated with the new anticoagulants. These experimental studies are valuable for filling gaps in knowledge, but the results need careful translation into routine clinical practice.	[Lauer, Arne; Pfeilschifter, Waltraud; Foerch, Christian] Goethe Univ Frankfurt, Dept Neurol, D-60526 Frankfurt, Germany; [Lauer, Arne; Lo, Eng H.; Foerch, Christian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Boston, MA USA; [Schaffer, Chris B.] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA	Goethe University Frankfurt; Harvard University; Harvard Medical School; Massachusetts General Hospital; Cornell University	Foerch, C (corresponding author), Goethe Univ Frankfurt, Dept Neurol, Schleusenweg 2-16, D-60526 Frankfurt, Germany.	foerch@em.uni-frankfurt.de	Schaffer, Chris B./A-7409-2008	Schaffer, Chris B./0000-0002-7800-9596	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS055104, R01NS076694, R37NS037074] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS076694, R37 NS037074, P01 NS055104] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilar MI, 2007, MAYO CLIN PROC, V82, P82, DOI 10.1016/s0025-6196(11)60970-1; Battinelli EM, 2011, CIRCULATION, V124, P1508, DOI 10.1161/CIRCULATIONAHA.111.054510; Bouchard BA, 1997, ARTERIOSCL THROM VAS, V17, P1, DOI 10.1161/01.ATV.17.1.1; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Broos K, 2011, BLOOD REV, V25, P155, DOI 10.1016/j.blre.2011.03.002; Campbell PG, 2011, WORLD NEUROSURG, V76, P100, DOI 10.1016/j.wneu.2011.02.010; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Cianchetti FA, 2010, BIOMEDICAL OPTICS; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; de Gans K, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-19; del Zoppo GJ, 2011, NEW ENGL J MED, V365, P952, DOI 10.1056/NEJMe1107516; Di Nisio M, 2005, NEW ENGL J MED, V353, P1028, DOI 10.1056/NEJMra044440; Dowlatshahi D, 2012, STROKE, V43, P1812, DOI 10.1161/STROKEAHA.112.652065; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; Elg M, 2001, THROMB RES, V101, P159, DOI 10.1016/S0049-3848(00)00398-4; Elg M, 2001, THROMB RES, V101, P145, DOI 10.1016/S0049-3848(00)00397-2; Elliott J, 2010, ANESTH ANALG, V110, P1419, DOI 10.1213/ANE.0b013e3181d568c8; Eriksson BI, 2004, J THROMB HAEMOST, V2, P1573, DOI 10.1111/j.1538-7836.2004.00890.x; Fang MC, 2012, STROKE, V43, P1795, DOI 10.1161/STROKEAHA.111.630731; Flaherty ML, 2008, NEUROLOGY, V71, P1084, DOI 10.1212/01.wnl.0000326895.58992.27; Flaherty ML, 2006, NEUROCRIT CARE, V5, P197, DOI 10.1385/NCC:5:3:197; Flaherty ML, 2010, SEMIN NEUROL, V30, P565, DOI 10.1055/s-0030-1268866; Flaherty ML, 2009, STROKE, V40, P1738, DOI 10.1161/STROKEAHA.108.538462; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Foerch C, 2006, STROKE, V37, P2165, DOI 10.1161/01.STR.0000231842.32153.74; Foerch C, 2009, J CEREBR BLOOD F MET, V29, P1015, DOI 10.1038/jcbfm.2009.27; Foerch C, 2008, STROKE, V39, P3397, DOI 10.1161/STROKEAHA.108.517482; FRANKE CL, 1990, STROKE, V21, P726, DOI 10.1161/01.STR.21.5.726; Friberg L, 2012, CIRCULATION, V125, P2298, DOI 10.1161/CIRCULATIONAHA.111.055079; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Goldstein JN, 2006, STROKE, V37, P151, DOI 10.1161/01.STR.0000195047.21562.23; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614; HIRSH J, 1994, ARCH INTERN MED, V154, P282, DOI 10.1001/archinte.154.3.282; Hua Y, 2007, STROKE, V38, P759, DOI 10.1161/01.STR.0000247868.97078.10; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Illanes S, 2011, STROKE, V42, P191, DOI 10.1161/STROKEAHA.110.593541; Illanes S, 2010, BRAIN RES, V1320, P135, DOI 10.1016/j.brainres.2010.01.015; Kaatz S, 2012, AM J HEMATOL, V87, pS141, DOI 10.1002/ajh.23202; Kawai N, 2006, ACTA NEUROCHIR SUPPL, V96, P212; Kirkman MA, 2011, J CEREBR BLOOD F MET, V31, P2135, DOI 10.1038/jcbfm.2011.124; Koltai K, 2008, CLIN HEMORHEOL MICRO, V40, P295, DOI 10.3233/CH-2008-1140; Kuwashiro T, 2011, CEREBROVASC DIS, V31, P170, DOI 10.1159/000321766; Lauer A, 2011, CIRCULATION, V124, P1654, DOI 10.1161/CIRCULATIONAHA.111.035972; Lauer A, 2011, J CEREBR BLOOD F MET, V31, P1736, DOI 10.1038/jcbfm.2011.22; Lee JM, 2007, STROKE, V38, P3289, DOI 10.1161/STROKEAHA.107.491621; Lee SH, 2009, NEUROLOGY, V72, P171, DOI 10.1212/01.wnl.0000339060.11702.dd; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Levine JM, 2007, NEUROCRIT CARE, V7, P58, DOI 10.1007/s12028-007-0039-3; Lovelock CE, 2010, STROKE, V41, P1222, DOI 10.1161/STROKEAHA.109.572594; Makris M, 1997, THROMB HAEMOSTASIS, V77, P477; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mayer SA, 2009, STROKE, V40, P833, DOI 10.1161/STROKEAHA.108.524470; Mihara K, 2005, J NEUROTRAUM, V22, P1362, DOI 10.1089/neu.2005.22.1362; Monroe D, 2002, ARTERIOSCL THROM VAS, V22, P1381, DOI 10.1161/01.ATV.0000031340.68494.34; Monroe DM, 2008, SEMIN HEMATOL, V45, pS7, DOI 10.1053/j.seminhematol.2008.03.013; Moussouttas M, 2010, NEUROCRIT CARE, V12, P24, DOI 10.1007/s12028-009-9290-0; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2011, NEUROCRIT CARE, V15, P442, DOI 10.1007/s12028-011-9557-0; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Nielsen VG, 2005, ACTA ANAESTH SCAND, V49, P222, DOI 10.1111/j.1399-6576.2005.00602.x; Nishimura N, 2006, NAT METHODS, V3, P99, DOI 10.1038/NMETH844; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Pinner NA, 2010, WORLD NEUROSURG, V74, P631, DOI 10.1016/j.wneu.2010.06.030; Rane A, 2010, HUM GENOMICS PROTEOM, V2010, DOI DOI 10.4061/2010/754919; Roquer J, 2005, J NEUROL, V252, P412, DOI 10.1007/s00415-005-0659-5; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Rosidi NL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026612; Ruggeri ZM, 2009, MICROCIRCULATION, V16, P58, DOI 10.1080/10739680802651477; Saloheimo P, 2006, STROKE, V37, P129, DOI 10.1161/01.STR.0000196991.03618.31; Sansing LH, 2009, NEUROLOGY, V72, P1397, DOI 10.1212/01.wnl.0000342709.31341.88; Schlunk F, 2012, STROKE, V43, P246, DOI 10.1161/STROKEAHA.111.629360; Smyth SS, 2009, J THROMB HAEMOST, V7, P1759, DOI 10.1111/j.1538-7836.2009.03586.x; Song TJ, 2013, EUR J NEUROL, V20, P502, DOI 10.1111/ene.12003; Sorensen B, 2006, THROMB HAEMOSTASIS, V96, P446, DOI 10.1160/TH06-04-0205; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000; Stead LG, 2010, CLIN NEUROL NEUROSUR, V112, P275, DOI 10.1016/j.clineuro.2009.12.002; Steiner T, 2011, CEREBROVASC DIS, V32, P409, DOI 10.1159/000330653; Thompson BB, 2010, NEUROLOGY, V75, P1333, DOI 10.1212/WNL.0b013e3181f735e5; Toyoda K, 2009, CEREBROVASC DIS, V27, P151, DOI 10.1159/000177924; Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177, DOI 10.1055/s-0037-1614439; van Ryn J, 2012, AM HEART ASS SCI SES; van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758; Vernooij MW, 2009, ARCH NEUROL-CHICAGO, V66, P714, DOI 10.1001/archneurol.2009.42; Voils SA, 2012, THROMB RES, V130, P833, DOI 10.1016/j.thromres.2012.10.001; Watanabe M, 2012, NEUROCRIT CARE, V16, P203, DOI 10.1007/s12028-011-9591-y; Weimar C, 2012, CURR NEUROL NEUROSCI, V12, P17, DOI 10.1007/s11910-011-0229-4; Wong KS, 2003, NEUROLOGY, V60, P511, DOI 10.1212/01.WNL.0000046583.40125.20; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Zhou W, 2013, STROKE, DOI [10.1161/STROKEAHA.112.675231, DOI 10.1161/STR0KEAHA.112.675231]; Zhou W, 2011, STROKE, V42, P3594, DOI 10.1161/STROKEAHA.111.624650; Zhou ZH, 2011, BRAIN RES BULL, V86, P235, DOI 10.1016/j.brainresbull.2011.07.012	99	42	45	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2013	12	4					394	405		10.1016/S1474-4422(13)70049-8	http://dx.doi.org/10.1016/S1474-4422(13)70049-8			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SZ	23518332	Green Accepted			2022-12-18	WOS:000318531600015
J	Andelic, N				Andelic, Nada			The epidemiology of traumatic brain injury	LANCET NEUROLOGY			English	Editorial Material									[Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway; [Andelic, Nada] Univ Oslo, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Fac Med, Oslo, Norway	University of Oslo; University of Oslo	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway.	nadand@ous-hf.no		Andelic, Nada/0000-0002-3719-4406				Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Feigin VL, 2012, LANCET NEUROL, P70262; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; TEASDALE G, 1974, LANCET, V2, P81; Thompson K, 2001, N C Med J, V62, P376	10	42	45	3	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					28	29		10.1016/S1474-4422(12)70294-6	http://dx.doi.org/10.1016/S1474-4422(12)70294-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23177533				2022-12-18	WOS:000312429400016
J	Langhorne, P; Sandercock, P; Prasad, K				Langhorne, Peter; Sandercock, Peter; Prasad, Kameshwar			Evidence-based practice for stroke	LANCET NEUROLOGY			English	Editorial Material							DISEASE; BURDEN		[Langhorne, Peter] Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; [Sandercock, Peter] Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; [Prasad, Kameshwar] All India Inst Med Sci, New Delhi 110029, India	University of Glasgow; University of Edinburgh; All India Institute of Medical Sciences (AIIMS) New Delhi	Langhorne, P (corresponding author), Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.	p.langhorne@clinmed.gla.ac.uk		Sandercock, Peter/0000-0001-8484-0135				Chen Z, 1997, J Stroke Cerebrovasc Dis, V6, P361, DOI 10.1016/S1052-3057(97)80219-4; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Gaziano TA, 2006, LANCET, V368, P679, DOI 10.1016/S0140-6736(06)69252-0; Govan L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub2; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; HAYNES B, 1999, BMJ-BRIT MED J, V319, P676; Heller RF, 2003, BMJ-BRIT MED J, V327, P1162, DOI 10.1136/bmj.327.7424.1162; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Langhorne P, 2005, LANCET, V365, P501; Lopez AD, 2006, ANN TROP MED PARASIT, V100, P481, DOI 10.1179/136485906X97417; Sackett DL, 1997, EVIDENCE BASED MED P; Sandercock PAG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000029.pub2; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213; WARLOW C, 2008, STROKE PRACICAL MANA	14	42	43	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2009	8	4					308	309		10.1016/S1474-4422(09)70060-2	http://dx.doi.org/10.1016/S1474-4422(09)70060-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	425CH	19296917				2022-12-18	WOS:000264614100006
J	Healy, DG				Healy, Daniel G.			Case-control studies in the genomic era: a clinician's guide	LANCET NEUROLOGY			English	Review							IDIOPATHIC PARKINSONS-DISEASE; MULTIPLE SYSTEM ATROPHY; FACTOR-H POLYMORPHISM; GENETIC ASSOCIATION; POPULATION STRATIFICATION; COMMON DISEASE; MACULAR DEGENERATION; LINKAGE-DISEQUILIBRIUM; ALLELIC ASSOCIATION; COMPLEX DISEASE	The goal of case-control association studies is to find genetic variants in the human genome that influence common traits. The Human Genome and HapMap projects have added fresh impetus to this goal by cataloguing the raw genetic data behind human DNA variation. Studies that associate these genetic variants with phenotype improve both molecular diagnostics and drug discovery and offer clinicians important opportunities to improve care of patients. In this review I focus on case-control studies, which are the most widely used design and expected to be the most powerful. I also address the problem of case-control non-replication, which is widespread despite enormous effort and use of resources. important causes of non-replication include inadequate statistical power to detect small and moderate effects, phenotype heterogeneity, population stratification, publication bias, and multiple comparison testing.	Inst Neurol, London WC1N 3BG, England; Guys Hosp, London SE1 9RT, England; St Thomas Hosp, London, England	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Healy, DG (corresponding author), Inst Neurol, Queen Sq, London WC1N 3BG, England.	danhealy@doctors.org.uk						Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Ardlie KG, 2002, AM J HUM GENET, V71, P304, DOI 10.1086/341719; Armitage P., 2001, STAT METHODS MED RES; Barton NH, 2002, NAT REV GENET, V3, P11, DOI 10.1038/nrg700; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; Biskup S, 2005, ANN NEUROL, V58, P905, DOI 10.1002/ana.20664; Blangero J, 2004, CURR OPIN GENET DEV, V14, P233, DOI 10.1016/j.gde.2004.04.009; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; Boguski MS, 2004, NAT NEUROSCI, V7, P429, DOI 10.1038/nn1232; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Breslow NE., 1980, IARC SCI PUBL, P5; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Cavalleri GL, 2005, BRAIN, V128, P1832, DOI 10.1093/brain/awh524; Cavalli-Sforza L L, 1994, HIST GEOGRAPHY HUMAN; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COUZIN J, 2001, SCIENCE, V298, P241; Craig DW, 2005, EXPERT REV MOL DIAGN, V5, P159, DOI 10.1586/14737159.5.2.159; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dichgans M, 2005, STROKE, V36, P2027, DOI 10.1161/01.STR.0000177498.21594.9e; Eaves LJ, 2001, ADV GENET, V42, P223, DOI 10.1016/S0065-2660(01)42025-6; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Flossmann E, 2004, STROKE, V35, P212, DOI 10.1161/01.STR.0000107187.84390.AA; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gatewood B K, 2000, Brief Bioinform, V1, P60, DOI 10.1093/bib/1.1.60; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Goldstein DB, 2003, NEW ENGL J MED, V348, P553, DOI 10.1056/NEJMe020173; Goldstein DB, 2001, NAT GENET, V29, P109, DOI 10.1038/ng1001-109; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Halldorsson BV, 2004, HUM HERED, V58, P190, DOI 10.1159/000083546; Healy DG, 2005, MOVEMENT DISORD, V20, P1338, DOI 10.1002/mds.20575; Helgason A, 2005, NAT GENET, V37, P90, DOI 10.1038/ng1492; Hirose S, 2005, EPILEPSIA, V46, P38, DOI 10.1111/j.0013-9580.2005.461011.x; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOFMAN KJ, 1993, ACAD MED, V68, P625, DOI 10.1097/00001888-199308000-00013; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; JOHNSON GC, 2003, NAT GENET, V29, P233; Kennedy D, 2004, SCIENCE, V305, P451, DOI 10.1126/science.305.5683.451; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; KNOWLER WC, 1988, AM J HUM GENET, V43, P520; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Kubota M, 1997, J NEUROL NEUROSUR PS, V62, P66, DOI 10.1136/jnnp.62.1.66; Kurz A, 2003, INT PSYCHOGERIATR, V15, P89, DOI 10.1017/S1041610203009025; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIGHT RJ, 1984, SUMMING SCI RES; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Marcus G., 2004, BIRTH MIND TINY NUMB; Masuda J, 2001, CURR OPIN NEUROL, V14, P77, DOI 10.1097/00019052-200102000-00012; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Mikkelsen TS, 2005, NATURE, V437, P69, DOI 10.1038/nature04072; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Ott J, 2004, NEUROLOGY, V63, P955, DOI 10.1212/WNL.63.6.955; Paulson HL, 2002, NEUROL CLIN, V20, P627, DOI 10.1016/S0733-8619(02)00009-9; Peltonen L, 2001, SCIENCE, V291, P1224, DOI 10.1126/science.291.5507.1224; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Reich DE, 2001, GENET EPIDEMIOL, V20, P4, DOI 10.1002/1098-2272(200101)20:1<4::AID-GEPI2>3.0.CO;2-T; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P6638; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sander HW, 2003, NEUROLOGY, V60, pS8, DOI 10.1212/WNL.60.8_suppl_3.S8; Schmidt D, 2002, EPILEPSY RES, V50, P71, DOI 10.1016/S0920-1211(02)00070-0; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Skipper L, 2005, HUM MOL GENET, V14, P3549, DOI 10.1093/hmg/ddi376; Soranzo N, 2004, GENOME RES, V14, P1333, DOI 10.1101/gr.1965304; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Syvanen AC, 2005, NAT GENET, V37, pS5, DOI 10.1038/ng1558; Tietjen I, 2003, NEURON, V38, P161, DOI 10.1016/S0896-6273(03)00229-0; Todd JA, 2001, NATURE, V411, P537, DOI 10.1038/35079223; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vanacore N, 2005, J NEURAL TRANSM, V112, P1605, DOI 10.1007/s00702-005-0380-7; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; Wright A. F., 2002, Pharmacogenomics Journal, V2, P75, DOI 10.1038/sj.tpj.6500085	94	42	43	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2006	5	8					701	707		10.1016/S1474-4422(06)70524-5	http://dx.doi.org/10.1016/S1474-4422(06)70524-5			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	068ZV	16857576				2022-12-18	WOS:000239415100022
J	Sadovnick, AD; Yee, IML; Ebers, GC				Sadovnick, AD; Yee, IML; Ebers, GC		Canadian Collaborative Study Grp	Multiple sclerosis and birth order: a longitudinal cohort study	LANCET NEUROLOGY			English	Article							RECURRENCE RISKS; GENETIC-BASIS; POPULATION; SIBLINGS; MS; CHILDREN; HYGIENE; TWINS; LIFE; AGE	Background Genetic epidemiological studies suggest both genetic and environmental factors have a role in multiple sclerosis (MS). Environmental effects are strongly suggested from geographical gradients, migration data, and discordance rates in twins. In epidemiological studies, risk of MS in offspring of small families and in those with an early birth-order position has been reported and interpreted in the context of the hygiene hypothesis, which is that infections at an early age, introduced by older siblings, are protective. We aimed to study the effect of birth order on MS risk. Methods A longitudinal, population-based sample of individuals with MS and their healthy siblings were identified from the Canadian Collaborative Project on Genetic Susceptibility to MS. Data were grouped according to single (simplex) or multiple (multiplex) siblings with MS in a sibship. Separate analyses were done for each sibship, size. Findings We studied 10 995 individuals with MS and 26 336 healthy siblings, and found no relation between MS risk and birth-order position. In simplex sibships of at least seven siblings, slightly more siblings who were born late in the birth order had MS; the same was found for the first-born sibling with MS in a multiplex sibship. Siblings with MS were slightly younger (p < 0.0001) than those without MS, contrary to the expected age at onset bias. Interpretation These findings do not support the hygiene hypothesis and could be due to a cohort effect resulting from increasing MS incidence. Birth order has no effect on MS risk in most families, and there is no support for the hypothesis that having older siblings protects against MS.	Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC V5Z 1M9, Canada; Univ Oxford, Dept Clin Neurol, Oxford, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England	University of British Columbia; University of British Columbia; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Sadovnick, AD (corresponding author), Univ British Columbia Hosp, Vancouver Coastal Hlth Author, 22111 Westbrook Mall,G-920,Detwiller Pavillion, Vancouver, BC V6T 2B5, Canada.	sadovnik@infinet.net		Ebers, George/0000-0003-4771-4177; Sadovnick, Dessa/0000-0003-2987-2008				Ahlgren C, 2005, NEUROEPIDEMIOLOGY, V24, P38, DOI 10.1159/000081048; Alotaibi S, 2004, JAMA-J AM MED ASSOC, V291, P1875, DOI 10.1001/jama.291.15.1875; Bager P, 2004, BRAIN, V127, P2491, DOI 10.1093/brain/awh283; BERGLIN CG, 1982, J EPIDEMIOL COMMUN H, V36, P298, DOI 10.1136/jech.36.4.298; Cardoso MRA, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-19; Cohen J., 2013, STAT POWER ANAL BEHA; Ebers GC, 2000, ANN NEUROL, V48, P927, DOI 10.1002/1531-8249(200012)48:6<927::AID-ANA14>3.3.CO;2-6; Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; EBERS GC, 1987, NEW ENGL J MED, V317, P51; ELEVIN LI, 2005, JAMA-J AM MED ASSOC, V293, P2496; ELIAN M, 1987, J NEUROL NEUROSUR PS, V50, P327, DOI 10.1136/jnnp.50.3.327; GAUDET JPC, 1995, NEUROEPIDEMIOLOGY, V14, P188, DOI 10.1159/000109795; GAUDET JPC, 1995, ACTA NEUROL SCAND, V91, P19; Gibbs S, 2004, INT J EPIDEMIOL, V33, P199, DOI 10.1093/ije/dyg267; Hammond SR, 2000, BRAIN, V123, P968, DOI 10.1093/brain/123.5.968; HARE EH, 1974, J BIOSOC SCI, V6, P139, DOI 10.1017/S0021932000009597; Hunter J. E, 1990, METHODS META ANAL CO; Hunter J.E., 1982, STUDYING ORG INNOVAT, V4; JAMES WH, 1984, J EPIDEMIOL COMMUN H, V38, P21, DOI 10.1136/jech.38.1.21; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Montgomery SM, 2004, EPIDEMIOLOGY, V15, P717, DOI 10.1097/01.ede.0000142138.46167.69; NEE L, 1995, ANN NY ACAD SCI, V753, P378, DOI 10.1111/j.1749-6632.1995.tb27566.x; Nielsen NM, 2002, INT J EPIDEMIOL, V31, P181, DOI 10.1093/ije/31.1.181; Ponsonby AL, 2005, JAMA-J AM MED ASSOC, V293, P463, DOI 10.1001/jama.293.4.463; Sadovnick AD, 1998, CAN J NEUROL SCI, V25, P216, DOI 10.1017/S0317167100034041; SADOVNICK AD, 1992, NEUROLOGY, V42, P991, DOI 10.1212/WNL.42.5.991; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309; Sadovnick AD, 2001, NEUROLOGY, V56, P784, DOI 10.1212/WNL.56.6.784; Sadovnick D, 2004, MULT SCLER, V10, pS162; Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1; Stefano S, 2003, AUTOIMMUNITY, V36, P257, DOI 10.1080/0891693031000151607; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Willer CJ, 2005, BMJ-BRIT MED J, V330, P120, DOI 10.1136/bmj.38301.686030.63; Willer CJ, 2003, P NATL ACAD SCI USA, V100, P12877, DOI 10.1073/pnas.1932604100; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	38	42	42	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					611	617		10.1016/S1474-4422(05)70170-8	http://dx.doi.org/10.1016/S1474-4422(05)70170-8			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16168929				2022-12-18	WOS:000232245900017
J	van Schaik, VN; Winer, JB; de Haan, R; Vermeulen, M				van Schaik, VN; Winer, JB; de Haan, R; Vermeulen, M			Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review	LANCET NEUROLOGY			English	Review							RANDOMIZED CONTROLLED TRIAL; LONG-TERM TREATMENT; PLASMA-EXCHANGE; IMMUNE GLOBULIN; DOUBLE-BLIND; POLYNEUROPATHY; INFUSION; CYCLOPHOSPHAMIDE; PREDNISONE; AUTOIMMUNE	This review discusses the efficacy and safety in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of intravenous immunoglobulin and compares this treatment with plasma exchange and prednisolone. We searched publications from 1985 onwards for randomised controlled studies examining the effects of intravenous immunoglobulin in patients with this immune-mediated neuromuscular disorder. Six trials, with 170 patients in total, were judged eligible. A significantly higher proportion of patients improved in disability within a month after the start of treatment with intravenous immunoglobulin than with placebo (relative risk 3.17 [95% CI 1.74 to 5.75]). During this period, intravenous immunoglobulin has similar efficacy to plasma exchange and oral prednisolone; therefore which of these treatments should be the first choice is currently uncertain. An algorithm on treatment approaches for CIDP is proposed.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands; Queen Elizabeth Hosp, Dept Neurol, Birmingham B15 2TH, W Midlands, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Birmingham	van Schaik, VN (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	i.n.vanschaik@amc.uva.nl						ALBERS JW, 1989, MUSCLE NERVE, V12, P435, DOI 10.1002/mus.880120602; Barnett MH, 1998, MUSCLE NERVE, V21, P454, DOI 10.1002/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.0.CO;2-8; BAROHN RJ, 1989, ARCH NEUROL-CHICAGO, V46, P878, DOI 10.1001/archneur.1989.00520440064022; Brannagan TH, 2002, NEUROLOGY, V58, P1856, DOI 10.1212/WNL.58.12.1856; Briellmann RS, 1998, EUR NEUROL, V39, P190; Buchwald B, 2002, ANN NEUROL, V51, P673, DOI 10.1002/ana.10205; CHOUDHARY PP, 1995, QJM-INT J MED, V88, P493; Cohen J., 2013, STAT POWER ANAL BEHA; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; CORNBLATH DR, 1991, ANN NEUROL, V30, P104, DOI 10.1002/ana.410300119; DONAGHY M, 1985, ANN NEUROL, V17, P49, DOI 10.1002/ana.410170112; DONAGHY M, 1994, J NEUROL NEUROSUR PS, V57, P778, DOI 10.1136/jnnp.57.7.778; DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79; DYCK PJ, 1982, ANN NEUROL, V11, P136, DOI 10.1002/ana.410110205; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; DYCK PJ, 1986, NEW ENGL J MED, V314, P461, DOI 10.1056/NEJM198602203140801; DYCK PJ, 1985, NEUROLOGY, V35, P1173, DOI 10.1212/WNL.35.8.1173; DYCK PJ, 1993, PERIPHERAL NEUROPATH, P1498; FAED JM, 1989, NEUROLOGY, V39, P422, DOI 10.1212/WNL.39.3.422; FEASBY TE, 1992, NEUROL CLIN, V10, P651, DOI 10.1016/S0733-8619(18)30202-0; GILLESPIE LD, 1998, INTERVENTIONS REDUCE; Good JL, 1998, NEUROLOGY, V51, P1735, DOI 10.1212/WNL.51.6.1735; Gorson KC, 1997, NEUROLOGY, V48, P321, DOI 10.1212/WNL.48.2.321; Grillo JA, 2001, NEUROLOGY, V57, P1699, DOI 10.1212/WNL.57.9.1699; GROSS MLP, 1981, J NEUROL SCI, V52, P69, DOI 10.1016/0022-510X(81)90135-0; Hadden RDM, 1999, NEUROLOGY, V53, P57, DOI 10.1212/WNL.53.1.57; Hahn AF, 1998, NEUROLOGY, V51, pS16, DOI 10.1212/WNL.51.6_Suppl_5.S16; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; HUGHES R, 1992, ARCH NEUROL-CHICAGO, V49, P612, DOI 10.1001/archneur.1992.00530300044009; HUGHES RAC, 2002, CYTOTOXIC DRUGS INTE; Kasamon YL, 2002, AM J HEMATOL, V69, P289, DOI 10.1002/ajh.10079; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kuntzer T, 1999, NEUROLOGY, V53, P1364, DOI 10.1212/WNL.53.6.1364; Lindenbaum Y, 2001, NEUROL CLIN, V19, P187, DOI 10.1016/S0733-8619(05)70012-8; Martin TD, 2000, TREATMENT NEUROLOGIC, P181; MATSUMURO K, 1994, J NEUROL SCI, V127, P170, DOI 10.1016/0022-510X(94)90070-1; MEHNDIRATTA MM, 2001, CORTICOSTEROIDS CHRO; Mendell JR, 2001, NEUROLOGY, V56, P445, DOI 10.1212/WNL.56.4.445; Molenaar DSM, 1997, J NEUROL NEUROSUR PS, V62, P388, DOI 10.1136/jnnp.62.4.388; Molenaar DSM, 2002, J NEUROL, V249, P400, DOI 10.1007/s004150200029; Molenaar DSM, 1998, J NEUROL NEUROSUR PS, V64, P84, DOI 10.1136/jnnp.64.1.84; Mowzoon N, 2001, J NEUROL SCI, V185, P119, DOI 10.1016/S0022-510X(01)00478-6; MULROW CD, 1997, COCHRANE COLLABORATI; POLLARD JD, 1987, MUSCLE NERVE, V10, P214, DOI 10.1002/mus.880100304; SERVER AC, 1979, ANN NEUROL, V6, P258, DOI 10.1002/ana.410060313; SIMMONS Z, 1993, NEUROLOGY, V43, P2202, DOI 10.1212/WNL.43.11.2202; Stiehm ER, 1996, INTRAVENOUS IMMUNOGLOBULIN, P193; Thompson N, 1996, J NEUROL, V243, P280, DOI 10.1007/BF00868527; Van Der Meche F. G. A., 1995, Annals of Neurology, V37, pS14; VANDERMECHE FGA, 1989, BRAIN, V112, P1563, DOI 10.1093/brain/112.6.1563; vanderMeche FGA, 1997, EUR NEUROL, V38, P230, DOI 10.1159/000113378; vanDijk GW, 1996, J NEUROL, V243, P318; VANDOORN PA, 1991, ARCH NEUROL-CHICAGO, V48, P217, DOI 10.1001/archneur.1991.00530140113024; VANDOORN PA, 1990, J NEUROIMMUNOL, V29, P57, DOI 10.1016/0165-5728(90)90147-F; VANSCHAIK IN, 1994, J NEUROL NEUROSUR PS, V57, P15, DOI 10.1136/jnnp.57.Suppl.15; VANSCHAIK IN, 2002, INTRAVENOUS IMMUNOGL; VERMEULEN M, 1985, J NEUROL SCI, V70, P317, DOI 10.1016/0022-510X(85)90173-X; VERMEULEN M, 1993, J NEUROL NEUROSUR PS, V56, P36, DOI 10.1136/jnnp.56.1.36; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311	60	42	44	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2002	1	8					491	498		10.1016/S1474-4422(02)00222-3	http://dx.doi.org/10.1016/S1474-4422(02)00222-3			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618PP	12849334				2022-12-18	WOS:000179426700024
J	Wilson, JF				Wilson, JF			Role of DARPP-32	LANCET NEUROLOGY			English	News Item																			0	42	43	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					4	4		10.1016/S1474-4422(02)00025-X	http://dx.doi.org/10.1016/S1474-4422(02)00025-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ					2022-12-18	WOS:000177694100004
J	Reich, DS; Arnold, DL; Vermersch, P; Bar-Or, A; Fox, RJ; Matta, A; Turner, T; Wallstrom, E; Zhang, XY; Mares, M; Khabirov, FA; Traboulsee, A				Reich, Daniel S.; Arnold, Douglas L.; Vermersch, Patrick; Bar-Or, Amit; Fox, Robert J.; Matta, Andre; Turner, Timothy; Wallstrom, Erik; Zhang, Xinyan; Mares, Miroslav; Khabirov, Farit A.; Traboulsee, Anthony			Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial	LANCET NEUROLOGY			English	Article							LESIONS; OCRELIZUMAB; NEUROINFLAMMATION; SURROGATE; DISEASE	Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active brain MRI lesions in patients with relapsing multiple sclerosis. Methods We did a 16-week, phase 2b, randomised, double-blind, placebo-controlled, crossover, dose-finding trial at 40 centres (academic sites, specialty clinics, and general neurology centres) in ten countries in Europe and North America. Eligible participants were adults aged 18-55 years with diagnosed relapsing multiple sclerosis (either relapsing-remitting or relapsing secondary progressive multiple sclerosis), and one or more of the following criteria: at least one relapse within the previous year, at least two relapses within the previous 2 years, or at least one active gadolinium-enhancing brain lesion in the 6 months before screening. Exclusion criteria included a diagnosis of primary progressive multiple sclerosis or a diagnosis of secondary progressive multiple sclerosis without relapse. We used a two-step randomisation process to randomly assign eligible participants (1:1) to two cohorts, then further randomly assign participants in each cohort (1:1:1:1) to four tolebrutinib dose groups (5, 15, 30, and 60 mg administered once daily as an oral tablet). Cohort 1 received tolebrutinib for 12 weeks, then matched placebo (ie, identical looking tablets) for 4 weeks; cohort 2 received 4 weeks of placebo followed by 12 weeks of tolebrutinib. Participants and investigators were masked for dose and tolebrutinib-placebo administration sequence; investigators, study team members, and study participants did not have access to unmasked data. MRI scans were done at screening and every 4 weeks over 16 weeks. The primary efficacy endpoint was the number of new gadolinium-enhancing lesions detected on the scan done after 12 weeks of tolebnitinib treatment (assessed at week 12 for cohort 1 and week 16 for cohort 2), relative to the scan done 4 weeks previously, and compared with the lesions accumulated during 4 weeks of placebo run-in period in cohort 2. Efficacy data were analysed in a modified intention-to-treat population, using a two-step multiple comparison procedure with modelling analysis. Safety was assessed for all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT03889639), EudraCT (2018-003927-12), and WHO (U1111-1220-0572), and has been completed. Findings Between May 14, 2019, and Jan 2, 2020, we enrolled and randomly assigned 130 participants to tolebrutinib: 33 to 5 mg, 32 to 15 mg, 33 to 30 mg, and 32 to 60 mg. 129 (99%) completed the treatment regimen and 126 were included in the primary analysis. At treatment week 12, there was a dose-dependent reduction in the number of new gadolinium-enhancing lesions (mean [SD] lesions per patient: placebo, 1.03 [2.50]; 5 mg, 1.39 [3.20];15 mg, 0.77 [148]; 30 mg, 0.76 [3.34 60 mg, 0.13 [0.43]; p=0.03). One serious adverse event was reported (one patient in the 60 mg group was admitted to hospital because of a multiple sclerosis relapse). The most common non-serious adverse event during tolebrutinib treatment was headache (in one13%1 of 33 in the 5 mg group; three19%] of 32 in the 15 mg group; one 13%] of 33 in the 30 mg group; and four [13%] of 32 in the 60 mg group). No safety-related discontinuations or treatmentrelated deaths occurred. Interpretation 12 weeks of tolebrutinib treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, the 60 mg dose being the most efficacious, and the drug was well tolerated. Reduction of acute inflammation, combined with the potential to modulate the immune response within the CNS, provides a scientific rationale to pursue phase 3 clinical trials of tolebrutinib in patients with relapsing and progressive forms of multiple sclerosis. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Reich, Daniel S.] NINDS, Translat Neuroradiol Sect, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Arnold, Douglas L.] McGill Univ, NeuroRx Res & Montreal Neurol Inst, Montreal, PQ, Canada; [Vermersch, Patrick] Univ Lille, FHU Imminent, CHU Lille, Lille Neurosci & Cognit,INSERM UMR S1172, Lille, France; [Bar-Or, Amit] Univ Penn, Ctr Neuroinflammat & Neurotherapeut, Philadelphia, PA 19104 USA; [Bar-Or, Amit] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Fox, Robert J.] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44106 USA; [Matta, Andre; Turner, Timothy; Wallstrom, Erik; Zhang, Xinyan] Sanofi, Cambridge, MA USA; [Mares, Miroslav] Pardubice Reg Hosp, Dept Neurol, Pardubice, Czech Republic; [Khabirov, Farit A.] Republican Clin Neurol Ctr, Kazan, Russia; [Traboulsee, Anthony] Univ British Columbia, Dept Med, Vancouver, BC, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); McGill University; Universite de Lille - ISITE; CHU Lille; Universite de Lille; University of Pennsylvania; University of Pennsylvania; Cleveland Clinic Foundation; Sanofi-Aventis; University of British Columbia	Reich, DS (corresponding author), NINDS, Translat Neuroradiol Sect, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	daniel.reich@nih.gov	Reich, Daniel S./E-5701-2010; Montalban, Xavier/J-5938-2016; Pashkovskyy, Valeriy/C-1120-2017; Bar-Or, Amit/AIC-1416-2022	Reich, Daniel S./0000-0002-2628-4334; Montalban, Xavier/0000-0002-0098-9918; Pashkovskyy, Valeriy/0000-0001-6066-371X; Turner, Timothy/0000-0001-9770-2647; Totolyan, Natalia/0000-0002-6715-8203; Uitdehaag, Bernard/0000-0002-9226-7364; Kantorova, Ema/0000-0003-4305-3607	Sanofi	Sanofi	Sanofi.	Absinta M, 2019, JAMA NEUROL, V76, P1474, DOI 10.1001/jamaneurol.2019.2399; Absinta M, 2016, J CLIN INVEST, V126, P2597, DOI 10.1172/JCI86198; Bunai T, 2018, J NEUROL SCI, V385, P30, DOI 10.1016/j.jns.2017.12.004; Dal-Bianco A, 2017, ACTA NEUROPATHOL, V133, P25, DOI 10.1007/s00401-016-1636-z; Datta G, 2017, BRAIN, V140, P2927, DOI 10.1093/brain/awx228; Elliott C, 2019, BRAIN, V142, P2787, DOI 10.1093/brain/awz212; Elliott C, 2019, MULT SCLER J, V25, P1915, DOI 10.1177/1352458518814117; Elliott C, 2013, IEEE T MED IMAGING, V32, P1490, DOI 10.1109/TMI.2013.2258403; Francesco MR, 2017, MULT SCLER J, V23, P511; Ghajarzadeh M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102585; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2020, NEW ENGL J MED, V383, P546, DOI 10.1056/NEJMoa1917246; Hendriks RW, 2011, NAT CHEM BIOL, V7, P4, DOI 10.1038/nchembio.502; Jackle K, 2020, BRAIN, V143, P2073, DOI 10.1093/brain/awaa158; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Keaney J, 2019, J NEUROIMMUNE PHARM, V14, P448, DOI 10.1007/s11481-019-09839-0; Liang CY, 2018, EUR J MED CHEM, V151, P315, DOI 10.1016/j.ejmech.2018.03.062; Lublin FD, 2020, NEUROLOGY, V94, P1088, DOI 10.1212/WNL.0000000000009636; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Magliozzi R, 2007, BRAIN, V130, P1089, DOI 10.1093/brain/awm038; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Montalban X, 2019, NEW ENGL J MED, V380, P2406, DOI 10.1056/NEJMoa1901981; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Schofield MA, 2003, OPT LETT, V28, P1194, DOI 10.1364/OL.28.001194; Selmaj K, 2013, LANCET NEUROL, V12, P756, DOI 10.1016/S1474-4422(13)70102-9; Smith PF, 2019, MULT SCLER J, V25, P52; Sormani MP, 2010, NEUROLOGY, V75, P302, DOI 10.1212/WNL.0b013e3181ea15aa; Sormani MP, 2013, LANCET NEUROL, V12, P669, DOI 10.1016/S1474-4422(13)70103-0; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Torke S, 2020, ACTA NEUROPATHOL, V140, P535, DOI 10.1007/s00401-020-02204-z; Weber ANR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01454; Zrzavy T, 2017, BRAIN, V140, P1900, DOI 10.1093/brain/awx113	33	41	41	11	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					729	738		10.1016/S1474-4422(21)00237-4	http://dx.doi.org/10.1016/S1474-4422(21)00237-4			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418400	Green Accepted			2022-12-18	WOS:000691876000016
J	Weaver, NA; Kuijf, HJ; Aben, HP; Abrigo, J; Bae, HJ; Barbay, M; Best, JG; Bordet, R; Chappell, FM; Chen, CPLH; Dondaine, T; van der Giessen, RS; Godefroy, O; Gyanwali, B; Hamilton, OKL; Hilal, S; Wajer, IMCH; Kang, Y; Kappelle, LJ; Kim, BJ; Kohler, S; de Kort, PLM; Koudstaal, PJ; Kuchcinski, G; Lam, BYK; Lee, BC; Lee, KJ; Lim, JS; Lopes, R; Makin, SDJ; Mendyk, AM; Mok, VCT; Oh, MS; van Oostenbrugge, RJ; Roussel, M; Shi, L; Staals, J; Valdes-Hernandez, MD; Venketasubramanian, N; Verhey, FRJ; Wardlaw, JM; Werring, DJ; Xin, X; Yu, KH; van Zandvoort, MJE; Zhao, L; Biesbroek, JM; Biessels, GJ				Weaver, Nick A.; Kuijf, Hugo J.; Aben, Hugo P.; Abrigo, Jill; Bae, Hee-Joon; Barbay, Melanie; Best, Jonathan G.; Bordet, Regis; Chappell, Francesca M.; Chen, Christopher P. L. H.; Dondaine, Thibaut; van der Giessen, Ruben S.; Godefroy, Olivier; Gyanwali, Bibek; Hamilton, Olivia K. L.; Hilal, Saima; Wajer, Irene M. C. Huenges; Kang, Yeonwook; Kappelle, L. Jaap; Kim, Beom Joon; Kohler, Sebastian; de Kort, Paul L. M.; Koudstaal, Peter J.; Kuchcinski, Gregory; Lam, Bonnie Y. K.; Lee, Byung-Chul; Lee, Keon-Joo; Lim, Jae-Sung; Lopes, Renaud; Makin, Stephen D. J.; Mendyk, Anne-Marie; Mok, Vincent C. T.; Oh, Mi Sun; van Oostenbrugge, Robert J.; Roussel, Martine; Shi, Lin; Staals, Julie; Valdes-Hernandez, Maria Del C.; Venketasubramanian, Narayanaswamy; Verhey, Frans R. J.; Wardlaw, Joanna M.; Werring, David J.; Xin, Xu; Yu, Kyung-Ho; van Zandvoort, Martine J. E.; Zhao, Lei; Biesbroek, J. Matthijs; Biessels, Geert Jan			Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	LANCET NEUROLOGY			English	Article							DEMENTIA; PREDICTION; ANATOMY; ATTACK	Background Post-stroke cognitive impairment (PSCI) occurs in approximately half of people in the first year after stroke. Infarct location is a potential determinant of PSCI, but a comprehensive map of strategic infarct locations predictive of PSCI is unavailable. We aimed to identify infarct locations most strongly predictive of PSCI after acute ischaemic stroke and use this information to develop a prediction model. Methods In this large-scale multicohort lesion-symptom mapping study, we pooled and harmonised individual patient data from 12 cohorts through the Meta-analyses on Strategic Lesion Locations for Vascular Cognitive Impairment using Lesion-Symptom Mapping (Meta VCI Map) consortium. The identified cohorts (as of Jan 1, 2019) comprised patients with acute symptomatic infarcts on CT or MRI (with available infarct segmentations) and a cognitive assessment up to 15 months after acute ischaemic stroke onset. PSCI was defined as performance lower than the fifth percentile of local normative data, on at least one cognitive domain on a multidomain neuropsychological assessment or on the Montreal Cognitive Assessment. Voxel-based lesion-symptom mapping (VLSM) was used to calculate voxel-wise odds ratios (ORs) for PSCI that were mapped onto a three-dimensional brain template to visualise PSCI risk per location. For the prediction model of PSCI risk, a location impact score on a 5-point scale was derived from the VLSM results on the basis of the mean voxel-wise coefficient (ln[OR]) within each patient's infarct. We did combined internal-external validation by leave-one-cohort-out cross-validation for all 12 cohorts using logistic regression. Predictive performance of a univariable model with only the location impact score was compared with a multivariable model with addition of other clinical PSCI predictors (age, sex, education, time interval between stroke onset and cognitive assessment, history of stroke, and total infarct volume). Testing of visual ratings was done by three clinicians, and accuracy, inter-rater reliability, and intra-rater reliability were assessed with Cohen's weighted kappa. Findings In our sample of 2950 patients (mean age 66 & middot;8 years [SD 11 & middot;6]; 1157 [39 & middot;2%] women), 1286 (43 & middot;6%) had PSCI. We achieved high lesion coverage of the brain in our analyses (86 & middot;9%). Infarcts in the left frontotemporal lobes, left thalamus, and right parietal lobe were strongly associated with PSCI (after false discovery rate correction, q<0 & middot;01; voxel-wise ORs >20). On cross-validation, the location impact score showed good correspondence, based on visual assessment of goodness of fit, between predicted and observed risk of PSCI across cohorts after adjusting for cohort specific PSCI occurrence. Cross-validations showed that the location impact score by itself had similar performance to the combined model with other PSCI predictors, while allowing for easy visual assessment. Therefore the univariable model with only the location impact score was selected as the final model. Correspondence between visual ratings and actual location impact score (Cohen's weighted kappa: range 0 & middot;88-0 & middot;92), inter-rater agreement (0 & middot;85-0 & middot;87), and intra-rater agreement (for a single rater, 0 & middot;95) were all high. Interpretation To the best of our knowledge, this study provides the first comprehensive map of strategic infarct locations associated with risk of PSCI. A location impact score was derived from this map that robustly predicted PSCI across cohorts. Furthermore, we developed a quick and reliable visual rating scale that might in the future be applied by clinicians to identify individual patients at risk of PSCI.	[Weaver, Nick A.; Wajer, Irene M. C. Huenges; Kappelle, L. Jaap; van Zandvoort, Martine J. E.; Biesbroek, J. Matthijs; Biessels, Geert Jan] Univ Med Ctr UMC, Dept Neurol & Neurosurg, Utrecht Brain Ctr, Utrecht, Netherlands; [Kuijf, Hugo J.] UMC Utrecht, Image Sci Inst, Utrecht, Netherlands; [Aben, Hugo P.; de Kort, Paul L. M.] Elisabeth Tweesteden Hosp, Dept Neurol, Tilburg, Netherlands; [Abrigo, Jill; Shi, Lin] Chinese Univ Hong Kong, Dept Imaging & Intervent Radiol, Hong Kong, Peoples R China; [Lam, Bonnie Y. K.; Mok, Vincent C. T.] Chinese Univ Hong Kong, Dept Med & Therapeut, Div Neurol, Hong Kong, Peoples R China; [Bae, Hee-Joon; Kim, Beom Joon; Lee, Keon-Joo] Seoul Natl Univ, Coll Med, Dept Neurol, Bundang Hosp, Seongnam, South Korea; [Barbay, Melanie; Godefroy, Olivier; Roussel, Martine] Jules Verne Picardy Univ, Amiens Univ Hosp, Dept Neurol, Lab Funct Neurosci, Amiens, France; [Best, Jonathan G.; Werring, David J.] UCL, Dept Brain Repair & Rehabil, Stroke Res Ctr, Queen Sq Inst Neurol, London, England; [Bordet, Regis; Dondaine, Thibaut; Kuchcinski, Gregory; Lopes, Renaud; Mendyk, Anne-Marie] Univ Lille, U1172 LilNCog Lille Neurosci & Cognit, CHU Lille, INSERM, Lille, France; [Chappell, Francesca M.; Hamilton, Olivia K. L.; Valdes-Hernandez, Maria Del C.; Wardlaw, Joanna M.] Univ Edinburgh, Neuroimaging Sci, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Chappell, Francesca M.; Hamilton, Olivia K. L.; Valdes-Hernandez, Maria Del C.; Wardlaw, Joanna M.] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Chen, Christopher P. L. H.; Gyanwali, Bibek; Hilal, Saima; Xin, Xu] Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore; [Chen, Christopher P. L. H.; Gyanwali, Bibek; Hilal, Saima; Xin, Xu] Natl Univ Hlth Syst, Memory Aging & Cognit Ctr, Singapore, Singapore; [van der Giessen, Ruben S.; Koudstaal, Peter J.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Hilal, Saima] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Hilal, Saima] Natl Univ Hlth Syst, Singapore, Singapore; [Wajer, Irene M. C. Huenges; van Zandvoort, Martine J. E.] Helmholtz Inst, Expt Psychol, Utrecht, Netherlands; [Kang, Yeonwook] Hallym Univ, Dept Psychol, Chunchon, South Korea; [Kohler, Sebastian; Verhey, Frans R. J.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands; [Lam, Bonnie Y. K.; Mok, Vincent C. T.] Chinese Univ Hong Kong, Gerald Choa Neurosci Ctr, Margaret Kam Ling Cheung Res Ctr Management Padci, Therese Pei Fong Chow Res Ctr Prevent Dementia, Hong Kong, Peoples R China; [Lee, Byung-Chul; Oh, Mi Sun; Yu, Kyung-Ho] Hallym Univ, Coll Med, Hallym Neurol Inst, Dept Neurol,Sacred Hosp, Anyang, South Korea; [Lim, Jae-Sung] Asan Med Ctr, Dept Neurol, Seoul, South Korea; [Makin, Stephen D. J.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [van Oostenbrugge, Robert J.; Staals, Julie] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands; [Shi, Lin; Zhao, Lei] BrainNow Res Inst, Shenzhen, Peoples R China; [Venketasubramanian, Narayanaswamy] Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore	Utrecht University; Utrecht University Medical Center; Elisabeth-TweeSteden Ziekenhuis (ETZ); Chinese University of Hong Kong; Chinese University of Hong Kong; Seoul National University (SNU); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; University of Edinburgh; University of Edinburgh; National University of Singapore; National University of Singapore; Erasmus University Rotterdam; Erasmus MC; National University of Singapore; National University of Singapore; Hallym University; Maastricht University; Chinese University of Hong Kong; Hallym University; University of Ulsan; Asan Medical Center; University of Glasgow; Maastricht University; Raffles Hospital	Biessels, GJ (corresponding author), UMC Utrecht, Dept Neurol & Neurosurg, NL-3508 GA Utrecht, Netherlands.	g.j.biessels@umcutrecht.nl	Werring, David/Q-8435-2019; Venketasubramanian, Narayanaswamy/GPP-5948-2022; Hernandez, María/GYU-3543-2022; Hilal, Saima/D-6028-2016; Lim, Jae-Sung/D-5555-2012; Kuijf, Hugo J/G-2711-2013; Hamilton, Olivia/AAY-7456-2020; Chen, Christopher/E-7023-2013; Lam, Bonnie Yin Ka/J-7578-2016; Kim, Beom Joon/C-2904-2011; Wardlaw, Joanna M/Y-3456-2019	Werring, David/0000-0003-2074-1861; Hilal, Saima/0000-0001-5434-5635; Lim, Jae-Sung/0000-0001-6157-2908; Kuijf, Hugo J/0000-0001-6997-9059; Hamilton, Olivia/0000-0002-5874-0058; Chen, Christopher/0000-0002-1047-9225; Lam, Bonnie Yin Ka/0000-0002-1656-2433; Kim, Beom Joon/0000-0002-2719-3012; Wardlaw, Joanna M/0000-0002-9812-6642	Netherlands Organisation for Health Research and Development	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	The Netherlands Organisation for Health Research and Development.	Aben HP, 2018, JMIR RES PROTOC, V7, DOI 10.2196/resprot.9431; Arnoux A, 2018, NEUROPSYCHOLOGIA, V121, P69, DOI 10.1016/j.neuropsychologia.2018.10.003; Barbay M, 2018, STROKE, V49, P1141, DOI 10.1161/STROKEAHA.117.018889; Biesbroek JM, 2019, JOVE-J VIS EXP, DOI 10.3791/59653; Biesbroek JM, 2017, CLIN SCI, V131, P715, DOI 10.1042/CS20160452; Biesbroek JM, 2014, NEUROPSYCHOLOGIA, V62, P68, DOI 10.1016/j.neuropsychologia.2014.07.013; Bournonville C, 2018, NEUROLOGY, V90, pE1879, DOI 10.1212/WNL.0000000000005553; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cook Nancy R, 2018, Diagn Progn Res, V2, P14, DOI 10.1186/s41512-018-0037-2; Dong YH, 2012, J NEUROL NEUROSUR PS, V83, P580, DOI 10.1136/jnnp-2011-302070; Douven E, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0588-1; Fonov V, 2011, NEUROIMAGE, V54, P313, DOI 10.1016/j.neuroimage.2010.07.033; Georgakis MK, 2019, NEUROLOGY, V92, pE1298, DOI 10.1212/WNL.0000000000007142; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Karnath HO, 2018, NEUROIMAGE, V165, P180, DOI 10.1016/j.neuroimage.2017.10.028; Karnath HO, 2017, BRAIN STRUCT FUNCT, V222, P2059, DOI 10.1007/s00429-016-1325-7; Lim JS, 2014, STROKE, V45, P1069, DOI 10.1161/STROKEAHA.113.004156; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mijajlovic MD, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0779-7; Munsch F, 2016, STROKE, V47, P66, DOI 10.1161/STROKEAHA.115.011242; Pendlebury ST, 2019, LANCET NEUROL, V18, P248, DOI 10.1016/S1474-4422(18)30442-3; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Pollock A, 2012, LANCET NEUROL, V11, P209, DOI 10.1016/S1474-4422(12)70029-7; Puy L, 2018, STROKE, V49, P2666, DOI 10.1161/STROKEAHA.118.021981; Sachdev P, 2014, ALZ DIS ASSOC DIS, V28, P206, DOI 10.1097/WAD.0000000000000034; Steyerberg E.W, 2019, CLIN PREDICTION MODE; Steyerberg EW, 2016, J CLIN EPIDEMIOL, V69, P245, DOI 10.1016/j.jclinepi.2015.04.005; Wardlaw JM, 2017, ALZHEIMERS DEMENT, V13, P634, DOI 10.1016/j.jalz.2016.09.006; Weaver NA, 2019, ALZH DEMENT-DADM, V11, P310, DOI 10.1016/j.dadm.2019.02.007; Wilson D, 2018, LANCET NEUROL, V17, P539, DOI 10.1016/S1474-4422(18)30145-5; Yu KH, 2013, STROKE, V44, P786, DOI 10.1161/STROKEAHA.112.668343; Zhao L, 2018, J CEREBR BLOOD F MET, V38, P1299, DOI 10.1177/0271678X17728162	32	41	41	9	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					448	459		10.1016/S1474-4422(21)00060-0	http://dx.doi.org/10.1016/S1474-4422(21)00060-0		MAY 2021	12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	33901427	Green Submitted, Green Published			2022-12-18	WOS:000653434700015
J	Salman, RAS; Minks, DP; Mitra, D; Rodrigues, MA; Bhatnagar, P; du Plessis, JC; Joshi, Y; Dennis, MS; Murray, GD; Newby, DE; Sandercock, PAG; Sprigg, N; Stephen, J; Sudlow, CLM; Werring, DJ; Whiteley, WN; Wardlaw, JM; White, PM; Baigent, C; Lasserson, DS; Carrie, J				Salman, Rustam Al-Shahi; Minks, David P.; Mitra, Dipayan; Rodrigues, Mark A.; Bhatnagar, Priya; du Plessis, Johann C.; Joshi, Yogish; Dennis, Martin S.; Murray, Gordon D.; Newby, David E.; Sandercock, Peter A. G.; Sprigg, Nikola; Stephen, Jacqueline; Sudlow, Cathie L. M.; Werring, David J.; Whiteley, William N.; Wardlaw, Joanna M.; White, Philip M.; Baigent, Colin; Lasserson, Daniel S.; Carrie, Johanna		RESTART Collaboration	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial	LANCET NEUROLOGY			English	Article							ACUTE ISCHEMIC-STROKE; ANTITHROMBOTIC THERAPY; SUPERFICIAL SIDEROSIS; AMYLOID ANGIOPATHY; CT; ASPIRIN; MICROBLEEDS; SIGNS	Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy. Methods RESTART was a prospective, randomised, open-label, blinded-endpoint, parallel-group trial at 122 hospitals in the UK that assessed whether starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. For this prespecified subgroup analysis, consultant neuroradiologists masked to treatment allocation reviewed brain CT or MRI scans performed before randomisation to confirm participant eligibility and rate features of the intracerebral haemorrhage and surrounding brain. We followed participants for primary (recurrent symptomatic intracerebral haemorrhage) and secondary (ischaemic stroke) outcomes for up to 5 years (reported elsewhere). For this report, we analysed eligible participants with intracerebral haemorrhage according to their treatment allocation in primary subgroup analyses of cerebral microbleeds on MRI and in exploratory subgroup analyses of other features on CT or MRI. The trial is registered with the ISRCTN registry, number ISRCTN71907627. Finding Between May 22, 2013, and May 31, 2018, 537 participants were enrolled, of whom 525 (98%) had intracerebral haemorrhage: 507 (97%) were diagnosed on CT (252 assigned to start antiplatelet therapy and 255 assigned to avoid antiplatelet therapy, of whom one withdrew and was not analysed) and 254 (48%) underwent the required brain MRI protocol (122 in the start antiplatelet therapy group and 132 in the avoid antiplatelet therapy group). There were no clinically or statistically significant hazards of antiplatelet therapy on recurrent intracerebral haemorrhage in primary subgroup analyses of cerebral microbleed presence (2 or more) versus absence (0 or 1) (adjusted hazard ratio [HR] 0.30 [95% CI 0.08-1.13] vs 0.77 [0.13-4.61]; p(interaction)=0.41), cerebral microbleed number 0-1 versus 2-4 versus 5 or more (HR 0.77 [0.13-4.62] vs 0.32 [0.03-3.66] vs 0.33 [0.07-1.60]; p(interaction)=0.75), or cerebral microbleed strictly lobar versus other location (HR 0.52 [0.004-6.79] vs 0.37 [0.09-1.28]; p(interaction)=0.85). There was no evidence of heterogeneity in the effects of antiplatelet therapy in any exploratory subgroup analyses (all p(interaction)>0.05). Interpretation Our findings exclude all but a very modest harmful effect of antiplatelet therapy on recurrent intracerebral haemorrhage in the presence of cerebral microbleeds. Further randomised trials are needed to replicate these findings and investigate them with greater precision. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.	[Salman, Rustam Al-Shahi; Rodrigues, Mark A.; Dennis, Martin S.; Sandercock, Peter A. G.; Sudlow, Cathie L. M.; Whiteley, William N.; Wardlaw, Joanna M.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Salman, Rustam Al-Shahi; Murray, Gordon D.; Stephen, Jacqueline; Sudlow, Cathie L. M.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Newby, David E.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Wardlaw, Joanna M.] Univ Edinburgh, Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Minks, David P.; Mitra, Dipayan; Bhatnagar, Priya; White, Philip M.] Newcastle Upon Tyne Hosp NHS Trust, Dept Neuroradiol, Newcastle Upon Tyne, Tyne & Wear, England; [Mitra, Dipayan; White, Philip M.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England; [Mitra, Dipayan; White, Philip M.] Newcastle Univ, Inst Ageing, Newcastle Upon Tyne, Tyne & Wear, England; [du Plessis, Johann C.] NHS Lothian, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland; [Joshi, Yogish] Addenbrookes Hosp, Dept Radiol, Cambridge, England; [Sprigg, Nikola] Univ Nottingham, Fac Med & Hlth Sci, Div Clin Neurosci, Nottingham, England; [Werring, David J.] Univ Coll London Queen Sq Inst Neurol, Dept Brain Repair & Rehabil, Stroke Res Grp, London, England	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Nottingham	Salman, RAS (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	rustam.al-shahi@ed.ac.uk	Strain, William/Y-9858-2019; Njoku, Kelechi/AAW-6462-2021; Wardlaw, Joanna M/Y-3456-2019; Newby, David Ernest/AAB-1364-2019; Hernandez, María/GYU-3543-2022; Werring, David/Q-8435-2019; Sullivan, Frank/L-8286-2019; Macleod, Malcolm Robert/B-2052-2010	Strain, William/0000-0002-6826-418X; Njoku, Kelechi/0000-0001-6528-3476; Wardlaw, Joanna M/0000-0002-9812-6642; Werring, David/0000-0003-2074-1861; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Sprigg, Nikola/0000-0002-5871-8168; Appleton, Jason/0000-0002-2604-4410; Cohen, David/0000-0001-7318-8567; Hansen, Christian/0000-0002-5949-0097; Emberson, Jonathan/0000-0001-7792-9422; Ford, Gary A/0000-0001-8719-4968; Rodrigues, Mark/0000-0002-4507-6872; Marigold, Richard/0000-0003-1924-1616; Emsley, Hedley/0000-0003-0129-4488; HAQUE, MOHAMMAD/0000-0003-0852-6368; Chatterjee, Kausik/0000-0002-3093-1469; Sullivan, Frank/0000-0002-6623-4964; Lasserson, Daniel/0000-0001-8274-5580; Harston, George/0000-0003-4916-5757; Papavasileiou, Vasileios/0000-0003-1486-1955; Whiteley, William/0000-0002-4816-8991; Randall, Marc/0000-0002-3196-182X; Crawford, Caroline/0000-0002-7464-0727; White, Philip/0000-0001-6007-6013; James, Martin/0000-0001-6065-6018; Parry-Jones, Adrian/0000-0002-4462-3846; Macleod, Malcolm Robert/0000-0001-9187-9839	British Heart Foundation [SP/12/2/20422]; National Institute for Health Research Clinical Research Network; National Health Service Research Scotland (NRS) Scottish Stroke Research Network; NRS through the Edinburgh Clinical Research Facility [E131252]; NHS Lothian Research and Development; Scottish Funding Council; Chief Scientist Office; University of Edinburgh; Lothian Health Board; MRC [G1002605, MC_G1002455, MC_UU_12026/5, G0300623, MC_U137686853, MR/J006971/1, G0400069, UKDRI-4002] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); National Institute for Health Research Clinical Research Network; National Health Service Research Scotland (NRS) Scottish Stroke Research Network; NRS through the Edinburgh Clinical Research Facility; NHS Lothian Research and Development; Scottish Funding Council; Chief Scientist Office; University of Edinburgh; Lothian Health Board; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank all participants, their relatives or carers, and their primary care practitioners; RESTART sites that recruited participants; the outcome event adjudicators; and the trial steering committee and the data monitoring committee. We are grateful to the independent members of the trial steering committee: Colin Baigent (MRC Population Health Research Unit, University of Oxford, Oxford, UK), Daniel S Lasserson (Institute of Applied Health Research, University of Birmingham, Birmingham, UK), and Johanna Carrie. We thank Edinburgh Clinical Trials Unit and the University of Edinburgh's Systematic Management, Archiving and Reviewing of Trial Images Service for their involvement. We thank the British Heart Foundation for funding the trial with a Special Project Grant (SP/12/2/20422) and continuing to support it while recruitment was challenging. The University of Edinburgh and the Lothian Health Board are co-sponsors. We acknowledge the support of the National Institute for Health Research Clinical Research Network, National Health Service Research Scotland (NRS) Scottish Stroke Research Network, and the support of the NRS through the Edinburgh Clinical Research Facility (E131252) and NHS Lothian Research and Development. Imaging acquisition, processing, and data collection were performed at the Edinburgh Imaging Facility, University of Edinburgh, which is part of the SINAPSE collaboration funded by the Scottish Funding Council and the Chief Scientist Office.	Biffi A, 2010, NEUROLOGY, V75, P693, DOI 10.1212/WNL.0b013e3181eee40f; Charidimou A, 2019, INT J STROKE, V14, P723, DOI 10.1177/1747493019830065; Charidimou A, 2017, NEUROLOGY, V89, P820, DOI 10.1212/WNL.0000000000004259; Charidimou A, 2015, BRAIN, V138, P2126, DOI 10.1093/brain/awv162; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; Cordonnier C, 2009, STROKE, V40, P94, DOI 10.1161/STROKEAHA.108.526996; Falcone GJ, 2014, STROKE, V45, P3151, DOI 10.1161/STROKEAHA.114.005787; Farrell C, 2009, EUR RADIOL, V19, P177, DOI 10.1007/s00330-008-1119-2; FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351, DOI 10.2214/ajr.149.2.351; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Haley KE, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886-013-0425-8; Heinze G, 2001, BIOMETRICS, V57, P114, DOI 10.1111/j.0006-341X.2001.00114.x; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Lee TWR, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005599.pub5, 10.1002/14651858.CD012144.pub2]; Linn J, 2010, NEUROLOGY, V74, P1346, DOI 10.1212/WNL.0b013e3181dad605; Newman GC, 2007, STROKE, V38, P862, DOI 10.1161/01.STR.0000257309.50643.0a; Poon MTC, 2014, J NEUROL NEUROSUR PS, V85, P660, DOI 10.1136/jnnp-2013-306476; Qiu JT, 2018, STROKE, V49, P1751, DOI 10.1161/STROKEAHA.118.021789; Rodrigues MA, 2018, LANCET NEUROL, V17, P232, DOI 10.1016/S1474-4422(18)30006-1; Salman RAS, 2019, LANCET, V393, P2613, DOI 10.1016/S0140-6736(19)30840-2; Salman RA, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3270-2; Salman RAS, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2542-6; Samarasekera N, 2015, STROKE, V46, P361, DOI 10.1161/STROKEAHA.114.007953; Shoamanesh A, 2017, ANN NEUROL, V82, P196, DOI 10.1002/ana.24988; Smith Eric E, 2006, Magn Reson Imaging Clin N Am, V14, P127, DOI 10.1016/j.mric.2006.06.002; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; Viswanathan A, 2006, NEUROLOGY, V66, P206, DOI 10.1212/01.wnl.0000194267.09060.77; Wang ZL, 2014, STROKE, V45, P2811, DOI 10.1161/STROKEAHA.114.004286; Wardlaw JM, 2003, J NEUROL NEUROSUR PS, V74, P452, DOI 10.1136/jnnp.74.4.452; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933; Wardlaw JM, 2007, STROKE, V38, P1250, DOI 10.1161/01.STR.0000259715.53166.25; Wardlaw JM, 2015, LANCET NEUROL, V14, P485, DOI 10.1016/S1474-4422(15)00012-5; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Wilson D, 2017, CURR OPIN NEUROL, V30, P38, DOI 10.1097/WCO.0000000000000411; Wilson D, 2016, NEUROLOGY, V87, P1501, DOI 10.1212/wnl.0000000000003183	36	41	44	2	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2019	18	7					643	652		10.1016/S1474-4422(19)30184-X	http://dx.doi.org/10.1016/S1474-4422(19)30184-X			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IC7SE	31129065	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000471176500013
J	Willeit, J; Geley, T; Schoch, J; Rinner, H; Tur, A; Kreuzer, H; Thiemann, N; Knoflach, M; Toell, T; Pechlaner, R; Willeit, K; Klingler, N; Praxmarer, S; Baubin, M; Beck, G; Berek, K; Dengg, C; Engelhardt, K; Erlacher, T; Fluckinger, T; Grander, W; Grossmann, J; Kathrein, H; Kaiser, N; Matosevic, B; Matzak, H; Mayr, M; Perfler, R; Poewe, W; Rauter, A; Schoenherr, G; Schoenherr, HR; Schinnerl, A; Spiss, H; Thurner, T; Vergeiner, G; Werner, P; Woll, E; Willeit, P; Kiechl, S				Willeit, Johann; Geley, Theresa; Schoech, Johannes; Rinner, Heinrich; Tuer, Andreas; Kreuzer, Hans; Thiemann, Norbert; Knoflach, Michael; Toell, Thomas; Pechlaner, Raimund; Willeit, Karin; Klingler, Natalie; Praxmarer, Silvia; Baubin, Michael; Beck, Gertrud; Berek, Klaus; Dengg, Christian; Engelhardt, Klaus; Erlacher, Thomas; Fluckinger, Thomas; Grander, Wilhelm; Grossmann, Josef; Kathrein, Hermann; Kaiser, Norbert; Matosevic, Benjamin; Matzak, Heinrich; Mayr, Markus; Perfler, Robert; Poewe, Werner; Rauter, Alexandra; Schoenherr, Gudrun; Schoenherr, Hans-Robert; Schinnerl, Adolf; Spiss, Heinrich; Thurner, Theresa; Vergeiner, Gernot; Werner, Philipp; Woell, Ewald; Willeit, Peter; Kiechl, Stefan			Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study	LANCET NEUROLOGY			English	Article							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; RANDOMIZED CONTROLLED-TRIAL; UNIT REGISTRY; RURAL-AREAS; PROJECT; TIME; ASSOCIATION; HOSPITALS	Background Intravenous thrombolysis for ischaemic stroke remains underused worldwide. We aimed to assess whether our statewide comprehensive stroke management programme would improve thrombolysis use and clinical outcome in patients. Methods In 2008-09, we designed the Tyrol Stroke Pathway, which provided information campaigns for the public and standardised the entire treatment pathway from stroke onset to outpatient rehabilitation. It was commenced in Tyrol, Austria, as a long-term routine-care programme and aimed to include all patients with stroke in the survey area. We focused on thrombolysis use and outcome in the first full 4 years of implementation (2010-13). Findings We enrolled 4947 (99%) of 4992 patients with ischaemic stroke who were admitted to hospitals in Tyrol; 675 (14%) of the enrollees were treated with alteplase. Thrombolysis administration in Tyrol increased after programme implementation, from 160 of 1238 patients (12-9%, 95% CI 11.1-14-9) in 2010 to 213 of 1266 patients (16.8%, 14-8-19.0) in 2013 (p(trent) (2010-13) < 0.0001). Differences in use of thrombolysis in the nine counties of Tyrol in 2010 (range, 2.2-22.6%) were reduced by 2013 (12.1-22-5%). Median statewide door-to-needle time decreased from 49 min (IQR 35-60) in 2010 to 44 min (29-60) in 2013; symptomatic post-thrombolysis intracerebral haemorrhages occurred in 28 of 675 patients (4.1%, 95% CI 2.8-5.9) during 2010-13. In four Austrian states without similar stroke programmes, thrombolysis administration remained stable or declined between 2010 and 2013 (mean reduction 14.4%, 95% CI 10.9-17.9). Although the 3-month mortality was not affected by our programme (137 [13%] of 1060 patients in 2010 vs 143 [13%] of 1069 patients in 2013), 3-month functional outcome significantly improved (modified Rankin Scale score 0-1 in 375 [40%] of 944 patients in 2010 vs 493 [53%] of 939 in 2013; score 0-2 in 531 [56%] patients in 2010 and 615 [65%] in 2013; Ptrend2010-13 <0.0001). Interpretation During the period of implementation of our comprehensive stroke management programme, thrombolysis administration increased and clinical outcome significantly improved, although mortality did not change. We hope that these results will guide health authorities and stroke physicians elsewhere when implementing similar programmes for patients with stroke.	[Willeit, Johann; Tuer, Andreas; Knoflach, Michael; Toell, Thomas; Pechlaner, Raimund; Willeit, Karin; Matosevic, Benjamin; Poewe, Werner; Schoenherr, Gudrun; Willeit, Peter; Kiechl, Stefan] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; [Geley, Theresa; Schoech, Johannes; Rinner, Heinrich; Kreuzer, Hans; Klingler, Natalie; Praxmarer, Silvia] Tyrolean Hlth Care Fund, Innsbruck, Austria; [Thiemann, Norbert] Tyrolean Reg Hlth Insurance, Innsbruck, Austria; [Baubin, Michael] Med Univ Innsbruck, Dept Anesthesia & Intens Care Med, A-6020 Innsbruck, Austria; [Beck, Gertrud; Engelhardt, Klaus] Reutte Cty Hosp, Dept Internal Med, Reutte, Austria; [Berek, Klaus; Mayr, Markus] Kufstein Cty Hosp, Dept Neurol, Kufstein, Austria; [Erlacher, Thomas; Grander, Wilhelm] Hall State Hosp, Dept Internal Med, Hall In Tirol, Austria; [Grossmann, Josef; Perfler, Robert] Lienz Cty Hosp, Dept Neurol, Lienz, Austria; [Kathrein, Hermann; Rauter, Alexandra] Schwaz Cty Hosp, Dept Internal Med, Schwaz, Austria; [Kaiser, Norbert; Thurner, Theresa] St Johann Cty Hosp, Dept Internal Med, St Johann, Austria; [Matzak, Heinrich] Hochzirl State Hosp, Dept Neurol, Zirl, Austria; [Schoenherr, Hans-Robert; Woell, Ewald] St Vinzenz Hosp Zams, Dept Internal Med, Zams, Austria; [Vergeiner, Gernot] Emergency Dispatch Ctr Tyrol, Innsbruck, Austria; [Werner, Philipp] Feldkirch Acad Teaching Hosp, Dept Acute Neurol & Stroke, Feldkirch, Austria; [Willeit, Peter] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England	Medical University of Innsbruck; Medical University of Innsbruck; University of Cambridge	Kiechl, S (corresponding author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	stefan.kiechl@i-med.ac.at	Willeit, Peter/HCI-7091-2022	Willeit, Peter/0000-0002-1866-7159; Knoflach, Michael/0000-0001-5576-6562; Pechlaner, Raimund/0000-0001-9006-5606	Reformpool of the Tyrolean Health Care Fund	Reformpool of the Tyrolean Health Care Fund	Reformpool of the Tyrolean Health Care Fund.	Adeoye O, 2011, STROKE, V42, P1952, DOI 10.1161/STROKEAHA.110.612358; Asplund K, 2011, STROKE, V42, P2492, DOI 10.1161/STROKEAHA.111.618587; Audebert HJ, 2006, LANCET NEUROL, V5, P742, DOI 10.1016/S1474-4422(06)70527-0; Boode B, 2007, CEREBROVASC DIS, V23, P294, DOI 10.1159/000098330; Dirks M, 2011, STROKE, V42, P1325, DOI 10.1161/STROKEAHA.110.596940; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Emberson J, 2014, LANCET; Fassbender K, 2013, LANCET NEUROL, V12, P585, DOI 10.1016/S1474-4422(13)70100-5; Fischer U, 2012, STROKE, V43, P1039, DOI 10.1161/STROKEAHA.111.630384; Grau AJ, 2010, STROKE, V41, P1495, DOI 10.1161/STROKEAHA.110.582239; Greisenegger S, 2014, STROKE, V45, P765, DOI 10.1161/STROKEAHA.113.003827; Gumbinger C, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3429; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kapral MK, 2013, CAN MED ASSOC J, V185, pE483, DOI 10.1503/cmaj.121418; Kaste M, 2013, LANCET NEUROL, V12, P2, DOI 10.1016/S1474-4422(12)70273-9; Knoflach M, 2012, NEUROLOGY, V78, P279, DOI 10.1212/WNL.0b013e31824367ab; Lahr MMH, 2012, STROKE, V43, P1336, DOI 10.1161/STROKEAHA.111.641795; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Meretoja A, 2010, STROKE, V41, P2239, DOI 10.1161/STROKEAHA.110.595173; Moradiya Y, 2013, NEUROLOGY, V81, P1986, DOI 10.1212/01.wnl.0000436946.08647.b5; Morgenstern LB, 2002, STROKE, V33, P160, DOI 10.1161/hs0102.101990; Muller-Barna P, 2014, STROKE, V45, P2739, DOI 10.1161/STROKEAHA.114.006141; Nadeau JO, 2005, CAN J NEUROL SCI, V32, P433, DOI 10.1017/S0317167100004418; Reiner-Deitemyer V, 2011, STROKE, V42, P1295, DOI 10.1161/STROKEAHA.110.604710; Rost NS, 2012, CIRC-CARDIOVASC QUAL, V5, P314, DOI 10.1161/CIRCOUTCOMES.111.962829; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Schwamm LH, 2013, CIRC-CARDIOVASC QUAL, V6, P543, DOI 10.1161/CIRCOUTCOMES.111.000303; Scott PA, 2013, LANCET NEUROL, V12, P139, DOI 10.1016/S1474-4422(12)70311-3; Seshadri S, 2007, LANCET NEUROL, V6, P1106, DOI 10.1016/S1474-4422(07)70291-0; Singer OC, 2012, CEREBROVASC DIS, V33, P316, DOI 10.1159/000335816; Trapl M, 2007, STROKE, V38, P2948, DOI 10.1161/STROKEAHA.107.483933; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Wiborg A, 2003, STROKE, V34, P2951, DOI 10.1161/01.STR.0000099125.30731.97	36	41	43	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					48	56		10.1016/S1474-4422(14)70286-8	http://dx.doi.org/10.1016/S1474-4422(14)70286-8			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25435129				2022-12-18	WOS:000346885300025
J	Lachance, DH; Lennon, VA; Pittock, SJ; Tracy, JA; Krecke, KN; Amrami, KK; Poeschla, EM; Orenstein, R; Scheithauer, BW; Sejvar, JJ; Holzbauer, S; DeVries, AS; Dyck, PJB				Lachance, Daniel H.; Lennon, Vanda A.; Pittock, Sean J.; Tracy, Jennifer A.; Krecke, Karl N.; Amrami, Kimberly K.; Poeschla, Eric M.; Orenstein, Robert; Scheithauer, Bernd W.; Sejvar, James J.; Holzbauer, Stacy; DeVries, Aaron S.; Dyck, P. James B.			An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study	LANCET NEUROLOGY			English	Article							MYELIN BASIC-PROTEIN; ENDOGENOUS RETROVIRUS; NERVOUS-TISSUE; ENCEPHALOMYELITIS; COMPLICATIONS; INFECTION; SCALE	Background Between November, 2006, and May, 2008, a subacute neurological syndrome affected workers from two swine abattoirs in Minnesota and Indiana who had occupational exposure to aerosolised porcine brain. We aimed to describe the pathogenic and immunological characteristics of this illness. Methods All patients from two abattoirs who presented or were referred to the Mayo Clinic (Rochester, MN, USA) with neurological symptoms were included. We recorded details of exposure to aerosolised brain tissue and did comprehensive neurological, laboratory, neuroimaging, electrophysiological, pathological, and autoimmune serological assessments. Healthy controls were recruited from the community and from workers at the plant in Minnesota. Findings 24 patients were identified (21 from Minnesota, three from Indiana). The shortest duration from first exposure to symptom onset was 4 weeks. No infectious agent that could trigger disease was identified. All patients developed polyradiculoneuropathy, which was usually sensory predominant and painful. Two patients had initial CNS manifestations: transverse myelitis and meningoencephalitis. Nerve conduction studies localised abnormalities to the most proximal and distal nerve segments. Quantitative sensory and autonomic testing revealed involvement of large and small sensory fibres and sweat fibres. MRI showed prominent abnormalities of roots and ganglia. Nerve biopsies identified mild demyelination, axonal degeneration, and perivascular inflammation. Protein concentrations were high in the CSF of 18 (86%) of 21 patients. Sera from all patients and 29 (34%) of 85 unaffected workplace controls (but none of 178 community controls) had a distinctive neural-reactive IgG; 75% of patients' sera contained an IgG specific to myelin basic protein. Seropositivity correlated directly with exposure risk in patients and controls. 17 patients required immunomodulatory therapies, six improved spontaneously, and one was lost to follow-up after exposure stopped. Interpretation The neurological disorder described is autoimmune in origin and is related to occupational exposure to multiple aerosolised porcine brain tissue antigens. The pattern of nerve involvement suggests vulnerability of nerve roots and terminals where the blood-nerve barrier is most permeable.	[Lachance, Daniel H.; Lennon, Vanda A.; Pittock, Sean J.; Tracy, Jennifer A.; Dyck, P. James B.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Lachance, Daniel H.; Lennon, Vanda A.; Pittock, Sean J.; Scheithauer, Bernd W.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Lennon, Vanda A.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Krecke, Karl N.; Amrami, Kimberly K.] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA; [Poeschla, Eric M.] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA; [Poeschla, Eric M.; Orenstein, Robert] Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA; [Holzbauer, Stacy; DeVries, Aaron S.] Minnesota Dept Hlth, St Paul, MN USA; [Sejvar, James J.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA; [Holzbauer, Stacy] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Dyck, PJB (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	dyck.pjames@mayo.edu		DeVries, Aaron/0000-0001-9211-0722	Centers for Disease Control and Prevention; Minnesota Department of Health; Mayo Clinic Foundation	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Minnesota Department of Health; Mayo Clinic Foundation	The Emerging Infections Program, Centers for Disease Control and Prevention, provided funding in part for A S DeVries. We thank R Schindler, B Larson, T Johnson, and C Dube (Austin Medical Center, Austin, MN, USA), P Reibold (Lafayette, IN, USA), and D Josephson (Indianapolis, IN, USA) for identification and referral of patients. We thank C Bower and medical staff from the Minnesota pork abattoir for their dedication to the patients. We thank C Hidalgo and the interpreter staff at Austin Medical Center and Mayo Clinic (Rochester, MN, USA); R Lynfield, State Epidemiologist (Minnesota Department of Health); Mayo Clinic staff S M Jenkins (Biomedical Statistics and Informatics), and M Peretz and D Saenz (Molecular Medicine) for assistance with porcine endogenous retrovirus PCR detection; and J E Norell and J K Engelstad (Peripheral Nerve Center, Mayo Clinic) and S T Eisenman and T J Kryzer (Neuroimmunology Laboratory, Mayo Clinic), for assistance with serological investigations. J F Poduslo, P Low, R D Fealey, and R D Brown provided valuable insight and intellectual contributions.; Funding Mayo Clinic Foundation; Minnesota Department of Health; Centers for Disease Control and Prevention.	Bach JF, 2005, J AUTOIMMUN, V25, P74, DOI 10.1016/j.jaut.2005.09.024; BURNET FM, 1967, MED J AUSTRALIA, V2, P1067; Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P122; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; DYCK PJ, 1980, ANN NEUROL, V8, P590, DOI 10.1002/ana.410080608; DYCK PJ, 1993, NEUROLOGY, V43, P1500, DOI 10.1212/WNL.43.8.1500; DYCK PJ, 1978, ANN NEUROL, V4, P502, DOI 10.1002/ana.410040605; FEALEY RD, 1989, MAYO CLIN PROC, V64, P617, DOI 10.1016/S0025-6196(12)65338-5; FENICHEL GM, 1982, ANN NEUROL, V12, P119, DOI 10.1002/ana.410120202; Gamaleia N, 1887, ANN I PASTEUR PARIS, V1, P63; HEMACHUDHA T, 1987, NEUROLOGY, V37, P550, DOI 10.1212/WNL.37.4.550; HEMACHUDHA T, 1987, NEW ENGL J MED, V316, P369, DOI 10.1056/NEJM198702123160703; KABAT EA, 1946, SCIENCE, V104, P362, DOI 10.1126/science.104.2703.362; Kraichely RE, 2010, DIGEST DIS SCI, V55, P307, DOI 10.1007/s10620-009-0838-9; Lachance DH, 2008, NEUROLOGY, V71, P153; Lachance DH, 2008, NEUROIMMUNOLOGY IN CLINICAL PRACTICE, P210; LAUGHLIN R, 2006, NEUROLOGY, V73, P39; LOW PA, 1993, MAYO CLIN PROC, V68, P748, DOI 10.1016/S0025-6196(12)60631-4; McFadzean A, 1952, B HONG KONG CHINESE, V4, P36; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Paton NI, 1999, LANCET, V354, P1253, DOI 10.1016/S0140-6736(99)04379-2; Pina-Oviedo S, 2008, ADV ANAT PATHOL, V15, P147, DOI 10.1097/PAP.0b013e31816f8519; Pittock SJ, 2006, MAYO CLIN PROC, V81, P1207, DOI 10.4065/81.9.1207; Pittock SJ, 2004, ANN NEUROL, V56, P715, DOI 10.1002/ana.20269; Rivers TM, 1935, J EXP MED, V61, P689, DOI 10.1084/jem.61.5.689; Sanchez-Ruiz M, 2008, J IMMUNOL, V180, P8421, DOI 10.4049/jimmunol.180.12.8421; WAKSMAN BH, 1955, J EXP MED, V102, P213, DOI 10.1084/jem.102.2.213	28	41	44	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					55	66		10.1016/S1474-4422(09)70296-0	http://dx.doi.org/10.1016/S1474-4422(09)70296-0			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	19945916				2022-12-18	WOS:000273199700024
J	DeVeber, G; Kirkham, F				DeVeber, Gabrielle; Kirkham, Fenella			Guidelines for the treatment and prevention of stroke in children	LANCET NEUROLOGY			English	Editorial Material							ISCHEMIC-STROKE; PEDIATRIC STROKE		[DeVeber, Gabrielle] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [Kirkham, Fenella] UCL Inst Child Hlth, London, England	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of London; University College London	DeVeber, G (corresponding author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	f.kirkham@ich.ucl.ac.uk	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958; /0000-0002-9584-0576				Bernard TJ, 2008, ANN NEUROL, V63, P679, DOI 10.1002/ana.21406; Golomb MR, 2006, NEUROLOGY, V67, P2053, DOI 10.1212/01.wnl.0000247281.98094.e2; Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Janjua N, 2007, STROKE, V38, P1850, DOI 10.1161/STROKEAHA.106.473983; Kirton A, 2008, LANCET NEUROL, V7, P507, DOI 10.1016/S1474-4422(08)70096-6; Kuhle S, 2006, STROKE, V37, P116, DOI 10.1161/01.STR.0000195044.44442.e0; McCarville MB, 2008, PEDIATR BLOOD CANCER, V50, P818, DOI 10.1002/pbc.21430; Monagle P, 2008, CHEST, V133, p887S, DOI 10.1378/chest.08-0762; National Collaborating Centre for Chronic Conditions, STROK NAT CLIN GUID; *NHS SICKL CELL TH, 2008, TRANSCR DOPPL SCANN; *NHS SICKL CELL TH, 2006, SICKL CELL DIS CHILD; *PAED STROK WORK G, 2004, STROK CHILDH CLIN GU; Roach ES, 2008, STROKE, V39, P2644, DOI 10.1161/STROKEAHA.108.189696; Zahuranec DB, 2005, STROKE, V36, P1825, DOI 10.1161/01.STR.0000177882.08802.3c; 2008, HANSARD REPORT PARLI	15	41	40	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					983	985		10.1016/S1474-4422(08)70231-X	http://dx.doi.org/10.1016/S1474-4422(08)70231-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP	18940691				2022-12-18	WOS:000260745800006
J	Hayward, P				Hayward, Peter			Traumatic brain injury: the signature of modern conflicts	LANCET NEUROLOGY			English	Editorial Material												peterhayward@yahoo.com							0	41	44	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2008	7	3					200	201		10.1016/S1474-4422(08)70032-2	http://dx.doi.org/10.1016/S1474-4422(08)70032-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	268KZ	18275921				2022-12-18	WOS:000253580000008
J	Touze, E; Rothwell, PM				Touze, Emmanuel; Rothwell, Peter M.			Heritability of ischaemic stroke in women compared with men: a genetic epidemiological study	LANCET NEUROLOGY			English	Article							PARENTAL CARDIOVASCULAR-DISEASE; MATERNAL TRANSMISSION; FAMILY-HISTORY; FETAL ORIGINS; CASE-FATALITY; RISK; MORTALITY	Background Ischaemic stroke is partly heritable. However, although the genetic and non-genetic factors responsible could be sex-specific, interactions between the sex of the parent affected and the sex of the proband or affected siblings are unknown. We sought to assess the relation between the sex and phenotype of affected probands and the sex of affected first-degree relatives. Methods We determined the prevalence of history of stroke in the mother, father, and other first-degree relatives in female and male probands with ischaemic stroke or transient ischaemic attack in the population-based Oxford Vascular Study (OXVASC). We validated our findings using unpublished individual patient data from two independent Oxford studies. Findings In OXVASC, detailed family history was available in 806 (93%) probands. Female probands were more likely than males to have at least one affected first-degree relative (146/423 vs 104/383; OR 1.4, 95% CI 1.1-2.0, p=0.02) due entirely to an excess of affected female relatives in female probands (female relative vs male relative OR=1.7, 1.3-2.4 p=0.0004; female only vs male only OR=2.1, 1.4-3.1, p=0.0001). Maternal stroke was more common than paternal stroke in female probands (OR=1.8, 1.2-2.7, p=0.001) but not in males (OR=1.1, 0.7-1.7, p=0.38), and female probands were more likely than males to have an affected sister (OR=3.1, 1.5-6.7, p=0.004) but not an affected brother (OR=1.1, 0.6-2.1, p=0.80). Ages at first stroke were also correlated within families among affected females (r=0.36, p=0.004) but not among affected males, such that the excess of affected female relatives of female probands was greatest when the difference in age at first stroke was less than 5 years (OR=3.7, 1.6-8.6, p=0.0007) and fell as the age difference increased (p for trend=0.004). These findings were independent of traditional risk factors and stroke subtype. Data from the other Oxford studies confirmed the excess maternal history of stroke in female probands (OR=2.3, 1.5-3.8, p<0.00001) and the lack in males (OR=1.0, 0.7-1.4, p=0.58). Interpretation Heritability of ischaemic stroke is greater in women than in men, with an excess of affected mothers and affected sisters in female probands independent of traditional vascular risk factors, which could be explained by sex-specific genetic, epigenetic, or non-genetic mechanisms.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211; Touze, Emmanuel/0000-0002-7254-2162	MRC [G0500987] Funding Source: UKRI; Medical Research Council [G0500987] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Armitage P., 2002, STAT METHODS MED RES; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Barker DJP, 2003, STROKE, V34, P1598, DOI 10.1161/01.STR.0000077257.27430.7E; Bushnell CD, 2006, STROKE, V37, P2387, DOI 10.1161/01.STR.0000236053.37695.15; Cameron NM, 2005, NEUROSCI BIOBEHAV R, V29, P843, DOI 10.1016/j.neubiorev.2005.03.022; Chang ET, 2006, JNCI-J NATL CANCER I, V98, P61, DOI 10.1093/jnci/djj005; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; DeStefano AL, 2001, CLIN GENET, V60, P13, DOI 10.1034/j.1399-0004.2001.600103.x; Diggle P., 2002, ANAL LONGITUDINAL DA; Drake AJ, 2004, J ENDOCRINOL, V180, P1, DOI 10.1677/joe.0.1800001; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Flossmann E, 2005, STROKE, V36, P830, DOI 10.1161/01.STR.0000158920.67013.53; Flossmann E, 2005, CEREBROVASC DIS, V19, P1, DOI 10.1159/000081905; Flossmann E, 2004, STROKE, V35, P212, DOI 10.1161/01.STR.0000107187.84390.AA; HANKEY GJ, 1991, LANCET, V337, P335, DOI 10.1016/0140-6736(91)90953-M; Harding JE, 2001, INT J EPIDEMIOL, V30, P15, DOI 10.1093/ije/30.1.15; Hassan A, 2000, BRAIN, V123, P1784, DOI 10.1093/brain/123.9.1784; Hopper JL, 2005, LANCET, V366, P1397, DOI 10.1016/S0140-6736(05)67570-8; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Kantarci OH, 2006, NEUROLOGY, V67, P305, DOI 10.1212/01.wnl.0000225070.13682.11; Karter AJ, 1999, DIABETES CARE, V22, P938, DOI 10.2337/diacare.22.6.938; Kinra S, 2003, HEART, V89, P834, DOI 10.1136/heart.89.8.834; Kovtun IV, 2000, HUM MOL GENET, V9, P2767, DOI 10.1093/hmg/9.18.2767; Lloyd-Jones DM, 2004, JAMA-J AM MED ASSOC, V291, P2204, DOI 10.1001/jama.291.18.2204; Murabito JM, 2004, ANN INTERN MED, V140, P434, DOI 10.7326/0003-4819-140-6-200403160-00010; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Pezzini A, 2005, STROKE, V36, P533, DOI 10.1161/01.STR.0000155741.31499.c2; Poulsen P, 2001, DIABETOLOGIA, V44, P537, DOI 10.1007/s001250051659; Rosand J, 2003, STROKE, V34, P2512, DOI 10.1161/01.STR.0000091844.02111.07; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; Schulz UGR, 2004, STROKE, V35, P819, DOI 10.1161/01.STR.0000121646.23955.0f; Singhal A, 2004, LANCET, V363, P1642, DOI 10.1016/S0140-6736(04)16210-7; Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550; Szolnoki Z, 2002, J NEUROL, V249, P1391, DOI 10.1007/s00415-002-0848-4; Thorand B, 2001, INT J EPIDEMIOL, V30, P1084, DOI 10.1093/ije/30.5.1084; Vijg J, 2005, ANNU REV MED, V56, P193, DOI 10.1146/annurev.med.56.082103.104617; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Worrall BB, 2006, STROKE, V37, P1955, DOI 10.1161/01.STR.0000234048.04053.39	40	41	44	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					125	133		10.1016/S1474-4422(06)70683-4	http://dx.doi.org/10.1016/S1474-4422(06)70683-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG	17239799				2022-12-18	WOS:000243795300015
J	Hogan, DB; Goldlist, B; Naglie, G; Patterson, C				Hogan, DB; Goldlist, B; Naglie, G; Patterson, C			Comparison studies of cholinesterase inhibitors for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; CONSORT STATEMENT; DONEPEZIL; RIVASTIGMINE; GALANTAMINE; GUIDELINES; 12-WEEK; DRUGS	There is uncertainty about which of the three available cholinesterase inhibitors should be prescribed as initial therapy for patients with Alzheimer's disease. We have assessed the reports of three trials that directly compared cholinesterase inhibitors. They were reviewed for sponsorship, authorship, main results, proportions of individuals who achieved maximum daily doses of the study cholinesterase inhibitors, and how the studies dealt with items on the CONSORT checklist for randomised controlled trials. All studies were funded by pharmaceutical companies, coauthored by their employees, and reported results that favoured the sponsor's product. In two studies, a significantly lower proportion of people achieved the target maximum daily dose for the comparator drug than for the sponsor's product. Between 27% and 55% of CONSORT items per study were rated as inadequately reported. The methodological limitations of these studies reduce our confidence in the validity of the conclusions drawn in the published reports.	Univ Calgary, Div Geriatr Med, Calgary, AB, Canada; Univ Toronto, Toronto Rehabil Inst, Geriatr Program, Univ Hlth Network,Div Gen Internal Med, Toronto, ON, Canada; Univ Toronto, Dept Med & Hlth Policy, Toronto, ON, Canada; Univ Toronto, Dept Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Div Geriatr Med, Toronto, ON, Canada; McMaster Univ, Div Geriatr Med, Hamilton, ON, Canada	University of Calgary; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University of Toronto; University of Toronto; McMaster University	Hogan, DB (corresponding author), Hlth Sci Ctr, Calgary, AB T2N 4N1, Canada.	dhogan@ucalgary.ca	Hogan, David Bryan/I-4360-2013	Hogan, David Bryan/0000-0002-9462-5460; Naglie, Gary/0000-0002-6274-0894				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bentham P, 2004, LANCET, V363, P2105; Bhandari M, 2004, CAN MED ASSOC J, V170, P477; Buchkowsky SS, 2004, ANN PHARMACOTHER, V38, P579, DOI 10.1345/aph.1D267; *CAN PHARM ASS, 2004, 2004 COMP PHARM SPEC, P171; Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Hirsch L, 2004, CAN MED ASSOC J, V170, P481; Hogan DB, 2002, CAN J NEUROL SCI, V29, P306, DOI 10.1017/S031716710000216X; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jones RW, 2004, INT J GERIATR PSYCH, V19, P58, DOI 10.1002/gps.1038; Lanctot KL, 2004, CAN MED ASSOC J, V170, P1372, DOI 10.1503/cmaj.1040150; LANCTOT KL, 2004, CMAJ, V170, P1374; Landow L, 2000, ANESTHESIOLOGY, V92, P1814, DOI 10.1097/00000542-200006000-00042; Levy R, 1997, ALZ DIS ASSOC DIS, V11, P33; Lewis SC, 2004, J NEUROL NEUROSUR PS, V75, P181, DOI 10.1136/jnnp.2003.025833; MANN H, J LIND LIB WHY COMP; McAlister FA, 1999, JAMA-J AM MED ASSOC, V282, P1371, DOI 10.1001/jama.282.14.1371; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; *NAT I CLIN EXC, 2001, GUID US DON RIV GAL; Reed CR, 1999, ACAD EMERG MED, V6, P833, DOI 10.1111/j.1553-2712.1999.tb01217.x; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P30; Scarpini E, 2003, LANCET NEUROL, V2, P539, DOI 10.1016/S1474-4422(03)00502-7; Sharma JC, 2002, INT J CLIN PRACT, V56, P414; Soares HP, 2004, BRIT MED J, V328, P22, DOI 10.1136/bmj.328.7430.22; SPILKER B, 1991, GUIDE CLIN TRIALS, P369; Thomas A, 2001, CLIN NEUROPHARMACOL, V24, P31, DOI 10.1097/00002826-200101000-00007; Wilcock G, 2003, DRUG AGING, V20, P777, DOI 10.2165/00002512-200320100-00006; Wilkinson DG, 2004, DRUG AGING, V21, P453, DOI 10.2165/00002512-200421070-00004; Wilkinson DG, 2002, INT J CLIN PRACT, V56, P441; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489	33	41	45	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2004	3	10					622	626		10.1016/S1474-4422(04)00883-X	http://dx.doi.org/10.1016/S1474-4422(04)00883-X			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	857SC	15380159				2022-12-18	WOS:000224137600016
J	Schwammenthal, Y; Tanne, D				Schwammenthal, Y; Tanne, D			Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials	LANCET NEUROLOGY			English	Review							CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; PLASMA HOMOCYSTEINE; CARDIOVASCULAR-DISEASE; RISK FACTOR; MYOCARDIAL-INFARCTION; POSTMENOPAUSAL WOMEN; VASCULAR-DISEASE; ISCHEMIC-STROKE	Background Homocysteine is an amino acid, the metabolism of which is linked to that of several vitamins-especially folic acid, B6 and B12. A high concentration of homocysteine in the plasma is linked to vascular diseased, including stroke. Concentrations of homocysteine, can be inexpensively and safely lowered by treatment with a combination of folate vitamin B12, and vitamin B6. However, whether the association between high plasma concentrations of homocysteine and vascular disease is causal is unclear. Recent developments Two studies have assessed the relation between dietary or supplementary vitamin intake on the risk of stroke. In a prospective observational study of 43,732 healthy men, there was an inverse relation between dietary folate intake band the risk of ischaemic stroke. The Vitamin Intervention for Stroke Prevention study (VISP) was the first large-scale randomised interventional study that investigated the lowering of homocysteine concentrations with B vitamins in patients with ischaemic stroke. There was an association between baseline homocysteine concentrations and vascular risk in this trial. Plasma concentrations of homocysteine were only modestly reduced by high-dose versus low-dose formulation, and there was no treatment effect on recurrent stroke, coronary events. or deaths. Limitations of VISP included that only patients with mild increases in baseline homocysteine concentrations were studied, only modest reductions of homocysteine concentrations were achieved, and follow up was short. In addition, fortification of food with folate and treatment of low vitamin-B12 concentrations may have masked the-effect of treatment on stroke risk. What next? When exposure can be safely-assigned at random in the case of B-vitamin therapy, randomised trials should be the standard proof to determine the effect of therapy. The results of the first randomised clinical trial of. B vitamins for secondary prevention of stroke were neutral. Larger trials with longer follow-up, selection of patients with higher plasma concentrations of homocysteine, and systematic assessment of cognitive functions and dementia are needed. In the meantime, homocysteine-lowering treatment thats cheap and well-tolerated should be considered a rational approach in patients at high risk of stroke and high concentrations of homocysteine.	Chaim Sheba Med Ctr, Dept Neurol, Stroke Unit, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Tanne, D (corresponding author), Chaim Sheba Med Ctr, Dept Neurol, Stroke Unit, IL-52621 Tel Hashomer, Israel.	tanne@post.tau.ac.il	Tanne, David/F-2560-2010	Tanne, David/0000-0002-6699-2220				Anderson JL, 2004, AM J MED, V116, P158, DOI 10.1016/j.amjmed.2003.10.024; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Bautista LE, 2002, J CLIN EPIDEMIOL, V55, P882, DOI 10.1016/S0895-4356(02)00434-1; Bosch J, 2002, BMJ-BRIT MED J, V324, P699, DOI 10.1136/bmj.324.7339.699; Carmel Ralph, 2003, Hematology Am Soc Hematol Educ Program, P62; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Collins R, 2004, LANCET, V363, P757; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Faraci FM, 2004, STROKE, V35, P345, DOI 10.1161/01.STR.0000115161.10646.67; Ford ES, 2002, INT J EPIDEMIOL, V31, P59, DOI 10.1093/ije/31.1.59; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hackam DG, 2000, AM J HYPERTENS, V13, P105, DOI 10.1016/S0895-7061(99)00180-6; He K, 2004, STROKE, V35, P169, DOI 10.1161/01.STR.0000106762.55994.86; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Prins ND, 2002, NEUROLOGY, V59, P1375, DOI 10.1212/01.WNL.0000032494.05619.93; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Tanne D, 2003, STROKE, V34, P632, DOI 10.1161/01.STR.0000060203.58958.35; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; UELAND PM, 1989, J LAB CLIN MED, V114, P473; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Welch GN, 1997, ANN NY ACAD SCI, V811, P48, DOI 10.1111/j.1749-6632.1997.tb51988.x	29	41	48	2	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2004	3	8					493	495		10.1016/S1474-4422(04)00826-9	http://dx.doi.org/10.1016/S1474-4422(04)00826-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	842OD	15261610				2022-12-18	WOS:000223012800021
J	Levy, M; Fujihara, K; Palace, J				Levy, Michael; Fujihara, Kazuo; Palace, Jacqueline			New therapies for neuromyelitis optica spectrum disorder	LANCET NEUROLOGY			English	Review							INTERLEUKIN-6 RECEPTOR BLOCKADE; DOUBLE-BLIND; CLINICAL-TRIALS; IGG PREDICTS; OPEN-LABEL; EFFICACY; RITUXIMAB; SAFETY; MULTICENTER; SATRALIZUMAB	Background Neuromyelitis optica spectrum disorder is an autoimmune disease of the CNS that primarily affects the optic nerves and spinal cord. Most patients have serum antibodies targeting the aquaporin-4 water channel expressed on the end-feet of astrocytes. Although the prevalence of neuromyelitis optica spectrum disorder is limited to around 1-2 people per 100 000, severe immune-mediated attacks can quickly lead to blindness and paralysis if undiagnosed and untreated. However, diagnosis is straightforward when the highly specific serum aquaporin-4 antibodies are detected with cell-based assays. Recent developments Four randomised controlled trials have tested the efficacy of three new therapies (eculizumab, satralizumab, and inebilizumab) for patients with neuromyelitis optica spectrum disorder that all showed a benefit in preventing future attacks. These therapies have different targets within the immune pathogenic process, and the four trials have similarities and differences that mean they might change the therapeutic landscape for people with neuromyelitis optica spectrum disorder in different ways. Efficacy, safety, tolerability, and practical considerations, including potential cost, differ for each drug and might affect the rate of use in real-world populations of patients with neuromyelitis optica spectrum disorder. Where next? Despite the rarity of neuromyelitis optica spectrum disorder, a relative abundance of preventive treatment options now exists. In the future, trials should focus on areas of unmet need, including aquaporin-4 seronegative disease, and on development of treatments for acute relapses and for recovery from autoimmune attacks in the CNS.	[Levy, Michael] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Levy, Michael] Harvard Med Sch, Boston, MA 02114 USA; [Fujihara, Kazuo] Fukushima Med Univ, Sch Med, Dept Multiple Sclerosis Therapeut, Koriyama, Fukushima, Japan; [Fujihara, Kazuo] Southern Tohoku Res Inst Neurosci, Koriyama, Fukushima, Japan; [Palace, Jacqueline] John Radcliffe Hosp, Dept Clin Neurol, Oxford, England; [Palace, Jacqueline] Univ Oxford, Oxford, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Fukushima Medical University; University of Oxford; University of Oxford	Levy, M (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Levy, M (corresponding author), Harvard Med Sch, Boston, MA 02114 USA.	mlevy11@mgh.harvard.edu			Biogen; Eisai; Mitsubishi Tanabe; Novartis; Chugai; Roche; Alexion; VielaBio; Teijin; Asahi Kasei Medical; Merck; Takeda; Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Welfare and Labor of Japan; National Health Services	Biogen(Biogen); Eisai(Eisai Co Ltd); Mitsubishi Tanabe(Mitsubishi Tanabe Pharma Corporation); Novartis(Novartis); Chugai; Roche(Roche Holding); Alexion; VielaBio; Teijin; Asahi Kasei Medical; Merck(Merck & Company); Takeda(Takeda Pharmaceutical Company Ltd); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Welfare and Labor of Japan(Ministry of Health, Labour and Welfare, Japan); National Health Services	ML received consulting fees from all three manufacturers involved in the trials discussed in this Rapid Review: Alexion, VielaBio, and Genentech/Roche/Chugai. In addition, ML has received consulting fees from Quest Diagnostics and UCB Pharmaceuticals. KF serves on scientific advisory boards for Biogen, Mitsubishi Tanabe, Novartis, Chugai, Alexion, VielaBio, and UCB; has received funding for travel and speaker honoraria from Biogen, Eisai, Mitsubishi Tanabe, Novartis, Chugai, Roche, Alexion, VielaBio, Teijin, Asahi Kasei Medical, Merck, and Takeda; and has received the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan. JP received consulting fees and is partly funded by highly specialised National Health Services to run a national congenital myasthenia service and a neuromyelitis service, has received support for scientific meetings and honoraria for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma and Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide ARGENX, UCB, and VielaBio, and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide, MedImmune, Bayer Schering, Genzyme, Chugai, and Alexion, UK MS society, Guthy Jackson Foundation, National Institute of Health Research, Oxford Health Services Research Committee, Medical Research Council, Grant for MS Innovation, John Fell Fund, and Myaware for research studies.	Agius MA, 2019, MULT SCLER J, V25, P235, DOI 10.1177/1352458517740641; Araki M, 2014, NEUROLOGY, V82, P1302, DOI 10.1212/WNL.0000000000000317; Ayzenberg I, 2013, JAMA NEUROL, V70, P394, DOI 10.1001/jamaneurol.2013.1246; Barros PO, 2016, CLIN EXP IMMUNOL, V183, P480, DOI 10.1111/cei.12733; Benecard, 2020, UPL APP TREAT RAR AU; Chihara N, 2011, P NATL ACAD SCI USA, V108, P3701, DOI 10.1073/pnas.1017385108; Cree BAC, 2019, LANCET, V394, P1352, DOI 10.1016/S0140-6736(19)31817-3; Cree BAC, 2016, MULT SCLER J, V22, P862, DOI 10.1177/1352458515620934; Damato V, 2016, JAMA NEUROL, V73, P1342, DOI 10.1001/jamaneurol.2016.1637; Dienz O, 2009, CLIN IMMUNOL, V130, P27, DOI 10.1016/j.clim.2008.08.018; Durozard P, 2020, ANN NEUROL, V87, P256, DOI 10.1002/ana.25648; Gao FL, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1261-2; George J., 2020, NMO GETS NEW DRUG; Heo YA, 2020, DRUGS, V80, P1477, DOI 10.1007/s40265-020-01380-2; Hinson SR, 2009, ARCH NEUROL-CHICAGO, V66, P1164, DOI 10.1001/archneurol.2009.188; Howard JF, 2017, LANCET NEUROL, V16, P976, DOI 10.1016/S1474-4422(17)30369-1; Jacob A, 2008, ARCH NEUROL-CHICAGO, V65, P1443, DOI 10.1001/archneur.65.11.noc80069; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Jurynczyk Maciej, 2019, Pract Neurol, V19, P187, DOI 10.1136/practneurol-2017-001787; Kessler RA, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000269; Kim SH, 2018, NEUROLOGY; Kim SH, 2015, JAMA NEUROL, V72, P989, DOI 10.1001/jamaneurol.2015.1276; Kimbrough DJ, 2012, MULT SCLER RELAT DIS, V1, P180, DOI 10.1016/j.msard.2012.06.002; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Levy M., 2019, MULT SCLER, V26, P515; Levy M, 2015, MULT SCLER RELAT DIS, V4, P512, DOI 10.1016/j.msard.2015.07.016; Levy M, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000005; Lewis AN, 2013, ECULIZUMAB SOLIRIS; Lucchinetti CF, 2002, BRAIN, V125, P1450, DOI 10.1093/brain/awf151; Matiello M, 2008, NEUROLOGY, V70, P2197, DOI 10.1212/01.wnl.0000303817.82134.da; Matsushita T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061835; Mealy MA, 2012, ARCH NEUROL-CHICAGO, V69, P1176, DOI 10.1001/archneurol.2012.314; Muppidi S, 2019, MUSCLE NERVE, V60, P14, DOI 10.1002/mus.26447; Narayan R, 2018, MULT SCLER RELAT DIS, V25, P66, DOI 10.1016/j.msard.2018.07.025; Nikoo Z, 2017, J NEUROL, V264, P2003, DOI 10.1007/s00415-017-8590-0; Oh J, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/460825; Paul F, 2018, EXPERT OPIN INV DRUG, V27, P265, DOI 10.1080/13543784.2018.1443077; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Pittock SJ, 2013, LANCET NEUROL, V12, P554, DOI 10.1016/S1474-4422(13)70076-0; Ringelstein M, 2015, JAMA NEUROL, V72, P756, DOI 10.1001/jamaneurol.2015.0533; Tahara M, 2020, LANCET NEUROL, V19, P298, DOI 10.1016/S1474-4422(20)30066-1; Takeshita Y, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000311; Traboulsee A, 2020, LANCET NEUROL, V19, P402, DOI 10.1016/S1474-4422(20)30078-8; Tradtrantip L, 2018, NEUROPHARMACOLOGY, V133, P345, DOI 10.1016/j.neuropharm.2018.02.002; Uzawa A, 2010, MULT SCLER J, V16, P1443, DOI 10.1177/1352458510379247; Weinshenker BG, 2006, ANN NEUROL, V59, P566, DOI 10.1002/ana.20770; Weinshenker BG, 2015, NEUROLOGY, V84, P1805, DOI 10.1212/WNL.0000000000001520; Wijnsma KL, 2019, CLIN PHARMACOKINET, V58, P859, DOI 10.1007/s40262-019-00742-8; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Wingerchuk DM, 2014, HAND CLINIC, V122, P581, DOI 10.1016/B978-0-444-52001-2.00025-X; Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747; Zhang C, 2020, LANCET NEUROL, V19, P391, DOI 10.1016/S1474-4422(20)30070-3	53	40	40	3	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					60	67		10.1016/S1474-4422(20)30392-6	http://dx.doi.org/10.1016/S1474-4422(20)30392-6			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33186537				2022-12-18	WOS:000600831400024
J	Ferreira, MLB; de Albuquerque, MDPM; de Brito, CAA; Franca, RFD; Moreira, AJP; Machado, MID; Melo, RP; Medialdea-Carrera, R; Mesquita, SD; Santos, ML; Mehta, R; Silva, RRE; Leonhard, SE; Ellul, M; Rosala-Hallas, A; Burnside, G; Turtle, L; Griffiths, MJ; Jacobs, BC; Bhojak, M; Willison, HJ; Pena, LJ; Pardo, CA; Ximenes, RAA; Martelli, CMT; Brown, DWG; Cordeiro, MT; Lant, S; Solomon, T				Brito Ferreira, Maria Lucia; Pessoa Militao de Albuquerque, Maria de Fatima; Antunes de Brito, Carlos Alexandre; de Oliveira Franca, Rafael Freitas; Porto Moreira, Alvaro Jose; de Morais Machado, Maria Iris; Melo, Roberta Paz; Medialdea-Carrera, Raquel; Mesquita, Solange Dornelas; Santos, Marcela Lopes; Mehta, Ravi; Ramos e Silva, Rafael; Leonhard, Sonja E.; Ellul, Mark; Rosala-Hallas, Anna; Burnside, Girvan; Turtle, Lance; Griffiths, Michael J.; Jacobs, Bart C.; Bhojak, Maneesh; Willison, Hugh J.; Pena, Lindomar Jose; Pardo, Carlos A.; Ximenes, Ricardo A. A.; Turchi Martelli, Celina Maria; Brown, David W. G.; Cordeiro, Marli Tenorio; Lant, Suzannah; Solomon, Tom			Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study	LANCET NEUROLOGY			English	Article							GUILLAIN-BARRE-SYNDROME; CASE DEFINITIONS; ENCEPHALITIS; DIAGNOSIS; GUIDELINES; COLLECTION; CRITERIA; DENGUE; STATE	Background Since 2015, the arthropod-borne viruses (arboviruses) Zika and chikungunya have spread across the Americas causing outbreaks, accompanied by increases in immune-mediated and infectious neurological disease. The spectrum of neurological manifestations linked to these viruses, and the importance of dual infection, are not known fully. We aimed to investigate whether neurological presentations differed according to the infecting arbovirus, and whether patients with dual infection had a different disease spectrum or severity. Methods We report a prospective observational study done during epidemics of Zika and chikungunya viruses in Recife, Pernambuco, a dengue-endemic area of Brazil. We recruited adults aged 18 years or older referred to Hospital da Restauracao, a secondary-level and tertiary-level hospital, with suspected acute neurological disease and a history of suspected arboviral infection. We looked for evidence of Zika, chikungunya, or dengue infection by viral RNA or specific IgM antibodies in serum or CSF. We grouped patients according to their arbovirus laboratory diagnosis and then compared demographic and clinical characteristics. Findings Between Dec 4, 2014, and Dec 4, 2016, 1410 patients were admitted to the hospital neurology service; 201 (14%) had symptoms consistent with arbovirus infection and sufficient samples for diagnostic testing and were included in the study. The median age was 48 years (IQR 34-60), and 106 (53%) were women. 148 (74%) of 201 patients had laboratory evidence of arboviral infection. 98 (49%) of them had a single viral infection (41 [20%] had Zika, 55 [27%] had chikungunya, and two [1%] had dengue infection), whereas 50 (25%) had evidence of dual infection, mostly with Zika and chikungunya viruses (46 [23%] patients). Patients positive for arbovirus infection presented with a broad range of CNS and peripheral nervous system (PNS) disease. Chikungunya infection was more often associated with CNS disease (26 [47%] of 55 patients with chikungunya infection vs six [15%] of 41 with Zika infection; p=0.0008), especially myelitis (12 [22%] patients). Zika infection was more often associated with PNS disease (26 [63%] of 41 patients with Zika infection vs nine [16%] of 55 with chikungunya infection; p=0.0001), particularly Guillain-Barre syndrome (25 [61%] patients). Patients with Guillain-Barre syndrome who had Zika and chikungunya dual infection had more aggressive disease, requiring intensive care support and longer hospital stays, than those with mono-infection (median 24 days [IQR 20-30] vs 17 days [10-20]; p=0.0028). Eight (17%) of 46 patients with Zika and chikungunya dual infection had a stroke or transient ischaemic attack, compared with five (6%) of 96 patients with Zika or chikungunya mono-infection (p=0.047). Interpretation There is a wide and overlapping spectrum of neurological manifestations caused by Zika or chikungunya mono-infection and by dual infections. The possible increased risk of acute cerebrovascular disease in patients with dual infection merits further investigation.	[Brito Ferreira, Maria Lucia; Porto Moreira, Alvaro Jose; de Morais Machado, Maria Iris; Melo, Roberta Paz; Mesquita, Solange Dornelas; Ramos e Silva, Rafael] Hosp Restauracao, Dept Neurol, Recife, PE, Brazil; [Pessoa Militao de Albuquerque, Maria de Fatima; Santos, Marcela Lopes; Turchi Martelli, Celina Maria] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Dept Collect Hlth, Recife, PE, Brazil; [de Oliveira Franca, Rafael Freitas; Pena, Lindomar Jose; Cordeiro, Marli Tenorio] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil; [Antunes de Brito, Carlos Alexandre] Fed Univ Pemambuco, Dept Clin Med, Recife, PE, Brazil; [Ximenes, Ricardo A. A.] Fed Univ Pemambuco, Dept Trop Med, Recife, PE, Brazil; [Medialdea-Carrera, Raquel; Mehta, Ravi; Ellul, Mark; Turtle, Lance; Griffiths, Michael J.; Lant, Suzannah; Solomon, Tom] Univ Liverpool, Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Inst Infect Vet & Ecol Sci, Liverpool, Merseyside, England; [Leonhard, Sonja E.; Jacobs, Bart C.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Jacobs, Bart C.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Ellul, Mark; Bhojak, Maneesh; Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England; [Rosala-Hallas, Anna; Burnside, Girvan] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England; [Turtle, Lance; Solomon, Tom] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England; [Griffiths, Michael J.] Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England; [Willison, Hugh J.] Univ Glasgow, Dept Neurol, Glasgow, Lanark, Scotland; [Willison, Hugh J.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Pardo, Carlos A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Div Neuroimmunol & Neuroinfect Disorders, Baltimore, MD 21205 USA; [Brown, David W. G.] Publ Hlth England, Blood Borne Virus Unit, Virus Reference Dept, London, England; [Brown, David W. G.] Fundacao Oswaldo Cruz, Evandro Chagas Natl Infect Dis Inst, Flavivirus Reference Lab, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; University of Liverpool; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Walton Centre; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Alder Hey Children's NHS Foundation Trust; University of Glasgow; University of Glasgow; Johns Hopkins University; Public Health England; Fundacao Oswaldo Cruz	Solomon, T (corresponding author), Univ Liverpool, Inst Infect Vet & Ecol Sci, NIHR Protect Res Unit Emerging & Zoonot Infect, Liverpool L69 7BE, Merseyside, England.	tsolomon@liverpool.ac.uk	willison, hugh/HCI-7819-2022; Freitas de Oliveira Franca, Rafael/ABB-2376-2021; Jacobs, Bart/ABE-2210-2021; Ellul, Mark/HGU-9086-2022	Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Ellul, Mark/0000-0002-6115-8245; Leonhard, Sonja/0000-0003-4832-6926; Burnside, Girvan/0000-0001-7398-1346; Mehta, Ravi/0000-0001-8211-1721; Lant, Suzannah/0000-0003-0852-7803	Fundacao do Amparo a Ciencia e Tecnologia de Pernambuco (FACEPE); EU's Horizon 2020 research and innovation programme; National Institute for Health Research; MRC [MC_PC_15096, MC_PC_15101] Funding Source: UKRI	Fundacao do Amparo a Ciencia e Tecnologia de Pernambuco (FACEPE); EU's Horizon 2020 research and innovation programme; National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Fundacao do Amparo a Ciencia e Tecnologia de Pernambuco (FACEPE), EU's Horizon 2020 research and innovation programme, National Institute for Health Research.	Acevedo Nathalie, 2017, Front Microbiol, V8, P42, DOI 10.3389/fmicb.2017.00042; Acosta-Ampudia Y, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00116; Barnes G, 2002, NEUROLOGY, V59, P499, DOI 10.1212/wnl.59.4.499; Benjamin LA, 2012, LANCET NEUROL, V11, P878, DOI 10.1016/S1474-4422(12)70205-3; Ferreira MLB, 2017, AM J TROP MED HYG, V97, P1405, DOI 10.4269/ajtmh.17-0106; Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6; Cassidy H, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02677; Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638; Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001; de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401; Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285; Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726; Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X; Hsu CH, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007084; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Kelly MJ, 2012, J INFECT DIS, V205, P106, DOI 10.1093/infdis/jir707; Kirkwood B., 2003, ESSENTIAL MED STAT; Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Lannuzel A, 2019, NEUROLOGY, V92, pE2406, DOI 10.1212/WNL.0000000000007536; Li HM, 2018, CAN MED ASSOC J, V190, pE285, DOI 10.1503/cmaj.170994; Magalhaes T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006055; Mallewa M, 2013, LANCET GLOB HEALTH, V1, pE153, DOI 10.1016/S2214-109X(13)70060-3; McGill F, 2016, J INFECTION, V72, P405, DOI 10.1016/j.jinf.2016.01.007; Mehta R, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1978; Mehta R, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006212; Montecillo-Aguado MR, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7239347; Munoz LS, 2017, J INFECT DIS, V216, pS897, DOI 10.1093/infdis/jix511; Nagel MA, 2017, J NEUROIMMUNOL, V308, P112, DOI 10.1016/j.jneuroim.2017.03.014; Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564; Rodrigues Faria Nuno, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.c97507e3e48efb946401755d468c28b2; Sejvar JJ, 2007, VACCINE, V25, P5771, DOI 10.1016/j.vaccine.2007.04.060; Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003; Silva MMO, 2019, CLIN INFECT DIS, V69, P1353, DOI 10.1093/cid/ciy1083; SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9; Solomon T, 2009, BRAINS DIS NERVOUS S, DOI 10.1093/med/9780198569381.003.0989; Stegmann-Planchard S, 2020, CLIN INFECT DIS, V70, P1233, DOI 10.1093/cid/ciz625; Styczynski AR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005869; Venkatesan A, 2013, CLIN INFECT DIS, V57, P1114, DOI 10.1093/cid/cit458	42	40	43	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					826	839		10.1016/S1474-4422(20)30232-5	http://dx.doi.org/10.1016/S1474-4422(20)30232-5			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949543	Green Published, Bronze			2022-12-18	WOS:000581119100020
J	Riva, N; Mora, G; Soraru, G; Lunetta, C; Ferraro, OE; Falzone, Y; Leocani, L; Fazio, R; Comola, M; Comi, G; Formaglio, F; Rossi, P; Clerici, M; Falzone, YM; Pozzi, L; Martinelli, D; Cerri, F; Diego, LI; Martinelli-Boneschi, F; Quattrini, A; Pieri, E; Marinou, K; Querin, G; Sansone, V; Maestri, E; Calvo, A; Chio, A				Riva, Nilo; Mora, Gabriele; Soraru, Gianni; Lunetta, Christian; Ferraro, Ottavia E.; Falzone, Yuri; Leocani, Letizia; Fazio, Raffaella; Comola, Mauro; Comi, Giancarlo; Formaglio, Fabio; Rossi, Paolo; Clerici, Marta; Falzone, Yuri Matteo; Pozzi, Laura; Martinelli, Daniele; Cerri, Federica; Diego, Lopez Ignazio; Martinelli-Boneschi, Filippo; Quattrini, Angelo; Pieri, Elisabetta; Marinou, Kalliopi; Querin, Giorgia; Sansone, Valeria; Maestri, Eleonora; Calvo, Andrea; Chio, Adriano		CANALS Study Grp	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial	LANCET NEUROLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MODIFIED ASHWORTH SCALE; MULTIPLE-SCLEROSIS; AMERICAN ACADEMY; CANNABIS; TETRAHYDROCANNABINOL; SUBCOMMITTEE; RELIABILITY; PROGRESSION; MANAGEMENT	Background Spasticity is a major determinant of disability and decline in quality of life in patients with motor neuron disease. Cannabinoids have been approved for symptomatic treatment of spasticity in multiple sclerosis. We investigated whether cannabinoids might also reduce spasticity in patients with motor neuron disease. Methods We did an investigator-initiated, randomised, double-blind, placebo-controlled, phase 2 clinical trial at four tertiary motor neuron disease centres in Italy. Eligible patients were aged 18-80 years; had possible, laboratory-supported probable, probable, or definite amyotrophic lateral sclerosis as defined by revised El Escorial criteria, or primary lateral sclerosis according to Pringle's criteria; had spasticity symptoms due to motor neuron disease for at least 3 months; had spasticity scores of 1 or greater in at least two muscle groups on the Modified Ashworth Scale; and were taking an antispasticity regimen that was maintained at a stable dose for 30 days before enrolment. Participants were assigned (1: 1) by an independent statistician via a computer-generated randomisation sequence to a standardised oromucosal spray (nabiximols) containing a defined combination of delta-9-tetrahydrocannabinol and cannabidiol (each 100 mu L actuation contained 2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol) or to placebo for 6 weeks. Participants self-titrated during the first 14 treatment days according to a predefined escalation scheme (maximum 12 actuations per 24 h), then maintained that dose for 4 weeks. The primary endpoint was the change in the score on the Modified Ashworth Scale, which was assessed at baseline and after 6 weeks. Safety and tolerability were also monitored. Participants, investigators, site personnel, and the study statistician were masked to treatment allocation. All randomised participants who received at least one dose of study drug were included in the analysis. This trial is registered with ClinicalTrials.gov, number NCT01776970. The trial is closed to new participants with follow-up completed. Findings Between Jan 19, 2013, and Dec 15, 2014, 60 participants were randomly assigned, and 59 participants were included in the final analysis (29 in the nabiximols group and 30 in the placebo group). Modified Ashworth Scale scores improved by a mean of 0.11 (SD 0.48) in the nabiximols group and deteriorated by a mean of 0.16 (0.47) in the placebo group (adjusted effect estimate -0.32 [95% CI -0.57 to -0.069]; p=0.013). Nabiximols was well tolerated, and no participants withdrew from the double-blind phase of the study. No serious adverse effects occurred. Interpretation In this proof-of-concept trial, nabiximols had a positive effect on spasticity symptoms in patients with motor neuron disease and had an acceptable safety and tolerability profile. These findings should be investigated further in larger clinical trials. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Riva, Nilo; Falzone, Yuri; Leocani, Letizia; Fazio, Raffaella; Comola, Mauro; Comi, Giancarlo] Univ Vita Salute San Raffaele, IRCCS, San Raffaele Sci Inst, Div Neurosci,Dept Neurol,Inst Expt Neurol, Milan, Italy; [Mora, Gabriele; Marinou, Kalliopi] IRCCS, Ist Clin Sci Maugeri, Amyotroph Lateral Sclerosis Ctr, Dept Neurorehabil, Milan, Italy; [Soraru, Gianni; Querin, Giorgia] Univ Padua, Neuromuscular Ctr, Dept Neurosci, Padua, Italy; [Lunetta, Christian; Sansone, Valeria; Maestri, Eleonora] Serena Onlus Fdn, NeuroMuscular Omnictr, Milan, Italy; [Ferraro, Ottavia E.] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Unit Biostat & Clin Epidemiol, Pavia, Italy; [Formaglio, Fabio; Rossi, Paolo; Clerici, Marta; Falzone, Yuri Matteo; Pozzi, Laura; Martinelli, Daniele; Cerri, Federica; Diego, Lopez Ignazio; Martinelli-Boneschi, Filippo; Quattrini, Angelo] Ist Sci San Raffaele, Inst Expt Neurol, Div Neurosci, Dept Neurol, Milan, Italy; [Pieri, Elisabetta] Independent Clin Res Consultant, Milan, Italy; [Calvo, Andrea; Chio, Adriano] Univ Turin, Rita Levi Montalcini Dept Neurosci, Amyotroph Lateral Sclerosis Ctr, Turin, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituti Clinici Scientifici Maugeri IRCCS; University of Padua; University of Pavia; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Turin	Comi, G (corresponding author), Ist Sci San Raffaele, Dept Neurol, Via Olgettina 48, I-20132 Milan, Italy.; Comi, G (corresponding author), Ist Sci San Raffaele, Inst Expt Neurol, Via Olgettina 48, I-20132 Milan, Italy.	comi.giancarlo@hsr.it	Sorarù, Gianni/AAB-8891-2019; Aktipi, Kalliopi Marinou/AAB-8246-2020; Cerri, Federica/AAO-1670-2020; Falzone, yuri matteo/GSD-2686-2022; Martinelli, Daniele/AAH-7641-2019; Leocani, Letizia/ABH-4703-2020; Formaglio, Fabio/ABC-1804-2020; Falzone, Yuri/AAC-2136-2022; Ferraro, Ottavia Eleonora/V-2090-2019; Mora, Gabriele/Z-2346-2019; CALVO, Andrea/K-4141-2016; Pozzi, Laura/AAN-2203-2020	Aktipi, Kalliopi Marinou/0000-0003-3384-0367; Martinelli, Daniele/0000-0001-6355-7947; Formaglio, Fabio/0000-0002-1070-8403; Ferraro, Ottavia Eleonora/0000-0002-4398-4885; Mora, Gabriele/0000-0002-8388-2373; CALVO, Andrea/0000-0002-5122-7243; Pozzi, Laura/0000-0003-2406-0713; Soraru, Gianni/0000-0001-9691-6328; Leocani, Letizia/0000-0001-9326-6753; martinelli boneschi, filippo/0000-0002-9955-1368; Chio, Adriano/0000-0001-9579-5341; falzone, yuri matteo/0000-0003-3233-1907	Italian Research Foundation for Amyotrophic Lateral Sclerosis	Italian Research Foundation for Amyotrophic Lateral Sclerosis	Italian Research Foundation for Amyotrophic Lateral Sclerosis.	Alexander SPH, 2016, PROG NEURO-PSYCHOPH, V64, P157, DOI 10.1016/j.pnpbp.2015.07.001; ALSUntangled Group, 2012, Amyotroph Lateral Scler, V13, P400, DOI 10.3109/17482968.2012.687264; Amtmann Dagmar, 2004, Am J Hosp Palliat Care, V21, P95, DOI 10.1177/104990910402100206; Ansari NN, 2012, NEUROREHABILITATION, V31, P215, DOI 10.3233/NRE-2012-0791; Ashworth NL, 2012, COCHRANE DB SYST REV, V2; Bethoux F, 2013, NEUROREHAB NEURAL RE, V27, P828, DOI 10.1177/1545968313496325; Bilsland LG, 2006, FASEB J, V20, P1003, DOI 10.1096/fj.05-4743fje; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Brettschneider J, 2013, COCHRANE DB SYST REV, V6; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Carter GT, 2010, AM J HOSP PALLIAT ME, V27, P347, DOI 10.1177/1049909110369531; Chio A, 2011, J NEUROL NEUROSUR PS, V82, P740, DOI 10.1136/jnnp.2010.235952; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; Collin C, 2010, NEUROL RES, V32, P451, DOI 10.1179/016164109X12590518685660; Drory VE, 2001, J NEUROL SCI, V191, P133, DOI 10.1016/S0022-510X(01)00610-4; Espejo-Porras F, 2018, AMYOTROPH LAT SCL FR, V19, P377, DOI 10.1080/21678421.2018.1425454; Koppel BS, 2014, NEUROLOGY, V82, P1556, DOI 10.1212/WNL.0000000000000363; Milinis K, 2018, ACTA NEUROL SCAND, V138, P47, DOI 10.1111/ane.12910; Miller RG, 2009, NEUROLOGY, V73, P1227, DOI 10.1212/WNL.0b013e3181bc01a4; Moreno-Martet M, 2014, CNS NEUROSCI THER, V20, P809, DOI 10.1111/cns.12262; Notcutt W, 2012, MULT SCLER J, V18, P219, DOI 10.1177/1352458511419700; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Otero-Romero S, 2016, MULT SCLER J, V22, P1386, DOI 10.1177/1352458516643600; Patti F, 2016, J NEUROL NEUROSUR PS, V87, P944, DOI 10.1136/jnnp-2015-312591; PRINGLE CE, 1992, BRAIN, V115, P495, DOI 10.1093/brain/115.2.495; Raman C, 2004, AMYOTROPH LATERAL SC, V5, P33, DOI 10.1080/14660820310016813; Russo E, 2006, MED HYPOTHESES, V66, P234, DOI 10.1016/j.mehy.2005.08.026; Shoemaker JL, 2007, J NEUROCHEM, V101, P87, DOI 10.1111/j.1471-4159.2006.04346.x; Tartaglia MC, 2007, ARCH NEUROL-CHICAGO, V64, P232, DOI 10.1001/archneur.64.2.232; Turner MR, 2004, NEUROBIOL DIS, V15, P601, DOI 10.1016/j.nbd.2003.12.012; Wade DT, 2010, MULT SCLER J, V16, P707, DOI 10.1177/1352458510367462; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Weber M, 2010, J NEUROL NEUROSUR PS, V81, P1135, DOI 10.1136/jnnp.2009.200642; Wright S, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-189; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zettl UK, 2016, THER ADV NEUROL DISO, V9, P9, DOI 10.1177/1756285615612659	36	40	42	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2019	18	2					155	164		10.1016/S1474-4422(18)30406-X	http://dx.doi.org/10.1016/S1474-4422(18)30406-X			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HI0TY	30554828				2022-12-18	WOS:000456158200010
J	Oliveria, SF; Rodriguez, RL; Bowers, D; Kantor, D; Hilliard, JD; Monari, EH; Scott, BM; Okun, MS; Foote, KD				Oliveria, Seth F.; Rodriguez, Ramon L.; Bowers, Dawn; Kantor, Daniel; Hilliard, Justin D.; Monari, Erin H.; Scott, Bonnie M.; Okun, Michael S.; Foote, Kelly D.			Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial	LANCET NEUROLOGY			English	Article							NUCLEUS	Background Efficacy in previous studies of surgical treatments of refractory multiple sclerosis tremor using lesioning or deep brain stimulation (DBS)has been variable. The aim of this study was to investigate the safety and efficacy of dual-lead thalamic DBS (one targeting the ventralis intermedius-ventralis oralis posterior nucleus border [the VIM lead] and one targeting the ventralis oralis anterior-ventralis oralis posterior border [the VO lead])for the treatment of multiple sclerosis tremor. Methods We did a single centre, single-blind, prospective, randomised pilot trial at the University of Florida Center for Movement Disorders and Neurorestoration clinic (Gainesville, FL, USA). We recruited adult patients with a clinical diagnosis of multiple sclerosis tremor refractory to previous medical therapy. Before surgery to implant both leads, we randomly assigned patients (1: 1)to receive 3 months of optimised single-lead DBS-either VIM or VO. We did the randomisation with a computer-generated sequence, using three blocks of four patients, and independent members of the Center did the assignment. Patients and all clinicians other than the DBS programming nurse were masked to the choice of lead. Patients underwent surgery 1 month after their baseline visit for implantation of the dual lead DBS system. A pulse generator and two extension cables were implanted in a second surgery 3-4 weeks later. Patients then received an initial 3-month period of continuous stimulation of either the VIM or VO lead followed by blinded safety assessment of their tremor with the Tolosa-Fahn-Marin Tremor Rating Scale (TRS)during optimised VIM or VO lead stimulation at the end of the 3 months. After this visit, both leads were activated in all patients for an additional 3 months, and optimally programmed during serial visits as dictated by a prespecified programming algorithm. At the 6-month follow-up visit, TRS score was measured, and mood and psychological batteries were administered under four stimulation conditions: VIM on, VO on, both on, and both off (the order of testing was chosen by a computer-generated random sequence, assigned by independent members of the centre, and enacted by an unmasked DBS programming nurse). Each of four stimulation settings were tested over 4 consecutive days, with stimulation settings held constant for at least 12 h before testing. The primary outcome was change in mean total TRS score at the 6-month postoperative assessment with both leads activated, compared with the preoperative baseline mean TRS score. Analysis was by intention to treat. Safety was analysed in all patients who received the surgical implantation except in one patient who discontinued before the safety assessment. This trial is registered with ClinicalTrials.gov, number NCT00954421. Findings Between Jan 16, 2007, and Dec 17, 2013, we enrolled 12 patients who were randomly assigned either to 3 initial months of VIM-only or VO-only stimulation. One patient from the VO-only group developed an infection necessitating DBS explantation, and was excluded from the assessment of the primary outcome. Compared with the mean baseline TRS score of 57.0 (SD 10.2), the mean score at 6 months decreased to 40.1 (17.6), -29.6% reduction; t=-0.28, p=0.03. Three of 11 patients did not respond to surgical intervention. One patient died suddenly 2 years after surgery, but this was judged to be unrelated to DBS implantation. Serious adverse events included a superficial wound infection in one patient that resolved with antibiotic therapy, and transient altered mental status and late multiple sclerosis exacerbation in another patient. The most common non-serious adverse events were headache and fatigue. Interpretation Dual lead thalamic DBS might be a safe and effective option for improving severe, refractory multiple sclerosis tremor. Larger studies are necessary to show whether this technique is widely applicable, safe in the long-term, and effective in treating multiple sclerosis tremor or other severe tremor disorders.	[Oliveria, Seth F.; Hilliard, Justin D.; Okun, Michael S.; Foote, Kelly D.] Univ Florida, Dept Neurosurg, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32610 USA; [Rodriguez, Ramon L.; Monari, Erin H.; Okun, Michael S.] Univ Florida, Dept Neurol, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32610 USA; [Bowers, Dawn; Scott, Bonnie M.] Univ Florida, Dept Clin & Hlth Psychol, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32610 USA; [Kantor, Daniel] Kantor Neurol, Coconut Creek, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Oliveria, SF (corresponding author), Univ Florida, Dept Neurosurg, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32610 USA.	seth.oliveria@neurosurgery.ufl.edu		Scott, Bonnie/0000-0002-4868-6238; Foote, Kelly/0000-0002-2436-4138; Hastings Monari, Erin/0000-0002-4075-3360	US National Institutes of Health; Cathy Donnellan, Albert E Einstein, and Birdie W Einstein Fund; William Merz Professorship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS052557] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cathy Donnellan, Albert E Einstein, and Birdie W Einstein Fund; William Merz Professorship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	US National Institutes of Health, the Cathy Donnellan, Albert E Einstein, and Birdie W Einstein Fund, and the William Merz Professorship.	Alusi SH, 2001, BRAIN, V124, P720, DOI 10.1093/brain/124.4.720; Diamond A, 2005, J NEUROL NEUROSUR PS, V76, P1188, DOI 10.1136/jnnp.2005.065334; Elble R, 2013, MOVEMENT DISORD, V28, P1793, DOI 10.1002/mds.25648; Foote KD, 2005, NEUROSURGERY, V56, P415, DOI 10.1227/01.NEU.0000147978.67424.42; Foote KD, 2006, NEUROSURGERY; Herzog J, 2007, BRAIN, V130, P1608, DOI 10.1093/brain/awm077; HIRAI T, 1983, BRAIN, V106, P1001, DOI 10.1093/brain/106.4.1001; Koch M, 2007, J NEUROL, V254, P133, DOI 10.1007/s00415-006-0296-7; Lim DA, 2007, STEREOT FUNCT NEUROS, V85, P144, DOI 10.1159/000099072; Lozano AM, 2000, ARCH MED RES, V31, P266, DOI 10.1016/S0188-4409(00)00081-3; Lyons KE, 2008, NEUROTHERAPEUTICS, V5, P331, DOI 10.1016/j.nurt.2008.01.004; Mehanna R, 2014, CEREBELLUM, V13, P425, DOI 10.1007/s12311-014-0552-9; Nandi D, 2004, J CLIN NEUROPHYSIOL, V21, P31, DOI 10.1097/00004691-200401000-00005; Schulder M, 2003, STEREOT FUNCT NEUROS, V80, P48, DOI 10.1159/000075160; Sudhyadhom A, 2009, NEUROIMAGE; Sudhyadhom Atchar, 2012, Open Neuroimag J, V6, P92, DOI 10.2174/1874440001206010092; Thevathasan W, 2011, J NEUROL NEUROSUR PS, V82, P419, DOI 10.1136/jnnp.2010.213900; Torres CV, 2010, NEUROSURGERY, V67, P646, DOI 10.1227/01.NEU.0000375506.18902.3E; Yamamoto T, 2004, J NEUROSURG, V101, P201, DOI 10.3171/jns.2004.101.2.0201; Yamamoto T, 2001, J NEUROSURG, V95, P1075, DOI 10.3171/jns.2001.95.6.1075; Yu H, 2009, STEREOT FUNCT NEUROS, V87, P309, DOI 10.1159/000230694	21	40	40	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2017	16	9					691	700		10.1016/S1474-4422(17)30166-7	http://dx.doi.org/10.1016/S1474-4422(17)30166-7			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FC8ZW	28642125				2022-12-18	WOS:000407131400010
J	Morbelli, S; Djekidel, M; Hesse, S; Pagani, M; Barthel, H				Morbelli, Silvia; Djekidel, Mehdi; Hesse, Swen; Pagani, Marco; Barthel, Henryk		EANM; SNMMI	Role of F-18-FDG-PET imaging in the diagnosis of autoimmune encephalitis	LANCET NEUROLOGY			English	Letter							PET; MRI		[Morbelli, Silvia] Univ Genoa, Deptartment Hlth Sci, Nucl Med, I-16132 Genoa, Italy; [Morbelli, Silvia] IRCCS Azienda Osped Univ San Martino IST, Genoa, Italy; [Djekidel, Mehdi] Qual Med Consulting, Hamden, CT USA; [Hesse, Swen; Barthel, Henryk] Univ Leipzig, Dept Nucl Med, Leipzig, Germany; [Pagani, Marco] CNR, Inst Cognit Sci & Technol, Rome, Italy; [Pagani, Marco] Karolinska Hosp, Dept Nucl Med, Stockholm, Sweden	University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Leipzig University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze e Tecnologie della Cognizione (ISTC-CNR); Karolinska Institutet; Karolinska University Hospital	Morbelli, S (corresponding author), Univ Genoa, Deptartment Hlth Sci, Nucl Med, I-16132 Genoa, Italy.; Morbelli, S (corresponding author), IRCCS Azienda Osped Univ San Martino IST, Genoa, Italy.	silviadaniela.morbelli@hsanmartino.it	pagani, marco/AAV-9176-2020	Morbelli, Silvia/0000-0002-7833-6095				Ances BM, 2005, BRAIN, V128, P1764, DOI 10.1093/brain/awh526; Antoine JC, 2016, LANCET NEUROL, V15, P349, DOI 10.1016/S1474-4422(16)00025-9; Baumgartner A, 2013, J NEUROL, V260, P2744, DOI 10.1007/s00415-013-7048-2; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Leypoldt F, 2012, J NEUROL NEUROSUR PS, V83, P681, DOI 10.1136/jnnp-2011-301969; Teipel S, 2015, LANCET NEUROL, V14, P1037, DOI 10.1016/S1474-4422(15)00093-9; Trevino-Peinado C, 2015, CLIN NUCL MED, V40, pE441, DOI 10.1097/RLU.0000000000000839	8	40	41	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					1009	1010		10.1016/S1474-4422(16)30140-5	http://dx.doi.org/10.1016/S1474-4422(16)30140-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27571149				2022-12-18	WOS:000381280300016
J	Pitcher, H				Pitcher, H			Alzheimer's disease could be "type 3 diabetes"	LANCET NEUROLOGY			English	News Item																		2006, J ALZHEIMERS DIS, V9, P13	1	40	48	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					388	389		10.1016/S1474-4422(06)70434-3	http://dx.doi.org/10.1016/S1474-4422(06)70434-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16639835				2022-12-18	WOS:000237147600017
J	El-Agnaf, OMA; Walsh, DM; Allsop, D				El-Agnaf, OMA; Walsh, DM; Allsop, D			Soluble oligomers for the diagnosis of neurodegenerative diseases	LANCET NEUROLOGY			English	Editorial Material							COMMON MECHANISM; PATHOGENESIS; PROTOFIBRILS; IMPLIES; POTENT		Univ Lancaster, Dept Biol Sci, Lancaster, England; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Lancaster University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	El-Agnaf, OMA (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster, England.		Allsop, David/B-9725-2008	Allsop, David/0000-0002-0513-5575				Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	11	40	42	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					461	462		10.1016/S1474-4422(03)00481-2	http://dx.doi.org/10.1016/S1474-4422(03)00481-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	12878433				2022-12-18	WOS:000184314700014
J	Mercuri, E; Muntoni, F; Baranello, G; Masson, R; Boespflug-Tanguy, O; Bruno, C; Corti, S; Daron, A; Deconinck, N; Servais, L; Straub, V; Ouyang, HJ; Chand, D; Tauscher-Wisniewski, S; Mendonca, N; Lavrov, A				Mercuri, Eugenio; Muntoni, Francesco; Baranello, Giovanni; Masson, Riccardo; Boespflug-Tanguy, Odile; Bruno, Claudio; Corti, Stefania; Daron, Aurore; Deconinck, Nicolas; Servais, Laurent; Straub, Volker; Ouyang, Haojun; Chand, Deepa; Tauscher-Wisniewski, Sitra; Mendonca, Nuno; Lavrov, Arseniy		STR1VE-EU Study Grp	Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial	LANCET NEUROLOGY			English	Article								Background Spinal muscular atrophy is a rare, autosomal recessive, neuromuscular disease caused by biallelic loss of the survival motor neuron 1 (SMN1) gene, resulting in motor neuron dysfunction. In this STR1VE-EU study, we aimed to evaluate the safety and efficacy of onasemnogene abeparvovec gene replacement therapy in infants with spinal muscular atrophy type 1, using broader eligibility criteria than those used in STR1VE-US. Methods STR1VE-EU was a multicentre, single-arm, single-dose, open-label phase 3 trial done at nine sites (hospitals and universities) in Italy (n=4), the UK (n=2), Belgium (n=2), and France (n=1). We enrolled patients younger than 6 months (180 days) with spinal muscular atrophy type 1 and the common biallelic pathogenic SMN1 exon 7-8 deletion or point mutations, and one or two copies of SMN2. Patients received a one-time intravenous infusion of onasemnogene abeparvovec (1.1 x 1014 vector genomes [vg]/kg). The outpatient follow-up consisted of assessments once per week starting at day 7 post-infusion for 4 weeks and then once per month until the end of the study (at age 18 months or early termination). The primary outcome was independent sitting for at least 10 s, as defined by the WHO Multicentre Growth Reference Study, at any visit up to the 18 months of age study visit, measured in the intention-to-treat population. Efficacy was compared with the Pediatric Neuromuscular Clinical Research (PNCR) natural history cohort. This trial is registered with ClinicalTrials.gov, NCT03461289 (completed). Findings From Aug 16, 2018, to Sept 11, 2020, 41 patients with spinal muscular atrophy were assessed for eligibility. The median age at onasemnogene abeparvovec dosing was 4.1 months (IQR 3.0-5.2). 32 (97%) of 33 patients completed the study and were included in the ITT population (one patient was excluded despite completing the study because of dosing at 181 days). 14 (44%, 97.5% CI 26-100) of 32 patients achieved the primary endpoint of functional independent sitting for at least 10 s at any visit up to the 18 months of age study visit (vs 0 of 23 untreated patients in the PNCR cohort; p<0.0001). 31 (97%, 95% CI 91-100) of 32 patients in the ITT population survived free from permanent ventilatory support at 14 months compared with six (26%, 8-44) of 23 patients in the PNCR natural history cohort (p<0.0001). 32 (97%) of 33 patients had at least one adverse event and six (18%) had adverse events that were considered serious and related to onasemnogene abeparvovec. The most common adverse events were pyrexia (22 [67%] of 33), upper respiratory infection (11 [33%]), and increased alanine aminotransferase (nine [27%]). One death, unrelated to the study drug, occurred from hypoxic-ischaemic brain damage because of a respiratory tract infection during the study. Interpretation STR1VE-EU showed efficacy of onasemnogene abeparvovec in infants with symptomatic spinal muscular atrophy type 1. No new safety signals were identified, but further studies are needed to show long-term safety. The benefit-risk profile of onasemnogene abeparvovec seems favourable for this patient population, including those with severe disease at baseline.	[Mercuri, Eugenio] Catholic Univ, Fdn Policlin Univ Agostino Gemelli IRCCS, Paediat Neurol Unit, Rome, Italy; [Mercuri, Eugenio] Catholic Univ, Fdn Policlin Univ Agostino Gemelli IRCCS, Nemo Clin Ctr, Rome, Italy; [Mercuri, Eugenio] Catholic Univ, Dept Child Neurol & Psychiat, I-00168 Rome, Italy; [Muntoni, Francesco; Baranello, Giovanni] UCL Great Ormond St Inst Child Hlth, Dubowitz Neuromuscular Ctr, London, England; [Baranello, Giovanni] NIHR Great Ormond St Hosp, Great Ormond St Inst Child Hlth, Biomed Res Ctr, London, England; [Baranello, Giovanni; Masson, Riccardo] Fdn IRCCS Ist Neurol Carlo Besta, Dev Neurol Unit, Milan, Italy; [Boespflug-Tanguy, Odile; Servais, Laurent] Hop Trousseau, AP HP, Inst Myol, I Mot, Paris, France; [Boespflug-Tanguy, Odile] Univ Paris, UMR 1141, Paris, France; [Bruno, Claudio] IRCCS Ist Giannina Gaslini, Ctr Translat & Expt Myol, Genoa, Italy; [Corti, Stefania] Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy; [Corti, Stefania] Fdn IRCCS Ca Grande Osped Maggiore Policlin, Neurol Unit, Milan, Italy; [Daron, Aurore] Ctr Hosp Univ Liege, Dept Pediat, Liege, Belgium; [Servais, Laurent] CHU Liege, Hop La Citadelle, Neuromuscular Reference Ctr, Liege, Belgium; [Deconinck, Nicolas] Univ Ziekenhuis Gent, Neuromuscular Reference Ctr, Ghent, Belgium; [Deconinck, Nicolas] Univ Libre Bruxelles, Neuromuscular Reference Ctr, Hop Univ Enfants Reine Fabiola, Brussels, Belgium; [Servais, Laurent] Univ Oxford, Dept Paediat, MDUK Oxford Neuromuscular Ctr, Oxford, England; [Straub, Volker] Newcastle Univ, Newcastle Hosp NHS Fdn Trust, John Walton Muscular Dystrophy Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Ouyang, Haojun; Chand, Deepa; Tauscher-Wisniewski, Sitra] Novartis Gene Therapies, Bannockburn, IL USA; [Chand, Deepa] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Chand, Deepa] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Mendonca, Nuno] Novartis Gene Therapies, Porto, Portugal; [Lavrov, Arseniy] Novartis Gene Therapies, Cambridge, England	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Liege; University of Liege; Ghent University; Ghent University Hospital; Universite Libre de Bruxelles; University of Oxford; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Mercuri, E (corresponding author), Catholic Univ, Dept Child Neurol & Psychiat, I-00168 Rome, Italy.	eumercuri@gmail.com	Masson, Riccardo/AAB-8896-2019; Corti, Stefania/K-6034-2016; Pera, Maria Carmela/J-6068-2018	Masson, Riccardo/0000-0002-9311-452X; Corti, Stefania/0000-0001-5425-969X; Pera, Maria Carmela/0000-0001-6777-1721; Coratti, Giorgia/0000-0001-6666-5628; Straub, Volker/0000-0001-9046-3540; Abel, Francois/0000-0002-5764-3416; Chand, Deepa/0000-0002-0745-9338; Antonaci, Laura/0000-0003-4753-8441; Pane, Marika/0000-0002-4851-6124	Novartis Gene Therapies - Novartis Gene Therapies	Novartis Gene Therapies - Novartis Gene Therapies	This study was funded by Novartis Gene Therapies. We thank the investigators, health-care providers, research staff, patients, and caregivers who participated in this study (appendix p 2). We also thank Hella Berkhout and Annabel Webb (Novartis, Basel, Switzerland), and Susan Williamson (Novartis, Bannockburn, IL, USA) for clinical operations support. We thank Aaron Kleyn for providing additional statistical support. Writing and editing assistance (including preparation of the draft manuscript under guidance of authors), incorporating author feedback, and manuscript submission was provided by Marjet Heitzer (Kay Square Scientific, Newtown Square, PA, USA). Writing and editorial support was funded by Novartis Gene Therapies.	Al-Zaidy SA, 2019, J NEUROMUSCULAR DIS, V6, P307, DOI 10.3233/JND-190403; Albers CA, 2007, J PSYCHOEDUC ASSESS, V25, P180, DOI 10.1177/0734282906297199; AveXis, 2021, ZOLGENSMA PRESCRIBIN; Biogen, 2020, SPINRAZA PRESCRIBING; Chand D, 2021, J HEPATOL, V74, P560, DOI 10.1016/j.jhep.2020.11.001; Chand DH, 2021, J PEDIATR-US, V231, P265, DOI 10.1016/j.jpeds.2020.11.054; Day JW, 2021, LANCET NEUROL, V20, P284, DOI 10.1016/S1474-4422(21)00001-6; de Onis M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548; De Sanctis R, 2016, NEUROMUSCULAR DISORD, V26, P754, DOI 10.1016/j.nmd.2016.10.002; Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741; Genentech, 2020, EVRYSDI PRESCRIBING; Glanzman AM, 2010, NEUROMUSCULAR DISORD, V20, P155, DOI 10.1016/j.nmd.2009.11.014; Glanzman AM, 2011, PEDIATR PHYS THER, V23, P322, DOI 10.1097/PEP.0b013e3182351f04; Kolb SJ, 2017, ANN NEUROL, V82, P883, DOI 10.1002/ana.25101; Mailman MD, 2002, GENET MED, V4, P20, DOI 10.1097/00125817-200201000-00004; McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mendell JR, 2021, JAMA NEUROL, V78, P834, DOI 10.1001/jamaneurol.2021.1272; Mercuri E, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01356-1; Wijnhoven Trudy M, 2004, Food Nutr Bull, V25, pS37; Xu LF, 2001, HUM GENE THER, V12, P563, DOI 10.1089/104303401300042500	21	39	44	4	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					832	841		10.1016/S1474-4422(21)00251-9	http://dx.doi.org/10.1016/S1474-4422(21)00251-9			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536405				2022-12-18	WOS:000701741000018
J	Kelly, PJ; Albers, GW; Chatzikonstantinou, A; De Marchis, GM; Ferrari, J; George, P; Katan, M; Knoflach, M; Kim, JS; Li, L; Lee, EJ; Olivot, JM; Purroy, F; Raposo, N; Rothwell, PM; Sharma, VK; Song, B; Tsivgoulis, G; Walsh, C; Xu, YM; Merwick, A				Kelly, Peter J.; Albers, Gregory W.; Chatzikonstantinou, Anastasios; De Marchis, Gian Marco; Ferrari, Julia; George, Paul; Katan, Mira; Knoflach, Michael; Kim, Jong S.; Li, Linxin; Lee, Eun-Jae; Olivot, Jean-Marc; Purroy, Francisco; Raposo, Nicolas; Rothwell, Peter M.; Sharma, Vijay K.; Song, Bo; Tsivgoulis, Georgios; Walsh, Cathal; Xu, Yuming; Merwick, Aine			Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies	LANCET NEUROLOGY			English	Article							ABCD(2) SCORE; MINOR STROKE; FEASIBILITY; PROGNOSIS; EMERGENCY; BRAIN; MRI; TIA	Background Identification of patients at highest risk of early stroke after transient ischaemic attack has been improved with imaging based scores. We aimed to compare the validity and prognostic utility of imaging-based stroke risk scores in patients after transient ischaemic attack. Methods We did a pooled analysis of published and unpublished individual-patient data from 16 cohort studies of transient ischaemic attack done in Asia, Europe, and the USA, with early brain and vascular imaging and follow up. All patients were assessed by stroke specialists in hospital settings as inpatients, in emergency departments, or in transient ischaemic attack clinics. Indusion criteria were stroke-specialist confirmed transient ischaemic attack, age of 18 years or older, and MRI done within 7 days of index transient ischaemic attack and before stroke recurrence. Multivariable logistic regression was done to analyse the predictive utility of abnormal diffusion-weighted MRI, carotid stenosis, and transient ischaemic attack within 1 week of index transient ischaemic attack (dual transient ischaemic attack) after adjusting for ABCD2 score. We compared the prognostic utility of the ABCD2, ABCD2-I, and ABCD3-I scores using discrimination, calibration, and risk reclassification. Findings In 2176 patients from 16 cohort studies done between 2005 and 2015, after adjusting for ABCD2 score, positive diffusion-weighted imaging (odds ratio [OR] 3.8, 95% CI 2.1-7.0), dual transient ischaemic attack (OR 3.3, 95% CI 1.8-5.8), and ipsilateral carotid stenosis (OR 4-7, 95% CI 2.6-8.6) were associated with 7 day stroke after index transient ischaemic attack (p<0.001 for all). 7 day stroke risk increased with increasing ABCD2-I and ABCD3-I scores (both p<0 " 001). Discrimination to identify early stroke risk was improved for ABCD2-I versus ABCD2 (2 day c statistic 0.74 vs 0.64; 1)=0.006). However, discrimination was further improved by ABCD3-I compared with ABCD2 (2 day c statistic 0.84 vs 0.64; p<0.001) and ABCD2-I (c statistic 0.84 vs 0.74; p<0.001). Early stroke risk reclassification was improved by ABCD3-I compared with ABCD2-I score (clinical net redassification improvement 33% at 2 days). Interpretation Although ABCD2-I and ABCD3-I showed validity, the ABCD3-I score reliably identified highest-risk patients at highest risk of a stroke after transient ischaemic attack with improved risk prediction compared with ABCD2-L Transient ischaemic attack management guided by ABCD3-I with immediate stroke-specialist assessment, urgent MRI, and vascular imaging should now be considered, with monitoring of safety and cost-effectiveness.	[Kelly, Peter J.; Merwick, Aine] Univ Coll Dublin, Dublin Acad Med Ctr, Mater Univ Hosp, Neurovasc Clin Sci Unit,Stroke Serv, Dublin, Ireland; [Kelly, Peter J.; Merwick, Aine] Univ Coll Dublin, Dublin Acad Med Ctr, Mater Univ Hosp, Dept Neurol, Dublin, Ireland; [Albers, Gregory W.; George, Paul] Stanford Stroke Ctr, Dept Neurol & Neurol Sci, Palo Alto, CA USA; [Chatzikonstantinou, Anastasios] Heidelberg Univ, Univ Med Mannheim, Dept Neurol, Mannheim, Germany; [De Marchis, Gian Marco] Univ Basel Hosp, Dept Neurol, Basel, Switzerland; [De Marchis, Gian Marco] Univ Basel Hosp, Stroke Ctr, Basel, Switzerland; [Ferrari, Julia] Hosp Barmherzige Breeder, Dept Neurol, Vienna, Austria; [Katan, Mira] Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland; [Knoflach, Michael] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Kim, Jong S.; Lee, Eun-Jae] Univ Ulsan, Dept Neurol, Asan Med Ctr, Seoul, South Korea; [Rothwell, Peter M.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford, England; [Olivot, Jean-Marc; Raposo, Nicolas] Purpan Univ Hosp, Stroke Unit, Dept Neurol, Toulouse, France; [Purroy, Francisco] Hosp Univ Arnau Vilanova Lleida, Dept Neurol, Stroke Unit, Lleida, Spain; [Purroy, Francisco] Univ Lleida, Biomed Res Inst Lleida, Lleida, Spain; [Sharma, Vijay K.] Natl Univ Singapore Hosp, Div Neurol, Dept Med, Singapore, Singapore; [Sharma, Vijay K.] Natl Univ Singapore, Sch Med, Singapore, Singapore; [Song, Bo; Xu, Yuming] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Peoples R China; [Tsivgoulis, Georgios] Univ Athens, Sch Med, Dept Neurol 2, Athens, Greece; [Tsivgoulis, Georgios] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN USA; [Walsh, Cathal] Univ Limerick, Dept Stat, Limerick, Ireland; [Merwick, Aine] Chelsea & Westminster NHS Fdn Trust, London, England	Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Stanford University; Ruprecht Karls University Heidelberg; University of Basel; University of Basel; University of Zurich; University Zurich Hospital; Medical University of Innsbruck; University of Ulsan; University of Oxford; CHU de Toulouse; University Hospital Arnau de Vilanova; Universitat de Lleida; National University of Singapore; National University of Singapore; Zhengzhou University; Athens Medical School; National & Kapodistrian University of Athens; University of Tennessee System; University of Tennessee Health Science Center; University of Limerick; Imperial College London	Kelly, PJ (corresponding author), Univ Coll Dublin, Dublin, Ireland.	pjkelly@mater.ie	Tsivgoulis, Georgios/AAD-5360-2020; Tsivgoulis, Georgios/AAD-7467-2019; sharma, Vijay/T-5286-2019; Purroy, Francisco/D-4538-2009; Li, Linxin/AAB-7774-2020; De Marchis, Gian Marco/J-5414-2019; sharma, Vijay K/A-6733-2009; Rothwell, Peter/ABE-5913-2020; Merwick, Aine/L-9754-2013	Tsivgoulis, Georgios/0000-0002-0640-3797; sharma, Vijay/0000-0002-8976-5696; Purroy, Francisco/0000-0002-1808-5968; Li, Linxin/0000-0002-3636-8355; De Marchis, Gian Marco/0000-0002-0342-9780; sharma, Vijay K/0000-0002-8976-5696; Rothwell, Peter/0000-0001-9739-9211; Katan, Mira/0000-0002-9265-8066; Merwick, Aine/0000-0001-7533-0117; Walsh, Cathal/0000-0001-6599-9562; George, Paul/0000-0002-1080-098X; Knoflach, Michael/0000-0001-5576-6562; Albers, Gregory/0000-0003-0263-4632	Health Research Board of Ireland; Irish Heart Foundation; Irish Health Service Executive, and National Lottery; National Medical Research Council of Singapore; Swiss National Science Foundation [PZ00P3 142422, PBBEP3-139388]; Bangerter-Rhyner Foundation; Swisslife Jubilaumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr Ettore Balli (Switzerland); De Quervain research grant from the Clinical Trial Unit of University of Bern; South Korea's Ministry for Health, Welfare, and Family Affairs [HI14C1985]; UK Wellcome Trust; Wolfson Foundation; UK Stroke Association; British Heart Foundation; Dunhill Medical Trust; National Institute of Health Research (NIHR); Medical Research Council; NIHR Oxford Biomedical Research Centre; Fondation Leducq	Health Research Board of Ireland; Irish Heart Foundation; Irish Health Service Executive, and National Lottery; National Medical Research Council of Singapore(National Medical Research Council, Singapore); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Bangerter-Rhyner Foundation; Swisslife Jubilaumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr Ettore Balli (Switzerland); De Quervain research grant from the Clinical Trial Unit of University of Bern; South Korea's Ministry for Health, Welfare, and Family Affairs; UK Wellcome Trust(Wellcome Trust); Wolfson Foundation; UK Stroke Association; British Heart Foundation(British Heart Foundation); Dunhill Medical Trust(Dunhill Medical Trust); National Institute of Health Research (NIHR)(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Fondation Leducq(Leducq Foundation)	This study was funded by the Health Research Board of Ireland, Irish Heart Foundation, Irish Health Service Executive, and National Lottery (PJK), National Medical Research Council of Singapore (VKS), Swiss National Science Foundation (PZ00P3 142422; MKn), Bangerter-Rhyner Foundation, Swiss National Science Foundation (PBBEP3-139388), Swisslife Jubilaumsstiftung for Medical Research, Swiss Neurological Society, Fondazione Dr Ettore Balli (Switzerland), De Quervain research grant from the Clinical Trial Unit of University of Bern (GMDM), South Korea's Ministry for Health, Welfare, and Family Affairs (HI14C1985; JSK), UK Wellcome Trust, Wolfson Foundation, UK Stroke Association, British Heart Foundation, Dunhill Medical Trust, National Institute of Health Research (NIHR), Medical Research Council, and the NIHR Oxford Biomedical Research Centre (PMR), Swiss National Science Foundation (PZ00P3 142422), and Fondation Leducq (MKa).	Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Amarenco P, 2009, STROKE, V40, P3091, DOI 10.1161/STROKEAHA.109.552042; Ay H, 2009, STROKE, V40, P181, DOI 10.1161/STROKEAHA.108.521476; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Casaubon LK, 2015, INT J STROKE, V10, P924, DOI 10.1111/ijs.12551; Chatzikonstantinou A, 2013, CEREBROVASC DIS, V36, P106, DOI 10.1159/000352060; Coutts SB, 2005, ANN NEUROL, V57, P848, DOI 10.1002/ana.20497; D'Agostino RB, 2004, HDB STAT, V23; Dolatabadi AA, 2013, J STROKE CEREBROVASC, V22, pE25, DOI 10.1016/j.jstrokecerebrovasdis.2012.03.007; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; European Stroke Organisation Executive Committee and ESO Writing Committee, 2008, CEREBROVASC DIS; Fisher CM, 1958, CEREBRAL VASCULAR DI, P81; Giles MF, 2007, LANCET NEUROL, V6, P1063, DOI 10.1016/S1474-4422(07)70274-0; Giles MF, 2010, STROKE, V41, P1907, DOI 10.1161/STROKEAHA.110.578971; Giles MF, 2010, STROKE, V41, P667, DOI 10.1161/STROKEAHA.109.571174; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Johnston SC, 2007, LANCET, V369, P283, DOI 10.1016/S0140-6736(07)60150-0; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Kiyohara T, 2014, STROKE, V45, P418, DOI 10.1161/STROKEAHA.113.003077; Lavallee PC, 2007, LANCET NEUROL, V6, P953, DOI 10.1016/S1474-4422(07)70248-X; Leening MJG, 2014, ANN INTERN MED, V160, P122, DOI 10.7326/M13-1522; Merwick A, 2010, LANCET NEUROL, V9, P1060, DOI 10.1016/S1474-4422(10)70240-4; Nah HW, 2014, INT J STROKE, V9, P895, DOI 10.1111/ijs.12212; National Institute for Health and Care Excellence, 2016, TIA ASS EARL MAN IM; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pencina MJ, 2011, STAT MED, V30, P11, DOI 10.1002/sim.4085; Prabhakaran S, 2007, ARCH NEUROL-CHICAGO, V64, P1105, DOI 10.1001/archneur.64.8.1105; Purroy F, 2013, EUR J NEUROL, V20, P1088, DOI 10.1111/ene.12141; Rothwell PM, 2007, LANCET, V370, P1432, DOI 10.1016/S0140-6736(07)61448-2; Rothwell PM, 2005, LANCET, V366, P29, DOI 10.1016/S0140-6736(05)66702-5; Song B, 2013, STROKE, V44, P1244, DOI 10.1161/STROKEAHA.113.000969; Tsivgoulis G, 2010, STROKE, V41, P836, DOI 10.1161/STROKEAHA.110.579169; Vora N, 2015, INT J STROKE, V10, P343, DOI 10.1111/ijs.12390; Wardlaw JM, 2015, NEUROLOGY, V85, P373, DOI 10.1212/WNL.0000000000001780	34	39	41	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2016	15	12					1236	1245		10.1016/s1474-4422(16)30236-8	http://dx.doi.org/10.1016/s1474-4422(16)30236-8			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA0YO	27751555	Green Submitted			2022-12-18	WOS:000386315700019
J	Edlow, JA; Selim, MH				Edlow, Jonathan A.; Selim, Magdy H.			Atypical presentations of acute cerebrovascular syndromes	LANCET NEUROLOGY			English	Review							FOREIGN ACCENT SYNDROME; PURE SENSORY STROKE; ACUTE PERIPHERAL VESTIBULOPATHY; CEREBRAL-ARTERY INFARCTION; TRANSIENT ISCHEMIC ATTACKS; LACUNAR PONTINE INFARCTION; CEREBELLAR INFARCTION; EMERGENCY-DEPARTMENT; MOVEMENT-DISORDERS; ESSENTIAL TREMOR	Correct diagnosis of acute stroke is of paramount importance to clinicians to enable selection of correct treatments and to ensure prevention of acute complications, including recurrent stroke. Timely diagnosis can be difficult in some cases because patients with acute stroke can present with atypical or uncommon symptoms that suggest another cause altogether. Publications on these patients suggest that the following strategies could help to reduce misdiagnosis. First, clinicians should suspect stroke in any patient with abrupt onset of neurological symptoms. Second, clinicians should be aware that some patients will initially present with various uncommon and atypical stroke symptoms. Third, a complete and systematic neurological examination should be routinely done in patients presenting with acute neurological symptoms because this might shed light on the true nature of the problem. Finally, clinicians should be aware that even with the most sophisticated neuroimaging tests, stroke might be missed in the early hours after the event.	[Edlow, Jonathan A.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, W Clin Ctr 2, Boston, MA 02215 USA; [Selim, Magdy H.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Edlow, Jonathan A.; Selim, Magdy H.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Edlow, JA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, W Clin Ctr 2, 1 Deaconess Rd W CC-2, Boston, MA 02215 USA.	jedlow@bidmc.harvard.edu	Edlow, Jonathan A/F-7128-2016					Alarcon F, 2004, J NEUROL NEUROSUR PS, V75, P1568, DOI 10.1136/jnnp.2003.011874; AMBROSETTO P, 1988, STROKE, V19, P784, DOI 10.1161/str.19.6.784b; Arnold M, 2006, J NEUROL NEUROSUR PS, V77, P1021, DOI 10.1136/jnnp.2006.094359; Baier B, 2010, NEUROLOGY, V74, P218, DOI 10.1212/WNL.0b013e3181cb3e64; Balakrishnan Preethi, 2008, Curr Treat Options Cardiovasc Med, V10, P216, DOI 10.1007/s11936-008-0023-z; Bejot Y, 2008, CLIN NEUROL NEUROSUR, V110, P190, DOI 10.1016/j.clineuro.2007.09.007; BRANDT T, 1995, NERVENARZT, V66, P267; CAPLAN LR, 1980, NEUROLOGY, V30, P72, DOI 10.1212/WNL.30.1.72; Carota A, 2001, NEUROLOGY, V57, P1902, DOI 10.1212/WNL.57.10.1902; Carrera E, 2004, STROKE, V35, P2826, DOI 10.1161/01.STR.0000147039.49252.2f; Celebisoy Mehmet, 2005, Neurol India, V53, P183; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Cohen DA, 2009, NEUROLOGY, V73, P566, DOI 10.1212/WNL.0b013e3181b2a4d8; Constantino AEA, 2003, J NEUROL, V250, P354, DOI 10.1007/s00415-003-0970-y; CUMMINGS JL, 1984, AM J PSYCHIAT, V141, P1084; deBruijn SFTM, 1996, LANCET, V348, P1623, DOI 10.1016/S0140-6736(96)07294-7; Denier C, 2010, ARCH NEUROL-CHICAGO, V67, P1219, DOI 10.1001/archneurol.2010.263; DEROUESNE C, 1984, STROKE, V15, P660, DOI 10.1161/01.STR.15.4.660; DONAT JR, 1980, NEUROLOGY, V30, P83, DOI 10.1212/WNL.30.1.83; Doubal FN, 2011, J NEUROL NEUROSUR PS, V82, P540, DOI 10.1136/jnnp.2009.190298; DUNNE JW, 1986, AUST NZ J MED, V16, P771, DOI 10.1111/j.1445-5994.1986.tb00034.x; Dupuis MJM, 2010, MOVEMENT DISORD, V25, P2884, DOI 10.1002/mds.23328; Edlow JA, 2008, LANCET NEUROL, V7, P951, DOI 10.1016/S1474-4422(08)70216-3; Edlow JA, 2008, ANN EMERG MED, V52, P407, DOI 10.1016/j.annemergmed.2008.07.001; Edlow JA, 2008, J EMERG MED, V34, P237, DOI 10.1016/j.jemermed.2007.10.003; FERBERT A, 1993, MOVEMENT DISORD, V8, P179, DOI 10.1002/mds.870080211; Ferro JM, 2008, STROKE, V39, P1152, DOI 10.1161/STROKEAHA.107.487363; Fiebach JB, 2002, STROKE, V33, P2206, DOI 10.1161/01.STR.0000026864.20339.CB; FISHER CM, 1962, CAN MED ASSOC J, V86, P1091; Gargano JW, 2011, J STROKE CEREBROVASC, V20, P494, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.022; Gass A, 2001, NEUROLOGY, V57, P1589, DOI 10.1212/WNL.57.9.1589; GhikaSchmid F, 1997, J NEUROL SCI, V146, P109, DOI 10.1016/S0022-510X(96)00290-0; Goldstein LB, 2005, JAMA-J AM MED ASSOC, V293, P2391, DOI 10.1001/jama.293.19.2391; Hand PJ, 2006, STROKE, V37, P769, DOI 10.1161/01.STR.0000204041.13466.4c; Handley A, 2009, AGE AGEING, V38, P260, DOI 10.1093/ageing/afp020; Hemmen Thomas M, 2008, J Stroke Cerebrovasc Dis, V17, P23, DOI 10.1016/j.jstrokecerebrovasdis.2007.09.008; Hiraga A, 2010, J NEUROL, V257, P1741, DOI 10.1007/s00415-010-5585-5; Hong CT, 2010, NEUROLOGY, V74, P437, DOI 10.1212/WNL.0b013e3181ccc746; Huff JS, 2002, EMERG MED CLIN N AM, V20, P583, DOI 10.1016/S0733-8627(02)00012-3; Huffman J, 2003, PSYCHOSOMATICS, V44, P65, DOI 10.1176/appi.psy.44.1.65; Kang SY, 2008, NEUROLOGY, V70, P2386, DOI 10.1212/01.wnl.0000314686.94007.d0; Kasow DL, 2000, AM J NEURORADIOL, V21, P1876; Kattah JC, 2009, STROKE, V40, P3504, DOI 10.1161/STROKEAHA.109.551234; KAUFMAN DK, 1994, STROKE, V25, P217, DOI 10.1161/01.STR.25.1.217; KAWAKAMI M, 1990, STROKE, V21, P1236, DOI 10.1161/str.21.8.1236a; Keane JR, 2010, CAN J NEUROL SCI, V37, P662, DOI 10.1017/S0317167100010866; Kerber KA, 2006, STROKE, V37, P2484, DOI 10.1161/01.STR.0000240329.48263.0d; Kidwell CS, 2004, JAMA-J AM MED ASSOC, V292, P1823, DOI 10.1001/jama.292.15.1823; Kim AS, 2011, ANN EMERG MED, V57, P34, DOI 10.1016/j.annemergmed.2010.06.559; Kim HA, 2010, STROKE, V41, P1558, DOI 10.1161/STROKEAHA.110.582783; Kim JS, 2006, MOVEMENT DISORD, V21, P1284, DOI 10.1002/mds.20894; KIM JS, 1994, STROKE, V25, P1994, DOI 10.1161/01.STR.25.10.1994; Kim JS, 2005, NEUROLOGY, V64, P1227, DOI 10.1212/01.WNL.0000156520.46056.6B; KIM JS, 1992, STROKE, V23, P983, DOI 10.1161/01.STR.23.7.983; Kim JS, 2001, BRAIN, V124, P299, DOI 10.1093/brain/124.2.299; KOTHARI RU, 1995, STROKE, V26, P2238, DOI 10.1161/01.STR.26.12.2238; Ku BD, 2007, J CLIN NEUROL, V3, P67, DOI 10.3988/jcn.2007.3.1.67; Kumral E, 2002, J NEUROL, V249, P1659, DOI 10.1007/s00415-002-0879-x; Kumral E, 1999, STROKE, V30, P100, DOI 10.1161/01.STR.30.1.100; Kumral E, 2001, ACTA NEUROL SCAND, V103, P35, DOI 10.1034/j.1600-0404.2001.00141.x; Kuruvilla A, 2011, J STROKE CEREBROVASC, V20, P523, DOI 10.1016/j.jstrokecerebrovasdis.2010.03.005; Lee BC, 1999, EUR NEUROL, V41, P53, DOI 10.1159/000008000; Lee H, 2006, NEUROLOGY, V67, P1178, DOI 10.1212/01.wnl.0000238500.02302.b4; Lee H, 2009, STROKE, V40, P3745, DOI 10.1161/STROKEAHA.109.564682; LEVINE DN, 1982, NEUROLOGY, V32, P267, DOI 10.1212/WNL.32.3.267; Maddula MP, 2010, INT J GERONTOL, V4, P47, DOI 10.1016/S1873-9598(10)70022-3; Maeder-Ingvar M, 2005, ARCH NEUROL-CHICAGO, V62, P1221, DOI 10.1001/archneur.62.8.1221; Marien P, 2006, CLIN NEUROL NEUROSUR, V108, P518, DOI 10.1016/j.clineuro.2005.06.006; Martin-Schild S, 2011, ANN EMERG MED, V57, P42, DOI 10.1016/j.annemergmed.2010.06.564; Mehdiratta M, 2007, ARCH NEUROL-CHICAGO, V64, P1348, DOI 10.1001/archneur.64.9.1348; Mullins ME, 2002, RADIOLOGY, V224, P353, DOI 10.1148/radiol.2242010873; Naidoo R, 2008, CAN J NEUROL SCI, V35, P360, DOI 10.1017/S0317167100008970; Nakajima Makoto, 2008, J Stroke Cerebrovasc Dis, V17, P382, DOI 10.1016/j.jstrokecerebrovasdis.2008.05.002; NIGHOGHOSSIAN N, 1995, STROKE, V26, P326, DOI 10.1161/01.STR.26.2.326; Nor AM, 2005, LANCET NEUROL, V4, P727, DOI 10.1016/S1474-4422(05)70201-5; Nor Azlisham Mohd, 2007, Expert Rev Neurother, V7, P989, DOI 10.1586/14737175.7.8.989; Paciaroni M, 2005, J NEUROL NEUROSUR PS, V76, P805, DOI 10.1136/jnnp.2004.047779; Paciaroni M, 1998, EUR NEUROL, V39, P211, DOI 10.1159/000007936; Peters N, 2009, J NEUROL, V256, P1146, DOI 10.1007/s00415-009-5104-8; PETERSON DI, 1987, ANN NEUROL, V22, P661, DOI 10.1002/ana.410220519; ROPPER AH, 1988, NEUROLOGY, V38, P1500, DOI 10.1212/WNL.38.9.1500-a; Runchey S, 2010, JAMA-J AM MED ASSOC, V303, P2280, DOI 10.1001/jama.2010.754; Salah AA, 2008, J MULTIMODAL USER IN, V2, P75, DOI 10.1186/1752-1947-2-75; Savitz SI, 2008, STROKE, V39, P1392, DOI 10.1161/STROKEAHA.107.503151; Savitz SI, 2007, ACAD EMERG MED, V14, P63, DOI 10.1197/j.aem.2006.06.060; Schellinger PD, 2010, NEUROLOGY, V75, P177, DOI 10.1212/WNL.0b013e3181e7c9dd; Schmahmann JD, 2003, STROKE, V34, P2264, DOI 10.1161/01.STR.0000087786.38997.9E; SCHNEIDER R, 1994, BRAIN, V117, P347, DOI 10.1093/brain/117.2.347; Selim M, 2002, CEREBROVASC DIS, V14, P54, DOI 10.1159/000063724; SHINTANI S, 1994, STROKE, V25, P1512, DOI 10.1161/01.STR.25.7.1512; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; Sinanovic O, 2010, PSYCHIAT DANUB, V22, P278; Spector AR, 2009, J STROKE CEREBROVASC, V18, P72, DOI 10.1016/j.jstrokecerebrovasdis.2008.08.003; Sudo K, 2004, LANCET, V363, P1364, DOI 10.1016/S0140-6736(04)16047-9; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Takahashi N, 2002, NEUROLOGY, V58, P1412, DOI 10.1212/WNL.58.9.1412; TATEMICHI TK, 1990, STROKE, V21, P341, DOI 10.1161/01.STR.21.2.341; Tentschert S, 2005, STROKE, V36, pE1, DOI 10.1161/01.STR.0000151360.03567.2b; Thomke F, 1999, J NEUROL NEUROSUR PS, V66, P340, DOI 10.1136/jnnp.66.3.340; Toledo M, 2008, STROKE, V39, P476, DOI 10.1161/STROKEAHA.107.498303; Urban PP, 1999, J NEUROL NEUROSUR PS, V66, P495, DOI 10.1136/jnnp.66.4.495; Urban PP, 2001, NEUROLOGY, V56, P1021, DOI 10.1212/WNL.56.8.1021; Vaidyanathan S, 2007, J Laryngol Otol, V121, pe9, DOI 10.1017/S0022215107006901; Wang X, 2008, J NEUROL SCI, V267, P147, DOI 10.1016/j.jns.2007.10.014; World Health Organization, CARD DIS ATL HEART D; Zhang XJ, 2006, J NEURO-OPHTHALMOL, V26, P180, DOI 10.1097/01.wno.0000235587.41040.39	106	39	43	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					550	560		10.1016/S1474-4422(11)70069-2	http://dx.doi.org/10.1016/S1474-4422(11)70069-2			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21601162				2022-12-18	WOS:000291376100014
J	Munot, P; Crow, YJ; Ganesan, V				Munot, Pinki; Crow, Yanick J.; Ganesan, Vijeya			Paediatric stroke: genetic insights into disease mechanisms and treatment targets	LANCET NEUROLOGY			English	Review							AUTOSOMAL-DOMINANT ARTERIOPATHY; MUSCLE-CELL-PROLIFERATION; ISCHEMIC-STROKE; SUBCORTICAL INFARCTS; CEREBRAL ARTERIOPATHY; LEUKOENCEPHALOPATHY CADASIL; PSEUDOXANTHOMA ELASTICUM; VASCULAR ANOMALIES; YOUNG-PATIENTS; RISK-FACTORS	In children, stroke is as common as brain tumour and causes substantial mortality and long-term morbidity, with recurrence in up to 20%. There are three sets of international clinical guidelines relating to childhood stroke; however, acute and preventive treatment recommendations are based on interventions effective in adults, rather than data regarding efficacy in children. A wide spectrum of risk factors underlies childhood stroke, and these risk factors vary from those encountered in adults. Specific disease mechanisms implicated in childhood arterial ischaemic stroke have received little attention, but an increased understanding of disease pathogenesis could lead to novel targeted treatment approaches. Here, we consider insights into the pathogenesis of childhood arterial ischaemic stroke and cerebral arteriopathy, provided by current knowledge of Mendelian diseases that are associated with an increased risk of these conditions. We give particular attention to aspects of vascular development, homoeostasis, and response to environmental effects. Our analysis highlights a potential role for interventions already licensed for pharmaceutical use, as well as new therapeutic targets and avenues for further research.	[Munot, Pinki; Ganesan, Vijeya] Great Ormond St Hosp Sick Children, Dept Neurol, London WC1N 3JH, England; [Crow, Yanick J.] Univ Manchester, Dept Med Genet, Acad Hlth Sci Ctr, Cent Manchester Fdn Trust Univ Hosp, Manchester, Lancs, England; [Ganesan, Vijeya] UCL, Neurosci Unit, Inst Child Hlth, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Manchester; University of London; University College London	Munot, P (corresponding author), Great Ormond St Hosp Sick Children, Dept Neurol, Great Ormond St, London WC1N 3JH, England.	munotp@gosh.nhs.uk	Crow, Yanick J/N-6120-2014	Crow, Yanick J/0000-0001-7211-7564; Munot, Pinki/0000-0001-9900-798X	Manchester National Institute for Health Research (NIHR); Biomedical Research Centre (BRC)	Manchester National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Biomedical Research Centre (BRC)	YJC acknowledges the support of Manchester National Institute for Health Research (NIHR) and Biomedical Research Centre (BAC).	Achrol AS, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS08302; Amlie-Lefond C, 2009, CIRCULATION, V119, P1417, DOI 10.1161/CIRCULATIONAHA.108.806307; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; AOYAGI M, 1995, STROKE, V26, P415, DOI 10.1161/01.STR.26.3.415; Baptista MV, 2010, STROKE, V41, P431, DOI 10.1161/STROKEAHA.109.570499; Berard E, 1998, PEDIATR NEPHROL, V12, P121, DOI 10.1007/s004670050418; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Bernard TJ, 2010, J PEDIATR-US, V156, P651, DOI 10.1016/j.jpeds.2009.10.034; Bober MB, 2010, AM J MED GENET A, V152A, P960, DOI 10.1002/ajmg.a.33252; Cartwright MS, 2006, NEUROLOGY, V67, P360, DOI 10.1212/01.wnl.0000225056.66762.f9; Chappell JC, 2010, CURR TOP DEV BIOL, V90, P43, DOI 10.1016/S0070-2153(10)90002-1; Charakida M, 2010, ATHEROSCLEROSIS, V208, P217, DOI 10.1016/j.atherosclerosis.2009.07.055; Choi JC, 2010, J CLIN NEUROL, V6, P1, DOI 10.3988/jcn.2010.6.1.1; Coucke PJ, 2006, NAT GENET, V38, P452, DOI 10.1038/ng1764; Danchaivijitr N, 2006, ANN NEUROL, V59, P620, DOI 10.1002/ana.20800; Dilworth JT, 2006, BIOCHEM PHARMACOL, V72, P1485, DOI 10.1016/j.bcp.2006.04.010; Djordjevic V, 2009, J CHILD NEUROL, V24, P823, DOI 10.1177/0883073808330164; Eleftheriou D, 2009, STROKE, V40, pE124; Emerick KM, 2005, J PEDIATR GASTR NUTR, V41, P99, DOI 10.1097/01.MPG.0000162776.67758.2F; Fukui M, 2000, NEUROPATHOLOGY, V20, pS61, DOI 10.1046/j.1440-1789.2000.00300.x; Fullerton HJ, 2007, PEDIATRICS, V119, P495, DOI 10.1542/peds.2006-2791; Fullerton HJ, 2002, NEUROLOGY, V59, P34, DOI 10.1212/WNL.59.1.34; Fullerton HJ, 2003, NEUROLOGY, V61, P189, DOI 10.1212/01.WNL.0000078894.79866.95; Ganesan V, 2003, ANN NEUROL, V53, P167, DOI 10.1002/ana.10423; Ganesan V, 2006, CIRCULATION, V114, P2170, DOI 10.1161/CIRCULATIONAHA.105.583690; Gardner MA, 2010, NEUROLOGY, V74, P372, DOI 10.1212/WNL.0b013e3181cbcd48; Gilden D, 2009, LANCET NEUROL, V8, P731, DOI 10.1016/S1474-4422(09)70134-6; Goldenberg NA, 2009, LANCET NEUROL, V8, P1120, DOI 10.1016/S1474-4422(09)70241-8; Gould DB, 2006, NEW ENGL J MED, V354, P1489, DOI 10.1056/NEJMoa053727; Granild-Jensen J, 2009, DEV MED CHILD NEUROL, V51, P754, DOI 10.1111/j.1469-8749.2008.03241.x; Guo DC, 2009, AM J HUM GENET, V84, P617, DOI 10.1016/j.ajhg.2009.04.007; Han H, 2003, J KOREAN MED SCI, V18, P876, DOI 10.3346/jkms.2003.18.6.876; Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560; Hartley J, 2010, J CHILD NEUROL, V25, P623, DOI 10.1177/0883073810361382; Herve D, 2010, NEUROLOGY, V75, P259, DOI 10.1212/WNL.0b013e3181e8ee3f; Hsich GE, 2000, PEDIATR NEUROL, V23, P425, DOI 10.1016/S0887-8994(00)00207-1; Inoue TK, 1997, CLIN NEUROL NEUROSUR, V99, pS234; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jurczyk A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011812; Kalidas Kavita, 2008, Expert Rev Neurother, V8, P1731, DOI 10.1586/14737175.8.11.1731; Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4; Karahan ZC, 2005, THROMB RES, V115, P393, DOI 10.1016/j.thromres.2004.09.008; Karetova D, 2010, VASA, V39, P123, DOI 10.1024/0301-1526/a000017; Kawai Mie, 1993, Acta Paediatrica Japonica, V35, P63; Kelly PJ, 2003, NEUROLOGY, V60, P275, DOI 10.1212/01.WNL.0000042479.55406.B3; Kraus JP, 1999, HUM MUTAT, V13, P362; Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0; Lasater EA, 2008, HUM MOL GENET, V17, P2336, DOI 10.1093/hmg/ddn134; Lasater EA, 2010, J CLIN INVEST, V120, P859, DOI 10.1172/JCI41443; Laube S, 2005, ARCH DIS CHILD, V90, P754, DOI 10.1136/adc.2004.062075; Lee YC, 2010, HUM MOL GENET, V19, P3721, DOI 10.1093/hmg/ddq286; Li Z H, 1984, Zhonghua Yan Ke Za Zhi, V20, P238; Lo W, 2009, J CHILD NEUROL, V24, P194, DOI 10.1177/0883073808322665; Lopez-Vicente M, 2010, J STROKE CEREBROVASC, V19, P175, DOI 10.1016/j.jstrokecerebrovasdis.2009.03.013; Mackay MT, 2010, STROKE, V41, pE216; Man BL, 2010, J CLIN NEUROSCI, V17, P1244, DOI 10.1016/j.jocn.2010.01.050; MASUDA J, 1993, STROKE, V24, P1960, DOI 10.1161/01.STR.24.12.1960; Mehta A, 2005, ACTA PAEDIATR, V94, P24, DOI 10.1080/08035320510028076; Meyer S, 2005, BRIT J DERMATOL, V153, P431, DOI 10.1111/j.1365-2133.2005.06658.x; Milewicz DM, 2010, AM J MED GENET A, V152A, P2437, DOI 10.1002/ajmg.a.33657; Milewicz DM, 2010, GENET MED, V12, P196, DOI 10.1097/GIM.0b013e3181cdd687; Miller SP, 2006, STROKE, V37, P2678, DOI 10.1161/01.STR.0000244810.91105.c9; Mineharu Y, 2008, NEUROLOGY, V70, P2357, DOI 10.1212/01.wnl.0000291012.49986.f9; Moller LB, 2009, BIOCHIMIE, V91, P1273, DOI 10.1016/j.biochi.2009.05.011; NICKERSON E, 1995, AM J HUM GENET, V56, P1156; Nopajaroonsri C, 1996, HUM PATHOL, V27, P982, DOI 10.1016/S0046-8177(96)90229-4; Okumura Keiko, 2007, No To Hattatsu, V39, P49; Plaisier E, 2007, NEW ENGL J MED, V357, P2687, DOI 10.1056/NEJMoa071906; Pober BR, 2010, NEW ENGL J MED, V362, P239, DOI 10.1056/NEJMra0903074; PUTMAN CM, 1995, AM J NEURORADIOL, V16, P1536; Ramesh V, 2010, DEV MED CHILD NEUROL, V52, P725, DOI 10.1111/j.1469-8749.2010.03727.x; Rauch A, 2008, SCIENCE, V319, P816, DOI 10.1126/science.1151174; Razvi SSM, 2005, J NEUROL NEUROSUR PS, V76, P739, DOI 10.1136/jnnp.2004.051847; Rea D, 2009, PEDIATRICS, V124, pE476, DOI 10.1542/peds.2009-0152; Reid AJ, 2010, J NEUROSURG-PEDIATR, V6, P244, DOI 10.3171/2010.5.PEDS09505; Rice GI, 2009, NAT GENET, V41, P829, DOI 10.1038/ng.373; SALYER WR, 1974, ANGIOLOGY, V25, P510, DOI 10.1177/000331977402500803; Segade F, 2010, FEBS LETT, V584, P2990, DOI 10.1016/j.febslet.2010.06.011; Shah S, 2010, EUR J PAEDIATR NEURO, V14, P182, DOI 10.1016/j.ejpn.2009.04.010; Shiga Atsushi, 2010, Brain and Nerve (Tokyo), V62, P595; Shimojima K, 2009, J HUM GENET, V54, P687, DOI 10.1038/jhg.2009.91; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; SOPER R, 1995, J PEDIATR-US, V126, P945, DOI 10.1016/S0022-3476(95)70217-2; Thiele H, 2010, HUM MUTAT, V31, pE1836, DOI 10.1002/humu.21357; Tumer Z, 2010, EUR J HUM GENET, V18, P511, DOI 10.1038/ejhg.2009.187; Uitto J, 2010, J INVEST DERMATOL, V130, P661, DOI 10.1038/jid.2009.411; Vahedi K, 2007, STROKE, V38, P1461, DOI 10.1161/STROKEAHA.106.475194; van den Berg JSP, 2000, CEREBROVASC DIS, V10, P315, DOI 10.1159/000016076; Wang JJ, 2009, INT J IMMUNOGENET, V36, P113, DOI 10.1111/j.1744-313X.2009.00833.x; Wang T, 2008, PROG BIOPHYS MOL BIO, V96, P499, DOI 10.1016/j.pbiomolbio.2007.07.006; Wollack JB, 1996, STROKE, V27, P143, DOI 10.1161/01.STR.27.1.143; YAMASHITA M, 1983, STROKE, V14, P50, DOI 10.1161/01.STR.14.1.50; Yamauchi T, 1997, CLIN NEUROL NEUROSUR, V99, pS162; Zieden Bo, 2005, Curr Atheroscler Rep, V7, P364, DOI 10.1007/s11883-005-0048-7	94	39	38	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2011	10	3					264	274		10.1016/S1474-4422(10)70327-6	http://dx.doi.org/10.1016/S1474-4422(10)70327-6			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	736HR	21349441				2022-12-18	WOS:000288482200014
J	Petersen, RC				Petersen, Ronald C.			Alzheimer's disease: progress in prediction	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; IDENTIFIES VARIANTS; CLU		Mayo Clin, Alzheimers Dis Res Ctr, Coll Med, Rochester, MN 55905 USA	Mayo Clinic	Petersen, RC (corresponding author), Mayo Clin, Alzheimers Dis Res Ctr, Coll Med, Rochester, MN 55905 USA.	peter8@mayo.edu			NIA NIH HHS [U19 AG010483, UO1 AG6786, P50 AG016574, P50 AG16574, P50 AG016574-13, U01 AG006786-26, UO1 AG24904, U01 AG006786] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG006786, U01AG024904, P50AG016574, U19AG010483] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; Mormino EC, 2009, BRAIN, V132, P1310, DOI 10.1093/brain/awn320; PETERSEN R, ARCH NEUROL IN PRESS; PETERSEN RC, NEUROLOGY IN PRESS; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Visser PJ, 2009, LANCET NEUROL, V8, P619, DOI 10.1016/S1474-4422(09)70139-5	10	39	40	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					4	5		10.1016/S1474-4422(09)70330-8	http://dx.doi.org/10.1016/S1474-4422(09)70330-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	20083022	Green Accepted			2022-12-18	WOS:000273199700003
J	Raspall-Chaure, M; Neville, BG; Scott, RC				Raspall-Chaure, Miquel; Neville, Brian G.; Scott, Rod C.			The medical management of the epilepsies in children: conceptual and practical considerations	LANCET NEUROLOGY			English	Review							QUALITY-OF-LIFE; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; RANDOMIZED CONTROLLED-TRIALS; 1ST ANTIEPILEPTIC DRUG; CHILDHOOD EPILEPSY; STANDARDS SUBCOMMITTEE; AMERICAN ACADEMY; INTRACTABLE EPILEPSY; REFRACTORY EPILEPSY; OUTCOME ASSESSMENT	Epilepsy in children encompasses several syndromes. The cardinal feature of these syndromes is a predisposition to epileptic seizures but each is associated with different prognoses. The goals of treatment will clearly differ between children who become seizure-free on antiepileptic drug (AED) treatment and those children with refractory epilepsy. Treatment should be tailored to the needs of the patient, with a comprehensive approach that addresses the common additional morbidities in children with epilepsy. In this Review, we present an overview of the medical management of epilepsy in children and discuss the dilemmas of everyday practice, such as selection of AED, assessment of outcome, monitoring of treatment, and the decision to withdraw medication when the child is free from seizures. Furthermore, we emphasise the need to establish rational goals for treatment, such as aiming for the best possible quality of life rather than freedom from seizures at all costs.	[Raspall-Chaure, Miquel; Neville, Brian G.; Scott, Rod C.] Wolfson Ctr Magnet Technol, UCL Inst Child Hlth, Neurosci Unit, London WC1N 2AP, England; [Raspall-Chaure, Miquel; Neville, Brian G.; Scott, Rod C.] Natl Ctr Young People Epilepsy, Lingfield, England; [Raspall-Chaure, Miquel; Neville, Brian G.; Scott, Rod C.] Great Ormond St Hosp Sick Children, Epilepsy Unit, London, England; [Scott, Rod C.] UCL Inst Child Hlth, Radiol & Phys Unit, London, England; [Raspall-Chaure, Miquel] Hosp Univ Vall Hebron, Dept Paediat Neurol, Barcelona, Spain	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Hospital Universitari Vall d'Hebron	Scott, RC (corresponding author), Wolfson Ctr Magnet Technol, UCL Inst Child Hlth, Neurosci Unit, Mecklenburgh Sq, London WC1N 2AP, England.	r.scott@ich.ucl.ac.uk	Scott, Rod/C-5363-2008	Raspall-Chaure, Miquel/0000-0002-3132-3342				Aldred C, 2004, J CHILD PSYCHOL PSYC, V45, P1420, DOI 10.1111/j.1469-7610.2004.00338.x; Alvarez N, 1998, J INTELL DISABIL RES, V42, P1; Andersson T, 1997, EPILEPSIA, V38, P225, DOI 10.1111/j.1528-1157.1997.tb01101.x; Arts WFM, 2004, BRAIN, V127, P1774, DOI 10.1093/brain/awh200; ARZIMANOGLOU A, 2004, GEN PRINCIPLES MANAG, P354; Banu SH, 2003, DEV MED CHILD NEUROL, V45, P477, DOI 10.1017/S0012162203000884; Baumann RJ, 2000, PEDIATR NEUROL, V23, P11, DOI 10.1016/S0887-8994(00)00148-X; Bazil CW, 2004, EPILEPSIA, V45, P3; BEGHI E, 1987, DEV MED CHILD NEUROL, V29, P363; Beghi E, 2004, LANCET NEUROL, V3, P618, DOI 10.1016/S1474-4422(04)00882-8; Ben-Menachem E, 2003, ACTA NEUROL SCAND, V108, P5, DOI 10.1034/j.1600-0404.108.s180.2.x; Ben-Menachem E, 2006, EPILEPSIA, V47, P62, DOI 10.1111/j.1528-1167.2006.00663.x; BENNETT HS, 1983, DEV MED CHILD NEUROL, V25, P735; Berg AT, 2006, ANN NEUROL, V60, P73, DOI 10.1002/ana.20852; Berg AT, 2006, EPILEPSIA, V47, P431, DOI 10.1111/j.1528-1167.2006.00440.x; Berg AT, 2001, EPILEPSIA, V42, P1553, DOI 10.1046/j.1528-1157.2001.21101.x; Berg AT, 2001, NEUROLOGY, V56, P1445, DOI 10.1212/WNL.56.11.1445; BERG AT, 1994, NEUROLOGY, V44, P601, DOI 10.1212/WNL.44.4.601; Besag FMC, 2002, J CHILD PSYCHOL PSYC, V43, P103, DOI 10.1111/1469-7610.00006; Birbeck GL, 2002, EPILEPSIA, V43, P535, DOI 10.1046/j.1528-1157.2002.32201.x; Bourgeois BFD, 2002, EPILEPSY RES, V52, P53, DOI 10.1016/S0920-1211(02)00185-7; Brodie M.J., 2002, NEUROLOGY S5, V58, P2; Bureau M, 2005, BRAIN DEV-JPN, V27, P178, DOI 10.1016/j.braindev.2004.01.008; Calvert S, 2005, EPILEPSIA, V46, P144; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; CAMFIELD C, 1986, NEUROLOGY, V36, P838, DOI 10.1212/WNL.36.6.838; Camfield P, 2005, NEUROLOGY, V64, P973, DOI 10.1212/01.WNL.0000154517.82748.A7; Camfield P, 2006, EPILEPSIA, V47, P31, DOI 10.1111/j.1528-1167.2006.00657.x; Camfield PR, 1997, J PEDIATR-US, V131, P821, DOI 10.1016/S0022-3476(97)70027-1; Chadwick D, 2007, EPILEPSIA, V48, P1259, DOI 10.1111/j.1528-1167.2007.01086.x; Chadwick D, 2006, EPILEPSIA, V47, P58, DOI 10.1111/j.1528-1167.2006.00662.x; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Cowan J, 2004, QUAL LIFE RES, V13, P1435, DOI 10.1023/B:QURE.0000040796.54498.69; Cramer JA, 2002, EPILEPSIA, V43, P1084, DOI 10.1046/j.1528-1157.2002.47501.x; Cross H, 2007, LANCET, V370, P314, DOI 10.1016/S0140-6736(07)61151-9; Cross JH, 2006, EPILEPSIA, V47, P952, DOI 10.1111/j.1528-1167.2006.00569.x; Davis E, 2006, DEV MED CHILD NEUROL, V48, P311, DOI 10.1017/S0012162206000673; Deckers CLP, 2003, EPILEPSY RES, V53, P1, DOI 10.1016/S0920-1211(02)00257-7; Deckers CLP, 2001, EPILEPSIA, V42, P1387, DOI 10.1046/j.1528-1157.2001.30800.x; Deckers CLP, 2000, EPILEPSIA, V41, P1364, DOI 10.1111/j.1528-1157.2000.tb00111.x; Dlugos DJ, 2001, NEUROLOGY, V57, P2259, DOI 10.1212/WNL.57.12.2259; Dooley J, 1996, NEUROLOGY, V46, P969, DOI 10.1212/WNL.46.4.969; DREIFUSS FE, 1987, NEUROLOGY, V37, P379, DOI 10.1212/WNL.37.3.379; Dulac O, 2001, EPILEPSIA, V42, P23, DOI 10.1046/j.1528-1157.2001.042suppl.3023.x; Dunn DW, 2003, DEV MED CHILD NEUROL, V45, P50, DOI 10.1017/S0012162203000094; El Sabbagh S, 2006, EPILEPSY BEHAV, V9, P573, DOI 10.1016/j.yebeh.2006.08.004; Elger CE, 1999, EPILEPSIA, V40, pS9, DOI 10.1111/j.1528-1157.1999.tb00926.x; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; FERNGREN H, 1991, ACTA PAEDIATR SCAND, V80, P458, DOI 10.1111/j.1651-2227.1991.tb11882.x; French J, 1999, NEUROLOGY, V52, P1540, DOI 10.1212/WNL.52.8.1540; French JA, 2004, NEUROLOGY, V62, P1252, DOI 10.1212/01.WNL.0000123693.82339.FC; French JA, 2004, NEUROLOGY, V62, P1261, DOI 10.1212/01.WNL.0000123695.22623.32; FROSCHER W, 1981, J NEUROL, V224, P193, DOI 10.1007/BF00313281; Gayatri NA, 2006, DEV MED CHILD NEUROL, V48, P394, DOI 10.1017/S0012162206000843; Geerts AT, 2005, NEUROLOGY, V64, P2136, DOI 10.1212/01.WNL.0000166035.26217.61; Gerstner T, 2006, EPILEPSIA, V47, P1136, DOI 10.1111/j.1528-1167.2006.00587.x; GILLHAM RA, 1988, J NEUROL NEUROSUR PS, V51, P929, DOI 10.1136/jnnp.51.7.929; Gilliam F, 2004, NEUROLOGY, V63, pS9, DOI 10.1212/WNL.63.10_suppl_4.S9; Gilliam F, 1999, NEUROLOGY, V53, P687, DOI 10.1212/WNL.53.4.687; Gilliam FG, 2004, NEUROLOGY, V62, P23, DOI 10.1212/WNL.62.1.23; Glauser T, 2006, EPILEPSIA, V47, P1094, DOI 10.1111/j.1528-1167.2006.00585.x; Goh S, 2005, NEUROLOGY, V65, P235, DOI 10.1212/01.wnl.0000168908.78118.99; Guerrini R, 2006, LANCET, V367, P499, DOI 10.1016/S0140-6736(06)68182-8; Guerrini R, 2002, EPILEPTIC DISORD, V4, pS9; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; Hirsch LJ, 2006, EPILEPSIA, V47, P318, DOI 10.1111/j.1528-1167.2006.00423.x; Holmes GL, 2002, EPILEPSY RES, V52, P35, DOI 10.1016/S0920-1211(02)00183-3; HUTTENLOCHER PR, 1990, ANN NEUROL, V28, P699, DOI 10.1002/ana.410280516; Jannuzzi G, 2000, EPILEPSIA, V41, P222, DOI 10.1111/j.1528-1157.2000.tb00144.x; Jones JE, 2002, EPILEPSIA, V43, P896, DOI 10.1046/j.1528-1157.2002.43201.x; Jonker DM, 2007, EPILEPSIA, V48, P412, DOI 10.1111/j.1528-1167.2006.00952.x; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; Kneen R, 2006, ARCH DIS CHILD, V91, P936, DOI 10.1136/adc.2005.080002; Kwan P, 2001, EPILEPSIA, V42, P1255, DOI 10.1046/j.1528-1157.2001.04501.x; Kwan P, 2004, J NEUROL NEUROSUR PS, V75, P1376, DOI 10.1136/jnnp.2004.045690; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Kwan P, 2001, LANCET, V357, P216, DOI 10.1016/S0140-6736(00)03600-X; Lagae L, 2006, SEIZURE-EUR J EPILEP, V15, P235, DOI 10.1016/j.seizure.2006.02.013; Loring DW, 2004, NEUROLOGY, V62, P872, DOI 10.1212/01.WNL.0000115653.82763.07; Lux AL, 2005, LANCET NEUROL, V4, P712, DOI 10.1016/S1474-4422(05)70199-X; Malow BA, 2004, MENT RETARD DEV D R, V10, P122, DOI 10.1002/mrdd.20023; Markand ON, 2000, EPILEPSIA, V41, P749, DOI 10.1111/j.1528-1157.2000.tb00238.x; Marsh ED, 2006, EPILEPSIA, V47, P1999, DOI 10.1111/j.1528-1167.2006.00894.x; Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7; Mattson RH, 1996, EPILEPSIA, V37, pS45, DOI 10.1111/j.1528-1157.1996.tb06039.x; McLachlan RS, 1997, ANN NEUROL, V41, P482, DOI 10.1002/ana.410410411; Naritoku DK, 2005, ANN PHARMACOTHER, V39, P418, DOI 10.1345/aph.1E403; National Institute for Clinical Excellence, 2004, DIAGN MAN EP AD CHIL; Neville BGR, 1999, BRAIN DEV-JPN, V21, P82, DOI 10.1016/S0387-7604(98)00097-7; Nicolai J, 2006, EPILEPSY BEHAV, V8, P56, DOI 10.1016/j.yebeh.2005.08.016; Nolan MA, 2003, EPILEPSY RES, V53, P139, DOI 10.1016/S0920-1211(02)00261-9; Panayiotopoulos CP, 2007, EPILEPSIA, V48, P1041, DOI 10.1111/j.1528-1167.2006.01092.x; Panayiotopoulos CP, 2007, EPILEPSIA, V48, P1268, DOI 10.1111/j.1528-1167.2007.01172.x; PENRY JK, 1989, EPILEPSIA, V30, pS19, DOI 10.1111/j.1528-1157.1989.tb05833.x; Perucca E, 2005, CNS DRUGS, V19, P897, DOI 10.2165/00023210-200519110-00001; Perucca E, 2003, EPILEPSIA, V44, P41, DOI 10.1046/j.1528-1157.44.s4.1.x; Perucca E, 2002, EPILEPSY RES, V52, P25, DOI 10.1016/S0920-1211(02)00182-1; Perucca E, 2001, EPILEPSIA, V42, P31, DOI 10.1046/j.1528-1157.2001.042suppl.3031.x; Perucca E, 2007, LANCET, V370, P313, DOI 10.1016/S0140-6736(07)61149-0; Peters JM, 2001, NEUROLOGY, V57, P537, DOI 10.1212/WNL.57.3.537; POINDEXTER AR, 1993, AM J MENT RETARD, V98, P34; Ranganathan LN, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005003.pub2; Richardson SP, 2004, EPILEPSY BEHAV, V5, P343, DOI 10.1016/j.yebeh.2004.01.006; Ronen Gabriel M, 2003, Health Qual Life Outcomes, V1, P36, DOI 10.1186/1477-7525-1-36; Sabaz M, 2006, NEUROLOGY, V66, P557, DOI 10.1212/01.wnl.0000197788.38783.09; Sabaz M, 2003, J PAEDIATR CHILD H, V39, P690, DOI 10.1046/j.1440-1754.2003.00270.x; Sander JW, 2004, EPILEPSIA, V45, P28, DOI 10.1111/j.0013-9580.2004.455005.x; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SCHMIDT D, 1983, EPILEPSIA, V24, P368, DOI 10.1111/j.1528-1157.1983.tb04900.x; Schmidt D, 2005, ACTA NEUROL SCAND, V111, P291, DOI 10.1111/j.1600-0404.2005.00408.x; Schmidt D, 2002, EPILEPSY RES, V52, P3, DOI 10.1016/S0920-1211(02)00180-8; SHINNAR S, 1994, ANN NEUROL, V35, P534, DOI 10.1002/ana.410350506; Sirven JI, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001902; SIVENIUS J, 1990, ACTA NEUROL SCAND, V81, P165; Smith MC, 2006, NEUROLOGY, V67, pS52, DOI 10.1212/WNL.67.12_suppl_4.S52; Specchio N, 2006, EPILEPSY RES, V70, pS156, DOI 10.1016/j.eplepsyres.2006.01.018; St Louis EK, 2007, EPILEPSY BEHAV, V11, P222, DOI 10.1016/j.yebeh.2007.04.007; Steinhoff BJ, 2003, ACTA NEUROL SCAND, V107, P87, DOI 10.1034/j.1600-0404.2003.01311.x; Tan M, 2005, ARCH DIS CHILD, V90, P57, DOI 10.1136/adc.2003.048504; Tassinari CA, 2000, CLIN NEUROPHYSIOL, V111, pS94, DOI 10.1016/S1388-2457(00)00408-9; Wiebe S, 1997, EPILEPSIA, V38, P430, DOI 10.1111/j.1528-1157.1997.tb01732.x; WOO E, 1988, EPILEPSIA, V29, P129, DOI 10.1111/j.1528-1157.1988.tb04408.x; Zaccara G, 2007, EPILEPSIA, V48, P1223, DOI 10.1111/j.1528-1167.2007.01041.x	123	39	41	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					57	69		10.1016/S1474-4422(07)70324-1	http://dx.doi.org/10.1016/S1474-4422(07)70324-1			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093563				2022-12-18	WOS:000252063300027
J	Audebert, H				Audebert, H			Telestroke: effective networking	LANCET NEUROLOGY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; TELEMEDIC PILOT PROJECT; ACUTE ISCHEMIC-STROKE; CARE TEMPIS; THROMBOLYSIS; RELIABILITY	Although stroke units and systemic thrombolysis are effective, use of these two treatment methods is restricted because of a widespread lack of expertise. New telecommunication technologies can help to overcome the lack of emergency-provider support in neurologically underserved areas. The status of "telestroke" as the application of telemedicine for acute stroke is presently passing from feasibility to routine use. Teleneurological examination is reliable and systemic thrombolysis can be extended with telemedical consultation. Telestroke, however, offers even more potential in overall acute stroke management. On the one hand, it provides rapid access to specialised interventions through initiation of interhospital transfers, and on the other hand, it might lead to major improvements in basic on-site stroke therapy.	Krankenhaus Harlaching, Stadt Klinikum Munchen GmbH, Dept Neurol, D-81545 Munich, Germany	Munchen Klinik	Audebert, H (corresponding author), Krankenhaus Harlaching, Stadt Klinikum Munchen GmbH, Dept Neurol, Sanat Pl 2, D-81545 Munich, Germany.	neuro.audebert@khmh.de		Audebert, Heinrich/0000-0002-4785-0366				Arora S, 2005, STROKE, V36, P1232, DOI 10.1161/01.STR.0000165902.18021.5b; Audebert HJ, 2005, DEUT MED WOCHENSCHR, V130, P2495, DOI 10.1055/s-2005-918593; Audebert HJ, 2005, CEREBROVASC DIS, V20, P362, DOI 10.1159/000088064; Audebert HJ, 2005, STROKE, V36, P287, DOI 10.1161/01.STR.0000153015.57892.66; Audebert HJ, 2004, NERVENARZT, V75, P161, DOI 10.1007/s00115-003-1659-2; BOGOUSSLAVSKY J, 2003, CEREBROVASC DIS, V15, P4; Caplan LR, 2004, JAMA-J AM MED ASSOC, V292, P1883, DOI 10.1001/jama.292.15.1883; Chua R, 2001, J NEUROL NEUROSUR PS, V71, P63, DOI 10.1136/jnnp.71.1.63; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Handschu R, 2003, STROKE, V34, P2842, DOI 10.1161/01.STR.0000102043.70312.E9; LaMonte MP, 2003, STROKE, V34, P725, DOI 10.1161/01.STR.0000056945.36583.37; Levine SR, 1999, STROKE, V30, P464, DOI 10.1161/01.STR.30.2.464; Meyer BC, 2005, NEUROLOGY, V64, P1058, DOI 10.1212/01.WNL.0000154601.26653.E7; Moulin T, 2005, J NEUROL NEUROSUR PS, V76, P760, DOI 10.1136/jnnp.2004.059121; Moulin T, 2004, CEREBROVASC DIS, V17, P6; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Nallamothu BK, 2005, CIRCULATION, V111, P761, DOI 10.1161/01.CIR.0000155258.44268.F8; Schenkel J, 2003, J NEUROL, V250, P320, DOI 10.1007/s00415-003-1004-5; Schwamm LH, 2004, ACAD EMERG MED, V11, P1193, DOI 10.1197/j.aem.2004.08.014; SCOTT PA, 2002, PROVIDER SUPPORT SYS; Shafqat S, 1999, STROKE, V30, P2141, DOI 10.1161/01.STR.30.10.2141; Sinclair SE, 2001, PHARMACOECONOMICS, V19, P927, DOI 10.2165/00019053-200119090-00004; Wang DZ, 2003, STROKE, V34, P2957, DOI 10.1161/01.STR.0000103837.32579.3C; Wang S, 2004, STROKE, V35, P1763, DOI 10.1161/01.STR.0000131858.63829.6e; Wang S, 2003, STROKE, V34, pE188, DOI 10.1161/01.STR.0000091847.82140.9D; Wiborg A, 2003, STROKE, V34, P2951, DOI 10.1161/01.STR.0000099125.30731.97; Wiborg A, 2000, AKTUEL NEUROL, V27, P119, DOI 10.1055/s-2007-1017532	27	39	39	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2006	5	3					279	282		10.1016/S1474-4422(06)70378-7	http://dx.doi.org/10.1016/S1474-4422(06)70378-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016PS	16488384				2022-12-18	WOS:000235632900023
J	Bianchin, MM; Velasco, TR				Bianchin, MM; Velasco, TR			Neurocysticercosis, mesial temporal lobe epilepsy, and hippocampal sclerosis: an association largely ignored	LANCET NEUROLOGY			English	Editorial Material									Univ Fed Rio Grande Sul, Div Neurol, Hosp Clin Porto Alegre, BR-90046900 Porto Alegre, RS, Brazil; Univ Sao Paulo, Dept Neurol Psychiat & Med Psychol, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil	Universidade Federal do Rio Grande do Sul; Universidade de Sao Paulo	Bianchin, MM (corresponding author), Univ Fed Rio Grande Sul, Div Neurol, Hosp Clin Porto Alegre, BR-90046900 Porto Alegre, RS, Brazil.	mmbianchin@rnp.fmrp.usp.br	Velasco, Tonicarlo/A-2013-2008; Bianchin, Marino/V-5956-2019; Velasco, Tonicarlo R/Q-2170-2016; Sakamoto, Americo C/H-5311-2012	Velasco, Tonicarlo R/0000-0001-7756-8882; 				Agapejev S, 2003, ARQ NEURO-PSIQUIAT, V61, P822, DOI 10.1590/S0004-282X2003000500022; Garcia HH, 2005, LANCET NEUROL, V4, P653, DOI 10.1016/S1474-4422(05)70194-0; Kobayashi E, 2001, ARQ NEURO-PSIQUIAT, V59, P255, DOI 10.1590/S0004-282X2001000200021; Nash TE, 2004, NEUROLOGY, V62, P1934, DOI 10.1212/01.WNL.0000129481.12067.06; Sakamoto A., 1999, EPILEPSIES ETIOLOGIE, P275; Wichert-Ana L, 2004, ARCH NEUROL-CHICAGO, V61, P1117, DOI 10.1001/archneur.61.7.1117	6	39	39	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					20	21		10.1016/S1474-4422(05)70269-6	http://dx.doi.org/10.1016/S1474-4422(05)70269-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361019				2022-12-18	WOS:000234328100015
J	Healy, DG; Abou-Sleiman, PM; Wood, NW				Healy, DG; Abou-Sleiman, PM; Wood, NW			PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism	LANCET NEUROLOGY			English	Review							EARLY-ONSET PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; LINKED DYSTONIA-PARKINSONISM; AUTOSOMAL-DOMINANT PARKINSONISM; SPINOCEREBELLAR ATAXIA TYPE-2; ALPHA-SYNUCLEIN; FRAGILE-X; TREMOR/ATAXIA SYNDROME; TAU GENE; GUADELOUPEAN PARKINSONISM	We provide a pragmatic guide for clinicians, and detail the recent developments in the genetics of Parkinson's disease that have shaped our current understanding and management of this disease and other parkinsonian disorders. These developments have been rapid, and in total over 20 genes have been identified, three of which were discovered in the past year. Although there are undoubtedly more genes to be found, the major challenge for the future is to determine how they function and whether they interact. These genes help us to understand the heterogeneity of parkinsonism, and also inform on the molecular and clinical features of individual parkinsonisms. However, their discovery also requires us to raise issues about genetic testing and genetic counselling.	Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Wood, NW (corresponding author), Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England.	n.wood@ion.ucl.ac.uk	Wood, Nicholas W/C-2505-2009	Wood, Nicholas W/0000-0002-9500-3348	Parkinson&apos;s UK [G-4029] Funding Source: Medline	Parkinson&apos;s UK(Parkinson&apos;s UK)		Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Aguiar PD, 2004, NEURON, V43, P169, DOI 10.1016/j.neuron.2004.06.028; Allingham-Hawkins SJ, 1999, AM J MED GENET, V83, P322, DOI 10.1002/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-B; Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Caparros-Lefebvre D, 2002, BRAIN, V125, P801, DOI 10.1093/brain/awf086; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Cookson MR, 2003, NEUROMOL MED, V3, P1, DOI 10.1385/NMM:3:1:1; Curtis ARJ, 2001, NAT GENET, V28, P350, DOI 10.1038/ng571; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; DeStefano AL, 2002, AM J HUM GENET, V70, P1089, DOI 10.1086/339814; DOBYNS WB, 1993, NEUROLOGY, V43, P2596, DOI 10.1212/WNL.43.12.2596; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Eriksen JL, 2003, NEURON, V40, P453, DOI 10.1016/S0896-6273(03)00684-6; Evidente VGH, 2002, MOVEMENT DISORD, V17, P1271, DOI 10.1002/mds.10271; Factor SA, 1997, MOVEMENT DISORD, V12, P783, DOI 10.1002/mds.870120528; Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Geschwind DH, 1999, AM J HUM GENET, V65, P764, DOI 10.1086/302558; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GIBB WRG, 1992, MOVEMENT DISORD, V7, P217, DOI 10.1002/mds.870070305; Greco CM, 2002, BRAIN, V125, P1760, DOI 10.1093/brain/awf184; Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966; Gwinn-Hardy K, 2001, ARCH NEUROL-CHICAGO, V58, P296, DOI 10.1001/archneur.58.2.296; Gwinn-Hardy K, 2000, NEUROLOGY, V55, P800, DOI 10.1212/WNL.55.6.800; Hagerman RJ, 2004, AM J HUM GENET, V74, P1051, DOI 10.1086/420700; Hagerman RJ, 2001, NEUROLOGY, V57, P127, DOI 10.1212/WNL.57.1.127; Hampshire DJ, 2001, J MED GENET, V38, P680, DOI 10.1136/jmg.38.10.680; Hardy J, 2003, SCIENCE, V300, P739, DOI 10.1126/science.300.5620.739; Hatano Y, 2004, ANN NEUROL, V56, P424, DOI 10.1002/ana.20251; Hayflick SJ, 2003, NEW ENGL J MED, V348, P33, DOI 10.1056/NEJMoa020817; Healy DG, 2004, J NEUROL NEUROSUR PS, V75, P962, DOI 10.1136/jnnp.2003.026203; Healy DG, 2004, NEUROLOGY, V63, P1486; Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Hering R, 2004, NEUROLOGY, V62, P1231, DOI 10.1212/01.WNL.0000118285.18383.90; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Houlden H, 2001, NEUROLOGY, V56, P1702, DOI 10.1212/WNL.56.12.1702; HUBBLE JP, 1993, NEUROLOGY, V43, P1693, DOI 10.1212/WNL.43.9.1693; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Izumi Y, 2001, NEUROSCI LETT, V300, P125, DOI 10.1016/S0304-3940(01)01557-9; Jacquemont S, 2004, JAMA-J AM MED ASSOC, V291, P460, DOI 10.1001/jama.291.4.460; Jacquemont S, 2003, AM J HUM GENET, V72, P869, DOI 10.1086/374321; KAMM C, 2004, WORLD MOV DIS C ROM, pS352; Kann M, 2002, ANN NEUROL, V51, P621, DOI 10.1002/ana.10179; Khan NL, 2002, BRAIN, V125, P2248, DOI 10.1093/brain/awf237; Khan NL, 2002, ANN NEUROL, V52, P849, DOI 10.1002/ana.10417; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lantos PL, 2002, NEUROLOGY, V58, P1169, DOI 10.1212/WNL.58.8.1169; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; LEE LV, 1991, MEDICINE, V70, P179, DOI 10.1097/00005792-199105000-00002; Lees AJ, 2003, MOVEMENT DISORD, V18, pS28, DOI 10.1002/mds.10559; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lincoln SJ, 2003, MOVEMENT DISORD, V18, P1306, DOI 10.1002/mds.10601; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Lohmann E, 2003, ANN NEUROL, V54, P176, DOI 10.1002/ana.10613; LOVE S, 1995, BRAIN, V118, P119, DOI 10.1093/brain/118.1.119; Lu CS, 2004, ARCH NEUROL-CHICAGO, V61, P35, DOI 10.1001/archneur.61.1.35; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; Maraganore DM, 2004, ANN NEUROL, V55, P512, DOI 10.1002/ana.20017; Marshall V, 2003, MOVEMENT DISORD, V18, P1415, DOI 10.1002/mds.10592; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Morris HR, 2001, BRAIN, V124, P2215, DOI 10.1093/brain/124.11.2215; Muenter MD, 1998, ANN NEUROL, V43, P768, DOI 10.1002/ana.410430612; Nichols WC, 2004, MOVEMENT DISORD, V19, P649, DOI 10.1002/mds.20097; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Nolte D, 2003, P NATL ACAD SCI USA, V100, P10347, DOI 10.1073/pnas.1831949100; NYGAARD TG, 1995, CURR OPIN NEUROL, V8, P310, DOI 10.1097/00019052-199508000-00011; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Pankratz N, 2003, AM J HUM GENET, V72, P1053, DOI 10.1086/374383; Pastor P, 2000, ANN NEUROL, V47, P242; Paviour DC, 2004, MOVEMENT DISORD, V19, P123, DOI 10.1002/mds.10644; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Pittock SJ, 2000, NEUROLOGY, V55, P991, DOI 10.1212/WNL.55.7.991; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quinn N, 1998, J NEUROL, V245, P709, DOI 10.1007/s004150050272; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Rohe CF, 2004, ANN NEUROL, V56, P427, DOI 10.1002/ana.20247; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Shen J, 2004, NEURON, V43, P301, DOI 10.1016/j.neuron.2004.07.012; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Steele JC, 2002, PARKINSONISM RELAT D, V9, P39, DOI 10.1016/S1353-8020(02)00043-3; Subramony SH, 2002, MOVEMENT DISORD, V17, P1068, DOI 10.1002/mds.10241; TAKAHASHI H, 1993, ADV NEUROL, V60, P586; Tan EK, 2004, NEUROLOGY, V63, P362, DOI 10.1212/01.WNL.0000130199.57181.7B; TURPIN JC, 1991, DEV NEUROSCI-BASEL, V13, P304, DOI 10.1159/000112177; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Valente EM, 2004, ANN NEUROL, V56, P336, DOI 10.1002/ana.20256; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Vanmolkot KRJ, 2003, ANN NEUROL, V54, P360, DOI 10.1002/ana.10674; VANWASSENAERVANHALL HN, 1995, AM J NEURORADIOL, V16, P2021; WALSHE FMR, 1955, J PARKINSON 1755 182, P265; WATERS CH, 1993, NEUROLOGY, V43, P1555, DOI 10.1212/WNL.43.8.1555; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Wszolek ZK, 2004, NEUROLOGY, V62, P1619, DOI 10.1212/01.WNL.0000125015.06989.DB; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Yokota T, 2003, BIOCHEM BIOPH RES CO, V312, P1342, DOI 10.1016/j.bbrc.2003.11.056; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zimprich A, 2004, AM J HUM GENET, V74, P11, DOI 10.1086/380647; ZUHLKE C, 1993, HUM MOL GENET, V2, P2063, DOI 10.1093/hmg/2.12.2063	127	39	41	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2004	3	11					652	662		10.1016/S1474-4422(04)00905-6	http://dx.doi.org/10.1016/S1474-4422(04)00905-6			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865CL	15488458				2022-12-18	WOS:000224680000018
J	Robba, C; Graziano, F; Rebora, P; Elli, F; Giussani, C; Oddo, M; Meyfroidt, G; Helbok, R; Taccone, FS; Prisco, L; Vincent, JL; Suarez, JI; Stocchetti, N; Citerio, G				Robba, Chiara; Graziano, Francesca; Rebora, Paola; Elli, Francesca; Giussani, Carlo; Oddo, Mauro; Meyfroidt, Geert; Helbok, Raimund; Taccone, Fabio S.; Prisco, Lara; Vincent, Jean-Louis; Suarez, Jose, I; Stocchetti, Nino; Citerio, Giuseppe		SYNAPSE-ICU Investigators	Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU) : an international, prospective observational cohort study	LANCET NEUROLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; CONSENSUS CONFERENCE; NEUROCRITICAL CARE; MANAGEMENT; GUIDELINES; PROFESSIONALS; HYPERTENSION; HEMORRHAGE; MORTALITY; SOCIETY	Background The indications for intracranial pressure (ICP) monitoring in patients with acute brain injury and the effects of ICP on patients' outcomes are uncertain. The aims of this study were to describe current ICP monitoring practises for patients with acute brain injury at centres around the world and to assess variations in indications for ICP monitoring and interventions, and their association with long-term patient outcomes. Methods We did a prospective, observational cohort study at 146 intensive care units (ICUs) in 42 countries. We assessed for eligibility all patients aged 18 years or older who were admitted to the ICU with either acute brain injury due to primary haemo-rrhagic stroke (including intracranial haemorrhage or subarachnoid haemorrhage) or traumatic brain injury. We included patients with altered levels of consciousness at ICU admission or within the first 48 h after the brain injury, as defined by the Glasgow Coma Scale (GCS) eye response score of 1 (no eye opening) and a GCS motor response score of at least 5 (not obeying commands). Patients not admitted to the ICU or with other forms of acute brain injury were excluded from the study. Between-centre differences in use of ICP monitoring were quantified by using the median odds ratio (MOR). We used the therapy intensity level (TIL) to quantify practice variations in ICP interventions. Primary endpoints were 6 month mortality and 6 month Glasgow Outcome Scale Extended (GOSE) score. A propensity score method with inverse probability of treatment weighting was used to estimate the association between use of ICP monitoring and these 6 month outcomes, independently of measured baseline covariates. This study is registered with ClinicalTrial.gov, NCT03257904. Findings Between March 15, 2018, and April 30, 2019, 4776 patients were assessed for eligibility and 2395 patients were included in the study, including 1287 (54%) with traumatic brain injury, 587 (25%) with intracranial haemorrhage, and 521 (22%) with subarachnoid haemorrhage. The median age of patients was 55 years (IQR 39-69) and 1567 (65%) patients were male. Considerable variability was recorded in the use of ICP monitoring across centres (MOR 4.5, 95% CI 3.8-4.9 between two randomly selected centres for patients with similar covariates). 6 month mortality was lower in patients who had ICP monitoring (441/1318 [34%]) than in those who were not monitored (517/1049 [49%]; p<0.0001). ICP monitoring was associated with significantly lower 6 month mortality in patients with at least one unreactive pupil (hazard ratio [HR] 0.35, 95% CI 0.26-0.47; p<0.0001), and better neurological outcome at 6 months (odds ratio 0.38, 95% CI 0.26-0.56; p=0.0025). Median TIL was higher in patients with ICP monitoring (9 [IQR 7-12]) than in those who were not monitored (5 [3-8]; p<0.0001) and an increment of one point in TIL was associated with a reduction in mortality (HR 0.94, 95% CI 0.91-0.98; p=0.0011). Interpretation The use of ICP monitoring and ICP management varies greatly across centres and countries. The use of ICP monitoring might be associated with a more intensive therapeutic approach and with lower 6-month mortality in more severe cases. Intracranial hypertension treatment guided by monitoring might be considered in severe cases due to the potential associated improvement in long-term clinical results. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Robba, Chiara] IRCCS, Policlin San Martino, Anesthesia & Intens Care, Oncol & Neurosci, Genoa, Italy; [Robba, Chiara] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Genoa, Italy; [Graziano, Francesca; Rebora, Paola; Elli, Francesca; Giussani, Carlo; Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy; [Graziano, Francesca; Rebora, Paola] Univ Milano Bicocca, Bicocca Bioinformat Biostat & Bioimaging Ctr B4, Sch Med & Surg, Milan, Italy; [Giussani, Carlo] Azienda Sociosanit Terr Monza, Osped San Gerardo, Neurosurg, Monza, Italy; [Oddo, Mauro] CHUV Lausanne Univ Hosp, Dept Intens Care Med, Lausanne, Switzerland; [Meyfroidt, Geert] Univ Hosp, Dept Intens Care Med, Leuven, Belgium; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurocrit Care Unit, Innsbruck, Austria; [Taccone, Fabio S.; Vincent, Jean-Louis] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Prisco, Lara] Oxford Univ Hosp Trust, Nuffield Dept Clin Neurosci, Oxford, England; [Suarez, Jose, I] Johns Hopkins Univ, Div Neurosci Crit Care, Sch Med, Baltimore, MD USA; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Milan, Italy; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Citerio, Giuseppe] Osped San Gerardo, Azienda Sociosanit Terr Monza, Neurointens Care Unit, Monza, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Milano-Bicocca; University of Milano-Bicocca; San Gerardo Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Medical University of Innsbruck; Universite Libre de Bruxelles; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Johns Hopkins University; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; San Gerardo Hospital	Citerio, G (corresponding author), Univ Milano Bicocca, Sch Med & Surg, Monza, Italy.	giuseppe.citerio@unimib.it	MAKRIS, DEMOSTHENES/J-5953-2015; Elhadi, Muhammed/AAU-5641-2020; Roka, Yam Bahadur/AHC-6818-2022; Lamperti, Massimo/K-7447-2019; GIUSSANI, CARLO GIORGIO/AAC-2941-2022; idowu, olufemi Emmanuel/AIC-7426-2022; Rebora, Paola/M-9098-2016; Galarza, Laura/ABB-2294-2020; Krieg, Sandro M./L-8902-2016; Ozair, Ahmad/B-9701-2018; Kovac, Natasa/H-2008-2017; Berty Gutierrez, Hedgar/I-1237-2018; Gritsan, Alexey/M-4261-2014	MAKRIS, DEMOSTHENES/0000-0003-1951-6421; Elhadi, Muhammed/0000-0001-6406-4212; Roka, Yam Bahadur/0000-0003-1458-3705; Lamperti, Massimo/0000-0001-8270-2724; GIUSSANI, CARLO GIORGIO/0000-0002-9033-2927; idowu, olufemi Emmanuel/0000-0001-9064-1562; Rebora, Paola/0000-0003-0606-5852; Galarza, Laura/0000-0002-4658-748X; Krieg, Sandro M./0000-0003-4050-1531; Ozair, Ahmad/0000-0001-6570-4541; Kovac, Natasa/0000-0002-8269-6675; Villa, Federico/0000-0001-6379-8003; Meyfroidt, Geert/0000-0003-4259-3935; Berty Gutierrez, Hedgar/0000-0003-4458-2930; SELLAMI, WALID/0000-0002-1446-4469; Spatenkova, Vera/0000-0003-4989-0967; Zerbi, Simone Maria/0000-0002-4957-3112; Gritsan, Alexey/0000-0002-0500-2887; kilapong, Bram/0000-0002-9863-9632; Skola, Josef/0000-0002-6795-3020; Shum, Hoi Ping/0000-0001-7002-3548; Prisco, Lara/0000-0001-6727-7870; GELORMINI, CAMILLA/0000-0002-4867-5037	University of Milano-Bicocca; European Society of Intensive Care Medicine	University of Milano-Bicocca; European Society of Intensive Care Medicine	University of Milano-Bicocca and the European Society of Intensive Care Medicine.	Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Chesnut R, 2020, INTENS CARE MED, V46, P919, DOI 10.1007/s00134-019-05900-x; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Citerio G, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026552; Citerio G, 2015, CURR OPIN CRIT CARE, V21, P113, DOI 10.1097/MCC.0000000000000179; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Helbok R, 2014, NEUROCRIT CARE, V21, P85, DOI 10.1007/s12028-014-0040-6; Helbok R, 2011, NEUROCRIT CARE, V14, P162, DOI 10.1007/s12028-010-9472-9; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Huijben JA, 2020, INTENS CARE MED, V46, P995, DOI 10.1007/s00134-020-05965-z; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Magni F, 2015, STROKE, V46, P2464, DOI 10.1161/STROKEAHA.115.010219; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Seder DB, 2009, CLIN CHEST MED, V30, P103, DOI 10.1016/j.ccm.2008.11.004; Shigemori M, 2012, NEUROL MED-CHIR, V52, P1; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woods KS, 2021, PEDIATR CRIT CARE ME, V22, P135, DOI 10.1097/PCC.0000000000002618; Zuercher P, 2016, J NEUROTRAUM, V33, P1768, DOI 10.1089/neu.2015.4266	31	38	38	2	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					548	558		10.1016/S1474-4422(21)00138-1	http://dx.doi.org/10.1016/S1474-4422(21)00138-1			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UD5TG	34146513	Green Submitted, Green Accepted			2022-12-18	WOS:000687268300014
J	Meretoja, A; Yassi, N; Wu, TY; Churilov, L; Sibolt, G; Jeng, JS; Kleinig, T; Spratt, NJ; Thijs, V; Wijeratne, T; Cho, DY; Shah, D; Cloud, GC; Phan, T; Bladin, C; Moey, A; Aviv, RI; Barras, CD; Sharma, G; Hsu, CY; Ma, H; Campbell, BCV; Mitchell, P; Yan, B; Parsons, MW; Tiainen, M; Curtze, S; Strbian, D; Tang, SC; Harvey, J; Levi, C; Donnan, GA; Davis, SM				Meretoja, Atte; Yassi, Nawaf; Wu, Teddy Y.; Churilov, Leonid; Sibolt, Gerli; Jeng, Jiann-Shing; Kleinig, Timothy; Spratt, Neil J.; Thijs, Vincent; Wijeratne, Tissa; Cho, Der-Yang; Shah, Darshan; Cloud, Geoffrey C.; Thanh Phan; Bladin, Christopher; Moey, Andrew; Aviv, Richard I.; Barras, Christen D.; Sharma, Gagan; Hsu, Chung Y.; Ma, Henry; Campbell, Bruce C. V.; Mitchell, Peter; Yan, Bernard; Parsons, Mark W.; Tiainen, Marjaana; Curtze, Sami; Strbian, Daniel; Tang, Sung-Chun; Harvey, Jackson; Levi, Christopher; Donnan, Geoffrey A.; Davis, Stephen M.			Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial	LANCET NEUROLOGY			English	Article							PREDICTS HEMATOMA EXPANSION; TRAUMA PATIENTS; GROWTH; GUIDELINES; MANAGEMENT; CRASH-2	Background Despite intracerebral haemorrhage causing 5% of deaths worldwide, few evidence-based therapeutic strategies other than stroke unit care exist. Tranexamic acid decreases haemorrhage in conditions such as acute trauma and menorrhoea. We aimed to assess whether tranexamic acid reduces intracerebral haemorrhage growth in patients with acute intracerebral haemorrhage. Methods We did a prospective, double-blind, randomised, placebo-controlled, investigator-led, phase 2 trial at 13 stroke centres in Australia, Finland, and Taiwan. Patients were eligible if they were aged 18 years or older, had an acute intracerebral haemorrhage fulfilling clinical criteria (eg, Glasgow Coma Scale score of >7, intracerebral haemorrhage volume <70 mL, no identified or suspected secondary cause of intracerebral haemorrhage, no thrombotic events within the previous 12 months, no planned surgery in the next 24 h, and no use of anticoagulation), had contrast extravasation on CT angiography (the so-called spot sign), and were treatable within 4.5 h of symptom onset and within 1 h of CT angiography. Patients were randomly assigned (1:1) to receive either 1 g of intravenous tranexamic acid over 10 min followed by 1 g over 8 h or matching placebo, started within 4.5 h of symptom onset. Randomisation was done using a centralised web-based procedure with randomly permuted blocks of varying size. All patients, investigators, and staff involved in patient management were masked to treatment. The primary outcome was intracerebral haemorrhage growth (>33% relative or >6 mL absolute) at 24 h. The primary and safety analyses were done in the intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT01702636). Findings Between March 1, 2013, and Aug 13, 2019, we enrolled and randomly assigned 100 participants to the tranexamic acid group (n=50) or the placebo group (n=50). Median age was 71 years (IQR 57-79) and median intracerebral haemorrhage volume was 14.6 mL (7.9-32.7) at baseline. The primary outcome was not different between the two groups: 26 (52%) patients in the placebo group and 22 (44%) in the tranexamic acid group had intracerebral haemorrhage growth (odds ratio [OR] 0.72 [95% CI 0.32-1.59], p=0.41). There was no evidence of a difference in the proportions of patients who died or had thromboembolic complications between the groups: eight (16%) in the placebo group vs 13 (26%) in the tranexamic acid group died and two (4%) vs one (2%) had thromboembolic complications. None of the deaths was considered related to study medication. Interpretation Our study does not provide evidence that tranexamic acid prevents intracerebral haemorrhage growth, although the treatment was safe with no increase in thromboembolic complications. Larger trials of tranexamic acid, with simpler recruitment methods and an earlier treatment window, are justified.	[Meretoja, Atte; Yassi, Nawaf; Thijs, Vincent; Bladin, Christopher; Campbell, Bruce C. V.; Donnan, Geoffrey A.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Meretoja, Atte; Yassi, Nawaf; Wu, Teddy Y.; Churilov, Leonid; Campbell, Bruce C. V.; Yan, Bernard; Parsons, Mark W.; Donnan, Geoffrey A.; Davis, Stephen M.] Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia; [Churilov, Leonid; Campbell, Bruce C. V.; Yan, Bernard] Royal Melbourne Hosp, Dept Math & Stat, Melbourne, Vic, Australia; [Barras, Christen D.; Sharma, Gagan; Mitchell, Peter] Royal Melbourne Hosp, Dept Radiol, Melbourne, Vic, Australia; [Meretoja, Atte; Sibolt, Gerli; Tiainen, Marjaana; Curtze, Sami; Strbian, Daniel] Univ Melbourne, Dept Neurol, Helsinki Univ Hosp, Melbourne, Vic, Australia; [Yassi, Nawaf] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Melbourne, Vic, Australia; [Wu, Teddy Y.] New Zealand Brain Res Inst, Christchurch, New Zealand; [Jeng, Jiann-Shing; Tang, Sung-Chun] National Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Kleinig, Timothy; Harvey, Jackson] Royal Adelaide Hosp, Dept Neurol, Adelaide, SA, Australia; [Spratt, Neil J.; Levi, Christopher] Univ Newcastle, Dept Neurol, Newcastle, NSW, Australia; [Thijs, Vincent] Austin Hosp, Dept Neurol, Heidelberg, Vic, Australia; [Wijeratne, Tissa] Western Hosp, Dept Neurol, Melbourne, Vic, Australia; [Cho, Der-Yang] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; [Hsu, Chung Y.] China Med Univ Hosp, Dept Neurol, Taichung, Taiwan; [Shah, Darshan] Princess Alexandra Hosp, Dept Neurol, Woolloongabba, Qld, Australia; [Cloud, Geoffrey C.] Alfred Hosp, Dept Neurol, Alfred, NY USA; [Cloud, Geoffrey C.] Monash Univ, Cent Clin Sch, Dept Clin Neurosci, Melbourne, Vic, Australia; [Thanh Phan; Ma, Henry] Monash Univ, Dept Neurol, Monash Med Ctr, Melbourne, Vic, Australia; [Thanh Phan; Ma, Henry] Monash Univ, Sch Clin Sci, Melbourne, Vic, Australia; [Bladin, Christopher] Monash Univ, Dept Neurosci, Eastern Hlth Med Sch, Melbourne, Vic, Australia; [Moey, Andrew] Lyell McEwin Hosp, Dept Neurol, Adelaide, SA, Australia; [Aviv, Richard I.] Ottawa Hosp, Neuroradiol Sect, Dept Radiol, Ottawa, ON, Canada; [Aviv, Richard I.] Univ Ottawa, Ottawa, ON, Canada; [Barras, Christen D.] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia; [Levi, Christopher] Univ New South Wales, Fac Med, Sydney Partnership Hlth Educ Res & Enterprise SPH, Sydney, NSW, Australia	Florey Institute of Neuroscience & Mental Health; Royal Melbourne Hospital; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne; Royal Adelaide Hospital; University of Newcastle; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Western Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Monash University; Monash University; Monash University; Monash University; Lyell McEwin Hospital; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; South Australian Health & Medical Research Institute (SAHMRI); University of Adelaide; University of New South Wales Sydney	Meretoja, A (corresponding author), Helsinki Univ Hosp, Dept Neurol, Helsinki 00029, Finland.	atte.meretoja@hus.fi	Campbell, Bruce/J-1220-2019; Thijs, Vincent/C-3647-2009; Campbell, Bruce/AGY-4147-2022; Spratt, Neil J/K-4208-2012; Davis, Stephen/L-5260-2013	Campbell, Bruce/0000-0003-3632-9433; Thijs, Vincent/0000-0002-6614-8417; Spratt, Neil J/0000-0002-9023-6177; Curtze, Sami/0000-0003-1545-8500; kleinig, Timothy/0000-0003-4430-3276; Wijeratne, Tissa/0000-0002-1701-7111; Yassi, Nawaf/0000-0002-0685-0060; MA, HENRY/0000-0002-0510-8059; Levi, Christopher/0000-0002-9474-796X; Davis, Stephen/0000-0003-0962-2300; JENG, JIANN-SHING/0000-0002-1456-3686; Cloud, Geoffrey/0000-0002-8365-6907; Tang, Sung-Chun/0000-0003-3731-5973	Australian National Health and Medical Research Council [1081718]; Royal Melbourne Hospital Foundation; National Health and Medical Research Council-National Heart Foundation Career Development-Future Leader Fellowship [GNT1110629/100827]; Canadian Institutes of Health Research [362185]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Royal Melbourne Hospital Foundation; National Health and Medical Research Council-National Heart Foundation Career Development-Future Leader Fellowship; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The study was funded by the Australian National Health and Medical Research Council, grant number 1081718, and the Royal Melbourne Hospital Foundation. NS was supported by a Cofunded National Health and Medical Research Council-National Heart Foundation Career Development-Future Leader Fellowship GNT1110629/100827. RA receives support from Canadian Institutes of Health Research, operating grant 362185.	Andrew DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076664; [Anonymous], 2008, COCHRANE DATABASE SY; Arumugam A, 2015, MALAYS J MED SCI, V22, P62; Baharoglu MI, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001245.pub2; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Campbell BCV, 2019, LANCET, V394, P139, DOI 10.1016/S0140-6736(19)31053-0; Churilov L, 2014, INT J STROKE, V9, P999, DOI 10.1111/ijs.12364; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Delcourt C, 2012, NEUROLOGY, V79, P314, DOI 10.1212/WNL.0b013e318260cbba; Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8; Gladstone DJ, 2019, JAMA NEUROL, V76, P1493, DOI 10.1001/jamaneurol.2019.2636; Goldstein JN, 2007, NEUROLOGY, V68, P889, DOI 10.1212/01.wnl.0000257087.22852.21; Goldstein LB, 2005, JAMA-J AM MED ASSOC, V293, P2391, DOI 10.1001/jama.293.19.2391; HALT-IT Trial Collaborators, 2020, LANCET, V395, P1927, DOI 10.1016/S0140-6736(20)30848-5; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hemphill JC, 2009, NEUROLOGY, V73, P1088, DOI 10.1212/WNL.0b013e3181b8b332; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Law ZK, 2017, EUR STROKE J, V2, P13, DOI 10.1177/2396987316676610; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Meretoja A, 2014, INT J STROKE, V9, P519, DOI 10.1111/ijs.12132; Meretoja A, 2012, STROKE, V43, P2592, DOI 10.1161/STROKEAHA.112.661603; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Salman RAS, 2018, LANCET NEUROL, V17, P885, DOI 10.1016/S1474-4422(18)30253-9; Salman RAS, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005951.pub4; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sprigg N, 2018, LANCET, V391, P2107, DOI 10.1016/S0140-6736(18)31033-X; Sprigg N, 2014, J STROKE CEREBROVASC, V23, P1312, DOI 10.1016/j.jstrokecerebrovasdis.2013.11.007; Steiner T, 2014, INT J STROKE, V9, P840, DOI 10.1111/ijs.12309; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; Wu TY, 2016, NEURORADIOLOGY, V58, P867, DOI 10.1007/s00234-016-1720-z	31	38	39	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					980	987		10.1016/S1474-4422(20)30369-0	http://dx.doi.org/10.1016/S1474-4422(20)30369-0			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PG3EL	33128912				2022-12-18	WOS:000599622000015
J	Kappos, L; Arnold, DL; Bar-Or, A; Camm, J; Derfuss, T; Kieseier, BC; Sprenger, T; Greenough, K; Ni, PP; Harada, T				Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Camm, John; Derfuss, Tobias; Kieseier, Bernd C.; Sprenger, Till; Greenough, Kristin; Ni, Pingping; Harada, Tomohiko			Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial	LANCET NEUROLOGY			English	Article							ORAL FINGOLIMOD; HEART-RATE; ALEMTUZUMAB; TERIFLUNOMIDE; MULTICENTER; INTERFERON; FUMARATE; FTY720	Background Patients with multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with autoimmune pathogenesis, have shown partial response to a number of imrnunomodulating treatments, but the search for more effective, safe, and convenient therapeutic options continues. Amiselimod is an oral selective modulator of sphingosine 1-phosphate 1 (S1P(1)) receptor, which is being developed for the treatment of various autoimmune-mediated diseases. We assessed the safety and efficacy of amiselimod in patients with relapsing remitting multiple sclerosis. Methods In this double-blind phase 2 trial, patients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres in Europe and Canada were randomly assigned (1:1:1:1) with an interactive web-response system to receive once daily oral amiselimod 0.1 mg, 0.2 mg, 0.4 mg, or placebo for 24 weeks. All study personnel, site personnel, investigators, and patients were masked to the treatment assignment during the study. The primary endpoint was the total number of gadolinium-enhanced T1-weighted lesions on monthly brain MRI scans from weeks 8 to 24. Analysis was done on the predefined evaluable population (all randomised patients who did not have any major protocol deviations, completed 24 weeks of treatment as planned, and had at least three valid post-dose MRI scans). This trial is registered with ClinicalTrials.gov, number NCT01742052. Findings Between Jan 31,2013, and Dec 24,2013,536 patients were screened and 415 patients randomly assigned to amiselimod 0.1 mg (n=105), 0.2 mg (n=103), 0.4 mg (n=104), or placebo (n=103). The median total number of gadolinium-enhanced T1-weighted lesions from weeks 8 to 24 did not differ between the amiselimod 0.1 mg and placebo groups (median 1.6 lesions [range 0-132] in the placebo group vs 2.0 [0-105] in the 0.1 mg group [median difference 0.0, 95% CI -1.0 to 0.0, p=0.7517]), but was significantly lower in the two higher amiselimod dose groups than in the placebo group (0.0 lesions [range 0-35] in the 0.2 mg group [median difference vs placebo -1.0, 95% CI -1.0 to 0.0, p=0.0021] and 0.0 [range 0-30] in the 0.4 mg group [-1.0, -1.2 to 0.0, p=0.0003]). The estimated incident rate ratio compared with placebo was dose-dependently decreased with amiselimod (0.1 mg 0.53 [95% CI 0.33-0. 85; p=0.0079], 0.2 mg 0.39 [95% CI 0.24-0.63; p=0.0001], and 0.4 mg 0.23 [95% CI 0.14-0.38; p<0.0001]). The incidence of treatment-emergent adverse events, including infections and cardiac disorders, were similar in the amiselimod treatment groups (59 [56%] of 105 patients in the 0.1 mg group, 69 [67%] of 103 in the 0.2 mg group, and 58 [56%] of 104 in the 0.4 mg group) to the incidence in the placebo group (66 [64%] of 103 patients); the most common treatment-emergent adverse events were headache (ten [10%], ten [10%], and ten [10%] vs four [4%]) and nasopharyngitis (nine [9%], seven [7%], ten [10%] vs eight [8%]). No serious treatment emergent adverse event was reported for more than one patient in any group and no clinically significant heart rate reduction was observed at any amiselimod dose. Interpretation Amiselimod 0.2 mg and 0.4 mg significantly reduced the total number of gadolinium-enhanced T1-weighted lesions. The safety and efficacy profiles of amiselimod suggest that this S1P, receptor modulator is a new potential treatment in multiple sclerosis and potentially other immune-mediated inflammatory diseases and deserves further investigation.	[Kappos, Ludwig; Derfuss, Tobias; Sprenger, Till] Univ Basel Hosp, Neurol, Basel, Switzerland; [Arnold, Douglas L.; Bar-Or, Amit] Montreal Neurol Inst, Montreal, PQ, Canada; [Camm, John] St Georges Univ London, London, England; [Kieseier, Bernd C.] Univ Dusseldorf, Dusseldorf, Germany; [Greenough, Kristin; Harada, Tomohiko] Mitsubishi Tanabe Pharma Europe, London, England	University of Basel; McGill University; St Georges University London; Heinrich Heine University Dusseldorf; Mitsubishi Tanabe Pharma Corporation	Kappos, L (corresponding author), Univ Basel Hosp, Neurol Clin & Policlin, Dept Med Clin Res Biomed & Biomed Engn, CH-4031 Basel, Switzerland.	ludwig.kappos@usb.ch	Bar-Or, Amit/AIC-1416-2022	Sprenger, Till/0000-0002-5390-819X; Arnold, Douglas/0000-0003-4266-0106	Mitsubishi Tanabe Pharma Corporation	Mitsubishi Tanabe Pharma Corporation(Mitsubishi Tanabe Pharma Corporation)	Mitsubishi Tanabe Pharma Corporation.	[Anonymous], 2010, GILENYA FDA APPROVED; Arnold DL, 2014, J NEUROL, V261, P1794, DOI 10.1007/s00415-014-7412-x; Bar-Or A., 2014, NEUROLOGY S, V82, pP3161; Bigaud M, 2014, BBA-MOL CELL BIOL L, V1841, P745, DOI 10.1016/j.bbalip.2013.11.001; Calabresi PA, 2014, LANCET NEUROL, V13, P545, DOI 10.1016/S1474-4422(14)70049-3; Camm J, 2014, AM HEART J, V168, P632, DOI 10.1016/j.ahj.2014.06.028; Cohen JA, 2016, LANCET NEUROL, V15, P373, DOI 10.1016/S1474-4422(16)00018-1; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cutter GR, 1999, BRAIN, V122, P871, DOI 10.1093/brain/122.5.871; DiMarco JP, 2014, MULT SCLER RELAT DIS, V3, P629, DOI 10.1016/j.msard.2014.05.005; European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), 2007, CPMPEWP56198REV1; Geurts JJG, 2012, LANCET NEUROL, V11, P1082, DOI 10.1016/S1474-4422(12)70230-2; Hauser SL, 2015, EFFICACY SAFETY OCRE; Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kappos L, 2015, MULT SCLER RELAT DIS, V4, P182, DOI 10.1016/j.msard.2015.04.001; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Koyrakh L, 2005, AM J TRANSPLANT, V5, P529, DOI 10.1111/j.1600-6143.2005.00754.x; Krosser S, 2015, J CLIN PHARMACOL, V55, P1051, DOI 10.1002/jcph.513; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lee JY, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.44; Legangneux E, 2013, BRIT J CLIN PHARMACO, V75, P831, DOI 10.1111/j.1365-2125.2012.04400.x; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Nakamura K, 2013, NEUROIMAGE-CLIN, V29, p10c7; O'Connor PW, 2006, NEUROLOGY, V66, P894, DOI 10.1212/01.wnl.0000203121.04509.31; Olsson T, 2014, J NEUROL NEUROSUR PS, V85, P1198, DOI 10.1136/jnnp-2013-307282; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Selmaj K, 2013, LANCET NEUROL, V12, P756, DOI 10.1016/S1474-4422(13)70102-9; Sormani MP, 2013, LANCET NEUROL, V12, P669, DOI 10.1016/S1474-4422(13)70103-0; Sugahara K, 2015, C EUR COMM TREATM RE, pP551; VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859; Wolinsky JS, 2013, MULT SCLER J, V19, P1310, DOI 10.1177/1352458513475723	38	38	39	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1148	1159		10.1016/S1474-4422(16)30192-2	http://dx.doi.org/10.1016/S1474-4422(16)30192-2			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DX3MJ	27543447				2022-12-18	WOS:000384276900017
J	Kaski, D; Bronstein, AM; Edwards, MJ; Stone, J				Kaski, Diego; Bronstein, Adolfo M.; Edwards, Mark J.; Stone, Jon			Cranial functional (psychogenic) movement disorders	LANCET NEUROLOGY			English	Review							TRANSCRANIAL MAGNETIC STIMULATION; NONEPILEPTIC SEIZURES; DIFFERENTIAL-DIAGNOSIS; CLINICAL-FEATURES; CONVERGENCE SPASM; MOTOR SYMPTOMS; SIGN; PHYSIOTHERAPY; PARALYSIS; RECOVERY	Functional (psychogenic) neurological symptoms are frequently encountered in neurological practice. Cranial movement disorders-affecting the eyes, face, jaw, tongue, or palate-are an under-recognised feature of patients with functional symptoms. They can present in isolation or in the context of other functional symptoms; in particular, for functional eye movements, positive clinical signs such as convergence spasms can be triggered by the clinical examination. Although the specialty of functional neurological disorders has expanded, appreciation of cranial functional movement disorders is still insufficient. Identification of the positive features of cranial functional movement disorders such as convergence and unilateral platysmal spasm might lend diagnostic weight to a suspected functional neurological disorder. Understanding of the differential diagnosis, which is broad and includes many organic causes (eg, stroke), is essential to make an early and accurate diagnosis to prevent complications and initiate appropriate management. Increased understanding of these disorders is also crucial to drive clinical trials and studies of individually tailored therapies.	[Kaski, Diego; Bronstein, Adolfo M.; Edwards, Mark J.] Natl Hosp Neurol & Neurosurg, Dept Neurootol, London WC1N 3BG, England; [Kaski, Diego; Bronstein, Adolfo M.] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Div Brain Sci, London, England; [Edwards, Mark J.] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement, London, England; [Stone, Jon] Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London; University of London; University College London; University of Edinburgh	Kaski, D (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neurootol, Queen Sq, London WC1N 3BG, England.	d.kaski@imperial.ac.uk	Stone, Jon/C-3119-2014; Edwards, Mark J/F-1052-2012; Kaski, Diego/GQY-5716-2022	Stone, Jon/0000-0001-9829-8092; Edwards, Mark J/0000-0002-8283-9015; Kaski, Diego/0000-0002-0591-646X	Medical Research Council (UK); National Health Service Research Scotland (NRS) Career Fellowship; MRC [MR/M02363X/1, MR/J004685/1] Funding Source: UKRI; Medical Research Council [MR/M02363X/1, MR/J004685/1] Funding Source: researchfish	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Health Service Research Scotland (NRS) Career Fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	AMB is supported by a research grant from the Medical Research Council (UK). JS is supported by a National Health Service Research Scotland (NRS) Career Fellowship.	Aybek S, 2014, JAMA PSYCHIAT, V71, P52, DOI 10.1001/jamapsychiatry.2013.2842; Baizabal-Carvallo JF, 2014, J NEUROL NEUROSUR PS, V85, P573, DOI 10.1136/jnnp-2013-305594; Bassani R, 2012, NEW ENGL J MED, V367, pE13, DOI 10.1056/NEJMicm1104924; Biousse V, 2004, NEUROLOGY, V62, P177, DOI 10.1212/01.WNL.0000103444.45882.D8; Bradley WG., 2004, NEUROLOGY CLIN PRACT; Bronstein AM, 2004, J NEUROL, V251, P381, DOI 10.1007/s00415-004-0410-7; Bruno E, 2013, EUR J NEUROL, V20, pE107, DOI 10.1111/ene.12181; Chastan N, 2010, MOVEMENT DISORD, V25, P1501, DOI 10.1002/mds.23187; Christoff Alexander, 2002, Am Orthopt J, V52, P110, DOI 10.3368/aoj.52.1.110; COGAN DG, 1955, ARCH OPHTHALMOL-CHIC, V54, P752; DAGI LR, 1987, AM J OPHTHALMOL, V103, P582, DOI 10.1016/S0002-9394(14)74283-7; Danchaivijitr C, 2004, J NEUROL NEUROSUR PS, V75, P24, DOI 10.1136/jnnp.2004.053413; Demartini B, 2015, EUR J NEUROL, V22, P527, DOI 10.1111/ene.12609; Demartini B, 2014, J NEUROL, V261, P2370, DOI 10.1007/s00415-014-7495-4; Devoize JL, 2001, J NEUROL NEUROSUR PS, V70, P516, DOI 10.1136/jnnp.70.4.516; Edwards MJ, 2014, MOVEMENT DISORD, V29, P849, DOI 10.1002/mds.25562; Edwards MJ, 2012, BRAIN, V135, P3495, DOI 10.1093/brain/aws129; Espay AJ, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0556-y; Fahn S, 2014, MOVEMENT DISORD, V29, P853, DOI 10.1002/mds.25899; Fasano A, 2012, MOVEMENT DISORD, V27, P1544, DOI 10.1002/mds.25190; Faucher C, 2004, OPTOMETRY VISION SCI, V81, P178, DOI 10.1097/00006324-200403000-00009; Fekete R, 2012, J NEUROL NEUROSUR PS, V83, P202, DOI 10.1136/jnnp-2011-300733; Baizabal-Carvallo JF, 2015, TREMOR OTHER HYPERK, V5, DOI 10.7916/D8VM4B13; Ganos C, 2014, PARKINSONISM RELAT D, V20, P1440, DOI 10.1016/j.parkreldis.2014.10.001; Garcin B, 2013, J NEUROL NEUROSUR PS, V84, P1043, DOI 10.1136/jnnp-2012-304062; Gibson LM, 2013, J ROY COLL PHYS EDIN, V43, P114, DOI 10.4997/JRCPE.2013.205; Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658; Gordon CR, 2012, NEUROLOGY, V78, P681, DOI 10.1212/WNL.0b013e318248df04; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; Jankovic J, 2011, J NEUROL NEUROSUR PS, V82, P1300, DOI 10.1136/jnnp-2011-300876; Jordbru AA, 2014, J REHABIL MED, V46, P181, DOI 10.2340/16501977-1246; Keane JR, 2006, ARCH NEUROL-CHICAGO, V63, P388, DOI 10.1001/archneur.63.3.388; KEANE JR, 1982, NEUROLOGY, V32, P757, DOI 10.1212/WNL.32.7.757; Kim JS, 2007, NEUROLOGY, V68, P1128, DOI 10.1212/01.wnl.0000258665.37827.f6; Kollbrunner J, 2010, SWISS MED WKLY, V140, P12, DOI smw-12776; LaFrance WC, 2014, JAMA PSYCHIAT, V71, P997, DOI 10.1001/jamapsychiatry.2014.817; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; LEIGH RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P1710, DOI 10.1001/archopht.1991.01080120094034; Lemos J, 2013, CURR OPIN NEUROL, V26, P59, DOI 10.1097/WCO.0b013e32835c5e1d; Lopez LI, 1996, BRAIN, V119, P465, DOI 10.1093/brain/119.2.465; Margari F, 2011, NEUROPSYCH DIS TREAT, V7, P223, DOI 10.2147/NDT.S15830; McWhirter L, 2015, BRAIN, V138, P1113, DOI 10.1093/brain/awv009; MEADOWS JC, 1973, J NEUROL SCI, V18, P249, DOI 10.1016/0022-510X(73)90010-5; Mehta AR, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0402-z; MOORE S, 1973, American Orthoptic Journal, V23, P71; Nielsen G, 2015, J NEUROL, V262, P674, DOI 10.1007/s00415-014-7631-1; Nielsen G, 2013, J PSYCHOSOM RES, V75, P93, DOI 10.1016/j.jpsychores.2013.05.006; Parees I, 2014, J NEUROL SCI, V338, P174, DOI 10.1016/j.jns.2013.12.046; Peckham EL, 2009, NEUROL CLIN, V27, P801, DOI 10.1016/j.ncl.2009.04.008; Perez DL, 2015, CLIN EEG NEUROSCI, V46, P4, DOI 10.1177/1550059414555905; Pollak TA, 2014, J NEUROL NEUROSUR PS, V85, P191, DOI 10.1136/jnnp-2012-304181; Schonfeldt-Lecuona C, 2006, J CLIN NEUROPHYSIOL, V23, P472; Schrag AE, 2013, BRAIN, V136, P770, DOI 10.1093/brain/awt008; Schwingenschuh P, 2011, NEUROLOGY, V76, P610, DOI 10.1212/WNL.0b013e31820c3074; Shah BB, 2015, PARKINSONISM RELAT D, V21, P407, DOI 10.1016/j.parkreldis.2015.01.013; Stamelou M, 2012, MOVEMENT DISORD, V27, P1164, DOI 10.1002/mds.24948; Stamey W, 2007, NEUROLOGY, V69, P402, DOI 10.1212/01.wnl.0000266389.52843.3b; Stone J., 2002, PRACT NEUROL, V2, P364; Stone Jon, 2015, Continuum (Minneap Minn), V21, P818, DOI 10.1212/01.CON.0000466669.02477.45; Stone Jon, 2013, Pract Neurol, V13, P104, DOI 10.1136/practneurol-2012-000422; Stone J, 2012, NEUROLOGY, V79, P282, DOI 10.1212/WNL.0b013e31825fdf63; Tan EK, 2001, J NEUROPSYCH CLIN N, V13, P380, DOI 10.1176/appi.neuropsych.13.3.380; Thenganatt MA, 2014, TREMOR OTHER HYPERK, V4, DOI 10.7916/D8FJ2F0Q; TROOST BT, 1979, NEUROLOGY, V29, P82, DOI 10.1212/WNL.29.1.82; Umapathi T, 2000, CEREBROVASC DIS, V10, P462, DOI 10.1159/000016108; Yaltho TC, 2011, MOVEMENT DISORD, V26, P1582, DOI 10.1002/mds.23692; ZAHN JR, 1978, J NEUROL NEUROSUR PS, V41, P617, DOI 10.1136/jnnp.41.7.617; Zappia JJ, 2013, CURR OPIN OTOLARYNGO, V21, P480, DOI 10.1097/MOO.0b013e32836463d6	68	38	38	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1196	1205		10.1016/S1474-4422(15)00226-4	http://dx.doi.org/10.1016/S1474-4422(15)00226-4			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26581970	Green Submitted			2022-12-18	WOS:000364855100014
J	Charles, A				Charles, Andrew			Vasodilation out of the picture as a cause of migraine headache	LANCET NEUROLOGY			English	Editorial Material							MAGNETIC-RESONANCE ANGIOGRAPHY; ARTERY		Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Headache Res & Treatment Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Charles, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Headache Res & Treatment Program, Los Angeles, CA 90095 USA.	acharles@ucla.edu						Amin FM, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70067-X; Asghar MS, 2011, ANN NEUROL, V69, P635, DOI 10.1002/ana.22292; Goadsby P.J., 2007, HDB EXP PHARM, V177, P129, DOI DOI 10.1007/978-3-540-33823-9_5; Graham JR, 1938, ARCH NEURO PSYCHIATR, V39, P737, DOI 10.1001/archneurpsyc.1938.02270040093005; Kruuse C, 2003, BRAIN, V126, P241, DOI 10.1093/brain/awg009; Mirza AF, 2012, J NEUROSCI, V32, P7572, DOI 10.1523/JNEUROSCI.0193-12.2012; Nagata E, 2009, INTERNAL MED, V48, P2133, DOI 10.2169/internalmedicine.48.2565; Rahmann A, 2008, CEPHALALGIA, V28, P226, DOI 10.1111/j.1468-2982.2007.01497.x; Schoonman GG, 2008, BRAIN, V131, P2192, DOI 10.1093/brain/awn094; Schytz HW, 2009, BRAIN, V132, P16, DOI 10.1093/brain/awn307; TUNIS MM, 1952, AM J MED SCI, V224, P565, DOI 10.1097/00000441-195211000-00013	11	38	41	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					419	420		10.1016/S1474-4422(13)70051-6	http://dx.doi.org/10.1016/S1474-4422(13)70051-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23578774				2022-12-18	WOS:000318836700004
J	Seibler, P; Djarmati, A; Langpap, B; Hagenah, J; Schmidt, A; Bruggemann, N; Siebner, H; Jabusch, HC; Altenmuller, E; Munchau, A; Lohmann, K; Klein, C				Seibler, Philip; Djarmati, Ana; Langpap, Brigitte; Hagenah, Johann; Schmidt, Alexander; Brueggemann, Norbert; Siebner, Hartwig; Jabusch, Hans-Christian; Altenmueller, Eckart; Muenchau, Alexander; Lohmann, Katja; Klein, Christine			A heterozygous frameshift mutation in PRKRA (DYT16) associated with generalised dystonia in a German patient	LANCET NEUROLOGY			English	Editorial Material									[Seibler, Philip; Djarmati, Ana; Langpap, Brigitte; Hagenah, Johann; Schmidt, Alexander; Brueggemann, Norbert; Siebner, Hartwig; Jabusch, Hans-Christian; Altenmueller, Eckart; Muenchau, Alexander; Lohmann, Katja; Klein, Christine] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany	University of Lubeck	Seibler, P (corresponding author), Med Univ Lubeck, Dept Neurol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	christine.klein@neuro.uni-luebeck.de	Altenmuller, Eckart/AAB-9948-2021; Siebner, Hartwig R/G-4052-2016; Klein, Christine/AGK-8003-2022; Seibler, Philip/K-4142-2019; Seibler, Philip/AAB-5097-2022	Klein, Christine/0000-0003-2102-3431; Seibler, Philip/0000-0002-3496-7194; Westenberger, Ana/0000-0001-8062-6959				Camargos S, 2008, LANCET NEUROL, V7, P207, DOI 10.1016/S1474-4422(08)70022-X; Klein C, 2007, LANCET NEUROL, V6, P652, DOI 10.1016/S1474-4422(07)70174-6	2	38	41	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2008	7	5					380	381		10.1016/S1474-4422(08)70075-9	http://dx.doi.org/10.1016/S1474-4422(08)70075-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	296AB	18420150				2022-12-18	WOS:000255514800006
J	Chaudhuri, A				Chaudhuri, A			Adjunctive dexamethasone treatment in acute bacterial meningitis	LANCET NEUROLOGY			English	Editorial Material							CEREBROSPINAL-FLUID; PNEUMOCOCCAL MENINGITIS; PROGNOSTIC-FACTORS; MENINGOCOCCAL DISEASE; INFECTIOUS-DISEASES; DOUBLE-BLIND; THERAPY; CHILDREN; ADULTS; PENICILLIN	The initiation of antibiotic treatment on suspicion of bacterial meningitis is important, but it is not enough to improve the prognosis for patients, especially those with pneumococcal meningitis. The mortality and morbidity of pneumococcal meningitis are still devastating, and results of a recent randomised trial have shown evidence in favour of dexamethasone treatment given before or with the first antibiotic dose. Adjuvant dexamethasone is unequivocally recommended in children and adults with haemophilus meningitis or pneumococcal meningitis. The benefit of adjunctive dexamethasone is likely to be greatest in patients who are otherwise healthy and present early with acute bacterial meningitis. Dexamethasone is not currently recommended for the treatment of gram-negative bacillary meningitis and neonatal meningitis. Dexamethasone, before or with the first dose of antibiotic, is likely to be one of the most significant practice changes that will benefit many adults and children with common types of acute bacterial meningitis and has been of proven value in the developed world.	Univ Glasgow, Inst Neurol Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Chaudhuri, A (corresponding author), So Glasgow Univ Hosp NHS Trust, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland.	ac54p@udcf.gla.ac.uk						ADAMS JH, 1992, MUIRS TXB PATHOLOGY, P824; ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P695; Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087; Auburtin M, 2002, AM J RESP CRIT CARE, V165, P713, DOI 10.1164/ajrccm.165.5.2105110; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; Chaudhuri A, 2002, POSTGRAD MED J, V78, P575, DOI 10.1136/pmj.78.924.575; Dawson KG, 1999, PEDIATR INFECT DIS J, V18, P816, DOI 10.1097/00006454-199902000-00015; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; de Gans J, 2003, NEW ENGL J MED, V348, P955; El Bashir H, 2003, ARCH DIS CHILD, V88, P615, DOI 10.1136/adc.88.7.615; Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; FELDMAN WE, 1977, NEW ENGL J MED, V296, P433, DOI 10.1056/NEJM197702242960806; Free SL, 1996, EPILEPSIA, V37, P400, DOI 10.1111/j.1528-1157.1996.tb00578.x; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1993, J INFECT DIS, V168, P657, DOI 10.1093/infdis/168.3.657; Gerber J, 2001, BRAIN PATHOL, V11, P422, DOI 10.1111/j.1750-3639.2001.tb00410.x; Gijwani D, 2002, NEUROL INDIA, V50, P63; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; GOSSAIN S, 1992, BRIT MED J, V305, P523, DOI 10.1136/bmj.305.6852.523-c; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Hastings R.C., 1991, JAMA-J AM MED ASSOC, V265, P2734, DOI [10.1001/jama.1991.03460200114048, DOI 10.1001/JAMA.1991.03460200114048]; Hodgson A, 2001, INT J EPIDEMIOL, V30, P1440, DOI 10.1093/ije/30.6.1440; John SM, 1999, NEW ZEAL MED J, V112, P134; Kanegaye JT, 2001, PEDIATRICS, V108, P1169; Kastenbauer S, 2003, BRAIN, V126, P1015, DOI 10.1093/brain/awg113; Kertesz DA, 1998, J INFECT DIS, V177, P1754, DOI 10.1086/517439; KROLL JS, 2000, INFECT DIS NERVOUS S, P259; Leach A, 1997, J INFECT DIS, V175, P200, DOI 10.1093/infdis/175.1.200; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; Lu CH, 2002, J CLIN NEUROSCI, V9, P533, DOI 10.1054/jocn.2001.1032; Macaluso A, 1996, ANN TROP PAEDIATR, V16, P193, DOI 10.1080/02724936.1996.11747825; McCracken GH, 2002, LANCET, V360, P183, DOI 10.1016/S0140-6736(02)09499-0; McIntyre PB, 1997, JAMA-J AM MED ASSOC, V278, P925, DOI 10.1001/jama.278.11.925; McVernon J, 2003, LANCET, V361, P1521, DOI 10.1016/S0140-6736(03)13171-6; MERTSOLA J, 1991, AM J DIS CHILD, V145, P1099, DOI 10.1001/archpedi.1991.02160100031019; Molyneux E, 1998, TROP MED INT HEALTH, V3, P610, DOI 10.1046/j.1365-3156.1998.00278.x; Molyneux EM, 2002, LANCET, V360, P211, DOI 10.1016/S0140-6736(02)09458-8; MURRAY JL, 1996, GLOBAL BURDEN DIS IN, V2; Nau R, 1999, J NEUROPATH EXP NEUR, V58, P265, DOI 10.1097/00005072-199903000-00006; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; Ostergaard C, 2000, CLIN EXP IMMUNOL, V122, P207, DOI 10.1046/j.1365-2249.2000.01357.x; PRASAD K, 2003, COCHRANE LIB; Qazi SA, 1996, ARCH DIS CHILD, V75, P482, DOI 10.1136/adc.75.6.482; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Reacher MH, 2000, BMJ-BRIT MED J, V320, P213, DOI 10.1136/bmj.320.7229.213; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHELD WM, 1980, J CLIN INVEST, V66, P243, DOI 10.1172/JCI109850; SCHELD WM, 1998, HARRISONS PRINCIPLES, P2419; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Simon RP, 2002, NEUROLOGY, V58, P167, DOI 10.1212/WNL.58.2.167; Sorensen HT, 1998, BRIT MED J, V316, P1016; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; Tauber MG, 1999, CLIN INFECT DIS, V28, P1, DOI 10.1086/515079; Thomas R, 1999, INTENS CARE MED, V25, P475, DOI 10.1007/s001340050883; Tunkel AR, 2003, NEW ENGL J MED, V348, P956; Tunkel AR, 2002, NEW ENGL J MED, V347, P1613, DOI 10.1056/NEJMe020131; van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2; van der Flier M, 2003, CLIN MICROBIOL REV, V16, P415, DOI 10.1128/CMR.16.3.415-429.2003; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; *WHO, GLOB STAT HIB IMM; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; YOSHIDA R, 1995, ANTIMICROB AGENTS CH, V39, P1196, DOI 10.1128/AAC.39.5.1196	66	38	46	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					54	62		10.1016/S1474-4422(03)00623-9	http://dx.doi.org/10.1016/S1474-4422(03)00623-9			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693112				2022-12-18	WOS:000187447100026
J	Cree, BAC; Cutter, G; Wolinsky, JS; Freedman, MS; Comi, G; Giovannoni, G; Hartung, HP; Arnold, D; Kuhle, J; Block, V; Munschauer, FE; Sedel, F; Lublin, FD				Cree, Bruce A. C.; Cutter, Gary; Wolinsky, Jerry S.; Freedman, Mark S.; Comi, Giancarlo; Giovannoni, Gavin; Hartung, Hans-Peter; Arnold, Douglas; Kuhle, Jens; Block, Valerie; Munschauer, Frederick E.; Sedel, Frederic; Lublin, Fred D.		SPI2 Invest Teams	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial	LANCET NEUROLOGY			English	Article							NEURODEGENERATION	Background There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-grade biotin (MD1003) might enhance neuronal and oligodendrocyte energetics, resulting in improved cell function, repair, or survival. The MS-SPI randomised, double-blind, placebo-controlled study found that MD1003 improved disability outcomes over 12 months in patients with progressive multiple sclerosis. The SPI2 study was designed to assess the safety and efficacy of MD1003 in progressive forms of multiple sclerosis in a larger, more representative patient cohort. Methods SPI2 was a randomised, double-blind, parallel-group, placebo-controlled trial done at 90 aca-demic and community multiple sclerosis clinics across 13 countries. Patients were aged 18-65 years, had a diagnosis of primary or secondary progressive multiple sclerosis fulfilling the revised International Panel criteria and Lublin criteria, a Kurtzke pyramidal functional subscore of at least 2 (defined as minimal disability), an expanded disability status scale (EDSS) score of 3.5-6.5, a timed 25-foot walk (TW25) of less than 40 s, evidence of clinical disability progression, and no relapses in the 2 years before enrolment. Concomitant disease-modifying therapies were allowed. Patients were randomly assigned (1:1) by an independent statistician using an interactive web response system, with stratification by study site and disease history, to receive MD1003 (oral biotin 100 mg three times daily) or placebo. Participants, investigators, and assessors were masked to treatment assignment. The primary endpoint was a composite of the proportion of participants with confirmed improvement in EDSS or TW25 at month 12, confirmed at month 15, versus baseline. The primary endpoint was assessed in the intention-to-treat analysis set, after all participants completed the month 15 visit. Safety analyses included all participants who received at least one dose of MD1003. This trial is registered with ClinicalTrials.gov (NCT02936037) and the EudraCT database (2016-000700-29). Findings From Feb 22, 2017, to June 8, 2018, 642 participants were randomly assigned MD1003 (n=326) or placebo (n=316). The double-blind, placebo-controlled phase of the study ended when the primary endpoint for the lastentered participant was assessed on Nov 15, 2019. The mean time in the placebo-controlled phase was 20.1 months (SD 5.3; range 15-27). For the primary outcome, 39 (12%) of 326 patients in the MD1003 group compared with 29 (9%) of 316 in the placebo group improved at month 12, with confirmation at month 15 (odds ratio 1.35 [95% CI 0.81-2.26]). Treatment-emergent adverse events occurred in 277 (84%) of 331 participants in the MD1003 group and in 264 (85%) of 311 in the placebo group. 87 (26%) of 331 participants in the MD1003 group and 82 (26%) of 311 participants in the placebo group had at least one serious treatment-emergent adverse event. One (<1%) person died in the MD1003 group and there were no deaths in the placebo group. Despite use of mitigation strategies, MD1003 led to inaccurate laboratory results for tests using biotinylated antibodies. Interpretation This study showed that MD1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1003 cannot be recommended for treatment of progressive multiple sclerosis.	[Cree, Bruce A. C.; Block, Valerie] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA 94158 USA; [Cutter, Gary] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA; [Wolinsky, Jerry S.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Freedman, Mark S.] Univ Ottawa, Ottawa, ON, Canada; [Freedman, Mark S.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Comi, Giancarlo] IRCCS San Raffaele Hosp, Inst Expt Neurol, Milan, Italy; [Giovannoni, Gavin] Blizard Inst, London, England; [Hartung, Hans-Peter] Heinrich Heine Univ, Med Fac, Dept Neurol, Dusseldorf, Germany; [Arnold, Douglas] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Kuhle, Jens] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, Basel, Switzerland; [Kuhle, Jens] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland; [Kuhle, Jens] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland; [Munschauer, Frederick E.] MedDay Pharmaceut, Boston, MA USA; [Sedel, Frederic] MedDay Pharmaceut, Paris, France; [Lublin, Fred D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Health Science Center Houston; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Heinrich Heine University Dusseldorf; McGill University; University of Basel; University of Basel; University of Basel; Icahn School of Medicine at Mount Sinai	Cree, BAC (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA 94158 USA.	bruce.cree@ucsf.edu	Cutter, Gary/AAY-5392-2021; Montalban, Xavier/J-5938-2016; Kuhle, Jens/AGE-3474-2022	Cutter, Gary/0000-0002-8455-980X; Montalban, Xavier/0000-0002-0098-9918; ZABAD, RANA KHALIL/0000-0003-3170-7108; Greenberg, Benjamin/0000-0002-2091-8201; Pozzilli, Carlo/0000-0002-6360-4798	MedDay Pharmaceuticals; National Institutes of Health [U2CEB021881]	MedDay Pharmaceuticals; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was sponsored and supported by MedDay Pharmaceuticals. The authors are grateful to all the participants, investigators (appendix pp 2-3), the data safety monitoring board, the clinical adjudication committee, analysis centres (appendix p 2), and MedDay employees who participated in SPI2. The authors are especially grateful to Mark Pletcher for data review. The National Institutes of Health-funded Eureka Research Platform (U2CEB021881) enabled step count collection. The authors of the study include academic members of the study steering committee and study employees.	Avery G, 2019, ANN CLIN BIOCHEM, V56, P424, DOI 10.1177/0004563219842231; Birnbaum G, 2017, MULT SCLER RELAT DIS, V18, P141, DOI 10.1016/j.msard.2017.09.030; Block VJ, 2017, J NEUROL, V264, P316, DOI 10.1007/s00415-016-8334-6; Block VJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0570; Bowen R, 2019, CLIN BIOCHEM, V74, P1, DOI 10.1016/j.clinbiochem.2019.08.012; Cree BAC, 2019, CURR OPIN NEUROL, V32, P365, DOI 10.1097/WCO.0000000000000700; Cui QL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233859; Faissner S, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419878323; Fourcade S, 2020, BRAIN PATHOL, V30, P945, DOI 10.1111/bpa.12869; Freedman MS, 2011, NEUROLOGY, V77, P1551, DOI 10.1212/WNL.0b013e318233b240; Granberg T, 2017, BRAIN, V140, P2912, DOI 10.1093/brain/awx247; Granella F, 2017, EUR COMM TREATM RES; Kapoor R, 2018, LANCET NEUROL, V17, P405, DOI 10.1016/S1474-4422(18)30069-3; Kappos L, 2018, LANCET, V391, P1263, DOI 10.1016/S0140-6736(18)30475-6; Kawachi I, 2017, J NEUROL NEUROSUR PS, V88, P137, DOI 10.1136/jnnp-2016-313300; Koch MW, 2020, MULT SCLER J, V26, P1540, DOI 10.1177/1352458519876701; Levin MC, 2014, DEGENER NEUROL NEURO, V4, P49, DOI 10.2147/DNND.S54391; Lublin F, 2016, LANCET, V387, P1075, DOI 10.1016/S0140-6736(15)01314-8; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Ruhling S, 2019, MOL NEUROBIOL, V56, P3984, DOI 10.1007/s12035-018-1353-9; Sedel F, 2016, NEUROPHARMACOLOGY, V110, P644, DOI 10.1016/j.neuropharm.2015.08.028; Sedel F, 2015, MULT SCLER RELAT DIS, V4, P159, DOI 10.1016/j.msard.2015.01.005; Sorensen PS, 2020, CURR OPIN NEUROL, V33, P262, DOI 10.1097/WCO.0000000000000811; Stys PK, 2012, NAT REV NEUROSCI, V13, P507, DOI 10.1038/nrn3275; Tong L, 2013, CELL MOL LIFE SCI, V70, P863, DOI 10.1007/s00018-012-1096-0; Tourbah A, 2016, MULT SCLER J, V22, P1719, DOI 10.1177/1352458516667568; Trapp BD, 2009, LANCET NEUROL, V8, P280, DOI 10.1016/S1474-4422(09)70043-2; Weigel KJ, 2014, ASN NEURO, V6, P43, DOI 10.1042/AN20130037	30	37	37	3	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					988	997		10.1016/S1474-4422(20)30347-1	http://dx.doi.org/10.1016/S1474-4422(20)30347-1			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PG3EL	33222767	Green Submitted			2022-12-18	WOS:000599622000016
J	Hopfner, F; Hoglinger, GU; Kuhlenbaumer, G; Pottegard, A; Wod, M; Christensen, K; Tanner, CM; Deuschl, G				Hopfner, Franziska; Hoeglinger, Gunter U.; Kuhlenbaeumer, Gregor; Pottegard, Anton; Wod, Mette; Christensen, Kaare; Tanner, Caroline M.; Deuschl, Gunther			beta-adrenoreceptors and the risk of Parkinson's disease	LANCET NEUROLOGY			English	Review							RANDOMIZED INTERVENTION TRIAL; ADRENERGIC-RECEPTORS; ALPHA-SYNUCLEIN; HEART-FAILURE; METAANALYSIS; PROPRANOLOL; METOPROLOL; MIGRAINE; BLOCKERS; FEATURES	Background beta-adrenoceptors are widely expressed in different human organs, mediate important body functions and are targeted by medications for various diseases (such as coronary heart disease and heart attack) and many beta-adrenoceptor acting drugs are listed on the WHO Model List of Essential Medicines. beta-adrenoceptor antagonists are used by billions of patients with neurological disorders, primarily for the treatment of migraine and action tremor (mainly essential tremor), worldwide. Recent developments An observational study reported a link between the chronic use of the beta-adrenoceptor antagonist propranolol and an increased risk of Parkinson's disease, while the chronic use of the beta-adrenoceptor agonists was associated with a decreased risk. Further support of this association was provided by a dose-dependent decrease in the risk of Parkinson's disease with chronic beta-adrenoceptor agonist (eg, salbutamol) use, and by functional data indicating a possible underlying molecular mechanism. Five additional epidemiological studies have examined the modulation of the risk of Parkinson's disease as a result of the use of beta-adrenoceptor-acting drugs in different populations. Overall, similar estimates but different interpretations of the associations were provided. Several findings suggest that the increase in risk of Parkinson's disease associated with beta-adrenoceptor antagonists use can be explained by reverse causation because prodromal Parkinson's disease is often associated with non-specific action tremor, which is usually treated with propranolol. The lower risk of Parkinson's disease seen in patients receiving beta-adrenoceptor agonists is likely to be indirectly mediated by smoking because smoking has a strong inverse association with Parkinson's disease (people that smoke have a reduced risk of developing Parkinson's disease). Smoking also causes chronic obstructive pulmonary disease, which is treated with beta-adrenoceptor-agonist medications. Even if causal, the effect of beta-adrenoceptor antagonists on the risk of Parkinson's disease would be small compared with other Parkinson's disease risk factors and would be similar to the risk evoked by pesticide exposure. The estimated risk of Parkinson's disease because of beta-adrenoceptor antagonists use corresponds to one case in 10 000 patients after 5 years of propranolol use, and would be considered a very rare adverse effect. Thus, not using beta-adrenoceptor antagonists would severely harm patients with recommended indications, such as heart disease or migraine. Similarly, 50 000 people would have to be treated for 5 years with salbutamol to prevent Parkinson's disease in one patient, suggesting that primary preventive therapy studies on disease modification are not warranted. Where next? Epidemiological evidence for a causal relationship between use of beta 2-adrenoceptor antagonists and the increased risk of Parkinson's disease is weak, with other explanations for the association being more probable. Future observational studies are warranted to clarify this association. However, given the very low risk associated with propranolol, most clinicians are unlikely to change their treatment approach.	[Hopfner, Franziska; Kuhlenbaeumer, Gregor; Deuschl, Gunther] Univ Kiel, Univ Med Ctr Schleswig Holstein, Dept Neurol, Kiel, Germany; [Hopfner, Franziska] Ludwig Maximilian Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany; [Hoeglinger, Gunter U.] Tech Univ Munich, Dept Neurol, Munich, Germany; [Hoeglinger, Gunter U.] German Ctr Neurodegenerat Dis, Munich, Germany; [Hoeglinger, Gunter U.] Munich Cluster Syst Neurol, Munich, Germany; [Hopfner, Franziska; Hoeglinger, Gunter U.] Hannover Med Sch, Dept Neurol, Hannover, Germany; [Pottegard, Anton] Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, Odense, Denmark; [Wod, Mette; Christensen, Kaare] Univ Southern Denmark, Unit Epidemiol Biostat & Biodemog, Danish Aging Res Ctr, Danish Twin Registry,Dept Publ Hlth, Odense, Denmark; [Christensen, Kaare] Odense Univ Hosp, Dept Clin Genet, Dept Clin Biochem & Pharmacol, Odense, Denmark; [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, San Francisco, CA USA; [Tanner, Caroline M.] San Francisco Vet Affairs Hlth Care Syst, San Francisco, CA USA	University of Kiel; Schleswig Holstein University Hospital; University of Munich; Technical University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Hannover Medical School; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of California System; University of California San Francisco	Deuschl, G (corresponding author), Christian Albrechts Univ Kiel, Univ Med Ctr Schleswig Holstein, Dept Neurol, D-24105 Kiel, Germany.	g.deuschl@neurologie.uni-kiel.de	Deuschl, Gunther/A-7986-2010; Höglinger, Günter U/F-2388-2015; Christensen, Kaare/C-2360-2009	Deuschl, Gunther/0000-0002-4176-9196; Höglinger, Günter U/0000-0001-7587-6187; Christensen, Kaare/0000-0002-5429-5292; Pottegard, Anton/0000-0001-9314-5679; Wod, Mette/0000-0001-9765-7321				Adler CH, 2011, MOVEMENT DISORD, V26, P372, DOI 10.1002/mds.23509; [Anonymous], 2018, ESS MED HLTH PROD; [Anonymous], CTCAE FIL; [Anonymous], MIGRAINE PROPHYLAXIS; Ascherio A, 2016, LANCET NEUROL, V15, P1255, DOI 10.1016/S1474-4422(16)30230-7; Becker C, 2008, DRUG SAFETY, V31, P399, DOI 10.2165/00002018-200831050-00004; Bellou V, 2016, PARKINSONISM RELAT D, V23, P1, DOI 10.1016/j.parkreldis.2015.12.008; Berg D, 2015, MOVEMENT DISORD, V30, P1600, DOI 10.1002/mds.26431; Braak H, 2006, MOVEMENT DISORD, V21, P2042, DOI 10.1002/mds.21065; Chang D, 2017, NAT GENET, V49, P1511, DOI 10.1038/ng.3955; Deuschl G, 2015, MOVEMENT DISORD, V30, P1327, DOI 10.1002/mds.26265; Deuschl G, 2011, LANCET NEUROL, V10, P148, DOI 10.1016/S1474-4422(10)70322-7; Dodick DW, 2018, LANCET, V391, P1315, DOI 10.1016/S0140-6736(18)30478-1; Dorsey ER, 2018, LANCET NEUROL, V17, P939, DOI 10.1016/S1474-4422(18)30295-3; Dorsey ER, 2018, J PARKINSON DIS, V8, pS3, DOI 10.3233/JPD-181474; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Gelber RP, 2012, CURR ALZHEIMER RES, V9, P664; GORMAN AL, 1993, PHARMACOL BIOCHEM BE, V45, P1; Gronich N, 2018, MOVEMENT DISORD, V33, P1465, DOI 10.1002/mds.108; Hernan MA, 2002, ANN NEUROL, V52, P276, DOI 10.1002/ana.10277; Hertz L, 2010, NEUROCHEM INT, V57, P411, DOI 10.1016/j.neuint.2010.03.019; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hjalmarson A, 1999, LANCET, V353, P2001; Hollenbach JA, 2019, P NATL ACAD SCI USA, V116, P7419, DOI 10.1073/pnas.1821778116; HOLROYD KA, 1991, HEADACHE, V31, P333, DOI 10.1111/j.1526-4610.1991.hed3105333.x; Hopfner F, 2019, NEUROLOGY, V93, pE135, DOI 10.1212/WNL.0000000000007694; Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4; Klapholz M, 2009, MAYO CLIN PROC, V84, P718, DOI 10.4065/84.8.718; KOLLER WC, 1984, NEUROLOGY, V34, P221, DOI 10.1212/WNL.34.2.221; KOLLER WC, 1986, ARCH NEUROL-CHICAGO, V43, P42, DOI 10.1001/archneur.1986.00520010038018; Konno T, 2016, PARKINSONISM RELAT D, V22, pS1, DOI 10.1016/j.parkreldis.2015.09.007; Koren G, 2019, CLIN DRUG INVEST, V39, P463, DOI 10.1007/s40261-019-00771-y; KURITZKY A, 1993, HEADACHE, V33, P198, DOI 10.1111/j.1526-4610.1993.hed33040198.x; Lewy F., 1914, DEUT Z NERVENHEILKD, V50, P50; Linde K, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003225.pub3; Lo RY, 2009, ARCH NEUROL-CHICAGO, V66, P1353, DOI 10.1001/archneurol.2009.221; Louis ED, 2016, PARKINSONISM RELAT D, V26, P82, DOI 10.1016/j.parkreldis.2016.02.026; Louis ED, 2010, MOVEMENT DISORD, V25, P534, DOI 10.1002/mds.22838; Magistrelli L, 2020, J NEUROIMMUNE PHARM, V15, P74, DOI 10.1007/s11481-018-09831-0; Marras C, 2019, MOVEMENT DISORD, V34, P801, DOI 10.1002/mds.27720; Metra M, 2017, LANCET, V390, P1981, DOI 10.1016/S0140-6736(17)31071-1; Mittal S, 2017, SCIENCE, V357, P891, DOI 10.1126/science.aaf3934; Mu S, 2011, NAT MED, V17, P573, DOI 10.1038/nm.2337; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Nielsen SS, 2018, ANN NEUROL, V84, P683, DOI 10.1002/ana.25341; Nielsen SS, 2017, NEUROLOGY, V89, P1448, DOI 10.1212/WNL.0000000000004536; Noyce AJ, 2012, ANN NEUROL, V72, P893, DOI 10.1002/ana.23687; Ong HT, 2007, BMJ-BRIT MED J, V334, P946, DOI 10.1136/bmj.39185.440382.47; Postuma RB, 2016, NAT REV NEUROL, V12, P622, DOI 10.1038/nrneurol.2016.152; Rabe KF, 2017, LANCET, V389, P1931, DOI 10.1016/S0140-6736(17)31222-9; Ritz B, 2010, MOVEMENT DISORD, V25, P1210, DOI 10.1002/mds.23102; Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052; Savitt D, 2019, DRUGS, V79, P797, DOI 10.1007/s40265-019-01104-1; SCARPACE PJ, 1988, NEUROBIOL AGING, V9, P53; Schrag A, 2015, LANCET NEUROL, V14, P57, DOI 10.1016/S1474-4422(14)70287-X; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Ton TGN, 2007, PARKINSONISM RELAT D, V13, P165, DOI 10.1016/j.parkreldis.2006.08.011; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Walters EH, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001385.pub2; World Health Organization, 2017, ATL COUNTR RES NEUR; Zheng SL, 2018, HEART, V104, P407, DOI 10.1136/heartjnl-2017-311652; Zheng W, 2005, AM J EPIDEMIOL, V162, P1123, DOI 10.1093/aje/kwi322	64	37	37	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					247	254		10.1016/S1474-4422(19)30400-4	http://dx.doi.org/10.1016/S1474-4422(19)30400-4			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	31999942				2022-12-18	WOS:000514832700021
J	Alexandrov, AV; Kohrmann, M; Soinne, L; Tsivgoulis, G; Barreto, AD; Demchuk, AM; Sharma, VK; Mikulik, R; Muir, KW; Brandt, G; Alleman, J; Grotta, JC; Levi, CR; Molina, CA; Saqqur, M; Mavridis, D; Psaltopoulou, T; Vosko, M; Fiebach, JB; Mandava, P; Kent, TA; Alexandrov, AW; Schellinger, PD				Alexandrov, Andrei, V; Kohrmann, Martin; Soinne, Lauri; Tsivgoulis, Georgios; Barreto, Andrew D.; Demchuk, Andrew M.; Sharma, Vijay K.; Mikulik, Robert; Muir, Keith W.; Brandt, Gordon; Alleman, John; Grotta, James C.; Levi, Christopher R.; Molina, Carlos A.; Saqqur, Maher; Mavridis, Dimitris; Psaltopoulou, Theodora; Vosko, Milan; Fiebach, Jochen B.; Mandava, Pitchaiah; Kent, Thomas A.; Alexandrov, Anne W.; Schellinger, Peter D.		CLOTBUST-ER Trial Investigators	Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial	LANCET NEUROLOGY			English	Article							ULTRASOUND-ENHANCED THROMBOLYSIS; TISSUE-PLASMINOGEN ACTIVATOR; ALTEPLASE; DEVICE	Background Pulsed-wave ultrasound increases the exposure of an intracranial thrombus to alteplase (recombinant tissue plasminogen activator), potentially facilitating early reperfusion. We aimed to ascertain if a novel operator-independent transcranial ultrasound device delivering low-power high-frequency ultrasound could improve functional outcome in patients treated with alteplase after acute ischaemic stroke. Methods We did a multicentre, double-blind, phase 3, randomised controlled trial (CLOTBUST-ER) at 76 medical centres in 14 countries. We included patients with acute ischaemic stroke (National Institutes of Health Stroke Scale score >= 10) who received intravenous thrombolysis (alteplase bolus) within 3 h of symptom onset in North America and within 4.5 h of symptom onset in all other countries. Participants were randomly allocated (1:1) via an interactive web response system to either active ultrasound (2 MHz pulsed-wave ultrasound for 120 min [sonothrombolysis]; intervention group) or sham ultrasound (control group). Ultrasound was delivered using an operator-independent device, which had to be activated within 30 min of the alteplase bolus. Participants, investigators, and those assessing outcomes were unaware of group assignments. The primary outcome was improvement in the modified Rankin Scale score at 90 days in patients enrolled within 3 h of symptom onset, assessed in the intention-to-treat population as a common odds ratio (cOR) using ordinal logistic regression shift analysis. This trial is registered with ClinicalTrials.gov , number NCT01098981. The trial was stopped early by the funder after the second interim analysis because of futility. Findings Between August, 2013, and April, 2015, 335 patients were randomly allocated to the intervention group and 341 patients to the control group. Compared with the control group, the adjusted cOR for an improvement in modified Rankin Scale score at 90 days in the intervention group was 1.05 (95% CI 0.77-1.45; p=0.74). 51 (16%) of 317 patients in the intervention group and 44 (13%) of 329 patients in the control group died (unadjusted OR 1.24, 95% CI 0 .80-1. 92; 13=0.37) and 83 (26%) and 79 (24%), respectively, had serious adverse events (1.12, 0.79-1.60; p=0.53). Interpretation Sonothrombolysis delivered by an operator-independent device to patients treated with alteplase after acute ischaemic stroke was feasible and most likely safe, but no clinical benefit was seen at 90 days. Sonothrombolysis could be further investigated either in randomised trials undertaken in stroke centres that are dependent on patient transfer for endovascular reperfusion therapies or in countries where these treatments cannot yet be offered as the standard of care. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Alexandrov, Andrei, V; Tsivgoulis, Georgios; Alexandrov, Anne W.] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA; [Kohrmann, Martin] Univ Klinikum Erlangen, Dept Neurol, Erlangen, Germany; [Kohrmann, Martin] Univ Duisburg Essen, Dept Neurol, Essen, Germany; [Soinne, Lauri] Univ Helsinki, Dept Neurol, Helsinki Univ Hosp & Clin Neurosci, Neurol, Helsinki, Finland; [Tsivgoulis, Georgios] Univ Athens, Dept Neurol 2, Attikon Univ Hosp, Sch Med, Athens, Greece; [Tsivgoulis, Georgios; Mikulik, Robert] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Tsivgoulis, Georgios; Mikulik, Robert] St Annes Univ Hosp Brno, Dept Neurol, Brno, Czech Republic; [Barreto, Andrew D.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA; [Demchuk, Andrew M.] Univ Calgary, Dept Clin Neurosci & Radiol, Hotchkiss Brain Inst, Calgary, AB, Canada; [Sharma, Vijay K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore; [Sharma, Vijay K.] Natl Univ Singapore Hosp, Div Neurol, Dept Med, Singapore, Singapore; [Mikulik, Robert] Masaryk Univ, Med Fac, Brno, Czech Republic; [Muir, Keith W.] Univ Glasgow, Inst Neurosci & Psychol, Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland; [Brandt, Gordon; Alleman, John] Cerevast Therapeut, Redmond, WA USA; [Grotta, James C.] Mem Hermann Hosp Texas Med Ctr, Clin Innovat & Res Inst, Houston, TX USA; [Levi, Christopher R.] Univ Newcastle, Dept Neurol, John Hunter Hosp, Newcastle, NSW, Australia; [Molina, Carlos A.] Autonomous Univ Barcelona, Vall dHebron Univ Hosp, Vall dHebron Res Inst, Stroke Unit,Dept Neurol, Barcelona, Spain; [Saqqur, Maher] Univ Alberta, Dept Med Neurol, Edmonton, AB, Canada; [Saqqur, Maher] Hamad Med Corp, Neurosci Inst, Doha, Qatar; [Mavridis, Dimitris] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Ioannina, Greece; [Mavridis, Dimitris] Univ Ioannina, Dept Primary Educ, Sch Educ, Ioannina, Greece; [Psaltopoulou, Theodora] Univ Athens, Dept Hyg Epidemiol & Med Stat, Med Sch, Athens, Greece; [Vosko, Milan] Kepler Univ Clin, Gen Hosp Linz AKH, Dept Neurol, Linz, Austria; [Fiebach, Jochen B.] Univ Med Berlin, Ctr Stroke Res Berlin, Charite, Berlin, Germany; [Mandava, Pitchaiah; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Stroke Outcomes Lab, Houston, TX 77030 USA; [Mandava, Pitchaiah; Kent, Thomas A.] Michael E DeBakey VA Med Ctr, Stroke Program, Houston, TX USA; [Mandava, Pitchaiah; Kent, Thomas A.] Ctr Translat Res Inflammatory Dis, Houston, TX USA; [Alexandrov, Anne W.] Australian Catholic Univ, Sydney, NSW, Australia; [Schellinger, Peter D.] Ruhr Univ Bochum, John Wesling Med Ctr Minden, Dept Neurol, Minden, Germany; [Schellinger, Peter D.] Ruhr Univ Bochum, John Wesling Med Ctr Minden, Dept Neurogeriatry, Minden, Germany	University of Tennessee System; University of Tennessee Health Science Center; University of Erlangen Nuremberg; University of Duisburg Essen; University of Helsinki; Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon; St Anne's University Hospital Brno (FNUSA-ICRC); St Anne's University Hospital Brno (FNUSA-ICRC); University of Texas System; University of Texas Health Science Center Houston; University of Calgary; National University of Singapore; National University of Singapore; Masaryk University Brno; Queen Elizabeth University Hospital (QEUH); University of Glasgow; John Hunter Hospital; University of Newcastle; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Alberta; Hamad Medical Corporation; University of Ioannina; University of Ioannina; National & Kapodistrian University of Athens; Kepler University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Baylor College of Medicine; Baylor College of Medicine; Australian Catholic University; Ruhr University Bochum; Ruhr University Bochum	Alexandrov, AV (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA.	avalexandrov@att.net	Soinne, Lauri/E-3703-2019; Psaltopoulou, Theodora/AAA-6878-2020; Tsivgoulis, Georgios/AAD-7467-2019; Tsivgoulis, Georgios/AAD-5360-2020; sharma, Vijay/T-5286-2019; Grotta, James/AAH-7423-2021; Muir, Keith W/A-7670-2011	Psaltopoulou, Theodora/0000-0002-1404-9716; Tsivgoulis, Georgios/0000-0002-0640-3797; sharma, Vijay/0000-0002-8976-5696; Muir, Keith W/0000-0001-9535-022X; Fiebach, Jochen B./0000-0002-7936-6958; Mikulik, Robert/0000-0002-7458-5166; Levi, Christopher/0000-0002-9474-796X; grotta, james/0000-0002-3667-4248	Cerevast Therapeutics	Cerevast Therapeutics	Cerevast Therapeutics.	Alexandrov AV, 2008, STROKE, V39, P1464, DOI 10.1161/STROKEAHA.107.505727; Alexandrov AV, 2012, J NEUROIMAGING, V22, P215, DOI 10.1111/j.1552-6569.2010.00523.x; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Barlinn K, 2014, INT J STROKE, V9, P1006, DOI 10.1111/ijs.12340; Barlinn K, 2013, STROKE, V44, P1641, DOI 10.1161/STROKEAHA.113.001122; Barreto AD, 2013, STROKE, V44, P3376, DOI 10.1161/STROKEAHA.113.002713; Barreto AD, 2012, STROKE, V43, P591, DOI 10.1161/STROKEAHA.111.617902; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300; Christou I, 2001, INT ANGIOL, V20, P208; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Leary Brendan Vaezy and Shahram., 2008, MARKETING CLEARANCE; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Molina CA, 2009, ANN NEUROL, V66, P28, DOI 10.1002/ana.21723; Quinn TJ, 2007, STROKE, V38, P2257, DOI 10.1161/STROKEAHA.106.480723; Ricci S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008348.pub2; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Schellinger PD, 2015, INT J STROKE, V10, P1141, DOI 10.1111/ijs.12536; Schlegel D, 2004, ARCH NEUROL-CHICAGO, V61, P1061, DOI 10.1001/archneur.61.7.1061; Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597; Tsivgoulis G, 2008, ULTRASONICS, V48, P303, DOI 10.1016/j.ultras.2007.11.008; Tsivgoulis G, 2007, NEUROTHERAPEUTICS, V4, P420, DOI 10.1016/j.nurt.2007.05.012; Tsivgoulis G, 2010, STROKE, V41, P280, DOI 10.1161/STROKEAHA.109.563304; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Whiteley WN, 2016, LANCET NEUROL, V15, P925, DOI [10.1016/s1474-4422(16)30076-X, 10.1016/S1474-4422(16)30076-X]	26	37	38	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					338	347		10.1016/S1474-4422(19)30026-2	http://dx.doi.org/10.1016/S1474-4422(19)30026-2			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30878103	Green Accepted			2022-12-18	WOS:000461169400011
J	Ruggieri, M; Pratico, AD; Scuderi, A; Sorge, G; Polizzi, A				Ruggieri, Martino; Pratico, Andrea D.; Scuderi, Antonino; Sorge, Giovanni; Polizzi, Agata			The multiple faces of artwork diagnoses	LANCET NEUROLOGY			English	Letter							NEUROFIBROMATOSIS; HISTORY		[Ruggieri, Martino; Pratico, Andrea D.] Univ Catania, Unit Rare Dis Nervous Syst Childhood, I-95124 Catania, Italy; [Sorge, Giovanni] Univ Catania, Dept Clin & Expt Med, Sect Pediat & Child Neuropsychiat, I-95124 Catania, Italy; [Pratico, Andrea D.] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy; [Scuderi, Antonino] Oculista Scuderi, Catania, Italy; [Polizzi, Agata] Ist Super Sanita, Natl Ctr Rare Dis, Rome, Italy; [Polizzi, Agata] CNR, Inst Neurol Sci, Catania, Italy	University of Catania; University of Catania; University of Catania; Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze Neurologiche (ISN-CNR)	Ruggieri, M (corresponding author), Univ Catania, Unit Rare Dis Nervous Syst Childhood, I-95124 Catania, Italy.	m.ruggieri@unict.it	Ruggieri, Martino Michele Lucio Giovanni/A-3055-2014					Bianucci Raffaella, 2016, Lancet Neurol, V15, P1123, DOI 10.1016/S1474-4422(16)30210-1; Brosius S, 2010, J HIST NEUROSCI, V19, P333, DOI 10.1080/09647041003642885; Ruggieri M, 2003, J MED GENET, V40, P227, DOI 10.1136/jmg.40.3.227; Ruggieri M, 2017, CHILD NERV SYST, V33, P549, DOI 10.1007/s00381-016-3226-8; The neurofibromatoses, 1994, PATHOGENIC CLIN OVER	5	37	37	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					417	418		10.1016/S1474-4422(17)30129-1	http://dx.doi.org/10.1016/S1474-4422(17)30129-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU1WD	28504104	Bronze			2022-12-18	WOS:000400815800007
J	Meininger, V; Genge, A; van den Berg, LH; Robberecht, W; Ludolph, A; Chio, A; Kim, SH; Leigh, PN; Kiernan, MC; Shefner, JM; Desnuelle, C; Morrison, KE; Petri, S; Boswell, D; Temple, J; Mohindra, R; Davies, M; Bullman, J; Rees, P; Lavrov, A				Meininger, Vincent; Genge, Angela; van den Berg, Leonard H.; Robberecht, Wim; Ludolph, Albert; Chio, Adriano; Kim, Seung H.; Leigh, P. Nigel; Kiernan, Matthew C.; Shefner, Jeremy M.; Desnuelle, Claude; Morrison, Karen E.; Petri, Susanne; Boswell, Diane; Temple, Jane; Mohindra, Rajat; Davies, Matt; Bullman, Jonathan; Rees, Paul; Lavrov, Arseniy		NOG112264 Study Grp	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial	LANCET NEUROLOGY			English	Article							RILUZOLE SERUM CONCENTRATIONS; NEURITE OUTGROWTH INHIBITOR; NOGO-A; EXPRESSION; ALS; DENERVATION; DIAGNOSIS; DISEASE; MARKER	Background Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1(G93A) mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefore, we aimed to assess the safety and efficacy of ozanezumab in patients with ALS. Methods This randomised, double-blind, placebo-controlled, phase 2 trial was done in 34 centres in 11 countries. Patients aged 18-80 years with a diagnosis of familial or sporadic ALS were randomly assigned (1:1), centrally according to a computer-generated allocation schedule, to receive ozanezumab (15 mg/kg) or placebo as intravenous infusions over 1 h every 2 weeks for 46 weeks, followed by assessments at week 48 and week 60. Patients and study personnel were masked to treatment assignment. The primary outcome was a joint-rank analysis of function (ALS Functional Rating Scale-Revised) and overall survival, analysed at 48 weeks in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01753076, and with GSK-ClinicalStudyRegister.com, NOG112264, and is completed. Findings Between Dec 20,2012, and Nov 1,2013, we recruited 307 patients, of whom 303 were randomly assigned to receive placebo (n=151) or ozanezumab (n=152). The adjusted mean of the joint-rank score was -14.9 (SE 13.5) for the ozanezumab group and 15.0 (13.6) for the placebo group, with a least squares mean difference of -30.0 (95% CI -67.9 to 7.9; p=0.12). Overall, reported adverse events, serious adverse events, and adverse events leading to permanent discontinuation of study drug or withdrawal from study were similar between the treatment groups, except for dyspepsia (ten [7%] in the ozanezumab group vs four [3%] in the placebo group), depression (11 [7%] vs five [3%]), and diarrhoea (25 [16%] vs 12 [8%]). Respiratory failure was the most common serious adverse event (12 [8%] vs seven [5%]). At week 60, the number of deaths was higher in the ozanezumab group (20 [13%]) than in the placebo group (16 [11%]), mainly as a result of respiratory failure (ten [7%] vs five [3%]). Two deaths were considered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and cerebrovascular accident in the placebo group). Interpretation Ozanezumab did not show efficacy compared with placebo in patients with ALS. Therefore, Nogo-A does not seem to be an effective therapeutic target in ALS.	[Meininger, Vincent] Ramsay Gen St Hop Prive Peupliers, Paris, France; [Genge, Angela] Montreal Neurol Hosp & Inst, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [van den Berg, Leonard H.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Utrecht, Netherlands; [Robberecht, Wim] Katholieke Univ Leuven, Expt Neurol Univ Hosp Leuven, Dept Neurosci, Leuven, Belgium; [Robberecht, Wim] Katholieke Univ Leuven, Expt Neurol Univ Hosp Leuven, Dept Neurol, Leuven, Belgium; [Ludolph, Albert] Univ Ulm, Dept Neurol, Ulm, Germany; [Chio, Adriano] Univ Turin, Rita Levi Montalcini, Dept Neurosci, Turin, Italy; [Kim, Seung H.] Hanyang Univ Med Ctr, Dept Neurol, Seoul, South Korea; [Leigh, P. Nigel] Univ Sussex, Brighton & Sussex Med Sch, Trafford Ctr Biomed Res, Brighton, E Sussex, England; [Kiernan, Matthew C.] Univ Sydney, Brain & Mind Ctr, Sydney Med Sch, Sydney, NSW, Australia; [Shefner, Jeremy M.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Desnuelle, Claude] Univ Hosp Nice, Dept Neurol, Nice, France; [Morrison, Karen E.] Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England; [Morrison, Karen E.] Univ Southampton, Southampton Univ Hosp, Fac Med, Southampton, Hants, England; [Petri, Susanne] Hannover Med Sch, Dept Neurol, Hannover, Germany; Neurosci Therapy Area Unit, Uxbridge, Middx, England; [Temple, Jane] GlaxoSmithKline, Clin Stat & Global Clin Safety & Pharmacovigilanc, R&D Projects Clin Platforms & Sci Quantitat Sci, Uxbridge, Middx, England; [Bullman, Jonathan] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Stevenage, Herts, England	McGill University; Utrecht University; Utrecht University Medical Center; KU Leuven; KU Leuven; Ulm University; University of Turin; Hanyang University; Hanyang University Hospital; University of Brighton; University of Sussex; University of Sydney; Barrow Neurological Institute; CHU Nice; University of Birmingham; University of Southampton; Hannover Medical School; GlaxoSmithKline; GlaxoSmithKline	Lavrov, A (corresponding author), GlaxoSmithKline, Neurosci Therapy Area Unit, Stockley Pk West, Uxbridge UB11 1BT, Middx, England.	arseniy.j.lavrov@gsk.com	Van Damme, Philip/A-6464-2009; Petri, Susanne/AID-7665-2022; Kim, Seung Hyun/T-5133-2017; Grosskreutz, Julian/G-2293-2010; Shefner, Jeremy/ABF-2901-2020; Leigh, Peter/AAD-5638-2019; Kiernan, Matthew C/E-4460-2011	Van Damme, Philip/0000-0002-4010-2357; Kim, Seung Hyun/0000-0001-9644-9598; Grosskreutz, Julian/0000-0001-9525-1424; Chio, Adriano/0000-0001-9579-5341; Davies, Matt/0000-0001-7545-8460; Kiernan, Matthew/0000-0001-9054-026X; Juntas Morales, Raul/0000-0003-2205-1741; BRUNETEAU, GAELLE/0000-0002-1905-7985	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	This study was funded by GlaxoSmithKline.	Askanas V, 2007, ANN NEUROL, V62, P676, DOI 10.1002/ana.21245; Beghi E, 2011, AMYOTROPH LATERAL SC, V12, P1, DOI 10.3109/17482968.2010.502940; Bellingham MC, 2011, CNS NEUROSCI THER, V17, P4, DOI 10.1111/j.1755-5949.2009.00116.x; Berges A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117355; Berry JD, 2013, AMYOTROPH LAT SCL FR, V14, P162, DOI 10.3109/21678421.2012.762930; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Bros-Facer V, 2014, HUM MOL GENET, V23, P4187, DOI 10.1093/hmg/ddu136; Bruneteau G, 2015, ANN CLIN TRANSL NEUR, V2, P362, DOI 10.1002/acn3.179; Castrillo-Viguera C, 2010, AMYOTROPH LATERAL SC, V11, P178, DOI 10.3109/17482960903093710; Cudkowicz ME, 2013, LANCET NEUROL, V12, P1059, DOI 10.1016/S1474-4422(13)70221-7; Dadon-Nachum M, 2011, J MOL NEUROSCI, V43, P470, DOI 10.1007/s12031-010-9467-1; DiBernardo AB, 2006, BBA-MOL BASIS DIS, V1762, P1139, DOI 10.1016/j.bbadis.2006.03.007; Dupuis L, 2002, NEUROBIOL DIS, V10, P358, DOI 10.1006/nbdi.2002.0522; Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt;1341::AID-SIM129&gt;3.0.CO;2-7; Gordon PH, 2013, AGING DIS, V4, P295, DOI 10.14336/AD.2013.0400295; Groeneveld GJ, 2001, J NEUROL SCI, V191, P121, DOI 10.1016/S0022-510X(01)00613-X; Groeneveld GJ, 2003, NEUROLOGY, V61, P1141, DOI 10.1212/01.WNL.0000090459.76784.49; Jokic N, 2005, ANN NEUROL, V57, P553, DOI 10.1002/ana.20420; Jokic N, 2006, EMBO REP, V7, P1162, DOI 10.1038/sj.embor.7400826; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Lynch AM, 2015, TOXICOL RES-UK, V4, P1333, DOI 10.1039/c5tx00179j; Meininger V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097803; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Mitsumoto H, 2014, LANCET NEUROL, V13, P1127, DOI 10.1016/S1474-4422(14)70129-2; Pradat PF, 2007, ANN NEUROL, V62, P15, DOI 10.1002/ana.21122; Robberecht W, 2013, NAT REV NEUROSCI, V14, P248, DOI 10.1038/nrn3430; Schwab ME, 2010, NAT REV NEUROSCI, V11, P799, DOI 10.1038/nrn2936; Talbot Kevin, 2009, Pract Neurol, V9, P303, DOI 10.1136/jnnp.2009.188151; Turner MR, 2013, LANCET NEUROL, V12, P310, DOI 10.1016/S1474-4422(13)70036-X; Wojcik S, 2006, Acta Myol, V25, P116	30	37	38	4	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2017	16	3					208	216		10.1016/S1474-4422(16)30399-4	http://dx.doi.org/10.1016/S1474-4422(16)30399-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK4ZC	28139349	Green Accepted, Green Published			2022-12-18	WOS:000393935700017
J	Engel, AG; Shen, XM; Selcen, D; Sine, SM				Engel, A. G.; Shen, X-M; Selcen, D.; Sine, S. M.			Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment (vol 14, pg 420, 2015)	LANCET NEUROLOGY			English	Correction															NINDS NIH HHS [R01 NS006277] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS006277] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Engel AG, 2015, LANCET NEUROL, V14, P420, DOI 10.1016/S1474-4422(14)70201-7	1	37	40	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2015	14	5					461	461		10.1016/S1474-4422(15)00010-1	http://dx.doi.org/10.1016/S1474-4422(15)00010-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6SY	25895926				2022-12-18	WOS:000353433900006
J	Bateman, R				Bateman, Randall			Alzheimer's disease and other dementias: advances in 2014	LANCET NEUROLOGY			English	Editorial Material							TRIALS		Washington Univ, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Bateman, R (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.	batemanr@neuro.wustl.edu		Bateman, Randall/0000-0002-7729-1702				Alexander R, 2014, CLIN TRIALS ALZH DIS, pP1; Ayutyanont N, 2014, J CLIN PSYCHIAT, V75, P652, DOI 10.4088/JCP.13m08927; Cady J, 2014, JAMA NEUROL, V71, P449, DOI 10.1001/jamaneurol.2013.6237; Choi SH, 2014, NATURE, V515, P274, DOI 10.1038/nature13800; Cruchaga C, 2014, NATURE, V505, P550, DOI 10.1038/nature12825; Cummings J., 2014, ALZH ASS INT C COP D; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Forman M., 2013, ALZHEIMERS DEMENT, V9, P139, DOI [10.1016/j.jalz.2013.04.083, DOI 10.1016/J.JALZ.2013.04.083]; Holmes BB, 2014, P NATL ACAD SCI USA, V111, pE4376, DOI 10.1073/pnas.1411649111; Mills SM, 2013, REV NEUROL-FRANCE, V169, P737, DOI 10.1016/j.neurol.2013.07.017; Okamura N, 2014, BRAIN, V137, P1762, DOI 10.1093/brain/awu064; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Sepulcre J, 2014, ALZHEIMERS DEMENT, V10, pP159; Shah M, 2014, J NUCL MED, V55, P871, DOI 10.2967/jnumed.113.136069; Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941; Tran HT, 2014, CELL REP, V7, P2054, DOI 10.1016/j.celrep.2014.05.033; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569	17	37	40	0	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					4	6		10.1016/S1474-4422(14)70301-1	http://dx.doi.org/10.1016/S1474-4422(14)70301-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496880				2022-12-18	WOS:000346885300003
J	Davis, LE				Davis, LE			Neurological infections: clinical advances, global threats	LANCET NEUROLOGY			English	Editorial Material									New Mexico VA Hlth Care Syst, Chief Neurol Serv, Albuquerque, NM 87108 USA		Davis, LE (corresponding author), New Mexico VA Hlth Care Syst, Chief Neurol Serv, Albuquerque, NM 87108 USA.	LEDavis@unm.edu						Davies NWS, 2005, J NEUROL NEUROSUR PS, V76, P82, DOI 10.1136/jnnp.2004.045336; de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307; Demma LJ, 2005, NEW ENGL J MED, V353, P587, DOI 10.1056/NEJMoa050043; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Weinberg A, 2005, J INFECT DIS, V191, P234, DOI 10.1086/426402	6	37	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					7	8		10.1016/S1474-4422(05)70259-3	http://dx.doi.org/10.1016/S1474-4422(05)70259-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361009				2022-12-18	WOS:000234328100005
J	Gold, R; Dalakas, MC; Toyka, KV				Gold, R; Dalakas, MC; Toyka, KV			Immunotherapy in autoimmune neuromuscular disorders	LANCET NEUROLOGY			English	Review							INFLAMMATORY DEMYELINATING POLYNEUROPATHY; T-CELL APOPTOSIS; GUILLAIN-BARRE-SYNDROME; ACETYLCHOLINE-RECEPTOR TURNOVER; DOSE INTRAVENOUS IMMUNOGLOBULIN; TRANSFERRED MYASTHENIA-GRAVIS; COSTIMULATORY MOLECULE BB-1; LAMBERT-EATON SYNDROME; RANDOMIZED-TRIAL; PLASMA-EXCHANGE	Important progress has been made in our understanding of the cellular and molecular processes underlying autoimmune neuromuscular diseases that has led us to identify targets for rational therapeutic intervention. Although antigen-specific immunotherapy is not yet available, old and new immunomodulatory treatments, alone or in combination, provide effective immunotherapy for most autoimmune disorders. In parallel, the achievements of molecular medicine provide more specific yet largely experimental therapeutic tools that need to be tested in the human diseases. Here we review the principles and targets of immunotherapy for autoimmune neuromuscular disorders, address applications and practical guidelines, and give an outlook on future developments.	Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis & Neuroimmunol, D-97080 Wurzburg, Germany; NINDS, Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA	University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Gold, R (corresponding author), Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis & Neuroimmunol, D-97080 Wurzburg, Germany.	r.gold@mail.uni-wuerzburg.de						Amemiya K, 2000, BRAIN, V123, P2030, DOI 10.1093/brain/123.10.2030; Amemiya K, 2000, CLIN IMMUNOL, V94, P99, DOI 10.1006/clim.1999.4823; [Anonymous], 1999, Neurology, V53, P457; Bachmann R, 1999, AM J PATHOL, V154, P1417, DOI 10.1016/S0002-9440(10)65395-3; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; Behrens L, 1997, BRAIN, V120, P929, DOI 10.1093/brain/120.6.929; BENDER A, 1995, J EXP MED, V181, P1863, DOI 10.1084/jem.181.5.1863; Berard JL, 1999, PHARMACOTHERAPY, V19, P1127, DOI 10.1592/phco.19.15.1127.30582; Bergner RM, 2000, AM J PSYCHOTHER, V54, P1; BERTA E, 1994, INT J ARTIF ORGANS, V17, P603, DOI 10.1177/039139889401701109; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Buchwald B, 2002, ANN NEUROL, V51, P673, DOI 10.1002/ana.10205; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; CHESTER KA, 1988, J NEUROIMMUNOL, V18, P97, DOI 10.1016/0165-5728(88)90058-6; Choi YC, 2000, NEUROLOGY, V54, P65, DOI 10.1212/WNL.54.1.65; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Confavreux C, 1996, NEUROLOGY, V46, P1607, DOI 10.1212/WNL.46.6.1607; Dalakas, 1995, ANN NEUROL S, V37, P2; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; Dalakas MC, 1996, ANN NEUROL, V39, P419, DOI 10.1002/ana.410390402; Dalakas MC, 1999, MUSCLE NERVE, V22, P1479, DOI 10.1002/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B; DALAKAS MC, 1994, SEMIN NEUROL, V14, P97, DOI 10.1055/s-2008-1041065; Dalakas MC, 2002, ANN NEUROL, V51, P667, DOI 10.1002/ana.10259; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Dalakas MC, 1999, CURR OPIN NEUROL, V12, P403, DOI 10.1097/00019052-199908000-00006; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; DUDEL J, 1979, EXP NEUROL, V66, P365, DOI 10.1016/0014-4886(79)90087-6; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Enders U, 1998, BRAIN, V121, P1257, DOI 10.1093/brain/121.7.1257; *G BARR SYNDR STUD, 1985, NEUROLOGY, V35, P1096; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; Goebels N, 1996, J CLIN INVEST, V97, P2905, DOI 10.1172/JCI118749; Gold N, 2000, INFLAMM BOWEL DIS, V6, P1; Gold R, 1999, BRAIN PATHOL, V9, P343; Gold R, 2001, J NEUROIMMUNOL, V117, P1, DOI 10.1016/S0165-5728(01)00330-7; GOLD R, 2001, IMMUNTHERAPIE NEUROL; GRIFFIN JW, 1994, PROG BRAIN RES, V101, P313; GRINYO J, 1995, LANCET, V345, P1321; Gronseth GS, 2000, NEUROLOGY, V55, P7, DOI 10.1212/WNL.55.1.7; Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512; Hadden RDM, 1999, NEUROLOGY, V53, P57, DOI 10.1212/WNL.53.1.57; Hahn AF, 1996, BRAIN, V119, P1055, DOI 10.1093/brain/119.4.1055; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202; HEININGER K, 1987, ANN NY ACAD SCI, V505, P898, DOI 10.1111/j.1749-6632.1987.tb51406.x; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; Hoffacker V, 2000, BLOOD, V96, P3872, DOI 10.1182/blood.V96.12.3872.h8003872_3872_3879; HOHLFELD R, 1985, ANN NEUROL, V17, P238, DOI 10.1002/ana.410170304; Hohlfeld R, 2002, J NEUROL, V249, P1147, DOI 10.1007/s00415-002-0802-5; HOHLFELD R, 1988, NEUROLOGY, V38, P258, DOI 10.1212/WNL.38.2.258; HOHLFELD R, 1996, NEUROLOGICAL DISORDE, P947; HOHLFELD R, 1993, MYASTHENIA GRAVIS, P235; Hughes RAC, 1997, LANCET, V349, P225; HUGHES RAC, 1993, LANCET, V341, P586; Janeway Jr C. A., 2001, IMMUNOBIOLOGY IMMUNE, V5th; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kiefer R, 1996, AM J PATHOL, V148, P211; Kiefer R, 2000, J NEUROL NEUROSUR PS, V69, P362, DOI 10.1136/jnnp.69.3.362; Kieseier BC, 1998, ANN NEUROL, V43, P427, DOI 10.1002/ana.410430404; Kieseier BC, 1999, CURR OPIN NEUROL, V12, P323, DOI 10.1097/00019052-199906000-00011; KIRCHNER T, 1988, AM J PATHOL, V130, P268; KIRCHNER T, 1986, VIRCHOWS ARCH B, V52, P237, DOI 10.1007/BF02889966; Korinthenberg R, 1999, NEUROPEDIATRICS, V30, P190, DOI 10.1055/s-2007-973489; Korn T, 2001, BRAIN, V124, P1791, DOI 10.1093/brain/124.9.1791; Kozak T, 2002, J NEUROL, V249, P1088, DOI 10.1007/s00415-002-0800-7; LANG B, 1983, J PHYSIOL-LONDON, V344, P335, DOI 10.1113/jphysiol.1983.sp014943; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; Leussink VI, 2002, ACTA NEUROPATHOL, V103, P131; Levine TD, 1999, NEUROLOGY, V52, P1701, DOI 10.1212/WNL.52.8.1701; LEYS K, 1991, ANN NEUROL, V29, P307, DOI 10.1002/ana.410290313; Li M, 2000, J NEUROIMMUNOL, V106, P1, DOI 10.1016/S0165-5728(99)00162-9; Link H, 2001, IMMUNOL REV, V184, P117, DOI 10.1034/j.1600-065x.2001.1840111.x; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; Mariette X, 1997, J NEUROL NEUROSUR PS, V63, P28, DOI 10.1136/jnnp.63.1.28; Martini R, 1997, J ANAT, V191, P321, DOI 10.1046/j.1469-7580.1997.19130321.x; Maurer M, 2002, NEUROMUSCULAR DISORD, V12, P405, DOI 10.1016/S0960-8966(01)00302-9; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Mueller M, 2001, AM J PATHOL, V159, P2187, DOI 10.1016/S0002-9440(10)63070-2; MULLERHERMELINK HK, 1993, ANN NY ACAD SCI, V681, P56, DOI 10.1111/j.1749-6632.1993.tb22869.x; Murata K, 1999, AM J PATHOL, V155, P453, DOI 10.1016/S0002-9440(10)65141-3; Murata K, 2000, BRAIN, V123, P1660, DOI 10.1093/brain/123.8.1660; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Leary CP, 2000, CURR OPIN NEUROL, V13, P583, DOI 10.1097/00019052-200010000-00013; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; PEDERSENBJERGAARD J, 1985, ANN INTERN MED, V103, P195, DOI 10.7326/0003-4819-103-2-195; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; Ransohoff RM, 1999, J NEUROIMMUNOL, V98, P57, DOI 10.1016/S0165-5728(99)00082-X; RAPHAEL JC, 1987, ANN NEUROL, V22, P753; Reder A. T., 1997, INTERFERON THER MULT, V352, P1; Renaud S, 2001, NEUROLOGY, V56, pA396; ROSENTHAL GJ, 1988, J IMMUNOL, V141, P410; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Schmid CD, 2000, J NEUROSCI, V20, P729, DOI 10.1523/JNEUROSCI.20-02-00729.2000; Schmidt J, 2001, J NEUROSCI RES, V65, P59, DOI 10.1002/jnr.1128; SCHMIED M, 1993, AM J PATHOL, V143, P446; Schneider C, 2000, J NEUROIMMUNOL, V107, P83, DOI 10.1016/S0165-5728(00)00254-X; Schneider C, 1999, ARCH NEUROL-CHICAGO, V56, P79, DOI 10.1001/archneur.56.1.79; Schneider C, 2001, EUR NEUROL, V46, P79, DOI 10.1159/000050768; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIBUYA N, 1994, J NEUROL NEUROSUR PS, V57, P578, DOI 10.1136/jnnp.57.5.578; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Smith KJ, 2001, ANN NEUROL, V49, P470; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602; Tacke M, 1997, EUR J IMMUNOL, V27, P239, DOI 10.1002/eji.1830270136; Toyka KV, 1999, REV NEUROL, V155, P849; Toyka KV, 1996, CURR OPIN NEUROL, V9, P240, DOI 10.1097/00019052-199606000-00016; TOYKA KV, 1975, SCIENCE, V190, P397, DOI 10.1126/science.1179220; TOYKA KV, 1987, KLIN NEUROIMMUNOLOGI; Uchiyama A, 2001, ANN THORAC SURG, V72, P1902, DOI 10.1016/S0003-4975(01)03210-6; van Doorn PA, 2002, NEUROMUSCULAR DISORD, V12, P781; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Vermeulen M, 2002, J NEUROL NEUROSUR PS, V72, P127, DOI 10.1136/jnnp.72.1.127; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weishaupt A, 2000, J IMMUNOL, V165, P7157, DOI 10.4049/jimmunol.165.12.7157; Weiss MD, 1998, NEUROLOGY, V51, P1738, DOI 10.1212/WNL.51.6.1738; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003; WIENDL H, IN PRESS BRAIN; WILLCOX N, 1987, AM J PATHOL, V127, P447; Willison HJ, 2001, J NEUROL SCI, V185, P1, DOI 10.1016/S0022-510X(01)00465-8; WILSON S, 1983, J NEUROL NEUROSUR PS, V46, P377, DOI 10.1136/jnnp.46.5.377; WILSON S, 1983, J NEUROL NEUROSUR PS, V46, P383, DOI 10.1136/jnnp.46.5.383; WITTE AS, 1986, NEUROLOGY, V36, P1533, DOI 10.1212/WNL.36.11.1533; Wohlleben G, 2000, GLIA, V30, P373, DOI 10.1002/(SICI)1098-1136(200006)30:4<373::AID-GLIA60>3.3.CO;2-R; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; Yuki N, 1996, J NEUROIMMUNOL, V70, P1, DOI 10.1016/S0165-5728(96)00042-2; Zettl UK, 1996, ACTA NEUROPATHOL, V91, P360, DOI 10.1007/s004010050437	135	37	38	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					22	32		10.1016/S1474-4422(03)00264-3	http://dx.doi.org/10.1016/S1474-4422(03)00264-3			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849298				2022-12-18	WOS:000180035800020
J	Miglis, MG; Adler, CH; Antelmi, E; Arnaldi, D; Baldelli, L; Boeve, BF; Cesari, M; Dall'Antonia, I; Diederich, NJ; Doppler, K; Dusek, P; Ferri, R; Gagnon, JF; Gan-Or, Z; Hermann, W; Hogl, B; Hu, MT; Iranzo, A; Janzen, A; Kuzkina, A; Lee, JY; Leenders, KL; Lewis, SJG; Liguori, C; Liu, J; Lo, C; Martens, KAE; Nepozitek, J; Plazzi, G; Provini, F; Puligheddu, M; Rolinski, M; Rusz, J; Stefani, A; Summers, RLS; Yoo, D; Zitser, J; Oertel, WH				Miglis, Mitchell G.; Adler, Charles H.; Antelmi, Elena; Arnaldi, Dario; Baldelli, Luca; Boeve, Bradley F.; Cesari, Matteo; Dall'Antonia, Irene; Diederich, Nico J.; Doppler, Kathrin; Dusek, Petr; Ferri, Raffaele; Gagnon, Jean-Francois; Gan-Or, Ziv; Hermann, Wiebke; Hoegl, Birgit; Hu, Michele T.; Iranzo, Alex; Janzen, Annette; Kuzkina, Anastasia; Lee, Jee-Young; Leenders, Klaus L.; Lewis, Simon J. G.; Liguori, Claudio; Liu, Jun; Lo, Christine; Martens, Kaylena A. Ehgoetz; Nepozitek, Jiri; Plazzi, Giuseppe; Provini, Federica; Puligheddu, Monica; Rolinski, Michal; Rusz, Jan; Stefani, Ambra; Summers, Rebekah L. S.; Yoo, Dallah; Zitser, Jennifer; Oertel, Wolfgang H.			Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder	LANCET NEUROLOGY			English	Review							TO-NIGHT VARIABILITY; REM-SLEEP; PARKINSONS-DISEASE; MUSCLE-ACTIVITY; ATONIA INDEX; IDENTIFICATION; DEPOSITS; NEURODEGENERATION; ASSOCIATION; THRESHOLDS	Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving alpha-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal alpha-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest alpha-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of alpha-synucleinopathy patients with isolated RBD might develop.	[Miglis, Mitchell G.] Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; [Miglis, Mitchell G.] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; [Adler, Charles H.] Mayo Clin, Dept Neurol, Coll Med, Scottsdale, AZ USA; [Antelmi, Elena] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy; [Arnaldi, Dario] Univ Genoa, Clin Neurol, DINOGMI, Genoa, Italy; [Arnaldi, Dario] IRCCS Osped Policlin San Martino, Genoa, Italy; [Baldelli, Luca; Provini, Federica] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Boeve, Bradley F.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Boeve, Bradley F.] Mayo Clin, Ctr Sleep Med, Rochester, MN USA; [Cesari, Matteo; Hoegl, Birgit; Stefani, Ambra] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Dall'Antonia, Irene; Dusek, Petr; Nepozitek, Jiri] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Dall'Antonia, Irene; Dusek, Petr; Nepozitek, Jiri] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Diederich, Nico J.] Ctr Hosp Luxembourg, Dept Neurosci, Luxembourg, Luxembourg; [Doppler, Kathrin; Kuzkina, Anastasia] Univ Wurzburg, Dept Neurol, Wurzburg, Germany; [Ferri, Raffaele] Oasi Res Inst IRCCS, Troina, Italy; [Gagnon, Jean-Francois] Hop Sacre Coeur Montreal, Ctr Adv Res Sleep Med, Ctr Integre Univ Sante & Serv Sociaux Nord Ile de, Montreal, PQ, Canada; [Gan-Or, Ziv] McGill Univ, Neurol Inst Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Gan-Or, Ziv] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Hermann, Wiebke] Univ Rostock, Dept Neurol, Rostock, Germany; [Hermann, Wiebke] German Ctr Neurodegenerat Dis DZNE, Res Site Rostock, Rostock, Germany; [Hu, Michele T.; Lo, Christine] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Iranzo, Alex] Univ Barcelona, Hosp Clin Barcelona, Sleep Disorders Ctr, Neurol Serv, Barcelona, Spain; [Janzen, Annette; Oertel, Wolfgang H.] Philipps Univ Marburg, Dept Neurol, Marburg, Germany; [Janzen, Annette; Oertel, Wolfgang H.] Philipps Univ Marburg, Sect Clin Neurosci, Marburg, Germany; [Lee, Jee-Young] Seoul Natl Univ, Dept Neurol, Coll Med, Seoul, South Korea; [Leenders, Klaus L.] Univ Med Ctr Groningen, Dept Nucl Med & Biomed Imaging, Groningen, Netherlands; [Lewis, Simon J. G.] Univ Sydney, ForeFront Parkinsons Dis Res Clin, Brain & Mind Ctr, Sydney, NSW, Australia; [Liguori, Claudio] Univ Roma Tor Vergata, Sleep Med Ctr, Dept Syst Med, Rome, Italy; [Liu, Jun] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China; [Martens, Kaylena A. Ehgoetz] Univ Waterloo, Fac Appl Hlth Sci, Dept Kinesiol, Waterloo, ON, Canada; [Plazzi, Giuseppe; Provini, Federica] Ist Sci Neurol Bologna, IRCCS, Bologna, Italy; [Plazzi, Giuseppe] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Modena, Italy; [Provini, Federica] Bellaria Hosp, UOC Clin Neurol Rete Metropolitana NEUROMET, Bologna, Italy; [Puligheddu, Monica] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy; [Rolinski, Michal] Univ Bristol, Inst Clin Neurosci, Bristol, Avon, England; [Rusz, Jan] Czech Tech Univ, Fac Elect Engn, Dept Circuit Theory, Prague, Czech Republic; [Summers, Rebekah L. S.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; [Yoo, Dallah] Kyung Hee Univ Hosp, Dept Neurol, Seoul, South Korea; [Zitser, Jennifer] Univ Calif San Francisco, Dept Neurol & Neurol Sci, San Francisco, CA 94143 USA; [Zitser, Jennifer] Tel Aviv Univ, Sackler Fac Med, Dept Neurol, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Oertel, Wolfgang H.] Helmholtz Ctr Hlth & Environm, Inst Neurogenom, Munich, Germany	Stanford University; Stanford University; Mayo Clinic; Mayo Clinic Phoenix; University of Verona; University of Genoa; University of Bologna; Mayo Clinic; Mayo Clinic; Medical University of Innsbruck; Charles University Prague; Charles University Prague; Luxembourg Hospital Center; University of Wurzburg; Universite de Montreal; McGill University; McGill University; University of Rostock; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Oxford; University of Barcelona; Hospital Clinic de Barcelona; Philipps University Marburg; Philipps University Marburg; Seoul National University (SNU); University of Groningen; University of Sydney; University of Rome Tor Vergata; Shanghai Jiao Tong University; University of Waterloo; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); Universita di Modena e Reggio Emilia; AUSL di Bologna; University of Cagliari; University of Bristol; Czech Technical University Prague; University of Minnesota System; University of Minnesota Twin Cities; Kyung Hee University; Kyung Hee University Hospital; University of California System; University of California San Francisco; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Miglis, MG (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA.	mmiglis@stanford.edu	Nepožitek, Jiří/G-7261-2017; Stefani, Ambra/AAK-2172-2020; Nepozitek, Jiri/AFB-6952-2022; Nepozitek, Jiri/AHA-9104-2022; Rusz, Jan/S-2054-2018; Cesari, Matteo/AAD-6292-2021; Adler, Charles/ABD-5276-2021; Yoo, Dallah/ABB-6365-2021; Arnaldi, Dario/F-8217-2013; Baldelli, Luca/AAZ-7555-2020; Lo, Christine/E-4285-2015; Dusek, Petr/F-9084-2017	Nepožitek, Jiří/0000-0002-3339-5286; Stefani, Ambra/0000-0003-4259-8824; Rusz, Jan/0000-0002-1036-3054; Cesari, Matteo/0000-0001-6554-1033; Arnaldi, Dario/0000-0001-6823-6069; Baldelli, Luca/0000-0003-3666-1735; Lo, Christine/0000-0002-5671-3881; Dusek, Petr/0000-0003-4877-9642; Summers, Rebekah/0000-0002-1783-3362; Hu, Michele/0000-0001-6382-5841; Dall'Antonia, Irene/0000-0001-7242-1179; Yoo, Dallah/0000-0002-9736-6118; Doppler, Kathrin/0000-0003-2883-0009; Miglis, Mitchell/0000-0001-8488-0313; Zitser, Jennifer/0000-0003-0200-6185	US NIH [R34 AG056639, P30 AG62677, U01 NS100620]; Czech Health Research Council [NU20-08-00445]; ParkinsonFonds Deutschland	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Czech Health Research Council; ParkinsonFonds Deutschland	BFB was supported by grants (R34 AG056639, P30 AG62677, U01 NS100620) from the US NIH. JR (NU20-08-00445) and PD (NU20-08-00445) were supported by grants from the Czech Health Research Council. WHO was supported by ParkinsonFonds Deutschland. No funding source had any role in the writing of the manuscript or the decision to submit for publication. No authors have been paid to write this Review by a pharmaceutical company or other agency.	Ahn J, 2018, NEUROLOGY, V91, pE1003, DOI 10.1212/WNL.0000000000006157; Al-Qassabi A, 2021, MOVEMENT DISORD, V36, P895, DOI 10.1002/mds.28399; Antelmi E, 2019, ANN CLIN TRANSL NEUR, V6, P1872, DOI 10.1002/acn3.50833; Antelmi E, 2017, NEUROLOGY, V88, P2128, DOI 10.1212/WNL.0000000000003989; Arnaldi D, 2021, SLEEP MED, V79, P205, DOI 10.1016/j.sleep.2020.02.011; Arnaldi D, 2021, BRAIN, V144, P278, DOI 10.1093/brain/awaa365; Arnaldi D, 2021, EUR J NEUROL, V28, P1210, DOI 10.1111/ene.14664; Arora S, 2018, NEUROLOGY, V91, P1528, DOI 10.1212/WNL.0000000000006366; Barber TR, 2020, ANN CLIN TRANSL NEUR, V7, P26, DOI 10.1002/acn3.50962; BARBER TR, 2017, SLEEP, V40, DOI [DOI 10.1093/SLEEP/ZSX071, 10.1093/sleep/zsx071]; Beach TG, 2009, ACTA NEUROPATHOL, V117, P613, DOI [10.1007/s00401-009-0538-8, 10.1007/s00401-010-0664-3]; Bencheikh BOA, 2018, PARKINSONISM RELAT D, V52, P98, DOI 10.1016/j.parkreldis.2018.03.019; Bezdicek O, 2018, CLIN NEUROPSYCHOL, V32, P1019, DOI 10.1080/13854046.2017.1394493; Califf RM, 2018, EXP BIOL MED, V243, P213, DOI 10.1177/1535370217750088; Campabadal A, 2020, NEUROIMAGE-CLIN, V25, DOI 10.1016/j.nicl.2019.102138; Campabadal A, 2019, PARKINSONISM RELAT D, V65, P197, DOI 10.1016/j.parkreldis.2019.06.013; Cheung CY, 2019, CURR OPIN NEUROL, V32, P82, DOI 10.1097/WCO.0000000000000645; De Cock VC, 2020, ANN CLIN TRANSL NEUR, V7, P280, DOI 10.1002/acn3.50982; Cooray N, 2019, CLIN NEUROPHYSIOL, V130, P505, DOI 10.1016/j.clinph.2019.01.011; Del Din S, 2020, J PARKINSON DIS, V10, P283, DOI 10.3233/JPD-191773; Donadio V, 2019, EUR J NEUROL, V26, P1245, DOI 10.1111/ene.13939; Donadio V, 2020, MOVEMENT DISORD, V35, P1649, DOI 10.1002/mds.28126; Dong X, 2018, ELECTROPHORESIS, V39, P3096, DOI 10.1002/elps.201800316; Doppler K, 2017, ACTA NEUROPATHOL, V133, P535, DOI 10.1007/s00401-017-1684-z; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; Dusek P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51710-y; Fereshtehnejad SM, 2019, BRAIN, V142, P2051, DOI 10.1093/brain/awz111; Ferini-Strambi L, 2019, EXPERT REV NEUROTHER, V19, P1069, DOI 10.1080/14737175.2019.1640603; Ferini-Strambi L, 2014, J NEUROL, V261, P1112, DOI 10.1007/s00415-014-7317-8; Fernandez-Santiago R, 2015, ANN NEUROL, V77, P895, DOI 10.1002/ana.24384; Ferri R, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy187; Ferri R, 2014, SLEEP MED, V15, P661, DOI 10.1016/j.sleep.2013.12.022; Ferri R, 2013, J CLIN SLEEP MED, V9, P253, DOI 10.5664/jcsm.2490; Ferri R, 2013, SLEEP MED, V14, P293, DOI 10.1016/j.sleep.2012.08.014; Figorilli M, 2020, SLEEP, V43, DOI 10.1093/sleep/zsz323; Frauscher B, 2014, SLEEP, V37, P1663, DOI 10.5665/sleep.4076; Frauscher B, 2012, SLEEP, V35, P835, DOI 10.5665/sleep.1886; Gan-Or Z, 2017, NEUROBIOL AGING, V49, DOI 10.1016/j.neurobiolaging.2016.10.002; Gan-Or Z, 2015, ANN CLIN TRANSL NEUR, V2, P941, DOI 10.1002/acn3.228; Hanuska J, 2019, J SLEEP RES, V28, DOI 10.1111/jsr.12742; Heintz-Buschart A, 2018, MOVEMENT DISORD, V33, P88, DOI 10.1002/mds.27105; Hogl B, 2018, NAT REV NEUROL, V14, P40, DOI 10.1038/nrneurol.2017.157; Honeycutt L, 2020, PARKINSONISM RELAT D, V75, P76, DOI 10.1016/j.parkreldis.2020.05.017; Horgusluoglu E, 2017, AM J MED GENET B, V174, P93, DOI 10.1002/ajmg.b.32429; Huang ZM, 2020, J CEREBR BLOOD F MET, V40, P552, DOI 10.1177/0271678X19828916; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Iranzo A, 2021, LANCET NEUROL, V20, P203, DOI 10.1016/S1474-4422(20)30449-X; Iranzo A, 2021, J NEUROL, V268, P963, DOI 10.1007/s00415-020-10229-3; Iranzo A, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy101; Iranzo A, 2017, ANN NEUROL, V82, P419, DOI 10.1002/ana.25026; Iranzo A, 2013, PARKINSONISM RELAT D, V19, P600, DOI 10.1016/j.parkreldis.2013.02.009; Iranzo A, 2011, LANCET NEUROL, V10, P797, DOI 10.1016/S1474-4422(11)70152-1; Jennings D, 2017, JAMA NEUROL, V74, P933, DOI 10.1001/jamaneurol.2017.0985; Jiang C, 2020, J NEUROL NEUROSUR PS, V91, P720, DOI 10.1136/jnnp-2019-322588; Khalil A, 2013, J CLIN SLEEP MED, V9, P1039, DOI 10.5664/jcsm.3078; Knudsen K, 2018, LANCET NEUROL, V17, P618, DOI 10.1016/S1474-4422(18)30162-5; Kogan RV, 2021, MOVEMENT DISORD, V36, P230, DOI 10.1002/mds.28260; Krohn L, 2020, NEUROLOGY, V95, pE1008, DOI 10.1212/WNL.0000000000010042; Krohn L, 2020, ANN NEUROL, V87, P584, DOI 10.1002/ana.25687; Krohn L, 2020, ANN NEUROL, V87, P139, DOI 10.1002/ana.25629; Krupicka R, 2020, SLEEP MED, V75, P45, DOI 10.1016/j.sleep.2020.07.019; Lanza G, 2020, SLEEP, V43, DOI 10.1093/sleep/zsz242; Lawton M, 2016, PARKINSONISM RELAT D, V33, P96, DOI 10.1016/j.parkreldis.2016.09.023; Lee H, 2015, MOVEMENT DISORD, V30, P1843, DOI 10.1002/mds.26416; Lee JY, 2020, MOVEMENT DISORD, V35, P349, DOI 10.1002/mds.27914; Lee JY, 2019, J NEURAL TRANSM, V126, P1695, DOI 10.1007/s00702-019-02097-7; Li J, 2018, MOVEMENT DISORD, V33, P1016, DOI 10.1002/mds.27385; Li YY, 2017, NEUROLOGY, V88, P1493, DOI 10.1212/WNL.0000000000003838; Mailankody P, 2019, J NEUROL SCI, V403, P67, DOI 10.1016/j.jns.2019.06.009; Marchand DG, 2018, ANN NEUROL, V83, P1016, DOI 10.1002/ana.25239; Marchand DG, 2017, SLEEP, V40, DOI 10.1093/sleep/zsw014; Martens KAE, 2019, MOVEMENT DISORD, V34, P1374, DOI 10.1002/mds.27780; McCarter SJ, 2020, CLIN AUTON RES, V30, P207, DOI 10.1007/s10286-020-00674-5; McCarter SJ, 2019, NEUROLOGY, V93, pE1171, DOI 10.1212/WNL.0000000000008127; McCarter SJ, 2017, SLEEP MED, V33, P23, DOI 10.1016/j.sleep.2016.03.013; McCarter SJ, 2014, SLEEP, V37, P1649, DOI 10.5665/sleep.4074; Meles SK, 2018, J NUCL MED, V59, P1437, DOI 10.2967/jnumed.117.202242; Melpignano A, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz142; Mondello S, 2018, NEUROLOGY, V91, pE1710, DOI 10.1212/WNL.0000000000006439; Munoz-Lopetegi A, 2021, SLEEP, V44, DOI 10.1093/sleep/zsaa089; Nepozitek J, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz132; Niu M, 2020, MOVEMENT DISORD, V35, pS369, DOI 10.1111/ene.14208; Ortuno-Lizaran I, 2018, MOVEMENT DISORD, V33, P1315, DOI 10.1002/mds.27392; Peever J, 2014, TRENDS NEUROSCI, V37, P279, DOI 10.1016/j.tins.2014.02.009; Postuma RB, 2019, BRAIN, V142, P744, DOI 10.1093/brain/awz030; Postuma RB, 2015, NEUROLOGY, V84, P1104, DOI 10.1212/WNL.0000000000001364; Postuma RB, 2011, ANN NEUROL, V69, P811, DOI 10.1002/ana.22282; Puligheddu M, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz128; Pyatigorskaya N, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx149; Rahayel S, 2021, ANN NEUROL, V89, P341, DOI 10.1002/ana.25962; Rahayel S, 2018, NEUROLOGY, V90, pE1759, DOI 10.1212/WNL.0000000000005523; Rahayel S, 2018, CEREB CORTEX, V28, P658, DOI 10.1093/cercor/bhx137; Rocchi C, 2018, SLEEP MED, V52, P163, DOI 10.1016/j.sleep.2018.08.023; Rossi M, 2020, ACTA NEUROPATHOL, V140, P49, DOI 10.1007/s00401-020-02160-8; Ruffini G, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00806; Rusz J, 2018, IEEE T NEUR SYS REH, V26, P1495, DOI 10.1109/TNSRE.2018.2851787; Sasai-Sakuma T, 2020, SLEEP, V43, DOI 10.1093/sleep/zsaa024; Shin C, 2019, EUR J NEUROL, V26, P1417, DOI 10.1111/ene.14025; Smith AM, 2018, MOVEMENT DISORD, V33, P1580, DOI 10.1002/mds.104; Sprenger FS, 2015, NEUROLOGY, V85, P1761, DOI 10.1212/WNL.0000000000002126; Stefani A, 2021, BRAIN, V144, P1118, DOI 10.1093/brain/awab005; Stokholm MG, 2020, EUR J NEUROL, V27, P644, DOI 10.1111/ene.14127; Terzaghi M, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz103; Vilas D, 2016, LANCET NEUROL, V15, P708, DOI 10.1016/S1474-4422(16)00080-6; Wilke C, 2020, MOVEMENT DISORD, V35, P1233, DOI 10.1002/mds.28026; Yang ZJ, 2016, SLEEP BREATH, V20, P1285, DOI 10.1007/s11325-016-1366-4; Zitser J, 2020, AUTON NEUROSCI-BASIC, V224, DOI 10.1016/j.autneu.2020.102645; Zitser J, 2020, SLEEP MED REV, V51, DOI 10.1016/j.smrv.2020.101283; Zitser J, 2019, AUTON NEUROSCI-BASIC, V220, DOI 10.1016/j.autneu.2019.05.005	109	36	36	14	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					671	684		10.1016/S1474-4422(21)00176-9	http://dx.doi.org/10.1016/S1474-4422(21)00176-9			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34302789	Green Published, Green Accepted			2022-12-18	WOS:000677684700019
J	Adams, D; Polydefkis, M; Gonzalez-Duarte, A; Wixner, J; Kristen, AV; Schmidt, HH; Berk, JL; Lopez, IAL; Dispenzieri, A; Quan, D; Conceicao, IM; Slama, MS; Gillmore, JD; Kyriakides, T; Ajroud-Driss, S; Waddington-Cruz, M; Mezei, MM; Plante-Bordeneuve, V; Attarian, S; Mauricio, E; Brannagan, TH; Ueda, M; Aldinc, E; Wang, JJ; White, MT; Vest, J; Berber, E; Sweetser, MT; Coelho, T				Adams, David; Polydefkis, Michael; Gonzalez-Duarte, Alejandra; Wixner, Jonas; Kristen, Arnt, V; Schmidt, Hartmut H.; Berk, John L.; Losada Lopez, Ines Asuncion; Dispenzieri, Angela; Quan, Dianna; Conceicao, Isabel M.; Slama, Michel S.; Gillmore, Julian D.; Kyriakides, Theodoros; Ajroud-Driss, Senda; Waddington-Cruz, Marcia; Mezei, Michelle M.; Plante-Bordeneuve, Violaine; Attarian, Shahram; Mauricio, Elizabeth; Brannagan, Thomas H., III; Ueda, Mitsuharu; Aldinc, Emre; Wang, Jing Jing; White, Matthew T.; Vest, John; Berber, Erhan; Sweetser, Marianne T.; Coelho, Teresa		Patisiran Global OLE Study Grp	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study	LANCET NEUROLOGY			English	Article							CARDIAC PHENOTYPE; WILD-TYPE; CARDIOMYOPATHY; DIAGNOSIS	Background Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0.3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4.0, 95 % CI -7.7 to -0.3; phase 2 OLE patisiran -4.7, -11.9 to 2.4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1.4, 95% CI -6.2 to 3.5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Adams, David] Univ Paris Saclay, U1195, INSERM, Le Kremlin Bicetre, France; [Adams, David] Ctr Hosp Univ Bicetre, AP HP, Neurol Dept, Le Kremlin Bicetre, France; [Polydefkis, Michael] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Gonzalez-Duarte, Alejandra] Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Wixner, Jonas] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden; [Kristen, Arnt, V] Heidelberg Univ, Dept Cardiol, Heidelberg, Germany; [Schmidt, Hartmut H.] Univ Munster, Munster, Germany; [Berk, John L.] Boston Med Ctr, Boston, MA USA; [Losada Lopez, Ines Asuncion] Balearic Isl Hlth Res Inst, Palma De Mallorca, Spain; [Dispenzieri, Angela] Mayo Clin, Div Hematol, Rochester, MN USA; [Quan, Dianna] Univ Colorado, Denver, CO 80202 USA; [Conceicao, Isabel M.] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon, Portugal; [Conceicao, Isabel M.] Fac Med, Lisbon, Portugal; [Slama, Michel S.] Univ Paris Saclay, Ctr Hosp Univ Xavier Bichat, AP HP, Ctr Competence Amylose Cardiaque,Cardiol Dept, Paris, France; [Gillmore, Julian D.] UCL, Royal Free Hosp, Natl Amyloidosis Ctr, London, England; [Kyriakides, Theodoros] Cyprus Inst Neurol & Genet, Nicosia, Cyprus; [Kyriakides, Theodoros] Univ Nicosia, Med Sch, Nicosia, Cyprus; [Ajroud-Driss, Senda] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Waddington-Cruz, Marcia] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; [Mezei, Michelle M.] Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC, Canada; [Plante-Bordeneuve, Violaine] Univ Paris Est Creteil, Ctr Hosp Univ, Henri Mondor Assistance Publ Hop Paris, Creteil, France; [Attarian, Shahram] Ctr Hosp Univ LaTimone, Neuromuscular Disorders & ALS Dept, Marseille, France; [Mauricio, Elizabeth] Mayo Clin, Jacksonville, FL 32224 USA; [Brannagan, Thomas H., III] Columbia Univ, Coll Phys & Surg, Neurol Dept, New York, NY USA; [Ueda, Mitsuharu] Kumamoto Univ Hosp, Dept Neurol, Kumamoto, Japan; [Aldinc, Emre; Wang, Jing Jing; White, Matthew T.; Vest, John; Sweetser, Marianne T.] Alnylam Pharmaceut, Cambridge, MA USA; [Berber, Erhan] Myokardia, Brisbane, CA USA; [Coelho, Teresa] Ctr Hosp Univ Porto, Porto, Portugal	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Johns Hopkins University; Umea University; Ruprecht Karls University Heidelberg; University of Munster; Boston Medical Center; Mayo Clinic; University of Colorado System; University of Colorado Denver; Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Nicosia; Northwestern University; Universidade Federal do Rio de Janeiro; University of British Columbia; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Mayo Clinic; Columbia University; Kumamoto University	Adams, D (corresponding author), Ctr Hosp Univ Bicetre, Neurol Dept, F-94270 Le Kremlin Bicetre, France.	david.adams@aphp.fr	INAMO, Jocelyn/AGZ-1674-2022; Wixner, Jonas/AAN-5812-2021; Conceicao, Isabel/AAC-6075-2022; Eugenia, Cisneros-Barroso/H-1519-2017; MV, Pinto/J-6234-2019; Deplanque, Dominique/E-4901-2015; ALTINKURT, EMRE/AAE-5097-2020; Zhelyazkova, Sashka/GQZ-9012-2022; wang, jing/GVT-8700-2022; Wang, Jin/GYA-2019-2022; Marques Junior, Wilson/G-4240-2012; Bisogni, Giulia/AAC-3708-2022; Ueda, Mitsuharu/Q-8595-2019; Romano, Angela/AAA-6621-2019; Kyriakides, Theodoros/AAW-4251-2021; WANG, JINGYI/GSJ-1241-2022; wang, jing/GRS-7509-2022; KARAMURSEL, SACIT/J-2130-2018	Wixner, Jonas/0000-0002-1536-1277; Conceicao, Isabel/0000-0003-0934-9631; Eugenia, Cisneros-Barroso/0000-0002-4109-4635; MV, Pinto/0000-0002-9890-6657; Deplanque, Dominique/0000-0002-4995-584X; ALTINKURT, EMRE/0000-0001-7967-825X; Marques Junior, Wilson/0000-0002-4589-2749; Bisogni, Giulia/0000-0001-7314-3393; Romano, Angela/0000-0002-2061-1509; KARAMURSEL, SACIT/0000-0002-7534-9392; Lee, Yi-Chung/0000-0003-0102-164X; Lin, Yi/0000-0002-1556-6416; Chao, Chi-Chao/0000-0001-6499-5789; Brannagan, Thomas/0000-0002-1812-8331; Su, Jen-Jen/0000-0001-5132-3334; Cantu-Brito, Carlos/0000-0001-7494-2015; Oliveira Santos, Miguel/0000-0002-8290-0410; Yeh, Shin-Joe/0000-0003-1511-6295; Barroso, Fabio/0000-0002-3647-1803; Tsai, Li-Kai/0000-0001-8420-6951; Russell, Stephen/0000-0002-0799-6432; Losada, Ines/0000-0002-4834-0843; Grapperon, Aude-Marie/0000-0002-4196-9374	Alnylam Pharmaceuticals (Cambridge, MA, USA)	Alnylam Pharmaceuticals (Cambridge, MA, USA)	This study was funded by Alnylam Pharmaceuticals (Cambridge, MA, USA). The authors thank the patients and their families for their valued contribution to this study. The authors would also like to thank the patisiran global OLE study group listed in the appendix (p 11). The authors thank Jennifer L S Willoughby, Katherine Alfond, and Anastasia McManus, of Alnylam Pharmaceuticals for editorial assistance. The authors acknowledge the medical writing services provided by Ed Childs of Adelphi Communications (Macclesfield, UK),	Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153; Adams D, 2019, NAT REV NEUROL, V15, P387, DOI 10.1038/s41582-019-0210-4; Adams D, 2015, NEUROLOGY, V85, P675, DOI 10.1212/WNL.0000000000001870; Alnylam Pharmaceuticals, 2019, US PRESCR INF GIVLAA; Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; Arruda-Olson AM, 2013, AMYLOID, V20, P263, DOI 10.3109/13506129.2013.845745; Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793; Berk JL, 2013, JAMA-J AM MED ASSOC, V310, P2658, DOI 10.1001/jama.2013.283815; Coelho T, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01399-4; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Coelho T, 2013, CURR MED RES OPIN, V29, P63, DOI 10.1185/03007995.2012.754348; Coelho T, 2012, NEUROLOGY, V79, P785, DOI 10.1212/WNL.0b013e3182661eb1; Damy T, 2016, EUR HEART J, V37, P1826, DOI 10.1093/eurheartj/ehv583; Gonzalez-Duarte A, 2020, J NEUROL, V267, P703, DOI 10.1007/s00415-019-09602-8; Klaassen SHC, 2018, AM J CARDIOL, V121, P107, DOI 10.1016/j.amjcard.2017.09.029; Kristen AV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173086; Maurer MS, 2018, NEW ENGL J MED, V379, P1007, DOI 10.1056/NEJMoa1805689; Mohty D, 2013, ARCH CARDIOVASC DIS, V106, P528, DOI 10.1016/j.acvd.2013.06.051; Rapezzi C, 2013, EUR HEART J, V34, P520, DOI 10.1093/eurheartj/ehs123; Ruberg FL, 2012, AM HEART J, V164, P222, DOI 10.1016/j.ahj.2012.04.015; Sattianayagam PT, 2012, EUR HEART J, V33, P1120, DOI 10.1093/eurheartj/ehr383; Solomon SD, 2019, CIRCULATION, V139, P431, DOI 10.1161/CIRCULATIONAHA.118.035831; Suhr OB, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0326-6; Swiecicki PL, 2015, AMYLOID, V22, P123, DOI 10.3109/13506129.2015.1019610; Wright RS, 2020, ORION POOLED ANAL PH	25	36	38	7	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					49	59		10.1016/S1474-4422(20)30368-9	http://dx.doi.org/10.1016/S1474-4422(20)30368-9			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33212063	Green Submitted			2022-12-18	WOS:000600831400023
J	Kivipelto, M; Mangialasche, F; Ngandu, T				Kivipelto, Miia; Mangialasche, Francesca; Ngandu, Tiia		World Wide Fingers Network	World Wide Fingers will advance dementia prevention	LANCET NEUROLOGY			English	Letter									[Kivipelto, Miia; Mangialasche, Francesca; Ngandu, Tiia] Karolinska Inst, Dept Clin Geriatr, Stockholm, Sweden; [Kivipelto, Miia; Ngandu, Tiia] Natl Inst Hlth & Welf, Helsinki, Finland; [Kivipelto, Miia] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland	Karolinska Institutet; Finland National Institute for Health & Welfare; University of Eastern Finland	Kivipelto, M (corresponding author), Karolinska Inst, Dept Clin Geriatr, Stockholm, Sweden.; Kivipelto, M (corresponding author), Natl Inst Hlth & Welf, Helsinki, Finland.; Kivipelto, M (corresponding author), Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland.	miia.kivipelto@ki.se	Chen, Christopher/E-7023-2013; Kivipelto, Miia/AAS-3557-2021	Chen, Christopher/0000-0002-1047-9225; Mangialasche, Francesca/0000-0002-2686-3926; Ngandu, Tiia/0000-0002-3698-2021; Lindstrom, Jaana/0000-0001-9255-020X; Hartmann, Tobias/0000-0001-7481-6430				[Anonymous], 2017, LANCET NEUROL, V16, P771, DOI 10.1016/S1474-4422(17)30256-9; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801	4	36	36	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					27	27		10.1016/S1474-4422(17)30431-3	http://dx.doi.org/10.1016/S1474-4422(17)30431-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29263003	Bronze			2022-12-18	WOS:000418570500019
J	Donnan, GA; Hankey, GJ; Davis, SM				Donnan, Geoffrey A.; Hankey, Graeme J.; Davis, Stephen M.			Intracerebral haemorrhage: a need for more data and new research directions	LANCET NEUROLOGY			English	Editorial Material							STROKE; OXFORDSHIRE; RISK; UK		[Donnan, Geoffrey A.] Florey Neurosci Inst, Carlton, Vic 3053, Australia; [Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia; [Davis, Stephen M.] Univ Melbourne, Royal Melbourne Hosp, Parkville, Vic 3050, Australia	Florey Institute of Neuroscience & Mental Health; Royal Perth Hospital; University of Western Australia; Royal Melbourne Hospital; University of Melbourne	Donnan, GA (corresponding author), Florey Neurosci Inst, Level 2,161 Barry St, Carlton, Vic 3053, Australia.	gdonnan@unimelb.edu.au	Hankey, Graeme J/H-4968-2014; Davis, Stephen M/L-5260-2013	Hankey, Graeme J/0000-0002-6044-7328; Davis, Stephen M/0000-0003-0962-2300; Donnan, Geoffrey/0000-0001-6324-3403				Anderson CS, 2008, LANCET NEUROL, V7, P391, DOI 10.1016/S1474-4422(08)70069-3; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Islam SM, 2008, STROKE, V39, P776, DOI 10.1161/STROKEAHA.107.493643; Kimura Y, 1998, INTERNAL MED, V37, P736, DOI 10.2169/internalmedicine.37.736; Labovitz DL, 2005, NEUROLOGY, V65, P518, DOI 10.1212/01.wnl.0000172915.71933.00; Lovelock CE, 2007, LANCET NEUROL, V6, P487, DOI 10.1016/S1474-4422(07)70107-2; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mayer SA, 2009, STROKE, V40, P833, DOI 10.1161/STROKEAHA.108.524470; Nagata C, 2004, STROKE, V35, P1543, DOI 10.1161/01.STR.0000130425.50441.b0; Prasad K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002244.pub3; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Rost NS, 2008, STROKE, V39, P2166, DOI 10.1161/STROKEAHA.107.501650; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0	14	36	36	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2010	9	2					133	134		10.1016/S1474-4422(10)70001-6	http://dx.doi.org/10.1016/S1474-4422(10)70001-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	547XB	20056490				2022-12-18	WOS:000273922000004
J	Qiu, J				Qiu, Jane			China Spinal Cord Injury Network: changes from within	LANCET NEUROLOGY			English	Editorial Material												jane@janeqiu.com							0	36	43	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					606	607		10.1016/S1474-4422(09)70162-0	http://dx.doi.org/10.1016/S1474-4422(09)70162-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19539234				2022-12-18	WOS:000267643700014
J	Simon-Sanchez, J; Singleton, A				Simon-Sanchez, Javier; Singleton, Andrew			Genome-wide association studies in neurological disorders	LANCET NEUROLOGY			English	Review							PERIODIC LIMB MOVEMENTS; GENETIC RISK-FACTOR; SUSCEPTIBILITY GENE; LATERAL-SCLEROSIS; REVEALS; LOCI	Background During the past decade, the genetic causes of monogenic forms of disease have been successfully defined; this work has helped the progression of basic scientific investigation into many disorders, and has helped to characterise several molecular biological processes. An important goal of genetic research is to extend this work and define genetic risk factor loci for complex disorders. The aim is for these data not only to offer further basic understanding of the disease process, but also to provide the opportunity to obtain genetic risk assessments that could be generalised to the public. Recent developments The development of resources such as the Human Genome Project and the international Human Haplotype Map Project, coupled with technological advances in ultra-high-throughput genotyping, have provided the basis for genome-wide association studies (GWAS). This approach has been successful for several complex disorders in a short time. Although GWAS are still a new method, these studies have been used for a small number of neurological disorders and, despite varied results for these conditions, GWAS can usefully show the power and limitations of this approach. Where next? GWAS have the potential to show and emphasise common genetic variability associated with disease. However, a challenge of this approach is that large sample series and considerable resources are required. One important consideration will be the interpretation of the results of GWAS in a clinically meaningful way and to discern the implications for all therapy areas, including neurological disorders; this challenge will require specialised skills and resources from both the medical and the scientific communities.	[Simon-Sanchez, Javier; Singleton, Andrew] NIA, Mol Genet Sect, Neurogenet Lab, Intramural Res Program,NIH, Bethesda, MD 20892 USA; [Simon-Sanchez, Javier] CSIC, Inst Biomed, Dept Genom & Prote, Unidad Genet Mol, Valencia, Spain; [Singleton, Andrew] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); University of Virginia	Singleton, A (corresponding author), NIA, Mol Genet Sect, Neurogenet Lab, Intramural Res Program,NIH, Bethesda, MD 20892 USA.	singleta@mail.nih.gov	Singleton, Andrew B/C-3010-2009	Simon Sanchez, Javier/0000-0001-5141-5829	National Institute on Aging; National Institutes of Health; Department of Health and Human Services; Intramural project [Z01 AG000949-02]; NATIONAL INSTITUTE ON AGING [Z01AG000949] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; Intramural project; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Intramural Research Program of the National Institute on Aging, the National Institutes of Health, and the Department of Health and Human Services, and relates to concepts developed under Intramural project Z01 AG000949-02.	Blcuw HM, 2008, LANCET NEUROL, V7, P319, DOI 10.1016/S1474-4422(08)70048-6; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419; Cronin S, 2008, HUM MOL GENET, V17, P768, DOI 10.1093/hmg/ddm361; Dunckley T, 2007, NEW ENGL J MED, V357, P775, DOI 10.1056/NEJMoa070174; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6; Goris A, 2006, AM J HUM GENET, V78, P1088, DOI 10.1086/504726; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Hunter DJ, 2007, NEW ENGL J MED, V357, P436, DOI 10.1056/NEJMp078120; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; Matarin M, 2008, NEUROGENETICS, V9, P101, DOI 10.1007/s10048-008-0119-3; Matarin M, 2007, LANCET NEUROL, V6, P414, DOI 10.1016/S1474-4422(07)70081-9; Pennisi E, 2007, SCIENCE, V318, P1842, DOI 10.1126/science.318.5858.1842; Sawcer S, 2008, LANCET NEUROL, V7, P567, DOI 10.1016/S1474-4422(08)70122-4; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Schymick JC, 2007, LANCET NEUROL, V6, P322, DOI 10.1016/S1474-4422(07)70037-6; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Simon-Sanchez J, 2008, HUM MUTAT, V29, P315, DOI 10.1002/humu.20626; Stefansson H, 2007, NEW ENGL J MED, V357, P639, DOI 10.1056/NEJMoa072743; Tan NCK, 2006, CURR OPIN NEUROL, V19, P157, DOI 10.1097/01.wco.0000218232.66054.46; van Es MA, 2008, NAT GENET, V40, P29, DOI 10.1038/ng.2007.52; van Es MA, 2007, LANCET NEUROL, V6, P869, DOI 10.1016/S1474-4422(07)70222-3; Vilarino-Guell C, 2008, NEW ENGL J MED, V358, P425, DOI 10.1056/NEJMc072518; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Winkelmann J, 2007, NAT GENET, V39, P1000, DOI 10.1038/ng2099; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	28	36	37	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					1067	1072		10.1016/S1474-4422(08)70241-2	http://dx.doi.org/10.1016/S1474-4422(08)70241-2			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP	18940696	Green Accepted			2022-12-18	WOS:000260745800018
J	Laureys, S; Piret, S; Ledoux, D				Laureys, S; Piret, S; Ledoux, D			Quantifying consciousness	LANCET NEUROLOGY			English	Letter							SCALE; COMA		Univ Liege, Fonds Natl Rech Sci, Cyclotron Res Ctr, Liege, Belgium; Univ Liege, Dept Neurol, Liege, Belgium; Ctr Hosp Univ Liege, Gen Intens Care Dept, Liege, Belgium	Fonds de la Recherche Scientifique - FNRS; University of Liege; University of Liege; University of Liege	Laureys, S (corresponding author), Univ Liege, Fonds Natl Rech Sci, Cyclotron Res Ctr, Liege, Belgium.	steven.laureys@ulg.ac.be	Ledoux, Didier/ABA-8401-2021; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Ledoux, Didier/0000-0002-9314-6564; Laureys, Steven/0000-0002-3096-3807; 				BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; LAUREYS S, 2002, YB INTENSIVE CARE EM, P715; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	6	36	36	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2005	4	12					789	790		10.1016/S1474-4422(05)70230-1	http://dx.doi.org/10.1016/S1474-4422(05)70230-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989SG	16297833				2022-12-18	WOS:000233693500003
J	Hurford, R; Wolters, FJ; Li, LX; Lau, KK; Kuker, W; Rothwell, PM				Hurford, Robert; Wolters, Frank J.; Li, Linxin; Lau, Kui Kai; Kuker, Wilhelm; Rothwell, Peter M.		Oxford Vasc Study Phenotyped Cohor	Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study	LANCET NEUROLOGY			English	Article							AGGRESSIVE MEDICAL THERAPY; ARTERIAL-STENOSIS; RECURRENT STROKE; CHINESE PATIENTS; VASCULAR EVENTS; CASE-FATALITY; RISK-FACTORS; SAMMPRIS; ATHEROSCLEROSIS; ASCERTAINMENT	Background Symptomatic intracranial stenosis was perceived to convey a high risk of recurrent stroke, but two previous trials (SAMMPRIS and VISSIT) did not show superiority of intracranial stenosis stenting over intensive medical management alone. These findings were partly due to a lower than expected risk of recurrent stroke without stenting, possibly reflecting the young age of recruits (median age <60 years), and raise questions about generalisability to routine clinical practice. We therefore studied the age-specific prevalence, predictors, and prognosis of symptomatic intracranial stenosis in a population-based cohort of patients with transient ischaemic attack and minor stroke on intensive medical management. Methods The Oxford Vascular Study (OXVASC) is a prospective incidence cohort study of all vascular events in a population of 92 728 people residing in Oxfordshire, UK. All patients, irrespective of age, with transient ischaemic attack and minor ischaemic stroke occurring between March 1, 2011, and March 1, 2018 (follow-up to Sept 28, 2018), were ascertained with multiple methods, including assessment in a dedicated daily emergency clinic and daily review of all hospital admissions. Imaging was by MR angiography of the intracranial and cervicocranial arteries, by CT angiography if MR angiography was contraindicated, and by transcranial Doppler and carotid ultrasound if CT angiography was contraindicated. All patients received intensive medical treatment without stenting, and those with intracranial vascular imaging were analysed in our study, which assessed the age-specific prevalence of 50-99% intracranial stenosis and the associated stroke risk of 50-99% and 70-99% stenosis (adjusted for age and vascular risk factors) during follow-up to Sept 28, 2018. Findings Of 1368 eligible patients with intracranial vascular imaging, 241 (17.6%) had 385 50-99% symptomatic or asymptomatic intracranial stenosis. The prevalence of symptomatic 50-99% intracranial stenosis increased from 29 (4.9%) of 596 at younger than 70 years to 10 (19.6%) of 51 at 90 years or older (ptrend<0.0001). Of 94 patients with 50-99% symptomatic intracranial stenosis, 14 (14.9%) had recurrent strokes (12 ischaemic and two haemorrhagic) during a median follow-up of 2.8 years (IQR 1.5-4.6). Although symptomatic intracranial stenosis conveyed an increased risk of ischaemic stroke compared with no intracranial stenosis (adjusted hazard ratio 1.43, 95% CI 1.04-1.96), the risk of same-territory ischaemic stroke in patients with 70-99% symptomatic intracranial stenosis tended to be less than those reported in the non-stenting groups of the previous trials (1-year risk 5.6% [95% CI 0.0-13.0] vs 9.4% [3.1-20.7] in VISSIT; 2-year risk 5.6% [0.0-13.0] vs 14.1% [10.1-19.4] in SAMMPRIS). Interpretation The prevalence of 50-99% symptomatic intracranial stenosis increases steeply with age in predominantly Caucasian patients with transient ischaemic attack and minor ischaemic stroke. However, the risk of recurrent stroke on intensive medical treatment of symptomatic intracranial stenosis is consistent with the two previous randomised controlled trials in younger cohorts, supporting the generalisability of the trial results to routine practice. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.	[Hurford, Robert; Wolters, Frank J.; Li, Linxin; Lau, Kui Kai; Kuker, Wilhelm; Rothwell, Peter M.] Univ Oxford, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England	University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England.	peter.rothwell@ndcn.ox.ac.uk	Wolters, Frank J./AAQ-8535-2020; Rothwell, Peter/ABE-5913-2020	Wolters, Frank J./0000-0003-2226-4050; Rothwell, Peter/0000-0001-9739-9211	Wellcome Trust; Wolfson Foundation; British Heart Foundation; National Institute for Health Research; National Institute for Health Research Oxford Biomedical Research Centre; Association of British Neurologists	Wellcome Trust(Wellcome Trust); Wolfson Foundation; British Heart Foundation(British Heart Foundation); National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Association of British Neurologists	Wellcome Trust, Wolfson Foundation, British Heart Foundation, National Institute for Health Research, National Institute for Health Research Oxford Biomedical Research Centre, Association of British Neurologists.	Abou-Chebl A, 2012, STROKE, V43, P616, DOI 10.1161/STROKEAHA.111.641563; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Amarenco P, 2018, NEW ENGL J MED, V378, P2182, DOI 10.1056/NEJMoa1802712; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Bejot Y, 2013, STROKE, V44, P1796, DOI 10.1161/STROKEAHA.113.000949; Chaturvedi S, 2015, STROKE, V46, P2562, DOI 10.1161/STROKEAHA.115.009656; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033; Coull AJ, 2004, STROKE, V35, P2041, DOI 10.1161/01.STR.0000137605.48864.2f; Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3; Feldmann E, 2007, NEUROLOGY, V68, P2099, DOI 10.1212/01.wnl.0000261488.05906.c1; Holmstedt CA, 2013, LANCET NEUROL, V12, P1106, DOI 10.1016/S1474-4422(13)70195-9; Huang YN, 1997, NEUROLOGY, V48, P524, DOI 10.1212/WNL.48.2.524; Hurford R, 2019, NEUROLOGY, V92, pE2455, DOI 10.1212/WNL.0000000000007531; Intercollegiate Stroke Working Party Royal College of Physicians, 2016, NAT CLIN GUID STROK; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Koopman C, 2013, EUR HEART J, V34, P3198, DOI 10.1093/eurheartj/eht368; Lau KK, 2017, STROKE, V48, P1470, DOI 10.1161/STROKEAHA.117.016694; Liu HM, 1996, STROKE, V27, P650, DOI 10.1161/01.STR.27.4.650; Mazighi M, 2006, NEUROLOGY, V66, P1187, DOI 10.1212/01.wnl.0000208404.94585.b2; National Institute for Health and Care Excellence, 2019, STROK TRANS ISCH ATT; Nederkoorn PJ, 2002, J VASC SURG, V36, P806, DOI 10.1067/mva.2002.127529; Qureshi AI, 2012, NEUROSURGERY, V70, pE264, DOI 10.1227/NEU.0b013e318239f318; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; Salami JA, 2017, JAMA CARDIOL, V2, P56, DOI 10.1001/jamacardio.2016.4700; Samuels OB, 2000, AM J NEURORADIOL, V21, P643; Schillinger G, 2017, INT J TECHNOL ASSESS, V33, P222, DOI 10.1017/S0266462317000411; Sharma M, 2019, CIRCULATION, V139, P1134, DOI 10.1161/CIRCULATIONAHA.118.035864; Suwanwela NC, 2003, NEUROEPIDEMIOLOGY, V22, P37, DOI 10.1159/000067112; Turan TN, 2017, NEUROLOGY, V88, P379, DOI 10.1212/WNL.0000000000003534; Turan TN, 2014, CEREBROVASC DIS, V37, P203, DOI 10.1159/000358120; WHO, 1971, CER DIS PREV TREATM; Wong KS, 2003, STROKE, V34, P2361, DOI 10.1161/01.STR.0000089017.90037.7A; Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693	35	35	37	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					413	421		10.1016/S1474-4422(20)30079-X	http://dx.doi.org/10.1016/S1474-4422(20)30079-X			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333899	Green Published, hybrid			2022-12-18	WOS:000573045100016
J	Stewart, W; Allinson, K; Al-Sarraj, S; Bachmeier, C; Barlow, K; Belli, A; Burns, MP; Carson, A; Crawford, F; Dams-O'Connor, K; Diaz-Arrastia, R; Dixon, CE; Edlow, BL; Ferguson, S; Fischl, B; Folkerth, RD; Gentleman, S; Giza, CC; Grady, MS; Helmy, A; Herceg, M; Holton, JL; Howell, D; Hutchinson, PJ; Iacono, D; Iglesias, JE; Ikonomovic, MD; Johnson, VE; Keene, CD; Kofler, JK; Koliatsos, VE; Lee, EB; Levin, H; Lifshitz, J; Ling, H; Loane, DJ; Love, S; Maas, AIR; Marklund, N; Master, CL; McElvenny, DM; Meaney, DF; Menon, DK; Montine, TJ; Mouzon, B; Mufson, EJ; Ojo, JO; Prins, M; Revesz, T; Ritchie, CW; Smith, C; Sylvester, R; Tang, CY; Trojanowski, JQ; Urankar, K; Vink, R; Wellington, C; Wilde, EA; Wilson, L; Yeates, K; Smith, DH				Stewart, William; Allinson, Kieren; Al-Sarraj, Safa; Bachmeier, Corbin; Barlow, Karen; Belli, Antonio; Burns, Mark P.; Carson, Alan; Crawford, Fiona; Dams-O'Connor, Kristen; Diaz-Arrastia, Ramon; Dixon, C. Edward; Edlow, Brian L.; Ferguson, Scott; Fischl, Bruce; Folkerth, Rebecca D.; Gentleman, Steve; Giza, Christopher C.; Grady, M. Sean; Helmy, Adel; Herceg, Mark; Holton, Janice L.; Howell, David; Hutchinson, Peter J.; Iacono, Diego; Iglesias, Juan E.; Ikonomovic, Milos D.; Johnson, Victoria E.; Keene, C. Dirk; Kofler, Julia K.; Koliatsos, Vassilis E.; Lee, Edward B.; Levin, Harvey; Lifshitz, Jonathan; Ling, Helen; Loane, David J.; Love, Seth; Maas, Andrew I. R.; Marklund, Niklas; Master, Christina L.; McElvenny, Damien M.; Meaney, David F.; Menon, David K.; Montine, Thomas J.; Mouzon, Benoit; Mufson, Elliott J.; Ojo, Joseph O.; Prins, Mayumi; Revesz, Tamas; Ritchie, Craig W.; Smith, Colin; Sylvester, Richard; Tang, Cheuk Y.; Trojanowski, John Q.; Urankar, Kathryn; Vink, Robert; Wellington, Cheryl; Wilde, Elisabeth A.; Wilson, Lindsay; Yeates, Keith; Smith, Douglas H.			Primum non nocere: a call for balance when reporting on CTE	LANCET NEUROLOGY			English	Letter							CHRONIC TRAUMATIC ENCEPHALOPATHY; CONSEQUENCES		[Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland; [Allinson, Kieren] Univ Cambridge, Cambridge Univ Hosp NHS Fdn Trust, Dept Pathol, Cambridge Biomed Campus, Cambridge, England; [Helmy, Adel; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge Biomed Campus, Cambridge, England; [Menon, David K.] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge Biomed Campus, Cambridge, England; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge Biomed Campus, Cambridge, England; [Al-Sarraj, Safa] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England; [Bachmeier, Corbin; Crawford, Fiona; Ferguson, Scott; Mouzon, Benoit; Ojo, Joseph O.] Roskamp Inst, Sarasota, FL USA; [Bachmeier, Corbin; Crawford, Fiona; Ferguson, Scott; Mouzon, Benoit; Ojo, Joseph O.] Open Univ, Milton Keynes, Bucks, England; [Bachmeier, Corbin] Bay Pines VA Healthcare Syst, Bay Pines, FL USA; [Barlow, Karen] Univ Queensland, Child Hlth Res Ctr, Fac Med, Brisbane, Qld, Australia; [Belli, Antonio] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England; [Burns, Mark P.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA; [Ritchie, Craig W.] Univ Edinburgh, Ctr Dementia Prevent, Edinburgh, Midlothian, Scotland; [Carson, Alan] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Smith, Colin] Univ Edinburgh, Acad Neuropathol, Edinburgh, Midlothian, Scotland; [Smith, Colin] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Crawford, Fiona; Ferguson, Scott; Mouzon, Benoit; Ojo, Joseph O.] James A Haley Vet Hosp, Tampa, FL USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Grady, M. Sean; Johnson, Victoria E.; Meaney, David F.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Diaz-Arrastia, Ramon; Johnson, Victoria E.; Meaney, David F.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Lee, Edward B.] Univ Penn, Translat Neuropathol Res Lab, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Kofler, Julia K.] Univ Pittsburgh, Dept Pathol, Div Neuropathol, Pittsburgh, PA USA; [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Dixon, C. Edward] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Ctr Neurotechnol & Neurorecovery, Boston, MA 02114 USA; [Edlow, Brian L.] Harvard Med Sch, Boston, MA USA; [Edlow, Brian L.; Fischl, Bruce] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Edlow, Brian L.; Fischl, Bruce] Harvard Med Sch, Charlestown, MA USA; [Folkerth, Rebecca D.] City New York Off Chief Med Examiner, New York, NY USA; [Folkerth, Rebecca D.] NYU, Sch Med, New York, NY USA; [Gentleman, Steve] Imperial Coll London, Div Brain Sci, Dept Med, London, England; [Giza, Christopher C.; Prins, Mayumi] Steve Tisch BrainSPORT Program, Los Angeles, CA USA; [Giza, Christopher C.; Prins, Mayumi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Giza, Christopher C.; Prins, Mayumi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Giza, Christopher C.; Prins, Mayumi] Univ Calif Los Angeles, UCLA Mattel Childrens Hosp, Los Angeles, CA USA; [Herceg, Mark] Phelps Hosp Northwell Hlth, Dept Phys Med & Rehabil, New York, NY USA; [Herceg, Mark] New York Med Coll, Sch Publ Hlth, New York, NY USA; [Holton, Janice L.; Ling, Helen; Revesz, Tamas] UCL Queen Sq Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England; [Howell, David] Childrens Hosp Colorado, Ctr Sports Med, Aurora, CO USA; [Howell, David] Univ Colorado, Sch Med, Dept Orthoped, Anschutz Med Campus, Aurora, CO USA; [Iacono, Diego] Biomed Res Inst New Jersey, Neuropathol Res, Cedar Knolls, NJ USA; [Iacono, Diego] Atlantic Hlth Syst, Atlantic Neurosci Inst, Morristown, NJ USA; [Iglesias, Juan E.] UCL, Dept Med Phys & Biomed Engn, Ctr Med Image Comp, London, England; [Sylvester, Richard] UCL, Homerton Univ Hosp NHS Trust, Natl Hosp Neurol & Neurosurg, London, England; [Iglesias, Juan E.] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Keene, C. Dirk] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Sheppard & Enoch Pratt Hosp, Neuropsychiat Program, Baltimore, MD 21204 USA; [Levin, Harvey] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Child Hlth, Phoenix, AZ USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Loane, David J.] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland; [Loane, David J.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin, Ireland; [Love, Seth; Urankar, Kathryn] Univ Bristol, Inst Clin Neurosci, Sch Med, Dementia Res Grp, Bristol, Avon, England; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Marklund, Niklas] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Neurosurg, Lund, Sweden; [Master, Christina L.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Master, Christina L.] Childrens Hosp Philadelphia, Div Orthoped Surg, Philadelphia, PA 19104 USA; [McElvenny, Damien M.] Inst Occupat Med, Div Res, Edinburgh, Midlothian, Scotland; [Montine, Thomas J.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Mufson, Elliott J.] Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA; [Mufson, Elliott J.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA; [Tang, Cheuk Y.] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA; [Vink, Robert] Univ South Australia, Hlth Sci, Adelaide, SA, Australia; [Wellington, Cheryl] Univ British Columbia, Sch Biomed Engn, Int Collaborat Repair Discoveries, Dept Pathol & Lab Med,Djavad Mowafaghian Ctr Brai, Vancouver, BC, Canada; [Wilde, Elisabeth A.] Univ Utah, Dept Neurol, Salt Lake City, UT USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Houston, TX 77030 USA; [Wilson, Lindsay] Univ Stirling, Div Psychol, Stirling, Scotland; [Yeates, Keith] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada	Queen Elizabeth University Hospital (QEUH); University of Glasgow; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of London; King's College London; Open University - UK; University of Queensland; University of Birmingham; Georgetown University; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; New York University; Imperial College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; New York Medical College; University of London; University College London; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Atlantic Health System; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Massachusetts Institute of Technology (MIT); University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Baylor College of Medicine; Barrow Neurological Institute; Phoenix Children's Hospital; University of Arizona; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Trinity College Dublin; Trinity College Dublin; University of Bristol; University of Antwerp; University of Antwerp; Lund University; Skane University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Stanford University; Barrow Neurological Institute; Barrow Neurological Institute; Icahn School of Medicine at Mount Sinai; University of South Australia; University of British Columbia; Utah System of Higher Education; University of Utah; Baylor College of Medicine; Baylor College of Medicine; University of Stirling; Alberta Childrens Hospital; University of Calgary; University of Calgary	Stewart, W (corresponding author), Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland.; Stewart, W (corresponding author), Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland.	william.stewart@glasgow.ac.uk	Maas, Andrew IR/C-5584-2013; Lee, Edward/AAU-8436-2021; Revesz, Tamas/A-8732-2010; Kofler, Julia/AAJ-8032-2021; Belli, Antonio/I-3799-2015; Barlow, Karen/I-6492-2019; Helmy, Adel/AAS-3084-2020; Loane, David/ABD-5177-2021; Iacono, Diego/K-8203-2016; Vink, Robert/S-5616-2019; Wilson, Lindsay/A-3659-2009; Yeates, Keith/AAJ-4223-2020; Johnson, Victoria/GVU-7127-2022; Barlow, Karen/C-1323-2014	Maas, Andrew IR/0000-0003-1612-1264; Revesz, Tamas/0000-0003-2501-0259; Belli, Antonio/0000-0002-3211-9933; Barlow, Karen/0000-0003-2612-8507; Helmy, Adel/0000-0002-0531-0556; Loane, David/0000-0003-0393-3503; Iacono, Diego/0000-0001-5511-0950; Vink, Robert/0000-0002-4885-0667; Wilson, Lindsay/0000-0003-4113-2328; Barlow, Karen/0000-0003-2612-8507; Yeates, Keith Owen/0000-0001-7680-2892; Love, Seth/0000-0001-8683-3625; Burns, Mark P/0000-0003-4750-2000; Meaney, David/0000-0002-0954-4122; Stewart, William/0000-0003-2199-2582; Master, Christina/0000-0002-6717-4270; Hutchinson, Peter/0000-0002-2796-1835	Medical Research Council [G0802251, G0502030, G1002277, G9439390, G0601025, G0600986] Funding Source: Medline; NIA NIH HHS [P30 AG010124, P01 AG017586] Funding Source: Medline; NINDS NIH HHS [R01 NS092398, R01 NS038104, R01 NS094003] Funding Source: Medline; Department of Health [II-C5-0715-20005, NIHR-RP-R3-12-013, 12/35/57, HTA/13/15/02] Funding Source: Medline; MRC [G1002277, G0601025, G9439390, G0502030, G0600986] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038104, R01NS094003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017586, P30AG010124] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Belson K, 2018, NY TIMES; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Manion E, 2008, AM J SURG PATHOL, V32, P732, DOI 10.1097/PAS.0b013e31815a04f5; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Moore A, 2006, EMBO REP, V7, P1193, DOI 10.1038/sj.embor.7400862; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X	7	35	36	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					231	233		10.1016/S1474-4422(19)30020-1	http://dx.doi.org/10.1016/S1474-4422(19)30020-1			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	30784550	Green Submitted, Bronze, Green Accepted, Green Published			2022-12-18	WOS:000458509100014
J	Biousse, V; Newman, NJ				Biousse, Valerie; Newman, Nancy J.			Diagnosis and clinical features of common optic neuropathies	LANCET NEUROLOGY			English	Review							OCULAR FUNDUS PHOTOGRAPHY; GIANT-CELL ARTERITIS; TEACHING OPHTHALMOSCOPY; MEDICAL-STUDENTS; NEURITIS; MANAGEMENT; CRITERIA; TRIAL; MANIFESTATIONS; HEADACHE	Disorders of the optic nerves (optic neuropathies) are some of the most common causes of visual loss, and can present in isolation or with associated neurological or systemic symptoms and signs. Several optic neuropathies especially inflammatory optic neuropathies are associated with neurological disorders and thus are often diagnosed and treated by neurologists. The mechanisms underlying optic neuropathies are diverse and typically manifest with decreased visual acuity, altered colour vision, and abnormal visual field in the affected eye. Diagnosis is made on the basis of clinical history and clinical examination, of which several aspects are particularly important, including the mode of onset of visual loss, the presence of pain with eye movements, the visual acuity, and the retention of colour vision. Advances in optic nerve imaging particularly retinal digital photography, optical coherence tomography, and MRI techniques have revolutionised the diagnosis and follow-up of patients with an optic neuropathy. Furthermore, improvement and generalisation of some ancillary tests, such as diagnostic antibodies for neuromyelitis optica, allows better phenotyping of the heterogeneous inflammatory optic neuropathies.	[Biousse, Valerie; Newman, Nancy J.] Emory Univ, Emory Eye Ctr, Neuroophthalmol Unit, Atlanta, GA 30322 USA	Emory University	Biousse, V (corresponding author), Emory Univ, Emory Eye Ctr, Neuroophthalmol Unit, Atlanta, GA 30322 USA.	vbiouss@emory.edu	Newman, Nancy/AAB-2532-2021		Research to Prevent Blindness Inc, New York; NIH/NEI [P30-EY06360]; NIH/NINDS [RO1NSO89694]	Research to Prevent Blindness Inc, New York(Research to Prevent Blindness (RPB)); NIH/NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	VB and NJN are consultants for GenSight Biologics. NJN is a consultant for Santhera Pharmaceuticals. VB and NJN are supported in part by an unrestricted departmental grant (Department of Ophthalmology) from Research to Prevent Blindness Inc, New York, by NIH/NEI core grant P30-EY06360 (Department of Ophthalmology, Emory University School of Medicine), and by NIH/NINDS (RO1NSO89694).	Archer EL, 2013, J CLIN SLEEP MED, V9, P613, DOI 10.5664/jcsm.2766; Arnold Anthony C, 2013, Trans Am Ophthalmol Soc, V111, P93; Avery RA, 2015, AM J OPHTHALMOL, V160, P944, DOI 10.1016/j.ajo.2015.07.036; Avery RA, 2014, J NEURO-OPHTHALMOL, V34, P284, DOI 10.1097/WNO.0000000000000154; Balcer LJ, 2015, BRAIN, V138, P11, DOI 10.1093/brain/awu335; BECK RW, 1987, OPHTHALMOLOGY, V94, P1503; Becker M, 2010, EUR J RADIOL, V74, P299, DOI 10.1016/j.ejrad.2009.09.029; Benbassat J, 2012, ACTA OPHTHALMOL, V90, P503, DOI 10.1111/j.1755-3768.2011.02221.x; Bennett JL, 2015, J NEUROL NEUROSUR PS, V86, P799, DOI 10.1136/jnnp-2014-308185; BERN C, 1995, NEW ENGL J MED, V333, P1176; Bidot S, 2015, J NEURO-OPHTHALMOL, V35, P400, DOI 10.1097/WNO.0000000000000303; Bidot S, 2015, SEMIN NEUROL, V35, P527, DOI 10.1055/s-0035-1563569; Biousse V, 2016, NEUROOPHTHALMOLOGY I; Biousse V, 2015, NEW ENGL J MED, V372, P2428, DOI 10.1056/NEJMra1413352; Boudreault K, 2016, SEMIN OPHTHALMOL, V31, P117, DOI 10.3109/08820538.2015.1114835; Brodsky M, 2008, ARCH NEUROL-CHICAGO, V65, P727, DOI 10.1001/archneur.65.6.727; Bruce BB, 2015, JAMA NEUROL, V72, P455, DOI 10.1001/jamaneurol.2014.4053; Bruce BB, 2013, ANN EMERG MED, V62, P28, DOI 10.1016/j.annemergmed.2013.01.010; Bruce BB, 2011, ACAD EMERG MED, V18, P928, DOI 10.1111/j.1553-2712.2011.01147.x; Bruce BB, 2011, NEW ENGL J MED, V364, P387, DOI 10.1056/NEJMc1009733; Campbell UB, 2015, J SEX MED, V12, P139, DOI 10.1111/jsm.12726; Danesh-Meyer HV, 2015, J CLIN NEUROSCI, V22, P1098, DOI 10.1016/j.jocn.2015.02.001; Dasgupta B, 2010, RHEUMATOLOGY, V49, P1594, DOI 10.1093/rheumatology/keq039a; Davis PC, 1996, AM J OPHTHALMOL, V121, P690, DOI 10.1016/S0002-9394(14)70636-1; Ducros A, 2015, LANCET NEUROL, V14, P655, DOI 10.1016/S1474-4422(15)00015-0; Estlin Katherine Anne Talbert, 2010, International Ophthalmology, V30, P63, DOI 10.1007/s10792-009-9293-z; Feuer WJ, 2016, OPHTHALMOLOGY, V123, P558, DOI 10.1016/j.ophtha.2015.10.025; Fisayo A, 2016, NEUROLOGY, V86, P341, DOI 10.1212/WNL.0000000000002318; Friedman DI, 2013, NEUROLOGY, V81, P1159, DOI 10.1212/WNL.0b013e3182a55f17; Friedman DI, 2002, NEUROLOGY, V59, P1492, DOI 10.1212/01.WNL.0000029570.69134.1B; Gaier ED, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0598-1; Gal RL, 2015, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD001430.PUB4; Gal RL, 2008, OPHTHALMOLOGY, V115, P1079, DOI 10.1016/j.ophtha.2007.08.004; Galetta SL, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000135; Grzybowski A, 2015, ACTA OPHTHALMOL, V93, P402, DOI 10.1111/aos.12515; Hayreh SS, 2013, GRAEF ARCH CLIN EXP, V251, P1873, DOI 10.1007/s00417-013-2399-z; HAYREH SS, 1994, AM J OPHTHALMOL, V118, P766, DOI 10.1016/S0002-9394(14)72557-7; Hayreh SS, 1998, AM J OPHTHALMOL, V125, P521, DOI 10.1016/S0002-9394(99)80193-7; Jarius S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-14; Javaheri M, 2007, BRIT J OPHTHALMOL, V91, P111, DOI 10.1136/bjo.2006.102541; Kelly LP, 2013, AM J OPHTHALMOL, V156, P1056, DOI 10.1016/j.ajo.2013.06.022; Keltner JL, 2010, ARCH OPHTHALMOL-CHIC, V128, P330, DOI 10.1001/archophthalmol.2010.16; Kim HJ, 2015, NEUROLOGY, V84, P1165, DOI 10.1212/WNL.0000000000001367; Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158; Kleiter I, 2016, ANN NEUROL, V79, P206, DOI 10.1002/ana.24554; Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170; Koul PA, 2015, LUNG INDIA, V32, P1, DOI 10.4103/0970-2113.148395; Le Page E, 2015, LANCET, V386, P974, DOI 10.1016/S0140-6736(15)61137-0; Lee LA, 2012, ANESTHESIOLOGY, V116, P15, DOI 10.1097/ALN.0b013e31823d012a; Lee SCM, 2014, J NEURO-OPHTHALMOL, V34, P278, DOI 10.1097/WNO.0000000000000155; Mackay Devin D, 2015, Neurol Clin Pract, V5, P150; Mackay DD, 2014, AM J OPHTHALMOL, V157, P747, DOI 10.1016/j.ajo.2013.12.013; Maldonado Ramiro S, 2015, Neurol Clin Pract, V5, P460, DOI 10.1212/CPJ.0000000000000187; Markey KA, 2016, LANCET NEUROL, V15, P78, DOI 10.1016/S1474-4422(15)00298-7; McCulley TJ, 2003, AM J OPHTHALMOL, V136, P1171, DOI 10.1016/S0002-9394(03)00676-7; Melamed E, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000134; Morrow MJ, 2012, J NEURO-OPHTHALMOL, V32, P154, DOI 10.1097/WNO.0b013e31825662f1; Moss HE, 2016, J NEURO-OPHTHALMOL, V36, P78, DOI 10.1097/WNO.0000000000000332; Murphy MA, 2005, J NEURO-OPHTHALMOL, V25, P232, DOI 10.1097/01.wno.0000177290.09649.38; Newman NJ, 2008, AM J OPHTHALMOL, V145, P604, DOI 10.1016/j.ajo.2007.09.016; Newman NJ, 2009, BRAIN, V132, P2306, DOI 10.1093/brain/awp195; Newman NJ, 2005, AM J OPHTHALMOL, V140, P517, DOI 10.1016/j.ajo.2005.03.017; Newman NJ, 2002, AM J OPHTHALMOL, V134, P317, DOI 10.1016/S0002-9394(02)01639-2; Odom JV, 2010, DOC OPHTHALMOL, V120, P111, DOI 10.1007/s10633-009-9195-4; Papadopoulos MC, 2014, NAT REV NEUROL, V10, P493, DOI 10.1038/nrneurol.2014.141; Peragallo J, 2013, CURR OPIN OPHTHALMOL, V24, P566, DOI 10.1097/ICU.0b013e3283654db2; Peragallo JH, 2015, CURR OPIN OPHTHALMOL, V26, P450, DOI 10.1097/ICU.0000000000000212; Petzold A, 2014, NAT REV NEUROL, V10, P447, DOI 10.1038/nrneurol.2014.108; Pomeranz HD, 2016, J NEURO-OPHTHALMOL, V36, P193, DOI 10.1097/WNO.0000000000000299; Preechawat P, 2007, AM J OPHTHALMOL, V144, P953, DOI 10.1016/j.ajo.2007.07.031; Purvin V, 2011, J NEURO-OPHTHALMOL, V31, P58, DOI 10.1097/WNO.0b013e31820cf78a; Ramanathan S, 2016, AUTOIMMUN REV, V15, P307, DOI 10.1016/j.autrev.2015.12.004; RIZZO JF, 1991, ARCH OPHTHALMOL-CHIC, V109, P1668, DOI 10.1001/archopht.1991.01080120052024; Sadda SR, 2001, AM J OPHTHALMOL, V132, P743, DOI 10.1016/S0002-9394(01)01199-0; Sadun AA, 2008, J NEURO-OPHTHALMOL, V28, P265, DOI 10.1097/WNO.0b013e31818f138f; Salvarani C, 2012, NAT REV RHEUMATOL, V8, P509, DOI 10.1038/nrrheum.2012.97; Sandbach J M, 2001, Ophthalmol Clin North Am, V14, P41; Shapey J, 2013, J CLIN NEUROSCI, V20, P1045, DOI 10.1016/j.jocn.2013.03.008; Singh AG, 2015, J RHEUMATOL, V42, P309, DOI 10.3899/jrheum.140188; Stangel M, 2013, NAT REV NEUROL, V9, P267, DOI 10.1038/nrneurol.2013.41; Thambisetty M, 2007, NEUROLOGY, V68, P229, DOI 10.1212/01.wnl.0000251312.19452.ec; Thulasi P, 2013, NEUROLOGY, V80, P432, DOI 10.1212/WNL.0b013e31827f0f20; Toosy AT, 2014, LANCET NEUROL, V13, P83, DOI 10.1016/S1474-4422(13)70259-X; Vuong LN, 2015, NEUROLOGY, V85, P256, DOI 10.1212/WNL.0000000000001759; Wall Michael, 2014, Continuum (Minneap Minn), V20, P1067, DOI 10.1212/01.CON.0000453302.20110.29; Wall M, 2014, JAMA-J AM MED ASSOC, V311, P1641, DOI 10.1001/jama.2014.3312; Wan X, 2016, SCI REP-UK, V6, DOI 10.1038/srep21587; Warner MA, 2012, ANESTHESIOLOGY, V116, P274, DOI 10.1097/ALN.0b013e31823c104d; Weerasinghe Dinushi, 2016, Pract Neurol, V16, P96, DOI 10.1136/practneurol-2015-001254; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002	91	35	35	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2016	15	13					1355	1367		10.1016/S1474-4422(16)30237-X	http://dx.doi.org/10.1016/S1474-4422(16)30237-X			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EB6XV	27839652				2022-12-18	WOS:000387529800021
J	Dulac, O; Plecko, B; Gataullina, S; Wolf, NI				Dulac, Olivier; Plecko, Barbara; Gataullina, Svetlana; Wolf, Nicole I.			Occasional seizures, epilepsy, and inborn errors of metabolism	LANCET NEUROLOGY			English	Review							PYRIDOXINE-DEPENDENT EPILEPSY; SEMIALDEHYDE DEHYDROGENASE-DEFICIENCY; EXOME SEQUENCING REVEALS; BASAL GANGLIA DISEASE; ADENYLOSUCCINATE LYASE DEFICIENCY; MOLYBDENUM COFACTOR DEFICIENCY; REFRACTORY STATUS EPILEPTICUS; ACID-RESPONSIVE SEIZURES; INFANTILE SPASMS; VALPROIC ACID	Seizures are a common paediatric problem, with inborn errors of metabolism being a rare underlying aetiology. The clinical presentation of inborn errors of metabolism is often associated with other neurological symptoms, such as hypotonia, movement disorders, and cognitive disturbances. However, the occurrence of epilepsy associated with inborn errors of metabolism represents a major challenge that needs to be identified quickly; for some cases, specific treatments are available, metabolic decompensation might be avoided, and accurate counselling can be given about recurrence risk. Some clinical presentations are more likely than others to point to an inborn error of metabolism as the cause of seizures. Knowledge of important findings at examination, and appropriate biochemical investigation of children with seizures of uncertain cause, can aid the diagnosis of an inborn error of metabolism and ascertain whether or not the seizures are amenable to specific metabolic treatment.	[Dulac, Olivier] Paris Descartes Univ, INSERM, U1129, Paris, France; [Gataullina, Svetlana] INSERM, U1129, Paris, France; [Dulac, Olivier] CEA, Gif Sur Yvette, France; [Dulac, Olivier] Hop Necker Enfants Malad, AP HP, Dept Paediat Neurol, F-75015 Paris, France; [Plecko, Barbara] Univ Zurich, Univ Childrens Hosp, Dept Child Neurol, CH-8006 Zurich, Switzerland; [Wolf, Nicole I.] Vrije Univ Amsterdam, Med Ctr, Dept Child Neurol, Amsterdam, Netherlands; [Wolf, Nicole I.] Neurosci Campus Amsterdam, Amsterdam, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University Children's Hospital Zurich; University of Zurich; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Dulac, O (corresponding author), Hop Necker Enfants Malad, AP HP, Dept Paediat Neurol, F-75015 Paris, France.	olivier.dulac63@gmail.com	Wolf, Nicole I/H-3943-2014	Wolf, Nicole I/0000-0003-1721-0728; Plecko, Barbara/0000-0002-3203-1325				Acker TM, 2011, MOL PHARMACOL, V80, P782, DOI 10.1124/mol.111.073239; AICARDI J, 1992, CURR OPIN NEUROL NEU, V5, P344; Anheim M, 2011, J NEUROL, V258, P316, DOI 10.1007/s00415-010-5702-5; Arrigoni-Martelli E, 2001, DRUG EXP CLIN RES, V27, P27; Arya R, 2013, CNS DRUGS, V27, P273, DOI 10.1007/s40263-013-0048-z; Bahi-Buisson N, 2006, EPILEPSIA, V47, P380, DOI 10.1111/j.1528-1167.2006.00432.x; Bahi-Buisson N, 2008, SEIZURE-EUR J EPILEP, V17, P658, DOI 10.1016/j.seizure.2008.01.005; Bahi-Buisson N, 2007, J CHILD NEUROL, V22, P1147, DOI 10.1177/0883073807306272; Banka S, 2011, AM J HUM GENET, V88, P216, DOI 10.1016/j.ajhg.2011.01.004; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P523; Barnerias C, 2008, BRAIN DEV-JPN, V30, P489, DOI 10.1016/j.braindev.2007.12.014; Barnerias C, 2010, DEV MED CHILD NEUROL, V52, pe1, DOI 10.1111/j.1469-8749.2009.03541.x; Baxter P, 1996, DEV MED CHILD NEUROL, V38, P998; Belachew D, 2013, JIMD REP, V11, P17, DOI 10.1007/8904_2013_217; BERNARDINA BD, 1983, EUR J PEDIATR, V140, P248, DOI 10.1007/BF00443371; Bindoff LA, 2011, EPILEPSIA, V52, P6, DOI 10.1111/j.1528-1167.2011.03223.x; BOYD SG, 1986, NEUROPEDIATRICS, V17, P75, DOI 10.1055/s-2008-1052505; Braissant O, 2010, MOL GENET METAB, V100, pS3, DOI 10.1016/j.ymgme.2010.02.010; Campeau PM, 2010, J CHILD NEUROL, V25, P94, DOI 10.1177/0883073809336119; Canafoglia L, 2006, MOVEMENT DISORD, V21, P1453, DOI 10.1002/mds.20984; Casarano M, 2012, JIMD REP, V2, P119, DOI 10.1007/8904_2011_60; Chen YB, 2013, INVEST OPHTH VIS SCI, V54, P4351, DOI 10.1167/iovs.13-11606; Christiaens FJC, 2003, BRAIN DEV-JPN, V25, P107, DOI 10.1016/S0387-7604(02)00164-X; CHUGANI HT, 1992, ANN NEUROL, V31, P212, DOI 10.1002/ana.410310212; COLAMARIA V, 1989, EPILEPSIA, V30, P573, DOI 10.1111/j.1528-1157.1989.tb05474.x; Dalla Bernardina Bernardo, 2005, Adv Neurol, V95, P59; DALLABERNARDINA B, 1979, NEUROPADIATRIE, V10, P209, DOI 10.1055/s-0028-1085326; de Koning TJ, 2004, CURR OPIN NEUROL, V17, P197, DOI 10.1097/00019052-200404000-00019; Dealberto MJCC, 2007, INT CLIN PSYCHOPHARM, V22, P330, DOI 10.1097/YIC.0b013e3281c61b28; Debs R, 2010, ARCH NEUROL-CHICAGO, V67, P126, DOI 10.1001/archneurol.2009.293; Demarque M, 2004, J NEUROSCI, V24, P3289, DOI 10.1523/JNEUROSCI.5338-03.2004; DEMEIRLEIR L, 1993, PEDIATR NEUROL, V9, P216, DOI 10.1016/0887-8994(93)90088-T; Desguerre I, 2003, NEUROPEDIATRICS, V34, P265; DiMauro S, 2002, ADV NEUROL, V89, P217; DREIFUSS FE, 1989, NEUROLOGY, V39, P201, DOI 10.1212/WNL.39.2.201; Dublin AB, 2002, AM J NEURORADIOL, V23, P484; El Sabbagh S, 2010, EPILEPSIA, V51, P1225, DOI 10.1111/j.1528-1167.2009.02504.x; El-Hattab AW, 2012, MOL GENET METAB, V105, P607, DOI 10.1016/j.ymgme.2012.01.016; Farrant RD, 2001, J BIOL CHEM, V276, P15107, DOI 10.1074/jbc.M010860200; Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410; Gallagher RC, 2009, ANN NEUROL, V65, P550, DOI 10.1002/ana.21568; Ganguly Sutapa, 2004, J Indian Med Assoc, V102, P174; Gataullina S, 2012, DEV MED CHILD NEUROL, V54, P1012, DOI 10.1111/j.1469-8749.2012.04400.x; Gerards M, 2013, BRAIN, V136, P882, DOI 10.1093/brain/awt013; Gordon N, 2010, BRAIN DEV-JPN, V32, P79, DOI 10.1016/j.braindev.2009.01.008; GOUTIERES F, 1985, ANN NEUROL, V17, P117, DOI 10.1002/ana.410170203; Grapp M, 2012, BRAIN, V135, P2022, DOI 10.1093/brain/aws122; Hartmann H, 2011, DEV MED CHILD NEUROL, V53, P1150, DOI 10.1111/j.1469-8749.2011.04033.x; Hitzert MM, 2012, PEDIATRICS, V130, pE1005, DOI 10.1542/peds.2011-3330; Hoffmann GF, 2007, J INHERIT METAB DIS, V30, P96, DOI 10.1007/s10545-006-0508-4; HYLAND K, 1995, J INHERIT METAB DIS, V18, P177, DOI 10.1007/BF00711760; Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x; Karimzadeh P, 2011, J CHILD NEUROL, V26, P152, DOI 10.1177/0883073810376245; Katayama Y, 2009, MITOCHONDRION, V9, P306, DOI 10.1016/j.mito.2009.04.002; Kevelam SH, 2013, BRAIN, V136, P1534, DOI 10.1093/brain/awt054; Klepper J, 1999, PEDIATR RES, V46, P677, DOI 10.1203/00006450-199912000-00006; KOSSAK BD, 1993, NEUROLOGY, V43, P2362, DOI 10.1212/WNL.43.11.2362; Kousi M, 2012, HUM MUTAT, V33, P42, DOI 10.1002/humu.21624; Krawitz PM, 2012, AM J HUM GENET, V91, P146, DOI 10.1016/j.ajhg.2012.05.004; Lamperti C, 2012, MOL GENET METAB, V107, P403, DOI 10.1016/j.ymgme.2012.08.020; Leary LD, 2003, EPILEPSIA, V44, P701, DOI 10.1046/j.1528-1157.2003.05302.x; Lee YM, 2008, EPILEPSIA, V49, P685, DOI 10.1111/j.1528-1167.2007.01522.x; Leen WG, 2013, JAMA NEUROL, V70, P1440, DOI 10.1001/jamaneurol.2013.3090; Leen WG, 2010, BRAIN, V133, P655, DOI 10.1093/brain/awp336; Leuzzi V, 2013, EPILEPSIA, V54, P217, DOI 10.1111/epi.12020; Mercimek-Mahmutoglu S, 2006, NEUROLOGY, V67, P480, DOI 10.1212/01.wnl.0000234852.43688.bf; Mercimek-Mahmutoglu S, 2010, MOL GENET METAB, V101, P409, DOI 10.1016/j.ymgme.2010.08.016; Mierzewska H, 2009, FOLIA NEUROPATHOL, V47, P314; Mikaeloff Y, 2000, EPILEPTIC DISORD, V2, P213; Milh M, 2007, EPILEPSIA, V48, P169, DOI 10.1111/j.1528-1167.2006.00839.x; Mills PB, 2006, NAT MED, V12, P307, DOI 10.1038/nm1366; Mills PB, 2014, BRAIN, V137, P1350, DOI 10.1093/brain/awu051; Mills PB, 2010, BRAIN, V133, P2148, DOI 10.1093/brain/awq143; Molinari F, 2005, AM J HUM GENET, V76, P334, DOI 10.1086/427564; Mouchegh K, 2007, J PEDIATR-US, V150, P57, DOI 10.1016/j.jpeds.2006.09.027; Nabbout R, 1999, ARCH DIS CHILD-FETAL, V81, pF125, DOI 10.1136/fn.81.2.F125; Nabbout R, 2010, EPILEPSIA, V51, P2033, DOI 10.1111/j.1528-1167.2010.02703.x; Narisawa K, 1992, J Nutr Sci Vitaminol (Tokyo), VSpec No, P585; Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70; Ofman R, 2003, AM J HUM GENET, V72, P1300, DOI 10.1086/375116; Ozturk OH, 2006, ARCH TOXICOL, V80, P671, DOI 10.1007/s00204-006-0125-x; Pearl PL, 2011, BRAIN DEV-JPN, V33, P796, DOI 10.1016/j.braindev.2011.04.013; Pearl PL, 2003, NEUROLOGY, V60, P1413, DOI 10.1212/01.WNL.0000059549.70717.80; Pineda M, 2000, DEV MED CHILD NEUROL, V42, P629, DOI 10.1017/S0012162200001171; Plecko B, 2007, HUM MUTAT, V28, P19, DOI 10.1002/humu.20433; Plecko B, 2014, NEUROLOGY, V82, P1425, DOI 10.1212/WNL.0000000000000344; Rahman S, 2013, DEV MED CHILD NEUROL, V55, P23, DOI 10.1111/j.1469-8749.2012.04406.x; Roger J, 2005, EPILEPSY SYNDROMES C; SALBERT BA, 1993, NEUROLOGY, V43, P1351, DOI 10.1212/WNL.43.7.1351; Saudubray JM, INBORN METABOLIC DIS, V7th; Scheffer IE, 2012, NEUROLOGY, V78, P524, DOI 10.1212/WNL.0b013e318248a245; Schulze A, 2003, ANN NEUROL, V53, P248, DOI 10.1002/ana.10455; Schuster B, 2013, HUM MUTAT, V34, P93, DOI 10.1002/humu.22221; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; Serrano M, 2012, MOVEMENT DISORD, V27, P1295, DOI 10.1002/mds.25008; Shimomura K, 2007, NEUROLOGY, V69, P1342, DOI 10.1212/01.wnl.0000268488.51776.53; Smithline Howard A, 2012, BMC Clin Pharmacol, V12, P4, DOI 10.1186/1472-6904-12-4; Sofou K, 2013, MITOCHONDRION, V13, P364, DOI 10.1016/j.mito.2013.04.008; Stanbury JBC, 1989, METABOLIC BASES INHE; Steinfeld R, 2009, AM J HUM GENET, V85, P354, DOI 10.1016/j.ajhg.2009.08.005; Steller J, 2014, NEUROPEDIATRICS, V45, P56, DOI 10.1055/s-0033-1341601; Stockler S, 2011, MOL GENET METAB, V104, P48, DOI 10.1016/j.ymgme.2011.05.014; Striano P, 2012, NEUROLOGY, V78, P557, DOI 10.1212/WNL.0b013e318247ff54; Struys EA, 2012, PEDIATRICS, V130, pE1716, DOI 10.1542/peds.2012-1094; SUGDEN MC, 1995, J NUTR, V125, pS1746; Surtees R, 2007, ARCH DIS CHILD, V92, P659, DOI 10.1136/adc.2007.116913; Tabarki B, 2013, NEUROLOGY, V80, P261, DOI 10.1212/WNL.0b013e31827deb4c; Tajima A, 2010, PEDIATR NEUROL, V42, P65, DOI 10.1016/j.pediatrneurol.2009.08.007; TASSINARI CA, 1978, REV EEG NEUROPHYSIOL, V8, P107, DOI 10.1016/S0370-4475(78)80126-9; Thakur V, 2006, PEDIATR CRIT CARE ME, V7, P273, DOI 10.1097/01.PCC.0000216682.56067.23; Valayannopoulos V, 2011, PEDIATR RES, V70, P638, DOI 10.1203/PDR.0b013e318232154f; van de Kamp JM, 2013, J MED GENET, V50, P463, DOI 10.1136/jmedgenet-2013-101658; van der Crabben SN, 2013, J INHERIT METAB DIS, V36, P613, DOI 10.1007/s10545-013-9592-4; Veldman A, 2010, PEDIATRICS, V125, pE1249, DOI 10.1542/peds.2009-2192; Visser NA, 2011, J NEUROL, V258, P218, DOI 10.1007/s00415-010-5721-2; Wibom R, 2009, NEW ENGL J MED, V361, P489, DOI 10.1056/NEJMoa0900591; Wolf NI, 2005, EPILEPTIC DISORD, V7, P67; Wolf NI, 2009, NEW ENGL J MED, V361, P1997, DOI 10.1056/NEJMc091723; Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x; Zempleni Janos, 2008, Expert Rev Endocrinol Metab, V3, P715, DOI 10.1586/17446651.3.6.715; Zeng WQ, 2005, AM J HUM GENET, V77, P16, DOI 10.1086/431216; Zschocke J, 2000, PEDIATR RES, V48, P852, DOI 10.1203/00006450-200012000-00025	124	35	36	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					727	739		10.1016/S1474-4422(14)70110-3	http://dx.doi.org/10.1016/S1474-4422(14)70110-3			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24943345				2022-12-18	WOS:000338483600018
J	Schretlen, DJ; Varvaris, M; Ho, TE; Vannorsdall, TD; Gordon, B; Harris, JC; Jinnah, HA				Schretlen, David J.; Varvaris, Mark; Ho, Tiffany E.; Vannorsdall, Tracy D.; Gordon, Barry; Harris, James C.; Jinnah, H. A.			Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study	LANCET NEUROLOGY			English	Article							ORBITOFRONTAL CORTEX; DISORDER; BEHAVIOR	Background Lesch-Nyhan disease is a rare, X-linked, neurodevelopmental metabolic disorder that is caused by abnormalities in the levels of hypoxanthine-guanine phosphoribosyltransferase enzyme activity. The neural substrates associated with Lesch-Nyhan disease remain poorly understood. We aimed to use voxel-based morphometry to identify affected brain regions in classic Lesch-Nyhan disease and Lesch-Nyhan variant disease, and to identify regions that differ between the two disease types. Methods In this cross-sectional study, we recruited patients with classic Lesch-Nyhan disease or Lesch-Nyhan variant disease from clinics, referrals, the Lesch-Nyhan Syndrome Registry, and the Matheny School and Hospital (Peapack, NJ, USA), and healthy controls from the Baltimore metropolitan area (MD, USA). We used voxel-based morphometry to analyse grey matter volume between groups using a three-group ANCOVA, followed by six pairwise post-hoc group comparisons. Findings Between Oct 3, 1993, and April 29, 2013, we recruited 21 patients with classic Lesch-Nyhan disease, 17 patients with variant disease, and 33 healthy controls. Patients with classic Lesch-Nyhan disease had a 20% reduction in intracranial volume (17% reduction in grey matter volume; 26% reduction in white matter volume) compared with healthy adults. The largest differences were in basal ganglia, and frontotemporal and limbic regions, with sparing of parieto-occipital regions. Grey matter volumes of patients with Lesch-Nyhan variant disease were invariably between those of patients with dassic Lesch-Nyhan disease and healthy controls. Compared with healthy controls, patients with classic disease showed additional grey matter volume reductions in the temporal lobe and left lateralised structures, and patients with variant disease showed additional reductions in lingual and precuneus regions with sparing of right frontal and temporal regions. Patients with dassic disease had reductions of volume in the ventral striatum and prefrontal areas compared with those with the variant form. Interpretation We noted regional abnormalities associated with known neurological and behavioural deficits in patients with classic Lesch-Nyhan disease. Patients with Lesch-Nyhan variant disease show milder grey matter abnormalities in many of the same brain regions and preservation of grey matter volume in other regions, which could provide important clues to the neural substrates of differences between the phenotypes.	[Schretlen, David J.; Varvaris, Mark; Ho, Tiffany E.; Vannorsdall, Tracy D.; Harris, James C.] Johns Hopkins Univ Hosp, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; [Schretlen, David J.] Johns Hopkins Univ Hosp, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA; [Gordon, Barry] Johns Hopkins Univ Hosp, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; [Gordon, Barry] Johns Hopkins Univ Hosp, Dept Cognit Sci, Baltimore, MD 21287 USA; [Jinnah, H. A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Jinnah, H. A.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA; [Jinnah, H. A.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Emory University; Emory University; Emory University	Schretlen, DJ (corresponding author), Johns Hopkins Univ Hosp, Meyer 218, Baltimore, MD 21287 USA.	dschret@jhmi.edu		Vannorsdall, Tracy/0000-0003-3103-1371	National Institute of Child Health and Human Development; Therapeutic Cognitive Neuroscience Fund; Benjamin and Adith Miller Family Endowment on Aging, Alzheimer's and Autism Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD053312] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Therapeutic Cognitive Neuroscience Fund; Benjamin and Adith Miller Family Endowment on Aging, Alzheimer's and Autism Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	National Institute of Child Health and Human Development, Therapeutic Cognitive Neuroscience Fund, and Benjamin and Adith Miller Family Endowment on Aging, Alzheimer's and Autism Research.	ANDERSON LT, 1994, J AUTISM DEV DISORD, V24, P67, DOI 10.1007/BF02172213; BAUMEISTER AA, 1985, NEUROSCI BIOBEHAV R, V9, P169, DOI 10.1016/0149-7634(85)90043-0; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; BURKE RE, 1985, NEUROLOGY, V35, P73, DOI 10.1212/WNL.35.1.73; Ernst M, 1996, NEW ENGL J MED, V334, P1568, DOI 10.1056/NEJM199606133342403; FATTAL A, 1984, ENZYME, V31, P55; Fu R, 2014, BRAIN, V137, P1282, DOI 10.1093/brain/awt202; HARA K, 1982, TOHOKU J EXP MED, V137, P275, DOI 10.1620/tjem.137.275; Harris JC, 1998, ARCH NEUROL-CHICAGO, V55, P547, DOI 10.1001/archneur.55.4.547; HATANAKA T, 1990, ACTA NEUROL SCAND, V81, P184; HOLDEIGEL M, 1987, RADIOLOGE, V27, P127; JANKOVIC J, 1988, ANN NEUROL, V23, P466, DOI 10.1002/ana.410230507; Jinnah HA, 2010, BRAIN, V133, P671, DOI 10.1093/brain/awq013; Jinnah HA, 2006, BRAIN, V129, P1201, DOI 10.1093/brain/awl056; Kaufman A.S., 2004, KAUFMANN BRIEF INTEL, V2nd ed.; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; LYNCH BJ, 1991, PEDIATR NEUROL, V7, P389, DOI 10.1016/0887-8994(91)90073-T; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Nyhan WL, 2000, ENVIRON HEALTH PERSP, V108, P409; Ochsner KN, 2006, PAIN, V120, P69, DOI 10.1016/j.pain.2005.10.014; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Saito Y, 2000, BRAIN DEV-JPN, V22, pS122; SALMAN R A, 1987, Journal of Oral Medicine, V42, P10; Schretlen DJ, 2005, DEV MED CHILD NEUROL, V47, P673, DOI 10.1017/S0012162205001374; Schretlen DJ, 2001, J INT NEUROPSYCH SOC, V7, P805, DOI 10.1017/S135561770177703X; Sterzer P, 2007, NEUROIMAGE, V37, P335, DOI 10.1016/j.neuroimage.2007.04.043; Taira T, 2003, J NEUROSURG, V98, P414, DOI 10.3171/jns.2003.98.2.0414; VANBOGAERT P, 1992, J INHERIT METAB DIS, V15, P790, DOI 10.1007/BF01800022; Visser JE, 2000, BRAIN RES REV, V32, P449, DOI 10.1016/S0165-0173(99)00094-6; WATTS RWE, 1982, Q J MED, V51, P43; Wong DF, 1996, P NATL ACAD SCI USA, V93, P5539, DOI 10.1073/pnas.93.11.5539	32	35	36	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1151	1158		10.1016/S1474-4422(13)70238-2	http://dx.doi.org/10.1016/S1474-4422(13)70238-2			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	265BG	24383089	Green Accepted			2022-12-18	WOS:000327924100010
J	Blumcke, I; Cross, JH; Spreafico, R				Blumcke, Ingmar; Cross, J. Helen; Spreafico, Roberto			The international consensus classification for hippocampal sclerosis: an important step towards accurate prognosis	LANCET NEUROLOGY			English	Editorial Material							TEMPORAL-LOBE EPILEPSY; FOCAL CORTICAL DYSPLASIAS; DIAGNOSTIC METHODS; TASK-FORCE; COMMISSION; PATTERNS; SURGERY		[Blumcke, Ingmar] Univ Hosp Erlangen, Dept Neuropathol, Erlangen, Germany; [Cross, J. Helen] UCL Inst Child Hlth, Great Ormond St Hosp Children, London, England; [Cross, J. Helen] Natl Ctr Young Epilepsy, London, England; [Spreafico, Roberto] IRCCS Fdn Carlo Besta Neurol Inst, Dept Epilepsy Clin & Expt Neurophysiol, Milan, Italy	University of Erlangen Nuremberg; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; IRCCS Istituto Neurologico Besta	Blumcke, I (corresponding author), Univ Hosp Erlangen, Dept Neuropathol, Erlangen, Germany.	bluemcke@uk-erlangen.de	Cross, J. Helen/ACK-3032-2022; Blumcke, Ingmar/D-4705-2018; Spreafico, Roberto/K-2301-2016	Cross, J. Helen/0000-0001-7345-4829; Blumcke, Ingmar/0000-0001-8676-0788; Spreafico, Roberto/0000-0002-6528-1240				Blumcke I, 2007, ACTA NEUROPATHOL, V113, P235, DOI 10.1007/s00401-006-0187-0; Blumcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220; Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x; Bruton CJ, 1988, MAUDSLEY MONOGRAPHS, P1; Coras R, 2012, EPILEPSIA, V53, P1341, DOI 10.1111/j.1528-1167.2012.03508.x; de Lanerolle NC, 2003, EPILEPSIA, V44, P677, DOI 10.1046/j.1528-1157.2003.32701.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Najm I, 2013, EPILEPSIA, V54, P772, DOI 10.1111/epi.12152; Schramm J, 2011, ACTA NEUROCHIR, V153, P221, DOI 10.1007/s00701-010-0901-5; Sommer W, 1880, ARCHIV F R PSYCHIATR, V10, P631, DOI [10.1007/BF02224538, DOI 10.1007/BF02224538]; Stefan H, 2009, J NEUROL NEUROSUR PS, V80, P196, DOI 10.1136/jnnp.2008.151860; Thom M, 2010, EPILEPSIA, V51, P1801, DOI 10.1111/j.1528-1167.2010.02681.x; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	13	35	35	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					844	846		10.1016/S1474-4422(13)70175-3	http://dx.doi.org/10.1016/S1474-4422(13)70175-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210WU	23948169				2022-12-18	WOS:000323866600005
J	Sharma, M; Kupferman, JC; Brosgol, Y; Paterno, K; Goodman, S; Prohovnik, I; Kirkham, FJ; Pavlakis, SG				Sharma, Madhu; Kupferman, Juan C.; Brosgol, Yuri; Paterno, Kara; Goodman, Sharon; Prohovnik, Isak; Kirkham, Fenella J.; Pavlakis, Steven G.			The effects of hypertension on the paediatric brain: a justifiable concern	LANCET NEUROLOGY			English	Article							REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY; SICKLE-CELL-DISEASE; BLOOD-PRESSURE; RISK-FACTORS; MASKED HYPERTENSION; COGNITIVE FUNCTION; CHILDHOOD HYPERTENSION; HEMORRHAGIC STROKE; FOLLOW-UP; CHILDREN	The prevalence of hypertension in children is increasing but its neurological effects are under-recognised. Here, we describe acute and chronic effects of childhood hypertension on the nervous system. Acute neurological involvement ranges from posterior reversible encephalopathy syndrome to, possibly, infarction and haemorrhage. Children with chronic hypertension are likely to have learning disabilities and deficiencies in executive function, which are potentially reversible with antihypertensive treatment. These cognitive defects may be secondary to abnormal regulation of cerebral blood flow. Raised blood pressure in childhood could also contribute to the early development of atherosclerosis, which can have both short-term and long-term adverse effects on vasculature. Clinical studies are needed to better define the full clinical range of paediatric hypertension on a child's nervous system. Furthermore, accurate biomarkers to define cognitive abnormalities and cerebral involvement need to be identified.	[Sharma, Madhu; Kupferman, Juan C.; Brosgol, Yuri; Paterno, Kara; Goodman, Sharon; Pavlakis, Steven G.] Maimonides Infants & Childrens Hosp, Dept Pediat, Brooklyn, NY 11219 USA; [Kupferman, Juan C.] SUNY, New York, NY USA; [Prohovnik, Isak] Mt Sinai Sch Med, New York, NY USA; [Kirkham, Fenella J.] UCL Inst Child Hlth, Neurosci Unit, London, England	Maimonides Medical Center; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry; Icahn School of Medicine at Mount Sinai; University of London; University College London	Pavlakis, SG (corresponding author), Maimonides Infants & Childrens Hosp, Dept Pediat, Brooklyn, NY 11219 USA.	spavlakis@maimonidesmed.org	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958	Maimonides Research Foundation; Empire State Clinical Trials Fellowship; Wellcome Trust	Maimonides Research Foundation; Empire State Clinical Trials Fellowship; Wellcome Trust(Wellcome TrustEuropean Commission)	SGP and JCK received support from Maimonides Research Foundation, and MS (with SGP) received support from Empire State Clinical Trials Fellowship. FJK was funded by the Wellcome Trust. The funding sources had no role in this report. We thank Jason Macdonald, Southampton University Hospitals NHS Trust, for providing the images in figure 2.	Awada A, 1998, J Stroke Cerebrovasc Dis, V7, P200; BEAUSANGLINDER M, 1981, ACTA PHYSIOL SCAND, V111, P193, DOI 10.1111/j.1748-1716.1981.tb06724.x; Brosgol Y, 2009, ANN NEUROL, V66, pS144; Brower MC, 1996, ARCH NEUROL-CHICAGO, V53, P1252, DOI 10.1001/archneur.1996.00550120060017; Chalmers J, 2003, J HYPERTENS, V21, P651, DOI 10.1097/01.hjh.0000052490.18130.95; CHILLON JM, 1997, PRIMER CEREBROVASCUL, P51; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Choi Y, 1997, J PEDIATR-US, V131, P258, DOI 10.1016/S0022-3476(97)70163-X; *CLINICALTRIALS GO, EFF HIGH BLOOD PERSS; Collins RT, 2009, J PEDIATR-US, V155, P165, DOI 10.1016/j.jpeds.2009.02.006; Croix B, 2006, PEDIATR NEPHROL, V21, P527, DOI 10.1007/s00467-006-0013-x; de Vries RR, 2003, NEUROPEDIATRICS, V34, P318; DEAL JE, 1992, ARCH DIS CHILD, V67, P1089, DOI 10.1136/adc.67.9.1089; DIENST J, 2010, NY TIMES        0118; Flynn JT, 2008, AM J HYPERTENS, V21, P605, DOI 10.1038/ajh.2008.159; Flynn JT, 2009, PEDIATR NEPHROL, V24, P1101, DOI 10.1007/s00467-008-1000-1; Ganesan V, 2003, ANN NEUROL, V53, P167, DOI 10.1002/ana.10423; Ganesan V, 2002, NEUROLOGY, V59, P1552, DOI 10.1212/01.WNL.0000033092.87560.1A; Ganesan V, 2006, CIRCULATION, V114, P2170, DOI 10.1161/CIRCULATIONAHA.105.583690; Hachinski V, 2007, STROKE, V38, P1396, DOI 10.1161/01.STR.0000260101.08944.e9; Hansen ML, 2007, JAMA-J AM MED ASSOC, V298, P874, DOI 10.1001/jama.298.8.874; Haymond M, 2007, PEDIATR DIABETES, V8, P74; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; HULSE JA, 1979, LANCET, V2, P553; Jones BV, 1997, AM J NEURORADIOL, V18, P101; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; Kirkham F, 2004, THROMB HAEMOSTASIS, V92, P697, DOI 10.1160/TH04-04-0209; Kuo HK, 2004, J GERONTOL A-BIOL, V59, P1191, DOI 10.1093/gerona/59.11.1191; Kupferman JC, 2007, PEDIATR NEUROL, V36, P125, DOI 10.1016/j.pediatrneurol.2006.08.010; Lande MB, 2006, HYPERTENSION, V48, P40, DOI 10.1161/01.HYP.0000227029.10536.e8; Lande MB, 2010, J PEDIATR-US, V157, P114, DOI 10.1016/j.jpeds.2009.12.053; Lande MB, 2003, J PEDIATR-US, V143, P720, DOI 10.1067/S0022-3476(03)00412-8; LANDE MB, 2008, J CLIN HYPERTENS SA, V10, pA154; LANDE MB, 2008, J CLIN HYPERTENS SA, V10, pA3; Le J, 2010, CIRC-CARDIOVASC IMAG, V3, P8, DOI 10.1161/CIRCIMAGING.109.880070; Lee VH, 2008, ARCH NEUROL-CHICAGO, V65, P205, DOI 10.1001/archneurol.2007.46; Lurbe E, 2008, CURR HYPERTENS REP, V10, P165, DOI 10.1007/s11906-008-0030-1; Manolio TA, 2003, CURR HYPERTENS REP, V5, P255, DOI 10.1007/s11906-003-0029-6; Master AM, 1939, ARCH INTERN MED, V64, P767, DOI 10.1001/archinte.1939.00190040108007; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P2222, DOI 10.1161/01.ATV.15.12.2222; MENKES JH, 2000, CHILD NEUROLOGY, P1120; MOORTHY S, 2002, INDIAN J RADIOL IMAG, V12, P321; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; Nguyen JH, 2009, J CLIN ENDOCR METAB, V94, P1, DOI 10.1210/jc.2008-1346; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Ohene-Frempong K, 1998, BLOOD, V91, P288; Ohkubo T, 2005, J AM COLL CARDIOL, V46, P508, DOI 10.1016/j.jacc.2005.03.070; Patel HP, 2005, CURR OPIN PEDIATR, V17, P210, DOI 10.1097/01.mop.0000150769.38484.b3; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Pavlakis SG, 1999, J CHILD NEUROL, V14, P277, DOI 10.1177/088307389901400502; Pegelow CH, 1997, AM J MED, V102, P171; Pinhas-Hamiel O, 2007, LANCET, V369, P1823, DOI 10.1016/S0140-6736(07)60821-6; Prohovnik I, 2009, J CEREBR BLOOD F MET, V29, P803, DOI 10.1038/jcbfm.2009.6; Rakototiana AF, 2008, ARCH PEDIATRIE, V15, P1531, DOI 10.1016/j.arcped.2008.07.013; Rosner B, 2009, HYPERTENSION, V54, P502, DOI 10.1161/HYPERTENSIONAHA.109.134049; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; ROYAL JE, 1978, LANCET, V2, P1207; RUBIN AM, 1987, NEUROLOGY, V37, P1072, DOI 10.1212/WNL.37.6.1072; Sarnaik SA, 2009, BLOOD, V114, P111, DOI 10.1182/blood.V114.22.262.262; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P379, DOI 10.2214/ajr.159.2.1632361; Scothorn DJ, 2002, J PEDIATR-US, V140, P348, DOI 10.1067/mpd.2002.122498; SEBIRE G, 1995, ARCH PEDIATRIE, V2, P513, DOI 10.1016/0929-693X(96)81193-6; Semplicini A, 2008, J HYPERTENS, V26, P1551, DOI 10.1097/HJH.0b013e328306a72d; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; SIMON RP, 2009, CLIN NEUROLOGY, V7, P292; Sorof J, 2002, HYPERTENSION, V40, P441, DOI 10.1161/01.HYP.0000032940.33466.12; Sorof JM, 2004, PEDIATRICS, V113, P475, DOI 10.1542/peds.113.3.475; Stott VL, 2005, INTERN MED J, V35, P83, DOI 10.1111/j.1445-5994.2004.00750.x; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; Strouse JJ, 2006, PEDIATRICS, V118, P1916, DOI 10.1542/peds.2006-1241; Suhr JA, 2004, PSYCHOSOM MED, V66, P291, DOI 10.1097/01.psy.0000127870.64234.9f; Thomas WJ, 2003, J AAPOS, V7, P217, DOI 10.1016/S1091-8531(03)00018-1; Urbina E, 2008, HYPERTENSION, V52, P433, DOI 10.1161/HYPERTENSIONAHA.108.190329; Urbina EM, 2009, HYPERTENSION, V54, P919, DOI 10.1161/HYPERTENSIONAHA.109.192639; Urbina EM, 2005, AM J HYPERTENS, V18, P767, DOI 10.1016/j.amjhyper.2004.12.017; Wang JJ, 2009, PEDIATR NEUROL, V40, P277, DOI 10.1016/j.pediatrneurol.2008.11.002; WHITWORTH JA, 1995, STEROIDS, V60, P76, DOI 10.1016/0039-128X(94)00033-9; Wirrell EC, 2007, CAN J NEUROL SCI, V34, P316, DOI 10.1017/S0317167100006740	79	35	36	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2010	9	9					933	940		10.1016/S1474-4422(10)70167-8	http://dx.doi.org/10.1016/S1474-4422(10)70167-8			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	645MX	20675195				2022-12-18	WOS:000281465900013
J	Mitchell, P; Gholkar, A; Vindlacheruvu, RR; Mendelow, AD				Mitchell, P; Gholkar, A; Vindlacheruvu, RR; Mendelow, AD			Unruptured intracranial aneurysms: benign curiosity or ticking bomb?	LANCET NEUROLOGY			English	Review							POLYCYSTIC KIDNEY-DISEASE; TERM-FOLLOW-UP; MAGNETIC-RESONANCE ANGIOGRAPHY; SUBARACHNOID HEMORRHAGE; CEREBRAL ANEURYSMS; SURGICAL-TREATMENT; NATURAL-HISTORY; ENDOVASCULAR TREATMENT; RANDOMIZED TREATMENT; FAMILY-HISTORY	15 years ago, the treatment of incidentally discovered intracranial aneurysms was straightforward with a good evidence base behind it. When intracranial aneurysms were identified, people were referred to neurosurgeons who would offer surgical repair if the patient was in reasonable health and had a good life expectancy. Since that time, several studies have given contradictory evidence for what should be done with these lesions, and a new technique for the repair of aneurysms, endovascular coil embolisation, has been developed. Here we review the research and make several recommendations. First, incidentally discovered aneurysms in the anterior circulation less than 7 mm in size in people with no personal or family history of subarachnoid haemorrhage should be left untreated. Second, people with remaining life expectancy of less than 20 years or so (le, those over age 60 years) should be informed that from a statistical point of view the benefits of treatment do not outweigh the risks. Third, in all other cases treatment with surgical clipping or coil embolisation should be advised. And finally, if surgical treatment is not feasible then medical hypotensive treatment may be a viable alternative.	Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Neuroradiol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle General Hospital	Mitchell, P (corresponding author), Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	patrick.mitchell@ncl.ac.uk	Mendelow, Alexander/AAW-2878-2021					ADAMSON J, 1994, STROKE, V25, P963, DOI 10.1161/01.STR.25.5.963; ALBERTS MJ, 1995, CAN J NEUROL SCI, V22, P121, DOI 10.1017/S0317167100040191; Alvord E C Jr, 1977, Clin Neurosurg, V24, P167; ALVORD EC, 1972, ARCH NEUROL-CHICAGO, V27, P273, DOI 10.1001/archneur.1972.00490160001001; Anderson C, 2003, STROKE, V34, P1771, DOI 10.1161/01.STR.0000077015.90334.A7; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z; ATKINSON JLD, 1989, J NEUROSURG, V70, P551, DOI 10.3171/jns.1989.70.4.0551; Bendok BR, 2003, NEUROSURGERY, V52, P1125, DOI 10.1227/01.NEU.0000057833.50219.25; Birchall D, 1999, AM J NEURORADIOL, V20, P411; Bromberg JEC, 1995, ANN NEUROL, V38, P929, DOI 10.1002/ana.410380614; Butler TJ, 2000, BRIT J RADIOL, V73, P601, DOI 10.1259/bjr.73.870.10911782; Carrizo AG, 1999, CRIT REV NEUROSURG, V9, P79, DOI 10.1007/s003290050114; CHANG HS, 1995, J NEUROSURG, V83, P413, DOI 10.3171/jns.1995.83.3.0413; Chyatte D, 2001, J NEUROSURG, V94, P417, DOI 10.3171/jns.2001.94.3.0417; Conway JE, 2001, STROKE, V32, P2481, DOI 10.1161/hs1101.098329; Crawley F, 1999, STROKE, V30, P312, DOI 10.1161/01.STR.30.2.312; DeBraekeleer M, 1996, ANN HUM GENET, V60, P99, DOI 10.1111/j.1469-1809.1996.tb01181.x; Deruty R, 1996, NEUROL RES, V18, P39, DOI 10.1080/01616412.1996.11740375; Dott NM, 1933, EDINBURGH MED J, V40, P219; Dovey Z, 2001, ARCH NEUROL-CHICAGO, V58, P559, DOI 10.1001/archneur.58.4.559; DRAKE CG, 1984, CAN J SURG, V27, P549; ESKESEN V, 1988, ACTA NEUROCHIR, V95, P99, DOI 10.1007/BF01790768; Eskesen V, 1988, Br J Neurosurg, V2, P379, DOI 10.3109/02688698809001009; Goddard AJP, 2002, J NEUROL NEUROSUR PS, V72, P485; GRAF CJ, 1971, J NEUROSURG, V35, P438, DOI 10.3171/jns.1971.35.4.0438; GRAF CJ, 1974, STROKE, V5, P557, DOI 10.1161/01.STR.5.4.557; Graf S, 2002, NEPHROL DIAL TRANSPL, V17, P819, DOI 10.1093/ndt/17.5.819; GUGLIELMI G, 1992, J NEUROSURG, V77, P515, DOI 10.3171/jns.1992.77.4.0515; HEISKANEN O, 1970, J NEUROSURG, V32, P295, DOI 10.3171/jns.1970.32.3.0295; HEISKANEN O, 1981, J NEUROSURG, V55, P524, DOI 10.3171/jns.1981.55.4.0524; HEISKANEN O, 1986, J NEUROSURG, V65, P451, DOI 10.3171/jns.1986.65.4.0451; Horikoshi T, 2002, NEUROL MED-CHIR, V42, P105, DOI 10.2176/nmc.42.105; HOUNSFIELD GN, 1980, J COMPUT ASSIST TOMO, V4, P665, DOI 10.1097/00004728-198010000-00017; Huston J, 1996, J AM SOC NEPHROL, V7, P2135; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; INAGAWA T, 1990, SURG NEUROL, V34, P361, DOI 10.1016/0090-3019(90)90237-J; Inamasu J, 2002, J NEURO-OPHTHALMOL, V22, P12, DOI 10.1097/00041327-200203000-00004; Iversen T, 1998, DEV HLTH EC, V6, P137; JAIN KK, 1982, ACTA NEUROCHIR, V66, P187, DOI 10.1007/BF02074505; JAKUBOWSKI J, 1978, J NEUROL NEUROSUR PS, V41, P972, DOI 10.1136/jnnp.41.11.972; Jane J A, 1977, Clin Neurosurg, V24, P176; JANE JA, 1985, J NEUROSURG, V62, P321, DOI 10.3171/jns.1985.62.3.0321; JHA AN, 1986, NEUROSURG PSYCHIATRY, V49, P893; Johnston SC, 2000, ANN NEUROL, V48, P11; Johnston SC, 2001, STROKE, V32, P597, DOI 10.1161/01.STR.32.3.597; Johnston SC, 1998, NEUROLOGY, V51, P411, DOI 10.1212/WNL.51.2.411; JOMIN M, 1987, ACTA NEUROCHIR, V84, P85, DOI 10.1007/BF01418829; Juvela S, 2002, ACTA NEUROCHIR SUPPL, V82, P27; Juvela S, 2008, J NEUROSURG, V108, P1052, DOI 10.3171/JNS/2008/108/5/1052; Kasuya H, 2000, NEUROSURGERY, V46, P1301, DOI 10.1097/00006123-200006000-00004; Kim TS, 1998, INVEST RADIOL, V33, P407, DOI 10.1097/00004424-199807000-00005; KING JT, 1994, J NEUROSURG, V81, P837, DOI 10.3171/jns.1994.81.6.0837; Kirkpatrick PJ, 1999, BRIT MED J, V319, P1512, DOI 10.1136/bmj.319.7224.1512; Lackner E, 2002, FORTSCHR NEUROL PSYC, V70, P438, DOI 10.1055/s-2002-33059; Leblanc R, 1997, CAN J NEUROL SCI, V24, P191, DOI 10.1017/S031716710002179X; LEBLANC R, 1987, CAN J NEUROL SCI, V14, P638; Leblanc R, 1999, NEUROSURGERY, V44, P871, DOI 10.1097/00006123-199904000-00110; Leppala JM, 1999, CIRCULATION, V100, P1209, DOI 10.1161/01.CIR.100.11.1209; LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219; Matsumoto E, 2002, NEUROL SURG TOKYO, V30, P829; MCKISSOC.W, 1965, LANCET, V1, P873; MCKISSOCK W, 1962, LANCET, V2, P417; MCKISSOCK W, 1960, LANCET, V1, P1203; Menghini VV, 1998, NEUROLOGY, V51, P405, DOI 10.1212/WNL.51.2.405; Mitchell P, 2000, J NEUROL NEUROSUR PS, V69, P760, DOI 10.1136/jnnp.69.6.760; Mitchell P, 2000, J NEUROL NEUROSUR PS, V68, P577, DOI 10.1136/jnnp.68.5.577; Mizoi K, 1995, SURG NEUROL, V44, P114, DOI 10.1016/0090-3019(95)00035-6; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Moniz E, 1927, REV NEUROL-FRANCE, V48, P72; MONIZ E, 1931, CEREBRAL ANGIOGRAPHY; Nakagawa T, 1999, J NEUROSURG, V91, P391, DOI 10.3171/jns.1999.91.3.0391; Nakajima F, 2000, J UROLOGY, V164, P311, DOI 10.1016/S0022-5347(05)67347-8; NIBBELINK DW, 1977, STROKE, V8, P202, DOI 10.1161/01.STR.8.2.202; NIBBELINK DW, 1974, STROKE, V5, P552, DOI 10.1161/01.STR.5.4.552; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; Okamoto K, 2003, STROKE, V34, P422, DOI 10.1161/01.STR.0000053851.17964.C6; Orz YI, 2000, SURG NEUROL, V53, P21, DOI 10.1016/S0090-3019(99)00171-8; PAKARINEN S, 1965, J NEUROSURG, V23, P438, DOI 10.3171/jns.1965.23.4.0438; POPE FM, 1981, LANCET, V1, P973; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P584, DOI 10.1212/WNL.36.4.584; Raaymakers TWM, 1999, NEUROLOGY, V53, P982, DOI 10.1212/WNL.53.5.982; Raaymakers TWM, 1998, NEUROLOGY, V51, P1125, DOI 10.1212/WNL.51.4.1125; Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531; Raaymakers TWM, 2000, J NEUROL NEUROSUR PS, V68, P571, DOI 10.1136/jnnp.68.5.571; Raftopoulos C, 2003, NEUROSURGERY, V52, P1280, DOI 10.1227/01.NEU.0000064568.71648.EC; RICE BJ, 1990, J NEUROSURG, V73, P165, DOI 10.3171/jns.1990.73.2.0165; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Ronkainen A, 1998, STROKE, V29, P359, DOI 10.1161/01.STR.29.2.359; RONKAINEN A, 1995, NEUROSURGERY, V37, P43, DOI 10.1227/00006123-199507000-00006; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; Rosenorn J, 1988, Br J Neurosurg, V2, P369, DOI 10.3109/02688698809001008; Saatci I, 1996, J VASC INTERV RADIOL, V7, P75, DOI 10.1016/S1051-0443(96)70736-4; SAHS AL, 1974, STROKE, V5, P550, DOI 10.1161/01.STR.5.4.550; SAHS AL, 1981, ANEURYSMAL SUBARACHN; SAMSON DS, 1977, J NEUROSURG, V46, P731, DOI 10.3171/jns.1977.46.6.0731; Schievink WI, 1997, NEUROSURGERY, V41, P866, DOI 10.1097/00006123-199710000-00019; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; SCHIEVINK WI, 1991, NEUROSURGERY, V29, P434, DOI 10.1227/00006123-199109000-00017; SERIZAWA T, 1992, Neurologia Medico-Chirurgica, V32, P342, DOI 10.2176/nmc.32.342; Slosberg P S, 1974, Clin Neurosurg, V21, P90; Slosberg P S, 1965, J Pract Nurs, V15, P27; Slosberg P S, 1979, Trans Am Neurol Assoc, V104, P180; SLOSBERG PS, 1973, MT SINAI J MED, V40, P82; SLOSBERG PS, 1982, ACTA NEUROCHIR, V62, P207, DOI 10.1007/BF01403626; Slosberg PS, 1997, ACTA NEUROCHIR, V139, P697, DOI 10.1007/BF01420041; Solomon RA, 1999, STROKE, V30, P1292, DOI 10.1161/01.STR.30.6.1292; SOLOMON RA, 1994, J NEUROSURG, V80, P440, DOI 10.3171/jns.1994.80.3.0440; TERBERG HWM, 1992, STROKE, V23, P1024, DOI 10.1161/01.STR.23.7.1024; TERBERG HWM, 1988, NEUROSURGERY, V23, P329, DOI 10.1227/00006123-198809000-00007; Teunissen LL, 1996, STROKE, V27, P544, DOI 10.1161/01.STR.27.3.544; Tsutsumi K, 1999, STROKE, V30, P1181, DOI 10.1161/01.STR.30.6.1181; Tsutsumi K, 2001, STROKE, V32, P1191, DOI 10.1161/01.STR.32.5.1191; van Lindert E, 1998, SURG NEUROL, V49, P481, DOI 10.1016/S0090-3019(96)00539-3; VANCREVEL H, 1986, NEUROLOGY, V36, P1335, DOI 10.1212/WNL.36.10.1335; vandenBerg JSP, 1996, STROKE, V27, P10, DOI 10.1161/01.STR.27.1.10; vanDijk MA, 1995, J AM SOC NEPHROL, V6, P1670; WANG PS, 1995, ARCH NEUROL-CHICAGO, V52, P202, DOI 10.1001/archneur.1995.00540260108026; White PM, 2000, RADIOLOGY, V217, P361, DOI 10.1148/radiology.217.2.r00nv06361; White PM, 2001, RADIOLOGY, V219, P739, DOI 10.1148/radiology.219.3.r01ma16739; White PM, 2001, J NEUROL NEUROSUR PS, V71, P322, DOI 10.1136/jnnp.71.3.322; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WIEBERS DO, 1981, NEW ENGL J MED, V304, P696, DOI 10.1056/NEJM198103193041203; WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023; Wills S, 2003, STROKE, V34, P1370, DOI 10.1161/01.STR.0000072822.35605.8B; WIRTH FP, 1983, NEUROSURGERY, V12, P507, DOI 10.1227/00006123-198305000-00005; Yasui N, 1997, NEUROSURGERY, V40, P1155, DOI 10.1097/00006123-199706000-00007; Yoshida S, 2000, NEUROL SURG TOKYO, V28, P1077; Yoshimoto Y, 1999, STROKE, V30, P1621, DOI 10.1161/01.STR.30.8.1621	130	35	38	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					85	92		10.1016/S1474-4422(03)00661-6	http://dx.doi.org/10.1016/S1474-4422(03)00661-6			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14747000				2022-12-18	WOS:000188818500018
J	Baxendale, S				Baxendale, S			Epilepsy at the movies: possession to presidential assassination	LANCET NEUROLOGY			English	Review							SEIZURES	In this review I examine the portrayal of epilepsy, seizures, and non-epileptic attack disorder in 62 movies produced over three-quarters of a century, across four continents, covering nine cinematic genres. While similar reviews of epilepsy in literature have suggested a progression in the understanding of epilepsy over time, this survey of the newer medium found examples of all of the ancient beliefs about epilepsy including demonic or divine possession, genius, lunacy, delinquency, and general "otherness". Nevertheless there has been a progressive trend towards more overt depictions of epilepsy. Male characters with idiopathic epilepsy tend to be mad, bad, and commonly dangerous, whereas characters with post-traumatic epilepsy are usually cast as heroes triumphing against the odds. Epilepsy in female characters tends to signify exotic vulnerability. The dramatic potential of seizures remains highly tempting to film writers and directors alike. Although it is not for the medical profession to dictate or censor cinematic content, a keen eye on these depictions will help us to understand and perhaps combat some of the stereotypes and myths that continue to surround epilepsy in the 21st century.	UCL, Inst Neurol, London, England	University of London; University College London	Baxendale, S (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Psychol, Queen Sq, London WC1N 3BG, England.		Baxendale, Sallie/AAN-8312-2020	Baxendale, Sallie/0000-0002-9930-6469				ABRAHAMS J, 1997, 1 DO NO HARM; Altman Robert, 1978, WEDDING; Archibugi Francesca, 1993, GRANDE COCOMERO; AZZARELLA D, 1972, WITCHES SALEM HORROR; Bellocchio Marco, 1965, PUGNI TASCA; BOCHNER H, 1994, PCU; BOWDEN M, 2002, BLACK HAWK; BROOKS M, 1970, 12 CHAIRS; Brooks Richard, 1958, BROTHERS KARAMAZOV; Burge Stuart, 1965, OTHELLO; COLUMBUS C, 2002, H POTTER CHAMBER SEC; COMENCINI L, 1985, STORIA, P2; Curtiz Michael, 1954, EGYPTIAN; Dan B, 1999, SEIZURE-EUR J EPILEP, V8, P238, DOI 10.1053/seiz.1999.0289; DAVIES A, 1993, FUGITIVE; DEPIMENTAL P, 2002, OESTERS NAM KEE; Dumont, 1997, VIE JESUS; Fairfax F, 1986, FIGHTING CHOICE; FORMAN M, 1975, 1 FLEW OVER CUCKOOS; Francis PA, 1999, SEIZURE-EUR J EPILEP, V8, P53, DOI 10.1053/seiz.1998.0246; Friedman D B, 1992, Seizure, V1, P307, DOI 10.1016/1059-1311(92)90041-X; FRIIS ML, 1974, ARCH NEUROL-CHICAGO, V31, P155, DOI 10.1001/archneur.1974.00490390037002; GIRALDI F, 1967, MINUTO PREGARE; GREENWOOD R, 1929, WHAT RED HELL; Hartley Hal, 1992, SIMPLE MEN; HARTLEY T, 1995, SAFE; HAWKES H, 1970, RIO LOBO; Haynes T., 1995, SAFE; HIDGES M, 1974, TERMINAL MAN; HU K, 1984, TIEN HSIA YI; Hunter S., 1999, LIGHTHOUSE; HUTNER N, 1996, CRUCIBLE; Jones JM, 2000, SOUTHERN MED J, V93, P1169; JORDAN G, 1983, PROMISE; KEATON D, 1992, WILDFLOWER; Kerson JF, 1999, EPILEPSIA, V40, P1163, DOI 10.1111/j.1528-1157.1999.tb00836.x; KLOTZEL A, 1993, CAPITALISMO SALVAGEM; Kurosawa Akira, 1951, IDIOT; LATSHAW S, 1991, VAMPIRE TRAILER PARK; LEHNER P, 1991, MEGAVILLE; LEONG PC, 1984, DANG DOI LAI MING; LLUCH V, 1971, LAIA; Lusic I, 1999, SEIZURE-EUR J EPILEP, V8, P218, DOI 10.1053/seiz.1999.0284; Mankiewicz Joseph L., 1963, CLEOPATRA; MARSHALL G, 1991, FRANKIE JOHNNY; Medak P, 1991, LET HIM HAVE IT; Minghella Anthony., 1996, ENGLISH PATIENT; MOORE T, 1986, NIGH MOTHER; Morey, 1937, SNOW WHITE 7 DWARVES; MUSTIZER M, 2001, OTHER HALF ME; NASCA S, 1975, PEPPINO VERGINE MARI; NASHEFF L, 1996, TREATMENT EPILEPSY; NEWMAN P, 1972, EFFECT GAMMA RAYS MA; NOLEN C, 2000, MEMENTO; Noyce P., 1999, BONE COLLECTOR; OZER IJ, 1991, EPILEPSIA, V32, P798, DOI 10.1111/j.1528-1157.1991.tb05536.x; PATE J, 1997, DECEIVER; POLIAKOFF S, 2003, LOST PRINCE; Powell Michael, 1946, MATTER LIFE DEATH; PYRIEV I, 1958, IDIOT; Richler, 1974, APPRENTICESHIP D KRA; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; Scorsese Martin, 1973, MEAN STREETS; Scott Ridley, 2001, BLACK HAWK; SEILER L, 1952, WINNING TEAM; SIEGAL D, 1949, NIGHT NIGHT; SILVERSTEIN E, 1987, FIGHT LIFE; Sirven JI, 2002, SEMIN NEUROL, V22, P237, DOI 10.1055/s-2002-36644; SPOTISWOODE R, 1994, MESMER; SUZUKI S, 1995, SUKIYAKI; TEMKIN OW, 1994, FALLING SICKNESS; TENNEY D, 1963, CURSE LIVING CORPSE; Van Sant Gus, 1989, DRUGSTORE COWBOY; Waltari Mika, 1949, EGYPTIAN; WISE R, 1971, ANDORMEDA STRAIN; Woo John, 1997, FACE; Wright Geoffrey, 1993, ROMPER STOMPER; YIN Y, 1998, HONG SE LIAN REN	79	35	35	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					764	770		10.1016/S1474-4422(03)00589-1	http://dx.doi.org/10.1016/S1474-4422(03)00589-1			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14636782				2022-12-18	WOS:000186665800020
J	Lauria, G; Pareyson, D; Pitzolu, MG; Bazzigaluppi, E				Lauria, G; Pareyson, D; Pitzolu, MG; Bazzigaluppi, E			Excellent response to steroid treatment in anti-GAD cerebellar ataxia	LANCET NEUROLOGY			English	Editorial Material							ACID DECARBOXYLASE AUTOANTIBODIES		Univ Brescia, Neurol Clin, Dept Clin Neurosci, I-25125 Brescia, Italy; Natl Neurol Inst Carlo Besta, Milan, Italy; S Raffaele Vita Salute Univ Hosp, Diabet & Endocrinol Unit, Milan, Italy; Inst Sci, Milan, Italy	University of Brescia; IRCCS Istituto Neurologico Besta	Lauria, G (corresponding author), Univ Brescia, Neurol Clin, Dept Clin Neurosci, Ple Spedali Civili,1, I-25125 Brescia, Italy.		lauria, giuseppe/AAN-5371-2020; bazzigaluppi, elena/AAN-5052-2020; Lauria, Giuseppe/T-1378-2017; Pareyson, Davide/K-5890-2016	lauria, giuseppe/0000-0001-9773-020X; bazzigaluppi, elena/0000-0002-6715-7454; Lauria, Giuseppe/0000-0001-9773-020X; Pareyson, Davide/0000-0001-6854-765X				Abele M, 1999, NEUROLOGY, V52, P857, DOI 10.1212/WNL.52.4.857; Hadjivassiliou M, 1998, LANCET, V352, P1582, DOI 10.1016/S0140-6736(98)05342-2; Honnorat J, 2001, ARCH NEUROL-CHICAGO, V58, P225, DOI 10.1001/archneur.58.2.225; Matsumoto S, 2002, J NEUROL NEUROSUR PS, V73, P345, DOI 10.1136/jnnp.73.3.345; Trivedi R, 2000, LANCET, V356, P565, DOI 10.1016/S0140-6736(00)02585-X	5	35	38	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					634	635		10.1016/S1474-4422(03)00534-9	http://dx.doi.org/10.1016/S1474-4422(03)00534-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723KR	14505586				2022-12-18	WOS:000185432000021
J	Azevedo, CJ; Kutz, C; Dix, A; Boster, A; Sanossian, N; Kaplan, J				Azevedo, Christina J.; Kutz, Christen; Dix, Amy; Boster, Aaron; Sanossian, Nerses; Kaplan, Jeffrey			Intracerebral haemorrhage during alemtuzumab administration	LANCET NEUROLOGY			English	Letter							RELAPSING MULTIPLE-SCLEROSIS		[Azevedo, Christina J.; Sanossian, Nerses] Univ Southern Calif, Dept Neurol, Los Angeles, CA 90033 USA; [Kutz, Christen] Colorado Springs Neurol Associates, Colorado Springs, CO USA; [Dix, Amy; Kaplan, Jeffrey] Coll Pk Family Care Ctr, Overland Pk, KS USA; [Boster, Aaron] OhioHlth Neurol Phys, Columbus, OH USA	University of Southern California	Azevedo, CJ (corresponding author), Univ Southern Calif, Dept Neurol, Los Angeles, CA 90033 USA.	cazevedo@usc.edu		Dix, Amy L./0000-0001-9242-3366				[Anonymous], 2019, LEMTR AL PRESCR INF; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Coles AJ, 2017, NEUROLOGY, V89, P1117, DOI 10.1212/WNL.0000000000004354; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Havrdova E, 2017, THER CLIN RISK MANAG, V13, P1423, DOI 10.2147/TCRM.S143509; Havrdova E, 2017, NEUROLOGY, V89, P1107, DOI 10.1212/WNL.0000000000004313; Hunter SF, 2017, INT J MS CARE S1, V19, P35; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; US Food and Drug Administration, 2018, FDA WARNS RAR SER RI	10	34	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					329	331		10.1016/S1474-4422(19)30076-6	http://dx.doi.org/10.1016/S1474-4422(19)30076-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30777657				2022-12-18	WOS:000461169400009
J	Carpentier, AF				Carpentier, AF			Neuro-oncology: the growing role of chemotherapy in glioma	LANCET NEUROLOGY			English	Editorial Material									Salpetriere Hosp, Dept Neurol Mazarin, Paris, France; Univ Paris 05, F-75270 Paris 06, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Carpentier, AF (corresponding author), Salpetriere Hosp, Dept Neurol Mazarin, Paris, France.	antoine.carpentier@psl.ap-hop-paris.fr		Carpentier, Antoine/0000-0003-2926-0060				Dalmau J, 2004, BRAIN, V127, P1831, DOI 10.1093/brain/awh203; Hoang-Xuan K, 2004, J CLIN ONCOL, V22, P3133, DOI 10.1200/JCO.2004.10.169; Iwadate Y, 2004, CANCER RES, V64, P2496, DOI 10.1158/0008-5472.CAN-03-1254; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Stupp R, 2004, J CLIN ONCOL, V22, p1S	5	34	34	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					4	5		10.1016/S1474-4422(04)00944-5	http://dx.doi.org/10.1016/S1474-4422(04)00944-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620846				2022-12-18	WOS:000226250200004
J	Traylor, M; Persyn, E; Tomppo, L; Klasson, S; Abedi, V; Bakker, MK; Torres, N; Li, LX; Bell, S; Rutten-Jacobs, L; Tozer, DJ; Griessenauer, CJ; Zhang, YF; Pedersen, A; Sharma, P; Jimenez-Conde, J; Rundek, T; Grewal, RP; Lindgren, A; Meschia, JF; Salomaa, V; Havulinna, A; Kourkoulis, C; Crawford, K; Marini, S; Mitchell, BD; Kittner, SJ; Rosand, J; Dichgans, M; Jern, C; Strbian, D; Fernandez-Cadenas, I; Zand, R; Ruigrok, Y; Rost, N; Lemmens, R; Rothwell, PM; Anderson, CD; Wardlaw, J; Lewis, CM; Markus, HS				Traylor, Matthew; Persyn, Elodie; Tomppo, Liisa; Klasson, Sofia; Abedi, Vida; Bakker, Mark K.; Torres, Nuria; Li, Linxin; Bell, Steven; Rutten-Jacobs, Loes; Tozer, Daniel J.; Griessenauer, Christoph J.; Zhang, Yanfei; Pedersen, Annie; Sharma, Pankaj; Jimenez-Conde, Jordi; Rundek, Tatjana; Grewal, Raji P.; Lindgren, Arne; Meschia, James F.; Salomaa, Veikko; Havulinna, Aki; Kourkoulis, Christina; Crawford, Katherine; Marini, Sandro; Mitchell, Braxton D.; Kittner, Steven J.; Rosand, Jonathan; Dichgans, Martin; Jern, Christina; Strbian, Daniel; Fernandez-Cadenas, Israel; Zand, Ramin; Ruigrok, Ynte; Rost, Natalia; Lemmens, Robin; Rothwell, Peter M.; Anderson, Christopher D.; Wardlaw, Joanna; Lewis, Cathryn M.; Markus, Hugh S.		Helsinki Stroke Study; Dutch Parelsnoer Inst Cerebrovasc; Natl Inst Neurological Disorders; UK DNA Lacunar Stroke Study; Int Stroke Genetics Consortium	Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	LANCET NEUROLOGY			English	Article							SMALL VESSEL DISEASE; ISCHEMIC-STROKE; SUBTYPES; VARIANTS; RISK; METAANALYSIS; LOCI; CLASSIFICATION; PATHOGENESIS; ONSET	Background The genetic basis of lacunar stroke is poorly understood, with a single locus on 16q24 identified to date. We sought to identify novel associations and provide mechanistic insights into the disease. Methods We did a pooled analysis of data from newly recruited patients with an MRI-confirmed diagnosis of lacunar stroke and existing genome-wide association studies (GWAS). Patients were recruited from hospitals in the UK as part of the UK DNA Lacunar Stroke studies 1 and 2 and from collaborators within the International Stroke Genetics Consortium. Cases and controls were stratified by ancestry and two meta-analyses were done: a European ancestry analysis, and a transethnic analysis that included all ancestry groups. We also did a multi-trait analysis of GWAS, in a joint analysis with a study of cerebral white matter hyperintensities (an aetiologically related radiological trait), to find additional genetic associations. We did a transcriptome-wide association study (TWAS) to detect genes for which expression is associated with lacunar stroke; identified significantly enriched pathways using multi-marker analysis of genomic annotation; and evaluated cardiovascular risk factors causally associated with the disease using mendelian randomisation. Findings Our meta-analysis comprised studies from Europe, the USA, and Australia, including 7338 cases and 254 798 controls, of which 2987 cases (matched with 29 540 controls) were confirmed using MRI. Five loci (ICA1L-WDR12-CARF-NBEAL1, ULK4, SPI1-SLC39A13-PSMC3-RAPSN, ZCCHC14, ZBTB14-EPB41L3) were found to be associated with lacunar stroke in the European or transethnic meta-analyses. A further seven loci (SLC25A44-PMF1-BGLAP, LOX-ZNF474-LOC100505841, FOXF2-FOXQ1, VTA1-GPR126, SH3PXD2A, HTRA1-ARMS2, COL4A2) were found to be associated in the multi-trait analysis with cerebral white matter hyperintensities (n=42 310). Two of the identified loci contain genes (COL4A2 and HTRA1) that are involved in monogenic lacunar stroke. The TWAS identified associations between the expression of six genes (SCL25A44, ULK4, CARF, FAM117B, ICA1L, NBEAL1) and lacunar stroke. Pathway analyses implicated disruption of the extracellular matrix, phosphatidylinositol 5 phosphate binding, and roundabout binding (false discovery rate <0.05). Mendelian randomisation analyses identified positive associations of elevated blood pressure, history of smoking, and type 2 diabetes with lacunar stroke. Interpretation Lacunar stroke has a substantial heritable component, with 12 loci now identified that could represent future treatment targets. These loci provide insights into lacunar stroke pathogenesis, highlighting disruption of the vascular extracellular matrix (COL4A2, LOX, SH3PXD2A, GPR126, HTRA1), pericyte differentiation (FOXF2, GPR126), TGF-beta signalling (HTRA1), and myelination (ULK4, GPR126) in disease risk. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.	[Traylor, Matthew] Queen Mary Univ London, Clin Pharmacol, London, England; [Traylor, Matthew] Queen Mary Univ London, Barts Heart Ctr, London, England; [Traylor, Matthew] Queen Mary Univ London, NIHR Barts Biomed Res Ctr, Barts Hlth NHS Trust, William Harvey Res Inst, London, England; [Lewis, Cathryn M.] Kings Coll London, Dept Med & Mol Genet, London, England; [Lewis, Cathryn M.] Kings Coll London, Social Genet & Dev Psychiat Ctr, London, England; [Tomppo, Liisa; Strbian, Daniel] Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland; [Klasson, Sofia; Pedersen, Annie; Jern, Christina] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Lab Med, Gothenburg, Sweden; [Abedi, Vida] Geisinger Hlth Syst, Dept Mol & Funct Genom, Weis Ctr Res, Danville, PA USA; [Griessenauer, Christoph J.; Zand, Ramin] Geisinger Hlth Syst, Neurosci Inst, Danville, PA USA; [Zhang, Yanfei] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA; [Bakker, Mark K.; Ruigrok, Ynte] Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Torres, Nuria; Fernandez-Cadenas, Israel] Hosp Santa Creu & Sant Pau, Stroke Pharmacogen & Genet, St Pau Inst Res, Barcelona, Spain; [Li, Linxin; Rothwell, Peter M.] Univ Oxford, Nuffield Dept Clin Neurosci, Ctr Prevent Stroke & Dementia, Oxford, England; [Bell, Steven; Tozer, Daniel J.; Markus, Hugh S.] Univ Cambridge, Clin Neurosci, Cambridge, England; [Rutten-Jacobs, Loes] F Hoffmann La Roche, Prod Dev Personalized Hlth Care, Basel, Switzerland; [Griessenauer, Christoph J.] Paracelsus Med Univ, Inst Neurointervent, Salzburg, Austria; [Sharma, Pankaj] Royal Holloway Univ London, Inst Cardiovasc Res, London, England; [Jimenez-Conde, Jordi] Univ Pompeu Fabra, Univ Autonoma Barcelona, IMIM Inst Hosp Mar Invest Med, Neurovasc Res Grp,Dept Neurol,Hosp Mar,DCEXS, Barcelona, Spain; [Rundek, Tatjana] Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Dept Neurol, Miami, FL 33136 USA; [Grewal, Raji P.] Seton Hall Univ, Neurosci Inst, St Francis Med Ctr, Sch Hlth & Med Sci, S Orange, NJ 07079 USA; [Lindgren, Arne] Skane Univ Hosp, Dept Neurol, Lund, Sweden; [Lindgren, Arne] Lund Univ, Dept Clin Sci Lund, Neurol, Lund, Sweden; [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; [Salomaa, Veikko; Havulinna, Aki] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Helsinki, Finland; [Havulinna, Aki] Inst Mol Med Finland FIMM HiLIFE, Helsinki, Finland; [Kourkoulis, Christina; Crawford, Katherine; Marini, Sandro; Rosand, Jonathan; Anderson, Christopher D.] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Kourkoulis, Christina; Rosand, Jonathan; Anderson, Christopher D.] Massachusetts Gen Hosp, Henry & Allison McCance Ctr Brain Hlth, Boston, MA 02114 USA; [Rosand, Jonathan; Anderson, Christopher D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Rost, Natalia] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA; [Kourkoulis, Christina; Crawford, Katherine; Marini, Sandro; Rosand, Jonathan; Anderson, Christopher D.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA; [Mitchell, Braxton D.] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA; [Kittner, Steven J.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Mitchell, Braxton D.; Kittner, Steven J.] Baltimore Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD USA; [Dichgans, Martin] Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res ISD, Munich, Germany; [Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Strbian, Daniel] Univ Helsinki, Clin Neurosci, Helsinki, Finland; [Fernandez-Cadenas, Israel] Univ Autonoma Barcelona, Neurovasc Res Lab, Inst Recerca Hosp Vall dHebron, Barcelona, Spain; [Fernandez-Cadenas, Israel] Univ Autonoma Barcelona, Neurovasc Unit, Inst Recerca Hosp Vall dHebron, Barcelona, Spain; [Lemmens, Robin] Katholieke Univ Leuven, Dept Neurosci, Expt Neurol, Leuven, Belgium; [Lemmens, Robin] Univ Hosp Leuven, VIB Ctr Brain & Dis Res, Dept Neurol, Leuven, Belgium; [Wardlaw, Joanna] Univ Edinburgh, Ctr Clin Brain Sci, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Wardlaw, Joanna] Univ Edinburgh, Row Fogo Ctr Res Ageing Brain, Edinburgh, Midlothian, Scotland	University of London; Queen Mary University London; University of London; Queen Mary University London; Barts Health NHS Trust; University of London; Queen Mary University London; University of London; King's College London; University of London; King's College London; University of Helsinki; Helsinki University Central Hospital; University of Gothenburg; Geisinger Health System; Geisinger Health System; Geisinger Health System; Utrecht University; Utrecht University Medical Center; Hospital of Santa Creu i Sant Pau; University of Oxford; University of Cambridge; Roche Holding; Paracelsus Private Medical University; University of London; Royal Holloway University London; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; University of Miami; Seton Hall University; Lund University; Skane University Hospital; Lund University; Mayo Clinic; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Geriatric Research Education & Clinical Center; University of Munich; University of Munich; University of Helsinki; Autonomous University of Barcelona; Autonomous University of Barcelona; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; University of Edinburgh; University of Edinburgh	Markus, HS (corresponding author), Univ Cambridge, Clin Neurosci, Stroke Res Grp, Cambridge CB2 0QQ, England.	hsm32@medschl.cam.ac.uk	Zhang, Yanfei/AAL-2148-2021; JIMENEZ-CONDE, JORDI/C-1941-2012; Mitchell, Braxton/CAF-0876-2022; Meschia, James/GPP-1636-2022; Torres-Aguila, Nuria P/S-6920-2019; Dichgans, Martin/HCH-3247-2022; sharma, pankaj/HGE-4423-2022; Rutten-Jacobs, Loes/C-7746-2013; Lewis, Cathryn/A-5225-2010	Zhang, Yanfei/0000-0002-9222-7725; Meschia, James/0000-0002-4475-8142; Torres-Aguila, Nuria P/0000-0002-9502-9310; Dichgans, Martin/0000-0002-0654-387X; Rutten-Jacobs, Loes/0000-0003-3223-885X; Tomppo, Liisa/0000-0002-9369-5846; Abedi, Vida/0000-0001-7689-933X; Lewis, Cathryn/0000-0002-8249-8476	Economic and Social Research Council; UK Biobank [11/NW/0382]; UK Young Lacunar Stroke DNA Study 2 (DNA Lacunar 2); British Heart Foundation Programme Grant [RG/16/4/32218]; US National Institute of Neurological Disorders and Stroke, National Institutes of Health [U01 NS069208, R01 NS100178]; Wellcome Trust; Stroke Association [TSA 2010/01]; Stroke Association Grant [TSA 2013/01]; Swedish Research Council [2018-02543]; Swedish Heart and Lung Foundation [20190203]; Swedish government; county councils [ALFGBG-720081]; Barts Charity; National Institute of Health Research (NIHR) Barts Biomedical Research Centre; FWO Flanders - NIHR Oxford Biomedical Research Centre; US National Institutes of Health [R01NS103924, K23NS086873]; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London; NIHR Senior Investigator award; Cambridge Universities NIHR Comprehensive Biomedical Research Centre	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); UK Biobank; UK Young Lacunar Stroke DNA Study 2 (DNA Lacunar 2); British Heart Foundation Programme Grant; US National Institute of Neurological Disorders and Stroke, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); Stroke Association; Stroke Association Grant; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish government; county councils; Barts Charity; National Institute of Health Research (NIHR) Barts Biomedical Research Centre; FWO Flanders - NIHR Oxford Biomedical Research Centre; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London(General Electric); NIHR Senior Investigator award; Cambridge Universities NIHR Comprehensive Biomedical Research Centre	The UK Household Longitudinal Study is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The survey was done by NatCen and the genome-wide scan data were analysed and deposited by the Wellcome Trust Sanger Institute. Information on how to access the data can be found on the Understanding Society website https://www.understandingsociety.ac.uk/.This research made use of the UK Biobank Resource under application number 36509. Ethical approval for UK Biobank was received from the research ethics committee (REC reference 11/NW/0382). We are grateful to deCODE genetics for providing data for this analysis. We acknowledge the contribution of Giorgio Boncoraglio (Fondazione IRCCS Instituto Neurologico Carlo Besta, Milan, Italy). This work, including collection and genotyping of the UK Young Lacunar Stroke DNA Study 2 (DNA Lacunar 2), was supported by a British Heart Foundation Programme Grant (RG/16/4/32218). The NINDS Stroke Genetics Network study was funded by the US National Institute of Neurological Disorders and Stroke, National Institutes of Health (U01 NS069208 and R01 NS100178). Collection of the UK Young Lacunar Stroke DNA Study 1 (DNA Lacunar) was primarily supported by the Wellcome Trust (WT072952), with additional support from the Stroke Association (TSA 2010/01). Genotyping of the DNA Lacunar samples was supported by a Stroke Association Grant (TSA 2013/01). The principal funding for the WTCCC2 stroke study was provided by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z and WT084724MA). Collection and genotyping of the Sahlgrenska Academy Study on Ischemic Stroke were primarily supported by the Swedish Research Council (grant #2018-02543), the Swedish Heart and Lung Foundation (20190203), and the Swedish state under the agreement between the Swedish government and the county councils (the ALF agreement, ALFGBG-720081). The genetic data from Geisinger was made available through the collaboration with Regeneron Genetic Centre. The Edinburgh Mild Stroke Study (MSS2) was funded by the Wellcome Trust (WT088134/Z/09/A). MT was supported by The Barts Charity and the National Institute of Health Research (NIHR) Barts Biomedical Research Centre. RL is a senior clinical investigator of FWO Flanders. PMR and the Oxford Vascular Study are funded by the NIHR Oxford Biomedical Research Centre and the Wellcome Trust. CDA is supported by the US National Institutes of Health (R01NS103924 and K23NS086873). CML is supported by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. HSM is supported by an NIHR Senior Investigator award, and his work is supported by the Cambridge Universities NIHR Comprehensive Biomedical Research Centre.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111; Bellenguez C, 2012, NAT GENET, V44, P328, DOI 10.1038/ng.1081; Bevan S, 2012, STROKE, V43, P3161, DOI 10.1161/STROKEAHA.112.665760; Bin BH, 2014, EMBO MOL MED, V6, P1028, DOI 10.15252/emmm.201303809; Bonder MJ, 2017, NAT GENET, V49, P131, DOI 10.1038/ng.3721; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Chauhan G, 2016, LANCET NEUROL, V15, P695, DOI [10.1016/s1474-4422(16)00102-2, 10.1016/S1474-4422(16)00102-2]; Chen L, 2016, CELL, V167, P1398, DOI 10.1016/j.cell.2016.10.026; Chung J, 2019, BRAIN, V142, P3176, DOI 10.1093/brain/awz233; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405; Fromer M, 2016, NAT NEUROSCI, V19, P1442, DOI 10.1038/nn.4399; Gaunt TR, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0926-z; Georgakis MK, 2020, BRAIN, V143, P597, DOI 10.1093/brain/awz413; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Guo DC, 2016, AM J HUM GENET, V99, P762, DOI 10.1016/j.ajhg.2016.06.034; Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506; Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560; Haycock PC, 2016, AM J CLIN NUTR, V103, P965, DOI 10.3945/ajcn.115.118216; Hindy G, 2018, STROKE, V49, P820, DOI 10.1161/STROKEAHA.117.019653; Hirose T, 2019, CELL TISSUE RES, V376, P137, DOI 10.1007/s00441-018-2977-9; Hoffmann TJ, 2017, NAT GENET, V49, P54, DOI 10.1038/ng.3715; Jerrard-Dunne P, 2003, STROKE, V34, P1364, DOI 10.1161/01.STR.0000069723.17984.FD; Joutel A, 2016, J CEREBR BLOOD F MET, V36, P143, DOI 10.1038/jcbfm.2015.62; Kamat MA, 2019, BIOINFORMATICS, V35, P4851, DOI 10.1093/bioinformatics/btz469; Kilarski LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136352; Lee SH, 2012, NAT GENET, V44, P247, DOI 10.1038/ng.1108; Liu MZ, 2019, NAT GENET, V51, P237, DOI 10.1038/s41588-018-0307-5; Liu M, 2018, GLIA, V66, P175, DOI 10.1002/glia.23236; Liu Min, 2017, Neurogenesis (Austin), V4, pe1313646, DOI 10.1080/23262133.2017.1313646; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Malik R, 2018, ANN NEUROL, V84, P934, DOI 10.1002/ana.25369; Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588-018-0058-3; Markus HS, 2007, CIRCULATION, V116, P2157, DOI 10.1161/CIRCULATIONAHA.107.699785; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Mehta P, 2017, DEV DYNAM, V246, P275, DOI 10.1002/dvdy.24473; Menezes MJ, 2014, J NEUROSCI, V34, P15260, DOI 10.1523/JNEUROSCI.3678-13.2014; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396; Paavola KJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005347; Pantoni L, 2010, LANCET NEUROL, V9, P689, DOI 10.1016/S1474-4422(10)70104-6; Persyn E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15932-3; Pirinen M, 2012, NAT GENET, V44, P848, DOI 10.1038/ng.2346; Raitakari OT, 2008, INT J EPIDEMIOL, V37, P1220, DOI 10.1093/ije/dym225; Rajajee V, 2008, J NEUROIMAGING, V18, P66, DOI 10.1111/j.1552-6569.2007.00150.x; Rajani RM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam9507; Rannikme K, 2017, NEUROLOGY, V89, P1829, DOI 10.1212/WNL.0000000000004560; Rosand J, 2016, LANCET NEUROL, V15, P174, DOI 10.1016/S1474-4422(15)00338-5; Rutten-Jacobs LCA, 2017, STROKE, V48, P2405, DOI 10.1161/STROKEAHA.117.017813; Staley JR, 2016, BIOINFORMATICS, V32, P3207, DOI 10.1093/bioinformatics/btw373; Su SL, 2012, J ORTHOP RES, V30, P9, DOI 10.1002/jor.21494; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan R, 2017, CLIN SCI, V131, P515, DOI 10.1042/CS20160825; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Traylor M, 2017, ANN NEUROL, V81, P383, DOI 10.1002/ana.24840; Turchin MC, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008431; Turley P, 2018, NAT GENET, V50, P229, DOI 10.1038/s41588-017-0009-4; Verhaaren BFJ, 2015, CIRC-CARDIOVASC GENE, V8, P398, DOI 10.1161/CIRCGENETICS.114.000858; Wardlaw JM, 2019, LANCET NEUROL, V18, P684, DOI 10.1016/S1474-4422(19)30079-1; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Winkler TW, 2014, NAT PROTOC, V9, P1192, DOI 10.1038/nprot.2014.071; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wright DJ, 2017, NAT GENET, V49, P674, DOI 10.1038/ng.3821; Wu Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1216-0; Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Yao Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4413; Yavorska OO, 2017, INT J EPIDEMIOL, V46, P1734, DOI 10.1093/ije/dyx034; Yengo L, 2018, HUM MOL GENET, V27, P3641, DOI 10.1093/hmg/ddy271; Yoneshiro T, 2019, NATURE, V572, P614, DOI 10.1038/s41586-019-1503-x	76	33	32	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					351	361		10.1016/S1474-4422(21)00031-4	http://dx.doi.org/10.1016/S1474-4422(21)00031-4		APR 2021	11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33773637	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000717465200017
J	Gao, GY; Wu, X; Feng, JF; Hui, JY; Mao, Q; Lecky, F; Lingsma, H; Maas, AIR; Jiang, JY				Gao, Guoyi; Wu, Xiang; Feng, Junfeng; Hui, Jiyuan; Mao, Qing; Lecky, Fiona; Lingsma, Hester; Maas, Andrew I. R.; Jiang, Jiyao		China CENTER-TBI Registry Particip	Clinical characteristics and outcomes in patients with traumatic brain injury in China: a prospective, multicentre, longitudinal, observational study	LANCET NEUROLOGY			English	Article							HEAD TRAUMA; CENTER-TBI; EPIDEMIOLOGY; MANAGEMENT; CARE; TRIAL	Background Large-scale studies are required to better characterise traumatic brain injury (TBI) and to identify the most effective treatment approaches for TBI. However, evidence is scarce and mostly originates from high-income countries. We aimed to describe the existing care for patients with TBI and the outcomes in China. Methods The Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) China registry is a prospective, multicentre, longitudinal, observational study done in 56 neurosurgical centres across China. We collected data of patients who were admitted to hospital with a clinical diagnosis of TBI and an indication for CT. Patients who were discharged directly from the emergency room were excluded. The primary endpoint was survival on discharge. Prognostic analyses were applied to identify predictors of mortality. Variations in mortality were compared between centres and provinces within China. Mortality was compared with expected mortality, estimated using the CRASH basic model. This study was registered with ClinicalTrials.gov, NCT02210221. Findings From Dec 22, 2014, to Aug 1, 2017, 13 627 patients with TBI from 56 centres were enrolled in the registry. Data from 13 138 patients from 52 hospitals in 22 provinces of China were analysed. Most patients were male (9782 [74%]), with a median age of 48 years (IQR 33-61). The median Glasgow Coma Scale (GCS) score was 13 (IQR 9-15), and the leading cause of injury was road-traffic incident (6548 [50%]). Overall, 637 (5%) patients died, including 552 (20%) patients with severe TBI. Age, GCS score, injury severity score, pupillary light reflex, CT findings (compressed basal cistern and midline shift >= 5 mm), presence of hypoxia, systemic hypotension, altitude higher than >500 m, and GDP per capita were significantly associated with survival in all patients with TBI. Variation in mortality existed between centres and regions. The expected 14-day mortality was 1116 (13%), but 544 (7%) deaths within 14 days were observed (observed to expected ratio 0 center dot 49 [95% CI 0 center dot 45-0 center dot 53]). I nterpretation The results show differences in mortality between centres and regions across China, which indicates potential for identifying best practices through comparative effectiveness research. The risk factors identified in prognostic analyses might contribute to developing benchmarks for assessing quality of care. Funding None. Copyright (c) 2020 Elsevier Ltd. All rights reserved.	[Gao, Guoyi; Wu, Xiang; Feng, Junfeng; Hui, Jiyuan; Mao, Qing; Jiang, Jiyao] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China; [Gao, Guoyi; Wu, Xiang; Feng, Junfeng; Hui, Jiyuan; Mao, Qing; Jiang, Jiyao] Shanghai Inst Head Trauma, Shanghai, Peoples R China; [Lecky, Fiona] Univ Sheffield, Ctr Urgent & Emergency Care Res, Sch Hlth & Related Res, Hlth Serv Res Sect, Sheffield, S Yorkshire, England; [Lingsma, Hester] Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, Rotterdam, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Jiang, Jiyao] Southwest Med Univ, Dept Neurosurg, Affiliated Hosp, Luzhou, Peoples R China; [Jiang, Jiyao] Shenzhen Univ, Shenzhen Peoples Hosp 2, Dept Neurosurg, Affiliated Hosp 1, Shenzhen, Peoples R China	Shanghai Jiao Tong University; University of Sheffield; Erasmus University Rotterdam; Erasmus MC; University of Antwerp; University of Antwerp; Southwest Medical University; Shenzhen University	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			European Commission [602150]	European Commission(European CommissionEuropean Commission Joint Research Centre)	We are immensely grateful to our patients with TBI for helping us in our efforts to improve care and outcomes for patients with TBI. We would like to thank Biyun Qian and Li Xie from the Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China, for their critical contributions to data analysis. The coordinating centre (Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University) received support from the European Commission 7th Framework program (602150), in the context of CENTER-TBI.	Bales JW, 2019, NEUROCRIT CARE, V31, P11, DOI 10.1007/s12028-019-00712-9; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Dijkland SA, 2020, J NEUROSURG, V133, P1132, DOI 10.3171/2019.5.JNS19483; Gardner RC, 2018, J NEUROTRAUM, V35, P889, DOI 10.1089/neu.2017.5371; Gravesteijn BY, 2020, ANAESTHESIA, V75, P45, DOI 10.1111/anae.14838; Hawley C, 2017, EMERG MED J, V34, P509, DOI 10.1136/emermed-2016-206506; Huijben JA, 2020, INTENS CARE MED, V46, P995, DOI 10.1007/s00134-020-05965-z; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Jiang JY, 2019, LANCET NEUROL, V18, P286, DOI 10.1016/S1474-4422(18)30469-1; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Karibe H, 2017, NEUROL MED-CHIR, V57, P418, DOI 10.2176/nmc.st.2017-0058; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Ma JH, 2017, J TRAUMA SURG, V19, P411; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Timmons SD, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS1296; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803	30	33	35	5	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					670	677		10.1016/S1474-4422(20)30182-4	http://dx.doi.org/10.1016/S1474-4422(20)30182-4			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702336	Green Accepted			2022-12-18	WOS:000573228000012
J	Kolias, AG; Rubiano, AM; Figaji, A; Servadei, F; Hutchinson, PJ				Kolias, Angelos G.; Rubiano, Andres M.; Figaji, Anthony; Servadei, Franco; Hutchinson, Peter J.			Traumatic brain injury: global collaboration for a global challenge	LANCET NEUROLOGY			English	Letter									[Kolias, Angelos G.; Hutchinson, Peter J.] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Kolias, Angelos G.; Hutchinson, Peter J.] Univ Cambridge, Cambridge CB2 0QQ, England; [Kolias, Angelos G.; Rubiano, Andres M.; Figaji, Anthony; Hutchinson, Peter J.] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England; [Rubiano, Andres M.] El Bosque Univ, INUB MEDITECH Res Grp, Neurosci Inst, Bogota, Colombia; [Figaji, Anthony] Univ Cape Town, Div Neurosurg, Cape Town, South Africa; [Figaji, Anthony] Univ Cape Town, Neurosci Inst, Cape Town, South Africa; [Servadei, Franco] Humanitas Univ & Res Hosp, Dept Neurosurg, Milan, Italy	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; University of Cambridge; Universidad El Bosque; University of Cape Town; University of Cape Town; Humanitas University	Kolias, AG (corresponding author), Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England.; Kolias, AG (corresponding author), Univ Cambridge, Cambridge CB2 0QQ, England.; Kolias, AG (corresponding author), Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.	ak721@cam.ac.uk	RUBIANO, ANDRES M/K-6704-2012; Figaji, Anthony/ADH-9410-2022	RUBIANO, ANDRES M/0000-0001-8931-3254; Figaji, Anthony/0000-0002-3357-6490; Kolias, Angelos/0000-0003-3992-0587; Hutchinson, Peter/0000-0002-2796-1835	NIHR [16/137/105]; MRC [G0600986, G0502030, G1002277, G0601025, G9439390] Funding Source: UKRI	NIHR(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	FS reports personal fees from Takeda Pharmaceutical Company, grants and personal fees from Integra LifeSciences, and grants and personal fees from Finceramica SpA. All other authors declare no competing interests. The NIHR Global Health Research Group on Neurotrauma was commissioned by the NIHR using Official Development Assistance funding (project 16/137/105). The views expressed in this Correspondence letter are those of the authors and are not necessarily those of the UK National Health Service, National Institute for Health Research, or the Department of Health. We would like to thank the existing members of the NIHR Global Health Research Group on Neurotrauma: Bilal Abou El Ela Bourquin, Amos Adeleye, Alexander Alamri, Tedy Apriawan, Tom Bashford, Mike Bath, Indira Devi Bhagavatula, Dhananjaya I Bhat, Mita Brahmbhatt, Carol Brayne, Evelyn Brealey, Natalia Budohoska, Karol Budohoski, Rowan Burnstein, David Clark, P. John Clarkson, Sujit Gnanakumar, Barbara Gregson, Dylan Griswold, Deepak Gupta, Thinn Hlaing, Corrado Iaccarino, Alexis Joannides, Mathew Joseph, Ahsan Ali Khan, Tariq Khan, Tsegazeab Laeke, Paul May, David Menon, Phyu Phyu Nwe Myint, Mu Mu Naing, Kee B Park, James Piercy, Hamisi K. Shabani, Tamara Tajsic, Myat Thu, Abenezer Tirsit, Manjul Tripathi, Rikin Trivedi, Carole Turner, Chris Uff, Sara Venturini, Vicknes Waran, Mark Wilson, and Sein Win.	Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500; Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Kolias AG, 2018, CURR TRAUMA REP, V4, P326, DOI 10.1007/s40719-018-0147-x; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X	4	33	34	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2019	18	2					136	137		10.1016/S1474-4422(18)30494-0	http://dx.doi.org/10.1016/S1474-4422(18)30494-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HI0TY	30663604	Green Submitted, Bronze			2022-12-18	WOS:000456158200008
J	Liu, SY; Wile, DJ; Fu, JF; Valerio, J; Shahinfard, E; McCormick, S; Mabrouk, R; Vafai, N; McKenzie, J; Neilson, N; Perez-Soriano, A; Arena, JE; Cherkasova, M; Chan, P; Zhang, J; Zabetian, CP; Aasly, JO; Wszolek, ZK; McKeown, MJ; Adam, MJ; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ				Liu, Shu-Ying; Wile, Daryl J.; Fu, Jessie Fanglu; Valerio, Jason; Shahinfard, Elham; McCormick, Siobhan; Mabrouk, Rostom; Vafai, Nasim; McKenzie, Jess; Neilson, Nicole; Perez-Soriano, Alexandra; Arena, Julieta E.; Cherkasova, Mariya; Chan, Piu; Zhang, Jing; Zabetian, Cyrus P.; Aasly, Jan O.; Wszolek, Zbigniew K.; McKeown, Martin J.; Adam, Michael J.; Ruth, Thomas J.; Schulzer, Michael; Sossi, Vesna; Stoessl, A. Jon			The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study	LANCET NEUROLOGY			English	Article							G2019S; ACETYLCHOLINESTERASE; INFLAMMATION; DYSFUNCTION; PHENOTYPE; DEFICITS	Background Markers of neuroinflammation are increased in some patients with LRRK2 Parkinson's disease compared with individuals with idiopathic Parkinson's disease, suggesting possible differences in disease pathogenesis. Previous PET studies have suggested amplified dopamine turnover and preserved serotonergic innervation in LRRK2 mutation carriers. We postulated that patients with LRRK2 mutations might show abnormalities of central cholinergic activity, even before the diagnosis of Parkinson's disease. Methods Between June, 2009, and December, 2015, we recruited participants from four movement disorder clinics in Canada, Norway, and the USA. Patients with Parkinson's disease were diagnosed by movement disorder neurologists on the basis of the UK Parkinson's Disease Society Brain Bank criteria. LRRK2 carrier status was confirmed by bidirectional Sanger sequencing. We used the PET tracer N-C-11-methyl-piperidin-4-yl propionate to scan for acetylcholinesterase activity. The primary outcome measure was rate of acetylcholinesterase hydrolysis, calculated using the striatal input method. We compared acetylcholinesterase hydrolysis rates between groups using ANCOVA, with adjustment for age based on the results of linear regression analysis. Findings We recruited 14 patients with LRRK2 Parkinson's disease, 16 LRRK2 mutation carriers without Parkinson's disease, eight patients with idiopathic Parkinson's disease, and 11 healthy controls. We noted significant between-group differences in rates of acetylcholinesterase hydrolysis in cortical regions (average cortex p=0.009, default mode network-related regions p=0.006, limbic network-related regions p=0.020) and the thalamus (p=0.008). LRRK2 mutation carriers without Parkinson's disease had increased acetylcholinesterase hydrolysis rates compared with healthy controls in the cortex (average cortex, p=0.046). Patients with LRRK2 Parkinson's disease had significantly higher acetylcholinesterase activity in some cortical regions (average cortex p=0.043, default mode network-related regions p=0.021) and the thalamus (thalamus p=0.004) compared with individuals with idiopathic disease. Acetylcholinesterase hydrolysis rates in healthy controls were correlated inversely with age. Interpretation LRRK2 mutations are associated with significantly increased cholinergic activity in the brain in mutation carriers without Parkinson's disease compared with healthy controls and in LRRK2 mutation carriers with Parkinson's disease compared with individuals with idiopathic disease. Changes in cholinergic activity might represent early and sustained attempts to compensate for LRRK2-related dysfunction, or alteration of acetylcholinesterase in non-neuronal cells.	[Liu, Shu-Ying; Valerio, Jason; Shahinfard, Elham; McCormick, Siobhan; Vafai, Nasim; McKenzie, Jess; Neilson, Nicole; Perez-Soriano, Alexandra; Arena, Julieta E.; Cherkasova, Mariya; McKeown, Martin J.; Schulzer, Michael; Stoessl, A. Jon] Univ British Columbia, Pacific Parkinsons Res Ctr, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 2B5, Canada; [Liu, Shu-Ying; Valerio, Jason; Shahinfard, Elham; McCormick, Siobhan; Vafai, Nasim; McKenzie, Jess; Neilson, Nicole; Perez-Soriano, Alexandra; Arena, Julieta E.; Cherkasova, Mariya; McKeown, Martin J.; Schulzer, Michael; Stoessl, A. Jon] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Liu, Shu-Ying; Chan, Piu] Capital Med Univ, Xuanwu Hosp, Dept Neurobiol Neurol & Geriatr, Beijing, Peoples R China; [Fu, Jessie Fanglu; Mabrouk, Rostom; Sossi, Vesna] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada; [Wile, Daryl J.] Univ British Columbia, Okanagan Southern Med Program, Kelowna, BC, Canada; [Zhang, Jing] Univ Washington, Dept Pathol, Seattle, WA USA; [Zabetian, Cyrus P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; [Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA USA; [Aasly, Jan O.] Norwegian Univ Sci & Technol, Trondheim, Norway; [Wszolek, Zbigniew K.] Mayo Clin, Jacksonville, FL 32224 USA; [Adam, Michael J.] Univ British Columbia, Dept Chem, Vancouver, BC, Canada; [Ruth, Thomas J.] TRIUMF Tri Univ Meson Facil, Vancouver, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute; Capital Medical University; University of British Columbia; University of British Columbia; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; Norwegian University of Science & Technology (NTNU); Mayo Clinic; University of British Columbia	Stoessl, AJ (corresponding author), Univ British Columbia, Pacific Parkinsons Res Ctr, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 2B5, Canada.; Stoessl, AJ (corresponding author), Vancouver Coastal Hlth, Vancouver, BC, Canada.	jstoessl@mail.ubc.ca	Chan, Piu/I-4580-2016; Mabrouk, Rostom/M-1674-2019; Wszolek, Zbigniew K./AAB-1431-2019; Stoessl, A Jon/J-9661-2015; McKeown, Martin J./Z-1253-2018; Fu, Jessie Fang Lu/ABB-5990-2020	Chan, Piu/0000-0003-1346-881X; Stoessl, A Jon/0000-0002-9778-7246; McKeown, Martin J./0000-0002-4048-0817; Fu, Jessie Fang Lu/0000-0002-4970-7811; Shahinfard, Elham/0000-0002-3526-0086; Liu, Shu-Ying/0000-0001-5787-1163; Perez Soriano, Alexandra/0000-0003-1614-7528	Michael J Fox Foundation; National Institutes of Health; Pacific Alzheimer Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS072187, R01NS065070, P50NS062684, R01NS057567] Funding Source: NIH RePORTER	Michael J Fox Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pacific Alzheimer Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Michael J Fox Foundation, National Institutes of Health, and Pacific Alzheimer Research Foundation.	Adams Jr, 2005, BRAIN, V128, P2777, DOI 10.1093/brain/awh607; Alcalay RN, 2013, MOVEMENT DISORD, V28, P1966, DOI 10.1002/mds.25647; Bohnen NI, 2015, JAMA NEUROL, V72, P194, DOI 10.1001/jamaneurol.2014.2757; Bohnen NI, 2010, BRAIN, V133, P1747, DOI 10.1093/brain/awq079; Bond CE, 2006, EUR J NEUROSCI, V24, P381, DOI 10.1111/j.1460-9568.2006.04898.x; Calabresi P, 2017, LANCET NEUROL, V16, P9, DOI 10.1016/S1474-4422(16)30345-3; Dzamko N, 2016, MOVEMENT DISORD, V31, P889, DOI 10.1002/mds.26529; Healy DG, 2008, LANCET NEUROL, V7, P583, DOI 10.1016/S1474-4422(08)70117-0; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jorgensen NP, 2017, EUR J NUCL MED MOL I, V44, P449, DOI 10.1007/s00259-016-3555-6; Kalia LV, 2015, JAMA NEUROL, V72, P100, DOI 10.1001/jamaneurol.2014.2704; Kotagal V, 2012, ANN NEUROL, V71, P560, DOI 10.1002/ana.22691; Marras C, 2016, MOVEMENT DISORD, V31, P1192, DOI 10.1002/mds.26614; Mirelman A, 2013, MOVEMENT DISORD, V28, P1683, DOI 10.1002/mds.25587; Morgane PJ, 2005, PROG NEUROBIOL, V75, P143, DOI 10.1016/j.pneurobio.2005.01.001; Muller MLTM, 2015, MOVEMENT DISORD, V30, P269, DOI 10.1002/mds.26061; Nagatsuka S, 2001, J CEREBR BLOOD F MET, V21, P1354, DOI 10.1097/00004647-200111000-00011; Nandhagopal R, 2008, NEUROLOGY, V71, P1790, DOI 10.1212/01.wnl.0000335973.66333.58; Ozelius LJ, 2006, NEW ENGL J MED, V354, P424, DOI 10.1056/NEJMc055509; Poulopoulos M, 2012, MOVEMENT DISORD, V27, P831, DOI 10.1002/mds.24962; Schapansky J, 2015, NEUROSCIENCE, V302, P74, DOI 10.1016/j.neuroscience.2014.09.049; Sierra M, 2013, NEUROLOGY, V80, P621, DOI 10.1212/WNL.0b013e31828250d6; Sossi V, 2010, MOVEMENT DISORD, V25, P2717, DOI 10.1002/mds.23356; Srivatsal S, 2015, MOVEMENT DISORD, V30, P728, DOI 10.1002/mds.26161; Thaler A, 2013, CORTEX, V49, P2501, DOI 10.1016/j.cortex.2012.12.017; Thullbery MD, 2005, J CELL BIOCHEM, V96, P599, DOI 10.1002/jcb.20530; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wile DJ, 2017, LANCET NEUROL, V16, P351, DOI 10.1016/S1474-4422(17)30056-X; Wile DJ, 2016, MOVEMENT DISORD, V31, P405, DOI 10.1002/mds.26450	30	33	33	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2018	17	4					309	316		10.1016/S1474-4422(18)30032-2	http://dx.doi.org/10.1016/S1474-4422(18)30032-2			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ3AO	29456161	Green Accepted			2022-12-18	WOS:000427458000014
J	Veatch, OJ; Keenan, BR; Gehrman, PR; Malow, BA; Pack, AI				Veatch, Olivia J.; Keenan, Brendan R.; Gehrman, Philip R.; Malow, Beth A.; Pack, Allan I.			Pleiotropic genetic effects influencing sleep and neurological disorders	LANCET NEUROLOGY			English	Review							RESTLESS-LEGS-SYNDROME; GENOME-WIDE ASSOCIATION; AUTISM SPECTRUM DISORDER; OXIDE-SYNTHASE NNOS; PER3 POLYMORPHISM; COMMON VARIANTS; SEGREGATION ANALYSIS; ADENOSINE-DEAMINASE; DQB1 LOCUS; NARCOLEPSY	Research evidence increasingly points to the large impact of sleep disturbances on public health. Many aspects of sleep are heritable and genes influencing traits such as timing, EEG characteristics, sleep duration, and response to sleep loss have been identified. Notably, large-scale genome-wide analyses have implicated numerous genes with small effects on sleep timing. Additionally, there has been considerable progress in the identification of genes influencing risk for some neurological sleep disorders. For restless legs syndrome, implicated variants are typically in genes associated with neuronal development. By contrast, genes conferring risk for narcolepsy function in the immune system. Many genetic variants associated with sleep disorders are also implicated in neurological disorders in which sleep abnormalities are common; for example, variation in genes involved in synaptic homoeostasis are implicated in autism spectrum disorder and sleep wake control. Further investigation into pleiotropic roles of genes influencing both sleep and neurological disorders could lead to new treatment strategies for a variety of sleep disturbances.	[Veatch, Olivia J.; Malow, Beth A.] Vanderbilt Univ, Dept Neurol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Veatch, Olivia J.; Keenan, Brendan R.; Gehrman, Philip R.; Pack, Allan I.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gehrman, Philip R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Pack, Allan I.] Univ Penn, Dept Med, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19104 USA	Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Veatch, OJ (corresponding author), Univ Penn, Ctr Sleep & Circadian Neurobiol, Perelman Sch Med, Philadelphia, PA 19104 USA.	veatcho@upenn.edu	Veatch, Olivia/ABE-7458-2021	Veatch, Olivia/0000-0002-5509-7749; Pack, Allan/0000-0002-2879-0484	National Institutes of Health [P01 AG17628, T32 HL07713]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017628] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors are supported by National Institutes of Health grants P01 AG17628 and T32 HL07713.	Allebrandt KV, 2013, MOL PSYCHIATR, V18, P122, DOI 10.1038/mp.2011.142; Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Amin N, 2016, EUR J HUM GENET, V24, P1488, DOI 10.1038/ejhg.2016.31; Archer SN, 2015, J SLEEP RES, V24, P476, DOI 10.1111/jsr.12307; Assefa SZ, 2015, AIMS NEUROSCI, V2, P155, DOI 10.3934/Neuroscience.2015.3.155; Bachmann V, 2012, CEREB CORTEX, V22, P962, DOI 10.1093/cercor/bhr173; Bachmann V, 2012, SLEEP, V35, P335, DOI 10.5665/sleep.1690; Ban HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018455; Beaulieu-Bonneau S, 2007, SLEEP, V30, P1739, DOI 10.1093/sleep/30.12.1739; Becchetti A, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00022; Bourgeron T, 2015, NAT REV NEUROSCI, V16, P551, DOI 10.1038/nrn3992; Bras J, 2015, CELL, V160, P570, DOI 10.1016/j.cell.2015.01.019; Byrne EM, 2013, AM J MED GENET B, V162B, P439, DOI 10.1002/ajmg.b.32168; Cade BE, 2016, HUM MOL GENET, V25, P167, DOI 10.1093/hmg/ddv434; Carpen JD, 2005, J SLEEP RES, V14, P293, DOI 10.1111/j.1365-2869.2005.00471.x; Carskadon M. A., 2016, PRINCIPLES PRACTICE, P15, DOI DOI 10.1016/B978-0-323-24288-2.00002-7; Chang AM, 2016, CHRONOBIOL INT, V33, P561, DOI 10.3109/07420528.2016.1167078; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Cortes A, 2015, MED RES REV, V35, P85, DOI 10.1002/med.21324; Cotten H. R., 2006, SLEEP DISORDERS SLEE; Dallaspezia S, 2016, J AFFECT DISORDERS, V192, P64, DOI 10.1016/j.jad.2015.11.039; Dauviltiers Y, 2005, SLEEP MED REV, V9, P91, DOI 10.1016/j.smrv.2004.06.001; Dement, 2017, PRINCIPLES PRACTICE, P627, DOI 10.1016/B978-0-323-24288-2.00062-3; Denis D, 2015, J SLEEP RES, V24, P438, DOI 10.1111/jsr.12282; Dijk DJ, 2010, SLEEP MED REV, V14, P151, DOI 10.1016/j.smrv.2009.07.002; Faraco J, 2011, SLEEP MED CLIN, V6, P217, DOI 10.1016/j.jsmc.2011.03.001; Faraco J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003270; Finan PH, 2013, SLEEP MED REV, V17, P173, DOI 10.1016/j.smrv.2012.03.003; Forero DA, 2016, SCHIZOPHR RES, V172, P68, DOI 10.1016/j.schres.2016.02.012; Frank MG, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/394946; Franken P, 2001, J NEUROSCI, V21, P2610, DOI 10.1523/JNEUROSCI.21-08-02610.2001; Freeman A, 2012, CURR BIOL, V22, P1142, DOI 10.1016/j.cub.2012.04.027; Gan-Or Z, 2015, SLEEP MED, V16, P1151, DOI 10.1016/j.sleep.2015.06.002; Gehrman PR, 2015, PSYCHIAT CLIN N AM, V38, P667, DOI 10.1016/j.psc.2015.07.004; Goel N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005874; Gottlieb DJ, 2015, MOL PSYCHIATR, V20, P1232, DOI 10.1038/mp.2014.133; Gottlieb DJ, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S9; Guindalini C, 2014, J NEUROSCI RES, V92, P1018, DOI 10.1002/jnr.23380; Gurney ME, PHOSPHODIESTERASE 4; Hallmayer J, 2009, NAT GENET, V41, P708, DOI 10.1038/ng.372; He Y, 2009, SCIENCE, V325, P866, DOI 10.1126/science.1174443; HEATH AC, 1990, SLEEP, V13, P318, DOI 10.1093/sleep/13.4.318; Heidbreder A, 2016, J CLIN SLEEP MED, V12, P565, DOI 10.5664/jcsm.5692; Hendricks JC, 2000, NEURON, V25, P129, DOI 10.1016/S0896-6273(00)80877-6; Hengen KB, 2016, CELL, V165, P180, DOI 10.1016/j.cell.2016.01.046; Holm A, 2015, EUR J HUM GENET, V23, P1573, DOI 10.1038/ejhg.2015.4; Hor H, 2011, AM J HUM GENET, V89, P474, DOI 10.1016/j.ajhg.2011.08.007; Hor H, 2010, NAT GENET, V42, P786, DOI 10.1038/ng.647; Hu YN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10448; Hublin C, 2003, SLEEP MED REV, V7, P413, DOI 10.1053/smrv.2001.0247; Jimenez-Jimenez FJ, 2015, J NEURAL TRANSM, V122, P819, DOI 10.1007/s00702-014-1322-z; Jockers R, 2016, BRIT J PHARMACOL, V173, P2702, DOI 10.1111/bph.13536; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Kalinchuk AV, 2006, EUR J NEUROSCI, V24, P1443, DOI 10.1111/j.1460-9568.2006.05019.x; Ko PRT, 2015, J CLIN SLEEP MED, V11, P1455, DOI 10.5664/jcsm.5288; Kornum BR, 2011, NAT GENET, V43, P66, DOI 10.1038/ng.734; Kronholm E, 2006, J SLEEP RES, V15, P276, DOI 10.1111/j.1365-2869.2006.00543.x; Lane JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10889; Liu R, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-1; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Luyster FS, 2012, SLEEP, V35, P727, DOI 10.5665/sleep.1846; Mackiewicz M, 2008, PHYSIOL GENOMICS, V33, P91, DOI 10.1152/physiolgenomics.00189.2007; Maire M, 2014, CORTEX, V52, P47, DOI 10.1016/j.cortex.2013.11.008; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; Mathias RA, 2006, HUM HERED, V62, P157, DOI 10.1159/000096443; Mazzotti DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044154; MCCARREN M, 1994, SLEEP, V17, P456, DOI 10.1093/sleep/17.5.456; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Mukherjee S, 2015, AM J RESP CRIT CARE, V191, P1450, DOI 10.1164/rccm.201504-0767ST; Myers CT, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0214-7; Naidoo N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035174; Oexie K, 2013, EUR J HUM GENET, V21, P410; Ollila HM, 2015, SLEEP, V38, P147, DOI 10.5665/sleep.4342; Ollila HM, 2014, J SLEEP RES, V23, P609, DOI 10.1111/jsr.12175; Overeem S, 2001, J CLIN NEUROPHYSIOL, V18, P78, DOI 10.1097/00004691-200103000-00002; Parsons MJ, 2013, AM J MED GENET B, V162B, P431, DOI 10.1002/ajmg.b.32106; Partch CL, 2014, TRENDS CELL BIOL, V24, P90, DOI 10.1016/j.tcb.2013.07.002; Pellegrino R, 2014, SLEEP, V37, P1327, DOI 10.5665/sleep.3924; Raizen DM, 2008, NATURE, V451, P569, DOI 10.1038/nature06535; Retey JV, 2005, P NATL ACAD SCI USA, V102, P15676, DOI 10.1073/pnas.0505414102; Sanders SJ, 2015, NEURON, V87, P1215, DOI 10.1016/j.neuron.2015.09.016; Saura CA, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00318; Scheinfeldt LB, 2015, AM J MED GENET B, V168, P697, DOI 10.1002/ajmg.b.32362; Schormair B, 2008, NAT GENET, V40, P946, DOI 10.1038/ng.190; Schulte EC, 2014, AM J HUM GENET, V95, P85, DOI 10.1016/j.ajhg.2014.06.005; Sehgal A, 2011, CELL, V146, P194, DOI 10.1016/j.cell.2011.07.004; Sorensen E, 2016, TRANSFUSION, V56, P622, DOI 10.1111/trf.13397; Spada J, 2016, J SLEEP RES, V25, P690, DOI 10.1111/jsr.12421; Stefansson H, 2007, NEW ENGL J MED, V357, P639, DOI 10.1056/NEJMoa072743; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Tafti M, 2016, SLEEP, V39, P581, DOI 10.5665/sleep.5532; Tafti M, 2015, SLEEP, V38, P153, DOI 10.5665/sleep.4344; Tafti M, 2014, SLEEP, V37, P19, DOI 10.5665/sleep.3300; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Thomas MSC, 2016, DEVELOPMENTAL SCI, V19, P284, DOI 10.1111/desc.12303; Tononi G, 2014, NEURON, V81, P12, DOI 10.1016/j.neuron.2013.12.025; Toth LA, 2013, COMPARATIVE MED, V63, P91; Toyoda H, 2015, BRAIN BEHAV IMMUN, V49, P148, DOI 10.1016/j.bbi.2015.05.003; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Veatch Olivia J, 2015, Curr Sleep Med Rep, V1, P131; Viola AU, 2007, CURR BIOL, V17, P613, DOI 10.1016/j.cub.2007.01.073; Viola AU, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.024; Watson NF, 2015, SLEEP, V38, P843, DOI 10.5665/sleep.4716; Weissbach A, 2012, MOVEMENT DISORD, V27, P1686, DOI 10.1002/mds.25191; Winkelmann J, 2002, ANN NEUROL, V52, P297, DOI 10.1002/ana.10282; Winkelmann J, 2008, MOVEMENT DISORD, V23, P350, DOI 10.1002/mds.21647; Winkelmann J, 2007, NAT GENET, V39, P1000, DOI 10.1038/ng2099; Winkelmann J, 2012, HUM MOL GENET, V21, P2205, DOI 10.1093/hmg/dds035; Wulff K, 2010, NAT REV NEUROSCI, V11, P589, DOI 10.1038/nrn2868; Yamasaki M, 2016, J HUM GENET, V61, P873, DOI 10.1038/jhg.2016.65; Yamasaki M, 2014, J HUM GENET, V59, P235, DOI 10.1038/jhg.2014.13; Yang QB, 2011, MOVEMENT DISORD, V26, P516, DOI 10.1002/mds.23459; Zhdanova IV, 2011, REV NEUROSCIENCE, V22, P27, DOI 10.1515/RNS.2011.005	114	33	33	1	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2017	16	2					158	170		10.1016/S1474-4422(16)30339-8	http://dx.doi.org/10.1016/S1474-4422(16)30339-8			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EH6VA	28102151	Green Accepted			2022-12-18	WOS:000391910800014
J	[Anonymous]				[Anonymous]			Solanezumab: too late in mild Alzheimer's disease?	LANCET NEUROLOGY			English	Editorial Material																			0	33	35	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2017	16	2					97	97		10.1016/S1474-4422(16)30395-7	http://dx.doi.org/10.1016/S1474-4422(16)30395-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EH6VA	28102152	Bronze			2022-12-18	WOS:000391910800001
J	Rademakers, R				Rademakers, Rosa			C9orf72 repeat expansions in patients with ALS and FTD	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL DEMENTIA; HEXANUCLEOTIDE REPEAT; DISEASE; LOCUS		Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic	Rademakers, R (corresponding author), Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.	rademakers.rosa@mayo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026251, P50AG016574, R56AG026251] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG016574, R01 AG026251, R56 AG026251] Funding Source: Medline; NINDS NIH HHS [R01 NS065782] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Byrne S, 2012, LANCET NEUROL, V11, P232, DOI 10.1016/S1474-4422(12)70014-5; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Majounie E, 2012, LANCET NEUROL, V11, P323, DOI 10.1016/S1474-4422(12)70043-1; Majounie E, 2012, NEW ENGL J MED, V366, P283, DOI 10.1056/NEJMc1113592; Mok K, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.08.005; Morita M, 2006, NEUROLOGY, V66, P839, DOI 10.1212/01.wnl.0000200048.53766.b4; Murray ME, 2011, ACTA NEUROPATHOL, V122, P673, DOI 10.1007/s00401-011-0907-y; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Talbot K, 2006, HUM MOL GENET, V15, pR182, DOI 10.1093/hmg/ddl202; Vance C, 2006, BRAIN, V129, P868, DOI 10.1093/brain/awl030	10	33	34	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2012	11	4					297	298		10.1016/S1474-4422(12)70046-7	http://dx.doi.org/10.1016/S1474-4422(12)70046-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	915CD	22406229	Green Accepted			2022-12-18	WOS:000301999600004
J	Bachoud-Levi, AC				Bachoud-Levi, Anne-Catherine			Neural grafts in Huntington's disease: viability after 10 years	LANCET NEUROLOGY			English	Editorial Material							FETAL STRIATAL TRANSPLANTATION; POSITRON-EMISSION-TOMOGRAPHY; DOPAMINE NEURONS		CHU Henri Mondor, Ctr Reference Malad Huntington, Serv Neurol, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Bachoud-Levi, AC (corresponding author), CHU Henri Mondor, Ctr Reference Malad Huntington, Serv Neurol, F-94010 Creteil, France.	bachoud@gmail.com	Bachoud-Lévi, Anne-Catherine/GYU-8680-2022	Bachoud-Lévi, Anne-Catherine/0000-0003-3000-2210				Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Cicchetti F, 2009, P NATL ACAD SCI USA, V106, P12483, DOI 10.1073/pnas.0904239106; Dunnett SB, 2007, BRAIN RES BULL, V72, P132, DOI 10.1016/j.brainresbull.2006.10.019; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Furtado S, 2005, ANN NEUROL, V58, P331, DOI 10.1002/ana.20564; Hauser RA, 2002, NEUROLOGY, V58, P687, DOI 10.1212/WNL.58.5.687; Krystkowiak P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000166; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Mendez I, 2008, NAT MED, V14, P507, DOI 10.1038/nm1752; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; PESCHANSKI M, 1995, NEUROSCIENCE, V68, P273, DOI 10.1016/0306-4522(95)00162-C; Reuter I, 2008, J NEUROL NEUROSUR PS, V79, P948, DOI 10.1136/jnnp.2007.142380	12	33	37	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					979	981		10.1016/S1474-4422(09)70278-9	http://dx.doi.org/10.1016/S1474-4422(09)70278-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC	19833293				2022-12-18	WOS:000271309600007
J	Romanelli, P; Anschel, DJ				Romanelli, Pantaleo; Anschel, David J.			Radiosurgery for epilepsy	LANCET NEUROLOGY			English	Review							CEREBRAL ARTERIOVENOUS-MALFORMATIONS; TEMPORAL-LOBE EPILEPSY; GAMMA-KNIFE SURGERY; LINEAR-ACCELERATOR RADIOSURGERY; PROTON-BEAM THERAPY; STEREOTACTIC RADIOSURGERY; BRAGG-PEAK; HYPOTHALAMIC HAMARTOMAS; CAVERNOUS MALFORMATIONS; RAT HIPPOCAMPUS	Radiosurgery is an emerging therapeutic approach for the treatment of medically intractable epileptogenic foci. A favourable seizure outcome was first reported in studies of the effects of radiosurgery in the treatment of arteriovenous malformations and tumours. Radiosurgery has since been applied to the treatment of complex partial seizures with mesial-temporal-lobe onset. Nearly simultaneously, experimental evidence supporting the usefulness of radiosurgery to improve or abolish seizures has confirmed that stereotactic irradiation can preferentially affect epileptogenic versus normal cortex. Further work is clearly needed, but this technique might become an important approach in the management of mesial-temporal and extratemporal epilepsy, especially if refractory seizures arise from eloquent cortex or surgically challenging regions of brain.	Neuromed IRCCS, Dept Neurosurg, Pozzilli, IS, Italy; SUNY, Dept Neurol, Long Isl Comprehens Epilepsy Ctr, New York, NY USA	IRCCS Neuromed; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry	Romanelli, P (corresponding author), Neuromed IRCCS, Dept Neurosurg, Via Atinense 18, Pozzilli, IS, Italy.	leoromanelli@neuromed.it						Amin-Hanjani S, 1998, NEUROSURGERY, V42, P1229, DOI 10.1097/00006123-199806000-00013; BARCIA JA, 1994, STEREOT FUNCT NEUROS, V63, P271, DOI 10.1159/000100331; BETTI OO, 1989, NEUROSURGERY, V24, P311, DOI 10.1227/00006123-198903000-00001; Brisman JL, 2003, NEUROSURGERY, V53, P951, DOI 10.1227/01.NEU.0000083629.92550.A5; Chen ZF, 2001, J NEUROSURG, V94, P270, DOI 10.3171/jns.2001.94.2.0270; Cmelak AJ, 2001, SEIZURE-EUR J EPILEP, V10, P442, DOI 10.1016/S1059-1311(01)90519-9; COFFEY RJ, 1995, MAYO CLIN PROC, V70, P214, DOI 10.4065/70.3.214; COLOMBO F, 1989, NEUROSURGERY, V24, P833, DOI 10.1227/00006123-198906000-00008; Dunoyer C, 2002, EPILEPSIA, V43, P292, DOI 10.1046/j.1528-1157.2002.06501.x; Eisenschenk S, 1998, STEREOT FUNCT NEUROS, V71, P51, DOI 10.1159/000029648; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; GAFFEY CT, 1981, INT J APPL RADIAT IS, V32, P779, DOI 10.1016/0020-708X(81)90153-8; Ganz JC, 2002, J NEUROSURG, V97, P644, DOI 10.3171/jns.2002.97.supplement_5.0644; Hadjipanayis CG, 2001, NEUROSURGERY, V48, P70, DOI 10.1097/00006123-200101000-00013; HEIKKINEN ER, 1989, STEREOT FUNCT NEUROS, V53, P157, DOI 10.1159/000099532; Hoh BL, 2000, NEUROSURGERY, V47, P346, DOI 10.1097/00006123-200008000-00015; Jenrow KA, 2004, NEUROSCI LETT, V371, P45, DOI 10.1016/j.neulet.2004.08.036; Kawai K, 2001, J NEUROSURG, V95, P883, DOI 10.3171/jns.2001.95.5.0883; Kida Y, 2000, J CLIN NEUROSCI, V7, P6, DOI 10.1054/jocn.2000.0701; Kim MS, 2005, J NEUROSURG, V102, P102, DOI 10.3171/jns.2005.102.s_supplement.0102; KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503; Kurita H, 1998, J NEUROL NEUROSUR PS, V65, P648, DOI 10.1136/jnnp.65.5.648; Laws ER, 2004, J NEURO-ONCOL, V69, P257, DOI 10.1023/B:NEON.0000041887.51906.b7; LEVY RP, 1989, NEUROSURGERY, V24, P841, DOI 10.1227/00006123-198906000-00009; Liscak R, 2002, J NEUROSURG, V97, P666, DOI 10.3171/jns.2002.97.supplement_5.0666; LISKAC R, 2005, J NEUROSURG S1, V102, P207; Liu KD, 2005, J NEUROSURG, V102, P81, DOI 10.3171/jns.2005.102.s_supplement.0081; Loeffler JS, 2003, NEUROSURGERY, V52, P1436, DOI 10.1227/01.NEU.0000064809.59806.E8; LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512; Maesawa S, 2000, J NEUROSURG, V93, P1033, DOI 10.3171/jns.2000.93.6.1033; Mori Y, 2000, NEUROSURGERY, V46, P157, DOI 10.1093/neurosurgery/46.1.157; POLLOCK BE, 1994, NEUROSURGERY, V35, P1, DOI 10.1227/00006123-199407000-00001; Regis J, 1996, STEREOT FUNCT NEUROS, V66, P29, DOI 10.1159/000099698; Regis J, 2004, ACT NEUR S, V91, P33; Regis J, 2004, EPILEPSIA, V45, P504, DOI 10.1111/j.0013-9580.2004.07903.x; REGIS J, 1995, STEREOT FUNCT NEUROS, V64, P193; Regis J, 2002, ACT NEUR S, V84, P37; Regis J, 2000, NEUROSURGERY, V47, P1091, DOI 10.1097/00006123-200011000-00013; Regis J, 2000, NEUROSURGERY, V47, P1343, DOI 10.1097/00006123-200012000-00014; Regis J, 1999, AM J NEURORADIOL, V20, P213; ROGERS LR, 1993, NEUROLOGY, V43, P1599, DOI 10.1212/WNL.43.8.1599; ROSSI GF, 1985, APPL NEUROPHYSIOL, V48, P127; Schauble B, 2004, NEUROLOGY, V63, P683, DOI 10.1212/01.WNL.0000134659.95217.6E; Schrottner O, 2002, ACT NEUR S, V84, P49; Schrottner O, 1998, STEREOT FUNCT NEUROS, V70, P50, DOI 10.1159/000056406; Schulze-Bonhage A, 2004, NEUROLOGY, V62, P644, DOI 10.1212/01.WNL.0000110194.77056.65; SEIFERT V, 1994, J NEUROSURG, V81, P683, DOI 10.3171/jns.1994.81.5.0683; Selch MT, 2005, MINIM INVAS NEUROSUR, V48, P310, DOI 10.1055/s-2005-915598; Shih YH, 2005, CLIN NEUROL NEUROSUR, V107, P108, DOI 10.1016/j.clineuro.2004.06.004; Srikijvilaikul T, 2004, NEUROSURGERY, V54, P1395, DOI 10.1227/01.NEU.0000124604.29767.EB; STEINBERG GK, 1990, NEW ENGL J MED, V323, P96, DOI 10.1056/NEJM199007123230205; STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001; SUTCLIFFE JC, 1992, BRIT J NEUROSURG, V6, P177, DOI 10.3109/02688699209002925; Unger F, 2002, ACT NEUR S, V84, P57; Whang CJ, 1996, STEREOT FUNCT NEUROS, V66, P349, DOI 10.1159/000099735; YAMAMOTO Y, 1995, J NEUROSURG, V83, P832, DOI 10.3171/jns.1995.83.5.0832	56	33	37	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2006	5	7					613	620		10.1016/S1474-4422(06)70496-3	http://dx.doi.org/10.1016/S1474-4422(06)70496-3			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	058PE	16781991				2022-12-18	WOS:000238676100022
J	Asplund, K				Asplund, K			What MONICA told us about stroke	LANCET NEUROLOGY			English	Editorial Material							CARDIOVASCULAR RISK-FACTORS; CORONARY-HEART-DISEASE; CASE-FATALITY; EVENT RATES; SUBARACHNOID HEMORRHAGE; PROJECT POPULATIONS; MORTALITY; HEALTH; TRENDS; COMMUNITY	The WHO MONICA (Multinational Monitoring of Determinants and Trends in Cardiovascular Disease) Project is the world's largest prospective study on cardiovascular disorders. In the stroke component, 34 715 individually validated stroke events were recorded; these happened during 21 . 7 million years of observation in 14 populations in Europe, Siberia, and China. Two important questions were addressed. What is driving stroke mortality trends-changes in stroke incidence (risk of stroke) or changes in survival? To what extent do changes in the population burden of classic cardiovascular risk factors affect stroke risk in the population? The seven lessons that I learnt from the MONICA study are described; some were about the limitations of an ecological study for testing of hypotheses and evaluation of community-based intervention programmes. Socioeconomic factors seem more important than classic risk factors for the establishment of stroke trends in the population, best shown by the development of stroke mortality in eastern Europe during the 10 years of the WHO MONICA Project. The simplest, most important, and, for clinicians, the most encouraging of the lessons is that quality of stroke care makes a profound difference, not only to the patient and his or her family but also to the burden of stroke in the population at large.	Natl Board Hlth & Welf, Umea, Sweden; Univ Umea Hosp, Dept Med, S-90185 Umea, Sweden	National Board of Health & Welfare; Umea University	Asplund, K (corresponding author), Natl Board Hlth & Welf, SE-10630 Stockholm, Sweden.	kjell.asplund@sos.se						Armstrong Timothy, 2003, Ethn Dis, V13, pS13; Asplund K, 1996, CEREBROVASC DIS, V6, P66, DOI 10.1159/000108000; ASPLUND K, 1995, STROKE, V26, P355, DOI 10.1161/01.STR.26.3.355; ASPLUND K, 1988, ACTA MED SCAND, P26; Asplund K, 2003, STROKE, V34, P2628, DOI 10.1161/01.STR.0000101664.02943.69; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Boedhi-Darmojo R., 1993, World Health Statistics Quarterly, V46, P119; BOTHIG S, 1989, INT J EPIDEMIOL, V18, pS29; Evans A, 2003, TWIN RES, V6, P432, DOI 10.1375/twin.6.5.432; Eyre H, 2004, STROKE, V35, P1999, DOI 10.1161/01.STR.0000133321.00456.00; Fortmann SP, 2000, AM J EPIDEMIOL, V152, P316, DOI 10.1093/aje/152.4.316; Gillum RF, 1997, STROKE, V28, P1527, DOI 10.1161/01.STR.28.8.1527; Ingall T, 2000, STROKE, V31, P1054, DOI 10.1161/01.STR.31.5.1054; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; LINDEBERG S, 1993, J INTERN MED, V233, P269, DOI 10.1111/j.1365-2796.1993.tb00986.x; Luepker RV, 1996, AM J EPIDEMIOL, V144, P351, DOI 10.1093/oxfordjournals.aje.a008936; Manhem K, 2000, J CARDIOVASC RISK, V7, P359; Peltonen L, 2003, TWIN RES, V6, P354, DOI 10.1375/twin.6.5.354; Peltonen M, 1998, J INTERN MED, V244, P1, DOI 10.1046/j.1365-2796.1998.00289.x; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; Reddy KS, 2002, PUBLIC HEALTH NUTR, V5, P231, DOI 10.1079/PHN2001298; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Sarti C, 2003, STROKE, V34, P1833, DOI 10.1161/01.STR.0000081224.15480.52; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Tolonen H, 2002, STROKE, V33, P2367, DOI 10.1161/01.STR.0000033131.27936.7F; Tulchinsky TH, 1996, AM J PUBLIC HEALTH, V86, P313, DOI 10.2105/AJPH.86.3.313; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Tunstall-Pedoe H., 2003, MONICA MONOGRAPH MUL; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; World Health Organization, WHO STAT INF SYST; Wu ZS, 2004, EUR J CARDIOV PREV R, V11, P275, DOI 10.1097/01.hjr.0000136566.89429.63; Wu ZS, 2001, CIRCULATION, V103, P462	32	33	36	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					64	68		10.1016/S1474-4422(04)00967-6	http://dx.doi.org/10.1016/S1474-4422(04)00967-6			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620858				2022-12-18	WOS:000226250200022
J	Hoglinger, GU; Litvan, I; Mendonca, N; Wang, DL; Zheng, H; Rendenbach-Mueller, B; Lon, HK; Jin, ZY; Fisseha, N; Budur, K; Gold, M; Ryman, D; Florian, H				Hoeglinger, Guenter U.; Litvan, Irene; Mendonca, Nuno; Wang, Deli; Zheng, Hui; Rendenbach-Mueller, Beatrice; Lon, Hoi-Kei; Jin, Ziyi; Fisseha, Nahome; Budur, Kumar; Gold, Michael; Ryman, Davis; Florian, Hana		Arise Investigators	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial	LANCET NEUROLOGY			English	Article							ANTI-TAU ANTIBODIES; DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; MOUSE MODEL; PASSIVE-IMMUNIZATION; PATHOLOGY; TIDEGLUSIB; ACCURACY; SURVIVAL; PROTEIN	Background Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy. Methods We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged >= 40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. Randomisation was done by the randomisation specialist of the study sponsor, who did not otherwise participate in the study. The sponsor, investigators, and participants were unaware of treatment allocations. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score in the intention-to-treat population. Adverse events were monitored in participants who received at least one dose of study drug. Prespecified interim futility criteria were based on a model-based effect size of 0 or lower when 60 participants had completed the 52-week treatment period and 0.12 or lower when 120 participants had completed the 52-week treatment period. This study is registered at ClinicalTrials.gov, number NCT02985879. Findings Between Dec 12, 2016, and Dec 31, 2018, 466 participants were screened, 378 were randomised. The study was terminated on July 3, 2019, after prespecified futility criteria were met at the second interim analysis. A total of 377 participants received a t least one dose of study drug and were included in the efficacy and safety analyses (2000 mg, n=126; 4000 mg, n=125; placebo, n=126). Least squares mean change from baseline to week 52 in PSPRS was similar in all groups (between-group difference vs placebo: 2000 mg, 0.0 [95% CI -2.6 to 2.6], effect size 0.000, p>0.99; 4000 mg, 1.0 [-1.6 to 3.6], -0.105, p=0.46). Most participants reported at least one adverse event (2000 mg, 111 [88%]; 4000 mg, 111 [89%]; placebo, 108 [86%]). Fall was the most common adverse event (2000 mg, 42 [33%]; 4000 mg, 54 [43%]; placebo, 49 [39%]). Proportions of patients with serious adverse events were similar among groups (2000 mg, 29 [23%]; 4000 mg, 34 [27%]; placebo, 33 [26%]). Fall was the most common treatment-emergent serious adverse event (2000 mg, five [4%1; 4000 mg, six [5%]; placebo, six [5%]). 26 deaths occurred during the study (2000 mg, nine [7%]; 4000 mg, nine [7%]; placebo, eight [6%]) but none was drug related. Interpretation A similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Hoeglinger, Guenter U.] German Ctr Neurodegenerat Dis, Munich, Germany; [Hoeglinger, Guenter U.] Tech Univ Munich, Dept Neurol, Munich, Germany; [Hoeglinger, Guenter U.] Hannover Med Sch, Dept Neurol, D-30625 Hannover, Germany; [Litvan, Irene] Univ Calif San Diego, Parkinson & Other Movement Disorders Ctr, La Jolla, CA 92093 USA; [Mendonca, Nuno; Fisseha, Nahome; Budur, Kumar; Gold, Michael; Ryman, Davis; Florian, Hana] AbbVie Inc, Neurosci, N Chicago, IL USA; [Wang, Deli; Zheng, Hui; Jin, Ziyi] AbbVie Inc, Data & Stat Sci, N Chicago, IL USA; [Lon, Hoi-Kei] AbbVie Inc, Clin Pharmacol & Pharmacometr, N Chicago, IL USA; [Rendenbach-Mueller, Beatrice] AbbVie Deutschland GmbH & Co KG, Neurosci, Ludwigshafen, Germany	Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Technical University of Munich; Hannover Medical School; University of California System; University of California San Diego; AbbVie; AbbVie; AbbVie; AbbVie	Hoglinger, GU (corresponding author), Hannover Med Sch, Dept Neurol, D-30625 Hannover, Germany.	hoeglinger.guenter@mh-hannover.de	Eleopra, Roberto/N-9296-2015; Hoglinger, Gunter/F-2388-2015; Meissner, Wassilios/C-7817-2015; Hatano, Taku/S-9039-2016	Eleopra, Roberto/0000-0002-6035-9715; Gold, Michael/0000-0002-4410-1669; Hoglinger, Gunter/0000-0001-7587-6187; Duquette, Antoine/0000-0002-8313-4068; Meissner, Wassilios/0000-0003-2172-7527; Hatano, Taku/0000-0002-6808-0444	AbbVie Inc.	AbbVie Inc.(AbbVie)	AbbVie Inc.	[Anonymous], 2018, EUR J NEUROSCI, V48, P3477; [Anonymous], 1996, NEUROLOGY, V47, P1; [Anonymous], 2015, ANN CLIN TRANSL NEUR, V2, P278; Asuni AA, 2007, J NEUROSCI, V27, P9115, DOI 10.1523/JNEUROSCI.2361-07.2007; Barthelemy NR, 2016, J ALZHEIMERS DIS, V51, P1033, DOI 10.3233/JAD-150962; Bensimon G, 2009, BRAIN, V132, P156, DOI 10.1093/brain/awn291; Biogen, 2019, IN PRESS; Boutajangout A, 2011, J NEUROCHEM, V118, P658, DOI 10.1111/j.1471-4159.2011.07337.x; Boxer AL, 2019, LANCET NEUROL, V18, P549, DOI 10.1016/S1474-4422(19)30139-5; Boxer AL, 2017, LANCET NEUROL, V16, P552, DOI 10.1016/S1474-4422(17)30157-6; Boxer AL, 2014, LANCET NEUROL, V13, P676, DOI 10.1016/S1474-4422(14)70088-2; Calne, CLIN RES CRITERIA DI; Chai XY, 2011, J BIOL CHEM, V286, P34457, DOI 10.1074/jbc.M111.229633; Clark, PEDUNCULOPONTINE TEG; ClinicalTrials.gov, 2020, STUDY BIIB092 PARTIC; Congdon EE, 2019, EBIOMEDICINE, V42, P157, DOI 10.1016/j.ebiom.2019.03.033; Courade JP, 2018, ACTA NEUROPATHOL, V136, P729, DOI 10.1007/s00401-018-1911-2; Coyle-Gilchrist ITS, 2016, NEUROLOGY, V86, P1736, DOI 10.1212/WNL.0000000000002638; Gallardo G, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a024331; Golbe LI, 2007, BRAIN, V130, P1552, DOI 10.1093/brain/awm032; Golbe LI, 2014, SEMIN NEUROL, V34, P151, DOI 10.1055/s-0034-1381736; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P842, DOI 10.1002/mds.26973; Hoglinger GU, 2014, MOVEMENT DISORD, V29, P479, DOI 10.1002/mds.25815; Ising C, 2017, J EXP MED, V214, P1227, DOI 10.1084/jem.20162125; Levin J, 2016, DTSCH ARZTEBL INT, V113, P61, DOI 10.3238/arztebl.2016.0061; Ling H, 2016, J MOV DISORD, V9, P3, DOI 10.14802/jmd.15060; Lopez OL, 1999, NEUROLOGY, V53, P1292, DOI 10.1212/WNL.53.6.1292; Mahan, ANTITAU ANTIBODY RED; O'Sullivan SS, 2008, BRAIN, V131, P1362, DOI 10.1093/brain/awn065; Osaki Y, 2004, MOVEMENT DISORD, V19, P181, DOI 10.1002/mds.10680; Payan CAM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022293; Respondek G, 2014, MOVEMENT DISORD, V29, P1758, DOI 10.1002/mds.26054; Rosler TW, 2019, PROG NEUROBIOL, V180, DOI 10.1016/j.pneurobio.2019.101644; Rolland Y, 2011, J NEUROL NEUROSUR PS, V82, P1025, DOI 10.1136/jnnp.2010.214890; Shoeibi A, 2019, PARKINSONISM RELAT D, V66, P87, DOI 10.1016/j.parkreldis.2019.07.010; Sigurdsson EM, 2018, J ALZHEIMERS DIS, V64, pS555, DOI 10.3233/JAD-179937; SIGURDSSON EM, J ALZHEIMERS DIS; Stamelou M, 2016, MOVEMENT DISORD, V31, P742, DOI 10.1002/mds.26580; Takigawa H, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.557; Tolosa E, 2014, MOVEMENT DISORD, V29, P470, DOI 10.1002/mds.25824; West T, 2017, JPAD-J PREV ALZHEIM, V4, P236, DOI 10.14283/jpad.2017.36; Yanamandra K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2029; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046	43	32	32	3	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					182	192		10.1016/S1474-4422(20)30489-0	http://dx.doi.org/10.1016/S1474-4422(20)30489-0			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609476	Bronze			2022-12-18	WOS:000620258400018
J	Zhao, J; Liu, RY				Zhao, Jing; Liu, Renyu			Stroke 1-2-0: a rapid response programme for stroke in China	LANCET NEUROLOGY			English	Letter									[Zhao, Jing] Fudan Univ, Minhang Hosp, Dept Neurol, Shanghai, Peoples R China; [Liu, Renyu] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Fudan University; University of Pennsylvania; Pennsylvania Medicine	Liu, RY (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	Iiur@uphs.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111421] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM111421] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Hodgson CS, 2007, STROKE, V38, P2631, DOI 10.1161/STROKEAHA.107.488809; Jiang B, 2016, SCI REP-UK, V6, DOI 10.1038/srep29795; Jin HQ, 2012, STROKE, V43, P362, DOI 10.1161/STROKEAHA.111.623512; Kleindorfer DO, 2007, STROKE, V38, P2864, DOI 10.1161/STROKEAHA.107.484329	4	32	42	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					27	28		10.1016/S1474-4422(16)30283-6	http://dx.doi.org/10.1016/S1474-4422(16)30283-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	28029517	Bronze, Green Accepted			2022-12-18	WOS:000389869200022
J	Mintzer, S; French, JA; Perucca, E; Cramer, JA; Messenheimer, JA; Blum, DE; Rogawski, MA; Baulac, M				Mintzer, Scott; French, Jacqueline A.; Perucca, Emilio; Cramer, Joyce A.; Messenheimer, John A.; Blum, David E.; Rogawski, Michael A.; Baulac, Michel			Is a separate monotherapy indication warranted for antiepileptic drugs?	LANCET NEUROLOGY			English	Article							PARTIAL-ONSET SEIZURES; CONTROLLED CLINICAL-TRIAL; CONTROLLED-RELEASE CARBAMAZEPINE; NEWLY-DIAGNOSED EPILEPSY; DOSE-RANGING TRIAL; DOUBLE-BLIND; FELBAMATE MONOTHERAPY; LAMOTRIGINE MONOTHERAPY; GABAPENTIN MONOTHERAPY; INITIAL MONOTHERAPY	Antiepileptic drugs (AEDs) are the only neurotherapeutics for which regulatory approval is consistently separated into monotherapy or adjunctive-therapy indications. Because head-to-head comparisons of AEDs (used in the European Union to approve drugs for monotherapy) have not shown substantial differences in efficacy between drugs, FDA approval for use of an AED as monotherapy has typically been based on trials with novel designs that have been criticised for reasons of ethics and clinical relevance. Many new-generation AEDs have not been approved for monotherapy, causing drug labelling and real-world use to be increasingly inconsistent, with negative consequences for patients. The regulatory requirement for separate monotherapy and adjunctive-therapy indications in epilepsy is unnecessarily restrictive. We recommend that regulatory agencies approve AEDs for the treatment of specific seizure types or epilepsy syndromes, irrespective of concomitant drug use.	[Mintzer, Scott] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [French, Jacqueline A.] NYU Langone Sch Med, New York, NY USA; [Perucca, Emilio] Univ Pavia, I-27100 Pavia, Italy; [Perucca, Emilio] C Mondino Natl Neurol Inst, Pavia, Italy; [Cramer, Joyce A.] Yale Univ, Sch Med, New Haven, CT USA; [Blum, David E.] Sunov Pharmaceut, Marlborough, MA USA; [Rogawski, Michael A.] Univ Calif Davis, Sacramento, CA 95817 USA; [Baulac, Michel] Hop La Pitie Salpetriere, Dept Neurol, Paris, France	Jefferson University; NYU Langone Medical Center; University of Pavia; IRCCS Fondazione Casimiro Mondino; Yale University; Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.; University of California System; University of California Davis; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	French, JA (corresponding author), NYU Comprehens Epilepsy Ctr, 223 East 34th St, New York, NY 10016 USA.	jacqueline.french@nyumc.org	Perucca, Emilio/Q-7308-2019; Rogawski, Michael A/B-6353-2009; French, Jacqueline/G-6795-2013	Rogawski, Michael A/0000-0002-3296-8193; Perucca, Emilio/0000-0001-8703-223X; French, Jacqueline/0000-0003-2242-8027	Commission on North American Affairs; Commission on European Affairs; Commission on Therapeutic Strategies of the International League Against Epilepsy (ILAE)	Commission on North American Affairs; Commission on European Affairs; Commission on Therapeutic Strategies of the International League Against Epilepsy (ILAE)	Our initiative was supported in part by funding from the Commission on North American Affairs, the Commission on European Affairs, and the Commission on Therapeutic Strategies of the International League Against Epilepsy (ILAE). We thank the members of the ILAE Task Force on Regulatory Affairs for their helpful contribution to the discussion that led to the preparation of this manuscript. In addition, we thank Verna Ilacqua (Ilacqua DiBona and Associates) for editorial assistance.	Abbvie, DEPAKOTE DIV SOD; [Anonymous], 2014, TOPAMAX TOP; [Anonymous], AZILECT RAS; [Anonymous], SUMMARY PRODUCT CHAR; Appleton RE, 1999, EPILEPSIA, V40, P1627, DOI 10.1111/j.1528-1157.1999.tb02049.x; Arroyo S, 2005, ACTA NEUROL SCAND, V112, P214, DOI 10.1111/j.1600-0404.2005.00485.x; AZILECT, SUMMARY PRODUCT CHAR; Barcs G, 2000, EPILEPSIA, V41, P1597; Baulac M, 2012, LANCET NEUROL, V11, P579, DOI 10.1016/S1474-4422(12)70105-9; Ben-Menachem E, 2000, EPILEPSIA, V41, P1276, DOI 10.1111/j.1528-1157.2000.tb04605.x; Bergey GK, 1997, NEUROLOGY, V49, P739, DOI 10.1212/WNL.49.3.739; Beydoun A, 2000, NEUROLOGY, V54, P2245, DOI 10.1212/WNL.54.12.2245; Beydoun A, 1997, NEUROLOGY, V49, P746, DOI 10.1212/WNL.49.3.746; Bill PA, 1997, EPILEPSY RES, V27, P195, DOI 10.1016/S0920-1211(97)00024-7; Biogen Idec, TYSABRI NAT; Boehringer Ingelheim Pharmaceuticals, MIRAPEX PRAM; Brodie M, 1997, EPILEPSIA S3, V38, P66; Brodie MJ, 2007, NEUROLOGY, V68, P402, DOI 10.1212/01.wnl.0000252941.50833.4a; Brodie MJ, 2014, EPILEPSY RES, V108, P989, DOI 10.1016/j.eplepsyres.2014.03.008; Brodie MJ, 2002, EPILEPSIA, V43, P993, DOI 10.1046/j.1528-1157.2002.45401.x; BRODIE MJ, 1995, LANCET, V345, P662; Chadwick D, 1999, LANCET, V354, P13, DOI 10.1016/S0140-6736(98)10531-7; Chadwick D, 2001, EPILEPSY BEHAV, V2, P324, DOI 10.1006/ebeh.2001.0227; Chadwick DW, 1998, NEUROLOGY, V51, P1282, DOI 10.1212/WNL.51.5.1282; Christe W, 1997, EPILEPSY RES, V26, P451, DOI 10.1016/S0920-1211(96)01013-3; Chung S, 2012, EPILEPSY RES, V101, P92, DOI 10.1016/j.eplepsyres.2012.03.007; DAM M, 1989, EPILEPSY RES, V3, P70; DEVINSKY O, 1995, EPILEPSY RES, V20, P241, DOI 10.1016/0920-1211(94)00084-A; Eichler HG, 2012, CLIN PHARMACOL THER, V91, P426, DOI 10.1038/clpt.2011.345; Eisai, ARICEPT DON; European Medicines Agency, GUID CLIN INV MED PR; Fattore C, 2011, EPILEPSIA, V52, P802, DOI 10.1111/j.1528-1167.2010.02976.x; FAUGHT E, 1993, NEUROLOGY, V43, P688, DOI 10.1212/WNL.43.4.688; Food and Drug Administration Center for Drug Evaluation and Research, 2011, SUMM MIN PER CENTR N; Forest Pharmaceuticals, NAMENDA MEM; French J, 2006, EPILEPSY RES, V68, P19, DOI 10.1016/j.eplepsyres.2005.09.011; French JA, 2014, ACTA NEUROL SCAND, V129, P143, DOI 10.1111/ane.12207; French JA, 2002, EPILEPSIA, V43, P3, DOI 10.1046/j.1528-1157.43.s.10.1.x; French J, 2014, NEUROLOGY, V82, P590, DOI 10.1212/WNL.0000000000000119; French JA, 2012, NEUROLOGY, V79, P589, DOI 10.1212/WNL.0b013e3182635735; French JA, 2012, NEUROTHERAPEUTICS, V9, P176, DOI 10.1007/s13311-011-0088-3; French JA, 2010, EPILEPSIA, V51, P1936, DOI 10.1111/j.1528-1167.2010.02650.x; Gilliam F, 1998, NEUROLOGY, V51, P1018, DOI 10.1212/WNL.51.4.1018; Gilliam FG, 2003, NEUROLOGY, V60, P196, DOI 10.1212/01.WNL.0000048200.12663.BC; Glauser T, 2013, EPILEPSIA, V54, P551, DOI 10.1111/epi.12074; Glauser TA, 2013, EPILEPSIA, V54, P141, DOI 10.1111/epi.12028; GlaxoSmithKline, REQUIP ROP; GlaxoSmithKline, LAMICTAL XR LAM EXT; GlaxoSmithKline, 2014, LAMICTAL LAM; Guerreiro MM, 1997, EPILEPSY RES, V27, P205, DOI 10.1016/S0920-1211(97)00025-9; Janssen Pharmaceuticals, RAZADYNE GAL; Karlawish JHT, 2001, EPILEPSY BEHAV, V2, P193, DOI 10.1006/ebeh.2001.0197; Kwan P, 2011, LANCET NEUROL, V10, P881, DOI 10.1016/S1474-4422(11)70154-5; LEBER PD, 1989, EPILEPSIA, V30, pS57, DOI 10.1111/j.1528-1157.1989.tb05816.x; Loscher W, 2011, SEIZURE-EUR J EPILEP, V20, P359, DOI 10.1016/j.seizure.2011.01.003; Loscher W, 2011, EPILEPSIA, V52, P657, DOI 10.1111/j.1528-1167.2011.03024.x; LYRICA (pregabalin), SUMMARY PRODUCT CHAR; LYRICA (pregabalin), LYRICA PREG; Marson AG, 2007, HEALTH TECHNOL ASSES, V11, pIX; Marson AG, 2009, CURR OPIN NEUROL, V22, P167, DOI 10.1097/WCO.0b013e3283292427; MATSUO F, 1993, NEUROLOGY, V43, P2284, DOI 10.1212/WNL.43.11.2284; NEUPRO, SUMMARY PRODUCT CHAR; NEURONTIN (gabapentin), SUMMARY PRODUCT CHAR; Nieto-Barrera M, 2001, EPILEPSY RES, V46, P145, DOI 10.1016/S0920-1211(01)00271-6; Novartis Pharmaceuticals, COMTAN ENT; Novartis Pharmaceuticals, EXELON RIV; Novartis Pharmaceuticals, 2014, TRILEPTAL OXC; Pazdera L, 2014, EPILEPSY CURR S1, V14, P1; Perucca E, 1999, EPILEPSY RES, V33, P247, DOI 10.1016/S0920-1211(98)00095-3; Perucca E, 2008, CNS DRUGS, V22, P917, DOI 10.2165/00023210-200822110-00003; Perucca E, 2012, EPILEPTIC DISORD, V14, P124, DOI 10.1684/epd.2012.0511; Porter Roger J, 2012, Handb Clin Neurol, V108, P663, DOI 10.1016/B978-0-444-52899-5.00021-6; Porter RJ, 2010, EPILEPSY RES, V89, P163, DOI 10.1016/j.eplepsyres.2010.02.005; Privitera M, 1996, NEUROLOGY, V46, P1678, DOI 10.1212/WNL.46.6.1678; Privitera MD, 2003, ACTA NEUROL SCAND, V107, P165, DOI 10.1034/j.1600-0404.2003.00093.x; REQUIP, SUMMARY PRODUCT CHAR; Rheims S, 2011, EPILEPSIA, V52, P219, DOI 10.1111/j.1528-1167.2010.02915.x; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; Sachdeo R, 2001, NEUROLOGY, V57, P864, DOI 10.1212/WNL.57.5.864; Sachdeo RC, 1997, EPILEPSIA, V38, P294, DOI 10.1111/j.1528-1157.1997.tb01120.x; Sachdeo RC, 1999, NEUROLOGY, V52, pA391; Saetre E, 2007, EPILEPSIA, V48, P1292, DOI 10.1111/j.1528-1167.2007.01128.x; Sake JK, 2010, CNS DRUGS, V24, P1055, DOI 10.2165/11587550-000000000-00000; Schachter SC, 1995, EPILEPSIA, V36, pS2, DOI 10.1111/j.1528-1157.1995.tb06011.x; Schachter SC, 1999, NEUROLOGY, V52, P732, DOI 10.1212/WNL.52.4.732; Schmidt D, 2013, EPILEPSY BEHAV, V27, P393, DOI 10.1016/j.yebeh.2013.01.015; Sperling MR, 2015, EPILEPSIA, V56, P546, DOI 10.1111/epi.12934; Steiner TJ, 1999, EPILEPSIA, V40, P601, DOI 10.1111/j.1528-1157.1999.tb05562.x; Steinhoff BJ, 2013, EPILEPSIA, V54, P1481, DOI 10.1111/epi.12212; THEODORE WH, 1995, EPILEPSIA, V36, P1105, DOI 10.1111/j.1528-1157.1995.tb00468.x; TOPAMAX (sodium valproate), SUMMARY PRODUCT CHAR; UCB, NEUPRO ROT; UCB, 2014, VIMPAT LAC; Vazquez Blanca, 1998, Epilepsia, V39, P67; Wechsler RT, 2014, EPILEPSIA, V55, P1088, DOI 10.1111/epi.12681; White HS, 2006, MODELS OF SEIZURES AND EPILEPSY, P539, DOI 10.1016/B978-012088554-1/50046-3; Wingerchuk DM, 2014, MAYO CLIN PROC, V89, P225, DOI 10.1016/j.mayocp.2013.11.002	98	32	32	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1229	1240		10.1016/S1474-4422(15)00229-X	http://dx.doi.org/10.1016/S1474-4422(15)00229-X			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26581972				2022-12-18	WOS:000364855100017
J	Rothwell, PM				Rothwell, Peter M.			Poor outcomes after endovascular treatment of symptomatic carotid stenosis: time for a moratorium	LANCET NEUROLOGY			English	Editorial Material							ENDARTERECTOMY; ANGIOPLASTY; SUBGROUPS; TRIAL		John Radcliffe Hosp, Oxford OX3 9DU, England	University of Oxford	Rothwell, PM (corresponding author), John Radcliffe Hosp, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Bonati LH, 2009, LANCET NEUROL, V8, P908, DOI 10.1016/S1474-4422(09)70227-3; Bond R, 2003, STROKE, V34, P2290, DOI 10.1161/01.STR.0000087785.01407.CC; BROWN MM, 2009, EUR STROK C 2009 MAY; Cunningham EJ, 2002, STROKE, V33, P2658, DOI 10.1161/01.STR.0000034397.72390.D3; Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0; Ederle J, 2009, LANCET NEUROL, V8, P898, DOI 10.1016/S1474-4422(09)70228-5; Gurm HS, 2008, NEW ENGL J MED, V358, P1572, DOI 10.1056/NEJMoa0708028; Hobson RW, 2002, J AM COLL SURGEONS, V194, pS9, DOI 10.1016/S1072-7515(01)01078-X; Lewis SC, 2008, LANCET, V372, P2132, DOI 10.1016/S0140-6736(08)61699-2; Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 2005, LANCET, V365, P256	13	32	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2009	8	10					871	873		10.1016/S1474-4422(09)70230-3	http://dx.doi.org/10.1016/S1474-4422(09)70230-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498BS	19717346				2022-12-18	WOS:000270111200003
J	Cornford, EM; Cornford, ME				Cornford, EM; Cornford, ME			New systems for delivery of drugs to the brain in neurological disease	LANCET NEUROLOGY			English	Review							ANTITRANSFERRIN RECEPTOR ANTIBODY; BARRIER IN-VIVO; GROWTH-FACTOR; MEDIATED DELIVERY; CHIMERIC PEPTIDES; FUSION PROTEINS; ANTISENSE GENE; BLOOD; TRANSPORT; VECTOR	The restricted or regulated entry of most blood-borne substances into the brain has been recognised for more than a century. The blood-brain barrier (BBB)-shielding function provided by endothelial cells is important in the treatment of neurological diseases because this exclusion of foreign substances also restricts entry of many potentially therapeutic agents into the brain. The recent identification of several neuroactive proteins of potential therapeutic value has highlighted the crucial need for effective and safe transcapillary delivery methods to the brain. One promising method is delivery through brain capillaries by augmentation of pinocytotic vesicles; delivery systems that use this cellular mechanism are in development. Recent investigations in animal models show that large molecules of neurotherapeutic potential can be conjugated to peptidomimetic ligands, which bind to selected peptide receptors, and are then internalised and transported in small vesicles across the cytoplasmic brain capillary barrier. These conjugates have been shown to remain functionally active and effective in animal models of neurological disease.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Dept Vet Affairs, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Harbor Med Ctr, Dept Pathol, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Cornford, EM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Blvd, Los Angeles, CA 90095 USA.	cornford@ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037360] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 37360] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; Ali SA, 1999, J BIOL CHEM, V274, P24066, DOI 10.1074/jbc.274.34.24066; Anderson WF, 1998, NATURE, V392, P25; BICKEL U, 1993, P NATL ACAD SCI USA, V90, P2618, DOI 10.1073/pnas.90.7.2618; Boado RJ, 1998, J PHARM SCI-US, V87, P1308, DOI 10.1021/js9800836; Broadwell RD, 1996, EXP NEUROL, V142, P47, DOI 10.1006/exnr.1996.0178; Cerletti A, 2000, J DRUG TARGET, V8, P435, DOI 10.3109/10611860008997919; Coloma MJ, 2000, PHARMACEUT RES, V17, P266, DOI 10.1023/A:1007592720793; Cornford EM, 1999, ADV DRUG DELIVER REV, V36, P145, DOI 10.1016/S0169-409X(98)00082-9; Cornford EM, 1998, J CEREBR BLOOD F MET, V18, P26, DOI 10.1097/00004647-199801000-00003; Debinski W, 1999, INT J ONCOL, V15, P481; Deguchi Y, 1999, BIOCONJUGATE CHEM, V10, P32, DOI 10.1021/bc9800522; Dewey RA, 1999, NAT MED, V5, P1256, DOI 10.1038/15207; Driesse MJ, 1998, GENE THER, V5, P1122, DOI 10.1038/sj.gt.3300695; FAUSTMANN PM, 1985, CELL TISSUE RES, V242, P399; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; FUKUTA M, 1994, PHARM RES-DORDR, V11, P1681, DOI 10.1023/A:1018942728317; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GRANHOLM AC, 1994, J PHARMACOL EXP THER, V268, P448; Hagihara N, 2000, CANCER RES, V60, P230; Hall WA, 2000, NEUROSURGERY, V46, P544, DOI 10.1097/00006123-200003000-00003; HO RJY, 1985, J IMMUNOL, V134, P4035; HUANG A, 1983, J BIOL CHEM, V258, P4034; HUANG A, 1981, J IMMUNOL METHODS, V46, P141, DOI 10.1016/0022-1759(81)90131-9; Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164; Huwyler J, 1998, J NEUROCHEM, V70, P883; Huwyler J, 1997, J PHARMACOL EXP THER, V282, P1541; Kang YS, 2000, J DRUG TARGET, V8, P425, DOI 10.3109/10611860008997918; KANG YS, 1994, PHARMACEUT RES, V11, P1257, DOI 10.1023/A:1018982125649; Keep RF, 2001, STROKE, V32, P1383; KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214; Kurihara A, 1999, BIOCONJUGATE CHEM, V10, P502, DOI 10.1021/bc980123x; Kurihara A, 1999, CANCER RES, V59, P6159; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lee HJ, 2000, J PHARMACOL EXP THER, V292, P1048; Lee HJ, 2002, J CEREBR BLOOD F MET, V22, P223, DOI 10.1097/00004647-200202000-00010; Li HY, 2002, MED RES REV, V22, P225, DOI 10.1002/med.10008; Li JY, 2001, J CEREBR BLOOD F MET, V21, P61, DOI 10.1097/00004647-200101000-00008; Li XB, 2000, J NAT TOXINS, V9, P73; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MINN A, 1991, BRAIN RES REV, V16, P65, DOI 10.1016/0165-0173(91)90020-9; NINGARAJ NS, 2002, J PHARMACOL EXP THER, V301, P1; PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V255, P893; Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P223; Pardridge WM, 2002, ARCH NEUROL-CHICAGO, V59, P35, DOI 10.1001/archneur.59.1.35; PARDRIDGE WM, 1995, P NATL ACAD SCI USA, V92, P5592, DOI 10.1073/pnas.92.12.5592; Pardridge WM, 1997, J NEUROCHEM, V68, P1278; PARDRIDGE WM, 1994, PHARMACEUT RES, V11, P738, DOI 10.1023/A:1018940732550; PARDRIDGE WM, 1990, ENDOCRINOLOGY, V126, P977, DOI 10.1210/endo-126-2-977; PARDRIDGE WM, 1987, BIOCHEM BIOPH RES CO, V146, P307, DOI 10.1016/0006-291X(87)90726-1; PARDRIDGE WM, 2001, PEPTICE DRUG DELIVER, P357; PARDRIDGE WM, 2001, NATURE REV, V1, P131; PARDRIDGE WM, 2001, BRAIN DRUG TARGETING, P353; Park E, 1998, J DRUG TARGET, V6, P53, DOI 10.3109/10611869808997881; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Rubanyi Gabor M., 2001, Molecular Aspects of Medicine, V22, P113, DOI 10.1016/S0098-2997(01)00004-8; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Shi NY, 2001, PHARMACEUT RES, V18, P1091, DOI 10.1023/A:1010910523202; Shi NY, 2001, P NATL ACAD SCI USA, V98, P12754, DOI 10.1073/pnas.221450098; Shi NY, 2000, P NATL ACAD SCI USA, V97, P14709, DOI 10.1073/pnas.250332397; SHIN SU, 1995, P NATL ACAD SCI USA, V92, P2820, DOI 10.1073/pnas.92.7.2820; Shusta EV, 2002, J CEREBR BLOOD F MET, V22, P245, DOI 10.1097/00004647-200203000-00001; Singh M, 1999, CURR PHARM DESIGN, V5, P443; Song BW, 2002, J PHARMACOL EXP THER, V301, P605, DOI 10.1124/jpet.301.2.605; STEWART PA, 1994, MICROSC RES TECHNIQ, V27, P516, DOI 10.1002/jemt.1070270606; Stewart PA, 2000, CELL MOL NEUROBIOL, V20, P149, DOI 10.1023/A:1007026504843; Takasawa K, 1997, J PHARMACOL EXP THER, V281, P369; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu DA, 1998, BRAIN RES, V791, P313, DOI 10.1016/S0006-8993(98)00139-5; Wu DF, 1999, P NATL ACAD SCI USA, V96, P254, DOI 10.1073/pnas.96.1.254; Wu DF, 1996, J PHARMACOL EXP THER, V279, P77; Wu DF, 1996, J PHARMACOL EXP THER, V276, P206; Zhang Y, 2002, J GENE MED, V4, P183, DOI 10.1002/jgm.255; Zhang Y, 2002, MOL THER, V6, P67, DOI 10.1006/mthe.2002.0633; Zhang Y, 2001, STROKE, V32, P1378, DOI 10.1161/01.STR.32.6.1378; Zhang Y, 2001, J NEUROIMMUNOL, V114, P168, DOI 10.1016/S0165-5728(01)00242-9; Zhang YQ, 2000, BRAIN RES, V887, P465, DOI 10.1016/S0006-8993(00)03037-7	80	32	41	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2002	1	5					306	315		10.1016/S1474-4422(02)00136-9	http://dx.doi.org/10.1016/S1474-4422(02)00136-9			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588LB	12849428				2022-12-18	WOS:000177702000018
J	Vallabh, SM; Minikel, EV; Schreiber, SL; Lander, ES				Vallabh, Sonia M.; Minikel, Eric Vallabh; Schreiber, Stuart L.; Lander, Eric S.			Towards a treatment for genetic prion disease: trials and biomarkers	LANCET NEUROLOGY			English	Review							CREUTZFELDT-JAKOB-DISEASE; CEREBROSPINAL-FLUID; HUNTINGTONS-DISEASE; EXTEND SURVIVAL; DOUBLE-BLIND; PROTEIN; MICE; PRP; ALZHEIMERS; DIAGNOSIS	Prion disease is a rare, fatal, and exceptionally rapid neurodegenerative disease. Although incurable, prion disease follows a clear pathogenic mechanism, in which a single gene gives rise to a single prion protein (PrP) capable of converting into the sole causal disease agent, the misfolded prion. As efforts progress to leverage this mechanistic knowledge toward rational therapies, a principal challenge will be the design of clinical trials. Previous trials in prion disease have been done in symptomatic patients who are often profoundly debilitated at enrolment. About 15% of prion disease cases are genetic, creating an opportunity for early therapeutic intervention to delay or prevent disease. Highly variable age of onset and absence of established prodromal biomarkers might render infeasible existing models for testing drugs before disease onset. Advancement of near-term targeted therapeutics could crucially depend on thoughtful design of rigorous presymptomatic trials.	[Vallabh, Sonia M.; Minikel, Eric Vallabh; Schreiber, Stuart L.; Lander, Eric S.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Schreiber, Stuart L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA USA; [Vallabh, Sonia M.; Minikel, Eric Vallabh] Massachusetts Gen Hosp, Dept Neurol, Henry & Allison McCance Ctr Brain Hlth, Boston, MA 02114 USA; [Lander, Eric S.] MIT, Dept Biol, Cambridge, MA USA; [Vallabh, Sonia M.; Minikel, Eric Vallabh; Schreiber, Stuart L.; Lander, Eric S.] Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Vallabh, SM (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.	svallabh@broadinstitute.org						Abu Rumeileh S, 2017, J ALZHEIMERS DIS, V55, P1471, DOI 10.3233/JAD-160740; Ahn M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098496; Appleby BS, 2014, J ALZHEIMERS DIS, V42, P833, DOI 10.3233/JAD-132465; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Benestad SL, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-87; Bennett CF, 2017, ANNU REV PHARMACOL, V57, P81, DOI 10.1146/annurev-pharmtox-010716-104846; Berry DB, 2013, P NATL ACAD SCI USA, V110, pE4160, DOI 10.1073/pnas.1317164110; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445; Cohen OS, 2015, J NEUROL, V262, P604, DOI 10.1007/s00415-014-7615-1; Colby DW, 2009, P NATL ACAD SCI USA, V106, P20417, DOI 10.1073/pnas.0910350106; Cortelli P, 2006, BRAIN, V129, P668, DOI 10.1093/brain/awl003; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; DeVos SL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0481; Doh-Ura K, 2004, J VIROL, V78, P4999, DOI 10.1128/JVI.78.10.4999-5006.2004; Dorey A, 2015, JAMA NEUROL, V72, P267, DOI 10.1001/jamaneurol.2014.4068; Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Foutz A, 2017, ANN NEUROL, V81, P79, DOI 10.1002/ana.24833; Franceschini A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10922-w; Friberg KN, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.6; Garber K, 2012, NAT BIOTECHNOL, V30, P731, DOI 10.1038/nbt0812-731; Geschwind MD, 2013, NEUROLOGY, V81, P2015, DOI 10.1212/WNL.0b013e3182a9f3b4; Giles K, 2016, J PHARMACOL EXP THER, V358, P537, DOI 10.1124/jpet.116.235556; Giles K, 2015, J PHARMACOL EXP THER, V355, P2, DOI 10.1124/jpet.115.224659; Haik S, 2014, LANCET NEUROL, V13, P150, DOI 10.1016/S1474-4422(13)70307-7; Kawasaki Y, 2007, J VIROL, V81, P12889, DOI 10.1128/JVI.01563-07; Klug GMJA, 2013, J NEUROL NEUROSUR PS, V84, P1372, DOI 10.1136/jnnp-2012-304820; Kordasiewicz HB, 2012, NEURON, V74, P1031, DOI 10.1016/j.neuron.2012.05.009; Kovacs GG, 2017, EUR J NEUROL, V24, P1326, DOI 10.1111/ene.13389; Kuffer A, 2016, NATURE, V536, P464, DOI 10.1038/nature19312; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lu D, 2013, J PHARMACOL EXP THER, V347, P325, DOI 10.1124/jpet.113.205799; Maddox RA, 2020, NEUROLOGY, V94, pE153, DOI 10.1212/WNL.0000000000008680; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; McCampbell A, 2018, J CLIN INVEST, V128, P3558, DOI 10.1172/JCI99081; McDade E, 2017, NATURE, V547, P153, DOI 10.1038/547153a; Mead S, 2006, EUR J HUM GENET, V14, P273, DOI 10.1038/sj.ejhg.5201544; Mead S, 2009, NEW ENGL J MED, V361, P2056, DOI 10.1056/NEJMoa0809716; Miller TM, 2013, LANCET NEUROL, V12, P435, DOI 10.1016/S1474-4422(13)70061-9; Minikel EV, 2019, MOL CELL PROTEOMICS, V18, P2388, DOI 10.1074/mcp.RA119.001702; Minikel EV, 2019, NEUROLOGY, V93, pE125, DOI 10.1212/WNL.0000000000007745; Minikel EV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5169; Minikel EV, 2019, BIORXIV, DOI [10.1101/530881, DOI 10.1101/530881]; Orru CD, 2015, MBIO, V6, DOI 10.1128/mBio.02451-14; Otto M., 2004, Neurology, V62, P714; Owen J, 2014, EUR J HUM GENET, V22, P1351, DOI 10.1038/ejhg.2014.42; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Paterson RW, 2012, ARCH NEUROL-CHICAGO, V69, P1578, DOI 10.1001/2013.jamaneurol.79; Pocchiari M, 2004, BRAIN, V127, P2348, DOI 10.1093/brain/awh249; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rabinovici GD, 2006, NEUROLOGY, V66, P286, DOI 10.1212/01.wnl.0000196440.00297.67; Raymond GJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131175; Richt JA, 2007, NAT BIOTECHNOL, V25, P132, DOI 10.1038/nbt1271; Rigo F, 2014, J PHARMACOL EXP THER, V350, P46, DOI 10.1124/jpet.113.212407; Rudge P, 2019, BRAIN, V142, P760, DOI 10.1093/brain/awy358; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2005, J GEN VIROL, V86, P2913, DOI 10.1099/vir.0.80947-0; Sandberg MK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5347; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Shibuya S, 1998, ANN NEUROL, V43, P826, DOI 10.1002/ana.410430618; Silber BM, 2014, BIOORGAN MED CHEM, V22, P1960, DOI 10.1016/j.bmc.2014.01.001; Skedsmo FS, 2020, FASEB J, V34, P2359, DOI 10.1096/fj.201902588R; Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941; Staffaroni AM, 2019, JAMA NEUROL, V76, P969, DOI 10.1001/jamaneurol.2019.1071; Steinacker P, 2016, SCI REP-UK, V6, DOI 10.1038/srep38737; Stewart LA, 2008, NEUROLOGY, V70, P1272, DOI 10.1212/01.wnl.0000308955.25760.c2; Tabrizi SJ, 2019, NEW ENGL J MED, V380, P2307, DOI 10.1056/NEJMoa1900907; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Thompson AGB, 2013, BRAIN, V136, P1116, DOI 10.1093/brain/awt048; Thompson AGB, 2018, J NEUROL NEUROSUR PS, V89, P955, DOI 10.1136/jnnp-2017-317793; Tsuboi Y, 2009, NEUROPATHOLOGY, V29, P632, DOI 10.1111/j.1440-1789.2009.01058.x; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation., 2018, EARL ALZH DIS DEV DR; US Food and Drug Administration, 2016, SPINRAZA NUS INJ INT; Vallabh SM, 2019, CEREBROSPINAL FLUID, DOI 10.1101/2019.12.13.19014217; Vallabh SM, 2019, P NATL ACAD SCI USA, V116, P7793, DOI 10.1073/pnas.1901947116; Villar-Pique A, 2019, MOL NEUROBIOL, V56, P2811, DOI 10.1007/s12035-018-1251-1; Wagner J, 2013, ACTA NEUROPATHOL, V125, P795, DOI 10.1007/s00401-013-1114-9; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748; Watts JC, 2016, ACTA NEUROPATHOL, V132, P593, DOI 10.1007/s00401-016-1585-6; White MD, 2008, P NATL ACAD SCI USA, V105, P10238, DOI 10.1073/pnas.0802759105; Will RG, 2003, BRIT MED BULL, V66, P255, DOI 10.1093/bmb/66.1.255	89	31	31	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					361	368		10.1016/S1474-4422(19)30403-X	http://dx.doi.org/10.1016/S1474-4422(19)30403-X			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32199098				2022-12-18	WOS:000520920500022
J	Factor, SA; Burkhard, PR; Caroff, S; Friedman, JH; Marras, C; Tinazzi, M; Comella, CL				Factor, Stewart A.; Burkhard, Pierre R.; Caroff, Stanley; Friedman, Joseph H.; Marras, Connie; Tinazzi, Michele; Comella, Cynthia L.			Recent developments in drug-induced movement disorders: a mixed picture	LANCET NEUROLOGY			English	Review							INDUCED PARKINSONISM; TARDIVE-DYSKINESIA; CLINICAL-FEATURES; NONMOTOR SYMPTOMS; DOUBLE-BLIND; FOLLOW-UP; DISEASE; AKATHISIA; PSYCHOSIS; TREMOR	A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people. Prevention of the development of drug-induced movement disorders is an important consideration when prescribing medications that can induce movement disorders. Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders. Future research should focus on development of safer antipsychotics and specific therapies for the different tardive syndromes and the treatment of drug-induced parkinsonism.	[Factor, Stewart A.] Emory Univ, Sch Med, Jean & Paul Amos Parkinsons Dis & Movement Disord, Atlanta, GA 30329 USA; [Burkhard, Pierre R.] Univ Geneva, Geneva Univ Hosp, Dept Neurol, Fac Med, Geneva, Switzerland; [Caroff, Stanley] Univ Penn, Perelman Sch Med, Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA; [Friedman, Joseph H.] Brown Univ, Warren Alpert Med Sch, Butler Hosp, Providence, RI 02912 USA; [Marras, Connie] Univ Toronto, Edmond J Safra Program Parkinsons Res, Toronto Western Hosp, Toronto, ON, Canada; [Tinazzi, Michele] Univ Verona, Dept Neurosci Biomed & Movement, Verona, Italy; [Comella, Cynthia L.] Rush Med Coll, Dept Neurol Sci, Chicago, IL 60612 USA	Emory University; University of Geneva; University of Pennsylvania; Pennsylvania Medicine; Brown University; Butler Hospital Rhode Island; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Verona; Rush University	Factor, SA (corresponding author), Emory Univ, Sch Med, Jean & Paul Amos Parkinsons Dis & Movement Disord, Atlanta, GA 30329 USA.	sfactor@emory.edu	TINAZZI, Michele/J-7134-2018	TINAZZI, Michele/0000-0002-2370-7063	National Institutes of Health; International Parkinson and Movement Disorders Society	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Parkinson and Movement Disorders Society	S SAF has salary and research support from the Vance Lanier Chair of Neurology and the Sartain Lanier Family Foundation; is a consultant to Neurocrine, Lundbeck, Teva, Avanir, Sunovion, Biogen, Prexton Therapeutics, and Adamas; and has grant support from Ipsen, Medtronics, Teva, US World Meds, Sunovion Therapeutics, Vaccinex, Voyager, Jazz Pharmaceuticals, CHDI Foundation, Michael J Fox Foundation, and NIH (grant U10-NS077366-01). PRB has grant support from Medtronic, Boston Scientific, AbbVie, Swiss Parkinson, and the Swiss National Science Foundation. SC is a consultant to Neurocrine Biosciences, Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and DisperSol Technologies; and received a research grant from Neurocrine Biosciences. JF has grant support from NIH andMichael J Fox Foundation; and is a consultant to Acadia Pharmaceuticals. CM is a consultant to Acorda Therapeutics; has honoraria for teaching from EMD Serono, steering committee for National Parkinson Foundation, and Michael J Fox Foundation; has grant support from The Michael J Fox Foundation, Canadian Institutes of Health Research, US Parkinson Foundation; and is a site principle investigator for clinical trial sponsored by the National Institutes of Health and International Parkinson and Movement Disorders Society. MT reports grants from Zambon, University of Verona, Verona Brain Research Foundation, Cattolica Foundation; and personal fees from UCB Pharma, Zambon, Lundbeck, Abbvie, and Movement Disorders Society, outside of the submitted work. CLC is a consultant to Neurocrine, ACADIA, Allergan, Ipsen, Lundbeck, Merz, Medtronic, and US World Meds; and has grants support from Allergan, Ipsen, Merz, NIH, and the Dystonia Coalition.	Abadie D, 2015, J CLIN PSYCHOPHARM, V35, P382, DOI 10.1097/JCP.0000000000000344; Alonso-Juarez M, 2017, PARKINSONISM RELAT D, V44, P147, DOI 10.1016/j.parkreldis.2017.09.011; Alty Jane, 2016, Pract Neurol, V16, P122, DOI 10.1136/practneurol-2015-001267; Anderson KE, 2017, LANCET PSYCHIAT, V4, P595, DOI 10.1016/S2215-0366(17)30236-5; Artusi CA, 2015, J NEUROL, V262, P2780, DOI 10.1007/s00415-015-7956-4; Baek JH, 2014, ACTA PSYCHIAT SCAND, V129, P17, DOI 10.1111/acps.12171; Basile G, 2014, J CLIN PHARM THER, V39, P452, DOI 10.1111/jcpt.12162; Bergman H, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21430; Bergman H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000205.pub3; Bhatia KP, 2018, MOVEMENT DISORD, V33, P75, DOI 10.1002/mds.27121; Bhidayasiri R, 2018, J NEUROL SCI, V389, P67, DOI 10.1016/j.jns.2018.02.010; Bonanni L, 2016, J NEUROL NEUROSUR PS, V87, P1123, DOI 10.1136/jnnp-2015-312914; Bondon-Guitton E, 2011, MOVEMENT DISORD, V26, P2226, DOI 10.1002/mds.23828; Brigo F, 2014, PARKINSONISM RELAT D, V20, P808, DOI 10.1016/j.parkreldis.2014.05.011; Brugger F, 2016, CNS DRUGS, V30, P527, DOI 10.1007/s40263-016-0341-8; Campbell EC, 2017, CLINICAL MANUAL OF PSYCHOPHARMACOLOGY IN THE MEDICALLY ILL, 2ND EDITION, P45; Carbon M, 2018, WORLD PSYCHIATRY, V17, P330, DOI 10.1002/wps.20579; Carbon M, 2017, J CLIN PSYCHIAT, V78, pE264, DOI 10.4088/JCP.16r10832; Caroff SN, 2018, J COMP EFFECT RES, V7, P135, DOI 10.2217/cer-2017-0065; Caroff SN, 2017, EXPERT REV NEUROTHER, V17, P871, DOI 10.1080/14737175.2017.1358616; Caroff SN, 2016, PSYCHIAT CLIN N AM, V39, P391, DOI 10.1016/j.psc.2016.04.003; Chung SJ, 2018, J NEUROL NEUROSUR PS, V89, P169, DOI 10.1136/jnnp-2017-315873; Cloud LJ, 2014, NEUROTHERAPEUTICS, V11, P166, DOI 10.1007/s13311-013-0222-5; D'Abreu A, 2018, J NEUROL SCI, V389, P17, DOI 10.1016/j.jns.2018.02.007; Das A, 2018, AM J ADDICT; Deng ZD, 2017, PARKINSONISM RELAT D, V41, P58, DOI 10.1016/j.parkreldis.2017.05.010; Factor SA, 2017, J CLIN PSYCHIAT, V78, P1344, DOI 10.4088/JCP.17m11777; Fernandez HH, 2017, NEUROLOGY, V88, P2003, DOI 10.1212/WNL.0000000000003960; Fleury V, 2018, PARKINSONISM RELAT D, V54, P30, DOI 10.1016/j.parkreldis.2018.03.030; Frei K, 2018, J NEUROL SCI, V389, P10, DOI 10.1016/j.jns.2018.02.008; Friedman JH, 2013, BEHAV NEUROL, V27, P469, DOI [10.1155/2013/645429, 10.3233/BEN-129016]; Friedman JH, 2014, PARKINSONISM RELAT D, V20, P1325, DOI 10.1016/j.parkreldis.2014.09.030; Friedman R. A., 2012, NY TIMES; Fujioka Shinsuke, 2016, eNeurologicalSci, V4, P19, DOI 10.1016/j.ensci.2016.04.007; Gruber D, 2018, BRAIN STIMUL, V11, P1368, DOI 10.1016/j.brs.2018.08.006; Gurrera RJ, 2017, J CLIN PSYCHOPHARM, V37, P67, DOI 10.1097/JCP.0000000000000640; Hauser RA, 2017, AM J PSYCHIAT, V174, P476, DOI 10.1176/appi.ajp.2017.16091037; Hermida AP, 2016, INT PSYCHOGERIATR, V28, P2101, DOI 10.1017/S1041610216001101; Hess CW, 2012, TREMOR OTHER HYPERK, V2; Huang Yanan, 2017, Shanghai Arch Psychiatry, V29, P295, DOI 10.11919/j.issn.1002-0829.217008; Juncal-Ruiz M, 2017, PSYCHOPHARMACOLOGY, V234, P2563, DOI 10.1007/s00213-017-4646-1; Kagi G, 2010, J NEUROL NEUROSUR PS, V81, P5, DOI 10.1136/jnnp.2008.157370; Kapur S, 2001, AM J PSYCHIAT, V158, P360, DOI 10.1176/appi.ajp.158.3.360; Laoutidis ZG, 2014, INT J NEUROPSYCHOPH, V17, P823, DOI 10.1017/S1461145713001417; Lin CC, 2018, J NEUROL SCI, V389, P48, DOI 10.1016/j.jns.2018.02.014; Lin HL, 2017, EUR J CLIN PHARMACOL, V73, P365, DOI 10.1007/s00228-016-2181-3; Long Term Care Community Coalition, 2018, MIDT REP IN US ANT D; Lopez-Sendon JL, 2012, DRUG AGING, V29, P105, DOI 10.2165/11598540-000000000-00000; Madruga-Garrido M, 2013, INT REV NEUROBIOL, V112, P481, DOI 10.1016/B978-0-12-411546-0.00016-0; Mailman RB, 2010, CURR PHARM DESIGN, V16, P488, DOI 10.2174/138161210790361461; Marras C, 2016, AM J GERIAT PSYCHIAT, V24, P301, DOI 10.1016/j.jagp.2015.11.004; Martino D, 2018, CAN J PSYCHIAT; Martino D, 2017, NEUROL-CLIN PRACT, V7, P163, DOI 10.1212/CPJ.0000000000000344; Masi G, 2014, J CHILD ADOL PSYCHOP, V24, P536, DOI 10.1089/cap.2014.0047; Mehta SH, 2015, NEUROL CLIN, V33, P153, DOI 10.1016/j.ncl.2014.09.011; Mentzel TQ, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17r11852; Morgan JC, 2005, LANCET NEUROL, V4, P866, DOI 10.1016/S1474-4422(05)70250-7; Morgan JC, 2017, TREMOR OTHER HYPERK, V7, DOI 10.7916/D8FJ2V9Q; Morgante F, 2017, PARKINSONISM RELAT D, V36, P89, DOI 10.1016/j.parkreldis.2016.12.022; Morley JF, 2014, J PARKINSON DIS, V4, P169, DOI 10.3233/JPD-130299; Munhoz RP, 2017, NEUROL SCI, V38, P319, DOI 10.1007/s10072-016-2771-y; Nguyen C. T., 2017, PRIM CARE COMPANION, V19; Niemann N, 2018, DRUGS, V78, P525, DOI 10.1007/s40265-018-0874-x; O'Brien CF, 2015, MOVEMENT DISORD, V30, P1681, DOI 10.1002/mds.26330; Park HW, 2017, CLIN EXP EMERG MED, V4, P133, DOI 10.15441/ceem.16.181; Pouclet-Courtemanche H, 2016, NEUROLOGY, V86, P651, DOI 10.1212/WNL.0000000000002370; Pringsheim T, 2018, CAN J PSYCHIAT, V63, P717, DOI 10.1177/0706743718786702; Rao P., 2016, TRANSL DEV PSYCHIAT, V4, P28537; Rashid A, 2018, PSYCHO-ONCOLOGY, V27, P1338, DOI 10.1002/pon.4597; Rinnerthaler M, 2005, EPILEPSIA, V46, P320, DOI 10.1111/j.0013-9580.2005.36204.x; Sanchez-Ramos J, 2015, INT REV NEUROBIOL, V120, P131, DOI 10.1016/bs.irn.2015.02.003; Savica R, 2017, MOVEMENT DISORD, V32, P227, DOI 10.1002/mds.26839; Savitt D, 2018, J NEUROL SCI, V389, P35, DOI 10.1016/j.jns.2018.02.005; Scorr LM, 2018, J NEUROL SCI, V389, P43, DOI 10.1016/j.jns.2018.02.006; Shaikh AG, 2015, PARKINSONISM RELAT D, V21, P116, DOI 10.1016/j.parkreldis.2014.11.013; Shin HW, 2015, NEUROL SCI, V36, P269, DOI 10.1007/s10072-014-1945-8; Shuaib UA, 2016, MOVEMENT DISORD, V31, P360, DOI 10.1002/mds.26467; Silver M, 2013, PARKINSONISM RELAT D, V19, P758, DOI 10.1016/j.parkreldis.2013.03.016; Sohn M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003784; Solmi M, 2018, DRUG DES DEV THER, V12, P1215, DOI 10.2147/DDDT.S133205; Stahl SM, 2017, CNS SPECTRUMS, V22, P1, DOI [10.1017/S109285291600095X, 10.1017/S1092852917000621]; Thomas JE, 2015, CURR NEUROPHARMACOL, V13, P681, DOI 10.2174/1570159X13666150115220221; Tinazzi M, 2014, SCHIZOPHR RES, V152, P344, DOI 10.1016/j.schres.2013.11.028; Velseboer DC, 2013, NEUROLOGY, V80, P627, DOI 10.1212/WNL.0b013e318281cc99; Waln O, 2013, TREMOR OTHER HYPERK, V3; Warren N, 2018, ACTA PSYCHIAT SCAND, V138, P401, DOI 10.1111/acps.12941; Werneke U, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0616-1; Yomtoob J, 2018, PARKINSONISM RELAT D, V53, P37, DOI 10.1016/j.parkreldis.2018.04.037; Zutshi D, 2014, TREMOR OTHER HYPERK, V4, DOI 10.7916/D8MS3R8C	89	31	32	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2019	18	9					880	890		10.1016/S1474-4422(19)30152-8	http://dx.doi.org/10.1016/S1474-4422(19)30152-8			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	IO1IZ	31279747				2022-12-18	WOS:000479136100020
J	Hennerici, MG; Kern, R; Szabo, K				Hennerici, Michael G.; Kern, Rolf; Szabo, Kristina			Non-pharmacological strategies for the treatment of acute ischaemic stroke	LANCET NEUROLOGY			English	Review							MIDDLE-CEREBRAL-ARTERY; TISSUE-PLASMINOGEN-ACTIVATOR; MECHANICAL THROMBECTOMY; DECOMPRESSIVE SURGERY; MALIGNANT INFARCTION; ENDOVASCULAR THERAPY; INTRAVENOUS THROMBOLYSIS; ANTERIOR CIRCULATION; FLOW RESTORATION; RANDOMIZED-TRIAL	Early recanalisation and an increase in collateral blood supply are predictors of favourable outcome in acute ischaemic stroke. Since individual responses to intravenous treatment with alteplase are heterogeneous, additional intra-arterial thrombolytic and mechanical endovascular treatment is increasingly given. Despite encouraging findings from single-centre studies, data from randomised clinical trials have not proven the hypothesis that interventional recanalisation leads to a better outcome. Advanced thrombectomy devices, the effect of ultrasound-enhanced thrombolysis, and imaging-guided selection of patients outside the currently approved time-window are all under investigation. Although neuroprotective agents have not shown benefit in clinical trials, non-pharmacological treatment strategies such as decompressive surgery, therapeutic hypothermia, transcranial laser treatment, or augmentation of cerebral collateral perfusion by different means (eg, partial aortic ocdusion or sphenopalatine ganglion stimulation) are topics of current research. The future of acute stroke therapy relies on evidence for individually tailored, effective, safe, and rapidly accessible treatment probably consisting of combined pharmacological and improved non-pharmacological approaches.	[Hennerici, Michael G.; Kern, Rolf; Szabo, Kristina] Heidelberg Univ, Univ Med Mannheim, Dept Neurol, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Hennerici, MG (corresponding author), Univ Med Mannheim, Dept Neurol, D-68135 Mannheim, Germany.	hennerici@neuro.ma.uni-heidelberg.de	Szabo, Kristina/AAE-7978-2021		Deutsche Forschungsgemeinschaft (DFG); Federal Ministry of Education and Research (BMBF, Germany); European Union; BMBF; DFG	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Federal Ministry of Education and Research (BMBF, Germany)(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); BMBF(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG))	MGH is consultant to and has served on advisory boards during the previous 2 years for Servier, Bayer, and Boehringer Ingelheim; has received grants from the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF, Germany), the European Union, and other organisations supporting clinical trials in the Department of Neurology at the University of Heidelberg in UMM Mannheim; and is Editor-in-Chief of Cerebrovascular Diseases and aboard member of other international journals. RK has received speaker's honoraria from Boehringer Ingelheim, Novartis, and Philips Healthcare; has received funding from BMBF; and is a member of the editorial board of Cerebrovascular Diseases. KS has received funding from DFG and is a member of the editorial board of Cerebrovascular Diseases.	Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Ahmed N, 2010, LANCET NEUROL, V9, P866, DOI 10.1016/S1474-4422(10)70165-4; Alexandrov AV, 2008, STROKE, V39, P1464, DOI 10.1161/STROKEAHA.107.505727; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Bose A, 2008, AM J NEURORADIOL, V29, P1409, DOI 10.3174/ajnr.A1110; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Broderick J, 2004, STROKE, V35, P904, DOI 10.1161/01.STR.0000121641.77121.98; Broderick JP, 2007, STROKE, V38, P2127, DOI 10.1161/STROKEAHA.107.483131; Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Burke JF, 2012, STROKE, V43, P2207, DOI 10.1161/STROKEAHA.112.656967; Candelise L, 2007, LANCET, V369, P299, DOI 10.1016/S0140-6736(07)60152-4; Castano C, 2010, STROKE, V41, P1836, DOI 10.1161/STROKEAHA.110.584904; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Costalat V, 2011, STROKE, V42, P1929, DOI 10.1161/STROKEAHA.110.608976; Daffertshofer M, 2005, STROKE, V36, P1441, DOI 10.1161/01.STR.0000170707.86793.1a; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Eggers J, 2008, STROKE, V39, P1470, DOI 10.1161/STROKEAHA.107.503870; Fischer U, 2005, STROKE, V36, P2121, DOI 10.1161/01.STR.0000182099.04994.fc; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Galimanis A, 2012, STROKE, V43, P1052, DOI 10.1161/STROKEAHA.111.639112; Grunwald IQ, 2009, EUR J NEUROL, V16, P1210, DOI 10.1111/j.1468-1331.2009.02750.x; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hammer MD, 2012, INT J STROKE, V7, P655, DOI 10.1111/j.1747-4949.2011.00719.x; Hammer M, 2009, CEREBROVASC DIS, V28, P406, DOI 10.1159/000235628; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; HENNERICI MG, 1991, J CARDIOVASC PHARM, V18, pS59; Henninger N, 2007, STROKE, V38, P2779, DOI 10.1161/STROKEAHA.107.485581; Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Huisa BN, 2013, INT J STROKE, V8, P315, DOI 10.1111/j.1747-4949.2011.00754.x; Juttler E, 2011, INT J STROKE, V6, P79, DOI 10.1111/j.1747-4949.2010.00544.x; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Khurana D, 2009, INT J STROKE, V4, P480, DOI 10.1111/j.1747-4949.2009.00385.x; Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; Kollmar R, 2012, CURR TREAT OPTION NE, V14, P188, DOI 10.1007/s11940-012-0164-y; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Langer D, 2009, STROKE, V40, P2761, DOI 10.1161/STROKEAHA.108.544957; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Larrue V, 2007, STROKE, V38, P472; Leker RR, 2012, CEREBROVASC DIS, V34, P263, DOI 10.1159/000342668; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Li J, 2010, J CEREBR BLOOD F MET, V30, P480, DOI 10.1038/jcbfm.2009.255; Ma H, 2012, INT J STROKE, V7, P74, DOI 10.1111/j.1747-4949.2011.00730.x; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mazighi M, 2009, LANCET NEUROL, V8, P802, DOI 10.1016/S1474-4422(09)70182-6; Mendonca N, 2014, J NEUROIMAGING, V24, P167, DOI 10.1111/j.1552-6569.2012.00730.x; Mendonca N, 2013, J NEUROIMAGING, V23, P7, DOI 10.1111/j.1552-6569.2011.00666.x; Mokin M, 2012, STROKE, V43, P2362, DOI 10.1161/STROKEAHA.112.655621; Molina CA, 2006, STROKE, V37, P425, DOI 10.1161/01.STR.0000199064.94588.39; Molina CA, 2009, ANN NEUROL, V66, P28, DOI 10.1002/ana.21723; Mpotsaris A, 2012, J NEUROL NEUROSUR PS, V83, P117, DOI 10.1136/jnnp.2010.225573; Nagao K, 2012, CURR OPIN CRIT CARE, V18, P239, DOI 10.1097/MCC.0b013e3283523f4a; Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9; Ogawa A, 2007, STROKE, V38, P2633, DOI 10.1161/STROKEAHA.107.488551; Rohde S, 2011, STROKE, V42, P2954, DOI 10.1161/STROKEAHA.111.616763; Roth C, 2010, STROKE, V41, P2559, DOI 10.1161/STROKEAHA.110.592071; Saether OD, 1996, EUR J VASC ENDOVASC, V12, P81; Roman LS, 2012, STROKE, V43, P1657, DOI 10.1161/STROKEAHA.111.640011; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1; Shuaib A, 2013, J NEUROINTERV SURG, V5, P21, DOI 10.1136/neurintsurg-2012-010562; Shuaib A, 2011, STROKE, V42, P1680, DOI 10.1161/STROKEAHA.110.609933; Smith WS, 2008, STROKE, V39, P1205, DOI 10.1161/STROKEAHA.107.497115; Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d; Stampfl S, 2011, AM J NEURORADIOL, V32, P1245, DOI 10.3174/ajnr.A2505; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; STOKLAND O, 1980, AM J PHYSIOL, V238, pH423, DOI 10.1152/ajpheart.1980.238.4.H423; Tattler E, 2013, CEREBROVASC DIS S3, V33; Thomalla G, 2013, INT J STROKE, DOI [10.1111/ijs.12011, DOI 10.1111/FIS.12011]; Tomsick T, 2008, AM J NEURORADIOL, V29, P582, DOI 10.3174/ajnr.A0843; Tong D, 2012, STROKE, V43, P1912, DOI 10.1161/STROKEAHA.111.644963; Toni D, 2004, CEREBROVASC DIS, V17, P30, DOI 10.1159/000074818; TRUBESTEIN G, 1976, CLIN SCI MOL MED, V51, pS697; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Yarnitsky D, 2005, SURG NEUROL, V64, P5, DOI 10.1016/j.surneu.2004.09.029; Zaidat OO, 2012, NEUROLOGY, V79, pS110, DOI 10.1212/WNL.0b013e3182695916; Zivin JA, 2014, INT J STROKE, V9, P950, DOI 10.1111/j.1747-4949.2012.00896.x; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	91	31	33	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2013	12	6					572	584		10.1016/S1474-4422(13)70091-7	http://dx.doi.org/10.1016/S1474-4422(13)70091-7			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161SL	23684083				2022-12-18	WOS:000320213500012
J	Galpern, WR; Corrigan-Curay, J; Lang, AE; Kahn, J; Tagle, D; Barker, RA; Freeman, TB; Goetz, CG; Kieburtz, K; Kim, SYH; Piantadosi, S; Rick, AC; Federoff, HJ				Galpern, Wendy R.; Corrigan-Curay, Jacqueline; Lang, Anthony E.; Kahn, Jeffrey; Tagle, Danilo; Barker, Roger A.; Freeman, Thomas B.; Goetz, Christopher G.; Kieburtz, Karl; Kim, Scott Y. H.; Piantadosi, Steven; Rick, Amy Comstock; Federoff, Howard J.			Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations	LANCET NEUROLOGY			English	Article							FETAL NIGRAL TRANSPLANTATION; ADVANCED PARKINSONS-DISEASE; PIGMENT EPITHELIAL-CELLS; LONG-TERM SURVIVAL; DOUBLE-BLIND; DOPAMINE NEURONS; INTRASTRIATAL TRANSPLANTATION; NEUROTROPHIC FACTOR; PLACEBO SURGERY; GENE-THERAPY	There have been several recent scientific advances in gene-based and cell-based therapies that might translate into novel therapeutic approaches for neurodegenerative disorders. Such therapies might need to be directly delivered into the CNS, and complex scientific and ethical assessment will be needed to determine whether a sham neurosurgical arm should be included in clinical trials assessing these agents. We have developed a framework of points for investigators to consider when designing trials that involve direct delivery of a therapeutic agent to the CNS. The inclusion of a sham neurosurgical arm will be guided in part by the objectives of the clinical study (preliminary safety, optimisation, and feasibility vs preliminary efficacy vs confirmatory efficacy) and the need to minimise bias and confounds. Throughout the clinical development process, the perspectives of researchers, ethicists, and patients must be considered, and risks should be minimised whenever possible in a manner that is consistent with good trial design.	[Galpern, Wendy R.] NINDS, Off Clin Res, NIH, Bethesda, MD 20892 USA; [Corrigan-Curay, Jacqueline] NIH, Off Biotechnol Act, Bethesda, MD 20892 USA; [Lang, Anthony E.] Toronto Western Hosp, Movement Disorders Ctr, Toronto, ON M5T 2S8, Canada; [Lang, Anthony E.] Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada; [Kahn, Jeffrey] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA; [Barker, Roger A.] Univ Cambridge, Dept Neurol, Cambridge, England; [Freeman, Thomas B.] Univ S Florida, Dept Neurosurg & Brain Repair, Tampa, FL USA; [Goetz, Christopher G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Kieburtz, Karl] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA; [Kim, Scott Y. H.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Kim, Scott Y. H.] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA; [Piantadosi, Steven] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Rick, Amy Comstock] Parkinsons Act Network, Washington, DC USA; [Federoff, Howard J.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Johns Hopkins University; University of Cambridge; State University System of Florida; University of South Florida; Rush University; University of Rochester; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cedars Sinai Medical Center; Georgetown University	Galpern, WR (corresponding author), NINDS, Off Clin Res, NIH, 6001 Execut Blvd,2225, Bethesda, MD 20892 USA.	galpernw@ninds.nih.gov	Lang, Anthony/ABF-8114-2021	Barker, Roger Alistair/0000-0001-8843-7730; Lang, Anthony/0000-0003-1229-3667; Kahn, Jeffrey/0000-0003-2493-2016	Canadian Institutes of Health Research; Dystonia Medical Research Foundation; Michael J Fox Foundation; National Parkinson Foundation; Ontario Problem Gambling Research Centre; National Institutes of Health (NIH); Parkinson's Disease Foundation; Movement Disorder Society; Medivation; National Eye Institute; NINDS; National Institute on Aging (NIA); National Institute of Child Health and Human Development; Neurosearch; Pfizer; NIA; Department of Defense; Medical Research Council [G0800784, G0800784B] Funding Source: researchfish; The Cure Parkinsons Trust [CPT4] Funding Source: researchfish; MRC [G0800784] Funding Source: UKRI	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Dystonia Medical Research Foundation; Michael J Fox Foundation; National Parkinson Foundation; Ontario Problem Gambling Research Centre; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parkinson's Disease Foundation; Movement Disorder Society; Medivation; National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Neurosearch; Pfizer(Pfizer); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Department of Defense(United States Department of Defense); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); The Cure Parkinsons Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	AEL is an adviser for Abbott, Anon Therapeutics, AstraZeneca, Avanir Pharmaceuticals, Biovail, Boehringer-Ingelheim, Cephalon, Ceregene, Eisai, GlaxoSmithKline, Lundbeck, Medtronic, Merck Serono, Novartis, Santhera, Solvay, and Teva; has received grants from Canadian Institutes of Health Research, Dystonia Medical Research Foundation, Michael J Fox Foundation, National Parkinson Foundation, and Ontario Problem Gambling Research Centre; has received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press; and has served as an expert witness in cases related to the welding industry. TBF is a consultant for SanBio, Spine Guard, Synthes Spine, Medtronic, Alnylam Pharmaceuticals, and Signus; Medical Director for Saneron CCEL Therapeutics; scientific advisory board member for Neural Stem; Founding Scientist, President, Chairman of the Board for Ciracell; receives fees for consulting for all the aforementioned companies; holds stock options for NeuralStem, Saneron, and Ciracell; has a licensing agreement with Medtronic Neuromodulation; and holds patents and provisional patents, numbers 7896889,7981120,7963980,8012159 B2,7699854,7416885, and 6528245. CGG receives honoraria for consulting and advisory board membership from Addex Pharma, Asubio, Biovail Technologies, Boston Scientific, Cleveland Medical Devices, Decision Resources, Dixon Group, ICON Clinical Research, Impax Pharmaceuticals, Ingenix (i3 Research), Intec Pharmaceuticals, Kenes International, Motac Neurosciences, Oxford Biomedica, United Bioscience Corporation, and UCB; grants or research funding from the National Institutes of Health (NIH) and Michael J Fox Foundation; honoraria from the Movement Disorder Society, American Academy of Neurology, University of Pennsylvania, Washington University, and University of Michigan; and royalties from Oxford University Press, Elsevier Publishers, Wolters Kluwer Health, and Lippincott, Wilkins and Williams. CGG directs the Rush Parkinson's Disease Research Center, which receives support from the Parkinson's Disease Foundation, and directs the translation programme for the MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale) and UDysRS (unified dyskinesia rating scale), for which he receives funds from the Movement Disorder Society. KK is a consultant for the National Institute of Neurological Disorders and Stroke (NINDS), The US Food and Drug Administration, The US Veteran's Administration, Abbott, Acorda, Aptiv, Biogen Idec, Biotie, Biovail, Boehringer Ingelheim, Ceregene, Civitas, Clintrex, Cynapsus, EMD Merck Serono, Genzyme, Impax, Intec, Ipsen, Isis, Knopp, Lilly, Link Medicine, Lundbeck, LZ Therapeutics, Merz, Novartis, Orion, Otsuka, Pharm2B, Phytopharm, Schering-Plough, Siena Biotech, Synosia, Solvay, Synagile, Teva, UCB Pharma, Vaccinex, Vectura, and Xenoport; receives grants or research support from Medivation, Michael J Fox Foundation, National Eye Institute, NINDS, National Institute on Aging (NIA), National Institute of Child Health and Human Development, Neurosearch, and Pfizer; and does legal consulting for Pfizer, Thompson Hine, and welding rod litigation defendants. HJF is founder, equity participant, and scientific advisor for MedGenesis; founder and equity participant of Socratec; board member for the American Federation for Aging Research and Biomedical Research and Education Foundation; adviser for Oxford University Parkinson's Disease Center; and has received grants from NINDS, NIA, and the Department of Defense.; All other authors declare that they have no conflicts of interest.; The National Institutes of Health (NIH) convened a meeting of international experts to discuss the complex issues surrounding the decision to include sham neurosurgical procedures in clinical trials at a workshop entitled Sham Neurological Procedures in Clinical Trials for Neurodegenerative Diseases: Scientific and Ethical Considerations (June 30 July 1,2010). The deliberations at this meeting were used in the development of this manuscript, and the authors acknowledge the contributions of the meeting participants. Authors were selected by the Organising Committee (WRG, JC-C, AEL, DT, and HJF) to represent the areas of expertise and opinions represented at the meeting. Authors include the members of the Organising Committee and a subset of meeting participants with expertise in clinical trials, neurology, neurosurgery, basic science research, ethics, and patient advocacy. A participant roster, slide presentations, written public comments, and a webcast are available online. The meeting was funded by the NIH. We also thank the following staff from the Office of Biotechnology Activities, NIH, for their contributions in bringing together this symposium: R Jambou, E Rosenthal, M O'Reilly, M Montgomery, and L Gargiulo. We also thank Perry Cohen for his contributions in the development of this symposium. The points described should not be interpreted to represent a consensus statement or the opinions of any individual or the NIH.	Albin RL, 2002, J MED ETHICS, V28, P324, DOI 10.1136/jme.28.5.322; Alterman RL, 2011, ANN NEUROL, V70, P5, DOI 10.1002/ana.22453; [Anonymous], 2002, Mov Disord, V17 Suppl 4, pS148; Appelbaum PS, 2010, CURR NEUROL NEUROSCI, V10, P367, DOI 10.1007/s11910-010-0123-5; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Bjorklund A, 2010, PROG BRAIN RES, V184, P265, DOI 10.1016/S0079-6123(10)84014-2; *CIOMS, 2002, INT ETH GUID BIOM RE; Cohen PD, 2007, NEUROTHERAPEUTICS, V4, P537, DOI 10.1016/j.nurt.2007.04.008; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Frank S, 2005, NEUROLOGY, V65, P1101, DOI 10.1212/01.wnl.0000171957.90640.b5; Frank SA, 2008, MOVEMENT DISORD, V23, P63, DOI 10.1002/mds.21775; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Goetz CG, 2005, MOVEMENT DISORD, V20, P523, DOI 10.1002/mds.20464; GOETZ CG, 1991, NEUROLOGY, V41, P1719, DOI 10.1212/WNL.41.11.1719; Goetz CG, 2008, MOVEMENT DISORD, V23, P690, DOI 10.1002/mds.21894; Gross RE, 2011, LANCET NEUROL, V10, P509, DOI 10.1016/S1474-4422(11)70097-7; Hallett M, 1999, NEUROLOGY, V53, P1910, DOI 10.1212/WNL.53.9.1910; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; Hauser RA, 2001, MOVEMENT DISORD, V16, P983; Horng SH, 2007, NEUROTHERAPEUTICS, V4, P531, DOI 10.1016/j.nurt.2007.03.001; Katsnelson A, 2011, NATURE, V476, P142, DOI 10.1038/476142a; Kim SY, RES STUDIES PATIENT; Kim SYH, 2005, ARCH NEUROL-CHICAGO, V62, P1357, DOI 10.1001/archneur.62.9.1357; Kimmelman J, 2011, MOVEMENT DISORD, V26, P1415, DOI 10.1002/mds.23770; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS10; LeWitt PA, 2011, LANCET NEUROL, V10, P309, DOI 10.1016/S1474-4422(11)70039-4; Lidstone SC, 2010, ARCH GEN PSYCHIAT, V67, P857, DOI 10.1001/archgenpsychiatry.2010.88; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; Marks WJ, 2010, LANCET NEUROL, V9, P1164, DOI 10.1016/S1474-4422(10)70254-4; McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412; Miller FG, 2003, AM J BIOETHICS, V3, P41, DOI 10.1162/152651603322614580; National Institutes of Health, SHAM NEUR PROC CLIN; Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; PESCHANSKI M, 1994, BRAIN, V117, P487, DOI 10.1093/brain/117.3.487; Piantadosi S, 2005, WILEY SER PROBAB ST, P1, DOI 10.1002/0471740136; Politis M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000976; Prehn AW, 2006, NEUROLOGY, V67, P1503, DOI 10.1212/01.wnl.0000240221.78518.5e; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Stover NP, 2005, ARCH NEUROL-CHICAGO, V62, P1833, DOI 10.1001/archneur.62.12.1833; Wakeman DR, 2011, MT SINAI J MED, V78, P126, DOI 10.1002/msj.20233; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115	54	31	31	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2012	11	7					643	650		10.1016/S1474-4422(12)70064-9	http://dx.doi.org/10.1016/S1474-4422(12)70064-9			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969YN	22710757				2022-12-18	WOS:000306095400011
J	Ment, LR; Vohr, BR				Ment, Laura R.; Vohr, Betty R.			Preterm birth and the developing brain	LANCET NEUROLOGY			English	Editorial Material							PREMATURELY BORN CHILDREN; VOLUME; INFANTS; GROWTH; AGE		[Ment, Laura R.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Vohr, Betty R.] Brown Univ, Warren Alpert Med Sch, Dept Pediat, Providence, RI 02912 USA	Yale University; Brown University	Ment, LR (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06510 USA.	laura.ment@yale.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027116] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS027116, R01 NS027116-19] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Als H, 2004, PEDIATRICS, V114, P1739, DOI 10.1542/peds.2004-1938; Boardman JP, 2007, ANN NEUROL, V62, P185, DOI 10.1002/ana.21171; Constable RT, 2008, PEDIATRICS, V121, P306, DOI 10.1542/peds.2007-0414; Counsell SJ, 2003, ARCH DIS CHILD-FETAL, V88, P269, DOI 10.1136/fn.88.4.F269; Counsell SJ, 2005, SEMIN FETAL NEONAT M, V10, P403, DOI 10.1016/j.siny.2005.05.003; Gimenez M, 2006, NEUROLOGY, V67, P1818, DOI 10.1212/01.wnl.0000244485.51898.93; Gimenez M, 2006, NEUROIMAGE, V32, P1485, DOI 10.1016/j.neuroimage.2006.05.013; Kapellou O, 2006, PLOS MED, V3, P1382, DOI 10.1371/journal.pmed.0030265; Larroque B, 2008, LANCET, V371, P813, DOI 10.1016/S0140-6736(08)60380-3; Ment LR, 2007, NAT CLIN PRACT NEURO, V3, P558, DOI 10.1038/ncpneuro0616; Nosarti C, 2008, BRAIN, V131, P205, DOI 10.1093/brain/awm282; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Reiss AL, 2004, J PEDIATR-US, V145, P242, DOI 10.1016/j.jpeds.2004.04.031; Rushe TM, 2004, ARCH DIS CHILD-FETAL, V89, P112, DOI 10.1136/adc.2001.005314; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Shaywitz BA, 2004, BIOL PSYCHIAT, V55, P926, DOI 10.1016/j.biopsych.2003.12.019; Vasileiadis GT, 2004, PEDIATRICS, V114, pE367, DOI 10.1542/peds.2004-0500	17	31	32	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2008	7	5					378	379		10.1016/S1474-4422(08)70073-5	http://dx.doi.org/10.1016/S1474-4422(08)70073-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	296AB	18420149	Green Accepted			2022-12-18	WOS:000255514800005
J	Ibrahim, A; Li, Y; Li, DQ; Raisman, G; El Masry, WS				Ibrahim, A; Li, Y; Li, DQ; Raisman, G; El Masry, WS			Olfactory ensheathing cells: ripples of an incoming tide?	LANCET NEUROLOGY			English	Article							SPINAL-CORD-INJURY; AXONAL REGENERATION; FUNCTIONAL RECOVERY; DELAYED TRANSPLANTATION; CORTICOSPINAL TRACT; LOCOMOTOR RECOVERY; GLIAL-CELLS; BULB; CNS; REPAIR	Until now, brain and spinal cord injuries that sever nerve fibres have resulted in a degree of incurable functional loss. An incoming tide of research is now beginning to challenge this as yet unbreached sea wall. One of the most promising approaches involves a recently discovered type of cell, the olfactory ensheathing cell, which can be obtained from the adult nasal lining. In animal models transplantation of cultured olfactory ensheathing cells into an injured spinal cord induces regeneration, remyelination of severed spinal nerve fibres, and functional recovery. Although several clinical centres worldwide have shown an interest in applying this approach to patients with spinal cord injury, there is no agreement on cell technology, and claims of beneficial results lack independent confirmation. Important aspects still need to be worked out at the laboratory level. Overall, the outlook is optimistic, but there is still some way to go.	UCL, Inst Neurol, Spinal Repair Unit, London WC1N 3BG, England; RJ & AH Orthopaed Hosp, Midland Ctr Spinal Injuries, Oswestry, Shrops, England	University of London; University College London	Raisman, G (corresponding author), UCL, Inst Neurol, Spinal Repair Unit, Queen Sq, London WC1N 3BG, England.	g.raisman@ion.ucl.ac.uk	Raisman, Geoffrey/B-3215-2009					Anderson DK, 2005, SPINAL CORD, V43, P453, DOI 10.1038/sj.sc.3101746; Au Edmund, 2002, Methods Mol Biol, V198, P49; BARBER PC, 1978, BRAIN RES, V147, P297, DOI 10.1016/0006-8993(78)90841-7; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Barnett SC, 2004, TRENDS NEUROSCI, V27, P54, DOI 10.1016/j.tins.2003.10.011; BARNETT SC, 1993, DEV BIOL, V155, P337, DOI 10.1006/dbio.1993.1033; Bianco JI, 2004, GLIA, V45, P111, DOI 10.1002/glia.10298; Boerger TO, 2000, J BONE JOINT SURG BR, V82B, P629, DOI 10.1302/0301-620X.82B5.11321; Boyd J G, 2003, Anat Rec B New Anat, V271, P49, DOI 10.1002/ar.b.10011; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cajal S. Ramon, 1928, DEGENERATION REGENER; CARR VM, 1992, EXP NEUROL, V115, P55, DOI 10.1016/0014-4886(92)90221-B; Curt A, 2005, LANCET, V365, P841, DOI 10.1016/S0140-6736(05)71031-X; Curt A, 2004, SPINAL CORD, V42, P1, DOI 10.1038/sj.sc.3101558; DEVON R, 1992, BRAIN RES, V589, P175; DOUCETTE JR, 1984, ANAT REC, V210, P385, DOI 10.1002/ar.1092100214; DOUCETTE JR, 1983, J ANAT, V137, P1; ElMasry WS, 1996, SPINE, V21, P614, DOI 10.1097/00007632-199603010-00015; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; Feron F, 2005, BRAIN, V128, P2951, DOI 10.1093/brain/awh657; Field PM, 2003, J NEUROCYTOL, V32, P317, DOI 10.1023/B:NEUR.0000010089.37032.48; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; FOLMAN Y, 1989, INJURY, V20, P92, DOI 10.1016/0020-1383(89)90148-4; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Fouad K, 2004, EUR J NEUROSCI, V20, P2479, DOI 10.1111/j.1460-9568.2004.03716.x; Frankel H L, 1969, Paraplegia, V7, P179; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713, DOI 10.1016/0306-4522(79)90002-2; Guest J, 2006, SPINAL CORD, V44, P135, DOI 10.1038/sj.sc.3101820; Herrera LP, 2005, J COMP NEUROL, V488, P427, DOI 10.1002/cne.20588; Huang HY, 2003, CHINESE MED J-PEKING, V116, P1488; Huard JMT, 1998, J COMP NEUROL, V400, P469; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Imaizumi T, 2000, NAT BIOTECHNOL, V18, P949, DOI 10.1038/79432; Jani HR, 2004, GLIA, V47, P130, DOI 10.1002/glia.20038; Jeffery ND, 2005, J NEUROTRAUM, V22, P1282, DOI 10.1089/neu.2005.22.1282; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Katoh S, 1996, SPINE, V21, P2345, DOI 10.1097/00007632-199610150-00008; KATOH S, 1994, J BONE JOINT SURG BR, V76B, P225, DOI 10.1302/0301-620X.76B2.8113281; KATOH S, 1995, PARAPLEGIA, V33, P506, DOI 10.1038/sc.1995.110; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; King VR, 2003, EXP NEUROL, V182, P383, DOI 10.1016/S0014-4886(03)00033-5; Kumar R, 2005, GLIA, V50, P12, DOI 10.1002/glia.20154; Lakatos A, 2003, BRAIN, V126, P598, DOI 10.1093/brain/awg055; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; Li Y, 2003, J NEUROSCI, V23, P727; LI Y, IN PRESS J NEUROCYTO; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; MACKAYSIM A, 1991, J NEUROSCI, V11, P979; MURPHY KP, 1990, MAYO CLIN PROC, V65, P949, DOI 10.1016/S0025-6196(12)65156-8; Nash HH, 2001, GLIA, V34, P81, DOI 10.1002/glia.1043; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; RAISMAN G, 1985, NEUROSCIENCE, V14, P237, DOI 10.1016/0306-4522(85)90176-9; RAISMAN G, 1969, BRAIN RES, V14, P25, DOI 10.1016/0006-8993(69)90029-8; Ramer LM, 2004, GLIA, V47, P189, DOI 10.1002/glia.20054; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; RAMONCUETO A, 1992, NEUROSCIENCE, V47, P213, DOI 10.1016/0306-4522(92)90134-N; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; Richter MW, 2005, J NEUROSCI, V25, P10700, DOI 10.1523/JNEUROSCI.3632-05.2005; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Schwob JE, 1999, J COMP NEUROL, V412, P439, DOI 10.1002/(SICI)1096-9861(19990927)412:3<439::AID-CNE5>3.0.CO;2-H; Senior K, 2002, LANCET NEUROL, V1, P269, DOI 10.1016/S1474-4422(02)00145-X; Shaw D, 2003, J CRANIOFAC SURG, V14, P308, DOI 10.1097/00001665-200305000-00008; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith PM, 2002, EXP NEUROL, V176, P402, DOI 10.1006/exnr.2002.7936; TATOR CH, 1987, CAN J NEUROL SCI, V14, P60; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; Watts J, 2005, LANCET, V365, P109, DOI 10.1016/S0140-6736(05)17721-6; Woerly S, 2000, NEUROSURG REV, V23, P59; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113	79	31	40	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					453	457		10.1016/S1474-4422(06)70444-6	http://dx.doi.org/10.1016/S1474-4422(06)70444-6			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16632316				2022-12-18	WOS:000237147600027
J	Quaglio, G; Gallucci, M; Brand, H; Dawood, A; Cobello, F				Quaglio, Gianluca; Gallucci, Maurizio; Brand, Helmut; Dawood, Amr; Cobello, Francesco			Traumatic brain injury: a priority for public health policy	LANCET NEUROLOGY			English	Editorial Material									[Quaglio, Gianluca; Dawood, Amr] European Parliament, Sci Foresight Unit STOA, European Parliamentary Res Serv, Brussels, Belgium; [Gallucci, Maurizio] Local Hlth Author 2 Marca Trevigiana, Cognit Impairment Ctr, Treviso, Italy; [Brand, Helmut] Univ Maastricht, Dept Int Hlth, Maastricht, Netherlands; [Brand, Helmut] Univ Maastricht, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [Quaglio, Gianluca; Cobello, Francesco] Univ Hosp Integrated Trust AOUI, Verona, Italy	Maastricht University; Maastricht University; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Quaglio, G (corresponding author), European Parliament, Sci Foresight Unit STOA, European Parliamentary Res Serv, Brussels, Belgium.; Quaglio, G (corresponding author), Univ Hosp Integrated Trust AOUI, Verona, Italy.	gianluca.quaglio@europarl.europa.eu	Gallucci, Maurizio/K-1422-2018; Brand, Helmut/F-6368-2013	Gallucci, Maurizio/0000-0001-6329-3195; Brand, Helmut/0000-0002-2755-0673				Brownson RC, 2006, AM J PREV MED, V30, P164, DOI 10.1016/j.amepre.2005.10.004; Carrillo MC., 2016, ALZHEIMERS ASS GLOBA; Greer SL, 2014, HEALTH POLICY, V116, P12, DOI 10.1016/j.healthpol.2014.01.019; Grimshaw JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jayaraman S, 2011, WORLD J SURG, V35, P505, DOI 10.1007/s00268-010-0871-z; Maas AIR, 2017, LANCET NEUROL; National Institutes of Health, INT ALZH DIS RES POR; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Quaglio G, 2015, LANCET NEUROL, V14, P243, DOI 10.1016/S1474-4422(15)70014-1; Walentas CD, 2011, ALZHEIMERS DEMENT, V7, P142, DOI 10.1016/j.jalz.2010.11.010	11	30	30	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2017	16	12					951	952		10.1016/S1474-4422(17)30370-8	http://dx.doi.org/10.1016/S1474-4422(17)30370-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM8DJ	29122519	Green Submitted			2022-12-18	WOS:000415315400005
J	Filippi, M; Agosta, F; Grosskreutz, J; Benatar, M; Kassubek, J; Verstraete, E; Turner, MR				Filippi, Massimo; Agosta, Federica; Grosskreutz, Julian; Benatar, Michael; Kassubek, Jan; Verstraete, Esther; Turner, Martin R.		Neuroimaging Soc ALS NiSALS	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material									[Filippi, Massimo; Agosta, Federica] Univ Vita Salute San Raffaele, Inst Expt Neurol, San Raffaele Sci Inst, Neuroimaging Res Unit, I-20132 Milan, Italy; [Filippi, Massimo] Univ Vita Salute San Raffaele, Inst Expt Neurol, San Raffaele Sci Inst, Dept Neurol, I-20132 Milan, Italy; [Grosskreutz, Julian] Univ Hosp Jena, Hans Berger Dept Neurol, Jena, Germany; [Benatar, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Kassubek, Jan] Univ Ulm, Dept Neurol, D-89069 Ulm, Germany; [Verstraete, Esther] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht, Netherlands; [Turner, Martin R.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Friedrich Schiller University of Jena; University of Miami; Ulm University; Utrecht University; Utrecht University Medical Center; University of Oxford	Filippi, M (corresponding author), Univ Vita Salute San Raffaele, Inst Expt Neurol, San Raffaele Sci Inst, Neuroimaging Res Unit, I-20132 Milan, Italy.	filippi.massimo@hsr.it	Filippi, Massimo/K-1755-2018; Kassubek, Jan/GPX-0910-2022; Grosskreutz, Julian/G-2293-2010; Kassubek, Jan/F-2774-2015; Benatar, Michael/AAF-6605-2019; Kassubek, Jan/O-1740-2019; Agosta, Federica/J-9908-2016	Filippi, Massimo/0000-0002-5485-0479; Kassubek, Jan/0000-0002-7106-9270; Grosskreutz, Julian/0000-0001-9525-1424; Kassubek, Jan/0000-0002-7106-9270; Benatar, Michael/0000-0003-4241-5135; Kassubek, Jan/0000-0002-7106-9270; Turner, Martin/0000-0003-0267-3180; Agosta, Federica/0000-0003-3121-4979	Motor Neurone Disease Association [Turner/Jan13/944-795] Funding Source: researchfish; MRC [MR/K000780/1, MR/K01014X/1] Funding Source: UKRI; Medical Research Council [MR/K000780/1, MR/K01014X/1] Funding Source: Medline; Motor Neurone Disease Association [TURNER/JAN13/944-795] Funding Source: Medline	Motor Neurone Disease Association; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Motor Neurone Disease Association		Abrahams S, 2013, AMYOTROPH LAT SCL FR, V14, P3, DOI 10.3109/21678421.2013.760149; Benatar M, 2012, NEUROLOGY, V79, P1732, DOI 10.1212/WNL.0b013e31826e9b1d; Braak H, 2013, NAT REV NEUROL, V9, P708, DOI 10.1038/nrneurol.2013.221; Carew JD, 2011, NEUROLOGY, V77, P1370, DOI 10.1212/WNL.0b013e318231526a; Chio A, 2014, LANCET NEUROL, V13, P1228, DOI 10.1016/S1474-4422(14)70167-X; Chio A, 2014, J NEUROL NEUROSUR PS, V85, P478, DOI 10.1136/jnnp-2013-305546; Foerster BR, 2013, JAMA NEUROL, V70, P1009, DOI 10.1001/jamaneurol.2013.234; Kassubek J, 2014, BRAIN, V137, P1733, DOI 10.1093/brain/awu090; Renton AE, 2014, NAT NEUROSCI, V17, P17, DOI 10.1038/nn.3584; Turner MR, 2013, LANCET NEUROL, V12, P310, DOI 10.1016/S1474-4422(13)70036-X; Turner MR, 2012, AMYOTROPH LATERAL SC, V13, P245, DOI 10.3109/17482968.2011.636050; Turner MR, 2011, LANCET NEUROL, V10, P400, DOI 10.1016/S1474-4422(11)70049-7; Verstraete E, 2014, HUM BRAIN MAPP, V35, P1351, DOI 10.1002/hbm.22258	13	30	30	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2015	14	8					786	788		10.1016/S1474-4422(15)00134-9	http://dx.doi.org/10.1016/S1474-4422(15)00134-9			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM7MZ	26194923				2022-12-18	WOS:000357879200006
J	Zetterberg, H; Blennow, K				Zetterberg, Henrik; Blennow, Kaj			Plasma A beta in Alzheimer's disease - up or down?	LANCET NEUROLOGY			English	Editorial Material							FOLLOW-UP; A-BETA-42		Univ Gothenburg, Sahlgrens Univ Hosp, Inst Neurosci & Physiol, Clin Neurochem Lab, S-43180 Molndal, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Zetterberg, H (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Inst Neurosci & Physiol, Clin Neurochem Lab, S-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se						Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; BLENNOW K, 2006, IN PRESS LANCET; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Irizarry Michael C, 2004, NeuroRx, V1, P226; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Kuo YM, 1999, BIOCHEM BIOPH RES CO, V257, P787, DOI 10.1006/bbrc.1999.0552; Mayeux R, 2003, NEUROLOGY, V61, P1185, DOI 10.1212/01.WNL.0000091890.32140.8F; Peskind ER, 2005, ALZ DIS ASSOC DIS, V19, P220, DOI 10.1097/01.wad.0000194014.43575.fd; Pomara N, 2005, AM J GERIAT PSYCHIAT, V13, P914; van Oijen M, 2006, LANCET NEUROL, V5, P655, DOI 10.1016/S1474-4422(06)70501-4	11	30	30	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2006	5	8					638	639		10.1016/S1474-4422(06)70503-8	http://dx.doi.org/10.1016/S1474-4422(06)70503-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	068ZV	16857565				2022-12-18	WOS:000239415100002
J	Bushnell, CD				Bushnell, CD			Oestrogen and stroke in women: assessment of risk	LANCET NEUROLOGY			English	Review							HORMONE REPLACEMENT THERAPY; DOSE ORAL-CONTRACEPTIVES; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; POSTMENOPAUSAL WOMEN; ISCHEMIC-STROKE; NITRIC-OXIDE; THROMBOEMBOLIC DISEASE; ENDOTHELIAL FUNCTION; BLOOD-COAGULATION	The Women's Health Initiative reported an increased risk of stroke with hormone therapy, which has had a major effect on the use of these drugs. The increased risk was unexpected because research with animals showed that oestrogen reduces the extent of experimental strokes, and in human beings, oestrogen improves endothelial-dependent blood flow and lipid profiles. The mechanisms of risk might be related to oestrogen's proinflammatory and prothrombotic effects. However, the overall risk is still uncertain because of the complex actions of oestrogen at different doses, with or without progesterone, and the presence or absence of atherosclerotic risk factors. A similar debate about oral contraceptives and stroke risk in young women continues as data accumulate. Further studies are needed to identify the mechanisms of risk of stroke with oestrogen, as well as the risk factors that put women at particularly high risk of stroke with these hormones.	Duke Univ, Med Ctr, Ctr Cerebrovasc Dis, Dept Med, Durham, NC 27710 USA	Duke University	Bushnell, CD (corresponding author), Duke Univ, Med Ctr, Ctr Cerebrovasc Dis, Dept Med, Box 2900, Durham, NC 27710 USA.	Cheryl.bushnell@duke.edu						Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; American Heart Association, 2003, HEART DIS STROK STAT; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Angeja BG, 2001, J AM COLL CARDIOL, V38, P1297, DOI 10.1016/S0735-1097(01)01551-0; Angerer P, 2000, J AM COLL CARDIOL, V36, P1789, DOI 10.1016/S0735-1097(00)00969-4; Angerer P, 2001, ARTERIOSCL THROM VAS, V21, P262, DOI 10.1161/01.ATV.21.2.262; AZMI NA, 1996, CIRCULATION, V94, P1857; Best PJM, 1998, ANN INTERN MED, V128, P285, DOI 10.7326/0003-4819-128-4-199802150-00006; Boudoulas KD, 2001, ARCH PATHOL LAB MED, V125, P112; Brownley KA, 2004, AM J OBSTET GYNECOL, V190, P1052, DOI 10.1016/j.ajog.2003.09.045; Bui MN, 2002, AM J CARDIOL, V90, P82, DOI 10.1016/S0002-9149(02)02397-4; Bukowska H, 2005, METABOLISM, V54, P72, DOI 10.1016/j.metabol.2004.07.015; Bushnell CD, 2004, NEUROLOGY, V62, P968, DOI 10.1212/01.WNL.0000115171.46508.19; Chan WS, 2004, ARCH INTERN MED, V164, P741, DOI 10.1001/archinte.164.7.741; Cushman M, 1999, ARTERIOSCL THROM VAS, V19, P893, DOI 10.1161/01.ATV.19.4.893; d'Arcangues C, 1999, CONTRACEPTION, V59, P31; ESPELAND MA, 1995, AM J EPIDEMIOL, V142, P1011, DOI 10.1093/oxfordjournals.aje.a117553; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; Fung MM, 1999, J WOMENS HEALTH, V8, P359, DOI 10.1089/jwh.1999.8.359; GANGAR KF, 1991, LANCET, V338, P839; Gerhard M, 1998, CIRCULATION, V98, P1158, DOI 10.1161/01.CIR.98.12.1158; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; Glueck CJ, 2002, METABOLISM, V51, P724, DOI 10.1053/meta.2002.32729; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; HASHIMOTO M, 1995, CIRCULATION, V92, P3431, DOI 10.1161/01.CIR.92.12.3431; Heinemann LAJ, 1997, BRIT MED J, V315, P1502, DOI 10.1136/bmj.315.7121.1502; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2002, CIRCULATION, V105, P2962, DOI 10.1161/01.CIR.0000019406.74017.B2; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Honisett SY, 2004, J CLIN ENDOCR METAB, V89, P4615, DOI 10.1210/jc.2003-031414; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hurn PD, 2003, STROKE, V34, P338, DOI 10.1161/01.STR.0000054051.88378.25; Kemmeren JM, 2002, STROKE, V33, P1202, DOI 10.1161/01.STR.0000015345.61324.3F; Koh KK, 2001, J AM COLL CARDIOL, V38, P1409, DOI 10.1016/S0735-1097(01)01566-2; Lemaitre RN, 2002, ARCH INTERN MED, V162, P1954, DOI 10.1001/archinte.162.17.1954; Levin RI, 2005, NEW ENGL J MED, V352, P1366, DOI 10.1056/NEJMe058051; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; Lidegaard O, 1998, CONTRACEPTION, V57, P303, DOI 10.1016/S0010-7824(98)00032-8; LIEBERMAN EH, 1994, ANN INTERN MED, V121, P936, DOI 10.7326/0003-4819-121-12-199412150-00005; Lim SC, 1999, J CLIN ENDOCR METAB, V84, P4159, DOI 10.1210/jc.84.11.4159; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; Lokkegaard E, 2003, ARCH NEUROL-CHICAGO, V60, P1379, DOI 10.1001/archneur.60.10.1379; Majmudar NG, 2000, J CLIN ENDOCR METAB, V85, P1577, DOI 10.1210/jc.85.4.1577; Martinelli I, 1996, THROMB HAEMOSTASIS, V75, P393; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McKenzie J, 2003, CLIN ENDOCRINOL, V59, P682, DOI 10.1046/j.1365-2265.2003.01906.x; Oliveira RLS, 2005, INT J CARDIOL, V99, P449, DOI 10.1016/j.ijcard.2004.10.009; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; PFEFFER RI, 1976, AM J EPIDEMIOL, V103, P445, DOI 10.1093/oxfordjournals.aje.a112246; Poulter NR, 1996, LANCET, V348, P498; Pradhan AD, 2002, JAMA-J AM MED ASSOC, V288, P980, DOI 10.1001/jama.288.8.980; Prestwood KM, 2004, J GERONTOL A-BIOL, V59, P827; Reiner AP, 2000, STROKE, V31, P1628, DOI 10.1161/01.STR.31.7.1628; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scarabin PY, 1997, ARTERIOSCL THROM VAS, V17, P3071, DOI 10.1161/01.ATV.17.11.3071; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Siritho S, 2003, STROKE, V34, P1575, DOI 10.1161/01.STR.0000077925.16041.6B; Slooter AJC, 2005, NEUROLOGY, V64, pA280; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; Sumino H, 2005, THROMB RES, V115, P359, DOI 10.1016/j.thromres.2004.08.017; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745	80	30	32	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					743	751		10.1016/S1474-4422(05)70220-9	http://dx.doi.org/10.1016/S1474-4422(05)70220-9			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16239181				2022-12-18	WOS:000233002400019
J	Vijiaratnam, N; Simuni, T; Bandmann, O; Morris, HR; Foltynie, T				Vijiaratnam, Nirosen; Simuni, Tanya; Bandmann, Oliver; Morris, Huw R.; Foltynie, Thomas			Progress towards therapies for disease modification in Parkinson's disease	LANCET NEUROLOGY			English	Article							REDUCES ALPHA-SYNUCLEIN; LRRK2 KINASE-ACTIVITY; DELAYED-START TRIAL; CLINICAL-TRIAL; MYELOPEROXIDASE INHIBITOR; MITOCHONDRIAL DYSFUNCTION; MODIFYING THERAPY; ANIMAL-MODELS; DOUBLE-BLIND; MOUSE MODEL	The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.	[Vijiaratnam, Nirosen; Morris, Huw R.; Foltynie, Thomas] UCL Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, London WC1N 3BG, England; [Vijiaratnam, Nirosen; Morris, Huw R.; Foltynie, Thomas] Natl Hosp Neurol & Neurosurg, Queen Sq, London, England; [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Parkinsons Dis & Movement Disorders Ctr, Chicago, IL 60611 USA; [Bandmann, Oliver] Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Northwestern University; Feinberg School of Medicine; University of Sheffield	Foltynie, T (corresponding author), UCL Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, London WC1N 3BG, England.	t.foltynie@ucl.ac.uk	Morris, Huw R/B-8527-2008	Morris, Huw R/0000-0002-5473-3774	Janet Owens charitable foundation	Janet Owens charitable foundation	NV's research time and position is funded by the Janet Owens charitable foundation.	Aflaki E, 2016, J NEUROSCI, V36, P7441, DOI 10.1523/JNEUROSCI.0636-16.2016; Alcalay RN, 2015, BRAIN, V138, P2648, DOI 10.1093/brain/awv179; ALEXANDER GM, 1994, NEUROLOGY, V44, P1511, DOI 10.1212/WNL.44.8.1511; Arora S, 2018, NEUROLOGY, V91, P1528, DOI 10.1212/WNL.0000000000006366; Athauda D, 2019, JAMA NEUROL, V76, P420, DOI 10.1001/jamaneurol.2018.4304; Athauda D, 2017, LANCET, V390, P1664, DOI 10.1016/S0140-6736(17)31585-4; Aviles-Olmos I, 2014, J PARKINSON DIS, V4, P337, DOI 10.3233/JPD-140364; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Barker RA, 2020, J PARKINSON DIS, V10, P875, DOI 10.3233/JPD-202004; Beal MF, 2014, JAMA NEUROL, V71, P543, DOI 10.1001/jamaneurol.2014.131; Becker C, 2008, NEUROLOGY, V70, P1438, DOI 10.1212/01.wnl.0000303818.38960.44; Bergstrom AL, 2016, MOVEMENT DISORD, V31, P203, DOI 10.1002/mds.26481; Bezard E, 2013, MOVEMENT DISORD, V28, P61, DOI 10.1002/mds.25108; Braak H, 2003, J NEURAL TRANSM, V110, P517, DOI 10.1007/s00702-002-0808-2; Broen JCA, 2020, NAT REV RHEUMATOL, V16, P167, DOI 10.1038/s41584-020-0374-8; Brown EG, 2020, NEUROTHERAPEUTICS, V17, P1406, DOI 10.1007/s13311-020-00942-2; Burbulla LF, 2017, SCIENCE, V357, P1255, DOI 10.1126/science.aam9080; Carling PJ, 2020, PROG NEUROBIOL, V187, DOI 10.1016/j.pneurobio.2020.101772; Carroll C., 2020, MDS VIRT C 2020 LAT; Carroll CB, 2017, J PARKINSON DIS, V7, P545, DOI 10.3233/JPD-171203; Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chen SC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28449-z; Chen ZM, 2013, NEUROL SCI, V34, P1559, DOI 10.1007/s10072-012-1284-6; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Cresto N, 2019, EUR J NEUROSCI, V49, P339, DOI 10.1111/ejn.14182; DEXTER DT, 1987, LANCET, V2, P1219; Di Maio R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar5429; Do J, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0336-2; Duty S, 2011, BRIT J PHARMACOL, V164, P1357, DOI 10.1111/j.1476-5381.2011.01426.x; Eberling JL, 2013, J PARKINSON DIS, V3, P565, DOI 10.3233/JPD-130247; Ekstrand MI, 2009, PARKINSONISM RELAT D, V15, pS185, DOI 10.1016/S1353-8020(09)70811-9; Elm JJ, 2012, MOVEMENT DISORD, V27, P1513, DOI 10.1002/mds.25175; Engelender S, 2017, TRENDS NEUROSCI, V40, P4, DOI 10.1016/j.tins.2016.10.008; Espay Alberto J, 2016, Mov Disord, V31, P1272, DOI 10.1002/mds.26642; Espay AJ, 2020, NEUROLOGY, V94, P481, DOI 10.1212/WNL.0000000000009107; Exner N, 2012, EMBO J, V31, P3038, DOI 10.1038/emboj.2012.170; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Fiske B., 2019, J PARKINSONS DIS, V9; Fowler AJ, 2018, CNS DRUGS, V32, P1, DOI 10.1007/s40263-018-0497-5; Gan-Or Z, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0860-4; Gao HM, 2011, ENVIRON HEALTH PERSP, V119, P807, DOI 10.1289/ehp.1003013; Gellhaar S, 2017, CELL TISSUE RES, V369, P445, DOI 10.1007/s00441-017-2626-8; Gendelman HE, 2017, NPJ PARKINSONS DIS, V3, DOI 10.1038/s41531-017-0013-5; Gong L, 2012, J NEUROCHEM, V123, P876, DOI 10.1111/jnc.12038; Gordon R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah4066; Greenland JC, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040527; Halliday GM, 2011, MOVEMENT DISORD, V26, P6, DOI 10.1002/mds.23455; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hebron ML, 2013, HUM MOL GENET, V22, P3315, DOI 10.1093/hmg/ddt192; Ilijic E, 2011, NEUROBIOL DIS, V43, P364, DOI 10.1016/j.nbd.2011.04.007; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Jucaite A, 2015, BRAIN, V138, P2687, DOI 10.1093/brain/awv184; Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3; Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299; Kieburtz K, 2021, MOVEMENT DISORD, V36, P59, DOI 10.1002/mds.28310; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Korecka JA, 2020, MOL THER-NUCL ACIDS, V21, P623, DOI 10.1016/j.omtn.2020.06.027; Langkammer C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162460; Lee BD, 2010, NAT MED, V16, P998, DOI 10.1038/nm.2199; Luk Kelvin C, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS85, DOI 10.1016/S1353-8020(13)70022-1; Manzoni C, 2013, BBA-MOL CELL RES, V1833, P2900, DOI 10.1016/j.bbamcr.2013.07.020; Mao XB, 2016, SCIENCE, V353, DOI 10.1126/science.aah3374; Martin-Bastida A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01402-2; McFarthing K, 2020, J PARKINSON DIS, V10, P757, DOI 10.3233/JPD-202128; McNeill A, 2014, BRAIN, V137, P1481, DOI 10.1093/brain/awu020; Mitchell T, 2019, HUM BRAIN MAPP, V40, P5094, DOI 10.1002/hbm.24760; Mittal S, 2017, SCIENCE, V357, P891, DOI 10.1126/science.aaf3934; Mollenhauer B, 2019, MOVEMENT DISORD, V34, P1354, DOI 10.1002/mds.27806; Mortiboys Heather, 2015, Neurology, V85, P846, DOI 10.1212/WNL.0000000000001905; Mortiboys H, 2013, BRAIN, V136, P3038, DOI 10.1093/brain/awt224; Mullin S, 2020, JAMA NEUROL, V77, P427, DOI 10.1001/jamaneurol.2019.4611; Nalls MA, 2019, LANCET NEUROL, V18, P1091, DOI 10.1016/S1474-4422(19)30320-5; Naoi M, 2020, J NEURAL TRANSM, V127, P131, DOI 10.1007/s00702-020-02150-w; Nguyen M, 2019, TRENDS NEUROSCI, V42, P140, DOI 10.1016/j.tins.2018.11.001; Nielsen SS, 2018, ANN NEUROL, V84, P683, DOI 10.1002/ana.25341; Orenstein SJ, 2013, NAT NEUROSCI, V16, P394, DOI 10.1038/nn.3350; Pagan F, 2016, J PARKINSON DIS, V6, P503, DOI 10.3233/JPD-160867; Pagan FL, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.470; Parkinson Study Group STEADY-PD III Investigators, 2020, Ann Intern Med, V172, P591, DOI 10.7326/M19-2534; Paumier KL, 2015, NEUROBIOL DIS, V82, P185, DOI 10.1016/j.nbd.2015.06.003; Pinto M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0090-7; Plagnol V, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002142; Posener JA, 2014, MOVEMENT DISORD, V29, pS259; Prasuhn Jannik, 2019, Neurol Res Pract, V1, P31, DOI 10.1186/s42466-019-0033-1; Qiao C, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1236-z; Rango M, 2020, MOVEMENT DISORD, V35, P504, DOI 10.1002/mds.27946; Rascol O, 2011, LANCET NEUROL, V10, P415, DOI 10.1016/S1474-4422(11)70073-4; Rocha EM, 2015, NEUROBIOL DIS, V82, P495, DOI 10.1016/j.nbd.2015.09.009; Sanchez-Guajardo V, 2013, J NEUROPATH EXP NEUR, V72, P624, DOI 10.1097/NEN.0b013e31829768d2; Sanofi, 2021, SAN DEL CLOS DOUBL D; Sardi SP, 2017, P NATL ACAD SCI USA, V114, P2699, DOI 10.1073/pnas.1616152114; Sathe AG, 2020, J CLIN PHARMACOL, V60, P744, DOI 10.1002/jcph.1575; Schenk DB, 2017, MOVEMENT DISORD, V32, P211, DOI 10.1002/mds.26878; Schneeberger A, 2016, MOVEMENT DISORD, V31, P214, DOI 10.1002/mds.26377; Schwarzschild MA, 2014, JAMA NEUROL, V71, P141, DOI 10.1001/jamaneurol.2013.5528; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; Simuni T, 2015, LANCET NEUROL, V14, P795, DOI 10.1016/S1474-4422(15)00144-1; Smits LM, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00359; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Thibault L, 2017, MOVEMENT DISORD, V32, P1365, DOI 10.1002/mds.27055; Uc EY, 2003, CLIN NEUROPHARMACOL, V26, P207, DOI 10.1097/00002826-200307000-00011; Velseboer DC, 2016, NEUROLOGY, V86, P986, DOI 10.1212/WNL.0000000000002437; Verschuur CVM, 2019, NEW ENGL J MED, V380, P315, DOI 10.1056/NEJMoa1809983; Volpicelli-Daley LA, 2011, NEURON, V72, P57, DOI 10.1016/j.neuron.2011.08.033; Williams-Gray CH, 2016, MOVEMENT DISORD, V31, P995, DOI 10.1002/mds.26563; Zhang LP, 2019, J PARKINSON DIS, V9, P157, DOI 10.3233/JPD-181503; Zhao HT, 2017, MOL THER-NUCL ACIDS, V8, P508, DOI 10.1016/j.omtn.2017.08.002	108	29	29	4	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					559	572		10.1016/S1474-4422(21)00061-2	http://dx.doi.org/10.1016/S1474-4422(21)00061-2			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UD5TG	34146514	Green Submitted			2022-12-18	WOS:000687268300015
J	Maas, AIR; Menon, DK				Maas, Andrew I. R.; Menon, David K.			Traumatic brain injury: rethinking ideas and approaches	LANCET NEUROLOGY			English	Editorial Material									[Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, B-2650 Edegem, Belgium; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England	University of Antwerp; University of Antwerp; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Maas, AIR (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264				Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; MAAS AIR, 2011, J NEUROTRAUM, DOI DOI 10.1089/NEU.2010.1599; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034	7	29	32	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					12	13		10.1016/S1474-4422(11)70267-8	http://dx.doi.org/10.1016/S1474-4422(11)70267-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172614				2022-12-18	WOS:000298513700008
J	Leone, M; Franzini, A; Cecchini, AP; Broggi, G; Bussone, G				Leone, Massimo; Franzini, Angelo; Cecchini, Alberto Proietti; Broggi, Giovanni; Bussone, Gennaro			Stimulation of occipital nerve for drug-resistant chronic cluster headache	LANCET NEUROLOGY			English	Editorial Material							INJECTION		Ist Nazl Neurol Carlo Besta, Milan, Italy	IRCCS Istituto Neurologico Besta	Leone, M (corresponding author), Ist Nazl Neurol Carlo Besta, Milan, Italy.	leone@istituto-besta.it	Leone, Massimo/K-3818-2016; Cecchini, Alberto Proietti/AAQ-9570-2021	Leone, Massimo/0000-0001-7475-4049; Cecchini, Alberto Proietti/0000-0003-3152-247X; franzini, angelo/0000-0001-7357-2358				Afridi SK, 2006, PAIN, V122, P126, DOI 10.1016/j.pain.2006.01.016; Ambrosini A, 2005, PAIN, V118, P92, DOI 10.1016/j.pain.2005.07.015; Anthony m, 1985, MIGRAINE CLIN RES AD, P169; Burns B, 2007, LANCET, V369, P1099, DOI 10.1016/S0140-6736(07)60328-6; Leone M, 2006, NEUROLOGY, V67, P150, DOI 10.1212/01.wnl.0000223319.56699.8a; Leone Massimo, 2004, Curr Pain Headache Rep, V8, P347, DOI 10.1007/s11916-996-0007-1; Magis D, 2007, LANCET NEUROL, V6, P314, DOI 10.1016/S1474-4422(07)70058-3; MANZONI GC, 1991, CEPHALALGIA, V11, P169, DOI 10.1046/j.1468-2982.1991.1104169.x; Popeney CA, 2003, HEADACHE, V43, P369, DOI 10.1046/j.1526-4610.2003.03072.x; Remahl AIMN, 2003, CEPHALALGIA, V23, P504, DOI 10.1046/j.1468-2982.2003.00531.x	10	29	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2007	6	4					289	291		10.1016/S1474-4422(07)70061-3	http://dx.doi.org/10.1016/S1474-4422(07)70061-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	149KE	17362827				2022-12-18	WOS:000245145000003
J	Chataway, J; Porter, B; Riazi, A; Heaney, D; Watt, H; Hobart, J; Thompson, A				Chataway, Jeremy; Porter, Bernadette; Riazi, Afsane; Heaney, Dominic; Watt, Hilary; Hobart, Jeremy; Thompson, Alan			Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial	LANCET NEUROLOGY			English	Article							DIAGNOSTIC-CRITERIA; HEALTH-CARE; METHYLPREDNISOLONE; SATISFACTION; GUIDELINES; IMPACT	Background Intravenous steroids are routinely used to treat disabling relapses in multiple sclerosis, and can be administered in an outpatient or home setting. We developed a rating scale that allowed us to compare the two strategies formally in a trial setting. Methods Patients who had a clinically significant multiple-sclerosis relapse within 4 weeks of onset were randomly assigned administration of a 3-day regimen of intravenous methylprednisolone either in an outpatient clinic (n=69) or at home (n=69). The MS relapse management scale (MSRMS) was developed to measure patients' experiences of relapse management as the primary outcome. Efficacy of the two treatment modalities was compared in terms of traditional measures and economic cost. A cost-minimisation. analysis was also done. Analysis was by intention to treat. Findings Of 149 eligible patients, 138 consented to participate in the trial and were randomly assigned to a treatment group. Coordination of care was significantly better in the home-treatment group (median score 4.5 [IQR 3.0-11.4]) than in the hospital-treatment group (12.1 [3.0-18.6]; p=0.024). The other dimensions of the MSRMS did not differ between groups (p>0.10). Administration of steroids was equally safe and effective in either location, and cost was either the same or cheaper when delivered at home than when delivered in hospital. Interpretation Treatment of relapses in multiple sclerosis with intravenous steroids can be effectively and safely administered at home, from both patient and economic perspectives. Moreover, the trial indicates the importance of explicit and valid outcome measures of all aspects of service delivery when making decisions about health policy. This finding has implications for complex service delivery care models for long-term diseases.	UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Univ London, Royal Holloway, Surrey, England; London Sch Hyg & Trop Med, London WC1, England; Peninsula Med Sch, Plymouth, Devon, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; Royal Holloway University London; University of London; London School of Hygiene & Tropical Medicine; University of Plymouth	Chataway, J (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	jeremychataway@fastmail.fm	Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496; Riazi, Afsane/0000-0001-8397-414X				ALAM SM, 1993, J NEUROL NEUROSUR PS, V56, P1219, DOI 10.1136/jnnp.56.11.1219; Barnes D, 1997, LANCET, V349, P902, DOI 10.1016/S0140-6736(96)06453-7; Borras JM, 2001, BRIT MED J, V322, P826, DOI 10.1136/bmj.322.7290.826; Chisholm D, 2000, BRIT J PSYCHIAT, V177, pS28, DOI 10.1192/bjp.177.39.s28; Cochran DAE, 2003, MOL CELL PROTEOMICS, V2, P1331, DOI 10.1074/mcp.M300055-MCP200; CURTIS I, 2004, 12 PSSRU U KENT; *DEP HLTH, 2005, IMPR CHRON DIS MAN; Department of Health, 2005, SUPP PEOPL LONG TERM; Department of Health, 2005, NAT SERV FRAM LONG T; Department of Health, 2005, RED BRAIN DAM FAST A, P1; FILIPPINI G, 2003, COCHRANE DB SYST REV; Gold MR, 1996, COST EFFECTIVENESS H; Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962; Hobart JC, 2003, NEUROLOGY, V60, P31, DOI 10.1212/WNL.60.1.31; Jenkinson C, 2002, QUAL SAF HEALTH CARE, V11, P335, DOI 10.1136/qhc.11.4.335; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 2003, NEUROLOGY, V61, P1528, DOI 10.1212/01.WNL.0000096175.39831.21; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Miller DM, 2000, MULT SCLER, V6, P267, DOI 10.1191/135245800678827770; National Institute of Clinical Excellence, 2003, MAN MULT SCLER PRIM; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Riazi A, 2003, MULT SCLER, V9, ps152; ROBINSON R, 1993, BRIT MED J, V307, P726, DOI 10.1136/bmj.307.6906.726; Sellebjerg F, 2005, EUR J NEUROL, V12, P939, DOI 10.1111/j.1468-1331.2005.01352.x; Tremlett HL, 1998, J NEUROL NEUROSUR PS, V65, P362, DOI 10.1136/jnnp.65.3.362; Ware JE, 1993, SF 36 HLTH SURVEY MA; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; [No title captured]	28	29	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2006	5	7					565	571		10.1016/S1474-4422(06)70450-1	http://dx.doi.org/10.1016/S1474-4422(06)70450-1			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	058PE	16781986				2022-12-18	WOS:000238676100017
J	Benveniste, H; Blackband, SJ				Benveniste, Helene; Blackband, Stephen J.			Translational neuroscience and magnetic-resonance microscopy	LANCET NEUROLOGY			English	Review							CEREBRAL-ARTERY OCCLUSION; TRANSGENIC MOUSE MODEL; BETA-AMYLOID PLAQUES; PET IMAGING AGENTS; IN-VIVO; FUNCTIONAL MRI; SOMATOSENSORY STIMULATION; ANESTHETIZED RATS; ISCHEMIC DAMAGE; BRAIN-STEM	Magnetic-resonance microscopy is a rapidly growing and a widely applied imaging method in translational neuroscience studies. Emphasis has been placed on anatomical, functional, and metabolic studies of genetically engineered mouse models of human disease and the need for efficient phenotyping at all levels. Magnetic-resonance microscopy is now implemented in many laboratories worldwide due to the availability of commercial high-field magnetic-resonance instruments for use in small animals, the development of accessories (including miniature radio-frequency coils), magnetic-resonance compatible physiological monitoring equipment, and access to adjustable anaesthesia techniques. Two of the major magnetic-resonance microscopy applications in the neurosciences-structural and functional magnetic-resonance microscopy-will be reviewed.	Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Natl High Magnet Field Lab, Tallahassee, FL USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University System of Florida; University of Florida; State University System of Florida; Florida State University	Benveniste, H (corresponding author), Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA.	benveniste@bnl.gov	Jovicich, Jorge/D-2293-2010		NCRR NIH HHS [P41 RR16105] Funding Source: Medline; NIBIB NIH HHS [R01 EB 00233-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR016105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000233] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Aiken N. R., 1995, J MAGN RESON ANAL, V1, P41; Albert MS, 1996, P NATL ACAD SCI USA, V93, P13547, DOI 10.1073/pnas.93.24.13547; Baslow MH, 2005, J MOL NEUROSCI, V26, P1, DOI 10.1385/JMN:26:1:001; Bell JD, 2000, GENE THER, V7, P1259, DOI 10.1038/sj.gt.3301218; Benveniste H, 2002, PROG NEUROBIOL, V67, P393, DOI 10.1016/S0301-0082(02)00020-5; BENVENISTE H, 2003, TECHNIQUES BIOMEDICA; Bock NA, 2005, MAGNET RESON MED, V54, P1311, DOI 10.1002/mrm.20683; Brau ACS, 2002, MAGN RESON MED, V47, P314, DOI 10.1002/mrm.10049; Dazai J, 2004, MAGN RESON MED, V52, P709, DOI 10.1002/mrm.20215; Delikatny EJ, 2005, RADIOL CLIN N AM, V43, P205, DOI 10.1016/j.rcl.2004.07.004; Devor A, 2005, P NATL ACAD SCI USA, V102, P3822, DOI 10.1073/pnas.0407789102; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Dunn JF, 1999, MUSCLE NERVE, V22, P1367, DOI 10.1002/(SICI)1097-4598(199910)22:10<1367::AID-MUS5>3.3.CO;2-8; Febo M, 2005, NEUROPSYCHOPHARMACOL, V30, P936, DOI 10.1038/sj.npp.1300653; FEDER T, 2005, PHYS TODAY       APR, P26; Fu R, 2005, J MAGN RESON, V177, P1, DOI 10.1016/j.jmr.2005.07.013; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; Gozzi A, 2005, J NEUROSCI METH, V142, P115, DOI 10.1016/j.jneumeth.2004.08.013; Gyngell ML, 1996, MAGNET RESON MED, V36, P13, DOI 10.1002/mrm.1910360104; HEDLUND LW, 1986, INVEST RADIOL, V21, P18, DOI 10.1097/00004424-198601000-00003; Hedlund LW, 2000, MAGN RESON IMAGING, V18, P753, DOI 10.1016/S0730-725X(00)00154-5; HELFAER MA, 1990, STROKE, V21, P795, DOI 10.1161/01.STR.21.5.795; Henkelman RM, 2005, PROG DRUG RES, V62, P151; Higuchi M, 2005, NAT NEUROSCI, V8, P527, DOI 10.1038/nn1422; Huang W, 1996, P NATL ACAD SCI USA, V93, P6037, DOI 10.1073/pnas.93.12.6037; HYDER F, 1994, J CEREBR BLOOD F MET, V14, P649, DOI 10.1038/jcbfm.1994.81; Klaunberg BA, 2004, LAB ANIMAL, V33, P28, DOI 10.1038/laban0304-28; KOETSKY AP, 2004, NEURORX, V1, P155; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; KUCHARCZYK J, 1991, MAGNET RESON MED, V19, P311, DOI 10.1002/mrm.1910190220; Lahti KM, 1999, MAGNET RESON MED, V41, P412, DOI 10.1002/(SICI)1522-2594(199902)41:2<412::AID-MRM28>3.0.CO;2-3; Lanza GM, 2004, J NUCL CARDIOL, V11, P733, DOI 10.1016/j.nuclcard.2004.09.002; Lee JH, 2005, MAGN RESON MED, V53, P640, DOI 10.1002/mrm.20368; LO EH, 1994, J CEREBR BLOOD F MET, V14, P597, DOI 10.1038/jcbfm.1994.74; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Ma Y, 2005, NEUROSCIENCE, V135, P1203, DOI 10.1016/j.neuroscience.2005.07.014; Magnitsky S, 2005, NEUROIMAGE, V26, P744, DOI 10.1016/j.neuroimage.2005.02.029; MANO I, 1983, INVEST RADIOL, V18, P345, DOI 10.1097/00004424-198307000-00010; Marota JJA, 2000, NEUROIMAGE, V11, P13, DOI 10.1006/nimg.1999.0520; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; Mueggler T, 2004, EUR J NEUROSCI, V20, P811, DOI 10.1111/j.1460-9568.2004.03534.x; Nordberg A, 2004, LANCET NEUROL, V3, P519, DOI 10.1016/S1474-4422(04)00853-1; Ono M, 2005, J MED CHEM, V48, P7253, DOI 10.1021/jm050635e; Pautler RG, 1998, MAGNET RESON MED, V40, P740, DOI 10.1002/mrm.1910400515; Pautler RG, 2004, PHYSIOLOGY, V19, P168, DOI 10.1152/physiol.00016.2004; Pirko Istvan, 2005, NeuroRx, V2, P250, DOI 10.1007/BF03206670; POEMER RB, 1990, MAGN RESON MED, V16, P192; Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175; Redwine JM, 2003, P NATL ACAD SCI USA, V100, P1381, DOI 10.1073/pnas.242746599; REITH W, 1995, NEUROLOGY, V45, P172, DOI 10.1212/WNL.45.1.172; ROUSSEL SA, 1994, NMR BIOMED, V7, P21, DOI 10.1002/nbm.1940070105; Rubins DJ, 2003, NEUROIMAGE, V20, P2100, DOI 10.1016/j.neuroimage.2003.07.011; SHAW NA, 1990, NEUROPHARMACOLOGY, V29, P561, DOI 10.1016/0028-3908(90)90068-3; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Silva AC, 2002, P NATL ACAD SCI USA, V99, P15182, DOI 10.1073/pnas.222561899; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Spires Tara L, 2005, NeuroRx, V2, P423, DOI 10.1602/neurorx.2.3.423; STEINBERG GK, 1993, NEUROL RES, V15, P174; Ten VS, 2004, STROKE, V35, P2183, DOI 10.1161/01.STR.0000137768.25203.df; THULBORN K, 2005, INT SOC MAGNETIC RES; Toyama H, 2005, EUR J NUCL MED MOL I, V32, P593, DOI 10.1007/s00259-005-1780-5; Tuor UI, 2000, PAIN, V87, P315, DOI 10.1016/S0304-3959(00)00293-1; Tyszka JM, 2005, CURR OPIN BIOTECH, V16, P93, DOI 10.1016/j.copbio.2004.11.004; Utriainen A, 2004, HUM MOL GENET, V13, P2089, DOI 10.1093/hmg/ddh213; Verheul H. B., 1992, Brain Topography, V5, P171, DOI 10.1007/BF01129046; Wainwright MS, 2004, ANN NEUROL, V56, P61, DOI 10.1002/ana.20142; Wang YM, 2004, J MOL NEUROSCI, V24, P55, DOI 10.1385/JMN:24:1:055; Yu O, 2004, MAGN RESON IMAGING, V22, P1139, DOI 10.1016/j.mri.2004.08.017; Yu X, 2005, NAT NEUROSCI, V8, P961, DOI 10.1038/nn1477; Zang DW, 2004, EUR J NEUROSCI, V20, P1745, DOI 10.1111/j.1460-9568.2004.03648.x; Zhan H, 2005, J NEUROSCI METH, V144, P143, DOI 10.1016/j.jneumeth.2004.10.008; ZHANG L, 2001, 57214 ABSTR SOC NEUR, P27; Zhang W, 2005, NUCL MED BIOL, V32, P799, DOI 10.1016/j.nucmedbio.2005.06.001; Zhang W, 2005, J MED CHEM, V48, P5980, DOI 10.1021/jm050166g	75	29	29	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					536	544		10.1016/S1474-4422(06)70472-0	http://dx.doi.org/10.1016/S1474-4422(06)70472-0			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16713925				2022-12-18	WOS:000237906000022
J	Roman, GC; Royall, DR				Roman, GC; Royall, DR			A diagnostic dilemma: is "Alzheimer's dementia" Alzheimer's disease, vascular dementia, or both?	LANCET NEUROLOGY			English	Editorial Material							POPULATION; EVOLUTION		Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA; Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Roman, GC (corresponding author), Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	ROMANG@uthscsa.edu						Braak H, 1998, J NEURAL TRANSM-SUPP, P127; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; Duyckaerts C, 1997, NEUROBIOL AGING, V18, P362, DOI 10.1016/S0197-4580(97)00047-X; Goulding JMR, 1999, J NEUROL NEUROSUR PS, V67, P654, DOI 10.1136/jnnp.67.5.654; Pratt RD, 2002, J NEUROL SCI, V203, P57, DOI 10.1016/S0022-510X(02)00266-6; Roman GC, 2003, NEUROEPIDEMIOLOGY, V22, P161, DOI 10.1159/000069885; Royall DR, 2000, J GERONTOL A-BIOL, V55, pM541, DOI 10.1093/gerona/55.9.M541; Royall DR, 2002, EXP AGING RES, V28, P143, DOI 10.1080/03610730252800166; Sassin I, 2000, ACTA NEUROPATHOL, V100, P259, DOI 10.1007/s004019900178; Vermeer SE, 2003, STROKE, V34, P392, DOI 10.1161/01.STR.0000052631.98405.15	10	29	29	2	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2004	3	3					141	141		10.1016/S1474-4422(04)00674-X	http://dx.doi.org/10.1016/S1474-4422(04)00674-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	802MK	14980525				2022-12-18	WOS:000220167400012
J	Ciccone, A				Ciccone, A			Consent to thrombolysis in acute ischaemic stroke: from trial to practice	LANCET NEUROLOGY			English	Article							PREFERENCES; RISK	Thrombolysis with intravenous alteplase for acute ischaemic stroke, which is already in clinical use in the USA and Canada, has recently been approved in the European Union. Until now, the use of alteplase has been limited to research or "off label" therapy in most of Europe. Despite the growing importance of this therapy and the many guidelines for use and comments on its effects, there is a lack of information about informed consent. The process of obtaining informed consent in the therapeutic decision process allows the patients to express their point of view on the risk-to-benefit ratio of thrombolytic therapy, on the different outcomes of stroke, and on the effect of thrombolysis. The discussion between the clinician and the patient or patient's family, during the process of obtaining consent to thrombolysis, can be problematic because therapy has to be given with extreme urgency. In this article, I highlight the importance of obtaining informed consent, help set out the process, and analyse the situations in which obtaining consent to thrombolysis may be legally and ethically avoided.	Osped Niguarda Ca Granda, Dept Neurosci, Stroke Unit, I-20162 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda	Ciccone, A (corresponding author), Osped Niguarda Ca Granda, Dept Neurosci, Stroke Unit, Piazza Osped Maggiore 3, I-20162 Milan, Italy.	Alfonso.Ciccone@pmp.it	Ciccone, Alfonso/AAB-6942-2022	Ciccone, Alfonso/0000-0002-4590-3575				[Anonymous], GOOD CLIN PRACTICE; Calman KC, 2002, LANCET, V360, P166, DOI 10.1016/S0140-6736(02)09421-7; Ciccone A, 2001, NEUROL SCI, V22, P339, DOI 10.1007/s100720100062; Ciccone A, 2001, CEREBROVASC DIS, V12, P335, DOI 10.1159/000047731; CICCONE A, 2003, EUR STROK C VAL SPAI; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; FORSTER A, 2002, COCHRANE LIB; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Hachinski V, 1996, JAMA-J AM MED ASSOC, V276, P995, DOI 10.1001/jama.276.12.995; *IT HLTH MIN, 1997, GAZZ UFF REP IT S, P191; *IT MIN JUST, 1998, GAZZ UFF REP IT 105; Koops L, 2002, BRIT MED J, V325, P415, DOI 10.1136/bmj.325.7361.415; Matchar DB, 1998, NEUROLOGY, V50, pA326; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V3333, P1581; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; Thornton H, 1998, LANCET, V352, P72, DOI 10.1016/S0140-6736(05)79560-X; Wardlaw JM, 2002, COCHRANE LIB	17	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					375	378		10.1016/S1474-4422(03)00412-5	http://dx.doi.org/10.1016/S1474-4422(03)00412-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH	12849154				2022-12-18	WOS:000183115000020
J	Jabbari, E; Koga, S; Valentino, RR; Reynolds, RH; Ferrari, R; Tan, MMX; Rowe, JB; Dafgard, CL; Scholz, SW; Dickson, DW; Warner, TT; Revesz, T; Hoglinger, GU; Ross, OA; Ryten, M; Hardy, J; Shoai, M; Morris, HR				Jabbari, Edwin; Koga, Shunsuke; Valentino, Rebecca R.; Reynolds, Regina H.; Ferrari, Raffaele; Tan, Manuela M. X.; Rowe, James B.; Dafgard, Clifton L.; Scholz, Sonja W.; Dickson, Dennis W.; Warner, Thomas T.; Revesz, Tanias; Hoeglinger, Gunter U.; Ross, Owen A.; Ryten, Mina; Hardy, John; Shoai, Maryam; Morris, Huw R.		PSP Genetics Grp	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study	LANCET NEUROLOGY			English	Article							PARKINSONS-DISEASE; TAU; IDENTIFICATION; ACTIVATION; BRAIN; RISK	Background The genetic basis of variation in the progression of primary tauopathies has not been determined. We aimed to identify genetic determinants of survival in progressive supranuclear palsy (PSP). Methods In stage one of this two stage genome-wide association study (GWAS), we included individuals with PSP, diagnosed according to pathological and clinical criteria, from two separate cohorts: the 2011 PSP GWAS cohort, from brain banks based at the Mayo Clinic (Jacksonville, FL, USA) and in Munich (Germany), and the University College London PSP cohort, from brain banks and the PROSPECT study, a UK-wide longitudinal study of patients with atypical parkinsonian syndromes. Individuals were included if they had clinical data available on sex, age at motor symptom onset, disease duration (from motor symptom onset to death or to the date of censoring, Dec 1, 2019, if individuals were alive), and PSP phenotype (with reference to the 2017 Movement Disorder Society criteria). Genotype data were used to do a survival GWAS using a Cox proportional hazards model. In stage two, data from additional individuals from the Mayo Clinic brain bank, which were obtained after the 2011 PSP GWAS, were used for a pooled analysis. We assessed the expression quantitative trait loci (eQTL) profile of variants that passed genome-wide significance in our GWAS using the Functional Mapping and Annotation of GWAS platform, and did colocalisation analyses using the eQTLGen and Psych ENCODE datasets. Findings Data were collected and analysed between Aug 1, 2016, and Feb 1, 2020. Data were available for 1001 individuals of white European ancestry with PSP in stage one. We found a genome-wide significant association with survival at chromosome 12 (lead single nucleotide polymorphism rs2242367, p=7.5 x10(-10), hazard ratio 1.42 [95% CI 1- 22-1- 67]). rs2242367 was associated with survival in the individuals added in stage two (n=238; p=0.049, 1.22 [1. 00-1. 481) and in the pooled analysis of both stages (n=1239; p=1.3 x10(-10), 1-37 [1- 25-1- 51]). An eQTL database screen revealed that rs2242367 is associated with increased expression of LRRK2 and two long intergenic non-coding RNAs (lncRNAs), LINC02555 and AC079630.4, in whole blood. Although we did not detect a colocalisation signal for LRRK2, analysis of the PSP survival signal and eQTLs for LINC02555 in the eQTLGen blood dataset revealed a posterior probability of hypothesis 4 of 0.77, suggesting colocalisation due to a single shared causal variant. Interpretation Genetic variation at the LRRK2 locus was associated with survival in PSP. The mechanism of this association might be through a lncRNA-regulated effect on LRRK2 expression because LINCO2555 has previously been shown to regulate LRRK2 expression. LRRK2 has been associated with sporadic and familial forms of Parkinson's disease, and our finding suggests a genetic overlap with PSP. Further functional studies will be important to assess the potential of LRRK2 modulation as a disease-modifying therapy for PSP and related tauopathies. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Jabbari, Edwin; Tan, Manuela M. X.; Morris, Huw R.] UCL, Dept Clin & Movement Neurosci, Queen Sq Inst Neurol, London WC1N 3BG, England; [Jabbari, Edwin; Tan, Manuela M. X.; Morris, Huw R.] UCL, Movement Disorders Ctr, Queen Sq Inst Neurol, London, England; [Reynolds, Regina H.; Ferrari, Raffaele; Ryten, Mina; Hardy, John; Shoai, Maryam] UCL, Dept Neurodegenerat Dis, Queen Sq Inst Neurol, London, England; [Warner, Thomas T.; Revesz, Tanias; Hardy, John] UCL, Reta Lila Weston Inst, Queen Sq Inst Neurol, London, England; [Warner, Thomas T.; Revesz, Tanias] UCL, Queen Sq Brain Bank Neurol Disorders, Queen Sq Inst Neurol, London, England; [Hardy, John] UCL, Queen Sq Inst Neurol, Dementia Res Inst, London, England; [Reynolds, Regina H.; Ryten, Mina] UCL, NIHR Great Ormond St Hosp, Biomed Res Ctr, London, England; [Reynolds, Regina H.; Ryten, Mina] UCL, Great Ormond St Inst Child Hlth Genet & Genom Med, London, England; [Koga, Shunsuke; Valentino, Rebecca R.; Dickson, Dennis W.; Ross, Owen A.] Mayo Clin, Dept Neurosci, Jacksonville, FL USA; [Rowe, James B.] Univ Cambridge, Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Neurosci, Cambridge, England; [Dafgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Scholz, Sonja W.] Johns Hopkins Univ, Med Ctr, Dept Neurol, Baltimore, MD 21218 USA; [Scholz, Sonja W.] NINDS, Neurodegenerat Dis Res Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Hoeglinger, Gunter U.] German Ctr Neurodegenerat Dis, Munich, Germany; [Hoeglinger, Gunter U.] Hannover Med Sch, Dept Neurol, Hannover, Germany; [Hardy, John] Hong Kong Univ Sci & Technol, Inst Adv Study, Hong Kong, Peoples R China	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Mayo Clinic; University of Cambridge; Uniformed Services University of the Health Sciences - USA; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Hannover Medical School; Hong Kong University of Science & Technology	Jabbari, E; Morris, HR (corresponding author), UCL, Dept Clin & Movement Neurosci, Queen Sq Inst Neurol, London WC1N 3BG, England.	e.jabbari@ucl.ac.uk; h.morris@ucl.ac.uk	Morris, Huw R/B-8527-2008; Koga, Shunsuke/AFL-8279-2022; Scholz, Sonja/AAN-6601-2021; Gibbs, J. Raphael/A-3984-2010; Warner, Thomas T/A-1454-2013; Koga, Shunsuke/ABE-7206-2020; Jabbari, Edwin/G-4268-2018; Hardy, John/C-2451-2009; Valentino, Rebecca/AAU-6108-2021; Mok, Kin/U-6893-2019; Scholz, Sonja W./R-5524-2017; Reynolds, Regina Hertfelder/T-4480-2019; Rowe, James/C-3661-2013; Hoglinger, Gunter/F-2388-2015	Morris, Huw R/0000-0002-5473-3774; Koga, Shunsuke/0000-0001-8868-9700; Scholz, Sonja/0000-0002-6623-0429; Gibbs, J. Raphael/0000-0002-6985-0658; Warner, Thomas T/0000-0001-6195-6995; Jabbari, Edwin/0000-0001-6844-882X; Hardy, John/0000-0002-3122-0423; Valentino, Rebecca/0000-0001-7253-961X; Mok, Kin/0000-0003-3145-880X; Scholz, Sonja W./0000-0002-6623-0429; Reynolds, Regina Hertfelder/0000-0001-6470-7919; Pantelyat, Alexander/0000-0002-6427-7485; Hu, Michele/0000-0001-6382-5841; Chia, Ruth/0000-0002-4709-7423; Rowe, James/0000-0001-7216-8679; Hoglinger, Gunter/0000-0001-7587-6187; Dalgard, Clifton/0000-0003-2025-8239; Shoai, Maryam/0000-0003-2499-8533; Burn, David/0000-0001-7658-1209	PSP Association; CBD Solutions; Medical Research Council (UK); MRC [G0900652, G0400074, MR/L023784/1, G0802462, G0502157, MR/M024962/1, MR/N026004/1, MR/N008324/1, MC_UU_00005/12, G1100540, UKDRI-1009, MC_U105597119, MR/S000992/1, MR/L016397/1, MC_EX_MR/N50192X/1] Funding Source: UKRI	PSP Association; CBD Solutions; Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	PSP Association, CBD Solutions, Medical Research Council (UK).	Alessi DR, 2018, SCIENCE, V360, P36, DOI 10.1126/science.aar5683; Nguyen APT, 2018, HUM MOL GENET, V27, P120, DOI 10.1093/hmg/ddx389; Bardai FH, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006265; Bevan-Jones WR, 2020, BRAIN, V143, P1010, DOI 10.1093/brain/awaa033; Blauwendraat C, 2017, NEUROBIOL AGING, V57, DOI 10.1016/j.neurobiolaging.2017.05.009; Boxer AL, 2019, LANCET NEUROL, V18, P549, DOI 10.1016/S1474-4422(19)30139-5; Boxer AL, 2014, LANCET NEUROL, V13, P676, DOI 10.1016/S1474-4422(14)70088-2; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; Cao W, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0284-2; Chen JA, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0270-8; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Coyle-Gilchrist ITS, 2016, NEUROLOGY, V86, P1736, DOI 10.1212/WNL.0000000000002638; de Lange KM, 2017, NAT GENET, V49, P256, DOI 10.1038/ng.3760; Elkouris M, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00058; Evans LD, 2020, WHOLE GENOME CRISPR, V2020, DOI DOI 10.1101/2020.08.11.246363; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gerhard A, 2006, MOVEMENT DISORD, V21, P89, DOI 10.1002/mds.20668; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Glasmacher SA, 2017, J NEUROL NEUROSUR PS, V88, P402, DOI 10.1136/jnnp-2016-314956; gnomAD, SINGL NUCL VAR 12 40; Grimm MJ, 2019, MOVEMENT DISORD, V34, P1228, DOI 10.1002/mds.27666; Guerreiro PS, 2016, MOL NEUROBIOL, V53, P3124, DOI 10.1007/s12035-015-9209-z; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987; Hoglinger GU, 2011, NAT GENET, V43, P699, DOI 10.1038/ng.859; Iwaki H, 2019, NEUROL-GENET, V5, DOI 10.1212/NXG.0000000000000348; Jabbari E, 2020, JAMA NEUROL, V77, P377, DOI 10.1001/jamaneurol.2019.4347; Jabbari E, 2018, ANN NEUROL, V84, P485, DOI 10.1002/ana.25308; Li YI, 2016, SCIENCE, V352, P600, DOI 10.1126/science.aad9417; Malpetti M, 2020, NEUROINFLAMMATION PR, DOI [10.1101/2020.05.19.20106393, DOI 10.1101/2020.05.19.20106393]; Maphis N, 2015, BRAIN, V138, P1738, DOI 10.1093/brain/awv081; Miklossy J, 2006, J NEUROPATH EXP NEUR, V65, P953, DOI 10.1097/01.jnen.0000235121.98052.54; Moehle MS, 2012, J NEUROSCI, V32, P1602, DOI 10.1523/JNEUROSCI.5601-11.2012; Moss DJH, 2017, LANCET NEUROL, V16, P701, DOI 10.1016/S1474-4422(17)30161-8; Mudher A, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0488-7; Nalls MA, 2019, LANCET NEUROL, V18, P1091, DOI 10.1016/S1474-4422(19)30320-5; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; Passamonti L, 2018, NEUROLOGY, V90, pE1989, DOI 10.1212/WNL.0000000000005610; Rohrer JD, 2011, NEURODEGENER DIS, V8, P149, DOI 10.1159/000319454; Sanchez-Contreras M, 2017, MOVEMENT DISORD, V32, P115, DOI 10.1002/mds.26815; Sanchez-Contreras MY, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0267-3; Tolosa E, 2014, MOVEMENT DISORD, V29, P470, DOI 10.1002/mds.25824; Tuck AC, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800124; van Iperen EPA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172082; Vosa U., 2018, UNRAVELING POLYGENIC, DOI [DOI 10.1101/447367, 10.1101/447367]; Wang DF, 2018, SCIENCE, V362, DOI 10.1126/science.aat8464; Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5; Zhao YF, 2019, WORLD ENVIRONMENTAL AND WATER RESOURCES CONGRESS 2019: HYDRAULICS, WATERWAYS, AND WATER DISTRIBUTION SYSTEMS ANALYSIS, P1	47	28	28	3	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					107	116		10.1016/S1474-4422(20)30394-X	http://dx.doi.org/10.1016/S1474-4422(20)30394-X		JAN 2021	10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33341150	Green Submitted, Green Accepted			2022-12-18	WOS:000610201500018
J	Munoz-Lopetegi, A; Graus, F; Dalmau, J; Santamaria, J				Munoz-Lopetegi, Amaia; Graus, Francesc; Dalmau, Josep; Santamaria, Joan			Sleep disorders in autoimmune encephalitis	LANCET NEUROLOGY			English	Review							PARANEOPLASTIC LIMBIC ENCEPHALITIS; NMDA RECEPTOR ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; AQUAPORIN 4 ANTIBODY; RAPID-EYE-MOVEMENT; NEUROMYELITIS-OPTICA; BEHAVIOR DISORDER; MORVAN SYNDROME; REM-SLEEP; SYMPTOMATIC NARCOLEPSY	Sleep disorders in people with autoimmune encephalitis have received little attention, probably overshadowed by the presence of other neurological and psychiatric symptoms in this group of conditions. However, sleep disorders are frequent, often severe, and usually persist beyond the acute disease stage, interfering with patients' recovery and quality of life. Because autoimmune encephalitis can affect any brain network involved in sleep initiation and regulation, all types of sleep disorders can occur, with varying distinct associations, frequency, and intensity. Anti-IgLON5 and anti-NMDA receptor encephalitis exemplify two diseases in which sleep disorders are prominent. In anti-IgLON5 disease, sleep disorders were the core symptoms that led to the description of this disease, whereas in anti-NMDA receptor encephalitis, sleep disorders vary according to the disease stage along with other neuropsychiatric symptoms. Comprehensive, systematic, multicentre studies are needed to characterise sleep disorders and their mechanisms in autoimmune encephalitis.	[Munoz-Lopetegi, Amaia; Dalmau, Josep; Santamaria, Joan] Univ Barcelona, Hosp Clin, Dept Neurol, Barcelona 08036, Spain; [Munoz-Lopetegi, Amaia; Graus, Francesc; Dalmau, Josep] Inst Invest Biomed August Pi & Sunyer, Expt Neuroimmunol Grp, Barcelona, Spain; [Dalmau, Josep] Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain; [Dalmau, Josep] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Dalmau, Josep] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Pennsylvania; ICREA	Dalmau, J (corresponding author), Univ Barcelona, Hosp Clin, Dept Neurol, Barcelona 08036, Spain.	jdalmau@clinic.cat		Dalmau, Josep/0000-0001-5856-2813; Munoz-Lopetegi, Amaia/0000-0002-8852-0187	Instituto Carlos III/FEDER [FIS 17/00234, PIE 16/00014]; La Caixa Foundation Health Research Award; AGAUR-Generalitat de Catalunya; Fundacio Cellex; Safra Foundation; CIBERER [CB15/00010]	Instituto Carlos III/FEDER; La Caixa Foundation Health Research Award; AGAUR-Generalitat de Catalunya(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya); Fundacio Cellex(Foundation CELLEX); Safra Foundation; CIBERER	JD is supported by Instituto Carlos III/FEDER (FIS 17/00234 and PIE 16/00014); CIBERER #CB15/00010; La Caixa Foundation Health Research Award; AGAUR-Generalitat de Catalunya; Fundacio Cellex; and Safra Foundation. We thank Federica Provini (IRCCS Instituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy) for providing video files of a patient with Morvan syndrome, Carles Gaig (Hospital Clinic, University Barcelona) for the critical review of the manuscript, and Xabier Munoz for assisting in developing some of the figures.	Abgrall G, 2015, SLEEP MED, V16, P894, DOI 10.1016/j.sleep.2015.03.017; Adams C, 2011, ARCH NEUROL-CHICAGO, V68, P521, DOI 10.1001/archneurol.2011.56; Al-Diwani A, 2019, LANCET PSYCHIAT, V6, P235, DOI 10.1016/S2215-0366(19)30001-X; Ang G, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0199-2; Arino H, 2020, NEUROLOGY, V95, pE671, DOI 10.1212/WNL.0000000000009987; Arino H, 2016, NEUROLOGY, V87, P759, DOI 10.1212/WNL.0000000000003009; Arnulf I, 2015, SLEEP MED CLIN, V10, P151, DOI 10.1016/j.jsmc.2015.02.001; Baiardi S, 2015, NEUROLOGY, V84, P2457, DOI 10.1212/WNL.0000000000001694; Barry R, 2018, AASM MANUAL SCORING; Bataller L, 2010, NEUROLOGY, V74, P265, DOI 10.1212/WNL.0b013e3181cb3e52; Bien CG, 2012, BRAIN, V135, P1622, DOI 10.1093/brain/aws082; Boronat A, 2013, ANN NEUROL, V73, P120, DOI 10.1002/ana.23756; Bruggemann N, 2016, MOVEMENT DISORD, V31, P762, DOI 10.1002/mds.26608; Brunetti V, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000577; Cabezudo-Garcia P, 2020, ACTA NEUROL SCAND, V141, P263, DOI 10.1111/ane.13207; Campbell IG, 1996, J NEUROPHYSIOL, V76, P3714, DOI 10.1152/jn.1996.76.6.3714; Carceles-Cordon M, 2020, ANN NEUROL, V88, P603, DOI 10.1002/ana.25829; Chung HY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015706; Cirelli C, 2005, NATURE, V434, P1087, DOI 10.1038/nature03486; Ciriaco M, 2013, J PHARMACOL PHARMACO, V4, pS94, DOI 10.4103/0976-500X.120975; Compta Y, 2007, SLEEP, V30, P767, DOI 10.1093/sleep/30.6.767; Cornelius JR, 2011, ARCH NEUROL-CHICAGO, V68, P733, DOI 10.1001/archneurol.2011.106; Dalmau J, 2004, BRAIN, V127, P1831, DOI 10.1093/brain/awh203; Dalmau J, 2017, PHYSIOL REV, V97, P839, DOI 10.1152/physrev.00010.2016; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Dauvilliers Y, 2013, JAMA NEUROL, V70, P1305, DOI 10.1001/jamaneurol.2013.2831; De Cock VC, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0503-8; Deguchi K, 2012, J NEUROL SCI, V312, P18, DOI 10.1016/j.jns.2011.08.031; DeSena AD, 2014, PEDIATR NEUROL, V51, P151, DOI 10.1016/j.pediatrneurol.2013.09.012; Donadio V, 2009, CLIN NEUROPHYSIOL, V120, P1139, DOI 10.1016/j.clinph.2009.04.006; Douglas CL, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-42; Erro ME, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000651; Etemadifar M, 2017, J RES MED SCI, V22, DOI 10.4103/1735-1995.202148; Feigal J, 2016, PSYCHOSOMATICS, V57, P310, DOI 10.1016/j.psym.2015.11.005; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; Gaig C, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000605; Gaig C, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz133; Gaig C, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0848-0; Gaig C, 2017, NEUROLOGY, V88, P1736, DOI 10.1212/WNL.0000000000003887; Gelpi E, 2016, ACTA NEUROPATHOL, V132, P531, DOI 10.1007/s00401-016-1591-8; Gent TC, 2018, CURR OPIN NEUROBIOL, V52, P188, DOI 10.1016/j.conb.2018.08.002; Giannini G, 2016, NEUROLOGY, V87, P1375, DOI 10.1212/WNL.0000000000003156; Gleichman AJ, 2014, ANN CLIN TRANSL NEUR, V1, P180, DOI 10.1002/acn3.43; Graus F, 2001, BRAIN, V124, P1138, DOI 10.1093/brain/124.6.1138; Graus Francesc, 2010, J Neurol, V257, P509, DOI 10.1007/s00415-009-5431-9; Guaita M, 2015, J CLIN SLEEP MED, V11, P1289, DOI 10.5664/jcsm.5188; Guaraldi P, 2011, SLEEP MED, V12, pS64, DOI 10.1016/j.sleep.2011.10.014; Gurrera RJ, 2019, PSYCHIAT CLIN NEUROS, V73, P262, DOI 10.1111/pcn.12821; Hara M, 2017, NEUROLOGY, V88, P1340, DOI 10.1212/WNL.0000000000003796; Harbourt K, 2020, PHARMACOEPIDEM DR S, V29, P684, DOI 10.1002/pds.5004; Hart IK, 1997, ANN NEUROL, V41, P238, DOI 10.1002/ana.410410215; Haselmann H, 2018, NEURON, V100, P91, DOI 10.1016/j.neuron.2018.07.048; Herranz-Perez V, 2010, BRAIN RES, V1307, P177, DOI 10.1016/j.brainres.2009.10.013; Hoftberger R, 2015, NEUROLOGY, V84, P2403, DOI 10.1212/WNL.0000000000001682; Hogl B, 2015, LANCET, V385, P1590, DOI 10.1016/S0140-6736(15)60445-7; Hoffmann LA, 2008, J NEUROL NEUROSUR PS, V79, P767, DOI 10.1136/jnnp.2007.118588; Honorat JA, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000385; Irani SR, 2012, ANN NEUROL, V72, P241, DOI 10.1002/ana.23577; Iranzo A, 2006, ANN NEUROL, V59, P178, DOI 10.1002/ana.20693; Isaac SO, 2003, J PHARMACOL EXP THER, V307, P386, DOI 10.1124/jpet.103.053918; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Josephs KA, 2004, J CLIN NEUROPHYSIOL, V21, P440, DOI 10.1097/00004691-200411000-00008; Kallollimath P, 2018, ANN INDIAN ACAD NEUR, V21, P156, DOI 10.4103/aian.AIAN_74_18; Kanbayashi T, 2009, ARCH NEUROL-CHICAGO, V66, P1563, DOI 10.1001/archneurol.2009.264; Kayser MS, 2013, JAMA NEUROL, V70, P1133, DOI 10.1001/jamaneurol.2013.3216; Kim KJ, 2013, SLEEP MED, V14, P382, DOI 10.1016/j.sleep.2012.10.024; Kornum BR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2016.100; Ladepeche L, 2018, CELL REP, V23, P3759, DOI 10.1016/j.celrep.2018.05.096; Lai MZ, 2009, ANN NEUROL, V65, P424, DOI 10.1002/ana.21589; Landolfi JC, 2003, NEURO-ONCOLOGY, V5, P214, DOI 10.1215/S1152851702000467; Lanuzza B, 2012, SLEEP MED, V13, P550, DOI 10.1016/j.sleep.2011.08.006; Li MS, 2015, NEUROSCI BULL, V31, P735, DOI 10.1007/s12264-015-1552-6; Li WS, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1099-z; Liguori R, 2001, BRAIN, V124, P2417, DOI 10.1093/brain/124.12.2417; Lugaresi E, 2011, SLEEP MED, V12, pS3, DOI 10.1016/j.sleep.2011.10.004; Luppi PH, 2019, HAND CLINIC, V160, P359, DOI 10.1016/B978-0-444-64032-1.00023-0; Mannara F, 2020, BRAIN, V143, P2709, DOI 10.1093/brain/awaa195; Marques IB, 2014, J NEUROL SCI, V336, P276, DOI 10.1016/j.jns.2013.10.034; Miller Del D, 2004, Prim Care Companion J Clin Psychiatry, V6, P3; Montagna M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00329; Montagna P, 2002, CLIN NEUROPHYSIOL, V113, P552, DOI 10.1016/S1388-2457(02)00022-6; Nissen MS, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01056; Nozaki H, 2009, SLEEP MED, V10, P253, DOI 10.1016/j.sleep.2007.11.022; Ohkawa T, 2013, J NEUROSCI, V33, P18161, DOI 10.1523/JNEUROSCI.3506-13.2013; Suero GO, 2018, NEUROLOGIA, V33, P18, DOI 10.1016/j.nrl.2016.05.010; Peng XY, 2015, ANN NEUROL, V77, P381, DOI 10.1002/ana.24293; Peter-Derex L, 2012, SLEEP MED, V13, P554, DOI 10.1016/j.sleep.2012.01.002; Petit-Pedrol M, 2018, BRAIN, V141, P3144, DOI 10.1093/brain/awy253; Pinatel D, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00265, 10.3389/fncel.2015.00265]; Planaguma J, 2015, BRAIN, V138, P94, DOI 10.1093/brain/awu310; Provini F, 2011, SLEEP MED, V12, P1041, DOI 10.1016/j.sleep.2011.05.005; Ren HT, 2016, J NEUROIMMUNOL, V300, P9, DOI 10.1016/j.jneuroim.2016.09.012; Rojas-Marcos I, 2007, NEURO-ONCOLOGY, V9, P75, DOI 10.1215/15228517-2006-013; Sabater L, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0689-1; Sabater L, 2014, LANCET NEUROL, V13, P575, DOI 10.1016/S1474-4422(14)70051-1; Sabharwal P, 2016, J CLIN SLEEP MED, V12, P763, DOI 10.5664/jcsm.5814; Saiz A, 2009, J NEUROL NEUROSUR PS, V80, P404, DOI 10.1136/jnnp.2008.158246; Santamaria J, 2014, LANCET NEUROL, V13, P18, DOI 10.1016/S1474-4422(13)70273-4; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Sateia MJ, 2014, CHEST, V146, P1387, DOI 10.1378/chest.14-0970; Scammell TE, 2017, NEURON, V93, P747, DOI 10.1016/j.neuron.2017.01.014; SCHENKEL E, 1989, NEUROSCI LETT, V98, P159, DOI 10.1016/0304-3940(89)90503-X; Serdaroglu E, 2018, NOROPSIKIYATRI ARS, V55, P320, DOI 10.5152/npa.2017.19442; Simabukuro MM, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000136; Souza Paulo Victor Sgobbi de, 2017, Arq Neuropsiquiatr, V75, P74, DOI 10.1590/0004-282X20160169; Suzuki K, 2012, ARCH NEUROL-CHICAGO, V69, P1355, DOI 10.1001/archneurol.2012.300; Tezer FI, 2012, ARCH NEUROL-CHICAGO, V69, P145, DOI 10.1001/archneur.69.1.145; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tobin WO, 2014, NEUROLOGY, V83, P1797, DOI 10.1212/WNL.0000000000000991; Vale TC, 2017, LANCET, V389, P1367, DOI 10.1016/S0140-6736(16)31459-3; van Sonderen A, 2016, NEUROLOGY, V87, P1449; van Sonderen A, 2016, NEUROLOGY, V87, P521, DOI 10.1212/WNL.0000000000002917; Wang ZQ, 2018, NATURE, V558, P435, DOI 10.1038/s41586-018-0218-8; Wei YC, 2013, J NEUROIMMUNOL, V261, P129, DOI 10.1016/j.jneuroim.2013.05.011; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729	116	28	29	4	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					1010	1022		10.1016/S1474-4422(20)30341-0	http://dx.doi.org/10.1016/S1474-4422(20)30341-0			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PG3EL	33212053				2022-12-18	WOS:000599622000018
J	Brainin, M; Feigin, VL; Norrving, B; Martins, SCO; Hankey, GJ; Hachinski, V				Brainin, Michael; Feigin, Valery L.; Norrving, Bo; Martins, Sheila Cristina Ouriques; Hankey, Graeme J.; Hachinski, Vladimir		World Stroke Org Board Directors	Global prevention of stroke and dementia: the WSO Declaration	LANCET NEUROLOGY			English	Editorial Material													Hankey, Graeme J/H-4968-2014; Feigin, Valery/AAF-2313-2019	Hankey, Graeme J/0000-0002-6044-7328; Martins, Sheila Cristina Ouriques/0000-0002-8452-712X					0	28	28	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					487	488		10.1016/S1474-4422(20)30141-1	http://dx.doi.org/10.1016/S1474-4422(20)30141-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470419				2022-12-18	WOS:000544059200008
J	Ludolph, AC; Schuster, J; Dorst, J; Dupuis, L; Dreyhaupt, J; Weishaupt, JH; Kassubek, J; Weiland, U; Petri, S; Meyer, T; Grosskreutz, J; Schrank, B; Boentert, M; Emmer, A; Hermann, A; Zeller, D; Prudlo, J; Winkler, AS; Grehl, T; Heneka, MT; Johannesen, SW; Goricke, B				Ludolph, Albert C.; Schuster, Joachim; Dorst, Johannes; Dupuis, Luc; Dreyhaupt, Jens; Weishaupt, Jochen H.; Kassubek, Jan; Weiland, Ulrike; Petri, Susanne; Meyer, Thomas; Grosskreutz, Julian; Schrank, Berthold; Boentert, Matthias; Emmer, Alexander; Hermann, Andreas; Zeller, Daniel; Prudlo, Johannes; Winkler, Andrea S.; Grehl, Torsten; Heneka, Michael T.; Johannesen, Siw Wollebaek; Goericke, Bettina		RAS-ALS Study Grp	Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial	LANCET NEUROLOGY			English	Article							DEXPRAMIPEXOLE; EMPOWER; DISEASE; MODEL; ALS	Background Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole. We sought to test whether or not rasagiline 1 mg/day can prolong survival in patients with amyotrophic lateral sclerosis also receiving riluzole. Methods Patients with possible, probable, or definite amyotrophic lateral sclerosis were enrolled to our randomised, placebo-controlled, parallel-group, double-blind, phase 2 trial from 15 German network for motor neuron diseases (MND-NET) centres (university hospitals or clinics). Eligible patients were aged at least 18 years, had onset of progressive weakness within the 36 months before the study, had disease duration of more than 6 months and less than 3 years, and had a best-sitting slow vital capacity of at least 50%. After a 4-week screening period, eligible patients were randomly assigned (1:1) to receive either rasagiline (1 mg/day) or placebo in addition to riluzole (100 mg/day), after stratification for site of onset (bulbar or spinal) and study centre. Patients and all personnel assessing outcome parameters were masked to treatment allocation. Patients were followed up 2, 6, 12, and 18 months after randomisation. The primary endpoint was survival time, defined as the time to death or time to study cutoff date (ie, the last patient's last visit plus 14 days). Analyses of primary outcome and safety measures were done in all patients who received at least one dose of trial treatment (intention-to-treat population). The trial is registered with ClinicalTrials.gov, number NCT01879241. Findings Between July 2, 2013, and Nov 11, 2014, 273 patients were screened for eligibility, and 252 patients were randomly assigned to receive rasagiline (n=127) or placebo (n=125). 126 patients taking rasagiline and 125 taking placebo were included in the intention-to-treat analysis. For the primary outcome, the survival probability at the end of the study was 0.43 (95% CI 0.25-0.59) in the rasagiline group (n=126) and 0.53 (0.43-0.62) in the placebo group (n=125). The estimated effect size (hazard ratio) was 0.91 (one-sided 97.5% CI -infinity to 1.34; p=0.31). Rasagiline was well tolerated, and most adverse events were due to amyotrophic lateral sclerosis disease progression rather than treatment; the most frequent of these were dysphagia (32 [25%] taking rasagiline vs 24 [19%] taking placebo) and respiratory failure (25 [20%] vs 31 [25%]). Frequency of adverse events were comparable between both groups. Interpretation Rasagiline was safe in patients with amyotrophic lateral sclerosis. There was no difference between groups in the primary outcome of survival, although post-hoc analysis suggested that rasagiline might modify disease progression in patients with an initial slope of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised greater than 0.5 points per month at baseline. This should be confirmed in another clinical trial. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Ludolph, Albert C.; Schuster, Joachim; Dorst, Johannes; Weishaupt, Jochen H.; Kassubek, Jan; Weiland, Ulrike] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany; [Dreyhaupt, Jens] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany; [Dupuis, Luc] Univ Strasbourg, INSERM, Strasbourg, France; [Petri, Susanne] Hannover Med Sch, Dept Neurol, Hannover, Germany; [Meyer, Thomas] Humboldt Univ, Charite Univ Med, Berlin, Germany; [Grosskreutz, Julian] Jena Univ Hosp, Dept Neurol, Jena, Germany; [Schrank, Berthold] DKD HELIOS Klin Wiesbaden, Dept Neurol, Wiesbaden, Germany; [Boentert, Matthias] Univ Hosp Munster, Dept Sleep Med & Neuromuscular Dis, Munster, Germany; [Emmer, Alexander] Univ Hosp Halle, Dept Neurol, Halle, Germany; [Hermann, Andreas] Univ Hosp Carl Gustav Carus, Dept Neurol, Dresden, Germany; [Zeller, Daniel] Univ Wurzburg, Dept Neurol, Wurzburg, Germany; [Prudlo, Johannes] Univ Rostock, Dept Neurol, Rostock, Germany; [Winkler, Andrea S.] Tech Univ Munich, Dept Neurol, Munich, Germany; [Grehl, Torsten] Univ Hosp Bergmannsheil, Dept Neurol, Bochum, Germany; [Heneka, Michael T.] Univ Bonn, Dept Neurol, Bonn, Germany; [Johannesen, Siw Wollebaek] Univ Regensburg, Dept Neurol, Regensburg, Germany; [Goericke, Bettina] Univ Hosp Gottingen, Dept Neurol, Gottingen, Germany	Ulm University; Ulm University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena; Helios Kliniken; University of Munster; Martin Luther University Halle Wittenberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Wurzburg; University of Rostock; Technical University of Munich; Ruhr University Bochum; University of Bonn; University of Regensburg; University of Gottingen	Ludolph, AC (corresponding author), Univ Ulm, Dept Neurol, D-89081 Ulm, Germany.	albert.ludolph@rku.de	Kassubek, Jan/F-2774-2015; Petri, Susanne/AID-7665-2022; Kassubek, Jan/O-1740-2019; Kraya, Torsten/AFS-5530-2022; Schulte-Mattler, Wilhelm/B-1015-2008; Dupuis, Luc/A-6981-2012; Dorst, Johannes/AAL-5984-2021; Heneka, Michael/AAE-8011-2019; Kassubek, Jan/GPX-0910-2022; Heneka, Michael/E-8072-2015; Grosskreutz, Julian/G-2293-2010	Kassubek, Jan/0000-0002-7106-9270; Kassubek, Jan/0000-0002-7106-9270; Kraya, Torsten/0000-0002-6060-3810; Schulte-Mattler, Wilhelm/0000-0001-7701-9648; Kassubek, Jan/0000-0002-7106-9270; Dupuis, Luc/0000-0002-0902-5824; Heneka, Michael/0000-0003-4996-1630; Grosskreutz, Julian/0000-0001-9525-1424; Meyer, Thomas/0000-0002-2736-7350	Teva Pharmaceutical Industries	Teva Pharmaceutical Industries(Teva Pharmaceutical Industries)	Teva Pharmaceutical Industries.	Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1; Bozik ME, 2014, AMYOTROPH LAT SCL FR, V15, P406, DOI 10.3109/21678421.2014.943672; Braak H, 2017, ACTA NEUROPATHOL, V133, P79, DOI 10.1007/s00401-016-1633-2; Braak H, 2013, NAT REV NEUROL, V9, P708, DOI 10.1038/nrneurol.2013.221; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Castrillo-Viguera C, 2010, AMYOTROPH LATERAL SC, V11, P178, DOI 10.3109/17482960903093710; Cudkowicz M, 2011, NAT MED, V17, P1652, DOI 10.1038/nm.2579; Cudkowicz ME, 2013, LANCET NEUROL, V12, P1059, DOI 10.1016/S1474-4422(13)70221-7; Dupuis L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037885; Eisen A, 2017, J NEUROL NEUROSUR PS, V88, P917, DOI 10.1136/jnnp-2017-315573; Fang T, 2018, LANCET NEUROL, V17, P416, DOI 10.1016/S1474-4422(18)30054-1; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Macchi Z, 2015, AMYOTROPH LAT SCL FR, V16, P345, DOI 10.3109/21678421.2015.1026826; Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335; Schulthess I, 2016, SCI REP-UK, V6, DOI 10.1038/srep38391; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937; Waibel S, 2004, J NEUROL, V251, P1080, DOI 10.1007/s00415-004-0481-5	17	28	28	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					681	688		10.1016/S1474-4422(18)30176-5	http://dx.doi.org/10.1016/S1474-4422(18)30176-5			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	29934198				2022-12-18	WOS:000439057500012
J	Zimmermann, JF; Butler, CR				Zimmermann, Jacqueline F.; Butler, Christopher R.			Accelerated long-term forgetting in asymptomatic APOE epsilon 4 carriers	LANCET NEUROLOGY			English	Letter							GENOTYPE; DISEASE; MEMORY; RISK		[Zimmermann, Jacqueline F.] Univ Toronto, Rotman Res Inst, Baycrest Ctr, Toronto, ON, Canada; [Butler, Christopher R.] Univ Oxford, Nuffield Dept Clin Neurosci, Memory Res Grp, Oxford OX3 9DU, England	University of Toronto; University Toronto Affiliates; Baycrest; University of Oxford	Butler, CR (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Memory Res Grp, Oxford OX3 9DU, England.	chris.butler@ndcn.ox.ac.uk		Butler, Christopher/0000-0002-7502-9284	Medical Research Council Clinician Scientist Fellowship [MR/K010395/1]; Weston Brain Institute International Fellowship in Neuroscience; MRC [MR/K010395/1] Funding Source: UKRI	Medical Research Council Clinician Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Weston Brain Institute International Fellowship in Neuroscience; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We declare no competing interests. CRB was supported by a Medical Research Council Clinician Scientist Fellowship (MR/K010395/1) and JFZ was supported by Weston Brain Institute International Fellowship in Neuroscience.	Beglopoulos V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11761; Caselli RJ, 2009, NEW ENGL J MED, V361, P255, DOI 10.1056/NEJMoa0809437; Jorm AF, 2007, NEUROPSYCHOLOGY, V21, P1, DOI 10.1037/0894-4105.21.1.1; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Weston PSJ, 2018, LANCET NEUROL, V17, P123, DOI 10.1016/S1474-4422(17)30434-9	6	28	28	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					394	395		10.1016/S1474-4422(18)30078-4	http://dx.doi.org/10.1016/S1474-4422(18)30078-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29573908	Bronze, Green Submitted			2022-12-18	WOS:000429968100012
J	Berge, E; Salman, RAS; van der Worp, HB; Stapf, C; Sandercock, P; Sprigg, N; Macleod, MR; Kelly, PJ; Nederkoorn, PJ; Ford, GA				Berge, Eivind; Salman, Rustam Al-Shahi; van der Worp, H. Bart; Stapf, Christian; Sandercock, Peter; Sprigg, Nikola; Macleod, Malcolm R.; Kelly, Peter J.; Nederkoorn, Paul J.; Ford, Gary A.		European Stroke Org Trials Network	Increasing value and reducing waste in stroke research	LANCET NEUROLOGY			English	Article							SYMPTOMATIC CAROTID STENOSIS; RANDOMIZED CONTROLLED-TRIALS; ACUTE ISCHEMIC-STROKE; CLINICAL-TRIALS; BLOOD-PRESSURE; DRUG TRIALS; PROTOCOL; COST; ENDARTERECTOMY; MULTICENTER	Stroke is a major burden to patients and society, and resources spent on stroke research must be used efficiently and produce good value in terms of improvements in human health. However, many instances of poor value from stroke research funding have resulted from the way in which stroke research topics have been chosen and how studies have been designed, conducted, analysed, regulated, managed, disseminated, or reported. A cooperative effort of European stroke researchers aimed to identify sources of inefficiency and waste, recommend approaches to increase value, and highlight examples of best practice in stroke research. Evidence suggests that progress has been made, but there is room for much improvement; researchers, funders, regulators, and other stakeholders in stroke research might consider these recommendations when planning new research.	[Berge, Eivind] Oslo Univ Hosp, Dept Internal Med & Cardiol, NO-0407 Oslo, Norway; [Salman, Rustam Al-Shahi; Sandercock, Peter; Macleod, Malcolm R.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [van der Worp, H. Bart] Univ Med Ctr, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Stapf, Christian] Univ Montreal, CRCHUM, Dept Neurosci, Montreal, PQ H3C 3J7, Canada; [Sprigg, Nikola] Univ Nottingham, Div Clin Neurosci, Stroke Trials Unit, Nottingham, England; [Kelly, Peter J.] Mater Univ Hosp, Stroke Serv, Dublin, Ireland; [Kelly, Peter J.] Univ Coll Dublin, Stroke Clin Trials Network Ireland, Dublin, Ireland; [Nederkoorn, Paul J.] Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Ford, Gary A.] Univ Oxford, Div Med Sci, Oxford, England	University of Oslo; University of Edinburgh; Utrecht University; Utrecht University Medical Center; Universite de Montreal; University of Nottingham; Mater Misericordiae University Hospital; University College Dublin; University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford	Berge, E (corresponding author), Oslo Univ Hosp, Dept Internal Med & Cardiol, NO-0407 Oslo, Norway.	eivind.berge@medisin.uio.no	Ford, Gary/AAY-6405-2020; Macleod, Malcolm Robert/B-2052-2010; Jatuzis, Dalius/I-2048-2016	Ford, Gary/0000-0001-8719-4968; Macleod, Malcolm Robert/0000-0001-9187-9839; Jatuzis, Dalius/0000-0001-6159-4795; Stapf, Christian/0000-0002-3193-1006; Al-Shahi Salman, Rustam/0000-0002-2108-9222	ESO; National Institute for Health Research [11/129/109] Funding Source: researchfish	ESO; National Institute for Health Research(National Institute for Health Research (NIHR))	The symposium about the application of REWARD principles to stroke research involved stroke researchers and representatives from industry and publishers. The symposium was organised jointly by the ESO Trials Network Committee and The Lancet Neurology and funded by the ESO.	Anderson CS, 2016, NEW ENGL J MED, V374, P2313, DOI 10.1056/NEJMoa1515510; [Anonymous], 1965, BMJ-BRIT MED J, V2, P870; [Anonymous], 2016, LANCET NEUROL, V15, P1295, DOI 10.1016/S1474-4422(16)30296-4; Antman EM, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002810; Armstrong PW, 2013, JAMA-J AM MED ASSOC, V310, P1563, DOI 10.1001/jama.2013.280383; Bath FJ, 1998, STROKE, V29, P2203, DOI 10.1161/01.STR.29.10.2203; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bath PMW, 2015, LANCET, V385, P617, DOI 10.1016/S0140-6736(14)61121-1; Berge E, 2016, INT J STROKE, V11, P663, DOI 10.1177/1747493016641963; Berge E, 2015, INT J STROKE, V10, P425, DOI 10.1111/ijs.12427; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Bierer BE, 2016, NEW ENGL J MED, V374, P2411, DOI 10.1056/NEJMp1605348; Bjork Bo-Christer, 2010, PLoS One, V5, pe11273, DOI 10.1371/journal.pone.0011273; Blommaert J, RATIONALIZING UNREAS; Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Chabriat H, 2009, LANCET NEUROL, V8, P643, DOI 10.1016/S1474-4422(09)70127-9; Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1; Chalmers I, 2013, J ROY SOC MED, V106, P482, DOI 10.1177/0141076813493063; Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9; Chambers M, 1999, PHARMACOECONOMICS, V16, P577, DOI 10.2165/00019053-199916050-00013; Chan AW, 2014, LANCET, V383, P257, DOI 10.1016/S0140-6736(13)62296-5; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Clark S, 2010, LANCET, V376, P10, DOI 10.1016/S0140-6736(10)61001-X; Clinical Trials Facilitation Groups, GUID DOC SPONS VOL H; Cochrane J, 2012, 3 INT STROKE TRIAL I; Darbyshire J, 2011, ANN ONCOL, V22, P36, DOI 10.1093/annonc/mdr424; Demaerschalk BM, 2010, AM J MANAG CARE, V16, P537; Dirnagl U, 2013, STROKE, V44, P1754, DOI 10.1161/STROKEAHA.113.000734; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; EQUATOR network, 2014, COLL IN INV 28 REH D; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Food and Drug Administration, 2015, FED REGISTER, V80, P58492; Ganesalingam J, 2015, STROKE, V46, P2591, DOI 10.1161/STROKEAHA.115.009396; Germans MR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-143; Gibson LM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-43; Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Hachinski V, 2006, STROKE, V37, P2220, DOI 10.1161/01.STR.0000237236.88823.47; Hanney Stephen R, 2006, Health Res Policy Syst, V4, P10, DOI 10.1186/1478-4505-4-10; Haug CJ, 2016, NEW ENGL J MED, V374, P2409, DOI 10.1056/NEJMp1605378; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Heneghan C, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1870-2; Hicks Diana, 2015, Nature, V520, P429, DOI 10.1038/520429a; Hoffmann TC, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009051; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Ioannidis JPA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002049; Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8; Ioannidis JPA, 2011, NATURE, V477, P529, DOI 10.1038/477529a; Johnston SC, 2008, STROKE, V39, P3431, DOI 10.1161/STROKEAHA.108.525584; Jones AP, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-50; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kleinert S, 2014, LANCET, V384, P2176, DOI 10.1016/S0140-6736(14)62047-X; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Landis S, 2013, STROKE, V44, P1217, DOI 10.1161/STROKEAHA.113.001534; Lees KR, 2012, STROKE, V43, P1163, DOI 10.1161/STROKEAHA.111.641423; Liebeskind DS, 2006, NEUROLOGY, V67, P973, DOI 10.1212/01.wnl.0000237331.16541.ac; Lindblad AS, 2014, CLIN TRIALS, V11, P205, DOI 10.1177/1740774513508028; Longo DL, 2016, NEW ENGL J MED, V374, P276, DOI 10.1056/NEJMe1516564; Luengo-Fernandez R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006648; Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; McKevitt C, 2004, STROKE, V35, P1499, DOI 10.1161/01.STR.0000127532.64840.36; Mead G, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0864-1; Mead GE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009286.pub2; Minnerup J, 2016, STROKE, V47, P267, DOI 10.1161/STROKEAHA.115.011695; Moher D, 2016, LANCET, V387, P1573, DOI 10.1016/S0140-6736(15)00307-4; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; Myles PS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-470; Oliver S, 1999, CRITICAL ISSUES SOCI, P139; Oliver S, 1997, NONRANDOM REFLECTION, P272; Patel MR, 2016, NEW ENGL J MED, V375, P407, DOI 10.1056/NEJMp1605260; Pendlebury ST, 2007, INT J STROKE, V2, P80, DOI 10.1111/j.1747-4949.2007.00126.x; Pollock A, 2014, INT J STROKE, V9, P313, DOI 10.1111/j.1747-4949.2012.00942.x; Rick J, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-407; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Sacco RL, 2015, INT J STROKE, V10, P4, DOI 10.1111/ijs.12625; Saka O, 2009, STROKE, V40, P24, DOI 10.1161/STROKEAHA.108.518043; Salman RA, 2014, LANCET, V383, P176, DOI 10.1016/S0140-6736(13)62297-7; Sandercock P, 1997, LANCET, V349, P1569; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.4103/0976-500X.72352, 10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344; Shaw L, 2014, EMERG MED J, V31, P994, DOI 10.1136/emermed-2013-202536; Shinton R, 2014, LANCET, V384, P659, DOI 10.1016/S0140-6736(14)61385-4; Smith V, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0732-z; Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080; Sprigg N, 2016, INT J STROKE, V11, P717, DOI 10.1177/1747493016641960; Taichman DB, 2016, LANCET, V387, pE9, DOI 10.1016/S0140-6736(15)01279-9; The Academy of Medical Sciences, 2011, NEW PATHW REG GOV HL; The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581, DOI [DOI 10.1056/NEJM199512143332401, 10.1056/NEJM199512143332401 PMID: 7477192, DOI 10.1056/NEJM199512143332401PMID:7477192]; Treweek S, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0776-0; Turner L, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-60; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; van der Worp HB, 2014, INT J STROKE, V9, P642, DOI 10.1111/ijs.12294; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; van Vliet P, 2016, J NEUROL PHYS THER, V40, P203, DOI 10.1097/NPT.0000000000000133; Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752; WHO, 2014, TOP 10 CAUS DEATH FA; Wieseler B, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001526; Wieseler B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d8141; Young C, 2005, LANCET, V366, P107, DOI 10.1016/S0140-6736(05)66846-8	103	28	28	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2017	16	5					399	408		10.1016/S1474-4422(17)30078-9	http://dx.doi.org/10.1016/S1474-4422(17)30078-9			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER4PH	28414653	Green Submitted, Green Accepted			2022-12-18	WOS:000398782100017
J	Mahowald, MW; Schenck, CH				Mahowald, Mark W.; Schenck, Carlos H.			REM sleep behaviour disorder: a marker of synucleinopathy	LANCET NEUROLOGY			English	Editorial Material							DISEASE		[Mahowald, Mark W.] Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA; [Mahowald, Mark W.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Schenck, Carlos H.] Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55415 USA; [Schenck, Carlos H.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Stanford University; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Mahowald, MW (corresponding author), Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA.	mahow002@umn.edu						Boeve BF, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70078-4; Braak H, 2008, NEUROLOGY, V70, P1916, DOI 10.1212/01.wnl.0000312279.49272.9f; Claassen DO, 2010, NEUROLOGY, V75, P494, DOI 10.1212/WNL.0b013e3181ec7fac; Derkinderen P, 2011, NEUROLOGY, V77, P1761, DOI 10.1212/WNL.0b013e318236ef60; Iranzo A, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70096-9; Iranzo A, 2006, LANCET NEUROL, V5, P572, DOI 10.1016/S1474-4422(06)70476-8; Lai YY, 2003, MOL NEUROBIOL, V27, P137, DOI 10.1385/MN:27:2:137; Langston JW, 2006, ANN NEUROL, V59, P591, DOI 10.1002/ana.20834; Mahowald MW, 2009, SLEEP MED, V10, P159, DOI 10.1016/j.sleep.2008.03.003; McKeith I, 2007, Pract Neurol, V7, P374, DOI 10.1136/jnnp.2007.134163; Postuma RB, 2010, J NEUROL NEUROSUR PS, V81, P1008, DOI 10.1136/jnnp.2009.174748; Schenck CH, 2011, NEUROLOGY, V77, P1030, DOI 10.1212/WNL.0b013e31822e14d7; SCHENCK CH, 1986, SLEEP, V9, P293, DOI 10.1093/sleep/9.2.293; Schenck CH, 2013, SLEEP MED IN PRESS; Trajanovic NN, 2013, SLEEP MED IN PRESS	15	28	30	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					417	419		10.1016/S1474-4422(13)70078-4	http://dx.doi.org/10.1016/S1474-4422(13)70078-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23578776				2022-12-18	WOS:000318836700003
J	Filippi, M; Rocca, MA				Filippi, Massimo; Rocca, Maria A.			Multiple sclerosis: new measures to monitor the disease	LANCET NEUROLOGY			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; NEUROMYELITIS-OPTICA; DIAGNOSTIC-CRITERIA; CONTROLLED PHASE-3; PATHOLOGY; LESIONS		[Filippi, Massimo; Rocca, Maria A.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Inst Expt Neurol, Neuroimaging Res Unit,Div Neurosci, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Filippi, M (corresponding author), Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Inst Expt Neurol, Neuroimaging Res Unit,Div Neurosci, I-20132 Milan, Italy.	filippi.massimo@hsr.it	Rocca, Maria Assunta/K-1619-2018; Filippi, Massimo/K-1755-2018	Rocca, Maria Assunta/0000-0003-2358-4320; Filippi, Massimo/0000-0002-5485-0479				Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Choi SR, 2012, BRAIN, V135, P2925, DOI 10.1093/brain/aws189; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Comi G, 2012, NEW ENGL J MED, V366, P1000, DOI 10.1056/NEJMoa1104318; Filippi M, 2010, NEUROLOGY, V75, P1988, DOI 10.1212/WNL.0b013e3181ff96f6; Giorgio A, 2011, NEUROLOGY, V77, P1896, DOI 10.1212/WNL.0b013e318238ee9b; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Kolasinski J, 2012, BRAIN, V135, P2938, DOI 10.1093/brain/aws242; Miller DH, 2012, LANCET NEUROL, V11, P131, DOI 10.1016/S1474-4422(11)70299-X; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Sadaka Y, 2012, ANN NEUROL, V72, P211, DOI 10.1002/ana.23575; Sinnecker T, 2012, NEUROLOGY, V79, P708, DOI 10.1212/WNL.0b013e3182648bc8; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74	13	28	29	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					12	13		10.1016/S1474-4422(12)70288-0	http://dx.doi.org/10.1016/S1474-4422(12)70288-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237892				2022-12-18	WOS:000312429400007
J	[Anonymous]				[Anonymous]			The changing landscape of traumatic brain injury research	LANCET NEUROLOGY			English	Editorial Material																			0	28	28	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2012	11	8					651	651		10.1016/S1474-4422(12)70166-7	http://dx.doi.org/10.1016/S1474-4422(12)70166-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983AX	22814533				2022-12-18	WOS:000307089700001
J	O'Donnell, M; Yusuf, S				O'Donnell, Martin; Yusuf, Salim			Tackling the global burden of stroke: the need for large-scale international studies	LANCET NEUROLOGY			English	Editorial Material							ACUTE CORONARY SYNDROMES; COUNTRIES		[O'Donnell, Martin; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton Gen Hosp, Hamilton, ON L8L 2X2, Canada	McMaster University; Population Health Research Institute	O'Donnell, M (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	odonnm@mcmaster.ca	O'Donnell, Martin/ABE-7459-2020	O'Donnell, Martin/0000-0002-7347-7761; Yusuf, Salim/0000-0003-4776-5601				Carapetis JR, 2007, NEW ENGL J MED, V357, P439, DOI 10.1056/NEJMp078039; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Fox KAA, 2002, EUR HEART J, V23, P1177, DOI 10.1053/euhj.2001.3081; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Truelsen T, 2007, LANCET NEUROL, V6, P134, DOI 10.1016/S1474-4422(06)70686-X; Xavier D, 2008, LANCET, V371, P1435, DOI 10.1016/S0140-6736(08)60623-6; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zhao D, 2008, STROKE, V39, P1668, DOI 10.1161/STROKEAHA.107.502807	8	28	28	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2009	8	4					306	307		10.1016/S1474-4422(09)70024-9	http://dx.doi.org/10.1016/S1474-4422(09)70024-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	425CH	19233731				2022-12-18	WOS:000264614100005
J	Leigh, PN; Meininger, V; Bensimon, G; Cudkowicz, M; Robberecht, W				Leigh, Peter N.; Meininger, V.; Bensimon, G.; Cudkowicz, M.; Robberecht, W.			Minocycline for patients with ALS	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; RILUZOLE		[Leigh, Peter N.; Meininger, V.; Bensimon, G.; Cudkowicz, M.; Robberecht, W.] Kings Coll London, MRC Ctr Neurodegenerat Res, Inst Psychiat, London, England	University of London; King's College London	Leigh, PN (corresponding author), Kings Coll London, MRC Ctr Neurodegenerat Res, Inst Psychiat, London, England.	n.leigh@iop.kci.ac.uk	Leigh, Peter/AAD-5638-2019; CUDKOWICZ, MERIT/GWM-6585-2022	CUDKOWICZ, MERIT/0000-0002-7075-1681				Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Gordon PH, 2004, NEUROLOGY, V62, P1845, DOI 10.1212/01.WNL.0000125321.92112.7E; Goulden V, 1996, BRIT J DERMATOL, V134, P693, DOI 10.1111/j.1365-2133.1996.tb06972.x; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Milane A, 2007, J NEUROCHEM, V103, P164, DOI 10.1111/j.1471-4159.2007.04772.x	6	28	28	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2008	7	2					119	120		10.1016/S1474-4422(08)70006-1	http://dx.doi.org/10.1016/S1474-4422(08)70006-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261PY	18207106				2022-12-18	WOS:000253093700006
J	Lang, AE; Langston, W; Stoess, AJ; Brodsky, M; Brooks, DJ; Dhawan, V; Elias, WJ; Lozano, AM; Moro, E; Nutt, JG; Stacy, M; Turner, D; Wooten, GF				Lang, AE; Langston, W; Stoess, AJ; Brodsky, M; Brooks, DJ; Dhawan, V; Elias, WJ; Lozano, AM; Moro, E; Nutt, JG; Stacy, M; Turner, D; Wooten, GF			GDNF in treatment of Parkinson's disease: response to editorial	LANCET NEUROLOGY			English	Editorial Material							NEUROTROPHIC FACTOR; INFUSION		Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Parkinson Inst, Sunnyvale, CA USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Oregon Hlth & Sci Univ, Portland, OR USA; Hammersmith Hosp, Imperial Coll, London, England; N Shore Long Isl Jewish Res Inst, Long Isl City, NY USA; Univ Virginia, Charlottesville, VA USA; Duke Univ, Durham, NC USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of British Columbia; Oregon Health & Science University; Imperial College London; Northwell Health; University of Virginia; Duke University	Lang, AE (corresponding author), Toronto Western Hosp, Toronto, ON M5T 2S8, Canada.	lang@uhnres.utoronto.ca	Lang, Anthony/ABF-8114-2021; Lozano, Andres M/A-5058-2012; Moro, Elena/AAC-3136-2019; Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246; Dhawan, Vijay/0000-0002-2418-5674; Brooks, David/0000-0003-2602-2518; Lozano, Andres M./0000-0001-8257-3694; Lang, Anthony/0000-0003-1229-3667				[Anonymous], 2005, LANCET NEUROL, V4, P787; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; LANG AE, 2006, ANN NEUROL      0120; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; SHERER TB, IN PRESS MOV DISORD; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216	7	28	30	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2006	5	3					200	202		10.1016/S1474-4422(06)70359-3	http://dx.doi.org/10.1016/S1474-4422(06)70359-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016PS	16488373				2022-12-18	WOS:000235632900004
J	Lees, KR; Hankey, GJ; Hacke, W				Lees, KR; Hankey, GJ; Hacke, W			Design of future acute-stroke treatment trials	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; MOLECULAR-WEIGHT HEPARIN; PLASMINOGEN-ACTIVATOR; CONSORT STATEMENT; CLASSIFICATION; ASPIRIN; THROMBOLYSIS; PROUROKINASE; SUBTYPES; INFARCTS	Very few trials of acute stroke treatments show efficacy of a tested agent on the prespecified primary outcome. We can learn many lessons from the studies that achieve only neutral results. Preclinical studies have been flawed by use of models of transient not permanent brain ischaemia, treatments that aim to protect cerebral grey matter independently of white matter, delivery of the study drug within too short a time window after ischaemic insult, use of surrogate outcome measures in the short term instead of function in the long-term, and small sample sizes. Clinical trials have been hampered by heterogeneity in causes of stroke and inability to classify subtypes of cause; the short time available to rescue ischaemic brain tissue; the haemorrhagic transformation that can cause severe functional consequences seen frequently in infarcted brain tissue; the lack of valid, reliable, sensitive, and simple tools for assessment of functional outcome; and, above all, small treatment effects that are difficult to detect or refute. In this review, we look at the designs and results of all controlled trials of treatments for ischaemic stroke, and try to identify opportunities to improve future treatment assessment.	Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Royal Perth Hosp, Stroke Unit, Perth, WA 6001, Australia; Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Heidelberg Univ, Dept Neurol, D-69115 Heidelberg, Germany	University of Glasgow; Royal Perth Hospital; University of Western Australia; University of Western Australia; Ruprecht Karls University Heidelberg	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Gardiner Inst, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk	Hankey, Graeme J/H-4968-2014; Hacke, Werner/ABE-8661-2020	Hankey, Graeme J/0000-0002-6044-7328; 				ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; ANDERSON CS, 1994, J NEUROL NEUROSUR PS, V57, P1173, DOI 10.1136/jnnp.57.10.1173; [Anonymous], 1998, JAMA, V279, P1265; [Anonymous], [No title captured]; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bath PMW, 2001, LANCET, V358, P702, DOI 10.1016/S0140-6736(01)05837-8; Berge E, 2000, LANCET, V355, P1205, DOI 10.1016/S0140-6736(00)02085-7; BOZIK ME, 2000, P 25 INT STROK C AHA; CANDELISE L, 1995, LANCET, V346, P1509; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Grotta J, 2001, CEREBROVASC DIS, V12, P258, DOI 10.1159/000047713; GUBITZ G, 2002, COCHRANE LIB; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kidwell CS, 2001, STROKE, V32, P1349, DOI 10.1161/01.STR.32.6.1349; KITTNER SJ, 1990, NEUROLOGY, V40, P281, DOI 10.1212/WNL.40.2.281; Lammie GA, 1999, CEREBROVASC DIS, V9, P82, DOI 10.1159/000015903; Lees KR, 2000, BRIT MED BULL, V56, P389, DOI 10.1258/0007142001903030; Lyden P, 2001, NEUROLOGY, V57, P1199, DOI 10.1212/WNL.57.7.1199; MADDEN K, 1994, NEUROLOGY, V44, pA271; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; RANKIN J, 1957, Scott Med J, V2, P200; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; Sandercock P, 1997, LANCET, V349, P1569; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; *STATL, 1999, CAS STUD BAYS STAT W; Stingele R, 2001, CEREBROVASC DIS, V11, P30, DOI 10.1159/000047608; Warach S, 1997, STROKE, V28, P481; WARACH S, 1996, CLIN MAGNETIC RESONA, V1, P828; Wardlaw JM, 2000, STROKE, V31, P1133, DOI 10.1161/01.STR.31.5.1133; Wardlaw JM, 2002, COCHRANE LIB; Warlow CP, 2000, STROKE PRACTICAL GUI	44	28	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					54	61		10.1016/S1474-4422(03)00267-9	http://dx.doi.org/10.1016/S1474-4422(03)00267-9			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849301				2022-12-18	WOS:000180035800023
J	Hafezparast, M; Ahmad-Annuar, A; Wood, NW; Tabrizi, SJ; Fisher, EMC				Hafezparast, M; Ahmad-Annuar, A; Wood, NW; Tabrizi, SJ; Fisher, EMC			Mouse models for neurological disease	LANCET NEUROLOGY			English	Review							SPINAL MUSCULAR-ATROPHY; PRADER-WILLI-SYNDROME; ALPHA-SYNUCLEIN; ANIMAL-MODELS; ENU MUTAGENESIS; GENOME-WIDE; TAY-SACHS; MOLECULAR-GENETICS; TRANSGENIC MODELS; LYSOSOMAL STORAGE	The mouse has many advantages over human beings for the study of genetics, including the unique property that genetic manipulation can be routinely carried out in the mouse genome. Most importantly, mice and human beings share the same mammalian genes, have many similar biochemical pathways, and have the same diseases. In the minority of cases where these features do not apply, we can still often gain new insights into mouse and human biology. In addition to existing mouse models, several major programmes have been set up to generate new mouse models of disease. Alongside these efforts are new initiatives for the clinical, behavioural, and physiological testing of mice. Molecular genetics has had a major influence on our understanding of the causes of neurological disorders in human beings, and much of this has come from work in mice.	UCL Natl Hosp Neurol & Neurosurg, Dept Neurodegenerat Dis, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Dept Mol Pathogenesis, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Fisher, EMC (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England.	e.fisher@prion.ucl.ac.uk	Hafezparast, Majid/N-8292-2019; AHMAD ANNUAR, AZLINA/B-8305-2010; Wood, Nicholas W/C-2505-2009; Hafezparast, Majid/H-6728-2018; Fisher, Elizabeth MC/C-2168-2008	Hafezparast, Majid/0000-0002-5262-7150; Wood, Nicholas W/0000-0002-9500-3348; Fisher, Elizabeth MC/0000-0003-2850-9936; Tabrizi, Sarah/0000-0003-2716-2045				Ahituv Nadav, 2000, Journal of Basic and Clinical Physiology and Pharmacology, V11, P181; Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Almqvist EW, 1999, AM J HUM GENET, V64, P1293, DOI 10.1086/302374; Baird PN, 2002, VISION RES, V42, P479, DOI 10.1016/S0042-6989(01)00232-2; BARAITSER M, 1997, GENETICS NEUROLOGICA; Barbieri S, 2001, ADV EXP MED BIOL, V487, P147; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Belknap JK, 2001, BEHAV GENET, V31, P5, DOI 10.1023/A:1010249607128; Bennett CL, 2001, CURR OPIN NEUROL, V14, P621, DOI 10.1097/00019052-200110000-00011; Bertram L, 2001, Curr Neurol Neurosci Rep, V1, P442, DOI 10.1007/s11910-001-0104-9; Boer H, 2002, LANCET, V359, P135, DOI 10.1016/S0140-6736(02)07340-3; Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; Brandner S, 2000, EXP PHYSIOL, V85, P705, DOI 10.1111/j.1469-445X.2000.02091.x; Brown SDM, 2001, CURR OPIN GENET DEV, V11, P268, DOI 10.1016/S0959-437X(00)00189-1; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bucan M, 2002, NAT REV GENET, V3, P114, DOI 10.1038/nrg728; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carrie I, 2000, BRIT J NUTR, V83, P439; Chapman PF, 2001, TRENDS GENET, V17, P254, DOI 10.1016/S0168-9525(01)02285-5; Chen YJ, 2000, NAT GENET, V24, P314, DOI 10.1038/73557; COHENTANNOUDJI M, 1995, MAMM GENOME, V6, P844, DOI 10.1007/BF00292433; Comings DE, 2001, ANN NY ACAD SCI, V931, P50; COOK SA, 1995, MAMM GENOME, V6, P187, DOI 10.1007/BF00293010; Cox GA, 1998, NEURON, V21, P1327, DOI 10.1016/S0896-6273(00)80652-2; Crawley J.N., 2007, WHATS WRONG MY MOUSE, P226; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; Davies W, 2001, ANN MED, V33, P428, DOI 10.3109/07853890108995956; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Deng HX, 2000, ARCH NEUROL-CHICAGO, V57, P1695, DOI 10.1001/archneur.57.12.1695; Dennis Melvin B Jr, 2002, ILAR J, V43, P100; Dierssen M, 2001, PHYSIOL BEHAV, V73, P859, DOI 10.1016/S0031-9384(01)00523-6; DiMauro S, 2001, SEMIN NEUROL, V21, P251, DOI 10.1055/s-2001-17942; Doble A, 2000, AMYOTROPH LATERAL SC, V1, P301, DOI 10.1080/146608200300079545; Duff K, 2001, BIOCHEM SOC SYMP, V67, P195; Elsea Sarah H, 2002, ILAR J, V43, P66; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Fischbeck KH, 2001, BRAIN RES BULL, V56, P161, DOI 10.1016/S0361-9230(01)00577-9; Flint J, 2001, NAT REV GENET, V2, P437, DOI 10.1038/35076585; Gabriel JM, 1999, P NATL ACAD SCI USA, V96, P9258, DOI 10.1073/pnas.96.16.9258; Garbay B, 1999, ANN NY ACAD SCI, V883, P262, DOI 10.1111/j.1749-6632.1999.tb08588.x; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Giess R, 2002, AM J HUM GENET, V70, P1277, DOI 10.1086/340427; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hademenos GJ, 2001, NEUROLOGY, V56, P997, DOI 10.1212/WNL.56.8.997; Hagge-Greenberg A, 2001, MAMM GENOME, V12, P938, DOI 10.1007/s00335-001-2087-x; Hanel ML, 2001, CLIN GENET, V59, P156, DOI 10.1034/j.1399-0004.2001.590303.x; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; Hardisty RE, 1999, BRIT J AUDIOL, V33, P279, DOI 10.3109/03005369909090110; HARPER P. S., 1996, HUNTINGTONS DIS; Heintz N, 2000, ANNU REV PHYSIOL, V62, P779, DOI 10.1146/annurev.physiol.62.1.779; Hernandez D, 1999, TRENDS GENET, V15, P241, DOI 10.1016/S0168-9525(99)01743-6; Hernandez D, 1999, HUM MOL GENET, V8, P923, DOI 10.1093/hmg/8.5.923; Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812; Hock B J Jr, 2001, Trends Genet, V17, pS7, DOI 10.1016/S0168-9525(01)02449-0; Hunter AJ, 2000, HUM MOL GENET, V9, P893, DOI 10.1093/hmg/9.6.893; Isaacs AM, 2000, HUM MOL GENET, V9, P1865, DOI 10.1093/hmg/9.12.1865; Jacobs HT, 2001, TRENDS GENET, V17, P653, DOI 10.1016/S0168-9525(01)02480-5; Janus C, 2001, PHYSIOL BEHAV, V73, P873, DOI 10.1016/S0031-9384(01)00524-8; Kooy RF, 1996, AM J MED GENET, V64, P241, DOI 10.1002/(SICI)1096-8628(19960809)64:2<241::AID-AJMG1>3.0.CO;2-X; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; Martini R, 2000, J NEUROSCI RES, V61, P244, DOI 10.1002/1097-4547(20000801)61:3<244::AID-JNR2>3.0.CO;2-R; Masliah E, 2000, J NEURAL TRANSM-SUPP, P175; Matin A, 2001, TRENDS GENET, V17, P727, DOI 10.1016/S0168-9525(01)02528-8; McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5; Menalled LB, 2002, TRENDS PHARMACOL SCI, V23, P32, DOI 10.1016/S0165-6147(00)01884-8; Miranda CJ, 2002, FEBS LETT, V512, P291, DOI 10.1016/S0014-5793(02)02251-2; Moore KJ, 2000, ANNU REV GENET, V34, P653, DOI 10.1146/annurev.genet.34.1.653; Morris RGM, 2001, PHILOS T R SOC B, V356, P1453, DOI 10.1098/rstb.2001.0945; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Nakada K, 2001, SEMIN CELL DEV BIOL, V12, P459, DOI 10.1006/scdb.2001.0283; Nelms KA, 2001, IMMUNITY, V15, P409, DOI 10.1016/S1074-7613(01)00199-6; Newbery HJ, 2002, TRENDS MOL MED, V8, P88, DOI 10.1016/S1471-4914(02)02283-9; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Nicholls RD, 1999, ACTA PAEDIATR, V88, P99, DOI 10.1111/j.1651-2227.1999.tb14414.x; Nicholson SJ, 2000, MAMM GENOME, V11, P1041, DOI 10.1007/s003350010205; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890; Phaneuf D, 1996, HUM MOL GENET, V5, P1, DOI 10.1093/hmg/5.1.1; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prasad S, 2002, J BIOSCIENCES, V27, P35, DOI 10.1007/BF02703682; Price DL, 2000, ANN NY ACAD SCI, V920, P179; Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7; Rafael JA, 2000, MAMM GENOME, V11, P725, DOI 10.1007/s003350010149; Reeves RH, 2001, TRENDS GENET, V17, P83, DOI 10.1016/S0168-9525(00)02172-7; Richardson James A, 2002, ILAR J, V43, P89; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rogers DC, 2001, NEUROSCI LETT, V306, P89, DOI 10.1016/S0304-3940(01)01885-7; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Runte M, 2001, HUM MOL GENET, V10, P2687, DOI 10.1093/hmg/10.23.2687; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Schaefer Andrew M., 2001, Current Opinion in Pharmacology, V1, P288; SCHAPIRA AHV, 2002, MITOCHONDRIAL DISORD; Scott MR, 2000, ARCH VIROL, P113; Sendtner M, 2001, CURR OPIN NEUROL, V14, P629, DOI 10.1097/00019052-200110000-00012; Shanske AL, 2001, ARCH PEDIAT ADOL MED, V155, P1210; Shelbourne PF, 2000, J ANAT, V196, P617, DOI 10.1046/j.1469-7580.2000.19640617.x; Shinohara T, 2001, HUM MOL GENET, V10, P1163, DOI 10.1093/hmg/10.11.1163; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Small DL, 2000, BRIT MED BULL, V56, P307, DOI 10.1258/0007142001903238; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Steel KP, 1995, ANNU REV GENET, V29, P675; Tecott LH, 2001, ARCH GEN PSYCHIAT, V58, P995, DOI 10.1001/archpsyc.58.11.995; Telling GC, 2000, NEUROPATH APPL NEURO, V26, P209, DOI 10.1046/j.1365-2990.2000.00253.x; Thaung C, 2002, HUM MOL GENET, V11, P755, DOI 10.1093/hmg/11.7.755; Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380; Thornton C, 1999, SEMIN NEUROL, V19, P25, DOI 10.1055/s-2008-1040823; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; van Leuven F, 2000, PROG NEUROBIOL, V61, P305, DOI 10.1016/S0301-0082(99)00055-6; Vaughan J, 1998, ANN NEUROL, V44, P270, DOI 10.1002/ana.410440221; Vogler C, 2001, PEDIATR DEVEL PATHOL, V4, P421, DOI 10.1007/s10024001-0079-1; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wehner JM, 2001, ANNU REV NEUROSCI, V24, P845, DOI 10.1146/annurev.neuro.24.1.845; Weinstein LS, 2001, BIOL PSYCHIAT, V50, P927, DOI 10.1016/S0006-3223(01)01295-1; WEXLER N, 1999, CLASSICAL CASES MED, P388; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zeesman S, 2002, AM J MED GENET, V107, P247, DOI 10.1002/ajmg.10132; Zeviani M, 2001, CURR OPIN NEUROL, V14, P553, DOI 10.1097/00019052-200110000-00002; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101; Zielenski J, 1999, NAT GENET, V22, P128, DOI 10.1038/9635	133	28	29	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					215	224		10.1016/S1474-4422(02)00100-X	http://dx.doi.org/10.1016/S1474-4422(02)00100-X			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849454				2022-12-18	WOS:000177701800018
J	[Anonymous]				[Anonymous]			Long COVID: understanding the neurological effects	LANCET NEUROLOGY			English	Editorial Material																			0	27	28	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					247	247		10.1016/S1474-4422(21)00059-4	http://dx.doi.org/10.1016/S1474-4422(21)00059-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743226	Bronze, Green Published			2022-12-18	WOS:000630325700003
J	Howard, R; Burns, A; Schneider, L				Howard, Robert; Burns, Alistair; Schneider, Lon			Antipsychotic prescribing to people with dementia during COVID-19	LANCET NEUROLOGY			English	Letter									[Howard, Robert] UCL, Div Psychiat, London W1T 7NF, England; [Burns, Alistair] Univ Manchester, Sch Psychiat & Behav Sci, Manchester, Lancs, England; [Schneider, Lon] Univ Southern Calif, Los Angeles, CA 90007 USA	University of London; University College London; University of Manchester; University of Southern California	Howard, R (corresponding author), UCL, Div Psychiat, London W1T 7NF, England.	robert.howard@ucl.ac.uk		Howard, Robert/0000-0002-3071-2338				Ballard C, 2006, NAT REV NEUROSCI, V7, P492, DOI 10.1038/nrn1926; Graham NSN, 2020, J INFECTION, V81, P411, DOI 10.1016/j.jinf.2020.05.073; NHS Digital, 2020, REC DEM DIAGN; UK Government, EXC MORT ENGL WEEKL; Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8	5	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					892	892		10.1016/S1474-4422(20)30370-7	http://dx.doi.org/10.1016/S1474-4422(20)30370-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3OI	33098796	Green Published, Bronze			2022-12-18	WOS:000581121200015
J	Ogawa, A; Toyoda, K; Kitagawa, K				Ogawa, A.; Toyoda, K.; Kitagawa, K.			Comparison of prasugrel and clopidogrel in patients with non-cardioernbolic ischaernic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I) (vol 18, pg 238, 2019)	LANCET NEUROLOGY			English	Correction																		Ogawa A, 2019, LANCET NEUROL, V18, P238, DOI 10.1016/S1474-4422(18)30449-6	1	27	27	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					E8	E8		10.1016/S1474-4422(18)30449-6	http://dx.doi.org/10.1016/S1474-4422(18)30449-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	30784555				2022-12-18	WOS:000562556500002
J	Goadsby, PJ; Sahai-Srivastava, S; Kezirian, EJ; Calhoun, AH; Matthews, DC; McAllister, PJ; Costantino, PD; Friedman, DI; Zuniga, JR; Mechtler, LL; Popat, SR; Rezai, AR; Dodick, DW				Goadsby, Peter J.; Sahai-Srivastava, Soma; Kezirian, Eric J.; Calhoun, Anne H.; Matthews, David C.; McAllister, Peter J.; Costantino, Peter D.; Friedman, Deborah I.; Zuniga, John R.; Mechtler, Laszlo L.; Popat, Saurin R.; Rezai, Ali R.; Dodick, David W.			Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial	LANCET NEUROLOGY			English	Article							OCCIPITAL NERVE-STIMULATION; HYPOTHALAMIC-STIMULATION; LOCALIZATION; ARTERIES; PATHWAY; SYSTEM; PAIN; FLOW; SPG	Background Chronic cluster headache is the most disabling form of cluster headache. The mainstay of treatment is attack prevention, but the available management options have little efficacy and are associated with substantial side-effects. In this study, we aimed to assess the safety and efficacy of sphenopalatine ganglion stimulation for treatment of chronic cluster headache. Methods We did a randomised, sham-controlled, parallel group, double-blind, safety and efficacy study at 21 headache centres in the USA. We recruited patients aged 22 years or older with chronic cluster headache, who reported a minimum of four cluster headache attacks per week that were unsuccessfully controlled by preventive treatments. Participants were randomly assigned (1:1) via an online adaptive randomisation procedure to either stimulation of the sphenopalatine ganglion or a sham control that delivered a cutaneous electrical stimulation. Patients and the clinical evaluator and surgeon were masked to group assignment. The primary efficacy endpoint, which was analysed with weighted generalised estimated equation logistic regression models, was the difference between groups in the proportion of stimulation-treated ipsilateral cluster attacks for which relief from pain was achieved 15 min after the start of stimulation without the use of acute drugs before that timepoint. Efficacy analyses were done in all patients who were implanted with a device and provided data for at least one treated attack during the 4-week experimental phase. Safety was assessed in all patients undergoing an implantation procedure up to the end of the open-label phase of the study, which followed the experimental phase. This trial is registered with ClinicalTrials.gov, number NCT02168764. Findings Between July 9, 2014, and Feb 14, 2017, 93 patients were enrolled and randomly assigned, 45 to the sphenopalatine ganglion stimulation group and 48 to the control group. 36 patients in the sphenopalatine ganglion stimulation group and 40 in the control group had at least one attack during the experimental phase and were included in efficacy analyses. The proportion of attacks for which pain relief was experienced at 15 min was 62.46% (95% CI 49.15-74.12) in the sphenopalatine ganglion stimulation group versus 38.87% (28.60-50.25) in the control group (odds ratio 2.62 [95% CI 1.28-5. 34]; p=0.008). Nine serious adverse events were reported by the end of the open-label phase. Three of these serious adverse events were related to the implantation procedure (aspiration during intubation, nausea and vomiting, and venous injury or compromise). A fourth serious adverse event was an infection that was attributed to both the stimulation device and the implantation procedure. The other five serious adverse events were unrelated. There were no unanticipated serious adverse events. Interpretation Sphenopalatine ganglion stimulation seems efficacious and is well tolerated, and potentially offers an alternative approach to the treatment of chronic cluster headache. Further research is need to clarify its place in clinical practice. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Goadsby, Peter J.] Kings Coll London, Natl Inst Hlth Res, Wellcome Trust Kings Clin Res Facil, London, England; [Goadsby, Peter J.] Kings Coll London, South London & Maudsley Biomed Res Ctr, London, England; [Sahai-Srivastava, Soma; Kezirian, Eric J.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Calhoun, Anne H.] Carolina Headache Inst, Durham, NC USA; [Matthews, David C.] Carolinas HealthCare Syst, Charlotte, NC USA; [McAllister, Peter J.] New England Inst Neurol & Headache, Stamford, CT USA; [Costantino, Peter D.] Northwell Hlth Syst, New York Head & Neck Inst, New York, NY USA; [Friedman, Deborah I.; Zuniga, John R.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Friedman, Deborah I.] Univ Texas Southwestern Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA; [Friedman, Deborah I.] Univ Texas Southwestern Med Ctr Dallas, Headache & Facial Pain Program, Dallas, TX 75390 USA; [Zuniga, John R.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Mechtler, Laszlo L.] Dent Neurol Inst, Dent Headache Ctr, Buffalo, NY USA; [Popat, Saurin R.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Otolaryngol Head & Neck Surg, Buffalo, NY USA; [Rezai, Ali R.] West Virginia Univ, Sch Med, Rockefeller Neurosci Inst, Morgantown, WV 26506 USA; [Dodick, David W.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA	University of London; King's College London; University of London; King's College London; University of Southern California; Carolinas HealthCare System; Northwell Health; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; West Virginia University; Mayo Clinic; Mayo Clinic Phoenix	Goadsby, PJ (corresponding author), Kings Coll Hosp London, Wellcome Fdn Bldg, London SE5 9PJ, England.	peter.goadsby@kcl.ac.uk	Friedman, Deborah I/HCG-8707-2022	Friedman, Deborah I/0000-0002-6652-6158; Goadsby, Peter/0000-0003-3260-5904	Autonomic Technologies	Autonomic Technologies	Autonomic Technologies.	Akerman S, 2012, BRAIN, V135, P3664, DOI 10.1093/brain/aws249; [Anonymous], 1908, NY MED J, V87, P989; Ansarinia M, 2010, HEADACHE, V50, P1164, DOI 10.1111/j.1526-4610.2010.01661.x; Asano E, 2013, NEUROLOGY, V80, P694, DOI 10.1212/WNL.0b013e3182825174; Assaf AT, 2016, INT J ORAL MAX SURG, V45, P245, DOI 10.1016/j.ijom.2015.09.023; Barloese M, 2015, CEPHALALGIA, V35, P969, DOI 10.1177/0333102414564892; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bratbak DF, 2016, CEPHALALGIA, V36, P503, DOI 10.1177/0333102415597891; Burns B, 2007, LANCET, V369, P1099, DOI 10.1016/S0140-6736(07)60328-6; Cohen AS, 2007, NEUROLOGY, V69, P668, DOI 10.1212/01.wnl.0000267319.18123.d3; Cohen AS, 2009, JAMA-J AM MED ASSOC, V302, P2451, DOI 10.1001/jama.2009.1855; de Coo IF, 2017, CEPHALALGIA, V37, P175; Dodick D, 2004, HEADACHE, V44, P414, DOI 10.1111/j.1526-4610.2004.04078.x; DRUMMOND PD, 1983, J NEUROL NEUROSUR PS, V46, P611, DOI 10.1136/jnnp.46.7.611; DRUMMOND PD, 1988, BRAIN, V111, P1199, DOI 10.1093/brain/111.5.1199; ECCLES R, 1973, J PHYSIOL-LONDON, V230, P213, DOI 10.1113/jphysiol.1973.sp010184; Goadsby PJ, 2018, CEPHALALGIA, V38, P959, DOI 10.1177/0333102417744362; Goadsby PJ, 2013, CEPHALALGIA, V33, P214, DOI 10.1177/0333102412468680; GOADSBY PJ, 1991, AM J PHYSIOL, V260, pR255, DOI 10.1152/ajpregu.1991.260.1.R255; Goadsby PJ, 1997, BRAIN, V120, P193, DOI 10.1093/brain/120.1.193; GOADSBY PJ, 1984, J AUTONOM NERV SYST, V10, P145, DOI 10.1016/0165-1838(84)90053-5; GOADSBY PJ, 1990, NEUROSCI LETT, V112, P282, DOI 10.1016/0304-3940(90)90217-W; GONZALEZ G, 1975, J NEUROSURG, V42, P696, DOI 10.3171/jns.1975.42.6.0696; Gray H., 1918, ANATOMY HUMAN BODY, V20th; James KE, 1996, STAT MED, V15, P1421; Jurgens TP, 2017, CEPHALALGIA, V37, P423, DOI 10.1177/0333102416649092; Kano H, 2011, J NEUROSURG, V114, P1736, DOI 10.3171/2010.3.JNS091843; Knight YE, 2005, BRAIN RES, V1045, P1, DOI 10.1016/j.brainres.2005.01.091; LAMBERT GA, 1984, J NEUROSURG, V61, P307, DOI 10.3171/jns.1984.61.2.0307; Leone M, 2001, NEW ENGL J MED, V345, P1428, DOI 10.1056/NEJM200111083451915; Leone M, 2006, NEUROLOGY, V67, P150, DOI 10.1212/01.wnl.0000223319.56699.8a; LIPTON RB, 1995, CEPHALALGIA, V15, P452, DOI 10.1046/j.1468-2982.1995.1506452.x; Magis D, 2007, LANCET NEUROL, V6, P314, DOI 10.1016/S1474-4422(07)70058-3; May A, 2005, LANCET, V366, P843, DOI 10.1016/S0140-6736(05)67217-0; May A, 1999, J CEREBR BLOOD F MET, V19, P115, DOI 10.1097/00004647-199902000-00001; May A, 2001, J CEREBR BLOOD F MET, V21, P1171, DOI 10.1097/00004647-200110000-00005; MEYER JS, 1970, ARCHIV OTOLARYNGOL, V92, P475; Narouze S, 2009, HEADACHE, V49, P571, DOI 10.1111/j.1526-4610.2008.01226.x; NESBITT AD, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E2407; Pietzsch JB, 2018, CEPHALALGIA, V38, P1455, DOI 10.1177/0333102418784689; Pietzsch JB, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0530-8; Pipolo C, 2010, NEUROL SCI, V31, P197, DOI 10.1007/s10072-010-0325-2; Schoenen J, 2005, BRAIN, V128, P940, DOI 10.1093/brain/awh411; Schoenen J, 2013, CEPHALALGIA, V33, P816, DOI 10.1177/0333102412473667; Schor LI, 2017, CEPHALALGIA, V37, P172; Schytz HW, 2013, CEPHALALGIA, V33, P831, DOI 10.1177/0333102413476370; Silberstein SD, 2016, HEADACHE, V56, P1317, DOI 10.1111/head.12896; SPENCER SE, 1990, BRAIN RES, V534, P149, DOI 10.1016/0006-8993(90)90125-U; Uddman R, 1999, J CEREBR BLOOD F MET, V19, P61, DOI 10.1097/00004647-199901000-00007; UDDMAN R, 1993, J CEREBR BLOOD F MET, V13, P291, DOI 10.1038/jcbfm.1993.36	50	27	32	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1081	1090		10.1016/S1474-4422(19)30322-9	http://dx.doi.org/10.1016/S1474-4422(19)30322-9			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31701891				2022-12-18	WOS:000495892200014
J	Ogawa, A; Toyoda, K; Kitagawa, K; Kitazono, T; Nagao, T; Yamagami, H; Uchiyama, S; Tanahashi, N; Matsumoto, M; Minematsu, K; Nagata, I; Nishikawa, M; Nanto, S; Abe, K; Ikeda, Y				Ogawa, Akira; Toyoda, Kazunori; Kitagawa, Kazuo; Kitazono, Takanari; Nagao, Takehiko; Yamagami, Hiroshi; Uchiyama, Shinichiro; Tanahashi, Norio; Matsumoto, Masayasu; Minematsu, Kazuo; Nagata, Izumi; Nishikawa, Masakatsu; Nanto, Shinsuke; Abe, Kenji; Ikeda, Yasuo		PRASTRO-I Study Grp	Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I)	LANCET NEUROLOGY			English	Article							ACUTE CORONARY SYNDROME; DOUBLE-BLIND; JAPANESE PATIENTS; SECONDARY PREVENTION; ASPIRIN; SAFETY; EFFICACY; CYP2C19; PHARMACOKINETICS; PHARMACODYNAMICS	Background The effect of prasugrel in terms of the prevention of recurrence of ischaemic stroke is unknown. We investigated the non-inferiority of prasugrel to clopidogrel for prevention of ischaemic stroke, myocardial infarction, and death from other vascular causes in Japanese patients with non-cardioembolic stroke. Methods In this phase 3 randomised, double-blind, non-inferiority trial, patients aged 20-74 years who had had a non-cardioembolic stroke in the previous 1-26 weeks were recruited from 224 hospitals in Japan. Eligible patients were randomly assigned (1: 1) to receive prasugrel (3.75 mg/day) or clopidogrel (75 mg/day) orally for 96-104 weeks. Randomisation was stratified according to stroke subtype. The randomisation schedule was generated by an independent statistician who created a computer-generated random number sequence. Patients, investigators, and the funder were masked to treatment allocation. The primary endpoint was combined incidence of ischaemic stroke (fatal and non-fatal), myocardial infarction (fatal and non-fatal), and death from other vascular causes in the intention-to-treat population. The safety endpoint was incidence of bleeding events, comprising life-threatening bleeding, major bleeding, and clinically relevant bleeding. The safety analysis was done in the population excluding trial patients with serious Good Clinical Practice violations, and those who had not taken the trial drug. The predefined non-inferiority margin was an upper 95% CI limit for the risk ratio (RR) of 1.35. The trial was registered with the Japan Pharmaceutical Information Center (JapicCTI-111582). Findings Patients were recruited between Sept 1, 2011, and June 12, 2015. 3747 patients (797 [21%] women) were enrolled, with a mean age of 62.1 (SD 8.5) years. 3753 patients were randomly assigned to treatment and, of these patients, 1885 in the prasugrel group and 1862 in the clopidogrel group were confirmed to have taken the trial drug at least once, and six patients withdrew from the trial before administration of the trial drug. Thus, a total of 3747 patients were included in the full analysis set. 73 (4%) of 1885 patients in the prasugrel group and 69 (4%) of 1862 patients in the clopidogrel group reached the primary endpoint (RR 1.05, 95% CI 0.76-1.44). The incidence of bleeding events was not significantly different between treatment groups; life-threatening bleeding was observed in 18 (1%) patients in the prasugrel group and 23 (1%) patients in the clopidogrel group (RR 0.77, 0.41-1.42). Interpretation The non-inferiority of prasugrel to clopidogrel for the prevention of ischaemic stroke, myocardial infarction, and death from other vascular causes was not confirmed in Japanese patients with non-cardioembolic stroke. No safety concerns were identified. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Ogawa, Akira] Iwate Med Univ, Dept Neurosurg, Morioka, Iwate 0208505, Japan; [Toyoda, Kazunori; Yamagami, Hiroshi; Minematsu, Kazuo] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Suita, Osaka, Japan; [Kitagawa, Kazuo] Tokyo Womens Med Univ, Sch Med, Dept Neurol, Tokyo, Japan; [Kitazono, Takanari] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka, Fukuoka, Japan; [Nagao, Takehiko] Nippon Med Sch Tama Nagayama Hosp, Dept Neurol, Tokyo, Japan; [Uchiyama, Shinichiro] Int Univ Hlth & Welf, Sanno Hosp, Ctr Brain & Cerebral Vessels, Tokyo, Japan; [Uchiyama, Shinichiro] Sanno Med Ctr, Tokyo, Japan; [Tanahashi, Norio] Saitama Med Univ, Dept Neurol, Int Med Ctr, Saitama, Japan; [Matsumoto, Masayasu] Sakai City Med Ctr, Dept Neurol, Osaka, Japan; [Nagata, Izumi] Kokura Mem Hosp, Dept Neurosurg, Fukuoka, Fukuoka, Japan; [Nishikawa, Masakatsu] Mie Univ Hosp, Clin Res Support Ctr, Tsu, Mie, Japan; [Nanto, Shinsuke] Nishinomiya Municipal Cent Hosp, Nishinomiya, Hyogo, Japan; [Abe, Kenji] Daiichi Sankyo, Tokyo, Japan; [Ikeda, Yasuo] Waseda Univ, Fac Sci & Engn, Tokyo, Japan	Iwate Medical University; National Cerebral & Cardiovascular Center - Japan; Tokyo Women's Medical University; Kyushu University; Nippon Medical School; International University of Health & Welfare; Saitama Medical University; Kokura Memorial Hospital; Mie University; Daiichi Sankyo Company Limited; Waseda University	Ogawa, A (corresponding author), Iwate Med Univ, Dept Neurosurg, Morioka, Iwate 0208505, Japan.	aogawa@iwate-med.ac.jp			Daiichi Sankyo	Daiichi Sankyo(Daiichi Sankyo Company Limited)	Daiichi Sankyo.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Alexopoulos D, 2011, JACC-CARDIOVASC INTE, V4, P403, DOI 10.1016/j.jcin.2010.12.011; Amarenco P, 2017, LANCET NEUROL, V16, P301, DOI 10.1016/S1474-4422(17)30038-8; Benavente OR, 2012, NEW ENGL J MED, V367, P817, DOI 10.1056/NEJMoa1204133; Feher G, 2010, WORLD J CARDIOL, V2, P171, DOI 10.4330/wjc.v2.i7.171; Fukuuchi Y, 2008, CEREBROVASC DIS, V25, P40, DOI 10.1159/000111498; Furuta Takahisa, 2005, Drug Metab Pharmacokinet, V20, P153, DOI 10.2133/dmpk.20.153; Gengo FM, 2008, J CLIN PHARMACOL, V48, P335, DOI 10.1177/0091270007313324; Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7; Isshiki T, 2014, CIRC J, V78, P2926, DOI 10.1253/circj.CJ-14-0266; Japan Stroke Society Committee on Guidelines for the Management of Stroke, 2017, JAP GUID MAN STROK U, P43; Kamouchi M, 2012, CEREBROVASC DIS, V34, P351, DOI 10.1159/000343503; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kitazono T, 2018, J THROMB THROMBOLYS, V46, P488, DOI 10.1007/s11239-018-1714-2; Kobayashi M, 2015, J ATHEROSCLER THROMB, V22, P1186, DOI 10.5551/jat.28639; Liu LP, 2015, NEUROLOGY, V85, P1154, DOI 10.1212/WNL.0000000000001972; Liu R, 2016, ACTA PHARMACOL SIN, V37, P882, DOI 10.1038/aps.2016.41; Maeda K, 2013, J STROKE CEREBROVASC, V22, P1070, DOI 10.1016/j.jstrokecerebrovasdis.2012.07.006; Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949; Meves SH, 2014, J THROMB THROMBOLYS, V37, P190, DOI 10.1007/s11239-013-0919-7; Nagao T, 2018, EXPERT OPIN PHARMACO, V19, P529, DOI 10.1080/14656566.2018.1444029; Ogawa H, 2016, J CARDIOL, V68, P29, DOI 10.1016/j.jjcc.2015.07.019; Saito S, 2014, CIRC J, V78, P1684, DOI 10.1253/circj.CJ-13-1482; Sanna T, 2014, NEW ENGL J MED, V370, P2478, DOI 10.1056/NEJMoa1313600; Shinohara Y, 2008, STROKE, V39, P1827, DOI 10.1161/STROKEAHA.107.505131; Toyoda K, 2009, DRUGS, V69, P633, DOI 10.2165/00003495-200969060-00001; Umemura K, 2016, CLIN PHARM DRUG DEV, V5, P480, DOI 10.1002/cpdd.259; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yi XY, 2016, J NEUROL, V263, P1612, DOI 10.1007/s00415-016-8181-5	30	27	27	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					238	247		10.1016/S1474-4422(18)30449-6	http://dx.doi.org/10.1016/S1474-4422(18)30449-6			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	30784555				2022-12-18	WOS:000458509100016
J	Stenager, E				Stenager, Egon			A global perspective on the burden of multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									[Stenager, Egon] Univ Southern Denmark, Dept Reg Res, DK-5000 Odense C, Denmark; [Stenager, Egon] Hosp Southern Jutland, Dept Neurol, MS Clin Southern Jutland Sonderborg Esbjerg Koldi, Sonderborg, Denmark	University of Southern Denmark; University of Southern Denmark	Stenager, E (corresponding author), Univ Southern Denmark, Dept Reg Res, DK-5000 Odense C, Denmark.; Stenager, E (corresponding author), Hosp Southern Jutland, Dept Neurol, MS Clin Southern Jutland Sonderborg Esbjerg Koldi, Sonderborg, Denmark.	egon.stenager3@rsyd.dk	Stenager, Egon/AAU-4463-2020					Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Joensen P, 2011, MULT SCLER, V17, P241, DOI 10.1177/1352458510386997; KROMANN N, 1980, ACTA MED SCAND, V208, P401; Mackenzie IS, 2014, J NEUROL NEUROSUR PS, V85, P76, DOI 10.1136/jnnp-2013-305450; Nielsen NM, 2018, MULT SCLER J, V24, P64; Nielsen NM, 2013, AM J EPIDEMIOL, V177, P1289, DOI 10.1093/aje/kws350; Pfleger CCH, 2010, MULT SCLER, V16, P121, DOI 10.1177/1352458509352196; Wallin MT, 2010, ACTA NEUROL SCAND, V122, P102, DOI 10.1111/j.1600-0404.2009.01266.x; Wallin MT, 2019, LANCET NEUROL, V18, P269, DOI 10.1016/S1474-4422(18)30443-5	9	27	29	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					227	228		10.1016/S1474-4422(18)30498-8	http://dx.doi.org/10.1016/S1474-4422(18)30498-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	30679041	hybrid, Green Published			2022-12-18	WOS:000458509100009
J	Hughes, R; Dalakas, MC; Merkies, I				Hughes, R.; Dalakas, M. C.; Merkies, I			Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial (vol 17, pg 689, 2018)	LANCET NEUROLOGY			English	Correction													Van Damme, Philip/A-6464-2009; Nobile-Orazio, Eduardo/B-7915-2013	Van Damme, Philip/0000-0002-4010-2357; Nobile-Orazio, Eduardo/0000-0003-2624-8138; gallia, francesca/0000-0002-6838-3429; Selmaj, Krzysztof/0000-0003-1213-7218; Kimiskidis, Vasilios/0000-0002-3335-3019; Day, Timothy/0000-0003-3133-7565; Roberts, Leslie/0000-0002-6040-8572; Brannagan, Thomas/0000-0002-1812-8331; Lunn, Michael/0000-0003-3174-6027; Chapman, Joab/0000-0002-2161-9764				Hughes R, 2018, LANCET NEUROL, V17, P933, DOI 10.1016/S1474-4422(18)30202-3	1	27	28	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2018	17	11					933	933		10.1016/S1474-4422(18)30202-3	http://dx.doi.org/10.1016/S1474-4422(18)30202-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GX3PG	30001923	Green Submitted			2022-12-18	WOS:000447637500015
J	Hughes, R; Dalakas, MC; Merkies, I; Latov, N; Leger, JM; Nobile-Orazio, E; Sobue, G; Genge, A; Cornblath, D; Merschhemke, M; Ervin, CM; Agoropoulou, C; Hartung, HP				Hughes, Richard; Dalakas, Marinos C.; Merkies, Ingemar; Latov, Norman; Leger, Jean-Marc; Nobile-Orazio, Eduardo; Sobue, Gen; Genge, Angela; Cornblath, David; Merschhemke, Martin; Ervin, Carolyn Marie; Agoropoulou, Catherine; Hartung, Hans-Peter			Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial	LANCET NEUROLOGY			English	Article							RELAPSING MULTIPLE-SCLEROSIS; GRIP STRENGTH; NEUROPATHIES; LYMPHOCYTE; FTY720; CIDP	Background Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis and was effective in experimental autoimmune neuritis in rats, a possible model for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We aimed to evaluate the efficacy of fingolimod in delaying disability progression in patients with CIDP who withdrew from currently effective treatments (intravenous immunoglobulin [IVIg] or corticosteroids). Methods This double-blind, multicentre, randomised, placebo-controlled, parallel-group, event-driven study was done at 48 neurology centres in Australia, Canada, Israel, Japan, the USA, and nine countries in Europe. Participants with CIDP who were receiving IVIg or corticosteroids were randomly assigned (1:1) to once-daily oral fingolimod 0.5 mg or placebo. Owing to the event-driven design, treatment duration was flexible and could be up to 4.5 years. Randomisation was done with an automated interactive voice response-web response system and was stratified by Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale scores. Previous IVIg treatment was discontinued after one final course ending the day before the first dose of fingolimod or placebo was given, whereas corticosteroids were tapered off over 8 weeks after randomisation. The primary endpoint was time to first confirmed worsening (>= 1 point increase on the adjusted INCAT disability scale score versus baseline) and was assessed in the full analysis set, which consisted of all patients who underwent randomisation and had at least one efficacy assessment for the primary analysis. The survival distribution functions of time to first worsening were estimated within each treatment group according to the Kaplan-Meier survival distribution function and compared with a stratified log-rank test. The trial is registered with ClinicalTrials.gov, number NCT01625182. Findings Of 106 participants randomly assigned between Jan 24, 2013, and March 10, 2016, 54 received fingolimod (41 who had been receiving IVIg and 13 who had been receiving corticosteroids) and 52 received placebo (41 who had been receiving IVIg and 11 who had been receiving corticosteroids). The trial ended for futility as recommended by an independent data monitoring committee after an interim analysis when 44 confirmed worsening events had occurred. At the end of the study, the survival estimate of the proportion of participants free from confirmed worsening was not significantly different between the fingolimod group (42%, 95% CI 23-60) and the placebo group (43%, 28-59; p=0.91). Adverse events occurred in 41 (76%) participants receiving fingolimod and 44 (85%) on placebo, and serious adverse events occurred in nine (17%) and four (8%) patients, respectively. The most common adverse events with fingolimod were headache (12 [22%] patients), hypertension (ten [19%]), and extremity pain (seven [13%]). Adverse events leading to study discontinuation occurred in seven (13%) participants on fingolimod and none on placebo. Interpretation Fingolimod 0.5 mg once-daily was not better than placebo for the treatment of CIDP. Future trial designs should take account of the possibility that if IVIg is stopped abruptly, some patients might relapse soon afterwards whereas others might remain in remission. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Hughes, Richard] Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England; [Dalakas, Marinos C.] Univ Athens, Sch Med, Unit Neuroimmunol, Dept Pathophysiol, Athens, Greece; [Dalakas, Marinos C.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA; [Merkies, Ingemar] Maastricht Univ, Med Ctr, Maastricht, Netherlands; [Merkies, Ingemar] St Elizabeth Hosp, Willemstad, Curacao; [Latov, Norman] Weill Cornell Med Coll, Dept Neurol, New York, NY USA; [Leger, Jean-Marc] Univ Hosp Pitie Salpetriere, Natl Referral Ctr Neuromuscular Dis, Paris, France; [Nobile-Orazio, Eduardo] Milan Univ, Humanitas Clin & Res Ctr, Dept Med Biotechnol & Translat Med, Milan, Italy; [Sobue, Gen] Nagoya Univ Hosp, Nagoya, Aichi, Japan; [Genge, Angela] Montreal Neurol Hosp & Inst, Clin Res Unit, ALS Clin, Montreal, PQ, Canada; [Cornblath, David] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Merschhemke, Martin; Ervin, Carolyn Marie; Agoropoulou, Catherine] Novartis Pharma AG, Basel, Switzerland; [Hartung, Hans-Peter] Univ Klinikum Dusseldorf, Dept Neurol, Dusseldorf, Germany; [Hartung, Hans-Peter] Heinrich Heine Univ, Ctr Neurol & Neuropsychiat, LVR Klinikum, Dusseldorf, Germany	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Athens Medical School; National & Kapodistrian University of Athens; Jefferson University; Maastricht University; Cornell University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Milan; Nagoya University; McGill University; Johns Hopkins University; Novartis; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf	Hughes, R (corresponding author), Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.	richard.hughes@ucl.ac.uk	Van Damme, Philip/A-6464-2009; Nobile-Orazio, Eduardo/B-7915-2013	Van Damme, Philip/0000-0002-4010-2357; Nobile-Orazio, Eduardo/0000-0003-2624-8138; gallia, francesca/0000-0002-6838-3429; Selmaj, Krzysztof/0000-0003-1213-7218; Kimiskidis, Vasilios/0000-0002-3335-3019; Day, Timothy/0000-0003-3133-7565; Roberts, Leslie/0000-0002-6040-8572; Brannagan, Thomas/0000-0002-1812-8331; Lunn, Michael/0000-0003-3174-6027; Chapman, Joab/0000-0002-2161-9764	Novartis Pharma	Novartis Pharma	Novartis Pharma.	Bail K, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0924-4; Breiner A, 2014, MUSCLE NERVE, V50, P164, DOI 10.1002/mus.24207; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Comi G, 2017, DRUGS, V77, P1755, DOI 10.1007/s40265-017-0814-1; Dimachkie MM, 2013, CURR TREAT OPTION NE, V15, P350, DOI 10.1007/s11940-013-0229-6; DiMarco JP, 2014, MULT SCLER RELAT DIS, V3, P629, DOI 10.1016/j.msard.2014.05.005; Draak THP, 2015, J PERIPHER NERV SYST, V20, P269, DOI 10.1111/jns.12126; Draak THP, 2014, NEUROLOGY, V83, P2124, DOI 10.1212/WNL.0000000000001044; Grutzke B, 2015, ANN CLIN TRANSL NEUR, V2, P119, DOI 10.1002/acn3.155; Huehnchen P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23949-4; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Khatri BO, 2016, THER ADV NEUROL DISO, V9, P130, DOI 10.1177/1756285616628766; Kim HJ, 2009, J NEUROIMMUNOL, V214, P93, DOI 10.1016/j.jneuroim.2009.07.006; Kohne A, 2012, ARCH NEUROL-CHICAGO, V69, P1280, DOI 10.1001/archneurol.2012.394; Kovarik JM, 2004, J CLIN PHARMACOL, V44, P532, DOI 10.1177/0091270004264165; Mahdi-Rogers M., 2013, COCHRANE DB SYST REV, V6; Mathey EK, 2015, J NEUROL NEUROSUR PS, V86, P973, DOI 10.1136/jnnp-2014-309697; Mausberg AK, 2013, NEUROLOGY, V80, P296, DOI 10.1212/WNL.0b013e31827debad; Oaklander AL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010369.pub2; Van den Bergh PYK, 2010, EUR J NEUROL, V17, P356, DOI 10.1111/j.1468-1331.2009.02930.x; van Nes SI, 2011, NEUROLOGY, V76, P337, DOI 10.1212/WNL.0b013e318208824b; van Schaik IN, 2018, LANCET NEUROL, V17, P35, DOI 10.1016/S1474-4422(17)30378-2; Vanhoutte EK, 2013, EUR J NEUROL, V20, P748, DOI 10.1111/j.1468-1331.2012.03851.x; Zhang Z, 2008, EXP NEUROL, V210, P681, DOI 10.1016/j.expneurol.2007.12.025	24	27	28	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					689	698		10.1016/S1474-4422(18)30202-3	http://dx.doi.org/10.1016/S1474-4422(18)30202-3			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30001923	Green Submitted			2022-12-18	WOS:000439057500013
J	Reiman, EM				Reiman, Eric M.			Alzheimer's disease and other dementias: advances in 2013	LANCET NEUROLOGY			English	Editorial Material							AMYLOID-BETA DEPOSITION; TAU PATHOLOGY; PET		[Reiman, Eric M.] Univ Arizona, Coll Med, Banner Alzheimers Inst, Phoenix, AZ 85004 USA; [Reiman, Eric M.] Univ Arizona, Coll Med, Banner Res, Translat Genom Res Inst, Phoenix, AZ USA; [Reiman, Eric M.] Arizona Alzheimers Consortium, Phoenix, AZ USA	Banner Research; Banner Health; Banner Alzheimer's Institute; University of Arizona; Translational Genomics Research Institute; University of Arizona	Reiman, EM (corresponding author), Univ Arizona, Coll Med, Banner Alzheimers Inst, Phoenix, AZ 85004 USA.	eric.reiman@bannerhealth.com						Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Dean DC, 2014, JAMA NEUROL, V71, P11, DOI 10.1001/jamaneurol.2013.4544; Fleisher AS, 2012, LANCET NEUROL, V11, P1057, DOI 10.1016/S1474-4422(12)70227-2; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2012.10.007, 10.1016/j.jalz.2013.06.001]; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Knickmeyer RC, 2014, CEREB CORTEX, V24, P1230, DOI 10.1093/cercor/bhs401; Kozauer N, 2013, NEW ENGL J MED, V368, P1169, DOI 10.1056/NEJMp1302513; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037; Okamura N, 2013, J NUCL MED, V54, P1420, DOI 10.2967/jnumed.112.117341; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046	15	27	32	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					3	5		10.1016/S1474-4422(13)70257-6	http://dx.doi.org/10.1016/S1474-4422(13)70257-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331781				2022-12-18	WOS:000329000900003
J	Titulaer, MJ; Kayser, MS; Dalmau, J				Titulaer, Maarten J.; Kayser, Matthew S.; Dalmau, Josep			Prevalence and treatment of anti-NMDA receptor encephalitis Reply	LANCET NEUROLOGY			English	Letter							ANTIBODIES; SCHIZOPHRENIA; AUTOANTIBODIES; SERUM		[Titulaer, Maarten J.; Kayser, Matthew S.; Dalmau, Josep] Hosp Univ Penn, Perelman Sch Med, Dept Neurol & Neurosci, Philadelphia, PA 19104 USA; [Titulaer, Maarten J.; Dalmau, Josep] Univ Barcelona, Hosp Clin, Dept Neurol, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Spain; [Dalmau, Josep] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	University of Pennsylvania; Pennsylvania Medicine; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA	Titulaer, MJ (corresponding author), Hosp Univ Penn, Perelman Sch Med, Dept Neurol & Neurosci, 3400 Spruce St, Philadelphia, PA 19104 USA.	josep.dalmau@uphs.upenn.edu		Dalmau, Josep/0000-0001-5856-2813; Kayser, Matthew/0000-0003-2359-4967; Titulaer, Maarten/0000-0002-1033-3840	ICREA Funding Source: Custom	ICREA(ICREA)		Armangue T, 2013, J PEDIATR-US, V162, P850, DOI 10.1016/j.jpeds.2012.10.011; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Leypoldt F, 2013, J CLIN NEUROSCI, DOI [10.1016/j.jocn.2012.03.036, DOI 10.1016/J.J0CN.2012.03.036]; Martinez-Hernandez E, 2011, NEUROLOGY, V77, P589, DOI 10.1212/WNL.0b013e318228c136; Masdeu JC, 2012, AM J PSYCHIAT, V169, P1120, DOI 10.1176/appi.ajp.2012.12050646; Panzer JA, 2013, NAT REV NEUROL, DOI [10.1038/nrneurol.2013.31, DOI 10.1038/NRNEUR01.2013.31]; Pruss H, 2012, NEUROLOGY, V78, P1743, DOI 10.1212/WNL.0b013e318258300d; Pruss H, 2010, NEUROLOGY, V75, P1735, DOI 10.1212/WNL.0b013e3181fc2a06; Pruss H, 2012, ANN NEUROL, V72, P902, DOI 10.1002/ana.23689; Rhoads J, 2011, SCHIZOPHR RES, V129, P213, DOI 10.1016/j.schres.2010.12.018; Steiner J, 2013, JAMA PSYCHIAT, V70, P271, DOI 10.1001/2013.jamapsychiatry.86; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Zandi MS, 2011, J NEUROL, V258, P686, DOI 10.1007/s00415-010-5788-9	13	27	29	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					425	426		10.1016/S1474-4422(13)70072-3	http://dx.doi.org/10.1016/S1474-4422(13)70072-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23602157				2022-12-18	WOS:000318836700011
J	Tan, K; Prerna, A; Leo, YS				Tan, Kevin; Prerna, Asha; Leo, Yee-Sin			Surveillance of H1N1-related neurological complications	LANCET NEUROLOGY			English	Letter									[Tan, Kevin; Prerna, Asha] Natl Inst Neurosci, Dept Neurol, Singapore, Singapore; [Leo, Yee-Sin] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore	National Neuroscience Institute (NNI); Tan Tock Seng Hospital	Tan, K (corresponding author), Natl Inst Neurosci, Dept Neurol, Singapore, Singapore.	kevin_tan@nni.com.sg		Tan, Kevin/0000-0001-5894-8839				[Anonymous], 2009, LANCET NEUROL, V8, P869; *HLTH SCI AUTH, HSA REG REV INFL H1N; Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535; 2009, MMWR MORB MORTAL WKL, V58, P773	4	27	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2010	9	2					142	143		10.1016/S1474-4422(10)70015-6	http://dx.doi.org/10.1016/S1474-4422(10)70015-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	547XB	20129164				2022-12-18	WOS:000273922000011
J	Donnan, GA; Davis, SM				Donnan, Geoffrey A.; Davis, Stephen M.			Breaking the 3 h barrier for treatment of acute ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material							ALTEPLASE; TISSUE		[Donnan, Geoffrey A.] Univ Melbourne, Natl Stroke Res Inst, Heidelberg West, Australia; [Davis, Stephen M.] Royal Melbourne Hosp, Dept Neurosci, Parkville, Vic 3050, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Melbourne Hospital	Donnan, GA (corresponding author), Univ Melbourne, Natl Stroke Res Inst, Heidelberg West, Australia.	gdonnan@unimelb.edu.au	Davis, Stephen M/L-5260-2013	Davis, Stephen M/0000-0003-0962-2300; Donnan, Geoffrey/0000-0001-6324-3403				Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Barber PA, 1999, NEUROLOGY, V52, P1125, DOI 10.1212/WNL.52.6.1125; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Khatri P, 2008, INT J STROKE, V3, P130, DOI 10.1111/j.1747-4949.2008.00151.x; Markus R, 2004, BRAIN, V127, P1427, DOI 10.1093/brain/awh162; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; Whiteley W, 2006, INT J STROKE, V1, P172, DOI 10.1111/j.1747-4949.2006.00043.x	12	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					981	982		10.1016/S1474-4422(08)70230-8	http://dx.doi.org/10.1016/S1474-4422(08)70230-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP	18940690				2022-12-18	WOS:000260745800005
J	Hughes, R				Hughes, R			Campylobacter jejuni in Guillain-Barre syndrome	LANCET NEUROLOGY			English	Editorial Material							NEUROPATHY; INFECTION; COMPLEX; MICE		Kings Coll London, Dept Clin Neurosci, Guys Kings & St Thomas Sch Med, London WC2R 2LS, England	University of London; King's College London	Hughes, R (corresponding author), Kings Coll London, Dept Clin Neurosci, Guys Kings & St Thomas Sch Med, London WC2R 2LS, England.	richard.a.hughes@kcl.ac.uk						Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758; Halstead SK, 2004, BRAIN, V127, P2109, DOI 10.1093/brain/awh231; Kuwabara S, 2004, NEUROLOGY, V63, P529, DOI 10.1212/01.WNL.0000133205.05169.04; Lunn MPT, 2000, J NEUROCHEM, V75, P404, DOI 10.1046/j.1471-4159.2000.0750404.x; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; Sheikh KA, 2004, ANN NEUROL, V56, P228, DOI 10.1002/ana.20173	6	27	28	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2004	3	11					644	644		10.1016/S1474-4422(04)00902-0	http://dx.doi.org/10.1016/S1474-4422(04)00902-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865CL	15488456				2022-12-18	WOS:000224680000015
J	Donnan, GA; Dewey, HM; Chambers, BR				Donnan, GA; Dewey, HM; Chambers, BR			Warfarin for atrial fibrillation: the end of an era?	LANCET NEUROLOGY			English	Review							ANTITHROMBOTIC THERAPY; STROKE PREVENTION; RHYTHM CONTROL; ANTICOAGULATION; XIMELAGATRAN; RISK; IDRAPARINUX; PREVALENCE; DEATH	Background Warfarin has been in routine clinical use for more than 50 years; however, it was not proven to be of benefit in both primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (AF) until about a decade ago. Despite its efficacy in reducing the risk of stroke in patients with AF by about 60%, with an absolute reduction of about 3% per year, there have always been barriers to its use. These barriers have included the need for monitoring the degree of anticoagulation with blood tests to measure the international normalised ratio, frequent dose adjustments to maintain this ratio within quite a narrow therapeutic range, and the risk of bleeding should the upper limits of this range be exceeded. Aspirin has also been used but is less effective. Recent developments New oral drugs are being tested; these may be as effective at reducing stroke risk as warfarin in patients with AF. Direct thrombin inhibitors such as ximelagatran are not inferior to warfarin and, based on results from the SPORTIF III and V trials, are perhaps safer, with no need for long-term monitoring and dose adjustment. However, the side-effect of raised amounts of the liver enzyme alanine amino-transferase in 6% of patients needs to be resolved. In the ACTIVE trial, the efficacy of a combination of antiplatelet drugs (aspirin plus clopidogrel) is being tested against dose-adjusted warfarin; and in AMADEUS, the factor-Xa inhibitor and pentasaccharide idraparinux is being assessed in a similar way. Several surgical procedures and devices are also being developed to control AF rhythm and prevent stroke. Where next? The place of these new drugs in the management of AF needs to be established. In the short term, it seems that ximelagatran will replace warfarin in patients for whom there is evidence of a favourable risk-to-benefit ratio. The SPORTIF population consists of patients with AF plus at least one risk factor. More information about the effect of raised liver enzymes will probably not be available until phase IV studies are completed. Combination antiplatelet drugs need to be tested further-perhaps even triple therapy with aspirin, clopidogrel, and dipyridamole-if the results of ACTIVE are encouraging. The place of surgical procedures and devices to control rhythm and prevent stroke is unclear. Whatever happens, there is a high probability that the days of warfarin are numbered.	Univ Melbourne, Dept Med, Natl Stroke Res Inst, Dept Neurol,Austin Hlth, Heidelberg, Vic 3081, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Donnan, GA (corresponding author), Univ Melbourne, Dept Med, Natl Stroke Res Inst, Dept Neurol,Austin Hlth, 300 Waterdale Rd, Heidelberg, Vic 3081, Australia.	gdonnan@unimelb.edu.au	DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403				Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; Cooper JM, 2002, NEW ENGL J MED, V346, P2062, DOI 10.1056/NEJMra012144; Crystal E, 2003, AM HEART J, V145, P174, DOI 10.1067/mhj.2003.44; Devereaux PJ, 2001, BMJ-BRIT MED J, V323, P1218, DOI 10.1136/bmj.323.7323.1218; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; DONNAN GA, 2001, PREVENTION STROKE, P275; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; Gouin-Thibault I, 2003, J THROMB HAEMOST, V1, P2054, DOI 10.1046/j.1538-7836.2003.00384.x; Gustafsson D, 2003, J INTERN MED, V254, P322, DOI 10.1046/j.1365-2796.2003.01225.x; Hankey GJ, 2001, MED J AUSTRALIA, V174, P234; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hohnloser SH, 2003, J CARDIOVASC ELECTR, V14, pS60, DOI 10.1046/j.1540-8167.14.s9.12.x; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Leckey R, 2000, CAN J CARDIOL, V16, P481; Mungall Dennis, 2002, Curr Opin Investig Drugs, V3, P905; OLSSON SB, 2000, LANCET, V362, P1691; Ostermayer Stefan, 2003, J Interv Cardiol, V16, P553, DOI 10.1046/j.1540-8183.2003.01055.x; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; Posada IS, 1999, AM HEART J, V138, P137, DOI 10.1016/S0002-8703(99)70259-0; Reiter M, 2003, BLOOD COAGUL FIBRIN, V14, P61, DOI 10.1097/00001721-200301000-00011; Savelieva I, 2000, J INTERV CARD ELECTR, V4, P369, DOI 10.1023/A:1009823001707; Saxena R, 2001, STROKE, V32, P2333, DOI 10.1161/hs1001.097093; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sundt Thoralf M. III, 1997, Cardiology Clinics, V15, P739; Taylor FC, 2001, BMJ-BRIT MED J, V322, P321, DOI 10.1136/bmj.322.7282.321; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0; Wang TJ, 2003, JAMA-J AM MED ASSOC, V290, P1049, DOI 10.1001/jama.290.8.1049; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Yusuf S, 2000, EUR HEART J, V21, P2033	35	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					305	308		10.1016/S1474-4422(04)00738-0	http://dx.doi.org/10.1016/S1474-4422(04)00738-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL	15099545				2022-12-18	WOS:000221160700024
J	Schoenen, J; Sandor, PS				Schoenen, J; Sandor, PS			Headache with focal neurological signs or symptoms: a complicated differential diagnosis	LANCET NEUROLOGY			English	Review							FAMILIAL HEMIPLEGIC MIGRAINE; SPONTANEOUS INTRACRANIAL HYPOTENSION; CLUSTER HEADACHE; OPHTHALMOPLEGIC MIGRAINE; SUBARACHNOID HEMORRHAGE; THUNDERCLAP HEADACHE; SUNCT SYNDROME; AURA; STROKE; PUNCTURE	Headache syndromes can be associated with focal neurological symptoms or signs. Good knowledge of primary headaches, a detailed history and a thorough clinical examination are prerequisites for their differential diagnosis. The neurological symptoms produced by the migraine aura are the most characteristic and recognisable. However, structural lesions, such as vascular malformations, can produce similar symptoms to migraine with aura, which highlights that paraclinical investigations are necessary in most patients with headache and focal neurological symptoms. In this review, we provide an overview of the differential diagnosis of the most common headache disorders with focal neurological symptoms or signs to refresh the practising neurologist's differential diagnostic knowledge for the clinical situation and to aid the teaching of neurology residents.	Univ Liege, Dept Neurol, Liege, Belgium; Univ Liege, Dept Neuroanat, Headache Res Unit, Liege, Belgium; Univ Zurich Hosp, Dept Neurol, Headache & Pain Unit, Zurich, Switzerland	University of Liege; University of Liege; University of Zurich; University Zurich Hospital	Schoenen, J (corresponding author), Univ Dept Neurol, CHR Citadelle, Blvd Xlleme Ligne, B-4000 Cointe Ougree, Belgium.	jean.schoenen@chrcitadelle.be	Sandor, Peter/GRJ-5508-2022					AMERI A, 1992, NEUROL CLIN, V10, P87, DOI 10.1016/S0733-8619(18)30235-4; Antonaci F, 1998, HEADACHE, V38, P122, DOI 10.1046/j.1526-4610.1998.3802122.x; BERG MJ, 1995, NEUROLOGY, V45, P1648, DOI 10.1212/WNL.45.9.1648; BIOUSSE V, 1994, CEPHALALGIA, V14, P33, DOI 10.1046/j.1468-2982.1994.1401033.x; Blattler T, 2003, NEUROLOGY, V60, P2012, DOI 10.1212/01.WNL.0000068015.58948.D3; BLAU JN, 1993, LANCET, V342, P723, DOI 10.1016/0140-6736(93)91713-V; Bousser MG, 2000, CEPHALALGIA, V20, P155, DOI 10.1046/j.1468-2982.2000.00035.x; BRUYN GW, 1984, CEPHALALGIA, V4, P191, DOI 10.1046/j.1468-2982.1984.0403191.x; BUSSONE G, 1991, CEPHALALGIA, V11, P123, DOI 10.1046/j.1468-2982.1991.1103123.x; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Christoforidis GA, 1998, NEURORADIOLOGY, V40, P636, DOI 10.1007/s002340050655; DALESSIO DJ, 1989, TXB PAIN, P386; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; DeBenedittis G, 1996, CEPHALALGIA, V16, P503, DOI 10.1046/j.1468-2982.1996.1607503.x; Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Edmeads J, 1986, HDB CLIN NEUROLOGY, V48, P273; EKBOM K, 1986, HDB CLIN NEUROLOGY, V4, P247; Goadsby PJ, 1997, BRAIN, V120, P193, DOI 10.1093/brain/120.1.193; GomezAranda F, 1997, BRAIN, V120, P1105, DOI 10.1093/brain/120.7.1105; HAAS DC, 1991, HEADACHE, V31, P509, DOI 10.1111/j.1526-4610.1991.hed3108509.x; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; KELLY RE, 1986, HDB CLIN NEUROLOGY, V4, P383; Kline LB, 2001, J NEUROL NEUROSUR PS, V71, P577, DOI 10.1136/jnnp.71.5.577; KUNTZ KM, 1992, NEUROLOGY, V42, P1884, DOI 10.1212/WNL.42.10.1884; Kurita H, 2000, ARCH NEUROL-CHICAGO, V57, P1219, DOI 10.1001/archneur.57.8.1219; Lance JW, 2001, CEPHALALGIA, V21, P84, DOI 10.1046/j.1468-2982.2001.00160.x; Landtblom AM, 2002, CEPHALALGIA, V22, P354, DOI 10.1046/j.1468-2982.2002.00368.x; Linn FHH, 2002, NEUROLOGIST, V8, P279, DOI 10.1097/00127893-200209000-00001; MacGregor EA, 1998, BRIT J FAM PLAN, V24, P53; Manzoni GC, 1998, CEPHALALGIA, V18, P138, DOI 10.1046/j.1468-2982.1998.1803138.x; MARCELIS J, 1991, ARCH NEUROL-CHICAGO, V48, P392, DOI 10.1001/archneur.1991.00530160060014; Mark AS, 1998, AM J NEURORADIOL, V19, P1887; MARKUS HS, 1991, J NEUROL NEUROSUR PS, V54, P1117, DOI 10.1136/jnnp.54.12.1117; May A, 1998, LANCET, V352, P275, DOI 10.1016/S0140-6736(98)02470-2; MITSIAS P, 1992, CEPHALALGIA, V12, P269, DOI 10.1046/j.1468-2982.1992.1205269.x; Miyazawa K, 2003, NEUROLOGY, V60, P941, DOI 10.1212/01.WNL.0000049933.51044.81; MORALES F, 1994, CEPHALALGIA, V14, P301, DOI 10.1046/j.1468-2982.1994.1404301.x; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; Russell MB, 1996, BRAIN, V119, P355, DOI 10.1093/brain/119.2.355; RUSSELL MB, 1995, J MED GENET, V32, P954, DOI 10.1136/jmg.32.12.954; RUSSELL RWR, 1986, HDB CLIN NEUROLOGY, V4, P309; Schoenen J, 1998, LANCET, V352, P253, DOI 10.1016/S0140-6736(05)60256-5; Schwaag S, 2003, HEADACHE, V43, P90, DOI 10.1046/j.1526-4610.2003.03023.x; Sidman R, 1996, ACAD EMERG MED, V3, P827, DOI 10.1111/j.1553-2712.1996.tb03526.x; SILBERSTEIN SD, 1992, HEADACHE, V32, P84, DOI 10.1111/j.1526-4610.1992.hed3202084.x; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2000, NEUROLOGY, V54, P219, DOI 10.1212/WNL.54.1.219; SJAASTAD O, 1986, HEADACHE, V4, P217; SJAASTAD O, 1992, MAJOR PROBLEMS NEURO, V23; TERRENCE CF, 2000, HEADACHES, P929; Thomsen LL, 2003, NEUROLOGY, V60, P595, DOI 10.1212/01.WNL.0000046524.25369.7D; Tietjen GE, 2000, NEUROEPIDEMIOLOGY, V19, P13, DOI 10.1159/000026233; TROOST BT, 1979, ANN NEUROL, V5, P199, DOI 10.1002/ana.410050216; Tzourio C, 2000, CEPHALALGIA, V20, P190, DOI 10.1046/j.1468-2982.2000.00041.x; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; Vilming ST, 2001, CEPHALALGIA, V21, P738, DOI 10.1046/j.1468-2982.2001.00200.x; WALL M, 1990, CEPHALALGIA, V10, P331, DOI 10.1046/j.1468-2982.1990.1006331.x; WATSON CPN, 1988, PAIN, V35, P289, DOI 10.1016/0304-3959(88)90139-X; WIJDICKS EFM, 1988, LANCET, V2, P68	61	27	28	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2004	3	4					237	245		10.1016/S1474-4422(04)00709-4	http://dx.doi.org/10.1016/S1474-4422(04)00709-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	814QU	15039036				2022-12-18	WOS:000220990000018
J	Bradbury, J				Bradbury, J			alpha-synuclein gene triplication discovered in Parkinson's disease	LANCET NEUROLOGY			English	News Item																			0	27	27	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					715	715		10.1016/S1474-4422(03)00601-X	http://dx.doi.org/10.1016/S1474-4422(03)00601-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14649238				2022-12-18	WOS:000186665800004
J	Uccelli, A; Laroni, A; Ali, R; Battaglia, MA; Blinkenberg, M; Brundin, L; Clanet, M; Fernandez, O; Marriot, J; Muraro, P; Nabavi, SM; Oliveri, RS; Radue, E; Tello, CR; Schiavetti, I; Sellner, J; Sorensen, PS; Sormani, MP; Wuerfel, JT; Freedman, MS				Uccelli, Antonio; Laroni, Alice; Ali, Rehiana; Battaglia, Mario Alberto; Blinkenberg, Morten; Brundin, Lou; Clanet, Michel; Fernandez, Oscar; Marriot, James; Muraro, Paolo; Nabavi, Seyed Massood; Oliveri, Roberto S.; Radue, Ernst; Tello, Cristina Ramo; Schiavetti, Irene; Sellner, Johann; Sorensen, Per Soelberg; Sormani, Maria Pia; Wuerfel, Jens Thomas; Freedman, Mark S.		MESEMS Investigators	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial	LANCET NEUROLOGY			English	Article							MARROW STROMAL CELLS; BONE-MARROW; TRANSPLANTATION; LUNG	Background Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study was devised to evaluate the safety, tolerability, and activity of autologous MSCs derived from bone marrow and infused intravenously in patients with active multiple sclerosis. Methods MESEMS is a randomised phase 2 trial done at 15 sites in nine countries. Patients (aged 18-50 years) with active relapsing-remitting or progressive multiple sclerosis were included if they had a disease duration of 2-15 years since onset of multiple sclerosis and an Expanded Disability Status Scale score of 2.5-6.5. Patients were randomly assigned (1:1), according to a crossover design, to receive a single intravenous dose of autologous bone marrow derived MSCs followed by placebo at week 24, or to receive placebo followed by autologous MSCs at week 24, with a follow-up visit at week 48. Primary objectives were to test safety and activity of MSC treatment. The primary safety endpoint was to assess the number and severity of adverse events within each treatment arm. The primary efficacy endpoint was the number of gadolinium-enhancing lesions (GELs) counted over week 4, 12, and 24 compared between treatment groups. The primary efficacy endpoint was assessed in the full analyis set, after all participants completed the week 24 visit. Efficacy endpoints were evaluated using a predefined statistical testing procedure. Safety was monitored throughout the study by recording vital signs and adverse events at each visit. Findings From July 16, 2012, until July 31, 2019, 144 patients were randomly assigned to first receive early intravenous infusion of autologous bone marrow-derived MSCs (n=69) or placebo (n=75). MSC treatment did not meet the primary endpoint of efficacy on the total number of GELs accumulated from baseline to week 24 (rate ratio [RR] 0.94, 95% CI 0.58-1.50; p=0.78). 213 adverse events were recorded, similarly distributed between groups (93 cases recorded in 35 [51%] of 69 patients treated first with MSCs vs 120 cases in 42 [56%] of 75 patients infused first with placebo). The most frequent adverse events reported were infection and infestations, with a total of 54 (25%) of 213 adverse events (18 [19%] of 93 in the early-MSC group and 36 [30%] of 120 in the delayed-MSC group). Nine serious adverse events were reported in seven patients treated with placebo versus none in the MSC group. All serious adverse events were considered to be unrelated to the treatment infusion. No deaths were reported during the study. Interpretation Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on GELs, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24. Thus, this study does not support the use of bone marrow-derived MSCs to treat active multiple sclerosis. Further studies should address the effect of MSCs on parameters related to tissue repair. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Uccelli, Antonio; Laroni, Alice] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy; [Uccelli, Antonio; Laroni, Alice] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy; [Schiavetti, Irene; Sormani, Maria Pia] Univ Genoa, Dept Hlth Sci, Genoa, Italy; [Uccelli, Antonio; Laroni, Alice; Sormani, Maria Pia] IRCCS Osped Polidin San Martino, Genoa, Italy; [Ali, Rehiana; Muraro, Paolo] Imperial Coll London, Dept Brain Sci, London, England; [Battaglia, Mario Alberto] Univ Siena, Dept Life Sci, Siena, Italy; [Battaglia, Mario Alberto] Italian Multiple Sclerosis Fdn, Genoa, Italy; [Blinkenberg, Morten; Sorensen, Per Soelberg] Univ Copenhagen, Danish Multiple Sclerosis Ctr, Dept Neurol, Copenhagen, Denmark; [Oliveri, Roberto S.] Univ Copenhagen, Cell Therapy Unit, Dept Clin Immunol, Copenhagen, Denmark; [Oliveri, Roberto S.] Rigshosp, Copenhagen, Denmark; [Brundin, Lou] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Brundin, Lou] Karolinska Univ Hosp, Div Neurol, Stockholm, Sweden; [Clanet, Michel] CHU Toulouse, Dept Neurol, Toulouse, France; [Fernandez, Oscar] Hosp Reg Univ, Inst Invest Biomed Malaga, Dept Neurol, Malaga, Spain; [Marriot, James] Univ Manitoba, Rady Fac Hlth Sci, Dept Internal Med, Max Rady Coll Med, Winnipeg, MB, Canada; [Nabavi, Seyed Massood] Acad Ctr Educ Culture & Res, Cell Sci Res Ctr, Royan Inst Stem Cell Biol & Technol, Dept Brain & Cognit Sci, Tehran, Iran; [Nabavi, Seyed Massood] Acad Ctr Educ Culture & Res, Regenerat Med Dept, Royan Inst Stem Cell Biol & Technol, Tehran, Iran; [Radue, Ernst; Wuerfel, Jens Thomas] Univ Basel, Med Image Anal Ctr, Basel, Switzerland; [Radue, Ernst; Wuerfel, Jens Thomas] Univ Basel, Dept Biomed Engn, Basel, Switzerland; [Tello, Cristina Ramo] Hosp Badalona Germans Trias & Pujol, Dept Neurosci, Multiple Sclerosis Unit, Badalona, Spain; [Sellner, Johann] Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria; [Sellner, Johann] Landesklinikum Mistelbach Ganserndorf, Dept Neurol, Mistelbach, Austria; [Freedman, Mark S.] Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada; [Freedman, Mark S.] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada	University of Genoa; University of Genoa; University of Genoa; Imperial College London; University of Siena; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; CHU de Toulouse; University of Manitoba; Academic Center for Education, Culture & Research (ACECR); Academic Center for Education, Culture & Research (ACECR); University of Basel; University of Basel; Hospital Germans Trias i Pujol; Paracelsus Private Medical University; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Freedman, MS (corresponding author), Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada.; Freedman, MS (corresponding author), Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada.; Uccelli, A (corresponding author), IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy.	auccelli@neurologia.unige.it; mfreedman@toh.ca	Laroni, Alice/K-4714-2016; Ramo-Tello, Cristina/N-9735-2016	Laroni, Alice/0000-0001-5599-9788; Ramo-Tello, Cristina/0000-0001-8643-5053; Brundin, Lou/0000-0003-4408-7817	Fondazione Italiana Sclerosi Multipla; European Committee for Treatment and Research in Multiple Sclerosis; Multiple Sclerosis International Federation; Compagnia di San Paolo; Danish Multiple Sclerosis Society; Toyota Foundation; Danish Blood Donors' Research Foundation; Spanish Health Research Institute Carlos 3, Foundacion Progreso y Salud; Royan Institute; Spinal Cord Injury and Tissue Regeneration Centre; Fondation pour l'aide a la recherche sur la sclerose en plaques (ARSEP); French Muscular Dystrophy Association (AFM) -Telethon; UK Stem Cell Foundation; Multiple Sclerosis Society of Canada; Multiple Sclerosis Scientific Research Foundation, and Research Manitoba [NCT01745783, NCT02035514]; EudraCT [2015-000137-78]	Fondazione Italiana Sclerosi Multipla(Fondazione Italiana Sclerosi Multipla (FISM)); European Committee for Treatment and Research in Multiple Sclerosis; Multiple Sclerosis International Federation; Compagnia di San Paolo(Compagnia di San Paolo); Danish Multiple Sclerosis Society; Toyota Foundation; Danish Blood Donors' Research Foundation; Spanish Health Research Institute Carlos 3, Foundacion Progreso y Salud; Royan Institute; Spinal Cord Injury and Tissue Regeneration Centre; Fondation pour l'aide a la recherche sur la sclerose en plaques (ARSEP); French Muscular Dystrophy Association (AFM) -Telethon; UK Stem Cell Foundation; Multiple Sclerosis Society of Canada; Multiple Sclerosis Scientific Research Foundation, and Research Manitoba; EudraCT	We acknowledge all the participants of the trial, the investigators and the members of the Independent Data Safety Monitoring Committee. We thank the funding bodies Fondazione Italiana Sclerosi Multipla, the European Committee for Treatment and Research in Multiple Sclerosis, the Multiple Sclerosis International Federation, Compagnia di San Paolo, the Danish Multiple Sclerosis Society, Toyota Foundation, the Danish Blood Donors' Research Foundation, Spanish Health Research Institute Carlos 3, Foundacion Progreso y Salud, the Royan Institute, the Spinal Cord Injury and Tissue Regeneration Centre, Fondation pour l'aide a la recherche sur la sclerose en plaques (ARSEP) , French Muscular Dystrophy Association (AFM) -Telethon, the UK Multiple Sclerosis Society, the UK Stem Cell Foundation, the Multiple Sclerosis Society of Canada, the Multiple Sclerosis Scientific Research Foundation, and Research Manitoba. Trial registration numbers were as follows: in Andalusia, NCT01745783; Badalona, NCT02035514; EudraCT, 2010-024081-21; Canada, ClinicalTrials.gov, NCT02239393; Copenhagen, EudraCT, 2012-000518-13; Italy, EudraCT, 2011-001295-19 and NCT01854957; London, EudraCT, 2012-002357-35 and NCT01606215; Salzburg, EudraCT, 2015-000137-78; Stockholm, NCT01730547; and Toulouse, NCT02403947.	Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Baldassari L.E., 2019, MULT SCLER J-EXP TRA, V5; Cohen JA, 2018, MULT SCLER J, V24, P501, DOI 10.1177/1352458517703802; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Connick P, 2012, LANCET NEUROL, V11, P150, DOI 10.1016/S1474-4422(11)70305-2; Eliopoulos N, 2005, BLOOD, V106, P4057, DOI 10.1182/blood-2005-03-1004; Freedman MS, 2010, MULT SCLER J, V16, P503, DOI 10.1177/1352458509359727; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009; Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Iacobaeus E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122102; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248; KATZ D, 1993, ANN NEUROL, V34, P661, DOI 10.1002/ana.410340507; Lanza C, 2009, J NEUROCHEM, V110, P1674, DOI 10.1111/j.1471-4159.2009.06268.x; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Llufriu S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113936; Lombardi M, 2019, ACTA NEUROPATHOL, V138, P987, DOI 10.1007/s00401-019-02049-1; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Petrou P, 2020, BRAIN, V143, P3574, DOI 10.1093/brain/awaa333; Santamaria G, 2021, CELL DEATH DIFFER, V28, P203, DOI 10.1038/s41418-020-0592-2; Schmuck EG, 2016, STEM CELL TRANSL MED, V5, P1668, DOI 10.5966/sctm.2015-0379; Shanks Niall, 2009, Philos Ethics Humanit Med, V4, P2, DOI 10.1186/1747-5341-4-2; Sormani MP, 1999, J NEUROL NEUROSUR PS, V66, P465, DOI 10.1136/jnnp.66.4.465; Sun LY, 2007, LUPUS, V16, P121, DOI 10.1177/0961203306075793; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Uccelli A, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3346-z; Uccelli A, 2011, LANCET NEUROL, V10, P649, DOI 10.1016/S1474-4422(11)70121-1; Vigo T, 2017, J ALLERGY CLIN IMMUN, V139, P1667, DOI 10.1016/j.jaci.2016.09.004; Yamout B, 2010, J NEUROIMMUNOL, V227, P185, DOI 10.1016/j.jneuroim.2010.07.013; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962	34	26	26	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					917	929		10.1016/S1474-4422(21)00301-X	http://dx.doi.org/10.1016/S1474-4422(21)00301-X			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL5PY	34687636				2022-12-18	WOS:000710458300015
J	Ng, YS; Bindoff, LA; Gorman, GS; Klopstock, T; Kornblum, C; Mancuso, M; McFarland, R; Sue, CM; Suomalainen, A; Taylor, RW; Thorburn, DR; Turnbull, DM				Ng, Yi Shiau; Bindoff, Laurence A.; Gorman, Grainne S.; Klopstock, Thomas; Kornblum, Cornelia; Mancuso, Michelangelo; McFarland, Robert; Sue, Carolyn M.; Suomalainen, Anu; Taylor, Robert W.; Thorburn, David R.; Turnbull, Doug M.			Mitochondrial disease in adults: recent advances and future promise	LANCET NEUROLOGY			English	Review							PHENOTYPIC HETEROGENEITY; MEDICAL GENETICS; AMERICAN-COLLEGE; LEIGH-SYNDROME; DNA; MUTATIONS; DIAGNOSIS; PATIENT; PREVALENCE; MYOPATHIES	Mitochondrial diseases are some of the most common inherited neurometabolic disorders, and major progress has been made in our understanding, diagnosis, and treatment of these conditions in the past 5 years. Development of national mitochondrial disease cohorts and international collaborations has changed our knowledge of the spectrum of clinical phenotypes and natural history of mitochondrial diseases. Advances in high-throughput sequencing technologies have altered the diagnostic algorithm for mitochondrial diseases by increasingly using a genetics-first approach, with more than 350 disease-causing genes identified to date. While the current management strategy for mitochondrial disease focuses on surveillance for multisystem involvement and effective symptomatic treatment, new endeavours are underway to find better treatments, including repurposing current drugs, use of novel small molecules, and gene therapies. Developments made in reproductive technology offer women the opportunity to prevent transmission of DNA-related mitochondrial disease to their children.	[Ng, Yi Shiau; Gorman, Grainne S.; McFarland, Robert; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Gorman, Grainne S.; McFarland, Robert; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Upon Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitodiondrial Di, Newcastle Upon Tyne, Tyne & Wear, England; [Ng, Yi Shiau; Gorman, Grainne S.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Directorate Neurosci, Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England; [Bindoff, Laurence A.] Univ Bergen, Dept Clin Med, Bergen, Norway; [Bindoff, Laurence A.] Haukeland Hosp, Dept Neurol, Neuro SysMed, Bergen, Norway; [Klopstock, Thomas] Ludwig Max Imilians Univ, LMU Hosp, Friedrich Baur Inst, Dept Neurol, Munich, Germany; [Klopstock, Thomas] German Ctr Neurodegenerat Dis, Munich, Germany; [Klopstock, Thomas] Munich Cluster Syst Neurol, Munich, Germany; [Kornblum, Cornelia] Univ Hosp Bonn, Dept Neurol, Neuromuscular Dis Sect, Bonn, Germany; [Kornblum, Cornelia] Univ Hosp Bonn, Ctr Rare Dis, Bonn, Germany; [Mancuso, Michelangelo] Univ Pisa, Neurol Inst, Dept Clin & Expt Med, Pisa, Italy; [Sue, Carolyn M.] Univ Sydney, Fac Med & Hlth, Kolling Inst, Dept Neurogenet, Sydney, NSW, Australia; [Sue, Carolyn M.] Northern Sydney Local Hlth Dist, Dept Neurol, Royal North Shore Hosp, St Leonards, NSW, Australia; [Suomalainen, Anu] Univ Helsinki, Res Program Stem Cells & Metab, Fac Med, Helsinki, Finland; [Suomalainen, Anu] Univ Helsinki, Hilife, Neurosci Ctr, Helsinki, Finland; [Suomalainen, Anu] Helsinki Univ Hosp, HUSlab, Helsinki, Finland; [Thorburn, David R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Thorburn, David R.] Royal Childrens Hosp, Victorian Clin Genet Serv, Melbourne, Vic, Australia; [Thorburn, David R.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Bergen; University of Bergen; Haukeland University Hospital; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn; University of Bonn; University of Pisa; University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Turnbull, DM (corresponding author), Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	doug.turnbull@ncl.ac.uk	Ng, Yi Shiau/AFF-1445-2022	Ng, Yi Shiau/0000-0002-7591-2034	Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Newcastle University Centre for Ageing and Vitality (Biotechnology and Biological Sciences Research Council) [G016354/1]; NIHR Biomedical Research Centre for Ageing and Age-Related Disease award; Lily Foundation; UK NHS; German Federal Ministry of Education and Research (Bonn, Germany) [01GM1906A, 01GM1920B]; European Commission; NIHR Clinical Lectureship in Neurology [CL-2016-01-003]; Telethon Grant [GUP09004]; Telethon-MITOCON [GSP16001, RF-2016-02361495]; GENOMIT; NHMRC [APP 1136800]; Mito Foundation; Aligning Science Across Parkinson's Collaborative Research Network; Spastic Paraplegia Foundation; US Department of Defense Congressionally Directed Medical Research Programs; Victorian Government's Operational Infrastructure Support Program; Academy of Finland	Wellcome Centre for Mitochondrial Research; Newcastle University Centre for Ageing and Vitality (Biotechnology and Biological Sciences Research Council)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIHR Biomedical Research Centre for Ageing and Age-Related Disease award; Lily Foundation; UK NHS; German Federal Ministry of Education and Research (Bonn, Germany); European Commission(European CommissionEuropean Commission Joint Research Centre); NIHR Clinical Lectureship in Neurology; Telethon Grant(Fondazione Telethon); Telethon-MITOCON(Fondazione Telethon); GENOMIT; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Mito Foundation; Aligning Science Across Parkinson's Collaborative Research Network; Spastic Paraplegia Foundation; US Department of Defense Congressionally Directed Medical Research Programs; Victorian Government's Operational Infrastructure Support Program; Academy of Finland(Academy of Finland)	The work in Newcastle, UK, is supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council [G016354/1]), NIHR Biomedical Research Centre for Ageing and Age-Related Disease award to the Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust, the Lily Foundation, and the UK NHS Specialist Commissioners, which funds the Rare Mitochondrial Disorders of Adults and Children Diagnostic Service in Newcastle upon Tyne. TK acknowledges support by the German Federal Ministry of Education and Research (Bonn, Germany) through grants to the German Network for Mitochondrial Disorders (01GM1906A) and to the E-Rare project GENOMIT (01GM1920B). TK is a member of the European Reference Network for Rare Neurological Diseases and of the European Reference Network for neuromuscular diseases (EURO-NMD), co-funded by the European Commission. YSN holds an NIHR Clinical Lectureship in Neurology (CL-2016-01-003). CK is a member of EURO-NMD, co-funded by the European Commission. MM is partly supported by Telethon Grant GUP09004 and Telethon-MITOCON grant GSP16001, RF-2016-02361495 and GENOMIT. CMS is a NHMRC practitioner fellow (APP 1136800) and is supported by research grants from NHMRC, the Mito Foundation, Aligning Science Across Parkinson's Collaborative Research Network, and the Spastic Paraplegia Foundation. DRT is supported by a fellowship and grants from NHMRC and by research grants from the US Department of Defense Congressionally Directed Medical Research Programs, the Mito Foundation, and the Victorian Government's Operational Infrastructure Support Program. AS has been funded by Academy of Finland,	Alston CL, 2011, EUR J HUM GENET, V19, P1226, DOI 10.1038/ejhg.2011.124; Altmann J, 2016, J NEUROL, V263, P961, DOI 10.1007/s00415-016-8086-3; Anagnostou ME, 2016, EPILEPSIA, V57, P1531, DOI 10.1111/epi.13508; Bax Bridget E, 2020, J Transl Genet Genom, V4, P1, DOI 10.20517/jtgg.2020.08; Borrelli E, 2016, SCI REP-UK, V6, DOI 10.1038/srep37332; Braz LP, 2021, NEUROL-CLIN PRACT, V11, P97, DOI 10.1212/CPJ.0000000000000795; Buzkova J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809091; Carelli V, 2016, BRAIN, V139, DOI 10.1093/brain/awv339; Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410; Catarino CB, 2020, J NEURO-OPHTHALMOL, V40, P558, DOI 10.1097/WNO.0000000000001023; Corazza G, 2019, GASTROENTEROLOGY, V156, P1525, DOI 10.1053/j.gastro.2018.12.011; Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209; de Laat P, 2015, NETH J MED, V73, P30; de Laat P, 2021, J MED GENET, V58, P48, DOI 10.1136/jmedgenet-2019-106800; De Vries MC, 2020, J INHERIT METAB DIS, V43, P800, DOI 10.1002/jimd.12196; Distelmaier F, 2017, BRAIN, V140, DOI 10.1093/brain/aww303; Dominguez-Gonzalez C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66940-8; Dominguez-Gonzalez C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506; Dominguez-Gonzalez C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z; Emmanuele V, 2012, ARCH NEUROL-CHICAGO, V69, P978, DOI 10.1001/archneurol.2012.206; Feeney CL, 2019, BJOG-INT J OBSTET GY, V126, P1380, DOI 10.1111/1471-0528.15667; Formichi P, 2020, NEUROL SCI, V41, P3653, DOI 10.1007/s10072-020-04422-5; Forsstrom S, 2019, CELL METAB, V30, P1040, DOI [10.1016/j.cmet.2019.013.019, 10.1016/j.cmet.2019.08.019]; Frazier AE, 2020, METHOD CELL BIOL, V155, P121, DOI 10.1016/bs.mcb.2019.11.007; Frazier AE, 2019, J BIOL CHEM, V294, P5386, DOI 10.1074/jbc.R117.809194; Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012; Gorman GS, 2018, LANCET, V392, P1191, DOI 10.1016/S0140-6736(18)31868-3; Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80; Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362; Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91; Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262; Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321; Greenfield A, 2017, NAT BIOTECHNOL, V35, P1059, DOI 10.1038/nbt.3997; Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082; Heighton JN, 2019, MITOCHONDRION, V49, P227, DOI 10.1016/j.mito.2019.09.002; Hikmat O, 2020, J INHERIT METAB DIS, V43, P726, DOI 10.1002/jimd.12211; Hirano M, 2021, J INHERIT METAB DIS, V44, P376, DOI 10.1002/jimd.12300; Jackson CB, 2020, TRENDS MOL MED, V26, P698, DOI 10.1016/j.molmed.2020.02.006; Jeppesen TD, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00349; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170; Koga Y, 2018, J NEUROL, V265, P2861, DOI 10.1007/s00415-018-9057-7; Kullar PJ, 2016, BRAIN, V139, pE33, DOI 10.1093/brain/aww051; Lake NJ, 2016, ANN NEUROL, V79, P190, DOI 10.1002/ana.24551; Lehtonen JM, 2021, J INHERIT METAB DIS, V44, P469, DOI 10.1002/jimd.12307; Lin Y, 2020, ANN CLIN TRANSL NEUR, V7, P1204, DOI 10.1002/acn3.51104; Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115; Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006; Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y; Mancuso M, 2014, MOVEMENT DISORD, V29, P722, DOI 10.1002/mds.25839; Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3; Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c; Maresca A, 2020, J MOL MED, V98, P1467, DOI 10.1007/s00109-020-01967-y; Marques-Matos C, 2016, JAMA NEUROL, V73, P604, DOI 10.1001/jamaneurol.2015.5061; Martikainen MH, 2016, JAMA NEUROL, V73, P668, DOI 10.1001/jamaneurol.2016.0355; Mok BY, 2020, NATURE, V583, P631, DOI 10.1038/s41586-020-2477-4; National Academy of Medicine National Academy of Sciences, 2020, HER HUM GEN ED; Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528; Ng YS, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00024; Ng Yi Shiau, 2019, Wellcome Open Res, V4, P201, DOI 10.12688/wellcomeopenres.15599.1; Ng YS, 2019, ANN NEUROL, V86, P310, DOI 10.1002/ana.25525; Ng YS, 2018, EBIOMEDICINE, V30, P86, DOI 10.1016/j.ebiom.2018.02.010; Ng YS, 2016, ANN NEUROL, V80, P686, DOI 10.1002/ana.24736; Ng YS, 2016, EUR HEART J, V37, P2552, DOI 10.1093/eurheartj/ehv306; Ng YS, 2015, LANCET NEUROL, V14, P1073, DOI 10.1016/S1474-4422(15)00253-7; Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019; Ohsawa Y, 2019, J NEUROL NEUROSUR PS, V90, P529, DOI 10.1136/jnnp-2018-317964; Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z; Pagon, 2000, GENEREVIEWS, P1993; Palculict ME, 2016, METHODS MOL BIOL, V1351, P3, DOI 10.1007/978-1-4939-3040-1_1; Pareyson D, 2013, LANCET NEUROL, V12, P1011, DOI 10.1016/S1474-4422(13)70158-3; Parikh S, 2019, J MED GENET, V56, P123, DOI 10.1136/jmedgenet-2018-105800; Parikh S, 2017, GENET MED, V19, DOI 10.1038/gim.2017.107; Pickett SJ, 2018, ANN CLIN TRANSL NEUR, V5, P333, DOI 10.1002/acn3.532; Pirinen E, 2020, CELL METAB, V31, P1078, DOI 10.1016/j.cmet.2020.04.008; Posey JE, 2017, NEW ENGL J MED, V376, P21, DOI 10.1056/NEJMoa1516767; Poulton J, 2019, NEUROMUSCULAR DISORD, V29, P725, DOI 10.1016/j.nmd.2019.08.004; Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488; Rius R, 2019, GENET MED, V21, P2823, DOI 10.1038/s41436-019-0568-0; Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051; Sallevelt SCEH, 2017, J MED GENET, V54, P114, DOI 10.1136/jmedgenet-2016-103876; Santarelli R, 2015, BRAIN, V138, P563, DOI 10.1093/brain/awu378; Shen LS, 2016, HUM MUTAT, V37, P540, DOI 10.1002/humu.22974; Sinnecker T, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1306-6; Sissler M, 2017, TRENDS MOL MED, V23, P693, DOI 10.1016/j.molmed.2017.06.002; Sofou K, 2018, J MED GENET, V55, P21, DOI 10.1136/jmedgenet-2017-104891; Sofou K, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-52; Stefanetti Renae J, 2020, Wellcome Open Res, V5, P84, DOI 10.12688/wellcomeopenres.15825.1; Stendel C, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000393; Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784; Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7; Tan J, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102730; Tankard RM, 2018, AM J HUM GENET, V103, P858, DOI 10.1016/j.ajhg.2018.10.015; Thauvin-Robinet C, 2019, EUR J HUM GENET, V27, P1197, DOI 10.1038/s41431-019-0384-7; Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104; Ticci C, 2020, NEUROGENETICS, V21, P87, DOI 10.1007/s10048-019-00601-5; Traschutz A, 2020, ANN NEUROL, V88, P251, DOI 10.1002/ana.25751; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310; Varhaug KN, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcaa222; Varhaug KN, 2020, ANN CLIN TRANSL NEUR, V7, P1318, DOI 10.1002/acn3.51119; Viscomi C, 2020, J INTERN MED, V287, P665, DOI 10.1111/joim.13046; Wagner M, 2019, J INHERIT METAB DIS, V42, P909, DOI 10.1002/jimd.12109; Warren C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70885-3; Watson E., 2020, J TRANSL GENET GENOM, V4, P188, DOI [10.20517/jtgg.2020.31, DOI 10.20517/JTGG.2020.31]; Wei W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15336-3; Whittaker RG, 2015, ANN NEUROL, V78, P949, DOI 10.1002/ana.24525; Wilson IJ, 2016, HUM MOL GENET, V25, P1031, DOI 10.1093/hmg/ddv626; Yatsuga S, 2015, ANN NEUROL, V78, P814, DOI 10.1002/ana.24506; Yokota Y, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01818-w; Yu-Wai-Man P, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz7423; Yu-Wai-Man P, 2013, OPHTHALMOLOGY, V120, P1712, DOI 10.1016/j.ophtha.2013.04.022	113	26	26	3	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					573	584		10.1016/S1474-4422(21)00098-3	http://dx.doi.org/10.1016/S1474-4422(21)00098-3			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UD5TG	34146515				2022-12-18	WOS:000687268300016
J	Vetvik, KG; MacGregor, EA				Vetvik, Kjersti Grotta; MacGregor, E. Anne			Menstrual migraine: a distinct disorder needing greater recognition	LANCET NEUROLOGY			English	Review							SHORT-TERM PREVENTION; HEADACHE FEDERATION EHF; IRON-DEFICIENCY ANEMIA; DOUBLE-BLIND; CLINICAL CHARACTERISTICS; PREMENSTRUAL-SYNDROME; CONSENSUS STATEMENT; FEMALE MIGRAINEURS; ORAL ZOLMITRIPTAN; POPULATION-SAMPLE	The term menstrual migraine refers to migraine that is associated with menstruation by more than chance, but it does not define pathophysiology. Menstrual migraine affects about 20-25% of female migraineurs in the general population, and 22-70% of patients presenting to headache clinics. In women diagnosed with menstrual migraine, perimenstrual migraine attacks are associated with substantially greater disability than their non-menstrual attacks. Loose interpretation of diagnostic criteria has led to conflicting results in studies on prevalence figures, clinical characteristics, and response to treatment. Importantly, clinical trials often do not distinguish between perimenstrual attacks in women diagnosed with menstrual migraine and attacks associated with menstruation by chance. Two pathophysiological mechanisms have been identified: oestrogen withdrawal and prostaglandin release. Although management strategies targeting these mechanisms might be effective, the evidence is not robust. Given how common and debilitating this distinct condition is, more research investment is needed to expand understanding of its pathophysiology and to develop more effective treatment strategies.	[Vetvik, Kjersti Grotta] Akershus Univ Hosp, Dept Neurol, Lrenskog, Norway; [MacGregor, E. Anne] St Bartholomews Hosp, Ctr Reprod Med, London EC1A 78E, England		MacGregor, EA (corresponding author), St Bartholomews Hosp, Ctr Reprod Med, London EC1A 78E, England.	a.macgregor@qmul.ac.uk		MacGregor, E Anne/0000-0002-4116-9828				Al-Waili N S, 2000, Eur J Med Res, V5, P176; Allais G, 2015, CEPHALALGIA, V35, P45, DOI 10.1177/0333102414542290; Allais G, 2011, NEUROL SCI, V32, pS99, DOI 10.1007/s10072-011-0547-y; Allais G, 2011, CEPHALALGIA, V31, P152, DOI 10.1177/0333102410378049; Allais G, 2011, CEPHALALGIA, V31, P144, DOI 10.1177/0333102410378048; Almen-Christensson A, 2011, FERTIL STERIL, V96, P498, DOI 10.1016/j.fertnstert.2011.05.089; [Anonymous], 2017, BJOG, V124, pe73, DOI 10.1111/1471-0528.14260; Antonova M, 2012, CEPHALALGIA, V32, P822, DOI 10.1177/0333102412451360; Barra M, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1035-7; Bartolini M, 2012, J HEADACHE PAIN, V13, P401, DOI 10.1007/s10194-012-0455-4; Brandes JL, 2009, CEPHALALGIA, V29, P1133, DOI 10.1111/j.1468-2982.2009.01840.x; Cady RK, 2011, HEADACHE, V51, P664, DOI 10.1111/j.1526-4610.2011.01894.x; Calhoun AH, 2017, HEADACHE, V57, P17, DOI 10.1111/head.12942; Couturier EGM, 2003, CEPHALALGIA, V23, P302, DOI 10.1046/j.1468-2982.2003.00516.x; Crawford MJ, 2009, HEADACHE, V49, P341, DOI 10.1111/j.1526-4610.2009.01347.x; CUPINI LM, 1995, CEPHALALGIA, V15, P140, DOI 10.1046/j.1468-2982.1995.015002140.x; Cutrer FM, 1996, HEADACHE, V36, P579, DOI 10.1046/j.1526-4610.1996.3610579.x; de Vries B, 2016, CEPHALALGIA, V36, P604, DOI 10.1177/0333102414566820; DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; DENNERSTEIN L, 1988, GYNECOL ENDOCRINOL, V2, P113, DOI 10.3109/09513598809023619; Diamond ML, 2008, HEADACHE, V48, P248, DOI 10.1111/j.1526-4610.2007.01019.x; Dowson Andrew J, 2005, J Headache Pain, V6, P81, DOI 10.1007/s10194-005-0156-3; Dzoljic E, 2002, HEADACHE, V42, P185, DOI 10.1046/j.1526-4610.2002.02050.x; Edelman A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004695.pub3; Eikermann-Haerter K, 2007, HEADACHE, V47, pS79, DOI 10.1111/j.1526-4610.2007.00818.x; Giacovazzo M, 1993, Drugs, V46 Suppl 1, P140; Granella F, 2000, CEPHALALGIA, V20, P701, DOI 10.1046/j.1468-2982.2000.00112.x; Gur-Ozmen S, 2016, PAIN MED, V17, P596, DOI 10.1093/pm/pnv029; Guven B, 2017, ACTA NEUROL BELG, V117, P671, DOI 10.1007/s13760-017-0802-y; Hale GE, 2009, MENOPAUSE, V16, P50, DOI [10.1097/GME.0b013e31817ee0c2, 10.1097/gme.0b013e31817ee0c2]; Ho TW, 2016, CEPHALALGIA, V36, P148, DOI 10.1177/0333102415584308; Hu Y, 2013, J HEADACHE PAIN, V14, DOI [10.1186/1129-2377-14-72, 10.1186/1129-2377-14-7]; Ibrahimi K, 2017, CEPHALALGIA, V37, P1164, DOI 10.1177/0333102416668659; Ibrahimi K, 2015, NEUROLOGY, V84, P125, DOI 10.1212/WNL.0000000000001142; Karli N, 2012, J HEADACHE PAIN, V13, P557, DOI 10.1007/s10194-012-0475-0; Labastida-Ramirez A, 2019, CEPHALALGIA, V39, P435, DOI 10.1177/0333102417739584; Labruijere S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087616; Landy S, 2004, INT J CLIN PRACT, V58, P913, DOI 10.1111/j.1368-5031.2004.00295.x; Gonzalez SL, 2019, CELL MOL NEUROBIOL, V39, P523, DOI 10.1007/s10571-018-0618-1; Li L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000976; Lichten EM, 1996, HEADACHE, V36, P367, DOI 10.1046/j.1526-4610.1996.3606367.x; Loder E, 2004, HEADACHE, V44, P120, DOI 10.1111/j.1526-4610.2004.04027.x; MacGregor EA, 2008, CURR PAIN HEADACHE R, V12, P468, DOI 10.1007/s11916-008-0079-1; MacGregor EA, 2006, NEUROLOGY, V67, P2154, DOI 10.1212/01.wnl.0000233888.18228.19; MacGregor EA, 2006, NEUROLOGY, V67, P2159, DOI 10.1212/01.wnl.0000249114.52802.55; MacGregor EA, 2007, J FAM PLAN REPROD H, V33, P83, DOI 10.1783/147118907780254312; MacGregor EA, 2018, BMJ SEX REPROD HEAL, V44, P214, DOI 10.1136/bmjsrh-2017-200036; MacGregor EA, 2013, HEADACHE, V53, P247, DOI 10.1111/head.12035; MacGregor EA, 2012, CURR PAIN HEADACHE R, V16, P452, DOI 10.1007/s11916-012-0282-y; MacGregor EA, 2010, HEADACHE, V50, P528, DOI 10.1111/j.1526-4610.2010.01625.x; MacGregor EA, 2004, LANCET NEUROL, V3, P354, DOI 10.1016/S1474-4422(04)00768-9; MacGregor EA, 2004, NEUROLOGY, V63, P351, DOI 10.1212/01.WNL.0000133134.68143.2E; Machado RB, 2010, CONTRACEPTION, V81, P202, DOI 10.1016/j.contraception.2009.09.006; Maleki N, 2019, ANN NEUROL, V85, P865, DOI 10.1002/ana.25476; Mannix LK, 2008, J WOMENS HEALTH, V17, P879, DOI 10.1089/jwh.2007.0440; Mannix LK, 2007, HEADACHE, V47, P1037, DOI 10.1111/j.1526-4610.2007.00855.x; Mannix LK, 2009, OBSTET GYNECOL, V114, P106, DOI 10.1097/AOG.0b013e3181a98e4d; Marcus DA, 2010, HEADACHE, V50, P539, DOI 10.1111/j.1526-4610.2010.01627.x; Martin V, 2008, HEADACHE, V48, P226, DOI 10.1111/j.1526-4610.2007.00947.x; Martin VT, 2005, HEADACHE, V45, P1190, DOI 10.1111/j.1526-4610.2005.00242.x; Massiou H, 2005, EUR J NEUROL, V12, P774, DOI 10.1111/j.1468-1331.2005.01076.x; Mattsson P, 2003, HEADACHE, V43, P27, DOI 10.1046/j.1526-4610.2003.03005.x; Nett R, 2008, HEADACHE, V48, P1194, DOI 10.1111/j.1526-4610.2008.01093.x; Newman L, 2001, HEADACHE, V41, P248, DOI 10.1046/j.1526-4610.2001.111006248.x; Paredes S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225729; Pavlovic JM, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01167-6; Pinkerman B, 2010, CEPHALALGIA, V30, P1187, DOI 10.1177/0333102409359315; Pollock CE, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0857-z; Puri V, 2005, NEUROPEPTIDES, V39, P409, DOI 10.1016/j.npep.2005.04.002; Russell MB, 1996, CEPHALALGIA, V16, P239, DOI 10.1046/j.1468-2982.1996.1604239.x; Sacco S, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0896-5; Sacco S, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0815-1; SANCES G, 1990, HEADACHE, V30, P705, DOI 10.1111/j.1526-4610.1990.hed3011705.x; Savi L, 2011, J HEADACHE PAIN, V12, P609, DOI 10.1007/s10194-011-0366-9; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2004, NEUROLOGY, V63, P261, DOI 10.1212/01.WNL.0000134620.30129.D6; Silberstein SD, 2002, HEADACHE, V42, P917, DOI 10.1046/j.1526-4610.2002.02214.x; Silberstein SD, 1999, CLIN THER, V21, P475, DOI 10.1016/S0149-2918(00)88303-4; Silberstein SD, 2000, OBSTET GYNECOL, V96, P237, DOI 10.1016/S0029-7844(00)00880-2; Silberstein SD, 2009, HEADACHE, V49, P1283, DOI 10.1111/j.1526-4610.2009.01509.x; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; SMITS MG, 1994, HEADACHE, V34, P103, DOI 10.1111/j.1526-4610.1994.hed3402103.x; SOLBACH MP, 1993, OBSTET GYNECOL, V82, P769; Stewart WF, 2000, NEUROLOGY, V55, P1517, DOI 10.1212/WNL.55.10.1517; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Sundic A, 2010, VOJNOSANIT PREGL, V67, P969, DOI 10.2298/VSP1012969S; Sutherland HG, 2017, GENE, V607, P36, DOI 10.1016/j.gene.2017.01.008; Szekely B, 1989, CEPHALALGIA, V9, P452; Tepper SJ, 2008, HEADACHE, V48, P1419, DOI 10.1111/j.1526-4610.2008.01304.x; Tuchman M, 2006, CNS DRUGS, V20, P1019, DOI 10.2165/00023210-200620120-00005; Tuchman MM, 2008, CNS DRUGS, V22, P877, DOI 10.2165/00023210-200822100-00007; Vetvik KG, 2014, CEPHALALGIA, V34, P280, DOI 10.1177/0333102413507637; Vetvik KG, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0931-6; Vetvik KG, 2015, CEPHALALGIA, V35, P1261, DOI 10.1177/0333102415575723; Vetvik KG, 2014, J HEADACHE PAIN, V15, P1, DOI 10.1186/1129-2377-15-30; Vukovic-Cvetkovic V, 2010, ACTA CLIN CROAT, V49, P389; Wang D, 2014, J NEUROL SCI, V346, P107, DOI 10.1016/j.jns.2014.08.002; Wang SJ, 2003, HEADACHE, V43, P470, DOI 10.1046/j.1526-4610.2003.03092.x	98	26	28	3	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					304	315		10.1016/S1474-4422(20)30482-8	http://dx.doi.org/10.1016/S1474-4422(20)30482-8		MAR 2021	12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33600767				2022-12-18	WOS:000630325700021
J	Fadda, G; Armangue, T; Hacohen, Y; Chitnis, T; Banwell, B				Fadda, Giulia; Armangue, Thais; Hacohen, Yael; Chitnis, Tanuja; Banwell, Brenda			Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care	LANCET NEUROLOGY			English	Review							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS-OPTICA; PLASMA-EXCHANGE; COGNITIVE IMPAIRMENT; ONSET; CHILDREN; SPECTRUM; MRI; RECOVERY; CRITERIA	The field of acquired CNS neuroimmune demyelination in children is transforming. Progress in assay development, refinement of diagnostic criteria, increased biological insights provided by advanced neuroimaging techniques, and high-level evidence for the therapeutic efficacy of biological agents are redefining diagnosis and care. Three distinct neuroimmune conditions-multiple sclerosis, myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (AQP4-NMOSD)-can now be distinguished, with evidence from humans and animal models supporting distinct pathobiological disease mechanisms. The development of highly effective therapies for adult-onset multiple sclerosis and AQP4-NMOSD that suppress relapse rate by more than 90% has motivated advocacy for trials in children. However, doing clinical trials is challenging because of the rarity of these conditions in the paediatric age group, necessitating new approaches to trial design, including age-based trajectory modelling based on phase 3 studies in adults. Despite these limitations, the future for children and adolescents living with multiple sclerosis, MOGAD, or AQP4-NMOSD is far brighter than in years past, and will be brighter still if successful therapies to promote remyelination, enhance neuroprotection, and remediate cognitive deficits can be further accelerated.	[Fadda, Giulia] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Fadda, Giulia] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Armangue, Thais] Univ Barcelona, Neuroimmunol Program, Inst Invest Biomed August Pi i Sunyer, Hosp Clin, Barcelona, Spain; [Armangue, Thais] Univ Barcelona, Pediat Neuroimmunol Unit, Neurol Dept, St Joan de Deu Childrens Hosp, Barcelona, Spain; [Hacohen, Yael] UCL Inst Neurol, Queen Sq MS Ctr, Dept Neuroinflammat, London, England; [Hacohen, Yael] Great Ormond St Hosp Sick Children, Paediat Neurol, London, England; [Chitnis, Tanuja] Massachusetts Gen Hosp, Dept Neurol, Partners Pediat Multiple Sclerosis Ctr, Boston, MA 02114 USA; [Banwell, Brenda] Childrens Hosp Philadelphia, Div Child Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; McGill University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Harvard University; Massachusetts General Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Banwell, B (corresponding author), Childrens Hosp Philadelphia, Div Child Neurol, Philadelphia, PA 19104 USA.	banwellb@email.chop.edu		Hacohen, Yael/0000-0001-8490-9657	clinical research training scholarship in multiple sclerosis from the American Academy of Neurology; Sanofi Genzyme	clinical research training scholarship in multiple sclerosis from the American Academy of Neurology; Sanofi Genzyme(Sanofi-AventisGenzyme Corporation)	GF is supported by a clinical research training scholarship in multiple sclerosis from the American Academy of Neurology and Sanofi Genzyme. The funding source had no involvement in the writing of the report or in the decision to submit for publication.	Abdel-Mannan O, 2021, MULT SCLER J, V27, P309, DOI 10.1177/1352458520910361; Absoud M, 2015, J NEUROL NEUROSUR PS, V86, P470, DOI 10.1136/jnnp-2014-308550; Akbar N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145906; Albassam F, 2020, DEV MED CHILD NEUROL, V62, P390, DOI 10.1111/dmcn.14336; Alroughani R, 2018, PEDIATR NEUROL, V83, P19, DOI 10.1016/j.pediatrneurol.2018.03.007; [Anonymous], 2020, JAMA NEUROL, V77, P1575, DOI 10.1001/jamaneurol.2020.3115; [Anonymous], 2013, EVID BASED SPINE CAR, V4, P167; Armangue T, 2020, LANCET NEUROL, V19, P234, DOI 10.1016/S1474-4422(19)30488-0; Arnold DL, 2020, J NEUROL NEUROSUR PS, V91, P483, DOI 10.1136/jnnp-2019-322138; Arvin AM, 2015, JAMA NEUROL, V72, P31, DOI 10.1001/jamaneurol.2014.3065; Aubert-Broche B, 2014, NEUROLOGY, V83, P2140, DOI 10.1212/WNL.0000000000001045; Banwell B, 2009, NEUROLOGY, V72, P232, DOI 10.1212/01.wnl.0000339482.84392.bd; Banwell B, 2011, LANCET NEUROL, V10, P436, DOI 10.1016/S1474-4422(11)70045-X; Bartels F, 2019, MULT SCLER J, V25, P927, DOI 10.1177/1352458519829698; Baruch NF, 2016, MULT SCLER J, V22, P354, DOI 10.1177/1352458515588781; Baumann M, 2015, J NEUROL NEUROSUR PS, V86, P265, DOI 10.1136/jnnp-2014-308346; Baumann M, 2018, J NEUROL, V265, P845, DOI 10.1007/s00415-018-8781-3; Bigi S, 2015, J CHILD NEUROL, V30, P874, DOI 10.1177/0883073814545883; Bonnan M, 2018, J NEUROL NEUROSUR PS, V89, P346, DOI 10.1136/jnnp-2017-316286; Brown RA, 2014, NEUROIMAGE-CLIN, V6, P237, DOI 10.1016/j.nicl.2014.09.003; Burman J, 2017, BONE MARROW TRANSPL, V52, P1133, DOI 10.1038/bmt.2017.40; Carroll S, 2019, EUR J PAEDIATR NEURO, V23, P70, DOI 10.1016/j.ejpn.2018.10.006; Charvet L, 2016, J CHILD NEUROL, V31, P1062, DOI 10.1177/0883073816636227; Chen JJ, 2020, NEUROLOGY, V95, pE111, DOI 10.1212/WNL.0000000000009758; Chitnis T, 2018, NEW ENGL J MED, V379, P1017, DOI 10.1056/NEJMoa1800149; Chitnis T, 2016, NEUROLOGY, V86, P245, DOI 10.1212/WNL.0000000000002283; Cree BAC, 2019, LANCET, V394, P1352, DOI 10.1016/S0140-6736(19)31817-3; Datta R, 2017, J NEUROIMAGING, V27, P447, DOI 10.1111/jon.12465; De Meo E, 2019, NEUROLOGY, V92, pE1709, DOI 10.1212/WNL.0000000000007267; Derfuss T, 2020, LANCET NEUROL, V19, P336, DOI 10.1016/S1474-4422(19)30391-6; Dubey D, 2019, JAMA NEUROL, V76, P301, DOI 10.1001/jamaneurol.2018.4053; Duignan S, 2019, DEV MED CHILD NEUROL, V61, P1039, DOI 10.1111/dmcn.14212; Duignan S, 2018, DEV MED CHILD NEUROL, V60, P958, DOI 10.1111/dmcn.13703; Durozard P, 2020, ANN NEUROL, V87, P256, DOI 10.1002/ana.25648; Fadda G, 2019, ANN NEUROL, V85, P340, DOI 10.1002/ana.25429; Fadda G, 2018, LANCET CHILD ADOLESC, V2, P191, DOI 10.1016/S2352-4642(18)30026-9; Farez MF, 2019, NEUROLOGY, V93, P584, DOI 10.1212/WNL.0000000000008157; Gartner Jutta, 2017, Mult Scler J Exp Transl Clin, V3, p2055217317747623, DOI 10.1177/2055217317747623; Gastaldi M, 2020, J NEUROL, V267, P3555, DOI 10.1007/s00415-020-10024-0; Ghassemi R, 2015, MULT SCLER J, V21, P718, DOI 10.1177/1352458514551594; Ghezzi A, 2021, MULT SCLER J, V27, P1814, DOI 10.1177/1352458520932798; Giacomini T, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2019.101917; Gorman MP, 2009, ARCH NEUROL-CHICAGO, V66, P54, DOI 10.1001/archneurol.2008.505; Gravesande KSV, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.08.010; Hacohen Y, 2021, MULT SCLER J, V27, P1970, DOI 10.1177/1352458520937644; Hacohen Y, 2018, DEV MED CHILD NEUROL, V60, P417, DOI 10.1111/dmcn.13649; Hacohen Y, 2020, MULT SCLER J, V26, P1372, DOI 10.1177/1352458519863781; Hacohen Y, 2019, CURR TREAT OPTION NE, V21, DOI 10.1007/s11940-019-0541-x; Hacohen Y, 2018, JAMA NEUROL, V75, P478, DOI 10.1001/jamaneurol.2017.4601; Hacohen Y, 2017, NEUROLOGY, V89, P269, DOI 10.1212/WNL.0000000000004117; Hacohen Y, 2014, J NEUROL NEUROSUR PS, V85, P456, DOI 10.1136/jnnp-2013-306411; Hennes EM, 2017, NEUROLOGY, V89, P900, DOI 10.1212/WNL.0000000000004312; Hoftberger R, 2020, ACTA NEUROPATHOL, V139, P875, DOI 10.1007/s00401-020-02132-y; Huppke P, 2019, MULT SCLER J, V25, P72, DOI 10.1177/1352458517732843; Jarius S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1144-2; Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0718-0; Jitprapaikulsan J, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000727; Kerbrat A, 2012, NEUROLOGY, V78, P194, DOI 10.1212/WNL.0b013e318240799a; Kessler RA, 2017, MULT SCLER RELAT DIS, V17, P198, DOI 10.1016/j.msard.2017.08.005; Kitley J, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000121; Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547; Krysko KM, 2020, ANN NEUROL, V88, P42, DOI 10.1002/ana.25737; Le Page E, 2015, LANCET, V386, P974, DOI 10.1016/S0140-6736(15)61137-0; Longoni G, 2017, BRAIN, V140, P1300, DOI 10.1093/brain/awx041; Lopez-Chiriboga AS, 2018, JAMA NEUROL, V75, P1355, DOI 10.1001/jamaneurol.2018.1814; Lucchinetti CF, 2014, BRAIN PATHOL, V24, P83, DOI 10.1111/bpa.12099; Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365; Majed M, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000231; Manguinao M, 2019, MULT SCLER RELAT DIS, V35, P50, DOI 10.1016/j.msard.2019.07.004; Mariotto S, 2019, NEUROLOGY, V93, pE1867, DOI 10.1212/WNL.0000000000008479; Mariotto S, 2017, J NEUROL, V264, P2420, DOI 10.1007/s00415-017-8635-4; McKay KA, 2019, JAMA NEUROL, V76, P1028, DOI 10.1001/jamaneurol.2019.1546; Mckay KA, 2019, NEUROLOGY, V92, pE2764, DOI 10.1212/WNL.0000000000007647; Mealy MA, 2018, MULT SCLER J, V24, P1737, DOI 10.1177/1352458517730131; Netravathi M, 2019, MULT SCLER RELAT DIS, V30, P85, DOI 10.1016/j.msard.2019.01.032; Nosadini M, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000188; O'Mahony J, 2015, PEDIATRICS, V136, pE115, DOI 10.1542/peds.2015-0028; Palace J, 2019, BRAIN, V142, P1310, DOI 10.1093/brain/awz054; Paolilo RB, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000837; Pfeifenbring S, 2015, ANN NEUROL, V77, P655, DOI 10.1002/ana.24364; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Popescu BFG, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-11; Ramanathan S, 2018, J NEUROL NEUROSUR PS, V89, P127, DOI 10.1136/jnnp-2017-316880; Ramanathan S, 2016, MULT SCLER J, V22, P470, DOI 10.1177/1352458515593406; Reindl M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000674; Renoux C, 2007, NEW ENGL J MED, V356, P2603, DOI 10.1056/NEJMoa067597; Rocca MA, 2016, MULT SCLER J, V22, P620, DOI 10.1177/1352458515596600; Rocca MA, 2016, MULT SCLER J, V22, P628, DOI 10.1177/1352458515598569; Rocca MA, 2015, MULT SCLER J, V21, P956, DOI 10.1177/1352458514557303; Ruano L, 2018, MULT SCLER J, V24, P1234, DOI 10.1177/1352458517717341; Savransky A, 2019, NEUROLOGY, V93, pE2065, DOI 10.1212/WNL.0000000000008551; Tenembaum S, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00339; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Valentino P, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000317; Verhey LH, 2013, NEUROLOGY, V81, P1215, DOI 10.1212/WNL.0b013e3182a6cb9b; Viscidi RP, 2011, CLIN VACCINE IMMUNOL, V18, P1737, DOI 10.1128/CVI.05175-11; Vishwas MS, 2013, AM J NEURORADIOL, V34, P417, DOI 10.3174/ajnr.A3216; Vukusic S, 2020, J NEURORADIOLOGY, DOI DOI 10.1016/J.; Wallach AI, 2020, MULT SCLER J, V26, P1938, DOI 10.1177/1352458519891984; Waters P, 2020, JAMA NEUROL, V77, P82, DOI 10.1001/jamaneurol.2019.2940; Waters P, 2016, J NEUROL NEUROSUR PS, V87, P1005, DOI 10.1136/jnnp-2015-312601; Waters PJ, 2019, NEUROLOGY, V92, pE1250, DOI 10.1212/WNL.0000000000007096; Waubant E, 2019, NEUROLOGY, V92, pE2538, DOI 10.1212/WNL.0000000000007572; Wegener-Panzer A, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000731; Weier K, 2016, MULT SCLER J, V22, P1266, DOI 10.1177/1352458515615224; Wells E, 2018, NAT REV NEUROL, V14, P433, DOI 10.1038/s41582-018-0024-9; Wendel EM, 2020, EUR J PAEDIATR NEURO, V27, P86, DOI 10.1016/j.ejpn.2020.04.002; Whittam DH, 2020, J NEUROL, V267, P3565, DOI 10.1007/s00415-020-10026-y; Whittam DH, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102251; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Wong YYM, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000528; Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747; Yan K, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102260; Zhou J, 2019, MULT SCLER RELAT DIS, V28, P4, DOI 10.1016/j.msard.2018.12.001; Zhou YF, 2019, MULT SCLER RELAT DIS, V28, P213, DOI 10.1016/j.msard.2018.12.038	115	26	29	4	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					136	149		10.1016/S1474-4422(20)30432-4	http://dx.doi.org/10.1016/S1474-4422(20)30432-4			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33484648	Green Submitted			2022-12-18	WOS:000610201500021
J	Pavel, A; Murray, DK; Stoessl, AJ				Pavel, Alexandra; Murray, Danielle K.; Stoessl, A. Jon			COVID-19 and selective vulnerability to Parkinson's disease	LANCET NEUROLOGY			English	Letter							INFECTIONS		[Pavel, Alexandra; Murray, Danielle K.; Stoessl, A. Jon] Univ British Columbia, Div Neurol, Pacific Parkinsons Res Ctr, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 2B5, Canada	University of British Columbia	Stoessl, AJ (corresponding author), Univ British Columbia, Div Neurol, Pacific Parkinsons Res Ctr, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 2B5, Canada.	jstoessl@mail.ubc.ca	; Stoessl, A Jon/J-9661-2015	Pavel, Alexandra/0000-0002-1114-3635; Stoessl, A Jon/0000-0002-9778-7246				Beatman EL, 2016, J VIROL, V90, P2767, DOI 10.1128/JVI.02949-15; Doobay MF, 2007, AM J PHYSIOL-REG I, V292, pR373, DOI 10.1152/ajpregu.00292.2006; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; Jang HM, 2009, P NATL ACAD SCI USA, V106, P14063, DOI 10.1073/pnas.0900096106; Lippi A, 2020, MOVEMENT DISORD, V35, P716, DOI 10.1002/mds.28084; Marreiros R, 2020, P NATL ACAD SCI USA, V117, P6741, DOI 10.1073/pnas.1906466117; Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08; Tulisiak CT, 2019, PROG MOL BIOL TRANSL, V168, P299, DOI 10.1016/bs.pmbts.2019.06.002; Victorino DB, 2020, J PARKINSON DIS, V10, P899, DOI 10.3233/JPD-202073	9	26	26	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					719	719		10.1016/S1474-4422(20)30269-6	http://dx.doi.org/10.1016/S1474-4422(20)30269-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	32822628	Bronze, Green Published			2022-12-18	WOS:000562556500007
J	Berge, E; Cohen, G; Roaldsen, MB; Lundstrom, E; Isaksson, E; Rudberg, AS; Slot, KB; Forbes, J; Smith, J; Drever, J; Wardlaw, JM; Lindley, RI; Sandercock, PAG; Whiteley, WN				Berge, Eivind; Cohen, Geoffrey; Roaldsen, Melinda B.; Lundstrom, Erik; Isaksson, Eva; Rudberg, Ann-Sofie; Slot, Karsten Bruins; Forbes, John; Smith, Joel; Drever, Jonathan; Wardlaw, Joanna M.; Lindley, Richard I.; Sandercock, Peter A. G.; Whiteley, William N.		IST-3 Collaborative Grp	Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial	LANCET NEUROLOGY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; FUNCTIONAL STATUS; THROMBOLYSIS; BENEFITS; UPDATE	Background The effect of alteplase on patient survival after ischaemic stroke is the subject of debate. We report the effect of intravenous alteplase on long-term survival after ischaemic stroke of participants in the Third International Stroke Trial (IST-3). Methods In IST-3, done at 156 hospitals in 12 countries (Australia, Europe, and the UK), participants (aged >18 years) were randomly assigned with a telephone voice-activated or web-based system in a 1: 1 ratio to treatment with intravenous 0.9 mg/kg alteplase plus standard care or standard care alone within 6 h of ischaemic stroke. We followed up participants in the UK and Scandinavia (Sweden and Norway) for survival up to 3 years after randomisation using data from national registries and compared survival in the two groups with proportional hazards survival analysis, adjusting for key prognostic variables. IST-3 is registered with the ISRCTN registry, number ISRCTN25765518. Findings Between May 5, 2000, and July 27, 2011, 3035 participants were enrolled in IST-3. Of these, 1948 (64%) of 3035 participants were scheduled for analysis of 3 year survival, and 1946 (>99%) of these were included in the analysis (967 [50%] in the alteplase plus standard care group and 979 [50%] in the standard care alone group). By 3 years after randomisation, 453 (47%) of 967 participants in the alteplase plus standard care group and 494 (50%) of 979 in the standard care alone group had died (risk difference 3.6% [95% CI -0.8 to 8.1]). Participants allocated to alteplase had a significantly higher hazard of death during the first 7 days (99 [10%] of 967 died in the alteplase plus standard care group vs 65 [7%] of 979 in the standard care alone group; hazard ratio 1.52 [95% CI 1.11-2.08]; p=0.004) and a significantly lower hazard of death between 8 days and 3 years (354 [41%] of 868 vs 429 [47%] of 914; 0.78 [0.68-0.90]; p=0.007). Interpretation Alteplase treatment within 6 h after ischaemic stroke was associated with a small, non-significant reduction in risk of death at 3 years, but among individuals who survived the acute phase, treatment was associated with a significant increase in long-term survival. These results are reassuring for clinicians who have expressed concerns about the effect of alteplase on survival.	[Berge, Eivind; Slot, Karsten Bruins] Oslo Univ Hosp, Dept Internal Med, Kirkeveien 166, NO-0407 Oslo, Norway; [Cohen, Geoffrey; Drever, Jonathan; Wardlaw, Joanna M.; Sandercock, Peter A. G.; Whiteley, William N.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Roaldsen, Melinda B.] Univ Hosp North Norway, Dept Neurol, Tromso, Norway; [Roaldsen, Melinda B.] Univ Tromso, Inst Clin Med, Tromso, Norway; [Lundstrom, Erik; Isaksson, Eva; Rudberg, Ann-Sofie] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Forbes, John] Univ Limerick, Hlth Res Inst, Limerick, Ireland; [Smith, Joel] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England; [Lindley, Richard I.] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia; [Lindley, Richard I.] Univ Sydney, Discipline Med, Sydney, NSW, Australia	University of Oslo; University of Edinburgh; UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso; Karolinska Institutet; University of Limerick; University of Oxford; George Institute for Global Health; University of Sydney; University of Sydney	Berge, E (corresponding author), Oslo Univ Hosp, Dept Internal Med, Kirkeveien 166, NO-0407 Oslo, Norway.	eivind.berge@medisin.uio.no	Lundstrom, Erik/AAQ-5629-2020; LundstrÃm, Erik/HGC-1847-2022; Rudberg, Ann-Sofie/ABD-7196-2021; Lueck, Christian Joseph/O-4031-2016; Hernandez, María/GYU-3543-2022; Wardlaw, Joanna M/Y-3456-2019; Zini, Andrea/K-1136-2014; Lindley, Richard/B-8148-2013	Lundstrom, Erik/0000-0002-5313-9052; Rudberg, Ann-Sofie/0000-0003-3616-9943; Lueck, Christian Joseph/0000-0003-1537-7612; Wardlaw, Joanna M/0000-0002-9812-6642; Zini, Andrea/0000-0003-1486-4507; Lindley, Richard/0000-0002-0104-5679; Isaksson, Eva/0000-0003-0289-8750; Whiteley, William/0000-0002-4816-8991; Roaldsen, Melinda/0000-0003-4848-9063	Heart and Stroke Scotland; UK Medical Research Council; Health Foundation UK; Stroke Association UK; Research Council of Norway; AFA Insurance; Swedish Heart Lung Fund; Foundation of Marianne and Marcus Wallenberg; Polish Ministry of Science and Education; Australian Heart Foundation; Australian National Health and Medical Research Council; Swiss National Research Foundation; Swiss Heart Foundation; Assessorato alla Sanita (Regione dell'Umbria, Italy); Danube University; National Institute for Health Research Oxford Biomedical Research Centre; Medical Research Council Clinician Scientist Fellowship; MRC [G0902303] Funding Source: UKRI; Medical Research Council [MR/K026992/1, G0902303] Funding Source: researchfish	Heart and Stroke Scotland; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Health Foundation UK; Stroke Association UK; Research Council of Norway(Research Council of Norway); AFA Insurance; Swedish Heart Lung Fund(Swedish Heart-Lung Foundation); Foundation of Marianne and Marcus Wallenberg; Polish Ministry of Science and Education(Ministry of Science and Higher Education, Poland); Australian Heart Foundation; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); Swiss Heart Foundation; Assessorato alla Sanita (Regione dell'Umbria, Italy); Danube University; National Institute for Health Research Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Medical Research Council Clinician Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funding for these analyses was provided by Heart and Stroke Scotland. The following organisations funded the trial: UK Medical Research Council, the Health Foundation UK, the Stroke Association UK, the Research Council of Norway, AFA Insurance, the Swedish Heart Lung Fund, the Foundation of Marianne and Marcus Wallenberg, the Polish Ministry of Science and Education, the Australian Heart Foundation, the Australian National Health and Medical Research Council, the Swiss National Research Foundation, the Swiss Heart Foundation, Assessorato alla Sanita (Regione dell'Umbria, Italy), and Danube University. JS is supported by the National Institute for Health Research Oxford Biomedical Research Centre. WNW was supported by a Medical Research Council Clinician Scientist Fellowship. The views expressed in this paper are the personal views of KBS and should not be understood or quoted as being made on behalf of or reflecting the position of the Norwegian Medicines Agency and/or the European Medicines Agency or one of its committees or working parties.	Alper BS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1075; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; Brown SGA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5215; Chan AW, 2014, LANCET, V383, P257, DOI 10.1016/S0140-6736(13)62296-5; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Koops L, 2002, BRIT MED J, V325, P415, DOI 10.1136/bmj.325.7361.415; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Lindley RI, 2015, STROKE, V46, P746, DOI 10.1161/STROKEAHA.114.006573; Magalhaes R, 2014, CEREBROVASC DIS, V38, P46, DOI 10.1159/000364938; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Sandercock P, 2016, 3 INT STROKE TRIAL I; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandercock P, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-252; Sandercock P, 2012, INT J STROKE, V7, P186, DOI 10.1111/j.1747-4949.2012.00782.x; Sandercock P, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-37; Shinton R, 2014, LANCET, V384, P659, DOI 10.1016/S0140-6736(14)61385-4; Slot KB, 2008, BRIT MED J, V336, P376, DOI 10.1136/bmj.39456.688333.BE; Wahlgren N, 2016, INT J STROKE, V11, P134, DOI 10.1177/1747493015609778; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Whiteley WN, 2014, STROKE, V45, P3612, DOI 10.1161/STROKEAHA.114.006890	23	26	28	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					1028	1034		10.1016/S1474-4422(16)30139-9	http://dx.doi.org/10.1016/S1474-4422(16)30139-9			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27450474	Green Submitted, Bronze			2022-12-18	WOS:000381280300019
J	Foo, JN; Liu, JJ; Tan, EK				Foo, Jia Nee; Liu, Jianjun; Tan, Eng-King			CHCHD2 and Parkinson's disease	LANCET NEUROLOGY			English	Letter									[Foo, Jia Nee; Liu, Jianjun] Agcy Sci Technol & Res Singapore, Genome Inst Singapore, Human Genet, Singapore, Singapore; [Tan, Eng-King] Singapore Gen Hosp, Dept Neurol, Natl Neurosci Inst, Singapore 169108, Singapore; [Tan, Eng-King] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Neuroscience Institute (NNI); Singapore General Hospital; National University of Singapore	Foo, JN (corresponding author), Agcy Sci Technol & Res Singapore, Genome Inst Singapore, Human Genet, Singapore, Singapore.	tan.eng.king@sgh.com.sg	Foo, Jia Nee/D-6069-2014	Foo, Jia Nee/0000-0001-9899-2308; Liu, Jianjun/0000-0002-3255-3019				Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2	1	26	26	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					681	682		10.1016/S1474-4422(15)00098-8	http://dx.doi.org/10.1016/S1474-4422(15)00098-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067114				2022-12-18	WOS:000356195900012
J	Friedman, D; French, JA				Friedman, Daniel; French, Jacqueline A.			Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions	LANCET NEUROLOGY			English	Article							PARTIAL-ONSET SEIZURES; DOSE-RANGING TRIAL; QUALITY-OF-LIFE; PLACEBO-RESPONSE; DOUBLE-BLIND; MONOTHERAPY TRIALS; UNEXPECTED DEATH; KEY FACTORS; EPILEPSY; LAMOTRIGINE	Clinical trials as part of antiepileptic drug development are increasingly expensive and complex, with many pitfalls that can derail even promising drugs and devices. Although a third of patients remain resistant to treatment, the availability of more than 20 approved antiepileptic drugs can reduce the incentive to enrol in trials of unproven agents, for which safety is not assured. The challenge of recruiting patients drives investigators to regions of the world where treatment options are more limited. This increases complexity and has potential implications for quality of the trial data. Furthermore, the availability of so many approved treatments raises questions about the ethics and safety of placebo-controlled trials in patients with epilepsy. Novel trial designs, such as time-to-event adjunctive therapy and historical-control monotherapy, might be more acceptable to patients and their doctors because they restrict exposure to placebo or ineffective treatments.	[Friedman, Daniel; French, Jacqueline A.] NYU, Comprehens Epilepsy Ctr, Dept Neurol, New York, NY 10016 USA	New York University	French, JA (corresponding author), NYU, Comprehens Epilepsy Ctr, Dept Neurol, 223 E 34th St, New York, NY 10016 USA.	jacqueline.french@nyumc.org	French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027	Milken Foundation; Epilepsy Therapy Project; NINDS; Epilepsy Study Consortium; GlaxoSmithKline	Milken Foundation; Epilepsy Therapy Project; NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Epilepsy Study Consortium; GlaxoSmithKline(GlaxoSmithKline)	DF receives royalties from book sales and has served on an advisory board for GlaxoSmithKline. JAF has received grant funding from The Milken Foundation, the Epilepsy Therapy Project, and NINDS. DF receives salary support from, and JAF is president of, the Epilepsy Study Consortium, a non-profit organisation dedicated to improving the lives of epilepsy patients. The Consortium receives payments for consulting and clinical trial activities from Cyberonics, Cypress Bioscience, Eisai Medical Research, Entra Pharmaceuticals, GlaxoSmithKline, Icagen, Intranasal/Ikano, Johnson and Johnson, Marinus, Neurotherapeutics, NeuroVista, Ono Pharma USA, Ovation/Lundbeck, Pfizer, Sepracor, SK Life Science, Supernus Pharmaceuticals, Taro, UCB/Schwartz Pharma, Upsher Smith, and Valeant. No funding was received for this Personal View.	Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003; Baulac M, 2006, EPILEPSY RES, V68, P77, DOI 10.1016/j.eplepsyres.2005.09.028; Baulac M, 2010, EPILEPSY RES, V91, P10, DOI 10.1016/j.eplepsyres.2010.05.008; Benbadis S, 2009, EFFICACY ADJUNCTIVE; Beydoun A, 2001, EPILEPSY BEHAV, V2, P187, DOI 10.1006/ebeh.2001.0198; Bialer M, 2010, NAT REV DRUG DISCOV, V9, P68, DOI 10.1038/nrd2997; Bien CG, 2001, EPILEPSY RES, V44, P1, DOI 10.1016/S0920-1211(01)00185-1; Birbeck GL, 2002, EPILEPSIA, V43, P535, DOI 10.1046/j.1528-1157.2002.32201.x; Biton V, 2009, BRIVARACETAM ADJUNCT; BOURGEOIS B, 1993, NEUROLOGY, V43, P693, DOI 10.1212/WNL.43.4.693; Bridge JA, 2009, AM J PSYCHIAT, V166, P42, DOI 10.1176/appi.ajp.2008.08020247; Brodie MJ, 2012, NEUROLOGY, V78, P1548, DOI 10.1212/WNL.0b013e3182563b19; Brodie MJ, 2006, EPILEPSY RES, V68, P70, DOI 10.1016/j.eplepsyres.2005.09.025; Callaghan BC, 2007, ANN NEUROL, V62, P382, DOI 10.1002/ana.21166; Choi HM, 2011, EPILEPSY RES, V93, P115, DOI 10.1016/j.eplepsyres.2010.11.005; Chung S, 2010, EPILEPSIA, V51, P958, DOI 10.1111/j.1528-1167.2009.02496.x; Devinsky O, 2011, NEW ENGL J MED, V365, P1801, DOI 10.1056/NEJMra1010481; Dickson M, 2004, NAT REV DRUG DISCOV, V3, P417, DOI 10.1038/nrd1382; Enck P, 2011, PHILOS T R SOC B, V366, P1889, DOI 10.1098/rstb.2010.0384; Faught E, 2008, NEUROLOGY, V71, P1586, DOI 10.1212/01.wnl.0000334751.89859.7f; Faught E, 1996, NEUROLOGY, V46, P1684, DOI 10.1212/WNL.46.6.1684; French JA, 2011, 2011 AM AC NEUR ANN; French JA, 2012, NEUROTHERAPEUTICS, V9, P176, DOI 10.1007/s13311-011-0088-3; French JA, 2010, EPILEPSIA, V51, P1936, DOI 10.1111/j.1528-1167.2010.02650.x; Gazzola DM, 2007, EPILEPSIA, V48, P1303, DOI 10.1111/j.1528-1167.2007.01136.x; Gilliam F, 1998, NEUROLOGY, V51, P1018, DOI 10.1212/WNL.51.4.1018; Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929; Guekht AB, 2010, EPILEPSY BEHAV, V17, P64, DOI 10.1016/j.yebeh.2009.10.007; Haut SR, 2005, NEUROLOGY, V65, P1313, DOI 10.1212/01.wnl.0000180685.84547.7f; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; Hesdorffer DC, 2011, EPILEPSIA, V52, P1150, DOI 10.1111/j.1528-1167.2010.02952.x; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; Jacoby A, 2009, NEUROL CLIN, V27, P843, DOI 10.1016/j.ncl.2009.06.003; Jozsef J, 2010, EPILEPSIA, V51, P1004, DOI 10.1111/j.1528-1167.2010.02566.x; Katz R, 2006, EPILEPSY RES, V68, P85, DOI 10.1016/j.eplepsyres.2005.09.034; Katz R., 2011, CLIN INVESTIGATOR, V1, P1487; Kim LG, 2006, LANCET NEUROL, V5, P317, DOI 10.1016/S1474-4422(06)70383-0; Kwan P, 2011, LANCET NEUROL, V10, P881, DOI 10.1016/S1474-4422(11)70154-5; Loscher W, 2011, EPILEPSIA, V52, P657, DOI 10.1111/j.1528-1167.2011.03024.x; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Mohanraj R, 2003, SEIZURE-EUR J EPILEP, V12, P413, DOI 10.1016/S1059-1311(03)00047-5; Niklson I, 2006, EPILEPTIC DISORD, V8, P37; Perucca E, 1998, EUR J CLIN PHARMACOL, V54, P1, DOI 10.1007/s002280050411; Perucca E, 2008, CNS DRUGS, V22, P917, DOI 10.2165/00023210-200822110-00003; Perucca E, 2010, EPILEPSIA, V51, P1933, DOI 10.1111/j.1528-1167.2010.02589.x; PLEDGER GW, 1991, EPILEPSIA, V32, P716, DOI 10.1111/j.1528-1157.1991.tb04715.x; Rheims S, 2011, EPILEPSIA, V52, P219, DOI 10.1111/j.1528-1167.2010.02915.x; Ryvlin P, 2011, LANCET NEUROL, V10, P961, DOI 10.1016/S1474-4422(11)70193-4; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; Sachdeo RC, 1997, EPILEPSIA, V38, P294, DOI 10.1111/j.1528-1157.1997.tb01120.x; Sperling MR, 2010, EPILEPSIA, V51, P333, DOI 10.1111/j.1528-1167.2009.02318.x; St Louis EK, 2009, CURR NEUROPHARMACOL, V7, P77, DOI 10.2174/157015909788848866; US Food and Drug Administration, 2008, DRUGS FDA FDA APPR P; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840	54	26	26	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2012	11	9					827	834		10.1016/S1474-4422(12)70177-1	http://dx.doi.org/10.1016/S1474-4422(12)70177-1			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	994DS	22898736				2022-12-18	WOS:000307911700017
J	Morrison, PJ				Morrison, Patrick J.			Accurate prevalence and uptake of testing for Huntington's disease	LANCET NEUROLOGY			English	Letter									[Morrison, Patrick J.] Belfast City Hosp, Reg Med Genet Ctr, Belfast BT9 7AB, Antrim, North Ireland; [Morrison, Patrick J.] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland	Belfast City Hospital; Ulster University	Morrison, PJ (corresponding author), Belfast City Hosp, Reg Med Genet Ctr, Belfast BT9 7AB, Antrim, North Ireland.							BATES G, 2002, HUNTINGTONS DIS; Li JL, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-71; MACMILLAN JC, 1993, J MED GENET, V30, P1012, DOI 10.1136/jmg.30.12.1012; MORRISON PJ, 1995, J MED GENET, V32, P524, DOI 10.1136/jmg.32.7.524; MORRISON PJ, 2010, CLIN GENET, DOI DOI 10.1111/J13990004201001538X; Spinney Laura, 2010, Lancet Neurol, V9, P760, DOI 10.1016/S1474-4422(10)70160-5	6	26	26	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2010	9	12					1147	1147		10.1016/S1474-4422(10)70287-8	http://dx.doi.org/10.1016/S1474-4422(10)70287-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	691KG	21087736				2022-12-18	WOS:000285078100008
J	Li, LX; Poon, MTC; Samarasekera, NE; Perry, LA; Moullaali, TJ; Rodrigues, MA; Loan, JJM; Stephen, J; Lerpiniere, C; Tuna, MA; Gutnikov, SA; Kuker, W; Silver, LE; Salman, RAS; Rothwell, PM				Li, Linxin; Poon, Michael T. C.; Samarasekera, Neshika E.; Perry, Luke A.; Moullaali, Tom J.; Rodrigues, Mark A.; Loan, James J. M.; Stephen, Jacqueline; Lerpiniere, Christine; Tuna, Maria A.; Gutnikov, Sergei A.; Kuker, Wilhelm; Silver, Louise E.; Salman, Rustam Al-Shahi; Rothwell, Peter M.			Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies	LANCET NEUROLOGY			English	Article							BLOOD-PRESSURE; OXFORDSHIRE; PREVENTION; MORTALITY; DISEASE; TRIAL; UK	Background Patients with stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) are at risk of recurrent ICH, ischaemic stroke, and other serious vascular events. We aimed to analyse these risks in population-based studies and compare them with the risks in RESTART, which assessed antiplatelet therapy after ICH. Methods We pooled individual patient data from two prospective, population-based inception cohort studies of all patients with an incident firs-in-a-lifetime ICH in Oxfordshire, England (Oxford Vascular Study; April 1, 2002, to Sept 28, 2018) and Lothian, Scotland, UK (Lothian Audit of the Treatment of Cerebral Haemorrhage; June 1, 2010, to May 31, 2013). We quantified the absolute and relative risks of recurrent ICH, ischaemic stroke, or any serious vascular event (non-fatal stroke, non-fatal myocardial infarction, or vascular death), stratified by ICH location (lobar vs non-lobar) and comorbid atrial fibrillation (AF). We compared pooled event rates with those after allocation to avoid antiplatelet therapy in RESTART. Findings Among 674 patients (mean age 74.7 years [SD 12.6], 320 [47%] men) with 1553 person-years of follow-up, 46 recurrent ICHs (event rate 3.2 per 100 patient-years, 95% CI 2.0-5.1) and 25 ischaemic strokes (1.7 per 100 patient-years, 0.8-3.3) were reported. Patients with lobar ICH (n=317) had higher risk of recurrent ICH (5.1 per 100 patient-years, 95% CI 3.6-7.2) than patients with non-lobar ICH (n=355; 1.8 per 100 patient-years, 1.0-3.3; hazard ratio [HR] 3.2, 95% CI 1.6-6.3; p=0.0010), but there was no evidence of a difference in the risk of ischaemic stroke (1.8 per 100 patient-years, 1.0-3.2, vs 1.6 per 100 patient-years, 0.6-4.4; HR 1.1, 95% CI 0.5-2.8). Conversely, there was no evidence of a difference in recurrent ICH rate in patients with AF (n=147; 3.3 per 100 patient-years, 95% CI 1.0-10.7) compared with those without (n=526; 3.2 per 100 patient-years, 2.2-4.7; HR 0.9, 95% CI 0.4-2.1), but the risk of ischaemic stroke was higher with AF (6.3 per 100 patient-years, 3.7-10.9, vs 0.7 per 100 patient-years, 0.1-5.6; HR 8.2, 3.3-20.3; p<0.0001), resulting in patients with AF having a higher risk of all serious vascular events than patients without AF (15.5 per 100 patient-years, 10.0-24.1, vs 6.8 per 100 patient-years, 3.6-12.5; HR 1.78, 95% CI 1.16-2.74; p=0.0090). Only for patients with lobar ICH without comorbid AF was the risk of recurrent ICH greater than the risk of ischaemic stroke (5.2 per 100 patient-years, 95% CI 3.6-7.5, vs 0.9 per 100 patient-years, 0.2-4.8; p=0.00034). Comparing data from the pooled population-based studies with that from patients allocated to not receive antiplatelet therapy in RESTART, there was no evidence of a difference in the rate of recurrent ICH (3.5 per 100 patient-years, 95% CI 1.9-6.0, vs 4.4 per 100 patient-years, 2.6-6.1) or ischaemic stroke (3.4 per 100 patient-years, 1.9-5.9, vs 5.3 per 100 patient-years, 3.3-7.2). Interpretation The risks of recurrent ICH, ischaemic stroke, and all serious vascular events after ICH differ by ICH location and comorbid AF. These data enable risk stratification of patients in clinical practice and ongoing randomised trials.	[Li, Linxin; Tuna, Maria A.; Gutnikov, Sergei A.; Kuker, Wilhelm; Silver, Louise E.; Rothwell, Peter M.] Univ Oxford, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clin Neurosci, Oxford, England; [Poon, Michael T. C.; Samarasekera, Neshika E.; Moullaali, Tom J.; Rodrigues, Mark A.; Loan, James J. M.; Lerpiniere, Christine; Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Poon, Michael T. C.; Stephen, Jacqueline; Salman, Rustam Al-Shahi] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Loan, James J. M.] Univ Edinburgh, Ctr Discovery Brain Sci, Edinburgh, Midlothian, Scotland; [Perry, Luke A.] Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Parkville, Vic, Australia; [Moullaali, Tom J.] George Inst Global Hlth, Sydney, NSW, Australia; [Rodrigues, Mark A.] NHS Lothian, Dept Neuroradiol, Edinburgh, Midlothian, Scotland	University of Oxford; University of Edinburgh; University of Edinburgh; University of Edinburgh; Royal Melbourne Hospital; George Institute for Global Health; University of Sydney	Salman, RAS (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	rustam.al-shahi@ed.ac.uk	Loan, James/AAS-5535-2021; Poon, Michael/AAV-1914-2021	Loan, James/0000-0002-6451-9448; Poon, Michael/0000-0002-0053-2184; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Samarasekera, Neshika/0000-0001-6840-0199; Rodrigues, Mark/0000-0002-4507-6872; Perry, Luke/0000-0002-7494-8406	UK Medical Research Council; British Heart Foundation; Wellcome Trust; National Institute for Health Research Oxford Biomedical Research Centre; Stroke Association	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome Trust); National Institute for Health Research Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Stroke Association	UK Medical Research Council, Stroke Association, British Heart Foundation, Wellcome Trust, and the National Institute for Health Research Oxford Biomedical Research Centre.	Almandoz JED, 2012, NEUROSURGERY, V70, P131, DOI 10.1227/NEU.0b013e31822fbf43; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Arima H, 2010, STROKE, V41, P394, DOI 10.1161/STROKEAHA.109.563932; Austin PC, 2017, STAT MED, V36, P4391, DOI 10.1002/sim.7501; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Banerjee G, 2020, J NEUROL NEUROSUR PS, V91, P840, DOI 10.1136/jnnp-2020-323079; Bhatnagar P, 2016, HEART, V102, P1945, DOI 10.1136/heartjnl-2016-309573; Biffi A, 2015, JAMA-J AM MED ASSOC, V314, P904, DOI 10.1001/jama.2015.10082; Casolla B, 2019, STROKE, V50, P1100, DOI 10.1161/STROKEAHA.118.024449; Chapman N, 2004, STROKE, V35, P116, DOI 10.1161/01.STR.0000106480.76217.6F; Charidimou A, 2017, NEUROLOGY, V89, P820, DOI 10.1212/WNL.0000000000004259; Charidimou A, 2017, J NEUROL SCI, V372, P178, DOI 10.1016/j.jns.2016.11.021; Chong BH, 2012, THROMB HAEMOSTASIS, V107, P241, DOI 10.1160/TH11-06-0439; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Hanger HC, 2007, J NEUROL NEUROSUR PS, V78, P836, DOI 10.1136/jnnp.2006.106500; Hill MD, 2000, STROKE, V31, P123, DOI 10.1161/01.STR.31.1.123; Inagawa T, 2005, SURG NEUROL, V64, P28, DOI 10.1016/j.surneu.2004.09.039; Kim J, 2018, HYPERTENSION, V72, P391, DOI 10.1161/HYPERTENSIONAHA.118.11139; Krishnamurthi RV, 2020, NEUROEPIDEMIOLOGY, V54, P171, DOI 10.1159/000506396; Kuramatsu JB, 2019, INT J STROKE, V14, P238, DOI 10.1177/1747493019828555; Leurent C, 2019, ANN CLIN TRANSL NEUR, V6, P795, DOI 10.1002/acn3.761; Li LX, 2020, J NEUROL NEUROSUR PS, V91, P580, DOI 10.1136/jnnp-2019-322663; Lovelock CE, 2007, LANCET NEUROL, V6, P487, DOI 10.1016/S1474-4422(07)70107-2; Lovett JK, 2003, STROKE, V34, pE138, DOI 10.1161/01.STR.0000080935.01264.91; Maxwell AE, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1909-4; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Nielsen PB, 2019, CEREBROVASC DIS, V48, P236, DOI 10.1159/000504926; Odutayo A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4482; Pasquini M, 2014, STROKE, V45, P2643, DOI 10.1161/STROKEAHA.114.006202; PASSERO S, 1995, STROKE, V26, P1189, DOI 10.1161/01.STR.26.7.1189; Poon MTC, 2014, J NEUROL NEUROSUR PS, V85, P660, DOI 10.1136/jnnp-2013-306476; Rodrigues MA, 2018, LANCET NEUROL, V17, P232, DOI 10.1016/S1474-4422(18)30006-1; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Salman RAS, 2019, LANCET, V393, P2613, DOI 10.1016/S0140-6736(19)30840-2; Salman RAS, 2019, LANCET NEUROL, V18, P643, DOI 10.1016/S1474-4422(19)30184-X; Samarasekera N, 2015, STROKE, V46, P361, DOI 10.1161/STROKEAHA.114.007953; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Viswanathan A, 2006, NEUROLOGY, V66, P206, DOI 10.1212/01.wnl.0000194267.09060.77; Weimar C, 2011, CEREBROVASC DIS, V32, P283, DOI 10.1159/000330643; Zia E, 2009, STROKE, V40, P3567, DOI 10.1161/STROKEAHA.109.556324	41	25	26	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					437	447		10.1016/S1474-4422(21)00075-2	http://dx.doi.org/10.1016/S1474-4422(21)00075-2			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	34022170	hybrid, Green Published			2022-12-18	WOS:000653434700014
J	Rapp, SR; Gaussoin, SA; Sachs, BC; Chelune, G; Supiano, MA; Lerner, AJ; Wadley, VG; Wilson, VM; Fine, LJ; Whittle, JC; Auchus, AP; Beddhu, S; Berlowitz, DR; Bress, AP; Johnson, KC; Krousel-Wood, M; Martindale-Adams, J; Miller, EC; Rifkin, DE; Snyder, JK; Tamariz, L; Wolfgram, DF; Cleveland, ML; Yang, MA; Nichols, LO; Bryan, RN; Reboussin, DM; Williamson, JD; Pajewski, NM				Rapp, Stephen R.; Gaussoin, Sarah A.; Sachs, Bonnie C.; Chelune, Gordon; Supiano, Mark A.; Lerner, Alan J.; Wadley, Virginia G.; Wilson, Valarie M.; Fine, Lawrence J.; Whittle, Jeff C.; Auchus, Alexander P.; Beddhu, Srinivasan; Berlowitz, Dan R.; Bress, Adam P.; Johnson, Karen C.; Krousel-Wood, Marie; Martindale-Adams, Jennifer; Miller, Eliza C.; Rifkin, Dena E.; Snyder, Joni K.; Tamariz, Leonardo; Wolfgram, Dawn F.; Cleveland, Maryjo L.; Yang, Mia; Nichols, Linda O.; Bryan, Robert Nick; Reboussin, David M.; Williamson, Jeff D.; Pajewski, Nicholas M.			Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial	LANCET NEUROLOGY			English	Article							DEMENTIA; RISK; HYPERTENSION; PREVENTION; DISEASE	Background Results from the Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive control of systolic blood pressure significantly reduced the occurrence of mild cognitive impairment, but not probable dementia. We investigated the effects of intensive lowering of systolic blood pressure on specific cognitive functions in a preplanned substudy of participants from SPRINT. Methods SPRINT was an open-label, multicentre, randomised controlled trial undertaken at 102 sites, including academic medical centres, Veterans Affairs medical centres, hospitals, and independent clinics, in the USA and Puerto Rico. Participants were adults aged 50 years or older with systolic blood pressure higher than 130 mm Hg, but without diabetes, history of stroke, or dementia. Participants were randomly assigned (1:1) to a systolic blood pressure goal of less than 120 mm Hg (intensive treatment) versus less than 140 mm Hg (standard treatment). All major classes of antihypertensive agents were included. A subgroup of randomly assigned participants including, but not limited to, participants enrolled in an MRI substudy was then selected for a concurrent substudy of cognitive function (target 2800 participants). Each individual was assessed with a screening cognitive test battery and an extended cognitive test battery at baseline and biennially during the planned 4-year follow-up. The primary outcomes for this substudy were standardised composite scores for memory (Logical Memory I and II, Modified Rey-Osterrieth Complex Figure [immediate recall], and Hopkins Verbal Learning Test-Revised [delayed recall]) and processing speed (Trail Making Test and Digit Symbol Coding). SPRINT was registered with ClinicalTrials.gov, NCT01206062. Findings From Nov 23, 2010, to Dec 28, 2012, 2921 participants (mean age 68.4 years [SD 8.6], 1080 [37%] women) who had been randomly assigned in SPRINT were enrolled in the substudy (1448 received intensive treatment and 1473 received standard treatment). SPRINT was terminated early due to benefit observed in the primary outcome (composite of cardiovascular events). After a median follow-up of 4.1 years (IQR 3.7-5.8), there was no between-group difference in memory, with an annual decline in mean standardised domain score of -0.005 (95% CI -0.010 to 0.001) in the intensive treatment group and -0.001 (-0.006 to 0.005) in the standard treatment group (between-group difference -0.004, 95% CI -0.012 to 0.004; p=0.33). Mean standardised processing speed domain scores declined more in the intensive treatment group (between-group difference -0.010, 95% CI -0.017 to -0.002; p=0.02), with an annual decline of -0.025 (-0.030 to -0.019) for the intensive treatment group and -0.015 (-0.021 to 0.009) for the standard treatment group. Interpretation Intensive treatment to lower systolic blood pressure did not result in a clinically relevant difference compared with standard treatment in memory or processing speed in a subgroup of participants from SPRINT. The effect of blood pressure lowering might not be evident in specific domains of cognitive function, but instead distributed across multiple domains.	[Rapp, Stephen R.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; [Gaussoin, Sarah A.; Reboussin, David M.; Pajewski, Nicholas M.] Wake Forest Sch Med, Dept Biostat & Data Sci, Winston Salem, NC 27157 USA; [Sachs, Bonnie C.] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC 27157 USA; [Wilson, Valarie M.; Cleveland, Maryjo L.; Yang, Mia; Williamson, Jeff D.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; [Chelune, Gordon] Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT USA; [Bress, Adam P.] Univ Utah, Sch Med, Dept Populat Hlth Sci, Salt Lake City, UT USA; [Supiano, Mark A.; Beddhu, Srinivasan] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA; [Supiano, Mark A.; Beddhu, Srinivasan] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; [Lerner, Alan J.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; [Wadley, Virginia G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Fine, Lawrence J.; Snyder, Joni K.] NHLBI, Clin Applicat & Prevent Branch, Bldg 10, Bethesda, MD 20892 USA; [Whittle, Jeff C.; Wolfgram, Dawn F.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Whittle, Jeff C.; Wolfgram, Dawn F.] Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA; [Auchus, Alexander P.] Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; [Berlowitz, Dan R.] Bedford Vet Affairs Med Ctr, Bedford, MA USA; [Berlowitz, Dan R.] Univ Massachusetts Lowell, Dept Publ Hlth, Lowell, MA USA; [Johnson, Karen C.; Martindale-Adams, Jennifer] Univ Tennessee, Dept Prevent Med, Hlth Sci Ctr, Memphis, TN USA; [Krousel-Wood, Marie] Tulane Univ, Dept Med, New Orleans, LA 70118 USA; [Krousel-Wood, Marie] Tulane Univ, Dept Epidemiol, New Orleans, LA 70118 USA; [Krousel-Wood, Marie] Ochsner Hlth Syst, New Orleans, LA USA; [Miller, Eliza C.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA; [Rifkin, Dena E.] Univ Calif San Diego, Div Nephrol Hypertens, La Jolla, CA 92093 USA; [Tamariz, Leonardo] Miami Vet Affairs Healthcare Syst, Miami, FL USA; [Tamariz, Leonardo] Univ Miami, Div Populat Hlth & Computat Med, Miami, FL USA; [Nichols, Linda O.] Vet Affairs Med Ctr, Prevent Med Sect, Memphis, TN USA; [Bryan, Robert Nick] Univ Texas Austin, Dell Med Sch, Dept Diagnost Med, Austin, TX 78712 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Case Western Reserve University; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; University of Mississippi; University of Mississippi Medical Center; University of Massachusetts System; University of Massachusetts Lowell; University of Tennessee System; University of Tennessee Health Science Center; Tulane University; Tulane University; Ochsner Health System; Columbia University; University of California System; University of California San Diego; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Texas System; University of Texas Austin	Rapp, SR (corresponding author), Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA.	srapp@wakehealth.edu	Wolfgram, Dawn/GRY-5720-2022; Miller, Eliza C./AAF-5332-2020; Pajewski, Nicholas/J-1096-2019	Miller, Eliza C./0000-0002-7108-8906; Supiano, Mark/0000-0002-5438-5087; Tamariz, Leonardo/0000-0003-1583-3534; Weiner, Daniel/0000-0002-8775-394X; Whittle, Jeff/0000-0002-9544-838X	National Institutes of Health (NIH) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001]; National Institutes of Health (National Heart, Lung, and Blood Institute) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001]; National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001]; National Institutes of Health (National Institute on Aging) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001]; National Institutes of Health (National Institute of Neurological Disorders and Stroke) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001]; Department of Veterans Affairs; National Center for Advancing Translational Sciences [UL1TR000439, UL1RR025755, UL1RR024134, UL1TR000003, UL1RR025771, UL1TR000093, UL1RR025752, UL1TR000073, UL1TR001064, UL1TR000050, UL1TR000005, 9U54TR000017-06, UL1TR000105-05, UL1 TR000445, UL1TR000075, UL1 TR000002, UL1 TR000064, UL1TR000433]; Centers of Biomedical Research Excellence National Institute of General Medical Sciences [P30GM103337]; NIH [K01HL133468, K23NS107645, R01AG055606]; Wake Forest Claude Pepper Center [P30AG021332]; Alzheimer's Association	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (National Heart, Lung, and Blood Institute)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health (National Institute on Aging)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health (National Institute of Neurological Disorders and Stroke)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Department of Veterans Affairs(US Department of Veterans Affairs); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Centers of Biomedical Research Excellence National Institute of General Medical Sciences; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wake Forest Claude Pepper Center; Alzheimer's Association(Alzheimer's Association)	The Systolic Blood Pressure Intervention Trial was funded by the National Institutes of Health (NIH; including the National Heart, Lung, and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute on Aging; and the National Institute of Neurological Disorders and Stroke) under contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C, and an interagency agreement A-HL-13-002-001. The trial was also supported by the Department of Veterans Affairs. Additional support was provided from the following National Center for Advancing Translational Sciences awards: UL1TR000439 (awarded to Case Western Reserve University); UL1RR025755 (Ohio State University); UL1RR024134 and UL1TR000003 (University of Pennsylvania); UL1RR025771 (Boston University); UL1TR000093 (Stanford University); UL1RR025752, UL1TR000073, and UL1TR001064 (Tufts University); UL1TR000050 (University of Illinois); UL1TR000005 (University of Pittsburgh); 9U54TR000017-06 (University of Texas Southwestern Medical Center); UL1TR000105-05 (University of Utah); UL1 TR000445 (Vanderbilt University); UL1TR000075 (George Washington University); UL1 TR000002 (University of California, Davis); UL1 TR000064 (University of Florida); and UL1TR000433 (University of Michigan); and by the Centers of Biomedical Research Excellence National Institute of General Medical Sciences award P30GM103337 (awarded to Tulane University). APB and ECM received additional support from NIH (K01HL133468 and K23NS107645). JDW and NMP received additional support from the Wake Forest Claude Pepper Center (P30AG021332). SRR, SAG, DMR, JDW, and NMP also received support from NIH (R01AG055606) and from the Alzheimer's Association.	Alber J, 2019, ALZH DEMENT-TRCI, V5, P107, DOI 10.1016/j.trci.2019.02.001; Ambrosius WT, 2014, CLIN TRIALS, V11, P532, DOI 10.1177/1740774514537404; [Anonymous], 2017, Circulation, V136, pe196, DOI 10.1161/CIR.0000000000000530; BECKER JT, 1987, CORTEX, V23, P59, DOI 10.1016/S0010-9452(87)80019-9; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Birns J, 2009, J HUM HYPERTENS, V23, P86, DOI 10.1038/jhh.2008.80; Birns J, 2006, J HYPERTENS, V24, P1907, DOI 10.1097/01.hjh.0000244934.81180.16; Bosch J, 2019, NEUROLOGY, V92, pE1435, DOI 10.1212/WNL.0000000000007174; Corrada MM, 2017, ALZHEIMERS DEMENT, V13, P103, DOI 10.1016/j.jalz.2016.09.007; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Elias MF, 2018, AM J HYPERTENS, V31, P631, DOI 10.1093/ajh/hpy033; Goodglass H, 1983, BOSTON NAMING TEST; Iadecola C, 2016, HYPERTENSION, V68, pE67, DOI 10.1161/HYP.0000000000000053; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lane CA, 2019, LANCET NEUROL, V18, P942, DOI 10.1016/S1474-4422(19)30228-5; Marpillat NL, 2013, J HYPERTENS, V31, P1073, DOI 10.1097/HJH.0b013e3283603f53; McGuinness B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004034.pub3; Nasrallah IM, 2019, JAMA-J AM MED ASSOC, V322, P524, DOI 10.1001/jama.2019.10551; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Qiu CX, 2003, ARCH NEUROL-CHICAGO, V60, P223, DOI 10.1001/archneur.60.2.223; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd Edn; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Walker KA, 2019, JAMA-J AM MED ASSOC, V322, P535, DOI 10.1001/jama.2019.10575; Walker KA, 2017, CURR HYPERTENS REP, V19, DOI 10.1007/s11906-017-0724-3; Wechsler, 2008, WECHSLER ADULT INTEL, DOI DOI 10.1037/T15169-000; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1996, WECHSLER ADULT INTEL; Williamson JD, 2019, JAMA-J AM MED ASSOC, V321, P553, DOI 10.1001/jama.2018.21442; Williamson JD, 2014, JAMA INTERN MED, V174, P324, DOI 10.1001/jamainternmed.2013.13656	32	25	27	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					899	907		10.1016/S1474-4422(20)30319-7	http://dx.doi.org/10.1016/S1474-4422(20)30319-7			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	OF3OI	33098800	Green Accepted			2022-12-18	WOS:000581121200022
J	Saji, N; Sakurai, T; Suzuki, K; Mizusawa, H; Toba, K				Saji, Naoki; Sakurai, Takashi; Suzuki, Keisuke; Mizusawa, Hidehiro; Toba, Kenji		ORANGE Investigators	ORANGE's challenge: developing wide-ranging dementia research in Japan	LANCET NEUROLOGY			English	Letter									[Saji, Naoki; Sakurai, Takashi] Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Aichi 4748511, Japan; [Suzuki, Keisuke] Natl Ctr Geriatr & Gerontol, Dept Clin Res, Innovat Ctr Clin Res, Obu, Aichi 4748511, Japan; [Mizusawa, Hidehiro] Natl Ctr Neurol & Psychiat, Tokyo, Japan; [Toba, Kenji] Natl Ctr Geriatr & Gerontol, Obu, Aichi, Japan	National Center for Geriatrics & Gerontology; National Center for Geriatrics & Gerontology; National Center for Neurology & Psychiatry - Japan; National Center for Geriatrics & Gerontology	Sakurai, T (corresponding author), Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Aichi 4748511, Japan.	tsakurai@ncgg.go.jp						Abe S, 2015, LANCET, V386, P2367, DOI 10.1016/S0140-6736(15)01172-1; Kaneko N, 2014, P JPN ACAD B-PHYS, V90, P353, DOI 10.2183/pjab.90.353; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Saji N, 2015, DISABIL REHABIL, V37, P331, DOI 10.3109/09638288.2014.918195; Soeda Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10216	5	25	25	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2016	15	7					661	662		10.1016/S1474-4422(16)30009-6	http://dx.doi.org/10.1016/S1474-4422(16)30009-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM7OG	27302232	Bronze			2022-12-18	WOS:000376549300015
J	Kivipelto, M; Solomon, A; Winblad, B				Kivipelto, M; Solomon, A; Winblad, B			Statin therapy in Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							SIMVASTATIN; CHOLESTEROL; PROTEIN; BRAIN		Karolinska Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Kivipelto, M (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.	miia.kivipelto@neurotec.ki.se	Kivipelto, Miia/AAS-3557-2021	Solomon, Alina/0000-0002-7166-9903; Kivipelto, Miia/0000-0003-0992-3875				Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Hoglund K, 2005, DEMENT GERIATR COGN, V19, P256, DOI 10.1159/000084550; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Michikawa M, 2003, MOL NEUROBIOL, V27, P1, DOI 10.1385/MN:27:1:1; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753	6	25	26	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2005	4	9					521	522		10.1016/S1474-4422(05)70150-2	http://dx.doi.org/10.1016/S1474-4422(05)70150-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VK	16109358				2022-12-18	WOS:000231476100004
J	Sarin, R; Murthy, V				Sarin, R; Murthy, V			Medical decompressive therapy for primary and metastatic intracranial tumours	LANCET NEUROLOGY			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; SPINAL-CORD COMPRESSION; DEXAMETHASONE TREATMENT; CEREBRAL EDEMA; BRAIN-TUMORS; PEPTIC-ULCER; ADRENOCORTICOSTEROID THERAPY; CRANIAL IRRADIATION; RADIATION RESPONSE; STEROID MYOPATHY	Medical decompressive therapy (MDT) with corticosteroids and mannitol is often used in patients with primary or metastatic brain tumours. This review highlights the lack of sound evidence regarding the indications and dosage schedule of steroids, prolonged use of which may cause debilitating complications. The available evidence supports the short-term use of MDT for raised intracranial pressure or progressive neurological deficits, but in the absence of these symptoms, MDT is not recommended for stable focal deficits, abnormal higher A mental functions, seizures, or as prophylaxis during cranial irradiation. A practical stepladder guideline (based on symptom severity) is A proposed with a starting daily dexamethasone dose of 6 mg for non-severe headache and or vomiting; 12 mg for progressive focal neurological deficit with or without non-severe headache or vomiting; and 24 mg dexamethasone with mannitol for severe headache, vomiting, or altered consciousness. Depending on the clinical response, dose can be increased to the next step(s) or tapered every 48 h (more slowly in patients who are dependent on steroids). A scheme for the assessment of efficacy and toxicity prevention is also proposed. The proposed guidelines may be used as a template for further clinical research.	Tata Mem Hosp, Dept Radiat Oncol, Bombay 400012, Maharashtra, India	Tata Memorial Centre (TMC); Tata Memorial Hospital	Sarin, R (corresponding author), Tata Mem Hosp, Dept Radiat Oncol, Bombay 400012, Maharashtra, India.	btf@braintumourindia.com		Sarin, Rajiv/0000-0002-6405-8282				AFIFI AK, 1968, JOHNS HOPKINS MED J, V123, P158; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ALDERSON P, 2000, COCHRANE LIB; Batchelor TT, 1997, NEUROLOGY, V48, P1234, DOI 10.1212/WNL.48.5.1234; BEDIKIAN AY, 1980, SOUTHERN MED J, V73, P1210, DOI 10.1097/00007611-198009000-00012; BENEDIKTSSON G, 1990, J NEURO-ONCOL, V8, P47; Borg M F, 1995, Australas Radiol, V39, P42, DOI 10.1111/j.1440-1673.1995.tb00230.x; BORGELT B, 1980, INT J RADIAT ONCOL, V6, P1, DOI 10.1016/0360-3016(80)90195-9; BROCK WA, 1984, INT J RADIAT ONCOL, V10, P2113, DOI 10.1016/0360-3016(84)90210-4; BROPHY TRO, 1984, J NEUROL NEUROSUR PS, V47, P1081, DOI 10.1136/jnnp.47.10.1081; Caincross JG, 1980, ANN NEUROL, V7, P529; CANTORE G, 1964, J NEUROSURG, V21, P278, DOI 10.3171/jns.1964.21.4.0278; CHALK JB, 1984, J NEUROL NEUROSUR PS, V47, P1087, DOI 10.1136/jnnp.47.10.1087; Chumas P, 1997, J NEUROL NEUROSUR PS, V62, P590, DOI 10.1136/jnnp.62.6.590; COIA LR, 1992, INT J RADIAT ONCOL, V23, P223, DOI 10.1016/0360-3016(92)90566-Z; CONN HO, 1985, J CHRON DIS, V38, P457, DOI 10.1016/0021-9681(85)90028-1; CONN HO, 1976, NEW ENGL J MED, V294, P473, DOI 10.1056/NEJM197602262940905; Cruz J, 2001, NEUROSURGERY, V49, P864; DAYTON MT, 1987, ARCH SURG-CHICAGO, V122, P376; DELATTRE JY, 1988, NEUROLOGY, V38, P194, DOI 10.1212/WNL.38.2.194; DROPCHO EJ, 1991, NEUROLOGY, V41, P1235, DOI 10.1212/WNL.41.8.1235; FADUL CE, 1988, NEUROLOGY, V38, P348, DOI 10.1212/WNL.38.3.348; FERRIGNO D, 1994, CHEST, V106, P1025, DOI 10.1378/chest.106.4.1025; FISHMAN RA, 1982, NEW ENGL J MED, V306, P359, DOI 10.1056/NEJM198202113060609; FRANK JI, 1993, MED CLIN N AM, V77, P61, DOI 10.1016/S0025-7125(16)30272-3; FRENCH LA, 1966, B NEW YORK ACAD MED, V42, P301; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; GALICICH JH, 1961, J LANCET, V81, P46; Gattis WA, 1996, ANN PHARMACOTHER, V30, P520, DOI 10.1177/106002809603000516; GREEN SB, 1983, CANCER TREAT REP, V67, P121; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gupta T, 2002, LANCET ONCOL, V3, P557, DOI 10.1016/S1470-2045(02)00853-7; HANKS GW, 1983, POSTGRAD MED J, V59, P702, DOI 10.1136/pgmj.59.697.702; HEIDENREICH S, 1994, CELL IMMUNOL, V157, P320, DOI 10.1006/cimm.1994.1230; HEIMDAL K, 1992, J NEURO-ONCOL, V12, P141; Hensley ML, 1999, J CLIN ONCOL, V17, P3333, DOI 10.1200/JCO.1999.17.10.3333; HENSON JW, 1991, ARCH NEUROL-CHICAGO, V48, P406, DOI 10.1001/archneur.1991.00530160074017; HICKSON RC, 1981, AM J PHYSIOL, V241, pE226, DOI 10.1152/ajpendo.1981.241.3.E226; HORTON J, 1971, AMER J ROENTGENOL RA, V111, P334, DOI 10.2214/ajr.111.2.334; Janssen G, 2000, KLIN PADIATR, V212, P189, DOI 10.1055/s-2000-9676; JARDEN JO, 1985, ANN NEUROL, V18, P636, DOI 10.1002/ana.410180603; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; KOFMAN S, 1957, JAMA-J AM MED ASSOC, V163, P1473, DOI 10.1001/jama.1957.02970510039008; LACKNER TE, 1991, PHARMACOTHERAPY, V11, P344; LEWIS GP, 1971, LANCET, V2, P778; LIEBERMAN A, 1977, J NEUROL NEUROSUR PS, V40, P678, DOI 10.1136/jnnp.40.7.678; LORDO CD, 1989, J NEUROSURG, V70, P767, DOI 10.3171/jns.1989.70.5.0767; Mariotta M, 1999, STRAHLENTHER ONKOL, V175, P392, DOI 10.1007/s000660050027; MARTENSON JA, 1985, J NEURO-ONCOL, V3, P77; McIntyre PB, 1997, JAMA-J AM MED ASSOC, V278, P925, DOI 10.1001/jama.278.11.925; Mercadante S, 2001, SUPPORT CARE CANCER, V9, P386, DOI 10.1007/s005200000218; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; NEUWELT EA, 1982, P NATL ACAD SCI-BIOL, V79, P4420, DOI 10.1073/pnas.79.14.4420; NISCE LZ, 1971, AMER J ROENTGENOL RA, V111, P329, DOI 10.2214/ajr.111.2.329; Pannullo S., 1993, PSYCHO-ONCOLOGY, V2, P233, DOI [10.1002/pon.2960020404., DOI 10.1002/PON.2960020404]; PETERS WP, 1972, NEW ENGL J MED, V286, P342, DOI 10.1056/NEJM197202172860703; Pickren JW, 1983, CANCER TREAT S, V2, P295; POSNER JB, 1995, NEUROLOGIC COMPLICAT, P37; PRASAD K, 2001, COCHRANE LIB; Priestman T J, 1996, Clin Oncol (R Coll Radiol), V8, P308, DOI 10.1016/S0936-6555(05)80717-4; REMINE SG, 1980, ANN SURG, V192, P581, DOI 10.1097/00000658-198010000-00016; RENAUDIN J, 1973, J NEUROSURG, V39, P302, DOI 10.3171/jns.1973.39.3.0302; Rieger J, 1999, EUR J PHARMACOL, V365, P301, DOI 10.1016/S0014-2999(98)00883-8; Roberts I, 2001, CRIT CARE, V5, P292, DOI 10.1186/cc1051; ROBERTS PA, 1987, J NEUROSURG, V66, P440, DOI 10.3171/jns.1987.66.3.0440; ROTTENBERG DA, 1977, NEUROLOGY, V27, P600, DOI 10.1212/WNL.27.7.600; RUDERMAN NB, 1965, CANCER, V18, P298, DOI 10.1002/1097-0142(196503)18:3<298::AID-CNCR2820180306>3.0.CO;2-H; SAHANI K, 1986, INDIAN J CANC, V23, P141; SALBECK R, 1990, CANCER, V66, P2007, DOI 10.1002/1097-0142(19901101)66:9<2007::AID-CNCR2820660927>3.0.CO;2-C; Sarin R, 1997, Clin Oncol (R Coll Radiol), V9, P272, DOI 10.1016/S0936-6555(97)80019-2; SCHLOSS MH, 1989, ACTA ONCOL, V28, P51, DOI 10.3109/02841868909111181; SLIVKA A, 1993, AM J MED, V94, P216, DOI 10.1016/0002-9343(93)90187-T; STIEFEL FC, 1989, CANCER INVEST, V7, P479, DOI 10.3109/07357908909041378; Straathof CSM, 1998, J NEURO-ONCOL, V37, P1, DOI 10.1023/A:1005835212246; Streffer JR, 2001, NEUROLOGY, V56, P1219, DOI 10.1212/WNL.56.9.1219; Tajima A, 1990, Adv Neurol, V52, P343; TARVER RD, 1984, RADIOLOGY, V153, P689, DOI 10.1148/radiology.153.3.6093189; Uzal D, 1998, RADIOTHER ONCOL, V48, P29, DOI 10.1016/S0167-8140(98)00036-X; Van Roost D, 2001, ACTA NEUROCHIR, V143, P37, DOI 10.1007/s007010170136; VECHT CJ, 1994, NEUROLOGY, V44, P675, DOI 10.1212/WNL.44.4.675; Vincent Frederick M., 1995, Comprehensive Therapy, V21, P524; WALKER AE, 1985, NEUROLOGY, V35, P219, DOI 10.1212/WNL.35.2.219; WEINER HL, 1993, NEUROSURGERY, V33, P40; WEINSTEIN JD, 1973, NEUROLOGY, V23, P121, DOI 10.1212/WNL.23.2.121; WEISSMAN DE, 1987, J NEURO-ONCOL, V5, P125, DOI 10.1007/BF02571300; WEISSMAN DE, 1988, J CLIN ONCOL, V6, P543, DOI 10.1200/JCO.1988.6.3.543; WEISSMAN DE, 1991, J NEURO-ONCOL, V11, P235, DOI 10.1007/BF00165531; WEN PY, 2000, CANC PRINCIPLES PRAC, P2655; WEN PY, 1997, CANC NERVOUS SYSTEM, P106; WOLFF JEA, 1994, ANTICANCER RES, V14, P1585; WOLFSON AH, 1994, AM J CLIN ONCOL-CANC, V17, P234, DOI 10.1097/00000421-199406000-00011; ZIMM S, 1981, CANCER, V48, P384, DOI 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8	93	25	25	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					357	365		10.1016/S1474-4422(03)00410-1	http://dx.doi.org/10.1016/S1474-4422(03)00410-1			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH	12849152				2022-12-18	WOS:000183115000018
J	Crosby, AH				Crosby, AH			Disruption of cellular transport: a common cause of neurodegeneration?	LANCET NEUROLOGY			English	Article							HEREDITARY SPASTIC PARAPLEGIA; AMYOTROPHIC-LATERAL-SCLEROSIS; KINESIN HEAVY-CHAIN; FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN GENE; AXONAL-TRANSPORT; MOTOR-NEURONS; TRAFFICKING; HUNTINGTIN; MUTATIONS	In many cases, the clinical manifestations of inherited neurodegenerative disorders appear after decades of normal function, which suggests that neurons may die through cumulative damage. Several genes that cause these diseases have been identified in recent years, but no common pathogenetic mechanism has been found. However, the most recent studies have begun to implicate the same mechanism in a range of neurodegenerative diseases, particularly those that involve motor neurons. The results of these studies suggest that the morphology and energy requirements of neurons make them particularly susceptible to the disruption of cellular transport systems.	Univ London St Georges Hosp, Sch Med, Dept Med Genet, London SW17 0RE, England	St Georges University London	Crosby, AH (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Med Genet, Cranmer Terrace, London SW17 0RE, England.		Crosby, Andrew H/E-2218-2015	Crosby, Andrew H/0000-0003-3667-9054				Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; Casari G, 2001, CURR OPIN GENET DEV, V11, P336, DOI 10.1016/S0959-437X(00)00199-4; Charvin D, 2003, HUM MOL GENET, V12, P71, DOI 10.1093/hmg/ddg004; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Crosby AH, 2002, AM J HUM GENET, V71, P1009, DOI 10.1086/344206; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Errico A, 2002, HUM MOL GENET, V11, P153, DOI 10.1093/hmg/11.2.153; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; FERREIRINHA F, 2001, MITOCHONDRION, V1, pS21; Fink JK, 2001, SEMIN NEUROL, V21, P199, DOI 10.1055/s-2001-15265; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hand CK, 2002, MUSCLE NERVE, V25, P135; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hoffner G, 2002, J CELL SCI, V115, P941; Hurd DD, 1996, GENETICS, V144, P1075; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; Kuljis RO, 1999, BRAIN RES, V842, P351, DOI 10.1016/S0006-8993(99)01813-2; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Li YK, 2002, J BIOL CHEM, V277, P28212, DOI 10.1074/jbc.M111612200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mack TGA, 2001, NEUROSCIENCE, V108, P701, DOI 10.1016/S0306-4522(01)00434-1; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Muglia M, 2002, ANN NEUROL, V51, P794, DOI 10.1002/ana.10185; Muller U, 2002, TRENDS MOL MED, V8, P152, DOI 10.1016/S1471-4914(02)02320-1; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; Patel H, 2002, NAT GENET, V31, P347, DOI 10.1038/ng937; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; Poorkaj P, 2002, ANN NEUROL, V52, P511, DOI 10.1002/ana.10340; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; Raiborg C, 2001, BIOCHEM SOC T, V29, P472, DOI 10.1042/BST0290472; Reid E, 2002, AM J HUM GENET, V71, P1189, DOI 10.1086/344210; SCHWARZ GA, 1956, ARCH NEURO PSYCHIATR, V75, P144, DOI 10.1001/archneurpsyc.1956.02330200038005; Shaw C E, 2001, Curr Neurol Neurosci Rep, V1, P69, DOI 10.1007/s11910-001-0078-7; Sheetz MP, 1998, PROG NEUROBIOL, V55, P577, DOI 10.1016/S0301-0082(98)00021-5; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Trinczek B, 1999, J CELL SCI, V112, P2355; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; Zhao XP, 2001, NAT GENET, V29, P326, DOI 10.1038/ng758	53	25	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2003	2	5					311	316		10.1016/S1474-4422(03)00383-1	http://dx.doi.org/10.1016/S1474-4422(03)00383-1			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	669RC	12849185				2022-12-18	WOS:000182363400019
J	Seshadri, S; Wolf, PA				Seshadri, S; Wolf, PA			Homocysteine and the brain: vascular risk factor or neurotoxin?	LANCET NEUROLOGY			English	Editorial Material														Seshadri, Sudha/0000-0001-6135-2622; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016495] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-25195] Funding Source: Medline; NIA NIH HHS [5R01-AG16495] Funding Source: Medline; NINDS NIH HHS [R01 NS017950, 5R01-NS17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; MCCULLY KS, 1969, AM J PATHOL, V56, P111; McIlroy SP, 2002, STROKE, V33, P2351, DOI 10.1161/01.STR.0000032550.90046.38; Prins ND, 2002, NEUROLOGY, V59, P1375, DOI 10.1212/01.WNL.0000032494.05619.93; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613	6	25	29	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					11	11		10.1016/S1474-4422(03)00258-8	http://dx.doi.org/10.1016/S1474-4422(03)00258-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849292				2022-12-18	WOS:000180035800015
J	Ding, D; Zhou, D; Sander, JW; Wang, WZ; Li, SC; Hong, Z				Ding, Ding; Zhou, Dong; Sander, Josemir W.; Wang, Wenzhi; Li, Shichuo; Hong, Zhen			Epilepsy in China: major progress in the past two decades	LANCET NEUROLOGY			English	Review							QUALITY-OF-LIFE; INDUCED CUTANEOUS REACTIONS; TEMPORAL-LOBE EPILEPSY; CONVULSIVE EPILEPSY; GLOBAL CAMPAIGN; RURAL CHINA; ANTIEPILEPTIC DRUGS; HLA-B-ASTERISK-1502 ALLELE; PHENOBARBITAL TREATMENT; PREMATURE MORTALITY	China has approximately 10 million people with epilepsy. There is a vast epilepsy treatment gap in China, mainly driven by deficiencies in health-care delivery and social discrimination resulting from cultural beliefs about epilepsy. WHO's Global Campaign Against Epilepsy project in China showed that it was possible to treat epilepsy in primary care settings, which was a notable milestone. The China Association Against Epilepsy has been a necessary force to stimulate interest in epilepsy care and research by the medical and scientific community. Nearly 20 different anti-seizure medications are now available in China. Non-pharmacological options are also available, but there are still unmet needs for epilepsy management. The Chinese epilepsy research portfolio is varied, but the areas in which there are the most concentrated focus and expertise are epidemiology and clinical research. The challenges for further improvement in delivering care for people with epilepsy in China are primarily related to public health and reducing inequalities within this vast country.	[Ding, Ding; Hong, Zhen] Fudan Univ, Huashan Hosp, Inst Neurol, Shanghai, Peoples R China; [Zhou, Dong] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China; [Sander, Josemir W.] NIHR Univ Coll London Hosp Biomed Res Ctr, UCL Queen Sq Inst Neurol, London WC1N 3BG, England; [Sander, Josemir W.] Chalfont Ctr Epilepsy, St Peter, Bucks, England; [Sander, Josemir W.] Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands; [Wang, Wenzhi] Beijing Neurosurg Inst, Dept Neu Roepidemiol, Beijing, Peoples R China; [Li, Shichuo] China Assoc Epilepsy, Beijing, Peoples R China	Fudan University; Sichuan University; University College London Hospitals NHS Foundation Trust; University of London; University College London	Sander, JW (corresponding author), NIHR Univ Coll London Hosp Biomed Res Ctr, UCL Queen Sq Inst Neurol, London WC1N 3BG, England.	l.sander@ucl.ac.uk	Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661				Alsharafi WA, 2016, EPILEPSIA, V57, P1931, DOI 10.1111/epi.13568; [Anonymous], REC MAN PEOPL EP COV; Baker GA, 2002, EPILEPSIA, V43, P26, DOI 10.1046/j.1528-1157.43.s.6.12.x; Beghi E, 2019, LANCET NEUROL, V18, P357, DOI 10.1016/S1474-4422(18)30454-X; Cen ZD, 2018, BRAIN, V141, P2280, DOI 10.1093/brain/awy160; Charlson FJ, 2016, LANCET, V388, P1984, DOI 10.1016/S0140-6736(16)30590-6; Chen BY, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00495; Chen C, 2019, EPILEPSIA, V60, P121, DOI 10.1111/epi.14614; Chen T, 2019, BRAIN RES BULL, V144, P187, DOI 10.1016/j.brainresbull.2018.11.001; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; Cheng DZ, 2017, PEDIATR NEUROL, V72, P36, DOI 10.1016/j.pediatrneurol.2016.12.005; Cheung YK, 2013, EPILEPSIA, V54, P1307, DOI 10.1111/epi.12217; Chi YJ, 2017, BRAIN RES BULL, V134, P273, DOI 10.1016/j.brainresbull.2017.08.010; China Association Against Epilepsy, EP CAR 5G ER 14 6 28; China Association Against Epilepsy, 2015, GUID CLIN DIAGN TREA; China Association Against Epilepsy, 2007, GUID CLIN DIAGN TREA; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Covanis A, 2015, EPILEPSIA, V56, P1651, DOI 10.1111/epi.13192; Davagnanam I, 2020, NEUROLOGY, V95, pE1236, DOI 10.1212/WNL.0000000000010171; Ding D, 2008, EPILEPSIA, V49, P535, DOI 10.1111/j.1528-1167.2007.01529_2.x; Ding D, 2006, LANCET NEUROL, V5, P823, DOI 10.1016/S1474-4422(06)70528-2; Ding D, 2013, EPILEPSIA, V54, P512, DOI 10.1111/epi.12048; Ding D, 2012, J NEUROL NEUROSUR PS, V83, P1139, DOI 10.1136/jnnp-2012-303042; Du XN, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-62; Gao L, 2015, EPILEPSY RES, V110, P146, DOI 10.1016/j.eplepsyres.2014.12.001; Ge Y, 2020, J NEUROL NEUROSUR PS, V91, P126, DOI 10.1136/jnnp-2019-321983; Ge Y, 2017, EPILEPSY BEHAV, V76, P76, DOI 10.1016/j.yebeh.2017.08.024; Ge Y, 2015, EPILEPSY RES, V116, P99, DOI 10.1016/j.eplepsyres.2015.07.006; Gui H, 2018, PHARMACOGENOMICS J, V18, P340, DOI 10.1038/tpj.2017.11; Guo WC, 2012, EPILEPSY BEHAV, V25, P282, DOI 10.1016/j.yebeh.2012.08.013; Guo YL, 2012, HUM MOL GENET, V21, P1184, DOI 10.1093/hmg/ddr550; Hao XT, 2020, EPILEPSIA, V61, P1166, DOI 10.1111/epi.16544; Hao XT, 2017, CNS DRUGS, V31, P237, DOI 10.1007/s40263-016-0397-5; He XJ., EPILEPSIA; Hong Z, CHIN J CLIN NEUROSCI; Hong Z, 2013, EPILEPSY BEHAV, V29, P457, DOI 10.1016/j.yebeh.2013.07.028; [胡湘蜀 Hu Xiangshu], 2012, [中华神经科杂志, Chinese Journal of Neurology], V45, P244; Huang SS, 2020, EPILEPSIA, V61, P1884, DOI 10.1111/epi.16635; International Bureau for Epilepsy, 2005, INT BUR EP ANN REP 2; Jiang YB, 2014, EPILEPSY BEHAV, V37, P139, DOI 10.1016/j.yebeh.2014.06.005; Jiang YW, 2012, HUM GENET, V131, P1217, DOI 10.1007/s00439-012-1149-3; Jin HB, 2016, SEIZURE-EUR J EPILEP, V37, P1, DOI 10.1016/j.seizure.2016.01.018; Kwan P, 2004, EPILEPSIA, V45, P1141, DOI 10.1111/j.0013-9580.2004.12704.x; Kwan P, 2008, PHARMACOGENET GENOM, V18, P989, DOI 10.1097/FPC.0b013e3283117d67; Kwan P, 2013, EPILEPSIA, V54, P537, DOI 10.1111/epi.12022; Kwan P, 2009, EPILEPSIA, V50, P1059, DOI 10.1111/j.1528-1167.2008.01938.x; Li BM, 2013, EXP THER MED, V5, P611, DOI 10.3892/etm.2012.823; Li C, 2010, EPILEPSIA, V51, P391, DOI 10.1111/j.1528-1167.2009.02270.x; Li S, 2015, J EPILEPSY, V7, P2; LI SC, 1985, EPILEPSIA, V26, P391, DOI 10.1111/j.1528-1157.1985.tb05669.x; Li SC, 2015, EPILEPSIA, V56, P1658, DOI 10.1111/epi.13208; Li SC, 2010, EPILEPSY BEHAV, V17, P242, DOI 10.1016/j.yebeh.2009.12.015; Liao WP, 2010, EPILEPSIA, V51, P1669, DOI 10.1111/j.1528-1167.2010.02645.x; Liu JM, 2013, EPILEPSY RES, V103, P288, DOI 10.1016/j.eplepsyres.2012.07.015; Liu SY, 2020, BRAIN, V143, P570, DOI 10.1093/brain/awz411; Long LL, 2016, EPILEPSIA, V57, P941, DOI 10.1111/epi.13372; Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524; Luan G, 2018, AES CAAE JOINT FOR N; Ma HY, 2018, EPILEPSIA, V59, P1621, DOI 10.1111/epi.14511; Ma TMK, 2010, SEIZURE-EUR J EPILEP, V19, P493, DOI 10.1016/j.seizure.2010.07.006; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Medical Doctor Association Neurology Branch, 2015, WHIT PAP INV PRACT N; Meng FG, 2015, CHINESE MED J-PEKING, V128, P2599, DOI 10.4103/0366-6999.166023; Mu J, 2011, NEUROLOGY, V77, P132, DOI 10.1212/WNL.0b013e318223c784; National Bureau of Statistics, 2018, CHIN STAT YB; National Center for Healthcare Quality Management in Neurological Diseases, 2018, HEALTHC QUAL REP DEP; National Health Commission, 2018, NAT MED SERV QUAL SA; Poo MM, 2016, NEURON, V92, P591, DOI 10.1016/j.neuron.2016.10.050; Shi YW, 2019, BRAIN, V142, P3028, DOI 10.1093/brain/awz250; Shi YW, 2017, NEUROLOGY, V88, P2183, DOI [10.1212/wnl.0000000000004008, 10.1212/WNL.0000000000004008]; Si Y, 2016, EPILEPSIA, V57, pE117, DOI 10.1111/epi.13395; Si Y, 2016, EPILEPSY BEHAV, V54, P65, DOI 10.1016/j.yebeh.2015.11.007; Sun W, 2012, EPILEPSIA, V53, P1782, DOI 10.1111/j.1528-1167.2012.03626.x; Tang Y., 2019, J EPILEPSY, V5, P161; Tao LH, 2018, EPILEPSY BEHAV, V85, P150, DOI 10.1016/j.yebeh.2018.06.003; Tong X, 2019, EPILEPSIA, V60, P246, DOI 10.1111/epi.14646; Wang B, 2015, ZHONGGUO WEISHENG JI, V34, P65; Wang D, 2016, EPILEPSIA, V57, P706, DOI 10.1111/epi.13348; Wang M., J NEUROL NEUROSURG P; Wang WZ, 2008, B WORLD HEALTH ORGAN, V86, P964, DOI 10.2471/BLT.07.047050; Wang WZ, 2006, LANCET NEUROL, V5, P46, DOI 10.1016/S1474-4422(05)70254-4; Wang WZ, 2003, NEUROLOGY, V60, P1544, DOI 10.1212/01.WNL.0000059867.35547.DE; [王学峰 Wang Xuefeng], 2004, [中华神经科杂志, Chinese Journal of Neurology], V37, P495; Wu DY, 2010, EPILEPSY RES, V90, P16, DOI 10.1016/j.eplepsyres.2010.03.001; Wu XT, 2010, EPILEPSY BEHAV, V19, P405, DOI 10.1016/j.yebeh.2010.08.007; Wu XQ, 2018, EPILEPSIA, V59, P1655, DOI 10.1111/epi.14533; Xiao FL, 2016, NEUROLOGY, V86, P544, DOI 10.1212/WNL.0000000000002358; Xiao Z, 2020, ACTA EPILEPTOL, V2, P19; Xiong WX, 2020, NEUROLOGY, V95, pE1479, DOI 10.1212/WNL.0000000000010034; Xu LS, 2010, EUR J NEUROL, V17, P189, DOI 10.1111/j.1468-1331.2009.02871.x; Xu XJ, 2015, HUM MUTAT, V36, P861, DOI 10.1002/humu.22819; Xu XJ., ZHONGHUA YI XUE ZA Z; Yang AC, 2016, EPILEPSIA, V57, P1369, DOI 10.1111/epi.13469; Yang L., 1989, CHIN J NEUROSURGERY, V5, P22; Yang TH, 2013, HUM BRAIN MAPP, V34, P1761, DOI 10.1002/hbm.22025; Yong L, 2006, ACTA NEUROL SCAND, V113, P167, DOI 10.1111/j.1600-0404.2005.00567.x; Yu PM, 2009, EPILEPSY BEHAV, V16, P99, DOI 10.1016/j.yebeh.2009.06.013; Yu PM, 2017, EPILEPSY BEHAV, V69, P126, DOI 10.1016/j.yebeh.2016.09.021; Yu T, 2018, BRAIN, V141, P2631, DOI 10.1093/brain/awy187; Yue L, 2011, EPILEPSY BEHAV, V22, P692, DOI 10.1016/j.yebeh.2011.08.022; Zeng S, 2019, J MED GENET, V56, P265, DOI 10.1136/jmedgenet-2018-105484; Zhang WW, 2016, SEIZURE-EUR J EPILEP, V39, P19, DOI 10.1016/j.seizure.2016.05.002; Zhang ZQ, 2011, BRAIN, V134, P2912, DOI 10.1093/brain/awr223; Zhao YH, 2008, EPILEPSY BEHAV, V12, P373, DOI 10.1016/j.yebeh.2007.10.012; Zhou D, 2017, J EPILEPSY, V3, P1; Zhu DT, 1998, EPILEPSIA, V39, P1208, DOI 10.1111/j.1528-1157.1998.tb01313.x; Zou XM, 2014, EPILEPSY BEHAV, V31, P129, DOI 10.1016/j.yebeh.2013.11.028	108	24	26	25	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					316	326		10.1016/S1474-4422(21)00023-5	http://dx.doi.org/10.1016/S1474-4422(21)00023-5			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743240	Green Submitted			2022-12-18	WOS:000630325700022
J	Kompanje, EJO; van Dijck, JTJM; Chalos, V; van den Berg, SA; Janssen, PM; Nederkoorn, PJ; van der Jagt, M; Citerio, G; Stocchetti, N; Dippel, DWJ; Peul, WC				Kompanje, Erwin J. O.; van Dijck, Jeroen T. J. M.; Chalos, Vicky; van den Berg, Sophie A.; Janssen, Paula M.; Nederkoorn, Paul J.; van der Jagt, Mathieu; Citerio, Giuseppe; Stocchetti, Nino; Dippel, Diederik W. J.; Peul, Wilco C.			Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke	LANCET NEUROLOGY			English	Article							SURROGATE DECISION-MAKERS; DEFERRED CONSENT; COMMUNITY CONSULTATION; CAPACITY ASSESSMENT; CARE RESEARCH; MINIMAL-RISK; TRIAL; ENROLLMENT; THROMBOLYSIS; PERSPECTIVES	Health-care professionals and researchers have a legal and ethical responsibility to inform patients before carrying out diagnostic tests or treatment interventions as part of a clinical study. Interventional research in emergency situations can involve patients with some degree of acute cognitive impairment, as is regularly the case in traumatic brain injury and ischaemic stroke. These patients or their proxies are often unable to provide informed consent within narrow therapeutic time windows. International regulations and national laws are criticised for being inconclusive or restrictive in providing solutions. Currently accepted consent alternatives are deferred consent, exception from consent, or waiver of consent. However, these alternatives appear under-utilised despite being ethically permissible, socially acceptable, and regulatorily compliant. We anticipate that, when the requirements for medical urgency are properly balanced with legal and ethical conduct, the increased use of these alternatives has the potential to improve the efficiency and quality of future emergency interventional studies in patients with an inability to provide informed consent.	[Chalos, Vicky] Univ Med Ctr, Erasmus Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Chalos, Vicky; van den Berg, Sophie A.; Janssen, Paula M.; Dippel, Diederik W. J.] Univ Med Ctr, Erasmus Med Ctr, Dept Neurol, Rotterdam, Netherlands; [Chalos, Vicky] Univ Med Ctr, Erasmus Med Ctr, Dept Radiol & Nucl Sci, Rotterdam, Netherlands; [Kompanje, Erwin J. O.; van der Jagt, Mathieu] Univ Med Ctr, Erasmus Med Ctr, Dept Intens Care Adult, NL-3015 GD Rotterdam, Netherlands; [Kompanje, Erwin J. O.] Erasmus Univ, Dept Eth & Philosophy Med, Rotterdam, Netherlands; [van Dijck, Jeroen T. J. M.; Peul, Wilco C.] Leiden Univ, Univ Neurosurg Ctr Holland, Med Ctr, Haaglanden Med Ctr, Leiden, Netherlands; [van Dijck, Jeroen T. J. M.; Peul, Wilco C.] Haga Teaching Hosp, The Hague, Netherlands; [van den Berg, Sophie A.; Nederkoorn, Paul J.] Amsterdam UMC, Dept Neurol, Amsterdam, Netherlands; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] Ca Grande Osped Maggiore Polklin Milano, Fdn Erasmus Med Ctr, Neuro Intens Care Unit, Milan, Italy	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Haaglanden Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Haga Hospital; University of Amsterdam; Vrije Universiteit Amsterdam; University of Milano-Bicocca; University of Milan	Kompanje, EJO (corresponding author), Univ Med Ctr, Erasmus Med Ctr, Dept Intens Care Adult, NL-3015 GD Rotterdam, Netherlands.	e.j.o.kompanje@erasmusmc.nl	van Dijck, Jeroen/AAM-4123-2021; van der Jagt, Mathieu/G-1905-2017	van Dijck, Jeroen/0000-0002-9893-632X; van der Jagt, Mathieu/0000-0003-2566-8325; Dippel, Diederik/0000-0002-9234-3515; Janssen, Paula/0000-0002-2673-8543	European Union seventh Framework Program; Hersenstichting Nederland (Dutch Brain Foundation); CONTRAST consortium: Netherlands Cardiovascular Research Initiative; Brain Foundation Netherlands; Health Holland; Top Sector Life Sciences; Medtronic; Cerenovus; Dutch Heart Foundation	European Union seventh Framework Program(European Commission); Hersenstichting Nederland (Dutch Brain Foundation); CONTRAST consortium: Netherlands Cardiovascular Research Initiative; Brain Foundation Netherlands; Health Holland; Top Sector Life Sciences; Medtronic(Medtronic); Cerenovus; Dutch Heart Foundation(Netherlands Heart Foundation)	We thank The European Union seventh Framework Program for funding the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI), and the Hersenstichting Nederland (Dutch Brain Foundation) for funding the Neurotraumatology Quality Registry (Net-QuRe). We also thank the funders of the CONTRAST consortium: Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation, the Brain Foundation Netherlands, Health Holland, Top Sector Life Sciences, Medtronic, and Cerenovus. Funders had no involvement in the study design, the collection, analysis and interpretation of data, the writing of this personal view, and the decision to submit the paper for publication.	Ali M, 2015, INT J STROKE, V10, P400, DOI 10.1111/ijs.12067; [Anonymous], 2016, INT ETH GUID HLTH RE; Barrett KA, 2012, INTENS CARE MED, V38, P1616, DOI 10.1007/s00134-012-2625-x; Berge E, 2016, INT J STROKE, V11, P663, DOI 10.1177/1747493016641963; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Bruni T, 2019, J MED ETHICS, V45, P299, DOI 10.1136/medethics-2018-104867; Bryant J, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-18; Burns KEA, 2017, ANN AM THORAC SOC, V14, P238, DOI 10.1513/AnnalsATS.201606-425OC; Burns KEA, 2013, AM J RESP CRIT CARE, V187, P1212, DOI 10.1164/rccm.201208-1537OC; Campbell BCV, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0118-8; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Devnani R, 2017, J GEN INTERN MED, V32, P1285, DOI 10.1007/s11606-017-4158-z; Dickert NW, 2017, AM J BIOETHICS, V17, P3, DOI 10.1080/15265161.2017.1388448; Dickert NW, 2015, CRIT CARE MED, V43, P603, DOI 10.1097/CCM.0000000000000747; Ecarnot F, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.04.42; Eltorki M, 2013, ACAD EMERG MED, V20, P822, DOI 10.1111/acem.12180; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Eubank L, 2018, RESUSCITATION, V130, P81, DOI 10.1016/j.resuscitation.2018.06.031; Fehr AE, 2015, ANN EMERG MED, V65, P162, DOI 10.1016/j.annemergmed.2014.06.023; Feldman WB, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7591; Feng KL, 2014, STROKE, V45, pE229, DOI 10.1161/STROKEAHA.114.006395; Fransen PSS, 2016, JAMA NEUROL, V73, P190, DOI 10.1001/jamaneurol.2015.3886; Furyk J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018562; Goldstein CE, 2018, BMC MED ETHICS, V19, DOI 10.1186/s12910-018-0253-x; Gomez CR, 2018, J STROKE CEREBROVASC, V27, P2214, DOI 10.1016/j.jstrokecerebrovasdis.2018.04.001; Grady C, 2017, NEW ENGL J MED, V376, P856, DOI 10.1056/NEJMra1603773; Harron K, 2015, PEDIATRICS, V136, pE1316, DOI 10.1542/peds.2015-0512; Harvin JA, 2019, J SURG RES, V234, P65, DOI 10.1016/j.jss.2018.09.007; Haussen DC, 2020, J NEUROINTERV SURG, V12, P483, DOI 10.1136/neurintsurg-2019-015283; Honarmand K, 2018, J INTENSIVE CARE MED, V33, P475, DOI 10.1177/0885066616680772; Hotter B, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0989-9; Hwang DY, 2020, NEUROLOGY, V94, pE2054, DOI 10.1212/WNL.0000000000009406; Jansen TC, 2007, INTENS CARE MED, V33, P894, DOI 10.1007/s00134-007-0580-8; Jansen TC, 2010, INTENS CARE MED, V36, P1962, DOI 10.1007/s00134-010-1988-0; Jansen TG, 2009, CRIT CARE MED, V37, pS65, DOI 10.1097/CCM.0b013e3181920851; Janssen PM, 2019, J STROKE CEREBROVASC, V28, DOI 10.1016/j.jstrokecerebrovasdis.2019.104447; Johnson LR, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4609; Johnson-Greene D, 2010, J HEAD TRAUMA REHAB, V25, P145, DOI 10.1097/HTR.0b013e3181d8287d; Kim DH, 2016, STROKE, V47, P232, DOI 10.1161/STROKEAHA.115.011687; Klein L, 2018, ACAD EMERG MED, V25, P1169, DOI 10.1111/acem.13438; Kompanje EJO, 2014, INTENS CARE MED, V40, P496, DOI 10.1007/s00134-014-3243-6; Long Bronwyn, 2011, J Trauma Nurs, V18, P204, DOI 10.1097/JTN.0b013e31823a453a; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Majersik JJ, 2019, CURR CARDIOL REP, V21, DOI 10.1007/s11886-019-1139-3; Mehta S, 2012, INTENS CARE MED, V38, P47, DOI 10.1007/s00134-011-2411-1; Mendelson SJ, 2018, NEUROLOGY, V90, pE359, DOI 10.1212/WNL.0000000000004905; Mendyk AM, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0018-8; Mohamadpour M, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00007; Mulder MJHL, 2018, CIRCULATION, V138, P232, DOI 10.1161/CIRCULATIONAHA.117.032600; Newman JT, 2012, CRIT CARE MED, V40, P2590, DOI 10.1097/CCM.0b013e318258ff19; Post R, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4118-5; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Rebers S, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0092-6; Roberts I, 2019, LANCET, V394, P1713, DOI 10.1016/S0140-6736(19)32233-0; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Shamy MCF, 2019, STROKE, V50, P1017, DOI 10.1161/STROKEAHA.118.024096; Shepherd V, 2019, AGE AGEING, V48, P903, DOI 10.1093/ageing/afz115; Shoirah H, 2019, J STROKE CEREBROVASC, V28, P1926, DOI 10.1016/j.jstrokecerebrovasdis.2019.03.046; Stanley RM, 2017, ACAD EMERG MED, V24, P31, DOI 10.1111/acem.13085; Terry MA, 2017, CRIT CARE MED, V45, P1450, DOI 10.1097/CCM.0000000000002539; Thomalla G, 2017, NEUROLOGY, V89, P1400, DOI 10.1212/WNL.0000000000004414; Topolovec-Vranic J, 2014, CAN RESPIR J, V21, P293, DOI 10.1155/2014/719270; United States Department of Health and Human Services, 2013, GUID I REV BOARDS CL; van Belle G, 2015, RESUSCITATION, V91, P76, DOI 10.1016/j.resuscitation.2014.11.029; van Wijk RPJ, 2020, J CRIT CARE, V59, P6, DOI 10.1016/j.jcrc.2020.05.004; Whitesides LW, 2017, CLIN TRIALS, V14, P180, DOI 10.1177/1740774516677276; Wolf SM, 2018, J LAW MED ETHICS, V46, P7, DOI 10.1177/1073110518766003; Woolfall K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008522; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Zinkstok SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166668	70	24	24	2	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					1033	1042		10.1016/S1474-4422(20)30276-3	http://dx.doi.org/10.1016/S1474-4422(20)30276-3			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	PG3EL	33098755	Green Published			2022-12-18	WOS:000599622000020
J	Lauwers, E; Lalli, G; Brandner, S; Collinge, J; Compernolle, V; Duyckaerts, C; Edgren, G; Haik, S; Hardy, J; Helmy, A; Ivinson, AJ; Jaunmuktane, Z; Jucker, M; Knight, R; Lemmens, R; Lin, IC; Love, S; Mead, S; Perry, VH; Pickett, J; Poppy, G; Radford, SE; Rousseau, F; Routledge, C; Schiavo, G; Schymkowitz, J; Selkoe, DJ; Smith, C; Thal, DR; Theys, T; Tiberghien, P; van den Burg, P; Vandekerckhove, P; Walton, C; Zaaijer, HL; Zetterberg, H; De Strooper, B				Lauwers, Elsa; Lalli, Giovanna; Brandner, Sebastian; Collinge, John; Compernolle, Veerle; Duyckaerts, Charles; Edgren, Gustaf; Haik, Stephane; Hardy, John; Helmy, Adel; Ivinson, Adrian J.; Jaunmuktane, Zane; Jucker, Mathias; Knight, Richard; Lemmens, Robin; Lin, I-Chun; Love, Seth; Mead, Simon; Perry, V. Hugh; Pickett, James; Poppy, Guy; Radford, Sheena E.; Rousseau, Frederic; Routledge, Carol; Schiavo, Giampietro; Schymkowitz, Joost; Selkoe, Dennis J.; Smith, Colin; Thal, Dietmar R.; Theys, Tom; Tiberghien, Pierre; van den Burg, Peter; Vandekerckhove, Philippe; Walton, Clare; Zaaijer, Hans L.; Zetterberg, Henrik; De Strooper, Bart			Potential human transmission of amyloid beta pathology: surveillance and risks	LANCET NEUROLOGY			English	Article							CREUTZFELDT-JAKOB-DISEASE; DURA-MATER; BLOOD-TRANSFUSION; GROWTH-HORMONE; PRION; ANGIOPATHY; PROTEIN; NEURODEGENERATION; ASSOCIATION; ALZHEIMERS	Studies in experimental animals show transmissibility of amyloidogenic proteins associated with prion diseases, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Although these data raise potential concerns for public health, convincing evidence for human iatrogenic transmission only exists for prions and amyloid beta after systemic injections of contaminated growth hormone extracts or dura mater grafts derived from cadavers. Even though these procedures are now obsolete, some reports raise the possibility of iatrogenic transmission of amyloid beta through putatively contaminated neurosurgical equipment. Iatrogenic transmission of amyloid beta might lead to amyloid deposition in the brain parenchyma and blood vessel walls, potentially resulting in cerebral amyloid angiopathy after several decades. Cerebral amyloid angiopathy can cause life-threatening brain haemorrhages; yet, there is no proof that the transmission of amyloid can also lead to Alzheimer's dementia. Large, long-term epidemiological studies and sensitive, cost-efficient tools to detect amyloid are needed to better understand any potential routes of amyloid beta transmission and to clarify whether other similar proteopathic seeds, such as tau or alpha-synuclein, can also be transferred iatrogenically.	[Lauwers, Elsa; Lemmens, Robin; Rousseau, Frederic; Schymkowitz, Joost; De Strooper, Bart] Katholieke Univ Leuven, VIB KU Leuven Ctr Brain & Dis Res, Leuven, Belgium; [Lauwers, Elsa; Lemmens, Robin; De Strooper, Bart] Katholieke Univ Leuven, Dept Neurosci, Leuven Brain Inst, Leuven, Belgium; [Rousseau, Frederic; Schymkowitz, Joost] Katholieke Univ Leuven, Dept Cellular & Mol Med, Leuven, Belgium; [Thal, Dietmar R.] Katholieke Univ Leuven, Dept Imaging & Pathol, Leuven, Belgium; [Vandekerckhove, Philippe] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Lalli, Giovanna; Hardy, John; Ivinson, Adrian J.; Lin, I-Chun; Perry, V. Hugh; Schiavo, Giampietro; Zetterberg, Henrik; De Strooper, Bart] UCL, UK Dementia Res Inst, London WC1E 6BT, England; [Brandner, Sebastian; Hardy, John; Zetterberg, Henrik] UCL, Dept Neurodegenerat Dis, UCL Queen Sq Inst Neurol, London, England; [Collinge, John; Mead, Simon] UCL, Med Res Council, Prion Unit, UCL,Inst Prion Dis, London, England; [Hardy, John] UCL, Reta Lila Weston Inst, UCL Queen Sq Inst Neurol, London, England; [Jaunmuktane, Zane] UCL, Dept Clin & Movement Neurosci, UCL Queen Sq Inst Neurol, London, England; [Jaunmuktane, Zane] UCL, Queen Sq Brain Bank Neurol Disorders, Queen Sq Inst Neurol, London, England; [Schiavo, Giampietro] UCL, Dept Neuromuscular Disorders, UCL Queen Sq Inst Neurol, London, England; [Brandner, Sebastian; Jaunmuktane, Zane] Univ Coll London Natl Hlth Serv Fdn Trust, Div Neuropathol, Natl Hosp Neurol & Neurosurg, London, England; [Compernolle, Veerle; Vandekerckhove, Philippe] Belgian Red Cross Flanders, Blood Serv, Mechelen, Belgium; [Compernolle, Veerle] Univ Ghent, Fac Med & Hlth Sci, Ghent, Belgium; [Duyckaerts, Charles; Haik, Stephane] Sorbonne Univ, Inst Cerveau & Moelle Epiniere, CNRS UMR, INSERM, Paris, France; [Duyckaerts, Charles; Haik, Stephane] Hop La Pitie Salpetriere, AP HP, Lab Neuropathol Raymond Escourolle, Paris, France; [Haik, Stephane] Hop La Pitie Salpetriere, AP HP, Cellule Natl Reference Malad Creutzfeldt Jakob, Paris, France; [Edgren, Gustaf] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden; [Edgren, Gustaf] Soder Sjukhuset, Dept Cardiol, Stockholm, Sweden; [Hardy, John] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Hardy, John] Hong Kong Univ Sci & Technol, Inst Adv Study, Hong Kong, Peoples R China; [Helmy, Adel] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Jucker, Mathias] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Jucker, Mathias] Ctr Neurodegenerat Dis, Tubingen, Germany; [Knight, Richard; Smith, Colin] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Knight, Richard] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Knight, Richard] Western Gen Hosp, Natl Creutzfeldt Jakob Dis Res & Surveillance Uni, Edinburgh, Midlothian, Scotland; [Lemmens, Robin] Univ Hosp Leuven, Dept Neurol, Leuven, Belgium; [Thal, Dietmar R.] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium; [Theys, Tom] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium; [Love, Seth] Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol, Avon, England; [Pickett, James; Walton, Clare] Alzheimers Soc, London, England; [Pickett, James] Epilepsy Res UK, London, England; [Poppy, Guy] Univ Southampton, Biol Sci, Southampton, Hants, England; [Radford, Sheena E.] Univ Leeds, Astbury Ctr Struct Mol Biol, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England; [Routledge, Carol] Alzheimers Res UK, Cambridge, England; [Selkoe, Dennis J.] Brigham & Womens Hosp, Dept Neurol, Ann Romney Ctr Neurol Dis, Boston, MA USA; [Selkoe, Dennis J.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA; [Tiberghien, Pierre] Etab Francais Sang, La Plaine St Denis, France; [Tiberghien, Pierre] Univ Franche Comte, Unite Mixte Rech, INSERM, Besancon, France; [van den Burg, Peter] European Blood Alliance, Brussels, Belgium; [van den Burg, Peter] Sanquin, Dept Transfus Med, Amsterdam, Netherlands; [Zaaijer, Hans L.] Sanquin, Dept Blood Borne Infect, Amsterdam, Netherlands; [Walton, Clare] Multiple Sclerosis Int Federat, London, England; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Clin Neurochem Lab, Gothenburg, Sweden	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven; KU Leuven; KU Leuven; University of London; University College London; University of London; University College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Ghent University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Karolinska Institutet; Sodersjukhuset Hospital; University College London Hospitals NHS Foundation Trust; University of London; University College London; Hong Kong University of Science & Technology; University of Cambridge; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Edinburgh; University of Edinburgh; University of Edinburgh; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; University of Bristol; University of Southampton; University of Leeds; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; University of Gothenburg; University of Gothenburg	De Strooper, B (corresponding author), UCL, UK Dementia Res Inst, London WC1E 6BT, England.	b.strooper@ukdri.ucl.ac.uk	Helmy, Adel/AAS-3084-2020; Tiberghien, Pierre/AAH-5878-2019; Hardy, John/C-2451-2009; Schymkowitz, Joost/AAV-3680-2021; Brandner, Sebastian/J-4562-2014; Thal, Dietmar R/O-7483-2018; Edgren, Gustaf/F-4013-2014	Helmy, Adel/0000-0002-0531-0556; Hardy, John/0000-0002-3122-0423; Brandner, Sebastian/0000-0002-9821-0342; Thal, Dietmar R/0000-0002-1036-1075; Theys, Tom/0000-0001-7595-3234; Tiberghien, Pierre/0000-0002-9310-8322; Edgren, Gustaf/0000-0002-2198-4745; Love, Seth/0000-0001-8683-3625; De Strooper, Bart/0000-0001-5455-5819; Radford, Sheena/0000-0002-3079-8039; Lauwers, Elsa/0000-0002-0283-1911; Mead, Simon/0000-0002-4326-1468	UK Dementia Research Institute (UK Medical Research Council); UK Dementia Research Institute (Alzheimer's Society); UK Dementia Research Institute (Alzheimer's Research UK); Belgian Red Cross; European Blood Alliance; Institut du Cerveau et de la Moelle Epiniere; Mission Lucidity; MRC [MC_UU_00024/1, UKDRI-1009, MC_U123160657, MR/L016400/1, UKDRI-1003, UKDRI-1004, MC_U123160651, G0701075, G0901254, UKDRI-1005, G0400713, MC_UU_00024/8, MC_UU_00024/9, MC_UP_1604/1, MR/N026004/1] Funding Source: UKRI; Medical Research Council [MC_U123160651, MC_UU_00024/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0617-10175] Funding Source: researchfish	UK Dementia Research Institute (UK Medical Research Council)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Dementia Research Institute (Alzheimer's Society); UK Dementia Research Institute (Alzheimer's Research UK); Belgian Red Cross; European Blood Alliance; Institut du Cerveau et de la Moelle Epiniere; Mission Lucidity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	We thank the UK Dementia Research Institute (which receives funding from the UK Medical Research Council, the Alzheimer's Society, and Alzheimer's Research UK), the Belgian Red Cross, the European Blood Alliance, the Institut du Cerveau et de la Moelle Epiniere, and Mission Lucidity for co-organising and funding the Amyloid Transmissibility Workshop that was held in London, UK, on Oct 7-8, 2019, and led to the present Personal View.	Aguzzi A, 2009, NATURE, V459, P924, DOI 10.1038/459924a; Banerjee G, 2019, ANN NEUROL, V85, P284, DOI 10.1002/ana.25407; Belondrade M, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00649-19; Benson MD, 2018, AMYLOID, V25, P215, DOI 10.1080/13506129.2018.1549825; Bougard D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1257; Brooke FJ, 2004, MED J AUSTRALIA, V180, P177, DOI 10.5694/j.1326-5377.2004.tb05863.x; Bu X-L, 2018, Mol Psychiatry, V23, P1948, DOI 10.1038/mp.2017.204; Burwinkel M, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0511-7; Cali I, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-017-0503-z; Chiti F, 2017, ANNU REV BIOCHEM, V86, P27, DOI 10.1146/annurev-biochem-061516-045115; Collinge J, 2016, NATURE, V539, P217, DOI 10.1038/nature20415; Collinge J, 2006, LANCET, V367, P2068, DOI 10.1016/S0140-6736(06)68930-7; Corbett GT, 2020, ACTA NEUROPATHOL, V139, P503, DOI 10.1007/s00401-019-02114-9; Darby SC, 2007, BLOOD, V110, P815, DOI 10.1182/blood-2006-10-050435; Duyckaerts C, 2019, CURR OPIN NEUROL, V32, P266, DOI 10.1097/WCO.0000000000000672; Duyckaerts C, 2018, ACTA NEUROPATHOL, V135, P201, DOI 10.1007/s00401-017-1791-x; Edgren G, 2016, ANN INTERN MED, V165, P316, DOI 10.7326/M15-2421; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Eisele YS, 2009, P NATL ACAD SCI USA, V106, P12926, DOI 10.1073/pnas.0903200106; Erana H, 2019, PRION, V13, P41, DOI 10.1080/19336896.2019.1569451; Fairfoul G, 2016, ANN CLIN TRANSL NEUR, V3, P812, DOI 10.1002/acn3.338; Fernandez-Bellot E, 2001, CELL MOL LIFE SCI, V58, P1857, DOI 10.1007/PL00000823; Frontzek K, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14287; Gallardo R, 2020, CURR OPIN STRUC BIOL, V60, P7, DOI 10.1016/j.sbi.2019.09.001; Giaccone G, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0719-1; Gomes LA, 2019, ACTA NEUROPATHOL, V138, P913, DOI 10.1007/s00401-019-02053-5; Hamaguchi T, 2019, J NEUROL SCI, V399, P3, DOI 10.1016/j.jns.2019.01.051; Hamaguchi T, 2016, ACTA NEUROPATHOL, V132, P313, DOI 10.1007/s00401-016-1588-3; Harbi D, 2014, PRION, V8, P161, DOI 10.4161/pri.27960; Heckmann JG, 1997, J NEUROL NEUROSUR PS, V63, P388, DOI 10.1136/jnnp.63.3.388; Herve D, 2018, ACTA NEUROPATHOL, V135, P801, DOI 10.1007/s00401-018-1828-9; Holmqvist J, 2020, TRANSFUSION, V60, P694, DOI 10.1111/trf.15751; Ironside JW, 2018, HAND CLINIC, V145, P393, DOI 10.1016/B978-0-12-802395-2.00028-6; Irwin DJ, 2013, JAMA NEUROL, V70, P462, DOI 10.1001/jamaneurol.2013.1933; Iwasaki Y, 2018, NEUROPATHOLOGY, V38, P549, DOI 10.1111/neup.12503; Jaunmuktane Z, 2019, DIAGN HISTOPATHOL, V25, P16, DOI [10.1016/j.mpdhp.2018.11.002, DOI 10.1016/J.MPDHP.2018.11.002]; Jaunmuktane Z, 2018, ACTA NEUROPATHOL, V135, P671, DOI 10.1007/s00401-018-1822-2; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Jucker M, 2018, NAT NEUROSCI, V21, P1341, DOI 10.1038/s41593-018-0238-6; Khodaparast L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03131-0; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P911, DOI 10.1007/s00401-016-1565-x; Kraus A, 2019, ACTA NEUROPATHOL, V137, P585, DOI 10.1007/s00401-018-1947-3; Li DN, 2019, NEUROL THER, V8, pS73, DOI 10.1007/s40120-019-00164-5; Lyon A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41055-x; Mahul-Mellier AL, 2020, P NATL ACAD SCI USA, V117, P4971, DOI 10.1073/pnas.1913904117; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; McAlary L, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00262; McDade E, 2017, NATURE, V547, P153, DOI 10.1038/547153a; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Nakayashiki T, 2001, MOL CELL, V7, P1121, DOI 10.1016/S1097-2765(01)00259-3; Nicot S, 2019, FASEB J, V33, P12073, DOI 10.1096/fj.201900354R; Orru CD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7785; Prince M., 2015, WORLD ALZHEIMER REPO, DOI DOI 10.1111/j.0963-7214.2004.00293.x; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Purro SA, 2018, NATURE, V564, P415, DOI 10.1038/s41586-018-0790-y; Ranke MB, 2018, NAT REV ENDOCRINOL, V14, P285, DOI 10.1038/nrendo.2018.22; Raposo N, 2020, J NEUROL NEUROSUR PS, V91, P440, DOI 10.1136/jnnp-2019-321927; Rasmussen J, 2018, ACTA NEUROPATHOL, V135, P965, DOI 10.1007/s00401-018-1848-5; Ritchie DL, 2017, ACTA NEUROPATHOL, V134, P221, DOI 10.1007/s00401-017-1703-0; Saijo E, 2020, ACTA NEUROPATHOL, V139, P63, DOI 10.1007/s00401-019-02080-2; Shahnawaz M, 2020, NATURE, V578, P273, DOI 10.1038/s41586-020-1984-7; Smith A, 2018, J HOSP INFECT, V100, pE70, DOI 10.1016/j.jhin.2018.03.001; Stohr J, 2012, P NATL ACAD SCI USA, V109, P11025, DOI 10.1073/pnas.1206555109; Urwin PJM, 2016, VOX SANG, V110, P310, DOI 10.1111/vox.12371; Vaquer-Alicea J, 2019, ANNU REV BIOCHEM, V88, P785, DOI 10.1146/annurev-biochem-061516-045049; Walker LC, 2015, ANNU REV NEUROSCI, V38, P87, DOI 10.1146/annurev-neuro-071714-033828; Walsh DM, 2016, NAT REV NEUROSCI, V17, P251, DOI 10.1038/nrn.2016.13; Zanusso G, 2016, NAT REV NEUROL, V12, P325, DOI 10.1038/nrneurol.2016.65	68	24	24	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					872	878		10.1016/S1474-4422(20)30238-6	http://dx.doi.org/10.1016/S1474-4422(20)30238-6			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949547	Green Submitted, Green Accepted			2022-12-18	WOS:000581119100024
J	Fassbender, K; Walter, S; Grunwald, IQ; Merzou, F; Mathur, S; Lesmeister, M; Liu, Y; Bertsch, T; Grotto, JC				Fassbender, Klaus; Walter, Silke; Grunwald, Iris Q.; Merzou, Fatma; Mathur, Shrey; Lesmeister, Martin; Liu, Yang; Bertsch, Thomas; Grotto, James C.			Prehospital stroke management in the thrombectomy era	LANCET NEUROLOGY			English	Review							LARGE-VESSEL OCCLUSION; ACUTE ISCHEMIC-STROKE; IN-AMBULANCE TELEMEDICINE; HEALTH-CARE PROFESSIONALS; MIDDLE CEREBRAL-ARTERY; MOBILE STROKE; ENDOVASCULAR THROMBECTOMY; MECHANICAL THROMBECTOMY; SUSPECTED STROKE; EUROPEAN STROKE	Acute stroke management has been revolutionised by evidence of the effectiveness of thrombectomy. Because time is brain in stroke care, the speed with which a patient with large vessel occlusion is transferred to a thrombectomycapable centre determines outcome. Therefore, each link in the stroke rescue chain, starting with symptom onset and ending with recanalisation, should be streamlined. However, in contrast to inhospital delays, prehospital delays are unchanged despite substantial efforts in quality improvement. Furthermore, thrombectomy is offered by only a few, usually distant, specialised centres and not by the many other, usually nearer, hospitals. To take maximum advantage of the first so-called golden hours after stroke, and because of the difficulty of on-scene triage decision making with respect to the target hospital offering the required level of care, the focus of stroke research has shifted to the prehospital setting. Current research focuses on the effects of public education, implementation of protocols for emergency medical services for streamlining clinical investigations and accurate triage, use of preclinical scales for stroke recognition, and deployment of novel technical solutions such as smartphone applications, telemedicine, and mobile stroke units.	[Fassbender, Klaus; Walter, Silke; Merzou, Fatma; Mathur, Shrey; Lesmeister, Martin; Liu, Yang] Saarland Univ, Med Ctr, Dept Neurol, D-66421 Homburg, Germany; [Grunwald, Iris Q.] Anglia Ruskin Univ, Sch Med, Chelmsford, England; [Grunwald, Iris Q.] Univ Dundee, Sch Med, Dundee, Scotland; [Bertsch, Thomas] Paracelsus Med Univ, Lab Med & Transfus Med, Inst Clin Chem, Nurnberg, Germany; [Grotto, James C.] Mem Hermann Hosp, Dept Neurol, Houston, TX USA	Universitatsklinikum des Saarlandes; Anglia Ruskin University; University of Dundee	Fassbender, K (corresponding author), Saarland Univ, Med Ctr, Dept Neurol, D-66421 Homburg, Germany.	klaus.fassbender@uks.eu	Grotta, James/AAH-7423-2021; Grunwald, Iris/AAY-2521-2021; Liu, Yang/GSD-5476-2022; MATHUR, SHREY/K-2098-2016	Grunwald, Iris/0000-0002-3404-7590; Walter, Silke/0000-0002-1176-2911; Fassbender, Klaus/0000-0003-3596-868X; Liu, Yang/0000-0002-7614-4233; Lesmeister, Martin/0000-0001-5228-6483; grotta, james/0000-0002-3667-4248; MATHUR, SHREY/0000-0002-2809-8244				Adeoye O, 2019, STROKE, V50, pE187, DOI 10.1161/STR.0000000000000173; Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Anderson CS, 2017, NEW ENGL J MED, V376, P2437, DOI 10.1056/NEJMoa1615715; Andersson E, 2018, PREHOSP DISASTER MED, V33, P63, DOI 10.1017/S1049023X17007178; Ashkenazi L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000520; Audebert HJ, 2020, INT STROK C LOS ANG; Bath PM, 2019, LANCET, V393, P1009, DOI 10.1016/S0140-6736(19)30194-1; Benoit JL, 2018, PREHOSP EMERG CARE, V22, P722, DOI 10.1080/10903127.2018.1465500; Bergrath S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036796; Brandler ES, 2015, J STROKE CEREBROVASC, V24, P2161, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.004; Brandler ES, 2014, NEUROLOGY, V82, P2241, DOI 10.1212/WNL.0000000000000523; Bray JE, 2015, STROKE, V46, P1377, DOI 10.1161/STROKEAHA.114.008515; Brekenfeld C, 2018, J NEUROINTERV SURG, V10, P932, DOI 10.1136/neurintsurg-2017-013634; de Sousa DA, 2019, EUR STROKE J, V4, P13, DOI 10.1177/2396987318786023; Dickson RL, 2019, PREHOSP EMERG CARE, V23, P612, DOI 10.1080/10903127.2019.1573281; Drenck N, 2019, SCAND J TRAUMA RESUS, V27, DOI 10.1186/s13049-018-0580-4; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Espinoza AV, 2016, CEREBROVASC DIS, V42, P15, DOI 10.1159/000444175; Fassbender K, 2003, STROKE, V34, pE44, DOI 10.1161/01.STR.0000075573.22885.3B; Fassbender K, 2017, LANCET NEUROL, V16, P227, DOI 10.1016/S1474-4422(17)30008-X; Fassbender K, 2013, LANCET NEUROL, V12, P585, DOI 10.1016/S1474-4422(13)70100-5; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Fladt J, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013101; Flynn D, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0118-5; Froehler MT, 2017, CIRCULATION, V136, P2311, DOI 10.1161/CIRCULATIONAHA.117.028920; Gonzales S, 2017, NEUROLOGY, V88, P441, DOI 10.1212/WNL.0000000000003562; Goyal M, 2016, RADIOLOGY, V279, P888, DOI 10.1148/radiol.2016160204; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Hastrup S, 2016, STROKE, V47, P1772, DOI 10.1161/STROKEAHA.115.012482; Heldner MR, 2016, J NEUROL, V263, P1633, DOI 10.1007/s00415-016-8180-6; Heldner MR, 2015, J NEUROL NEUROSUR PS, V86, P755, DOI 10.1136/jnnp-2014-308401; Helwig SA, 2019, JAMA NEUROL, V76, P1484, DOI 10.1001/jamaneurol.2019.2829; Hickey A, 2018, EUR STROKE J, V3, P117, DOI 10.1177/2396987317753453; Holodinsky JK, 2018, JAMA NEUROL, V75, P1477, DOI 10.1001/jamaneurol.2018.2424; Hui FK, 2018, J NEUROINTERV SURG, V10, P225, DOI 10.1136/neurintsurg-2017-013050; Itrat A, 2016, JAMA NEUROL, V73, P162, DOI 10.1001/jamaneurol.2015.3849; Jaiteh LES, 2017, NEUROLOGY, V89, P144, DOI 10.1212/WNL.0000000000004080; Janssen PM, 2019, STROKE, V50, P665, DOI 10.1161/STROKEAHA.118.021633; Jayaraman MV, 2017, J NEUROINTERV SURG, V9, P330, DOI 10.1136/neurintsurg-2016-012275; Katz BS, 2017, STROKE, V48, P2164, DOI 10.1161/STROKEAHA.116.015971; Katz BS, 2015, STROKE, V46, P1508, DOI 10.1161/STROKEAHA.115.008804; Kobayashi A, 2018, EUR J NEUROL, V25, P425, DOI 10.1111/ene.13539; Kodankandath TV, 2017, J STROKE CEREBROVASC, V26, P192, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.008; Kostopoulos P, 2012, NEUROLOGY, V78, P1849, DOI 10.1212/WNL.0b013e318258f773; Leira EC, 2016, EUR STROKE J, V1, P171, DOI 10.1177/2396987316658994; Lima FO, 2016, STROKE, V47, P1997, DOI 10.1161/STROKEAHA.116.013301; Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046; McDonald M, 2019, INT STROK C HON US F; McMullan JT, 2017, PREHOSP EMERG CARE, V21, P481, DOI 10.1080/10903127.2016.1274349; McTaggart RA, 2017, JAMA NEUROL, V74, P793, DOI 10.1001/jamaneurol.2017.0477; Milne MSW, 2017, STROKE, V48, P791, DOI 10.1161/STROKEAHA.116.015321; Mochari-Greenberger H, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002099; Mokin M, 2017, J NEUROINTERV SURG, V9, P442, DOI 10.1136/neurintsurg-2016-012331; Muller-Nordhorn J, 2009, ARCH INTERN MED, V169, P1484, DOI 10.1001/archinternmed.2009.232; Mullen MT, 2018, STROKE, V49, P1021, DOI 10.1161/STROKEAHA.118.020691; Mullen MT, 2015, NEUROLOGY, V84, P1196, DOI 10.1212/WNL.0000000000001390; Munich Stephan A, 2017, Neurointervention, V12, P69, DOI 10.5469/neuroint.2017.12.2.69; Nazliel B, 2008, STROKE, V39, P2264, DOI 10.1161/STROKEAHA.107.508127; Ng FC, 2017, STROKE, V48, P1976, DOI 10.1161/STROKEAHA.117.017235; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Nogueira RG, 2017, STROKE, V48, P1278, DOI 10.1161/STROKEAHA.116.016026; Noorian AR, 2018, STROKE, V49, P565, DOI 10.1161/STROKEAHA.117.019228; Ogungbo B, 2013, NEUROLOGY, V81, P2134, DOI 10.1212/01.wnl.0000437293.13194.12; Oostema JA, 2015, STROKE, V46, P1513, DOI 10.1161/STROKEAHA.115.008650; Parikh NS, 2018, STROKE, V49, P370, DOI 10.1161/STROKEAHA.117.018166; Parker SA, 2015, STROKE, V46, P1384, DOI 10.1161/STROKEAHA.114.007993; de la Ossa NP, 2014, STROKE, V45, P87, DOI 10.1161/STROKEAHA.113.003071; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Prabhakaran S, 2011, STROKE, V42, P1626, DOI 10.1161/STROKEAHA.110.609750; Pride GL, 2017, J NEUROINTERV SURG, V9, P801, DOI 10.1136/neurintsurg-2016-012699; Psychogios MN, 2017, STROKE, V48, P3152, DOI 10.1161/STROKEAHA.117.018077; Pulvers JN, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00617; Puolakka T, 2016, STROKE, V47, P3038, DOI 10.1161/STROKEAHA.116.014531; Ragoschke-Schumm A, 2015, CEREBROVASC DIS, V40, P251, DOI 10.1159/000440850; Rai AT, 2017, J NEUROINTERV SURG, V9, P722, DOI 10.1136/neurintsurg-2016-012515; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Saver JL, 2015, NEW ENGL J MED, V372, P528, DOI 10.1056/NEJMoa1408827; Scheitz JF, 2017, STROKE, V48, P290, DOI 10.1161/STROKEAHA.116.014431; Seker F, 2018, INT J STROKE, V13, P696, DOI 10.1177/1747493018765267; Sequeira D, 2016, PREHOSP EMERG CARE, V20, P723, DOI 10.3109/10903127.2016.1168889; Singer OC, 2005, STROKE, V36, P773, DOI 10.1161/01.STR.0000157591.61322.df; Skolarus LE, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003331; Skrypnik D., 2019, START ACUTE STROKE P; Smith EE, 2018, STROKE, V49, pE111, DOI 10.1161/STR.0000000000000160; Sun CHJ, 2013, CIRCULATION, V127, P1139, DOI 10.1161/CIRCULATIONAHA.112.000506; Tatlisumak T, 2015, STROKE, V46, P1468, DOI 10.1161/STROKEAHA.115.008386; Teleb MS, 2017, J NEUROINTERV SURG, V9, P122, DOI 10.1136/neurintsurg-2015-012131; Thomalla G, 2018, NEW ENGL J MED, V379, P611, DOI 10.1056/NEJMoa1804355; Turc G, 2019, EUR STROKE J, V4, P6, DOI 10.1177/2396987319832140; Turc G, 2016, STROKE, V47, P1466, DOI 10.1161/STROKEAHA.116.013144; Uchiyama N, 2016, NEUROL MED-CHIR, V56, P737, DOI 10.2176/nmc.oa.2016-0101; Venema E, 2018, J NEUROINTERV SURG, V10, P424, DOI 10.1136/neurintsurg-2017-013198; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31678-6, 10.1016/S0140-6736(16)31012-1]; Walter S, 2018, INT J STROKE, V13, P568, DOI 10.1177/1747493018784450; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Walter S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013758; Waqas M, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104504; Wechsler LR, 2017, STROKE, V48, pE3, DOI 10.1161/STR.0000000000000114; Wei D, 2017, STROKE, V48, P3295, DOI 10.1161/STROKEAHA.117.018149; Williams O, 2019, JAMA NEUROL, V76, P1211, DOI 10.1001/jamaneurol.2019.1741; Williams O, 2018, STROKE, V49, P972, DOI 10.1161/STROKEAHA.117.019861; Wu TC, 2017, STROKE, V48, P493, DOI 10.1161/STROKEAHA.116.015363; Wu TC, 2014, STROKE, V45, P2342, DOI 10.1161/STROKEAHA.114.005193; Zaidi SF, 2017, J NEUROINTERV SURG, V9, P631, DOI 10.1136/neurintsurg-2016-012476; Zhao H, 2019, INT J STROKE, V14, P265, DOI 10.1177/1747493018790081; Zhao H, 2018, STROKE, V49, P945, DOI 10.1161/STROKEAHA.117.019307	106	24	24	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2020	19	7					601	610		10.1016/S1474-4422(20)30102-2	http://dx.doi.org/10.1016/S1474-4422(20)30102-2			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MF5BW	32562685				2022-12-18	WOS:000545358600017
J	Thompson, R; Spendiff, S; Roos, A; Bourque, PR; Chardon, JW; Kirschner, J; Horvath, R; Lochmuller, H				Thompson, Rachel; Spendiff, Sally; Roos, Andreas; Bourque, Pierre R.; Chardon, Jodi Warman; Kirschner, Janbernd; Horvath, Rita; Lochmueller, Hanns			Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development	LANCET NEUROLOGY			English	Review							CONGENITAL MUSCULAR-DYSTROPHY; MUTATIONS; IDENTIFICATION; HETEROGENEITY; DISCOVERY; PLATFORM; HEALTH; OMICS	Advances in DNA sequencing technologies have resulted in a near doubling, in under 10 years, of the number of causal genes identified for inherited neuromuscular disorders. However, around half of patients, whether children or adults, do not receive a molecular diagnosis after initial diagnostic workup. Massively parallel technologies targeting RNA, proteins, and metabolites are being increasingly used to diagnose these unsolved cases. The use of these technologies to delineate pathways, biomarkers, and therapeutic targets has led to new approaches entering the drug development pipeline. However, these technologies might give rise to misleading conclusions if used in isolation, and traditional techniques including comprehensive neurological evaluation, histopathology, and biochemistry continue to have a crucial role in diagnostics. For optimal diagnosis, prognosis, and precision medicine, no single ruling technology exists. Instead, an interdisciplinary approach combining novel and traditional neurological techniques with computer-aided analysis and international data sharing is needed to advance the diagnosis and treatment of neuromuscular disorders.	[Thompson, Rachel; Spendiff, Sally; Chardon, Jodi Warman; Lochmueller, Hanns] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; [Roos, Andreas] Univ Hosp Essen, Dept Neuropediat, Essen, Germany; [Bourque, Pierre R.; Chardon, Jodi Warman; Lochmueller, Hanns] Univ Ottawa, Brain & Mind Res Inst, Ottawa, ON, Canada; [Bourque, Pierre R.; Chardon, Jodi Warman; Lochmueller, Hanns] Ottawa Res Inst, Dept Med, Ottawa, ON, Canada; [Kirschner, Janbernd] Univ Hosp Bonn, Fac Med, Dept Neuropediat, Bonn, Germany; [Kirschner, Janbernd; Lochmueller, Hanns] Univ Med Ctr Freiburg, Fac Med, Dept Neuropediat & Muscle Disorders, Freiburg, Germany; [Horvath, Rita] Univ Cambridge, Dept Clin Neurosci, Cambridge, England	University of Ottawa; Children's Hospital of Eastern Ontario; University of Duisburg Essen; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Bonn; University of Freiburg; University of Cambridge	Lochmuller, H (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada.	hlochmuller@toh.ca	Horvath, Rita/AAY-7042-2020; Kirschner, Janbernd/Q-1493-2019; Warman Chardon, Jodi/B-6062-2016	Kirschner, Janbernd/0000-0003-1618-7386; Warman Chardon, Jodi/0000-0002-0187-2199; Thompson, Rachel/0000-0002-6889-0121; Spendiff, Sally/0000-0001-9579-3514	Canadian Institutes of Health Research [FDN-167281]; Canadian Institutes of Health Research; Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C); Canada Foundation for Innovation [CFI-JELF 38412]; Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health) [950-232279]; EU Horizon 2020 Solve-RD [779257]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C)(Muscular Dystrophy Association); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health); EU Horizon 2020 Solve-RD	HL gratefully acknowledges support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279), and the EU Horizon 2020 Solve-RD (779257). We thank our colleagues in neurology and neuromuscular genetics worldwide whose work we have reviewed and the many patients and families whose generous participation in our research over the years has enabled the advances in neuromuscular disease diagnostics and therapies we see today.	Adams D, 2019, NAT REV NEUROL, V15, P387, DOI 10.1038/s41582-019-0210-4; Ameur A, 2019, TRENDS BIOTECHNOL, V37, P72, DOI 10.1016/j.tibtech.2018.07.013; Ankala A, 2015, ANN NEUROL, V77, P206, DOI 10.1002/ana.24303; Astrea G, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0863-x; Austin CP, 2018, CTS-CLIN TRANSL SCI, V11, P21, DOI 10.1111/cts.12500; Bansagi B, 2017, NEUROLOGY, V88, P1226, DOI 10.1212/WNL.0000000000003772; Barthelemy F, 2018, METHODS MOL BIOL, V1828, P489, DOI 10.1007/978-1-4939-8651-4_31; Boca SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153461; Bolduc V, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124403; Bonne Gisele, 2018, Neuromuscul Disord, V28, P1031, DOI 10.1016/j.nmd.2018.09.006; Borras E, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201700180; Boycott KM, 2019, CELL, V177, P32, DOI 10.1016/j.cell.2019.02.040; Buzkova J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809091; Cheung AK, 2018, J MED CHEM, V61, P11021, DOI 10.1021/acs.jmedchem.8b01291; Choi BO, 2012, HUM MUTAT, V33, P1610, DOI 10.1002/humu.22143; Cortese A, 2019, NAT GENET, V51, P649, DOI 10.1038/s41588-019-0372-4; Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Durmus H, 2011, NEUROLOGY, V76, P227, DOI 10.1212/WNL.0b013e318207b043; Engel Andrew G, 2018, Handb Clin Neurol, V148, P565, DOI 10.1016/B978-0-444-64076-5.00037-5; Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Gazzerro E, 2011, Handb Clin Neurol, V101, P135, DOI 10.1016/B978-0-08-045031-5.00010-4; Ghaoui R, 2015, JAMA NEUROL, V72, P1424, DOI 10.1001/jamaneurol.2015.2274; Ghiassian SD, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004120; Gonorazky HD, 2019, AM J HUM GENET, V104, P1007, DOI 10.1016/j.ajhg.2019.04.004; Gonzaga-Jauregui C, 2015, CELL REP, V12, P1169, DOI 10.1016/j.celrep.2015.07.023; Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262; Guttsches AK, 2017, ANN NEUROL, V81, P227, DOI 10.1002/ana.24847; Harris E, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0699-9; Herrmann DN, 2014, AM J HUM GENET, V95, P332, DOI 10.1016/j.ajhg.2014.08.007; Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310; Ishiura H, 2019, NAT GENET, V51, P1222, DOI 10.1038/s41588-019-0458-z; Ito Y, 2018, AM J HUM GENET, V103, P144, DOI 10.1016/j.ajhg.2018.06.001; Karczewski K.J., 2019, GENOMICS, DOI [10.1101/531210, DOI 10.1101/531210]; Karczewski KJ, 2018, NAT REV GENET, V19, P299, DOI 10.1038/nrg.2018.4; Kergourlay V, 2014, HUM MUTAT, V35, P1532, DOI 10.1002/humu.22710; Kingsmore SF, 2019, AM J HUM GENET, V105, P719, DOI 10.1016/j.ajhg.2019.08.009; Klein AF, 2019, J CLIN INVEST, V129, P4739, DOI 10.1172/JCI128205; Kley RA, 2013, MOL CELL PROTEOMICS, V12, P215, DOI 10.1074/mcp.M112.023176; Kohler S, 2019, NUCLEIC ACIDS RES, V47, pD1018, DOI 10.1093/nar/gky1105; Kohda M, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005679; Kohler Sebastian, 2019, Curr Protoc Hum Genet, V103, pe92, DOI 10.1002/cphg.92; Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824; Kuhl I, 2017, ELIFE, V6, DOI 10.7554/eLife.30952; Lee JJY, 2018, GENET MED, V20, P151, DOI 10.1038/gim.2017.108; Lee Y, 2018, J CLIN INVEST, V128, P1164, DOI 10.1172/JCI97103; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lek Monkol, 2014, J Neuromuscul Dis, V1, P135; Lochmuller H, 2018, EUR J HUM GENET, V26, P778, DOI 10.1038/s41431-018-0115-5; Luo SS, 2017, NEUROMUSCULAR DISORD, V27, P557, DOI 10.1016/j.nmd.2017.03.004; Maerkens A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0280-0; Maerkens A, 2013, J PROTEOMICS, V90, P14, DOI 10.1016/j.jprot.2013.04.026; Malcher J, 2018, MOL THER-NUCL ACIDS, V13, P198, DOI 10.1016/j.omtn.2018.08.013; Martin PT, 2009, AM J PHYSIOL-CELL PH, V296, pC476, DOI 10.1152/ajpcell.00456.2008; Matos CM, 2019, J CLIN NEUROSCI, V67, P14, DOI 10.1016/j.jocn.2019.06.041; Mitsuhashi S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05772-5; Moliner AM, 2017, ADV EXP MED BIOL, V1031, P561, DOI 10.1007/978-3-319-67144-4_30; Montes-Chinea NI, 2018, NEUROL-GENET, V4, DOI 10.1212/NXG.0000000000000282; O'Grady GL, 2016, ANN NEUROL, V80, P101, DOI 10.1002/ana.24687; Philippakis AA, 2015, HUM MUTAT, V36, P915, DOI 10.1002/humu.22858; Pickett SJ, 2018, ANN CLIN TRANSL NEUR, V5, P333, DOI 10.1002/acn3.532; Poulton J, 2019, NEUROMUSCULAR DISORD, V29, P725, DOI 10.1016/j.nmd.2019.08.004; Punetha Jaya, 2016, J Neuromuscul Dis, V3, P209; Ratni H, 2018, J MED CHEM, V61, P6501, DOI 10.1021/acs.jmedchem.8b00741; Rau F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8205; Reddy HM, 2017, J HUM GENET, V62, P243, DOI 10.1038/jhg.2016.116; Roos A, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201700073; Schessl J, 2008, J CLIN INVEST, V118, P904, DOI 10.1172/JCI34450; Schorling DC, 2020, J NEUROMUSCULAR DIS, V7, P1, DOI 10.3233/JND-190424; Smedley D, 2015, NAT PROTOC, V10, P2004, DOI 10.1038/nprot.2015.124; Soldevilla B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178376; Stark Z, 2019, AM J HUM GENET, V104, P13, DOI 10.1016/j.ajhg.2018.11.014; Tan TY, 2017, JAMA PEDIATR, V171, P855, DOI 10.1001/jamapediatrics.2017.1755; Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184; Theunissen TEJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00400; Thomas PJ, 2016, AM J PATHOL, V186, P2429, DOI 10.1016/j.ajpath.2016.05.021; Thompson R, 2019, HUM MUTAT, V40, P1797, DOI 10.1002/humu.23792; Thompson R, 2019, EMERG TOP LIFE SCI, V3, P19, DOI 10.1042/ETLS20180100; Vaidyanathan R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01548; van Karnebeek CDM, 2018, J INHERIT METAB DIS, V41, P571, DOI 10.1007/s10545-017-0128-1; van Karnebeek CDM, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-47; Vill K, 2017, J Neuromuscul Dis, V4, P315, DOI 10.3233/JND-170231; Vissers LELM, 2017, GENET MED, V19, P1055, DOI 10.1038/gim.2017.1; Wiessner M, 2017, AM J HUM GENET, V100, P523, DOI 10.1016/j.ajhg.2017.01.024; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089; Wright Caroline F, 2018, Nat Rev Genet, V19, P325, DOI 10.1038/nrg.2018.12; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yis U, 2017, J CHILD NEUROL, V32, P759, DOI 10.1177/0883073817705252; Yu B, 2019, AM J EPIDEMIOL, V188, P991, DOI 10.1093/aje/kwz028; Zhang RY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49279-7	90	24	24	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					522	532		10.1016/S1474-4422(20)30028-4	http://dx.doi.org/10.1016/S1474-4422(20)30028-4			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470424				2022-12-18	WOS:000544059200013
J	Balin, BJ; Hudson, AP				Balin, Brian J.; Hudson, Alan P.			Herpes viruses and Alzheimer's disease: new evidence in the debate	LANCET NEUROLOGY			English	Editorial Material							CHLAMYDIA-PNEUMONIAE; TYPE-1; BRAIN; RISK		[Balin, Brian J.] Philadelphia Coll Osteopath Med, Dept Biomed Sci, Philadelphia, PA 19131 USA; [Hudson, Alan P.] Wayne State Univ, Sch Med, Dept Biochem Microbiol & Immunol, Detroit, MI USA	Wayne State University	Balin, BJ (corresponding author), Philadelphia Coll Osteopath Med, Dept Biomed Sci, Philadelphia, PA 19131 USA.	brianba@pcom.edu						Balin BJ, 1998, MED MICROBIOL IMMUN, V187, P23, DOI 10.1007/s004300050071; Chen VCH, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.16m11312; Eimer WA, 2018, NEURON, V99, P56, DOI 10.1016/j.neuron.2018.06.030; Gerard HC, 2006, FEMS IMMUNOL MED MIC, V48, P355, DOI 10.1111/j.1574-695X.2006.00154.x; Itzhaki RF, 1997, LANCET, V349, P241, DOI 10.1016/S0140-6736(96)10149-5; Itzhaki RF, 2016, J ALZHEIMERS DIS, V51, P979, DOI 10.3233/JAD-160152; Kumar DKV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1059; Little CS, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00304; Readhead B, 2018, NEURON, V99, P64, DOI 10.1016/j.neuron.2018.05.023; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Tsai MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188490; Tzeng NS, 2018, NEUROTHERAPEUTICS, V15, P417, DOI 10.1007/s13311-018-0611-x; Wozniak MA, 2009, J PATHOL, V217, P131, DOI 10.1002/path.2449	13	24	26	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2018	17	10					839	841		10.1016/S1474-4422(18)30316-8	http://dx.doi.org/10.1016/S1474-4422(18)30316-8			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GT9LD	30264721				2022-12-18	WOS:000444862200008
J	Giovannoni, G				Giovannoni, Gavin			The neurodegenerative prodrome in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							PERFORMANCE; DISEASE		[Giovannoni, Gavin] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London E1 2AT, England	University of London; Queen Mary University London	Giovannoni, G (corresponding author), Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London E1 2AT, England.	g.giovannoni@qmul.ac.uk						Amato MP, 2012, NEUROLOGY, V78, P309, DOI 10.1212/WNL.0b013e31824528c9; Aubert-Broche B, 2014, NEUROLOGY, V83, P2140, DOI 10.1212/WNL.0000000000001045; Cortese M, 2016, ANN NEUROL, V80, P616, DOI 10.1002/ana.24769; Dobson R, 2013, J NEUROL NEUROSUR PS, V84, pe2; ENGELL T, 1989, ACTA NEUROL SCAND, V79, P428, DOI 10.1111/j.1600-0404.1989.tb03811.x; Flier FJ, 1999, THEOR MED BIOETH, V20, P577, DOI 10.1023/A:1009994603779; Kurtzke JF, 2000, J NEUROVIROL, V6, pS134; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Ramagopalan SV, 2010, LANCET NEUROL, V9, P727, DOI 10.1016/S1474-4422(10)70094-6; Sinay V, 2015, MULT SCLER J, V21, P945, DOI 10.1177/1352458514554054; Wijnands JMA, 2017, LANCET NEUROL, V16, P445, DOI 10.1016/S1474-4422(17)30076-5	11	24	24	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					413	414		10.1016/S1474-4422(17)30127-8	http://dx.doi.org/10.1016/S1474-4422(17)30127-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU1WD	28504102				2022-12-18	WOS:000400815800004
J	Oh, J; Calabresi, PA				Oh, Jiwon; Calabresi, Peter A.			Emerging injectable therapies for multiple sclerosis	LANCET NEUROLOGY			English	Review							ANTI-CD20 MONOCLONAL-ANTIBODY; THERAPEUTIC LYMPHOCYTE DEPLETION; DOUBLE-BLIND; INTERFERON BETA-1A; MAGNETIC-RESONANCE; RHEUMATOID-ARTHRITIS; DISEASE PROGRESSION; GLATIRAMER ACETATE; ALEMTUZUMAB; MULTICENTER	Available treatment options for relapsing-remitting multiple sclerosis (MS) have expanded in recent years, and several injectable therapies are under development. In this Rapid Review, we summarise emerging injectable therapies for relapsing-remitting MS, and discuss pharmacological mechanisms, clinical trials, adverse events, and use in clinical practice. Many new potential treatments for MS are at an intermediate to advanced stage of development. Alemtuzumab is a monoclonal antibody that has shown efficacy in phase 3 trials but, because of serious adverse events associated with this drug, clinical monitoring is essential. Pegylated interferon beta-1a has shown efficacy in a phase 3 trial. Daclizumab and ocrelizumab are monoclonal antibodies that have shown efficacy and acceptable safety profiles in phase 2 trials; both are under investigation in ongoing phase 3 trials. Ofatumumab is a monoclonal antibody that has shown efficacy in a small phase 2 trial. Animal models suggest that anti-LINGO1 antibody has remyelinating potential, and phase 2 trials of the antibody are underway. Further clarification of purported mechanisms of action and continued surveillance will be essential to establish the safety and clinical efficacy of these drugs in patients with relapsing-remitting MS.	[Oh, Jiwon; Calabresi, Peter A.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA	Johns Hopkins University	Oh, J (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, Pathol 627, Baltimore, MD 21287 USA.	joh20@jhmi.edu	Calabresi, Peter A./AAF-2288-2019	Calabresi, Peter/0000-0002-7776-6472	MS Society of Canada	MS Society of Canada	JO is supported by a transitional career development award from the MS Society of Canada.	Aktas O, 2010, TRENDS NEUROSCI, V33, P140, DOI 10.1016/j.tins.2009.12.002; Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Bielekova B, 2009, ARCH NEUROL-CHICAGO, V66, P483, DOI 10.1001/archneurol.2009.50; Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829; Cadavid D, 2013, NEUROLOGY, V80; Calabresi P, 2012, NEUROLOGY, V78; Cheson BD, 2010, J CLIN ONCOL, V28, P3525, DOI 10.1200/JCO.2010.27.9836; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Coles AJ, 2012, NEUROLOGY, V78, P1069, DOI 10.1212/WNL.0b013e31824e8ee7; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64.abs; Cox AL, 2005, EUR J IMMUNOL, V35, P3332, DOI 10.1002/eji.200535075; CRESPI MD, 1986, BIOCHEM BIOPH RES CO, V136, P521, DOI 10.1016/0006-291X(86)90471-7; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Emery P, 2010, ARTHRITIS RHEUM S10, V62, P414; Farina C, 2005, LANCET NEUROL, V4, P567, DOI 10.1016/S1474-4422(05)70167-8; Fox E, 2012, 28 C EUR COMM TREATM; Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2652, DOI 10.1002/art.23732; Giovannoni G, 2011, MULT SCLER J, V17, pS508; Giovannoni G, 2012, 28 C EUR COMM TREATM; Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hill-Cawthorne GA, 2012, J NEUROL NEUROSUR PS, V83, P298, DOI 10.1136/jnnp-2011-300826; Hu X, 2012, J CLIN PHARMACOL, V52, P798, DOI 10.1177/0091270011407068; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; James Danelle F, 2007, Future Oncol, V3, P29, DOI 10.2217/14796694.3.1.29; Jevsevar S, 2010, BIOTECHNOL J, V5, P113, DOI 10.1002/biot.200900218; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Jones JL, 2009, J CLIN INVEST, V119, P2052, DOI 10.1172/JCI37878; Kappos L, 2012, 28 C EUR COMM TREATM; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Kausar F, 2009, EXPERT OPIN BIOL TH, V9, P889, DOI 10.1517/14712590903018837; Kieseier BC, 2012, CNS DRUGS, V26, P205, DOI 10.2165/11596970-000000000-00000; Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110-000000000-00000; Lee X, 2007, J NEUROSCI, V27, P220, DOI 10.1523/JNEUROSCI.4175-06.2007; Li BH, 2008, CANCER RES, V68, P2400, DOI 10.1158/0008-5472.CAN-07-6663; Li DKB, 1999, ANN NEUROL, V46, P197, DOI 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P; Lublin F, 2012, NEUROLOGY, V78; Marriott JJ, 2010, NEUROLOGY, V74, P1463, DOI 10.1212/WNL.0b013e3181dc1ae0; Mehta LRG, 2007, CONTINUUM LIFELONG L, V13, P144; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Mi S, 2009, ANN NEUROL, V65, P304, DOI 10.1002/ana.21581; Morgan RD, 2012, TRANSPLANTATION, V93, P1179, DOI 10.1097/TP.0b013e318257ad41; Natsume A, 2008, DRUG DES DEV THER, V3, P7; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Simon JH, 1998, ANN NEUROL, V43, P79, DOI 10.1002/ana.410430114; Soelberg Sorensen P, 2010, 26 C EUR COMM TREATM; Taylor PC, 2011, ANN RHEUM DIS, V70, P2119, DOI 10.1136/ard.2011.151522; Thompson SAJ, 2010, J CLIN IMMUNOL, V30, P99, DOI 10.1007/s10875-009-9327-3; Tran J, 2012, NEUROLOGY, V78; Wuest SC, 2011, NAT MED, V17, P604, DOI 10.1038/nm.2365; Wynn D, 2010, LANCET NEUROL, V9, P381, DOI 10.1016/S1474-4422(10)70033-8; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Zhao XH, 2007, MOL CELL NEUROSCI, V36, P260, DOI 10.1016/j.mcn.2007.07.008	61	24	26	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2013	12	11					1115	1126		10.1016/S1474-4422(13)70192-3	http://dx.doi.org/10.1016/S1474-4422(13)70192-3			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239ZC	24090587				2022-12-18	WOS:000326063500014
J	Baron, R; Wasner, G; Binder, A				Baron, Ralf; Wasner, Gunnar; Binder, Andreas			Chronic pain: genes, plasticity, and phenotypes	LANCET NEUROLOGY			English	Editorial Material							OSTEOARTHRITIS; TANEZUMAB		[Baron, Ralf; Wasner, Gunnar; Binder, Andreas] Univ Kiel, Div Neurol Pain Res & Therapy, Dept Neurol, D-24098 Kiel, Germany	University of Kiel	Baron, R (corresponding author), Univ Kiel, Div Neurol Pain Res & Therapy, Dept Neurol, D-24098 Kiel, Germany.	r.baron@neurologie.uni-kiel.de						De Felice M, 2011, PAIN, V152, P2701, DOI 10.1016/j.pain.2011.06.008; Dib-Hajj SD, 2005, BRAIN, V128, P1847, DOI 10.1093/brain/awh514; Faber CG, 2012, ANN NEUROL, V71, P26, DOI 10.1002/ana.22485; Goldberg YP, 2012, PAIN, V153, P80, DOI 10.1016/j.pain.2011.09.008; Gustin SM, 2011, J NEUROSCI, V31, P5956, DOI 10.1523/JNEUROSCI.5980-10.2011; Gwilym SE, 2010, ARTHRITIS RHEUM-US, V62, P2930, DOI 10.1002/art.27585; Katz N, 2011, PAIN, V152, P2248, DOI 10.1016/j.pain.2011.05.003; Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510; Maier C, 2010, PAIN, V150, P439, DOI 10.1016/j.pain.2010.05.002	9	24	24	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					19	21		10.1016/S1474-4422(11)70281-2	http://dx.doi.org/10.1016/S1474-4422(11)70281-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172618				2022-12-18	WOS:000298513700012
J	Kountouras, J; Deretzi, G; Grigoriadis, N; Zavos, C; Boziki, M; Gavalas, E; Katsinelos, P; Tzilves, D; Giouleme, O; Lazaraki, G				Kountouras, Jannis; Deretzi, Georgia; Grigoriadis, Nikolaos; Zavos, Christos; Boziki, Marina; Gavalas, Emmanuel; Katsinelos, Panagiotis; Tzilves, Dimitrios; Giouleme, Olga; Lazaraki, Georgia			Guillain-Barre syndrome	LANCET NEUROLOGY			English	Editorial Material							HELICOBACTER-PYLORI		[Kountouras, Jannis; Deretzi, Georgia; Zavos, Christos; Boziki, Marina; Gavalas, Emmanuel; Katsinelos, Panagiotis; Tzilves, Dimitrios; Giouleme, Olga; Lazaraki, Georgia] Aristotle Univ Thessaloniki, Ippokrat Hosp, Med Clin 2, Dept Med, GR-54006 Thessaloniki, Greece; [Grigoriadis, Nikolaos] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol, GR-54006 Thessaloniki, Greece	Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Ahepa University Hospital	Kountouras, J (corresponding author), Aristotle Univ Thessaloniki, Ippokrat Hosp, Med Clin 2, Dept Med, GR-54006 Thessaloniki, Greece.	jannis@med.auth.gr	Lazaraki, Georgia/AAJ-1449-2020; Zavos, Christos/N-8618-2015; Boziki, Marina/AAV-2196-2021	Zavos, Christos/0000-0002-3443-7791; Boziki, Marina/0000-0002-6601-5163; Giouleme, Olga/0000-0003-0176-3598				Chiba S., 2003, Helicobacter, V8, P445; Chiba S, 2002, J NEUROL NEUROSUR PS, V73, P76, DOI 10.1136/jnnp.73.1.76; Kountouras J, 2005, EUR J NEUROL, V12, P139, DOI 10.1111/j.1468-1331.2004.00977.x; Moran AP, 2001, J AUTOIMMUN, V16, P241, DOI 10.1006/jaut.2000.0490; van Doorn PA, 2008, LANCET NEUROL, V7, P939, DOI 10.1016/S1474-4422(08)70215-1	5	24	24	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1080	1081		10.1016/S1474-4422(08)70247-3	http://dx.doi.org/10.1016/S1474-4422(08)70247-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	19007730				2022-12-18	WOS:000261396000006
J	Skoog, I				Skoog, Ingmar			Anti hypertensive treatment and dementia prevention	LANCET NEUROLOGY			English	Editorial Material							BLOOD-PRESSURE; SYSTOLIC HYPERTENSION; COGNITIVE FUNCTION; DOUBLE-BLIND; DISEASE; TRIAL		Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Neuropsychiat Epidemiol Unite, Gothenburg, Sweden	University of Gothenburg	Skoog, I (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Neuropsychiat Epidemiol Unite, Gothenburg, Sweden.	ingmar.skoog@neuro.gu.se						APPLEGATE WB, 1994, ARCH INTERN MED, V154, P2154, DOI 10.1001/archinte.154.19.2154; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Khachaturian AS, 2006, ARCH NEUROL-CHICAGO, V63, P686, DOI 10.1001/archneur.63.5.noc60013; Peters R, 2008, LANCET NEUROL, V7, P683, DOI 10.1016/S1474-4422(08)70143-1; Skoog I, 2005, AM J HYPERTENS, V18, P1052, DOI 10.1016/j.amjhyper.2005.02.013; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; SKOOG I, 2006, TRIAL DESIGNS OUTCOM, P189; Skoog I, 2006, NEUROL RES, V28, P605, DOI 10.1179/016164106X130506; Tzourio C, 2003, ARCH INTERN MED, V163, P1069	10	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					664	665		10.1016/S1474-4422(08)70144-3	http://dx.doi.org/10.1016/S1474-4422(08)70144-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18614403				2022-12-18	WOS:000257969700002
J	McCarthy, M				McCarthy, Michael			Allen Brain Atlas maps 21000 genes of the mouse brain	LANCET NEUROLOGY			English	News Item																			0	24	24	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2006	5	11					907	908		10.1016/S1474-4422(06)70594-4	http://dx.doi.org/10.1016/S1474-4422(06)70594-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099JY	17086647				2022-12-18	WOS:000241591600012
J	Whitehouse, P; Gaines, AD; Lindstrom, H; Graham, JE				Whitehouse, P; Gaines, AD; Lindstrom, H; Graham, JE			Anthropological contributions to the understanding of age-related cognitive impairment	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE; OLD-AGE; CULTURAL-ASPECTS; AMERICAN CAREGIVERS; AFRICAN-AMERICAN; DEMENTIA; PERSPECTIVE; CLASSIFICATION; POPULATION; EXPERIENCE	Medical anthropology has not only helped us to understand the social, political, and ethical foundations of modem biomedicine, but also improved the identification and treatment of patients in various geographic, sociological, and medical contexts. In this article, we present an anthropological perspective on the understanding, diagnosis, and treatment of age-related cognitive impairment. The ubiquity of cognitive changes in the growing number of elderly people around the world, and the many diverse responses that human communities have taken to such challenges, require biocultural approaches. Anthropology can serve as an ally in accomplishing the goal of improving the quality of life of those with cognitive impairment by highlighting the role of sociocultural processes that influence the development, meaning, and experience of dementia. So too can it serve as a framework for criticism of biomedical research, theory, and practice.	Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44120 USA; Case Western Reserve Univ, Dept Anthropol, Cleveland, OH 44120 USA; Case Western Reserve Univ, Dept Integrat Studies, Cleveland, OH 44120 USA; Dalhousie Univ, Fac Med, Halifax, NS, Canada	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Dalhousie University	Whitehouse, P (corresponding author), Case Western Reserve Univ, Dept Neurol, 12200 Fairhill Rd,Suite C357, Cleveland, OH 44120 USA.	peter.whitehouse@case.edu		Graham, Janice/0000-0002-6326-8122	NATIONAL INSTITUTE ON AGING [R01AG020916, R01AG017511] Funding Source: NIH RePORTER; NIA NIH HHS [AG/HG-20916, AG17511-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1983, LOCAL KNOWLEDGE FURT, P64; Association A.P., 2000, DIAGN STAT MAN MENT; BALLENGER JF, 2000, CONCEPTS ALZHEIMER D, P83; Barber M, 2002, LANCET NEUROL, V1, P10, DOI 10.1016/S1474-4422(02)00009-1; Chatterji R, 1998, CULT MED PSYCHIAT, V22, P355, DOI 10.1023/A:1005442300388; COHEN GD, 1997, 7 DEADLY MYTHS UNCOV; COHEN L, 1994, ANNU REV ANTHROPOL, V23, P137, DOI 10.1146/annurev.an.23.100194.001033; COHEN L, 1995, MED ANTHROPOL Q, V9, P314, DOI 10.1525/maq.1995.9.3.02a00030; Cohen Lawrence, 1998, NO AGING INDIA ALZHE; CORNER L, IN PRESS PHILOS PSYC; Csordas T.J., 1994, SACRED SELF CULTURAL; Deal William E., 2000, CARING ELDERLY JAPAN, P318; DEBAGGIO T, 2003, GETS DARK ENLIGHTENE; DeBaggio Thomas, 2002, LOSING MY MIND INTIM; Dein S, 1997, AGING MENT HEALTH, V1, P112, DOI 10.1080/13607869757209; Downs M, 2000, AGEING SOC, V20, P369, DOI 10.1017/S0144686X99007758; Dumit Joseph, 2003, PICTURING PERSONHOOD; Farmer P, 2003, PATHOLOGIES POWER HL; FISHMAN J, 2003, THESIS SAN FRANCISCO; FONER N, 1994, CAREGIVING DILEMMA; Fox K, 1999, CULT MED PSYCHIAT, V23, P501, DOI 10.1023/A:1005520105518; Fox PJ, 1999, GENET TEST, V3, P13, DOI 10.1089/gte.1999.3.13; GAINES A D, 1979, Culture Medicine and Psychiatry, V3, P381, DOI 10.1007/BF00051465; Gaines A. D., 2004, ENCY BIOETHICS, P2243; Gaines A. D., 2004, ENCY MED ANTHR, P95; GAINES AD, 1992, SOC SCI MED, V35, P3, DOI 10.1016/0277-9536(92)90115-7; Gaines AD, 1998, GENETIC TESTING FOR ALZHEIMER DISEASE, P256; Gaines AD, 1999, SERVING MINORITY ELDERS IN THE 21ST CENTURY, P180; Gaines AD, 1998, ALZ DIS ASSOC DIS, V12, P295, DOI 10.1097/00002093-199812000-00008; GAINES AD, 1985, CULTURAL CONCEPTIONS, P167; GAINES AD, 1985, PHYSICIANS W MED ANT, P223; GAINES AD, 2004, LANCET NEUROL, V3, P380; GAINES AD, IN PRESS PHILOS PSYC; Gaines Atwood D, 1991, ANTHROPOL MED, P221, DOI DOI 10.1007/978-3-322-87859-5_17; Geertz, 2017, INTERPRETATION CULTU; Graham J., 1992, SANTE CULTURE HLTH, V8, P55; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Graham JE, 1999, AM J EPIDEMIOL, V150, P1045, DOI 10.1093/oxfordjournals.aje.a009928; Graham JE, 2001, INT PSYCHOGERIATR, V13, P131, DOI 10.1017/S1041610201007529; GRAHAM JE, 1996, THESIS U MONTREAL; HAHN RA, 1985, PHYSICIANS W MED; HARAWAY D, 1993, KNOWLEDGE POWER PRAC, P365; HARDING NH, 1997, CONFUSED PROFESSIONA; HENDERSON JN, 1993, GERONTOLOGIST, V33, P409, DOI 10.1093/geront/33.3.409; HENDERSON JN, 1994, ALZ DIS ASSOC DIS, V8, pS410; Henderson JN, 1995, CULTURE LONG TERM CA; Herbert CP, 2001, CAN J NEUROL SCI, V28, pS77, DOI 10.1017/S0317167100001244; HERSKOVITS E, 1995, MED ANTHROPOL Q, V9, P146, DOI 10.1525/maq.1995.9.2.02a00030; Hicks MHR, 1999, CULT MED PSYCHIAT, V23, P415, DOI 10.1023/A:1005563918721; Hinton WL, 1999, CULT MED PSYCHIAT, V23, P453, DOI 10.1023/A:1005516002792; Holstein M, 1997, J AGING STUD, V11, P1, DOI 10.1016/S0890-4065(97)90008-6; Holstein Martha, 2000, CONCEPTS ALZHEIMERS, P158; Ikels C, 1998, CULT MED PSYCHIAT, V22, P257, DOI 10.1023/A:1005399215185; IKELS C, 2002, J CROSS CULT GERONTO, V17, P1; Keith J, 1994, AGING EXPERIENCE DIV; KILNER JF, 1984, HASTINGS CENT REP, V14, P18, DOI 10.2307/3561183; Kitwood T.M., 1997, DEMENTIA RECONSIDERE; Kleinman A, 1995, WRITING MARGINS DISC; Kleinman A., 1981, PATIENTS HEALERS CON; Kleinman A., 1989, ILLNESS NARRATIVES S; LABARRE W, 1946, J PERS, V14, P169; LEIBING A, IN PRESS THINKING DE; Leibing Annete, 1997, MED ANTHR BRAZIL; Leibing Annette, 2002, J Cross Cult Gerontol, V17, P213, DOI 10.1023/A:1021278405228; LOCK M, 2001, 2 DEAD ORGAN TRANSPL; Lock M., 1993, ENCOUNTERS AGING; MacKnight C, 1999, J AM GERIATR SOC, V47, P1294, DOI 10.1111/j.1532-5415.1999.tb07428.x; MARSHALL P, 1994, CAMB Q HEALTHC ETHIC, V3, P321, DOI 10.1017/S0963180100005132; Orr R D, 1995, Arch Fam Med, V4, P159; Ortiz A, 1999, CULT MED PSYCHIAT, V23, P477, DOI 10.1023/A:1005568019630; Pollitt PA, 1996, PSYCHOL MED, V26, P1061, DOI 10.1017/S0033291700035388; Post SG, 1998, J CLIN ETHIC, V9, P71; Poveda AM, 2003, GERIATR NURS, V24, P26, DOI 10.1067/mgn.2003.15; Rosenberg CE, 2002, MILBANK Q, V80, P237, DOI 10.1111/1468-0009.t01-1-00003; Savishinsky J., 1991, ENDS TIME LIFE WORK; SCHUTZ J, 1987, AGING CHINA FAMILY E; Stafford PB, 2003, GRAY AREAS ETHNOGRAP; Taylor JS, 2003, ACAD MED, V78, P555, DOI 10.1097/00001888-200306000-00003; THOMAS WH, 2004, OLD PEOPLE FOR ELDER; Traphagan J W, 1998, J Cross Cult Gerontol, V13, P81, DOI 10.1023/A:1006566300463; Traphagan John W, 2002, J Cross Cult Gerontol, V17, P253, DOI 10.1023/A:1021238215228; Traphagan John W., 2000, TAMING OBLIVION AGIN; Traphagan JW, 1998, ETHNOLOGY, V37, P333, DOI 10.2307/3773786; Whitehouse PJ, 2001, ALZ DIS ASSOC DIS, V15, P59, DOI 10.1097/00002093-200104000-00001; Whitehouse PJ, 2003, LANCET, V361, P1227, DOI 10.1016/S0140-6736(03)12937-6; WHITEHOUSE PJ, 2004, TRIAL DESIGNS OUTCOM; WHITEHOUSE PJ, IN PRESS DEMENTIA; WHITEHOUSE PJ, 2004, PSYCHIAT TIMES, P87; Williams-Jones B, 2003, NEW GENET SOC, V22, P271, DOI 10.1080/1463677032000147225	89	24	25	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2005	4	5					320	326		10.1016/S1474-4422(05)70075-2	http://dx.doi.org/10.1016/S1474-4422(05)70075-2			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	919AE	15847845				2022-12-18	WOS:000228589900023
J	Newman, SP; Harrison, MJG				Newman, SP; Harrison, MJG			Coronary-artery bypass surgery and the brain: persisting concerns	LANCET NEUROLOGY			English	Review							HYPOTHERMIC CARDIOPULMONARY BYPASS; NERVOUS-SYSTEM DYSFUNCTION; CARDIAC-SURGERY; RANDOMIZED-TRIAL; HEART-SURGERY; GRAFT-SURGERY; OFF-PUMP; NEUROLOGIC COMPLICATIONS; PARTICULATE EMBOLI; COGNITIVE DECLINE	Mortality after coronary-artery bypass surgery (CABS) has fallen steadily over recent years. Concern remains, however, about the effect of this surgery on the brain. The problem of brain damage after CABS is multifactorial, involving microembolism, disturbed perfusion, metabolic derangement, and inflammatory responses. Microemboli numbers have been linked to the likelihood of neuropsychological deterioration after surgery. Risk factors for cerebral changes after CABS include older age, gender, neurological disease, diabetes, and calcification of the aorta. These risk factors are important because, in comparison with the early 1990s, patients undergoing CABS are now older and tend to have a greater number of comorbid conditions. Changes in surgical technique, such as the introduction of arterial-line filters and membrane oxygenators, have led to a reduction of both microemboli and neuropsychological disturbance. However, the problem persists, prompting further studies on surgical technique and neuroprotective strategies.	UCL, Sch Med, Unit Hlth Psychol, Middlesex Hosp, London W1N 8AA, England	University of London; University College London; UCL Medical School	Newman, SP (corresponding author), UCL, Sch Med, Unit Hlth Psychol, Middlesex Hosp, Mortimer St, London W1N 8AA, England.	S.Newman@ucl.ac.uk		Newman, Stanton/0000-0001-6712-6079				AROM KV, 1995, J CARDIAC SURG, V10, P221, DOI 10.1111/j.1540-8191.1995.tb00602.x; Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Barbut D, 1997, ANN THORAC SURG, V64, P454, DOI 10.1016/S0003-4975(97)00523-7; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; BASHEIN G, 1990, ANESTHESIOLOGY, V72, P7, DOI 10.1097/00000542-199001000-00003; BLAUTH C, 1989, Perfusion (London), V4, P123, DOI 10.1177/026765918900400207; BLAUTH CI, 1995, ANN THORAC SURG, V59, P1300, DOI 10.1016/0003-4975(95)00105-T; Bowles BJ, 2001, CHEST, V119, P25, DOI 10.1378/chest.119.1.25; BRIERLEY J. B., 1963, THORAX, V18, P291, DOI 10.1136/thx.18.4.291; Buss MI, 1996, ANN THORAC SURG, V61, P1423, DOI 10.1016/0003-4975(96)00125-7; CAINE N, 1991, BMJ-BRIT MED J, V302, P511, DOI 10.1136/bmj.302.6775.511; Caplan LR, 2001, ARCH NEUROL-CHICAGO, V58, P549, DOI 10.1001/archneur.58.4.549; COKER LH, 2000, BRAIN CARDIAC SURG, P51; CONNOLLY JE, 1978, J THORAC CARDIOV SUR, V76, P733; DAVID P, 1978, CLEVELAND CLIN Q, V45, P177, DOI 10.3949/ccjm.45.1.177; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GEORGIADES D, 1999, J THORAC CARDIOVASC, V119, P138; GILMAN S, 1965, NEW ENGL J MED, V272, P489, DOI 10.1056/NEJM196503112721001; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Grocott HP, 2002, STROKE, V33, P537, DOI 10.1161/hs0202.102600; Harringer W, 2000, ANN THORAC SURG, V70, P1119, DOI 10.1016/S0003-4975(00)01760-4; HARRIS DN, 1993, LANCET, V342, P586, DOI 10.1016/0140-6736(93)91412-F; Hart JC, 2000, ANN THORAC SURG, V70, P1017, DOI 10.1016/S0003-4975(00)01799-9; Hogue CW, 1999, CIRCULATION, V100, P642, DOI 10.1161/01.CIR.100.6.642; Hogue CW, 2001, CIRCULATION, V103, P2133; *INT PATH LAB MED, 2002, CARD PATH IND; KONG RS, IN PRESS ANESTHESIOL; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Llinas R, 2000, PROG CARDIOVASC DIS, V43, P101, DOI 10.1053/pcad.2000.9030; MARSHALL WG, 1989, ANN THORAC SURG, V48, P339, DOI 10.1016/S0003-4975(10)62852-4; MARTIN TD, 1994, ANN THORAC SURG, V57, P298, DOI 10.1016/0003-4975(94)90987-3; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; MOODY D, 2002, WFUSM DIVISION RADIO; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; Morricone L, 1999, ACTA DIABETOL, V36, P77, DOI 10.1007/s005920050149; Mullges W, 2000, CRIT CARE MED, V28, P1808, DOI 10.1097/00003246-200006000-00020; MURKIN JM, 1995, J THORAC CARDIOV SUR, V110, P349, DOI 10.1016/S0022-5223(95)70230-X; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; NEWMAN S, 1987, CURR PSYCHOL RES REV, V6, P115, DOI 10.1007/BF02686616; Newman S.P., 2000, BRAIN CARDIAC SURG, P21; ORENSTEIN JM, 1982, HUM PATHOL, V13, P1082, DOI 10.1016/S0046-8177(82)80243-8; Patel RL, 1996, J THORAC CARDIOV SUR, V111, P1267, DOI 10.1016/S0022-5223(96)70230-1; Plourde G, 1997, J THORAC CARDIOV SUR, V114, P123, DOI 10.1016/S0022-5223(97)70125-9; Plume SK, 2001, ANN THORAC SURG, V72, P314, DOI 10.1016/S0003-4975(01)02453-5; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; Regragui I, 1996, J THORAC CARDIOV SUR, V112, P1036, DOI 10.1016/S0022-5223(96)70105-8; Reichenspurner H, 2000, J THORAC CARDIOV SUR, V119, P233, DOI 10.1016/S0022-5223(00)70178-4; RICOTTA JJ, 1995, J VASC SURG, V21, P259; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; Rutkow IM, 1997, ARCH SURG-CHICAGO, V132, P983; SANO T, 1992, ANESTHESIOLOGY, V76, P161; Schmitt B, 1998, BRAIN DEV-JPN, V20, P536, DOI 10.1016/S0387-7604(98)00046-1; Selnes OA, 2001, ARCH NEUROL-CHICAGO, V58, P598, DOI 10.1001/archneur.58.4.598; SHAW PJ, 1987, Q J MED, V62, P259; Silver B, 2001, STROKE, V32, P1512; SIMONETTA AB, 2000, BRAIN CARDIAC SURG, P71; SMITH PLC, 1986, LANCET, V1, P823; Stamou SC, 2001, STROKE, V32, P1508, DOI 10.1161/01.STR.32.7.1508; TAKAHASHI S, 1993, RADIOLOGY, V189, P449, DOI 10.1148/radiology.189.2.8210374; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TONER I, 1994, J NEUROSURG ANESTH, V6, P163; Trehan N, 2001, ANN THORAC SURG, V72, pS1026, DOI 10.1016/S0003-4975(01)02936-8; Ura M, 2000, J AM COLL CARDIOL, V35, P1303, DOI 10.1016/S0735-1097(00)00548-9; van Dijk D, 2001, CIRCULATION, V104, P1761, DOI 10.1161/hc4001.097036; van Wermeskerken GK, 2000, ANN THORAC SURG, V69, P1077, DOI 10.1016/S0003-4975(99)01443-5; VENN G, 1987, BRIT HEART J, V57, P565; Wahlgren NG, 1997, INT REV NEUROBIOL, V40, P337; WHITAKER DC, 2001, PERFUSION, V16, P264; WILLIAMS IM, 1971, LANCET, V2, P688; Wityk RJ, 2001, ARCH NEUROL-CHICAGO, V58, P571, DOI 10.1001/archneur.58.4.571; WONG BI, 1992, LANCET, V339, P1383, DOI 10.1016/0140-6736(92)91200-R	73	24	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2002	1	2					119	125		10.1016/S1474-4422(02)00043-1	http://dx.doi.org/10.1016/S1474-4422(02)00043-1			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HA	12849516				2022-12-18	WOS:000177695000020
J	Weintraub, D; Aarsland, D; Chaudhuri, KR; Dobkin, RD; Leentjens, AFG; Rodriguez-Violante, M; Schrag, A				Weintraub, Daniel; Aarsland, Dag; Chaudhuri, Kallol Ray; Dobkin, Roseanne D.; Leentjens, Albert F. G.; Rodriguez-Violante, Mayela; Schrag, Anette			The neuropsychiatry of Parkinson's disease: advances and challenges	LANCET NEUROLOGY			English	Review							IMPULSE CONTROL DISORDERS; DEPRESSIVE SYMPTOMS; DE-NOVO; ANXIETY; DOPAMINE; HALLUCINATIONS; PSYCHOSIS; TRIAL; THERAPY; APATHY	In people with Parkinson's disease, neuropsychiatric signs and symptoms are common throughout the disease course. These symptoms can be disabling and as clinically relevant as motor symptoms, and their presentation can be similar to, or distinct from, their counterparts in the general population. Correlates and risk factors for developing neuropsychiatric signs and symptoms include demographic, clinical, and psychosocial characteristics. The underlying neurobiology of these presentations is complex and not well understood, with the strongest evidence for neuropathological changes associated with Parkinson's disease, mechanisms linked to dopaminergic therapy, and effects not specific to Parkinson's disease. Assessment instruments and formal diagnostic criteria exist, but there is little routine screening of these signs and symptoms in clinical practice. Mounting evidence supports a range of pharmacological and non-pharmacological interventions, but relatively few efficacious treatment options exist. Optimising the management of neuropsychiatric presentations in people with Parkinson's disease will require additional research, raised awareness, specialised training, and development of innovative models of care.	[Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Weintraub, Daniel] Corporal Michael J Crescenz Philadelphia Vet Affa, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA; [Aarsland, Dag; Chaudhuri, Kallol Ray] Kings Coll London, Dept Neurosci, Inst Psychiat Psychol & Neurosci, London, England; [Chaudhuri, Kallol Ray] Kings Coll London, Parkinsons Fdn Ctr Excellence, Kings Coll Hosp, London, England; [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Dis, Stavanger, Norway; [Dobkin, Roseanne D.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA; [Leentjens, Albert F. G.] Maastricht Univ Hosp, Dept Psychiat, Maastricht, Netherlands; [Leentjens, Albert F. G.] Maastricht Univ Hosp, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Rodriguez-Violante, Mayela] Natl Inst Neurol & Neurosurg, Clin Neurodegenerat Dis Res Unit, Mexico City, DF, Mexico; [Schrag, Anette] UCL, Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, London, England	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Stavanger University Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); University of London; University College London	Weintraub, D (corresponding author), Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.; Weintraub, D (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.	daniel.weintraub@pennmedicine.upenn.edu	Rodríguez-Violante, Mayela/G-7056-2015	Rodríguez-Violante, Mayela/0000-0002-6041-9941; Ray Chaudhuri, K/0000-0003-2815-0505; Aarsland, Dag/0000-0001-6314-216X	UK National Institute for Health Research Biomedical Research Centre; Maudsley NHS Foundation Trust; King's College London; University College London; UK National Institute for Health Research, University College London Hospitals Biomedical Research Centre	UK National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); Maudsley NHS Foundation Trust; King's College London(General Electric); University College London(General Electric); UK National Institute for Health Research, University College London Hospitals Biomedical Research Centre	DW is employed by the Crescenz Veterans Affairs Medical Center. For DA, this Review represents work partly supported by the UK National Institute for Health Research Biomedical Research Centre, Maudsley NHS Foundation Trust, and King's College London. AS is supported by University College London and the UK National Institute for Health Research, University College London Hospitals Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the UK National Institute for Health Research, the UK National Institute for Health Research Department of Health and Social Care, the US Government, or the US Department of Veterans Affairs.	Antonini A, 2020, MOVEMENT DISORD, V35, P905, DOI 10.1002/mds.28104; APA Work Group on Alzheimer's Disease and other Dementias, 2007, Am J Psychiatry, V164, P5; Babiloni C, 2020, NEUROBIOL AGING, V91, P88, DOI 10.1016/j.neurobiolaging.2020.02.029; Barone P, 2015, EUR J NEUROL, V22, P1184, DOI 10.1111/ene.12724; Barone P, 2010, LANCET NEUROL, V9, P573, DOI 10.1016/S1474-4422(10)70106-X; Barrell K, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00999; Barrett MJ, 2018, NEUROLOGY, V90, pE1618, DOI 10.1212/WNL.0000000000005421; Barrett MJ, 2017, PARKINSONISM RELAT D, V43, P56, DOI 10.1016/j.parkreldis.2017.07.011; Berardelli I, 2019, CNS NEUROL DISORD-DR, V18, P466, DOI 10.2174/1871527318666190703093345; Berg D, 2015, MOVEMENT DISORD, V30, P1600, DOI 10.1002/mds.26431; Broen MPG, 2016, MOVEMENT DISORD, V31, P1125, DOI 10.1002/mds.26643; Burton A, 2020, LANCET NEUROL, V19, P385, DOI 10.1016/S1474-4422(20)30115-0; Carey G, 2021, MOVEMENT DISORD, V36, P327, DOI 10.1002/mds.28404; Cartoon J, 2019, AUSTRALAS PSYCHIATRY, V27, P456, DOI 10.1177/1039856219839476; Chaudhuri KR, 2020, MOVEMENT DISORD, V35, P116, DOI 10.1002/mds.27862; Chen HM, 2021, PARKINSONISM RELAT D, V83, P86, DOI 10.1016/j.parkreldis.2020.12.025; Claassen DO, 2017, MOVEMENT DISORD, V32, P1574, DOI 10.1002/mds.27047; Corvol JC, 2018, NEUROLOGY, V91, pE189, DOI 10.1212/WNL.0000000000005816; Cummings J, 2014, LANCET, V383, P533, DOI 10.1016/S0140-6736(13)62106-6; D'Iorio A, 2018, NEUROSCI BIOBEHAV R, V94, P1, DOI 10.1016/j.neubiorev.2018.08.004; Dafsari HS, 2019, MOVEMENT DISORD, V34, P353, DOI 10.1002/mds.27626; Damman OC, 2019, HEALTH EXPECT, V22, P939, DOI 10.1111/hex.12899; den Brok MGHE, 2015, MOVEMENT DISORD, V30, P759, DOI 10.1002/mds.26208; Dlay JK, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10020078; Dobkin RD, 2021, MOVEMENT DISORD, V36, P2549, DOI 10.1002/mds.28548; Dobkin RD, 2020, NEUROLOGY, V94, pE1764, DOI 10.1212/WNL.0000000000009292; Drew DS, 2020, BRAIN, V143, P2502, DOI 10.1093/brain/awaa198; Dujardin K, 2015, PARKINSONISM RELAT D, V21, P1299, DOI 10.1016/j.parkreldis.2015.08.032; Eisinger RS, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00086; Estevao C, 2021, BJPSYCH BULL, V45, P32, DOI 10.1192/bjb.2020.122; Fantini ML, 2020, ANN NEUROL, V88, P759, DOI 10.1002/ana.25798; Fenelon G, 2010, MOVEMENT DISORD, V25, P763, DOI 10.1002/mds.22839; Ffytche DH, 2017, NAT REV NEUROL, V13, P81, DOI 10.1038/nrneurol.2016.200; Garlovsky JK, 2016, J CLIN PSYCHOL, V72, P979, DOI 10.1002/jclp.22308; Guo Y, 2019, MOVEMENT DISORD, V34, P876, DOI 10.1002/mds.27665; Gustafsson H, 2015, NEUROLOGY, V84, P2422, DOI 10.1212/WNL.0000000000001684; Habets J, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/15628; Hammes J, 2019, BRAIN, V142, P733, DOI 10.1093/brain/awz007; Hauser RA, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0610-7; Hommel ALAJ, 2020, MOV DISORD CLIN PRAC, V7, P531, DOI 10.1002/mdc3.12968; Iketani R, 2020, PARKINSONISM RELAT D, V78, P82, DOI 10.1016/j.parkreldis.2020.07.021; Irmen F, 2020, ANN NEUROL, V87, P962, DOI 10.1002/ana.25734; Iyer KK, 2020, J AFFECT DISORDERS, V277, P875, DOI 10.1016/j.jad.2020.08.086; Joling M, 2018, J NEUROL NEUROSUR PS, V89, P89, DOI 10.1136/jnnp-2017-316193; Kazmi H, 2021, J NEUROL NEUROSUR PS, V92, P158, DOI 10.1136/jnnp-2020-324266; Kim R, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117157; Kraemmer J, 2016, J NEUROL NEUROSUR PS, V87, P1106, DOI 10.1136/jnnp-2015-312848; Kua ZJ, 2018, J GERIATR PSYCH NEUR, V31, P227, DOI 10.1177/0891988718788641; Kwok JYY, 2019, JAMA NEUROL, V76, P755, DOI 10.1001/jamaneurol.2019.0534; Landau S, 2016, PSYCHOL MED, V46, P657, DOI 10.1017/S0033291715002196; Latella D, 2019, J NEUROL SCI, V398, P101, DOI 10.1016/j.jns.2019.01.034; Le Heron C, 2019, J NEUROL NEUROSUR PS, V90, P302, DOI 10.1136/jnnp-2018-318265; Le Heron C, 2018, BRAIN, V141, P1455, DOI 10.1093/brain/awy110; Lhommee Eugenie, 2018, Lancet Neurol, V17, P223, DOI 10.1016/S1474-4422(18)30035-8; Li SQ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019642; Liao H, FRONT NEUROSCI, V14; Lin FB, 2021, SLEEP MED, V83, P280, DOI 10.1016/j.sleep.2021.03.035; Liu XY, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.591183; Lu HT, 2020, J NEUROL, V267, P331, DOI 10.1007/s00415-019-09588-3; Lubomski M, 2020, J AFFECT DISORDERS, V277, P1038, DOI 10.1016/j.jad.2020.09.032; Lueken U, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1564; Marin-Lahoz J, 2019, ANN NEUROL, V86, P762, DOI 10.1002/ana.25581; Marinus J, 2018, LANCET NEUROL, V17, P559, DOI 10.1016/S1474-4422(18)30127-3; Markovic V, 2020, J NEUROL, V267, P1127, DOI 10.1007/s00415-019-09692-4; Martinez-Martin P, 2020, EUR J NEUROL, V27, P944, DOI 10.1111/ene.14169; Martinez-Martin P, 2020, MOVEMENT DISORD, V35, P969, DOI 10.1002/mds.28002; Martinez-Martin P, 2016, MOVEMENT DISORD, V31, P270, DOI 10.1002/mds.26522; Martini A, 2020, PARKINSONISM RELAT D, V78, P165, DOI 10.1016/j.parkreldis.2020.07.020; Mestre TA, 2021, J PARKINSON DIS, V11, P395, DOI 10.3233/JPD-202472; Mills KA, 2018, INT J GERIATR PSYCH, V33, P642, DOI 10.1002/gps.4834; Moonen AJH, 2021, MOVEMENT DISORD, V36, P2539, DOI 10.1002/mds.28533; O'Brien J, 2020, J NEUROL NEUROSUR PS, V91, P512, DOI 10.1136/jnnp-2019-322702; Ou RW, 2021, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.620762; Pagonabarraga J, 2016, MOVEMENT DISORD, V31, P45, DOI 10.1002/mds.26432; Patterson L, 2019, BRAIN PATHOL, V29, P544, DOI 10.1111/bpa.12697; Payer DE, 2015, MOVEMENT DISORD, V30, P160, DOI 10.1002/mds.26135; Peball M, 2020, ANN NEUROL, V88, P712, DOI 10.1002/ana.25864; Pena E, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11020232; Petrucci S, 2020, MOVEMENT DISORD, V35, P2106, DOI 10.1002/mds.28195; Petry-Schmelzer JN, 2019, BRAIN, V142, P3592, DOI 10.1093/brain/awz285; Picillo M, 2021, J NEUROL, V268, P448, DOI 10.1007/s00415-020-10156-3; Pontone GM, 2019, NPJ PARKINSON DIS, V5, DOI 10.1038/s41531-019-0102-8; Rabinak CA, 2010, ARCH NEUROL-CHICAGO, V67, P58, DOI 10.1001/archneurol.2009.294; Ramezani M, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.587992; Rutten S, 2015, PARKINSONISM RELAT D, V21, P189, DOI 10.1016/j.parkreldis.2014.11.019; Saari L, 2021, ANN NEUROL, V89, P1046, DOI 10.1002/ana.26046; Santangelo G, 2019, NEUROSCI BIOBEHAV R, V107, P672, DOI 10.1016/j.neubiorev.2019.09.041; Santangelo G, 2013, BEHAV NEUROL, V27, P501, DOI [10.1155/2013/851890, 10.3233/BEN-129025]; Santin MD, 2021, MOVEMENT DISORD, V36, P750, DOI 10.1002/mds.28320; Sawada H, 2018, J NEUROL NEUROSUR PS, V89, P1332, DOI 10.1136/jnnp-2018-318107; Schneider RB, 2020, PARKINSONISM RELAT D, V81, P69, DOI 10.1016/j.parkreldis.2020.10.020; Schrag A, 2015, LANCET NEUROL, V14, P57, DOI 10.1016/S1474-4422(14)70287-X; Scott BM, 2020, NEUROLOGY, V95, pE2769, DOI 10.1212/WNL.0000000000010965; Seppi K, 2019, MOVEMENT DISORD, V34, P180, DOI 10.1002/mds.27602; Shepard MD, 2019, J NEUROL NEUROSUR PS, V90, P822, DOI 10.1136/jnnp-2018-319815; Siciliano M, 2018, MOVEMENT DISORD, V33, P1712, DOI 10.1002/mds.27461; Smith KM, 2016, J NEUROL NEUROSUR PS, V87, P864, DOI 10.1136/jnnp-2015-311827; Smith KM, 2015, JAMA NEUROL, V72, P88, DOI 10.1001/jamaneurol.2014.2472; Stankevich Y, 2018, AM J GERIAT PSYCHIAT, V26, P1079, DOI 10.1016/j.jagp.2018.06.012; Takamiya A, 2021, MOVEMENT DISORD, V36, P50, DOI 10.1002/mds.28335; Tariot PN, 2021, NEW ENGL J MED, V385, P309, DOI 10.1056/NEJMoa2034634; Thobois S, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0788-0; Thomas A, 2010, ANN NEUROL, V68, P400, DOI 10.1002/ana.22029; Tuijt R, 2020, PARKINSONS DIS-US, V2020, DOI 10.1155/2020/8857385; van der Velden RMJ, 2018, MOVEMENT DISORD, V33, P1521, DOI 10.1002/mds.27465; Vignando M., MAPPING BRAIN STRUCT, V2021, DOI [10.1101/2021.02.17.21251558, DOI 10.1101/2021.02.17.21251558]; Voon V, 2011, ANN NEUROL, V69, P986, DOI 10.1002/ana.22356; Weintraub D, 2020, ANN CLIN TRANSL NEUR, V7, P449, DOI 10.1002/acn3.51022; Weintraub D, 2016, JAMA NEUROL, V73, P535, DOI 10.1001/jamaneurol.2016.0031; Weintraub D, 2013, NEUROLOGY, V80, P176, DOI 10.1212/WNL.0b013e31827b915c; Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65; Wen MC, 2022, PSYCHOL MED, V52, P264, DOI 10.1017/S0033291720001907; Wu PL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181515; Zarkali A, 2020, BRAIN, V143, P3435, DOI 10.1093/brain/awaa270; Zarkali A, 2020, NEUROLOGY, V94, pE1525, DOI 10.1212/WNL.0000000000009014; Zheng JH, 2017, J NEUROL SCI, V375, P231, DOI 10.1016/j.jns.2017.02.001; Zhu K, 2017, EUR J NEUROL, V24, P404, DOI 10.1111/ene.13217; Zoon TJC, 2021, MOVEMENT DISORD, V36, P317, DOI 10.1002/mds.28390	118	23	23	29	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					89	102		10.1016/S1474-4422(21)00330-6	http://dx.doi.org/10.1016/S1474-4422(21)00330-6			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	XV0SP	34942142	Green Submitted, Green Accepted			2022-12-18	WOS:000734663200025
J	Fortea, J; Zaman, SH; Hartley, S; Rafii, MS; Head, E; Carmona-Iragui, M				Fortea, Juan; Zaman, Shahid H.; Hartley, Sigan; Rafii, Michael S.; Head, Elizabeth; Carmona-Iragui, Maria			Alzheimer's disease associated with Down syndrome: a genetic form of dementia	LANCET NEUROLOGY			English	Review							NEUROFILAMENT LIGHT-CHAIN; AMYLOID DEPOSITION; BIOMARKER CHANGES; SYNDROME BRAIN; A-BETA; ADULTS; PLASMA; ONSET; AGE; MORTALITY	Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. Diagnosis of dementia remains a clinical challenge because of the lack of validated diagnostic criteria in this population, and because symptoms are overshadowed by the intellectual disability associated with Down syndrome. In people with Down syndrome, fluid and imaging biomarkers have shown good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease. Most importantly, there are no treatments to prevent Alzheimer's disease, even though adults with Down syndrome could be an optimal population in whom to conduct Alzheimer's disease prevention trials. Unprecedented research activity in Down syndrome is rapidly changing this bleak scenario that will translate into disease-modifying therapies that could benefit other populations.	[Fortea, Juan; Carmona-Iragui, Maria] Univ Autonoma Barcelona, Biomed Res Inst St Pau, Hosp Santa Creu & St Pau, St Pau Memory Unit,Dept Neurol, Barcelona 08025, Spain; [Fortea, Juan; Carmona-Iragui, Maria] Fundacio Catalana Sindrome, Barcelona Med Ctr, Barcelona, Spain; [Fortea, Juan; Carmona-Iragui, Maria] CIBERNED, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Zaman, Shahid H.] Univ Cambridge, Sch Clin Med, Dept Psychiat, Cambridge, England; [Zaman, Shahid H.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England; [Hartley, Sigan] Univ Wisconsin, Waisman Ctr, Madison, WI USA; [Rafii, Michael S.] Univ Southern Calif, Alzheimers Therapeut Res Inst ATRI, Keck Sch Med, San Diego, CA USA; [Head, Elizabeth] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA	Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; CIBERNED; University of Cambridge; University of Wisconsin System; University of Wisconsin Madison; University of Southern California; University of California System; University of California Irvine	Fortea, J (corresponding author), Univ Autonoma Barcelona, Biomed Res Inst St Pau, Hosp Santa Creu & St Pau, St Pau Memory Unit,Dept Neurol, Barcelona 08025, Spain.	jfortea@santpau.cat	Fortea, Juan/AFU-3179-2022	Fortea, Juan/0000-0002-1340-638X; Carmona Iragui, Maria/0000-0001-6914-2339	Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional, Unio'n Europea; Instituto de Salud Carlos III - Una manera de hacer Europa; NIH; Fundacio'La Marato'TV3; Generalitat de Catalunya; Alzheimer's Association; Global Brain Health Institute; Jerome Lejeune Foundation; Societat Catalana de Neurologia; Fundacio'Catalana Sindrome de Down	Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional, Unio'n Europea; Instituto de Salud Carlos III - Una manera de hacer Europa; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fundacio'La Marato'TV3; Generalitat de Catalunya(Generalitat de Catalunya); Alzheimer's Association(Alzheimer's Association); Global Brain Health Institute; Jerome Lejeune Foundation; Societat Catalana de Neurologia; Fundacio'Catalana Sindrome de Down	Our research is funded by the Instituto de Salud Carlos III, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unio'n Europea, Una manera de hacer Europa; NIH; Fundacio'La Marato'TV3; Generalitat de Catalunya; Alzheimer's Association; Global Brain Health Institute; Jerome Lejeune Foundation; and Societat Catalana de Neurologia. We would like to acknowledge Jordi Pegueroles and Mateus Aranha (Memory Unit of Sant Pau Hospital, Barcelona, Spain) ; Iban Aldecoa (NTB-Biobanc-IDIBAPS-Hospital Clinic, Barcelona, Spain) ; Alessandra C Martini (Department of Pathology and Laboratory Medicine University of California, Irvine, CA, USA) ; Marie-Claude Potier and Alexandra Botte (Paris Brain Institute ICM Sorbonne Universite, Hopital de la Pitie-Salpetriere, Paris, France) for helping with acquiring, providing, and assembling images for the figures. JF and MCI gratefully acknowledge Fundacio'Catalana Sindrome de Down for their support and the members of the Alzheimer's Down Unit and the Memory Unit from the Hospital de la Santa Creu I Sant Pau for their daily work and dedication. We thank all the individuals with Down syndrome who participate in research projects and their families. Their generosity is enabling and will help with important advances in the field of Alzheimer's disease.	Acosta-Baena N, 2011, LANCET NEUROL, V10, P213, DOI 10.1016/S1474-4422(10)70323-9; Alafuzoff I, 2018, HAND CLINIC, V145, P573, DOI 10.1016/B978-0-12-802395-2.00036-5; Alcolea D, 2021, J NEUROL NEUROSUR PS, V92, P1206, DOI 10.1136/jnnp-2021-326603; Altuna M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132776; Annus T, 2017, NEUROBIOL AGING, V53, P11, DOI 10.1016/j.neurobiolaging.2017.01.009; Ball S., 2006, CAMDEX DS CAMBRIDGE; Ballard C, 2016, LANCET NEUROL, V15, P622, DOI 10.1016/S1474-4422(16)00063-6; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bejanin A, 2021, JAMA NEUROL, V78, P937, DOI 10.1001/jamaneurol.2021.1893; Belbin O, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00398-0; Benejam B, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12047; Beresford-Webb JA, 2021, BJPSYCH OPEN, V7, DOI 10.1192/bjo.2021.36; Betthauser, 2020, ALZHEIMERS DEMENT, V12, P1; Botte A, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00956-z; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Buss L, 2016, F1000RES, V5, P1; Carmona-Iragui M, 2021, LANCET NEUROL, V20, P605, DOI 10.1016/S1474-4422(21)00129-0; Carmona-Iragui M, 2019, DEV NEUROBIOL, V79, P716, DOI 10.1002/dneu.22709; Carmona-Iragui M, 2017, ALZHEIMERS DEMENT, V13, P1251, DOI 10.1016/j.jalz.2017.03.007; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cenini G, 2012, BBA-MOL BASIS DIS, V1822, P130, DOI 10.1016/j.bbadis.2011.10.001; Cody KA, 2020, NEUROBIOL AGING, V93, P44, DOI 10.1016/j.neurobiolaging.2020.04.018; Cohen AD, 2018, ALZHEIMERS DEMENT, V14, P743, DOI 10.1016/j.jalz.2018.01.002; Davidson YS, 2011, ACTA NEUROPATHOL, V122, P703, DOI 10.1007/s00401-011-0879-y; de Graaf G, 2017, AM J MED GENET A, V173, P2710, DOI 10.1002/ajmg.a.38402; Dekker AD, 2018, J ALZHEIMERS DIS, V63, P797, DOI 10.3233/JAD-170920; Dekker Alain D, 2017, Alzheimers Dement (Amst), V8, P1, DOI 10.1016/j.dadm.2017.02.006; Doran E, 2017, J ALZHEIMERS DIS, V56, P459, DOI 10.3233/JAD-160836; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Edgin JO, 2017, AJIDD-AM J INTELLECT, V122, P215, DOI 10.1352/1944-7558-122.3.215; Englund A, 2013, AM J MED GENET A, V161A, P642, DOI 10.1002/ajmg.a.35706; Englund H, 2007, DEMENT GERIATR COGN, V24, P369, DOI 10.1159/000109215; Esbensen AJ, 2017, AJIDD-AM J INTELLECT, V122, P247, DOI 10.1352/1944-7558-122.3.247; Fagan AM, 2021, LANCET NEUROL, V20, P615, DOI 10.1016/S1474-4422(21)00139-3; Firth NC, 2018, ANN CLIN TRANSL NEUR, V5, P741, DOI 10.1002/acn3.571; Fleisher AS, 2015, JAMA NEUROL, V72, P316, DOI 10.1001/jamaneurol.2014.3314; Flores-Aguilar L, 2020, BRAIN, V143, P3653, DOI 10.1093/brain/awaa326; Fortea J, 2020, LANCET, V395, P1988, DOI 10.1016/S0140-6736(20)30689-9; Fortea J, 2018, LANCET NEUROL, V17, P860, DOI 10.1016/S1474-4422(18)30285-0; Gholipour T, 2017, EPILEPSY BEHAV, V68, P11, DOI 10.1016/j.yebeh.2016.12.014; Gimenez S, 2018, J CLIN SLEEP MED, V14, P1725, DOI 10.5664/jcsm.7382; GODRIDGE H, 1987, J NEUROL NEUROSUR PS, V50, P775, DOI 10.1136/jnnp.50.6.775; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Haier RJ, 2003, NEUROLOGY, V61, P1673, DOI 10.1212/01.WNL.0000098935.36984.25; Hamlett ED, 2017, ALZHEIMERS DEMENT, V13, P541, DOI 10.1016/j.jalz.2016.08.012; Handen BL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12065; Hanney M, 2012, LANCET, V379, P528, DOI 10.1016/S0140-6736(11)61676-0; Hartley SL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12096; Hartley SL, 2017, NEUROBIOL AGING, V58, P68, DOI 10.1016/j.neurobiolaging.2017.05.019; Head E, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0499-4; Henson RL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12057; Hithersay R, 2021, ALZHEIMERS DEMENT, V17, P595, DOI 10.1002/alz.12222; Hithersay R, 2019, JAMA NEUROL, V76, P152, DOI 10.1001/jamaneurol.2018.3616; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Johnson S.C., 2020, TRANSL RES CLIN INTE, V6, P1; Kamer Angela R, 2016, Alzheimers Dement (Amst), V2, P49, DOI 10.1016/j.dadm.2016.01.001; Landes SD, 2020, DISABIL HEALTH J, V13, DOI 10.1016/j.dhjo.2020.100947; Lao PJ, 2020, ANN NEUROL, V88, P1165, DOI 10.1002/ana.25905; Lao Patrick J, 2018, Alzheimers Dement (Amst), V10, P638, DOI 10.1016/j.dadm.2018.08.007; Lautarescu BA, 2017, NEUROPSYCHOL REV, V27, P31, DOI 10.1007/s11065-017-9341-9; Lee, 2020, ALZHEIMERS DEMENT, V12, P1; Lee S, 2016, ANN NEUROL, V79, P929, DOI 10.1002/ana.24647; Lefter S, 2011, J CLIN NEUROPHYSIOL, V28, P469, DOI 10.1097/WNP.0b013e318230da76; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lengyel Z, 2006, PEDIATR NEUROL, V34, P270, DOI 10.1016/j.pediatrneurol.2005.08.035; Leverenz JB, 1998, EXP NEUROL, V150, P296, DOI 10.1006/exnr.1997.6777; Lippa CF, 2009, ARCH NEUROL-CHICAGO, V66, P1483, DOI 10.1001/archneurol.2009.277; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Livingstone N, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011546.pub2; Lleo A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24319-x; Lleo A, 2015, NAT REV NEUROL, V11, P41, DOI 10.1038/nrneurol.2014.232; Lott IT, 2019, NAT REV NEUROL, V15, P135, DOI 10.1038/s41582-018-0132-6; Lott IT, 2010, LANCET NEUROL, V9, P623, DOI 10.1016/S1474-4422(10)70112-5; Mak E, 2019, ALZH DEMENT-DADM, V11, P654, DOI 10.1016/j.dadm.2019.04.006; Mann DMA, 2018, ACTA NEUROPATHOL, V136, P569, DOI 10.1007/s00401-018-1866-3; MANN DMA, 1988, MECH AGEING DEV, V43, P99, DOI 10.1016/0047-6374(88)90041-3; Matthews Dawn C, 2016, Alzheimers Dement (N Y), V2, P69, DOI 10.1016/j.trci.2016.02.004; McCarron M, 2017, J INTELL DISABIL RES, V61, P843, DOI 10.1111/jir.12390; McCarty, 2020, ALZHEIMERS DEMENT, V12, P1; McDade E, 2018, JAMA NEUROL, V75, P536, DOI 10.1001/jamaneurol.2017.4026; Meeus M, 2015, ACTA NEUROL BELG, V115, P569, DOI 10.1007/s13760-015-0457-5; Montal V, 2021, ANN NEUROL, V90, P407, DOI 10.1002/ana.26178; Moulder KL, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt213; Neale N, 2018, NEUROIMAGE-CLIN, V17, P263, DOI 10.1016/j.nicl.2017.10.022; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Pentz R, 2021, ALZHEIMERS DEMENT, V17, P605, DOI 10.1002/alz.12229; Perez SE, 2019, ACTA NEUROPATHOL, V137, P413, DOI 10.1007/s00401-019-01965-6; Petersen ME, 2021, J ALZHEIMERS DIS, V79, P671, DOI 10.3233/JAD-201167; Petersen ME, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12039; Prasher VP, 2008, INT J GERIATR PSYCH, V23, P1134, DOI 10.1002/gps.2039; PULSIFER MB, 2020, ALZHEIMERS DEMENT, V12, P1; Quiroz YT, 2020, LANCET NEUROL, V19, P513, DOI 10.1016/S1474-4422(20)30137-X; Rafii MS, 2017, J ALZHEIMERS DIS, V60, P439, DOI 10.3233/JAD-170390; ROSAS HD, 2020, ALZHEIMERS DEMENT, V12, P1; Santoro JD, 2021, J NEUROL, V268, P4495, DOI 10.1007/s00415-020-10179-w; Scheltens P, 2021, LANCET, V397, P1577, DOI 10.1016/S0140-6736(20)32205-4; Schupf N, 2020, ALZHEIMERS DEMENT, V12, P1; Schupf N, 2007, ARCH NEUROL-CHICAGO, V64, P1007, DOI 10.1001/archneur.64.7.1007; Shepherd C, 2009, ACTA NEUROPATHOL, V118, P37, DOI 10.1007/s00401-009-0521-4; Sinai A, 2018, J ALZHEIMERS DIS, V61, P717, DOI 10.3233/JAD-170624; Sinai A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153917; Startin CM, 2019, ALZHEIMERS DEMENT, V15, P245, DOI 10.1016/j.jalz.2018.08.009; Startin Carla M, 2016, Wellcome Open Res, V1, P11, DOI 10.12688/wellcomeopenres.9961.1; Strydom Andre, 2018, Alzheimers Dement (N Y), V4, P703, DOI 10.1016/j.trci.2018.10.006; Strydom A, 2009, PROG NEURO-PSYCHOPH, V33, P76, DOI 10.1016/j.pnpbp.2008.10.006; Sullivan KD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13858-3; Taylor DH, 2002, J CLIN EPIDEMIOL, V55, P929, DOI 10.1016/S0895-4356(02)00452-3; Tudorascu DL, 2019, NEUROBIOL AGING, V73, P171, DOI 10.1016/j.neurobiolaging.2018.09.030; US Department of Health and Human Services (Food and Drug Administration), 2018, EARL ALZH DIS DEV DR; Videla S, 2015, T21 RES SOC SOC B, V2, P4; Villemagne VL, 2009, ARCH NEUROL-CHICAGO, V66, P1537, DOI 10.1001/archneurol.2009.285; Wilcock DM, 2015, NEUROBIOL AGING, V36, P2468, DOI 10.1016/j.neurobiolaging.2015.05.016; Wilson M, 2020, AM J NEURORADIOL, V41, P2146, DOI 10.3174/ajnr.A6770; Wiseman FK, 2018, BRAIN, V141, P2457, DOI 10.1093/brain/awy159; Xu Y, 2021, J AM GERIATR SOC, V69, P2011, DOI 10.1111/jgs.17101; Zetterberg H, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0448-1	116	23	23	3	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					930	942		10.1016/S1474-4422(21)00245-3	http://dx.doi.org/10.1016/S1474-4422(21)00245-3			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	WL5PY	34687637	Green Accepted			2022-12-18	WOS:000710458300016
J	Engelter, ST; Traenka, C; Gensicke, H; Schaedelin, SA; Luft, AR; Simonetti, BG; Fischer, U; Michel, P; Sirimarco, G; Kagi, G; Vehoff, J; Nedeltchev, K; Kahles, T; Kellert, L; Rosenbaum, S; von Rennenberg, R; Sztajzel, R; Leib, SL; Jung, S; Gralla, J; Bruni, N; Seiffge, D; Feil, K; Polymeris, AA; Steiner, L; Hamann, J; Bonati, LH; Brehm, A; De Marchis, GM; Peters, N; Stippich, C; Nolte, CH; Christensen, H; Wegener, S; Psychogios, MN; Arnold, M; Lyrer, P				Engelter, Stefan T.; Traenka, Christopher; Gensicke, Henrik; Schaedelin, Sabine A.; Luft, Andreas R.; Simonetti, Barbara Goeggel; Fischer, Urs; Michel, Patrik; Sirimarco, Gaia; Kagi, Georg; Vehoff, Jochen; Nedeltchev, Krassen; Kahles, Timo; Kellert, Lars; Rosenbaum, Sverre; von Rennenberg, Regina; Sztajzel, Roman; Leib, Stephen L.; Jung, Simon; Gralla, Jan; Bruni, Nicole; Seiffge, David; Feil, Katharina; Polymeris, Alexandros A.; Steiner, Levke; Hamann, Janne; Bonati, Leo H.; Brehm, Alex; De Marchis, Gian Marco; Peters, Nils; Stippich, Christoph; Nolte, Christian H.; Christensen, Hanne; Wegener, Susanne; Psychogios, Marios-Nikos; Arnold, Marcel; Lyrer, Philippe		TREAT-CAD Investigators	Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial	LANCET NEUROLOGY			English	Article							ORAL ANTICOAGULANTS; ISCHEMIC-STROKE; BRAIN INFARCTS; DIAGNOSIS; ANTIPLATELETS; MICROBLEEDS; UPDATE	Background Cervical artery dissection is a major cause of stroke in young people (aged <50 years). Historically, clinicians have preferred using oral anticoagulation with vitamin K antagonists for patients with cervical artery dissection, although some current guidelines-based on available evidence from mostly observational studies-suggest using aspirin. If proven to be non-inferior to vitamin K antagonists, aspirin might be preferable, due to its ease of use and lower cost. We aimed to test the non-inferiority of aspirin to vitamin K antagonists in patients with cervical artery dissection. Methods We did a multicentre, randomised, open-label, non-inferiority trial in ten stroke centres across Switzerland, Germany, and Denmark. We randomly assigned (1:1) patients aged older than 18 years who had symptomatic, MRI-verified, cervical artery dissection within 2 weeks before enrolment, to receive either aspirin 300 mg once daily or a vitamin K antagonist (phenprocoumon, acenocoumarol, or warfarin; target international normalised ratio [INR] 2.0-3.0) for 90 days. Randomisation was computer-generated using an interactive web response system, with stratification according to participating site. Independent imaging core laboratory adjudicators were masked to treatment allocation, but investigators, patients, and clinical event adjudicators were aware of treatment allocation. The primary endpoint was a composite of clinical outcomes (stroke, major haemorrhage, or death) and MRI outcomes (new ischaemic or haemorrhagic brain lesions) in the per-protocol population, assessed at 14 days (clinical and MRI outcomes) and 90 days (clinical outcomes only) after commencing treatment. Non-inferiority of aspirin would be shown if the upper limit of the two-sided 95% CI of the absolute risk difference between groups was less than 12% (non-inferiority margin). This trial is registered with ClinicalTrials.gov, NCT02046460. Findings Between Sept 11, 2013, and Dec 21, 2018, we enrolled 194 patients; 100 (52%) were assigned to the aspirin group and 94 (48%) were assigned to the vitamin K antagonist group. The per-protocol population included 173 patients; 91 (53%) in the aspirin group and 82 (47%) in the vitamin K antagonist group. The primary endpoint occurred in 21 (23%) of 91 patients in the aspirin group and in 12 (15%) of 82 patients in the vitamin K antagonist group (absolute difference 8% [95% CI -4 to 21], non-inferiority p=0.55). Thus, non-inferiority of aspirin was not shown. Seven patients (8%) in the aspirin group and none in the vitamin K antagonist group had ischaemic strokes. One patient (1%) in the vitamin K antagonist group and none in the aspirin group had major extracranial haemorrhage. There were no deaths. Subclinical MRI outcomes were recorded in 14 patients (15%) in the aspirin group and in 11 patients (13%) in the vitamin K antagonist group. There were 19 adverse events in the aspirin group, and 26 in the vitamin K antagonist group. Interpretation Our findings did not show that aspirin was non-inferior to vitamin K antagonists in the treatment of cervical artery dissection. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Engelter, Stefan T.; Traenka, Christopher; Gensicke, Henrik; Seiffge, David; Polymeris, Alexandros A.; Bonati, Leo H.; De Marchis, Gian Marco; Peters, Nils; Lyrer, Philippe] Univ Hosp Basel, Dept Neurol, Basel, Switzerland; [Engelter, Stefan T.; Traenka, Christopher; Gensicke, Henrik; Seiffge, David; Polymeris, Alexandros A.; Bonati, Leo H.; De Marchis, Gian Marco; Peters, Nils; Lyrer, Philippe] Univ Hosp Basel, Stroke Ctr, Basel, Switzerland; [Schaedelin, Sabine A.; Bruni, Nicole] Univ Hosp Basel, Dept Clin Res, Basel, Switzerland; [Schaedelin, Sabine A.; Bruni, Nicole] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland; [Brehm, Alex; Psychogios, Marios-Nikos] Univ Hosp Basel, Dept Neuroradiol, Clin Radiol & Nucl Med, Basel, Switzerland; Univ Basel, Basel, Switzerland; [Engelter, Stefan T.; Traenka, Christopher; Gensicke, Henrik; Peters, Nils] Univ Basel, Neurol & Neurorehabil, Univ Hosp Geriatr Med Felix Platter, CH-4055 Basel, Switzerland; [Luft, Andreas R.; Steiner, Levke; Hamann, Janne] Univ Hosp Zurich, Div Vasc Neurol & Neurorehabil, Dept Neurol, Zurich, Switzerland; [Stippich, Christoph] Univ Hosp Zurich, Dept Neuroradiol, Zurich, Switzerland; Univ Zurich, Zurich, Switzerland; [Luft, Andreas R.] Cereneo, Ctr Neurol & Rehabil, Vitznau, Switzerland; [Simonetti, Barbara Goeggel; Fischer, Urs; Jung, Simon; Seiffge, David; De Marchis, Gian Marco; Arnold, Marcel] Univ Bern, Univ Hosp Bern, Dept Neurol, Bern, Switzerland; [Leib, Stephen L.] Univ Bern, Univ Hosp Bern, Inst Infect Dis, Bern, Switzerland; [Gralla, Jan] Univ Bern, Univ Hosp Bern, Inst Diagnost & Intervent Neuroradiol, Bern, Switzerland; [Simonetti, Barbara Goeggel] San Giovanni Hosp, Inst Paediat Southern Switzerland, Dept Neuropaediat, Bellinzona, Switzerland; [Michel, Patrik; Sirimarco, Gaia] CHU Vaudois, Stroke Ctr, Lausanne, Switzerland; [Michel, Patrik; Sirimarco, Gaia] CHU Vaudois, Neurol Serv, Dept Clin Neurosci, Lausanne, Switzerland; [Michel, Patrik; Sirimarco, Gaia] Univ Lausanne, Lausanne, Switzerland; [Kagi, Georg; Vehoff, Jochen] Cantonal Hosp St Gallen, Dept Neurol, St Gallen, Switzerland; [Kagi, Georg; Vehoff, Jochen] Cantonal Hosp St Gallen, Stroke Ctr, St Gallen, Switzerland; [Nedeltchev, Krassen; Kahles, Timo] Hosp Aarau, Dept Neurol, Aarau, Switzerland; [Nedeltchev, Krassen; Kahles, Timo] Hosp Aarau, Stroke Ctr, Aarau, Switzerland; [Kellert, Lars; Feil, Katharina] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany; [Kellert, Lars] Univ Hosp LMU Munich, Inst Stroke & Dementia Res, Munich, Germany; [Rosenbaum, Sverre; Christensen, Hanne] Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark; [Rosenbaum, Sverre; Christensen, Hanne] Univ Copenhagen, Copenhagen, Denmark; [von Rennenberg, Regina; Nolte, Christian H.] Charite Univ Med Berlin, Klin & Hsch Ambulanz Neurol, Berlin, Germany; [von Rennenberg, Regina; Nolte, Christian H.] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [von Rennenberg, Regina; Nolte, Christian H.] Humboldt Univ, Freie Univ Berlin, Berlin Inst Hlth, Berlin, Germany; [Sztajzel, Roman] Univ Hosp Geneva & Med Sch, Dept Neurol, Geneva, Switzerland; [Sztajzel, Roman] Univ Hosp Geneva & Med Sch, Stroke Ctr, Geneva, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Regional Hospital of Bellinzona & Valleys, San Giovanni; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Kantonsspital St. Gallen; Kantonsspital St. Gallen; University of Munich; University of Munich; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; University of Geneva; University of Geneva	Engelter, ST (corresponding author), Univ Basel, Neurol & Neurorehabil, Univ Hosp Geriatr Med Felix Platter, CH-4055 Basel, Switzerland.	stefan.engelter@felixplatter.ch	Sveikata, Lukas/AAT-4084-2020; De Marchis, Gian Marco/J-5414-2019; Polymeris, Alexandros/ABG-4291-2021; Nolte, Christian/AAA-2651-2022; Polymeris, Alexandros/AHB-4688-2022	Sveikata, Lukas/0000-0001-8015-7929; De Marchis, Gian Marco/0000-0002-0342-9780; Polymeris, Alexandros/0000-0002-9475-2208; Nolte, Christian/0000-0001-5577-1775; Polymeris, Alexandros/0000-0002-9475-2208; Seiffge, David/0000-0003-3890-3849; Fischer, Urs/0000-0003-0521-4051; Wagner, Benjamin/0000-0001-9330-1790; Bontinis, Alkis/0000-0002-9998-1886; Gensicke, Henrik/0000-0002-0949-2422; Correia, Pamela/0000-0002-2414-2367; Fisch, Urs/0000-0003-1557-9062; Erdur, Hebun/0000-0001-5383-9625; Christensen, Hanne/0000-0002-7472-3194; /0000-0002-1106-6123	Swiss National Science Foundation [140340]; Swiss Heart Foundation; Stroke Funds Basel, University Hospital Basel; University of Basel; Academic Society Basel	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Heart Foundation; Stroke Funds Basel, University Hospital Basel; University of Basel; Academic Society Basel	We gratefully acknowledge the work of the data safety monitoring board and the clinical event adjudicators. This trial was funded by Swiss National Science Foundation (grant 140340), Swiss Heart Foundation, Stroke Funds Basel, University Hospital Basel, University of Basel, and Academic Society Basel.	Ahmed N, 2017, EUR STROKE J, V2, P95, DOI 10.1177/2396987317699144; Amarenco P, 2018, NEW ENGL J MED, V378, P2182, DOI 10.1056/NEJMoa1802712; Bae HJ, 2016, STROKE, V47, P1413, DOI 10.1161/STROKEAHA.115.011516; Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0; Brott TG, 2011, STROKE, V42, pE420, DOI 10.1161/STR.0b013e3182112d08; Cappellari M, 2017, INT J CARDIOL, V244, P282, DOI 10.1016/j.ijcard.2017.06.006; Caprio FZ, 2014, CEREBROVASC DIS, V38, P247, DOI 10.1159/000366265; Chowdhury MM, 2015, EUR J VASC ENDOVASC, V50, P148, DOI 10.1016/j.ejvs.2015.04.034; Debette S, 2009, LANCET NEUROL, V8, P668, DOI 10.1016/S1474-4422(09)70084-5; Engelter ST, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0769-3; Gensicke H, 2015, EUR J NEUROL, V22, P859, DOI 10.1111/ene.12682; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Hayreh SS, 2005, AM J OPHTHALMOL, V140, P376, DOI 10.1016/j.ajo.2005.03.038; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Kasner SE, 2015, LANCET NEUROL, V14, P342, DOI 10.1016/S1474-4422(14)70271-6; Kawasaki Y, 2010, AM J BIOSTATISTICS, V1, P23; Kennedy F, 2012, NEUROLOGY, V79, P686, DOI 10.1212/WNL.0b013e318264e36b; Kim YK, 2009, THROMB RES, V123, P810, DOI 10.1016/j.thromres.2009.01.013; Lichy C, 2015, INT J STROKE, V10, P360, DOI 10.1111/j.1747-4949.2012.00954.x; Lyrer P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000255.pub2; Malferrari G, 2019, NEUROL SCI, V40, P1591, DOI 10.1007/s10072-019-03882-8; Markus HS, 2015, LANCET NEUROL, V14, P361, DOI 10.1016/S1474-4422(15)70018-9; Menon R, 2008, J NEUROL NEUROSUR PS, V79, P1122, DOI 10.1136/jnnp.2007.138800; Menon RK, 2008, J NEUROL NEUROSUR PS, V79, P612, DOI 10.1136/jnnp.2007.127639; Morris NA, 2017, STROKE, V48, P551, DOI 10.1161/STROKEAHA.116.015185; Mustanoja S, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.349; Mustanoja S, 2014, INT J STROKE, V9, P85, DOI 10.1111/j.1747-4949.2012.00904.x; O'Donnell MJ, 2016, AM HEART J, V178, P145, DOI 10.1016/j.ahj.2016.03.019; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Ringelstein E, 2016, S1 GUIDELINE SPONTAN; Sarikaya H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072697; Sharma M, 2020, STROKE, V51, P2901, DOI 10.1161/STROKEAHA.120.029762; Sondergaard L, 2017, NEW ENGL J MED, V377, P1033, DOI 10.1056/NEJMoa1707404; Speck V, 2014, J STROKE CEREBROVASC, V23, P335, DOI 10.1016/j.jstrokecerebrovasdis.2013.03.033; Traenka C, 2020, EUR STROKE J, V5, P309, DOI 10.1177/2396987320921151; Traenka C, 2019, EUR STROKE J, V4, P127, DOI 10.1177/2396987318824491; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340	37	23	24	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					341	350		10.1016/S1474-4422(21)00044-2	http://dx.doi.org/10.1016/S1474-4422(21)00044-2		APR 2021	10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33765420	Green Accepted			2022-12-18	WOS:000717465200016
J	Zuurbier, SM; Hickman, CR; Tolias, CS; Rinkel, LA; Leyrer, R; Flemming, KD; Bervini, D; Lanzino, G; Wityk, RJ; Schneble, HM; Sure, U; Salman, RA; Counsell, CE; Dodds, H; Stewart, GE; St George, EJ; White, PM; Papanastassiou, V; Warlow, CP; Ritchie, V; Roberts, RC; Sellar, RJ; Bhattacharya, JJ				Zuurbier, Susanna M.; Hickman, Charlotte R.; Tolias, Christos S.; Rinkel, Leon A.; Leyrer, Rebecca; Flemming, Kelly D.; Bervini, David; Lanzino, Giuseppe; Wityk, Robert J.; Schneble, Hans-Martin; Sure, Ulrich; Salman, Rustam Al-Shahi; Counsell, C. E.; Dodds, H.; Stewart, G. E.; St George, E. J.; White, P. M.; Papanastassiou, V.; Warlow, C. P.; Ritchie, V.; Roberts, R. C.; Sellar, R. J.; Bhattacharya, J. J.		Scottish Audit Intracranial Vasc	Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis	LANCET NEUROLOGY			English	Review							CLINICAL-COURSE	Background Antithrombotic (anticoagulant or antiplatelet) therapy is withheld from some patients with cerebral cavernous malformations, because of uncertainty around the safety of these drugs in such patients. We aimed to establish whether antithrombotic therapy is associated with an increased risk of intracranial haemorrhage in adults with cerebral cavernous malformations. Methods In this population-based, cohort study, we used data from the Scottish Audit of Intracranial Vascular Malformations, which prospectively identified individuals aged 16 years and older living in Scotland who were first diagnosed with a cerebral cavernous malformation during 1999-2003 or 2006-10. We compared the association between use of antithrombotic therapy after first presentation and the occurrence of intracranial haemorrhage or persistent or progressive focal neurological deficit due to the cerebral cavernous malformations during up to 15 years of prospective follow-up with multivariable Cox proportional hazards regression assessed in all individuals identified in the database. We also did a systematic review and meta-analysis, in which we searched Ovid MEDLINE and Embase from database inception to Feb 1, 2019, to identify comparative studies to calculate the intracranial haemorrhage incidence rate ratio according to antithrombotic therapy use. We then generated a pooled estimate using the inverse variance method and a random effects model. Findings We assessed 300 of 306 individuals with a cerebral cavernous malformation who were eligible for study. 61 used antithrombotic therapy (ten [16%1 of 61 used anticoagulation) for a mean duration of 7.4 years (SD 5.4) during follow-up. Antithrombotic therapy use was associated with a lower risk of subsequent intracranial haemorrhage or focal neurological deficit (one 12.%] of 61 vs 29 112%1 of 239, adjusted hazard ratio [HR] 0.12, 95% CI 0. 02-0.8; p=0.037). In a meta-analysis of six cohort studies including 1342 patients, antithrombotic therapy use was associated with a lower risk of intracranial haemorrhage (eight [3%] of 253 vs 152 [14%] of 1089; incidence rate ratio 0.25, 95% CI 0.13-0.51; p<0. 0001; I-2=0%). Interpretation Antithrombotic therapy use is associated with a lower risk of intracranial haemorrhage or focal neurological deficit from cerebral cavernous malformations than avoidance of antithrombotic therapy. These findings provide reassurance about safety for clinical practice and require further investigation in a randomised controlled trial. Copyright (C) 2019 The Authors. Published by Elsevier Ltd.	[Zuurbier, Susanna M.] Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Hickman, Charlotte R.; Tolias, Christos S.] Univ Edinburgh, Edinburgh Med Sch, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland; [Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Salman, Rustam Al-Shahi] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Rinkel, Leon A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Leyrer, Rebecca; Sure, Ulrich] Univ Duisburg Essen, Dept Neurosurg, Essen, Germany; [Flemming, Kelly D.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Lanzino, Giuseppe] Mayo Clin, Dept Neurosurg, Rochester, MN USA; [Bervini, David] Bern Univ Hosp, Inselspital, Dept Neurosurg, Bern, Switzerland; [Wityk, Robert J.] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA; [Schneble, Hans-Martin] Hop Lariboisiere, Dept Neurol, Paris, France; [Salman, Rustam Al-Shahi] NHS Lothian, Edinburgh, Midlothian, Scotland; [Counsell, C. E.] NHS Grampian, Aberdeen, Scotland; [Dodds, H.] NHS Natl Serv Scotland, Glasgow, Lanark, Scotland; [Stewart, G. E.] NHS Tayside, Dundee, Scotland; [St George, E. J.] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [White, P. M.] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Papanastassiou, V.] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [Warlow, C. P.; Sellar, R. J.] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Ritchie, V.] Fauldhouse Hlth Ctr, Fauldhouse, Scotland; [Roberts, R. C.] Dundee Univ, Dundee, Scotland; [Bhattacharya, J. J.] NHS Greater Glasgow, Glasgow, Lanark, Scotland	University of Amsterdam; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Groningen; University of Duisburg Essen; Mayo Clinic; Mayo Clinic; University of Bern; University Hospital of Bern; Johns Hopkins University; Johns Hopkins Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; NHS National Services Scotland; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Edinburgh; University of Dundee	Salman, RA (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	Rustam.Al-Shahi@ed.ac.uk	Rinkel, Leon A./GXV-6426-2022	Rinkel, Leon A./0000-0002-0291-8515; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Bervini, David/0000-0003-4873-4452	UK Medical Research Council; Chief Scientist Office of the Scottish Government; Stroke Association; Cavernoma Alliance UK; Remmert Adriaan Laan Foundation; MRC [G1002605] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office of the Scottish Government; Stroke Association; Cavernoma Alliance UK; Remmert Adriaan Laan Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	UK Medical Research Council, Chief Scientist Office of the Scottish Government, The Stroke Association, Cavernoma Alliance UK, and the Remmert Adriaan Laan Foundation.	Abe M, 2005, ACTA NEUROPATHOL, V109, P503, DOI 10.1007/s00401-005-0994-8; Akers A, 2017, NEUROSURGERY, V80, P665, DOI 10.1093/neuros/nyx091; Al-Shahi R, 2003, STROKE, V34, P1163, DOI 10.1161/01.STR.0000069018.90456.C9; Bervini D, 2019, J NEUROSURG, V130, P1922, DOI 10.3171/2018.1.JNS172547; Bradburn MJ, 2003, BRIT J CANCER, V89, P605, DOI 10.1038/sj.bjc.6601120; Clark TG, 2002, LANCET, V359, P1309, DOI 10.1016/S0140-6736(02)08272-7; Coutinho J, 2011, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD002005.PUB2; Coutinho JM, 2014, ANN NEUROL, V75, P908, DOI 10.1002/ana.24180; Eisa-Beygi S, 2014, STROKE, V45, P1859, DOI 10.1161/STROKEAHA.114.005132; Flemming K., 2018, 4 BELL NEUR C CAV MA; Flemming KD, 2013, J NEUROSURG, V118, P43, DOI 10.3171/2012.8.JNS112050; Frischer JM, 2008, J NEUROL NEUROSURG P; Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8; Labouge P, 2007, LANCET NEUROL, V6, P237, DOI 10.1016/S1474-4422(07)70053-4; Morris Z, 2009, BMJ-BRIT MED J, V339, pb3016, DOI [10.1136/bmj.b3016, DOI 10.1136/BMJ.B3016]; RIGAMONTI D, 1987, J NEUROSURG, V67, P518, DOI 10.3171/jns.1987.67.4.0518; Salman RAS, 2019, LANCET NEUROL, V18, P643, DOI 10.1016/S1474-4422(19)30184-X; Salman RAS, 2012, LANCET NEUROL, V11, P217, DOI 10.1016/S1474-4422(12)70004-2; Salman RAS, 2008, STROKE, V39, P3222, DOI 10.1161/STROKEAHA.108.515544; Schneble HM, 2012, STROKE, V43, P3196, DOI 10.1161/STROKEAHA.112.668533; Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354; Whitehead KJ, 2009, NAT MED, V15, P177, DOI 10.1038/nm.1911; Wityk RJ, 2014, AM AC NEUR 66 ANN M; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422	24	23	22	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					935	941		10.1016/S1474-4422(19)30231-5	http://dx.doi.org/10.1016/S1474-4422(19)30231-5			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IX6HN	31401075	Green Published, hybrid			2022-12-18	WOS:000485784000018
J	Ford, GA; Bhakta, BB; Cozens, A; Hartley, S; Holloway, I; Meads, D; Pearn, J; Ruddock, S; Sackley, CM; Saloniki, EC; Santorelli, G; Walker, MF; Farrin, AJ				Ford, Gary A.; Bhakta, Bipin B.; Cozens, Alastair; Hartley, Suzanne; Holloway, Ivana; Meads, David; Pearn, John; Ruddock, Sharon; Sackley, Catherine M.; Saloniki, Eirini-Christina; Santorelli, Gillian; Walker, Marion F.; Farrin, Amanda J.			Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial	LANCET NEUROLOGY			English	Article							MOTOR RECOVERY; LEVODOPA; PHYSIOTHERAPY; AMPHETAMINE	Background Dopamine is a key modulator of striatal function and learning and might improve motor recovery after stroke. Previous small trials of dopamine agonists after stroke provide equivocal evidence of effectiveness on improving motor recovery. We aimed to assess the safety and efficacy of co-careldopa plus routine occupational and physical therapy during early rehabilitation after stroke. Methods This double-blind, multicentre, randomised controlled trial of co-careldopa versus placebo in addition to routine NHS occupational and physical therapy was done at 51 UK NHS acute inpatient stroke rehabilitation services. We recruited patients with new or recurrent clinically diagnosed ischaemic or haemorrhagic (excluding subarachnoid haemorrhage) stroke 5-42 days before randomisation, who were unable to walk 10 m or more, had a score of less than 7 points on the Rivermead Mobility Index, were expected to need rehabilitation, and were able to access rehabilitation after discharge from hospital. Participants were assigned (1:1) using stratified random blocks to receive 6 weeks of oral co-careldopa or matched placebo in addition to routine NHS physiotherapy and occupational therapy. The initial two doses of co-careldopa were 62.5 mg (50 mg of levodopa and 12.5 mg of carbidopa) and the remaining doses were 125 mg (100 mg of levodopa and 25 mg of carbidopa). Participants were required to take a single oral tablet 45-60 min before physiotherapy or occupational therapy session. The primary outcome was ability to walk independently, defined as a Rivermead Mobility Index score of 7 or more, at 8 weeks. Primary and safety analyses were done in the intention-to-treat population. The trial is registered on the ISRCTN registry, number IS RCTN99643613. Findings Between May 30, 2011, and March 28, 2014, of 1574 patients found eligible, 593 (mean age 68.5 years) were randomly assigned to either the co-careldopa group (n=308) or to the placebo group (n=285), on an average 18 days after stroke onset. Primary outcome data were available for all 593 patients. We found no evidence that the ability to walk independently improved with co-careldopa (125 [41%] of 308 patients) compared with placebo (127 [45%] of 285 patients; odds ratio 0.78 [95% CI 0.53-1.15]) at 8 weeks. Mortality at 12 months did not differ between the two groups (22 [7%] vs 17 [6%]). Serious adverse events were largely similar between groups. Vomiting during therapy sessions, after taking the study drug, was the most frequent adverse event and was more frequent in the co-careldopa group than the placebo group (19 [6.2%] vs 9 [3.2%]). Interpretation Co-careldopa in addition to routine occupational and physical therapy does not seem to improve walking after stroke. Further research might identify subgroups of patients with stroke who could benefit from dopaminergic therapy at different doses or times after stroke with more intensive motor therapy. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.	[Ford, Gary A.] Univ Oxford, Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Bhakta, Bipin B.; Pearn, John] Univ Leeds, Acad Dept Rehabil Med, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Hartley, Suzanne; Holloway, Ivana; Ruddock, Sharon; Santorelli, Gillian; Farrin, Amanda J.] Univ Leeds, Clin Trials Res Unit, Leeds Inst Clin Trials Res, Leeds, W Yorkshire, England; [Meads, David] Univ Leeds, Acad Unit Hlth Econ, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England; [Cozens, Alastair] NHS Grampian, Aberdeen, Scotland; [Sackley, Catherine M.] Kings Coll London, Fac Life Sci & Med, Sch Populat & Environm Sci, London, England; [Saloniki, Eirini-Christina] Univ Kent, Ctr Hlth Serv Studies & Personal Social Serv, Res Unit, Canterbury, Kent, England; [Walker, Marion F.] Univ Nottingham, Queens Med Ctr, Rehabil & Ageing, Nottingham, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Leeds; University of Leeds; University of Leeds; University of London; King's College London; University of Kent; University of Nottingham	Ford, GA (corresponding author), Oxford Acad Hlth Sci Network, Magdalen Ctr North, Oxford Sci Business Park, Oxford OX4 4GA, England.	gary.ford@ouh.nhs.uk	Ford, Gary/AAY-6405-2020	Ford, Gary/0000-0001-8719-4968; Farrin, Amanda/0000-0002-2876-0584; Saloniki, Eirini-Christina/0000-0002-5867-2702; sackley, catherine/0000-0002-8580-6622	Medical Research Council	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Medical Research Council.	Acler M, 2009, RESTOR NEUROL NEUROS, V27, P277, DOI 10.3233/RNN-2009-0477; [Anonymous], 1988, USERS GUIDE GEN HLTH; Berends HI, 2009, EUR J PHYS REHAB MED, V45, P621; Bhakta BB, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-316; Boyd LA, 2017, INT J STROKE, V12, P480, DOI 10.1177/1747493017714176; Collen F M, 1991, Int Disabil Stud, V13, P50; Cramer SC, 2009, STROKE, V40, P3034, DOI 10.1161/STROKEAHA.109.552075; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Leblois A, 2006, J NEUROSCI, V26, P3567, DOI 10.1523/JNEUROSCI.5050-05.2006; MAHONEY F I, 1965, Md State Med J, V14, P61; MCENTEE WJ, 1987, YALE J BIOL MED, V60, P187; Michielsen HJ, 2003, J PSYCHOSOM RES, V54, P345, DOI 10.1016/S0022-3999(02)00392-6; Molina-Luna K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007082; Nambu A, 2008, CURR OPIN NEUROBIOL, V18, P595, DOI 10.1016/j.conb.2008.11.001; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Penta M, 2001, STROKE, V32, P1627, DOI 10.1161/01.STR.32.7.1627; Resterneyer C, 2007, RESTOR NEUROL NEUROS, V25, P143; Rosser N, 2008, ARCH PHYS MED REHAB, V89, P1633, DOI 10.1016/j.apmr.2008.02.030; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Sonde L, 2007, ACTA NEUROL SCAND, V115, P55, DOI 10.1111/j.1600-0404.2006.00728.x; Sprigg N, 2009, J NEUROL SCI, V285, P3, DOI 10.1016/j.jns.2009.04.040; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; 2011, ACTA NEUROL SCAND, V123, P266, DOI DOI 10.1111/J.1600-0404.2010.01395.X	26	23	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2019	18	6					530	538		10.1016/S1474-4422(19)30147-4	http://dx.doi.org/10.1016/S1474-4422(19)30147-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HY7RQ	31122493	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000468334100013
J	Yan, XX; Ma, C; Bao, AM; Wang, XM; Gai, WP				Yan, Xiao-Xin; Ma, Chao; Bao, Ai-Min; Wang, Xiao-Min; Gai, Wei-Ping			Brain banking as a cornerstone of neuroscience in China	LANCET NEUROLOGY			English	Letter									[Yan, Xiao-Xin] Cent South Univ Xiangya Sch Med, Dept Anat & Neurobiol, Changsha, Hunan, Peoples R China; [Ma, Chao] Chinese Acad Med Sci, Ctr Neurosci, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Ma, Chao] Peking Union Med Coll, Sch Basic Med, Dept Human Anat Histol & Embryol, Beijing 100021, Peoples R China; [Bao, Ai-Min] Zhejiang Univ, Sch Med, Minist Hlth China, Dept Neurobiol,Key Lab Med Neurobiol, Hangzhou 310003, Zhejiang, Peoples R China; [Bao, Ai-Min] Zhejiang Univ, Sch Med, Zhejiang Prov Key Lab Neurobiol, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Xiao-Min] Capital Med Univ, Minist Educ, Dept Neurobiol, Key Lab Neurodegenerat Disorders, Beijing, Peoples R China; [Gai, Wei-Ping] Flinders Univ S Australia, Sch Med, Dept Human Physiol, Bedford Pk, SA 5042, Australia; [Gai, Wei-Ping] Flinders Univ S Australia, Sch Med, Ctr Neurosci, Bedford Pk, SA 5042, Australia	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Zhejiang University; Zhejiang University; Capital Medical University; Flinders University South Australia; Flinders University South Australia	Yan, XX (corresponding author), Cent South Univ Xiangya Sch Med, Dept Anat & Neurobiol, Changsha, Hunan, Peoples R China.	yanxiaoxin@csu.edu.cn	Gai, Wei-Ping/A-3700-2008					Chung K, 2013, NAT METHODS, V10, P508, DOI [10.1038/NMETH.2481, 10.1038/nmeth.2481]; Kang HJ, 2011, NATURE, V478, P483, DOI 10.1038/nature10523; Peng XZ, 2011, SCIENCE, V333, P581, DOI 10.1126/science.1209396; Samarasekera N, 2013, LANCET NEUROL, V12, P1096, DOI 10.1016/S1474-4422(13)70202-3; Zeng HK, 2012, CELL, V149, P483, DOI 10.1016/j.cell.2012.02.052	5	23	27	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2015	14	2					136	136		10.1016/S1474-4422(14)70259-5	http://dx.doi.org/10.1016/S1474-4422(14)70259-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY9KS	25772887				2022-12-18	WOS:000347869400008
J	Giaccone, G; Arzberger, T; Alafuzoff, I; Al-Sarraj, S; Budka, H; Duyckaerts, C; Falkai, P; Ferrer, I; Ironside, JW; Kovacs, GG; Meyronet, D; Parchi, P; Patsouris, E; Revesz, T; Riederer, P; Rozemuller, A; Schmitt, A; Winblad, B; Kretzschmar, H				Giaccone, Giorgio; Arzberger, Thomas; Alafuzoff, Irina; Al-Sarraj, Safa; Budka, Herbert; Duyckaerts, Charles; Falkai, Peter; Ferrer, Isidro; Ironside, James W.; Kovacs, Gabor G.; Meyronet, David; Parchi, Piero; Patsouris, Efstratios; Revesz, Tomas; Riederer, Peter; Rozemuller, Annemieke; Schmitt, Andrea; Winblad, Bengt; Kretzschmar, Hans		BrainNet Europe Consortium	New lexicon and criteria for the diagnosis of Alzheimer's disease	LANCET NEUROLOGY			English	Letter							BRAINNET EUROPE CONSORTIUM		[Giaccone, Giorgio] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy; [Arzberger, Thomas; Kretzschmar, Hans] Univ Munich, Ctr Neuropathol & Pr Res, Munich, Germany; [Alafuzoff, Irina] Uppsala Univ, Uppsala, Sweden; [Al-Sarraj, Safa] London Inst Psychiat, London, England; [Budka, Herbert; Kovacs, Gabor G.] Med Univ Vienna, Inst Neurol, Vienna, Austria; [Duyckaerts, Charles] Univ Paris 06, AP HP, F-75252 Paris 05, France; [Falkai, Peter; Schmitt, Andrea] Univ Gottingen, Dept Psychiat, Gottingen, Germany; [Ferrer, Isidro] Univ Barcelona, Barcelona, Spain; [Ironside, James W.] Univ Edinburgh, Western Gen Hosp, Edinburgh, Midlothian, Scotland; [Meyronet, David] Univ Lyon, Lyon, France; [Parchi, Piero] Univ Bologna, Bologna, Italy; [Patsouris, Efstratios] Natl & Capodistrian Univ Athens, Athens, Greece; [Revesz, Tomas] Inst Neurol, London WC1N 3BG, England; [Riederer, Peter] Univ Wurzburg, Wurzburg, Germany; [Rozemuller, Annemieke] Netherlands Brain Bank, Amsterdam, Netherlands; [Winblad, Bengt] Karolinska Inst, KI Alzheimer Dis Res Ctr, Huddinge, Sweden	IRCCS Istituto Neurologico Besta; University of Munich; Uppsala University; University of London; King's College London; Medical University of Vienna; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite; University of Gottingen; University of Barcelona; University of Edinburgh; University of Bologna; National & Kapodistrian University of Athens; University of London; University College London; University of Wurzburg; Karolinska Institutet	Giaccone, G (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy.	giaccone@istituto-besta.it	Schmitt, Andrea/V-3003-2018; Falkai, Peter/E-3273-2017; Revesz, Tamas/A-8732-2010; Giaccone, Giorgio/J-6212-2012; giaccone, giorgio/AAB-9978-2019; Budka, Herbert/I-3486-2019; Rozemuller, Annemieke/C-2084-2008; Sohrabi, Hamid/D-2744-2013; Kovacs, Gabor/A-7468-2013; Parchi, Piero/L-9833-2015	Schmitt, Andrea/0000-0002-5426-4023; Falkai, Peter/0000-0003-2873-8667; Revesz, Tamas/0000-0003-2501-0259; giaccone, giorgio/0000-0002-4803-0802; Budka, Herbert/0000-0002-1933-1577; Sohrabi, Hamid/0000-0001-8017-8682; Kovacs, Gabor/0000-0003-3841-5511; Parchi, Piero/0000-0002-9444-9524; Ironside, James/0000-0001-5869-2108	Medical Research Council [MC_G0901943, G0600953, G0900580, G0901945] Funding Source: Medline; MRC [G0600953, MC_G0901943, G0901945, G0900580] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alafuzoff I, 2006, J NEUROPATH EXP NEUR, V65, P740, DOI 10.1097/01.jnen.0000229986.17548.27; [Anonymous], 1997, NEUROBIOL AGING S4, V18, pS1; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Kovacs GG, 2008, DEMENT GERIATR COGN, V26, P343, DOI 10.1159/000161560; Oksengard AR, 2010, DEMENT GERIATR COGN, V30, P374, DOI 10.1159/000321121	5	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2011	10	4					298	299		10.1016/S1474-4422(11)70055-2	http://dx.doi.org/10.1016/S1474-4422(11)70055-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745SB	21435593				2022-12-18	WOS:000289185000011
J	Burns, A				Burns, Alistair			Alzheimer's disease: on the verges of treatment and prevention	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-BLIND		Univ Manchester, Psychiat Res Grp, Manchester M13 9PL, Lancs, England	University of Manchester	Burns, A (corresponding author), Univ Manchester, Psychiat Res Grp, Manchester M13 9PL, Lancs, England.	alistair.burns@manchester.ac.uk		Burns, Alistair/0000-0002-9837-0645				Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; ELAN, WYETH PRESENT ENCOUR; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4; Peters R, 2008, LANCET NEUROL, V7, P683, DOI 10.1016/S1474-4422(08)70143-1; SULLIVAN MG, TRAMIPROSATE FALLS S; Wilcock GK, 2008, LANCET NEUROL, V7, P483, DOI 10.1016/S1474-4422(08)70090-5	8	23	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					4	5		10.1016/S1474-4422(08)70271-0	http://dx.doi.org/10.1016/S1474-4422(08)70271-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081500				2022-12-18	WOS:000261860700003
J	Geschwind, D				Geschwind, D			GENSAT: a genomic resource for neuroscience research	LANCET NEUROLOGY			English	Editorial Material									Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Geschwind, D (corresponding author), Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90024 USA.	dhg@ucla.edu						Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; Heintz N, 2001, NAT REV NEUROSCI, V2, P861, DOI 10.1038/35104049	2	23	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					82	82		10.1016/S1474-4422(03)00658-6	http://dx.doi.org/10.1016/S1474-4422(03)00658-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14746997				2022-12-18	WOS:000188818500015
J	Hayden, MR				Hayden, MR			Predictive testing for Huntington's disease: a universal model?	LANCET NEUROLOGY			English	Editorial Material									Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				CREIGHTON S, IN PRESS CLIN GENET; Goizet C, 2002, NEUROLOGY, V59, P1330, DOI 10.1212/01.WNL.0000032255.75650.C2; Harper PS, 2000, J MED GENET, V37, P567, DOI 10.1136/jmg.37.8.567; Hayden MR, 2000, LANCET, V356, P1944, DOI 10.1016/S0140-6736(00)03301-8; WENT L, 1994, J MED GENET, V31, P555	5	23	23	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2003	2	3					141	142		10.1016/S1474-4422(03)00317-X	http://dx.doi.org/10.1016/S1474-4422(03)00317-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648NV	12849232				2022-12-18	WOS:000181158200010
J	Ryvlin, P; Rheims, S; Hirsch, LJ; Sokolov, A; Jehi, L				Ryvlin, Philippe; Rheims, Sylvain; Hirsch, Lawrence J.; Sokolov, Arseny; Jehi, Lara			Neuromodulation in epilepsy: state-of-the-art approved therapies	LANCET NEUROLOGY			English	Review							VAGUS-NERVE-STIMULATION; DEEP BRAIN-STIMULATION; DRUG-RESISTANT EPILEPSY; ANTERIOR THALAMIC NUCLEI; LONG-TERM TREATMENT; RESPONSIVE NEUROSTIMULATION; INTRACTABLE EPILEPSY; ICTAL TACHYCARDIA; FOCAL EPILEPSY; EFFICACY	Three neuromodulation therapies have been appropriately tested and approved in refractory focal e pile ps ie s: vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (ANT-D BS), and closed-loop responsive neurostimulation of the epileptogenic zone or zones. These therapies are primarily palliative. Only a few individuals have achieved complete freedom from seizures for more than 12 months with these therapies, whereas more than half have benefited from long-term reduction in seizure frequency of more than 50%. Implantation -related adverse events primarily include infection and pain at the implant site. Intracranial haemorrhage is a frequent adverse event for ANT-D BS and responsive neurostimulation. Other stimulation-specific side -effects are observed with VNS and ANT-DBS. Biomarkers to predict response to neuromodulation therapies are not available, and high-level evidence to aid decision making about when and for whom these therapies should be preferred over other antiepileptic treatments is scant. Future studies are thus needed to address these shortfalls in knowledge, approve other forms of neuromodulation, and develop personalised closed -loop therapies with embedded machine learning. Until then, neuromodulation could be considered for individuals with intractable seizures, ideally after the possibility of curative surgical treatment has been carefully assessed and ruled out or judged less appropriate.	[Ryvlin, Philippe; Sokolov, Arseny] Lausanne Univ Hosp, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland; [Ryvlin, Philippe; Sokolov, Arseny] Univ Lausanne, Lausanne, Switzerland; [Rheims, Sylvain] Lyon 1 Univ, Hosp Civils Lyon, Lyon Neurosci Res Ctr,Dept Funct Neurol & Epilept, Inst Natl Sante & Rech Med U1028,Epilepsy Inst,CN, Lyon, France; [Hirsch, Lawrence J.] Yale Univ, Sch Med, Comprehens Epilepsy Ctr, Dept Neurol, New Haven, CT USA; [Jehi, Lara] Cleveland Clin, Epilepsy Ctr, Cleveland, OH 44106 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Yale University; Cleveland Clinic Foundation	Ryvlin, P (corresponding author), Lausanne Univ Hosp, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland.	philippe.ryvlin@chuv.ch		Rheims, Sylvain/0000-0002-4663-8515	National Institutes of Health [R01 NS097719]; EU's Horizon 2020 Research and Innovation Programme [785907, 945539]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EU's Horizon 2020 Research and Innovation Programme	LJ receives a National Institutes of Health grant (R01 NS097719). PR is the recipient of the EU's Horizon 2020 Research and Innovation Programme under grant agreements 785907 (HBP SGA2) and 945539 (HBP SGA3); the funder had no role in the writing of the report.	Assenza G, 2020, NEUROL SCI, V41, P3075, DOI 10.1007/s10072-020-04479-2; Baud MO, 2018, NEUROLOGY, V91, P967, DOI 10.1212/WNL.0000000000006548; Ben-Menachem E, 2002, LANCET NEUROL, V1, P477, DOI 10.1016/S1474-4422(02)00220-X; Bergey GK, 2015, NEUROLOGY, V84, P810, DOI 10.1212/WNL.0000000000001280; Boon P, 2015, SEIZURE-EUR J EPILEP, V32, P52, DOI 10.1016/j.seizure.2015.08.011; Buentjen L, 2014, STEREOT FUNCT NEUROS, V92, P25, DOI 10.1159/000351525; Chen ZB, 2018, JAMA NEUROL, V75, P279, DOI 10.1001/jamaneurol.2017.3949; Conway CR, 2018, EPILEPSY BEHAV, V88, P25, DOI 10.1016/j.yebeh.2018.06.007; Dibue M, 2021, ACTA NEUROL SCAND, V143, P497, DOI 10.1111/ane.13375; Dolezalova I, 2019, EPILEPSY BEHAV REP, V12, DOI 10.1016/j.ebr.2019.100344; Eggleston KS, 2014, SEIZURE-EUR J EPILEP, V23, P496, DOI 10.1016/j.seizure.2014.02.012; Elger G, 2000, EPILEPSY RES, V42, P203, DOI 10.1016/S0920-1211(00)00181-9; Elizebath R, 2021, EPILEPSY BEHAV, V116, DOI 10.1016/j.yebeh.2021.107796; Ellens NR, 2018, STEREOT FUNCT NEUROS, V96, P259, DOI 10.1159/000492232; Englot DJ, 2017, EPILEPSY BEHAV, V66, P4, DOI 10.1016/j.yebeh.2016.10.005; Englot DJ, 2016, NEUROSURGERY, V79, P345, DOI 10.1227/NEU.0000000000001165; Englot DJ, 2011, NEUROSURG CLIN N AM, V22, P443, DOI 10.1016/j.nec.2011.07.002; Evangelista E, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00192; Fan JJ, 2019, CNS NEUROSCI THER, V25, P1222, DOI 10.1111/cns.13209; Fasano A, 2012, LANCET NEUROL, V11, P429, DOI 10.1016/S1474-4422(12)70049-2; Fernandez L, 2015, EPILEPSY RES, V112, P37, DOI 10.1016/j.eplepsyres.2015.02.009; Fisher RS, 2015, ACTA NEUROL SCAND, V131, P1, DOI 10.1111/ane.12288; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Fisher RS, 2016, NEUROMODULATION, V19, P188, DOI 10.1111/ner.12376; Fraschini M, 2013, NEUROSCI LETT, V536, P14, DOI 10.1016/j.neulet.2012.12.044; GEORGE R, 1995, NEUROLOGY, V45, P224, DOI 10.1212/wnl.45.2.224; Gonzalez HFJ, 2019, NEUROSURG CLIN N AM, V30, P219, DOI 10.1016/j.nec.2018.12.005; Guo ZS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00858; Hadjinicolaou A, 2020, EPILEPSY RES, V167, DOI 10.1016/j.eplepsyres.2020.106431; Hamilton P, 2018, SEIZURE-EUR J EPILEP, V58, P120, DOI 10.1016/j.seizure.2018.03.022; Handforth A, 1998, NEUROLOGY, V51, P48, DOI 10.1212/WNL.51.1.48; Harden CL, 2000, EPILEPSY BEHAV, V1, P93, DOI 10.1006/ebeh.2000.0046; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; Heck CN, 2014, EPILEPSIA, V55, P432, DOI 10.1111/epi.12534; Herrman H, 2019, ACTA NEUROL SCAND, V139, P294, DOI 10.1111/ane.13047; Hirsch LJ, 2020, EPILEPSIA, V61, P408, DOI 10.1111/epi.16442; Hodl S, 2020, EUR J NEUROL, V27, P1178, DOI 10.1111/ene.14270; Jain P, 2021, NEUROLOGY, V96, P1041, DOI 10.1212/WNL.0000000000012030; Jaseja H, 2010, MED HYPOTHESES, V74, P855, DOI 10.1016/j.mehy.2009.11.031; Kaufmann E, 2020, SEIZURE-EUR J EPILEP, V81, P201, DOI 10.1016/j.seizure.2020.08.015; Kawaji H, 2020, NEUROSCI LETT, V716, DOI 10.1016/j.neulet.2019.134636; King-Stephens D, 2015, EPILEPSIA, V56, P959, DOI 10.1111/epi.13010; Klinkenberg S, 2013, EUR J PAEDIATR NEURO, V17, P82, DOI 10.1016/j.ejpn.2012.07.003; Klinkenberg S, 2012, DEV MED CHILD NEUROL, V54, P855, DOI 10.1111/j.1469-8749.2012.04305.x; Kokkinos V, 2019, JAMA NEUROL, V76, P800, DOI 10.1001/jamaneurol.2019.0658; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; Krishna V, 2016, NEUROSURGERY, V78, P802, DOI 10.1227/NEU.0000000000001197; Kulju T, 2019, NEUROMODULATION, V22, P630, DOI 10.1111/ner.12897; Kwan Harwood, 2016, Bioelectron Med, V3, P1; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Lam J, 2021, EPILEPSY RES, V172, DOI 10.1016/j.eplepsyres.2021.106591; Lehtimaki K, 2016, BRAIN STIMUL, V9, P268, DOI 10.1016/j.brs.2015.09.014; Lehtimaki K, 2019, NEUROSURGERY, V84, P141, DOI 10.1093/neuros/nyy023; Liu HY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21669-3; Lo WB, 2021, CHILD NERV SYST, V37, P1237, DOI 10.1007/s00381-020-04962-3; Markert MS, 2019, EXPERT REV NEUROTHER, V19, P17, DOI [10.1080/14737175.2019.1554433, 10.1515/9783110614039-001]; Marrosu F, 2003, EPILEPSY RES, V55, P59, DOI 10.1016/S0920-1211(03)00107-4; Marzec M, 2003, EPILEPSIA, V44, P930, DOI 10.1046/j.1528-1157.2003.56202.x; Middlebrooks EH, 2020, WORLD NEUROSURG, V136, P357, DOI 10.1016/j.wneu.2020.01.108; Middlebrooks EH, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.5.FOCUS18151; Mithani K, 2020, NEUROIMAGE-CLIN, V26, DOI 10.1016/j.nicl.2020.102205; Mithani K, 2019, ANN NEUROL, V86, P743, DOI 10.1002/ana.25574; Morrell MJ, 2011, NEUROLOGY, V77, P1295, DOI 10.1212/WNL.0b013e3182302056; Morris GL, 2013, NEUROLOGY, V81, P1453, DOI 10.1212/WNL.0b013e3182a393d1; Morris GL, 1999, NEUROLOGY, V53, P1731, DOI 10.1212/WNL.53.8.1731; Mottonen T, 2015, NEUROIMAGE-CLIN, V7, P823, DOI 10.1016/j.nicl.2015.03.001; Nair DR, 2020, NEUROLOGY, V95, pE1244, DOI 10.1212/WNL.0000000000010154; Nichols JA, 2011, NEUROSCIENCE, V189, P207, DOI 10.1016/j.neuroscience.2011.05.024; O'Rourke G, 2017, SEIZURE-EUR J EPILEP, V45, P160, DOI 10.1016/j.seizure.2016.12.006; Park HR, 2019, STEREOT FUNCT NEUROS, V97, P176, DOI 10.1159/000502344; Perucca E, 2020, LANCET NEUROL, V19, P544, DOI 10.1016/S1474-4422(20)30035-1; Perucca P, 2012, LANCET NEUROL, V11, P792, DOI 10.1016/S1474-4422(12)70153-9; Proix T, 2021, LANCET NEUROL, V20, P127, DOI 10.1016/S1474-4422(20)30396-3; Quraishi IH, 2020, EPILEPSIA, V61, P138, DOI 10.1111/epi.16412; Raedt R, 2011, J NEUROCHEM, V117, P461, DOI 10.1111/j.1471-4159.2011.07214.x; Revesz D, 2016, J NEUROSURG-PEDIATR, V18, P97, DOI 10.3171/2016.1.PEDS15534; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Russo A, 2021, J CHILD NEUROL, V36, P365, DOI 10.1177/0883073820974855; Ryvlin P, 2018, EPILEPSIA, V59, P562, DOI 10.1111/epi.14002; Ryvlin P, 2014, LANCET NEUROL, V13, P1114, DOI 10.1016/S1474-4422(14)70156-5; Ryvlin P, 2014, EPILEPSIA, V55, P893, DOI 10.1111/epi.12611; Salanova V, 2021, EPILEPSIA, V62, P1306, DOI 10.1111/epi.16895; Salanova V, 2015, NEUROLOGY, V84, P1017, DOI 10.1212/WNL.0000000000001334; Salvade A, 2018, EPILEPSY BEHAV, V79, P126, DOI 10.1016/j.yebeh.2017.10.040; Schaper FLWVJ, 2020, NEUROSURGERY, V87, P602, DOI 10.1093/neuros/nyaa141; Scherer M, 2020, NEUROIMAGE, V218, DOI 10.1016/j.neuroimage.2020.116967; Shi L, 2015, EXP NEUROL, V265, P94, DOI 10.1016/j.expneurol.2015.01.003; Sprengers M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008497.pub3; Sveinsson O, 2020, NEUROLOGY, V94, pE419, DOI 10.1212/WNL.0000000000008741; Troster AI, 2017, SEIZURE-EUR J EPILEP, V45, P133, DOI 10.1016/j.seizure.2016.12.014; Tzadok M, 2019, SEIZURE-EUR J EPILEP, V71, P140, DOI 10.1016/j.seizure.2019.07.006; Voges BR, 2015, EPILEPSIA, V56, pe99, DOI 10.1111/epi.13045; Wang AJ, 2020, STEREOT FUNCT NEUROS, V98, P21, DOI 10.1159/000504859; Wang YC, 2020, EPILEPSY RES, V159, DOI 10.1016/j.eplepsyres.2019.106248; Wang YC, 2019, EPILEPSY RES, V153, P1, DOI 10.1016/j.eplepsyres.2019.03.010; Ye VC, 2021, CHILD NERV SYST, V37, P259, DOI 10.1007/s00381-020-04698-0; Yu T, 2018, BRAIN, V141, P2631, DOI 10.1093/brain/awy187; Zambrelli E, 2016, EPILEPSIA, V57, pE24, DOI 10.1111/epi.13252; Zhu J, 2020, EPILEPSY RES, V167, DOI 10.1016/j.eplepsyres.2020.106432	99	22	23	11	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					1038	1047		10.1016/S1474-4422(21)00300-8	http://dx.doi.org/10.1016/S1474-4422(21)00300-8		NOV 2021	10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34710360				2022-12-18	WOS:000755602800028
J	Wright, GEB; Black, HF; Collins, JA; Gall-Duncan, T; Caron, NS; Pearson, CE; Hayden, MR				Wright, Galen E. B.; Black, Halley Findlay; Collins, Jennifer A.; Gall-Duncan, Terence; Caron, Nicholas S.; Pearson, Christopher E.; Hayden, Michael R.			Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies	LANCET NEUROLOGY			English	Review							DNA-LIGASE-I; CAG REPEAT; SOMATIC EXPANSION; GENE; MUTATION; INSTABILITY; NUSINERSEN; BRAIN; FAN1; SUSCEPTIBILITY	Background Huntington's disease is a fatal neurodegenerative disorder that is caused by CAG-CAA repeat expansion, encoding polyglutamine, in the huntingtin (HTI) gene. Current age-of-clinical-onset prediction models for Huntington's disease are based on polyglutamine length and explain only a proportion of the variability in age of onset observed between patients. These length-based assays do not interrogate the underlying genetic variation, because known genetic variants in this region do not alter the protein coding sequence. Given that individuals with identical repeat lengths can present with Huntington's disease decades apart, the search for genetic modifiers of clinical age of onset has become an active area of research. Recent developments Results from three independent genetic studies of Huntington's disease have shown that glutamine-encoding CAA variants that interrupt DNA CAG repeat tracts, but do not alter polyglutamnine length or polyglutamine homogeneity, are associated with substantial differences in age of onset of Huntington's disease in carriers. A variant that results in the loss of CAA interruption is associated with early onset and is particularly relevant to individuals that carry alleles in the reduced penetrance range (ie, CAG 36-39). Approximately a third of clinically manifesting carriers of reduced penetrance alleles, defined by current diagnostics, carry this variant. Somatic repeat instability, modified by interrupted CAG tracts, is the most probable cause mediating this effect. This relationship is supported by genome-wide screens for disease modifiers, which have revealed the importance of DNA-repair genes in Huntington's disease (ie, FAN1, LIG1, MLH1, MSH3, PMS1, and PMS2). Where next? Focus needs to be placed on refining our understanding of the effect of the loss-of-interruption and duplication-of-interruption variants and other interrupting sequence variants on age of onset, and assessing their effect in disease-relevant brain tissues, as well as in diverse population groups, such as individuals from Africa and Asia. Diagnostic tests should be augmented or updated, since current tests do not assess the underlying DNA sequence variation, especially when assessing individuals that carry alleles in the reduced penetrance range. Future studies should explore somatic repeat instability and DNA repair as new therapeutic targets to modify age of onset in Huntington's disease and in other repeat-mediated disorders. Disease-modifying therapies could potentially be developed by therapeutically targeting these processes. Promising approaches include therapeutically targeting the expanded repeat or directly perturbing key DNA-repair genes (eg, with antisense oligonucleotides or small molecules). Targeting the CAG repeat directly with naphthyridine-azaquinolone, a compound that induces contractions, and altering the expression of MSH3, represent two viable therapeutic strategies. However, as a first step, the capability of such novel therapeutic approaches to delay clinical onset in animal models should be assessed.	[Wright, Galen E. B.; Black, Halley Findlay; Collins, Jennifer A.; Caron, Nicholas S.; Hayden, Michael R.] Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC, Canada; [Wright, Galen E. B.; Black, Halley Findlay; Collins, Jennifer A.; Caron, Nicholas S.; Hayden, Michael R.] BC Childrens Hosp Res Inst, Vancouver, BC, Canada; [Wright, Galen E. B.] Univ Manitoba, Kleysen Inst Adv Med, Dept Pharmacol & Therapeut, Neurosci Res Program, Winnipeg, MB, Canada; [Gall-Duncan, Terence; Pearson, Christopher E.] Hosp Sick Children, Peter Gilgan Ctr Res & Leaming, Program Genet & Genome Biol, Toronto, ON, Canada; [Gall-Duncan, Terence; Pearson, Christopher E.] Univ Toronto, Program Mol Genet, Toronto, ON, Canada	University of British Columbia; University of Manitoba; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hayden, MR (corresponding author), Univ British Columbia, BC Childrens Hosp Res Inst, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Hayden, Michael/D-8581-2011	Hayden, Michael/0000-0001-5159-1419; Caron, Nicholas/0000-0002-3877-455X	Canadian Institutes of Health Research; BC Children's Hospital Research Institute	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); BC Children's Hospital Research Institute	MRH reports grants from the Canadian Institutes of Health Research, during the conduct of the Rapid Review, and personal fees from Xenon, Aurinia, and Ionis, outside the submitted work. CEP has a patent, methods of treating diseases associated with repeat instability, licensed to BridgeBio. NSC reports grants from Huntington's Disease Society of America and the James Family Fellowship, outside the submitted work. HFB reports a fellowship with BC Children's Hospital Research Institute, during the conduct of the Rapid Review. All other authors declare no competing interests.	Akcimen F, 2020, AGING-US, V12, P4742, DOI 10.18632/aging.102825; Arrasate M, 2012, EXP NEUROL, V238, P1, DOI 10.1016/j.expneurol.2011.12.013; Aviolat H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55202-x; Bahat A, 2019, MOL CELL, V76, P617, DOI 10.1016/j.molcel.2019.08.024; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Batra R, 2017, CELL, V170, P899, DOI 10.1016/j.cell.2017.07.010; Bettencourt C, 2016, ANN NEUROL, V79, P983, DOI 10.1002/ana.24656; Black HF, 2020, GENET MED, V22, P2108, DOI 10.1038/s41436-020-0917-z; Caron NS, 2020, NUCLEIC ACIDS RES, V48, P36, DOI 10.1093/nar/gkz976; Castel AL, 2010, NAT REV MOL CELL BIO, V11, P165, DOI 10.1038/nrm2854; Castel AL, 2009, J BIOL CHEM, V284, P26631, DOI 10.1074/jbc.M109.034405; Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; Ciosi M, 2020, PROTOCOL EXCHANGE, DOI [10.21203/rs.2.1581/v2, DOI 10.21203/RS.2.1581/V2]; Ciosi M, 2019, EBIOMEDICINE, V48, P568, DOI 10.1016/j.ebiom.2019.09.020; Dabrowska M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00075; Darras BT, 2019, NEUROLOGY, V92, pE2492, DOI 10.1212/WNL.0000000000007527; Dolzhenko E, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02017-z; Dolzhenko E, 2019, BIOINFORMATICS, V35, P4754, DOI 10.1093/bioinformatics/btz431; Ekman FK, 2019, MOL THER-NUCL ACIDS, V17, P829, DOI 10.1016/j.omtn.2019.07.009; Evers MM, 2018, MOL THER, V26, P2163, DOI 10.1016/j.ymthe.2018.06.021; Figueroa KP, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000155; Finkel RS, 2016, LANCET, V388, P3017, DOI 10.1016/S0140-6736(16)31408-8; Flower M, 2019, BRAIN, V142, P1876, DOI 10.1093/brain/awz115; Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623; Fusilli C, 2018, LANCET NEUROL, V17, P986, DOI 10.1016/S1474-4422(18)30294-1; Garcia-Nieto PE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1919-5; Gardiner SL, 2019, JAMA NEUROL, V76, P650, DOI 10.1001/jamaneurol.2019.0423; GOLDBERG YP, 1995, HUM MOL GENET, V4, P1911, DOI 10.1093/hmg/4.10.1911; Gomes-Pereira M, 2004, HUM MOL GENET, V13, P1815, DOI 10.1093/hmg/ddh186; Goold R, 2019, HUM MOL GENET, V28, P650, DOI 10.1093/hmg/ddy375; Halabi A, 2018, NUCLEIC ACIDS RES, V46, P4022, DOI 10.1093/nar/gky143; Hayward BE, 2020, NUCLEIC ACIDS RES, V48, P7856, DOI 10.1093/nar/gkaa573; Hu YJ, 2017, J NEUROL SCI, V382, P87, DOI 10.1016/j.jns.2017.08.3256; Ionita-Laza I, 2014, P NATL ACAD SCI USA, V111, P343, DOI 10.1073/pnas.1309475110; Kennedy L, 2003, HUM MOL GENET, V12, P3359, DOI 10.1093/hmg/ddg352; Keogh N, 2017, NUCLEIC ACIDS RES, V45, P10068, DOI 10.1093/nar/gkx650; Keum JW, 2016, AM J HUM GENET, V98, P287, DOI 10.1016/j.ajhg.2015.12.018; Khan E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53410-z; Kim KH, 2020, AM J HUM GENET, V107, P96, DOI 10.1016/j.ajhg.2020.05.012; Kim YE, 2017, PARKINSONISM RELAT D, V40, P69, DOI 10.1016/j.parkreldis.2017.04.003; Langbehn DR, 2004, CLIN GENET, V65, P267, DOI 10.1111/j.1399-0004.2004.00241.x; Lee JM, 2019, CELL, V178, P887, DOI 10.1016/j.cell.2019.06.036; Lee JM, 2015, CELL, V162, P516, DOI 10.1016/j.cell.2015.07.003; Li ZY, 2019, NATURE, V575, P203, DOI 10.1038/s41586-019-1722-1; Lieberman AP, 2019, ANNU REV PATHOL-MECH, V14, P1, DOI 10.1146/annurev-pathmechdis-012418-012857; Lokanga RA, 2013, HUM MUTAT, V34, P157, DOI 10.1002/humu.22177; Long JD, 2018, AM J HUM GENET, V103, P349, DOI 10.1016/j.ajhg.2018.07.017; Maiuri T, 2019, NEUROTHERAPEUTICS, V16, P948, DOI 10.1007/s13311-019-00768-7; Marti E, 2016, BRAIN PATHOL, V26, P779, DOI 10.1111/bpa.12427; McPhee SWJ, 2006, J GENE MED, V8, P577, DOI 10.1002/jgm.885; Mergener R, 2020, NEUROMOL MED, V22, P133, DOI 10.1007/s12017-019-08572-4; Migliore S, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00453; Minikel EV, 2020, NATURE, V581, P459, DOI 10.1038/s41586-020-2267-z; Mittermeyer G, 2012, HUM GENE THER, V23, P377, DOI 10.1089/hum.2011.220; Monteys AM, 2017, MOL THER, V25, P12, DOI 10.1016/j.ymthe.2016.11.010; Moss DJH, 2017, LANCET NEUROL, V16, P701, DOI 10.1016/S1474-4422(17)30161-8; Nakamori M, 2020, NAT GENET, V52, P146, DOI 10.1038/s41588-019-0575-8; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nethisinghe S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00200; Nolin SL, 2019, AM J MED GENET A, V179, P1148, DOI 10.1002/ajmg.a.61165; Ooi J, 2019, CELL REP, V26, P2494, DOI 10.1016/j.celrep.2019.02.008; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Pinto RM, 2020, HUM MOL GENET, V29, P2551, DOI 10.1093/hmg/ddaa139; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Ramos DM, 2019, J CLIN INVEST, V129, P4817, DOI 10.1172/JCI124120; Ronzitti G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00670; Scahill RI, 2020, LANCET NEUROL, V19, P502, DOI 10.1016/S1474-4422(20)30143-5; ScaleHD, 2020, AUT HUNT DIS GEN PIP; Schilling J, 2019, J MOL BIOL, V431, P1869, DOI 10.1016/j.jmb.2019.01.034; Sha YZ, 2019, ECON MODEL, V83, P8, DOI 10.1016/j.econmod.2019.09.016; Shin JW, 2016, HUM MOL GENET, V25, P4566, DOI 10.1093/hmg/ddw286; Southwell AL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar3959; Southwell AL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12166; Swami M, 2009, HUM MOL GENET, V18, P3039, DOI 10.1093/hmg/ddp242; Tabrizi SJ, 2019, NEW ENGL J MED, V380, P2307, DOI 10.1056/NEJMoa1900907; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; ten Broeke SW, 2018, J CLIN ONCOL, V36, P2961, DOI 10.1200/JCO.2018.78.4777; Tome S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003280; Wertz MH, 2020, NEURON, V106, P76, DOI 10.1016/j.neuron.2020.01.004; Westemeyer M, 2020, GENET MED, V22, P1320, DOI 10.1038/s41436-020-0807-4; Wright GEB, 2019, AM J HUM GENET, V104, P1116, DOI 10.1016/j.ajhg.2019.04.007; Xu PN, 2020, NUCLEIC ACIDS RES, V48, P2232, DOI 10.1093/nar/gkaa036; Zeitler B, 2019, NAT MED, V25, P1131, DOI 10.1038/s41591-019-0478-3; Zhao XN, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007719; Zhou WB, 2012, NAT GENET, V44, P910, DOI 10.1038/ng.2347; Zu T, 2011, P NATL ACAD SCI USA, V108, P260, DOI 10.1073/pnas.1013343108	87	22	22	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					930	939		10.1016/S1474-4422(20)30343-4	http://dx.doi.org/10.1016/S1474-4422(20)30343-4			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3OI	33098802				2022-12-18	WOS:000581121200025
J	Siclari, F; Valli, K; Arnulf, I				Siclari, Francesca; Valli, Katja; Arnulf, Isabelle			Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders	LANCET NEUROLOGY			English	Review							EYE-MOVEMENT SLEEP; REM-SLEEP; BEHAVIOR DISORDER; PARKINSONS-DISEASE; CONGENITALLY BLIND; APNEA; FREQUENCY; RECALL; WAKING; CONSCIOUSNESS	Dreams are experiences that occur during sleep, while we are disconnected from the environment. Thanks to recent progress in neuroimaging techniques, it is now becoming possible to relate dream features to specific patterns of brain activity. Some conditions occurring in patients with neurological disorders, such as lucid dreams and parasomnias, not only have diagnostic value, but also offer a window into the dream process. They show that dreaming is reflected in physiological signals, behaviours, and brain activity patterns, and that the body can enact dream content Yet, the dream body can also be distinct from the real body; in their dreams, patients with congenital paraplegia can walk, those with sleep apnoea rarely suffocate, and phantom limb pain can disappear. These conditions provide valuable models for future studies investigating the mechanisms that underlie oneiric experiences.	[Siclari, Francesca] Lausanne Univ Hosp, Ctr Invest & Res Sleep, Lausanne, Switzerland; [Siclari, Francesca] Lausanne Univ Hosp, Dept Clin Neurosci, Lausanne, Switzerland; [Siclari, Francesca] Univ Lausanne, Lausanne, Switzerland; [Valli, Katja] Univ Turku, Dept Psychol, Turku, Finland; [Valli, Katja] Univ Turku, Turku Brain & Mind Ctr, Turku, Finland; [Valli, Katja] Univ Skovde, Dept Cognit Neurosci & Philosophy, Skovde, Sweden; [Valli, Katja] Turku Univ Hosp, Dept Perioperat Serv Intens Care & Pain Med, Turku, Finland; [Arnulf, Isabelle] Paris Brain Inst, Paris, France; [Arnulf, Isabelle] Sorbonne Univ, Paris, France; [Arnulf, Isabelle] AP HP, Sleep Disorders Unit, F-75013 Paris, France	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Turku; University of Turku; University of Skovde; University of Turku; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP)	Arnulf, I (corresponding author), AP HP, Sleep Disorders Unit, F-75013 Paris, France.	isabelle.arnulf@aphp.fr	Siclari, Francesca/AFO-9175-2022	Siclari, Francesca/0000-0003-2061-9719; Valli, Katja/0000-0002-5133-8664				Alfonsi V, 2019, SLEEP MED REV, V44, P12, DOI 10.1016/j.smrv.2018.12.001; American Academy of Sleep Medicine, 2014, INT CLASS SLEEP DIS, DOI DOI 10.1176/APPI.BOOKS.9780890425596.893619; Anang JBM, 2014, NEUROLOGY, V83, P1253, DOI 10.1212/WNL.0000000000000842; Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Arnaldi D, 2017, SLEEP MED REV, V36, P82, DOI 10.1016/j.smrv.2016.11.002; Arnulf I, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx159; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BaHammam AS, 2013, SLEEP MED, V14, P149, DOI 10.1016/j.sleep.2012.07.007; Baird B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36190-w; Bekrater-Bodmann R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119552; Bernardi G, 2019, J NEUROSCI, V39, P2686, DOI 10.1523/JNEUROSCI.2298-18.2019; Bertolo H, 2003, COGNITIVE BRAIN RES, V15, P277, DOI 10.1016/S0926-6410(02)00199-4; Borchert JS, 2019, J MED INTERNET RES, V21, DOI 10.2196/13371; Carrasco E, 2006, J SLEEP RES, V15, P430, DOI 10.1111/j.1365-2869.2006.00553.x; Cipolli C, 2008, BRAIN RES BULL, V77, P206, DOI 10.1016/j.brainresbull.2008.07.012; Cle M, 2019, J SLEEP RES, V28, DOI 10.1111/jsr.12814; Dalwadi DA, 2018, PHARMACOL REV, V70, P684, DOI 10.1124/pr.117.013706; De Cock VC, 2007, BRAIN, V130, P450, DOI 10.1093/brain/awl363; De Gennaro L, 2016, HUM BRAIN MAPP, V37, P1136, DOI 10.1002/hbm.23095; Di Pauli F, 2018, J CLIN SLEEP MED, V14, P41, DOI 10.5664/jcsm.6876; DIMSDALE JE, 1992, J PSYCHOSOM RES, V36, P229, DOI 10.1016/0022-3999(92)90087-I; Dodet P, 2015, SLEEP, V38, P487, DOI 10.5665/sleep.4516; Dresler M, 2012, SLEEP, V35, P1017, DOI 10.5665/sleep.1974; Dresler M, 2011, CURR BIOL, V21, P1833, DOI 10.1016/j.cub.2011.09.029; Ehrminger M, 2016, BRAIN, V139, P1180, DOI 10.1093/brain/aww006; Erlacher D, 2014, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.01013; ERMANN M, 1993, PSYCHOTHER PSYCH MED, V43, P333; Fantini ML, 2005, NEUROLOGY, V65, P1010, DOI 10.1212/01.wnl.0000179346.39655.e0; Feige B, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy032; Fernandez-Arcos A, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz086; Fernandez-Arcos A, 2016, SLEEP, V39, P121, DOI 10.5665/sleep.5332; Filevich E, 2015, J NEUROSCI, V35, P1082, DOI 10.1523/JNEUROSCI.3342-14.2015; Forsaa EB, 2010, ARCH NEUROL-CHICAGO, V67, P996, DOI 10.1001/archneurol.2010.166; Fosse R, 2002, SLEEP, V25, P724, DOI 10.1093/sleep/25.7.724; GROSS M, 1994, DREAMING, V4, P195, DOI 10.1037/h0094412; Haridi M, 2017, J SLEEP RES, V26, P614, DOI 10.1111/jsr.12544; Horikawa T, 2013, SCIENCE, V340, P639, DOI 10.1126/science.1234330; Hublin C, 1999, AM J MED GENET, V88, P329, DOI 10.1002/(SICI)1096-8628(19990820)88:4<329::AID-AJMG8>3.0.CO;2-E; Iranzo A, 2016, LANCET NEUROL, V15, P405, DOI 10.1016/S1474-4422(16)00057-0; Jetly R, 2015, PSYCHONEUROENDOCRINO, V51, P585, DOI 10.1016/j.psyneuen.2014.11.002; Jung Y, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-016-0433-2; Knudsen K, 2018, LANCET NEUROL, V17, P618, DOI 10.1016/S1474-4422(18)30162-5; LaBerge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05547-0; Lacaux C, 2019, BRAIN, V142, P1988, DOI 10.1093/brain/awz137; Leclair-Visonneau L, 2010, BRAIN, V133, P1737, DOI 10.1093/brain/awq110; Leu-Semenescu S, 2013, BRAIN, V136, P3076, DOI 10.1093/brain/awt229; Lortie-Lussier M, 2019, DREAMS UNDERSTANDING, P201; Malinowski JE, 2014, J SLEEP RES, V23, P441, DOI 10.1111/jsr.12134; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Matsunaga S, 2019, J ALZHEIMERS DIS, V71, P513, DOI 10.3233/JAD-190546; Meaidi A, 2014, SLEEP MED, V15, P586, DOI 10.1016/j.sleep.2013.12.008; Morgenthaler TI, 2018, J CLIN SLEEP MED, V14, P1041, DOI 10.5664/jcsm.7178; Mota-Rolim Sergio A, 2013, Front Hum Neurosci, V7, P836, DOI 10.3389/fnhum.2013.00836; Nielsen TA, 2000, BEHAV BRAIN SCI, V23, P851, DOI 10.1017/S0140525X0000399X; Nielsen T, 2007, SLEEP MED REV, V11, P295, DOI 10.1016/j.smrv.2007.03.004; Nir Y, 2010, TRENDS COGN SCI, V14, P88, DOI 10.1016/j.tics.2009.12.001; Oudiette D, 2009, NEUROLOGY, V72, P551, DOI 10.1212/01.wnl.0000341936.78678.3a; Oudiette D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21067-9; Oudiette D, 2012, CONSCIOUS COGN, V21, P1129, DOI 10.1016/j.concog.2012.04.010; Oudiette D, 2009, SLEEP, V32, P1621, DOI 10.1093/sleep/32.12.1621; Pagel JF, 2010, J CLIN SLEEP MED, V6, P69; Perusse AD, 2016, SLEEP MED, V20, P147, DOI 10.1016/j.sleep.2015.08.007; Pinter MM, 1999, J NEUROL NEUROSUR PS, V66, P436, DOI 10.1136/jnnp.66.4.436; Polini F, 2017, SLEEP MED, V30, P1, DOI 10.1016/j.sleep.2016.11.002; Postuma RB, 2019, BRAIN, V142, P744, DOI 10.1093/brain/awz030; Postuma Ronald B, 2012, Mov Disord, V27, P913, DOI 10.1002/mds.25037; Rak M, 2015, SLEEP, V38, P787, DOI 10.5665/sleep.4676; Raskind MA, 2018, NEW ENGL J MED, V378, P507, DOI 10.1056/NEJMoa1507598; Raskind MA, 2013, AM J PSYCHIAT, V170, P1003, DOI 10.1176/appi.ajp.2013.12081133; Revonsuo A., 2015, OPENMIND, P1, DOI DOI 10.15502/9783958570375; Robert G, 2014, SLEEP, V37, P409, DOI 10.5665/sleep.3426; Sandman N, 2013, SLEEP, V36, P1041, DOI 10.5665/sleep.2806; Saurat MT, 2011, CONSCIOUS COGN, V20, P1425, DOI 10.1016/j.concog.2011.05.015; Schenck CH, 2002, SLEEP, V25, P120, DOI 10.1093/sleep/25.2.120; Schredl M, 1998, J SLEEP RES, V7, P191, DOI 10.1046/j.1365-2869.1998.00113.x; Schredl M, 2003, CONSCIOUS COGN, V12, P298, DOI 10.1016/S1053-8100(02)00072-7; SCHREDL M, 1999, SOMNOLOGIE, V3, P319, DOI DOI 10.1007/s11818-999-0042-3; Schredl M., 2019, DREAMS UNDERSTANDING, P167; Schredl M, 2006, SLEEP BREATH, V10, P203, DOI 10.1007/s11325-006-0076-8; Schwartz S, 2002, TRENDS COGN SCI, V6, P23, DOI 10.1016/S1364-6613(00)01818-0; SHARF B, 1978, J NEURAL TRANSM, V43, P143, DOI 10.1007/BF01579073; Siclari F, 2018, J NEUROSCI, V38, P9175, DOI 10.1523/JNEUROSCI.0855-18.2018; Siclari F, 2017, CURR OPIN NEUROBIOL, V44, P222, DOI 10.1016/j.conb.2017.05.008; Siclari F, 2017, NAT NEUROSCI, V20, P872, DOI 10.1038/nn.4545; Siclari F, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00542; Solms M, 2000, BEHAV BRAIN SCI, V23, P843, DOI 10.1017/S0140525X00003988; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Tickell-Painter M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006491.pub4; Tononi G, 2008, BIOL BULL-US, V215, P216, DOI 10.2307/25470707; Tribl GG, 2013, SLEEP MED REV, V17, P133, DOI 10.1016/j.smrv.2012.05.001; Uguccioni G, 2013, SLEEP MED, V14, P391, DOI 10.1016/j.sleep.2013.01.014; Valli K, 2012, J SLEEP RES, V21, P21, DOI 10.1111/j.1365-2869.2011.00938.x; Vetrugno R, 2008, J NEUROL NEUROSUR PS, V79, P481, DOI 10.1136/jnnp.2007.129783; Voss U, 2014, NAT NEUROSCI, V17, P810, DOI 10.1038/nn.3719; Voss U, 2011, CONSCIOUS COGN, V20, P673, DOI 10.1016/j.concog.2010.10.020; Voss U, 2009, SLEEP, V32, P1191, DOI 10.1093/sleep/32.9.1191; Vyazovskiy VV, 2011, NATURE, V472, P443, DOI 10.1038/nature10009; Wamsley E, 2014, SLEEP, V37, P419, DOI 10.5665/sleep.3428; Wassing R, 2016, P NATL ACAD SCI USA, V113, P2538, DOI 10.1073/pnas.1522520113; Windt JM, 2015, DREAMING: A CONCEPTUAL FRAMEWORK FOR PHILOSOPHY OF MIND AND EMPIRICAL RESEARCH, P1, DOI 10.7551/mitpress/9780262028677.001.0001; Zadra A, 2013, LANCET NEUROL, V12, P285, DOI 10.1016/S1474-4422(12)70322-8	101	22	22	2	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					849	859		10.1016/S1474-4422(20)30275-1	http://dx.doi.org/10.1016/S1474-4422(20)30275-1			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	OF3NN	32949545	Green Published			2022-12-18	WOS:000581119100022
J	Nonnekes, J; Post, B; Tetrud, JW; Langston, JW; Bloem, BR				Nonnekes, Jorik; Post, Bart; Tetrud, James W.; Langston, J. William; Bloem, Bastiaan R.			MPTP-induced parkinsonism: an historical case series	LANCET NEUROLOGY			English	Letter							TREMOR		[Nonnekes, Jorik] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Rehabil, Nijmegen, Netherlands; [Post, Bart; Bloem, Bastiaan R.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands; [Tetrud, James W.; Langston, J. William] Parkinsons Inst, Sunnyvale, CA 94085 USA	Radboud University Nijmegen; Radboud University Nijmegen	Langston, JW (corresponding author), Parkinsons Inst, Sunnyvale, CA 94085 USA.	jwlangston@parkinsonsinstitute.org	Nonnekes, Jorik/P-6648-2015; Bloem, Bastiaan/H-8013-2014	Bloem, Bastiaan/0000-0002-6371-3337; Nonnekes, Jorik/0000-0003-2434-1427	AbbVie; Zambon; Bial	AbbVie(AbbVie); Zambon; Bial(Bial Group)	BRB has received honoraria from serving on scientific advisory boards for Zambon and Kyowa Kirin; fees for speaking at conferences from AbbVie, Zambon, and Bial; and research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, Union Chimique Belge, Stichting ParkinsonFonds, Hersenstichting Nederland, Parkinson's Foundation, Verily Life Sciences, Topsector Life Sciences and Health, and Parkinson Vereniging, outside the submitted work. JN has received consultancy fees from Ipsen, outside the submitted work. BP, JWT, and JWL declare no competing interests.	BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; Helmich RC, 2012, BRAIN, V135, P3206, DOI 10.1093/brain/aws023; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Nonnekes J, 2015, LANCET NEUROL, V14, P768, DOI 10.1016/S1474-4422(15)00041-1; RAMSAY RR, 1986, LIFE SCI, V39, P581, DOI 10.1016/0024-3205(86)90037-8; Rivlin-Etzion M, 2006, CURR OPIN NEUROBIOL, V16, P629, DOI 10.1016/j.conb.2006.10.002; Thenganatt MA, 2014, JAMA NEUROL, V71, P499, DOI 10.1001/jamaneurol.2013.6233; Zaidel A, 2009, CURR OPIN NEUROL, V22, P387, DOI 10.1097/WCO.0b013e32832d9d67	8	22	23	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2018	17	4					300	301		10.1016/S1474-4422(18)30072-3	http://dx.doi.org/10.1016/S1474-4422(18)30072-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ3AO	29553378	Bronze			2022-12-18	WOS:000427458000012
J	Kivipelto, M; Mangialasche, F; Ngandu, T				Kivipelto, Miia; Mangialasche, Francesca; Ngandu, Tiia			Can lifestyle changes prevent cognitive impairment?	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA		[Kivipelto, Miia; Ngandu, Tiia] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki 00271, Finland; [Kivipelto, Miia; Ngandu, Tiia] Karolinska Inst, Ctr Alzheimer Res, Div Clin Geriatr, Stockholm, Sweden; [Kivipelto, Miia; Mangialasche, Francesca] Stockholm Univ, Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Kivipelto, Miia] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland	Finland National Institute for Health & Welfare; Karolinska Institutet; Karolinska Institutet; Stockholm University; University of Eastern Finland	Kivipelto, M (corresponding author), Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki 00271, Finland.; Kivipelto, M (corresponding author), Karolinska Inst, Ctr Alzheimer Res, Div Clin Geriatr, Stockholm, Sweden.; Kivipelto, M (corresponding author), Stockholm Univ, Karolinska Inst, Aging Res Ctr, Stockholm, Sweden.; Kivipelto, M (corresponding author), Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland.	miia.kivipelto@ki.se	Kivipelto, Miia/AAS-3557-2021	Mangialasche, Francesca/0000-0002-2686-3926; Ngandu, Tiia/0000-0002-3698-2021				Andrieu S., 2017, LANCET NEUROL; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Richard E, 2012, J NEUROL SCI, V322, P64, DOI 10.1016/j.jns.2012.06.012; Shah H, 2016, LANCET NEUROL, V15, P1283, DOI 10.1016/S1474-4422(16)30235-6; Smith AD, 2017, LANCET NEUROL, V16, P181, DOI 10.1016/S1474-4422(16)30401-X; Solomon A, 2014, J INTERN MED, V275, P229, DOI 10.1111/joim.12178; van Charante EPM, 2016, LANCET, V388, P797, DOI 10.1016/S0140-6736(16)30950-3	8	22	22	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2017	16	5					338	339		10.1016/S1474-4422(17)30080-7	http://dx.doi.org/10.1016/S1474-4422(17)30080-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER4PH	28359750				2022-12-18	WOS:000398782100005
J	Thompson, A				Thompson, Alan			Multiple sclerosis: the upward trajectory continues	LANCET NEUROLOGY			English	Editorial Material							COMORBIDITY; TRIAL		[Thompson, Alan] UCL, Inst Neurol, Fac Brain Sci, London WC1N 3BG, England	University of London; University College London	Thompson, A (corresponding author), UCL, Inst Neurol, Fac Brain Sci, London WC1N 3BG, England.	alan.thompson@ucl.ac.uk	Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496				Bodini B, 2016, ANN NEUROL, V79, P726, DOI 10.1002/ana.24620; Desai RA, 2016, ANN NEUROL, V79, P591, DOI 10.1002/ana.24607; Kantarci OH, 2016, ANN NEUROL, V79, P288, DOI 10.1002/ana.24564; Lublin F, 2016, LANCET, V387, P1075, DOI 10.1016/S0140-6736(15)01314-8; Marrie RA, 2016, NEUROLOGY, V86, P1437, DOI 10.1212/WNL.0000000000002471; Marrie RA, 2016, NEUROLOGY, V86, P1446, DOI 10.1212/WNL.0000000000002474; Raftopoulos R, 2016, LANCET NEUROL, V15, P259, DOI 10.1016/S1474-4422(16)00004-1	7	22	22	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					10	12		10.1016/S1474-4422(16)30343-X	http://dx.doi.org/10.1016/S1474-4422(16)30343-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979338	Green Submitted			2022-12-18	WOS:000389869200007
J	Kwakkel, G; Meskers, CGM				Kwakkel, Gert; Meskers, Carel G. M.			Effects of robotic therapy of the arm after stroke	LANCET NEUROLOGY			English	Editorial Material							UPPER-LIMB RECOVERY; ASSISTED THERAPY		[Kwakkel, Gert; Meskers, Carel G. M.] Vrije Univ Med Ctr, MOVE Res Inst Amsterdam, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Kwakkel, G (corresponding author), Vrije Univ Med Ctr, MOVE Res Inst Amsterdam, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands.	g.kwakkel@vumc.nl		Kwakkel, Gert/0000-0002-4041-4043; Meskers, Carel/0000-0002-5056-5611				Buma F, 2013, RESTOR NEUROL NEUROS, V31, P707, DOI 10.3233/RNN-130332; DUNCAN PW, 1994, STROKE, V25, P1181, DOI 10.1161/01.STR.25.6.1181; Ellis MD, 2009, NEUROREHAB NEURAL RE, V23, P862, DOI 10.1177/1545968309332927; Harris JE, 2010, STROKE, V41, P136, DOI 10.1161/STROKEAHA.109.567438; Klamroth-Marganska V, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70305-3; Kwakkel G, 2013, INT J STROKE, V8, P25, DOI 10.1111/j.1747-4949.2012.00967.x; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Mehrholz J, 2012, COCHRANE DB SYST REV, V6; van Kordelaar J, 2013, NEUROREHAB NEURAL RE, V27, P854, DOI 10.1177/1545968313496327	11	22	22	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2014	13	2					132	133		10.1016/S1474-4422(13)70285-0	http://dx.doi.org/10.1016/S1474-4422(13)70285-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	301QE	24382581				2022-12-18	WOS:000330546200004
J	Ozelius, LJ				Ozelius, Laurie J.			Clinical spectrum of disease associated with ATP1A3 mutations	LANCET NEUROLOGY			English	Editorial Material							ONSET DYSTONIA-PARKINSONISM; ALTERNATING HEMIPLEGIA; CHILDHOOD		[Ozelius, Laurie J.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Ozelius, Laurie J.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Ozelius, LJ (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA.	laurie.ozelius@mssm.edu			NINDS NIH HHS [NS058949, NS037409] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS037409, R01NS058949, P01NS037409] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbano RL, 2012, PARKINSONISM RELAT D, V18, P737, DOI 10.1016/j.parkreldis.2012.03.020; Benarroch EE, 2011, NEUROLOGY, V77, P281, DOI [10.1212/WNL.0b013e31822550e2, 10.1212/WNL.0b013e3182074c2f]; Brashear A, DEV MED CHI IN PRESS; Brashear A, 2007, BRAIN, V130, P828, DOI 10.1093/brain/awl340; Neville BGR, 2007, DEV MED CHILD NEUROL, V49, P777, DOI 10.1111/j.1469-8749.2007.00777.x; Ozelius LJ, 2011, MOVEMENT DISORD, V26, P1106, DOI 10.1002/mds.23775; Panagiotakaki E, 2010, BRAIN, V133, P3598, DOI 10.1093/brain/awq295; Pittock SJ, 2000, NEUROLOGY, V55, P991, DOI 10.1212/WNL.55.7.991; Rosewich H, 2012, OPTN SRTR ANN REP; Sweney MT, 2009, PEDIATRICS, V123, pe534, DOI 10.1542/peds.2008-2027	10	22	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2012	11	9					741	743		10.1016/S1474-4422(12)70185-0	http://dx.doi.org/10.1016/S1474-4422(12)70185-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	994DS	22857851				2022-12-18	WOS:000307911700003
J	Hartung, HP; Aktas, O				Hartung, Hans-Peter; Aktas, Orhan			Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria	LANCET NEUROLOGY			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ORAL FINGOLIMOD; NATALIZUMAB		[Hartung, Hans-Peter; Aktas, Orhan] Univ Dusseldorf, Dept Neurol, Multiple Sclerosis Ctr, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Hartung, HP (corresponding author), Univ Dusseldorf, Dept Neurol, Multiple Sclerosis Ctr, D-40225 Dusseldorf, Germany.	hans-peter.hartung@uni-duesseldorf.de	Aktas, Orhan/B-7623-2009	Aktas, Orhan/0000-0002-2020-9210				Aktas O, 2010, TRENDS NEUROSCI, V33, P140, DOI 10.1016/j.tins.2009.12.002; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Coles AJ, 2011, LANCET NEUROL, V10, P338, DOI 10.1016/S1474-4422(11)70020-5; GIOVANNONI G, 2011, LANCET NEUROL, DOI DOI 10.1016/S1474-422(11)70023-0; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Hartung HP, 2010, LANCET NEUROL, V9, P454, DOI 10.1016/S1474-4422(10)70088-0; Havrdova E, 2009, LANCET NEUROL, V8, P254, DOI 10.1016/S1474-4422(09)70021-3; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397	10	22	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2011	10	4					293	295		10.1016/S1474-4422(11)70043-6	http://dx.doi.org/10.1016/S1474-4422(11)70043-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745SB	21397566				2022-12-18	WOS:000289185000004
J	Berg, AT; Cross, JH				Berg, Anne T.; Cross, J. Helen			Towards a modern classification of the epilepsies?	LANCET NEUROLOGY			English	Editorial Material									[Berg, Anne T.] Childrens Mem Hosp, Epilepsy Ctr, Chicago, IL 60614 USA; [Cross, J. Helen] Great Ormond St Hosp Sick Children, UCL Inst Child Hlth, London WC1N 2AP, England; [Cross, J. Helen] Wolfson Ctr Magnet Technol, Natl Ctr Young People Epilepsy, London WC1N 2AP, England	Ann & Robert H. Lurie Children's Hospital of Chicago; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Berg, AT (corresponding author), Childrens Mem Hosp, Epilepsy Ctr, Chicago, IL 60614 USA.	atberg@childrensmemorial.org	Cross, J. Helen/ACK-3032-2022	Cross, J. Helen/0000-0001-7345-4829				[Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; GASTAUT H, 1970, EPILEPSIA, V11, P102, DOI 10.1111/j.1528-1157.1970.tb03871.x; Merlis J K, 1970, Epilepsia, V11, P114, DOI 10.1111/j.1528-1157.1970.tb03873.x	5	22	22	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					459	461		10.1016/S1474-4422(10)70024-7	http://dx.doi.org/10.1016/S1474-4422(10)70024-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY	20227346				2022-12-18	WOS:000277384600008
J	Aartsma-Rus, A; van Ommen, GJB				Aartsma-Rus, Annemieke; van Ommen, Gert-Jan B.			Less is more: therapeutic exon skipping for Duchenne muscular dystrophy	LANCET NEUROLOGY			English	Editorial Material							ANTISENSE; EXPRESSION		[Aartsma-Rus, Annemieke; van Ommen, Gert-Jan B.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Aartsma-Rus, A (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, NL-2300 RC Leiden, Netherlands.	gjvo@lumc.nl		Aartsma-Rus, Annemieke/0000-0003-1565-654X				Aartsma-Rus A, 2003, HUM MOL GENET, V12, P907, DOI 10.1093/hmg/ddg100; Aartsma-Rus A, 2004, AM J HUM GENET, V74, P83, DOI 10.1086/381039; Aartsma-Rus A, 2006, MOL THER, V14, P401, DOI 10.1016/j.ymthe.2006.02.022; Aartsma-Rus A, 2009, HUM MUTAT, V30, P293, DOI 10.1002/humu.20918; Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345; Heemskerk HA, 2009, J GENE MED, V11, P257, DOI 10.1002/jgm.1288; Hoffman EP, 2007, NEW ENGL J MED, V357, P2719, DOI 10.1056/NEJMe0707795; KINALI M, 2009, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(09)70211-X; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; van Deutekom JCT, 2001, HUM MOL GENET, V10, P1547, DOI 10.1093/hmg/10.15.1547; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; van Vliet L, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-105; Yokota T, 2009, ANN NEUROL, V65, P667, DOI 10.1002/ana.21627	14	22	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2009	8	10					873	875		10.1016/S1474-4422(09)70229-7	http://dx.doi.org/10.1016/S1474-4422(09)70229-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498BS	19713153				2022-12-18	WOS:000270111200004
J	Lyden, PD; Lees, KR; Davis, SM				Lyden, Patrick D.; Lees, Kennedy R.; Davis, Stephen M.			Alteplase for acute stroke revisited: the first 10 years	LANCET NEUROLOGY			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; THROMBOLYTIC THERAPY; COST-EFFECTIVENESS; OUTCOMES; SAFETY; TPA		VA Stroke Ctr, San Diego, CA USA; Univ Calif San Diego, Stroke Ctr, San Diego, CA USA; Univ Glasgow, Western Infirm, Glasgow G12 8QQ, Lanark, Scotland; Univ Melbourne, Royal Melbourne Hosp, Parkville, Vic 3052, Australia	University of California System; University of California San Diego; University of Glasgow; Royal Melbourne Hospital; University of Melbourne	Lyden, PD (corresponding author), VA Stroke Ctr, San Diego, CA USA.	plyden@ucsd.edu	Davis, Stephen M/L-5260-2013	Davis, Stephen M/0000-0003-0962-2300				Barber PA, 2001, NEUROLOGY, V56, P1015, DOI 10.1212/WNL.56.8.1015; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Caplan LR, 1997, NEW ENGL J MED, V337, P1309; Davis SM, 2005, CURR OPIN NEUROL, V18, P47, DOI 10.1097/00019052-200502000-00010; Ernst R, 2000, STROKE, V31, P2552, DOI 10.1161/01.STR.31.11.2552; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Gilligan A, 2000, STROKE, V31, P2887; Graham GD, 2003, STROKE, V34, P2847, DOI 10.1161/01.STR.0000101752.23813.C3; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 2004, LANCET, V363, P768; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Lindley RI, 2005, LANCET NEUROL, V4, P249, DOI 10.1016/S1474-4422(05)70044-2; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Nadareishvili Z, 1999, NEUROLOGY, V52, P895; Patel SC, 2001, JAMA-J AM MED ASSOC, V286, P2830, DOI 10.1001/jama.286.22.2830; Sandercock P, 2004, STROKE, V35, P1490, DOI 10.1161/01.STR.0000126871.98801.6E; Saver JL, 2004, ARCH NEUROL-CHICAGO, V61, P1066, DOI 10.1001/archneur.61.7.1066; Sinclair SE, 2001, PHARMACOECONOMICS, V19, P927, DOI 10.2165/00019053-200119090-00004; Smith EE, 2005, STROKE, V36, P2497, DOI 10.1161/01.STR.0000185798.78817.f3; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611	24	22	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2006	5	9					722	724		10.1016/S1474-4422(06)70530-0	http://dx.doi.org/10.1016/S1474-4422(06)70530-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	076QS	16914399				2022-12-18	WOS:000239973400002
J	Imray, CHE; Tiivas, CAS				Imray, CHE; Tiivas, CAS			Are some strokes preventable? The potential role of transcranial doppler in transient ischaernic attacks of carotid origin	LANCET NEUROLOGY			English	Editorial Material							ARTERY STENOSIS; ISCHEMIC ATTACK; CEREBRAL MICROEMBOLISM; SYMPTOMATIC PATIENTS; EMBOLIC SIGNALS; PREDICTS STROKE; HIGH-RISK; ENDARTERECTOMY; SURGERY; EMERGENCY	Transient ischaemic attacks (TIA) are more than just ministrokes. The high frequency of early stroke following TIA has resulted in the recent publication of guidelines in the UK. The guidelines recommend that patients attend a neurovascular clinic within 7 days of the index event to expedite investigation and treatment and so reduce the risk of a subsequent (potentially more serious) neurological event. After a TIA or stroke caused by carotid-artery disease, there is an increase in cerebral microemboli detectable by transcranial doppler (TCD). High microembolic loads appear to be surrogate markers for future neurological events, and the pharmacological efficacy of therapeutic interventions can now be rapidly and non-invasively assessed in the clinic or at the bedside. Medical treatments can now be optimised, avoiding the need for urgent or emergency carotid surgery and therefore allowing patients to undergo safer elective surgery when appropriate.	Univ Hosp Coventry & Warwickshire NHS Trust, Coventry & Warwickshire Cty Vasc Unit, Coventry CV2 2DX, W Midlands, England; Univ Hosp Coventry & Warwickshire NHS Trust, Clin Phys & Biomed Engn Dept, Coventry CV2 2DX, W Midlands, England	University of Warwick; University of Warwick	Imray, CHE (corresponding author), Univ Hosp Coventry & Warwickshire NHS Trust, Coventry & Warwickshire Cty Vasc Unit, Coventry CV2 2DX, W Midlands, England.	chrisimray@aol.com		Christopher, Imray/0000-0001-9889-6308				Ackerstaff RGA, 2000, STROKE, V31, P1817, DOI 10.1161/01.STR.31.8.1817; Babikian VL, 1997, STROKE, V28, P1314, DOI 10.1161/01.STR.28.7.1314; Blaser T, 2004, STROKE, V35, P2155, DOI 10.1161/01.STR.0000136768.63532.70; Blaser T, 2002, STROKE, V33, P1057, DOI 10.1161/01.STR.0000013671.70986.39; BOND R, 2003, STROKE, V34, P2302; Brandl R, 2001, VASA-J VASCULAR DIS, V30, P115, DOI 10.1024/0301-1526.30.2.115; Chang YF, 2000, J NONDESTRUCT EVAL, V19, P1, DOI 10.1023/A:1006671706818; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; Daffertshofer M, 2004, STROKE, V35, P2453, DOI 10.1161/01.STR.0000144050.90132.8e; Eckstein HH, 1999, CEREBROVASC DIS, V9, P270, DOI 10.1159/000015978; Forteza AM, 1996, STROKE, V27, P687, DOI 10.1161/01.STR.27.4.687; Gao S, 2004, STROKE, V35, P2832, DOI 10.1161/01.STR.0000147035.31297.b6; GAUNT ME, 1994, BRIT J SURG, V81, P1435, DOI 10.1002/bjs.1800811009; GERTLER JP, 1994, J VASC SURG, V19, P42; Goertler M, 1999, STROKE, V30, P66, DOI 10.1161/01.STR.30.1.66; Goertler M, 2002, J NEUROL NEUROSUR PS, V72, P338, DOI 10.1136/jnnp.72.3.338; GOLDSTONE J, 1976, ARCH SURG-CHICAGO, V111, P1284; GREENHALGH RM, 1993, EUR J VASCULAR SURG, V7, P25, DOI 10.1016/S0950-821X(05)80950-8; Hayes PD, 2000, EUR J VASC ENDOVASC, V19, P56, DOI 10.1053/ejvs.1999.0948; Imray C, 2004, BMJ-BRIT MED J, V329, P1344, DOI 10.1136/bmj.329.7478.1344; Imray C, 2004, LANCET, V363, P1553, DOI 10.1016/S0140-6736(04)16162-X; Imray CHE, 2005, J APPL PHYSIOL, V99, P699, DOI 10.1152/japplphysiol.00973.2004; JANSEN C, 1993, STROKE, V24, P665, DOI 10.1161/01.STR.24.5.665; JANSEN C, 1994, STROKE, V25, P992, DOI 10.1161/01.STR.25.5.992; Jansen C, 1993, Ann Vasc Surg, V7, P95, DOI 10.1007/BF02042666; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Junghans U, 2003, CIRCULATION, V107, P2717, DOI 10.1161/01.CIR.0000070544.15890.0E; Kaposzta Z, 2002, CIRCULATION, V105, P1480, DOI 10.1161/01.CIR.0000012347.47001.97; Lennard N, 1997, J VASC SURG, V26, P579, DOI 10.1016/S0741-5214(97)70055-7; Lennard NS, 2003, BRIT J SURG, V90, P166, DOI 10.1002/bjs.4030; Levi CR, 1997, EUR J VASC ENDOVASC, V14, P170, DOI 10.1016/S1078-5884(97)80187-6; Levi CR, 1997, BRAIN, V120, P621, DOI 10.1093/brain/120.4.621; Mackinnon AD, 2004, STROKE, V35, P73, DOI 10.1161/01.STR.0000106915.83041.0A; Markus HS, 2005, CIRCULATION, V111, P2233, DOI 10.1161/01.CIR.0000163561.90680.1C; Markus HS, 2005, STROKE, V36, P971, DOI 10.1161/01.STR.0000162717.62684.40; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3332; MENTZER RM, 1981, SURGERY, V89, P60; Molloy J, 1999, STROKE, V30, P1440, DOI 10.1161/01.STR.30.7.1440; Naylor AR, 2000, J VASC SURG, V32, P750, DOI 10.1067/mva.2000.108007; NEHLER MR, 1993, ARCH SURG-CHICAGO, V128, P1117; Payne DA, 2004, CIRCULATION, V109, P1476, DOI 10.1161/01.CIR.0000121739.05643.E6; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2005, NEUROLOGY, V64, P817, DOI 10.1212/01.WNL.0000152985.32732.EE; *ROYAL COLL PHYS, 2004, NAT CLIN GUID STOK, P31; Schneider C, 1999, WORLD J SURG, V23, P1163, DOI 10.1007/s002689900640; SIEBLER M, 1995, STROKE, V26, P2184, DOI 10.1161/01.STR.26.11.2184; Sliwka U, 1997, STROKE, V28, P358, DOI 10.1161/01.STR.28.2.358; SMITH JL, 1995, STROKE, V26, P2281, DOI 10.1161/01.STR.26.12.2281; SPENCER MP, 1995, STROKE, V26, P1123, DOI 10.1161/01.STR.26.6.1123; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Valton L, 1998, STROKE, V29, P2125, DOI 10.1161/01.STR.29.10.2125; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WILSON SE, 1993, J VASC SURG, V17, P249, DOI 10.1016/0741-5214(93)90410-N	53	22	23	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2005	4	9					580	586		10.1016/S1474-4422(05)70169-1	http://dx.doi.org/10.1016/S1474-4422(05)70169-1			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VK	16109365				2022-12-18	WOS:000231476100019
J	Bradbury, J				Bradbury, J			Hope for AD with NGF gene-therapy trial	LANCET NEUROLOGY			English	News Item																			0	22	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2005	4	6					335	335		10.1016/S1474-4422(05)70086-7	http://dx.doi.org/10.1016/S1474-4422(05)70086-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	931EQ	15931729				2022-12-18	WOS:000229469000009
J	Breitner, JCS				Breitner, JCS			NSAIDs and Alzheimer's disease: how far to generalise from trials?	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; CACHE COUNTY; PLACEBO; WOMEN		VA Puget Sound Hlth Care Syst, GRECC S182, Seattle, WA 98108 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Breitner, JCS (corresponding author), VA Puget Sound Hlth Care Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA.							Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Martin BK, 2002, CONTROL CLIN TRIALS, V23, P93, DOI 10.1016/S0197-2456(01)00189-1; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	7	22	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2003	2	9					527	527		10.1016/S1474-4422(03)00498-8	http://dx.doi.org/10.1016/S1474-4422(03)00498-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717VT	12941571				2022-12-18	WOS:000185112000013
J	Feigin, V; Anderson, N; Gunn, A; Rodgers, A; Anderson, C				Feigin, V; Anderson, N; Gunn, A; Rodgers, A; Anderson, C			The emerging role of therapeutic hypothermia in acute stroke	LANCET NEUROLOGY			English	Editorial Material							MODERATE HYPOTHERMIA		Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand	University of Auckland	Feigin, V (corresponding author), Univ Auckland, Clin Trials Res Unit, Private Bag 92019,3 Ferncroft St, Auckland 1, New Zealand.		Feigin, Valery/AAF-2313-2019	Rodgers, Anthony/0000-0003-1282-1896; Anderson, Craig/0000-0002-7248-4863; Gunn, Alistair/0000-0003-0656-7035; Feigin, Valery L./0000-0002-6372-1740				Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; HEISS WD, 1994, CURR OPIN NEUROL, V7, P11, DOI 10.1097/00019052-199402000-00004; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; MacLellan C, 2002, BRAIN RES, V958, P192, DOI 10.1016/S0006-8993(02)03702-2; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Olsen TS, 2003, LANCET NEUROL, V2, P410, DOI 10.1016/S1474-4422(03)00436-8; Schwab S, 1998, ACT NEUR S, V71, P131	8	22	25	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2003	2	9					529	529		10.1016/S1474-4422(03)00500-3	http://dx.doi.org/10.1016/S1474-4422(03)00500-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717VT	12941573				2022-12-18	WOS:000185112000015
J	Burns, DK; Alexander, RC; Welsh-Bohmer, KA; Culp, M; Chiang, C; O'Neil, J; Evans, RM; Harrigan, P; Plassman, BL; Burke, JR; Wu, JT; Lutz, MW; Haneline, S; Schwarz, AJ; Schneider, LS; Yaffe, K; Saunders, AM; Ratti, E				Burns, Daniel K.; Alexander, Robert C.; Welsh-Bohmer, Kathleen A.; Culp, Meredith; Chiang, Carl; O'Neil, Janet; Evans, Rebecca M.; Harrigan, Patrick; Plassman, Brenda L.; Burke, James R.; Wu, Jingtao; Lutz, Michael W.; Haneline, Stephen; Schwarz, Adam J.; Schneider, Lon S.; Yaffe, Kristine; Saunders, Ann M.; Ratti, Emiliangelo		TOMMORROW Study Investigators	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial	LANCET NEUROLOGY			English	Article							APOLIPOPROTEIN-E; GLUCOSE-METABOLISM; GINKGO-BILOBA; PREVENTION; DEMENTIA; INDIVIDUALS; GENETICS; TARGET	Background The identification of people at risk of cognitive impairment is essential for improving recruitment in secondary prevention trials of Alzheimer's disease. We aimed to test and qualify a biomarker risk assignment algorithm (BRAA) to identify participants at risk of developing mild cognitive impairment due to Alzheimer's disease within 5 years, and to evaluate the safety and efficacy of low-dose pioglitazone to delay onset of mild cognitive impairment in these at-risk participants. Methods In this phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study, we enrolled cognitively healthy, community living participants aged 65-83 years from 57 academic affiliated and private research clinics in Australia, Germany, Switzerland, the UK, and the USA. By use of the BRAA, participants were grouped as high risk or low risk. Participants at high risk were randomly assigned 1:1 to receive oral pioglitazone (0.8 mg/day sustained release) or placebo, and all low-risk participants received placebo. Study investigators, site staff, sponsor personnel, and study participants were masked to genotype, risk assignment, and treatment assignment. The planned study duration was the time to accumulate 202 events of mild cognitive impairment due to Alzheimer's disease in White participants who were at high risk (the population on whom the genetic analyses that informed the BRAA development was done). Primary endpoints were time-to-event comparisons between participants at high risk and low risk given placebo ( for the BRAA objective), and between participants at high risk given pioglitazone or placebo (for the efficacy objective). The primary analysis included all participants who were randomly assigned, received at least one dose of study drug, and had at least one valid post-baseline visit, with significance set at p=0.01. The safety analysis included all participants who were randomly assigned and received at least one dose of study medication. An efficacy futility analysis was planned for when approximately 33% of the anticipated events occurred in the high-risk, White, non-Hispanic or Latino group. This trial is registered with ClinicalTrials.gov, NCT01931566. Findings Between Aug 28, 2013, and Dec 21, 2015, we enrolled 3494 participants (3061 at high risk and 433 at low risk). Of those participants, 1545 were randomly assigned to pioglitazone and 1516 to placebo. 1104 participants discontinued treatment (464 assigned to the pioglitazone group, 501 in the placebo high risk group, and 139 in the placebo low risk group). 3399 participants had at least one dose of study drug or placebo and at least one post-baseline follow-up visit, and were included in the efficacy analysis. 3465 participants were included in the safety analysis (1531 assigned to the pioglitazone group, 1507 in the placebo high risk group, and 427 in the placebo low risk group). In the full analysis set, 46 (3.3%) of 1406 participants at high risk given placebo had mild cognitive impairment due to Alzheimer's disease, versus four (1.0%) of 402 participants at low risk given placebo (hazard ratio 3.26, 99% CI 0.85-12.45; p=0.023). 39 (2.7%) of 1430 participants at high risk given pioglitazone had mild cognitive impairment, versus 46 (3.3%) of 1406 participants at high risk given placebo (hazard ratio 0.80, 99% CI 0.45-1.40; p=0.307). In the safety analysis set, seven (0.5%) of 1531 participants at high risk given pioglitazone died versus 21 (1.4%) of 1507 participants at high risk given placebo. There were no other notable differences in adverse events between groups. The study was terminated in January, 2018, after failing to meet the non-futility threshold. Interpretation Pioglitazone did not delay the onset of mild cognitive impairment. The biomarker algorithm demonstrated a 3 times enrichment of events in the high risk placebo group compared with the low risk placebo group, but did not reach the pre-specified significance threshold. Because we did not complete the study as planned, findings can only be considered exploratory. The conduct of this study could prove useful to future clinical development strategies for Alzheimer's disease prevention studies. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Burns, Daniel K.; Chiang, Carl; Haneline, Stephen; Saunders, Ann M.] Zinfandel Pharmaceut, Durham, NC 27708 USA; [Alexander, Robert C.; Culp, Meredith; Evans, Rebecca M.; Wu, Jingtao; Schwarz, Adam J.; Ratti, Emiliangelo] Takeda Dev Ctr Amer, Cambridge, MA USA; [Welsh-Bohmer, Kathleen A.; Plassman, Brenda L.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA; [Burke, James R.; Lutz, Michael W.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA; [O'Neil, Janet; Harrigan, Patrick] Takeda Dev Ctr Amer, Deerfield, IL USA; [Schneider, Lon S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA; [Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA	Takeda Pharmaceutical Company Ltd; Takeda Development Center Americas, Inc.; Duke University; Duke University; Takeda Pharmaceutical Company Ltd; Takeda Development Center Americas, Inc.; University of Southern California; University of California System; University of California San Francisco	Burns, DK (corresponding author), Zinfandel Pharmaceut, Durham, NC 27708 USA.	dburns@zinfandelpharma.com	Wu, Jing/GZK-5063-2022	Peters, Oliver/0000-0003-0568-2998; Middleton, Lefkos/0000-0002-8615-3723	Takeda; Zinfandel	Takeda(Takeda Pharmaceutical Company Ltd); Zinfandel	Takeda and Zinfandel.	Aisen PS, 2020, JPAD-J PREV ALZHEIM, V7, P195, DOI 10.14283/jpad.2020.20; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Burns DK, 2019, ALZH DEMENT-TRCI, V5, P661, DOI 10.1016/j.trci.2019.09.010; Cao B, 2018, DIABETES OBES METAB, V20, P2467, DOI 10.1111/dom.13373; Castellani R, 2002, J NEUROSCI RES, V70, P357, DOI 10.1002/jnr.10389; Chou PS, 2017, J DIABETES COMPLICAT, V31, P1053, DOI 10.1016/j.jdiacomp.2017.01.006; Corona JC, 2016, FREE RADICAL BIO MED, V100, P153, DOI 10.1016/j.freeradbiomed.2016.06.023; Crenshaw DG, 2013, CLIN PHARMACOL THER, V93, P177, DOI 10.1038/clpt.2012.222; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Egan MF, 2019, NEW ENGL J MED, V380, P1408, DOI 10.1056/NEJMoa1812840; Elmaleh DR, 2019, J ALZHEIMERS DIS, V71, P715, DOI 10.3233/JAD-190507; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 2006, ALZ DIS ASSOC DIS, V20, pS152, DOI 10.1097/01.wad.0000213873.25053.2b; Geldmacher DS, 2011, ARCH NEUROL-CHICAGO, V68, P45, DOI 10.1001/archneurol.2010.229; Heneka MT, 2015, ANN NEUROL, V78, P284, DOI 10.1002/ana.24439; Imbimbo BP, 2019, EXPERT OPIN INV DRUG, V28, P967, DOI 10.1080/13543784.2019.1683160; Lanoiselee HM, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002270; Lutz Michael W, 2016, Alzheimers Dement (N Y), V2, P30; Lyketsos CG, 2007, NEUROLOGY, V68, P1800; McCleery J, 2019, AGE AGEING, V48, P174, DOI 10.1093/ageing/afy167; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Mosconi L, 2009, NEUROLOGY, V72, P513, DOI 10.1212/01.wnl.0000333247.51383.43; Reiman EM, 2005, P NATL ACAD SCI USA, V102, P8299, DOI 10.1073/pnas.0500579102; Reiman EM, 2001, P NATL ACAD SCI USA, V98, P3334, DOI 10.1073/pnas.061509598; Ridge PG, 2018, CURR GENET MED REP, V6, P1, DOI 10.1007/s40142-018-0132-2; Roses A, 2016, ALZHEIMERS DEMENT, V12, P687, DOI 10.1016/j.jalz.2016.03.015; Sato T, 2011, NEUROBIOL AGING, V32, P1626, DOI 10.1016/j.neurobiolaging.2009.10.009; Saunders AM, 2000, BBA-MOL BASIS DIS, V1502, P85, DOI 10.1016/S0925-4439(00)00035-1; Selkoe DJ, 2019, NAT REV NEUROL, V15, P365, DOI 10.1038/s41582-019-0205-1; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941; Tariot Pierre N, 2018, Alzheimers Dement (N Y), V4, P150, DOI 10.1016/j.trci.2018.02.002; Vellas B, 2012, LANCET NEUROL, V11, P851, DOI 10.1016/S1474-4422(12)70206-5	33	21	22	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					537	547		10.1016/S1474-4422(21)00043-0	http://dx.doi.org/10.1016/S1474-4422(21)00043-0			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UD5TG	34146512				2022-12-18	WOS:000687268300013
J	Wasay, M; Grisold, W; Carroll, W; Shakir, R				Wasay, Mohammad; Grisold, Wolfgang; Carroll, William; Shakir, Raad			World Brain Day 2016: celebrating brain health in an ageing population	LANCET NEUROLOGY			English	Letter							CHRONIC DISEASES; PREVALENCE; DISABILITY; COUNTRIES; PEOPLE; BURDEN		[Wasay, Mohammad] Aga Khan Univ, Karachi, Pakistan; [Wasay, Mohammad] World Federat Neurol, Publ Awareness & Advocacy Comm, London SW6 3JA, England; [Grisold, Wolfgang] KFJ Hosp, Dept Neurol, Vienna, Austria; [Carroll, William] Sir Charles Gairdner Hosp, Perth, WA, Australia; [Shakir, Raad] Imperial Coll, London, England	Aga Khan University; University of Western Australia; Imperial College London	Wasay, M (corresponding author), Aga Khan Univ, Karachi, Pakistan.; Wasay, M (corresponding author), World Federat Neurol, Publ Awareness & Advocacy Comm, London SW6 3JA, England.	mohammad.wasay@aku.edu						de Rijk MC, 2000, NEUROLOGY, V54, pS21; Ferri CP, 2011, J NEUROL NEUROSUR PS, V82, P1074, DOI 10.1136/jnnp.2010.234153; Sousa RM, 2009, LANCET, V374, P1821, DOI 10.1016/S0140-6736(09)61829-8; TISON F, 1994, ACTA NEUROL SCAND, V90, P111; United Nations Department of Economic and Social Affairs Population Division, 2015, WORLD POP PROSP 2015; US CDC, 2013, STAT AG AM 2013; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4	7	21	21	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					1008	1008		10.1016/S1474-4422(16)30171-5	http://dx.doi.org/10.1016/S1474-4422(16)30171-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27452915	Bronze, Green Submitted			2022-12-18	WOS:000381280300015
J	Stocchetti, N				Stocchetti, Nino			Traumatic brain injury: problems and opportunities	LANCET NEUROLOGY			English	Editorial Material									Univ Milan, Granda Osped Maggiore Policlin, Fdn IRCCS Ca, Dept Pathophysiopathol & Transplantat,Neurosurg I, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Stocchetti, N (corresponding author), Univ Milan, Granda Osped Maggiore Policlin, Fdn IRCCS Ca, Dept Pathophysiopathol & Transplantat,Neurosurg I, Via F Sforza35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Stocchetti, Nino/O-7444-2017	Stocchetti, Nino/0000-0003-3250-6834				Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; [Anonymous], 2013, MMWR MORB MORTAL WKL, V62, P177; Klein AM, 2013, J NEUROTRAUM, V30, P1476, DOI 10.1089/neu.2012.2735; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22	5	21	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					14	16		10.1016/S1474-4422(13)70280-1	http://dx.doi.org/10.1016/S1474-4422(13)70280-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331787				2022-12-18	WOS:000329000900009
J	Liba, Z; Sebronova, V; Komarek, V; Sediva, A; Sedlacek, P				Liba, Zuzana; Sebronova, Vera; Komarek, Vladimir; Sediva, Anna; Sedlacek, Petr			Prevalence and treatment of anti-NMDA receptor encephalitis	LANCET NEUROLOGY			English	Letter									[Liba, Zuzana; Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Neurol, Prague 15006, Czech Republic; [Sediva, Anna] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Immunol, Prague 15006, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic	Charles University Prague; Motol University Hospital; Charles University Prague; Motol University Hospital; Charles University Prague; Motol University Hospital	Liba, Z (corresponding author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Neurol, Prague 15006, Czech Republic.	zuzana.liba@gmail.com	Sediva, Anna/AAE-2774-2019; Sediva, Anna/J-5904-2017	Sediva, Anna/0000-0001-7730-2304; 				Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Jones JL, 2010, BRAIN, V133, P2232, DOI 10.1093/brain/awq176; Peery HE, 2012, AUTOIMMUN REV, V11, P863, DOI 10.1016/j.autrev.2012.03.001; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tuzun E, 2009, ACTA NEUROPATHOL, V118, P737, DOI 10.1007/s00401-009-0582-4	5	21	27	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					424	425		10.1016/S1474-4422(13)70070-X	http://dx.doi.org/10.1016/S1474-4422(13)70070-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23602156	Bronze			2022-12-18	WOS:000318836700010
J	Geschwind, MD				Geschwind, Michael D.			Clinical trials for prion disease: difficult challenges, but hope for the future	LANCET NEUROLOGY			English	Editorial Material							QUINACRINE; EFFICACY		Univ Calif San Francisco, Med Ctr, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Geschwind, MD (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Neurol, Memory & Aging Ctr, Box 1207, San Francisco, CA 94143 USA.	mgeschwind@memory.ucsf.edu			NIA NIH HHS [R01 AG031189-01A1, R01 AG031189] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG031189] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BONE I, 2006, UNIT UKCS, P1; Collinge J, 2009, LANCET NEUROL, V8, P334, DOI 10.1016/S1474-4422(09)70049-3; Engel GL, 1966, JAMA-J AM MED ASSOC, V197, P505; Haik S, 2004, NEUROLOGY, V63, P2413, DOI 10.1212/01.WNL.0000148596.15681.4D; Kennedy A., 2002, BMJ-BRIT MED J, V324, P239; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Nakajima M, 2004, DEMENT GERIATR COGN, V17, P158, DOI 10.1159/000076350; Otto M, 2004, NEUROLOGY, V62, P714, DOI 10.1212/01.WNL.0000113764.35026.EF; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Trevitt CR, 2006, BRAIN, V129, P2241, DOI 10.1093/brain/awl150; CJD CREUTZFELDT JAKO	11	21	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2009	8	4					304	306		10.1016/S1474-4422(09)70050-X	http://dx.doi.org/10.1016/S1474-4422(09)70050-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	425CH	19278901	Green Accepted			2022-12-18	WOS:000264614100004
J	Rutkove, S				Rutkove, Seward			Electrical impedance myography as a biomarker for ALS	LANCET NEUROLOGY			English	Letter							AMYOTROPHIC-LATERAL-SCLEROSIS; NEUROMUSCULAR DISEASE		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Rutkove, S (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	srutkove@bidmc.harvard.edu		Rutkove, Seward/0000-0002-6375-3312	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042037, K24NS060951] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS042037-04, K24 NS060951-01A1, R01 NS042037, K24 NS060951] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Esper GJ, 2006, MUSCLE NERVE, V34, P595, DOI 10.1002/mus.20626; Garmirian LP, 2009, MUSCLE NERVE, V39, P16, DOI 10.1002/mus.21115; Rutkove SB, 2002, MUSCLE NERVE, V25, P390, DOI 10.1002/mus.10048; Rutkove SB, 2007, CLIN NEUROPHYSIOL, V118, P2413, DOI 10.1016/j.clinph.2007.08.004; Turner MR, 2009, LANCET NEUROL, V8, P94, DOI 10.1016/S1474-4422(08)70293-X	5	21	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2009	8	3					226	226		10.1016/S1474-4422(09)70030-4	http://dx.doi.org/10.1016/S1474-4422(09)70030-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	412FZ	19233030	Green Accepted			2022-12-18	WOS:000263711200008
J	Shemie, SD				Shemie, S. D.			Diagnosis of brain death in children - Technology and the inadequate lexicon of death	LANCET NEUROLOGY			English	Article							EXTRACORPOREAL MEMBRANE-OXYGENATION; ORGAN DONATION; APNEA THRESHOLD; TRANSPLANTATION; EXPERIENCES; GUIDELINES; ATTITUDES; FAMILIES; CRITERIA; INJURY		McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Div Pediat Crit Care, Montreal, PQ H3H 1P3, Canada	McGill University	Shemie, SD (corresponding author), McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Div Pediat Crit Care, Montreal, PQ H3H 1P3, Canada.	sam.shemie@muhc.mcgill.ca						[Anonymous], 1987, PEDIATRICS, V80, P298; Bernat JL, 2006, J CLIN ETHIC, V17, P122; BLACK MD, 1995, ANN THORAC SURG, V60, P133; Brilli RJ, 2000, CRIT CARE MED, V28, P1257, DOI 10.1097/00003246-200004000-00081; Chen YS, 2003, J AM COLL CARDIOL, V41, P197, DOI 10.1016/S0735-1097(02)02716-X; Coolican M B, 1994, Crit Care Nurs Clin North Am, V6, P607; DeVita M A, 2001, Prog Transplant, V11, P58; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Joffe AR, 2006, ARCH PEDIAT ADOL MED, V160, P747, DOI 10.1001/archpedi.160.7.747; KAMEI C, 2002, HIDAMARI NO BYOSHITS; Lagiewska B, 1996, TRANSPLANT P, V28, P165; LYNN J, 1982, CRIT CARE MED, V10, P62; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Mathur M, 2005, CRIT CARE MED, V33, pA4, DOI 10.1097/00003246-200512002-00015; MEJIA RE, 1995, JAMA-J AM MED ASSOC, V274, P550, DOI 10.1001/jama.274.7.550; Morioka M, 2001, HASTINGS CENT REP, V31, P41, DOI 10.2307/3527955; MORIOKA M, 2001, EUBIOS J ASIAN INT B, V11, P108; Ormrod JA, 2005, ANAESTHESIA, V60, P1002, DOI 10.1111/j.1365-2044.2005.04297.x; Pallis C., 1996, ABC BRAINSTEM DEATH; PEARSON IY, 1995, ANAESTH INTENS CARE, V23, P88, DOI 10.1177/0310057X9502300116; PELLETIER M, 1992, J ADV NURS, V17, P90, DOI 10.1111/j.1365-2648.1992.tb01822.x; Powner DJ, 2003, CRIT CARE MED, V31, P1241, DOI 10.1097/01.CCM.0000059643.45027.96; Quartz SR, 1997, BEHAV BRAIN SCI, V20, P537; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; Shemie SD, 2006, CAN MED ASSOC J, V175, pS1, DOI 10.1503/cmaj.060895; Shewmon DA, 1998, NEUROLOGY, V51, P1538, DOI 10.1212/WNL.51.6.1538; Taylor RM, 1997, SEMIN NEUROL, V17, P265, DOI 10.1055/s-2008-1040938; Truog RD, 2003, CRIT CARE MED, V31, P2391, DOI 10.1097/01.CCM.0000090869.19410.3C; UNICEF, 1989, CONV RIGHTS CHILD; Vardis R, 1998, CRIT CARE MED, V26, P1917, DOI 10.1097/00003246-199811000-00040; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20	31	21	21	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					87	92		10.1016/S1474-4422(06)70680-9	http://dx.doi.org/10.1016/S1474-4422(06)70680-9			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166805				2022-12-18	WOS:000243039000022
J	Harper, PS; Gevers, S; de Wert, G; Creighton, S; Bombard, Y; Hayden, MR				Harper, PS; Gevers, S; de Wert, G; Creighton, S; Bombard, Y; Hayden, MR			Genetic testing and Huntington's disease: issues of employment	LANCET NEUROLOGY			English	Editorial Material							PSYCHOLOGICAL CONSEQUENCES; PREDICTIVE TEST; DISCRIMINATION		Univ Wales Coll Cardiff, Coll Med, Inst Med Genet, Cardiff, S Glam, Wales; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Maastricht Univ, Maastricht, Netherlands; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC, Canada	Cardiff University; University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; University of British Columbia	Harper, PS (corresponding author), Univ Wales Coll Cardiff, Coll Med, Inst Med Genet, Cardiff, S Glam, Wales.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				Almqvist EW, 2003, CLIN GENET, V64, P300, DOI 10.1034/j.1399-0004.2003.00157.x; BATES G, 2002, HUNTINGTONS DIS; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; Bundey S, 1997, LANCET, V349, P4, DOI 10.1016/S0140-6736(05)62155-1; Burgermeister J, 2003, BRIT MED J, V327, P827, DOI 10.1136/bmj.327.7419.827-a; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 2003, SCIENCE, V302, P745, DOI 10.1126/science.302.5646.745; *COUNC EUR, 2000, MED EX PREC EMPL PRI; Creighton S, 2003, CLIN GENET, V63, P462, DOI 10.1034/j.1399-0004.2003.00093.x; *EUR GROUP ETH, 2003, ETH ASP GEN TEST WOR; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; HARPER PS, 1992, J MED GENET, V29, P239, DOI 10.1136/jmg.29.4.239; HARPER PS, 1992, AM J HUM GENET, V50, P460; Hendriks A., 1994, EUROPEAN J HLTH LAW, V1, P229; *HUM GEN COMM, 2002, INS INF BAL INT PERS; Hum. Genet. Adv. Comm, 1999, IMPL GEN TEST EMPL; *INT LAB ORG, 1997, TECHN ETH GUID WORK; Lemmens T, 2000, McGill Law J, V45, P347; Otlowski MF, 2002, GENET MED, V4, P392, DOI 10.1097/00125817-200209000-00011; PENROSE LS, 1946, LANCET, V1, P949; Rothstein MA, 2001, GENET MED, V3, P354, DOI 10.1097/00125817-200109000-00005; TYLER A, 1992, BRIT MED J, V304, P1593, DOI 10.1136/bmj.304.6842.1593; *UN KINGS DEP HLTH, 2003, INH FUT; WENDT GG, 1972, HINTINGTONSCHE CCHOR; WENT L, 1994, J MED GENET, V31, P555; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34	26	21	21	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2004	3	4					249	252		10.1016/S1474-4422(04)00711-2	http://dx.doi.org/10.1016/S1474-4422(04)00711-2			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	814QU	15039038				2022-12-18	WOS:000220990000020
J	Meyer, HE; Klose, J; Hamacher, M				Meyer, HE; Klose, J; Hamacher, M			HBPP and the pursuit of standardisation	LANCET NEUROLOGY			English	Editorial Material									Ruhr Univ Bochum, Med Proteom Ctr, D-44801 Bochum, Germany	Ruhr University Bochum	Meyer, HE (corresponding author), Ruhr Univ Bochum, Med Proteom Ctr, ZKF E143,Univ Str 150, D-44801 Bochum, Germany.								0	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2003	2	11					657	658		10.1016/S1474-4422(03)00580-5	http://dx.doi.org/10.1016/S1474-4422(03)00580-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	734ZN	14572731				2022-12-18	WOS:000186088000012
J	Jacobi, H; du Montcel, ST; Romanzetti, S; Harmuth, F; Mariotti, C; Nanetti, L; Rakowicz, M; Makowicz, G; Durr, A; Monin, ML; Filla, A; Roca, A; Schols, L; Hengel, H; Infante, J; Kang, JS; Timmann, D; Casali, C; Masciullo, M; Baliko, L; Melegh, B; Nachbauer, W; Burk-Gergs, K; Schulz, JB; Riess, O; Reetz, K; Klockgether, T				Jacobi, Heike; du Montcel, Sophie Tezenas; Romanzetti, Sandro; Harmuth, Florian; Mariotti, Caterina; Nanetti, Lorenzo; Rakowicz, Maria; Makowicz, Grzegorz; Durr, Alexandra; Monin, Marie-Lorraine; Filla, Alessandro; Roca, Alessandro; Schoels, Ludger; Hengel, Holger; Infante, Jon; Kang, Jun-Suk; Timmann, Dagmar; Casali, Carlo; Masciullo, Marcella; Baliko, Laszlo; Melegh, Bela; Nachbauer, Wolfgang; Buerk-Gergs, Katrin; Schulz, Jorg B.; Riess, Olaf; Reetz, Kathrin; Klockgether, Thomas			Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study	LANCET NEUROLOGY			English	Article							PROGRESSION; VALIDATION; DISEASE; ONSET; DYSFUNCTION; SEVERITY; SYMPTOMS; MUTATION; FEATURES; SCALE	Background Spinocerebellar ataxias (SCAs) are autosomal dominant neurodegenerative diseases. Our aim was to study the conversion to manifest ataxia among apparently healthy carriers of mutations associated with the most common SCAs (SCA1, SCA2, SCA3, and SCA6), and the sensitivity of clinical and functional measures to detect change in these individuals. Methods In this prospective, longitudinal, observational cohort study, based at 14 referral centres in seven European countries, we enrolled children or siblings of patients with SCA1, SCA2, SCA3, or SCA6. Eligible individuals were those without ataxia, defined by a score on the Scale for the Assessment and Rating of Ataxia (SARA) of less than 3; participants had to be aged 18-50 years for children or siblings of patients with SCA1, SCA2, or SCA3, and 35-70 years for children or siblings of patients with SCA6. Study visits took place at recruitment and after 2, 4, and 6 years (plus or minus 3 months). We did genetic testing to identify mutation carriers, with results concealed to the participant and dinical investigator. We assessed patients with clinical scales, questionnaires of patient-reported outcome measures, a rating of the examiner's confidence of presence of ataxia, and performance-based coordination tests. Conversion to ataxia was defined by an SARA score of 3 or higher. We analysed the association of factors at baseline with conversion to ataxia and the evolution of outcome parameters on temporal scales (time from inclusion and time to predicted age at ataxia onset) in the context of mutation status and conversion status. This study is registered with ClinicalTrials.gov, NCT01037777. Findings Between Sept 13, 2008, and Oct 28, 2015, 302 participants were enrolled. We analysed data for 252 participants with at least one follow-up visit. 83 (33%) participants were from families affected by SCA1, 99 (39%) by SCA2, 46 (18%) by SCA3, and 24 (10%) by SCA6. In participants who carried SCA mutations, 26 (52%) of 50 SCA1 carriers, 22 (59%) of 37 SCA2 carriers, 11 (42%) of 26 SCA3 carriers, and two (13%) of 15 SCA6 carriers converted to ataxia. One (3%) of 33 SCA1 non-carriers and one (2%) of 62 SCA2 non-carriers converted to ataxia. Owing to the small number of people who met our criteria for ataxia, subsequent analyses could not be done in carriers of the SCA6 mutation. Baseline factors associated with conversion were age (hazard ratio 1.13 [95% CI 1. 03-1. 24]; p=0.011), CAG repeat length (1.25 [1- 11-1. 41]; p=0 . 0002), and ataxia confidence rating (1.72 [1.23-2.41]; p=0 . 0015) for SCA1; age (1.08 [1.02-1-14]; p=0.0077) and CAG repeat length (1.65 [1.27-2.13]; p=0.0001) for SCA2; and age (1.27 [1.09-1.50]; p=0.0031), confidence rating (2.60 [1.23-5.47]; p=0.012), and double vision (14.83 [245-102.44]; p=0 . 0063) for SCA3. From the time of indusion, the SARA scores of SCA1, SCA2, and SCA3 mutation carriers increased, whereas they remained stable in non-carriers. On a timescale defined by the predicted time of ataxia onset, SARA progression in SCA1, SCA2, and SCA3 mutation carriers was non-linear, with marginal progression before ataxia and increasing progression after ataxia onset. Interpretation Our study provides quantitative data on the conversion of non-ataxic SCA1, SCA2, and SCA3 mutation carriers to manifest ataxia. Our data could prove useful for the design of preventive trials aimed at delaying the onset of ataxia by aiding sample size calculations and stratification of study participants. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Jacobi, Heike] Univ Hosp Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; [Jacobi, Heike; Klockgether, Thomas] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [du Montcel, Sophie Tezenas] Univ Hosp Pitie Salpetriere, Inst Natl Sante & Rech Med, Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ,AP HP, Paris, France; [Romanzetti, Sandro; Schulz, Jorg B.; Reetz, Kathrin] Rhein Westfalische TH Aachen, Dept Neurol, Aachen, Germany; [Romanzetti, Sandro; Schulz, Jorg B.; Reetz, Kathrin] Forschungszentrum Julich, Inst Mol Neurosci & Neurointaging, Aachen, Germany; [Romanzetti, Sandro; Schulz, Jorg B.; Reetz, Kathrin] Rhein Westfalische TH, Aachen, Germany; [Harmuth, Florian; Riess, Olaf] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany; [Schoels, Ludger; Hengel, Holger] Univ Tubingen, Dept Neurol, Hertie Inst Clin Brain Res, Tubingen, Germany; [Riess, Olaf] Univ Tubingen, Rare Dis Ctr Tubingen, Tubingen, Germany; [Mariotti, Caterina; Nanetti, Lorenzo] Fdn IRCCS Ist Neurobg Carlo Besta, Unit Med Genet & Neurogenet, Milan, Italy; [Rakowicz, Maria] Inst Psychiat & Neurol, Neurol Dept 1, Warsaw, Poland; [Makowicz, Grzegorz] Inst Psychiat & Neurol, Dept Neuroradiol, Warsaw, Poland; [Durr, Alexandra; Monin, Marie-Lorraine] Sorbonne Univ, Univ Hosp Pitie Salpetriere, Inst Cerve,Paris Brain Inst, AP HP,Inst Natl Sante & Rech Med,Ctr Natl Rech Sc, Paris, France; [Filla, Alessandro; Roca, Alessandro] Univ Naples Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy; [Schoels, Ludger; Hengel, Holger] German Res Ctr Neurodegenerat Dis DZNE, Tubingen, Germany; [Infante, Jon] Univ Cantabria, Univ Hosp Marques Valdecilla, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Neurol Serv,Inst Invest Marques Valdecilla, Santander, Spain; [Kang, Jun-Suk] Goethe Univ, Dept Neurol, Frankfurt, Germany; [Timmann, Dagmar] Univ Duisburg Essen, Essen Univ Hosp, Dept Neurol, Essen, Germany; [Casali, Carlo] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Rome, Italy; [Masciullo, Marcella] IRCCS Fdn Santa Lucia, Spinal Rehabil Lab, Rome, Italy; [Baliko, Laszlo] Magyar Imre Hosp, Dept Neurol, Ajka, Hungary; [Melegh, Bela] Univ Pecs, Dept Med Genet, Pecs, Hungary; [Melegh, Bela] Univ Pecs, Szentagothai Res Ctr, Pecs, Hungary; [Nachbauer, Wolfgang] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Buerk-Gergs, Katrin] Philipps Univ Marburg, Dept Neurol, Marburg, Germany; [Buerk-Gergs, Katrin] Schmieder Stuttgart Gerlingen, Gerlingen, Germany; [Klockgether, Thomas] Univ Hosp Bonn, Dept Neurol, Bonn, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; RWTH Aachen University; Helmholtz Association; Research Center Julich; RWTH Aachen University; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Institute of Psychiatry & Neurology; Institute of Psychiatry & Neurology; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Naples Federico II; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); CIBERNED; Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; Goethe University Frankfurt; University of Duisburg Essen; Sapienza University Rome; IRCCS Santa Lucia; University of Pecs; University of Pecs; Medical University of Innsbruck; Philipps University Marburg; University of Bonn	Jacobi, H (corresponding author), Univ Hosp Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany.	heike.jacobi@med.uni-heidelberg.de	Schöls, Ludger/ABB-2482-2021; Tezenas du Montcel, Sophie/A-6207-2012; Mariotti, Caterina/AAP-9425-2021; Reetz, Kathrin/H-9510-2012; nanetti, lorenzo/A-7361-2013; MASCIULLO, Marcella/J-9144-2016	Schöls, Ludger/0000-0001-7774-5025; Tezenas du Montcel, Sophie/0000-0002-2866-4330; Mariotti, Caterina/0000-0003-2405-3564; Reetz, Kathrin/0000-0002-9730-9228; nanetti, lorenzo/0000-0002-1952-4539; MASCIULLO, Marcella/0000-0003-1368-7692; Infante, Jon/0000-0003-4025-4606	European Research Area Network for Research Programmes on Rare Diseases; Polish Ministry of Science and Higher Education; Italian Ministry of Health; European Community's Seventh Framework Programme	European Research Area Network for Research Programmes on Rare Diseases; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Italian Ministry of Health(Ministry of Health, Italy); European Community's Seventh Framework Programme(European Commission)	European Research Area Network for Research Programmes on Rare Diseases, Polish Ministry of Science and Higher Education, Italian Ministry of Health, European Community's Seventh Framework Programme.	Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Buysse D J, 1989, Psychiatry Res, V28, P193; Cecchin CR, 2007, COMMUNITY GENET, V10, P19, DOI 10.1159/000096276; Christova P, 2008, ARCH NEUROL-CHICAGO, V65, P530, DOI 10.1001/archneur.65.4.530; de Mattos EP, 2019, J NEUROL NEUROSUR PS, V90, P203, DOI 10.1136/jnnp-2018-319200; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Du Montcel ST, 2008, BRAIN, V131, P1352, DOI 10.1093/brain/awn059; du Montcel ST, 2014, J MED GENET, V51, P479, DOI 10.1136/jmedgenet-2013-102200; Durr A, 2010, LANCET NEUROL, V9, P885, DOI 10.1016/S1474-4422(10)70183-6; Globas C, 2008, MOV DISORD; Guerrini L, 2004, BRAIN, V127, P1785, DOI 10.1093/brain/awh201; Hogarth P, 2005, MOVEMENT DISORD, V20, P293, DOI 10.1002/mds.20332; Jacobi H, 2013, CEREBELLUM, V12, P418, DOI 10.1007/s12311-012-0421-3; Jacobi H, 2018, J NEUROL, V265, P2040, DOI 10.1007/s00415-018-8954-0; Jacobi H, 2013, LANCET NEUROL, V12, P650, DOI 10.1016/S1474-4422(13)70104-2; Klein A, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00171; Klockgether T, 1998, BRAIN, V121, P1687, DOI 10.1093/brain/121.9.1687; Klockgether T, 1998, BRAIN, V121, P589, DOI 10.1093/brain/121.4.589; Klockgether T, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0074-3; McMurtray AM, 2006, J NEUROPSYCH CLIN N, V18, P420, DOI 10.1176/appi.neuropsych.18.3.420; Nanetti L, 2017, GAIT POSTURE, V57, P11, DOI 10.1016/j.gaitpost.2017.05.007; Reetz K, 2018, ANN CLIN TRANSL NEUR, V5, P128, DOI 10.1002/acn3.504; Rezende TJR, 2018, ANN NEUROL, V84, P401, DOI 10.1002/ana.25297; Schmitz-Hubsch T, 2008, NEUROLOGY, V71, P982, DOI 10.1212/01.wnl.0000325057.33666.72; Schmitz-Hubsch T, 2008, NEUROLOGY, V71, P486, DOI 10.1212/01.wnl.0000324863.76290.19; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Schmitz-Hubsch T, 2010, MOVEMENT DISORD, V25, P587, DOI 10.1002/mds.22740; Schols L, 1998, NEUROLOGY, V51, P1603, DOI 10.1212/WNL.51.6.1603; Schulz JB, 2010, NEUROIMAGE, V49, P158, DOI 10.1016/j.neuroimage.2009.07.027; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7; Tustison NJ, 2014, NEUROIMAGE, V99, P166, DOI 10.1016/j.neuroimage.2014.05.044; Velazquez-Perez L, 2018, CLIN NEUROPHYSIOL, V129, P895, DOI 10.1016/j.clinph.2018.01.066; Velazquez-Perez L, 2014, LANCET NEUROL, V13, P482, DOI 10.1016/S1474-4422(14)70027-4; Velazquez-Perez L, 2010, J NEUROL SCI, V290, P22, DOI 10.1016/j.jns.2009.12.013; Warrenburg BPCV, 2005, ANN NEUROL, V57, P505, DOI 10.1002/ana.20424; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Xu HL, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.719	38	20	20	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					738	747		10.1016/S1474-4422(20)30235-0	http://dx.doi.org/10.1016/S1474-4422(20)30235-0			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	32822634	Green Published			2022-12-18	WOS:000562556500016
J	Diener, HC				Diener, Hans-Christoph			CGRP as a new target in prevention and treatment of migraine Comment	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; GENE-RELATED PEPTIDE; DOUBLE-BLIND; RECEPTOR		[Diener, Hans-Christoph] Univ Duisburg Essen, Dept Neurol, Univ Hosp Essen, D-45147 Essen, Germany; [Diener, Hans-Christoph] Univ Duisburg Essen, Headache Ctr, Univ Hosp Essen, D-45147 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Diener, HC (corresponding author), Univ Duisburg Essen, Dept Neurol, Univ Hosp Essen, D-45147 Essen, Germany.	hans.diener@uk-essen.de	Diener, Hans-Christoph/AAF-7275-2019					Asghar MS, 2010, NEUROLOGY, V75, P1520, DOI 10.1212/WNL.0b013e3181f9626a; Berger A, 2012, PAIN PRACT, V12, P541, DOI 10.1111/j.1533-2500.2012.00530.x; Diener HC, 2011, CEPHALALGIA, V31, P573, DOI 10.1177/0333102410388435; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Dodick DW, 2014, LANCET NEUROL; Edvinsson L, 2013, CURR PROTEIN PEPT SC, V14, P386, DOI 10.2174/13892037113149990055; GOADSBY PJ, 2000, MOL B INT U, V10, P159; Hewitt DJ, 2011, CEPHALALGIA, V31, P712, DOI 10.1177/0333102411398399; Ho TW, 2014, NEUROLOGY, V83, P958, DOI 10.1212/WNL.0000000000000771; Marcus R, 2014, CEPHALALGIA, V34, P114, DOI 10.1177/0333102413500727; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505	11	20	24	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1065	1067		10.1016/S1474-4422(14)70228-5	http://dx.doi.org/10.1016/S1474-4422(14)70228-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25297015				2022-12-18	WOS:000343783900004
J	Cadotte, DW; Fehlings, MG				Cadotte, David W.; Fehlings, Michael G.			Will imaging biomarkers transform spinal cord injury trials?	LANCET NEUROLOGY			English	Editorial Material							CLINICAL-TRIALS; ICCP PANEL; GUIDELINES; CONDUCT		[Cadotte, David W.] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Krembil Neurosci Ctr,Spinal Program, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada	Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Cadotte, DW (corresponding author), Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Krembil Neurosci Ctr,Spinal Program, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364				Cadotte DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045560; Cadotte David W, 2011, Expert Opin Med Diagn, V5, P121, DOI 10.1517/17530059.2011.556111; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Steeves JD, 2007, SPINAL CORD, V45, P206, DOI 10.1038/sj.sc.3102008; Stroman PW, 2014, NEUROIMAGE, V84, P1070, DOI 10.1016/j.neuroimage.2013.04.124; Stroman PW, 2012, CLIN NEUROL NEUROSUR, V114, P460, DOI 10.1016/j.clineuro.2012.01.003; Wilson JR, 2012, J NEUROSURG-SPINE, V17, P11, DOI 10.3171/2012.4.AOSPINE1245; Wilson JR, 2012, J NEUROTRAUM, V29, P2263, DOI 10.1089/neu.2012.2417	13	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					843	844		10.1016/S1474-4422(13)70157-1	http://dx.doi.org/10.1016/S1474-4422(13)70157-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210WU	23827393				2022-12-18	WOS:000323866600004
J	Frisoni, GB; Hampel, H; O'Brien, JT; Ritchie, K; Winblad, B				Frisoni, Giovanni B.; Hampel, Harald; O'Brien, John T.; Ritchie, Karen; Winblad, Bengt			Revised criteria for Alzheimer's disease: what are the lessons for clinicians?	LANCET NEUROLOGY			English	Editorial Material							ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; RECOMMENDATIONS; BIOMARKERS		[Frisoni, Giovanni B.] Fatebenefratelli, Inst Recovero & Cura Carattere Sci, I-25125 Brescia, Italy; [Hampel, Harald] Goethe Univ Frankfurt, Dept Psychiat Psychosomat Med & Psychotherapy, Frankfurt, Germany; [O'Brien, John T.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Ritchie, Karen] INSERM, U1061, Montpellier, France; [Ritchie, Karen] Univ London Imperial Coll Sci Technol & Med, London, England; [Winblad, Bengt] Karolinska Inst, Alzheimer Dis Res Ctr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden	IRCCS Fatebenefratelli; Goethe University Frankfurt; Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Imperial College London; Karolinska Institutet	Frisoni, GB (corresponding author), Fatebenefratelli, Inst Recovero & Cura Carattere Sci, I-25125 Brescia, Italy.	gfrisoni@fatebenefratelli.it	Frisoni, Giovanni B./K-1360-2016; Ritchie, Karen/G-3571-2013; Frisoni, Giovanni/K-1360-2016	Frisoni, Giovanni B./0000-0002-6419-1753; Ritchie, Karen/0000-0002-0688-8982; O'Brien, John/0000-0002-0837-5080; Frisoni, Giovanni/0000-0001-7075-7082; Hampel, Harald/0000-0003-0894-8982				Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Braak H, 2011, ACTA NEUROPATHOL, V121, P589, DOI 10.1007/s00401-011-0825-z; CHMP, 2008, GUID MED PROD TREATM; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Frisoni GB, 2011, ALZHEIMERS DEMENT, V7, P171, DOI 10.1016/j.jalz.2010.06.007; Hampel H, 2010, NAT REV DRUG DISCOV, V9, P560, DOI 10.1038/nrd3115; Hort J, 2010, EUR J NEUROL, V17, P1236, DOI 10.1111/j.1468-1331.2010.03040.x; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Mattsson N, 2010, CLIN CHEM LAB MED, V48, P603, DOI 10.1515/CCLM.2010.131; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003	13	20	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2011	10	7					598	601		10.1016/S1474-4422(11)70126-0	http://dx.doi.org/10.1016/S1474-4422(11)70126-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789BD	21683925				2022-12-18	WOS:000292487400006
J	Miller, D; Leary, SM				Miller, D.; Leary, S. M.			Primary-progressive multiple sclerosis (vol 6, pg 903, 2007)	LANCET NEUROLOGY			English	Correction																		Miller D, 2009, LANCET NEUROL, V8, P699, DOI 10.1016/S1474-4422(07)70243-0	1	20	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2009	8	8					699	699		10.1016/S1474-4422(07)70243-0	http://dx.doi.org/10.1016/S1474-4422(07)70243-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	477YV	17884680				2022-12-18	WOS:000268555800007
J	Qiu, J				Qiu, Jane			Epilepsy surgery: challenges for developing countries	LANCET NEUROLOGY			English	Editorial Material												jane@janeqiu.com							0	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2009	8	5					420	421		10.1016/S1474-4422(09)70096-1	http://dx.doi.org/10.1016/S1474-4422(09)70096-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435UE	19375660	Bronze			2022-12-18	WOS:000265368000007
J	Striano, P; Striano, S; Minetti, C; Zara, F				Striano, Pasquale; Striano, Salvatore; Minetti, Carlo; Zara, Federico			Refractory, life-threatening status epilepticus in a 3-year-old girl	LANCET NEUROLOGY			English	Article							SEVERE MYOCLONIC EPILEPSY; CONVULSIVE STATUS EPILEPTICUS; CHANNEL GENE SCN1A; DE-NOVO MUTATIONS; FEBRILE SEIZURES; INFANCY SMEI; LAMOTRIGINE; SUBUNIT; EXACERBATION; AGGRAVATION		[Striano, Pasquale; Minetti, Carlo; Zara, Federico] G Gaslini Inst Children, Unit Muscular & Neurodegenerat Dis, I-16147 Genoa, Italy; [Striano, Pasquale; Striano, Salvatore] Univ Naples Federico II, Dept Neurol Sci, Epilepsy Ctr, Naples, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Naples Federico II	Striano, P (corresponding author), G Gaslini Inst Children, Unit Muscular & Neurodegenerat Dis, Largo Gaslini 5, I-16147 Genoa, Italy.	pstriano@email.it	Zara, Federico/U-3477-2017; Striano, Pasquale/F-9117-2014; Minetti, Carlo/K-4666-2018	Zara, Federico/0000-0001-9744-5222; Striano, Pasquale/0000-0002-6065-1476; Minetti, Carlo/0000-0002-0640-1804				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BALE LF, 2004, J CHILD NEUROL, V19, P405; Benlounis A, 2001, EPILEPSIA, V42, P204, DOI 10.1046/j.1528-1157.2001.25299.x; Berkovic SF, 2006, LANCET NEUROL, V5, P488, DOI 10.1016/S1474-4422(06)70446-X; Biraben A, 2000, NEUROLOGY, V55, P1758; Biton V, 2006, EXPERT OPIN DRUG MET, V2, P1009, DOI 10.1517/17425255.2.6.1009; Caraballo RH, 2005, EPILEPSIA, V46, P1539, DOI 10.1111/j.1528-1167.2005.05705.x; Catterall WA, 2001, NATURE, V409, P988, DOI 10.1038/35059188; Ceulemans B, 2004, J CHILD NEUROL, V19, P516, DOI 10.1177/08830738040190070701; Ceulemans BPGM, 2004, PEDIATR NEUROL, V30, P236, DOI 10.1016/j.pediatrneurol.2003.10.012; Chaves J, 2005, EPILEPSIA, V46, P133, DOI 10.1111/j.1528-1167.2005.00325.x; Chin RFM, 2006, LANCET, V368, P222, DOI 10.1016/S0140-6736(06)69043-0; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Crespel A, 2005, NEUROLOGY, V65, P762, DOI 10.1212/01.wnl.0000174517.21383.36; Dalla Bernardina B, 1982, Rev Electroencephalogr Neurophysiol Clin, V12, P21; Depienne Christel, 2006, Hum Mutat, V27, P389, DOI 10.1002/humu.9419; Dichgans M, 2005, LANCET, V366, P371, DOI 10.1016/S0140-6736(05)66786-4; DRAVET C, 2005, ADV NEUROL, P7; Dravet C., 1978, VIE ME, V8, P543, DOI DOI 10.1016/S0370-4475(78)80126-9; DRAVET C, 2005, ADV NEUROL, P127; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; Fujiwara T, 2003, BRAIN, V126, P531, DOI 10.1093/brain/awg053; Fukuma G, 2004, EPILEPSIA, V45, P140, DOI 10.1111/j.0013-9580.2004.15103.x; Gelisse P, 2004, EPILEPSIA, V45, P1282, DOI 10.1111/j.0013-9580.2004.19704.x; Genmaro E, 2006, BIOCHEM BIOPH RES CO, V341, P489, DOI 10.1016/j.bbrc.2005.12.209; Genton P, 2006, EPILEPSIA, V47, P2083, DOI 10.1111/j.1528-1167.2006.00829.x; George Alfred L Jr, 2004, Epilepsy Curr, V4, P65, DOI 10.1111/j.1535-7597.2004.42010.x; Grosso S, 2007, NEUROLOGY, V69, P609, DOI 10.1212/01.wnl.0000266666.10404.53; Guerrini R, 1998, EPILEPSIA, V39, P508, DOI 10.1111/j.1528-1157.1998.tb01413.x; Guerrini R, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb05118.x; Guerrini R, 1999, BRAIN DEV-JPN, V21, P420, DOI 10.1016/S0387-7604(99)00048-0; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Harkin LA, 2007, BRAIN, V130, P843, DOI 10.1093/brain/awm002; HATTORI J, 2007, EPILEPSIA, DOI DOI 10.1111/J.1528-1167.2007.01475; Jansen FE, 2006, NEUROLOGY, V67, P2224, DOI 10.1212/01.wnl.0000249312.73155.7d; Kanai K, 2004, NEUROLOGY, V63, P329, DOI 10.1212/01.WNL.0000129829.31179.5B; Kanazawa O, 2001, BRAIN DEV-JPN, V23, P749, DOI 10.1016/S0387-7604(01)00279-0; KASSAI B, 2007, EPILEPSIA, DOI DOI 10.0111/J.1528-1167.2007.01423.X; Kroll-Seger J, 2006, NEUROPEDIATRICS, V37, P325, DOI 10.1055/s-2007-964867; Madia F, 2006, NEUROLOGY, V67, P1230, DOI 10.1212/01.wnl.0000238513.70878.54; Mancardi MM, 2006, EPILEPSIA, V47, P1629, DOI 10.1111/j.1528-1167.2006.00641.x; Marini C, 2007, EPILEPSIA, V48, P1678, DOI 10.1111/j.1528-1167.2007.01122.x; Marini C, 2006, EPILEPSIA, V47, P1737, DOI 10.1111/j.1528-1167.2006.00675.x; Martin MS, 2007, HUM MOL GENET, V16, P2892, DOI 10.1093/hmg/ddm248; Mulley JC, 2006, NEUROLOGY, V67, P1094, DOI 10.1212/01.wnl.0000237322.04338.2b; Mulley JC, 2005, HUM MUTAT, V25, P535, DOI 10.1002/humu.20178; Nabbout R, 2003, NEUROLOGY, V60, P1961, DOI 10.1212/01.WNL.0000069463.41870.2F; Nabbout R, 2003, J CLIN NEUROPHYSIOL, V20, P393, DOI 10.1097/00004691-200311000-00002; OGUNI H, 1994, EPILEPSIA, V35, P1140, DOI 10.1111/j.1528-1157.1994.tb01780.x; Ohmori I, 2008, EPILEPSIA, V49, P521, DOI 10.1111/j.1528-1167.2007.01411.x; Raspall-Chaure M, 2006, LANCET NEUROL, V5, P769, DOI 10.1016/S1474-4422(06)70546-4; Rhodes TH, 2004, P NATL ACAD SCI USA, V101, P11147, DOI 10.1073/pnas.0402482101; Stephani U, 2006, EPILEPSIA, V47, P53, DOI 10.1111/j.1528-1167.2006.00690.x; Striano P, 2007, NEUROLOGY, V69, P250, DOI 10.1212/01.wnl.0000265222.24102.db; Striano P, 2007, EPILEPSIA, V48, P1092, DOI 10.1111/j.1528-1167.2007.01020.x; Striano P, 2007, EPILEPSIA, V48, P1995, DOI 10.1111/j.1528-1167.2007.01198.x; Sugawara T, 2003, EPILEPSY RES, V54, P201, DOI 10.1016/S0920-1211(03)00084-6; Suls A, 2006, HUM MUTAT, V27, P914, DOI 10.1002/humu.20350; Thomas P, 2006, BRAIN, V129, P1281, DOI 10.1093/brain/awl047; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANMOLKOT KR, 2007, HUM MUTAT, V278, P522; Wallace RH, 2003, NEUROLOGY, V61, P765, DOI 10.1212/01.WNL.0000086379.71183.78; Wisniewski KE, 2001, NEUROLOGY, V57, P576, DOI 10.1212/WNL.57.4.576	65	20	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2008	7	3					278	284		10.1016/S1474-4422(08)70043-7	http://dx.doi.org/10.1016/S1474-4422(08)70043-7			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	268KZ	18275929				2022-12-18	WOS:000253580000019
J	Fullwood, NJ; Hayashi, Y; Allsop, D				Fullwood, Nigel J.; Hayashi, Yoshihito; Allsop, David			Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis	LANCET NEUROLOGY			English	Editorial Material							A-BETA; DEMENTIA		Univ Lancaster, Dept Biol Sci, Lancaster, England; Miyazaki Univ, Miyazaki Med Coll, Dept Neuropsychiat, Miyazaki, Japan	Lancaster University; University of Miyazaki	Fullwood, NJ (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster, England.	d.allsop@lancaster.ac.uk	Allsop, David/B-9725-2008	Allsop, David/0000-0002-0513-5575; Fullwood, Nigel James/0000-0002-9405-8515				Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; van Oijen M, 2006, LANCET NEUROL, V5, P655, DOI 10.1016/S1474-4422(06)70501-4; Walsh DM, 2005, BIOCHEM SOC T, V33, P1087, DOI 10.1042/BST0331087; Zetterberg H, 2006, LANCET NEUROL, V5, P638, DOI 10.1016/S1474-4422(06)70503-8	5	20	22	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					1000	1001		10.1016/S1474-4422(06)70611-1	http://dx.doi.org/10.1016/S1474-4422(06)70611-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	17110278				2022-12-18	WOS:000242266100009
J	Moses, H; Nagel, MA; Gilden, DH				Moses, Howard; Nagel, Maria A.; Gilden, Donald H.			Acute cerebellar ataxia in a 41 year old woman	LANCET NEUROLOGY			English	Article							VIRUS CEREBELLITIS; HERPES-ZOSTER; ENCEPHALITIS; MANIFESTATION		Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University; Johns Hopkins Medicine	Gilden, DH (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, Mail Stop B182,4200 E 9th Ave, Denver, CO 80262 USA.	don.gilden@uchsc.edu						Arav-Boger R, 2002, PEDIATR INFECT DIS J, V21, P353, DOI 10.1097/00006454-200204000-00021; Brechtelsbauer DL, 1997, NEURORADIOLOGY, V39, P19, DOI 10.1007/s002340050359; Chiappini E, 2002, J PEDIATR-US, V140, P250, DOI 10.1067/mpd.2002.121934; Ciardi M, 2003, CLIN INFECT DIS, V36, pE50, DOI 10.1086/345781; CONNOLLY AM, 1994, ANN NEUROL, V35, P673, DOI 10.1002/ana.410350607; Dorresteijn LDA, 2003, LANCET, V362, P1120, DOI 10.1016/S0140-6736(03)14468-6; Forghani B., 2000, VARICELLA ZOSTER VIR, P351; Fukushima R, 2004, J NEUROL NEUROSUR PS, V75, P485, DOI 10.1136/jnnp.2002.008011; Hevner R, 2003, LANCET NEUROL, V2, P567, DOI 10.1016/S1474-4422(03)00506-4; Kakourou T, 1998, J AM ACAD DERMATOL, V39, P207, DOI 10.1016/S0190-9622(98)70076-3; Kanzaki A, 1994, Rinsho Shinkeigaku, V34, P399; Kato Z, 2003, EUR J PEDIATR, V162, P801, DOI 10.1007/s00431-003-1287-7; KLOCKGETHER T, 1993, J NEUROL, V240, P17, DOI 10.1007/BF00838440; Kwon SU, 1999, CLIN NEUROL NEUROSUR, V101, P62, DOI 10.1016/S0303-8467(99)00009-8; LIBERMAN J, 1975, AM J MED, V59, P356; Park JW, 2004, CLIN NEUROL NEUROSUR, V106, P118, DOI 10.1016/j.clineuro.2003.10.009; Ratzka P, 2006, LANCET, V367, P182, DOI 10.1016/S0140-6736(06)67967-1; SANDBERGWOLLHEIM M, 1987, J NEUROL SCI, V81, P45, DOI 10.1016/0022-510X(87)90182-1; SCHWEISFURTH H, 1987, KLIN WOCHENSCHR, V65, P955, DOI 10.1007/BF01717829; Tanosaki M, 2001, Rinsho Shinkeigaku, V41, P31; Wong S, 2004, NEUROLOGY, V62, P2332, DOI 10.1212/01.WNL.0000130347.69790.E8	21	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2006	5	11					984	988		10.1016/S1474-4422(06)70601-9	http://dx.doi.org/10.1016/S1474-4422(06)70601-9			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099JY	17052665				2022-12-18	WOS:000241591600021
J	Doraiswamy, PM; Husain, MM				Doraiswamy, PM; Husain, MM			Anticholinergic drugs and elderly people: a no brainer?	LANCET NEUROLOGY			English	Editorial Material							CHOLINESTERASE-INHIBITORS		Duke Univ, Med Ctr, Durham, NC 27706 USA; Univ Texas, SW Med Ctr, Dallas, TX USA	Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Doraiswamy, PM (corresponding author), Duke Univ, Med Ctr, Durham, NC 27706 USA.	dorai001@mc.duke.edu						Ancelin ML, 2006, BMJ-BRIT MED J, V332, P455, DOI 10.1136/bmj.38740.439664.DE; Carnahan RM, 2004, J AM GERIATR SOC, V52, P2082, DOI 10.1111/j.1532-5415.2004.52563.x; Gill SS, 2005, ARCH INTERN MED, V165, P808, DOI 10.1001/archinte.165.7.808; Mulsant BH, 2003, ARCH GEN PSYCHIAT, V60, P198, DOI 10.1001/archpsyc.60.2.198; Perry EK, 2003, ANN NEUROL, V54, P235, DOI 10.1002/ana.10639	5	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					379	380		10.1016/S1474-4422(06)70421-5	http://dx.doi.org/10.1016/S1474-4422(06)70421-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16632303				2022-12-18	WOS:000237147600005
J	[Anonymous]				[Anonymous]			Tackling the global burden of stroke	LANCET NEUROLOGY			English	Editorial Material																			0	20	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					689	689		10.1016/S0140-6736(05)	http://dx.doi.org/10.1016/S0140-6736(05)			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16239171				2022-12-18	WOS:000233002400001
J	Pfefferbaum, A				Pfefferbaum, A			Alcoholism damages the brain, but does moderate alcohol use?	LANCET NEUROLOGY			English	Editorial Material							ADULTS		SRI Int, Program Neurosci, Menlo Pk, CA 94025 USA	SRI International	Pfefferbaum, A (corresponding author), SRI Int, Program Neurosci, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.	dolf@synapse.sri.com						Ding JZ, 2004, STROKE, V35, P16, DOI 10.1161/01.STR.0000105929.88691.8E; Mukamal Kenneth J, 2004, Am J Geriatr Cardiol, V13, P22, DOI 10.1111/j.1076-7460.2004.01334.x; Mukamal KJ, 2001, STROKE, V32, P1939, DOI 10.1161/hs0901.095723; Pfefferbaum A, 1997, ALCOHOL CLIN EXP RES, V21, P521, DOI 10.1111/j.1530-0277.1997.tb03798.x; Sullivan EV, 2003, NEUROLOGY, V61, P1716, DOI 10.1212/01.WNL.0000098940.31882.BB; Victor M., 1989, WERNICKE KORSAKOFF S, V2nd	6	20	20	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2004	3	3					143	144		10.1016/S1474-4422(04)00676-3	http://dx.doi.org/10.1016/S1474-4422(04)00676-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	802MK	14980527				2022-12-18	WOS:000220167400014
J	Rockwood, K; Wallack, M; Tallis, R				Rockwood, K; Wallack, M; Tallis, R			The treatment of Alzheimer's disease: success short of cure	LANCET NEUROLOGY			English	Editorial Material							QUALITATIVE-ANALYSIS; RATING-SCALE; DEMENTIA; CARE; RELIABILITY; IMPRESSION; VALIDITY; ISSUES	Metaphor has an important role in the discussion of scientific discovery because it enables researchers to talk about things of which their understanding is incomplete. Alzheimer's disease (AD) can be seen as a journey down a path, which becomes steadily less pleasant and ends in a wholly undesirable destination. To further the metaphor, treatments can be seen as attempts to help the patient return to the starting point, to slow the journey, or to stop at some point on the path. However, treatment may be successful but may not return the patient to their starting point or slow disease progression. We argue that treatments that steer the patient down a different path, to a destination preferable to that at the end of the AD path, can also be seen as successful. This metaphor has practical implications for clinical trials. It highlights the importance of individualised outcome measures that incorporate patients' preferences and should encourage us to develop better means of enabling the recovery of self. To understand how there can be treatment success short of cure, without knowing at the outset what from that success may take, will require systematic observation and careful description of patients' experiences.	Dalhousie Univ, Halifax, NS B3H 3J5, Canada; Mem Univ Newfoundland, St Johns, NF, Canada; Univ Manchester, Manchester M13 9PL, Lancs, England	Dalhousie University; Memorial University Newfoundland; University of Manchester	Rockwood, K (corresponding author), Ctr Hlth Care Elderly, 1421-5955 Vet Mem Lane, Halifax, NS B3H 2E1, Canada.		Rockwood, Kenneth/AAD-8951-2019					Bogardus ST, 2001, AM J MED, V110, P97, DOI 10.1016/S0002-9343(00)00668-9; Brasted PJ, 1999, P NATL ACAD SCI USA, V96, P10524, DOI 10.1073/pnas.96.18.10524; Burns A, 2002, J NEUROL NEUROSUR PS, V73, P471, DOI 10.1136/jnnp.73.5.471; Cook KF, 2001, SOC SCI MED, V53, P1275, DOI 10.1016/S0277-9536(00)00409-3; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; FEINSTEIN AR, 1994, ANN INTERN MED, V120, P799, DOI 10.7326/0003-4819-120-9-199405010-00012; GRAY J, 1999, CLIN DIAGNOSIS MANAG, P269; Joffres C, 2003, DEMENT GERIATR COGN, V15, P26, DOI 10.1159/000066673; Joffres C, 2000, INT PSYCHOGERIATR, V12, P403, DOI 10.1017/S1041610200006505; Kane R., 1996, SIGNIFICANCE FREE WI; Keller E. F., 2002, MAKING SENSE LIFE EX; Kirusek T. J., 1968, COMMUNITY MENTAL HLT, V4, P443; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS10; Livingston G, 2000, INT J GERIATR PSYCH, V15, P203, DOI 10.1002/(SICI)1099-1166(200003)15:3<203::AID-GPS100>3.0.CO;2-9; Pomeroy Valerie, 2002, Physiother Res Int, V7, P76, DOI 10.1002/pri.244; Quinn J, 2002, NEUROLOGY, V58, P433, DOI 10.1212/WNL.58.3.433; Rockwood K, 2002, J NEUROL NEUROSUR PS, V73, P500, DOI 10.1136/jnnp.73.5.500; Rockwood K, 2002, INT J GERIATR PSYCH, V17, P1006, DOI 10.1002/gps.733; Rockwood K, 2001, NEUROEPIDEMIOLOGY, V20, P51, DOI 10.1159/000054761; Rockwood K, 2000, J AM GERIATR SOC, V48, P1080, DOI 10.1111/j.1532-5415.2000.tb04783.x; ROCKWOOD K, 2002, NEUROBIOL AGING S1, V23, pA628; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142; Von Korff M, 2002, BRIT MED J, V325, P92, DOI 10.1136/bmj.325.7355.92	26	20	20	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					630	633		10.1016/S1474-4422(03)00533-7	http://dx.doi.org/10.1016/S1474-4422(03)00533-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	723KR	14505585				2022-12-18	WOS:000185432000020
J	Senior, K				Senior, K			Olfactory ensheathing cells to be used in spinal-cord repair trial	LANCET NEUROLOGY			English	News Item																			0	20	23	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2002	1	5					269	269		10.1016/S1474-4422(02)00145-X	http://dx.doi.org/10.1016/S1474-4422(02)00145-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588LB	12849411				2022-12-18	WOS:000177702000002
J	Lees, KR				Lees, KR			Management of acute stroke	LANCET NEUROLOGY			English	Review							ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; SPECIAL WRITING GROUP; TISSUE-PLASMINOGEN-ACTIVATOR; BLOOD-PRESSURE; THROMBOLYTIC THERAPY; HEMORRHAGIC TRANSFORMATION; INTRACEREBRAL HEMORRHAGE; CLINICAL-TRIALS; HEMICRANIECTOMY	Acute stroke is a medical emergency. The outcome is influenced by the rapidity and quality of initial care, which is best delivered by specialists with appropriate facilities, including 24 h access to computed tomography. Stroke management requires attention to simple details and has been summarised in clinical guidelines. General measures include control of blood glucose concentration, temperature, fluid balance, and oxygenation. Blood-pressure management is a matter for continuing research. Aspirin should be started early in ischaemic stroke, but heparin has doubtful value; antiembolism stockings may be preferable. Thrombolysis has a substantial benefit in selected circumstances, and trials continue to examine a wider role. Neuroprotection remains experimental, though magnesium is potentially of interest. Early neurosurgery has a role limited to decompression of lesions in the posterior fossa but is under trial for large hemispheric infarcts and moderate intracerebral bleeds.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk						*ABC ISCH STROK IN, 2002, STROKE, V31, P601; ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ADAMS HP, 1994, CIRCULATION, V90, P1588, DOI 10.1161/01.CIR.90.3.1588; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; ALBERTS MJ, 1992, STROKE, V23, P352, DOI 10.1161/01.STR.23.3.352; ASPLUND K, 1987, STROKE, V18, P691; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; Bath FJ, 1997, CEREBROVASC DIS, V7, P205, DOI 10.1159/000108192; Bath PMW, 2000, STROKE, V31, P1770, DOI 10.1161/01.STR.31.7.1770; Bath PMW, 2001, LANCET, V358, P702, DOI 10.1016/S0140-6736(01)05837-8; BATH PMW, 2000, INTERVENTIONS DYSPHA; Bradford Andrew, 2000, Curr Control Trials Cardiovasc Med, V1, P184, DOI 10.1186/CVM-1-3-184; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; CANDELISE L, 1995, LANCET, V346, P1509; CARLBERG B, 1991, CEREBROVASC DIS, V1, P281, DOI 10.1159/000108855; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Cornu C, 2000, STROKE, V31, P1555, DOI 10.1161/01.STR.31.7.1555; Culebras A, 1997, STROKE, V28, P1480, DOI 10.1161/01.STR.28.7.1480; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Demchuk AM, 2000, CAN J NEUROL SCI, V27, P274, DOI 10.1017/S0317167100000986; Donnan G, 1998, STROKE, V29, P1730; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; *EUR STROK COUNC, 1995, PAN EUR CONS M STROK; Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Grotta JC, 1999, STROKE, V30, P1528, DOI 10.1161/01.STR.30.8.1528; Hacke W, 1999, LANCET, V353, P67, DOI 10.1016/S0140-6736(05)74842-X; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2000, CEREBROVASC DIS, V10, P22, DOI 10.1159/000047578; Harbison J, 1999, LANCET, V353, P1935, DOI 10.1016/S0140-6736(99)00966-6; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kaste M, 2000, CEREBROVASC DIS, V10, P1, DOI 10.1159/000047576; Kidwell C S, 1998, Prehosp Emerg Care, V2, P267, DOI 10.1080/10903129808958878; KIERS L, 1992, J NEUROL NEUROSUR PS, V55, P263, DOI 10.1136/jnnp.55.4.263; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; LEE KR, 2001, EUR NEUROL, V45, P6; LEE KR, 2001, STROKE, V33, P308; Lees KR, 2000, BRIT MED BULL, V56, P389, DOI 10.1258/0007142001903030; Lees KR, 2000, BRIT MED BULL, V56, P401, DOI 10.1258/0007142001903049; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Muir K, 2000, STROKE, V31, P2811; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V355, P145; OLINGER CP, 1988, ANN EMERG MED, V17, P1208, DOI 10.1016/S0196-0644(88)80071-4; Potter JF, 1999, QJM-INT J MED, V92, P63, DOI 10.1093/qjmed/92.2.63; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Sandercock P, 1997, LANCET, V349, P1569; Saxena R, 2000, STROKE, V31, P546; Schellinger PD, 2001, CRIT CARE MED, V29, P1812, DOI 10.1097/00003246-200109000-00027; Schellinger PD, 2001, CRIT CARE MED, V29, P1819, DOI 10.1097/00003246-200109000-00028; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; Siddique MS, 2000, BRIT MED BULL, V56, P444, DOI 10.1258/0007142001903085; Smithard DG, 1997, DYSPHAGIA, V12, P188, DOI 10.1007/PL00009535; Steiner T, 2001, NEUROLOGY, V57, pS61, DOI 10.1212/WNL.57.suppl_2.S61; *STROK UN TRIAL CO, 2000, ORG INP STROK UN CAR; VONKUMMER R, 1992, STROKE, V23, P646, DOI 10.1161/01.STR.23.5.646; WAHLGREN NG, 1994, CEREBROVASC DIS, V4, P204, DOI 10.1159/000108483; WAHLGREN NG, 2001, CEREBROVASC DIS, V11, P79; Walters M, 2000, STROKE, V31, P2834; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; WARDLAW JM, 2000, THROMBOLYSIS ACUTE I; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303	75	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					41	50		10.1016/S1474-4422(02)00005-4	http://dx.doi.org/10.1016/S1474-4422(02)00005-4			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ	12849544				2022-12-18	WOS:000177694100019
J	Goutman, SA; Hardiman, O; Al-Chalabi, A; Chio, A; Savelieff, MG; Kiernan, MC; Feldman, EL				Goutman, Stephen A.; Hardiman, Orla; Al-Chalabi, Ammar; Chio, Adriano; Savelieff, Masha G.; Kiernan, Matthew C.; Feldman, Eva L.			Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Article							C9ORF72 REPEAT EXPANSION; NUCLEOCYTOPLASMIC TRANSPORT; MULTISTEP PROCESS; ANALYSES IDENTIFY; PHASE-SEPARATION; ALS; TDP-43; PROTEINS; GENES; ASSOCIATION	Amyotrophic lateral sclerosis is a fatal neurodegenerative disease. The discovery of genes associated with arnyotrophic lateral sclerosis, commencing with SOD1 in 1993, started fairly gradually. Recent advances in genetic technology have led to the rapid identification of multiple new genes associated with the disease, and to a new understanding of oligogenic and polygenic disease risk. The overlap of genes associated with amyotrophic lateral sclerosis with those of other neurodegenerative diseases is shedding light on the phenotypic spectrum of neurodegeneration, leading to a better understanding of genotype-phenotype correlations. A deepening knowledge of the genetic architecture is allowing the characterisation of the molecular steps caused by various mutations that converge on recurrent dysregulated pathways. Of crucial relevance, mutations associated with amyotrophic lateral sclerosis are amenable to novel gene-based therapeutic options, an approach in use for other neurological illnesses. Lastly, the exposome-the summation of lifetime environmental exposures-has emerged as an influential component for amyotrophic lateral sclerosis through the gene-time-environment hypothesis. Our improved understanding of all these aspects will lead to long-awaited therapies and the identification of modifiable risks factors.	[Goutman, Stephen A.; Savelieff, Masha G.; Feldman, Eva L.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; [Hardiman, Orla] Trinity Coll Dublin, Acad Unit Neurol, Trinity Biomed Sci Inst, Dublin, Ireland; [Al-Chalabi, Ammar] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Dept Basic & Clin Neurosci, London, England; [Al-Chalabi, Ammar] Kings Coll London, Dept Neurol, London, England; [Chio, Adriano] Univ Turin, Rita Levi Montalcini Dept Neurosci, Turin, Italy; [Kiernan, Matthew C.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Kiernan, Matthew C.] Royal Prince Alfred Hosp, Dept Neurol, Sydney, NSW, Australia	University of Michigan System; University of Michigan; Trinity College Dublin; University of London; King's College London; University of London; King's College London; University of Turin; University of Sydney; University of Sydney	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Michigan Med, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Goutman, Stephen/0000-0001-8780-6637	National ALS Registry/CDC/ATSDR [1R01TS000289, R01TS000327]; National ALS Registry/CDC/ATSDR CDCP-DHHS-US [CDC/ATSDR 200-2013-56856]; NIEHS [K23ES027221, R01ES030049]; NINDS [R01NS127188, R01NS120926]; NeuroNetwork for Emerging Therapies; NeuroNetwork Therapeutic Discovery Fund; Peter R Clark Fund for ALS Research; Sinai Medical Staff Foundation; University of Michigan; Science Foundation Ireland [13/RC2015, 16/RC/3948]; Thierry Latran Foundation; Health Research Board (Ireland); National Institute for Health Research [NIHR202421]; EU Joint Programme-Neurodegenerative Disease Research (JPND) project; JPND: Medical Research Council [MR/L501529/1, MR/R024804/1]; Economic and Social Research Council [ES/L008238/1]; Motor Neurone Disease Association; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London; Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata) [RF-2016-02362405]; Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research [2017SNW5MB]; European Commission's Health Seventh Framework Programme [259867]; Joint ProgrammeNeurodegenerative Disease Research (Strength, ALS-Care and BrainMend projects); Department of Excellence grant of the Italian Ministry of Education; National Health and Medical Research Council of Australia Program Grant [APP1132524, APP1153439, APP1156093]; Horizon 2020; My Name'5 Doddie Foundation; ALS Association	National ALS Registry/CDC/ATSDR; National ALS Registry/CDC/ATSDR CDCP-DHHS-US; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NeuroNetwork for Emerging Therapies; NeuroNetwork Therapeutic Discovery Fund; Peter R Clark Fund for ALS Research; Sinai Medical Staff Foundation; University of Michigan(University of Michigan System); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Thierry Latran Foundation; Health Research Board (Ireland); National Institute for Health Research(National Institute for Health Research (NIHR)); EU Joint Programme-Neurodegenerative Disease Research (JPND) project; JPND: Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Motor Neurone Disease Association; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London(General Electric); Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata)(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Finalizzata (MOH-RF)); Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research; European Commission's Health Seventh Framework Programme; Joint ProgrammeNeurodegenerative Disease Research (Strength, ALS-Care and BrainMend projects); Department of Excellence grant of the Italian Ministry of Education; National Health and Medical Research Council of Australia Program Grant(National Health and Medical Research Council (NHMRC) of Australia); Horizon 2020; My Name'5 Doddie Foundation; ALS Association	SAG and ELF receive funding from the National ALS Registry/CDC/ATSDR (1R01TS000289; R01TS000327); National ALS Registry/CDC/ATSDR CDCP-DHHS-US (CDC/ATSDR 200-2013-56856); NIEHS K23ES027221; NIEHS R01ES030049; NINDS R01NS127188 and R01NS120926; NeuroNetwork for Emerging Therapies, the NeuroNetwork Therapeutic Discovery Fund, the Peter R Clark Fund for ALS Research, the Sinai Medical Staff Foundation, Scott L Pranger, University of Michigan. OH receives funding from Science Foundation Ireland (13/RC2015, 16/RC/3948), Thierry Latran Foundation, and the Health Research Board (Ireland). AA-C is a Senior Investigator for the National Institute for Health Research (NIHR202421). This is an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND: Medical Research Council (MR/L501529/1; MR/R024804/1), Economic and Social Research Council (ES/L008238/1), and the Motor Neurone Disease Association. This study represents independent research partly funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. AC received funding from the Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata, grant RF-2016-02362405); the Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research (grant 2017SNW5MB); the European Commission's Health Seventh Framework Programme (FP7/2007-2013 under grant agreement 259867); the Joint ProgrammeNeurodegenerative Disease Research (Strength, ALS-Care and BrainMend projects), granted by Italian Ministry of Education, University and Research; and the Department of Excellence grant of the Italian Ministry of Education, University and Research to the Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy. MCK receives funding from the National Health and Medical Research Council of Australia Program Grant (APP1132524), Partnership Project (APP1153439), and Practitioner Fellowship (APP1156093) schemes. Funding from Horizon 2020, the ALS Association, and My Name'5 Doddie Foundation are also acknowledged.	AI-Chalabi A, 2014, LANCET NEUROL, V13, P1108, DOI 10.1016/S1474-4422(14)70219-4; Al-Chalabi A, 2010, J NEUROL NEUROSUR PS, V81, P1324, DOI 10.1136/jnnp.2010.207464; Al-Chalabi A, 2013, NAT REV NEUROL, V9, P617, DOI 10.1038/nrneurol.2013.203; Al-Chalabi A, 2011, HUM HERED, V71, P281, DOI 10.1159/000330167; Amado DA, 2021, MOL THER, V29, P3345, DOI 10.1016/j.ymthe.2021.04.008; Antenora A, 2017, ANN CLIN TRANSL NEUR, V4, P687, DOI 10.1002/acn3.437; Bandres-Ciga S, 2019, ANN NEUROL, V85, P470, DOI 10.1002/ana.25431; Bean DM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060668; Bede P, 2018, AMYOTROPH LAT SCL FR, V19, P232, DOI 10.1080/21678421.2017.1407795; Beers DR, 2019, LANCET NEUROL, V18, P211, DOI 10.1016/S1474-4422(18)30394-6; Boeynaems S, 2017, MOL CELL, V65, P1044, DOI 10.1016/j.molcel.2017.02.013; Byrne S, 2012, J NEUROL NEUROSUR PS, V83, P365, DOI 10.1136/jnnp-2011-301530; Byrne S, 2012, LANCET NEUROL, V11, P232, DOI 10.1016/S1474-4422(12)70014-5; Cali CP, 2019, ACTA NEUROPATHOL, V138, P795, DOI 10.1007/s00401-019-02045-5; Chia R, 2018, LANCET NEUROL, V17, P94, DOI 10.1016/S1474-4422(17)30401-5; Chio A, 2020, NEUROLOGY, V94, pE802, DOI 10.1212/WNL.0000000000008869; Chio A, 2018, NEUROLOGY, V91, pE635, DOI 10.1212/WNL.0000000000005996; Chou CC, 2018, NAT NEUROSCI, V21, P228, DOI 10.1038/s41593-017-0047-3; Cook CN, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb3774; Cooper-Knock J, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108456; Coque E, 2019, P NATL ACAD SCI USA, V116, P2312, DOI 10.1073/pnas.1815961116; Crockford C, 2018, NEUROLOGY, V91, pE1370, DOI 10.1212/WNL.0000000000006317; Devenney EM, 2021, ANN CLIN TRANSL NEUR, V8, P1576, DOI 10.1002/acn3.51363; Devenney EM, 2018, NEUROLOGY, V91, P1498, DOI 10.1212/WNL.0000000000006344; Dewan R, 2021, NEURON, V109, DOI 10.1016/j.neuron.2020.11.005; Dukic S, 2019, HUM BRAIN MAPP, V40, P4827, DOI 10.1002/hbm.24740; Ebbert MTW, 2018, ADV NEUROBIOL, V20, P1, DOI 10.1007/978-3-319-89689-2_1; Eftekharzadeh B, 2018, NEURON, V99, P925, DOI 10.1016/j.neuron.2018.07.039; Freibaum BD, 2015, NATURE, V525, P129, DOI 10.1038/nature14974; Gaj T, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aar3952; Garton FC, 2021, EUR J NEUROL, V28, P421, DOI 10.1111/ene.14554; Gasset-Rosa F, 2019, NEURON, V102, P339, DOI 10.1016/j.neuron.2019.02.038; Gasset-Rosa F, 2017, NEURON, V94, P48, DOI 10.1016/j.neuron.2017.03.027; Goutman SA, 2022, LANCET NEUROL, V21, P480, DOI 10.1016/S1474-4422(21)00465-8; Goutman SA, 2020, JAMA NEUROL, V77, P543, DOI 10.1001/jamaneurol.2020.0051; Goutman SA, 2019, J NEUROL NEUROSUR PS, V90, P907, DOI 10.1136/jnnp-2018-319785; Goutman Stephen A, 2018, Handb Clin Neurol, V148, P603, DOI 10.1016/B978-0-444-64076-5.00039-9; Gregory JM, 2020, CURR GENET MED REP, V8, P121, DOI 10.1007/s40142-020-00194-8; Grollemund V, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00135; Hardiman O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.71; Nguyen HP, 2018, TRENDS GENET, V34, P404, DOI 10.1016/j.tig.2018.03.001; Jia XM, 2018, ANN NEUROL, V84, P51, DOI 10.1002/ana.25263; Julian TH, 2021, EBIOMEDICINE, V68, DOI 10.1016/j.ebiom.2021.103397; Kenna KP, 2013, J MED GENET, V50, P776, DOI 10.1136/jmedgenet-2013-101795; Kenna KP, 2013, HUM MUTAT, V34, P836, DOI 10.1002/humu.22303; Khosravi B, 2020, EMBO J, V39, DOI 10.15252/embj.2019102811; Khosravi B, 2017, HUM MOL GENET, V26, P790, DOI 10.1093/hmg/ddw432; Kim HJ, 2017, NEURON, V96, P285, DOI 10.1016/j.neuron.2017.07.029; Klim JR, 2019, NAT NEUROSCI, V22, P167, DOI 10.1038/s41593-018-0300-4; Knott GJ, 2018, SCIENCE, V361, P866, DOI 10.1126/science.aat5011; Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192; Li CY, 2020, MOL NEUROBIOL, V57, P4622, DOI 10.1007/s12035-020-02053-7; Lim CKW, 2020, MOL THER, V28, P1177, DOI 10.1016/j.ymthe.2020.01.005; Lin YC, 2021, NAT NEUROSCI, V24, P1077, DOI 10.1038/s41593-021-00859-9; Ling SC, 2013, NEURON, V79, P416, DOI 10.1016/j.neuron.2013.07.033; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Mackenzie IRA, 2010, LANCET NEUROL, V9, P995, DOI 10.1016/S1474-4422(10)70195-2; Mahoney CJ, 2021, CNS DRUGS, V35, P483, DOI 10.1007/s40263-021-00820-1; McCann EP, 2021, J MED GENET, V58, P87, DOI 10.1136/jmedgenet-2020-106866; McCauley ME, 2020, NATURE, V585, P96, DOI 10.1038/s41586-020-2625-x; McHutchison CA, 2020, J NEUROL NEUROSUR PS, V91, P245, DOI 10.1136/jnnp-2019-321737; McLaughlin RL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14774; McMackin R, 2021, NEUROBIOL AGING, V104, P57, DOI 10.1016/j.neurobiolaging.2021.03.002; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Mitra J, 2019, P NATL ACAD SCI USA, V116, P4696, DOI 10.1073/pnas.1818415116; Moll T, 2020, BRAIN, V143, P1332, DOI 10.1093/brain/awz358; Moss DJH, 2014, NEUROLOGY, V82, P292, DOI 10.1212/WNL.0000000000000061; Murdock BJ, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.147129; Murdock BJ, 2017, JAMA NEUROL, V74, P1446, DOI 10.1001/jamaneurol.2017.2255; Neuenschwander AG, 2014, JAMA NEUROL, V71, P1529, DOI 10.1001/jamaneurol.2014.2082; Nezhad HG, 2021, AMYOTROPH LAT SCL FR, V22, P579, DOI 10.1080/21678421.2020.1853172; Nicolas A, 2018, NEURON, V97, P1268, DOI 10.1016/j.neuron.2018.02.027; O'Brien M, 2017, JAMA NEUROL, V74, P1425, DOI 10.1001/jamaneurol.2017.2699; Orme T, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-0879-z; Pakravan D, 2021, J MOL CELL BIOL, V13, P15, DOI 10.1093/jmcb/mjaa049; Pender N, 2020, CURR OPIN NEUROL, V33, P649, DOI 10.1097/WCO.0000000000000862; Pokrishevsky E, 2016, SCI REP-UK, V6, DOI 10.1038/srep22155; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148; Ryan M, 2019, JAMA NEUROL, V76, P1367, DOI 10.1001/jamaneurol.2019.2044; Ryan M, 2018, NEUROL-GENET, V4, DOI 10.1212/NXG.0000000000000239; Saberi S, 2018, ACTA NEUROPATHOL, V135, P459, DOI 10.1007/s00401-017-1793-8; Sackmann C, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00540; Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4; Shahrizaila N, 2016, J NEUROL NEUROSUR PS, V87, P821, DOI 10.1136/jnnp-2015-312751; Shang JW, 2017, NEUROSCIENCE, V350, P158, DOI 10.1016/j.neuroscience.2017.03.024; Shepheard SR, 2021, J NEUROL NEUROSUR PS, V92, P510, DOI 10.1136/jnnp-2020-325014; Tu SC, 2018, J NEUROL NEUROSUR PS, V89, P1250, DOI 10.1136/jnnp-2018-318625; van Rheenen W, 2016, NAT GENET, V48, P1043, DOI 10.1038/ng.3622; Vucic S, 2020, NEUROLOGY, V94, pE1657, DOI 10.1212/WNL.0000000000009015; Wang MD, 2017, NEUROTOXICOLOGY, V61, P101, DOI 10.1016/j.neuro.2016.06.015; Westergard T, 2016, CELL REP, V17, P645, DOI 10.1016/j.celrep.2016.09.032; Wood A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094705; Yang CP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03247-3; Yang LH, 2020, PROG NEURO-PSYCHOPH, V97, DOI 10.1016/j.pnpbp.2019.109771; Yu CH, 2020, CELL, V183, P636, DOI 10.1016/j.cell.2020.09.020; Zhang K, 2015, NATURE, V525, P56, DOI 10.1038/nature14973; Zhang YJ, 2019, SCIENCE, V363, P707, DOI 10.1126/science.aav2606; Zou ZY, 2017, J NEUROL NEUROSUR PS, V88, P540, DOI 10.1136/jnnp-2016-315018	100	19	19	22	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2022	21	5					465	479		10.1016/S1474-4422(21)00414-2	http://dx.doi.org/10.1016/S1474-4422(21)00414-2			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	2R9KM	35334234				2022-12-18	WOS:000821423000019
J	Mercuri, E; Deconinck, N; Mazzone, ES; Nascimento, A; Oskoui, M; Saito, K; Vuillerot, C; Baranello, G; Boespflug-Tanguy, O; Goemans, N; Kirschner, J; Kostera-Pruszczyk, A; Servais, L; Gerber, M; Gorni, K; Khwaja, O; Kletzl, H; Scalco, RS; Staunton, H; Yeung, WY; Martin, C; Fontoura, P; Day, JW				Mercuri, Eugenio; Deconinck, Nicolas; Mazzone, Elena S.; Nascimento, Andres; Oskoui, Maryam; Saito, Kayoko; Vuillerot, Carole; Baranello, Giovanni; Boespflug-Tanguy, Odile; Goemans, Nathalie; Kirschner, Janbernd; Kostera-Pruszczyk, Anna; Servais, Laurent; Gerber, Marianne; Gorni, Ksenija; Khwaja, Omar; Kletzl, Heidemarie; Scalco, Renata S.; Staunton, Hannah; Yeung, Wai Yin; Martin, Carmen; Fontoura, Paulo; Day, John W.		SUNFISH Study Grp	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial	LANCET NEUROLOGY			English	Article							MOTOR FUNCTION MEASURE; SURVIVAL; SMA	Background Risdiplam is an oral small molecule approved for the treatment of patients with spinal muscular atrophy, with approval for use in patients with type 2 and type 3 spinal muscular atrophy granted on the basis of unpublished data. The drug modifies pre-mRNA splicing of the SMN2 gene to increase production of functional SMN. We aimed to investigate the safety and efficacy of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. Methods In this phase 3, randomised, double-blind, placebo-controlled study, patients aged 2-25 years with confirmed 5q autosomal recessive type 2 or type 3 spinal muscular atrophy were recruited from 42 hospitals in 14 countries across Europe, North America, South America, and Asia. Participants were eligible if they were non-ambulant, could sit independently, and had a score of at least 2 in entry item A of the Revised Upper Limb Module. Patients were stratified by age and randomly assigned (2:1) to receive either daily oral risdiplam, at a dose of 5.00 mg (for individuals weighing >= 20 kg) or 0.25 mg/kg (for individuals weighing <20 kg), or daily oral placebo (matched to risdiplam in colour and taste). Randomisation was conducted by permutated block randomisation with a computerised system run by an external party. Patients, investigators, and all individuals in direct contact with patients were masked to treatment assignment. The primary endpoint was the change from baseline in the 32-item Motor Function Measure total score at month 12. All individuals who were randomly assigned to risdiplam or placebo, and who did not meet the prespecified missing item criteria for exclusion, were included in the primary efficacy analysis. Individuals who received at least one dose of risdiplam or placebo were included in the safety analysis. SUNFISH is registered with ClinicalTrials.gov, NCT02908685. Recruitment is closed; the study is ongoing. Findings Between Oct 9, 2017, and Sept 4, 2018, 180 patients were randomly assigned to receive risdiplam (n=120) or placebo (n=60). For analysis of the primary endpoint, 115 patients from the risdiplam group and 59 patients from the placebo group were included. At month 12, the least squares mean change from baseline in 32-item Motor Function Measure was 1.36 (95% CI 0.61 to 2.11) in the risdiplam group and -0.19 (-1.22 to 0.84) in the placebo group, with a treatment difference of 1.55 (0.30 to 2.81, p=0.016) in favour of risdiplam. 120 patients who received risdiplam and 60 who received placebo were included in safety analyses. Adverse events that were reported in at least 5% more patients who received risdiplam than those who received placebo were pyrexia (25 [21%] of 120 patients who received risdiplam vs ten [17%] of 60 patients who received placebo), diarrhoea (20 [17%] vs five [8%]), rash (20 [17%] vs one [2%]), mouth and aphthous ulcers (eight [7%] vs 0), urinary tract infection (eight [7%] vs 0), and arthralgias (six [5%] vs 0). The incidence of serious adverse events was similar between treatment groups (24 [20%] of 120 patients in the risdiplam group; 11 [18%] of 60 patients in the placebo group), with the exception of pneumonia (nine [8%] in the risdiplam group; one [2%] in the placebo group). Interpretation Risdiplam resulted in a significant improvement in motor function compared with placebo in patients aged 2-25 years with type 2 or non-ambulant type 3 spinal muscular atrophy. Our exploratory subgroup analyses showed that motor function was generally improved in younger individuals and stabilised in older individuals, which requires confirmation in further studies. SUNFISH part 2 is ongoing and will provide additional evidence regarding the long-term safety and efficacy of risdiplam. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Mercuri, Eugenio; Mazzone, Elena S.] Catholic Univ, Paediat Neurol & Nemo Ctr, I-00168 Rome, Italy; [Mercuri, Eugenio; Mazzone, Elena S.] Policlin Gemelli, I-00168 Rome, Italy; [Deconinck, Nicolas] UZ Gent, Neuromuscular Reference Ctr, Ghent, Belgium; [Deconinck, Nicolas] Univ Libre Bruxelles, Queen Fabiola Childrens Univ Hosp, Neuromuscular Reference Ctr, Brussels, Belgium; [Nascimento, Andres] CIBERER ISC III, Fdn St Joan de Deu, Hosp St Joan de Diu, Neuromuscular Unit,Neuropaediat Dept, Barcelona, Spain; [Oskoui, Maryam] McGill Univ, Dept Pediat, Montreal, PQ, Canada; [Oskoui, Maryam] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Saito, Kayoko] Tokyo Womens Med Univ, Inst Med Genet, Tokyo, Japan; [Vuillerot, Carole] CHU Lyon, Hop Femme Mere Enfant, Serv Reeduc Pediat Infantile LEscale, Bron, France; [Vuillerot, Carole] Univ Lyon, INSERM U1217, Neuromyogen Inst, CNRS UMR 5310, Lyon, France; [Baranello, Giovanni] UCL, Great Ormond St NHS Trust, Dubowitz Neuromuscular Ctr, NIHR Great Ormond St Hosp Biomed Res Ctr,Great Or, London, England; [Baranello, Giovanni] Fdn IRCCS Ist Neurol Carlo Besta, Dev Neurol Unit, Milan, Italy; [Boespflug-Tanguy, Odile; Servais, Laurent] Hop Armand Trousseau, AP HP, Inst Myol, I Mot, Paris, France; [Boespflug-Tanguy, Odile] Univ Paris, NeuroDiderot, UMR 1141, Paris, France; [Goemans, Nathalie] Univ Hosp Leuven, Neuromuscular Reference Ctr, Dept Paediat & Child Neurol, Leuven, Belgium; [Kirschner, Janbernd] Univ Freiburg, Dept Neuropediat & Muscle Disorders, Med Ctr, Freiburg, Germany; [Kirschner, Janbernd] Univ Hosp Bonn, Fac Med, Div Neuropediat, Bonn, Germany; [Kostera-Pruszczyk, Anna] Med Univ Warsaw, Dept Neurol, Warsaw, Poland; [Servais, Laurent] Univ Oxford, MDUK Oxford Neuromuscular Ctr, Dept Paediat, Oxford, England; [Servais, Laurent] Ctr Hosp Reg Citadelle, Reference Ctr Neuromuscular Dis, Liege, Belgium; [Gerber, Marianne; Gorni, Ksenija; Khwaja, Omar; Kletzl, Heidemarie; Scalco, Renata S.; Fontoura, Paulo] F Hoffmann La Roche, Basel, Switzerland; [Staunton, Hannah; Yeung, Wai Yin; Martin, Carmen] Roche Prod, Welwyn Garden City, Herts, England; [Khwaja, Omar] Voyager Therapeut, Cambridge, MA USA; [Day, John W.] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Ghent University; Ghent University Hospital; Universite Libre de Bruxelles; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; McGill University; McGill University; Tokyo Women's Medical University; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; University Hospital Leuven; University of Freiburg; University of Bonn; Medical University of Warsaw; University of Oxford; Roche Holding; Roche Holding; Stanford University	Mercuri, E (corresponding author), Catholic Univ, Paediat Neurol & Nemo Ctr, I-00168 Rome, Italy.; Mercuri, E (corresponding author), Policlin Agostino Gemelli, I-00168 Rome, Italy.	eugeniomaria.mercuri@unicatt.it	Coratti, Giorgia/Y-6292-2019; Masson, Riccardo/AAB-8896-2019; Yeung, Wai Yin (Winnie)/AAV-2799-2020; Kirschner, Janbernd/Q-1493-2019; Coratti, Giorgia/AAV-3224-2021; Pera, Maria Carmela/J-6068-2018	Coratti, Giorgia/0000-0001-6666-5628; Masson, Riccardo/0000-0002-9311-452X; Yeung, Wai Yin (Winnie)/0000-0002-9999-1048; Kirschner, Janbernd/0000-0003-1618-7386; Coratti, Giorgia/0000-0001-6666-5628; Munell Casadesus, Francina/0000-0001-8580-2819; Kosac, Ana/0000-0002-8657-1933; Saito, Kayoko/0000-0003-2632-0873; Milascevic, Darko/0000-0003-4034-8434; Kira, Ryutaro/0000-0002-6878-5081; Rossetto, Julia/0000-0001-9620-6609; Duong, Tina/0000-0003-3177-4722; Pera, Maria Carmela/0000-0001-6777-1721; Day, John/0000-0002-0086-9529; D'AMICO, GUGLIELMO/0000-0003-3758-7397	F Hoffmann-La Roche	F Hoffmann-La Roche(Hoffmann-La Roche)	F Hoffmann-La Roche.	Annoussamy M, 2021, ANN CLIN TRANSL NEUR, V8, P359, DOI 10.1002/acn3.51281; Berard C, 2005, NEUROMUSCULAR DISORD, V15, P463, DOI 10.1016/j.nmd.2005.03.004; Biogen, 2016, SPINRAZA NUS INTR US; Biogen, 2017, SUMMARY PRODUCT CHAR; Coon CD, 2018, QUAL LIFE RES, V27, P33, DOI 10.1007/s11136-017-1616-3; Day J, 2020, NEUROMUSCULAR DISORD, V30, pS123, DOI 10.1016/j.nmd.2020.08.262; Dunlop BW, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7030040; European Medicines Agency, 2020, ZOLG; European Medicines Agency, 2021, SUMM OP IN AUTH; FDA, 2019, ON AB XIOI APPR; Gusset N, 2021, NEUROMUSCULAR DISORD, V31, P419, DOI 10.1016/j.nmd.2021.01.012; Immohr LI, 2017, INT J PHARMACEUT, V530, P201, DOI 10.1016/j.ijpharm.2017.07.069; Kaufmann P, 2011, ARCH NEUROL-CHICAGO, V68, P779, DOI 10.1001/archneurol.2010.373; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Mazzone, 2014, REVISED UPPER LIMB M; Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504; Mercuri E, 2019, NEUROLOGY, V93, pE1241, DOI 10.1212/WNL.0000000000008166; Mercuri E, 2016, NEUROMUSCULAR DISORD, V26, P126, DOI 10.1016/j.nmd.2015.10.006; Ratni H, 2018, J MED CHEM, V61, P6501, DOI 10.1021/acs.jmedchem.8b00741; Scoto F., NEUROLOGY, V96, P587; Singh RN, 2017, BBA-GENE REGUL MECH, V1860, P299, DOI 10.1016/j.bbagrm.2016.12.008; Smart T, 2018, CURESMA VOICE PATIEN; Staunton D., IN PRESS; Sturm S, 2019, BRIT J CLIN PHARMACO, V85, P181, DOI 10.1111/bcp.13786; Talbot K, 2017, GENE THER, V24, P529, DOI 10.1038/gt.2017.52; Trundell D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238786; Trundell D, 2020, NEUROL THER, V9, P575, DOI 10.1007/s40120-020-00206-3; U.S. Food & Drug Administration, 2018, PAT FOC DRUG DEV GUI; US Food and Drug Administration, 2020, EVRYSDI RISD OR SOL; Vuillerot C, 2013, ARCH PHYS MED REHAB, V94, P1555, DOI 10.1016/j.apmr.2013.01.014; Wijngaarde CA, 2020, NEUROLOGY, V95, pE1988, DOI 10.1212/WNL.0000000000010540; Wijngaarde CA, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01367-y	33	19	20	12	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					42	52		10.1016/S1474-4422(21)00367-7	http://dx.doi.org/10.1016/S1474-4422(21)00367-7			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942136				2022-12-18	WOS:000734663200021
J	Brown, JWL; Cunniffe, NG; Prados, F; Kanber, B; Jones, JL; Needham, E; Georgieva, Z; Rog, D; Pearson, OR; Overell, J; MacManus, D; Samson, RS; Stutters, J; Ffrench-Constant, C; Wheeler-Kingshott, CAMG; Moran, C; Flynn, PD; Michell, AW; Franklin, RJM; Chandran, S; Altmann, DR; Chard, DT; Connick, P; Coles, AJ				Brown, J. William L.; Cunniffe, Nick G.; Prados, Ferran; Kanber, Baris; Jones, Joanne L.; Needham, Edward; Georgieva, Zoya; Rog, David; Pearson, Owen R.; Overell, James; MacManus, David; Samson, Rebecca S.; Stutters, Jonathan; Ffrench-Constant, Charles; Wheeler-Kingshott, Claudia A. M. Gandini; Moran, Carla; Flynn, Paul D.; Michell, Andrew W.; Franklin, Robin J. M.; Chandran, Siddharthan; Altmann, Daniel R.; Chard, Declan T.; Connick, Peter; Coles, Alasdair J.			Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One) a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study	LANCET NEUROLOGY			English	Article							MAGNETIZATION-TRANSFER RATIO; CORTICAL REMYELINATION; MYELIN; DEMYELINATION; FUMARATE; THERAPY; MRI	Background Progressive disability in multiple sclerosis occurs because CNS axons degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma agonists promote remyelination. We aimed to assess the safety and efficacy of a non-selective retinoid X receptor agonist in promoting remyelination in people with multiple sclerosis. Methods This randomised, double-blind, placebo-controlled, parallel-group, phase 2a trial (CCMR One) recruited patients with relapsing-remitting multiple sclerosis from two centres in the UK. Eligible participants were aged 18-50 years and had been receiving dimethyl fumarate for at least 6 months. Via a web-based system run by an independent statistician, participants were randomly assigned (1:1), by probability-weighted minimisation using four binary factors, to receive 300 mg/m 2 of body surface area per day of oral bexarotene or oral placebo for 6 months. Participants, investigators, and outcome assessors were masked to treatment allocation. MRI scans were done at baseline and at 6 months. The primary safety outcome was the number of adverse events and withdrawals attributable to bexarotene. The primary efficacy outcome was the patient-level change in mean lesional magnetisation transfer ratio between baseline and month 6 for lesions that had a baseline magnetisation transfer ratio less than the within-patient median. We analysed the primary safety outcome in the safety population, which comprised participants who received at least one dose of their allocated treatment. We analysed the primary efficacy outcome in the intention-to-treat population, which comprised all patients who completed the study. This study is registered in the ISRCTN Registry, 14265371, and has been completed. Findings Between Jan 17,2017, and May 17,2019,52 participants were randomly assigned to receive either bexarotene (n=26) or placebo (n=26). Participants who received bexarotene had a higher mean number of adverse events (6.12 [SD 3.09]; 159 events in total) than did participants who received placebo (1.63 [SD 1.50]; 39 events in total). All bexarotene-treated participants had at least one adverse event, which included central hypothyroidism (n=26 vs none on placebo), hypertriglyceridaemia (n=24 vs none on placebo), rash (n=13 vs one on placebo), and neutropenia (n=10 vs none on placebo). Five (19%) participants on bexarotene and two (8%) on placebo discontinued the study drug due to adverse events. One episode of cholecystitis in a placebo-treated participant was the only serious adverse event. The change in mean lesional magnetisation transfer ratio was not different between the bexarotene group (0.25 percentage units [pu; SD 0.981) and the placebo group (0.09 pu [0.84]; adjusted bexarotene-placebo difference 0.16 pu, 95% CI -0.39 to 0.71; p=0.55). Interpretation We do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome. However, statistically significant effects were seen in some exploratory MRI and electrophysiological analyses, suggesting that other retinoid X receptor agonists might have small biological effects that could be investigated in further studies. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Brown, J. William L.; Cunniffe, Nick G.; Jones, Joanne L.; Needham, Edward; Georgieva, Zoya; Michell, Andrew W.; Franklin, Robin J. M.; Coles, Alasdair J.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Moran, Carla] Univ Cambridge, Welkome Trust MRC Inst Metab Sci, Cambridge, England; [Flynn, Paul D.] Univ Cambridge, Div Cardiovasc Med, Dept Med, Cambridge, England; [Franklin, Robin J. M.] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England; [Brown, J. William L.; Prados, Ferran; Kanber, Baris; MacManus, David; Samson, Rebecca S.; Stutters, Jonathan; Wheeler-Kingshott, Claudia A. M. Gandini; Chard, Declan T.] UCL, NMR Res Unit, Queen Sq Multiple Sclerosis Ctr, UCL Queen Sq Inst Neurol, London, England; [Prados, Ferran; Kanber, Baris] UCL, Ctr Med Image Comp, Dept Med Phys & Biomed Engn, London, England; [Brown, J. William L.] Univ Melbourne, Clin Outcomes Res Unit, Melbourne, Vic, Australia; [Prados, Ferran] Univ Oberta Catalunya, E Hlth Ctr, Barcelona, Spain; [Kanber, Baris; Chard, Declan T.] Univ Coll London Hosp NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, London, England; [Kanber, Baris; Chard, Declan T.] UCL, London, England; [Rog, David] Salford Royal NHS Fdn Trust, Maischester Ctr Clin Neurosci, Salford, Lancs, England; [Pearson, Owen R.] Swansea Bay Univ Hlth Board, Dept Neurol, Swansea, W Glam, Wales; [Overell, James] F Hoffmann La Roche, Prod Dev Neurosci, Basel, Switzerland; [Overell, James] Univ Glasgow, Inst Neurol Sci, Glasgow, Lanark, Scotland; [Ffrench-Constant, Charles; Chandran, Siddharthan; Connick, Peter] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Chandran, Siddharthan] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Wheeler-Kingshott, Claudia A. M. Gandini] IRCCS Mondino Fdn, Brain Connect Ctr, Pavia, Italy; [Wheeler-Kingshott, Claudia A. M. Gandini] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Altmann, Daniel R.] London Sch Hyg & Trop Med, Med Stat Dept, London, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of London; University College London; University of London; University College London; University of Melbourne; UOC Universitat Oberta de Catalunya; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Salford Royal NHS Foundation Trust; Roche Holding; University of Glasgow; University of Edinburgh; University of Edinburgh; IRCCS Fondazione Casimiro Mondino; University of Pavia; University of London; London School of Hygiene & Tropical Medicine	Cunniffe, NG (corresponding author), Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0QQ, England.	ngc26@cam.ac.uk		Rog, David/0000-0002-7262-4248; Jones, Joanne/0000-0003-4974-1371; Overell, James/0000-0002-3998-9819; MacManus, David/0000-0002-0902-977X; Brown, William/0000-0002-7737-5834; Georgieva, Zoya/0000-0002-9531-8884; Gandini Wheeler-Kingshott, Claudia A.M./0000-0002-4832-1300; Samson, Rebecca/0000-0002-0197-702X; Needham, Edward/0000-0001-7042-7462	Multiple Sclerosis Society of the United Kingdom	Multiple Sclerosis Society of the United Kingdom	Multiple Sclerosis Society of the United Kingdom.	Albert M, 2007, BRAIN PATHOL, V17, P129, DOI 10.1111/j.1750-3639.2006.00043.x; Altmann DR, 2014, MULT SCLER RELAT DIS, V3, P237, DOI 10.1016/j.msard.2013.09.007; Berman S, 2020, NEUROIMAGE, V221, DOI 10.1016/j.neuroimage.2020.117204; Cadavid Diego, 2017, Lancet Neurol, V16, P189, DOI 10.1016/S1474-4422(16)30377-5; Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Connick Peter, 2012, Lancet Neurol, V11, P150, DOI 10.1016/S1474-4422(11)70305-2; Cunniffe N, 2021, J NEUROL, V268, P30, DOI 10.1007/s00415-019-09421-x; Deshmukh VA, 2013, NATURE, V502, P327, DOI 10.1038/nature12647; Duvic M, 2001, ARCH DERMATOL, V137, P581; emc, 2021, TARGR CAPS; Franklin RJM, 2017, NAT REV NEUROSCI, V18, P753, DOI 10.1038/nrn.2017.136; Goldschmidt T, 2009, NEUROLOGY, V72, P1914, DOI 10.1212/WNL.0b013e3181a8260a; Green AJ, 2017, LANCET, V390, P2481, DOI 10.1016/S0140-6736(17)32346-2; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Huang JK, 2011, NAT NEUROSCI, V14, P45, DOI 10.1038/nn.2702; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Kilsdonk ID, 2016, BRAIN, V139, P1472, DOI 10.1093/brain/aww037; Lubetzki C, 2020, LANCET NEUROL, V19, P678, DOI 10.1016/S1474-4422(20)30140-X; Mei F, 2014, NAT MED, V20, P954, DOI 10.1038/nm.3618; Miller DH, 2015, NEUROLOGY, V84, P1145, DOI 10.1212/WNL.0000000000001360; Natrajan MS, 2015, BRAIN, V138, P3581, DOI 10.1093/brain/awv289; Patrikios P, 2006, BRAIN, V129, P3165, DOI 10.1093/brain/awl217; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Schmierer K, 2010, BRAIN, V133, P858, DOI 10.1093/brain/awp335; Schwartzbach CJ, 2017, J NEUROL, V264, P304, DOI 10.1007/s00415-016-8341-7; Sharma V, 2006, ENDOCRINOLOGY, V147, P1438, DOI 10.1210/en.2005-0706; Strijbis EMM, 2017, J NEUROPATH EXP NEUR, V76, P390, DOI 10.1093/jnen/nlx023; Tintore M, 2019, NAT REV NEUROL, V15, P53, DOI 10.1038/s41582-018-0082-z; Wagner CE, 2009, J MED CHEM, V52, P5950, DOI 10.1021/jm900496b; Wu JG, 2014, BIOCHEM BIOPH RES CO, V452, P554, DOI 10.1016/j.bbrc.2014.08.111; Yamasaki R, 2019, ADV EXP MED BIOL, V1190, P217, DOI 10.1007/978-981-32-9636-7_14	31	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					709	720		10.1016/S1474-4422(21)00179-4	http://dx.doi.org/10.1016/S1474-4422(21)00179-4			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418398	Green Submitted, Green Accepted			2022-12-18	WOS:000691876000014
J	Ashina, H; Eigenbrodt, AK; Seifert, T; Sinclair, AJ; Scher, AI; Schytz, HW; Lee, MJ; De Icco, R; Finkel, AG; Ashina, M				Ashina, Hakan; Eigenbrodt, Anna K.; Seifert, Tad; Sinclair, Alexandra J.; Scher, Ann, I; Schytz, Henrik W.; Lee, Mi Ji; De Icco, Roberto; Finkel, Alan G.; Ashina, Messoud			Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment	LANCET NEUROLOGY			English	Review							RISK-FACTORS; CHRONIC PAIN; NATURAL-HISTORY; EFNS GUIDELINE; CONCUSSION; PREVALENCE; MIGRAINE; DISORDERS; SOLDIERS; SPORTS	Post-traumatic headache is a common sequela of traumatic brain injury and is classified as a secondary headache disorder. In the past 10 years, considerable progress has been made to better understand the clinical features of this disorder, generating momentum to identify effective therapies. Post-traumatic headache is increasingly being recognised as a heterogeneous headache disorder, with patients often classified into subphenotypes that might be more responsive to specific therapies. Such considerations are not accounted for in three iterations of diagnostic criteria published by the International Headache Society. The scarcity of evidence-based approaches has left clinicians to choose therapies on the basis of the primary headache phenotype (eg, migraine and tension-type headache) and that are most compatible with the clinical picture. A concerted effort is needed to address these shortcomings and should include large prospective cohort studies as well as randomised controlled trials. This approach, in turn, will result in better disease characterisation and availability of evidence-based treatment options.	[Ashina, Hakan; Eigenbrodt, Anna K.; Schytz, Henrik W.; Ashina, Messoud] Univ Copenhagen, Rigshosp Glostrup, Fac Hlth & Med Sci, Danish Headache Ctr,Dept Neurol, DK-2600 Copenhagen, Denmark; [Seifert, Tad] Norton Healthcare, Louisville, KY USA; [Sinclair, Alexandra J.] Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham, W Midlands, England; [Scher, Ann, I] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD USA; [Lee, Mi Ji] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea; [De Icco, Roberto] IRCCS Mondino Fdn, Headache Sci & Neurorehabil Ctr, Pavia, Italy; [De Icco, Roberto] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Finkel, Alan G.] Carolina Headache Inst, Durham, NC USA; [Ashina, Messoud] Danish Knowledge Ctr Headache Disorders, Glostrup, Denmark; [Ashina, Messoud] IM Sechenov First Moscow State Med Univ, Dept Nervous Dis, Inst Profess Educ, Moscow, Russia; [Ashina, Messoud] Azerbaijan Med Univ, Dept Neurol, Baku, Azerbaijan	University of Copenhagen; University of Birmingham; Uniformed Services University of the Health Sciences - USA; Sungkyunkwan University (SKKU); Samsung Medical Center; IRCCS Fondazione Casimiro Mondino; University of Pavia; Sechenov First Moscow State Medical University; Ministry of Education of Azerbaijan Republic; Azerbaijan Medical University	Ashina, M (corresponding author), Univ Copenhagen, Rigshosp Glostrup, Fac Hlth & Med Sci, Danish Headache Ctr,Dept Neurol, DK-2600 Copenhagen, Denmark.	ashina@dadinet.dk	Ashina, Messoud/AFU-1246-2022	Ashina, Messoud/0000-0003-0951-5804; Schytz, Henrik Winther/0000-0002-6262-2986; Ashina, Hakan/0000-0002-6268-727X; Lee, Mi Ji/0000-0003-1364-1969; Scher, Ann/0000-0003-4599-9834				Aaseth K, 2008, CEPHALALGIA, V28, P705, DOI 10.1111/j.1468-2982.2008.01577.x; Al-Khazali HM, 2020, PAIN, V161, P880, DOI 10.1097/j.pain.0000000000001805; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashina H, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01202-6; Ashina H, 2020, ANN NEUROL, V88, P1220, DOI 10.1002/ana.25915; Ashina H, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01136-z; Ashina H, 2020, CEPHALALGIA, V40, P554, DOI 10.1177/0333102420909865; Ashina H, 2019, NAT REV NEUROL, V15, P607, DOI 10.1038/s41582-019-0243-8; Ashina M, 2020, NEW ENGL J MED, V383, P1866, DOI 10.1056/NEJMra1915327; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bendtsen L, 2010, EUR J NEUROL, V17, P1318, DOI 10.1111/j.1468-1331.2010.03070.x; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Cohen SP, 2012, CEPHALALGIA, V32, P94, DOI 10.1177/0333102411422382; DePadilla L, 2018, MMWR-MORBID MORTAL W, V67, P682, DOI 10.15585/mmwr.mm6724a3; Diener HC, 2019, LANCET NEUROL, V18, P891, DOI 10.1016/S1474-4422(19)30146-2; Diener HC, 2016, NAT REV NEUROL, V12, P575, DOI 10.1038/nrneurol.2016.124; Diener HC, 2012, NAT REV NEUROL, V8, P162, DOI 10.1038/nrneurol.2012.13; Evers S, 2009, EUR J NEUROL, V16, P968, DOI 10.1111/j.1468-1331.2009.02748.x; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Ferdosi H, 2019, AM J EPIDEMIOL, V188, P77, DOI 10.1093/aje/kwy199; Finkel AG, 2017, HEADACHE, V57, P719, DOI 10.1111/head.13056; Frenette LC, 2019, BRAIN INJURY, V33, P189, DOI 10.1080/02699052.2018.1542506; Grangeon L, 2020, J NEUROL NEUROSUR PS, V91, P572, DOI 10.1136/jnnp-2019-322725; Hansen JM, 2010, CEPHALALGIA, V30, P1179, DOI 10.1177/0333102410368444; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hurwitz M, 2020, HEADACHE, V60, P713, DOI 10.1111/head.13748; Iljazi A, 2021, CEPHALALGIA, V41, P701, DOI 10.1177/0333102420981666; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kim SK, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01103-8; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kjeldgaard D, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-81; Kjeldgaard D, 2014, CEPHALALGIA, V34, P191, DOI 10.1177/0333102413505236; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Larsen EL, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1051-7; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; May A, 2016, NAT REV NEUROL, V12, P455, DOI 10.1038/nrneurol.2016.93; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Metti A, 2020, NEUROLOGY, V94, pE1137, DOI 10.1212/WNL.0000000000008935; Military Health System, 2020, DOD NUMB TRAUM BRAIN; Minen MT, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0697-7; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nordhaug LH, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0838-2; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Phipps H, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.559318; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; Scholten AC, 2016, J NEUROTRAUM, V33, P1969, DOI 10.1089/neu.2015.4252; Schwab K, 2017, NEUROLOGY, V88, P1571, DOI 10.1212/WNL.0000000000003839; Schwedt TJ, 2021, CEPHALALGIA, V41, P464, DOI 10.1177/0333102420970188; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silverberg ND, 2021, ARCH PHYS MED REHAB, V102, P76, DOI 10.1016/j.apmr.2020.08.022; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Stacey A, 2017, J NEUROTRAUM, V34, P1558, DOI 10.1089/neu.2016.4721; Stein MB, 2019, JAMA PSYCHIAT, V76, P249, DOI 10.1001/jamapsychiatry.2018.4288; Steiner TJ, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-018-0899-2; Stilling J, 2020, J NEUROTRAUM, V37, P312, DOI 10.1089/neu.2019.6692; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Voormolen DC, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111921; Xu HM, 2016, WORLD NEUROSURG, V88, P289, DOI 10.1016/j.wneu.2015.12.028; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; Yilmaz T, 2017, EMERG MED J, V34, P800, DOI 10.1136/emermed-2015-205429; Zirovich MD, 2021, MIL MED, V186, P493, DOI 10.1093/milmed/usaa391	77	19	19	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					460	469		10.1016/S1474-4422(21)00094-6	http://dx.doi.org/10.1016/S1474-4422(21)00094-6		MAY 2021	10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	34022171				2022-12-18	WOS:000653434700016
J	Jones, E; Hummerich, H; Vir, E; Uphill, J; Dimitriadis, A; Speedy, H; Campbell, T; Norsworthy, P; Quinn, L; Whitfield, J; Linehan, J; Jaunmuktane, Z; Brandner, S; Jat, P; Nihat, A; Mok, TH; Ahmed, P; Collins, S; Stehmann, C; Sarros, S; Kovacs, GG; Geschwind, MD; Golubjatnikov, A; Frontzek, K; Budka, H; Aguzzi, A; Karamujic-Comic, H; van der Lee, SJ; Ibrahim-Verbaas, CA; van Duijn, CM; Sikorska, B; Golanska, E; Liberski, PP; Calero, M; Calero, O; Sanchez-Juan, P; Salas, A; Martinon-Torres, F; Bouaziz-Amar, E; Haik, S; Laplanche, JL; Brandel, JP; Amouyel, P; Lambert, JC; Parchi, P; Bartoletti-Stella, A; Capellari, S; Poleggi, A; Ladogana, A; Pocchiari, M; Aneli, S; Matullo, G; Knight, R; Zafar, S; Zerr, I; Booth, S; Coulthart, MB; Jansen, GH; Glisic, K; Blevins, J; Gambetti, P; Safar, J; Appleby, B; Collinge, J; Mead, S				Jones, Emma; Hummerich, Holger; Vir, Emmanuelle; Uphill, James; Dimitriadis, Athanasios; Speedy, Helen; Campbell, Tracy; Norsworthy, Penny; Quinn, Liam; Whitfield, Jerome; Linehan, Jacqueline; Jaunmuktane, Zane; Brandner, Sebastian; Jat, Parmjit; Nihat, Akin; Mok, Tze How; Ahmed, Parvin; Collins, Steven; Stehmann, Christiane; Sarros, Shannon; Kovacs, Gabor G.; Geschwind, Michael D.; Golubjatnikov, Aili; Frontzek, Karl; Budka, Herbert; Aguzzi, Adriano; Karamujic-Comic, Hata; van der Lee, Sven J.; Ibrahim-Verbaas, Carla A.; van Duijn, Cornelia M.; Sikorska, Beata; Golanska, Ewa; Liberski, Pawel P.; Calero, Miguel; Calero, Olga; Sanchez-Juan, Pascual; Salas, Antonio; Martinon-Torres, Federico; Bouaziz-Amar, Elodie; Haik, Stephane; Laplanche, Jean-Louis; Brandel, Jean-Phillipe; Amouyel, Phillipe; Lambert, Jean-Charles; Parchi, Piero; Bartoletti-Stella, Anna; Capellari, Sabina; Poleggi, Anna; Ladogana, Anna; Pocchiari, Maurizio; Aneli, Serena; Matullo, Giuseppe; Knight, Richard; Zafar, Saima; Zerr, Inga; Booth, Stephanie; Coulthart, Michael B.; Jansen, Gerard H.; Glisic, Katie; Blevins, Janis; Gambetti, Pierluigi; Safar, Jiri; Appleby, Brian; Collinge, John; Mead, Simon			Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study	LANCET NEUROLOGY			English	Article							OUTCOME MEASURE; PRION DISEASES; VARIANT; HISTORY; SIGNALS; PROTEIN	Background Human prion diseases are rare and usually rapidly fatal neurodegenerative disorders, the most common being sporadic Creutzfeldt-Jakob disease (sCJD). Variants in the PRNP gene that encodes prion protein are strong risk factors for sCJD but, although the condition has similar heritability to other neurodegenerative disorders, no other genetic risk loci have been confirmed. We aimed to discover new genetic risk factors for sCJD, and their causal mechanisms. Methods We did a genome-wide association study of sCJD in European ancestry populations (patients diagnosed with probable or definite sCJD identified at national CJD referral centres) with a two-stage study design using genotyping arrays and exome sequencing. Conditional, transcriptional, and histological analyses of implicated genes and proteins in brain tissues, and tests of the effects of risk variants on clinical phenotypes, were done using deep longitudinal clinical cohort data. Control data from healthy individuals were obtained from publicly available datasets matched for country. Findings Samples from 5208 cases were obtained between 1990 and 2014. We found 41 genome-wide significant single nucleotide polymorphisms (SNPs) and independently replicated findings at three loci associated with sCJD risk; within PRNP (rs1799990; additive model odds ratio [OR] 1.23 [95% CI 1.17-1.30], p=2.68 x 10(-15); heterozygous model p=1.01 x 10(-135)), STX6 (rs3747957; OR 1.16 [1.10-1.22], p=9.74 x 10(-9)), and GAL3ST1 (rs2267161; OR 1.18 [1.12-1.25], p=8.60 x 10(-10)). Follow-up analyses showed that associations at PRNP and GAL3ST1 are likely to be caused by common variants that alter the protein sequence, whereas risk variants in STX6 are associated with increased expression of the major transcripts in disease-relevant brain regions. Interpretation We present, to our knowledge, the first evidence of statistically robust genetic associations in sporadic human prion disease that implicate intracellular trafficking and sphingolipid metabolism as molecular causal mechanisms. Risk SNPs in STX6 are shared with progressive supranuclear palsy, a neurodegenerative disease associated with misfolding of protein tau, indicating that sCJD might share the same causal mechanisms as prion-like disorders. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Jones, Emma; Hummerich, Holger; Vir, Emmanuelle; Uphill, James; Dimitriadis, Athanasios; Speedy, Helen; Campbell, Tracy; Norsworthy, Penny; Quinn, Liam; Whitfield, Jerome; Linehan, Jacqueline; Jat, Parmjit; Nihat, Akin; Mok, Tze How; Ahmed, Parvin; Collinge, John; Mead, Simon] UCL, Med Res Council, Prion Unit, Inst Prion Dis, London W1W 7FF, England; [Nihat, Akin; Mok, Tze How; Collinge, John; Mead, Simon] Univ Coll London Hosp Natl Hlth Serv Fdn Trust, Natl Prion Clin, London, England; [Jaunmuktane, Zane; Brandner, Sebastian] Univ Coll London Hosp Natl Hlth Serv Fdn Trust, Div Neuropathol, London, England; [Jaunmuktane, Zane] Univ Coll London Queen Sq, Dept Clin & Movement Neurosci, Inst Neurol, London, England; [Jaunmuktane, Zane] Univ Coll London Queen Sq, Queen Sq Brain Bank Neurol Disorders, Inst Neurol, London, England; [Brandner, Sebastian] Univ Coll London Queen Sq, Dept Neurodegenerat Dis, Inst Neurol, London, England; [Collins, Steven; Stehmann, Christiane; Sarros, Shannon] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Australian Natl Creutzfeldt Jakob Dis Registry, Melbourne, Vic, Australia; [Kovacs, Gabor G.] Med Univ Vienna, Inst Neurol, Vienna, Austria; [Kovacs, Gabor G.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kovacs, Gabor G.] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; [Kovacs, Gabor G.] Univ Hlth Network, Krembil Brain Inst, Lab Med Program, Toronto, ON, Canada; [Geschwind, Michael D.; Golubjatnikov, Aili] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA; [Frontzek, Karl; Budka, Herbert; Aguzzi, Adriano] Univ Zurich, Inst Neuropathol, Zurich, Switzerland; [Budka, Herbert] Med Univ Vienna, Vienna, Austria; [Karamujic-Comic, Hata; van der Lee, Sven J.; Ibrahim-Verbaas, Carla A.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [van Duijn, Cornelia M.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Sikorska, Beata; Golanska, Ewa; Liberski, Pawel P.] Med Univ Lodz, Dept Mol Pathol & Neuropathol, Lodz, Poland; [Calero, Miguel; Calero, Olga] Inst Salud Carlos III, Chron Dis Programme UFIEC CROSADIS, CIEN Fdn, Queen Sofia Fdn Alzheimer Ctr, Madrid, Spain; [Calero, Miguel; Calero, Olga] Inst Salud Carlos III, Network Ctr Biomed Res Neurodegenerat Dis CIBERNE, CIEN Fdn, Queen Sofia Fdn Alzheimer Ctr, Madrid, Spain; [Calero, Miguel; Calero, Olga] Inst Salud Carlos III, Alzheimer Dis Res Unit, CIEN Fdn, Queen Sofia Fdn Alzheimer Ctr, Madrid, Spain; [Sanchez-Juan, Pascual] Univ Cantabria, Univ Hosp Marques de Valdecilla, Neurol Serv, Santander, Spain; [Sanchez-Juan, Pascual] CIBERNED, Santander, Spain; [Sanchez-Juan, Pascual] IDIVAL, Santander, Spain; [Salas, Antonio] Univ Santiago de Compostela, Unidade Xenet, Fac Med, Inst Ciencias Forenses INCIFOR, Galicia, Spain; [Salas, Antonio] Hosp Clin Univ Santiago SERGAS, Inst Invest Sanitarias IDIS, GenPoB Res Grp, Galicia, Spain; [Martinon-Torres, Federico] Hosp Clin Univ Santiago de Compostela, Dept Paediat, Translat Paediat & Infect Dis, Galicia, Spain; [Bouaziz-Amar, Elodie; Laplanche, Jean-Louis] Univ Paris, Lariboisiere Hosp, AP HP, Dept Biochem & Mol Biol, Paris, France; [Haik, Stephane; Brandel, Jean-Phillipe] Sorbonne Univ, INSERM U1127, Inst Cerveau & Moelle Epiniere, CNRS,UMR 7225, Paris, France; [Haik, Stephane; Brandel, Jean-Phillipe] Univ Hosp Pitie Salpetriere, AP HP, Cellule Natl Reference Malad Creutzfeldt Jakob, Paris, France; [Amouyel, Phillipe; Lambert, Jean-Charles] Univ Lille, Inst Pasteur Lille, Labex DISTALZ, INSERM,CHU Lille,RID AGE U1167, Lille, France; [Parchi, Piero; Bartoletti-Stella, Anna; Capellari, Sabina] IRCCS, Ist Sci Neurol Bologna, Bologna, Italy; [Capellari, Sabina] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Parchi, Piero] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Poleggi, Anna; Ladogana, Anna; Pocchiari, Maurizio] Ist Super Sanita, Dept Neurosci, Rome, Italy; [Aneli, Serena; Matullo, Giuseppe] Univ Turin, Dept Med Sci, Turin, Italy; [Knight, Richard] Natl Creutzfeldt Jakob Dis Res & Surveillance Uni, Edinburgh, Midlothian, Scotland; [Zafar, Saima; Zerr, Inga] Univ Med Sch, Clin Dementia Ctr, Dept Neurol, Gottingen, Germany; [Zafar, Saima; Zerr, Inga] Univ Med Sch, Natl Reference Ctr Creutzfeldt Jakob Dis Surveill, Gottingen, Germany; [Zafar, Saima; Zerr, Inga] German Ctr Neurodegenerat Dis DZNE, Gottingen, Germany; [Zafar, Saima] Natl Univ Sci & Technol, Biomed Engn & Sci Dept, Sch Mech & Mfg Engn, Islamabad, Pakistan; [Booth, Stephanie] Publ Hlth Agcy Canada, Prion Dis Program, Winnipeg, MB, Canada; [Coulthart, Michael B.] Publ Hlth Agcy Canada, Canadian Creutzfeldt Jakob Dis Surveillance Syst, Ottawa, ON, Canada; [Jansen, Gerard H.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Glisic, Katie; Blevins, Janis; Gambetti, Pierluigi; Safar, Jiri; Appleby, Brian] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Glisic, Katie; Blevins, Janis; Gambetti, Pierluigi; Safar, Jiri; Appleby, Brian] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Glisic, Katie; Blevins, Janis; Gambetti, Pierluigi; Safar, Jiri; Appleby, Brian] Case Western Reserve Univ, Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Medical University of Vienna; University of Toronto; University of Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of California System; University of California San Francisco; University of Zurich; Medical University of Vienna; Erasmus University Rotterdam; Erasmus MC; University of Oxford; Medical University Lodz; Instituto de Salud Carlos III; Unidad Funcional de Investigacion de Enfermedades Cronicas (UFIEC); Instituto de Salud Carlos III; Instituto de Salud Carlos III; Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; CIBERNED; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University of Bologna; University of Bologna; Istituto Superiore di Sanita (ISS); University of Turin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); National University of Sciences & Technology - Pakistan; Public Health Agency of Canada; Public Health Agency of Canada; University of Ottawa; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Mead, S (corresponding author), UCL, Med Res Council, Prion Unit, Inst Prion Dis, London W1W 7FF, England.	s.mead@prion.ucl.ac.uk	lambert, jean-charles/F-8787-2013; Aneli, Serena/AAU-1253-2021; Brandner, Sebastian/J-4562-2014; Salas, Antonio/U-2029-2019; Salas, Antonio/E-3977-2012; Calero, Miguel/H-5691-2015; Zafar, Saima/GWZ-7001-2022; Zafar, Saima/AAE-2799-2019; Bouaziz-Amar, Elodie/S-8984-2016; Kovacs, Gabor/A-7468-2013; Budka, Herbert/I-3486-2019; Parchi, Piero/L-9833-2015; Golanska, Ewa/S-9444-2016; Sikorska, Beata/H-7138-2016; Martinon-Torres, Federico/E-4982-2016	lambert, jean-charles/0000-0003-0829-7817; Aneli, Serena/0000-0003-4303-2507; Brandner, Sebastian/0000-0002-9821-0342; Salas, Antonio/0000-0002-2336-702X; Salas, Antonio/0000-0002-2336-702X; Calero, Miguel/0000-0001-5366-3324; Zafar, Saima/0000-0002-4261-0339; Bouaziz-Amar, Elodie/0000-0003-0880-5826; Kovacs, Gabor/0000-0003-3841-5511; Budka, Herbert/0000-0002-1933-1577; Parchi, Piero/0000-0002-9444-9524; Mead, Simon/0000-0002-4326-1468; Booth, Stephanie/0000-0001-8108-5955; LAPLANCHE, Jean-Louis/0000-0003-2836-2903; Golanska, Ewa/0000-0001-9612-9201; ladogana, Anna/0000-0002-7504-6906; Poleggi, Anna/0000-0001-7094-7767; Sikorska, Beata/0000-0002-6166-0729; Aguzzi, Adriano/0000-0002-0344-6708; Liberski, Pawel P./0000-0001-6507-4682; Dimitriadis, Athanasios/0000-0002-6640-074X; Stehmann, Christiane/0000-0001-8282-9151; Nihat, Akin/0000-0003-2892-1402; Van Duijn, Cornelia/0000-0002-2374-9204; Martinon-Torres, Federico/0000-0002-9023-581X; Norsworthy, Penny/0000-0002-5572-8491	Medical Research Council; UK National Institute of Health Research through the Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust; MRC [MC_U123160651, MC_UU_00024/9, MC_UU_00024/1, MC_U123160657, G0400713] Funding Source: UKRI; Medical Research Council [MC_UU_00024/1, MC_U123160651] Funding Source: researchfish; National Institute for Health Research [NF-SI-0617-10175] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute of Health Research through the Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Medical Research Council and the UK National Institute of Health Research in part through the Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust.	Agostini F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074244; Bartoletti-Stella A, 2019, MOL NEUROBIOL, V56, P5009, DOI 10.1007/s12035-018-1421-1; Bratosiewicz-Wasik J, 2012, PRION, V6, P413, DOI 10.4161/pri.21773; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Brown CA, 2014, HUM MOL GENET, V23, P5102, DOI 10.1093/hmg/ddu233; Chen JA, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0270-8; Claussnitzer M, 2020, NATURE, V577, P179, DOI [10.1038/d41586-019-03833-5, 10.1038/s41586-019-1879-7]; Colin M, 2020, ACTA NEUROPATHOL, V139, P3, DOI 10.1007/s00401-019-02087-9; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Collinge J, 2016, NATURE, V539, P217, DOI 10.1038/nature20415; Goold R, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1282; Goold R, 2015, MOL CELL NEUROSCI, V66, P12, DOI 10.1016/j.mcn.2014.12.009; Hoglinger GU, 2011, NAT GENET, V43, P699, DOI 10.1038/ng.859; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003; Hormozdiari F, 2014, GENETICS, V198, P497, DOI 10.1534/genetics.114.167908; Hwang D, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.10; Jones E, 2020, NEUROBIOL DIS, V142, DOI 10.1016/j.nbd.2020.104973; Kichaev G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004722; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Koriath C, 2020, MOL PSYCHIATR, V25, P3399, DOI 10.1038/s41380-018-0224-0; Kuffer A, 2016, NATURE, V536, P464, DOI 10.1038/nature19312; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Maddox RA, 2020, NEUROLOGY, V94, pE153, DOI 10.1212/WNL.0000000000008680; Mead S, 2001, AM J HUM GENET, V69, P1225, DOI 10.1086/324710; Mead S, 2019, ANNU REV GENET, V53, P117, DOI 10.1146/annurev-genet-120213-092352; Mead S, 2016, JAMA NEUROL, V73, P447, DOI 10.1001/jamaneurol.2015.4885; Mead S, 2012, HUM MOL GENET, V21, P1897, DOI 10.1093/hmg/ddr607; Mead S, 2009, LANCET NEUROL, V8, P57, DOI 10.1016/S1474-4422(08)70265-5; Meissner B, 2009, J NEUROL, V256, P355, DOI 10.1007/s00415-009-0026-z; National CJD Research and Surveillance Unit, 2017, 26 ANN REP; Platt FM, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0025-4; Rydbirk R, 2016, SCI REP-UK, V6, DOI 10.1038/srep37116; Sanchez-Juan P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123654; Sanchez-Juan P, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.011; Sanchez-Juan P, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-73; Skedsmo FS, 2020, FASEB J, V34, P2359, DOI 10.1096/fj.201902588R; Speed D, 2019, NAT GENET, V51, P277, DOI 10.1038/s41588-018-0279-5; Takahashi T, 2012, J LIPID RES, V53, P1437, DOI 10.1194/jlr.R026682; Thompson AGB, 2013, BRAIN, V136, P1116, DOI 10.1093/brain/awt048; Vollmert C, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.040931; Webb TEF, 2008, J NEUROPATH EXP NEUR, V67, P838, DOI 10.1097/NEN.0b013e318182f36e; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x; Yamasaki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30775-1; Yang Jian, 2011, Am J Hum Genet, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Yim YI, 2015, J CELL SCI, V128, P1434, DOI 10.1242/jcs.165472; Zhao BX, 2021, MOL PSYCHIATR, V26, P3943, DOI 10.1038/s41380-019-0569-z	50	19	19	2	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					840	848		10.1016/S1474-4422(20)30273-8	http://dx.doi.org/10.1016/S1474-4422(20)30273-8			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949544	Green Accepted, Green Submitted			2022-12-18	WOS:000581119100021
J	[Anonymous]				[Anonymous]			The neurological impact of COVID-19	LANCET NEUROLOGY			English	Editorial Material																			0	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					471	471		10.1016/S1474-4422(20)30142-3	http://dx.doi.org/10.1016/S1474-4422(20)30142-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470408	Green Published, Bronze			2022-12-18	WOS:000544059200001
J	Freeman, J; Hendrie, W; Jarrett, L; Hawton, A; Barton, A; Dennett, R; Jones, B; Zajicek, J; Creanor, S				Freeman, Jennifer; Hendrie, Wendy; Jarrett, Louise; Hawton, Annie; Barton, Andrew; Dennett, Rachel; Jones, Ben; Zajicek, John; Creanor, Siobhan			Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis	LANCET NEUROLOGY			English	Article							PHYSICAL-ACTIVITY; HEALTH; ADULTS; MOBILITY	Background People severely impaired with progressive multiple sclerosis spend much of their day sitting, with very few options to improve motor function. As a result, secondary physical and psychosocial complications can occur. Effective and feasible self-management strategies are needed to reduce sedentary behaviour and enhance motor function. In this study, we aimed to assess the clinical and cost effectiveness of a home-based, self-managed, standing frame programme. Methods SUMS was a pragmatic, multicentre, randomised controlled superiority trial of people with progressive multiple sclerosis and severe mobility impairment, undertaken in eight centres from two regions in the UK. The study had assessor-blinded outcome assessments with use of clinician-rated and patient-rated measures at baseline, 20 weeks, and 36 weeks. After baseline assessment, participants were randomised (1:1) by computer-generated assignment to either a standing frame programme plus usual care or usual care alone. The intervention consisted of two home-based physiotherapy sessions (60 min each) to set up the standing frame programme, supported by six follow-up telephone calls (15 min per call). Participants were asked to stand for 30 min, three times per week over 20 weeks, and encouraged to continue in the longer term, although no further physiotherapy support was provided. The primary clinical outcome was motor function measured by the Amended Motor Club Assessment (AMCA) score at week 36, analysed in the modified intention-to-treat population (excluding only patients who were deemed ineligible after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be used, or those who did not provide baseline and week 36 measurements). A 9-point AMCA score change was considered clinically meaningful a priori. Adverse events were collected through a daily preformatted patient diary throughout the 36 weeks and analysed in the modified intention-to-treat population. An economic assessment established the resources required to provide the standing frame programme, estimated intervention costs, and estimate cost effectiveness. This trial is registered with the International Standard Randomised Controlled Trials, number ISRCTN69614598. Findings Between Sept 16, 2015, and April 28, 2017, 285 people with progressive multiple sclerosis were screened for eligibility, and 140 were randomly assigned to either the standing frame group (n=71) or the usual care group (n=69). Of these, 122 completed the primary outcome assessment (61 participants in both groups) for the modified intention-to-treat analysis. The use of the standing frame resulted in a significant increase in AMCA score compared with that for usual care alone, with a fully adjusted between-group difference in AMCA score at 36 weeks of 4.7 points (95% CI 1.9-7.5; p=0.0014). For adverse events collected through patient diaries, we observed a disparity between the two groups in the frequency of short-term musculoskeletal pain (486 [41%] of 1188 adverse events in the standing frame group vs 160 [22%] of 736 adverse events in the usual care group), which was potentially related to the intervention. The musculoskeletal pain lasted longer than 7 days in five participants (two in the standing frame group and three in the usual care group). No serious adverse events related to the study occurred. The standing frame group had a mean 0.018 (95% CI -0.014 to 0.051) additional quality-adjusted life-years (QALYs) compared with those of the usual care group, and the estimated incremental cost-per-QALY was approximately 14700 pound. Interpretation The standing frame programme significantly increased motor function in people with severe progressive multiple sclerosis, although not to the degree that was considered a priori as clinically meaningful. The standing frame is one of the first physiotherapy interventions to be effective in this population. We suggest that the programme is feasible as a home-based, self-managed intervention that could be routinely implemented in clinical practice in the UK. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.	[Freeman, Jennifer; Hendrie, Wendy; Jarrett, Louise; Dennett, Rachel] Univ Plymouth, Fac Hlth & Human Sci, Sch Hlth Profess, Peninsula Allied Hlth Ctr, Plymouth PL6 8BH, Devon, England; [Hendrie, Wendy] Norwich MS Ctr, Norwich, Norfolk, England; [Jarrett, Louise] Royal Devon & Exeter NHS Fdn Trust, Mardon Neurorehabil Ctr, Exeter, Devon, England; [Hawton, Annie] Univ Exeter, Sch Med, Hlth Econ Grp, Exeter, Devon, England; [Barton, Andrew] Univ Plymouth, NIHR Res Design Serv, Fac Med & Dent, Plymouth, Devon, England; [Jones, Ben; Creanor, Siobhan] Univ Plymouth, Med Stat Grp, Fac Med & Dent, Plymouth, Devon, England; [Creanor, Siobhan] Univ Plymouth, Peninsula Clin Trials Unit, Fac Med & Dent, Plymouth, Devon, England; [Zajicek, John] Univ St Andrews, Sch Med Med & Biol Sci, St Andrews, Fife, Scotland	University of Plymouth; University of Exeter; University of Exeter; University of Plymouth; University of Plymouth; University of Plymouth; University of St Andrews	Freeman, J (corresponding author), Univ Plymouth, Fac Hlth & Human Sci, Sch Hlth Profess, Peninsula Allied Hlth Ctr, Plymouth PL6 8BH, Devon, England.	jenny.freeman@plymouth.ac.uk	Freeman, Jennifer/AAN-1217-2021	Jones, Ben/0000-0001-7374-1107; Murray, Dianna/0000-0003-3481-825X; Hawton, Annemarie/0000-0002-1336-5899	UK National Institute of Health Research	UK National Institute of Health Research(National Institute for Health Research (NIHR))	UK National Institute of Health Research.	Backus D, 2016, ARCH PHYS MED REHAB, V97, pS210, DOI 10.1016/j.apmr.2015.09.027; Baker K, 2007, INT J THER REHABIL, V14, P104, DOI 10.12968/ijtr.2007.14.3.23523; Boutron I, 2017, ANN INTERN MED, V167, P40, DOI 10.7326/M17-0046; Craig J, 2003, J NEUROL NEUROSUR PS, V74, P1225, DOI 10.1136/jnnp.74.9.1225; De Souza L H, 1996, Physiother Res Int, V1, P98; Department of Health, 2005, NAT SERV FRAM LONG T; Edwards T, 2017, MULT SCLER RELAT DIS, V16, P31, DOI 10.1016/j.msard.2017.06.003; Freeman JA, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0581-8; Giesser BSE, 2011, PRIMER MULTIPLE SCLE, V2nd; Heesen C, 2008, MULT SCLER, V14, P988, DOI 10.1177/1352458508088916; Hendrie WA, 2015, DISABIL REHABIL, V37, P1178, DOI 10.3109/09638288.2014.957790; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Kobelt G, 2017, MULT SCLER J, V23, P1123, DOI 10.1177/1352458517694432; Latimer-Cheung AE, 2013, ARCH PHYS MED REHAB, V94, P1800, DOI 10.1016/j.apmr.2013.04.020; Marra CA, 2005, SOC SCI MED, V60, P1571, DOI 10.1016/j.socscimed.2004.08.034; Marrie RA, 2009, MULT SCLER J, V15, P105, DOI 10.1177/1352458508096680; Middleton KR, 2013, AM J LIFESTYLE MED, V7, P395, DOI 10.1177/1559827613488867; National Institute of Clinical Excellence, 2014, MULT SCLER MAN MULT; Newman M, 2012, CLIN REHABIL, V26, P1059, DOI 10.1177/0269215512443373; NICE, 2014, BEH CHANG IND APPR P; Nordstrom B, 2013, PHYSIOTHER CAN, V65, P344, DOI 10.3138/ptc.2012-27; Polman Chris H, 2011, Ann Neurol, V69, P292, DOI 10.1002/ana.22366; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Sasaki J., 2018, MULT SCLER J EXP TRA, V4, p2055217318754368, DOI DOI 10.1177/2055217318754368; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.4103/0976-500X.72352, 10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Skjerbaek AG, 2014, MULT SCLER J, V20, P627, DOI 10.1177/1352458513505351; Streber R, 2016, ARCH PHYS MED REHAB, V97, P633, DOI 10.1016/j.apmr.2015.11.020; Sussman JB, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2073	29	19	18	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2019	18	8					736	747		10.1016/S1474-4422(19)30190-5	http://dx.doi.org/10.1016/S1474-4422(19)30190-5			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IH7ZF	31301748	Green Published, hybrid			2022-12-18	WOS:000474722800015
J	Grunseich, C; Miller, R; Swan, T; Glass, DJ; El Mouelhi, M; Fornaro, M; Petricoul, O; Vostiar, I; Roubenoff, R; Meriggioli, MN; Kokkinis, A; Guber, RD; Budron, MS; Vissing, J; Soraru, G; Mozaffar, T; Ludolph, A; Kissel, JT; Fischbeck, KH				Grunseich, Christopher; Miller, Ram; Swan, Therese; Glass, David J.; El Mouelhi, Mohamed; Fornaro, Mara; Petricoul, Olivier; Vostiar, Igor; Roubenoff, Ronenn; Meriggioli, Matthew N.; Kokkinis, Angela; Guber, Robert D.; Budron, Maher S.; Vissing, John; Soraru, Gianni; Mozaffar, Tahseen; Ludolph, Albert; Kissel, John T.; Fischbeck, Kenneth H.		BVS857 Study Grp	Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial	LANCET NEUROLOGY			English	Article							GROWTH-FACTOR-I; EXERCISE; DISEASE; GLUCOSE; BINDING; AKT	Background Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by CAG repeat expansion in the androgen receptor gene. Patients with this disease have low concentrations of insulin-like growth factor-1 (IGF-1), and studies of overexpression and administration of IGF-1 showed benefit in a transgenic model; thus the IGF-1 pathway presents as a potential treatment target. We assessed safety, tolerability, and preliminary efficacy of BVS857, an IGF-1 mimetic, in patients with spinal and bulbar muscular atrophy. Methods In this randomised, double-blind, placebo-controlled trial, we recruited patients from neuromuscular centres in Denmark (Copenhagen), Germany (Ulm), Italy (Padova), and three sites within the USA (Bethesda, MD; Irvine, CA; and Columbus, OH). Eligible patients were 18 years or older with a confirmed genetic diagnosis of spinal and bulbar muscular atrophy, were ambulatory, had symptomatic weakness, and had serum IGF-1 concentrations of 170 ng/mL or lower. Patients were randomly assigned (2:1) to study drug or placebo by a number scheme. Patients, investigators, and study personnel were masked to treatment assignment. After a safety and tolerability assessment with eight patients, BVS857 was administered once a week (0.06 mg/kg intravenously) for 12 weeks. Primary outcome measures were safety, tolerability, and the effects of BVS857 on thigh muscle volume (TMV) measured by MRI. The ratio of TMV at day 85 to baseline was analysed with ANCOVA per protocol. Secondary outcomes of muscle strength and function were measured with the Adult Myopathy Assessment Tool, lean body mass through dual energy x-ray absorptiometry, and BVS857 pharmacokinetics. This trial was registered with ClinicalTrials.gov, NCT02024932. Findings 31 patients were assessed for eligibility, 27 of whom were randomly assigned to either BVS857 treatment (n=18) or placebo (n=9), and 24 were included in the preliminary efficacy analysis (BVS857 group, n=15; placebo group, n=9). BVS857 was generally safe with no serious adverse events. No significant differences were found in adverse events between the BVS857 and placebo groups. Immunogenicity was detected in 13 (72%) of 18 patients in the BVS857 group, including crossreacting antibodies with neutralising capacity to endogenous IGF-1 in five patients. TMV decreased from baseline to day 85 in the placebo group (-3.4% [-110 cm(3)]) but not in the BVS857 group (0% [2 cm(3)]). A significant difference in change in TMV was observed in the BVS857 group versus the placebo group (geometric-mean ratio 1.04 [90% CI 1.01-1.07]; p=0.02). There were no differences between groups in measures of muscle strength and function. Interpretation TMV remained stable in patients with spinal and bulbar muscular atrophy after being given BVS857 for 12 weeks. The intervention was associated with high incidence of immunogenicity and did not improve muscle strength or function. Additional studies might be needed to assess the efficacy of activating the IGF-1 pathway in this disease. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Grunseich, Christopher; Kokkinis, Angela; Guber, Robert D.; Budron, Maher S.; Fischbeck, Kenneth H.] NINDS, Neurogenet Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Miller, Ram; Swan, Therese; Glass, David J.] Novartis Inst Biomed Res, Cambridge, MA USA; [El Mouelhi, Mohamed] Novartis Inst Biomed Res, E Hanover, NJ USA; [Fornaro, Mara; Petricoul, Olivier; Vostiar, Igor; Roubenoff, Ronenn] Novartis Inst Biomed Res, Basel, Switzerland; [Meriggioli, Matthew N.] AveXis Inc, Bannockburn, IL USA; [Vissing, John] Univ Copenhagen, Rigshosp, Copenhagen Neuromuscular Ctr, Dept Neurol, Copenhagen, Denmark; [Soraru, Gianni] Univ Padua, Dept Neurosci, Padua, Italy; [Mozaffar, Tahseen] Univ Calif Irvine, ALS & Neuromuscular Ctr, Orange, CA 92668 USA; [Ludolph, Albert] Univ Ulm, Dept Neurol, Ulm, Germany; [Kissel, John T.] Ohio State Univ, Wexner Med Ctr, Dept Neurol, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Novartis; Novartis; Novartis; Rigshospitalet; University of Copenhagen; University of Padua; University of California System; University of California Irvine; Ulm University; University System of Ohio; Ohio State University	Grunseich, C (corresponding author), NINDS, Neurogenet Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	christopher.grunseich@nih.gov	Mozaffar, Tahseen/AAE-6971-2020; Glass, David/AAI-3910-2021; Martinelli, Ilaria/AAB-2799-2019; Sorarù, Gianni/AAB-8891-2019	Martinelli, Ilaria/0000-0003-2566-3671; Soraru, Gianni/0000-0001-9691-6328	Novartis Pharmaceuticals; US National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003037] Funding Source: NIH RePORTER	Novartis Pharmaceuticals(Novartis); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Novartis Pharmaceuticals and the US National Institutes of Health.	Amato AA, 2014, NEUROLOGY, V83, P2239, DOI 10.1212/WNL.0000000000001070; Atsuta N, 2006, BRAIN, V129, P1446, DOI 10.1093/brain/awl096; Banno H, 2009, ANN NEUROL, V65, P140, DOI 10.1002/ana.21540; Chernausek SD, 2007, J CLIN ENDOCR METAB, V92, P902, DOI 10.1210/jc.2006-1610; Colao A, 2008, EUR J ENDOCRINOL, V159, P389, DOI 10.1530/EJE-08-0201; Dejager S, 2002, J CLIN ENDOCR METAB, V87, P3893, DOI 10.1210/jc.87.8.3893; Fernandez-Rhodes LE, 2011, LANCET NEUROL, V10, P140, DOI 10.1016/S1474-4422(10)70321-5; Guber RD, 2018, MUSCLE NERVE, V57, P40, DOI 10.1002/mus.25957; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; Harris-Love MO, 2014, REHABIL RES PRACT, V2014, DOI 10.1155/2014/873872; Hashizume A, 2017, J NEUROL NEUROSUR PS, V88, P1026, DOI 10.1136/jnnp-2017-316015; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; Joassard OR, 2013, INT J BIOCHEM CELL B, V45, P2309, DOI 10.1016/j.biocel.2013.06.025; Katsuno M, 2010, LANCET NEUROL, V9, P875, DOI 10.1016/S1474-4422(10)70182-4; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Milioto C, 2017, SCI REP-UK, V7, DOI 10.1038/srep41046; Nakatsuji H, 2017, J NEUROL, V264, P839, DOI 10.1007/s00415-017-8405-3; Palazzolo I, 2007, HUM MOL GENET, V16, P1593, DOI 10.1093/hmg/ddm109; Palazzolo I, 2009, NEURON, V63, P316, DOI 10.1016/j.neuron.2009.07.019; Preisler N, 2009, NEUROLOGY, V72, P317, DOI 10.1212/01.wnl.0000341274.61236.02; Querin G, 2013, NEUROLOGY, V80, P2095, DOI 10.1212/WNL.0b013e318295d766; Rhodes LE, 2009, BRAIN, V132, P3242, DOI 10.1093/brain/awp258; Rinaldi C, 2012, MOL MED, V18, P1261, DOI 10.2119/molmed.2012.00271; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Schwarz AJ, 1996, J CLIN ENDOCR METAB, V81, P3492, DOI 10.1210/jc.81.10.3492; Shrader JA, 2015, ANN CLIN TRANSL NEUR, V2, P739, DOI 10.1002/acn3.208; Sorenson EJ, 2008, NEUROLOGY, V71, P1770, DOI 10.1212/01.wnl.0000335970.78664.36; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463	30	19	19	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1043	1052		10.1016/S1474-4422(18)30320-X	http://dx.doi.org/10.1016/S1474-4422(18)30320-X			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30337273	Green Accepted			2022-12-18	WOS:000450119300014
J	Radbruch, A; Roberts, DR; Clement, O; Rovira, A; Quattrocchi, CC				Radbruch, Alexander; Roberts, Donna R.; Clement, Olivier; Rovira, Alex; Quattrocchi, Carlo Cosimo			Chelated or dechelated gadolinium deposition	LANCET NEUROLOGY			English	Letter							CONTRAST AGENTS; HEALTHY RATS; BRAIN		[Radbruch, Alexander] German Canc Res Ctr, Dept Radiol, Heidelberg, Germany; [Radbruch, Alexander] Univ Duisburg Essen, Univ Hosp Essen, Dept Diagnost & Intervent Radiol & Neuroradiol, Essen, Germany; [Roberts, Donna R.] Med Univ South Carolina, Dept Radiol & Radiol Sci, Charleston, SC USA; [Clement, Olivier] Hop Europeen Georges Pompidou, AP HP, Dept Radiol, Paris, France; [Clement, Olivier] Univ Paris 05, INSERM, UMR 970, Paris, France; [Radbruch, Alexander] Vall Hebron Univ Hosp, Neuroradiol Sect, Barcelona, Spain; [Quattrocchi, Carlo Cosimo] Univ Campus Biomed Roma, Dept Fac Med & Surg, Rome, Italy	Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; Medical University of South Carolina; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hospital Universitari Vall d'Hebron; University Campus Bio-Medico - Rome Italy	Radbruch, A (corresponding author), German Canc Res Ctr, Dept Radiol, Heidelberg, Germany.; Radbruch, A (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Diagnost & Intervent Radiol & Neuroradiol, Essen, Germany.; Radbruch, A (corresponding author), Vall Hebron Univ Hosp, Neuroradiol Sect, Barcelona, Spain.	a.radbruch@dkfz.de	Rovira, Alex/AAX-3973-2020; Radbruch, Alexander/ABA-6277-2021	Quattrocchi, Carlo Cosimo/0000-0001-6823-7707; Radbruch, Alexander/0000-0001-6238-6525	Bayer	Bayer(Bayer AG)	We have received no funding for the generation of this letter. ARa serves on the scientific advisory boards for GE Healthcare, Bracco, Bayer, Guerbet, and AbbVie; has received speaker honoraria from Bayer, Guerbet, Siemens, and Medscape; and is a consultant for, and has received institutional study support from, Guerbet and Bayer. DRR is a consultant and advisory board member for Guerbet and a member of the US Food and Drug Administration Medical Imaging Drugs Advisory Committee for Gadovist. ARo serves on scientific advisory boards for Novartis, Sanofi Genzyme, and OLEA Medical; has received speaker honoraria from Bayer, Sanofi Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries, Novartis, Roche, and Biogen Idec; and has research agreements with Siemens AG and icometrix. OC serves on the scientific advisory boards of Bracco and Guerbet. CCQ has received speaker and personal fees from Bayer.	Frenzel T, 2017, INVEST RADIOL, V52, P396, DOI 10.1097/RLI.0000000000000352; Frenzel T, 2008, INVEST RADIOL, V43, P817, DOI 10.1097/RLI.0b013e3181852171; Gulani V, 2017, LANCET NEUROL, V16, P564, DOI 10.1016/S1474-4422(17)30158-8; Jost G, 2017, EUR RADIOL, V27, P2877, DOI 10.1007/s00330-016-4654-2; Radbruch A, 2017, RADIOLOGY, V282, P699, DOI 10.1148/radiol.2016162241; Robert P, 2016, INVEST RADIOL, V51, P73, DOI 10.1097/RLI.0000000000000241	6	19	19	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2017	16	12					955	955		10.1016/S1474-4422(17)30364-2	http://dx.doi.org/10.1016/S1474-4422(17)30364-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM8DJ	29165253	Bronze			2022-12-18	WOS:000415315400011
J	Manes, F				Manes, Facundo			The huge burden of dementia in Latin America	LANCET NEUROLOGY			English	Letter									[Manes, Facundo] Favaloro Univ, Natl Sci & Tech Res Council, Inst Cognit Neurol INECO, Inst Neurosci,CONICET, Buenos Aires, DF, Argentina; [Manes, Facundo] Diego Port Univ, UDP INECO Fdn Core Neurosci, Santiago, Chile; [Manes, Facundo] Australian Res Council ACR, Ctr Excellence Cognit & Its Disorders, Sydney, NSW, Australia	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Manes, F (corresponding author), Favaloro Univ, Natl Sci & Tech Res Council, Inst Cognit Neurol INECO, Inst Neurosci,CONICET, Buenos Aires, DF, Argentina.	fmanes@ineco.org.ar						[Anonymous], 2015, LANCET NEUROL, V14, P1143; Gleichgerrcht E, 2011, J MOL NEUROSCI, V45, P609, DOI 10.1007/s12031-011-9556-9; Nitrini R, 2009, INT PSYCHOGERIATR, V21, P622, DOI 10.1017/S1041610209009430; Prince M., 2015, WORLD ALZHEIMERS REP	4	19	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					29	29		10.1016/S1474-4422(15)00360-9	http://dx.doi.org/10.1016/S1474-4422(15)00360-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700903	Bronze			2022-12-18	WOS:000366313900017
J	Fasano, A; Lang, AE				Fasano, Alfonso; Lang, Anthony E.			Unfreezing of gait in patients with Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									[Fasano, Alfonso] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada; Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Fasano, A (corresponding author), Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada.	lang@uhnres.utoronto.ca	Lang, Anthony/ABF-8114-2021; Fasano, Alfonso/K-2558-2018	Fasano, Alfonso/0000-0001-5346-0180; Lang, Anthony/0000-0003-1229-3667				Bohnen NI, 2014, MOVEMENT DISORD, V29, P1118, DOI 10.1002/mds.25929; Nieuwboer A, 2013, MOVEMENT DISORD, V28, P1509, DOI 10.1002/mds.25683; Nonnekes J, 2015, LANCET NEUROL; Perez-Lloret S, 2014, JAMA NEUROL, V71, P884, DOI 10.1001/jamaneurol.2014.753; Perry EK, 2003, ANN NEUROL, V54, P235, DOI 10.1002/ana.10639; Thevathasan W, 2012, BRAIN, V135, P1446, DOI 10.1093/brain/aws039	6	19	20	3	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					675	677		10.1016/S1474-4422(15)00053-8	http://dx.doi.org/10.1016/S1474-4422(15)00053-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26018594				2022-12-18	WOS:000356195900006
J	Kaste, M				Kaste, Markku			Stroke: advances in thrombolysis	LANCET NEUROLOGY			English	Editorial Material							ALTEPLASE		Univ Helsinki, Dept Neurol, Cent Hosp, FI-00029 Helsinki, Hus, Finland	Hyvinkaan Sairaala; University of Helsinki; Helsinki University Central Hospital	Kaste, M (corresponding author), Univ Helsinki, Dept Neurol, Cent Hosp, FI-00029 Helsinki, Hus, Finland.	markku.kaste@hus.fi		Kaste, Markku/0000-0001-6557-6412				Fonarow GC, 2011, STROKE, V42, P2933; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; Kaste M, 2012, LANCET NEUROL, V11, P930, DOI 10.1016/S1474-4422(12)70229-6; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Langhorne P, 2012, LANCET NEUROL, V11, P341, DOI 10.1016/S1474-4422(12)70024-8; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Leys D, 2007, STROKE, V38, P2985, DOI 10.1161/STROKEAHA.107.487967; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842; Rha JH, 2012, INT J STROKE, DOI [10.1111/j.17474949.2012.00895.x, DOI 10.1111/J.17474949.2012.00895.X]; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Strbian D, 2012, ANN NEUROL, V71, P634, DOI 10.1002/ana.23546; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4	15	19	19	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					2	4		10.1016/S1474-4422(12)70273-9	http://dx.doi.org/10.1016/S1474-4422(12)70273-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237887				2022-12-18	WOS:000312429400002
J	Levin, H; Smith, D				Levin, Harvey; Smith, Douglas			Traumatic brain injury: networks and neuropathology	LANCET NEUROLOGY			English	Editorial Material									[Levin, Harvey] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Smith, Douglas] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Baylor College of Medicine; University of Pennsylvania	Levin, H (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.	hlevin@bcm.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038104, P01NS056202] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS056202, P01 NS056202, R01 NS038104] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Johnson V., BRAIN IN PRESS; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125	10	19	24	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					15	16		10.1016/S1474-4422(12)70300-9	http://dx.doi.org/10.1016/S1474-4422(12)70300-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237894	Green Accepted			2022-12-18	WOS:000312429400009
J	Sperling, RA; Johnson, KA				Sperling, Reisa A.; Johnson, Keith A.			Dementia: new criteria but no new treatments	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DISEASE; RECOMMENDATIONS		[Sperling, Reisa A.; Johnson, Keith A.] Harvard Univ, Sch Med, Dept Neurol,Masschusetts Gen Hosp, Ctr Alzheimer Res & Treatment,Brigham & Womens Ho, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sperling, RA (corresponding author), Harvard Univ, Sch Med, Dept Neurol,Masschusetts Gen Hosp, Ctr Alzheimer Res & Treatment,Brigham & Womens Ho, Boston, MA 02115 USA.	reisa@rics.bwh.harvard.edu						Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; OSTROWITZKI S, 2011, ARCH NEUROL     1010, DOI DOI 10.1001/ARCHNEUROL.2011.1538; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Salloway S, 2011, NEUROLOGY, V77, P1253, DOI 10.1212/WNL.0b013e3182309fa5; Siemers E, 2011, ALZHEIMERS DEMENT S, V7, pS484, DOI DOI 10.1016/J.JALZ.2011.05.2355; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Wolk DA, 2011, ARCH NEUROL-CHICAGO, V68, P1398, DOI 10.1001/archneurol.2011.153	11	19	20	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					4	5		10.1016/S1474-4422(11)70272-1	http://dx.doi.org/10.1016/S1474-4422(11)70272-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172609				2022-12-18	WOS:000298513700003
J	Jankovic, J				Jankovic, Joseph			Parkinson's disease and movement disorders: moving forward	LANCET NEUROLOGY			English	Editorial Material							ROTIGOTINE; DYSTONIA		Baylor Coll Med, Dept Neurol, Parkinsons Dis & Movement Disorders Clin, Houston, TX 77030 USA	Baylor College of Medicine	Jankovic, J (corresponding author), Baylor Coll Med, Dept Neurol, Parkinsons Dis & Movement Disorders Clin, Houston, TX 77030 USA.	josephj@bcm.tmc.edu						Abeliovich A, 2007, DEV BIOL, V304, P447, DOI 10.1016/j.ydbio.2007.01.032; Barlow BK, 2007, REPROD TOXICOL, V23, P457, DOI 10.1016/j.reprotox.2007.01.007; Brashear A, 2007, BRAIN, V130, P828, DOI 10.1093/brain/awl340; Deng H, 2007, BRAIN, V130, P1456, DOI 10.1093/brain/awm018; LeWitt PA, 2007, NEUROLOGY, V68, P1262, DOI 10.1212/01.wnl.0000259516.61938.bb; Stefansson H, 2007, NEW ENGL J MED, V357, P639, DOI 10.1056/NEJMoa072743; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Vidailhet M, 2007, LANCET NEUROL, V6, P223, DOI 10.1016/S1474-4422(07)70035-2; Watts RL, 2007, NEUROLOGY, V68, P272, DOI 10.1212/01.wnl.0000252355.79284.22	9	19	20	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					9	11		10.1016/S1474-4422(07)70302-2	http://dx.doi.org/10.1016/S1474-4422(07)70302-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093549				2022-12-18	WOS:000252063300006
J	Munari, LM				Munari, LM			Lack of evidence for use of glatiramer acetate in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-BLIND; PILOT TRIAL; MULTICENTER		Azienda Osped Niguarda Ca Granda, Granada, Spain; Natl Neurol Inst Carlo Besta, Unit Neuroepidemiol, Milan, Italy	IRCCS Istituto Neurologico Besta	Munari, LM (corresponding author), Azienda Osped Niguarda Ca Granda, Granada, Spain.	luca.munari@ospedaleniguarda.it						BORNSTEIN MB, 1991, NEUROLOGY, V41, P533, DOI 10.1212/WNL.41.4.533; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64.abs; Filippini G, 2003, LANCET, V361, P545, DOI 10.1016/S0140-6736(03)12512-3; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; MUNARI L, 2004, COCHRANE LIB; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407	7	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2004	3	11					641	641		10.1016/S1474-4422(04)00899-3	http://dx.doi.org/10.1016/S1474-4422(04)00899-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865CL	15488453				2022-12-18	WOS:000224680000012
J	Hevner, R; Vilela, M; Rostomily, R; Cohrs, R; Mahalingam, R; Wellish, M; Gilden, DH				Hevner, R; Vilela, M; Rostomily, R; Cohrs, R; Mahalingam, R; Wellish, M; Gilden, DH			An unusual cause of trigeminal-distribution pain and tumour	LANCET NEUROLOGY			English	Review							ZOSTER-SINE-HERPETE; SENSORY NEUROPATHY; POSTHERPETIC NEURALGIA; VIRUS; DNA; VZV; NEURINOMA; MIMICKING; GANGLIA		Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gilden, DH (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, Campus Mail Stop B-182,4200 E 9th Ave, Denver, CO 80262 USA.				NIA NIH HHS [AG06127] Funding Source: Medline; NINDS NIH HHS [NS32623] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS032623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG006127, R01AG006127] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn JY, 2002, J NEUROSURG, V96, P585, DOI 10.3171/jns.2002.96.3.0585; BARRETT AP, 1993, ORAL SURG ORAL MED O, V75, P173, DOI 10.1016/0030-4220(93)90089-M; COHRS RJ, 1994, J VIROL, V68, P7900, DOI 10.1128/JVI.68.12.7900-7908.1994; Dominguez J, 1999, ACTA NEUROCHIR, V141, P269, DOI 10.1007/s007010050297; EASTON HG, 1970, LANCET, V2, P1065; Gilden DH, 2003, J NEUROVIROL, V9, P404, DOI 10.1080/13550280390201722; GILDEN DH, 1991, NEUROLOGY, V41, P1215, DOI 10.1212/WNL.41.8.1215; GILDEN DH, 1994, ANN NEUROL, V35, P530, DOI 10.1002/ana.410350505; Gilden DH, 2001, VIRUS GENES, V23, P145, DOI 10.1023/A:1011883919058; LEWIS GW, 1958, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5093.418; MAHALINGAM R, 1995, J NEUROVIROL, V1, P130, DOI 10.3109/13550289509111018; MAHALINGAM R, 1990, NEW ENGL J MED, V323, P627, DOI 10.1056/NEJM199009063231002; Morita Y, 2003, J NEUROL SCI, V212, P7, DOI 10.1016/S0022-510X(03)00081-9; Rorick MB, 1996, NEUROLOGY, V46, P1455, DOI 10.1212/WNL.46.5.1455; RUDRA T, 1990, BRIT J CLIN PRACT, V44, P284; Savas A, 1999, NEUROSURGERY, V45, P1246, DOI 10.1097/00006123-199911000-00053; Seidel E, 2000, NEUROLOGY, V54, P1191, DOI 10.1212/WNL.54.5.1191; SEVICK RJ, 1991, J COMPUT ASSIST TOMO, V15, P605, DOI 10.1097/00004728-199107000-00015; VAFAI A, 1988, P NATL ACAD SCI USA, V85, P2767, DOI 10.1073/pnas.85.8.2767	19	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2003	2	9					567	571		10.1016/S1474-4422(03)00506-4	http://dx.doi.org/10.1016/S1474-4422(03)00506-4			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717VT	12941580				2022-12-18	WOS:000185112000021
J	Kaste, M				Kaste, M			Approval of alteplase in Europe: will it change stroke management?	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC STROKE; THROMBOLYSIS; CARE		Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00029 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Kaste, M (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00029 Helsinki, Finland.	markku.kaste@hus.fi		Kaste, Markku/0000-0001-6557-6412				Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Graham GD, 2002, ANN NEUROL, V52, pS24; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Harraf F, 2002, BMJ-BRIT MED J, V325, P17, DOI 10.1136/bmj.325.7354.17; Kaste M, 2001, STROKE, V32, P2717, DOI 10.1161/hs1101.098639; KASTE M, 2002, P 7 INT S THROMB AC; Lenzer J, 2002, BRIT MED J, V324, P723, DOI 10.1136/bmj.324.7339.723; Lindsberg PJ, 2003, CURR OPIN NEUROL, V16, P73, DOI 10.1097/00019052-200302000-00010; LINDSBERG PJ, IN PRESS STROKE; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Wardlaw JM, 2000, COCHRANE DB SYST REV	14	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					207	208		10.1016/S1474-4422(03)00343-0	http://dx.doi.org/10.1016/S1474-4422(03)00343-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849203				2022-12-18	WOS:000181726700011
J	Mignot, E; Mayleben, D; Fietzeet, I				Mignot, E.; Mayleben, D.; Fietzeet, I			Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)	LANCET NEUROLOGY			English	Correction														Liow, Kore/0000-0001-6452-9227; Bassetti, Claudio/0000-0002-4535-0245				Mignot E, 2022, LANCET NEUROL, V21, DOI 10.1016/S1474-4422(21)00436-1	1	18	18	12	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3								10.1016/S1474-4422(21)00436-1	http://dx.doi.org/10.1016/S1474-4422(21)00436-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35065036				2022-12-18	WOS:000759721800002
J	Mignot, E; Mayleben, D; Fietze, I; Leger, D; Zammit, G; Bassetti, CLA; Pain, S; Kinter, DS; Roth, T				Mignot, Emmanuel; Mayleben, David; Fietze, Ingo; Leger, Damien; Zammit, Gary; Bassetti, Claudio L. A.; Pain, Scott; Kinter, Dalma Seboek; Roth, Thomas			Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials	LANCET NEUROLOGY			English	Article							SLEEP	Background Daytime functioning is impaired in people with insomnia disorder. Currently available dual orexin receptor antagonists have shown efficacy in insomnia disorder, but do not address all aspects of this disease. We aimed to assess safety and efficacy of daridorexant, a novel orexin receptor antagonist, on night-time and daytime symptoms of insomnia. Methods We did two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials at 156 sites in 17 countries. Adults (aged >= 18 years) with insomnia disorder were randomly assigned using interactive response technology (1:1:1) to receive daridorexant 50 mg, 25 mg, or placebo (study 1) or daridorexant 25 mg, 10 mg, or placebo (study 2) every evening for 3 months. Participants, investigators, and site personnel were masked to treatment allocation. The primary endpoints were change from baseline in wake time after sleep onset (WASO) and latency to persistent sleep (LPS), measured by polysomnography, at months 1 and 3. The secondary endpoints were change from baseline in self-reported total sleep time and the sleepiness domain score of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) at months 1 and 3. Study-wise type I error rate (5%) was controlled for all pairwise comparisons. Efficacy was analysed in all randomly assigned participants, and safety in all participants who received at least one dose of treatment. The studies are registered at ClinicalTrials.gov, NCT03545191 (study 1) and NCT03575104 (study 2). Findings Between June 4, 2018 and Feb 25, 2020, 930 participants were randomly assigned to receive daridorexant 50 mg (n=310), daridorexant 25 mg (n=310), or placebo (n= 310) in study 1. Between May 29, 2018, and May 14, 2020, 924 participants were randomly assigned to receive daridorexant 25 mg (n=309), daridorexant 10 mg (n=307), or placebo (n=308) in study 2. In study 1, WASO and LPS were significantly reduced among participants in the daridorexant 50 mg group compared with participants in the placebo group at month 1 (least squares mean [LSM] difference -22.8 min [95% CI -28.0 to -17.6], p<0.0001 for WASO; -11.4 min [-16.0 to - 6.7], p<0.0001 for LPS) and month 3 (-18.3 min [-23.9 to -12.7], p< 0.0001 for WASO; -11.7 min [-16.3 to -7.0], p<0.0001 for LPS). WASO and LPS were significantly reduced among participants in the daridorexant 25 mg group compared with the placebo group at month 1 (LSM difference -12.2 min [-17.4 to -7.0], p<0.0001 for WASO; -8.3 min [-13.0 to -3.6], p=0.0005 for LPS) and month 3 (-11.9 min [-17.5 to -6.2], p<0.0001 for WASO; -7.6 min [-12.3 to -2.9], p=0.0015 for LPS). Compared with placebo, participants in the daridorexant 50 mg group had significantly improved self-reported total sleep time at month 1 (LSM difference 22.1 min [14.4 to 29.7], p<0.0001) and month 3 (19.8 min [10.6 to 28.9], p<0.0001), and IDSIQ sleepiness domain scores at month 1 (-1.8 [- 2.5 to -1.0], p<0.0001) and month 3 (-1.9 [-2.9 to -0.9], p= 0.0002). Compared with the placebo group, participants in the daridorexant 25 mg group had significantly improved self-reported total sleep time at month 1 (LSM difference 12.6 min [5.0 to 20.3], p=0.0013) and month 3 (9.9 min [0.8 to 19.1], p=0.033), but not IDSIQ sleepiness domain scores (-0.8 [-1.5 to 0.01], p=0.055 at month 1; -1.0 [- 2.0 to 0.01], p=0.053 at month 3). In study 2, WASO was significantly reduced among participants in the daridorexant 25 mg group compared with participants in the placebo group at month 1 (LSM difference -11.6 min [-17.6 to -5.6], p=0.0001) and month 3 (-10.3 min [-17.0 to - 3.5], p=0.0028), whereas no significant differences in LPS were observed at month 1 (-6.5 min [-12.3 to -0.6], p=0.030) or month 3 (-9.0 [-15.3 to -2.7], p=0.0053). Compared with the placebo group, participants in the daridorexant 25 mg group had significant improvement in self-reported total sleep time at month 1 (LSM difference 16.1 min [8.2 to 24.0], p<0.0001) and month 3 (19.1 [10.1 to 28.0], p<0.0001), but not in IDSIQ sleepiness domain scores (-0.8 [-1.6 to 0.1], p=0.073 at month 1; -1.3 [-2.2 to -0.3], p=0.012 at month 3). Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for WASO (LSM difference -2.7 min [-8.7 to 3.2], p=0.37 at month 1; -2.0 [-8.7 to 4.8], p=0.57 at month 3), LPS (-2.6 min [-8.4 to 3.2], p=0.38 at month 1; -3.2 min [-9.5 to 3.1], p=0.32 at month 3), self-reported total sleep time (13.4 min [5.5 to 21.2], p=0.0009 at month 1; 13.6 min [4.7 to 22.5], p=0.0028 at month 3), nor IDSIQ sleepiness domain scores (-0.4 [- 1.3 to 0.4], p=0.30 at month 1; -0.7 [-1.7 to 0.2], p=0.14 at month 3). Overall incidence of adverse events was comparable between treatment groups (116 [38%] of 308 participants in the daridorexant 50 mg group, 117 [38%] of 310 in the daridorexant 25 mg group, and 105 [34%] of 309 in the placebo group in study 1; 121 [39%] of 308 participants in the daridorexant 25 mg group, 117 [38%] of 306 in the daridorexant 10 mg group, and 100 [33%] of 306 in the placebo group). Nasopharyngitis and headache were the most common adverse events in all groups. One death (cardiac arrest) occurred in the daridorexant 25 mg group in study 1, which was not deemed to be treatment-related. Interpretation Daridorexant 25 mg and 50 mg improved sleep outcomes, and daridorexant 50 mg also improved daytime functioning, in people with insomnia disorder, with a favourable safety profile. Copyright (C) 2022 Elsevier Ltd. All rights reserved.	[Mignot, Emmanuel] Stanford Ctr Sleep Res & Med, Palo Alto, CA 94304 USA; [Mayleben, David] CTI Clin Res Ctr, Cincinnati, OH USA; [Fietze, Ingo] Charite, Ctr Sleep Med, Berlin, Germany; [Fietze, Ingo] Fourth Peoples Hosp Guangyuan City, Dept Med, Guangyuan, Peoples R China; [Leger, Damien] Univ Paris, Vigilance Fatigue Sommeil & Sante Publ, ERC 7330, Paris, France; [Leger, Damien] Hop Hotel Dieu, AP HP, Ctr Sommeil & Vigilance, Paris, France; [Zammit, Gary] Clinilabs Drug Dev Corp, New York, NY USA; [Bassetti, Claudio L. A.] Univ Bern, Dept Neurol, Bern, Switzerland; [Bassetti, Claudio L. A.] Sechenov First Moscow State Univ, Dept Neurol, Moscow, Russia; [Pain, Scott] Idorsia Pharmaceut, Dept Biometry, Allschwil, Switzerland; [Kinter, Dalma Seboek] Idorsia Pharmaceut, Dept Therapeut Area Unit, Allschwil, Switzerland; [Roth, Thomas] Henry Ford Hosp, Sleep Disorders & Res Ctr, Div Sleep Med, Detroit, MI 48202 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Bern; Sechenov First Moscow State Medical University; Idorsia Pharmaceuticals Ltd; Idorsia Pharmaceuticals Ltd; Henry Ford Health System; Henry Ford Hospital	Mignot, E (corresponding author), Stanford Ctr Sleep Res & Med, Palo Alto, CA 94304 USA.	mignot@stanford.edu		Liow, Kore/0000-0001-6452-9227; Bassetti, Claudio/0000-0002-4535-0245				American Psychiatric Association, 1990, BENZ DEP TOX AB TASK; [Anonymous], 2013, MANUAL MENTAL DISORD; Bianchi MT, 2013, J SLEEP RES, V22, P557, DOI 10.1111/jsr.12046; Black SW, 2013, SLEEP, V36, P325, DOI 10.5665/sleep.2442; Bretz F, 2009, STAT MED, V28, P586, DOI 10.1002/sim.3495; Carey Thomas J, 2005, Behav Sleep Med, V3, P73, DOI 10.1207/s15402010bsm0302_2; Dauvilliers Y, 2020, ANN NEUROL, V87, P347, DOI 10.1002/ana.25680; Gotter AL, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-109; Herring WJ, 2016, BIOL PSYCHIAT, V79, P136, DOI 10.1016/j.biopsych.2014.10.003; Horvath TL, 1999, J COMP NEUROL, V415, P145; Hudgens S, 2021, PATIENT, V14, P249, DOI 10.1007/s40271-020-00474-z; Irwin M, 2003, BRAIN BEHAV IMMUN, V17, P365, DOI 10.1016/S0889-1591(03)00031-X; Kishi T, 2020, J PSYCHIATR RES, V128, P68, DOI 10.1016/j.jpsychires.2020.05.025; KRYGER MH, 1991, SLEEP, V14, P399, DOI 10.1093/sleep/14.5.399; Kyle SD, 2010, BEHAV SLEEP MED, V8, P123, DOI 10.1080/15402002.2010.487450; Morin CM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.26; Muehlan C, 2019, EUR NEUROPSYCHOPHARM, V29, P847, DOI 10.1016/j.euroneuro.2019.05.009; Muehlan C, 2018, CLIN PHARMACOL THER, V104, P1022, DOI 10.1002/cpt.1046; Neylan TC, 2020, SLEEP, V43, DOI 10.1093/sleep/zsaa080; Patel D, 2018, J CLIN SLEEP MED, V14, P1017, DOI 10.5664/jcsm.7172; Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175; Riemann D, 2017, J SLEEP RES, V26, P675, DOI 10.1111/jsr.12594; Rosenberg R, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.18254; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Treiber A, 2017, J PHARMACOL EXP THER, V362, P489, DOI 10.1124/jpet.117.241596; Wilson S, 2019, J PSYCHOPHARMACOL, V33, P923, DOI 10.1177/0269881119855343; Zammit G, 2020, NEUROLOGY, V94, pE2222, DOI 10.1212/WNL.0000000000009475	27	18	18	12	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					125	139		10.1016/S1474-4422(21)00436-1	http://dx.doi.org/10.1016/S1474-4422(21)00436-1			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065036				2022-12-18	WOS:000769111800014
J	Haeusler, KG; Kirchhof, P; Kunze, C; Tutuncu, S; Fiessler, C; Malsch, C; Olma, MC; Jawad-Ul-Qamar, M; Kramer, M; Wachter, R; Michalski, D; Kraft, A; Rizos, T; Groschel, K; Thomalla, G; Nabavi, DG; Rother, J; Laufs, U; Veltkamp, R; Heuschmann, PU; Endres, M				Haeusler, Karl Georg; Kirchhof, Paulus; Kunze, Claudia; Tuetuencue, Serdar; Fiessler, Cornelia; Malsch, Carolin; Olma, Manuel C.; Jawad-Ul-Qamar, Muhammad; Kraemer, Michael; Wachter, Rolf; Michalski, Dominik; Kraft, Andrea; Rizos, Timolaos; Groeschel, Klaus; Thomalla, Goetz; Nabavi, Darius G.; Roether, Joachim; Laufs, Ulrich; Veltkamp, Roland; Heuschmann, Peter U.; Endres, Matthias		MonDAFIS Investigators	Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study	LANCET NEUROLOGY			English	Article								Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedures for atrial fibrillation detection (control group) or additional Holter-ECG recording for up to 7 days in hospital (intervention group). Patients were stratified by centre using a random permuted block design. The primary outcome was the proportion of patients on oral anticoagulants at 12 months after the index event in the intention-to-treat population. Secondary outcomes included the number of patients with newly diagnosed atrial fibrillation in hospital and the composite of recurrent stroke, major bleeding, myocardial infarction, or death after 6 months, 12 months, and 24 months. This trial was registered with ClinicalTrials.gov, NCT02204267, and is completed and closed for participants. Findings Between Dec 9, 2014, and Sept 11, 2017, 3465 patients were randomly assigned, 1735 (50.1%) to the intervention group and 1730 (49.9%) to the control group. Oral anticoagulation status was available in 2920 (84.3%) patients at 12 months (1484 [50.8%] in the intervention group and 1436 [49.2%] in the control group). For the primary outcome, at 12 months, 203 (13.7%) of 1484 patients in the intervention group versus 169 (11.8%) of 1436 in the control group were on oral anticoagulants (odds ratio [OR] 1.2 [95% CI 0.9-1.5]; p=0.13). Atrial fibrillation was newly detected in patients in hospital in 97 (5.8%) of 1714 in the intervention group versus 68 (4.0%) of 1717 in the control group (hazard ratio [HR] 1.4 [95% CI 1.0-2.0]; p=0.024). The composite of cardiovascular outcomes and death did not differ between patients randomly assigned to the intervention group versus the control group at 24 months (232 [13.5%] of 1714 vs 249 [14.5%] of 1717; HR 0.9 [0.8-1.1]; p=0.43). Skin reactions due to study ECG electrodes were reported in 56 (3.3%) patients in the intervention group. All-cause death occured in 73 (4.3%) patients in the intervention group and in 103 (6.0%) patients in the control group (OR 0.7 [0.5-0.9]). Interpretation Systematic core centrally reviewed ECG monitoring is feasible and increases the detection rate of atrial fibrillation in unselected patients hospitalised with acute ischaemic stroke or transient ischaemic attack, if added to usual diagnostic care in certified German stroke units. However, we found no effect of systematic ECG monitoring on the rate of oral anticoagulant use after 12 months and further efforts are needed to improve secondary stroke prevention.	[Haeusler, Karl Georg; Kunze, Claudia; Tuetuencue, Serdar; Olma, Manuel C.; Kraemer, Michael; Endres, Matthias] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [Olma, Manuel C.; Endres, Matthias] Charite Univ Med Berlin, Klin & Hsch Ambulanz Neurol, Abt Expt Neurol, Berlin, Germany; [Haeusler, Karl Georg] Univ Klinikum Wurzburg, Dept Neurol, Wurzburg, Germany; [Haeusler, Karl Georg; Kirchhof, Paulus] German Atrial Fibrillat Network AFNET, Munster, Germany; [Kirchhof, Paulus; Jawad-Ul-Qamar, Muhammad] Univ Birmingham, Coll Med & Dent Sci, Med Sch, Inst Cardiovasc Sci, Birmingham, W Midlands, England; [Kirchhof, Paulus; Jawad-Ul-Qamar, Muhammad] Univ Hosp Birmingham NHS Fdn Trust, Dept Cardiol, Birmingham, W Midlands, England; [Kirchhof, Paulus; Jawad-Ul-Qamar, Muhammad] Sandwell & West Birmingham NHS Trust, Birmingham, W Midlands, England; [Kirchhof, Paulus] Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany; [Fiessler, Cornelia; Malsch, Carolin; Heuschmann, Peter U.] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Wachter, Rolf; Laufs, Ulrich] Univ Klinikum Leipzig, Klin & Poliklin Kardiol, Leipzig, Germany; [Wachter, Rolf] Univ Med Gottingen, Klin Kardiol & Pneumol, Gottingen, Germany; [Wachter, Rolf] German Ctr Cardiovasc Res, Gottingen, Germany; [Michalski, Dominik] Univ Leipzig, Dept Neurol, Leipzig, Germany; [Kraft, Andrea] Krankenhaus Martha Maria Halle, Klin Neurol, Hate, Germany; [Rizos, Timolaos] Heidelberg Univ, Dept Neurol, Heidelberg, Germany; [Groeschel, Klaus] Johannes Gutenberg Univ Mainz, Dept Neurol, Univ Med Ctr, Mainz, Germany; [Thomalla, Goetz] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany; [Nabavi, Darius G.] Vivantes Klinikum Neukolln, Dept Neurol, Berlin, Germany; [Roether, Joachim] Asklepios Klin Altona, Dept Neurol, Hamburg, Germany; [Veltkamp, Roland] Alfried Krupp Hosp, Dept Neurol, Essen, Germany; [Veltkamp, Roland] Imperial Coll London, Dept Brain Sci, London, England; [Heuschmann, Peter U.] Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany; [Heuschmann, Peter U.] Univ Hosp Wurzburg, Clin Trial Ctr Wurzburg, Wurzburg, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis DZNE, Berlin, Germany; [Endres, Matthias] German Ctr Cardiovasc Res DZHK, Berlin, Germany; [Endres, Matthias] Excellence Cluster NeuroCure, Berlin, Germany; [Endres, Matthias] Berlin Inst Hlth BIH, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Birmingham; University of Birmingham; University of Wurzburg; Leipzig University; University of Gottingen; German Centre for Cardiovascular Research; Leipzig University; Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf; VIivantes Klinikum Neukolln; Asklepios Klinik Altona; Alfried Krupp Hospital; Imperial College London; University of Wurzburg; University of Wurzburg; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); German Centre for Cardiovascular Research; Berlin Institute of Health	Endres, M (corresponding author), Charite Univ Med Berlin, Klin & Hsch Ambulanz Neurol, D-10117 Berlin, Germany.	matthias.endres@charite.de	Häusler, Karl Georg/AAS-5962-2021; Wachter, Rolf/AAA-4037-2020; Kirchhof, Paulus/AAT-7074-2021	Kirchhof, Paulus/0000-0002-1881-0197; Dietzel, Joanna/0000-0003-4739-4230; Tutuncu, Serdar/0000-0002-5057-7487; Endres, Matthias/0000-0001-6520-3720	Bayer Vital	Bayer Vital(Bayer AG)	Bayer Vital.	Diener HC, 2019, NEW ENGL J MED, V380, P1906, DOI 10.1056/NEJMoa1813959; Glader EL, 2010, STROKE, V41, P397, DOI 10.1161/STROKEAHA.109.566950; Gladstone DJ, 2014, NEW ENGL J MED, V370, P2467, DOI 10.1056/NEJMoa1311376; Grond M, 2013, STROKE, V44, P3357, DOI 10.1161/STROKEAHA.113.001884; Haeusler KG, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0871-1; Haeusler KG, 2018, CLIN RES CARDIOL, V107, P871, DOI 10.1007/s00392-018-1256-9; Haeusler KG, 2016, AM HEART J, V172, P19, DOI 10.1016/j.ahj.2015.10.010; Hart RG, 2018, NEW ENGL J MED, V378, P2191, DOI 10.1056/NEJMoa1802686; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Hindricks G, 2021, EUR HEART J, V42, P546, DOI 10.1093/eurheartj/ehaa945; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Sanna T, 2014, NEW ENGL J MED, V370, P2478, DOI 10.1056/NEJMoa1313600; Scheitz JF, 2015, STROKE, V46, P1196, DOI 10.1161/STROKEAHA.115.008681; Schnabel RB, 2019, CIRCULATION, V140, P1834, DOI 10.1161/CIRCULATIONAHA.119.040267; Stahrenberg R, 2010, STROKE, V41, P2884, DOI 10.1161/STROKEAHA.110.591958; Wachter R, 2017, LANCET NEUROL	17	18	18	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					426	436		10.1016/S1474-4422(21)00067-3	http://dx.doi.org/10.1016/S1474-4422(21)00067-3			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	34022169				2022-12-18	WOS:000653434700013
J	Best, JG; Ambler, G; Wilson, D; Lee, KJ; Lim, JS; Shiozawa, M; Koga, M; Li, LX; Lovelock, C; Chabriat, H; Hennerici, M; Wong, YK; Mak, HKF; Prats-Sanchez, L; Martinez-Domeno, A; Inamura, S; Yoshifuji, K; Arsava, EM; Horstmann, S; Purrucker, J; Lam, BYK; Wong, A; Kim, YD; Song, TJ; Lemmens, R; Eppinger, S; Gattringer, T; Uysal, E; Tanriverdi, Z; Bornstein, NM; Ben Assayag, E; Hallevi, H; Molad, J; Nishihara, M; Tanaka, J; Coutts, SB; Polymeris, A; Wagner, B; Seiffge, DJ; Lyrer, P; Algra, A; Kappelle, LJ; Salman, RAS; Jager, HR; Lip, GYH; Fischer, U; El-Koussy, M; Mas, JL; Legrand, L; Karayiannis, C; Phan, T; Gunkel, S; Christ, N; Abrigo, J; Leung, T; Chu, W; Chappell, F; Makin, S; Hayden, D; Williams, DJ; Mess, WH; Nederkoorn, PJ; Barbato, C; Browning, S; Wiegertjes, K; Tuladhar, AM; Maaijwee, N; Guevarra, AC; Yatawara, C; Mendyk, AM; Delmaire, C; Kohler, S; van Oostenbrugge, R; Zhou, Y; Xu, C; Hilal, S; Gyanwali, B; Chen, C; Lou, M; Staals, J; Bordet, R; Kandiah, N; de Leeuw, FE; Simister, R; Hendrikse, J; Kelly, PJ; Wardlaw, J; Soo, Y; Fluri, F; Srikanth, V; Calvet, D; Jung, S; Kwa, VIH; Engelter, ST; Peters, N; Smith, EE; Hara, H; Yakushiji, Y; Orken, DN; Fazekas, F; Thijs, V; Heo, JH; Mok, V; Veltkamp, R; Ay, H; Imaizumi, T; Gomez-Anson, B; Lau, KK; Jouvent, E; Rothwell, PM; Toyoda, K; Bae, HJ; Marti-Fabregas, J; Werring, DJ				Best, Jonathan G.; Ambler, Gareth; Wilson, Duncan; Lee, Keon-Joo; Lim, Jae-Sung; Shiozawa, Masayuki; Koga, Masatoshi; Li, Linxin; Lovelock, Caroline; Chabriat, Hugues; Hennerici, Michael; Wong, Yuen Kwun; Mak, Henry Ka Fung; Prats-Sanchez, Luis; Martinez-Domeno, Alejandro; Inamura, Shigeru; Yoshifuji, Kazuhisa; Arsava, Ethem Murat; Horstmann, Solveig; Purrucker, Jan; Lam, Bonnie Yin Ka; Wong, Adrian; Kim, Young Dae; Song, Tae-Jin; Lemmens, Robin; Eppinger, Sebastian; Gattringer, Thomas; Uysal, Ender; Tanriverdi, Zeynep; Bornstein, Natan M.; Ben Assayag, Einor; Hallevi, Hen; Molad, Jeremy; Nishihara, Masashi; Tanaka, Jun; Coutts, Shelagh B.; Polymeris, Alexandros; Wagner, Benjamin; Seiffge, David J.; Lyrer, Philippe; Algra, Ale; Kappelle, L. Jaap; Salman, Rustam Al-Shahi; Jager, Hans R.; Lip, Gregory Y. H.; Fischer, Urs; El-Koussy, Marwan; Mas, Jean-Louis; Legrand, Laurence; Karayiannis, Christopher; Thanh Phan; Gunkel, Sarah; Christ, Nicolas; Abrigo, Jill; Leung, Thomas; Chu, Winnie; Chappell, Francesca; Makin, Stephen; Hayden, Derek; Williams, David J.; Mess, Werner H.; Nederkoorn, Paul J.; Barbato, Carmen; Browning, Simone; Wiegertjes, Kim; Tuladhar, Anil M.; Maaijwee, Noortje; Guevarra, Anne Cristine; Yatawara, Chathuri; Mendyk, Anne-Marie; Delmaire, Christine; Kohler, Sebastian; van Oostenbrugge, Robert; Zhou, Ying; Xu, Chao; Hilal, Saima; Gyanwali, Bibek; Chen, Christopher; Lou, Min; Staals, Julie; Bordet, Regis; Kandiah, Nagaendran; de Leeuw, Frank-Erik; Simister, Robert; Hendrikse, Jeroen; Kelly, Peter J.; Wardlaw, Joanna; Soo, Yannie; Fluri, Felix; Srikanth, Velandai; Calvet, David; Jung, Simon; Kwa, Vincent I. H.; Engelter, Stefan T.; Peters, Nils; Smith, Eric E.; Hara, Hideo; Yakushiji, Yusuke; Orken, Dilek Necioglu; Fazekas, Franz; Thijs, Vincent; Heo, Ji Hoe; Mok, Vincent; Veltkamp, Roland; Ay, Hakan; Imaizumi, Toshio; Gomez-Anson, Beatriz; Lau, Kui Kai; Jouvent, Eric; Rothwell, Peter M.; Toyoda, Kazunori; Bae, Hee-Joon; Marti-Fabregas, Joan; Werring, David J.		Microbleeds Int Collaborative	Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies	LANCET NEUROLOGY			English	Article							ATRIAL-FIBRILLATION; EXTERNAL VALIDATION; METAANALYSIS; MODELS	Background Balancing the risks of recurrent ischaemic stroke and intracranial haemorrhage is important for patients treated with antithrombotic therapy after ischaemic stroke or transient ischaemic attack. However, existing predictive models offer insufficient performance, particularly for assessing the risk of intracranial haemorrhage. We aimed to develop new risk scores incorporating clinical variables and cerebral microbleeds, an MRI biomarker of intracranial haemorrhage and ischaemic stroke risk. Methods We did a pooled analysis of individual-patient data from the Microbleeds International Collaborative Network (MICON), which includes 38 hospital-based prospective cohort studies from 18 countries. All studies recruited participants with previous ischaemic stroke or transient ischaemic attack, acquired baseline MRI allowing quantification of cerebral microbleeds, and followed-up participants for ischaemic stroke and intracranial haemorrhage. Participants not taking antithrombotic drugs were excluded. We developed Cox regression models to predict the 5-year risks of intracranial haemorrhage and ischaemic stroke, selecting candidate predictors on biological relevance and simplifying models using backward elimination. We derived integer risk scores for clinical use. We assessed model performance in internal validation, adjusted for optimism using bootstrapping. Findings The included studies recruited participants between Aug 28, 2001, and Feb 4, 2018. 15 766 participants had follow-up for intracranial haemorrhage, and 15 784 for ischaemic stroke. Over a median follow-up of 2 years, 184 intracranial haemorrhages and 1048 ischaemic strokes were reported. The risk models we developed included cerebral microbleed burden and simple clinical variables. Optimism-adjusted c indices were 0.73 (95% CI 0.69-0.77) with a calibration slope of 0.94 (0.81-1.06) for the intracranial haemorrhage model and 0.63 (0.62-0.65) with a calibration slope of 0.97 (0.87-1.07) for the ischaemic stroke model. There was good agreement between predicted and observed risk for both models. Interpretation The MICON risk scores, incorporating clinical variables and cerebral microbleeds, offer predictive value for the long-term risks of intracranial haemorrhage and ischaemic stroke in patients prescribed antithrombotic therapy for secondary stroke prevention; external validation is warranted. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Best, Jonathan G.; Wilson, Duncan; Seiffge, David J.; Barbato, Carmen; Browning, Simone; Simister, Robert; Werring, David J.] UCL, Dept Brain Repair & Rehabil, UCL Stroke Res Ctr, Queen Sq Inst Neurol, London WC1B SEH, England; [Ambler, Gareth] UCL, Dept Stat Sci, Gower St, London, England; [Wilson, Duncan] New Zealand Brain Res Inst, Christchurch, New Zealand; [Lee, Keon-Joo; Bae, Hee-Joon] Seoul Natl Univ, Coll Med, Dept Neurol, Bundang Hosp, Seongnam, South Korea; [Lim, Jae-Sung] Hallym Univ, Coll Med, Hallym Neurol Inst, Dept Neurol,Sacred Heart Hosp, Anyang, South Korea; [Shiozawa, Masayuki; Koga, Masatoshi; Toyoda, Kazunori] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Suita, Osaka, Japan; [Li, Linxin; Lovelock, Caroline; Rothwell, Peter M.] Univ Oxford, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clin Neurosci, Oxford, England; [Chabriat, Hugues; Jouvent, Eric] Lariboisiere Hosp, Assistance Publ Hop Paris, Dept Neurol, Paris, France; [Chabriat, Hugues; Jouvent, Eric] Univ Paris, Federat Hosp Univ NeuroVasc, Paris, France; [Chabriat, Hugues; Jouvent, Eric] INSERM U1141, Paris, France; [Hennerici, Michael] Heidelberg Univ, Dept Neurol, Univ Med Mannheim, Mannheim, Germany; [Wong, Yuen Kwun; Lau, Kui Kai] Univ Hong Kong, Dept Med, Div Neurol, Hong Kong, Peoples R China; [Mak, Henry Ka Fung] Univ Hong Kong, Dept Diagnost Radiol, Hong Kong, Peoples R China; [Prats-Sanchez, Luis; Martinez-Domeno, Alejandro; Marti-Fabregas, Joan] Hosp Santa Creu & Sant Pau, Dept Neurol, Biomed Res Inst, Barcelona, Spain; [Gomez-Anson, Beatriz] Hosp Santa Creu & Sant Pau, Unit Neuroradiol, Biomed Res Inst, Barcelona, Spain; [Inamura, Shigeru; Yoshifuji, Kazuhisa; Imaizumi, Toshio] Kushiro City Gen Hosp, Dept Neurosurg, Kushiro, Hokkaido, Japan; [Arsava, Ethem Murat; Ay, Hakan] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging,Dept Neurol, Boston, MA 02115 USA; [Horstmann, Solveig; Purrucker, Jan; Veltkamp, Roland] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany; [Lam, Bonnie Yin Ka; Wong, Adrian; Mok, Vincent] Chinese Univ Hong Kong, Therese Pei Fong Chow Res Ctr Prevent Dementia, Gerald Choa Neurosci Ctr, Lui Che Woo Inst Innovat Med,Dept Med & Therapeut, Hong Kong, Peoples R China; [Kim, Young Dae; Heo, Ji Hoe] Yonsei Univ, Dept Neurol, Coll Med, Seoul, South Korea; [Song, Tae-Jin] Ewha Womans Univ, Seoul Hosp, Dept Neurol, Coll Med, Seoul, South Korea; [Lemmens, Robin] Katholieke Univ Leuven, Dept Neurosci, Expt Neurol, Leuven, Belgium; [Lemmens, Robin] Univ Hosp Leuven, Ctr Brain & Dis Res Dept Neurol, Vlaams Inst Biotechnol, Leuven, Belgium; [Lemmens, Robin] Univ Hosp Leuven, Dept Neurol, Leuven, Belgium; [Eppinger, Sebastian; Gattringer, Thomas; Fazekas, Franz] Med Univ Graz, Dept Neurol, Graz, Austria; [Uysal, Ender] Saglik Bilimleri Univ, Sisli Etfal Educ & Res Hosp, Dept Radiol, Istanbul, Turkey; [Tanriverdi, Zeynep] Izmir Katip Elebi Univ, Dept Neurol, Ataturk Educ & Res Hosp, Izmir, Turkey; [Bornstein, Natan M.; Ben Assayag, Einor; Hallevi, Hen; Molad, Jeremy] Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv, Israel; [Bornstein, Natan M.; Ben Assayag, Einor; Hallevi, Hen; Molad, Jeremy] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Nishihara, Masashi] Saga Univ, Dept Radiol, Fac Med, Saga, Japan; [Tanaka, Jun; Hara, Hideo; Yakushiji, Yusuke] Saga Univ, Dept Internal Med, Div Neurol, Fac Med, Saga, Japan; [Coutts, Shelagh B.; Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci Radiol & Community Hlth Sci, Calgary, AB, Canada; [Polymeris, Alexandros; Wagner, Benjamin; Seiffge, David J.; Lyrer, Philippe; Engelter, Stefan T.; Peters, Nils] Univ Hosp Basel, Dept Neurol, Basel, Switzerland; [Polymeris, Alexandros; Wagner, Benjamin; Seiffge, David J.; Lyrer, Philippe; Engelter, Stefan T.; Peters, Nils] Univ Hosp Basel, Stroke Ctr, Basel, Switzerland; [Polymeris, Alexandros; Wagner, Benjamin; Seiffge, David J.; Lyrer, Philippe; Engelter, Stefan T.; Peters, Nils] Univ Basel, Basel, Switzerland; [Algra, Ale] Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Algra, Ale; Kappelle, L. Jaap] Univ Utrecht, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Hendrikse, Jeroen] Univ Utrecht, Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands; [Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Sch Clin Sci, Edinburgh, Midlothian, Scotland; [Jager, Hans R.] UCL, Lysholm Dept Neuroradiol, London, England; [Jager, Hans R.] UCL, Neuroradiol Acad Unit, Dept Brain Repair & Rehabil, London, England; [Jager, Hans R.] Inst Neurol, London, England; [Jager, Hans R.] Natl Hosp Neurol & Neurosurg, London, England; [Lip, Gregory Y. H.] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England; [Lip, Gregory Y. H.] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England; [Lip, Gregory Y. H.] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark; [Seiffge, David J.; Fischer, Urs; Jung, Simon] Univ Bern, Univ Hosp Inselspital Bern, Dept Neurol, Bern, Switzerland; [El-Koussy, Marwan] Univ Bern, Univ Hosp Inselspital Bern, Dept Diagnost & Intervent Neuroradiol, Bern, Switzerland; [Mas, Jean-Louis; Calvet, David] Univ Paris, Dept Neurol, INSERM, Inst Psychiat & Neurosci Paris,St Anne Hosp, Paris, France; [Legrand, Laurence] Univ Paris, Dept Neuroradiol, Inst Psychiat & Neurosci Paris, St Anne Hosp,INSERM, Paris, France; [Karayiannis, Christopher; Srikanth, Velandai] Monash Univ, Peninsula Clin Sch, Peninsula Hlth, Melbourne, Vic, Australia; [Thanh Phan] Monash Univ, Sch Clin Sci, Stroke & Ageing Res Grp, Monash Hlth, Melbourne, Vic, Australia; [Gunkel, Sarah; Christ, Nicolas; Fluri, Felix] Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany; [Abrigo, Jill; Chu, Winnie] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Imaging & Intervent Radiol, Hong Kong, Peoples R China; [Leung, Thomas; Soo, Yannie] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China; [Chappell, Francesca; Wardlaw, Joanna] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh Imaging, Edinburgh, Midlothian, Scotland; [Chappell, Francesca; Wardlaw, Joanna] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Makin, Stephen] Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen, Scotland; [Hayden, Derek; Kelly, Peter J.] Univ Coll Dublin, Neurovasc Res Unit, Stroke Clin Trials Network Ireland, Dublin, Ireland; [Hayden, Derek; Kelly, Peter J.] Univ Coll Dublin, Stroke Clin Trials Network Ireland, Hlth Res Board, Dublin, Ireland; [Hayden, Derek] Trinity Coll Dublin, Dept Med Gerontol, Dublin, Ireland; [Williams, David J.] Univ Med & Hlth Sci Dublin, Royal Coll Surg Ireland, Dept Geriatr & Stroke Med, Dublin, Ireland; [Williams, David J.] Beaumont Hosp Dublin, Dept Geriatr & Stroke Med, Dublin, Ireland; [Mess, Werner H.] Maastricht Univ Med Ctr, Dept Clin Neurophysiol, Maastricht, Netherlands; [Nederkoorn, Paul J.] Amsterdam Univ Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Barbato, Carmen; Browning, Simone; Simister, Robert] Univ Coll London Hosp NHS Trust, Comprehens Stroke Serv, London, England; [Wiegertjes, Kim; Tuladhar, Anil M.; de Leeuw, Frank-Erik] Radboud Univ Nijmegen Med Ctr, Donders Ctr Med Neurosci, Donders Inst Brain, Dept Neurol, Nijmegen, Netherlands; [Maaijwee, Noortje] Lucerne State Hosp, Neuroctr, Dept Neurol & Neurorehabil, Luzern, Switzerland; [Guevarra, Anne Cristine; Yatawara, Chathuri; Kandiah, Nagaendran] Natl Neurosci Inst, Dept Neurol, Singapore, Singapore; [Mendyk, Anne-Marie; Delmaire, Christine; Bordet, Regis] Univ Lille, Ctr Hosp Univ Lille, INSERM, Degenerat & Vasc Cognit Disorders, Lille, France; [Delmaire, Christine] Fdn Adolphe De Rothschild, Dept Radiol, Paris, France; [Kohler, Sebastian] Maastricht Univ Med Ctr, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands; [van Oostenbrugge, Robert; Staals, Julie] Maastricht Univ Med Ctr, Cardiovasc Res Inst Maastricht, Dept Neurol, Maastricht, Netherlands; [Zhou, Ying; Xu, Chao; Lou, Min] Zhejiang Univ, Sch Med, Dept Neurol, Affiliated Hosp 2, Hangzhou, Peoples R China; [Hilal, Saima; Gyanwali, Bibek; Chen, Christopher] Natl Univ Singapore, Memory Aging & Cognit Ctr, Yong Loo Lin Sch Med, Singapore, Singapore; [Kwa, Vincent I. H.] Onze Lieve Vrouw Hosp, Dept Neurol, Amsterdam, Netherlands; [Engelter, Stefan T.; Peters, Nils] Univ Basel, Dept Geriatr Med FELIX PLATTER, Neurol & Neurorehabil, Basel, Switzerland; [Yakushiji, Yusuke] Kansai Med Univ, Dept Neurol, Osaka, Japan; [Orken, Dilek Necioglu] Mem Sisli Hosp, Dept Neurol, Istanbul, Turkey; [Thijs, Vincent] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Stroke Div, Heidelberg, Vic, Australia; [Thijs, Vincent] Austin Hlth, Dept Neurol, Heidelberg, Vic, Australia; [Veltkamp, Roland] Imperial Coll London, Dept Brain Sci, London, England; [Ay, Hakan] Takeda, Cambridge, MA USA	University of London; University College London; University of London; University College London; Seoul National University (SNU); Hallym University; National Cerebral & Cardiovascular Center - Japan; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg; University of Hong Kong; University of Hong Kong; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Hospital of Santa Creu i Sant Pau; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Hospital of Santa Creu i Sant Pau; Harvard University; Harvard Medical School; Massachusetts General Hospital; Ruprecht Karls University Heidelberg; Chinese University of Hong Kong; Yonsei University; Yonsei University Health System; Ewha Womans University; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Medical University of Graz; Istanbul Sisli Hamidiye Etfal Training & Research Hospital; University of Health Sciences Turkey; Izmir Ataturk Training & Research Hospital; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Saga University; Saga University; University of Calgary; University of Basel; University of Basel; University of Basel; Utrecht University; Utrecht University; Utrecht University; Utrecht University Medical Center; University of Edinburgh; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Liverpool; Liverpool Heart & Chest Hospital; Aalborg University; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; GHU PARIS Psychiatrie Neurosciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Monash University; Monash University; University of Wurzburg; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Edinburgh; University of Edinburgh; University of Aberdeen; University College Dublin; Health Research Board - Ireland; University College Dublin; Trinity College Dublin; Royal College of Surgeons - Ireland; Maastricht University; Maastricht University Medical Centre (MUMC); University College London Hospitals NHS Foundation Trust; University of London; University College London; Radboud University Nijmegen; National Neuroscience Institute (NNI); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Zhejiang University; National University of Singapore; Onze Lieve Vrouwe Gasthuis Hospital; University of Basel; Kansai Medical University; Memorial Healthcare Group; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Imperial College London	Werring, DJ (corresponding author), UCL, Queen Sq Inst Neurol, Dept Brain Repair & Rehabil, UCL Stroke Res Ctr, London WC1B SEH, England.	d.werring@ucl.ac.uk	Thijs, Vincent/C-3647-2009; Wardlaw, Joanna M/Y-3456-2019; Leung, Thomas W/AAU-6475-2021; Jouvent, Eric/B-4320-2014; tanriverdi, zeynep/AAA-5759-2022; Lim, Jae-Sung/D-5555-2012; Kim, Beom Joon/C-2904-2011; Werring, David/Q-8435-2019; Kooi, M. Eline/D-3848-2016; Koga, Masatoshi/GWR-2715-2022; Hilal, Saima/D-6028-2016; Chen, Christopher/E-7023-2013; Polymeris, Alexandros/ABG-4291-2021; Polymeris, Alexandros/AHB-4688-2022; Hernandez, María/GYU-3543-2022; Lam, Bonnie Yin Ka/J-7578-2016; Guisado-Alonso, Daniel/F-3399-2018; Chu, Winnie/F-8449-2014; Jager, Hans Rolf/K-1868-2013	Thijs, Vincent/0000-0002-6614-8417; Wardlaw, Joanna M/0000-0002-9812-6642; Leung, Thomas W/0000-0001-8193-0709; Jouvent, Eric/0000-0001-7797-2236; Lim, Jae-Sung/0000-0001-6157-2908; Kim, Beom Joon/0000-0002-2719-3012; Werring, David/0000-0003-2074-1861; Kooi, M. Eline/0000-0001-7562-5724; Koga, Masatoshi/0000-0002-6758-4026; Hilal, Saima/0000-0001-5434-5635; Chen, Christopher/0000-0002-1047-9225; Polymeris, Alexandros/0000-0002-9475-2208; Polymeris, Alexandros/0000-0002-9475-2208; Lam, Bonnie Yin Ka/0000-0002-1656-2433; Leff, Alexander/0000-0002-0831-3541; Guisado-Alonso, Daniel/0000-0002-5799-3184; Chu, Winnie/0000-0003-4962-4132; Parry-Jones, Adrian/0000-0002-4462-3846; Seiffge, David/0000-0003-3890-3849; BEIGNEUX, Ysoline/0000-0001-5749-1865; Randall, Marc/0000-0002-3196-182X; Wagner, Benjamin/0000-0001-9330-1790; Sprigg, Nikola/0000-0002-5871-8168; Makin, Stephen/0000-0001-8701-9043; Kim, Young Dae/0000-0001-5750-2616; Browning, Simone/0000-0003-1506-5053; Brown, Martin M/0000-0002-3273-1356; Perry, Richard/0000-0002-4536-9018; Thrippleton, Michael/0000-0001-7858-9917; Jager, Hans Rolf/0000-0002-6403-4184; Price, Christopher/0000-0003-3566-3157; Martinez-Domeno, Alejandro/0000-0002-9933-3192; Miwa, Kaori/0000-0002-7948-3636; Guevarra, Anne Cristine/0000-0003-1817-7130; Slater, Lee-Anne/0000-0002-1140-8664; Fischer, Urs/0000-0003-0521-4051; Marti-Fabregas, Joan/0000-0001-9229-8649; Zerna, Charlotte/0000-0001-5969-8990; Heo, Ji Hoe/0000-0001-9898-3321; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Legrand, Laurence/0000-0003-3951-7405; Kwan, Joseph/0000-0003-4635-3322; CAMPS-RENOM, POL/0000-0001-6587-6271; Simister, Robert/0000-0003-0578-6711	British Heart Foundation and Stroke Association	British Heart Foundation and Stroke Association	British Heart Foundation and Stroke Association.	Amarenco P, 2017, CEREBROVASC DIS, V43, P145, DOI 10.1159/000453459; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Berg DD, 2019, CIRCULATION, V139, P760, DOI 10.1161/CIRCULATIONAHA.118.038312; Borre ED, 2018, THROMB HAEMOSTASIS, V118, P2171, DOI 10.1055/s-0038-1675400; Chao TF, 2018, INT J CARDIOL, V254, P157, DOI 10.1016/j.ijcard.2017.11.025; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.7326/M14-0697, 10.1186/s12916-014-0241-z, 10.1016/j.eururo.2014.11.025, 10.1136/bmj.g7594, 10.1016/j.jclinepi.2014.11.010, 10.1002/bjs.9736, 10.7326/M14-0698]; Dichgans M, 2016, ALZHEIMERS DEMENT, V12, P1235, DOI 10.1016/j.jalz.2016.06.004; Friberg L, 2012, EUR HEART J, V33, P1500, DOI 10.1093/eurheartj/ehr488; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Hijazi Z, 2016, LANCET, V387, P2302, DOI 10.1016/S0140-6736(16)00741-8; Hilkens NA, 2016, J THROMB HAEMOST, V14, P167, DOI 10.1111/jth.13196; Hilkens NA, 2018, STROKE, V49, P601, DOI 10.1161/STROKEAHA.117.019259; Hilkens NA, 2017, NEUROLOGY, V89, P936, DOI 10.1212/WNL.0000000000004289; Mehndiratta MM, 2014, J NEUROL NEUROSUR PS, V85, P1308, DOI 10.1136/jnnp-2013-306992; Oldgren J, 2016, CIRCULATION, V134, P1697, DOI 10.1161/CIRCULATIONAHA.116.022802; Royston P, 2004, STAT MED, V23, P907, DOI 10.1002/sim.1691; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Senoo K, 2016, AM J MED, V129, P600, DOI 10.1016/j.amjmed.2015.10.001; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2016, J CLIN EPIDEMIOL, V69, P245, DOI 10.1016/j.jclinepi.2015.04.005; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Vickers AJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-13; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Wilson D, 2019, LANCET NEUROL, V18, P653, DOI 10.1016/S1474-4422(19)30197-8; Wilson D, 2018, LANCET NEUROL, V17, P539, DOI 10.1016/S1474-4422(18)30145-5; Wilson D, 2014, EXPERT REV NEUROTHER, V14, P661, DOI 10.1586/14737175.2014.918506; Zhu WG, 2017, INT J CARDIOL, V227, P436, DOI 10.1016/j.ijcard.2016.11.015	28	18	20	2	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					294	303		10.1016/S1474-4422(21)00024-7	http://dx.doi.org/10.1016/S1474-4422(21)00024-7			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743239	Green Submitted, Green Accepted			2022-12-18	WOS:000630325700020
J	Fehlings, MG; Badhiwala, JH; Ahn, H; Farhadi, HF; Shaffrey, CI; Nassr, A; Mummaneni, P; Arnold, PM; Jacobs, WB; Riew, KD; Kelly, M; Brodke, DS; Vaccaro, AR; Hilibrand, AS; Wilson, J; Harrop, JS; Yoon, ST; Kim, KD; Fourney, DR; Santaguida, C; Massicotte, EM; Kopjar, B				Fehlings, Michael G.; Badhiwala, Jetan H.; Ahn, Henry; Farhadi, H. Francis; Shaffrey, Christopher, I; Nassr, Ahmad; Mummaneni, Praveen; Arnold, Paul M.; Jacobs, W. Bradley; Riew, K. Daniel; Kelly, Michael; Brodke, Darrel S.; Vaccaro, Alexander R.; Hilibrand, Alan S.; Wilson, Jason; Harrop, James S.; Yoon, S. Tim; Kim, Kee D.; Fourney, Daryl R.; Santaguida, Carlo; Massicotte, Eric M.; Kopjar, Branko			Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial	LANCET NEUROLOGY			English	Article							SPINAL-CORD-INJURY; QUALITY-OF-LIFE; SPONDYLOTIC MYELOPATHY; SURGICAL DECOMPRESSION; NEUROPATHIC PAIN; RODENT MODEL; COMPRESSION; MECHANISMS; SYSTEM	Background Degenerative cervical myelopathy represents the most common form of non-traumatic spinal cord injury. This trial investigated whether riluzole enhances outcomes in patients undergoing decompression surgery for degenerative cervical myelopathy. Methods This multicentre, double-blind, placebo-controlled, randomised, phase 3 trial was done at 16 university-affiliated centres in Canada and the USA. Patients with moderate-to-severe degenerative cervical myelopathy aged 18-80 years, who had a modified Japanese Orthopaedic Association (mJOA) score of 8-14, were eligible. Patients were randomly assigned (1:1) to receive either oral riluzole (50 mg twice a day for 14 days before surgery and then for 28 days after surgery) or placebo. Randomisation was done using permuted blocks stratified by study site. Patients, physicians, and outcome assessors remained masked to treatment group allocation. The primary endpoint was change in mJOA score from baseline to 6 months in the intention-to-treat (ITT) population, defined as all individuals who underwent randomisation and surgical decompression. Adverse events were analysed in the modified intention-to-treat (mITT) population, defined as all patients who underwent randomisation, including those who did not ultimately undergo surgical decompression. This study is registered with ClinicalTrials.gov, NCT01257828. Findings From Jan 31,2012, to May 16,2017,408 patients were screened. Of those screened, 300 were eligible (mITT population); 290 patients underwent decompression surgery (ITT population) and received either riluzole (ii=141) or placebo (n=149). There was no difference between the riluzole and placebo groups in the primary endpoint of change in InjOA score at 6-month follow-up: 2.45 points (95% CI 2.08 to 2.82 points) versus 2.83 points (2.47 to 3.19), difference -0.38 points (-0.90 to 0.13; p=0.14). The most common adverse events were neck or arm or shoulder pain, arm paraesthesia, dysphagia, and worsening of myelopathy. There were 43 serious adverse events in 33 (22%) of 147 patients in the riluzole group and 34 serious adverse events in 29 (19%) of 153 patients in the placebo group. The most frequent severe adverse events were osteoarthrosis of non-spinal joints, worsening of myelopathy, and wound complications. Interpretation In this trial, adjuvant treatment for 6 weeks perioperatively with riluzole did not improve functional recovery beyond decompressive surgery in patients with moderate-to-severe degenerative cervical myelopathy. Whether riluzole has other benefits in this patient population merits further study. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Fehlings, Michael G.; Badhiwala, Jetan H.; Massicotte, Eric M.] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Ahn, Henry] Univ Toronto, Div Orthopaed Surg, St Michaels Hosp, Toronto, ON, Canada; [Farhadi, H. Francis] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Shaffrey, Christopher, I] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA; [Nassr, Ahmad] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA; [Mummaneni, Praveen] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA; [Arnold, Paul M.] Kansas Univ Med Ctr, Dept Neurosurg, Kansas City, KS USA; [Jacobs, W. Bradley] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Riew, K. Daniel] Columbia Univ, Dept Orthoped Surg, New York, NY USA; [Kelly, Michael] Washington Univ, Dept Orthopaed Surg, St Louis, MO 63110 USA; [Brodke, Darrel S.] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA; [Vaccaro, Alexander R.; Hilibrand, Alan S.] Thomas Jefferson Univ, Dept Orthopaed Surg, Rothman Orthopaed Inst, Philadelphia, PA 19107 USA; [Wilson, Jason] Louisiana State Univ, Dept Neurosurg, New Orleans, LA USA; [Harrop, James S.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Yoon, S. Tim] Emory Univ, Dept Orthopaed, Atlanta, GA 30322 USA; [Kim, Kee D.] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA; [Fourney, Daryl R.] Univ Saskatchewan, Div Neurosurg, Saskatoon, SK, Canada; [Santaguida, Carlo] McGill Univ Hlth Ctr, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Kopjar, Branko] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University System of Ohio; Ohio State University; University of Virginia; Mayo Clinic; University of California System; University of California San Francisco; University of Kansas; University of Kansas Medical Center; University of Calgary; Columbia University; Washington University (WUSTL); Utah System of Higher Education; University of Utah; Jefferson University; Rothman Institute; Louisiana State University System; Jefferson University; Emory University; University of California System; University of California Davis; University of Saskatchewan; McGill University; University of Washington; University of Washington Seattle	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.ca	Kelly, Michael P/CAE-8607-2022	Kelly, Michael P/0000-0001-6221-7406	AO Spine North America	AO Spine North America	This study was sponsored by AO Spine North America, a non-profit foundation.	Akter F, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00138; Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Badhiwala JH, 2020, NAT REV NEUROL, V16, P108, DOI 10.1038/s41582-019-0303-0; BENZEL EC, 1991, J SPINAL DISORD, V4, P286, DOI 10.1097/00002517-199109000-00005; Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002; Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021; David G, 2019, NAT REV NEUROL, V15, P718, DOI 10.1038/s41582-019-0270-5; Davies B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031486; Davies BM, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k186; Dhillon RS, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0359-7; Fehlings MG, 2016, SPINAL CORD, V54, P8, DOI 10.1038/sc.2015.95; Fehlings MG, 1999, SPINE, V24, P605, DOI 10.1097/00007632-199903150-00023; Fehlings MG, 2017, GLOB SPINE J, V7, p53S, DOI 10.1177/2192568217710137; Fehlings MG, 2015, SPINE, V40, P1322, DOI 10.1097/BRS.0000000000000988; Fehlings MG, 2013, SPINE, V38, pS68, DOI 10.1097/BRS.0b013e3182a7e9b0; Fehlings MG, 2013, J BONE JOINT SURG AM, V95A, P1651, DOI 10.2106/JBJS.L.00589; Freund P, 2019, LANCET NEUROL, V18, P1123, DOI 10.1016/S1474-4422(19)30138-3; Fumagalli E, 2008, EUR J PHARMACOL, V578, P171, DOI 10.1016/j.ejphar.2007.10.023; Furlan JC, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS1648; Goh GS, 2020, SPINE J, V20, P1785, DOI 10.1016/j.spinee.2020.06.021; Harrell F. E., 2001, REGRESSION MODELING; Karadimas SK, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac6524; Kopjar B, 2015, SPINE, V40, pE23, DOI 10.1097/BRS.0000000000000648; Kretschmer BD, 1998, N-S ARCH PHARMACOL, V358, P181, DOI 10.1007/PL00005241; Lang-Lazdunski L, 1999, J THORAC CARDIOV SUR, V117, P881, DOI 10.1016/S0022-5223(99)70367-3; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Moon ES, 2014, NEUROBIOL DIS, V62, P394, DOI 10.1016/j.nbd.2013.10.020; Osikowicz M, 2013, EXP PHYSIOL, V98, P372, DOI 10.1113/expphysiol.2012.069922; Sakurai H, 2019, J AFFECT DISORDERS, V258, P102, DOI 10.1016/j.jad.2019.06.065; Schwartz G, 2002, PROG BRAIN RES, V137, P177; Singh A, 2001, J Outcome Meas, V5, P798; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; Wu Y, 2014, NEUROSCIENCE, V265, P302, DOI 10.1016/j.neuroscience.2014.01.059; Wu YC, 2013, J NEUROTRAUM, V30, P441, DOI 10.1089/neu.2012.2622; Yonenobu K, 2001, SPINE, V26, P1890, DOI 10.1097/00007632-200109010-00014; Yu WR, 2011, BRAIN, V134, P1277, DOI 10.1093/brain/awr054; Zhou FF, 2015, EUR SPINE J, V24, P2918, DOI 10.1007/s00586-015-4208-3	37	18	19	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					98	106		10.1016/S1474-4422(20)30407-5	http://dx.doi.org/10.1016/S1474-4422(20)30407-5		JAN 2021	9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33357512				2022-12-18	WOS:000610201500017
J	Partinen, M				Partinen, Markku			Sleep research in 2020: COVID-19-related sleep disorders	LANCET NEUROLOGY			English	Editorial Material									[Partinen, Markku] Univ Helsinki, Helsinki Sleep Clin, Vitalmed Res Ctr, Helsinki 00380, Finland; [Partinen, Markku] Univ Helsinki, Dept Neurosci, Helsinki 00380, Finland	University of Helsinki; University of Helsinki	Partinen, M (corresponding author), Univ Helsinki, Helsinki Sleep Clin, Vitalmed Res Ctr, Helsinki 00380, Finland.; Partinen, M (corresponding author), Univ Helsinki, Dept Neurosci, Helsinki 00380, Finland.	markku.partinen@helsinki.fi		Partinen, Markku/0000-0002-8182-9368				Altena E, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13052; Bojarskaite L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17062-2; Casagrande M, 2020, SLEEP MED, V75, P12, DOI 10.1016/j.sleep.2020.05.011; Hablitz LM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18115-2; Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954; Partinen M, 2021, J SLEEP RES, V30, DOI 10.1111/jsr.13206; Rasmussen R, 2020, PROG NEUROBIOL, V193, DOI 10.1016/j.pneurobio.2020.101802; Sanchez-de-la-Torre M, 2020, LANCET RESP MED, V8, P359, DOI 10.1016/S2213-2600(19)30271-1; Wimms AJ, 2020, LANCET RESP MED, V8, P349, DOI 10.1016/S2213-2600(19)30402-3	9	18	18	3	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					15	+		10.1016/S1474-4422(20)30456-7	http://dx.doi.org/10.1016/S1474-4422(20)30456-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33340475	Green Published, Bronze			2022-12-18	WOS:000600831400011
J	Markus, HS; Harshfield, EL; Compter, A; Kuker, W; Kappelle, LJ; Clifton, A; van der Worp, HB; Rothwell, P; Algra, A				Markus, Hugh S.; Harshfield, Eric L.; Compter, Annette; Kuker, Wilhelm; Kappelle, L. Jaap; Clifton, Andrew; van der Worp, H. Bart; Rothwell, Peter; Algra, Ale		Vertebral Stenosis Trialists Coll	Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis	LANCET NEUROLOGY			English	Article							MEDICAL-TREATMENT; ISCHEMIC ATTACK; STROKE; ANGIOPLASTY; CLOPIDOGREL; ASPIRIN; THERAPY	Background Symptomatic vertebral artery stenosis is associated with a high risk of recurrent stroke, with higher risks for intracranial than for extracranial stenosis. Vertebral artery stenosis can be treated with stenting with good technical results, but whether it results in improved clinical outcome is uncertain. We aimed to compare vertebral stenting with medical treatment for symptomatic vertebral stenosis. Methods We did a preplanned pooled individual patient data analysis of three completed randomised controlled trials comparing stenting with medical treatment in patients with symptomatic vertebral stenosis. The primary outcome was any fatal or non-fatal stroke. Analyses were performed for vertebral stenosis at any location and separately for extracranial and intracranial stenoses. Data from the intention-to-treat analysis were used for all studies. We estimated hazard ratios (HRs) with 95% CIs using Cox proportional-hazards regression models stratified by trial. Findings Data were from 354 individuals from three trials, induding 179 patients from VIST (148 with extracranial stenosis and 31 with intracranial stenosis), 115 patients from VAST (96 with extracranial stenosis and 19 with intracranial stenosis), and 60 patients with intracranial stenosis from SAMMPRIS (no patients had extracranial stenosis). Across all trials, 168 participants (46 with intracranial stenosis and 122 with extracranial stenosis) were randomly assigned to medical treatment and 186 to stenting (64 with intracranial stenosis and 122 with extracranial stenosis). In the stenting group, the frequency of periprocedural stroke or death was higher for intracranial stenosis than for extracranial stenosis (ten (16%) of 64 patients vs one (1%) of 121 patients; p<0.0001). During 1036 person-years of follow-up, the hazard ratio (HR) for any stroke in the stenting group compared with the medical treatment group was 0.81% CI 0.45-144; p=0.47). For extracranial stenosis alone the HR was 0.63 (95% CI 0.27-1.46) and for intracranial stenosis alone it was 1.06 (0.46-2.42; p(intreaction)=0.395). Interpretation Stenting for vertebral stenosis has a much higher risk for intracranial, compared with extracranial, stenosis. This pooled analysis did not show evidence of a benefit for stroke prevention for either treatment. There was no evidence of benefit of stenting for intracranial stenosis. Stenting for extracranial stenosis might be beneficial, but further larger trials are required to determine the treatment effect in this subgroup. Copyright 2019 Elsevier Ltd. All rights reserved.	[Markus, Hugh S.; Harshfield, Eric L.] Univ Cambridge, Dept Clin Neurosci, Stroke Res Grp, Cambridge CB2 0QQ, England; [Compter, Annette] Netherlands Canc Inst, Dept Neurol, Amsterdam, Netherlands; [Kuker, Wilhelm; Rothwell, Peter] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England; [Kappelle, L. Jaap; van der Worp, H. Bart; Algra, Ale] Univ Utrecht, Univ Med Ctr, UMC Utrecht Brain Ctr, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Algra, Ale] Univ Utrecht, Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Clifton, Andrew] St George Hosp, Dept Neuroradiol, London, England	University of Cambridge; Netherlands Cancer Institute; University of Oxford; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; St Georges University London	Markus, HS (corresponding author), Univ Cambridge, Dept Clin Neurosci, Stroke Res Grp, Cambridge CB2 0QQ, England.	hsm32@medschl.cam.ac.uk	Piechowski-Jozwiak, Bartlomiej/HCI-4426-2022; Rothwell, Peter/ABE-5913-2020; Harshfield, Eric L/AAG-8081-2020	Rothwell, Peter/0000-0001-9739-9211; Harshfield, Eric L/0000-0001-8767-0928; Markus, Hugh Stephen/0000-0002-9794-5996; Emsley, Hedley/0000-0003-0129-4488; PIECHOWSKI-JOZWIAK, BARTLOMIEJ/0000-0002-1886-9949	UK National Institute for Health Research Senior Investigator award; CoSTREAM project - European Union's Horizon 2020 research and innovation programme [667375]; National Institute for Health ReSearch Biomedical Research Centre, Oxford; Wellcome Trust	UK National Institute for Health Research Senior Investigator award; CoSTREAM project - European Union's Horizon 2020 research and innovation programme; National Institute for Health ReSearch Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission)	HSM is supported by a UK National Institute for Health Research Senior Investigator award. His research is supported by infrastructural support from the Cambridge University Hospital Trust, National Institute for Health Research Biomedical Research Centre. EH's salary is supported by the CoSTREAM project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 667375. PR is supported by the National Institute for Health ReSearch Biomedical Research Centre, Oxford, and by the Wellcome Trust.	Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Compter A, 2015, LANCET NEUROL, V14, P606, DOI 10.1016/S1474-4422(15)00017-4; Coward LJ, 2007, STROKE, V38, P1526, DOI 10.1161/STROKEAHA.106.471862; Eberhardt O, 2006, J VASC SURG, V43, P1145, DOI 10.1016/j.jvs.2006.02.027; Gulli G, 2013, STROKE, V44, P598, DOI 10.1161/STROKEAHA.112.669929; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Markus HS, 2005, CIRCULATION, V111, P2233, DOI 10.1161/01.CIR.0000163561.90680.1C; Markus HS, 2017, NEUROLOGY, V89, P1229, DOI 10.1212/WNL.0000000000004385; Markus HS, 2013, LANCET NEUROL, V12, P989, DOI 10.1016/S1474-4422(13)70211-4; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Stayman AN, 2011, STROKE, V42, P2212, DOI 10.1161/STROKEAHA.110.611459; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693	13	18	18	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2019	18	7					666	673		10.1016/S1474-4422(19)30149-8	http://dx.doi.org/10.1016/S1474-4422(19)30149-8			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IC7SE	31130429	Green Submitted, Green Accepted			2022-12-18	WOS:000471176500015
J	[Anonymous]				[Anonymous]			Air pollution and brain health: an emerging issue	LANCET NEUROLOGY			English	Editorial Material																			0	18	19	2	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					103	103		10.1016/S1474-4422(17)30462-3	http://dx.doi.org/10.1016/S1474-4422(17)30462-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29413304	Bronze			2022-12-18	WOS:000422828500001
J	Braun, H; Schreiber, S				Braun, Holger; Schreiber, Stefanie			Microbleeds in cerebral small vessel disease	LANCET NEUROLOGY			English	Letter							SHRSP		[Braun, Holger; Schreiber, Stefanie] Deutsch Zentrum Neurodegenerat Erkrankungen, D-39120 Magdeburg, Germany; [Schreiber, Stefanie] Otto Von Guericke Univ, Neurol Klin, Magdeburg, Germany	Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Otto von Guericke University	Braun, H (corresponding author), Deutsch Zentrum Neurodegenerat Erkrankungen, D-39120 Magdeburg, Germany.	holger.braun@ifn-magdeburg.de	Schreiber, Stefanie/S-3223-2019	Schreiber, Stefanie/0000-0003-4439-4374				[Anonymous], 2013, LANCET NEUROL, V12, P483; Benavente OR, 2012, NEW ENGL J MED, V367, P817, DOI 10.1056/NEJMoa1204133; Braun H, 2012, J NEUROL SCI, V322, P71, DOI 10.1016/j.jns.2012.06.013; Bueche Celine Zoe, 2013, Exp Transl Stroke Med, V5, P5, DOI 10.1186/2040-7378-5-5; Jeon SB, 2009, NEUROLOGY, V73, P1638, DOI 10.1212/WNL.0b013e3181bd110f; Klohs J, 2012, J NEUROSCI, V32, P1705, DOI 10.1523/JNEUROSCI.5626-11.2012; Schreiber Stefanie, 2013, Exp Transl Stroke Med, V5, P4, DOI 10.1186/2040-7378-5-4; Schreiber S, 2012, J CEREBR BLOOD F MET, V32, P278, DOI 10.1038/jcbfm.2011.122; Schreiber S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026287	9	18	21	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2013	12	8					735	736		10.1016/S1474-4422(13)70148-0	http://dx.doi.org/10.1016/S1474-4422(13)70148-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195GP	23867194				2022-12-18	WOS:000322690600009
J	Rabinstein, AA				Rabinstein, Alejandro A.			Secondary brain injury after aneurysmal subarachnoid haemorrhage: more than vasospasm	LANCET NEUROLOGY			English	Editorial Material							CEREBRAL VASOSPASM; DOUBLE-BLIND; CLAZOSENTAN; ENDOTHELIN		Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu						Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Dorhout Mees SM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000277.pub3; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Rabinstein AA, 2010, LANCET NEUROL, V9, P504, DOI 10.1016/S1474-4422(10)70087-9; Rinkel GJE, 2011, LANCET NEUROL, V10, P349, DOI 10.1016/S1474-4422(11)70017-5; Romano JG, 2008, J NEUROIMAGING, V18, P396, DOI 10.1111/j.1552-6569.2007.00215.x; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; Vatter H, 2007, J NEUROSURG, V107, P121, DOI 10.3171/JNS-07/07/0121; Vergouwen MDI, 2009, J CEREBR BLOOD F MET, V29, P1444, DOI 10.1038/jcbfm.2009.59	11	18	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2011	10	7					593	595		10.1016/S1474-4422(11)70122-3	http://dx.doi.org/10.1016/S1474-4422(11)70122-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789BD	21640652				2022-12-18	WOS:000292487400003
J	Vellas, B				Vellas, Bruno			Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed	LANCET NEUROLOGY			English	Editorial Material							SAFETY; TRIAL		Univ Toulouse, INSERM, U558, Ctr Memoire Resource & Rech, F-31300 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse	Vellas, B (corresponding author), Univ Toulouse, INSERM, U558, Ctr Memoire Resource & Rech, F-31300 Toulouse, France.	vellas.b@chu-toulouse.fr						Aisen PS, 2008, LANCET NEUROL, V7, P468, DOI 10.1016/S1474-4422(08)70091-7; Galasko DR, 2007, ALZ DIS ASSOC DIS, V21, P292, DOI 10.1097/WAD.0b013e31815d1048; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Wilcock GK, 2008, LANCET NEUROL, V7, P483, DOI 10.1016/S1474-4422(08)70090-5	4	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2010	9	3					235	237		10.1016/S1474-4422(10)70030-2	http://dx.doi.org/10.1016/S1474-4422(10)70030-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	565BL	20170836				2022-12-18	WOS:000275263400006
J	Hennerici, MG				Hennerici, Michael G.			What are the mechanisms for post-stroke dementia?	LANCET NEUROLOGY			English	Editorial Material							STROKE PATIENTS		Univ Heidelberg, Univ Klinikum Mannheim, Dept Neurol, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg	Hennerici, MG (corresponding author), Univ Heidelberg, Univ Klinikum Mannheim, Dept Neurol, D-68135 Mannheim, Germany.	hennerici@neuro.ma.uni-heidelberg.de						Brunnstrom H, 2009, ARCH GERONTOL GERIAT, V49, P146, DOI 10.1016/j.archger.2008.06.005; Ferrucci L, 1996, J AM GERIATR SOC, V44, P237; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Henon H, 1997, STROKE, V28, P2429, DOI 10.1161/01.STR.28.12.2429; Iadecola C, 2003, STROKE, V34, P335, DOI 10.1161/01.STR.0000054050.51530.76; Iadecola C, 2009, STROKE, V40, pS40, DOI 10.1161/STROKEAHA.108.533638; Inzitari D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2477; Pantoni L, 2005, NEUROEPIDEMIOLOGY, V24, P51, DOI 10.1159/000081050; Pasquier F, 1997, J NEUROL, V244, P135, DOI 10.1007/s004150050064; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; VICTOROFF J, 1995, AM J PSYCHIAT, V152, P1476	12	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					973	975		10.1016/S1474-4422(09)70261-3	http://dx.doi.org/10.1016/S1474-4422(09)70261-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC	19782002				2022-12-18	WOS:000271309600004
J	Mitchell, P; Gregson, BA; Crossman, J; Gerber, C; Jenkins, A; Nicholson, C; Todd, NV; Ross, N; Bhattathiri, P; Nissen, J; Crawford, PJ; Wynne-Jones, G; Sengupta, RP; Graham, L; Gani, A; Davis, M; Gray, C; Barer, D; Dorman, P; Millar, D; Williamson, J; Durham, H; Jones, A; Hastie, H; Mendelow, AD				Mitchell, Patrick; Gregson, Barbara A.; Crossman, John; Gerber, Chris; Jenkins, Alastair; Nicholson, Claire; Todd, Nick V.; Ross, Nick; Bhattathiri, Parameswaran; Nissen, Justin; Crawford, Peter J.; Wynne-Jones, Guy; Sengupta, Robin P.; Graham, Laura; Gani, Akif; Davis, Michelle; Gray, Chris; Barer, David; Dorman, Paul; Millar, David; Williamson, Julia; Durham, Holly; Jones, Alison; Hastie, Helen; Mendelow, A. David			Reassessment of the HAMLET study	LANCET NEUROLOGY			English	Letter							MIDDLE CEREBRAL-ARTERY; EDEMA TRIAL HAMLET; DECOMPRESSIVE SURGERY; MALIGNANT INFARCTION; HEMICRANIECTOMY; MULTICENTER		[Mitchell, Patrick; Gregson, Barbara A.; Crossman, John; Gerber, Chris; Jenkins, Alastair; Nicholson, Claire; Todd, Nick V.; Ross, Nick; Bhattathiri, Parameswaran; Nissen, Justin; Crawford, Peter J.; Wynne-Jones, Guy; Sengupta, Robin P.; Graham, Laura; Gani, Akif; Davis, Michelle; Gray, Chris; Barer, David; Dorman, Paul; Millar, David; Williamson, Julia; Durham, Holly; Jones, Alison; Hastie, Helen; Mendelow, A. David] Newcastle Gen Hosp, Neurosci Directorate, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital	Mitchell, P (corresponding author), Newcastle Gen Hosp, Neurosci Directorate, Ward 31,Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	a.d.mendelow@ncl.ac.uk	Mendelow, Alexander/AAW-2878-2021	Gregson, Barbara/0000-0003-4868-9137				Hofmeijer J, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-29; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; *NAT COLL CTR CHRO, 2008, 68 NICE NAT COLL CTR; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	6	18	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					602	603		10.1016/S1474-4422(09)70157-7	http://dx.doi.org/10.1016/S1474-4422(09)70157-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19539229				2022-12-18	WOS:000267643700009
J	Solomon, T				Solomon, Tom			New vaccines for Japanese encephalitis	LANCET NEUROLOGY			English	Editorial Material							IMMUNOGENICITY; SAFETY; JE		[Solomon, Tom] Univ Liverpool, Liverpool Sch Trop Med, Div Neurol Sci, Brain Infect Grp, Liverpool L69 3GA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Solomon, T (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Neurol Sci, Brain Infect Grp, Liverpool L69 3GA, Merseyside, England.	tsolomon@liv.ac.uk		Solomon, Tom/0000-0001-7266-6547	MRC [G116/194] Funding Source: UKRI; Medical Research Council [G116/194] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Caramello P, 2007, J TRAVEL MED, V14, P346, DOI 10.1111/j.1708-8305.2007.00140.x; Monath TP, 2003, J INFECT DIS, V188, P1213, DOI 10.1086/378356; Shlim DR, 2002, CLIN INFECT DIS, V35, P183, DOI 10.1086/341247; Tandan JB, 2007, VACCINE, V25, P5041, DOI 10.1016/j.vaccine.2007.04.052; Tauber E, 2007, LANCET, V370, P1847, DOI 10.1016/S0140-6736(07)61780-2	5	18	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2008	7	2					116	118		10.1016/S1474-4422(08)70004-8	http://dx.doi.org/10.1016/S1474-4422(08)70004-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261PY	18207104				2022-12-18	WOS:000253093700004
J	Romano, S; Salvetti, M; Ceccherini, I; De Simone, T; Savoiardo, M				Romano, Silvia; Salvetti, Marco; Ceccherini, Isabella; De Simone, Tiziana; Savoiardo, Mario			Brainstem signs with progressing atrophy of medulla oblongata and upper cervical spinal cord	LANCET NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; BASAL GANGLIA GERMINOMA; ALEXANDER-DISEASE; PALATAL MYOCLONUS; BEHCETS-DISEASE; MR; MUTATION; ONSET; GFAP; LEUKODYSTROPHY		Ist Nazl Neurol Carlo Besta, Dept Neuroradiol, I-20133 Milan, Italy; Inst G Gaslini, Mol Genet Lab, Genoa, Italy; Univ Roma La Sapienza, S Andrea Hosp, Ctr Expt Neurol Therapy, I-00161 Rome, Italy; Univ Roma La Sapienza, S Andrea Hosp, Dept Neurol, I-00161 Rome, Italy	IRCCS Istituto Neurologico Besta; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Savoiardo, M (corresponding author), Ist Nazl Neurol Carlo Besta, Dept Neuroradiol, Via Celoria 11, I-20133 Milan, Italy.	msavoiardo@instituto-besta.it	Salvetti, Marco/K-3836-2016; Ceccherini, Isabella/P-8195-2014; Romano, Silvia/P-7984-2015	Ceccherini, Isabella/0000-0001-8732-1955; Romano, Silvia/0000-0003-0499-8843				Adem Carmen, 2005, Radiology, V234, P111, DOI 10.1148/radiol.2341021806; Akman-Demir G, 1999, BRAIN, V122, P2171, DOI 10.1093/brain/122.11.2171; ALEXANDER WS, 1949, BRAIN, V72, P373, DOI 10.1093/brain/72.3.373; Armao DM, 2000, AM J NEURORADIOL, V21, P1122; Azizlerli G, 2003, INT J DERMATOL, V42, P803, DOI 10.1046/j.1365-4362.2003.01893.x; Barkhof F, 1997, BRAIN, V120, P2059, DOI 10.1093/brain/120.11.2059; Barkovich AJ, 2000, AM J NEURORADIOL, V21, P1099; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Brockmann K, 2003, EUR NEUROL, V50, P100, DOI 10.1159/000072507; Brockmann K, 2003, J NEUROL, V250, P300, DOI 10.1007/s00415-003-0995-2; Cagli S, 2004, BRIT J NEUROSURG, V18, P174, DOI 10.1080/02688690410001681055; Cotton F, 2003, NEUROLOGY, V60, P640, DOI 10.1212/01.WNL.0000046587.83503.1E; Farina L, 2000, AM J NEURORADIOL, V21, P1478; Farina L, 2002, AM J NEURORADIOL, V23, P1095; FARRELL K, 1984, ANN NEUROL, V15, P605, DOI 10.1002/ana.410150616; Fatemi A, 2005, NEUROLOGY, V64, P1739, DOI 10.1212/01.WNL.0000164458.02141.06; Ferreira S, 2005, RHEUMATOLOGY, V44, P434, DOI 10.1093/rheumatology/keh532; FRIEDE RL, 1964, ARCH NEUROL-CHICAGO, V11, P514; Garcia-Rivera CA, 2001, NEUROLOGY, V57, P1755, DOI 10.1212/WNL.57.10.1755; Gorospe JR, 2002, NEUROLOGY, V58, P1494, DOI 10.1212/WNL.58.10.1494; Guillamo JS, 2001, CURR OPIN NEUROL, V14, P711, DOI 10.1097/00019052-200112000-00006; Hagemann TL, 2005, HUM MOL GENET, V14, P2443, DOI 10.1093/hmg/ddi248; Imamura A, 2002, BRAIN DEV-JPN, V24, P723, DOI 10.1016/S0387-7604(02)00080-3; IWAKI T, 1993, AM J PATHOL, V143, P487; Kidd D, 1999, BRAIN, V122, P2183, DOI 10.1093/brain/122.11.2183; Kocer N, 1999, AM J NEURORADIOL, V20, P1015; KRIVIT W, 1999, CURR OPIN NEUROL, V20, P167; Kunavarapu C, 2001, J RHEUMATOL, V28, P874; LAKHANPAL S, 1985, HUM PATHOL, V16, P790, DOI 10.1016/S0046-8177(85)80250-1; Li R, 2005, ANN NEUROL, V57, P310, DOI 10.1002/ana.20406; Linnankivi T, 2004, NEUROLOGY, V63, P688, DOI 10.1212/01.WNL.0000134658.35601.41; Loes DJ, 1999, AM J NEURORADIOL, V20, P316; MARTINEZ R, 1995, AM J NEURORADIOL, V16, P1787; Messing A, 1998, AM J PATHOL, V152, P391; Messing A, 2003, GLIA, V43, P87, DOI 10.1002/glia.10219; Namekawa M, 2002, ANN NEUROL, V52, P779, DOI 10.1002/ana.10375; Nowak DA, 2001, J NEUROL, V248, P363, DOI 10.1007/s004150170175; Okamoto K, 2002, NEURORADIOLOGY, V44, P389, DOI 10.1007/s00234-001-0735-1; Okamoto Y, 2002, J NEUROL SCI, V195, P71, DOI 10.1016/S0022-510X(01)00687-6; Ozelame RV, 2006, PEDIATR RADIOL, V36, P325, DOI 10.1007/s00247-005-0063-4; PAULUS W, 2000, PATHOLOGY GENETICS T, P204; Prayer D, 2004, AM J NEURORADIOL, V25, P880; Satoh JI, 1997, NEUROLOGY, V49, P1392, DOI 10.1212/WNL.49.5.1392; Schwankhaus JD, 1995, NEUROLOGY, V45, P2266, DOI 10.1212/WNL.45.12.2266; Shiihara T, 2004, J NEUROL SCI, V225, P125, DOI 10.1016/j.jns.2004.07.008; Staba MJ, 1997, BONE MARROW TRANSPL, V20, P247, DOI 10.1038/sj.bmt.1700871; Stumpf E, 2003, ARCH NEUROL-CHICAGO, V60, P1307, DOI 10.1001/archneur.60.9.1307; Sudo A, 2003, AM J NEURORADIOL, V24, P1909; Taillia H, 2004, REV NEUROL-FRANCE, V160, P585, DOI 10.1016/S0035-3787(04)70993-5; Tan CHA, 2002, HOSP MED, V63, P115; Thyagarajan D, 2004, MOVEMENT DISORD, V19, P1244, DOI 10.1002/mds.20161; van der Knaap MS, 2006, NEUROLOGY, V66, P494, DOI 10.1212/01.wnl.0000198770.80743.37; van der Knaap MS, 2005, ANN NEUROL, V57, P327, DOI 10.1002/ana.20381; van der Knaap MS, 2003, ANN NEUROL, V53, P252, DOI 10.1002/ana.10456; van der Knaap MS, 2001, AM J NEURORADIOL, V22, P541; VANDERKNAAP MS, 1991, NEURORADIOLOGY, V33, P478, DOI 10.1007/BF00588038; VANDERKNAAP MS, 1989, AM J NEURORADIOL, V10, P99; VANDERKNAAP MS, 2005, MAGNETIC RESONANCE M, P416; Wippold FJ, 2006, AM J NEURORADIOL, V27, P958; ZEVIANI M, 2002, CEREBELLUM ITS DISOR, P548	60	18	19	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					562	570		10.1016/S1474-4422(07)70129-1	http://dx.doi.org/10.1016/S1474-4422(07)70129-1			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509491				2022-12-18	WOS:000247044900021
J	Hill, MD				Hill, Michael D.			Stroke: the dashed hopes of neuroprotection	LANCET NEUROLOGY			English	News Item							RANDOMIZED CONTROLLED-TRIAL; ENDARTERECTOMY; ASPIRIN		Univ Calgary, Foothills Hosp, Hotchkins Brain Inst, Calgary, AB T2N 2T9, Canada	University of Calgary	Hill, MD (corresponding author), Univ Calgary, Foothills Hosp, Hotchkins Brain Inst, Calgary, AB T2N 2T9, Canada.	michael.hill@calgaryhealthregion.ca	Hill, Michael D/C-9073-2012	Hill, Michael D/0000-0002-6269-1543				Amarenco P, 2006, NEW ENGL J MED, V355, P549; Connolly S, 2006, LANCET, V367, P1903, DOI 10.1016/s0140-6736(06)68845-4; Halkes PHA, 2006, LANCET, V367, P1665; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	7	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					2	3		10.1016/S1474-4422(06)70658-5	http://dx.doi.org/10.1016/S1474-4422(06)70658-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166787				2022-12-18	WOS:000243039000002
J	Scott, RC				Scott, RC			Buccal midazolam as rescue therapy for acute seizures	LANCET NEUROLOGY			English	Editorial Material							RECTAL DIAZEPAM; TRIAL		UCL, Neurosci Unit, Inst Child Hlth, London, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Scott, RC (corresponding author), UCL, Neurosci Unit, Inst Child Hlth, Mortimer St, London, England.	rscott@ich.ucl.ac.uk	Scott, Rod/C-5363-2008					CHIN RF, EUR J NEUROL, V11, P800; Chin RFM, 2005, ARCH DIS CHILD, V90, P66, DOI 10.1136/adc.2003.038844; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; McIntyre J, 2005, LANCET, V366, P205, DOI 10.1016/S0140-6736(05)66909-7; Scott RC, 1999, LANCET, V353, P623, DOI 10.1016/S0140-6736(98)06425-3; Wilson MT, 2004, ARCH DIS CHILD, V89, P50, DOI 10.1136/adc.2002.019836	6	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					592	593		10.1016/S1474-4422(05)70178-2	http://dx.doi.org/10.1016/S1474-4422(05)70178-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16168926				2022-12-18	WOS:000232245900006
J	Stocchi, F				Stocchi, F			Pathological gambling in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									IRCCS, NEUROMED, Inst Neurol, Pozzilli, Italy	IRCCS Neuromed	Stocchi, F (corresponding author), IRCCS, NEUROMED, Inst Neurol, Pozzilli, Italy.	fabrizio.stocchi@fastwebnet.it	stocchi, fabrizio/K-5089-2016	stocchi, fabrizio/0000-0002-5763-0033				Agid Y, 2003, ADV NEUROL, V91, P365; Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Dodd ML, 2005, ARCH NEUROL-CHICAGO, V62, P1377, DOI 10.1001/archneur.62.9.noc50009; Maricle RA, 1998, NEUROLOGY, V50, P1890, DOI 10.1212/WNL.50.6.1890; MENZA MA, 1993, NEUROLOGY, V43, P505, DOI 10.1212/WNL.43.3_Part_1.505	5	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					590	592		10.1016/S1474-4422(05)70177-0	http://dx.doi.org/10.1016/S1474-4422(05)70177-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16168925				2022-12-18	WOS:000232245900005
J	Rocca, WA				Rocca, WA			Prevalence of Parkinson's disease in China	LANCET NEUROLOGY			English	Letter							DIAGNOSTIC-CRITERIA		Mayo Clin & Mayo Fdn, Coll Med, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA	Mayo Clinic	Rocca, WA (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA.	rocca@mayo.edu	Rocca, Walter/Z-5335-2019					Bower JH, 2000, MOVEMENT DISORD, V15, P819, DOI 10.1002/1531-8257(200009)15:5<819::AID-MDS1009>3.0.CO;2-P; Cavalli-Sforza LL, 2003, NAT GENET, V33, P266, DOI 10.1038/ng1113; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; deRijk MC, 1997, NEUROLOGY, V48, P1277, DOI 10.1212/WNL.48.5.1277; Zhang ZX, 2005, LANCET, V365, P595, DOI 10.1016/S0140-6736(05)70801-1	5	18	21	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2005	4	6					328	329		10.1016/S1474-4422(05)70079-X	http://dx.doi.org/10.1016/S1474-4422(05)70079-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	931EQ	15907734				2022-12-18	WOS:000229469000003
J	Tietjen, GE				Tietjen, GE			Stroke and migraine linked by silent lesions	LANCET NEUROLOGY			English	Editorial Material							RISK		Med Coll Ohio, Dept Neurol, Toledo, OH 43699 USA		Tietjen, GE (corresponding author), Med Coll Ohio, Dept Neurol, Toledo, OH 43699 USA.	GTIETJEN@mco.edu						Donaghy M, 2002, J NEUROL NEUROSUR PS, V73, P747, DOI 10.1136/jnnp.73.6.747; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Tzourio C, 2003, CEPHALALGIA, V23, P914, DOI 10.1046/j.1468-2982.2003.00613.x; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; ZIEGLER DK, 1991, CEPHALALGIA, V11, P147, DOI 10.1046/j.1468-2982.1991.1103147.x	5	18	18	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					267	267		10.1016/S1474-4422(04)00729-X	http://dx.doi.org/10.1016/S1474-4422(04)00729-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL	15099537				2022-12-18	WOS:000221160700015
J	Maguire, GA; Riley, GD; Yu, BP				Maguire, GA; Riley, GD; Yu, BP			A neurological basis of stuttering?	LANCET NEUROLOGY			English	Letter							CEREBRAL BLOOD-FLOW		Univ Calif Irvine, Irvine Med Ctr, Dept Psychiat, Orange, CA 92868 USA	University of California System; University of California Irvine	Maguire, GA (corresponding author), Univ Calif Irvine, Irvine Med Ctr, Dept Psychiat, Route 88,101 City Dr, Orange, CA 92868 USA.	gamaguir@uci.edu						BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P966; Maguire G. A., 2000, INT J NEUROPSYCHOPH, V3, pS12; Maguire GA, 2000, J CLIN PSYCHOPHARM, V20, P479, DOI 10.1097/00004714-200008000-00013; POOL KD, 1991, ARCH NEUROL-CHICAGO, V48, P509, DOI 10.1001/archneur.1991.00530170069022; Sommer M, 2002, LANCET, V360, P380, DOI 10.1016/S0140-6736(02)09610-1; WOOD F, 1980, BRAIN LANG, V9, P141, DOI 10.1016/0093-934X(80)90079-6; Wu JC, 1997, INT CONGR SER, V1146, P329; Wu JC, 1997, NEUROREPORT, V8, P767, DOI 10.1097/00001756-199702100-00037; WU JC, 1995, NEUROREPORT, V6, P501, DOI 10.1097/00001756-199502000-00024	9	18	19	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					407	407		10.1016/S1474-4422(02)00217-X	http://dx.doi.org/10.1016/S1474-4422(02)00217-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC	12849360				2022-12-18	WOS:000178732300015
J	Orellana, C				Orellana, C			Controversy over brain surgery for heroin addiction in Russia	LANCET NEUROLOGY			English	News Item																			0	18	19	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2002	1	6					333	333		10.1016/S1474-4422(02)00175-8	http://dx.doi.org/10.1016/S1474-4422(02)00175-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599PB	12849380				2022-12-18	WOS:000178343200003
J	Reetz, K; Dogan, I; Hilgers, RD; Giunti, P; Parkinson, MH; Mariotti, C; Nanetti, L; Durr, A; Ewenczyk, C; Boesch, S; Nachbauer, W; Klopstock, T; Stendel, C; Garrido, FJRD; Rummey, C; Schols, L; Hayer, SN; Klockgether, T; Giordano, I; Didszun, C; Rai, M; Pandolfo, M; Schulz, JB				Reetz, Kathrin; Dogan, Imis; Hilgers, Ralf-Dieter; Giunti, Paola; Parkinson, Michael H.; Mariotti, Caterina; Nanetti, Lorenzo; Durr, Alexandra; Ewenczyk, Claire; Boesch, Sylvia; Nachbauer, Wolfgang; Klopstock, Thomas; Stendel, Claudia; de Rivera Garrido, Francisco Javier Rodriguez; Rummey, Christian; Schoels, Ludger; Hayer, Stefanie N.; Klockgether, Thomas; Giordano, Ilaria; Didszun, Claire; Rai, Myriam; Pandolfo, Massimo; Schulz, Jorg B.		EFACTS Study Grp	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study	LANCET NEUROLOGY			English	Article							RATING-SCALE; FOLLOW-UP; PERFORMANCE	Background The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia. Methods EFACTS is a prospective, observational cohort study based on an ongoing and open-ended registry. Patients with genetically confirmed Friedreich's ataxia were seen annually at 11 clinical centres in seven European countries (Austria, Belgium, France, Germany, Italy, Spain, and the UK). Data from baseline to 4-year follow-up were included in the current analysis. Our primary endpoints were the Scale for the Assessment and Rating of Ataxia (SARA) and the activities of daily living (ADL). Linear mixed-effect models were used to analyse annual disease progression for the entire cohort and subgroups defined by age of onset and ambulatory abilities. Power calculations were done for potential trial designs. This study is registered with ClinicalTrials.gov, NCT02069509. Findings Between Sept 15, 2010, and Nov 20, 2018, of 914 individuals assessed for eligibility, 602 patients were included. Of these, 552 (92%) patients contributed data with at least one follow-up visit. Annual progression rate for SARA was 0.82 points (SE 0.05) in the overall cohort, and higher in patients who were ambulatory (1.12 [0.07]) than non-ambulatory (0.50 [0.07]). ADL worsened by 0.93 (SE 0.05) points per year in the entire cohort, with similar progression rates in patients who were ambulatory (0.94 [0.07]) and non-ambulatory (0.91 [0.08]). Although both SARA and ADL showed slightly greater worsening in patients with typical onset (symptom onset at <= 24 years) than those with late onset (symptom onset >= 25 years), differences in progression slopes were not significant. For a 2-year parallel-group trial, 230 (115 per group) patients would be required to detect a 50% reduction in SARA progression at 80% power: 118 (59 per group) if only individuals who are ambulatory are included. With ADL as the primary outcome, 190 (95 per group) patients with Friedreich's ataxia would be needed, and fewer patients would be required if only individuals with early-onset are included. Interpretation Our findings for stage-dependent progression rates have important implications for clinicians and researchers, as they provide reliable outcome measures to monitor disease progression, and enable tailored sample size calculation to guide upcoming clinical trial designs in Friedreich's ataxia. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Reetz, Kathrin; Dogan, Imis; Didszun, Claire; Schulz, Jorg B.] Rhein Westfal TH Aachen, Dept Neurol, D-52074 Aachen, Germany; [Hilgers, Ralf-Dieter] Rhein Westfal TH Aachen, Dept Med Stat, Aachen, Germany; [Reetz, Kathrin; Dogan, Imis; Schulz, Jorg B.] Forschungszentrum Julich, JARA BRAIN Inst Mol Neurosci & Neuroimaging, Aachen, Germany; [Reetz, Kathrin; Dogan, Imis; Schulz, Jorg B.] Rhein Westfal TH Aachen, Aachen, Germany; [Giunti, Paola; Parkinson, Michael H.] UCL Queen Sq Inst Neurol, Ataxia Ctr, Dept Clin & Movement Neurosci, London, England; [Mariotti, Caterina; Nanetti, Lorenzo] Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, Milan, Italy; [Durr, Alexandra; Ewenczyk, Claire] Sorbonne Univ, Univ Hosp Pitie Salpetriere, AP HP, Paris Brain Inst,ICM Inst Cerveau,CNRS,INSERM, Paris, France; [Boesch, Sylvia; Nachbauer, Wolfgang] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Klopstock, Thomas; Stendel, Claudia] LMU, Univ Hosp, Friedrich Baur Inst, Dept Neurol, Munich, Germany; [Klopstock, Thomas; Stendel, Claudia] German Ctr Neurodegenerat Dis, Munich, Germany; [Klopstock, Thomas] Munich Cluster Syst Neurol, Munich, Germany; [de Rivera Garrido, Francisco Javier Rodriguez] Hosp Univ La Paz, Reference Unit Hereditary Ataxias & Paraplegias, Dept Neurol, IdiPAZ, Madrid, Spain; [Rummey, Christian] Clin Data Sci, Basel, Switzerland; [Schoels, Ludger; Hayer, Stefanie N.] Univ Tubingen, Dept Neurol, Tubingen, Germany; [Schoels, Ludger; Hayer, Stefanie N.] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Schoels, Ludger] German Ctr Neurodegenerat Dis, Tubingen, Germany; [Klockgether, Thomas; Giordano, Ilaria] Univ Hosp Bonn, Dept Neurol, Bonn, Germany; [Klockgether, Thomas] German Ctr Neurodegenerat Dis, Bonn, Germany; [Rai, Myriam; Pandolfo, Massimo] Univ Libre Bruxelles, Lab Expt Neurol, Brussels, Belgium	RWTH Aachen University; RWTH Aachen University; Helmholtz Association; Research Center Julich; RWTH Aachen University; University of London; University College London; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Medical University of Innsbruck; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Hospital Universitario La Paz; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Universite Libre de Bruxelles	Reetz, K (corresponding author), Rhein Westfal TH Aachen, Dept Neurol, D-52074 Aachen, Germany.	kreetz@ukaachen.de	nanetti, lorenzo/A-7361-2013; Mongelli, Alessia/AAL-5869-2021; Fichera, Mario/AAC-3207-2022; Castaldo, Anna/AAH-6390-2021; Reetz, Kathrin/H-9510-2012; Mariotti, Caterina/AAP-9425-2021; Palau, Francesc/A-9391-2014	nanetti, lorenzo/0000-0002-1952-4539; Mongelli, Alessia/0000-0003-4405-0643; Fichera, Mario/0000-0002-9609-3787; Castaldo, Anna/0000-0003-3459-3521; Reetz, Kathrin/0000-0002-9730-9228; Mariotti, Caterina/0000-0003-2405-3564; Dogan, Imis/0000-0002-6632-197X; Schols, Ludger/0000-0001-7774-5025; Palau, Francesc/0000-0002-8635-5421; Koutsis, Georgios/0000-0002-8980-8377; Solanky, Nita/0000-0001-8304-5543; Boesch, Sylvia/0000-0003-1657-7368	European Commission; Voyager Therapeutics; EuroAtaxia	European Commission(European CommissionEuropean Commission Joint Research Centre); Voyager Therapeutics; EuroAtaxia	European Commission, Voyager Therapeutics, and EuroAtaxia.	Anheim M, 2009, BRAIN, V132, P2688, DOI 10.1093/brain/awp211; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Dogan I, 2019, J NEUROL NEUROSUR PS, V90, P615, DOI 10.1136/jnnp-2018-318422; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Greiner Wolfgang, 2003, Eur J Health Econ, V4, P222, DOI 10.1007/s10198-003-0182-5; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; Hohenfeld C, 2019, CEREBELLUM, V18, P896, DOI 10.1007/s12311-019-01073-x; Jacobi H, 2013, CEREBELLUM, V12, P418, DOI 10.1007/s12311-012-0421-3; Metz G, 2013, BRAIN, V136, P259, DOI 10.1093/brain/aws309; Milne SC, 2018, CLIN REHABIL, V32, P630, DOI 10.1177/0269215517736903; Pandolfo M, 2006, METH MOLEC MED, V126, P197; Pandolfo M, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000415; Patel M, 2016, ANN CLIN TRANSL NEUR, V3, P684, DOI 10.1002/acn3.332; Pousset F, 2015, JAMA NEUROL, V72, P1334, DOI 10.1001/jamaneurol.2015.1855; Reetz K, 2018, NEUROLOGY, V91, pE917, DOI 10.1212/WNL.0000000000006121; Reetz K, 2017, LANCET NEUROL, V16, P954, DOI 10.1016/S1474-4422(16)30287-3; Reetz K, 2015, LANCET NEUROL, V14, P174, DOI 10.1016/S1474-4422(14)70321-7; Regner SR, 2012, J CHILD NEUROL, V27, P1152, DOI 10.1177/0883073812448462; Rummey C, 2019, NEUROL-GENET, V5, DOI 10.1212/NXG.0000000000000371; Rummey C, 2020, ECLINICALMEDICINE, V18, DOI 10.1016/j.eclinm.2019.11.006; Schmitz-Hubsch T, 2008, NEUROLOGY, V71, P486, DOI 10.1212/01.wnl.0000324863.76290.19; Schmitz-Hubsch T, 2010, NEUROLOGY, V74, P678, DOI 10.1212/WNL.0b013e3181d1a6c9; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Schwarz CJ, 2014, COURSE NOTES BEGINNI; Subramony SH, 2005, NEUROLOGY, V64, P1261, DOI 10.1212/01.WNL.0000156802.15466.79; Tai G, 2017, J NEUROL, V264, P1768, DOI 10.1007/s00415-017-8566-0; Tai G, 2015, J NEUROL NEUROSUR PS, V86, P660, DOI 10.1136/jnnp-2014-308022; TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	30	17	17	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					362	372		10.1016/S1474-4422(21)00027-2	http://dx.doi.org/10.1016/S1474-4422(21)00027-2		APR 2021	11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33770527	Green Submitted			2022-12-18	WOS:000717465200018
J	Obermann, M; Nagel, S; Ose, C; Sonuc, N; Scherag, A; Storch, P; Gaul, C; Boger, A; Kraya, T; Jansen, JP; Straube, A; Freilinger, T; Kaube, H; Jurgens, TP; Diener, HC; Katsarava, Z; Kleinschnitz, C; Holle, D				Obermann, Mark; Naegel, Steffen; Ose, Claudia; Sonuc, Niluefer; Scherag, Andre; Storch, Peter; Gaul, Charly; Boeger, Andreas; Kraya, Torsten; Jansen, Jan-Peter; Straube, Andreas; Freilinger, Tobias; Kaube, Holger; Juergens, Tim P.; Diener, Hans-Christoph; Katsarava, Zaza; Kleinschnitz, Christoph; Holle, Dagny			Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial	LANCET NEUROLOGY			English	Article							PATHOPHYSIOLOGY; GUIDELINES	Background Prednisone is commonly used for initial short-term therapy of episodic cluster headaches before preventive medication such as verapamil becomes effective, but this strategy has not been tested in large randomised trials. We aimed to access the safety and efficacy of this treatment approach. Methods This study was a multicentre, randomised, double-blind, placebo-controlled trial done in ten specialised headache centres in Germany. Patients with episodic cluster headaches who were aged between 18 and 65 years and within a current pain episode for not more than 30 days, received 100 mg oral prednisone for 5 days followed by tapering of 20 mg every 3 days, or matching placebo (17 days total exposure). All patients received oral verapamil for long-term prevention, starting with 40 mg three times daily and increasing to 120 mg three times daily by day 19; patients then continued with verapamil 120 mg throughout the study. Randomisation was computer-generated at a 1:1 ratio by use of an interactive web-response system, with stratification according to age, sex, and participating site. Participants, investigators, and those assessing outcomes were unaware of treatment allocation. The primary endpoint was the mean number of attacks within the first week of treatment with prednisone compared with placebo. An attack was defined as a unilateral headache with moderate-to-severe intensity of at least five on a numerical rating scale. All efficacy and safety analyses were done in the modified intention-to-treat (mITT) population, which consisted of all patients who had been randomly assigned to a trial group and received at least one dose of prednisone or placebo. The study was stopped early due to slow recruitment and expired funding. The study was registered with EudraCT (2011-006204-13) and with the German Clinical Trials Register (DRKS00004716). Findings Between April 5, 2013, and Jan 11, 2018, 118 patients were enrolled in the study. Two patients dropped out immediately and 116 patients were randomly assigned (57 patients to prednisone and 59 patients to placebo); 109 patients were included in the mITT analysis (53 patients assigned to prednisone and 56 patients assigned to placebo). Participants in the prednisone group had a mean of 7.1 (SD 6.5) attacks within the first week compared with 9.5 (6.0) attacks in the placebo group (difference -2.4 attacks, 95% CI -4.8 to -0.03; p=0.002). Two serious adverse events occurred, both in the placebo group (inguinal hernia and severe deterioration of cluster headache). A total of 270 adverse events were observed: in the prednisone group, 37 (71%) of 52 patients reported 135 adverse events (most common were headache, palpitations, dizziness, and nausea) and in the placebo group, 39 (71%) of 55 patients had 135 adverse events (most common were nausea, dizziness, and headache). Interpretation Oral prednisone was an effective short-term preventive therapy in our population of patients with episodic cluster headache. Our findings support the use of prednisone as a first-line treatment in parallel to the up-titration of verapamil, although the efficacy of prednisone alongside other long-term prevention requires additional investigation. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Obermann, Mark] Asklepios Hosp Sthildautal, Ctr Neurol, D-38723 Seesen, Germany; [Obermann, Mark; Naegel, Steffen; Katsarava, Zaza; Kleinschnitz, Christoph; Holle, Dagny] Univ Hosp Essen, Dept Neurol, Essen, Germany; [Ose, Claudia; Sonuc, Niluefer; Scherag, Andre; Diener, Hans-Christoph] Univ Hosp Essen, Ctr Clin Trials Essen ZKSE, Essen, Germany; [Naegel, Steffen; Kraya, Torsten] Martin Luther Univ Halle Wittenberg, Dept Neurol, Halle, Germany; [Scherag, Andre] Jena Univ Hosp, Inst Med Stat Comp & Data Sci, Jena, Germany; [Storch, Peter] Jena Univ Hosp, Dept Neurol, Jena, Germany; [Gaul, Charly] Migraine & Headache Clin, Konigstein, Germany; [Boeger, Andreas] Vitos Pain Ctr Kassel, Dept Pain Med, Kassel, Germany; [Kraya, Torsten] St Georg Hosp, Dept Neurol, Leipzig, Germany; [Jansen, Jan-Peter] Pain Ctr, Berlin, Germany; [Straube, Andreas] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany; [Freilinger, Tobias] Hosp Passau, Dept Neurol, Passau, Germany; [Freilinger, Tobias] Eberhard Karls Univ Tubingen, Hertie Inst Clin Brain Res, Ctr Neurol, Tubingen, Germany; [Kaube, Holger] Neurol & Headache Ctr, Munich, Germany; [Juergens, Tim P.] Univ Med Ctr Rostock, Dept Neurol, Rostock, Germany; [Katsarava, Zaza] Evangel Hosp Unna, Dept Neurol, Unna, Germany; [Katsarava, Zaza] EVEX Med Corp, Tbilisi, Georgia; [Katsarava, Zaza] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Moscow, Russia	University of Duisburg Essen; University of Duisburg Essen; Martin Luther University Halle Wittenberg; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Rostock; Sechenov First Moscow State Medical University	Obermann, M (corresponding author), Asklepios Hosp Sthildautal, Ctr Neurol, D-38723 Seesen, Germany.	mark.obermann@uni-due.de		Kleinschnitz, Christoph/0000-0002-1650-8875	German Federal Ministry of Education and Research (BMBF) [BMBF 01KG1205]	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The German Federal Ministry of Education and Research (BMBF) funded this study (BMBF 01KG1205). There was no commercial writing support. We thank Prof Heiner Wienecke and Dr Herbert Hirche for their invaluable service at the data monitoring safety board and continuous support for the study. Tremendous thanks go to Jan Burmeister, Susanne van Triel, and Michaela Berent for their relentless organisational and logistic effort for the study.	Ambrosini A, 2005, PAIN, V118, P92, DOI 10.1016/j.pain.2005.07.015; Antonaci F, 2005, CEPHALALGIA, V25, P290, DOI 10.1111/j.1468-2982.2004.00855.x; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; COUCH JR, 1978, HEADACHE, V18, P219, DOI 10.1111/j.1526-4610.1978.hed1804219.x; DEVOIZE JL, 1986, HEADACHE, V26, P126, DOI 10.1111/j.1526-4610.1986.hed2603126.x; DUVOISIN RC, 1972, J AMER MED ASSOC, V222, P1403, DOI 10.1001/jama.222.11.1403; FRIEDMAN AP, 1958, NEUROLOGY, V8, P653, DOI 10.1212/WNL.8.9.653; Gaul C, 2011, DTSCH ARZTEBL INT, V108, P543, DOI 10.3238/arztebl.2011.0543; Goadsby PJ, 2019, N ENGL J MED; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Hoffmann J, 2018, LANCET NEUROL, V17, P75, DOI 10.1016/S1474-4422(17)30405-2; Holle D, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-99; HORTON B T, 1952, J Lancet, V72, P92; JAMMES JL, 1975, DIS NERV SYST, V36, P375; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Leone M, 2000, NEUROLOGY, V54, P1382, DOI 10.1212/WNL.54.6.1382; Leroux E, 2011, LANCET NEUROL, V10, P891, DOI 10.1016/S1474-4422(11)70186-7; LIPTON RB, 1995, CEPHALALGIA, V15, P452, DOI 10.1046/j.1468-2982.1995.1506452.x; May A, 2006, EUR J NEUROL, V13, P1066, DOI 10.1111/j.1468-1331.2006.01566.x; May A, 2005, SCHMERZ, V19, P544, DOI 10.1007/s00482-005-0443-6; Meyer TD, 2001, DIAGNOSTICA, V47, P208, DOI 10.1026//0012-1924.47.4.208; Mir P, 2003, NEUROL SCI, V24, P318, DOI 10.1007/s10072-003-0182-3; NESBITT AD, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E2407; Page SJ, 2013, AM J OCCUP THER, V67, P154, DOI 10.5014/ajot.2013.006197; Richards RN, 2008, J CUTAN MED SURG, V12, P77, DOI 10.2310/7750.2008.07029; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Steiner TJ, 1997, CEPHALALGIA, V17, P673, DOI 10.1046/j.1468-2982.1997.1706673.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	29	17	17	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					29	37		10.1016/S1474-4422(20)30363-X	http://dx.doi.org/10.1016/S1474-4422(20)30363-X			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33245858				2022-12-18	WOS:000600831400021
J	Helbok, R; Chou, SHY; Beghi, E; Mainali, S; Frontera, J; Robertson, C; Fink, E; Schober, M; Moro, E; McNett, M; Bassetti, CL				Helbok, Raimund; Chou, Sherry Hsiang-Yi; Beghi, Ettore; Mainali, Shraddha; Frontera, Jennifer; Robertson, Courtney; Fink, Ericka; Schober, Michelle; Moro, Elena; McNett, Molly; Bassetti, Claudio L.		GCS-NeuroCOVID Consortium; EAN COVID Task Force	NeuroCOVID: it's time to join forces globally	LANCET NEUROLOGY			English	Letter									[Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; [Chou, Sherry Hsiang-Yi; Fink, Ericka] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Beghi, Ettore] Ist Ric Farmacol Mario Negri IRCCS, Dept Neurosci, Milan, Italy; [Mainali, Shraddha] Ohio State Univ, Coll Med, Dept Neurol, Columbus, OH 43210 USA; [McNett, Molly] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA; [Frontera, Jennifer] NYU, Grossman Sch Med, New York, NY USA; [Robertson, Courtney] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Schober, Michelle] Univ Utah, Sch Med, Salt Lake City, UT USA; [Moro, Elena] Grenoble Alpes Univ, Ctr Hosp Univ Grenoble, Div Neurol, Grenoble, France; [Bassetti, Claudio L.] Univ Bern, Dept Neurol, Inselspital, Bern, Switzerland	Medical University of Innsbruck; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; New York University; Johns Hopkins University; Utah System of Higher Education; University of Utah; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Bern	Helbok, R (corresponding author), Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria.	raimund.helbok@i-med.ac.at	Helbok, Raimund/AAA-8361-2021; Beghi, Ettore/AAA-7426-2020; Mainali, Shraddha/AAA-4670-2021; Fink, Ericka/AAU-9792-2021	Beghi, Ettore/0000-0003-2542-0469; Azzam, Ahmed Y/0000-0002-4256-0159; Bassetti, Claudio/0000-0002-4535-0245	National Institutes of Health, National Center for Advancing Translational Health [R21NS113037]; University of Pittsburgh Dean's Faculty Advancement Award	National Institutes of Health, National Center for Advancing Translational Health; University of Pittsburgh Dean's Faculty Advancement Award	SH-YC reports grants from the National Institutes of Health, National Center for Advancing Translational Health (R21NS113037), and the University of Pittsburgh Dean's Faculty Advancement Award. EB reports grants from the Italian Ministry of Health, Associazione IDIC 15, and the American ALS Association, and personal fees from Arvelle Therapeutics, outside the submitted work. SM reports grant support from the Center for Clinical and Translational Science at The Ohio State University, sponsored by a National Center for Advancing Translational Sciences Award (UL1TR002733), outside the submitted work. JF reports grants from the National Institutes of Health, National Institute on Aging, and the National Institute of Neurological Disorders and Stroke, outside the submitted work. EF reports grants from the National Institutes of Health, outside the submitted work. EM reports personal fees from Medtronic, Abbott, and Newronika, outside the submitted work. All other authors declare no competing interests.	[Anonymous], 2020, LANCET NEUROL, V19, P471, DOI 10.1016/S1474-4422(20)30142-3; Frontera J, 2020, NEUROCRIT CARE, V33, P25, DOI 10.1007/s12028-020-00995-3; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Moro E, 2020, EUR J NEUROL, V27, P1727, DOI 10.1111/ene.14407	5	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					805	+		10.1016/S1474-4422(20)30322-7	http://dx.doi.org/10.1016/S1474-4422(20)30322-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949535	Green Published, Bronze			2022-12-18	WOS:000581119100009
J	Norton, EJ; Bandyopadhyay, S; Moudgil-Joshi, J				Norton, Emma Jane; Bandyopadhyay, Soham; Moudgil-Joshi, Jigishaa		Neurol Neurosurg Interest Grp	Social media could address the gender gap in neurosurgery	LANCET NEUROLOGY			English	Letter									[Norton, Emma Jane] St Georges Univ London, London, England; [Bandyopadhyay, Soham] Univ Oxford, Div Med Sci, Oxford OX3 9DU, England; [Moudgil-Joshi, Jigishaa] Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland	St Georges University London; University of Oxford; University of Edinburgh	Bandyopadhyay, S (corresponding author), Univ Oxford, Div Med Sci, Oxford OX3 9DU, England.	nansiggroup@gmail.com		Bandyopadhyay, Soham/0000-0001-6553-3842; Bligh, Emily/0000-0002-3428-2697; , Jigi/0000-0002-6674-0912				Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878; Guraya SY, 2016, N AM J MED SCI, V8, P268, DOI 10.4103/1947-2714.187131; NHS digital, 2018, NARR NHS GEND DIV ME; Spetzler Robert F, 2011, Asian J Neurosurg, V6, P6, DOI 10.4103/1793-5482.85627	4	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					382	383		10.1016/S1474-4422(20)30080-6	http://dx.doi.org/10.1016/S1474-4422(20)30080-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32192575	Bronze			2022-12-18	WOS:000573045100024
J	[Anonymous]				[Anonymous]			Patient-reported outcomes in the spotlight	LANCET NEUROLOGY			English	Editorial Material																			0	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2019	18	11					981	981		10.1016/S1474-4422(19)30357-6	http://dx.doi.org/10.1016/S1474-4422(19)30357-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JC8HI	31609205	Bronze			2022-12-18	WOS:000489517000002
J	Launer, LJ				Launer, Lenore J.			Statistics on the burden of dementia: need for stronger data	LANCET NEUROLOGY			English	Editorial Material									[Launer, Lenore J.] NIA, Neuroepidemiol Sect, Intramural Res Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Launer, LJ (corresponding author), NIA, Neuroepidemiol Sect, Intramural Res Program, NIH, Bethesda, MD 20892 USA.	launerl@nia.nih.gov			Intramural NIH HHS [ZIA AG007280] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		GBD 2016 Dementia Collaborators, 2018, LANCET NEUROL; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Launer LJ, 2011, ALZHEIMERS DEMENT, V7, P10, DOI 10.1016/j.jalz.2010.11.003; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Satizabal C, 2016, NEW ENGL J MED, V375, P93, DOI 10.1056/NEJMc1604823; Schwarzinger M, 2018, LANCET PUBLIC HEALTH, V3, pE124, DOI 10.1016/S2468-2667(18)30022-7; Weuve J, 2015, ALZHEIMERS DEMENT, V11, P1098, DOI 10.1016/j.jalz.2015.06.1885; White LR, 2016, NEUROLOGY, V86, P1000, DOI 10.1212/WNL.0000000000002480	9	17	18	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					25	27		10.1016/S1474-4422(18)30456-3	http://dx.doi.org/10.1016/S1474-4422(18)30456-3			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30497966	hybrid, Green Accepted			2022-12-18	WOS:000453007700018
J	Mosley, RL; Gendelman, HE				Mosley, R. Lee; Gendelman, Howard E.			T cells and Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							AUTOIMMUNE-DISEASES; SYSTEM		[Mosley, R. Lee; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Gendelman, HE (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	hegendel@unmc.edu			Carol Swarts Neuroscience Research Laboratory; Frances and Louis Blumkin Foundation; Nebraska Neuroscience Alliance; DoD [W81XWH11-1-0700]; NIH [R01-NS034139, R01-NS070190]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070190] Funding Source: NIH RePORTER	Carol Swarts Neuroscience Research Laboratory; Frances and Louis Blumkin Foundation; Nebraska Neuroscience Alliance; DoD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We declare no competing interests. RLM and HEG are supported through the Carol Swarts Neuroscience Research Laboratory, the Frances and Louis Blumkin Foundation, and the Nebraska Neuroscience Alliance and by DoD grant W81XWH11-1-0700 and NIH grants R01-NS034139 and R01-NS070190.	Benner EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001376; Cebrian C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4633; Danke NA, 2004, J IMMUNOL, V172, P5967, DOI 10.4049/jimmunol.172.10.5967; De Virgilio A, 2016, AUTOIMMUN REV, V15, P1005, DOI 10.1016/j.autrev.2016.07.022; Gendelman HE, 2017, NPJ PARKINSONS DIS, V3, DOI 10.1038/s41531-017-0013-5; Mosley RL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009381; Pilli D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00652; Richards DM, 2016, TRENDS IMMUNOL, V37, P114, DOI 10.1016/j.it.2015.12.005; Saunders JAH, 2012, J NEUROIMMUNE PHARM, V7, P927, DOI 10.1007/s11481-012-9402-z; Schneeberger A, 2016, MOVEMENT DISORD, V31, P214, DOI 10.1002/mds.26377; Sulzer D, 2017, NATURE, V546, P656, DOI 10.1038/nature22815; Witoelar A, 2017, JAMA NEUROL, V74, P780, DOI 10.1001/jamaneurol.2017.0469	12	17	17	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					769	771		10.1016/S1474-4422(17)30276-4	http://dx.doi.org/10.1016/S1474-4422(17)30276-4			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28807669				2022-12-18	WOS:000410379900007
J	Burton, A				Burton, Adrian			Epilepsy and two evolving societies	LANCET NEUROLOGY			English	Editorial Material																			0	17	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					499	500		10.1016/S1474-4422(17)30164-3	http://dx.doi.org/10.1016/S1474-4422(17)30164-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4MH	28499853	Bronze			2022-12-18	WOS:000403208400010
J	Hachinski, V; Azarpazhooh, MR				Hachinski, Vladimir; Azarpazhooh, Mahmoud Reza			Stroke is a burdensome but preventable brain disorder	LANCET NEUROLOGY			English	Editorial Material							GLOBAL BURDEN; DISEASE		[Hachinski, Vladimir; Azarpazhooh, Mahmoud Reza] Univ Western Ontario, London Hlth Sci Ctr, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada; [Azarpazhooh, Mahmoud Reza] Mashhad Univ Med Sci, Ghaem Hosp, Dept Neurol, Mashhad, Iran	London Health Sciences Centre; Western University (University of Western Ontario); Mashhad University Medical Science	Hachinski, V (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada.	Vladimir.hachinski@lhsc.on.ca						[Anonymous], 2012, POL DECL HIGH LEV M; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Feigin VL, 2016, LANCET NEUROL; Hachinski V, 2015, STROKE, V46, P3039, DOI 10.1161/STROKEAHA.115.011237; Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Sawa GM, 2010, STROKE, V41, pe41; Sposato LA, 2015, JAMA NEUROL, V72, P1529, DOI 10.1001/jamaneurol.2015.2816; UN Department of Economic and Social Affairs Population Division, WORLD URB PROSP 2014	10	17	18	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2016	15	9					892	893		10.1016/S1474-4422(16)30120-X	http://dx.doi.org/10.1016/S1474-4422(16)30120-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1YY	27291522				2022-12-18	WOS:000381279200002
J	Salman, RAS; Kitchen, N; Thomson, J; Ganesan, V; Mallucci, C; Radatz, M				Salman, Rustam Al-Shahi; Kitchen, Neil; Thomson, Jennifer; Ganesan, Vijeya; Mallucci, Conor; Radatz, Matthias		Cavernoma Priority Setting Partner	Top ten research priorities for brain and spine cavernous malformations	LANCET NEUROLOGY			English	Letter							INDIVIDUAL PATIENT DATA; METAANALYSIS		[Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg, Edinburgh EH16 4SB, Midlothian, Scotland; [Kitchen, Neil] Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England; [Thomson, Jennifer] Chapel Allerton Hosp, Yorkshire Reg Clin Genet Serv, Harehills Lane, Leeds, W Yorkshire, England; [Ganesan, Vijeya] UCL, Inst Child Hlth, London, England; [Mallucci, Conor] Alder Hey Childrens NHS Fdn Trust, Eaton Rd,West Derby, Liverpool, Merseyside, England; [Radatz, Matthias] Royal Hallamshire Hosp, Natl Ctr Stereotact Radiosurg, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England	University of Edinburgh; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Chapel Allerton Hospital; University of London; University College London; Alder Hey Children's NHS Foundation Trust; University of Sheffield	Salman, RAS (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg, Edinburgh EH16 4SB, Midlothian, Scotland.	psp@cavernoma.org.uk		Al-Shahi Salman, Rustam/0000-0002-2108-9222; Mallucci, Conor/0000-0002-5509-0547	Medical Research Council [G108/613, G1002605] Funding Source: Medline; Chief Scientist Office [CZG/2/265] Funding Source: Medline; MRC [G108/613, G1002605] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Badhiwala JH, 2014, J NEUROSURG-SPINE, V21, P662, DOI 10.3171/2014.6.SPINE13949; Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1; Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8; Labouge P, 2007, LANCET NEUROL, V6, P237, DOI 10.1016/S1474-4422(07)70053-4; Rosenow F, 2013, EPILEPSIA, V54, P2025, DOI 10.1111/epi.12402	5	17	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					354	355		10.1016/S1474-4422(16)00039-9	http://dx.doi.org/10.1016/S1474-4422(16)00039-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26831334	Bronze, Green Submitted			2022-12-18	WOS:000371974000012
J	Bar-Or, A				Bar-Or, Amit			Multiple sclerosis and related disorders: evolving pathophysiologic insights	LANCET NEUROLOGY			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; FLUID		[Bar-Or, Amit] Montreal Neurol Inst, McGill Univ, Montreal, PQ H3A 2B4, Canada	McGill University	Bar-Or, A (corresponding author), Montreal Neurol Inst, McGill Univ, Montreal, PQ H3A 2B4, Canada.	amit.bar-or@mcgill.ca	Bar-Or, Amit/AIC-1416-2022					Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Farez MF, 2015, CELL, V162, P1338, DOI 10.1016/j.cell.2015.08.025; Kowarik MC, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0240-9; Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Wang Y, 2015, BRAIN, V138, P1223, DOI 10.1093/brain/awv046; Weller RO, 1996, BRAIN PATHOL, V6, P275, DOI 10.1111/j.1750-3639.1996.tb00855.x	9	17	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					9	11		10.1016/S1474-4422(15)00342-7	http://dx.doi.org/10.1016/S1474-4422(15)00342-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700897				2022-12-18	WOS:000366313900006
J	Forbes, SC; Willcocks, RJ; Rooney, WD; Walter, GA; Vandenborne, K				Forbes, Sean C.; Willcocks, Rebecca J.; Rooney, William D.; Walter, Glenn A.; Vandenborne, Krista			MRI quantifies neuromuscular disease progression	LANCET NEUROLOGY			English	Editorial Material							CLINICAL-TRIALS; MUSCLES; BOYS		[Forbes, Sean C.; Willcocks, Rebecca J.; Vandenborne, Krista] Univ Florida, Dept Phys Therapy, Gainesville, FL 32610 USA; [Walter, Glenn A.] Univ Florida, Dept Physiol, Gainesville, FL 32610 USA; [Rooney, William D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Oregon Health & Science University	Forbes, SC (corresponding author), Univ Florida, Dept Phys Therapy, Gainesville, FL 32610 USA.	kvandenb@phhp.ufl.edu			NIAMS NIH HHS [R01AR065943, R01AR056973, R01 AR056973, R01 AR065943] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056973, R01AR065943] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arpan I, 2014, NEUROLOGY, V83, P974, DOI 10.1212/WNL.0000000000000775; Azzabou N, 2014, PEDIATR RADIOL, V44, P1620, DOI 10.1007/s00247-014-3038-5; Bonati U, 2015, NEUROMUSCULAR DISORD, V25, P679, DOI 10.1016/j.nmd.2015.05.006; Forbes SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106435; Forbes SC, 2013, RADIOLOGY, V269, P198, DOI 10.1148/radiol.13121948; Hoffman EP, 2013, DISCOV MED, V16, P233; Li K, 2014, NMR BIOMED, V27, P1070, DOI 10.1002/nbm.3159; Loughran T, 2015, RADIOLOGY, V275, P570, DOI 10.1148/radiol.14141191; Machann J, 2000, MAGN RESON IMAGING, V18, P189, DOI 10.1016/S0730-725X(99)00132-0; Morrow JM, 2015, LANCET NEUROL; Rooney WD, 2011, P 19 ANN M INT SOC M, V19, P138; Triplett WT, 2014, MAGN RESON MED, V72, P8, DOI 10.1002/mrm.24917; Willcocks RJ, 2014, NEUROMUSCULAR DISORD, V24, P393, DOI 10.1016/j.nmd.2013.12.012; Willis TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070993	14	17	17	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					26	28		10.1016/S1474-4422(15)00320-8	http://dx.doi.org/10.1016/S1474-4422(15)00320-8			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26549781	Green Accepted, hybrid			2022-12-18	WOS:000366313900015
J	Antonini, A; Tinazzi, M				Antonini, Angelo; Tinazzi, Michele			Targeting pain in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; NONMOTOR SYMPTOMS; DOUBLE-BLIND; ROTIGOTINE		[Antonini, Angelo] IRCCS Hosp San Camillo, Parkinson & Movement Disorders Unit, Venice, Italy; [Tinazzi, Michele] Univ Verona, Dept Neurol & Movement Sci, I-37100 Verona, Italy	IRCCS Ospedale San Camillo; University of Verona	Antonini, A (corresponding author), IRCCS Hosp San Camillo, Parkinson & Movement Disorders Unit, Venice, Italy.	angelo3000@yahoo.com	TINAZZI, Michele/J-7134-2018; Antonini, Angelo/H-9726-2019	TINAZZI, Michele/0000-0002-2370-7063; Antonini, Angelo/0000-0003-1040-2807				Ahmedzai SH, 2015, SUPPORT CARE CANCER, V23, P823, DOI 10.1007/s00520-014-2435-5; Antonini A, 2015, EUR J NEUROL, V22, P1402, DOI 10.1111/ene.12757; Antonini A, 2013, NEUROLOGY, V80, P784, DOI 10.1212/WNL.0b013e318285c16d; Antonini A, 2012, J NEUROL, V259, P2621, DOI 10.1007/s00415-012-6557-8; Barone P, 2010, LANCET NEUROL, V9, P573, DOI 10.1016/S1474-4422(10)70106-X; Chaudhuri KR, 2015, MOVEMENT DISORD, V30, P1623, DOI 10.1002/mds.26270; Chaudhuri KR, 2013, PARKINSONISM RELAT D, V19, P660, DOI 10.1016/j.parkreldis.2013.02.018; Defazio G, 2013, EUR J NEUROL, V20, P1517, DOI 10.1111/ene.12260; Defazio G, 2008, ARCH NEUROL-CHICAGO, V65, P1191, DOI 10.1001/archneurol.2008.2; Tinazzi M, 2008, PAIN, V136, P117, DOI 10.1016/j.pain.2007.06.022; Trenkwalder C, 2015, LANCET NEUROL	11	17	18	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1144	1145		10.1016/S1474-4422(15)00286-0	http://dx.doi.org/10.1016/S1474-4422(15)00286-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26494525				2022-12-18	WOS:000364855100002
J	Dennis, M; Graham, C; Smith, J; Forbes, J; Sandercock, P				Dennis, Martin; Graham, Catriona; Smith, Joel; Forbes, John; Sandercock, Peter		CLOTS Clots Legs sTockings Stroke	Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial	LANCET NEUROLOGY			English	Article							DEEP-VEIN THROMBOSIS; SURVIVAL; REDUCE; RISK	Background The results of the CLOTS 3 trial showed that intermittent pneumatic compression (IPC) reduced the risk of deep vein thrombosis and improved survival in immobile patients with stroke. IPC is now being widely used in stroke units. Here we describe the disability, living circumstances, quality of life, and hospital costs of patients in CLOTS 3. Methods In CLOTS 3, a parallel group trial in 94 UK hospitals, immobile patients with stroke from days 0 to 3 of admission were assigned with a computer-generated allocation sequence in a 1:1 ratio to IPC or no IPC through a central randomisation system. We followed up patients at about 6 months with postal or telephone questionnaire to assess the secondary endpoints: disability (Oxford Handicap Scale [OHS]), living circumstances, health-related quality of life (EQ5D-3L), and hospital costs (based on use of IPC and length of hospital stay). Patients and carers who completed the postal questionnaires were not masked to treatment allocation, but telephone follow-up in non-responders was masked. All analyses were by intention to treat. This trial is registered, number ISRCTN93529999. Findings Between Dec 8, 2008, and Sept 6, 2012, we enrolled 2876 patients, with 1438 in each group. Despite the previously reported reduction in the risk of proximal deep vein thrombosis at 30 days (primary endpoint), there were no significant differences in disability (OHS 0-2 vs 3-6, adjusted odds ratio [OR] 0.98, 95% CI 0.80 to 1.19, p=0. 83; adjusted ordinal analysis common OR 0.97, 95% CI 0.86 to 1.11), living circumstances (institutional care vs not; adjusted OR 1.11, 95% CI 0.89 to 1.37; p=0. 358), or health-related quality of life (median utility value 0.26, IQR -0.07 to 0.66 with IPC, and 0.27, -0.06 to 0.64, with no IPC; p=0.952). The estimated cost of IPC was 64.10 pound per patient (SD 28.3). The direct costs of preventing a deep vein thrombosis and death were 1282 pound (95% CI 785 to 3077) and 2756 pound (1346 to not estimable), respectively, with IPC. Hospital costs increased by 451 pound with IPC compared with no IPC because of a longer stay in hospital (mean 44-5 days [SD 37.6] vs 42.8 days [37.2]; mean difference 1.8 days, 95% CI -1.0 to 4.5). By 6 months, despite an increase in survival (IPC 152.5 days [SD 60.6] vs no IPC 148.1 days [64.3]; mean difference 4.5 days, 95% CI -0.2 to 9.1), there was a non-significant increase in quality-adjusted survival associated with IPC (IPC 27.6 days [SD 40.6] vs no IPC 26.7 days [39.6]; mean difference 0-9 days, 95% CI -2.1 to 3.9). Interpretation IPC is inexpensive, prevents deep vein thrombosis, improves survival but not functional outcomes, and does not lead to a significant gain in quality-adjusted survival. When deciding whether to treat patients with IPC, cinicians need to take into account all these potential effects.	[Dennis, Martin] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland	University of Edinburgh	Dennis, M (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg FU303h,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	martin.dennis@ed.ac.uk	Piechowski-Jozwiak, Bartlomiej/HCI-4426-2022; Macleod, Malcolm Robert/B-2052-2010; Wardlaw, Joanna M/Y-3456-2019	Macleod, Malcolm Robert/0000-0001-9187-9839; Wardlaw, Joanna M/0000-0002-9812-6642; Cranswick, Gina/0000-0002-4479-6034; Tyrrell, Pippa/0000-0001-9609-1231; Piechowski-Jozwiak, Bartlomiej/0000-0001-7814-0028; Kwan, Joseph/0000-0003-4635-3322; PIECHOWSKI-JOZWIAK, BARTLOMIEJ/0000-0002-1886-9949	University of Edinburgh; NHS Lothian; Chief Scientist Office of the Scottish Government [CZH/4/417]; NIHR HTA Programme; NIHR; Scottish Stroke Research network; NHS Research Scotland; National Institute for Health Research [08/14/03] Funding Source: researchfish; Chief Scientist Office [CZG/2/378, CZH/4/417] Funding Source: researchfish	University of Edinburgh; NHS Lothian; Chief Scientist Office of the Scottish Government; NIHR HTA Programme; NIHR(National Institute for Health Research (NIHR)); Scottish Stroke Research network; NHS Research Scotland; National Institute for Health Research(National Institute for Health Research (NIHR)); Chief Scientist Office	The study was jointly sponsored by the University of Edinburgh and NHS Lothian. The start-up phase of the trial (December, 2008, to March, 2010) was funded by the Chief Scientist Office of the Scottish Government (reference CZH/4/417). The main phase of the trial was funded by the NIHR HTA Programme (reference 08/14/03). Covidien lent its Kendall Express Sequential Compression System Controllers to our 105 centres and donated supplies of their sleeves. It also provided logistical help in keeping our centres supplied with sleeves and training materials relevant to the use of their devices. Recruitment and follow-up was supported by the NIHR funded UK Stroke research network and the Scottish Stroke Research network, which was supported by NHS Research Scotland. A full description of the trial will be published in the HTA journal series. The views and opinions expressed in this report are those of the authors and do not necessarily reflect those of the UK Department of Health or the Chief Scientist Office of the Scottish Government.	BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; Dennis M, 2011, J THROMB HAEMOST, V9, P2193, DOI 10.1111/j.1538-7836.2011.04486.x; Dennis M, 2013, LANCET, V382, P516, DOI 10.1016/S0140-6736(13)61050-8; Dennis M, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-66; Dennis M, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-26; Dennis M, 2011, J NEUROL NEUROSUR PS, V82, P1067, DOI 10.1136/jnnp.2010.235945; DoH, 2013, NHS REF COSTS 2011 2; Dolan P, 1995, SOCIAL TARIFF EUROQO; Kelly J, 2001, STROKE, V32, P262, DOI 10.1161/01.STR.32.1.262; Lacut K, 2005, NEUROLOGY, V65, P865, DOI 10.1212/01.wnl.0000176073.80532.a2; Mihaylova B, 2011, HEALTH ECON, V20, P897, DOI 10.1002/hec.1653; MIYAMOTO JM, 1988, J EXP PSYCHOL GEN, V117, P3, DOI 10.1037/0096-3445.117.1.3; Naccarato M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001922.pub3; NAO, 2005, RED BRAIN DAM FAST A; NHS Improving Quality, IPC SLEEV FAQ 4 29 0; PRASAD BK, 1982, AGE AGEING, V11, P42, DOI 10.1093/ageing/11.1.42; Slot KB, 2008, BRIT MED J, V336, P376, DOI 10.1136/bmj.39456.688333.BE; Szende A, 2007, EQ 5D VALUE SETS INV; Westendorp WF, 2012, STROKE, V43, pE113, DOI 10.1161/STROKEAHA.112.671420; Woodman K., 2013, PEER SUPP BREASTF GU; Zellner A, 1962, J AM STAT SOC, V57, P500	23	17	18	3	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2014	13	12					1186	1192		10.1016/S1474-4422(14)70258-3	http://dx.doi.org/10.1016/S1474-4422(14)70258-3			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU5XG	25453458	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000345676300008
J	Sharshar, T; Bozza, F; Chretien, F				Sharshar, Tarek; Bozza, Fernando; Chretien, Fabrice			Neuropathological processes in sepsis Comment	LANCET NEUROLOGY			English	Editorial Material							SEPTIC SHOCK; DYSFUNCTION; DEATH		[Sharshar, Tarek] Univ Versailles, Raymond Poincare Hosp, AP HP, F-92380 Paris, France; [Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Dept Histopathol & Anim Models, Paris, France; [Bozza, Fernando] Fundacao Oswaldo Cruz, Evandro Chagas Inst, Rio De Janeiro, Brazil; [Bozza, Fernando] DOr Inst Res & Educ, Rio De Janeiro, Brazil	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Fundacao Oswaldo Cruz; Instituto Evandro Chagas; IDOR - Instituto D'Or de Ensino e Pesquisa	Sharshar, T (corresponding author), Univ Versailles, Raymond Poincare Hosp, AP HP, F-92380 Paris, France.	tarek.sharshar@rpc.aphp.fr	Chretien, fabrice B/D-4035-2018; Sharshar, Tarek/ABF-4117-2021; Bozza, Fernando A/A-2618-2013	Chretien, fabrice B/0000-0002-2794-1383; Bozza, Fernando A/0000-0003-4878-0256				Adam N, 2013, EXPERT REV ANTI-INFE, V11, P211, DOI [10.1586/ERI.12.159, 10.1586/eri.12.159]; d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899; Shah FA, 2013, AM J RESP CRIT CARE, V188, P586, DOI 10.1164/rccm.201212-2154OC; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4; Sharshar T, 2011, CRIT CARE MED, V39, P1960, DOI 10.1097/CCM.0b013e31821b843b; van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7; Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1	11	17	17	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					534	536		10.1016/S1474-4422(14)70064-X	http://dx.doi.org/10.1016/S1474-4422(14)70064-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK	24849853				2022-12-18	WOS:000337212700007
J	French, JA				French, Jacqueline A.			P-glycoprotein expression and antiepileptic drug resistance	LANCET NEUROLOGY			English	Editorial Material							PHARMACORESISTANCE		NYU, Comprehens Epilepsy Ctr, New York, NY 10016 USA	New York University	French, JA (corresponding author), NYU, Comprehens Epilepsy Ctr, 223 East 34th St, New York, NY 10016 USA.	Jacqueline.French@nyumc.org	French, Jacqueline/G-6795-2013	French, Jacqueline/0000-0003-2242-8027				Brodie MJ, 2013, EPILEPSIA, V54, P194, DOI 10.1111/j.1528-1167.2012.03722.x; Feldmann M, 2013, LANCET NEUROL, V12, P777, DOI 10.1016/S1474-4422(13)70109-1; Haerian BS, 2010, SEIZURE-EUR J EPILEP, V19, P339, DOI 10.1016/j.seizure.2010.05.004; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Rogawski MA, 2013, EPILEPSIA, V54, P33, DOI 10.1111/epi.12182; Srivastava AK, 2013, EPILEPSY RES, V104, P26, DOI 10.1016/j.eplepsyres.2012.10.003	6	17	18	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2013	12	8					732	733		10.1016/S1474-4422(13)70128-5	http://dx.doi.org/10.1016/S1474-4422(13)70128-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195GP	23786895				2022-12-18	WOS:000322690600005
J	Marion, DW				Marion, Donald W.			Decompressive craniectomy in diffuse traumatic brain injury	LANCET NEUROLOGY			English	Editorial Material									Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Marion, DW (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA.	donald.marion@us.army.mil	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702				Arikan R, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Schreckinger M, 2009, NEUROCRIT CARE, V11, P427, DOI 10.1007/s12028-009-9256-2	8	17	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					497	498		10.1016/S1474-4422(11)70098-9	http://dx.doi.org/10.1016/S1474-4422(11)70098-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21601156				2022-12-18	WOS:000291376100005
J	Lannfelt, L; Blennow, K; Zetterberg, H				Lannfelt, L.; Blennow, K.; Zetterberg, H.			Safety, efficacy, and biomarker findings of PBT2 in targeting A beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008)	LANCET NEUROLOGY			English	Correction																		Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4	1	17	17	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					981	981		10.1016/S1474-4422(08)70167-4	http://dx.doi.org/10.1016/S1474-4422(08)70167-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC					2022-12-18	WOS:000271309600008
J	Thompson, AJ				Thompson, Alan J.			Multiple sclerosis-a global disorder and still poorly managed	LANCET NEUROLOGY			English	Editorial Material									UCL, Inst Neurol, London WC1N 3BG, England	University of London; University College London	Thompson, AJ (corresponding author), UCL, Inst Neurol, Queen Sq, London WC1N 3BG, England.		Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496				*NIH CLIN EXC, 2004, CLIN GUID ROYAL COLL, V8; Wade D, 2008, NATL AUDIT SERVICES; *WHO MULT SCLER IN, 2006, NEUR DIS PUBL HLTH C; World Health Organization, 2008, ATL MULT SCLER RES W; 2008, LANCET NEUROL, V7, P467	5	17	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1078	1079		10.1016/S1474-4422(08)70246-1	http://dx.doi.org/10.1016/S1474-4422(08)70246-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	19007729				2022-12-18	WOS:000261396000005
J	Gauthier, S; Dubois, B; Feldman, H; Scheltens, P				Gauthier, Serge; Dubois, Bruno; Feldman, Howard; Scheltens, Philip			Revised research diagnostic criteria for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; TRIAL		[Gauthier, Serge] Douglas Mental Hlth Res Inst, McGill Ctr Studies Aging, Montreal, PQ, Canada; [Dubois, Bruno] Univ Paris 06, Paris, France; [Dubois, Bruno] Hop La Pitie Salpetriere, Paris, France; [Feldman, Howard] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada; [Feldman, Howard] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Scheltens, Philip] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Scheltens, Philip] Vrije Univ Amsterdam Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands	McGill University; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of British Columbia; Vancouver Coastal Health Research Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Gauthier, S (corresponding author), Douglas Mental Hlth Res Inst, McGill Ctr Studies Aging, Montreal, PQ, Canada.	serge.gauthier@mcgill.ca	Scheltens, Philip/AAL-9631-2020; Scheltens, Philip/E-1205-2012	Scheltens, Philip/0000-0002-1046-6408; Feldman, Howard/0000-0002-9258-4538				Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Galasko DR, 2005, NEUROLOGY, V64, pA144; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Rowe CC, 2008, LANCET NEUROL, V7, P129, DOI 10.1016/S1474-4422(08)70001-2; Salloway S, 2004, NEUROLOGY, V63, P651, DOI 10.1212/01.WNL.0000134664.80320.92; Van der Linden M, 2004, EVALUATION TROUBLES, P25; Vellas B, 2007, LANCET NEUROL, V6, P56, DOI 10.1016/S1474-4422(06)70677-9	8	17	19	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					668	670		10.1016/S1474-4422(08)70146-7	http://dx.doi.org/10.1016/S1474-4422(08)70146-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18635012				2022-12-18	WOS:000257969700005
J	Schellinger, PD				Schellinger, Peter D.			EPITHET: failed chance or new hope?	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; THROMBOLYTIC THERAPY; DESMOTEPLASE; DIFFUSION; MISMATCH		Univ Erlangen Nurnberg, Dept Neurol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Schellinger, PD (corresponding author), Univ Erlangen Nurnberg, Dept Neurol, D-91054 Erlangen, Germany.	peter.schellinger@uk-erlangen.de						Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; DAVIS SM, 2008, LANCET NEUROL   0222; *ECASS 3, EUR COOP AC STROK ST; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; GAUDINSKI MR, IN PRESS STROKE; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Kane I, 2007, J NEUROL NEUROSUR PS, V78, P485, DOI 10.1136/jnnp.2006.100347; Kane I, 2007, STROKE, V38, P3158, DOI 10.1161/STROKEAHA.107.483842; Schellinger PD, 2001, CRIT CARE MED, V29, P1812, DOI 10.1097/00003246-200109000-00027; Schellinger PD, 2003, STROKE, V34, P575, DOI 10.1161/01.STR.0000051504.10095.9C; Schellinger PD, 2007, STROKE, V38, P2640, DOI 10.1161/STROKEAHA.107.483255	11	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2008	7	4					286	287		10.1016/S1474-4422(08)70045-0	http://dx.doi.org/10.1016/S1474-4422(08)70045-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	285PF	18296123				2022-12-18	WOS:000254788000002
J	Janjua, N; Brisman, JL				Janjua, Nazli; Brisman, Jonathan L.			Endovascular treatment of acute ischaemic stroke	LANCET NEUROLOGY			English	Review							TISSUE-PLASMINOGEN-ACTIVATOR; BASILAR ARTERY-OCCLUSION; MECHANICAL EMBOLUS REMOVAL; MIDDLE CEREBRAL-ARTERY; INTRAARTERIAL THROMBOLYSIS; FIBRINOLYTIC THERAPY; ANGIOPLASTY; RECANALIZATION; THROMBOSIS; DIFFUSION	The emphasis of treatments for acute ischaemic stroke during the past two decades has been on revascularisation. Endovascular treatment is a promising alternative for patients who are ineligible for standard intravenous thrombolytic therapy; however, its use is limited by the few randomised trials reported and the small number of practising neurointerventionalists. Although data are still being collected, important progress has been made. In this Review, we summarise the findings of the major clinical trials of endovascular treatment, and show that endovascular treatment of acute ischaemic stroke is a therapeutic option for patients who are disqualified from or do not improve on treatment with intravenous alteplase. Moreover, the American Heart Association has expanded its guidelines to include endovascular stroke therapies as a treatment option.	[Janjua, Nazli] Long Isl Coll Hosp, Dept Neurol, Brooklyn, NY 11201 USA; [Janjua, Nazli] SUNY, Hlth Sci Ctr, Brooklyn, NY USA; [Brisman, Jonathan L.] Winthrop Univ Hosp, Dept Cerebrovasc & Endovasc Neurosurg, Mineola, NY USA	Long Island College Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; SUNY Maritime College; Winthrop University Hospital	Janjua, N (corresponding author), Long Isl Coll Hosp, Dept Neurol, 339 Hicks St, Brooklyn, NY 11201 USA.	NJanjua@chpnet.org						*ACGME, PROGR REQ RES ED END; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; Bendszus M, 1998, NEURORADIOLOGY, V40, P54, DOI 10.1007/s002340050540; Berlis A, 2004, STROKE, V35, P1112, DOI 10.1161/01.STR.0000124126.17508.d3; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bourekas EC, 2005, NEUROCRIT CARE, V2, P179, DOI 10.1385/NCC:2:2:179; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; Broderick J, 2004, STROKE, V35, P904, DOI 10.1161/01.STR.0000121641.77121.98; Broderick JP, 2007, STROKE, V38, P2127, DOI 10.1161/STROKEAHA.107.483131; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BUTCHER KS, 2003, AM STROK ASS 28 INT; Christou I, 2001, INT ANGIOL, V20, P208; Cognard C, 2000, CHILD NERV SYST, V16, P496, DOI 10.1007/s003819900197; Davalos A, 2004, NEUROLOGY, V62, P2187, DOI 10.1212/01.WNL.0000130570.41127.EA; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; Endo S, 1998, AM J NEURORADIOL, V19, P1169; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; Gobin YP, 2004, STROKE, V35, P2848, DOI 10.1161/01.STR.0000147718.12954.60; Golomb MR, 2003, J CHILD NEUROL, V18, P420, DOI 10.1177/08830738030180060301; Gonner F, 1998, STROKE, V29, P1894, DOI 10.1161/01.STR.29.9.1894; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Gruber A, 2000, NEUROLOGY, V54, P1684, DOI 10.1212/WNL.54.8.1684; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 2007, CEREBROVASC DIS, V23, P1; Jahan R, 1999, AM J NEURORADIOL, V20, P1291; JANJUA N, 2005, NEUROCRIT CARE SOC, V2; Janjua N, 2007, STROKE, V38, P1850, DOI 10.1161/STROKEAHA.106.473983; JANSEN O, 1995, AM J NEURORADIOL, V16, P1977; Johnson SC, 2005, NEUROLOGY, V64, P654; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; KIDWELL C, 2007, STROKE, V38; Kirton A, 2003, PEDIATRICS, V112, pE248, DOI 10.1542/peds.112.3.e248; Labiche LA, 2003, J NEUROIMAGING, V13, P28, DOI 10.1177/1051228402239714; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Mahon BR, 2003, AM J NEURORADIOL, V24, P534; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Ostrem JL, 2004, STROKE, V35, pE30, DOI 10.1161/01.STR.0000113783.45745.BE; Prosser J, 2005, STROKE, V36, P1700, DOI 10.1161/01.STR.0000173407.40773.17; Qureshi AI, 2007, LANCET NEUROL, V6, P816, DOI 10.1016/S1474-4422(07)70217-X; Qureshi AI, 2007, J NEUROIMAGING, V17, P124, DOI 10.1111/j.1552-6569.2007.00099.x; Rubiera M, 2006, STROKE, V37, P2301, DOI 10.1161/01.STR.0000237070.80133.1d; Smith WS, 2006, AM J NEURORADIOL, V27, P1177; Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d; Sungarian A, 2003, PEDIATR NEUROSURG, V38, P16, DOI 10.1159/000067557; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WARACH S, 2006, AM STROK ASS 31 INT; Wijdicks EFM, 1997, MAYO CLIN PROC, V72, P1005, DOI 10.4065/72.11.1005; Zangerle A, 2007, NEUROLOGY, V68, P39, DOI 10.1212/01.wnl.0000250341.38014.d2; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; Zijlstra F, 1999, NEW ENGL J MED, V341, P1413, DOI 10.1056/NEJM199911043411901	54	17	17	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2007	6	12					1086	1093		10.1016/S1474-4422(07)70269-7	http://dx.doi.org/10.1016/S1474-4422(07)70269-7			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239UI	17974482				2022-12-18	WOS:000251543100015
J	Lang, AE				Lang, Anthony E.			Neuroprotection in Parkinson's disease: and now for something completely different?	LANCET NEUROLOGY			English	Editorial Material							PROGRESSION; LEVODOPA; DEPRENYL; TRIAL; NEED		Univ Toronto, Toronto, ON, Canada	University of Toronto	Lang, AE (corresponding author), Univ Toronto, Toronto, ON, Canada.	lang@uhnres.utoronto.ca	Lang, Anthony/ABF-8114-2021	Lang, Anthony/0000-0003-1229-3667				Fahn S, 2004, NEW ENGL J MED, V351, P2498; Holloway R, 2000, JAMA-J AM MED ASSOC, V284, P1931, DOI 10.1001/jama.284.15.1931; KIEBUTZ K, 2006, NEUROLOGY S4, V66, pSS50; Olanow CW, 2006, LANCET NEUROL, V5, P1013, DOI 10.1016/S1474-4422(06)70602-0; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; Palhagen S, 2006, NEUROLOGY, V66, P1200, DOI 10.1212/01.wnl.0000204007.46190.54; Rascol O, 2002, MOVEMENT DISORD, V17, pS39; Ravina B, 2006, NEUROLOGY, V66, P664; Ravina BM, 2003, NEUROLOGY, V60, P1234, DOI 10.1212/01.WNL.0000058760.13152.1A; Schapira AHV, 2006, ANN NEUROL, V59, P559, DOI 10.1002/ana.20789; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; Shoulson I., 2006, NEUROLOGY, V67, P185; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; Waldmeier P, 2006, BIOCHEM PHARMACOL, V72, P1197, DOI 10.1016/j.bcp.2006.06.031; Whone AL, 2003, ANN NEUROL, V54, P93, DOI 10.1002/ana.10609	16	17	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					990	991		10.1016/S1474-4422(06)70605-6	http://dx.doi.org/10.1016/S1474-4422(06)70605-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	17110271				2022-12-18	WOS:000242266100002
J	Hofman, A; de Jong, PTVM; van Duijn, CM; Breteler, MMB				Hofman, Albert; de Jong, Paulus T. V. M.; van Duijn, Cornelia M.; Breteler, Monique M. B.			Epidemiology of neurological diseases in elderly people: what did we learn from the Rotterdam Study?	LANCET NEUROLOGY			English	Article							WHITE-MATTER LESIONS; SILENT BRAIN INFARCTS; AGE-RELATED MACULOPATHY; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE-A2; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRECURSOR PROTEIN GENE; FACTOR-H POLYMORPHISM; COGNITIVE FUNCTION; ALZHEIMERS-DISEASE; DIETARY ANTIOXIDANTS	The Rotterdam Study is a prospective cohort study that has been ongoing since 1990 in the city of Rotterdam, the Netherlands, among 7983 people aged 55 years or older. One part of the study targets neurological diseases, others deal with cardiovascular, ophthalmological, and endocrine diseases. The findings of the Rotterdam Study have been presented in some 500 research articles and reports. Here we give the reasons for the study and its design, and present a summary of what has been learned about the frequencies and causes of neurological diseases. Perhaps the most important message from the Rotterdam Study is the great potential for prevention or postponement of neurological diseases in elderly people. The time for preventive nihilism is over.	Erasmus MC, Dept Epidemiol Biostat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Hofman, A (corresponding author), Erasmus MC, Dept Epidemiol Biostat, Rotterdam, Netherlands.	a.hofman@erasmusmc.nl	Breteler, Monique M.B./J-5058-2014	Breteler, Monique M.B./0000-0002-0626-9305; Van Duijn, Cornelia/0000-0002-2374-9204				ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; Barendregt JJ, 2005, EUR J EPIDEMIOL, V20, P827, DOI 10.1007/s10654-005-2227-9; Bots ML, 1996, STROKE, V27, P1499, DOI 10.1161/01.STR.27.9.1499; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Bots ML, 1997, STROKE, V28, P768, DOI 10.1161/01.STR.28.4.768; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; de Groot JC, 2000, ARCH GEN PSYCHIAT, V57, P1071, DOI 10.1001/archpsyc.57.11.1071; de Groot JC, 2000, ANN NEUROL, V47, P145; de Groot JC, 2002, ANN NEUROL, V52, P335, DOI 10.1002/ana.10294; de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE; de Leeuw FE, 1999, ANN NEUROL, V46, P827, DOI 10.1002/1531-8249(199912)46:6<827::AID-ANA4>3.0.CO;2-H; den Heijer T, 2003, ARCH NEUROL-CHICAGO, V60, P213, DOI 10.1001/archneur.60.2.213; deRijk MC, 1995, NEUROLOGY, V45, P2143, DOI 10.1212/WNL.45.12.2143; deRijk MC, 1997, ARCH NEUROL-CHICAGO, V54, P762, DOI 10.1001/archneur.1997.00550180070015; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Engelhart MJ, 2004, ARCH NEUROL-CHICAGO, V61, P668, DOI 10.1001/archneur.61.5.668; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Geerlings MI, 2003, ANN NEUROL, V53, P607, DOI 10.1002/ana.10521; Geerlings MI, 2001, JAMA-J AM MED ASSOC, V285, P1475, DOI 10.1001/jama.285.11.1475; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; Hollander M, 2002, CIRCULATION, V105, P2872, DOI 10.1161/01.CIR.0000018650.58984.75; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; IKRAM MK, IN PRESS AM J EPIDEM; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Jama JW, 1996, AM J EPIDEMIOL, V144, P275, DOI 10.1093/oxfordjournals.aje.a008922; Kalmijn S, 1999, AM J EPIDEMIOL, V150, P283, DOI 10.1093/oxfordjournals.aje.a010000; Kalmijn S, 2000, J CLIN ENDOCR METAB, V85, P4551, DOI 10.1210/jc.85.12.4551; Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kraepelin Emil, 1987, MEMOIRS; Launer LJ, 2000, NEUROLOGY, V54, pS1; Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3; Oei HHS, 2005, CIRCULATION, V111, P570, DOI 10.1161/01.CIR.0000154553.12214.CD; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Peto R, 1997, BRIT MED J, V315, P1030, DOI 10.1136/bmj.315.7115.1030; Prins ND, 2004, ARCH NEUROL-CHICAGO, V61, P1531, DOI 10.1001/archneur.61.10.1531; Prins ND, 2002, NEUROLOGY, V59, P1375, DOI 10.1212/01.WNL.0000032494.05619.93; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Tiemeier H, 2004, ARCH GEN PSYCHIAT, V61, P369, DOI 10.1001/archpsyc.61.4.369; van der Meer IM, 2002, STROKE, V33, P2750, DOI 10.1161/01.STR.0000044168.00485.02; van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101; van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519; van Oijen M, 2006, ANN NEUROL, V59, P139, DOI 10.1002/ana.20721; VANDUIJN CM, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91611-W; Vermeer SE, 2002, STROKE, V33, P21, DOI 10.1161/hs0102.101629; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Vermeer SE, 2003, STROKE, V34, P392, DOI 10.1161/01.STR.0000052631.98405.15; Vermeer SE, 2002, ANN NEUROL, V51, P285, DOI 10.1002/ana.10111; VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205; Vliegenthart R, 2002, STROKE, V33, P462, DOI 10.1161/hs0202.103071; Voko Z, 2003, NEUROLOGY, V61, P1273, DOI 10.1212/01.WNL.0000090458.67821.A3	65	17	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					545	550		10.1016/S1474-4422(06)70473-2	http://dx.doi.org/10.1016/S1474-4422(06)70473-2			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16713926				2022-12-18	WOS:000237906000023
J	Penn, RD; Dalvi, A; Slevin, J; Young, B; Gash, D; Gerhardt, G; Hutchinson, M				Penn, RD; Dalvi, A; Slevin, J; Young, B; Gash, D; Gerhardt, G; Hutchinson, M			GDNF in treatment of Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							NEUROTROPHIC FACTOR		Univ Chicago, Chicago, IL 60637 USA; Univ Kentucky, Lexington, KY 40506 USA; NYU, New York, NY USA	University of Chicago; University of Kentucky; New York University	Penn, RD (corresponding author), Univ Chicago, Chicago, IL 60637 USA.	rpenn@surgery.bsd.uchicago.edu						[Anonymous], 2005, LANCET NEUROL, V4, P787; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; LANG AE, 2006, ANN NEUROL      0120; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; SLEVIN JT, 2005, J NEUROSURG, V102, P16	5	17	17	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2006	5	3					202	203		10.1016/S1474-4422(06)70360-X	http://dx.doi.org/10.1016/S1474-4422(06)70360-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016PS	16488374				2022-12-18	WOS:000235632900005
J	Kwa, VIH				Kwa, VIH			Our eyes: windows to our souls or crystal balls?	LANCET NEUROLOGY			English	Editorial Material							STROKE		Slotervaart Hosp, Amsterdam, Netherlands	Slotervaart Hospital	Kwa, VIH (corresponding author), Slotervaart Hosp, Louwesweg 6, Amsterdam, Netherlands.	Nevkw@slz.nl						Mitchell P, 2005, NEUROLOGY, V65, P1005, DOI 10.1212/01.wnl.0000179177.15900.ca; Nakayama T, 1997, STROKE, V28, P45, DOI 10.1161/01.STR.28.1.45; Ostrow P T, 1993, Adv Neurol, V62, P93; van den Born BJH, 2005, BMJ-BRIT MED J, V331, P73, DOI 10.1136/bmj.331.7508.73; Wardlaw JM, 2003, STROKE, V34, P806, DOI 10.1161/01.STR.0000058480.77236.B3; Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865	6	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2006	5	2					108	110		10.1016/S1474-4422(06)70332-5	http://dx.doi.org/10.1016/S1474-4422(06)70332-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	006RO	16426984				2022-12-18	WOS:000234914800005
J	Scolding, N				Scolding, N			Devic's disease and autoantibodies	LANCET NEUROLOGY			English	Letter							NEUROMYELITIS-OPTICA		Univ Bristol, Frenchay Hosp, Inst Clin Neurosci, Dept Neurol, Bristol BS31 1HS, Avon, England	University of Bristol	Scolding, N (corresponding author), Univ Bristol, Frenchay Hosp, Inst Clin Neurosci, Dept Neurol, Bristol BS31 1HS, Avon, England.	n.scolding@bristol.ac.uk						BENNETTO L, 2005, IN PRESS J NEUROL; Devic E., 1895, C FRANC MED 1 SESS L, P434; Ghezzi A, 2004, J NEUROL, V251, P47, DOI 10.1007/s00415-004-0271-0; Keegan M, 2002, NEUROLOGY, V58, P143, DOI 10.1212/WNL.58.1.143; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lucchinetti CF, 2002, BRAIN, V125, P1450, DOI 10.1093/brain/awf151; Mandler RN, 1998, NEUROLOGY, V51, P1219, DOI 10.1212/WNL.51.4.1219; MANDLER RN, 1993, ANN NEUROL, V34, P162, DOI 10.1002/ana.410340211; Miyazawa I, 2002, J NEUROL, V249, P351, DOI 10.1007/s004150200020; Scolding N, 2001, J NEUROL NEUROSUR S2, V71, pii9; Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107	11	17	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2005	4	3					136	137		10.1016/S1474-4422(05)00996-8	http://dx.doi.org/10.1016/S1474-4422(05)00996-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	901QT	15721820				2022-12-18	WOS:000227297700002
J	Masterman, T; Hillert, J				Masterman, T; Hillert, J			The telltale scan: APOE epsilon 4 in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							BRAIN ATROPHY; MS		Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Div Neurol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Masterman, T (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Div Neurol, Stockholm, Sweden.	Thomas.Masterman@neurotec.ki.se						Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Fisher E, 2002, NEUROLOGY, V59, P1412, DOI 10.1212/01.WNL.0000036271.49066.06; Masterman T, 2002, MULT SCLER, V8, P98, DOI 10.1191/1352458502ms787oa	5	17	22	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					331	331		10.1016/S1474-4422(04)00763-X	http://dx.doi.org/10.1016/S1474-4422(04)00763-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15157846				2022-12-18	WOS:000221663000012
J	Whitehouse, P; Frisoni, GB; Post, S				Whitehouse, P; Frisoni, GB; Post, S			Breaking the diagnosis of dementia - Diagnostic disclosure: the way forward	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; COMPETENCE; ATTITUDES; TRUTH; TELL		Case Western Reserve Univ, Cleveland, OH 44106 USA; IRCCS San Giovanni Dio FBF, Brescia, Italy; Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH USA	Case Western Reserve University; IRCCS Fatebenefratelli; Case Western Reserve University	Whitehouse, P (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.		Frisoni, Giovanni B./K-1360-2016; Frisoni, Giovanni/K-1360-2016	Frisoni, Giovanni B./0000-0002-6419-1753; Frisoni, Giovanni/0000-0001-7075-7082	NIA NIH HHS [U19 AG010483] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U19AG010483] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGS Clin Practice Comm, 2003, J AM GERIATR SOC, V51, P869; *ALZH CAN, 1997, TOUGH ISS ETH GUID A; *ALZH DIS ASS, 2001, ETH ISS ALZH DIS; [Anonymous], 2000, MORAL CHALLENGE ALZH; BAHRO M, 1995, J AM GERIATR SOC, V43, P41, DOI 10.1111/j.1532-5415.1995.tb06240.x; Cohen-Mansfield J, 2001, AM J GERIAT PSYCHIAT, V9, P361, DOI 10.1176/appi.ajgp.9.4.361; DEBAGGIO T, 2002, LOSING MIND; DeCarli C, 2003, LANCET NEUROL, V2, P15, DOI 10.1016/S1474-4422(03)00262-X; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Fazel S, 1999, LANCET, V354, P48, DOI 10.1016/S0140-6736(99)01911-X; Frisoni GB, 2003, ARCH NEUROL-CHICAGO, V60, P1023, DOI 10.1001/archneur.60.7.1023-a; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; Gordon M, 2001, CAN FAM PHYSICIAN, V47, P1803; JAMETON A, 1995, ENCY BIOETHICS, P1225; Kim SYH, 2001, AM J PSYCHIAT, V158, P712, DOI 10.1176/appi.ajp.158.5.712; Marzanski M, 2000, J MED ETHICS, V26, P108, DOI 10.1136/jme.26.2.108; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Pucci E, 2003, J MED ETHICS, V29, P51, DOI 10.1136/jme.29.1.51; RICHIE K, 2002, LANCET, V360, P1759; SUNDSMO M, 2003, ALZH ASS NAT ALZH DI; Turnbull Q, 2003, J GERIATR PSYCH NEUR, V16, P90, DOI 10.1177/0891988703016002005; Wald C, 2003, INT J GERIATR PSYCH, V18, P313, DOI 10.1002/gps.828; Whitehouse PJ, 2003, LANCET, V361, P1227, DOI 10.1016/S0140-6736(03)12937-6; WHITEHOUSE PJ, IN PRESS PSYCHIAT TI; WHITEHOUSE PJ, 2002, CONCEPTS ALZHEIMER D, V360, P1759; Yesavage JA, 2002, NEUROLOGY, V59, P123, DOI 10.1212/WNL.59.1.123	27	17	18	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					124	128		10.1016/S1474-4422(03)00666-5	http://dx.doi.org/10.1016/S1474-4422(03)00666-5			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	772AQ	14747005				2022-12-18	WOS:000188818500023
J	Reid, E				Reid, E			Many pathways lead to hereditary spastic paraplegia	LANCET NEUROLOGY			English	Editorial Material									Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Reid, E (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Box 134, Cambridge CB2 2QQ, England.	ereid@hgmp.mrc.ac.uk	Reid, Evan/F-3250-2010	Reid, Evan/0000-0003-1623-7304				Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Crosby AH, 2002, AM J HUM GENET, V71, P1009, DOI 10.1086/344206; Hodgkinson CA, 2002, NEUROLOGY, V59, P1905, DOI 10.1212/01.WNL.0000036909.49629.21; Reid E, 2003, J MED GENET, V40, P81, DOI 10.1136/jmg.40.2.81	5	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					210	210		10.1016/S1474-4422(03)00345-4	http://dx.doi.org/10.1016/S1474-4422(03)00345-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849205				2022-12-18	WOS:000181726700013
J	Andres-Barquin, PJ				Andres-Barquin, PJ			Santiago Ramon y Cajal and the Spanish school of neurology	LANCET NEUROLOGY			English	Review								Advances in neurology are now possible thanks to the endeavours of a few scientists who in the past laid firm foundations for the study of the nervous system. Santiago Ramon y Cajal (1852-1934) was one such pioneer of brain exploration and is acknowledged as the founder of modern neuroscience. He described the structure and organisation of virtually all parts of the nervous system and developed theories, including the neuron doctrine and the law of functional polarisation, that are the cornerstones of neuroscience. In addition to devoting his life to research, Ramon y Cajal was a dedicated teacher and mentor and created a school that greatly contributed to the flourishing of neurology.	F Hoffmann La Roche & Co Ltd, Dept Neurosci, CH-4070 Basel, Switzerland	Roche Holding	Andres-Barquin, PJ (corresponding author), F Hoffmann La Roche & Co Ltd, Dept Neurosci, Bldg 93-340, CH-4070 Basel, Switzerland.	pedro-j.andres@roche.com						Albright TD, 2000, CELL, V100, pS1; Andres-Barquin PJ, 2001, ENDEAVOUR, V25, P13, DOI 10.1016/S0160-9327(00)01334-X; BERECIARTU JDR, 1993, PIO RIOHORTEGA EPIST; Cajal, 1913, TRAB LAB INVEST BIOL, V11, P255; CAJAL SR, 1934, MUNDO VISTO 80 ANOS; CAJAL SR, 1989, SELECCION TRABAJOS I; CAJAL SRY, 1988, CAJAL CEREBRAL CORTE, P1; CAJAL SRY, 1990, NEW IDEAS STRUCTURE; CAJAL SRY, 1923, RECUERDOS VIDA; CRAIGIE EH, 1962, AM J PSYCHIAT, V118, P837; DECARLOSSEGOVIA JA, 2001, RAMON CAJAL FAMILIA; DeFelipe J., 1991, CAJALS DEGENERATION; del R?o-Hortega P., 1921, B REAL SOC ESPAN HIS, V21, P63; del Rio-Hortega P, 1939, LANCET, V1, P1023; Del Rio-Hortega P, 1927, B JOHNS HOPKINS HOSP, V41, P278; DELRIOHORTEGA P, 1962, MICROSCOPIC ANAT TUM; DELRIOHORTEGA P, 1998, ARBOR, V161, P151; DEVIANI A, 1991, PIO DEL RIO HORTEGA; FERNANDEZSANTAR.J, 2002, HORIZONTES CULTURALE, P67; GARCIALASAOSA J, 1980, ARAGON HIST, P432; GIBSON WC, 1994, J HIST MED ALL SCI, V49, P546, DOI 10.1093/jhmas/49.4.546; GRANT G, GOLGI SHARED 1906 NO; Insua A.S.A., 1986, MAESTRO YO; JUNQUERA SRY, 1988, ARAGON MUNDO, P366; Katz-Sidlow RJ, 1998, ARCH NEUROL-CHICAGO, V55, P237, DOI 10.1001/archneur.55.2.237; KRUGER L, 1990, J COMP NEUROL, V300, P1, DOI 10.1002/cne.903000102; Lopez-Pinero JM., 2000, CAJAL; LOPEZPIFIERO JM, 2000, BIBLIOGRAFIA CAJALIA; *NOB FDN, NOB PRIZ PHYS MED; Paweletz N, 2001, NAT REV MOL CELL BIO, V2, P475, DOI 10.1038/35073102; PICCOLINO M, 1988, TRENDS NEUROSCI, V11, P521, DOI 10.1016/0166-2236(88)90175-0; Ramon y Cajal S, 1890, ANAT ANZEIGER, V5, P85; Ramon y Cajal S, 1933, ELEMENTOS TECNICA MI; Ramon y Cajal S., 1999, ADVICE YOUNG INVESTI; Raper J. A., 1999, FUNDAMENTAL NEUROSCI, P519; Rodriguez E, 1977, ASI ERA CAJAL; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SANCHEZRON JM, 1999, CINCEL MARTILLO PIED; SWANSON LW, 1999, FUNDAMENTAL NEUROSCI, P9; TELLO F, 1923, THESIS MADRID; TELLO F, 1914, TRAB LAB INVEST BIOL, V12, P273; TELLO JF, 1907, TRAB LAB INVEST BIOL, V5, P117; *UN COORD BIBL, 2002, CAT INF RED BIBL CSI; VERASEMPERE FJ, 2001, SANTIAGO RAMON CAJAL	44	17	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					445	452		10.1016/S1474-4422(02)00192-8	http://dx.doi.org/10.1016/S1474-4422(02)00192-8			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC	12849367				2022-12-18	WOS:000178732300022
J	Rascol, O; Fabbri, M; Poewe, W				Rascol, Olivier; Fabbri, Margherita; Poewe, Werner			Amantadine in the treatment of Parkinson's disease and other movement disorders	LANCET NEUROLOGY			English	Article							LEVODOPA-INDUCED DYSKINESIA; PLACEBO-CONTROLLED TRIAL; EXTENDED-RELEASE CAPSULES; TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; HYDROCHLORIDE TREATMENT; INTRAVENOUS AMANTADINE; MULTIPLE-SCLEROSIS; HUNTINGTONS-DISEASE; AMERICAN ACADEMY	The efficacy of amantadine in the symptomatic treatment of patients with Parkinson's disease, discovered serendipitously more than 50 years ago, has stood the test of time and the drug is still commonly used by neurologists today. Its pharmacological actions are unique in combining dopaminergic and glutamatergic properties, which account for its dual effect on parkinsonian signs and symptoms and levodopa-induced dyskinesias. Furthermore, amantadine has additional and less well-defined pharmacological effects, including on anticholinergic and serotonergic activity. Evidence from randomised controlled trials over the past 5 years has confirmed the efficacy of amantadine to treat levodopa-induced dyskinesias in patients with Parkinson's disease, and clinical studies have also provided support for its potential to reduce motor fluctuations. Other uses of amantadine, such as in the treatment of drug -induced parkinsonism, atypical parkinsonism, Huntington's disease, or tardive dyskinesia, lack a strong evidence base. Future trials should examine its role in the management of motor and non-motor symptoms in patients with early Parkinson's disease and those with other movement disorders.	[Rascol, Olivier; Fabbri, Margherita] Univ Toulouse 3, Toulouse NeuroToul Ctr Excellence Neurodegenerat, Toulouse Parkinson Expert Ctr, Dept Clin Pharmacol & Neurosci, Toulouse, France; [Rascol, Olivier; Fabbri, Margherita] Univ Toulouse 3, CHU Toulouse, INSERM, French NS Park F CRIN Network, Toulouse, France; [Poewe, Werner] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Medical University of Innsbruck	Rascol, O (corresponding author), Univ Toulouse 3, Toulouse NeuroToul Ctr Excellence Neurodegenerat, Toulouse Parkinson Expert Ctr, Dept Clin Pharmacol & Neurosci, Toulouse, France.; Rascol, O (corresponding author), Univ Toulouse 3, INSERM, CHU Toulouse, French NS Park F CRIN Network, F-31000 Toulouse, France.	olivier.rascol@univ-tlse3.fr						Angus S, 1997, J CLIN PSYCHOPHARM, V17, P88, DOI 10.1097/00004714-199704000-00004; [Anonymous], FIGARO; APPLETON DB, 1970, MED J AUSTRALIA, V2, P626, DOI 10.5694/j.1326-5377.1970.tb50238.x; Armstrong MJ, 2012, NEUROLOGY, V79, P597, DOI 10.1212/WNL.0b013e318263c443; Assemblee Nationale, PROP LOI; Available from:, 2020, THERANEKRON D6 RICHT; BAILEY EV, 1975, ARCH INT PHARMACOD T, V216, P246; BAUER RB, 1974, NEUROLOGY, V24, P715, DOI 10.1212/WNL.24.8.715; Bezard E, 2013, MOVEMENT DISORD, V28, P1088, DOI 10.1002/mds.25366; Bido S, 2011, J NEUROCHEM, V118, P1043, DOI 10.1111/j.1471-4159.2011.07376.x; Blanchet PJ, 1998, MOVEMENT DISORD, V13, P798, DOI 10.1002/mds.870130507; Blanpied TA, 2005, J NEUROSCI, V25, P3312, DOI 10.1523/JNEUROSCI.4262-04.2005; Botez MI, 1996, J NEUROL NEUROSUR PS, V61, P259, DOI 10.1136/jnnp.61.3.259; Botez MI, 1999, EUR NEUROL, V41, P212, DOI 10.1159/000008053; Burgunder Jean-Marc, 2011, PLoS Curr, V3, pRRN1260, DOI 10.1371/currents.RRN1260; Calabresi P, 2010, LANCET NEUROL, V9, P1106, DOI 10.1016/S1474-4422(10)70218-0; Caroff SN, 2020, CLIN PSYCHOPHARM NEU, V18, P493, DOI 10.9758/cpn.2020.18.4.493; CEDARBAUM JM, 1987, CLIN PHARMACOKINET, V13, P141, DOI 10.2165/00003088-198713030-00002; Cera N, 2014, NEUROPSYCH DIS TREAT, V10, P1093, DOI 10.2147/NDT.S54423; Chase TN, 2000, TRENDS NEUROSCI, V23, pS86, DOI 10.1016/S1471-1931(00)00018-5; Crispo JAG, 2015, EUR J CLIN PHARMACOL, V71, P1011, DOI 10.1007/s00228-015-1881-4; DALLOS V, 1970, BMJ-BRIT MED J, V4, P24, DOI 10.1136/bmj.4.5726.24; Danysz W, 2021, J NEURAL TRANSM, V128, P127, DOI 10.1007/s00702-021-02306-2; DECKER BL, 1971, NEW ENGL J MED, V285, P860; Deep P, 1999, SYNAPSE, V34, P313, DOI 10.1002/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1; Del Dotto P, 2001, MOVEMENT DISORD, V16, P515, DOI 10.1002/mds.1112; deVries T, 2019, NEUROL THER, V8, P449, DOI 10.1007/s40120-019-0144-1; Duty S, 2012, CNS DRUGS, V26, P1017, DOI 10.1007/s40263-012-0016-z; Eggert K, 2010, MOVEMENT DISORD, V25, P896, DOI 10.1002/mds.22974; Elmer LW, 2018, CNS DRUGS, V32, P387, DOI 10.1007/s40263-018-0498-4; Espay AJ, 2018, ANN NEUROL, V84, P797, DOI 10.1002/ana.25364; Factor SA, 1998, NEUROLOGY, V50, P1456, DOI 10.1212/WNL.50.5.1456; Ferreira JJ, 2013, EUR J NEUROL, V20, P5, DOI 10.1111/j.1468-1331.2012.03866.x; Fox SH, 2018, MOVEMENT DISORD, V33, P1248, DOI 10.1002/mds.27372; FREEMAN SE, 1985, J MOL CELL CARDIOL, V17, P9, DOI 10.1016/S0022-2828(85)80088-2; Giacino JT, 2018, NEUROLOGY, V91, P450, DOI 10.1212/WNL.0000000000005926; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2003, J HEAD TRAUMA REHAB, V18, P4, DOI 10.1097/00001199-200301000-00003; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Goetz CG, 2013, MOVEMENT DISORD, V28, P341, DOI 10.1002/mds.25321; Hauser RA, 2019, CLIN PHARMACOKINET, V58, P77, DOI 10.1007/s40262-018-0663-4; Hauser RA, 2016, INT J NEUROSCI, V126, P942, DOI 10.3109/00207454.2016.1154552; Hill MP, 2004, J PHARMACOL EXP THER, V310, P386, DOI 10.1124/jpet.104.066191; Hornykiewicz O, 2010, J NEUROL, V257, pS249, DOI 10.1007/s00415-010-5741-y; JACKSON JA, 1983, ANN NEUROL, V13, P273, DOI 10.1002/ana.410130308; Kakkar R, 1997, BRAIN RES, V749, P290, DOI 10.1016/S0006-8993(96)01318-2; KELLY JT, 1971, J CLIN PHARMACOL N D, V11, P211; Ko WKD, 2014, MOVEMENT DISORD, V29, P772, DOI 10.1002/mds.25859; Kobylecki C, 2011, MOVEMENT DISORD, V26, P2354, DOI 10.1002/mds.23867; Kompoliti K, 1998, ARCH NEUROL-CHICAGO, V55, P1099, DOI 10.1001/archneur.55.8.1099; Kong M, 2017, ONCOTARGET, V8, P57316, DOI 10.18632/oncotarget.17622; Konig P, 1996, NEUROPSYCHOBIOLOGY, V33, P80, DOI 10.1159/000119254; KORNHUBER J, 1991, EUR J PHARM-MOLEC PH, V206, P297, DOI 10.1016/0922-4106(91)90113-V; KORNHUBER J, 1993, J NEURAL TRANSM-PARK, V6, P63, DOI 10.1007/BF02252624; Ledinek AH, 2013, CLIN NEUROL NEUROSUR, V115, pS86, DOI 10.1016/j.clineuro.2013.09.029; Lee JY, 2013, J NEUROL, V260, P3030, DOI 10.1007/s00415-013-7108-7; Lees A, 2016, W BURROUGHS EXPT; Lucetti C, 2003, NEUROLOGY, V60, P1995, DOI 10.1212/01.WNL.0000068165.07883.64; LUSTIG HS, 1992, BRAIN RES, V597, P148, DOI 10.1016/0006-8993(92)91517-I; Malkani R, 2012, CLIN NEUROPHARMACOL, V35, P266, DOI 10.1097/WNF.0b013e31826e3406; Matsubayashi H, 1997, J PHARMACOL EXP THER, V281, P834; Mehta S, 2018, NEUROLOGY, V90; Merello M, 1999, CLIN NEUROPHARMACOL, V22, P273; MERRY RTG, 1974, J INT MED RES, V2, P137, DOI 10.1177/030006057400200206; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; Metman LV, 2002, NEUROLOGY, V59, P694; Metman LV, 1999, ARCH NEUROL-CHICAGO, V56, P1383, DOI 10.1001/archneur.56.11.1383; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Miyasaki JM, 1999, NEUROLOGY, V52, P1720; Moresco RM, 2002, J NEURAL TRANSM, V109, P1265, DOI 10.1007/s00702-002-0694-7; NIEFORTH KA, 1993, CLIN NEUROPHARMACOL, V16, P338, DOI 10.1097/00002826-199308000-00006; Nisar T, 2019, LANCET NEUROL, V18, P1080, DOI 10.1016/S1474-4422(19)30361-8; Nonnekes J, 2015, LANCET NEUROL, V14, P768, DOI 10.1016/S1474-4422(15)00041-1; Nourbakhsh B, 2021, LANCET NEUROL, V20, P38, DOI 10.1016/S1474-4422(20)30354-9; O'Suilleabhain P, 2003, ARCH NEUROL-CHICAGO, V60, P996, DOI 10.1001/archneur.60.7.996; Oertel W, 2017, MOVEMENT DISORD, V32, P1701, DOI 10.1002/mds.27131; Ory-Magne F, 2014, NEUROLOGY, V82, P300, DOI 10.1212/WNL.0000000000000050; Ossola B, 2011, NEUROPHARMACOLOGY, V61, P574, DOI 10.1016/j.neuropharm.2011.04.030; Pahwa R, 2017, JAMA NEUROL, V74, P941, DOI 10.1001/jamaneurol.2017.0943; Pahwa R, 2015, MOVEMENT DISORD, V30, P788, DOI 10.1002/mds.26159; Papa SM, 1996, ANN NEUROL, V39, P574, DOI 10.1002/ana.410390505; Pappa S, 2010, CLIN NEUROPHARMACOL, V33, P271, DOI 10.1097/WNF.0b013e3181ffde32; PAULSON G, 1993, NEUROLOGY, V43, P1296; Peeters M, 2004, EUR J NEUROSCI, V19, P2212, DOI 10.1111/j.0953-816X.2004.03297.x; Peeters M, 2002, BRAIN RES, V949, P32, DOI 10.1016/S0006-8993(02)02961-X; Rammes G, 2001, NEUROSCI LETT, V306, P81, DOI 10.1016/S0304-3940(01)01872-9; Rascol O, 2002, LANCET, V359, P1589, DOI 10.1016/S0140-6736(02)08520-3; Rascol O, 2020, DRUG AGING, V37, P215, DOI 10.1007/s40266-019-00740-2; Raz A, 2013, CLIN NEUROPHARMACOL, V36, P166, DOI 10.1097/WNF.0b013e31829bd066; Rosa MM, 2010, MOVEMENT DISORD, V25, P1053, DOI 10.1002/mds.23038; Schachtele S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155649; Schneider WN, 1999, BRAIN INJURY, V13, P863; Schrag A, 1999, MOVEMENT DISORD, V14, P252, DOI 10.1002/1531-8257(199903)14:2<252::AID-MDS1009>3.0.CO;2-N; SCHWAB R S, 1969, Transactions of the American Neurological Association, V94, P85; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Shaygannejad V, 2012, NEUROL RES, V34, P854, DOI 10.1179/1743132812Y.0000000081; Shen WX, 2020, J CLIN INVEST, V130, P2593, DOI 10.1172/JCI133398; Silver D E, 1971, Trans Am Neurol Assoc, V96, P307; Simonet C, 2020, PRACT NEUROL, V20, P15, DOI 10.1136/practneurol-2018-002075; Sommerauer C, 2012, NEUROPHARMACOLOGY, V62, P1708, DOI 10.1016/j.neuropharm.2011.11.017; Thomas A, 2010, ANN NEUROL, V68, P400, DOI 10.1002/ana.22029; Trenkwalder C, 2016, MOVEMENT DISORD, V31, P1054, DOI 10.1002/mds.26585; Uitti RJ, 1996, NEUROLOGY, V46, P1551, DOI 10.1212/WNL.46.6.1551; Von Voigtlander P F, 1971, Science, V174, P408, DOI 10.1126/science.174.4007.408; Weintraub D, 2010, ANN NEUROL, V68, P963, DOI 10.1002/ana.22164; Wenning GK, 2005, CLIN NEUROPHARMACOL, V28, P225, DOI 10.1097/01.wnf.0000183240.47960.f0; WESEMANN W, 1979, J NEURAL TRANSM, V44, P263, DOI 10.1007/BF01250322; WESEMANN W, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1241; Wolf E, 2010, MOVEMENT DISORD, V25, P1357, DOI 10.1002/mds.23034; Zhang Zhen-Xin, 2014, BMC Res Notes, V7, P65, DOI 10.1186/1756-0500-7-65	110	16	16	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					1048	1056		10.1016/S1474-4422(21)00249-0	http://dx.doi.org/10.1016/S1474-4422(21)00249-0		NOV 2021	9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34678171				2022-12-18	WOS:000755602800029
J	Fagan, AM; Henson, RL; Li, Y; Boerwinkle, AH; Xiong, CJ; Bateman, RJ; Goate, A; Ances, BM; Doran, E; Christian, BT; Lai, F; Rosas, HD; Schupf, N; Krinsky-McHale, S; Silverman, W; Lee, JH; Klunk, WE; Handen, BL; Allegri, RF; Chhatwal, JP; Day, GS; Graff-Radford, NR; Jucker, M; Levin, J; Martins, RN; Masters, CL; Mori, H; Mummery, CJ; Niimi, Y; Ringman, JM; Salloway, S; Schofield, PR; Shoji, M; Lott, IT				Fagan, Anne M.; Henson, Rachel L.; Li, Yan; Boerwinkle, Anna H.; Xiong, Chengjie; Bateman, Randall J.; Goate, Alison; Ances, Beau M.; Doran, Eric; Christian, Bradley T.; Lai, Florence; Rosas, H. Diana; Schupf, Nicole; Krinsky-McHale, Sharon; Silverman, Wayne; Lee, Joseph H.; Klunk, William E.; Handen, Benjamin L.; Allegri, Ricardo F.; Chhatwal, Jasmeer P.; Day, Gregory S.; Graff-Radford, Neill R.; Jucker, Mathias; Levin, Johannes; Martins, Ralph N.; Masters, Colin L.; Mori, Hiroshi; Mummery, Catherine J.; Niimi, Yoshiki; Ringman, John M.; Salloway, Stephen; Schofield, Peter R.; Shoji, Mikio; Lott, Ira T.		Alzheimers Biomarker Consortium-Do; Dominantly Inherited Alzheimer Net	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study	LANCET NEUROLOGY			English	Article							DIAGNOSTIC PERFORMANCE; AMYLOID-BETA; TAU; DEMENTIA; ADULTS	Background Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease pathology by the age of 40 years and are at high risk for dementia given their increased life expectancy compared with adults with Down syndrome in the past. We aimed to compare CSF biomarker patterns in Down syndrome with those of carriers of autosomal dominant Alzheimer's disease mutations to enhance our understanding of disease mechanisms in these two genetic groups at high risk for Alzheimer's disease. Methods We did a cross-sectional study using data from adults enrolled in the Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) study, a multisite longitudinal study of Alzheimer's disease in Down syndrome, as well as a cohort of carriers of autosomal dominant Alzheimer's disease mutations and non-carrier sibling controls enrolled in the Dominantly Inherited Alzheimer Network (DIAN) study. For ABC-DS, participants with baseline CSF, available clinical diagnosis, and apolipoprotein E genotype as of Jan 31, 2019, were included in the analysis. DIAN participants with baseline CSF, available clinical diagnosis, and apolipoprotein E genotype as of June 30, 2018, were evaluated as comparator groups. CSF samples obtained from adults with Down syndrome, similarly aged carriers of autosomal dominant Alzheimer's disease mutations, and non-carrier siblings (aged 30-61 years) were analysed for markers of amyloid ll (All1-40, All1-42); tau phosphorylated at threonine 181-related processes; neuronal, axonal, or synaptic injury (total tau, visinin-like protein 1, neurofilament light chain [NfL], synaptosomal-associated protein 25); and astrogliosis and neuroinflammation (chitinase-3-like protein 1 [YKL-40]) via immunoassay. Biomarker concentrations were compared as a function of dementia status (asymptomatic or symptomatic), and linear regression was used to evaluate and compare the relationship between biomarker concentrations and age among groups. Findings We assessed CSF samples from 341 individuals (178 [52%] women, 163 [48%] men, aged 30-61 years). Participants were adults with Down syndrome (n=41), similarly aged carriers of autosomal dominant Alzheimer's disease mutations (n=192), and non-carrier siblings (n=108). Individuals with Down syndrome had patterns of Alzheimer's disease-related CSF biomarkers remarkably similar to carriers of autosomal dominant Alzheimer's disease mutations, including reductions (all p<0.0080) in All1-42 to All1-40 ratio and increases in markers of phosphorylated tau-related processes; neuronal, axonal, and synaptic injury (p<0.080); and astrogliosis and neuroinflammation, with greater degrees of abnormality in individuals with dementia. Differences included overall higher concentrations of All and YKL-40 (both p<0.0008) in Down syndrome and potential elevations in CSF tau (p<0.010) and NfL (p<0.0001) in the asymptomatic stage (ie, no dementia symptoms). Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Fagan, Anne M.; Henson, Rachel L.; Li, Yan; Boerwinkle, Anna H.; Bateman, Randall J.; Ances, Beau M.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Xiong, Chengjie] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Goate, Alison] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA; [Doran, Eric; Silverman, Wayne; Lott, Ira T.] UC Irvine, Sch Med, Dept Pediat, Irvine, CA USA; [Christian, Bradley T.] Univ Wisconsin, Waisman Ctr, Dept Med Phys, Madison, WI 53705 USA; [Christian, Bradley T.] Univ Wisconsin, Waisman Ctr, Dept Psychiat, Madison, WI 53705 USA; [Lai, Florence; Rosas, H. Diana; Chhatwal, Jasmeer P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Schupf, Nicole; Lee, Joseph H.] Columbia Univ, Irving Med Ctr, Dept Epidemiol, New York, NY USA; [Schupf, Nicole; Lee, Joseph H.] Columbia Univ, Irving Med Ctr, Dept Neurol, New York, NY USA; [Krinsky-McHale, Sharon] New York State Inst Basic Res Dev Disabil, Staten Isl, NY USA; [Klunk, William E.; Handen, Benjamin L.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Allegri, Ricardo F.] Inst Neurol Fleni, Dept Cognit Neurol, Buenos Aires, DF, Argentina; [Day, Gregory S.; Graff-Radford, Neill R.] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA; [Jucker, Mathias] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Cellular Neurol, Tubingen, Germany; [Jucker, Mathias] German Ctr Neurodegenerat Dis, Tubingen, Germany; [Levin, Johannes] Ludwig Maximilians Univ Munchen, German Ctr Neurodegenerat Dis, Dept Neurol, Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Martins, Ralph N.] Edith Cowan Univ, Sch Med Hlth & Sci, Joondalup, WA, Australia; [Masters, Colin L.] Florey Inst, Melbourne, Vic, Australia; [Masters, Colin L.] Univ Melbourne, Melbourne, Vic, Australia; [Mori, Hiroshi] Osaka City Univ, Med Sch, Dept Clin Neurosci, Abeno Ku, Osaka, Japan; [Mummery, Catherine J.] UCL, Dementia Res Ctr, Inst Neurol, London, England; [Niimi, Yoshiki] Univ Tokyo, Unit Early & Exploratory Clin Dev, Tokyo, Japan; [Ringman, John M.] Univ Southern Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90007 USA; [Salloway, Stephen] Brown Univ, Butler Hosp, Memory & Aging Program, Providence, RI 02912 USA; [Schofield, Peter R.] Univ New South Wales, Sch Med Sci, Neurosci Res Australia, Sydney, NSW, Australia; [Shoji, Mikio] Geriatr Res Inst & Hosp, Maebashi, Gumma, Japan	Washington University (WUSTL); Washington University (WUSTL); Icahn School of Medicine at Mount Sinai; University of California System; University of California Irvine; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Massachusetts General Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Institute for Basic Research in Developmental Disabilities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Munich; Edith Cowan University; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Osaka Metropolitan University; University of London; University College London; University of Tokyo; University of Southern California; Brown University; Butler Hospital Rhode Island; Neuroscience Research Australia; University of New South Wales Sydney	Fagan, AM (corresponding author), Washington Univ, Sch Med, Alzheimer Dis Res Ctr, St Louis, MO 63110 USA.	fagana@wustl.edu	Day, Gregory/I-3439-2019; Handen, Benjamin/GRY-0095-2022; Levin, Johannes/W-8686-2019; ALLEGRI, RICARDO FRANCISCO/AAY-4898-2021	Day, Gregory/0000-0001-5133-5538; Levin, Johannes/0000-0001-5092-4306; Shoji, Mikio/0000-0003-1027-1712; Klunk, William/0000-0001-5512-0251	National Institute on Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; German Center for Neurodegenerative Diseases; Japan Agency for Medical Research and Development	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); German Center for Neurodegenerative Diseases; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	National Institute on Aging, Eunice Kennedy Shriver National Institute of Child Health and Human Development, German Center for Neurodegenerative Diseases, and Japan Agency for Medical Research and Development.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bridel C, 2019, JAMA NEUROL, V76, P1035, DOI 10.1001/jamaneurol.2019.1534; Brier MR, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2362; Dekker Alain D, 2017, Alzheimers Dement (Amst), V8, P1, DOI 10.1016/j.dadm.2017.02.006; Fortea J, 2020, LANCET, V395, P1988, DOI 10.1016/S0140-6736(20)30689-9; Fortea J, 2018, LANCET NEUROL, V17, P860, DOI 10.1016/S1474-4422(18)30285-0; Fuller JT, 2019, JPAD-J PREV ALZHEIM, V6, P112, DOI 10.14283/jpad.2019.6; Gallardo G, 2019, ADV EXP MED BIOL, V1184, P187, DOI 10.1007/978-981-32-9358-8_16; Gordon BA, 2019, BRAIN, V142, P1063, DOI 10.1093/brain/awz019; Guzman-Velez E, 2021, ALZHEIMERS DEMENT, V17, P813, DOI 10.1002/alz.12248; Handen BL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12065; Hartley D, 2015, ALZHEIMERS DEMENT, V11, P700, DOI 10.1016/j.jalz.2014.10.007; Head E, 2016, CURR ALZHEIMER RES, V13, P18, DOI 10.2174/1567205012666151020114607; Henson RL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12057; Karch Celeste M, 2015, Biol Psychiatry, V77, P43, DOI 10.1016/j.biopsych.2014.05.006; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Lott IT, 2019, NAT REV NEUROL, V15, P135, DOI 10.1038/s41582-018-0132-6; MANN DMA, 1988, HISTOPATHOLOGY, V13, P125, DOI 10.1111/j.1365-2559.1988.tb02018.x; Mattsson N, 2012, NEUROLOGY, V78, P468, DOI 10.1212/WNL.0b013e3182477eed; Mattsson N, 2019, JAMA NEUROL, V76, P791, DOI 10.1001/jamaneurol.2019.0765; Mengel D, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00593-7; Molinuevo JL, 2018, ACTA NEUROPATHOL, V136, P821, DOI 10.1007/s00401-018-1932-x; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris John C, 2012, Clin Investig (Lond), V2, P975; Natte R, 2001, ANN NEUROL, V50, P765, DOI 10.1002/ana.10040; Nelson LD, 2011, ARCH NEUROL-CHICAGO, V68, P768, DOI 10.1001/archneurol.2011.104; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Petersen M, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12023; Portelius E, 2014, NEURODEGENER DIS, V14, P98, DOI 10.1159/000358800; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Quiroz YT, 2020, LANCET NEUROL, V19, P513, DOI 10.1016/S1474-4422(20)30137-X; Ryman Davis C, 2014, Neurology, V83, P253, DOI 10.1212/WNL.0000000000000596; Sadowski R, 1999, ACTA NEUROPATHOL, V97, P156, DOI 10.1007/s004010050968; Schindler SE, 2019, ALZHEIMERS DEMENT, V15, P655, DOI 10.1016/j.jalz.2018.12.019; Startin CM, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0477-0; Strydom A, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0367-x; Wang XN, 2020, J ALZHEIMERS DIS, V73, P819, DOI 10.3233/JAD-190714; Wilcock DM, 2015, NEUROBIOL AGING, V36, P2468, DOI 10.1016/j.neurobiolaging.2015.05.016; Zis P, 2018, FREE RADICAL BIO MED, V114, P3, DOI 10.1016/j.freeradbiomed.2017.08.024	39	16	16	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					615	626		10.1016/S1474-4422(21)00139-3	http://dx.doi.org/10.1016/S1474-4422(21)00139-3			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34302786	Green Accepted			2022-12-18	WOS:000677684700015
J	Koehler, PJ; Nonnekes, J; Bloem, BR				Koehler, Peter J.; Nonnekes, Jorik; Bloem, Bastiaan R.			Freezing of gait before the introduction of levodopa	LANCET NEUROLOGY			English	Editorial Material													Bloem, Bastiaan/H-8013-2014	Bloem, Bastiaan/0000-0002-6371-3337; Nonnekes, Jorik/0000-0003-2434-1427					0	16	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					97	97		10.1016/S1474-4422(19)30091-2	http://dx.doi.org/10.1016/S1474-4422(19)30091-2		JAN 2021	1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	30982582				2022-12-18	WOS:000610201500016
J	Winkler, AS; Knauss, S; Schmutzhard, E; Leonardi, M; Padovani, A; Abd-Allah, F; Charway-Felli, A; Emmerich, JV; Umapathi, T; Satishchandra, P; Hoo, FK; Dalmau, J; Oreja-Guevara, C; Ferreira, LB; Pfausler, B; Michael, B; Tagliavini, F; Hoglinger, G; Endres, M; Klein, C; Hemmer, B; Correll, W; Sejvar, J; Solomon, T				Winkler, Andrea Sylvia; Knauss, Samuel; Schmutzhard, Erich; Leonardi, Matilde; Padovani, Alessandro; Abd-Allah, Foad; Charway-Felli, Augustina; Emmerich, Julius Valentin; Umapathi, Thirugnanam; Satishchandra, Parthasarthy; Hoo, Fan Kee; Dalmau, Josep; Oreja-Guevara, Celia; Ferreira, Lucia Brito; Pfausler, Bettina; Michael, Benedict; Tagliavini, Fabrizio; Hoglinger, Gunter; Endres, Matthias; Klein, Christine; Hemmer, Bernhard; Correll, William; Sejvar, James; Solomon, Tom			A call for a global COVID-19 Neuro Research Coalition	LANCET NEUROLOGY			English	Letter									[Winkler, Andrea Sylvia] Tech Univ Munich, Klinikum Rechts Isar, Ctr Global Hlth, Dept Neurol, Munich, Germany; [Winkler, Andrea Sylvia] Univ Oslo, Ctr Global Hlth, Inst Hlth & Soc, Oslo, Norway; [Knauss, Samuel; Emmerich, Julius Valentin; Endres, Matthias] Charite Univ Med Berlin, Dept Neurol & Expt Neurol, Berlin, Germany; [Knauss, Samuel; Emmerich, Julius Valentin; Endres, Matthias] Free Univ Berlin, Berlin, Germany; [Knauss, Samuel; Emmerich, Julius Valentin; Endres, Matthias] Humboldt Univ, Berlin, Germany; [Knauss, Samuel; Emmerich, Julius Valentin; Endres, Matthias] Berlin Inst Hlth, Berlin, Germany; [Schmutzhard, Erich; Pfausler, Bettina] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Leonardi, Matilde] Fdn Ist Ricovero Cura Carattere Sci IRCCS, Ist Neurol Carlo Besta, Italian WHO Collaborating Ctr Res Branch, Neurol Publ Hlth,Disabil Unit, Milan, Italy; [Padovani, Alessandro] Univ Brescia, Inst Neurol, Brescia, Italy; [Abd-Allah, Foad] Cairo Univ, Kasr Al Ainy Sch Med, Dept Neurol, Cairo, Egypt; [Abd-Allah, Foad; Charway-Felli, Augustina] African Acad Neurol, Cape Town, South Africa; [Charway-Felli, Augustina] 37 Mil Hosp, Accra, Ghana; [Umapathi, Thirugnanam] Univ Putra, Fac Med & Hlth Sci, Dept Internal Med, Neurol Unit, Serdang, Malaysia; [Satishchandra, Parthasarthy] Natl Inst Mental Hlth & Neurosci, Bangalore, Karnataka, India; [Hoo, Fan Kee] Natl Neurosci Inst, Singapore, Singapore; [Dalmau, Josep] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Barcelona, Spain; [Dalmau, Josep] Catalan Inst Res & Adv Studies, Barcelona, Spain; [Oreja-Guevara, Celia] Univ Complutense Madrid, Fac Med, Dept Med, Dept Neurol,Hosp Clin San Carlos, Madrid, Spain; [Ferreira, Lucia Brito] Hosp Restauracao, Dept Neurol, Recife, PE, Brazil; [Michael, Benedict; Solomon, Tom] Univ Liverpool, Protect Res Unit Emerging & Zoonot Infect, Natl Inst Hlth Res Hlth, Liverpool, Merseyside, England; [Michael, Benedict] Walton Ctr Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, England; [Tagliavini, Fabrizio] Fdn Ist Ricovero & Cura Carattere Sci IRCSS, Ist Neurol Carlo Besta, Milan, Italy; [Tagliavini, Fabrizio] Italian IRCCS Network Neuroscie & Neurorehabil, Milan, Italy; [Hoglinger, Gunter] Hannover Med Sch, Dept Neurol, Hannover, Germany; [Klein, Christine] Univ Lubeck, Inst Neurogenet, Lubeck, Germany; [Hemmer, Bernhard] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Munich, Germany; [Correll, William] Sir Charles Gairdner Hosp, Dept Neurol, Perth, WA, Australia; [Correll, William] Univ Western Australia, Perron Inst, Ctr Neuromuscular & Neurol Disorders, Perth, WA, Australia; [Correll, William] World Federat Neurol, London, England; [Sejvar, James] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA USA	Technical University of Munich; University of Oslo; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Medical University of Innsbruck; IRCCS Istituto Neurologico Besta; University of Brescia; Egyptian Knowledge Bank (EKB); Cairo University; Universiti Putra Malaysia; National Institute of Mental Health & Neurosciences - India; National Neuroscience Institute (NNI); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA; Complutense University of Madrid; Hospital Clinico San Carlos; University of Liverpool; Walton Centre; IRCCS Istituto Neurologico Besta; Hannover Medical School; University of Lubeck; Technical University of Munich; University of Western Australia; University of Western Australia; Centers for Disease Control & Prevention - USA	Winkler, AS (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Ctr Global Hlth, Dept Neurol, Munich, Germany.; Winkler, AS (corresponding author), Univ Oslo, Ctr Global Hlth, Inst Hlth & Soc, Oslo, Norway.	andrea.winkler@tum.de	Hemmer, Bernhard/GPX-8451-2022; Höglinger, Günter U/F-2388-2015; Klein, Christine/AGK-8003-2022; Hemmer, Bernhard/AAU-3066-2021; Padovani, Alessandro/ABI-7312-2020; Hemmer, Bernhard/AAT-8388-2021; Tagliavini, Fabrizio/AAO-7891-2021; Hoo, Fan Kee/J-2591-2013	Hemmer, Bernhard/0000-0001-5985-6784; Höglinger, Günter U/0000-0001-7587-6187; Padovani, Alessandro/0000-0002-0119-3639; Tagliavini, Fabrizio/0000-0003-1039-7315; Endres, Matthias/0000-0001-6520-3720; Emmrich, Julius/0000-0002-3393-0840; Schmutzhard, Erich/0000-0003-3295-7491; Klein, Christine/0000-0003-2102-3431; Michael, Benedict/0000-0002-8693-8926; Dalmau, Josep/0000-0001-5856-2813; Hoo, Fan Kee/0000-0003-1687-627X	Data Safety Monitoring Committee of the GlaxoSmithKline Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children [GSK3390107A]; MRC [MR/V033441/1, MR/V03605X/1] Funding Source: UKRI	Data Safety Monitoring Committee of the GlaxoSmithKline Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	ME reports grants from Bayer and fees paid to their institution from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKline, Sanofi, Covidien, and Novartis, all outside of the submitted work. TS reports fees paid to their institution from GlaxoSmithKline Ebola Vaccine programme, Siemens Diagnostics Clinical Advisory Board, Siemens Healthineers Clinical Advisory Board, Data Safety Monitoring Committee of the GlaxoSmithKline Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children GSK3390107A (ChAd3 EBO-Z) vaccine, during the conduct of the study. TS has a patent test for bacterial meningitis based on a blood test, filed for patent pending (GB 1606537.7). All other authors declare no competing interests. ASW and SK contributed equally.	Colson PW, 2020, AIDS BEHAV, V24, P3436, DOI 10.1007/s10461-020-02901-6; COVID-19 Clinical Res Coalition, 2020, LANCET, V395, P1322, DOI 10.1016/S0140-6736(20)30798-4; Helmich RC, 2020, J PARKINSON DIS, V10, P351, DOI 10.3233/JPD-202038; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127	5	16	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					482	484		10.1016/S1474-4422(20)30150-2	http://dx.doi.org/10.1016/S1474-4422(20)30150-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470416	Green Published, Bronze			2022-12-18	WOS:000544059200020
J	Chabriat, H; Bassetti, CL; Marx, U; Audoli-Inthavong, ML; Sors, A; Lambert, E; Wattez, M; Hermann, DM				Chabriat, Hugues; Bassetti, Claudio L.; Marx, Ute; Audoli-Inthavong, Marie-Laure; Sors, Aurore; Lambert, Estelle; Wattez, Marine; Hermann, Dirk M.		RESTORE BRAIN Study Investigators	Safety and efficacy of GABA(A) alpha 5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial	LANCET NEUROLOGY			English	Article							TONIC INHIBITION; RECOVERY; BRAIN; THERAPY	Background S44819, a selective GABA(A) alpha 5 receptor antagonist, reduces tonic post-ischaemic inhibition of the periinfarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitability in a transcranial magnetic stimulation study in healthy volunteers. The Randomized Efficacy and Safety Trial of Oral GABA(A) alpha 5 antagonist S44819 after Recent ischemic Event (RESTORE BRAIN) aimed to evaluate the safety and efficacy of S44819 for enhancing clinical recovery of patients with ischaemic stroke. Methods RESTORE BRAIN was an international, randomised, double-blind, parallel-group, placebo-controlled, multicentre phase 2 trial that evaluated the safety and efficacy of oral S44189 in patients with recent ischaemic stroke. The study was done in specialised stroke units in 92 actively recruiting centres in 14 countries: ten were European countries (Belgium, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, and the UK) and four were non-European countries (Australia, Brazil, Canada, and South Korea). Patients aged 18-85 years with acute ischaemic stroke involving cerebral cortex (National Institute of Health Stroke Scale [NIHSS] score 7-20) without previous disability were eligible for inclusion. Participants were randomly assigned to receive 150 mg S44819 twice a day, 300 mg S44819 twice a day, or placebo twice a day by a balanced, non-adaptive randomisation method with a 1:1:1 ratio. Treatment randomisation and allocation were centralised via the interactive web response system using computer-generated random sequences with a block size of 3. Blinding of treatment was achieved by identical appearance and taste of all sachets. Patients, investigators and individuals involved in the analysis of the trial were masked to group assignment. The primary endpoint was the modified Rankin Scale (mRS) score 90 days from onset of treatment, evaluated by shift analysis (predefined main analysis) or by dichotomised analyses using 0-1 versus 2-6 and 0-2 versus 3-6 cutoffs (predefined secondary analysis). Secondary endpoints were the effects of S44819 on the NIHSS and Montreal Cognitive Assessment (MoCA) scores, time needed to complete parts A and B of the Trail Making Test, and the Barthel index. Efficacy analyses were done on all patients who received at least one dose of treatment and had at least one mRS score taken after day 5 (specifically, on or after day 30). Safety was compared across treatment groups for all patients who received at least one dose of treatment. The study was registered at ClinicalTrials.gov, NCT02877615. Findings Between Dec 19, 2016, and Nov 16, 2018, 585 patients were enrolled in the study. Of these, 197 (34%) were randomly assigned to receive 150 mg S44819 twice a day, 195 (33%) to receive 300 mg S44819 twice a day, and 193 (33%) to receive placebo twice a day. 189 (96%) of 197 patients in the 150 mg S44819 group, 188 (96%) of 195 patients in the 300 mg S44819 group, and 191 (99%) patients in the placebo group received at least one dose of treatment and had at least one mRS score taken after day 5, and were included in efficacy analyses. 195 (99%) of 197 patients in the 150 mg S44819 group, 194 (99%) of 195 patients in the 300 mg S44819 group, and 193 (100%) patients in the placebo group received at least one dose of treatment, and were included in safety analyses. The primary endpoint of mRS at day 90 did not differ between each of the two S44819 groups and the placebo group (OR 0.91 [95% CI 0.64-1.31]; p=0.80 for 150 mg S44819 compared with placebo and OR 1.17 [95% CI 0.81-1.67]; p=0.80 for 300 mg S44819 compared with placebo). Likewise, dichotomised mRS scores at day 90 (mRS 0-2 vs 3-6 or mRS 0-1 vs 2-6) did not differ between groups. Secondary endpoints did not reveal any significant group differences. The median NIHSS score at day 90 did not differ between groups (4 [IQR 2-8] in 150 mg S44819 group, 4 [2-7] in 300 mg S44819 group, and 4 [2-6] in placebo group), nor did the number of patients at day 90 with an NIHSS score of up to 5 (95 [61%] of 156 in 150 mg S44819 group, 106 [66%] of 161 in 300 mg S44819 group, and 104 [66%] of 157 in placebo group) versus more than 5 (61 [39%] in 150 mg S44819 group, 55 [34%] in 300 mg S44819 group, and 53 [34%] in placebo group). Likewise, the median MoCA score (22.0 [IQR 17.0-26.0] in 150 mg S44819 group, 23.0 [19.0-26.5] in 300 mg S44819 group, and 22.0 [17.0-26.0] in placebo group), time needed to complete parts A (50 s [IQR 42-68] in 150 mg S44819 group, 49 s [36-63] in 300 mg S44819 group, and 50 s [38-68] in placebo group) and B (107 s [81-144] in 150 mg S44819 group, 121 s [76-159] in 300 mg S44819 group, and 130 s [86-175] in placebo group) of the Trail Making Test, and the Barthel index (90 [IQR 60-100] in 150 mg S44819 group, 90 [70-100] in 300 mg S44819 group, and 90 [70-100] in placebo group) were similar in all groups. Number and type of adverse events were similar between the three groups. There were no drug-related adverse events and no drug-related deaths. Interpretation There was no evidence that S44819 improved clinical outcome in patients after ischaemic stroke, and thus S44819 cannot be recommended for stroke therapy. The concept of tonic inhibition after stroke should be re-evaluated in humans. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Chabriat, Hugues] Paris Diderot Univ, Lariboisiere Hosp, Dept Neurol, Paris, France; [Chabriat, Hugues] INSERM, U1141, Paris, France; [Bassetti, Claudio L.] Univ Hosp Berne, Dept Neurol, Bern, Switzerland; [Marx, Ute; Audoli-Inthavong, Marie-Laure; Sors, Aurore; Lambert, Estelle; Wattez, Marine] IRIS, Suresnes, France; [Hermann, Dirk M.] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, D-45122 Essen, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Bern; University Hospital of Bern; Servier; Institut de Recherches Internationales Servier; University of Duisburg Essen	Hermann, DM (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, D-45122 Essen, Germany.	dirk.hermann@uk-essen.de	Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk/GZB-9350-2022; IBiS, Neurovascular/P-5842-2016; Hermann, Dirk M./AAT-3652-2021; Toni, Danilo/K-3151-2016; Butcher, Ken/ABC-6632-2020; Vecsei, Laszlo/B-2066-2010; Chabriat, Hugues/G-5699-2010; Davis, Stephen/L-5260-2013; Brola, Waldemar/D-8813-2014	IBiS, Neurovascular/0000-0001-9511-0672; Hermann, Dirk M./0000-0003-0198-3152; Ximenez-Carrillo Rico, Alvaro/0000-0002-4195-7752; Sibon, igor/0000-0002-1171-4215; Cloud, Geoffrey/0000-0002-8365-6907; Toni, Danilo/0000-0003-2735-8427; wein, theodore/0000-0002-8994-8628; Csanyi, Attila/0000-0002-2368-3751; Butcher, Ken/0000-0002-0590-7918; Vecsei, Laszlo/0000-0001-8037-3672; Sprigg, Nikola/0000-0002-5871-8168; Dippel, Diederik/0000-0002-9234-3515; kleinig, Timothy/0000-0003-4430-3276; Rejdak, Konrad/0000-0002-7019-6681; Chabriat, Hugues/0000-0001-8436-6074; Davis, Stephen/0000-0003-0962-2300; Brola, Waldemar/0000-0002-7955-3454; Bassetti, Claudio/0000-0002-4535-0245				Carmichael ST, 2016, ANN NEUROL, V79, P895, DOI 10.1002/ana.24653; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Darmani G, 2016, J NEUROSCI, V36, P12312, DOI 10.1523/JNEUROSCI.1689-16.2016; Etherington LA, 2017, NEUROPHARMACOLOGY, V125, P353, DOI 10.1016/j.neuropharm.2017.08.012; Gacsalyi I, 2017, NEUROPHARMACOLOGY, V125, P30, DOI 10.1016/j.neuropharm.2017.07.005; Hermann DM, 2019, NEURAL REGEN RES, V14, P1517, DOI 10.4103/1673-5374.255963; Hermann DM, 2012, LANCET NEUROL, V11, P369, DOI 10.1016/S1474-4422(12)70039-X; Johnson W, 2016, B WORLD HEALTH ORGAN, V94, P634, DOI 10.2471/BLT.16.181636; Kanazawa M, 2019, J CEREBR BLOOD F MET, V39, DOI 10.1177/0271678X19834158; Lake EMR, 2015, J CEREBR BLOOD F MET, V35, P1601, DOI 10.1038/jcbfm.2015.86; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Pace M, 2019, BIORXIV, DOI [10.1101/721282 (preprint), DOI 10.1101/721282]; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Wahl AS, 2014, SCIENCE, V344, P1250, DOI 10.1126/science.1253050; Wang YC, 2018, STROKE, V49, P2495, DOI 10.1161/STROKEAHA.118.021378	16	16	16	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					226	233		10.1016/S1474-4422(20)30004-1	http://dx.doi.org/10.1016/S1474-4422(20)30004-1			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	32085836	Green Published			2022-12-18	WOS:000514832700019
J	Panza, F; Lozupone, M; Logroscino, G				Panza, Francesco; Lozupone, Madia; Logroscino, Giancarlo			Understanding frailty to predict and prevent dementia	LANCET NEUROLOGY			English	Editorial Material									[Panza, Francesco; Lozupone, Madia; Logroscino, Giancarlo] Univ Bari Aldo Moro, Dept Basic Med Neurosci & Sense Organs, Neurodegenerat Dis Unit, Bari, Italy; [Panza, Francesco; Logroscino, Giancarlo] Univ Bari Aldo Moro, Pia Fdn Cardinale G Panico, Ctr Neurodegenerat Dis & Aging Brain, Dept Clin Res Neurol, Lecce, Italy; [Panza, Francesco] Fdn IRCCS Casa Sollievo Sofferenza, Geriatr Unit, Foggia, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Panza, F (corresponding author), Univ Bari Aldo Moro, Dept Basic Med Neurosci & Sense Organs, Neurodegenerat Dis Unit, Bari, Italy.; Panza, F (corresponding author), Univ Bari Aldo Moro, Pia Fdn Cardinale G Panico, Ctr Neurodegenerat Dis & Aging Brain, Dept Clin Res Neurol, Lecce, Italy.; Panza, F (corresponding author), Fdn IRCCS Casa Sollievo Sofferenza, Geriatr Unit, Foggia, Italy.	geriat.dot@uniba.it	Panza, Francesco/Y-2539-2019; Panza, Francesco/M-6804-2017; Lozupone, Madia/F-7262-2018	Panza, Francesco/0000-0002-7220-0656; Panza, Francesco/0000-0002-7220-0656; Lozupone, Madia/0000-0002-1674-9724				Andrieu S, 2017, LANCET NEUROL, V16, P377, DOI 10.1016/S1474-4422(17)30040-6; Liu ZY, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1174-8; Lozupone M, 2018, J ALZHEIMERS DIS, V65, P989, DOI 10.3233/JAD-180466; Panza F, 2018, J ALZHEIMERS DIS, V62, P993, DOI 10.3233/JAD-170963; Solfrizzi V, 2017, AM J GERIAT PSYCHIAT, V25, P1236, DOI 10.1016/j.jagp.2017.05.018; Solfrizzi V, 2017, J AM MED DIR ASSOC, V18, DOI 10.1016/j.jamda.2016.10.012; Strandberg TE, 2007, LANCET, V369, P1328, DOI [10.1016/S0140-6736(07)60613-8, 10.1016/S0140-6736(12)62167-9]; Wallace LMK, 2019, LANCET NEUROL, V18, P177, DOI 10.1016/S1474-4422(18)30371-5	8	16	16	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2019	18	2					133	134		10.1016/S1474-4422(18)30446-0	http://dx.doi.org/10.1016/S1474-4422(18)30446-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HI0TY	30663601				2022-12-18	WOS:000456158200005
J	Tesson, C; Brefel-Courbon, C; Corvol, JC; Lesage, S; Brice, A				Tesson, Christelle; Brefel-Courbon, Christine; Corvol, Jean-Christophe; Lesage, Suzanne; Brice, Alexis		French Parkinson's Dis Genetics St	LRP10 in alpha-synucleinopathies	LANCET NEUROLOGY			English	Letter									[Tesson, Christelle; Corvol, Jean-Christophe; Lesage, Suzanne; Brice, Alexis] UPMC Paris 06 Univ, Sorbonne Univ, Hop Salpetriere,UMR S1127, Brain & Spinal Cord Inst ICM,Inserm U1127,CNRS UM, Paris, France; [Brefel-Courbon, Christine] Univ Toulouse, Fac Med, Toulouse Neuroimaging Ctr, Dept Clin & Med Pharmacol,UMR 1214, Toulouse, France; [Corvol, Jean-Christophe] Pitie Neurosci Clin Invest Ctr CIC 1422, Paris, France; [Brice, Alexis] Publ Hosp Paris, AP HP, GHPS, Pitie Salpetriere Hosp Grp,Dept Genet, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Brice, A (corresponding author), UPMC Paris 06 Univ, Sorbonne Univ, Hop Salpetriere,UMR S1127, Brain & Spinal Cord Inst ICM,Inserm U1127,CNRS UM, Paris, France.	alexis.brice@icm-institute.org	brice, alexis/AAE-8275-2019; Corvol, Jean-Christophe/F-2124-2017; Brice, Alexis/A-2170-2009	brice, alexis/0000-0002-0941-3990; Corvol, Jean-Christophe/0000-0001-7325-0199; Anheim, Mathieu/0000-0001-8121-0605	Actelion; Michael J Fox Foundation; Ipsen; Sanofi; Novartis; Clevexel; French Agence Nationale de Recherche; Association pour la Recherche en Neuro-imagerie et Neuropsychologie; AP-HP; France Parkinson Association; Federation pour la Recherche sur le Cerveau; Mohammed V University (Rabat); Fondation de France; Fondation pour la Recherche Medicale; Fondation Maladies Rares (ex GIS); Fondation Roger de Spoelberch; Prix Allianz Institut de France; French programme Investissements d'avenir [ANR-10-IAIHU-06]	Actelion; Michael J Fox Foundation; Ipsen(Ipsen); Sanofi; Novartis(Novartis); Clevexel; French Agence Nationale de Recherche(French National Research Agency (ANR)); Association pour la Recherche en Neuro-imagerie et Neuropsychologie; AP-HP; France Parkinson Association; Federation pour la Recherche sur le Cerveau; Mohammed V University (Rabat); Fondation de France(Fondation de France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation Maladies Rares (ex GIS); Fondation Roger de Spoelberch; Prix Allianz Institut de France; French programme Investissements d'avenir(French National Research Agency (ANR))	J-CC has served on scientific advisory boards for Clevexel, Biogen, Air Liquide, BrainEver, Theranexus, BMS, Zambon, Pfizer, Abbvie, Amarantus, and Alzprotect; has received research grants from Actelion, Michael J Fox Foundation, Ipsen, and Sanofi; and has received travel grants from Novartis and Clevexel. AB has received grants from French Agence Nationale de Recherche, Association pour la Recherche en Neuro-imagerie et Neuropsychologie, AP-HP, France Parkinson Association and Federation pour la Recherche sur le Cerveau, Mohammed V University (Rabat), Fondation de France, Fondation pour la Recherche Medicale, Fondation Maladies Rares (ex GIS), Fondation Roger de Spoelberch, and Prix Allianz Institut de France. SL reports grants from the French programme Investissements d'avenir (ANR-10-IAIHU-06) and Fondation de France. CB-C has served on scientific advisory boards for Teva, Aguettant, UCB, Zambon, Abbvie, and Orkyn. CT declares no competing interests.	Klein C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a008888; Quadri M, 2018, LANCET NEUROL, V17, P597, DOI 10.1016/S1474-4422(18)30179-0	2	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1034	1034		10.1016/S1474-4422(18)30400-9	http://dx.doi.org/10.1016/S1474-4422(18)30400-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30507386	Green Submitted, Bronze			2022-12-18	WOS:000450119300011
J	Partinen, M; Kornum, BR; Plazzi, G; Jennum, P; Julkunen, I; Vaarala, O				Partinen, Markku; Kornum, Birgitte Rahbek; Plazzi, Giuseppe; Jennum, Poul; Julkunen, Ilkka; Vaarala, Outi			Does autoreactivity have a role in narcolepsy?	LANCET NEUROLOGY			English	Letter									[Partinen, Markku] Vitalmed Res Ctr, Helsinki Sleep Clin, Helsinki, Finland; [Partinen, Markku] Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland; [Vaarala, Outi] Univ Helsinki, Inst Clin Med, Helsinki, Finland; [Kornum, Birgitte Rahbek] Univ Copenhagen, Dept Diagnost, Mol Sleep Lab, Glostrup Hosp, Glostrup, Denmark; [Kornum, Birgitte Rahbek; Jennum, Poul] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, Danish Ctr Sleep Med, Glostrup, Denmark; [Plazzi, Giuseppe] Univ Bologna, Dept Biomed & Neuromotor Sci, I-40126 Bologna, Italy; [Plazzi, Giuseppe] IRCCS Ist Sci Neurol, Bologna, Italy; [Julkunen, Ilkka] Univ Turku, Dept Virol, Turku, Finland; [Julkunen, Ilkka] Natl Inst Hlth & Welf, Dept Infect Dis Surveillance & Control, Helsinki, Finland; [Vaarala, Outi] AstraZeneca, Resp Inflammatory & Autoimmune Dis, Innovat Med, Molndal, Sweden	University of Helsinki; University of Helsinki; University of Copenhagen; University of Copenhagen; University of Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University of Turku; Finland National Institute for Health & Welfare; AstraZeneca	Partinen, M (corresponding author), Vitalmed Res Ctr, Helsinki Sleep Clin, Helsinki, Finland.	markku.partinen@helsinki.fi	Kornum, Birgitte Rahbek/K-9193-2015; Plazzi, Giuseppe/AAB-9627-2020	Kornum, Birgitte Rahbek/0000-0002-2515-9451; Plazzi, Giuseppe/0000-0002-1051-0472; Partinen, Markku/0000-0002-8182-9368	Lundbeck Foundation [R105-2011-9362] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Bergman P, 2014, P NATL ACAD SCI USA, V111, pE3735, DOI 10.1073/pnas.1412189111; De la Herran-Arita AK, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009995; Katzav A, 2013, J AUTOIMMUN, V45, P24, DOI 10.1016/j.jaut.2013.06.010; Partinen M, 2014, LANCET NEUROL, V13, P600, DOI 10.1016/S1474-4422(14)70075-4	4	16	16	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1072	1073		10.1016/S1474-4422(14)70168-1	http://dx.doi.org/10.1016/S1474-4422(14)70168-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25316012				2022-12-18	WOS:000343783900012
J	Amouyel, P				Amouyel, Philippe			From genes to stroke subtypes	LANCET NEUROLOGY			English	Editorial Material							SEQUENCE VARIANT; ASSOCIATION; SUSCEPTIBILITY; DISEASE; RISK		Univ Lille 2, INSERM, IPL, Inst Pasteur Lille,UMR744, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Amouyel, P (corresponding author), Univ Lille 2, INSERM, IPL, Inst Pasteur Lille,UMR744, 1 Rue Calmette, F-59019 Lille, France.	philippe.amouyel@pasteur-lille.fr		Amouyel, Philippe/0000-0001-9088-234X				Baltimore D, 2001, NATURE, V409, P814, DOI 10.1038/35057267; Debette S, 2009, INT J STROKE, V4, P224, DOI 10.1111/j.1747-4949.2009.00281.x; Gretarsdottir S, 2008, ANN NEUROL, V64, P402, DOI 10.1002/ana.21480; Gudbjartsson DF, 2009, NAT GENET, V41, P876, DOI 10.1038/ng.417; Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72; Holmes David, 2011, Lancet Neurol, V10, P502, DOI 10.1016/S1474-4422(11)70079-5; Lambert JC, 2010, NAT GENET, V42, P189, DOI 10.1038/ng0310-189; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Nails MA, 2011, LANCET, V377, P641, DOI 10.1016/S0140-6736(10)62345-8; Traylor M, 2012, LANCET, DOI DOI 10.1016/51474-4422(12)70234-X; Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609	11	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2012	11	11					931	933		10.1016/S1474-4422(12)70235-1	http://dx.doi.org/10.1016/S1474-4422(12)70235-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	028KW	23041236				2022-12-18	WOS:000310422200003
J	[Anonymous]				[Anonymous]			NeuroNEXT: accelerating drug development in neurology	LANCET NEUROLOGY			English	Editorial Material															NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS077352] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2012	11	2					119	119		10.1016/S1474-4422(12)70008-X	http://dx.doi.org/10.1016/S1474-4422(12)70008-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	885EF	22265207	Bronze			2022-12-18	WOS:000299760600001
J	Graus, F; Dalmau, J				Graus, Francesc; Dalmau, Josep			CNS autoimmunity: new findings and pending issues	LANCET NEUROLOGY			English	Editorial Material							LIMBIC ENCEPHALITIS; ANTIBODIES; SEIZURES		[Graus, Francesc; Dalmau, Josep] Serv Neurol, Barcelona, Spain; [Graus, Francesc; Dalmau, Josep] Inst Recerca Biomed August Pi & Sunyer, Barcelona, Spain; [Dalmau, Josep] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain; [Dalmau, Josep] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA; University of Pennsylvania	Graus, F (corresponding author), Serv Neurol, Barcelona, Spain.	josep.dalmau@uphs.upenn.edu	Graus, Francesc/K-9904-2018	Dalmau, Josep/0000-0001-5856-2813; Graus, Francesc/0000-0002-8924-8322	ICREA Funding Source: Custom; NCI NIH HHS [R56 CA089054, R01 CA107192, R01 CA089054, R01CA89054] Funding Source: Medline; NIMH NIH HHS [R01MH094741, R01 MH094741] Funding Source: Medline; NINDS NIH HHS [R01 NS077851, R01NS077851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089054, R56CA089054, R01CA107192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH094741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS077851] Funding Source: NIH RePORTER	ICREA(ICREA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrade DM, 2011, NEUROLOGY, V76, P1355, DOI 10.1212/WNL.0b013e3182152808; Boronat A, 2011, NEUROLOGY, V76, P795, DOI 10.1212/WNL.0b013e31820e7b8d; Cash SS, 2011, NEW ENGL J MED, V365, P1825, DOI 10.1056/NEJMcpc1100924; Cornelius JR, 2011, ARCH NEUROL-CHICAGO, V68, P733, DOI 10.1001/archneurol.2011.106; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Irani SR, 2011, ANN NEUROL, V69, P892, DOI 10.1002/ana.22307; Irani SR, 2010, BRAIN, V133, P2734, DOI 10.1093/brain/awq213; Lai MZ, 2010, LANCET NEUROL, V9, P776, DOI 10.1016/S1474-4422(10)70137-X; Lancaster E, 2011, NEUROLOGY, V77, P1698, DOI 10.1212/WNL.0b013e3182364a44; Lancaster E, 2011, ANN NEUROL, V69, P303, DOI 10.1002/ana.22297; Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2; Martinez-Hernandez E, 2011, NEUROLOGY, V77, P589, DOI 10.1212/WNL.0b013e318228c136	12	16	16	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					17	19		10.1016/S1474-4422(11)70280-0	http://dx.doi.org/10.1016/S1474-4422(11)70280-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172617	Green Accepted			2022-12-18	WOS:000298513700011
J	Brown, MM; Raine, R				Brown, Martin M.; Raine, Rosalind			Should sex influence the choice between carotid stenting and carotid endarterectomy?	LANCET NEUROLOGY			English	Editorial Material							ACUTE STROKE; STENOSIS; TRIAL		[Brown, Martin M.] UCL, Inst Neurol, London, England; [Raine, Rosalind] UCL, Dept Epidemiol & Publ Hlth, London, England	University of London; University College London; University of London; University College London	Brown, MM (corresponding author), UCL, Inst Neurol, London, England.	m.brown@ion.ucl.ac.uk		Brown, Martin M/0000-0002-3273-1356; Raine, Rosalind/0000-0003-0904-749X				Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781; Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Di Carlo A, 2003, STROKE, V34, P1114, DOI 10.1161/01.STR.0000068410.07397.D7; Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Ederle J, 2009, LANCET NEUROL, V8, P898, DOI 10.1016/S1474-4422(09)70228-5; Foerch C, 2007, STROKE, V38, P2123, DOI 10.1161/STROKEAHA.106.478495; Howard VJ, 2011, LANCET NEUROL, V10, P530, DOI 10.1016/S1474-4422(11)70080-1; Macdonald S, 2009, STROKE, V40, P1698, DOI 10.1161/STROKEAHA.109.547117; Marquardt L, 2010, STROKE, V41, pE11, DOI 10.1161/STROKEAHA.109.561837; Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983	13	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					494	497		10.1016/S1474-4422(11)70103-X	http://dx.doi.org/10.1016/S1474-4422(11)70103-X			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21550315				2022-12-18	WOS:000291376100004
J	Elbaz, A				Elbaz, Alexis			LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							MUTATION; G2019S; PENETRANCE; COHORT		Hop La Pitie Salpetriere, INSERM, Unit 708, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Elbaz, A (corresponding author), Hop La Pitie Salpetriere, INSERM, Unit 708, 47 Bvd Hop, F-75651 Paris 13, France.	elbaz@chups.jussieu.fr	Elbaz, Alexis/F-8952-2017	Elbaz, Alexis/0000-0001-9724-5490				Clark LN, 2006, NEUROLOGY, V67, P1786, DOI 10.1212/01.wnl.0000244345.49809.36; Gail MH, 1999, GENET EPIDEMIOL, V16, P15, DOI 10.1002/(SICI)1098-2272(1999)16:1<15::AID-GEPI3>3.0.CO;2-8; Goldwurm S, 2007, NEUROLOGY, V68, P1141, DOI 10.1212/01.wnl.0000254483.19854.ef; Haugarvoll K, 2008, NEUROLOGY, V70, P1456, DOI 10.1212/01.wnl.0000304044.22253.03; Healy DG, 2008, LANCET NEUROL, V7, P583, DOI 10.1016/S1474-4422(08)70117-0; Hulihan MM, 2008, LANCET NEUROL, V7, P591, DOI 10.1016/S1474-4422(08)70116-9; Kachergus J, 2005, AM J HUM GENET, V76, P672, DOI 10.1086/429256; Ozelius LJ, 2006, NEW ENGL J MED, V354, P424, DOI 10.1056/NEJMc055509; Williams-Gray CH, 2006, J NEUROL NEUROSUR PS, V77, P665, DOI 10.1136/jnnp.2005.085019	9	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2008	7	7					562	564		10.1016/S1474-4422(08)70118-2	http://dx.doi.org/10.1016/S1474-4422(08)70118-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	320DJ	18539536				2022-12-18	WOS:000257213600002
J	Kikuchi, S; Fukazawa, T				Kikuchi, S; Fukazawa, T			"OSMS is NMO, but not MS": confirmed by NMO-IgG?	LANCET NEUROLOGY			English	Editorial Material							NEUROMYELITIS-OPTICA; MULTIPLE-SCLEROSIS; SERUM AUTOANTIBODY; MARKER		Hokkaido Univ, Grad Sch Med, Dept Neurol, Sapporo, Hokkaido 060, Japan; Nishimaruyama Hosp, Dept Neurol, Sapporo, Hokkaido, Japan	Hokkaido University	Kikuchi, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurol, Sapporo, Hokkaido 060, Japan.	skikuti@med.hokudai.ac.jp						Cree BAC, 2005, NEUROLOGY, V64, P1270, DOI 10.1212/01.WNL.0000159399.81861.D5; Cree BAC, 2004, NEUROLOGY, V63, P2039, DOI 10.1212/01.WNL.0000145762.60562.5D; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Saida T, 2005, NEUROLOGY, V64, P621, DOI 10.1212/01.WNL.0000151856.10387.E2; Wingerchuk DM, 2005, NEUROLOGY, V64, pA38; Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107	7	16	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					594	595		10.1016/S1474-4422(05)70179-4	http://dx.doi.org/10.1016/S1474-4422(05)70179-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16168927				2022-12-18	WOS:000232245900007
J	Sheth, RD				Sheth, RD			Bone health in epilepsy	LANCET NEUROLOGY			English	Editorial Material							MINERAL DENSITY		Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sheth, RD (corresponding author), Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.	sheth@neurology.wisc.edu		Sheth, Raj D/0000-0003-3966-5643				Drezner MK, 2004, EPILEPSY BEHAV, V5, pS41, DOI 10.1016/j.yebeh.2003.11.028; Ensrud KE, 2004, NEUROLOGY, V62, P2051, DOI 10.1212/01.WNL.0000125185.74276.D2; Sheth RD, 1996, PEDIATRICS, V98, P948; SHETH RD, 1995, J PEDIATR-US, V127, P256, DOI 10.1016/S0022-3476(95)70304-7; Sheth RD, 2002, EPILEPSIA, V43, P1453, DOI 10.1046/j.1528-1157.2002.48102.x	5	16	16	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2004	3	9					516	516		10.1016/S1474-4422(04)00848-8	http://dx.doi.org/10.1016/S1474-4422(04)00848-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	849VD	15324717				2022-12-18	WOS:000223568300012
J	Chitnis, T; Banwell, B; Kappos, L; Arnold, DL; Gucuyener, K; Deiva, K; Skripchenko, N; Cui, LY; Saubadu, S; Hu, W; Benamor, M; Le-Halpere, A; Truffinet, P; Tardieu, M				Chitnis, Tanuja; Banwell, Brenda; Kappos, Ludwig; Arnold, Douglas L.; Guecueyener, Kivilcim; Deiva, Kumaran; Skripchenko, Natalia; Cui, Li-Ying; Saubadu, Stephane; Hu, Wenruo; Benamor, Myriam; Le-Halpere, Annaig; Truffinet, Philippe; Tardieu, Marc		Terikids Invest	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial	LANCET NEUROLOGY			English	Article							ORAL TERIFLUNOMIDE; INTERFERON BETA-1A; CLINICAL-FEATURES; DISEASE; ONSET; MS; GUIDELINE; REVISIONS; CRITERIA	Background Therapeutic options for children with multiple sclerosis are scarce. Teriflunomide is approved in more than 80 countries for the treatment of adults with relapsing multiple sclerosis. The TERIKIDS study examined the safety and efficacy of teriflunomide in children with relapsing multiple sclerosis. Methods The TERIKIDS trial was a multicentre, phase 3, double-blind, parallel-group, randomised, placebo controlled study conducted at 57 clinical centres in 22 countries in Asia, Europe, the Middle East, North Africa, and North America. The trial enrolled patients aged 10-17 years, diagnosed with relapsing multiple sclerosis and with at least one relapse in the year preceding screening or at least two relapses in the 2 years preceding screening. Patients were randomly assigned (2:1) to oral teriflunomide (dosage equivalent to 14 tng in adults) or matching placebo, using an interactive web and voice response system, for up to 96 weeks. Personnel in all sites and all patients were masked to study treatment in the double-blind period. Early entry into a subsequent 96 -week open-label extension phase was possible before the end of the double-blind period for patients with confirmed clinical relapse or high MRI activity (at least five new or enlarged T2 lesions at week 24, followed by at least nine new or enlarged T2 lesions at week 36, or at least five new or enlarged T2 lesions at weeks 36 and 48, or at weeks 48 and 72). The primary endpoint was time to first confirmed clinical relapse by the end of the double-blind period. Key secondary imaging endpoints were number of new or enlarged T2 lesions and number of gadolinium-enhancing lesions per MRI scan. Efficacy endpoints were analysed in the intention-to-treat population, and safety was assessed in all patients randomly assigned to treatment and exposed to the double-blind study medication. This study is registered with ClinicalTrials.gov (trial number NCT02201108) and is closed to recruitment, but an additional optional open-label extension is ongoing. Findings Between July 24, 2014, and the date of last patient visit on Oct 25, 2019, 185 patients were screened for eligibility, 166 (90%) were enrolled, and 109 were randomly assigned teriflunomide and 57 were randomly assigned placebo. 102 (94%) of 109 and 53 (93%) of 57 completed the double-blind period. Switch to the ongoing open -label extension because of high MRI activity was more frequent than anticipated in the placebo group (14 [13%] of 109 patients in the teriflunomide group vs 15 [26%] of 57 in the placebo group), decreasing the power of the study. After 96 weeks, there was no difference in time to first confirmed clinical relapse with teriflunomide compared with placebo (hazard ratio 0.66, 95% CI 0.39-1.11; p=0. 29). Teriflunomide reduced the number of new or enlarged T2 lesions versus placebo by 55% (relative risk 0 " 45, 95% CI 0 " 29-0- 71; p=0 " 00061), and the number of gadolinium enhancing lesions by 75% (relative risk 0. 25, 0.13-0. 51; p<0. 0001). Adverse events occurred in 96 (88%) patients in the teriflunomide group and 47 (82%) patients in the placebo group; serious adverse events occurred in 12 (11%) patients in the teriflunomide group and 6 (11%) patients in the placebo group. Nasopharyngitis, upper-respiratorytract infection, alopecia, paraesthesia, abdominal pain, and increased blood creatine phosphokinase were more frequent with teriflunomide than with placebo. During the double-blind phase, four patients in the teriflunomide group had pancreatic adverse events (two with acute pancreatitis and two with pancreatic enzyme elevation), of which three events led to treatment discontinuation. Interpretation No significant difference in time to first confirmed clinical relapse was found, possibly because more patients than expected switched from the double-blind to the open -label treatment period because of high MRI activity. Key secondary imaging analyses and a prespecified sensitivity analysis of probability of relapse or high MRI activity suggest that teriflunomide might have beneficial effects in children with relapsing multiple sclerosis by reducing the risk of focal inflammatory activity.	[Chitnis, Tanuja] Massachusetts Gen Hosp Children, Boston, MA USA; [Banwell, Brenda] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Banwell, Brenda] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kappos, Ludwig] Univ Basel, Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci Basel, Dept Med, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci Basel, Dept Clin Res, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci Basel, Dept Biomed Engn, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Basel, Switzerland; [Arnold, Douglas L.] NeuroRx Res, Montreal, PQ, Canada; [Arnold, Douglas L.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Guecueyener, Kivilcim] Gazi Univ, Tip Fak Pediat Noroloji Bilim, Ankara, Turkey; [Deiva, Kumaran; Tardieu, Marc] Hop Univ Paris Sud, Paris, France; [Skripchenko, Natalia] FSBI Res Inst Paediat Infect Dis FMBA Russia, St Petersburg, Russia; [Cui, Li-Ying] Peking Union Med Coll Hosp, Beijing, Peoples R China; [Saubadu, Stephane; Benamor, Myriam; Le-Halpere, Annaig; Truffinet, Philippe] Sanofi, Chilly Mazarin, France; [Hu, Wenruo] Sanofi, Beijing, Peoples R China	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Basel; University of Basel; University of Basel; University of Basel; McGill University; Gazi University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Sanofi-Aventis; Sanofi France; Sanofi-Aventis	Chitnis, T (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	tchitnis@rics.bwh.harvard.edu	Türkoğlu, Recai/B-9336-2014; Skripchenko, Natalia V./G-7694-2012	Türkoğlu, Recai/0000-0001-9724-851X; Skripchenko, Natalia V./0000-0001-8927-3176; kissani, najib/0000-0002-8105-5622	Sanofi	Sanofi	Sanofi.	[Anonymous], 2018, FDA EXPANDS APPROVAL; Aubagio, 2019, TER SUMM PROD CHAR; Banwell BL, 2014, HAND CLINIC, V122, P427, DOI 10.1016/B978-0-444-52001-2.00018-2; Bar-Or A, 2016, NEUROLOGY, V87, pS12, DOI 10.1212/WNL.0000000000002821; Boiko A, 2002, NEUROLOGY, V59, P1006, DOI 10.1212/WNL.59.7.1006; Chitnis T, 2012, MULT SCLER J, V18, P116, DOI 10.1177/1352458511430704; Chitnis T, 2018, NEW ENGL J MED, V379, P1017, DOI 10.1056/NEJMoa1800149; Chitnis T, 2013, MULT SCLER J, V19, P1255, DOI 10.1177/1352458513488842; Chitnis T, 2013, NEUROLOGY, V80, P1161, DOI 10.1212/WNL.0b013e318288694e; Confavreux C, 2014, LANCET NEUROL, V13, P247, DOI 10.1016/S1474-4422(13)70308-9; Ghezzi A, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0433-y; Gorman MP, 2009, ARCH NEUROL-CHICAGO, V66, P54, DOI 10.1001/archneurol.2008.505; Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547; Krysko KM, 2020, ANN NEUROL, V88, P42, DOI 10.1002/ana.25737; Miller AE, 2014, LANCET NEUROL, V13, P977, DOI 10.1016/S1474-4422(14)70191-7; Montalban X, 2018, EUR J NEUROL, V25, P215, DOI 10.1111/ene.13536; Ness JM, 2007, NEUROLOGY, V68, pS37, DOI 10.1212/01.wnl.0000259447.77476.a9; O'Connor P, 2016, NEUROLOGY, V86, P920, DOI 10.1212/WNL.0000000000002441; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; O'Connor PW, 2006, NEUROLOGY, V66, P894, DOI 10.1212/01.wnl.0000203121.04509.31; Pharmaletter, 2018, EU APPR GIL CHILDR A; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Radue EW, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000390; Rae-Grant A, 2018, NEUROLOGY, V90, P777, DOI 10.1212/WNL.0000000000005347; Renoux C, 2007, NEW ENGL J MED, V356, P2603, DOI 10.1056/NEJMoa067597; Sprenger T, 2020, MULT SCLER J, V26, P1207, DOI 10.1177/1352458519855722; Verhey LH, 2013, NEUROLOGY, V81, P1215, DOI 10.1212/WNL.0b013e3182a6cb9b; Vermersch P, 2014, MULT SCLER J, V20, P705, DOI 10.1177/1352458513507821; Vukusic S, 2020, MULT SCLER J, V26, P829, DOI 10.1177/1352458519843055; Waldman A, 2016, NEUROLOGY, V87, pS74, DOI 10.1212/WNL.0000000000003028; Wassmer E, 2016, NEUROLOGY, V87, pS110, DOI 10.1212/WNL.0000000000002880; Waubant E, 2019, NEUROLOGY, V92, pE2538, DOI 10.1212/WNL.0000000000007572; Waubant E, 2009, ARCH NEUROL-CHICAGO, V66, P967, DOI 10.1001/archneurol.2009.135; Wolinsky JS, 2013, MULT SCLER J, V19, P1310, DOI 10.1177/1352458513475723	34	15	15	3	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					1001	1011		10.1016/S1474-4422(21)00364-1	http://dx.doi.org/10.1016/S1474-4422(21)00364-1			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34800398				2022-12-18	WOS:000755602800025
J	Sharabi, Y; Vatine, GD; Ashkenazi, A				Sharabi, Yehonatan; Vatine, Gad D.; Ashkenazi, Avraham			Parkinson's disease outside the brain: targeting the autonomic nervous system	LANCET NEUROLOGY			English	Article							ALPHA-SYNUCLEIN PATHOLOGY; ORTHOSTATIC HYPOTENSION; DOPAMINERGIC-NEURONS; DYSFUNCTION; SYMPTOMS; NEURODEGENERATION; MECHANISMS; CONVERSION; PHENOTYPES; AUTOPHAGY	Patients with Parkinson's disease present with signs and symptoms of dysregulation of the peripheral autonomic nervous system that can even precede motor deficits. This dysregulation might reflect early pathology and therefore could be targeted for the development of prodromal or diagnostic biomarkers. Only a few objective clinical tests assess disease progression and are used to evaluate the entire spectrum of autonomic dysregulation in patients with Parkinson's disease. However, results from epidemiological studies and findings from new animal models suggest that the dysfunctional autonomic nervous system is a probable route by which Parkinson's disease pathology can spread both to and from the CNS. The autonomic innervation of the gut, heart, and skin is affected by alpha-synuclein pathology in the early stages of the disease and might initiate alpha-synuclein spread via the autonomic connectome to the CNS. The development of easy-to-use and reliable clinical tests of autonomic nervous system function seems crucial for early diagnosis, and for developing strategies to stop or prevent neurodegeneration in Parkinson's disease.	[Sharabi, Yehonatan; Ashkenazi, Avraham] Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel; [Ashkenazi, Avraham] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel; [Sharabi, Yehonatan] Chaim Sheba Med Ctr, Hypertens Unit, Tel Hashomer, Israel; [Vatine, Gad D.] Ben Gurion Univ Negev, Regenerat Med & Stem Cell RMSC Res Ctr, Fac Hlth Sci, Dept Physiol & Cell Biol, Beer Sheva, Israel; [Vatine, Gad D.] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Beer Sheva, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Chaim Sheba Medical Center; Ben Gurion University; Ben Gurion University	Ashkenazi, A (corresponding author), Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel.; Vatine, GD (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, IL-8410501 Beer Sheva, Israel.	vatineg@bgu.ac.il; ashkenaziavi@tauex.tau.ac.il	Vatine, Gad/ABF-3907-2021	Ashkenazi, Avraham/0000-0002-1253-497X	Azrieli Foundation; Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease; Israel Science Foundation (ISF) [1621/18]; Ministry of Science and Technology (MOST) [3-15647]	Azrieli Foundation; Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease; Israel Science Foundation (ISF)(Israel Science Foundation); Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China)	AA reports grants from the Azrieli Foundation and The Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease. GDV reports grants from The Israel Science Foundation (ISF; 1621/18) and The Ministry of Science and Technology (MOST; Israel 3-15647). YS declares no competing interests.	Annerino DM, 2012, ACTA NEUROPATHOL, V124, P665, DOI 10.1007/s00401-012-1040-2; Asahina M, 2013, J NEUROL NEUROSUR PS, V84, P674, DOI 10.1136/jnnp-2012-303135; Baden P, 2019, NEUROBIOL DIS, V127, P1, DOI 10.1016/j.nbd.2019.01.023; Badillo-Ramirez I, 2019, NEUROCHEM INT, V129, DOI 10.1016/j.neuint.2019.104514; Bieri G, 2019, ACTA NEUROPATHOL, V137, P961, DOI 10.1007/s00401-019-01995-0; Borghammer P, 2019, J PARKINSON DIS, V9, pS281, DOI 10.3233/JPD-191721; Brundin P, 2017, J NEUROSCI, V37, P9808, DOI 10.1523/JNEUROSCI.1788-16.2017; Cagle Brianna S., 2019, Current Opinion in Toxicology, V13, P16, DOI 10.1016/j.cotox.2018.12.002; Candelise N, 2019, ANN NEUROL, V85, P691, DOI 10.1002/ana.25446; Carmo-Goncalves P, 2020, ACS CHEM NEUROSCI, V11, P3541, DOI 10.1021/acschemneuro.0c00527; Cersosimo MG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9642524; Challis C, 2020, NAT NEUROSCI, V23, P327, DOI 10.1038/s41593-020-0589-7; Chen HL, 2017, NEUROLOGY, V89, P1441, DOI 10.1212/WNL.0000000000004382; Cheshire WP, 2019, CLIN AUTON RES, V29, P215, DOI 10.1007/s10286-019-00598-9; Dayan E, 2018, NEUROLOGY, V90, pE2051, DOI 10.1212/WNL.0000000000005641; De Pablo-Fernandez E, 2017, JAMA NEUROL, V74, P970, DOI 10.1001/jamaneurol.2017.1125; Deza-Ponzio R, 2018, NEUROTOXICOLOGY, V68, P19, DOI 10.1016/j.neuro.2018.06.005; Doppler CEJ, 2021, SLEEP, V44, DOI 10.1093/sleep/zsab040; Duz OA, 2020, ACTA NEUROL BELG, V120, P915, DOI 10.1007/s13760-019-01113-7; Fattahi F, 2016, NATURE, V531, P105, DOI 10.1038/nature16951; Fearon C, 2021, MOVEMENT DISORD, V36, P594, DOI 10.1002/mds.28493; Fernandez-Arcos A, 2018, SLEEP MED, V52, P14, DOI 10.1016/j.sleep.2018.08.003; Fornai F, 2021, NEUROSCI BIOBEHAV R, V123, P238, DOI 10.1016/j.neubiorev.2021.01.015; Galves M, 2019, TRENDS BIOCHEM SCI, V44, P872, DOI 10.1016/j.tibs.2019.04.007; Gelpi E, 2014, MOVEMENT DISORD, V29, P1010, DOI 10.1002/mds.25776; Goldstein DS, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130441; Goldstein DS, 2019, BRAIN RES, V1702, P74, DOI 10.1016/j.brainres.2017.09.033; Goldstein DS, 2013, J NEUROCHEM, V126, P591, DOI 10.1111/jnc.12345; Goldstein DS, 2012, CLIN AUTON RES, V22, P57, DOI 10.1007/s10286-011-0136-4; Guimaraes MZP, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00277; Hartfield EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087388; Henderson MX, 2020, NEURON, V105, P822, DOI 10.1016/j.neuron.2019.12.004; Herrera A, 2017, ACS CHEM NEUROSCI, V8, P702, DOI 10.1021/acschemneuro.7b00034; Ho R, 2016, NAT NEUROSCI, V19, P1256, DOI 10.1038/nn.4345; Horsager J, 2020, BRAIN, V143, P3077, DOI 10.1093/brain/awaa238; Isonaka R, 2019, CLIN AUTON RES, V29, P587, DOI 10.1007/s10286-019-00644-6; Jain S, 2011, MOVEMENT DISORD, V26, P1344, DOI 10.1002/mds.23628; Jennings D, 2017, JAMA NEUROL, V74, P933, DOI 10.1001/jamaneurol.2017.0985; Jinsmaa Y, 2020, J PHARMACOL EXP THER, V372, P157, DOI 10.1124/jpet.119.262246; Johansen KK, 2018, CASE REP NEUROL MED, V2018, DOI 10.1155/2018/6838965; Kaufmann H, 2017, ANN NEUROL, V81, P287, DOI 10.1002/ana.24877; Kim JW, 2020, CELL STEM CELL, V27, P633, DOI 10.1016/j.stem.2020.08.002; Kim S, 2019, NEURON, V103, P627, DOI 10.1016/j.neuron.2019.05.035; Knudsen K, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0889-4; Knudsen K, 2018, LANCET NEUROL, V17, P618, DOI 10.1016/S1474-4422(18)30162-5; Kotagal V, 2016, PARKINSONISM RELAT D, V32, P127, DOI 10.1016/j.parkreldis.2016.09.011; Kumar ST, 2020, NEUROBIOL DIS, V146, DOI 10.1016/j.nbd.2020.105086; Kumar VB, 2019, EUR J PHARMACOL, V845, P65, DOI 10.1016/j.ejphar.2018.12.027; Laperle AH, 2020, NAT MED, V26, P289, DOI 10.1038/s41591-019-0739-1; Lima VD, 2019, ACS CHEM NEUROSCI, V10, P690, DOI 10.1021/acschemneuro.8b00498; Liu BJ, 2017, NEUROLOGY, V88, P1996, DOI 10.1212/WNL.0000000000003961; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Maetzler W, 2015, J NEURAL TRANSM, V122, P419, DOI 10.1007/s00702-014-1276-1; Malek N, 2017, MOV DISORD CLIN PRAC, V4, P509, DOI 10.1002/mdc3.12454; Manfredsson FP, 2018, NEUROBIOL DIS, V112, P106, DOI 10.1016/j.nbd.2018.01.008; Manne S, 2020, MOVEMENT DISORD, V35, P268, DOI 10.1002/mds.27907; Masato A, 2021, CURR NEUROPHARMACOL, V19, P1618, DOI 10.2174/1570159X19666210203162617; Matheoud D, 2019, NATURE, V571, P565, DOI 10.1038/s41586-019-1405-y; Mazzetti S, 2020, BRAIN, V143, P920, DOI 10.1093/brain/awaa008; Mazzulli JR, 2011, CELL, V146, P37, DOI 10.1016/j.cell.2011.06.001; McCorry LK, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj710478; McDonald C, 2017, PARKINSONISM RELAT D, V35, P8, DOI 10.1016/j.parkreldis.2016.10.024; Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022; Mertens J, 2015, CELL STEM CELL, V17, P705, DOI 10.1016/j.stem.2015.09.001; Milazzo V, 2018, PARKINSONISM RELAT D, V56, P82, DOI 10.1016/j.parkreldis.2018.06.032; Navarro-Otano J, 2013, PARKINSONISM RELAT D, V19, P27, DOI 10.1016/j.parkreldis.2012.07.005; Nikolakopoulou P, 2020, BRAIN, V143, P3181, DOI 10.1093/brain/awaa268; Norcliffe-Kaufmann L, 2018, ANN NEUROL, V83, P522, DOI 10.1002/ana.25170; Noyce AJ, 2017, MOVEMENT DISORD, V32, P219, DOI 10.1002/mds.26898; Palma JA, 2018, MOVEMENT DISORD, V33, P372, DOI 10.1002/mds.27344; Park JY, 2019, CHINESE MED J-PEKING, V132, P1919, DOI 10.1097/CM9.0000000000000359; Peelaerts W, 2015, NATURE, V522, P340, DOI 10.1038/nature14547; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Sarafian TA, 2019, J NEUROSCI RES, V97, P1689, DOI 10.1002/jnr.24513; Segura-Aguilar J, 2014, J NEUROCHEM, V129, P898, DOI 10.1111/jnc.12686; Sommerauer M, 2018, BRAIN, V141, P496, DOI 10.1093/brain/awx348; Sun J, 2021, CNS NEUROSCI THER, V27, P540, DOI 10.1111/cns.13589; Svensson E, 2015, ANN NEUROL, V78, P522, DOI 10.1002/ana.24448; Takayama Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148559; Tan AH, 2014, PARKINSONISM RELAT D, V20, P535, DOI 10.1016/j.parkreldis.2014.02.019; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Thaler A, 2018, MOVEMENT DISORD, V33, P1656, DOI 10.1002/mds.27490; Toru S, 2018, EUR NEUROL, V79, P27, DOI 10.1159/000484409; Tsukita K, 2020, J NEUROL, V267, P3248, DOI 10.1007/s00415-020-09992-0; Tysnes OB, 2015, ANN NEUROL, V78, P1011, DOI 10.1002/ana.24531; Vallelonga F, 2019, HYPERTENS RES, V42, P1552, DOI 10.1038/s41440-019-0267-x; Van Den Berge N, 2019, ACTA NEUROPATHOL, V138, P535, DOI 10.1007/s00401-019-02040-w; van Wamelen DJ, 2019, J NEUROL, V266, P1736, DOI 10.1007/s00415-019-09325-w; Vatine GD, 2019, CELL STEM CELL, V24, P995, DOI 10.1016/j.stem.2019.05.011; Vatine GD, 2017, CELL STEM CELL, V20, P831, DOI 10.1016/j.stem.2017.04.002; Vera E, 2016, CELL REP, V17, P1184, DOI 10.1016/j.celrep.2016.09.062; Vichayanrat E, 2017, EUR J NEUROL, V24, P90, DOI 10.1111/ene.13135; Vilas D, 2019, J NEUROL NEUROSUR PS, V90, P832, DOI 10.1136/jnnp-2018-318473; Villumsen M, 2019, GUT, V68, P18, DOI 10.1136/gutjnl-2017-315666; Wakabayashi K, 2020, NEUROPATHOLOGY, V40, P415, DOI 10.1111/neup.12691; Wakeman DR, 2017, STEM CELL REP, V9, P149, DOI 10.1016/j.stemcr.2017.04.033; Wang JY, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.577128; Workman MJ, 2017, NAT MED, V23, P49, DOI 10.1038/nm.4233; Yalcin A, 2016, AGING DIS, V7, DOI 10.14336/AD.2015.0819; Yilmaz R, 2019, J NEURAL TRANSM, V126, P803, DOI 10.1007/s00702-019-02001-3; 2019, HYPERTENSION, V73, P910, DOI DOI 10.1161/HYPERTENSIONAHA.118.12642	101	15	15	6	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					868	876		10.1016/S1474-4422(21)00219-2	http://dx.doi.org/10.1016/S1474-4422(21)00219-2			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536407				2022-12-18	WOS:000701741000021
J	Menon, DK; Bryant, C				Menon, David K.; Bryant, Chris			Time for change in acquired brain injury	LANCET NEUROLOGY			English	Letter									[Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England; [Bryant, Chris] Houses Parliament, All Party Parliamentary Grp Acquired Brain Injury, London, England	University of Cambridge	Menon, DK (corresponding author), Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England.	dkm13@cam.ac.uk						All- Party Parliamentary Group on Acquired Brain Injury, ACQ BRAIN INJ NEUR T; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X	2	15	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					28	28		10.1016/S1474-4422(18)30463-0	http://dx.doi.org/10.1016/S1474-4422(18)30463-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30563679	Bronze			2022-12-18	WOS:000453007700019
J	Reuter, U				Reuter, Uwe			GBD 2016: still no improvement in the burden of migraine	LANCET NEUROLOGY			English	Editorial Material									[Reuter, Uwe] Charite Univ Med Berlin, Deptartment Neurol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reuter, U (corresponding author), Charite Univ Med Berlin, Deptartment Neurol, D-10117 Berlin, Germany.	uwe.reuter@charite.de			Alder Pharmaceuticals	Alder Pharmaceuticals	UR reports personal fees from Allergan, CoLucid, Autonomic Technologies, Medscape, and Streamed Up; grants to Charite Universitatsmedizin Berlin and personal fees from Amgen, Electrocore, Eli Lilly, Novartis, and Teva; and grants from Alder Pharmaceuticals to Charite Universitatsmedizin Berlin.	Dodick DW, 2018, LANCET, V391, P1315, DOI 10.1016/S0140-6736(18)30478-1; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Henning V, 2018, CEPHALALGIA, V38, P551, DOI 10.1177/0333102417699180; Marinho F, 2018, LANCET, V392, P760, DOI 10.1016/S0140-6736(18)31221-2; Peroutka SJ, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0454-z; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2	8	15	18	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2018	17	11					929	930		10.1016/S1474-4422(18)30360-0	http://dx.doi.org/10.1016/S1474-4422(18)30360-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GX3PG	30353862	hybrid			2022-12-18	WOS:000447637500003
J	Graus, F; Dalmau, J				Graus, Francesc; Dalmau, Josep			Role of F-18-FDG-PET imaging in the diagnosis of autoimmune encephalitis reply	LANCET NEUROLOGY			English	Letter							PET; MRI		[Graus, Francesc; Dalmau, Josep] IDIBAPS, Neuroimmunol Program, Barcelona, Spain; [Graus, Francesc] Univ Barcelona, Hosp Clin, Serv Neurol, E-08036 Barcelona, Spain; [Dalmau, Josep] ICREA, Barcelona, Spain; [Dalmau, Josep] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; ICREA; University of Pennsylvania	Graus, F (corresponding author), IDIBAPS, Neuroimmunol Program, Barcelona, Spain.; Graus, F (corresponding author), Univ Barcelona, Hosp Clin, Serv Neurol, E-08036 Barcelona, Spain.	fgraus@clinic.cat		Dalmau, Josep/0000-0001-5856-2813; Graus, Francesc/0000-0002-8924-8322	ICREA Funding Source: Custom	ICREA(ICREA)		Baumgartner A, 2013, J NEUROL, V260, P2744, DOI 10.1007/s00415-013-7048-2; Dhermain FG, 2010, LANCET NEUROL, V9, P906, DOI 10.1016/S1474-4422(10)70181-2; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Leypoldt F, 2012, J NEUROL NEUROSUR PS, V83, P681, DOI 10.1136/jnnp-2011-301969; Vollmer TL, 2016, NEUROLOGY, V86, P1655, DOI 10.1212/WNL.0000000000002641; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541	6	15	16	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					1010	1010		10.1016/S1474-4422(16)30130-2	http://dx.doi.org/10.1016/S1474-4422(16)30130-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27571150	Bronze			2022-12-18	WOS:000381280300017
J	Thompson, AJ				Thompson, Alan J.			A much-needed focus on progression in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							DISABILITY; MS		UCL, Fac Brain Sci, London WC1E 6BT, England	University of London; University College London	Thompson, AJ (corresponding author), UCL, Fac Brain Sci, Mortimer St, London WC1E 6BT, England.	alan.thompson@ucl.ac.uk	Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496				Browne P, 2014, NEUROLOGY, V83, P1022, DOI 10.1212/WNL.0000000000000768; Chataway J, 2011, MULT SCLER J, V17, P81, DOI 10.1177/1352458510382129; Coetzee T, 2015, LANCET NEUROL, V14, P132, DOI 10.1016/S1474-4422(14)70323-0; Feinstein A, 2015, LANCET NEUROL, V14, P194, DOI 10.1016/S1474-4422(14)70231-5; Feinstein A, 2014, MULT SCLER J, V20, P269, DOI 10.1177/1352458514521309; Fox RJ, 2014, NEUROLOGY, V83, P1488, DOI 10.1212/WNL.0000000000000921; Hauser SL, 2013, ANN NEUROL, V74, P317, DOI 10.1002/ana.24009; Jensen HB, 2014, THER ADV NEUROL DISO, V7, P97, DOI 10.1177/1756285613512712; Kobelt G, 2006, J NEUROL NEUROSUR PS, V77, P918, DOI 10.1136/jnnp.2006.090365; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Ontaneda D, 2015, LANCET NEUROL, V14, P208, DOI 10.1016/S1474-4422(14)70264-9; Palace J, 2014, LANCET, V383, P2189, DOI 10.1016/S0140-6736(13)62641-0; Scalfari A, 2011, NEUROLOGY, V77, P1246, DOI 10.1212/WNL.0b013e318230a17d; Sorbara CD, 2014, NEURON, V84, P1183, DOI 10.1016/j.neuron.2014.11.006; Stys PK, 2012, NAT REV NEUROSCI, V13, P507, DOI 10.1038/nrn3275; Thompson AJ, 2010, LANCET NEUROL, V9, P1182, DOI 10.1016/S1474-4422(10)70249-0	17	15	16	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2015	14	2					133	135		10.1016/S1474-4422(14)70330-8	http://dx.doi.org/10.1016/S1474-4422(14)70330-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY9KS	25772885				2022-12-18	WOS:000347869400007
J	[Anonymous]				[Anonymous]			Dementia warning for the Asia-Pacific region	LANCET NEUROLOGY			English	Editorial Material																			0	15	15	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					1	1		10.1016/S1474-4422(14)70312-6	http://dx.doi.org/10.1016/S1474-4422(14)70312-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496878	Bronze			2022-12-18	WOS:000346885300001
J	van Middendorp, J; Allison, H; Cowan, K				van Middendorp, Joosti; Allison, Harriet; Cowan, Katherine		Spinal Cord Injury Priority Settin	Top ten research priorities for spinal cord injury	LANCET NEUROLOGY			English	Letter									[van Middendorp, Joosti; Allison, Harriet] Buckinghamshire NHS Healthcare Trust, Stoke Mandeville Hosp, Natl Spinal Injuries Ctr, Stoke Mandeville Spinal Fdn, Aylesbury HP21 8AL, Bucks, England; [van Middendorp, Joosti] Univ Oxford, Harris Manchester Coll, Oxford, England; [Cowan, Katherine] Natl Inst Hlth Res Evaluat Trials & Studies Coord, James Lind Alliance, Southampton, Hants, England	University of Oxford	van Middendorp, J (corresponding author), Buckinghamshire NHS Healthcare Trust, Stoke Mandeville Hosp, Natl Spinal Injuries Ctr, Stoke Mandeville Spinal Fdn, Aylesbury HP21 8AL, Bucks, England.	jvanmiddendorp@gmail.com						van Middendorp JJ, 2010, EUR SPINE J, V19, P1815, DOI 10.1007/s00586-010-1523-6	1	15	15	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2014	13	12					1167	1167		10.1016/S1474-4422(14)70253-4	http://dx.doi.org/10.1016/S1474-4422(14)70253-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU5XG	25453451				2022-12-18	WOS:000345676300005
J	Hsieh, CY; Lin, HJ; Chen, CH; Lai, ECC; Yang, YHK				Hsieh, Cheng-Yang; Lin, Huey-Juan; Chen, Chih-Hung; Lai, Edward Chia-Cheng; Yang, Yea-Huei Kao			Chronic kidney disease and stroke	LANCET NEUROLOGY			English	Letter							TERM		[Hsieh, Cheng-Yang] Tainan Sin Lau Hosp, Dept Neurol, Tainan, Taiwan; [Lin, Huey-Juan] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Chen, Chih-Hung] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Neurol, Tainan 70101, Taiwan; [Chen, Chih-Hung] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan; [Lai, Edward Chia-Cheng; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan	Chi Mei Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University	Hsieh, CY (corresponding author), Tainan Sin Lau Hosp, Dept Neurol, Tainan, Taiwan.	yhkao@mail.ncku.edu.tw	Hsieh, Cheng-Yang/W-4841-2019	Hsieh, Cheng-Yang/0000-0002-8772-4073				Covic A, 2008, NEPHROL DIAL TRANSPL, V23, P2228, DOI 10.1093/ndt/gfm591; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051; Toyoda K, 2014, LANCET NEUROL, V13, P823, DOI 10.1016/S1474-4422(14)70026-2; Tsagalis G, 2009, NEPHROL DIAL TRANSPL, V24, P194, DOI 10.1093/ndt/gfn471	5	15	18	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1071	1071		10.1016/S1474-4422(14)70199-1	http://dx.doi.org/10.1016/S1474-4422(14)70199-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25316010				2022-12-18	WOS:000343783900010
J	Schwarzschild, MA; Macklin, EA; Ascherio, A				Schwarzschild, Michael A.; Macklin, Eric A.; Ascherio, Alberto		Parkinson Study Grp SURE-PD Invest	Urate and neuroprotection trials	LANCET NEUROLOGY			English	Letter							PARKINSON DISEASE; URIC-ACID; SERUM		[Schwarzschild, Michael A.; Macklin, Eric A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Schwarzschild, MA (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	MSchwarzschild@mgh.harvard.edu	Macklin, Eric A/E-2955-2013	Macklin, Eric A/0000-0003-1618-3502				Abraham A, 2014, J NEUROL, V261, P1133, DOI 10.1007/s00415-014-7331-x; Ascherio A, 2009, ARCH NEUROL-CHICAGO, V66, P1460, DOI 10.1001/archneurol.2009.247; Chamorro A, 2014, LANCET NEUROL, V13, P453, DOI 10.1016/S1474-4422(14)70054-7; Chen XQ, 2012, CURR NEUROL NEUROSCI, V12, P367, DOI 10.1007/s11910-012-0282-7; Schwarzschild MA, 2014, JAMA NEUROL, V71, P141, DOI 10.1001/jamaneurol.2013.5528	5	15	17	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2014	13	8					758	758		10.1016/S1474-4422(14)70138-3	http://dx.doi.org/10.1016/S1474-4422(14)70138-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AL9JB	25030508				2022-12-18	WOS:000339456300009
J	Riemann, D; Spiegelhalder, K				Riemann, Dieter; Spiegelhalder, Kai			Orexin receptor antagonists: a new treatment for insomnia?	LANCET NEUROLOGY			English	Editorial Material									[Riemann, Dieter; Spiegelhalder, Kai] Univ Freiburg, Med Ctr, Dept Clin Psychol & Psychophysiol Sleep Med, D-79104 Freiburg, Germany	University of Freiburg	Riemann, D (corresponding author), Univ Freiburg, Med Ctr, Dept Clin Psychol & Psychophysiol Sleep Med, Hauptstr 5, D-79104 Freiburg, Germany.	dieter.riemann@uniklinik-freiburg.de	Riemann, Dieter/R-4013-2019; Spiegelhalder, Kai/B-7861-2019	Riemann, Dieter/0000-0002-1968-6220				Actelion, ACT GSK DISC CLIN DE; APA APA, 2013, DIAGN STAT MAN MENT; Buscemi N, 2007, J GEN INTERN MED, V22, P1335, DOI 10.1007/s11606-007-0251-z; Dundar Y, 2004, HUM PSYCHOPHARM CLIN, V19, P305, DOI 10.1002/hup.594; Farkas R., SUVOREXANT SAFETY EF; Glass J, 2005, BMJ-BRIT MED J, V331, P1; Herring WJ, 2012, NEUROLOGY, V79, P2265, DOI 10.1212/WNL.0b013e31827688ee; Huedo-Medina TB, 2012, BMJ-BRIT MED J, V345, P1; Michelson D, 2014, LANCET NEUROL; Mieda M, 2012, PROG BRAIN RES, V198, P5, DOI 10.1016/B978-0-444-59489-1.00002-1; Morin CM, 2012, LANCET, V379, P1129, DOI 10.1016/S0140-6736(11)60750-2; Riemann D, 2010, SLEEP MED REV, V14, P19, DOI 10.1016/j.smrv.2009.04.002; Riemann D, 2009, SLEEP MED REV, V13, P205, DOI 10.1016/j.smrv.2008.06.001; Tafti M, 2007, NAT MED, V13, P525, DOI 10.1038/nm0507-525	14	15	16	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2014	13	5					441	443		10.1016/S1474-4422(13)70311-9	http://dx.doi.org/10.1016/S1474-4422(13)70311-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG0LX	24680373				2022-12-18	WOS:000335108100003
J	Wisniewski, T				Wisniewski, Thomas			Active immunotherapy for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material									NYU, Sch Med, Dept Neurol Psychiat & Pathol, New York, NY 10016 USA	New York University	Wisniewski, T (corresponding author), NYU, Sch Med, Dept Neurol Psychiat & Pathol, Alexandria E River Sci Pk, New York, NY 10016 USA.	thomas.wisniewski@nyumc.org	Wisniewski, Thomas/Q-6525-2019	Wisniewski, Thomas/0000-0002-3379-8966	NIA NIH HHS [P30 AG008051, R01 AG020245] Funding Source: Medline; NINDS NIH HHS [R01 NS073502] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008051, R01AG020245] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alzheimer's Disease International, 2011, WORLD ALZH REP; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Goni F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013391; Grill JD, 2010, EXPERT REV NEUROTHER, V10, P711, DOI [10.1586/ern.10.29, 10.1586/ERN.10.29]; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Morgan D, 2011, J INTERN MED, V269, P54, DOI 10.1111/j.1365-2796.2010.02315.x; Winblad B, 2012, LANCET NEUROL, V11, P597, DOI 10.1016/S1474-4422(12)70140-0; Wisniewski T, 2008, LANCET NEUROL, V7, P805, DOI 10.1016/S1474-4422(08)70170-4; Wisniewski T, 2010, BBA-MOL BASIS DIS, V1802, P847, DOI 10.1016/j.bbadis.2010.05.004	11	15	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2012	11	7					571	572		10.1016/S1474-4422(12)70136-9	http://dx.doi.org/10.1016/S1474-4422(12)70136-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969YN	22677257	Green Accepted			2022-12-18	WOS:000306095400004
J	Shi, M; Zhang, J				Shi, Min; Zhang, Jing			CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease	LANCET NEUROLOGY			English	Letter							ALZHEIMERS		[Shi, Min; Zhang, Jing] Univ Washington, Div Neuropathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Shi, M (corresponding author), Univ Washington, Div Neuropathol, Seattle, WA 98195 USA.	zhangj@uw.edu	Shi, Min/G-6165-2012	Shi, Min/0000-0002-6901-2558	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004696, P30ES007033, R01ES016873, R01ES019277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS062684, R21NS060252, R01NS057567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025327, R01AG033398] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG025327, R01 AG033398, AG025327, AG033398] Funding Source: Medline; NIEHS NIH HHS [ES016873, ES019277, P42 ES004696, P30ES007033-6364, R01 ES016873, ES0046965897] Funding Source: Medline; NINDS NIH HHS [P50 NS062684, R01 NS057567, R21 NS060252, NS060252, NS062684-6221, NS057567] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdo WF, 2007, NEUROBIOL AGING, V28, P742, DOI 10.1016/j.neurobiolaging.2006.03.010; Alves G, 2010, J NEUROL NEUROSUR PS, V81, P1080, DOI 10.1136/jnnp.2009.199950; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hong Z, 2010, BRAIN, V133, P713, DOI 10.1093/brain/awq008; Mollenhauer B, 2011, LANCET NEUROL, V10, P230, DOI 10.1016/S1474-4422(11)70014-X; Montine TJ, 2010, MOVEMENT DISORD, V25, P2682, DOI 10.1002/mds.23287; Shi M, 2011, ANN NEUROL, V69, P570, DOI 10.1002/ana.22311; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Tsigelny IF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003135	10	15	15	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2011	10	8					681	681		10.1016/S1474-4422(11)70130-2	http://dx.doi.org/10.1016/S1474-4422(11)70130-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803WJ	21777821				2022-12-18	WOS:000293612600008
J	Palfi, S				Palfi, Stephane			Towards gene therapy for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							DELIVERY; MONKEYS		Assistance Publ Hop Paris, Grp Henri Mondor Albert Chenevier, Serv Neurochirurg, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Palfi, S (corresponding author), Assistance Publ Hop Paris, Grp Henri Mondor Albert Chenevier, Serv Neurochirurg, F-94010 Creteil, France.	stephane.palfi@hmn.aphp.fr						Azzouz M, 2002, J NEUROSCI, V22, P10302; Forsayeth JR, 2006, MOL THER, V14, P571, DOI 10.1016/j.ymthe.2006.04.008; JARRAYA B, 2004, DOPAMINE PRODUCTION; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kirik D, 2002, P NATL ACAD SCI USA, V99, P4708, DOI 10.1073/pnas.062047599; Kordower JH, 2006, ANN NEUROL, V60, P706, DOI 10.1002/ana.21032; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; Olanow CW, 2006, LANCET NEUROL, V5, P677, DOI 10.1016/S1474-4422(06)70521-X	9	15	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2008	7	5					375	376		10.1016/S1474-4422(08)70066-8	http://dx.doi.org/10.1016/S1474-4422(08)70066-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	296AB	18387851				2022-12-18	WOS:000255514800003
J	Qiu, J				Qiu, Jane			Probing islands of consciousness in the damaged brain	LANCET NEUROLOGY			English	Editorial Material																			0	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2007	6	11					946	947		10.1016/S1474-4422(07)70255-7	http://dx.doi.org/10.1016/S1474-4422(07)70255-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	226VX	17945148				2022-12-18	WOS:000250617700006
J	Dulac, O; Nabbout, R; Plouin, P; Chiron, C; Scheffer, IE				Dulac, Olivier; Nabbout, Rima; Plouin, Perrine; Chiron, Catherine; Scheffer, Ingrid E.			Early seizures: causal events or predisposition to adult epilepsy?	LANCET NEUROLOGY			English	Review							TEMPORAL-LOBE EPILEPSY; REFRACTORY STATUS EPILEPTICUS; FAMILIAL FEBRILE CONVULSIONS; HIPPOCAMPAL SCLEROSIS; GENERALIZED EPILEPSY; MAGNETIC-RESONANCE; INFANTILE SPASMS; SODIUM-CHANNEL; CHILDREN; ONSET	Past studies have been unable to confirm whether early seizures predispose to epilepsy in adults. Seizures in infancy were Classically thought to cause brain lesions that led to epilepsy in adulthood. However, these infants were not thought to have epilepsy, but acute events that included seizures. Accumulating evidence suggests that early seizures may be associated with, or cause, brain damage; or alternatively, they may be the first expression of a genetic or lesional predisposition to epilepsy. The course of early seizures ranges from transient to life-long, depending on epilepsy syndrome, causes, and treatment. The main factors that determine late or persisting epilepsy after the occurrence of early seizures are protracted seizures, tonic seizures, and involvement of mesial temporal structures. A developmental approach to seizure disorders will aid understanding of epilepsy in adults and improve the design of antiepileptic agents for children and adults.	Necker Enfants Malad Hosp, AP HP, Dept Neuropediat, Ctr Reference Epilepsies Rares, F-75015 Paris, France; INSERM, U663, Paris, France; Univ Paris 05, Paris, France; Univ Melbourne, Dept Med, Austin Hlth, Melbourne, Vic, Australia; Univ Melbourne, Dept Paediat, Austin Hlth, Melbourne, Vic, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Children's Hospital Melbourne	Nabbout, R (corresponding author), Necker Enfants Malad Hosp, AP HP, Dept Neuropediat, Ctr Reference Epilepsies Rares, 149 Rue Sevres, F-75015 Paris, France.	rimanabbout@yahoo.com	Scheffer, Ingrid E/G-1668-2013; Chiron, Catherine/E-8506-2016	Scheffer, Ingrid E/0000-0002-2311-2174; Chiron, Catherine/0000-0002-9096-1694				ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Arroyo S, 2002, EPILEPSIA, V43, P437, DOI 10.1046/j.1528-1157.2002.38501.x; AUER R, 2006, ACTA NEUROPATHOL, V64, P177; Baulac S, 2001, ANN NEUROL, V49, P786, DOI 10.1002/ana.1014; Baulac S, 2004, LANCET NEUROL, V3, P421, DOI 10.1016/S1474-4422(04)00808-7; Ben-Ari Y, 2006, LANCET NEUROL, V5, P1055, DOI 10.1016/S1474-4422(06)70626-3; BETHUNE P, 1993, AM J DIS CHILD, V147, P35, DOI 10.1001/archpedi.1993.02160250037013; Bigel MG, 2001, EPILEPSY BEHAV, V2, P37, DOI 10.1006/ebeh.2000.0146; BILLARD C, 1982, ARCH FR PEDIATR, V39, P677; CAMFIELD P, 1994, DEV MED CHILD NEUROL, V36, P887; Camfield P, 2003, EPILEPSIA, V44, P1592, DOI 10.1111/j.0013-9580.2003.29203.x; CAMFIELD P, 2006, EPILEPTIC SYNDROMES, P147; CENDES F, 1993, NEUROLOGY, V43, P1083, DOI 10.1212/WNL.43.6.1083; Chassoux F, 2000, BRAIN, V123, P1733, DOI 10.1093/brain/123.8.1733; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHIRON C, 1991, J CHILD NEUROL, V6, pS52; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Chiron C, 1999, Adv Neurol, V81, P89; CHIRON C, 1992, J NUCL MED, V33, P696; Chiron C, 1997, BRAIN, V120, P1057, DOI 10.1093/brain/120.6.1057; CHIRON C, 1990, LANCET, V335, P363, DOI 10.1016/0140-6736(90)90660-W; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Cohen I, 2003, BIOL CELL, V95, P329, DOI 10.1016/S0248-4900(03)00081-9; COPPOLA G, 1995, EPILEPSIA, V36, P1017, DOI 10.1111/j.1528-1157.1995.tb00961.x; DeLong GR, 1997, ANN NEUROL, V42, P11, DOI 10.1002/ana.410420105; Depondt C, 2002, NEUROLOGY, V58, P1429, DOI 10.1212/WNL.58.9.1429; DONAT JF, 1991, EPILEPSIA, V32, P504, DOI 10.1111/j.1528-1157.1991.tb04684.x; DOOSE H, 1970, Neuropaediatrie, V2, P59, DOI 10.1055/s-0028-1091841; DUCHOWNY M, 1992, J CHILD NEUROL, V7, P66, DOI 10.1177/088307389200700112; DULAC O, 1993, EPILEPSIA, V34, pS7, DOI 10.1111/j.1528-1157.1993.tb04593.x; Eisermann MM, 2003, EPILEPSY RES, V55, P21, DOI 10.1016/S0920-1211(03)00088-3; Eisermann MM, 2006, EPILEPSIA, V47, P1035, DOI 10.1111/j.1528-1167.2006.00518.x; Elterman RD, 2001, NEUROLOGY, V57, P1416, DOI 10.1212/WNL.57.8.1416; Engel J, 2001, EPILEPSIA, V42, P316, DOI 10.1046/j.1528-1157.2001.t01-1-36500.x; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; Fernandez G, 1998, NEUROLOGY, V50, P909, DOI 10.1212/WNL.50.4.909; Ferrie CD, 1997, EPILEPSIA, V38, P285, DOI 10.1111/j.1528-1157.1997.tb01119.x; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; GASTAUT H, 1960, EPILEPSIA, V1, P418; GASTAUT H, 1969, EPILEPSIA, V10, P3, DOI 10.1111/j.1528-1157.1969.tb03823.x; GASTAUT H., 1966, EPILESPSIA, V7, P139; Grunewald RA, 2001, J NEUROL NEUROSUR PS, V71, P638, DOI 10.1136/jnnp.71.5.638; Harvey AS, 1997, NEUROLOGY, V49, P960, DOI 10.1212/WNL.49.4.960; HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x; Jackson GD, 1998, NEUROLOGY, V51, P78, DOI 10.1212/WNL.51.1.78; Jackson GD, 1999, DEV NEUROSCI-BASEL, V21, P207, DOI 10.1159/000017400; Jambaque I, 2006, DEV MED CHILD NEUROL, V48, P223, DOI 10.1017/S0012162206000478; Janszky J, 2004, NEUROLOGY, V63, P1296, DOI 10.1212/01.WNL.0000140701.40447.88; JEAVONS PM, 1961, ARCH DIS CHILD, V36, P17, DOI 10.1136/adc.36.185.17; JENNETT B, 1975, EPILEPSY NON MISSILE; Johnson EW, 1998, HUM MOL GENET, V7, P63, DOI 10.1093/hmg/7.1.63; Kaiboriboon K, 2002, AM J NEURORADIOL, V23, P1003; Kakviainen R, 2002, PROG BRAIN RES, V135, P279; Kaminska A, 1999, EPILEPSY RES, V36, P15, DOI 10.1016/S0920-1211(99)00021-2; Khalilov I, 2005, NEURON, V48, P787, DOI 10.1016/j.neuron.2005.09.026; Kobayashi E, 2001, ARQ NEURO-PSIQUIAT, V59, P255, DOI 10.1590/S0004-282X2001000200021; Koo B, 1996, EPILEPSIA, V37, P1068, DOI 10.1111/j.1528-1157.1996.tb01026.x; Kothare SV, 2001, J CHILD NEUROL, V16, P562, DOI 10.2310/7010.2001.16853; Kramer U, 2005, J CHILD NEUROL, V20, P184, DOI 10.1177/08830738050200030301; Lawn N, 2004, NEUROLOGY, V62, P1352, DOI 10.1212/01.WNL.0000120544.64972.10; Le Van Quyen M, 2006, TRENDS NEUROSCI, V29, P419, DOI 10.1016/j.tins.2006.06.001; LENNOX WG, 1950, PEDIATRICS, V5, P626; Lennox-Buchtal M., 1973, ELECROENCEPH CLIN NE, V32, P1; Lopez E, 2005, EPILEPSIA, V46, P241; LUNA D, 1989, EPILEPSIA, V30, P827, DOI 10.1111/j.1528-1157.1989.tb05346.x; Luna D, 1988, EPIDEMIOLOGIE EPILEP, P41; Maihara T, 1999, EPILEPSIA, V40, P110, DOI 10.1111/j.1528-1157.1999.tb01997.x; MASLAND RL, 1960, EPILEPSIA, V1, P512; Mathern GW, 2002, PROG BRAIN RES, V135, P237; Mikaeloff Y, 2006, EPILEPSY RES, V69, P67, DOI 10.1016/j.eplepsyres.2006.01.002; Mitchell LA, 2003, AM J NEURORADIOL, V24, P1670; Nabbout R, 2002, BRAIN, V125, P2668, DOI 10.1093/brain/awf281; NELSON KB, 1986, AM J DIS CHILD, V140, P1053, DOI 10.1001/archpedi.1986.02140240099034; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; Ohtahara Shunsuke, 1997, Indian Journal of Pediatrics, V64, P603, DOI 10.1007/BF02726112; Okujava M, 2002, EUR RADIOL, V12, P1840, DOI 10.1007/s00330-001-1140-1; OUNSTED C, 1985, ARCH NEUROL-CHICAGO, V42, P1058, DOI 10.1001/archneur.1985.04060100040017; Plouin Perrine, 1992, P3; Pocecco M, 1998, ACTA PAEDIATR, V87, P542, DOI 10.1080/08035259850158254; Prayson RA, 2004, HUM PATHOL, V35, P734, DOI 10.1016/j.humpath.2004.02.013; Riney CJ, 2006, EPILEPSIA, V47, P159, DOI 10.1111/j.1528-1167.2006.00382.x; Roger J., 1964, LENCEPHALOPATHIE MYO, P111; ROGER J, 1992, EPILEPTIC SYNDROMES, P3; Rozycka A, 2003, EPILEPSIA, V44, P1113, DOI 10.1046/j.1528-1157.2003.07603.x; Sahin M, 2003, NEUROLOGY, V61, P398, DOI 10.1212/01.WNL.0000073139.53008.F2; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Scott RC, 2003, BRAIN, V126, P2551, DOI 10.1093/brain/awg262; Shinnar S, 2000, ANN NEUROL, V48, P140, DOI 10.1002/1531-8249(200008)48:2<140::AID-ANA2>3.0.CO;2-Y; Squier W, 2003, DEV MED CHILD NEUROL, V45, P580, DOI 10.1017/S0012162203001075; STANLEY CA, 1983, PEDIATR RES, V17, P877, DOI 10.1203/00006450-198311000-00008; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Takanashi J, 2006, NEUROLOGY, V66, P1304, DOI 10.1212/01.wnl.0000210487.36667.a5; TALWAR D, 1994, EPILEPSIA, V35, P1154, DOI 10.1111/j.1528-1157.1994.tb01782.x; TERRABUSTAMANTE VC, 2007, SEIZURES, V23, P321; Trevathan E, 2003, EPILEPSIA, V44, P19, DOI 10.1046/j.1528-1157.44.s7.1.x; Trinka E, 2002, EPILEPSY RES, V50, P283, DOI 10.1016/S0920-1211(02)00083-9; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; VINING EPG, 1987, PEDIATRICS, V80, P165; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252	104	15	16	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					643	651		10.1016/S1474-4422(07)70173-4	http://dx.doi.org/10.1016/S1474-4422(07)70173-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ	17582364				2022-12-18	WOS:000247673000019
J	Love, R				Love, R			Calorie restriction may be neuroprotective in AD and PD	LANCET NEUROLOGY			English	News Item																			0	15	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					84	84		10.1016/S1474-4422(05)00985-3	http://dx.doi.org/10.1016/S1474-4422(05)00985-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15709227				2022-12-18	WOS:000226712300016
J	Gendelman, HE; Persidsky, Y				Gendelman, HE; Persidsky, Y			Infections of the nervous system	LANCET NEUROLOGY			English	Editorial Material							VACCINE		Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68182 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68182 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68182 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Gendelman, HE (corresponding author), Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, 600 S 42nd St, Omaha, NE 68182 USA.	hegendel@unmc.edu	Gendelman, Howard E/G-8242-2012					Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; Leroy EM, 2004, SCIENCE, V303, P387, DOI 10.1126/science.1092528; Reinert RR, 2004, INT J MED MICROBIOL, V294, P277, DOI 10.1016/j.ijmm.2004.04.004; Roberts L, 2004, SCIENCE, V305, P24, DOI 10.1126/science.305.5680.24; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Verez-Bencomo V, 2004, SCIENCE, V305, P522, DOI 10.1126/science.1095209	7	15	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					12	13		10.1016/S1474-4422(04)00951-2	http://dx.doi.org/10.1016/S1474-4422(04)00951-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620853	Green Published, Bronze			2022-12-18	WOS:000226250200011
J	Ravishankar, K				Ravishankar, K			Barriers to headache care in India and efforts to improve the situation	LANCET NEUROLOGY			English	Editorial Material								With the recent launch of the joint Global Campaign to reduce the burden of headache by the World Headache Alliance (WHA), the International Headache Society (IHS), the European Headache Federation (EHF), and WHO, a welcome focus on the management of migraine is expected. Migraine management is influenced by numerous factors that are regionally different around the world. Through a discussion of the "barriers to care" of migraine in India, I attempt to appraise the academic headache community of the need for region-specific guidelines derived from the standard guidelines. Some of these barriers are within the control of the patient, some are within the control of the treating physician, and many are beyond the control of both. The efforts needed to remedy the situation are also discussed. Hopefully this article will serve to emphasise again the well-known maxim that treatment of migraine is much more than just a prescription.	Jaslok Hosp & Res Ctr, Headache & Migraine Clin, Bombay 400026, Maharashtra, India; Lilavati Hosp & Res Ctr, Bombay, Maharashtra, India		Ravishankar, K (corresponding author), Jaslok Hosp & Res Ctr, Headache & Migraine Clin, 15 G Deshmukh Marg, Bombay 400026, Maharashtra, India.	dr_k_ravishankar@vsnl.com						*COUNTR DAT, 2004, IND POP PROJ; *NAT, 2004, PROF ED; Ravishankar K, 2003, CEPHALALGIA, V23, P577; Steiner TJ, 2004, LANCET NEUROL, V3, P204, DOI 10.1016/S1474-4422(04)00703-3; WALTER FS, 2001, NEUROLOGY S11, V56, pS20	5	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2004	3	9					564	567		10.1016/S1474-4422(04)00855-5	http://dx.doi.org/10.1016/S1474-4422(04)00855-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	849VD	15324725				2022-12-18	WOS:000223568300021
J	[Anonymous]				[Anonymous]			Neuromarketing: beyond branding	LANCET NEUROLOGY			English	Editorial Material																			0	15	16	8	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					71	71		10.1016/S1474-4422(03)00643-4	http://dx.doi.org/10.1016/S1474-4422(03)00643-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14746993	Bronze			2022-12-18	WOS:000188818500001
J	Olesen, J; Goadsby, P; Steiner, T				Olesen, J; Goadsby, P; Steiner, T			The International Classification of Headache Disorders: 2nd edition	LANCET NEUROLOGY			English	Editorial Material									Glostrup Cty Hosp, Dept Neurol, Glostrup, Denmark	University of Copenhagen	Olesen, J (corresponding author), Glostrup Cty Hosp, Dept Neurol, Glostrup, Denmark.	jeol@glostruphosp.kbhamt.dk	Goadsby, Peter J/Z-1970-2019	Goadsby, Peter J/0000-0003-3260-5904				Headache Classification Committee of the International Headache Society (IHS), INT CLASS HEAD DIS, V3rd; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x	2	15	17	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					720	720		10.1016/S1474-4422(03)00590-8	http://dx.doi.org/10.1016/S1474-4422(03)00590-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV					2022-12-18	WOS:000186665800011
J	Hooker, J; Eccher, M; Lakshminarayan, K; Souza-Lima, FC; Rejdak, K; Kwiecinski, H; Corea, F; Lima, JML				Hooker, J; Eccher, M; Lakshminarayan, K; Souza-Lima, FC; Rejdak, K; Kwiecinski, H; Corea, F; Lima, JML			Neurology training around the world	LANCET NEUROLOGY			English	Editorial Material							EFNS TASK-FORCE; EDUCATION; EUROPE		UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Hosp Quinta Dor, Rio De Janeiro, Brazil; Med Univ, Dept Neurol, Lublin, Poland; Med Univ, Dept Neurol, Warsaw, Poland; Univ Vita E Salute San Raffaele, Neurol Clin, Milan, Italy; Univ Perugia, Dipartimento Neurosci, I-06100 Perugia, Italy; Hosp Geral Santo Antonio, Serv Neurol, Oporto, Portugal	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Cleveland Clinic Foundation; University of Minnesota System; University of Minnesota Twin Cities; Medical University of Lublin; Vita-Salute San Raffaele University; University of Perugia	Hooker, J (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.		corea, francesco/ABH-1776-2020	corea, francesco/0000-0002-5864-9991; Rejdak, Konrad/0000-0002-7019-6681; Lakshminarayan, Kamakshi/0000-0002-8564-8986				Bartos A, 2001, EUR J NEUROL, V8, P551, DOI 10.1046/j.1468-1331.2001.00288.x; Bergen DC, 2002, J NEUROL SCI, V198, P3, DOI 10.1016/S0022-510X(02)00071-0; Grisold W, 1999, EUR J NEUROL, V6, P259, DOI 10.1046/j.1468-1331.1999.630259.x; Pontes C, 2001, EUR J NEUROL, V8, P381, DOI 10.1046/j.1468-1331.2001.00248.x	4	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2003	2	9					572	579		10.1016/S1474-4422(03)00507-6	http://dx.doi.org/10.1016/S1474-4422(03)00507-6			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717VT	12941581	Green Published			2022-12-18	WOS:000185112000022
J	Haley, RW				Haley, RW			Gulf war syndrome: narrowing the possibilities	LANCET NEUROLOGY			English	Editorial Material							CASE-DEFINITION; NERVOUS-SYSTEM; VETERANS; SARIN; PARAOXONASE; DYSFUNCTION		Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Haley, RW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Haley, Robert/P-9026-2014	Haley, Robert/0000-0001-8849-9579				Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; EDDINGTON P, 1997, GASSED GULF INSIDE S; Haley RW, 2000, RADIOLOGY, V215, P807, DOI 10.1148/radiology.215.3.r00jn48807; Haley RW, 2002, AM J PUBLIC HEALTH, V92, P46, DOI 10.2105/AJPH.92.1.46; Haley RW, 2001, PSYCHIAT RES, V102, P175, DOI 10.1016/S0165-1781(01)00241-4; Haley RW, 1999, TOXICOL APPL PHARM, V157, P227, DOI 10.1006/taap.1999.8703; Henderson RF, 2002, TOXICOL APPL PHARM, V184, P67, DOI 10.1006/taap.2002.9495; Ismail K, 2002, BMJ-BRIT MED J, V325, P576, DOI 10.1136/bmj.325.7364.576; Jamal GA, 1996, J NEUROL NEUROSUR PS, V60, P449, DOI 10.1136/jnnp.60.4.449; Kalra R, 2002, TOXICOL APPL PHARM, V184, P82, DOI 10.1006/taap.2002.9497; Mackness B, 2000, BIOCHEM BIOPH RES CO, V276, P729, DOI 10.1006/bbrc.2000.3526; MATIN MA, 1985, METHOD FIND EXP CLIN, V7, P79; MEYERHOFF DJ, 2001, P INT SOC MAG RESON, V9, P994; Sharief MK, 2002, NEUROLOGY, V59, P1518, DOI 10.1212/01.WNL.0000032755.27372.FC; THOMPSON J, 2003, COMMUNICATION   1026; TUCKER JB, 1991, EVIDENCE IRAQ USED C; WOLFE GI, 2003, ELECTRODIAGNOSTIC ME; 2003, COALITION CHEM DETEC; 2003, RIEGLE REPORT	19	15	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2003	2	5					272	273		10.1016/S1474-4422(03)00376-4	http://dx.doi.org/10.1016/S1474-4422(03)00376-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	669RC	12849177				2022-12-18	WOS:000182363400014
J	Baker, D; Adamson, P; Greenwood, J				Baker, D; Adamson, P; Greenwood, J			Potential of statins for the treatment of multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; DISEASE		UCL, Inst Neurol, Neuroinflammat Grp, London, England; UCL, Inst Ophthalmol, Div Cell Biol, London, England	University of London; King's College London; University College London; University of London; University College London	Baker, D (corresponding author), UCL, Inst Neurol, Neuroinflammat Grp, Mortimer St, London, England.	j.greenwood@ucl.ac.uk		Greenwood, John/0000-0003-4496-2984				Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	5	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					9	10		10.1016/S1474-4422(03)00256-4	http://dx.doi.org/10.1016/S1474-4422(03)00256-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849290				2022-12-18	WOS:000180035800013
J	Behari, M; Bhatnagar, SP; Muthane, U; Deo, D				Behari, M; Bhatnagar, SP; Muthane, U; Deo, D			Experiences of Parkinson's disease in India	LANCET NEUROLOGY			English	Editorial Material									All India Inst Med Sci, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Behari, M (corresponding author), All India Inst Med Sci, New Delhi, India.							[Anonymous], 2001, CENS IND; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BANERJEE D, 2002, HLTH INSURANCE INDIA; BHARUCHA NE, 1988, ARCH NEUROL-CHICAGO, V45, P1321, DOI 10.1001/archneur.1988.00520360039008; DIZDAR N, 1994, ACTA NEUROL SCAND, V90, P345; Ellis RP, 2000, ECON POLIT WEEKLY, V35, P207; Hughes AJ, 2001, NEUROLOGY, V57, P1497, DOI 10.1212/WNL.57.8.1497; LITTLEFIELD RS, 2002, DRUG BENEFIT TRENDS, V13, P38; Loff B, 2002, LANCET, V359, P956, DOI 10.1016/S0140-6736(02)08059-5; Pang T, 2002, BMJ-BRIT MED J, V324, P499, DOI 10.1136/bmj.324.7336.499; Rajendran PR, 2001, NEUROLOGY, V57, P790, DOI 10.1212/WNL.57.5.790; VAIDYA AB, 1978, NEUROL INDIA, V26, P171; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x; WATSON R, 2002, BRIT MED J, V324, P634	14	15	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					258	262		10.1016/S1474-4422(02)00105-9	http://dx.doi.org/10.1016/S1474-4422(02)00105-9			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849459				2022-12-18	WOS:000177701800023
J	Morenas-Rodriguez, E; Li, Y; Nuscher, B; Franzmeier, N; Xiong, CJ; Suarez-Calvet, M; Fagan, AM; Schultz, S; Gordon, BA; Benzinger, TLS; Hassenstab, J; McDade, E; Feederle, R; Karch, CM; Schlepckow, K; Morris, JC; Kleinberger, G; Nellgard, B; Voglein, J; Blennow, K; Zetterberg, H; Ewers, M; Jucker, M; Levin, J; Bateman, RJ; Haass, C				Morenas-Rodriguez, Estrella; Li, Yan; Nuscher, Brigitte; Franzmeier, Nicolai; Xiong, Chengjie; Suarez-Calvet, Marc; Fagan, Anne M.; Schultz, Stephanie; Gordon, Brian A.; Benzinger, Tammie L. S.; Hassenstab, Jason; McDade, Eric; Feederle, Regina; Karch, Celeste M.; Schlepckow, Kai; Morris, John C.; Kleinberger, Gernot; Nellgard, Bengt; Voglein, Jonathan; Blennow, Kaj; Zetterberg, Henrik; Ewers, Michael; Jucker, Mathias; Levin, Johannes; Bateman, Randall J.; Haass, Christian		Dominantly Inherited Alzheimer Net	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study	LANCET NEUROLOGY			English	Article							CEREBROSPINAL-FLUID; A-BETA; PATHOLOGY; TAU	Background Therapeutic modulation of TREM2-dependent microglial function might provide an additional strategy to slow the progression of Alzheimer's disease. Although studies in animal models suggest that TREM2 is protective against Alzheimer's pathology, its effect on tau pathology and its potential beneficial role in people with Alzheimer's disease is still unclear. Our aim was to study associations between the dynamics of soluble TREM2, as a biomarker of TREM2 signalling, and amyloid beta (A beta) deposition, tau-related pathology, neuroimaging markers, and cognitive decline, during the progression of autosomal dominant Alzheimer's disease. Methods We did a longitudinal analysis of data from the Dominantly Inherited Alzheimer Network (DIAN) observational study, which includes families with a history of autosomal dominant Alzheimer's disease. Participants aged over 18 years who were enrolled in DIAN between Jan 1, 2009, and July 31, 2019, were categorised as either carriers of pathogenic variants in PSEN1 , PSEN2 , and APP genes (n=155) or non-carriers (n=93). We measured amounts of cleaved soluble TREM2 using a novel immunoassay in CSF samples obtained every 2 years from participants who were asymptomatic (Clinical Dementia Rating [CDR]=0) and annually for those who were symptomatic (CDR > 0). CSF concentrations of A beta 40, A beta 42, total tau (t-tau), and tau phosphorylated on threonine 181 (p-tau) were measured by validated immunoassays. Predefined neuroimaging measurements were total cortical uptake of Pittsburgh compound B PET (PiB-PET), cortical thickness in the precuneus ascertained by MRI, and hippocampal volume determined by MRI. Cognition was measured using a validated cognitive composite (including DIAN word list test, logical memory delayed recall, digit symbol coding test [total score], and minimental status examination). We based our statistical analysis on univariate and bivariate linear mixed effects models. Findings In carriers of pathogenic variants, a high amyloid burden at baseline, represented by low CSF A beta 42 (beta=-4.28 x 10(-2) [SE 0.013], p=0.0012), but not high cortical uptake in PiB-PET (beta=-5.51 x 10(-3) [0.011], p=0.63), was the only predictor of an augmented annual rate of subsequent increase in soluble TREM2. Augmented annual rates of increase in soluble TREM2 were associated with a diminished rate of decrease in amyloid deposition, as measured by A beta 42 in CSF (r=0.56 [0.22], p=0.011), in presymptomatic carriers of pathogenic variants, and with diminished annual rate of increase in PiB-PET (r=-0.67 [0.25], p=0.0060) in symptomatic carriers of pathogenic variants. Presymptomatic carriers of pathogenic variants with annual rates of increase in soluble TREM2 lower than the median showed a correlation between enhanced annual rates of increase in p-tau in CSF and augmented annual rates of increase in PiB-PET signal (r=0.45 [0.21], p=0.035), that was not observed in those with rates of increase in soluble TREM2 higher than the median. Furthermore, presymptomatic carriers of pathogenic variants with rates of increase in soluble TREM2 above or below the median had opposite associations between A beta 42 in CSF and PiB-PET uptake when assessed longitudinally. Augmented annual rates of increase in soluble TREM2 in presymptomatic carriers of pathogenic variants correlated with decreased cortical shrinkage in the precuneus (r=0.46 [0.22]), p=0.040) and diminished cognitive decline (r=0.67 [0.22], p=0.0020). Interpretation Our findings in autosomal dominant Alzheimer's disease position the TREM2 response within the amyloid cascade immediately after the first pathological changes in A beta aggregation and further support the role of TREM2 on A beta plaque deposition and compaction. Furthermore, these findings underpin a beneficial effect of TREM2 on A beta deposition, A beta-dependent tau pathology, cortical shrinkage, and cognitive decline. Soluble TREM2 could, therefore, be a key marker for clinical trial design and interpretation. Efforts to develop TREM2-boosting therapies are ongoing. Funding German Research Foundation, US National Institutes of Health.Copyright (C) 2022 Elsevier Ltd. All rights reserved.	[Morenas-Rodriguez, Estrella; Nuscher, Brigitte; Feederle, Regina; Schlepckow, Kai; Kleinberger, Gernot; Voglein, Jonathan; Ewers, Michael; Levin, Johannes; Haass, Christian] German Ctr Neurodegenerat Dis, Munich, Germany; [Morenas-Rodriguez, Estrella; Nuscher, Brigitte; Schlepckow, Kai; Kleinberger, Gernot; Haass, Christian] Ludwig Maximilians Univ Munchen, Fac Med, Biomed Ctr, Metab Biochem, Munich, Germany; [Franzmeier, Nicolai; Ewers, Michael] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany; [Voglein, Jonathan; Levin, Johannes] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Dept Neurol, Munich, Germany; [Li, Yan; Xiong, Chengjie] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Fagan, Anne M.; Hassenstab, Jason; McDade, Eric; Morris, John C.; Bateman, Randall J.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Schultz, Stephanie; Gordon, Brian A.; Benzinger, Tammie L. S.] Washington Univ, Mallinckrodt Inst Radiol, Sch Med, St Louis, MO USA; [Karch, Celeste M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Suarez-Calvet, Marc] Pasqua Maragall Fdn, Barcelonasseta Brain Res Ctr, Barcelona, Spain; [Suarez-Calvet, Marc] Hosp del Mar, Serv Neurol, Med Res Inst, Barcelona, Spain; [Suarez-Calvet, Marc] Ctr Invest Biomed Red Fragilidady Envejecimiento, Madrid, Spain; [Levin, Johannes; Haass, Christian] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Feederle, Regina] Helmholtz Ctr, Inst Diabet & Obes, Monoclonal Antibody Core Facil, Munich, Germany; [Feederle, Regina] German Res Ctr Environm Hlth, Neuherberg, Germany; [Nellgard, Bengt] Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care, Molndal, Sweden; [Nellgard, Bengt] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, Dept Neurodegenerat Dis, UCL Queens Sq Inst Neurol, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Zetterberg, Henrik] Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China; [Jucker, Mathias] German Ctr Neurodegenerat Dis, Tubingen, Germany; [Jucker, Mathias] Hertie Inst Clin Brain Res, Dept Cellular Neurol, Tubingen, Germany	Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Munich; University of Munich; University of Munich; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Sahlgrenska University Hospital; University of Gothenburg; University of Gothenburg; Sahlgrenska University Hospital; University of London; University College London; University of London; University College London; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Morenas-Rodriguez, E (corresponding author), Hosp Univ 12 Octubre, Dept Neurol, Memory Unit, Madrid 28041, Spain.	estrella.morenas.rodriguez@gmail.com	Gordon, Brian/U-7794-2019; Levin, Johannes/E-4052-2010; Berman, Sarah/I-2792-2014	Gordon, Brian/0000-0003-2109-2955; Levin, Johannes/0000-0001-5092-4306; McCullough, Austin/0000-0001-9192-111X; Berman, Sarah/0000-0002-5096-4962	German Research Foundation; US National Institutes of Health	German Research Foundation(German Research Foundation (DFG)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	German Research Foundation, US National Institutes of Health.	Bartl M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257372; Bateman RJ, 2017, ALZHEIMERS DEMENT, V13, P8, DOI 10.1016/j.jalz.2016.07.005; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Deming Y, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau2291; Edwin Trine Holt, 2020, Alzheimers Dement (Amst), V12, pe12128, DOI 10.1002/dad2.12128; Ewers M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012308; Ewers M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav6221; Falcon C, 2019, NEUROIMAGE-CLIN, V23, DOI 10.1016/j.nicl.2019.101801; Fieuws S, 2004, STAT MED, V23, P3093, DOI 10.1002/sim.1885; Gordon BA, 2018, LANCET NEUROL, V17, P241, DOI 10.1016/S1474-4422(18)30028-0; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Huang YT, 2021, NAT IMMUNOL, V22, P586, DOI 10.1038/s41590-021-00913-5; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093; Kunkle BW, 2019, NAT GENET, V51, P414, DOI 10.1038/s41588-019-0358-2; Lee SH, 2021, NEURON, V109, P1283, DOI 10.1016/j.neuron.2021.02.010; Lewcock JW, 2020, NEURON, V108, P801, DOI 10.1016/j.neuron.2020.09.029; Luo JQ, 2022, J APPL STAT, V49, P2246, DOI 10.1080/02664763.2021.1899141; Mazaheri F, 2017, EMBO REP, V18, P1186, DOI 10.15252/embr.201743922; McDade E, 2018, NEUROLOGY, V91, pE1295, DOI 10.1212/WNL.0000000000006277; Meilandt WJ, 2020, J NEUROSCI, V40, P1956, DOI 10.1523/JNEUROSCI.1871-19.2019; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Parhizkar S, 2019, NAT NEUROSCI, V22, P191, DOI 10.1038/s41593-018-0296-9; Pascoal TA, 2021, NAT MED, V27, P1592, DOI 10.1038/s41591-021-01456-w; Piccio L, 2016, ACTA NEUROPATHOL, V131, P925, DOI 10.1007/s00401-016-1533-5; Schlepckow K, 2017, EMBO MOL MED, V9, P1356, DOI 10.15252/emmm.201707672; Schmitz TW, 2020, J NEUROSCI, V40, P1931, DOI 10.1523/JNEUROSCI.1184-19.2019; Small SA, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb1717; Suarez-Calvet M, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-018-0301-5; Suarez-Calvet M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1767; Suarez-Calvet M, 2016, EMBO MOL MED, V8, P466, DOI 10.15252/emmm.201506123; Toledo JB, 2015, JAMA NEUROL, V72, P571, DOI 10.1001/jamaneurol.2014.4829; Tsubuki S, 2003, LANCET, V361, P1957, DOI 10.1016/S0140-6736(03)13555-6; Uhlmann RE, 2020, NAT NEUROSCI, V23, P1580, DOI 10.1038/s41593-020-00737-w; Xu ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102312; Zhang PF, 2021, MOL NEUROBIOL, V58, P3388, DOI 10.1007/s12035-021-02348-3	37	14	14	7	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2022	21	4					329	341		10.1016/S1474-4422(22)00027-8	http://dx.doi.org/10.1016/S1474-4422(22)00027-8			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	1Y0JM	35305339	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000807832700014
J	Wiegers, EJA; Lingsma, HF; Huijben, JA; Cooper, DJ; Citerio, G; Frisvold, S; Helbok, R; Maas, AIR; Menon, DK; Moore, EM; Stocchetti, N; Dippel, DW; Steyerberg, EW; van der Jagt, M				Wiegers, Eveline Janine Anna; Lingsma, Hester Floor; Huijben, Jilske Antonia; Cooper, David James; Citerio, Giuseppe; Frisvold, Shirin; Helbok, Raimund; Maas, Andrew Ian Ramsay; Menon, David Krishna; Moore, Elizabeth Madeleine; Stocchetti, Nino; Dippel, Diederik Willem; Steyerberg, Ewout Willem; van der Jagt, Mathieu		CENTER-TBI Collaboration Grp; OzENTER-TBI Collaboration Grp	Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI) : a prospective, multicentre, comparative effectiveness study	LANCET NEUROLOGY			English	Article							INTRACRANIAL-PRESSURE; MANAGEMENT; GUIDELINES	Background Fluid therapy-the administration of fluids to maintain adequate organ tissue perfusion and oxygenation-is essential in patients admitted to the intensive care unit (ICU) with traumatic brain injury. We aimed to quantify the variability in fluid management policies in patients with traumatic brain injury and to study the effect of this variability on patients' outcomes. Methods We did a prospective, multicentre, comparative effectiveness study of two observational cohorts: CENTER-TBI in Europe and OzENTER-TBI in Australia. Patients from 55 hospitals in 18 countries, aged 16 years or older with traumatic brain injury requiring a head CT, and admitted to the ICU were included in this analysis. We extracted data on demographics, injury, and clinical and treatment characteristics, and calculated the mean daily fluid balance (difference between fluid input and loss) and mean daily fluid input during ICU stay per patient. We analysed the association of fluid balance and input with ICU mortality and functional outcome at 6 months, measured by the Glasgow Outcome Scale Extended (GOSE). Patient-level analyses relied on adjustment for key characteristics per patient, whereas centre-level analyses used the centre as the instrumental variable. Findings 2125 patients enrolled in CENTER-TBI and OzENTER-TBI between Dec 19, 2014, and Dec 17, 2017, were eligible for inclusion in this analysis. The median age was 50 years (IQR 31 to 66) and 1566 (74%) of patients were male. The median of the mean daily fluid input ranged from 1middot48 L (IQR 1middot12 to 2middot09) to 4middot23 L (3middot78 to 4middot94) across centres. The median of the mean daily fluid balance ranged from -0middot85 L (IQR -1middot51 to -0middot49) to 1middot13 L (0middot99 to 1middot37) across centres. In patient-level analyses, a mean positive daily fluid balance was associated with higher ICU mortality (odds ratio [OR] 1middot10 [95% CI 1middot07 to 1middot12] per 0middot1 L increase) and worse functional outcome (1middot04 [1middot02 to 1middot05] per 0middot1 L increase); higher mean daily fluid input was also associated with higher ICU mortality (1middot05 [1middot03 to 1middot06] per 0middot1 L increase) and worse functional outcome (1middot04 [1middot03 to 1middot04] per 1-point decrease of the GOSE per 0middot1 L increase). Centre-level analyses showed similar associations of higher fluid balance with ICU mortality (OR 1middot17 [95% CI 1middot05 to 1middot29]) and worse functional outcome (1middot07 [1middot02 to 1middot13]), but higher fluid input was not associated with ICU mortality (OR 0middot95 [0middot90 to 1middot00]) or worse functional outcome (1middot01 [0middot98 to 1middot03]). Interpretation In critically ill patients with traumatic brain injury, there is significant variability in fluid management, with more positive fluid balances being associated with worse outcomes. These results, when added to previous evidence, suggest that aiming for neutral fluid balances, indicating a state of normovolaemia, contributes to improved outcome. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Wiegers, Eveline Janine Anna; Lingsma, Hester Floor; Huijben, Jilske Antonia; Steyerberg, Ewout Willem] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands; [Cooper, David James] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Cooper, David James] Alfred, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Monza, MB, Italy; [Citerio, Giuseppe] ASST Monza, San Gerardo Hosp, Neurointens Care Unit, Monza, MB, Italy; [Frisvold, Shirin] Univ Hosp North Norway, Dept Intens Care Med, Tromso, Norway; [Frisvold, Shirin] UiT Arctic Univ Norway, Tromso, Norway; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol Neurocrit Care, Anichstr, Innsbruck, Austria; [Maas, Andrew Ian Ramsay] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew Ian Ramsay] Univ Antwerp, Edegem, Belgium; [Menon, David Krishna] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Moore, Elizabeth Madeleine] Monash Univ, Sch Publ Hlth & Prevent Med, Transfus Res Unit, Melbourne, Vic, Australia; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci Intens Care Unit, Milan, Italy; [Dippel, Diederik Willem] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Steyerberg, Ewout Willem] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [van der Jagt, Mathieu] Erasmus MC Univ Med Ctr, Dept Intens Care Adults, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Monash University; University of Milano-Bicocca; San Gerardo Hospital; UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso; Medical University of Innsbruck; University of Antwerp; University of Antwerp; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Monash University; IRCCS Ca Granda Ospedale Maggiore Policlinico; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	van der Jagt, M (corresponding author), Erasmus MC Univ Med Ctr, Dept Intens Care Adults, NL-3000 CA Rotterdam, Netherlands.	m.vanderjagt@erasmusmc.nl	Gomez, Pedro A./E-2411-2014; Rossi, Sandra/AHH-8015-2022; Posti, Jussi P./Y-2908-2019; Volovici, Victor/AAZ-8901-2020; Lagares, Alfonso/B-2969-2011; Vande Vyvere, Thijs/AAB-5180-2022; Ercole, Ari/B-6288-2009; Sahuquillo, Juan/B-3577-2008; Raj, Rahul/K-7693-2012; Majdan, Marek/K-5017-2012; van der Jagt, Mathieu/G-1905-2017	Gomez, Pedro A./0000-0002-4185-5238; Rossi, Sandra/0000-0002-9963-8121; Posti, Jussi P./0000-0002-5925-5193; Volovici, Victor/0000-0002-5798-5360; Lagares, Alfonso/0000-0003-3996-0554; Vande Vyvere, Thijs/0000-0003-4032-5443; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Williams, Guy/0000-0001-5223-6654; Schmidt, Silke/0000-0002-4194-1937; Radoi, Andreea/0000-0002-0677-3544; Newcombe, Virginia/0000-0001-6044-9035; Parizel, Paul M./0000-0002-0221-2854; Azzolini, Maria Luisa/0000-0002-3084-7064; Ercole, Ari/0000-0001-8350-8093; Sahuquillo, Juan/0000-0003-0713-5875; Ragauskas, Arminas/0000-0001-9695-9512; Wiegers, Eveline/0000-0003-1768-7550; Coles, Jonathan/0000-0003-4013-679X; Castano-Leon, Ana M/0000-0002-7918-5049; Golubovic, Jagos/0000-0001-5524-246X; Raj, Rahul/0000-0003-4243-9591; Dark, Paul/0000-0003-3309-0164; Sanchez-Porras, Renan/0000-0002-9084-8114; Kondziella, Daniel/0000-0001-5562-9808; Van Essen, Thomas/0000-0003-4657-5283; Stewart, William/0000-0003-2199-2582; Majdan, Marek/0000-0001-8037-742X; Zeiler, Frederick/0000-0003-1737-0510; Huijben, Jilske (Antonia)/0000-0002-2892-5406; van der Naalt, Joukje/0000-0001-9873-2418; van der Jagt, Mathieu/0000-0003-2566-8325; Gratz, Johannes/0000-0001-8717-0544	European Commission 7th Framework program; Australian Health and Medical Research Council	European Commission 7th Framework program; Australian Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	European Commission 7th Framework program and the Australian Health and Medical Research Council.	Beaubien-Souligny W, 2020, ULTRASOUND J, V12, DOI 10.1186/s13089-020-00163-w; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Brookhart M Alan, 2007, Int J Biostat, V3, P14; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cnossen MC, 2018, CLIN EPIDEMIOL, V10, P841, DOI 10.2147/CLEP.S154500; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Kuehn BM, 2011, JAMA-J AM MED ASSOC, V305, P1846, DOI 10.1001/jama.2011.597; Li HP, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01764-7; Luo JF, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0239-8; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; MCMANUS ML, 1993, ANESTHESIOLOGY, V78, P1132, DOI 10.1097/00000542-199306000-00017; Mutoh T, 2009, STROKE, V40, P2368, DOI 10.1161/STROKEAHA.109.547463; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Oddo M, 2018, INTENS CARE MED, V44, P449, DOI 10.1007/s00134-018-5086-z; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Van Regenmortel N, 2018, INTENS CARE MED, V44, P409, DOI 10.1007/s00134-018-5147-3; Volovici V, 2019, WORLD NEUROSURG, V125, pE515, DOI 10.1016/j.wneu.2019.01.116; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	29	14	14	3	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					627	638		10.1016/S1474-4422(21)00162-9	http://dx.doi.org/10.1016/S1474-4422(21)00162-9			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34302787	Green Published, Green Submitted			2022-12-18	WOS:000677684700016
J	Westeneng, HJ; van Veenhuijzen, K; van der Spek, RA; Peters, S; Visser, AE; van Rheenen, W; Veldink, JH; van den Berg, LH				Westeneng, Henk-Jan; van Veenhuijzen, Kevin; van der Spek, Rick A.; Peters, Susan; Visser, Anne E.; van Rheenen, Wouter; Veldink, Jan H.; van den Berg, Leonard H.			Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study	LANCET NEUROLOGY			English	Article							BODY-MASS INDEX; MENDELIAN RANDOMIZATION; FRONTOTEMPORAL DEMENTIA; REPEAT EXPANSIONS; PHYSICAL-ACTIVITY; RISK; ALCOHOL; DISEASE; FAT	Background Amyotrophic lateral sclerosis (ALS) is considered to be caused by both genetic and environmental factors. The causal cascade is, however, not known. We aimed to assess lifestyle during the presymptomatic phase of ALS, stratified by C9orf72 mutation, and examine evidence supporting causality of lifestyle factors. Methods This study was a longitudinal, population-based, case-control study that used data from the Prospective ALS study the Netherlands. We included patients with a C9orf72 mutation (C9+ group), patients without a C9orf72 mutation (C9- group), and controls. Patients fulfilled the revised El Escorial criteria and were recruited through neurologists and rehabilitation physicians in the Netherlands as well as the Dutch Neuromuscular Patient Association and ALS Centrum website. 1322 population-based controls, matched for age and sex, were enrolled via the patients' general practitioners. Blood relatives or spouses of patients were not eligible as controls. We studied the relationship between ALS risk and smoking, alcohol, physical activity, body-mass index (BMI), and energy intake by the use of structured questionnaires. Smoking, physical activity, and BMI were longitudinally assessed up to 50 years before onset (defined as the period before onset of muscle weakness or bulbar symptoms for cases, or age at completing the questionnaire for controls). We calculated posterior probabilities (P(theta vertical bar x)) for causal effects of smoking, alcohol, and BMI, using Bayesian instrumental variable analyses. Findings Between Jan 1, 2006 and Jan 27, 2016, we included 143 patients in the C9+ group, 1322 patients in the C9- group, and 1322 controls. Compared with controls, cigarette pack-years (C9+ group mean difference from control 3.15, 95% CI 0.36 to 5.93, p=0.027; C9- group 3.20, 2.02 to 4.39, p<0.0001) and daily energy intake at symptom onset (C9+ group 712 kJ, 95% CI 212 to 1213, p=0.0053; C9- group 497, 295 to 700, p<0.0001) were higher in the C9+ and C9- groups, whereas current BMI (C9+ group -2.01 kg/m(2), 95% CI -2.73 to -1.29, p<0.0001; C9- group -1.35, -1.64 to -1.06, p<0.0001) and lifetime alcohol consumption (C9+ group -5388 units, 95% CI -9113 to -1663, p=0.0046; C9- group -2185, -3748 to -622, p=0.0062) were lower in the C9+ and C9- groups. Median BMI during the presymptomatic phase for the C9+ group was lower (-0.69 kg/m(2), 95% CI -1.24 to -0.13, p=0.015) and physical activity was similar (-348 metabolic equivalent of task [MET], 95% CI -966 to 270, p=0.27) to controls, whereas both the median BMI during the presymptomatic phase (0.27 kg/m(2), 95% CI 0.04 to 0.50, p=0.022) and physical activity (585 MET, 291 to 878, p=0.0001) were higher in the C9- group than controls. Longitudinal analyses showed more cigarette pack-years in the C9- (starting 47 years pre-onset) and C9+ (starting 24 years pre-onset) groups, and higher physical activity over time in the C9- group (starting >30 years pre-onset). BMI of the C9+ group increased more slowly and was significantly lower (starting at 36 years pre-onset) than in controls, whereas the BMI of the C9- group was higher than controls (23-49 years pre-onset, becoming lower 10 years pre-onset). Instrumental variable analyses supported causal effects of alcohol consumption (P(theta vertical bar x)=0.9347) and smoking (P(theta vertical bar x)=0.9859) on ALS in the C9- group. We found evidence supporting a causal effect of increased BMI at younger age (mean 33.8 years, SD 11.7) in the C9- group (P[theta vertical bar x]=0.9272), but not at older ages. Interpretation Lifestyle during the presymptomatic phase differs between patients with ALS and controls decades before onset, depends on C9- status, and is probably part of the presymptomatic causal cascade. Identification of modifiable disease-causing lifestyle factors offers opportunities to lower risk of developing neurodegenerative disease. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Westeneng, Henk-Jan; van Veenhuijzen, Kevin; van der Spek, Rick A.; Peters, Susan; Visser, Anne E.; van Rheenen, Wouter; Veldink, Jan H.; van den Berg, Leonard H.] Univ Med Ctr Utrecht, Dept Neurol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Peters, Susan] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	van den Berg, LH (corresponding author), Univ Med Ctr Utrecht, Dept Neurol, NL-3508 GA Utrecht, Netherlands.	l.h.vandenBerg@umcutrecht.nl		Veldink, Jan/0000-0001-5572-9657; Peters, Susan/0000-0001-5662-1971	Netherlands ALS Foundation	Netherlands ALS Foundation	Netherlands ALS Foundation.	Abrahao KP, 2017, NEURON, V96, P1223, DOI 10.1016/j.neuron.2017.10.032; AI-Chalabi A, 2014, LANCET NEUROL, V13, P1108, DOI 10.1016/S1474-4422(14)70219-4; Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; ANONYMOUS, 2015, LANCET NEUROL, V14, P235; Armon C, 2018, J NEUROL SCI, V391, P134, DOI 10.1016/j.jns.2018.05.016; Bandres-Ciga S, 2019, ANN NEUROL, V85, P470, DOI 10.1002/ana.25431; Brown RH, 2017, NEW ENGL J MED, V377, P162, DOI [10.1038/nrdp.2017.85, 10.1016/S0140-6736(10)61156-7, 10.1016/S0140-6736(17)31287-4, 10.1056/NEJMra1603471, 10.1038/nrdp.2017.71, 10.1056/NEJMc1710379]; Burgess S, 2017, STAT METHODS MED RES, V26, P2333, DOI 10.1177/0962280215597579; Byrne S, 2012, LANCET NEUROL, V11, P232, DOI 10.1016/S1474-4422(12)70014-5; D'Ovidio F, 2019, J NEUROL NEUROSUR PS, V90, P11, DOI 10.1136/jnnp-2018-318559; Didelez V, 2007, STAT METHODS MED RES, V16, P309, DOI 10.1177/0962280206077743; Dimou, 2019, PEERJ PREPRINTS, DOI [10.7287/peerj.preprints.27857v1, 10.7287/peerj.preprints.27857, DOI 10.7287/PEERJ.PREPRINTS.27857, DOI 10.7287/PEERJ.PREPRINTS.27857V1]; Dupuis L, 2011, LANCET NEUROL, V10, P75, DOI 10.1016/S1474-4422(10)70224-6; Gallo V, 2013, NEUROLOGY, V80, P829, DOI 10.1212/WNL.0b013e3182840689; Greenland S, 2000, INT J EPIDEMIOL, V29, P1102, DOI 10.1093/oxfordjournals.ije.a019909; Huisman MHB, 2015, JAMA NEUROL, V72, P1155, DOI 10.1001/jamaneurol.2015.1584; Huisman MHB, 2013, J NEUROL NEUROSUR PS, V84, P976, DOI 10.1136/jnnp-2012-304724; Huisman MHB, 2011, J NEUROL NEUROSUR PS, V82, P1165, DOI 10.1136/jnnp.2011.244939; Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034; Liao CX, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2967-3; Little R.J.A., 1987, STAT ANAL MISSING DA; Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177; Mitchell WK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00260; Murphy NA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02364-1; Nakken O, 2019, NEUROLOGY, V93, pE424, DOI 10.1212/WNL.0000000000007861; O'Brien M, 2017, JAMA NEUROL, V74, P1425, DOI 10.1001/jamaneurol.2017.2699; Peter RS, 2017, EUR J EPIDEMIOL, V32, P901, DOI 10.1007/s10654-017-0318-z; Peters S, 2020, J NEUROL NEUROSUR PS, V91, P33, DOI 10.1136/jnnp-2019-320986; Pupillo E, 2014, ANN NEUROL, V75, P708, DOI 10.1002/ana.24150; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Rohrer JD, 2015, LANCET NEUROL, V14, P253, DOI 10.1016/S1474-4422(14)70324-2; Sachdev HS, 2005, AM J CLIN NUTR, V82, P456, DOI 10.1093/ajcn/82.2.456; Salat D, 2016, LANCET NEUROL, V15, P637, DOI 10.1016/S1474-4422(16)00060-0; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; Steyn FJ, 2018, J NEUROL NEUROSUR PS, V89, P1016, DOI 10.1136/jnnp-2017-317887; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; van Blitterswijk M, 2012, CURR OPIN NEUROL, V25, P689, DOI 10.1097/WCO.0b013e32835a3efb; van Rheenen W, 2016, NAT GENET, V48, P1043, DOI 10.1038/ng.3622; van Rheenen W, 2012, NEUROLOGY, V79, P878, DOI 10.1212/WNL.0b013e3182661d14; Visser AE, 2018, J NEUROL NEUROSUR PS, V89, P797, DOI 10.1136/jnnp-2017-317724; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Zeng P, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00543; Zhan YQ, 2019, ANN NEUROL, V85, P482, DOI 10.1002/ana.25443; Zhang LJ, 2020, ANN NEUROL, V87, P434, DOI 10.1002/ana.25671	44	14	15	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					373	384		10.1016/S1474-4422(21)00042-9	http://dx.doi.org/10.1016/S1474-4422(21)00042-9			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33894192				2022-12-18	WOS:000717465200019
J	Ibanez, A; Kosik, KS				Ibanez, Agustin; Kosik, Kenneth S.		Latin Amer & Caribbean Consortium	COVID-19 in older people with cognitive impairment in Latin America	LANCET NEUROLOGY			English	Letter									[Ibanez, Agustin] Univ Calif San Francisco, Global Brain Hlth Inst GBHI, San Francisco, CA 94143 USA; [Kosik, Kenneth S.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; [Kosik, Kenneth S.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California San Francisco; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Ibanez, A (corresponding author), Univ Calif San Francisco, Global Brain Hlth Inst GBHI, San Francisco, CA 94143 USA.	agustin.ibanez@gbhi.org	Ibanez, Agustin/H-7976-2015	Ibanez, Agustin/0000-0001-6758-5101; Guerrero, Alejandra/0000-0003-1578-6002; Santamaria Garcia, Hernando/0000-0001-9422-3579	CONICET; CONICYT; FONDECYT [1170010, 1171200]; FONCYT-PICT [2017-1318, 2017-1820]; FONDAP [15150012]; AND; INECO Enunciation; Inter -American Development Bank; Global Brain Health Institute [ALZ UK-20-639295]; National Institutes of Health; National Institute on Aging [R01 AG057234]; Multi -Partner Consortium to Expand Dementia Research in Latin America (ReDLat)	CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); CONICYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); FONCYT-PICT(ANPCyTFONCyT); FONDAP; AND; INECO Enunciation; Inter -American Development Bank; Global Brain Health Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Multi -Partner Consortium to Expand Dementia Research in Latin America (ReDLat)	We thank Alzheimer's Association, the Global Brain Health Institute, the Tau Consortium, the National Institutes of Health and National Institute on Aging, Inter -American Development Bank, and the Multi -Partner Consortium to Expand Dementia Research in Latin America (ReDLat). We also thank Margherita Melloni for her insightful revision of an early version of this manuscript. The contents of this publication arc solely the responsibility of the authors and do not represent the official views of these institutions. Al is partly supported by grants from CONICET, CONICYT and FONDECYT Regular (1170010 and 1171200), FONCYT-PICT (2017-1318 and 2017-1820), AND and FONDAP (15150012), the INECO Enunciation, the Inter -American Development Bank, the Global Brain Health Institute (ALZ UK-20-639295), National Institutes of Health and National Institute on Aging (R01 AG057234), and the Multi -Partner Consortium to Expand Dementia Research in Latin America (ReDLat). KSK declares no competing interests. This Comment was written on behalf of the Latin America and the Caribbean Consortium on Dementia (LAC-CD); see the appendix (pp 1-2) for the full Consortium author list.	Burki T, 2020, LANCET INFECT DIS, V20, P547, DOI 10.1016/S1473-3099(20)30303-0; Caruso Bloeck M, 2017, LONG TERM CARE LATIN; Delgado D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082798; Kitroeff N, 2020, ITS NOT VIRUS MEXICO; Llibre-Guerra JJ, 2020, INT PSYCHOGERIATR, V32, P1143, DOI 10.1017/S1041610220000848; Parra MA, 2018, NEUROLOGY, V90, P222, DOI 10.1212/WNL.0000000000004897; Ritchie H., 2019, AGE STRUCTURE; Wunsch-Vincent S, 2016, INFORMAL EC DEVELOPI	8	14	15	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					719	721		10.1016/S1474-4422(20)30270-2	http://dx.doi.org/10.1016/S1474-4422(20)30270-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	32822627	Bronze, Green Published, Green Submitted			2022-12-18	WOS:000562556500008
J	Kia, DA; Sabir, MS; Ahmed, S; Trinh, J; Bandres-Ciga, S				Kia, Demis A.; Sabir, Marya S.; Ahmed, Sarah; Trinh, Joanne; Bandres-Ciga, Sara		Int Parkinson's Dis Genomics Conso	LRP10 in alpha-synucleinopathies	LANCET NEUROLOGY			English	Letter									[Kia, Demis A.] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Sabir, Marya S.; Ahmed, Sarah] Natl Inst Neurol Disorders & Stroke, Neurodegenerat Dis Res Unit, NIH, Bethesda, MD USA; [Ahmed, Sarah; Bandres-Ciga, Sara] NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA; [Trinh, Joanne] Univ Lubeck, Inst Neurogenet, Lubeck, Germany	University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Lubeck	Bandres-Ciga, S (corresponding author), NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA.	sara.bandresciga@nih.gov	Dols-Icardo, Oriol/AAC-1181-2020; Alvarez, Ignacio/AAB-3929-2019; Blázquez Estrada, Marta/AAG-2988-2021; Lubbe, Steven/L-8261-2013; Sevilla, Francisco Escamilla/M-5077-2019; Gibbs, J. Raphael/A-3984-2010; Taba, Pille/B-1014-2019; Morris, Huw R/B-8527-2008; Gasser, Thomas/GNH-5293-2022; Castrillo, Juan Carlos Martinez/F-3119-2013; Fernandez, Manel/AAC-2447-2020; Scholz, Sonja/AAN-6601-2021; Scholz, Sonja W./R-5524-2017; Mok, Kin/U-6893-2019; Mínguez-Castellanos, Adolfo/AAB-7796-2021; Diez-Fairen, Monica/AAC-2467-2020; Pastor, Pau/C-9834-2009; Ciga, Sara Bandres/AAA-5036-2020; Trinh, Joanne/ABD-5085-2021; Mok, Kin Ying/F-5860-2012; alvarez, victoria/GXV-1088-2022; alvarez, victoria/ABC-7891-2021; Hernández, Francisco Javier Barrero/J-4142-2018; Singleton, Andrew B/C-3010-2009; Corvol, Jean-Christophe/F-2124-2017; Ezquerra, Mario/I-1233-2014; Hardy, John/C-2451-2009; Menendez Gonzalez, Manuel/GSJ-2393-2022; Fernandez-Santiago, Ruben/K-3808-2014; Quinn, John/A-2972-2010; Shepherd, Claire/C-9807-2011; Oinas, Minna/X-2511-2019; Wood, Nicholas/C-2505-2009; Koks, Sulev/H-3655-2015	Dols-Icardo, Oriol/0000-0003-2656-8748; Alvarez, Ignacio/0000-0002-8537-3935; Blázquez Estrada, Marta/0000-0003-3348-9992; Lubbe, Steven/0000-0002-7103-6671; Sevilla, Francisco Escamilla/0000-0003-2149-2668; Gibbs, J. Raphael/0000-0002-6985-0658; Morris, Huw R/0000-0002-5473-3774; Gasser, Thomas/0000-0002-1069-1146; Castrillo, Juan Carlos Martinez/0000-0001-7744-6850; Fernandez, Manel/0000-0002-8558-9920; Scholz, Sonja/0000-0002-6623-0429; Scholz, Sonja W./0000-0002-6623-0429; Mok, Kin/0000-0003-3145-880X; Mínguez-Castellanos, Adolfo/0000-0001-7086-1867; Diez-Fairen, Monica/0000-0003-1882-0309; Pastor, Pau/0000-0002-7493-8777; Mok, Kin Ying/0000-0003-3145-880X; alvarez, victoria/0000-0002-1916-2523; alvarez, victoria/0000-0002-1916-2523; Hernández, Francisco Javier Barrero/0000-0001-8490-2789; Corvol, Jean-Christophe/0000-0001-7325-0199; Kaiyrzhanov, Rauan/0000-0003-1640-4010; Lovering, Ruth/0000-0002-9791-0064; Ezquerra, Mario/0000-0003-3246-6641; van Hilten, Jacobus/0000-0002-7030-0362; Taba, Pille/0000-0002-1315-1065; Schreglmann, Sebastian/0000-0002-4129-5808; Ahmed, Sarah/0000-0003-0247-2557; Orme, Tatiana/0000-0002-8304-3326; Heutink, Peter/0000-0001-5218-1737; Mencacci, Niccolo Emanuele/0000-0003-3383-9665; Adarmes Gomez, Astrid Daniela/0000-0002-1337-9289; Brice, Alexis/0000-0002-0941-3990; Botia, Juan A./0000-0002-6992-598X; Neto, Joao Luis/0000-0003-0863-158X; Hardy, John/0000-0002-3122-0423; Infante, Jon/0000-0003-4025-4606; Martinez-Torres, Irene/0000-0003-0758-0813; Kinghorn, Kerri J/0000-0003-2048-4332; Iwaki, Hirotaka/0000-0002-8982-7885; Gonzalez-Aramburu, Isabel/0000-0002-3696-4093; Schulte, Claudia/0000-0003-4006-1265; Menendez Gonzalez, Manuel/0000-0002-5218-0774; Bandres Ciga, Sara/0000-0003-0056-1361; Tejera-Parrado, Cristina/0000-0001-8001-5621; Jimenez-Escrig, Adriano/0000-0002-4927-1886; Guerreiro, Rita/0000-0001-5879-3486; Bras, Jose/0000-0001-8186-0333; Fernandez-Santiago, Ruben/0000-0002-4582-0702; Chelban, Viorica/0000-0002-5817-6290; Myllykangas, Liisa/0000-0002-2237-5466; Rizig, Mie/0000-0003-2420-4449; Perinan, Maria Teresa/0000-0001-7412-7440; Quinn, John/0000-0003-3551-7803; Shepherd, Claire/0000-0002-0399-3218; Oinas, Minna/0000-0002-6150-091X; Wood, Nicholas/0000-0002-9500-3348; Koks, Sulev/0000-0001-6087-6643; Morris, John/0000-0001-9820-5618; Ross, Owen/0000-0003-4813-756X	MRC [G1100643, G0700943] Funding Source: UKRI; Medical Research Council [G1100643, G0700943] Funding Source: Medline; Parkinson&apos;s UK [H-1703, K-1501] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Parkinson&apos;s UK(Parkinson&apos;s UK)		Quadri M, 2018, LANCET NEUROL, V17, P597, DOI 10.1016/S1474-4422(18)30179-0; Wu BL, 2016, ANN HUM GENET, V80, P136, DOI 10.1111/ahg.12147	2	14	14	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1032	1032		10.1016/S1474-4422(18)30401-0	http://dx.doi.org/10.1016/S1474-4422(18)30401-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30507383	Bronze			2022-12-18	WOS:000450119300008
J	Gelfand, JM				Gelfand, Jeffrey M.			Autoimmune encephalitis after herpes simplex encephalitis: insights into pathogenesis	LANCET NEUROLOGY			English	Editorial Material							ASPARTATE RECEPTOR ANTIBODIES; RELAPSE		[Gelfand, Jeffrey M.] Univ Calif San Francisco, Weill Inst Neurosci, MS & Neuroinflammat Clin, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	Gelfand, JM (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, MS & Neuroinflammat Clin, San Francisco, CA 94158 USA.	jeffrey.gelfand@ucsf.edu			Genentech; Quest Diagnostics; Biogen	Genentech(Roche HoldingGenentech); Quest Diagnostics; Biogen(Biogen)	I have received research support to UCSF from Genentech and Quest Diagnostics and personal fees for consulting from Biogen.	Armangue T, 2018, LANCET NEUROL, V17, P760, DOI 10.1016/S1474-4422(18)30244-8; George BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104169; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hacohen Y, 2014, MOVEMENT DISORD, V29, P90, DOI 10.1002/mds.25626; Lim HK, 2014, NEUROLOGY, V83, P1888, DOI 10.1212/WNL.0000000000000999; Nosadini M, 2017, DEV MED CHILD NEUROL, V59, P796, DOI 10.1111/dmcn.13448; Planaguma J, 2015, BRAIN, V138, P94, DOI 10.1093/brain/awu310; Schabitz WR, 2014, NEUROLOGY, V83, P2309, DOI 10.1212/WNL.0000000000001072; Skoldenberg B, 2006, J NEUROL, V253, P163, DOI 10.1007/s00415-005-0941-6; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1	10	14	16	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2018	17	9					733	735		10.1016/S1474-4422(18)30279-5	http://dx.doi.org/10.1016/S1474-4422(18)30279-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GQ3AO	30049613				2022-12-18	WOS:000441532100003
J	Maas, AIR; Lingsma, HF				Maas, Andrew I. R.; Lingsma, Hester F.			ALERT-TBI study on biomarkers for TBI: has science suffered?	LANCET NEUROLOGY			English	Editorial Material							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; RULE		[Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, NL-3015 CE Rotterdam, Netherlands	University of Antwerp; Erasmus University Rotterdam; Erasmus MC	Maas, AIR (corresponding author), Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264	European Union Framework Programme [7]; Integra Life Sciences	European Union Framework Programme(European Commission); Integra Life Sciences	AIRM declares grants from the European Union Framework Programme 7, and personal fees for speaking and consultancy from Integra Life Sciences. HFL declares no competing interests.	Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Mondello S, 2021, J NEUROTRAUM, V38, P1086, DOI 10.1089/neu.2017.5182; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0533-y	6	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2018	17	9					737	738		10.1016/S1474-4422(18)30275-8	http://dx.doi.org/10.1016/S1474-4422(18)30275-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GQ3AO	30054150				2022-12-18	WOS:000441532100005
J	Thompson, AJ; Reingold, SC; Cohen, JA				Thompson, Alan J.; Reingold, Stephen C.; Cohen, Jeffrey A.		Int Panel Diag Multiple Sclerosis	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis Reply	LANCET NEUROLOGY			English	Letter							CEREBROSPINAL-FLUID ANALYSIS		[Thompson, Alan J.] UCL, Fac Brain Sci, London, England; [Reingold, Stephen C.] Sci & Clin Review Associates, Salisbury, CT USA; [Cohen, Jeffrey A.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA	University of London; University College London; Cleveland Clinic Foundation	Cohen, JA (corresponding author), Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.	cohenj@ccf.org	Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496; Reingold, Stephen/0000-0003-4485-8634	University College London Hospitals National Institute for Health Research Biomedical Research Centre; National Multiple Sclerosis Society; European Committee for Treatment and Research in Multiple Sclerosis; F Hoffmann-LaRoche; Ionis Pharmaceuticals; MedDay Pharmaceuticals SA; MedImmune; Merck Serono; Novartis; Observatoire Francais pour la Sclerose en Plaques; Opexa Therapeutics; Teva Pharmaceuticals Industries; TG Therapeutics; Scientific and Clinical Review Associates	University College London Hospitals National Institute for Health Research Biomedical Research Centre; National Multiple Sclerosis Society(National Multiple Sclerosis Society); European Committee for Treatment and Research in Multiple Sclerosis; F Hoffmann-LaRoche(Hoffmann-La Roche); Ionis Pharmaceuticals; MedDay Pharmaceuticals SA; MedImmune(AstraZenecaMedimmune); Merck Serono(Merck & Company); Novartis(Novartis); Observatoire Francais pour la Sclerose en Plaques; Opexa Therapeutics; Teva Pharmaceuticals Industries(Teva Pharmaceutical Industries); TG Therapeutics; Scientific and Clinical Review Associates	AJT reports personal fees and other support from MedDay, Novartis, Eisai Ltd, Biogen Idec, TEVA, and Hoffman-La Roche outside the submitted work; Editorial Board membership of The Lancet Neurology; being Editor-in-Chief of Multiple Sclerosis Journal, for which he receives an honorarium from SAGE Publications; being Chair, Scientific Advisory Board of the International Progressive MS Alliance (PMSA), for which he receives support for travel to international meetings; being a member of the National MS Society (USA) Research Programs Advisory Committee, for which he receives support for travel to international meetings; being Chair, International Medical and Scientific Board, and Board Member (2005-2015), for Multiple Sclerosis International Federation (MSIF), for which he receives support for travel to international meetings; and being a member of MSIF International Medical and Scientific Board (since 2015). He has received honoraria and support for travel for lecturing from EXCEMED, and has received support from the University College London Hospitals National Institute for Health Research Biomedical Research Centre. SCR reports: personal fees and other support from the National Multiple Sclerosis Society and the European Committee for Treatment and Research in Multiple Sclerosis; personal fees and other support from F Hoffmann-LaRoche, Ionis Pharmaceuticals, MedDay Pharmaceuticals SA, MedImmune, Merck Serono, and Novartis; other support from the Observatoire Francais pour la Sclerose en Plaques; personal fees from Opexa Therapeutics, Teva Pharmaceuticals Industries, and TG Therapeutics; and personal fees and non-financial support from Scientific and Clinical Review Associates. JAC reports personal fees from Adamas and Celgene outside the submitted work, and has served as a co-editor of Multiple Sclerosis Journal-Experimental, Translational and Clinical.	ANDERSSON M, 1994, J NEUROL NEUROSUR PS, V57, P897, DOI 10.1136/jnnp.57.8.897; Freedman MS, 2005, ARCH NEUROL-CHICAGO, V62, P865, DOI 10.1001/archneur.62.6.865; Keegan BM, 2016, NEUROLOGY, V87, P1713, DOI 10.1212/WNL.0000000000003235; Stangel M, 2013, NAT REV NEUROL, V9, P267, DOI 10.1038/nrneurol.2013.41; Thompson A, 2017, LANCET NEUROL, V16, P10, DOI 10.1016/S1474-4422(16)30343-X	5	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					499	500		10.1016/S1474-4422(18)30168-6	http://dx.doi.org/10.1016/S1474-4422(18)30168-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778360	Green Submitted, Bronze			2022-12-18	WOS:000432463400019
J	Gilhus, NE				Gilhus, Nils Erik			Eculizumab: a treatment option for mysthenia gravis?	LANCET NEUROLOGY			English	Editorial Material							MYASTHENIA-GRAVIS		[Gilhus, Nils Erik] Univ Bergen, Dept Clin Med, Bergen, Norway; [Gilhus, Nils Erik] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Gilhus, NE (corresponding author), Univ Bergen, Dept Clin Med, Bergen, Norway.; Gilhus, NE (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.	nils.erik.gilhus@helse-bergen.no						Andersen JB, 2016, MUSCLE NERVE, V54, P1041, DOI 10.1002/mus.25205; Evoli A, 2017, CURR OPIN NEUROL, V30, P464, DOI 10.1097/WCO.0000000000000473; Gilhus NE, 2016, NEW ENGL J MED, V375, P2570, DOI 10.1056/NEJMra1602678; Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3; Howard J.F., 2017, LANCET NEUROL, V16, P976; Koneczny I, 2017, J AUTOIMMUN, V77, P104, DOI 10.1016/j.jaut.2016.11.005; Ricklin D, 2017, MOL IMMUNOL, V89, P10, DOI 10.1016/j.molimm.2017.05.013; Schepelmann K, 2010, J NEUROL, V257, P15, DOI 10.1007/s00415-009-5256-6; Tandan R, 2017, MUSCLE NERVE, V56, P185, DOI 10.1002/mus.25597; van den Brand JAJG, 2017, NEPHROL DIAL TRANSPL, V32, P115, DOI 10.1093/ndt/gfw353	10	14	14	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2017	16	12					947	948		10.1016/S1474-4422(17)30363-0	http://dx.doi.org/10.1016/S1474-4422(17)30363-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM8DJ	29066164				2022-12-18	WOS:000415315400003
J	[Anonymous]				[Anonymous]			Pointing the way to primary prevention of dementia (vol 16, pg 677, 2017)	LANCET NEUROLOGY			English	Correction																		[Anonymous], 2017, LANCET NEUROL, V16, P771, DOI 10.1016/S1474-4422(17)30256-9	1	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					771	771		10.1016/S1474-4422(17)30256-9	http://dx.doi.org/10.1016/S1474-4422(17)30256-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28816113	Bronze			2022-12-18	WOS:000410379900008
J	[Anonymous]				[Anonymous]			Pointing the way to primary prevention of dementia	LANCET NEUROLOGY			English	Editorial Material																			0	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2017	16	9					677	677		10.1016/S1474-4422(17)30256-9	http://dx.doi.org/10.1016/S1474-4422(17)30256-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FC8ZW	28816113	Bronze			2022-12-18	WOS:000407131400001
J	Hohlfeld, R; Meinl, E				Hohlfeld, Reinhard; Meinl, Edgar			Ocrelizumab in multiple sclerosis: markers and mechanisms	LANCET NEUROLOGY			English	Editorial Material							T-CELLS; B-CELLS; RITUXIMAB; ANTIBODIES		[Hohlfeld, Reinhard; Meinl, Edgar] Ludwig Maximilians Univ Munchen, Inst Clin Neuroimmunol, Univ Hosp, Munich, Germany; [Hohlfeld, Reinhard; Meinl, Edgar] Ludwig Maximilians Univ Munchen, Biomed Ctr, Munich, Germany; [Hohlfeld, Reinhard; Meinl, Edgar] Munich Cluster Syst Neurol SyNergy, Munich, Germany	University of Munich; University of Munich; University of Munich	Hohlfeld, R (corresponding author), Ludwig Maximilians Univ Munchen, Inst Clin Neuroimmunol, Univ Hosp, Munich, Germany.; Hohlfeld, R (corresponding author), Ludwig Maximilians Univ Munchen, Biomed Ctr, Munich, Germany.; Hohlfeld, R (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.	reinhard.hohlfeld@med.uni-muenchen.de		Meinl, Edgar/0000-0002-2570-6785	Actelion; Bayer; Biogen; Genzyme-Sanofi; Medday; Merck-Serono; Novartis; Roche; Teva	Actelion; Bayer(Bayer AG); Biogen(Biogen); Genzyme-Sanofi(Sanofi-AventisGenzyme Corporation); Medday; Merck-Serono(Merck & Company); Novartis(Novartis); Roche(Roche Holding); Teva(Teva Pharmaceutical Industries)	RH has received grant support or personal fees from Actelion, Bayer, Biogen, Genzyme-Sanofi, Medday, Merck-Serono, Novartis, Roche and Teva. EM has received grant support or personal fees from Genzyme-Sanofi, Novartis and Roche.	Brandle SM, 2016, P NATL ACAD SCI USA, V113, P7864, DOI 10.1073/pnas.1522730113; Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029; Flach AC, 2016, P NATL ACAD SCI USA, V113, P3323, DOI 10.1073/pnas.1519608113; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hoffmann FS, 2015, J IMMUNOL, V194, P542, DOI 10.4049/jimmunol.1402070; Hohlfeld R, 2016, LANCET NEUROL, V15, P317, DOI 10.1016/S1474-4422(15)00313-0; Komori M, 2016, ANN CLIN TRANSL NEUR, V3, P166, DOI 10.1002/acn3.293; Laurent SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8333; Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Palanichamy A, 2014, J IMMUNOL, V193, P580, DOI 10.4049/jimmunol.1400118; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089	12	14	16	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					259	261		10.1016/S1474-4422(17)30048-0	http://dx.doi.org/10.1016/S1474-4422(17)30048-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28327329				2022-12-18	WOS:000396336600007
J	Van der Flier, WM				Van der Flier, W. M.			Clinical heterogeneity in familial Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							PROGRESSIVE APHASIA; VARIANTS; ATROPHY; AGE		[Van der Flier, W. M.] Vrije Univ Amsterdam, Med Ctr, Amsterdam Neurosci, Dept Neurol, NL-1081 HV Amsterdam, Netherlands; [Van der Flier, W. M.] Vrije Univ Amsterdam, Med Ctr, Amsterdam Neurosci, Alzheimer Ctr, NL-1081 HV Amsterdam, Netherlands; [Van der Flier, W. M.] Vrije Univ Amsterdam, Med Ctr, Amsterdam Neurosci, Dept Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Van der Flier, WM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam Neurosci, Dept Neurol, NL-1081 HV Amsterdam, Netherlands.; Van der Flier, WM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam Neurosci, Alzheimer Ctr, NL-1081 HV Amsterdam, Netherlands.; Van der Flier, WM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam Neurosci, Dept Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands.	wm.vdflier@vumc.nl		van der Flier, Wiesje/0000-0001-8766-6224				Barnes J, 2015, ALZHEIMERS DEMENT, V11, P1349, DOI 10.1016/j.jalz.2014.12.007; Crutch SJ, 2013, ALZHEIMERS DEMENT, V9, P463, DOI 10.1016/j.jalz.2012.11.004; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Koedam ELGE, 2010, J ALZHEIMERS DIS, V19, P1401, DOI 10.3233/JAD-2010-1337; Mandelli ML, 2016, BRAIN, V139, P2778, DOI 10.1093/brain/aww195; Mattsson N, 2016, J NEUROL NEUROSUR PS, V87, P1000, DOI 10.1136/jnnp-2015-311321; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; Miller ZA, 2013, BRAIN, V136, P3461, DOI 10.1093/brain/awt242; Moulder KL, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt213; Ossenkoppele R, 2015, BRAIN, V138, P2732, DOI 10.1093/brain/awv191; Ryan NS, 2016, LANCET NEUROL; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Tang M, 2016, LANCET NEUROL; van der Flier WM, 2011, LANCET NEUROL, V10, P280, DOI 10.1016/S1474-4422(10)70306-9	16	14	14	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2016	15	13					1296	1298		10.1016/S1474-4422(16)30275-7	http://dx.doi.org/10.1016/S1474-4422(16)30275-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EB6XV	27777021	hybrid			2022-12-18	WOS:000387529800002
J	Wray, S; Fox, NC				Wray, Selina; Fox, Nick C.			Stem cell therapy for Alzheimer's disease: hope or hype?	LANCET NEUROLOGY			English	Editorial Material							INTRACELLULAR A-BETA; DEMENTIA		[Wray, Selina] UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England; [Fox, Nick C.] UCL Inst Neurol, Dept Neurodegenerat, Dementia Res Ctr, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Wray, S (corresponding author), UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England.	selina.wray@ucl.ac.uk	Fox, Nick C/B-1319-2009; Fox, Nick C/AAE-1849-2021; Wray, Selina/C-3682-2009	Fox, Nick C/0000-0002-6660-657X; Fox, Nick C/0000-0002-6660-657X; Wray, Selina/0000-0003-3062-7050	Alzheimers Research UK [ARUK-Network2011-6-ICE] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10123, NF-SI-0513-10134] Funding Source: researchfish	Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); National Institute for Health Research(National Institute for Health Research (NIHR))		Barker RA, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.17; Barry J, CURR STEM CELL REP, V1, P110; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Hunsberger J.G., 2015, LANCET NEUROL; Kondo T, 2013, CELL STEM CELL, V12, P487, DOI 10.1016/j.stem.2013.01.009; Liu-Seifert Hong, 2015, Alzheimers Dement (N Y), V1, P111, DOI 10.1016/j.trci.2015.06.006; Livesey FJ, 2014, HUM MOL GENET, V23, pR35, DOI 10.1093/hmg/ddu302; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Prince M., 2015, WORLD ALZHEIMERS REP; Sposito T, 2015, HUM MOL GENET, V24, P5260, DOI 10.1093/hmg/ddv246	10	14	14	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2016	15	2					133	135		10.1016/S1474-4422(15)00382-8	http://dx.doi.org/10.1016/S1474-4422(15)00382-8			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA9GC	26704440				2022-12-18	WOS:000368116000007
J	Antonini, A; Poewe, W				Antonini, Angelo; Poewe, Werner			Adenosine A(2A) receptor antagonists in Parkinson's disease: still in the running	LANCET NEUROLOGY			English	Editorial Material							ISTRADEFYLLINE; THERAPY		[Antonini, Angelo] IRCCS Hosp San Camillo, Parkinson & Movement Disorders Unit, I-30126 Venice, Italy; [Poewe, Werner] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	IRCCS Ospedale San Camillo; Medical University of Innsbruck	Antonini, A (corresponding author), IRCCS Hosp San Camillo, Parkinson & Movement Disorders Unit, I-30126 Venice, Italy.	angelo3000@yahoo.com	Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807				Antonini A, 2011, J NEUROL, V258, P579, DOI 10.1007/s00415-010-5793-z; Bibbiani F, 2003, EXP NEUROL, V184, P285, DOI 10.1016/S0014-4886(03)00250-4; Hauser RA, 2014, LANCET NEUROL; Hauser RA, 2011, LANCET NEUROL, V10, P221, DOI 10.1016/S1474-4422(11)70012-6; Kalia LV, 2013, MOVEMENT DISORD, V28, P131, DOI 10.1002/mds.25273; Merck, 2013, MERCK PROV UPD PHAS; Mizuno Y, 2013, MOVEMENT DISORD, V28, P1138, DOI 10.1002/mds.25418; POEWE WH, 1986, NEUROLOGY, V36, P1528, DOI 10.1212/WNL.36.11.1528; Pourcher E, 2012, PARKINSONISM RELAT D, V18, P178, DOI 10.1016/j.parkreldis.2011.09.023; Rascol O, 2005, LANCET, V365, P947, DOI 10.1016/S0140-6736(05)71083-7	10	14	14	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2014	13	8					748	749		10.1016/S1474-4422(14)70153-X	http://dx.doi.org/10.1016/S1474-4422(14)70153-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AL9JB	25008550				2022-12-18	WOS:000339456300002
J	Laureys, S; Bodart, O; Gosseries, O				Laureys, Steven; Bodart, Olivier; Gosseries, Olivia			The Glasgow Coma Scale: time for critical reappraisal?	LANCET NEUROLOGY			English	Editorial Material							MINIMALLY CONSCIOUS STATE; UNRESPONSIVE WAKEFULNESS		[Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Belgian Natl Fund Sci Res, Coma Sci Grp, Liege, Belgium; Univ Liege, Dept Neurol, Liege, Belgium; Univ Hosp Liege, Liege, Belgium	Fonds de la Recherche Scientifique - FNRS; University of Liege; University of Liege; University of Liege	Laureys, S (corresponding author), Univ Liege, Cyclotron Res Ctr, Belgian Natl Fund Sci Res, Coma Sci Grp, Liege, Belgium.	coma@ulg.ac.be	Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/A-3349-2011; Laureys, Steven/AAN-2097-2021	Gosseries, Olivia/0000-0001-9011-7496; Laureys, Steven/0000-0002-3096-3807				Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Laureys S, 2005, LANCET NEUROL, V4, P789, DOI 10.1016/S1474-4422(05)70230-1; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Suys T, NEUROCRIT C IN PRESS; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	14	14	15	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2014	13	8					755	757		10.1016/S1474-4422(14)70152-8	http://dx.doi.org/10.1016/S1474-4422(14)70152-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AL9JB	25030507	Green Submitted			2022-12-18	WOS:000339456300006
J	Naggara, O; Darsaut, T; Ttystram, D; Tselikas, L; Raymond, J				Naggara, Olivier; Darsaut, Tim; Ttystram, Denis; Tselikas, Lambros; Raymond, Jean			Unruptured intracranial aneurysms: why we must not perpetuate the impasse for another 25 years	LANCET NEUROLOGY			English	Letter							ENDOVASCULAR TREATMENT; SAFETY; METAANALYSIS; RUPTURE; COHORT; RISK		[Naggara, Olivier; Ttystram, Denis; Tselikas, Lambros] Paris Descartes Univ, Dept Neuroradiol, Ctr Hosp St Anne, INSERM,UMR894, F-75014 Paris, France; [Darsaut, Tim] Univ Alberta Hosp, Mackenzie Hlth Sci Ctr, Dept Surg, Div Neurosurg, Edmonton, AB T6G 2B7, Canada; [Raymond, Jean] Univ Montreal, Int Consortium Neuroendovasc Ctr, Intervent Neuroradiol Res Unit, Dept Radiol,CHUM Notre Dame Hosp, Montreal, PQ, Canada	GHU PARIS Psychiatrie Neurosciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Alberta; Universite de Montreal	Naggara, O (corresponding author), Paris Descartes Univ, Dept Neuroradiol, Ctr Hosp St Anne, INSERM,UMR894, F-75014 Paris, France.	o.naggara@ch-sainte-anne.fr	Naggara, Olivier/R-3939-2017	Naggara, Olivier/0000-0002-9544-379X; Trystram, Denis/0000-0003-1496-222X				Brinjikji W, 2011, AM J NEURORADIOL, V32, P1071, DOI 10.3174/ajnr.A2453; Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1; Greving JP, 2009, NEUROLOGY, V73, P258, DOI 10.1212/01.wnl.0b013e3181a2a4ea; Kotowski M, 2013, J NEUROL NEUROSUR PS, V84, P42, DOI 10.1136/jnnp-2011-302068; Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260; Naggara ON, 2012, RADIOLOGY, V263, P828, DOI 10.1148/radiol.12112114; Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982; Raymond J, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-64; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	9	14	15	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					537	538		10.1016/S1474-4422(14)70091-2	http://dx.doi.org/10.1016/S1474-4422(14)70091-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK	24849854				2022-12-18	WOS:000337212700010
J	Scuteri, A				Scuteri, Angelo			Brain injury as end-organ damage in hypertension	LANCET NEUROLOGY			English	Editorial Material							INDEPENDENT PREDICTOR; LONGITUDINAL CHANGES		Ist Ricovero & Cura Carattere Sci, Ist Nazl Ricovero & Cura Anziani, I-00189 Rome, Italy		Scuteri, A (corresponding author), Ist Ricovero & Cura Carattere Sci, Ist Nazl Ricovero & Cura Anziani, I-00189 Rome, Italy.	angeloelefante@interfree.it		SCUTERI, ANGELO/0000-0003-4784-5441				Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Lamar M, 2003, NEUROLOGY, V60, P82, DOI 10.1212/WNL.60.1.82; Maillard P, 2012, LANCET NEUROL; Maillard P, 2009, NEURORADIOLOGY, V51, P209, DOI 10.1007/s00234-008-0489-0; Najjar SS, 2008, J AM COLL CARDIOL, V51, P1377, DOI 10.1016/j.jacc.2007.10.065; Nilsson PM, 2008, J HYPERTENS, V26, P1049, DOI 10.1097/HJH.0b013e3282f82c3e; SCUTERI A, 2012, EXP GERONTOL; Scuteri A, 2007, J HYPERTENS, V25, P1035, DOI 10.1097/HJH.0b013e3280895b55; Scuteri A, 2011, J HYPERTENS, V29, P1469, DOI 10.1097/HJH.0b013e328347cc17; Scuteri A, 2010, EUR HEART J, V31, P602, DOI 10.1093/eurheartj/ehp491	10	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2012	11	12					1015	1017		10.1016/S1474-4422(12)70265-X	http://dx.doi.org/10.1016/S1474-4422(12)70265-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044CX	23122891				2022-12-18	WOS:000311598100003
J	Petzold, A				Petzold, Axel			Microcystic macular oedema in MS: T2 lesion or black hole?	LANCET NEUROLOGY			English	Editorial Material							POTASSIUM CHANNEL KIR4.1; MULTIPLE-SCLEROSIS		[Petzold, Axel] Vrije Univ Amsterdam Med Ctr, MS Ctr Amsterdam, NL-1081 HV Amsterdam, Netherlands; [Petzold, Axel] UCL Inst Neurol, Dept Neuroinflammat, London WC1N 3BG, England	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of London; University College London	Petzold, A (corresponding author), Vrije Univ Amsterdam Med Ctr, MS Ctr Amsterdam, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	a.petzold@vumc.nl	Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749				Abegg M, 2012, BRAIN, V135, DOI 10.1093/brain/aws215; Balk LJ, 2012, BRAIN, DOI [10.1093/brain/aws218, DOI 10.1093/BRAIN/AWS218]; Gelfand JM, 2012, BRAIN, V135, P1786, DOI 10.1093/brain/aws098; Petzold A, 2010, LANCET NEUROL, V9, P921, DOI 10.1016/S1474-4422(10)70168-X; Saidha S, 2012, LANCET NEUROL, DOI DOI 10.1016/51474-4422(12)70213-2; Srivastava R, 2012, NEW ENGL J MED, V367, P115, DOI 10.1056/NEJMoa1110740; Tewarie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034823; Udagawa T, 2012, NEUROSCIENCE, V215, P209, DOI 10.1016/j.neuroscience.2012.04.037; VANBUREN JM, 1963, J NEUROL NEUROSUR PS, V26, P402	9	14	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2012	11	11					933	934		10.1016/S1474-4422(12)70231-4	http://dx.doi.org/10.1016/S1474-4422(12)70231-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	028KW	23041238				2022-12-18	WOS:000310422200004
J	[Anonymous]				[Anonymous]			Rare neurological diseases: a united approach is needed	LANCET NEUROLOGY			English	Editorial Material																			0	14	14	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2011	10	2					109	109		10.1016/S1474-4422(11)70001-1	http://dx.doi.org/10.1016/S1474-4422(11)70001-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	721IT	21256450				2022-12-18	WOS:000287347500001
J	Roosink, M; Geurts, ACH; Ijzerman, MJ				Roosink, Meyke; Geurts, Alexander C. H.; Ijzerman, Maarten J.			Defining post-stroke pain: diagnostic challenges	LANCET NEUROLOGY			English	Letter									[Roosink, Meyke; Ijzerman, Maarten J.] Univ Twente, MIRA, Inst Biomed Technol & Tech Med, NL-7500 AE Enschede, Netherlands; [Geurts, Alexander C. H.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Evidence Based Practice, NL-6525 ED Nijmegen, Netherlands; [Geurts, Alexander C. H.] Radboud Univ Nijmegen, Dept Rehabil, Donders Ctr Neurosci, NL-6525 ED Nijmegen, Netherlands	University of Twente; Radboud University Nijmegen; Radboud University Nijmegen	Roosink, M (corresponding author), Univ Twente, MIRA, Inst Biomed Technol & Tech Med, POB 217, NL-7500 AE Enschede, Netherlands.	m.roosink@utwente.nl	Geurts, Alexander/H-8032-2014; IJzerman, Maarten/AAB-6894-2020; IJzerman, Maarten J/Q-8963-2016	Geurts, Alexander/0000-0001-7478-1119; IJzerman, Maarten/0000-0001-5788-5805; IJzerman, Maarten J/0000-0001-5788-5805				Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Lindgren I, 2007, STROKE, V38, P343, DOI 10.1161/01.STR.0000254598.16739.4e; Roosink M., 2009, EUR J PAIN, V13, pS44	3	14	15	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					344	344		10.1016/S1474-4422(10)70072-7	http://dx.doi.org/10.1016/S1474-4422(10)70072-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA	20298959				2022-12-18	WOS:000276142000010
J	Mayeux, R; Hyslop, PSG				Mayeux, Richard; Hyslop, Peter St George			Alzheimer's disease: advances in trafficking	LANCET NEUROLOGY			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; SORLA/LR11; ASSOCIATION; BRAIN; SORL1		[Mayeux, Richard] Columbia Univ Coll Phys & Surg, Taub Inst Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Mayeux, Richard] Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Hyslop, Peter St George] Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON M55 3H2, Canada	Columbia University; Columbia University; University of Toronto	Mayeux, R (corresponding author), Columbia Univ Coll Phys & Surg, Taub Inst Alzheimers Dis & Aging Brain, 630 W 168th St, New York, NY 10032 USA.	rpm2@columbia.edu	Mayeux, Richard/E-9788-2013	Mayeux, Richard/0000-0001-6519-9696	NATIONAL INSTITUTE ON AGING [P01AG007232, R37AG015473] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG007232, R37 AG015473, R37 AG015473-10, R37 AG015473-09] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Fiete D, 2007, J BIOL CHEM, V282, P1873, DOI 10.1074/jbc.M606455200; LEE JH, 2007, NEUROLOGY; Lee JH, 2007, ARCH NEUROL-CHICAGO, V64, P501, DOI 10.1001/archneur.64.4.501; LI Y, 2007, NEUROBIOL DIS; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; SAGER KL, 2007, ANN NEUROL; Schmidt V, 2007, J BIOL CHEM, V282, P32956, DOI 10.1074/jbc.M705073200; Seshadri S, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S15; WEBSTER JA, 2007, NEURODEGENER DIS	10	14	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					2	3		10.1016/S1474-4422(07)70298-3	http://dx.doi.org/10.1016/S1474-4422(07)70298-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093545	Green Accepted			2022-12-18	WOS:000252063300002
J	Foster, NL				Foster, Norman L.			A new framework for the diagnosis of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; NINCDS-ADRDA CRITERIA; CLINICAL-DIAGNOSIS; WORK GROUP; DEMENTIA; TRIALS		UCL, Neurol Inst, Dept Clin & Expt Epilepsy, SEIN Epilepsy Inst Netherlands Fdn, London WC1N 3BG, England	University of London; University College London	Foster, NL (corresponding author), UCL, Neurol Inst, Dept Clin & Expt Epilepsy, SEIN Epilepsy Inst Netherlands Fdn, Queen Sq, London WC1N 3BG, England.	norman.foster@hsc.utah.edu						Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Frank RA, 2003, NEUROBIOL AGING, V24, P521, DOI 10.1016/S0197-4580(03)00002-2; Jelic V, 2006, J NEUROL NEUROSUR PS, V77, P429, DOI 10.1136/jnnp.2005.072926; Jicha GA, 2006, ARCH NEUROL-CHICAGO, V63, P674, DOI 10.1001/archneur.63.5.674; Kraybill ML, 2005, NEUROLOGY, V64, P2069, DOI 10.1212/01.WNL.0000165987.89198.65; Langa KM, 2004, JAMA-J AM MED ASSOC, V292, P2901, DOI 10.1001/jama.292.23.2901; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; SCHNEIDER JA, 2007, NEUROLOGY; TIERNEY MC, 1988, NEUROLOGY, V38, P359, DOI 10.1212/WNL.38.3.359; Varma AR, 1999, J NEUROL NEUROSUR PS, V66, P184, DOI 10.1136/jnnp.66.2.184	11	14	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2007	6	8					667	669		10.1016/S1474-4422(07)70179-5	http://dx.doi.org/10.1016/S1474-4422(07)70179-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	193HJ	17616483				2022-12-18	WOS:000248264800004
J	Wild, EJ; Tabrizi, SJ				Wild, Edward J.; Tabrizi, Sarah J.			Predict-HD and the future of therapeutic trials	LANCET NEUROLOGY			English	Editorial Material									UCL, Dept Neurodegenerat Dis, Neurol Inst, London WC1N 3BG, England; Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Wild, EJ (corresponding author), UCL, Dept Neurodegenerat Dis, Neurol Inst, Queen Sq, London WC1N 3BG, England.	sarah.tabrizi@prion.ucl.ac.uk	Wild, Edward/G-1436-2016	Wild, Edward/0000-0002-6921-7887; Tabrizi, Sarah/0000-0003-2716-2045	NINDS NIH HHS [R01 NS040068] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040068] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATES G, 2002, HUNTINGTONS DIS; Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102; GOLDING CV, 2006, NEUROLOGY; HENLEY SM, IN PRESS NEUROLOGY; Paulsen JS, 2006, ARCH NEUROL-CHICAGO, V63, P883, DOI 10.1001/archneur.63.6.883	5	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2006	5	9					724	725		10.1016/S1474-4422(06)70531-2	http://dx.doi.org/10.1016/S1474-4422(06)70531-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	076QS	16914400				2022-12-18	WOS:000239973400003
J	Sorensen, PS				Sorensen, PS			Multiple sclerosis: pathophysiology revisited	LANCET NEUROLOGY			English	Editorial Material							T-CELLS		Univ Copenhagen Hosp, Dept Neurol, Rigshosp, Copenhagen Multiple Sclerosis Ctr, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Sorensen, PS (corresponding author), Univ Copenhagen Hosp, Dept Neurol, Rigshosp, Copenhagen Multiple Sclerosis Ctr, DK-2100 Copenhagen, Denmark.	pss@rh.dk		Sorensen, Per Soelberg/0000-0002-2818-3780				Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Bielekova B, 2004, P NATL ACAD SCI USA, V101, P8705, DOI 10.1073/pnas.0402653101; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Skulina C, 2004, P NATL ACAD SCI USA, V101, P2428, DOI 10.1073/pnas.0308689100; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579	5	14	15	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					9	10		10.1016/S1474-4422(04)00948-2	http://dx.doi.org/10.1016/S1474-4422(04)00948-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620850				2022-12-18	WOS:000226250200008
J	Bonita, R; Truelsen, T				Bonita, R; Truelsen, T			Stroke in sub-Saharan Africa: a neglected chronic disease	LANCET NEUROLOGY			English	Editorial Material							HYPERTENSION; MORTALITY; ZIMBABWE		WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Bonita, R (corresponding author), WHO, Ave Appia 20, CH-1211 Geneva 27, Switzerland.	bonitar@who.int	Truelsen, Thomas/AAY-1549-2020					[Anonymous], 2000, J Med Assoc Thai, V83, P1; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Imam I, 2002, ANN TROP MED PARASIT, V96, P435, DOI 10.1179/000349802125001276; MATENGA J, 1986, BRIT MED J, V292, P1649, DOI 10.1136/bmj.292.6536.1649; Matenga JA, 1997, S AFR MED J, V87, P1371; MCLIGEYO SO, 1993, E AFR MED J, V70, P37; Poungvarin N, 1998, LANCET, V352, pSIII19; Steyn K, 2001, J HYPERTENS, V19, P1717, DOI 10.1097/00004872-200110000-00004; Truelsen T, 2001, INT J EPIDEMIOL, V30, pS11, DOI 10.1093/ije/30.suppl_1.S11; Walker RW, 2000, LANCET, V355, P1684, DOI 10.1016/S0140-6736(00)02240-6; Walker RW, 2003, STROKE, V34, P1604, DOI 10.1161/01.STR.0000077943.63718.67; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487	12	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					592	592		10.1016/S1474-4422(03)00524-6	http://dx.doi.org/10.1016/S1474-4422(03)00524-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723KR	14505578				2022-12-18	WOS:000185432000010
J	Wolinsky, JS; Toyka, KV; Kappos, L; Grossberg, SE				Wolinsky, JS; Toyka, KV; Kappos, L; Grossberg, SE			Interferon-beta antibodies: implications for the treatment of MS	LANCET NEUROLOGY			English	Editorial Material							NEUTRALIZING ANTIBODIES		Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis & Neuroimmunol, D-8700 Wurzburg, Germany	University of Wurzburg	Toyka, KV (corresponding author), Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis & Neuroimmunol, Josef Schneider Str 11, D-8700 Wurzburg, Germany.	kv.toyka@mail.uni-wuerzburg.de						Bertolotto A, 2003, NEUROLOGY, V60, P634, DOI 10.1212/01.WNL.0000046662.03894.C5; Giovannoni G, 2002, J NEUROL NEUROSUR PS, V73, P465, DOI 10.1136/jnnp.73.5.465; Grossberg SE, 2001, J INTERF CYTOK RES, V21, P743, DOI 10.1089/107999001753124471; Polman C, 2003, NEUROLOGY, V60, P37, DOI 10.1212/WNL.60.1.37; Pozzilli C, 2002, J NEUROL, V249, P50, DOI 10.1007/PL00007847; Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818	6	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2003	2	9					528	528		10.1016/S1474-4422(03)00499-X	http://dx.doi.org/10.1016/S1474-4422(03)00499-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717VT	12941572				2022-12-18	WOS:000185112000014
J	Bezard, E				Bezard, E			Neuroprotection for Parkinson's disease: a call for clinically driven experimental design	LANCET NEUROLOGY			English	Letter									Univ Victor Segalen, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bezard, E (corresponding author), Univ Victor Segalen, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France.		Bezard, Erwan/ABD-5153-2021	Bezard, Erwan/0000-0002-0410-4638				Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Ravina BM, 2003, NEUROLOGY, V60, P1234, DOI 10.1212/01.WNL.0000058760.13152.1A; 2003, LANCET NEUROLOGY, V2, P267	6	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2003	2	7					393	393		10.1016/S1474-4422(03)00432-0	http://dx.doi.org/10.1016/S1474-4422(03)00432-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	694GF	12849115				2022-12-18	WOS:000183765300011
J	Dale, RC				Dale, RC			Childhood opsoclonus myoclonus	LANCET NEUROLOGY			English	Editorial Material							CHILDRENS CANCER GROUP; ATAXIA SYNDROME; ANTINEURONAL ANTIBODIES; NEUROBLASTOMA		UCL, Inst Child Hlth, Neurosci Unit, London, England	University of London; University College London	Dale, RC (corresponding author), UCL, Inst Child Hlth, Neurosci Unit, Mortimer St, London, England.	R.Dale@ion.ucl.ac.uk						Antunes NL, 2000, J PEDIAT HEMATOL ONC, V22, P315, DOI 10.1097/00043426-200007000-00007; Cooper R, 2001, MED PEDIATR ONCOL, V36, P623, DOI 10.1002/mpo.1139; Hayward K, 2001, J PEDIATR-US, V139, P552, DOI 10.1067/mpd.2001.118200; Mitchell WG, 2002, PEDIATRICS, V109, P86; Rudnick E, 2001, MED PEDIATR ONCOL, V36, P612, DOI 10.1002/mpo.1138	5	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2003	2	5					270	270		10.1016/S1474-4422(03)00374-0	http://dx.doi.org/10.1016/S1474-4422(03)00374-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	669RC	12849175				2022-12-18	WOS:000182363400012
J	Durr, A				Durr, A			Friedreich's ataxia: treatment within reach	LANCET NEUROLOGY			English	Review							TRIPLET-REPEAT EXPANSION; GAA TRINUCLEOTIDE REPEAT; RETAINED TENDON REFLEXES; DOT-TTC REPEATS; CLINICAL-FEATURES; MOLECULAR-GENETICS; IRON ACCUMULATION; FRDA GENE; IN-VIVO; MISSENSE MUTATION	Friedreich's ataxia (FA) is the most prevalent cerebellar ataxia in children and adults in Europe. FA is one of a growing number of diseases known to be caused by triplet-repeat expansions. The causative mutation is a GAA trinucleotide-repeat expansion in the first intron of the frataxin gene. The mitochondrial localisation of frataxin and decreased oxidation activity in vivo and in vitro show that FA is a mitochondrial disease. Frataxin is involved in iron metabolism and may protect mitochondria from oxidative damage. The understanding of the disease has only just begun and possible treatments are within reach. In this review I discuss the clinical knowledge of FA and recent developments that have helped to elucidate the pathogenesis of the disease and made the first therapeutic attempts possible.	Hop La Pitie Salpetriere, Dept Genet Cytogenet & Embryol, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Durr, A (corresponding author), Hop La Pitie Salpetriere, Dept Genet Cytogenet & Embryol, 47 Blvd Hop, F-75013 Paris, France.							Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bartolo C, 1998, AM J MED GENET, V79, P396, DOI 10.1002/(SICI)1096-8628(19981012)79:5<396::AID-AJMG13>3.3.CO;2-B; Berciano J, 1998, NEUROLOGY, V51, P1772, DOI 10.1212/WNL.51.6.1772-a; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; Cossee M, 1999, ANN NEUROL, V45, P200, DOI 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U; De Michele G, 1998, J NEUROL, V245, P166, DOI 10.1007/s004150050198; Delatycki MB, 1999, HUM GENET, V105, P343, DOI 10.1007/s004390051112; Delatycki MB, 1998, J MED GENET, V35, P713, DOI 10.1136/jmg.35.9.713; DeMichele G, 1996, NEUROLOGY, V47, P1260, DOI 10.1212/WNL.47.5.1260; DEMICHELE G, 1994, J NEUROL NEUROSUR PS, V57, P977, DOI 10.1136/jnnp.57.8.977; DOUDNEY K, 1997, HUM MUTAT, V11, P415; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Epplen C, 1997, HUM GENET, V99, P834, DOI 10.1007/s004390050458; Filla A, 1996, AM J HUM GENET, V59, P554; Forrest SM, 1998, NEUROGENETICS, V1, P253, DOI 10.1007/s100480050037; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Gates PC, 1998, NEUROGENETICS, V1, P297, DOI 10.1007/s100480050045; Gellera C, 1997, NEUROLOGY, V49, P1153, DOI 10.1212/WNL.49.4.1153; Geschwind DH, 1997, NEUROLOGY, V49, P1004, DOI 10.1212/WNL.49.4.1004; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Hanna MG, 1998, MOVEMENT DISORD, V13, P339, DOI 10.1002/mds.870130223; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Illarioshkin SN, 2000, EUR J NEUROL, V7, P535, DOI 10.1046/j.1468-1331.2000.00113.x; Isnard R, 1997, CIRCULATION, V95, P2247, DOI 10.1161/01.CIR.95.9.2247; Juvonen V, 2002, HUM GENET, V110, P36, DOI 10.1007/s00439-001-0642-x; KLOCKGETHER T, 1993, ARCH NEUROL-CHICAGO, V50, P803, DOI 10.1001/archneur.1993.00540080014006; Klockgether T, 1996, NEUROLOGY, V46, P118, DOI 10.1212/WNL.46.1.118; Kostrzewa M, 1997, NEUROGENETICS, V1, P43, DOI 10.1007/s100480050007; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Labuda M, 2000, NEUROLOGY, V54, P2322, DOI 10.1212/WNL.54.12.2322; LACCONE A, 1997, HUM MUTAT, V11, P415; LAMARCHE JB, 1980, CAN J NEUROL SCI, V7, P389, DOI 10.1017/S0317167100022927; Lamont PJ, 1997, BRAIN, V120, P673, DOI 10.1093/brain/120.4.673; Lhatoo SD, 2001, NEUROLOGY, V56, P1776, DOI 10.1212/WNL.56.12.1776; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Lodi R, 2001, ANN NEUROL, V49, P590; Monros E, 1997, AM J HUM GENET, V61, P101, DOI 10.1086/513887; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; PALAU F, 1995, ANN NEUROL, V37, P359, DOI 10.1002/ana.410370312; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Pianese L, 1997, AM J HUM GENET, V60, P460; Pook M A, 2000, J Med Genet, V37, pE38, DOI 10.1136/jmg.37.11.e38; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Ragno M, 1997, NEUROLOGY, V49, P1617, DOI 10.1212/WNL.49.6.1617; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0; Rustin P, 2002, FREE RADICAL RES, V36, P467, DOI 10.1080/10715760290021333; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Santoro L, 1999, J NEUROL NEUROSUR PS, V66, P93, DOI 10.1136/jnnp.66.1.93; Schols L, 1997, BRAIN, V120, P2131, DOI 10.1093/brain/120.12.2131; Schols L, 2001, NEUROSCI LETT, V306, P169, DOI 10.1016/S0304-3940(01)01892-4; Smeyers P, 1996, HUM GENET, V97, P824; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Waldvogel D, 1999, ANN NEUROL, V46, P123, DOI 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H; Webb S, 1999, J NEUROL NEUROSUR PS, V67, P217, DOI 10.1136/jnnp.67.2.217; Wilson RB, 1998, ANN NEUROL, V44, P132, DOI 10.1002/ana.410440121; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425; Zuhlke C, 1998, HUM GENET, V103, P102, DOI 10.1007/s004390050791	71	14	14	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2002	1	6					370	374		10.1016/S1474-4422(02)00162-X	http://dx.doi.org/10.1016/S1474-4422(02)00162-X			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599PB	12849398				2022-12-18	WOS:000178343200021
J	Filippi, M				Filippi, M			Predictive value of MRI findings in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									Inst Sci, Dept Neurosci, Neuroimaging Res Unit, Milan, Italy; Univ San Raffaele, Milan, Italy	Vita-Salute San Raffaele University	Filippi, M (corresponding author), Inst Sci, Dept Neurosci, Neuroimaging Res Unit, Milan, Italy.	filippi.massimo@hsr.it	Filippi, Massimo/K-1755-2018	Filippi, Massimo/0000-0002-5485-0479				Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Filippi M, 2001, NEUROL SCI, V22, pS49, DOI 10.1007/s100720100033; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032	5	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					9	9		10.1016/S1474-4422(02)00008-X	http://dx.doi.org/10.1016/S1474-4422(02)00008-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ	12849538				2022-12-18	WOS:000177694100013
J	Hallett, M; Aybek, S; Dworetzky, BA; McWhirter, L; Staab, JP; Stone, J				Hallett, Mark; Aybek, Selma; Dworetzky, Barbara A.; McWhirter, Laura; Staab, Jeffrey P.; Stone, Jon			Functional neurological disorder: new subtypes and shared mechanisms	LANCET NEUROLOGY			English	Review							PSYCHOGENIC NONEPILEPTIC SEIZURES; QUALITY-OF-LIFE; MOVEMENT-DISORDERS; MOTOR INHIBITION; DIAGNOSIS; EPILEPSY; EEG; ASSOCIATION; BIOMARKERS; FREQUENCY	Functional neurological disorder is common in neurological practice. A new approach to the positive diagnosis of this disorder focuses on recognisable patterns of genuinely experienced symptoms and signs that show variability within the same task and between different tasks over time. Psychological stressors are common risk factors for functional neurological disorder, but are often absent. Four entities-functional seizures, functional movement disorders, persistent perceptual postural dizziness, and functional cognitive disorder-show similarities in aetiology and pathophysiology and are variants of a disorder at the interface between neurology and psychiatry. All four entities have distinctive features and can be diagnosed with the support of clinical neurophysiological studies and other biomarkers. The pathophysiology of functional neurological disorder includes overactivity of the limbic system, the development of an internal symptom model as part of a predictive coding framework, and dysfunction of brain networks that gives movement the sense of voluntariness. Evidence supports tailored multidisciplinary treatment that can involve physical and psychological therapy approaches.	[Hallett, Mark] NINDS, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA; [Aybek, Selma] Bern Univ Hosp, Inseispital, Neurol Dept, Psychosomat Med Unit, Bern, Switzerland; [Dworetzky, Barbara A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [McWhirter, Laura; Stone, Jon] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Staab, Jeffrey P.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Staab, Jeffrey P.] Mayo Clin, Dept Otorhinolasyngol Head & Neck Surg, Rochester, MN USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Bern; University Hospital of Bern; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Edinburgh; Mayo Clinic; Mayo Clinic	Hallett, M (corresponding author), NINDS, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA.	hallettm@ninds.nih.gov			National Institute of Neurological Disorders and Stroke Intramural Program; Andrew J Trustey Research Fund; National Health Service Scotland Research Career Fellowship; US Army Medical Research and Development Command via the Congressionally Directed Medical Research Program [W81XWH1810760]; Swiss National Science Foundation [PP00P3_176985]; Baillie Gifford Clinical Research Fellowship; NHS Scotland Chief Scientist's Office	National Institute of Neurological Disorders and Stroke Intramural Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Andrew J Trustey Research Fund; National Health Service Scotland Research Career Fellowship; US Army Medical Research and Development Command via the Congressionally Directed Medical Research Program; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Baillie Gifford Clinical Research Fellowship; NHS Scotland Chief Scientist's Office	MH is supported by the National Institute of Neurological Disorders and Stroke Intramural Program. BAD is supported by the Andrew J Trustey Research Fund. JS is supported by a National Health Service Scotland Research Career Fellowship. JPS is supported by a grant (W81XWH1810760) from the US Army Medical Research and Development Command via the Congressionally Directed Medical Research Program. SA is supported by a grant from the Swiss National Science Foundation (PP00P3_176985). LM is supported by a Baillie Gifford Clinical Research Fellowship and the NHS Scotland Chief Scientist's Office. We thank Stoyan Popkirov for the graphic concept in figure 1.	Akkaoui MA, 2020, J NEUROPSYCH CLIN N, V32, P4, DOI 10.1176/appi.neuropsych.19030058; Amin U, 2019, J CLIN NEUROPHYSIOL, V36, P294, DOI 10.1097/WNP.0000000000000572; Apazoglou K, 2018, J NEUROL NEUROSUR PS, V89, P552, DOI 10.1136/jnnp-2017-316469; Baizabal-Carvallo JF, 2017, J NEUROL, V264, P1482, DOI 10.1007/s00415-017-8551-7; Ball HA, 2020, BRAIN, V143, P2895, DOI 10.1093/brain/awaa224; Baslet G, 2021, J NEUROPSYCH CLIN N, V33, P27, DOI 10.1176/appi.neuropsych.19120354; Bass C, 2016, HAND CLINIC, V139, P509, DOI 10.1016/B978-0-12-801772-2.00042-4; Begue I, 2019, NEUROIMAGE-CLIN, V22, DOI 10.1016/j.nicl.2019.101798; Bhome R, 2019, COGN NEUROPSYCHIATRY, V24, P152, DOI 10.1080/13546805.2019.1590190; Bhome R, 2019, COGN NEUROPSYCHIATRY, V24, P311, DOI 10.1080/13546805.2019.1651708; Bhome R, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021610; Brown RJ, 2016, CLIN PSYCHOL REV, V47, P55, DOI 10.1016/j.cpr.2016.06.003; Brown RJ, 2016, CLIN PSYCHOL REV, V45, P157, DOI 10.1016/j.cpr.2016.01.003; Carlson P, 2017, SEIZURE-EUR J EPILEP, V45, P142, DOI 10.1016/j.seizure.2016.12.007; Carson A, 2016, HAND CLINIC, V139, P47, DOI 10.1016/B978-0-12-801772-2.00005-9; Chouksey A, 2019, TREMOR OTHER HYPERK, V9, DOI 10.7916/tohm.v0.691; Cojan Y, 2009, NEUROIMAGE, V47, P1026, DOI 10.1016/j.neuroimage.2009.05.023; Demartini B, 2020, PARKINSONISM RELAT D, V76, P108, DOI 10.1016/j.parkreldis.2019.05.004; Dreissen YEM, 2016, HAND CLINIC, V139, P247, DOI 10.1016/B978-0-12-801772-2.00021-7; Dreissen YEM, 2019, J NEUROL NEUROSUR PS, V90, P1244, DOI 10.1136/jnnp-2018-320071; Duncan R, 2011, EPILEPSY BEHAV, V20, P308, DOI 10.1016/j.yebeh.2010.10.022; Espay AJ, 2018, JAMA NEUROL, V75, P1132, DOI 10.1001/jamaneurol.2018.1264; Fend M, 2020, BRAIN, V143, P1278, DOI 10.1093/brain/awaa037; Baizabal-Carvallo JF, 2019, NEUROBIOL DIS, V127, P32, DOI 10.1016/j.nbd.2019.02.013; Foroughi AA, 2020, SEIZURE-EUR J EPILEP, V81, P269, DOI 10.1016/j.seizure.2020.08.024; Frucht L, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.605262; Gallucci-Neto J, 2021, J ACAD CONSULT-LIAIS, V62, P29, DOI 10.1016/j.psym.2020.05.016; Ganos C, 2019, NEUROLOGY, V93, P750, DOI 10.1212/WNL.0000000000008372; Gargalas S, 2017, J NEUROL NEUROSUR PS, V88, P2, DOI 10.1136/jnnp-2015-311114; Gasparini S, 2019, EUR J NEUROL, V26, P205, DOI 10.1111/ene.13818; Gelauff J, 2016, HAND CLINIC, V139, P523, DOI 10.1016/B978-0-12-801772-2.00043-6; Gelauff JM, 2020, NEUROLOGY, V95, pE1883, DOI 10.1212/WNL.0000000000010381; Gilmour GS, 2021, EPILEPSY BEHAV, V121, DOI 10.1016/j.yebeh.2021.108030; Gilmour GS, 2021, CAN J NEUROL SCI, V48, P204, DOI 10.1017/cjn.2020.159; Gilmour GS, 2020, J NEUROL, V267, P2164, DOI 10.1007/s00415-020-09772-w; Gledhill JM, 2021, NEUROLOGY, V96, pE1443, DOI 10.1212/WNL.0000000000011552; Goldstein LH, 2020, LANCET PSYCHIAT, V7, P491, DOI 10.1016/S2215-0366(20)30128-0; Goldstein LH, 2019, EPILEPSIA, V60, P2182, DOI 10.1111/epi.16350; Gupta A, 2009, CURR OPIN NEUROL, V22, P430, DOI 10.1097/WCO.0b013e32832dc169; Gutkin M, 2021, J NEUROL NEUROSUR PS, V92, P36, DOI 10.1136/jnnp-2019-321926; Hallett M, 2016, FUNCTIONAL NEUROLOGI, V139; Hanzlikova Z, 2019, MOVEMENT DISORD, V34, P1022, DOI 10.1002/mds.27706; Harris SR, 2019, EUR J PEDIATR, V178, P581, DOI 10.1007/s00431-019-03317-8; Hassa T, 2016, NEUROIMAGE-CLIN, V11, P719, DOI 10.1016/j.nicl.2016.05.009; Hingray C, 2018, EPILEPSIA, V59, P203, DOI 10.1111/epi.13952; Hobbs FDR, 2016, LANCET, V387, P2323, DOI 10.1016/S0140-6736(16)00620-6; Husain AM, 2021, J CLIN NEUROPHYSIOL, V38, P432, DOI 10.1097/WNP.0000000000000703; Huys ACML, 2021, BRAIN, V144, P3436, DOI 10.1093/brain/awab230; Indovina I, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184274; Indranada AM, 2018, SEIZURE-EUR J EPILEP, V59, P108, DOI 10.1016/j.seizure.2018.05.007; Jackson L, 2021, CLIN PARK RELAT DISO, V5; Jenkins L, 2016, EPILEPSY BEHAV, V64, P257, DOI 10.1016/j.yebeh.2016.08.008; Jones B, 2016, EPILEPSIA, V57, P171, DOI 10.1111/epi.13268; Kanaan RA, 2011, J NEUROL NEUROSUR PS, V82, P961, DOI 10.1136/jnnp.2010.233114; Kanemoto Kousuke, 2017, Epilepsia Open, V2, P307, DOI 10.1002/epi4.12060; Kletenik I, 2022, J NEUROL, V269, P3258, DOI 10.1007/s00415-021-10943-6; Kramer G, 2018, CLIN NEUROPHYSIOL, V129, P13, DOI 10.1016/j.clinph.2017.10.002; Kranick S, 2011, MOVEMENT DISORD, V26, P1844, DOI 10.1002/mds.23830; Kusmakar S, 2019, EPILEPSIA, V60, P165, DOI 10.1111/epi.14619; Kutlubaev MA, 2018, EPILEPSY BEHAV, V89, P70, DOI 10.1016/j.yebeh.2018.10.010; Kuwabara J, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102609; LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356; Lagrand T, 2021, EUR J NEUROL, V28, P33, DOI 10.1111/ene.14488; Lidstone SC, 2022, J NEUROL NEUROSUR PS, DOI 10.1136/jnnp-2021-328462; Ludwig L, 2018, LANCET PSYCHIAT, V5, P307, DOI 10.1016/S2215-0366(18)30051-8; MacDuffie KE, 2021, CNS SPECTRUMS, V26, P587, DOI 10.1017/S1092852920002084; Mantyh WG, 2019, NEUROLOGY, V92, pE2620, DOI 10.1212/WNL.0000000000007569; Maurer CW, 2016, PARKINSONISM RELAT D, V30, P18, DOI 10.1016/j.parkreldis.2016.06.009; McWhirter L, 2022, CNS SPECTRUMS, V27, P331, DOI 10.1017/S1092852920002096; McWhirter L, 2020, J NEUROL NEUROSUR PS, V91, P945, DOI 10.1136/jnnp-2020-323776; McWhirter L, 2020, LANCET PSYCHIAT, V7, P191, DOI 10.1016/S2215-0366(19)30405-5; Morgante F, 2018, MOVEMENT DISORD, V33, P1340, DOI 10.1002/mds.27402; Myers L, 2017, EPILEPSY BEHAV, V66, P86, DOI 10.1016/j.yebeh.2016.10.019; Nada EH, 2019, ANN OTO RHINOL LARYN, V128, P323, DOI 10.1177/0003489418823017; Nicholson C, 2020, J NEUROL NEUROSUR PS, V91, P1037, DOI 10.1136/jnnp-2019-322281; Nielsen G, 2017, J NEUROL NEUROSUR PS, V88, P484, DOI 10.1136/jnnp-2016-314408; Nightscales R, 2020, NEUROLOGY, V95, pE643, DOI 10.1212/WNL.0000000000009855; Nonnekes J, 2020, NEUROLOGY, V94, P1093, DOI 10.1212/WNL.0000000000009649; Novakova B, 2019, EPILEPSY BEHAV, V94, P169, DOI 10.1016/j.yebeh.2019.03.002; Oto M, 2005, J NEUROL NEUROSUR PS, V76, P1682, DOI 10.1136/jnnp.2005.064063; Parees I, 2014, BRAIN, V137, P2916, DOI 10.1093/brain/awu237; Perez DL, 2021, NEUROIMAGE-CLIN, V30, DOI 10.1016/j.nicl.2021.102623; Perez DL, 2021, J NEUROL NEUROSUR PS, V92, P668, DOI 10.1136/jnnp-2020-323953; Peterson KT, 2018, PSYCHOSOMATICS, V59, P601, DOI 10.1016/j.psym.2018.03.001; Pick S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037198; Popkirov S, 2020, EPILEPSIA, V61, P1931, DOI 10.1111/epi.16629; Reuber M, 2018, ALZ DIS ASSOC DIS, V32, P197, DOI 10.1097/WAD.0000000000000231; Sadnicka A, 2020, BRAIN, V143, P674, DOI 10.1093/brain/awz387; Schmidt T, 2021, MOV DISORD CLIN PRAC, V8, P911, DOI 10.1002/mdc3.13268; Spagnolo PA, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11060791; Spagnolo PA, 2021, NEUROSCI BIOBEHAV R, V127, P25, DOI 10.1016/j.neubiorev.2021.04.005; Spagnolo PA, 2020, J NEUROL NEUROSUR PS, V91, P814, DOI 10.1136/jnnp-2019-322636; Staab JP, 2020, SEMIN NEUROL, V40, P130, DOI 10.1055/s-0039-3402736; Staab JP, 2017, J VESTIBUL RES-EQUIL, V27, P191, DOI 10.3233/VES-170622; Stephen CD, 2021, ANN CLIN TRANSL NEUR, V8, P732, DOI 10.1002/acn3.51307; Stephen CD, 2021, JAMA NEUROL, V78, P88, DOI 10.1001/jamaneurol.2020.3753; Stone J, 2018, J NEUROL SCI, V395, P35, DOI 10.1016/j.jns.2018.09.031; Stone J, 2016, HAND CLINIC, V139, P25, DOI 10.1016/B978-0-12-801772-2.00003-5; Stone J, 2016, HAND CLINIC, V139, P543, DOI 10.1016/B978-0-12-801772-2.00044-8; Stone J, 2020, BRAIN, V143, P393, DOI 10.1093/brain/awz420; Stone Jon, 2013, Pract Neurol, V13, P104, DOI 10.1136/practneurol-2012-000422; Sundararajan T, 2016, SEIZURE-EUR J EPILEP, V35, P11, DOI 10.1016/j.seizure.2015.12.011; Syed TU, 2019, SEIZURE-EUR J EPILEP, V66, P104, DOI 10.1016/j.seizure.2019.01.018; Tatum WO, 2020, JAMA NEUROL, V77, P593, DOI 10.1001/jamaneurol.2019.4785; Teodoro T, 2020, EUR J NEUROL, V27, P985, DOI 10.1111/ene.14189; Teodoro T, 2018, J NEUROL NEUROSUR PS, V89, P1308, DOI 10.1136/jnnp-2017-317823; Thomsen BLC, 2020, J NEUROL NEUROSUR PS, V91, P1261, DOI 10.1136/jnnp-2020-323141; Tinazzi M, 2021, EUR J NEUROL, V28, P1752, DOI 10.1111/ene.14674; Tinazzi M, 2020, MOV DISORD CLIN PRAC, V7, P920, DOI 10.1002/mdc3.13077; Van den Bergh O, 2017, NEUROSCI BIOBEHAV R, V74, P185, DOI 10.1016/j.neubiorev.2017.01.015; van der Salm SMA, 2014, NEUROLOGY, V83, P1862, DOI 10.1212/WNL.0000000000000982; Vechetova G, 2018, J PSYCHOSOM RES, V115, P32, DOI 10.1016/j.jpsychores.2018.10.001; Villagran A, 2021, EPILEPSIA, V62, P1528, DOI 10.1111/epi.16949; Voon V, 2010, NEUROLOGY, V74, P223, DOI 10.1212/WNL.0b013e3181ca00e9; Walzl D, 2019, J NEUROL, V266, P2018, DOI 10.1007/s00415-019-09356-3; Wardrope A, 2020, NEUROL-CLIN PRACT, V10, P96, DOI 10.1212/CPJ.0000000000000726; Wardrope A, 2020, EPILEPSIA, V61, P758, DOI 10.1111/epi.16471; Watson C, 2019, J CHILD NEUROL, V34, P325, DOI 10.1177/0883073819830193; Williamson JC, 2018, INT PSYCHOGERIATR, V30, P1569, DOI 10.1017/S1041610218000121; Wurthmann S, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02417-z; Xu Y, 2016, SEIZURE-EUR J EPILEP, V41, P167, DOI 10.1016/j.seizure.2016.08.005; Yu YC, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8518631; Zanzmera P, 2019, EPILEPSY BEHAV, V94, P258, DOI 10.1016/j.yebeh.2019.03.034	123	13	13	9	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					537	550		10.1016/S1474-4422(21)00422-1	http://dx.doi.org/10.1016/S1474-4422(21)00422-1			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35430029				2022-12-18	WOS:000844093900001
J	Goutman, SA; Hardiman, O; Al-Chalabi, A; Chio, A; Savelieff, MG; Kiernan, MC; Feldman, EL				Goutman, Stephen A.; Hardiman, Orla; Al-Chalabi, Ammar; Chio, Adriano; Savelieff, Masha G.; Kiernan, Matthew C.; Feldman, Eva L.			Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Article							ALSFRS-R; STAGING SYSTEM; VALIDATION; MRI; NEUROFILAMENTS; CONNECTOME; PREVALENCE; PREDICTION; CRITERIA; POINT	The diagnosis of amyotrophic lateral sclerosis can be challenging due to its heterogeneity in clinical presentation and overlap with other neurological disorders. Diagnosis early in the disease course can improve outcomes as timely interventions can slow disease progression. An evolving awareness of disease genotypes and phenotypes and new diagnostic criteria, such as the recent Gold Coast criteria, could expedite diagnosis. Improved prognosis, such as that achieved with the survival model from the European Network for the Cure of ALS, could inform the patient and their family about disease course and improve end-of-life planning. Novel staging and scoring systems can help monitor disease progression and might potentially serve as clinical trial outcomes. Lastly, new tools, such as fluid biomarkers, imaging modalities, and neuromuscular electrophysiological measurements, might increase diagnostic and prognostic accuracy.	[Goutman, Stephen A.; Savelieff, Masha G.; Feldman, Eva L.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; [Hardiman, Orla] Trinity Coll Dublin, Acad Unit Neurol, Trinity Biomed Sci Inst, Dublin, Ireland; [Al-Chalabi, Ammar] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Dept Basic & Clin Neurosci, London, England; [Al-Chalabi, Ammar] Kings Coll London, Dept Neurol, London, England; [Chio, Adriano] Univ Turin, Rita Levi Montalcini Dept Neurosci, Turin, Italy; [Kiernan, Matthew C.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Kiernan, Matthew C.] Royal Prince Alfred Hosp, Dept Neurol, Sydney, NSW, Australia	University of Michigan System; University of Michigan; Trinity College Dublin; University of London; King's College London; University of London; King's College London; University of Turin; University of Sydney; University of Sydney	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Michigan Med, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Goutman, Stephen/0000-0001-8780-6637	National ALS Registry/CDC/ATSDR [1R01TS000289, R01TS000327]; National ALS Registry/CDC/ATSDR CDCP-DHHS-US [CDC/ATSDR 200-2013-56856]; NIEHS [K23ES027221, R01ES030049]; NINDS [R01NS127188, R01NS120926]; NeuroNetwork for Emerging Therapies; NeuroNetwork Therapeutic Discovery Fund; Peter R Clark Fund for ALS Research; Sinai Medical Staff Foundation; Scott L Pranger; University of Michigan; Science Foundation Ireland [13/RC2015, 16/RC/3948]; Thierry Latran Foundation; Health Research Board (Ireland); Senior Investigator for the National Institute for Health Research [NIHR202421]; JPND: Medical Research Council [MR/L501529/1, MR/R024804/1]; Economic and Social Research Council [ES/L008238/1]; Motor Neurone Disease Association; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust; King's College London; Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata) [RF2016-02362405]; Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research [2017SNW5MB]; European Commission's Health Seventh Framework Programme [FP7/2007-2013, 259867]; Joint Programme-Neurodegenerative Disease Research (Strength, ALS-Care and Brain-Mend projects) - Italian Ministry of Education, University and Research; Department of Excellence grant of the Italian Ministry of Education, University and Research, Italy; National Health and Medical Research Council of Australia Program [APP1132524, APP1153439, APP1156093]; Horizon 2020; ALS Association; My Name'5 Doddie Foundation	National ALS Registry/CDC/ATSDR; National ALS Registry/CDC/ATSDR CDCP-DHHS-US; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NeuroNetwork for Emerging Therapies; NeuroNetwork Therapeutic Discovery Fund; Peter R Clark Fund for ALS Research; Sinai Medical Staff Foundation; Scott L Pranger; University of Michigan(University of Michigan System); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Thierry Latran Foundation; Health Research Board (Ireland); Senior Investigator for the National Institute for Health Research; JPND: Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Motor Neurone Disease Association; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust; King's College London(General Electric); Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata)(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Finalizzata (MOH-RF)); Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research; European Commission's Health Seventh Framework Programme; Joint Programme-Neurodegenerative Disease Research (Strength, ALS-Care and Brain-Mend projects) - Italian Ministry of Education, University and Research; Department of Excellence grant of the Italian Ministry of Education, University and Research, Italy; National Health and Medical Research Council of Australia Program(National Health and Medical Research Council (NHMRC) of Australia); Horizon 2020; ALS Association; My Name'5 Doddie Foundation	SAG and ELF receive funding from the National ALS Registry/CDC/ATSDR (1R01TS000289; R01TS000327); National ALS Registry/CDC/ATSDR CDCP-DHHS-US (CDC/ATSDR 200-2013-56856); NIEHS K23ES027221; NIEHS R01ES030049; NINDS R01NS127188 and R01NS120926; NeuroNetwork for Emerging Therapies, the NeuroNetwork Therapeutic Discovery Fund, the Peter R Clark Fund for ALS Research, the Sinai Medical Staff Foundation, Scott L Pranger, University of Michigan. OH receives funding from Science Foundation Ireland (13/RC2015, 16/RC/3948), Thierry Latran Foundation, and the Health Research Board (Ireland). AA-C is a Senior Investigator for the National Institute for Health Research (NIHR202421). This is an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND: Medical Research Council (MR/L501529/1; MR/R024804/1), Economic and Social Research Council (ES/L008238/1), and the Motor Neurone Disease Association. This study represents independent research partly funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. AC received funding from the Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata, grant RF2016-02362405); the Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research (grant 2017SNW5MB); the European Commission's Health Seventh Framework Programme (FP7/2007-2013 under grant agreement 259867); the Joint Programme-Neurodegenerative Disease Research (Strength, ALS-Care and Brain-Mend projects), granted by Italian Ministry of Education, University and Research; and the Department of Excellence grant of the Italian Ministry of Education, University and Research to the Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy. MCK receives funding from the National Health and Medical Research Council of Australia Program Grant (APP1132524), Partnership Project (APP1153439), and Practitioner Fellowship (APP1156093) schemes. Funding from Horizon 2020, the ALS Association, and My Name'5 Doddie Foundation are also acknowledged.	Acosta-Cabronero J, 2018, RADIOLOGY, V289, P195, DOI 10.1148/radiol.2018180112; Agarwal S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81612-x; Agosta F, 2019, EUR J NEUROL, V26, P1143, DOI 10.1111/ene.13957; Al-Chalabi A, 2021, J NEUROL NEUROSUR PS, V92, P165, DOI 10.1136/jnnp-2020-323271; Alshikho MJ, 2018, ANN NEUROL, V83, P1186, DOI 10.1002/ana.25251; Arthur KC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12408; Basaia S, 2020, NEUROLOGY, V95, pE2552, DOI 10.1212/WNL.0000000000010731; Bede P, 2018, AMYOTROPH LAT SCL FR, V19, P232, DOI 10.1080/21678421.2017.1407795; Bedlack RS, 2016, NEUROLOGY, V86, P808, DOI 10.1212/WNL.0000000000002251; Benatar M, 2020, NEUROLOGY, V95, pE59, DOI 10.1212/WNL.0000000000009559; Benatar M, 2019, AMYOTROPH LAT SCL FR, V20, P303, DOI 10.1080/21678421.2019.1587634; Benatar M, 2018, ANN NEUROL, V84, P130, DOI 10.1002/ana.25276; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Burke T, 2017, ANN CLIN TRANSL NEUR, V4, P305, DOI 10.1002/acn3.407; Caga J, 2018, AMYOTROPH LAT SCL FR, V19, P599, DOI 10.1080/21678421.2018.1497659; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; Chia R, 2018, LANCET NEUROL, V17, P94, DOI 10.1016/S1474-4422(17)30401-5; Chio A, 2013, NEUROEPIDEMIOLOGY, V41, P118, DOI 10.1159/000351153; Chio A, 2020, NEUROLOGY, V94, pE802, DOI 10.1212/WNL.0000000000008869; Chio A, 2015, J NEUROL NEUROSUR PS, V86, P38, DOI 10.1136/jnnp-2013-306589; Chio A, 2011, J NEUROL NEUROSUR PS, V82, P740, DOI 10.1136/jnnp.2010.235952; Choi SJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57366-y; Costa J, 2012, ARCH NEUROL-CHICAGO, V69, P1410, DOI 10.1001/archneurol.2012.254; Crockford C, 2018, NEUROLOGY, V91, pE1370, DOI 10.1212/WNL.0000000000006317; D'hulst L, 2018, AMYOTROPH LAT SCL FR, V19, P570, DOI 10.1080/21678421.2018.1476548; de Carvalho M, 2017, J NEUROL NEUROSUR PS, V88, P773, DOI 10.1136/jnnp-2017-315574; Devenney EM, 2018, NEUROLOGY, V91, P1498, DOI 10.1212/WNL.0000000000006344; Dewan R, 2021, NEURON, V109, DOI 10.1016/j.neuron.2020.11.005; Dharmadasa T, 2021, EUR J NEUROL, V28, P90, DOI 10.1111/ene.14515; Dharmadasa T, 2020, CLIN NEUROPHYSIOL, V131, P958, DOI 10.1016/j.clinph.2019.11.057; Dukic S, 2019, HUM BRAIN MAPP, V40, P4827, DOI 10.1002/hbm.24740; Eisen A, 2017, J NEUROL NEUROSUR PS, V88, P917, DOI 10.1136/jnnp-2017-315573; El Mendili MM, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00350; Elamin M, 2017, AMYOTROPH LAT SCL FR, V18, P68, DOI 10.1080/21678421.2016.1248976; Elamin M, 2013, NEUROLOGY, V80, P1590, DOI 10.1212/WNL.0b013e31828f18ac; Estevez-Fraga C, 2021, NEUROL-GENET, V7, DOI 10.1212/NXG.0000000000000575; Fabes J, 2017, ACAD RADIOL, V24, P1187, DOI 10.1016/j.acra.2017.04.008; Fang T, 2017, AMYOTROPH LAT SCL FR, V18, P227, DOI 10.1080/21678421.2016.1265565; Ferraro PM, 2017, NEUROIMAGE-CLIN, V16, P240, DOI 10.1016/j.nicl.2017.08.002; Fournier CN, 2020, JAMA NEUROL, V77, P480, DOI 10.1001/jamaneurol.2019.4490; Gafson AR, 2020, BRAIN, V143, P1975, DOI 10.1093/brain/awaa098; Galvin M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179796; Geevasinga N, 2015, EUR J NEUROL, V22, P826, DOI 10.1111/ene.12669; Goutman SA, 2022, LANCET NEUROL, V21, P465, DOI 10.1016/S1474-4422(21)00414-2; Goutman Stephen A, 2018, Handb Clin Neurol, V148, P603, DOI 10.1016/B978-0-444-64076-5.00039-9; Goutman Stephen A, 2017, Continuum (Minneap Minn), V23, P1332, DOI 10.1212/CON.0000000000000535; Grollemund V, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00135; Halbgebauer S, 2022, J NEUROL NEUROSUR PS, V93, P68, DOI 10.1136/jnnp-2021-327129; Hannaford A, 2021, ANN NEUROL, V89, P979, DOI 10.1002/ana.26045; Huang F, 2020, ANN CLIN TRANSL NEUR, V7, P1103, DOI 10.1002/acn3.51078; Huynh W, 2019, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01141; Kalra S, 2020, NEUROLOGY, V95, pE943, DOI 10.1212/WNL.0000000000010235; Kassubek J, 2019, CURR OPIN NEUROL, V32, P740, DOI 10.1097/WCO.0000000000000728; Kiernan MC, 2021, NAT REV NEUROL, V17, P104, DOI 10.1038/s41582-020-00434-z; Lenglet T, 2017, REV NEUROL-FRANCE, V173, P280, DOI 10.1016/j.neurol.2017.04.003; Luna J, 2021, AMYOTROPH LAT SCL FR, V22, P478, DOI 10.1080/21678421.2021.1903506; Manjaly ZR, 2010, AMYOTROPH LATERAL SC, V11, P439, DOI 10.3109/17482961003610853; Marin B, 2017, INT J EPIDEMIOL, V46, P57, DOI 10.1093/ije/dyw061; McLaughlin RL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14774; Mehta P, 2018, MMWR-MORBID MORTAL W, V67, P1285, DOI 10.15585/mmwr.mm6746a1; Meier JM, 2020, ANN NEUROL, V87, P725, DOI 10.1002/ana.25706; Menke RAL, 2018, NEUROIMAGE-CLIN, V17, P953, DOI 10.1016/j.nicl.2017.12.025; Menon P, 2020, ANN CLIN TRANSL NEUR, V7, P733, DOI 10.1002/acn3.51039; Menon P, 2019, ANN CLIN TRANSL NEUR, V6, P1373, DOI 10.1002/acn3.50819; Menon P, 2015, LANCET NEUROL, V14, P478, DOI 10.1016/S1474-4422(15)00014-9; Moglia C, 2021, NEUROL SCI, V42, P1207, DOI 10.1007/s10072-020-04751-5; Moss DJH, 2014, NEUROLOGY, V82, P292, DOI 10.1212/WNL.0000000000000061; Murphy NA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02364-1; Nasseroleslami B, 2019, CEREB CORTEX, V29, P27, DOI 10.1093/cercor/bhx301; Nicholson K, 2018, MUSCLE NERVE, V57, P20, DOI 10.1002/mus.25712; Pinto-Grau M, 2021, NEUROL-CLIN PRACT, V11, pE634, DOI 10.1212/CPJ.0000000000001006; Pirola A, 2019, CLIN NEUROL NEUROSUR, V184, DOI 10.1016/j.clineuro.2019.105456; Poesen K, 2017, NEUROLOGY, V88, P2302, DOI 10.1212/WNL.0000000000004029; Pugdahl K, 2021, CLIN NEUROPHYSIOL, V132, P3183, DOI 10.1016/j.clinph.2021.08.014; Querin G, 2017, EUR J NEUROL, V24, P1040, DOI 10.1111/ene.13329; Querin G, 2019, ANN NEUROL, V86, P158, DOI 10.1002/ana.25520; Rabinovici Gil D, 2015, Continuum (Minneap Minn), V21, P646, DOI 10.1212/01.CON.0000466658.05156.54; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Richards D, 2020, J NEUROL SCI, V417, DOI 10.1016/j.jns.2020.117054; Roche JC, 2012, BRAIN, V135, P847, DOI 10.1093/brain/awr351; Roeben B, 2019, J NEUROL SCI, V406, DOI 10.1016/j.jns.2019.116440; Rooney J, 2017, J NEUROL NEUROSUR PS, V88, P381, DOI 10.1136/jnnp-2016-314661; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Ryan M, 2019, JAMA NEUROL, V76, P1367, DOI 10.1001/jamaneurol.2019.2044; Saba L, 2016, CEREB CORTEX, V26, P1512, DOI 10.1093/cercor/bhu317; Schuster C, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0854-x; Schuster C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167331; Shefner JM, 2020, CLIN NEUROPHYSIOL, V131, P1975, DOI 10.1016/j.clinph.2020.04.005; Shen DC, 2021, TRANSL NEURODEGENER, V10, DOI 10.1186/s40035-021-00253-2; Sorrentino P, 2018, NEUROIMAGE-CLIN, V20, P564, DOI 10.1016/j.nicl.2018.08.001; Strong MJ, 2017, AMYOTROPH LAT SCL FR, V18, P153, DOI 10.1080/21678421.2016.1267768; Swash M, 2020, J NEUROL NEUROSUR PS, V91, P227, DOI 10.1136/jnnp-2019-321938; Swinnen B, 2014, NAT REV NEUROL, V10, P661, DOI 10.1038/nrneurol.2014.184; Talman P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012054; Tang M, 2019, NEUROINFORMATICS, V17, P407, DOI 10.1007/s12021-018-9406-9; van den Berg LH, 2019, NEUROLOGY, V92, pE1610, DOI 10.1212/WNL.0000000000007242; van Eijk RPA, 2021, AMYOTROPH LAT SCL FR, V22, P300, DOI 10.1080/21678421.2021.1879865; Van Weehaeghe D, 2020, EUR J NUCL MED MOL I, V47, P2681, DOI 10.1007/s00259-020-04786-y; Verde F, 2019, CURR OPIN NEUROL, V32, P747, DOI 10.1097/WCO.0000000000000744; Vucic S, 2021, MUSCLE NERVE, V64, P532, DOI 10.1002/mus.27392; Vucic S, 2021, NEUROSCI LETT, V759, DOI 10.1016/j.neulet.2021.136039; Vucic S, 2018, CURR OPIN NEUROL, V31, P640, DOI 10.1097/WCO.0000000000000593; Wainger BJ, 2021, JAMA NEUROL, V78, P186, DOI 10.1001/jamaneurol.2020.4300; Welton T, 2019, NEUROIMAGE-CLIN, V24, DOI 10.1016/j.nicl.2019.101953; Westeneng HJ, 2018, LANCET NEUROL, V17, P662, DOI 10.1016/S1474-4422(18)30241-2; Westeneng HJ, 2018, LANCET NEUROL, V17, P423, DOI 10.1016/S1474-4422(18)30089-9; Xu L, 2020, J NEUROL, V267, P944, DOI 10.1007/s00415-019-09652-y; Yang CP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03247-3	108	13	13	11	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2022	21	5					480	493		10.1016/S1474-4422(21)00465-8	http://dx.doi.org/10.1016/S1474-4422(21)00465-8			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	2R9KM	35334233				2022-12-18	WOS:000821423000020
J	Knight, EMP; Amin, S; Bahi-Buisson, N; Benke, TA; Cross, JH; Demarest, ST; Olson, HE; Specchio, N; Fleming, TR; Aimetti, AA; Gasior, M; Devinsky, O				Knight, Elia M. Pestana; Amin, Sam; Bahi-Buisson, Nadia; Benke, Tim A.; Cross, J. Helen; Demarest, Scott T.; Olson, Heather E.; Specchio, Nicola; Fleming, Thomas R.; Aimetti, Alex A.; Gasior, Maciej; Devinsky, Orrin		Marigold Trial Grp	Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	LANCET NEUROLOGY			English	Article							FUNCTIONAL ABILITIES; ANTIEPILEPTIC DRUGS; SEIZURES; CANNABIDIOL; EPILEPSIES; SPASMS	Background CDKL5 deficiency disorder (CDD) is a rare, X-linked, developmental and epileptic encephalopa thy characterised by severe global developmental impairment and seizures that can begin in the first few months after birth and are often treatment refractory. Ganaxolone, an investigational neuroactive steroid, reduced seizure frequency in an open-label, phase 2 trial that included patients with CDD. We aimed to further assess the efficacy and safety of ganaxolone in patients with CDD-associated refractory epilepsy. Methods In the double-blind phase of this randomised, placebo-controlled, phase 3 trial, done at 39 outpatient clinics in eight countries (Australia, France, Israel, Italy, Poland, Russia, the UK, and the USA), patients were eligible if they were aged 2-21 years with a pathogenic or probably pathogenic CDKL5 variant and at least 16 major motor seizures (defined as bilateral tonic, generalised tonic-clonic, bilateral clonic, atonic, or focal to bilateral tonic-clonic) per 28 days in each 4-week period of an 8-week historical period. After a 6-week prospective baseline period, patients were randomly assigned (1:1) via an interactive web response system to receive either enteral adjunctive ganaxolone or matching enteral adjunctive placebo (maximum dose 63 mg/kg per day for patients weighing <= 28 kg or 1800 mg/day for patients weighing >28 kg) for 17 weeks. Patients, caregivers, investigators (including those analysing data), trial staff, and the sponsor (other than the investigational product manager) were masked to treatment allocation. The primary efficacy endpoint was percentage change in median 28-day major motor seizure frequency from the baseline period to the 17-week double-blind phase and was analysed (using a Wilcoxon-rank sum test) in all patients who received at least one dose of trial treatment and for whom baseline data were available. Safety (compared descriptively across groups) was analysed in all patients who received at least one dose of trial treatment. This study is registered with ClinicalTrials.gov, NCT03572933, and the open-label extension phase is ongoing. Findings Between June 25, 2018, and July 2, 2020, 114 patients were screened for eligibility, of whom 101 (median age 6 years [IQR 3 to 101) were randomly assigned to receive either ganaxolone (n=50) or placebo (n=51). All patients received at least one dose of a study drug, but seizure frequency for one patient in the ganaxolone group was not recorded at baseline and so the primary endpoint was analysed in a population of 100 patients. There was a median percentage change in 28-day major motor seizure frequency of -30.7% (IQR -49.5 to -1.9) in the ganaxolone group and of -6.9% (-24.1 to 39.7) in the placebo group (p=0.0036). The Hodges-Lehmann estimate of median difference in responses to ganaxolone versus placebo was -27.1% (95% CI -47.9 to - 9.6). Treatment-emergent adverse events occurred in 43 (86%) of 50 patients in the ganaxolone group and in 45 (88%) of 51 patients in the placebo group. Somnolence, pyrexia, and upper respiratory tract infections occurred in at least 10% of patients in the ganaxolone group and more frequently than in the placebo group. Serious adverse events occurred in six (12%) patients in the ganaxolone group and in five (10%) patients in the placebo group. Two (4%) patients in the ganaxolone group and four (8%) patients in the placebo group discontinued the trial. There were no deaths in the double-blind phase. Interpretation Ganaxolone significantly reduced the frequency of CDD-associated seizures compared with placebo and was generally well tolerated. Results from what is, to our knowledge, the first controlled trial in CDD suggest a potential treatment benefit for ganaxolone. Long-term treatment is being assessed in the ongoing open-label extension phase of this trial. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Knight, Elia M. Pestana] Cleveland Clin, Cleveland Neurol Inst, Epilepsy Ctr, Cleveland, OH 44195 USA; [Amin, Sam] Univ Hosp Bristol & Weston, Pediat Neurol, Bristol, Avon, England; [Bahi-Buisson, Nadia] Necker Enfants Malad Univ Hosp, Pediat Neurol, Paris, France; [Benke, Tim A.; Demarest, Scott T.] Univ Colorado, Childrens Hosp Colorado, Sch Med, Dept Pediat & Neurol, Aurora, CO USA; [Cross, J. Helen] UCL NIHR BRC Great Ormond St Inst Child Hlth, London, England; [Olson, Heather E.] Boston Childrens Hosp, Dept Neurol, Div Epilepsy & Clin Neurophysiol, Boston, MA USA; [Olson, Heather E.] Boston Childrens Hosp, Dept Neurol, Epilepsy Genet Program, Boston, MA USA; [Olson, Heather E.] Harvard Med Sch, Boston, MA 02115 USA; [Specchio, Nicola] IRCCS, Bambino Gesu Childrens Hosp, Dept Neurosci, Rare & Complex Epilepsy Unit, Rome, Italy; [Fleming, Thomas R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Aimetti, Alex A.; Gasior, Maciej] Marinus Pharmaceut, Radnor, PA USA; [Devinsky, Orrin] NYU, Langone Comprehens Epilepsy Ctr, New York, NY USA	Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; IRCCS Bambino Gesu; University of Washington; University of Washington Seattle; New York University	Knight, EMP (corresponding author), Cleveland Clin, Cleveland Neurol Inst, Epilepsy Ctr, Cleveland, OH 44195 USA.	pestane@ccf.org	; Scheffer, Ingrid/G-1668-2013	Cross, Helen/0000-0001-7345-4829; Scheffer, Ingrid/0000-0002-2311-2174; Guerrini, Renzo/0000-0002-7272-7079	Marinus Pharmaceuticals	Marinus Pharmaceuticals	Marinus Pharmaceuticals.	Amendola E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091613; Archer HL, 2006, J MED GENET, V43, P729, DOI 10.1136/jmg.2006.041467; Bahi-Buisson N, 2008, EPILEPSIA, V49, P1027, DOI 10.1111/j.1528-1167.2007.01520.x; Bartnik M, 2011, GENET MED, V13, P447, DOI 10.1097/GIM.0b013e31820605f5; Carter RB, 1997, J PHARMACOL EXP THER, V280, P1284; Demarest ST, 2019, EPILEPSIA, V60, P1733, DOI 10.1111/epi.16285; Devinsky O, 2021, ANN CLIN TRANSL NEUR, V8, P639, DOI 10.1002/acn3.51306; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Fallah MS, 2020, NEUROSCIENCE, V445, P50, DOI 10.1016/j.neuroscience.2020.01.041; Fehr S, 2016, NEUROLOGY, V87, P2206, DOI 10.1212/WNL.0000000000003352; Fehr S, 2016, AM J MED GENET A, V170, P2860, DOI 10.1002/ajmg.a.37851; Fehr S, 2015, J NEURODEV DISORD, V7, DOI 10.1186/1866-1955-7-2; Fehr S, 2013, EUR J HUM GENET, V21, P266, DOI 10.1038/ejhg.2012.156; Frullanti E, 2019, INT J GENOMICS, V2019, DOI 10.1155/2019/6956934; Fuchs C, 2014, NEUROBIOL DIS, V70, P53, DOI 10.1016/j.nbd.2014.06.006; Gasior M, 2000, NEUROPHARMACOLOGY, V39, P1184, DOI 10.1016/S0028-3908(99)00190-2; Jakimiec M, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10020107; Kadam SD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205098; Kilstrup-Nielsen C, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/728267; Klein KM, 2011, NEUROLOGY, V76, P1436, DOI 10.1212/WNL.0b013e3182166e58; Krishnaraj R, 2017, HUM MUTAT, V38, P922, DOI 10.1002/humu.23263; Lagae L, 2019, LANCET, V394, P2243, DOI 10.1016/S0140-6736(19)32500-0; Lattanzi S, 2021, EXPERT REV NEUROTHER, V21, P1317, DOI 10.1080/14737175.2021.1904895; Mangatt M, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0418-y; Muller A, 2016, EUR J PAEDIATR NEURO, V20, P147, DOI 10.1016/j.ejpn.2015.09.001; Olson HE, 2019, PEDIATR NEUROL, V97, P18, DOI 10.1016/j.pediatrneurol.2019.02.015; Perucca E, 2012, EPILEPTIC DISORD, V14, P124, DOI 10.1684/epd.2012.0511; Pizzo R, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00261; Rees CA, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002966; Saporito MS, 2019, J PHARMACOL EXP THER, V368, P326, DOI 10.1124/jpet.118.252155; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Siri B, 2021, EUR J PAEDIATR NEURO, V33, P9, DOI 10.1016/j.ejpn.2021.04.007; Sivilia S, 2016, GENES BRAIN BEHAV, V15, P491, DOI 10.1111/gbb.12292; Specchio N, 2018, AM EPILEPSY SOC ANN; Stosser MB, 2018, GENET MED, V20, P403, DOI 10.1038/gim.2017.114; Symonds JD, 2019, BRAIN, V142, P2303, DOI 10.1093/brain/awz195; Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3; Zhu YC, 2019, DEV NEUROBIOL, V79, P8, DOI 10.1002/dneu.22639	38	13	13	12	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2022	21	5					417	427		10.1016/S1474-4422(22)00077-1	http://dx.doi.org/10.1016/S1474-4422(22)00077-1			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	2R9KM	35429480	Green Submitted			2022-12-18	WOS:000821423000015
J	Vidailhet, M				Vidailhet, Marie			Essential tremor-plus: a temporary label	LANCET NEUROLOGY			English	Editorial Material							ATAXIAS		[Vidailhet, Marie] Salpetriere Hosp, AP HP, Dept Neurol, F-75013 Paris, France; [Vidailhet, Marie] Salpetriere Hosp, AP HP, Inst Cerveau & Moelle Epiniere, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Vidailhet, M (corresponding author), Salpetriere Hosp, AP HP, Dept Neurol, F-75013 Paris, France.; Vidailhet, M (corresponding author), Salpetriere Hosp, AP HP, Inst Cerveau & Moelle Epiniere, F-75013 Paris, France.	marie.vidailhet@aphp.fr						Bhatia KP, 2018, MOVEMENT DISORD, V33, P75, DOI 10.1002/mds.27121; Fasano A, 2018, MOVEMENT DISORD, V33, P58, DOI 10.1002/mds.27288; Louis ED, 2019, LANCET NEUROL, DOI [10.1016/S1474-4422(19)30320-5, DOI 10.1016/S1474-4422(19)30320-5]; Nieuwhof F, 2018, CURR OPIN NEUROL, V31, P455, DOI 10.1097/WCO.0000000000000582; Rajput AH, 2019, MOVEMENT DISORD, V34, P1031, DOI 10.1002/mds.27729; Synofzik M, 2019, NEURON, V101, P560, DOI 10.1016/j.neuron.2019.01.049; Synofzik M, 2017, MOVEMENT DISORD, V32, P332, DOI 10.1002/mds.26944	7	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					202	203		10.1016/S1474-4422(19)30442-9	http://dx.doi.org/10.1016/S1474-4422(19)30442-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	31767342				2022-12-18	WOS:000514832700008
J	[Anonymous]				[Anonymous]			Response to the growing dementia burden must be faster	LANCET NEUROLOGY			English	Editorial Material																			0	13	13	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					651	651		10.1016/S0140-6736(18)31258-3	http://dx.doi.org/10.1016/S0140-6736(18)31258-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30033050				2022-12-18	WOS:000439057500001
J	Schneider, L				Schneider, Lon			Alzheimer's disease and other dementias: update on research	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-BLIND; PLACEBO; EFFICACY; ABT-126; SAFETY		[Schneider, Lon] Univ Southern Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA	University of Southern California	Schneider, L (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Florian H, 2016, J ALZHEIMERS DIS, V51, P1237, DOI 10.3233/JAD-150978; Gault LM, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0210-1; Gault Laura M, 2015, Alzheimers Dement (N Y), V1, P81, DOI 10.1016/j.trci.2015.06.001; Gauthier S., 2016, LANCET; Gleason CE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001833; Kennedy ME, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9704; Maher-Edwards Gareth, 2015, Alzheimers Dement (N Y), V1, P23, DOI 10.1016/j.trci.2015.04.001; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; van Charante EPM, 2016, LANCET, V388, P797, DOI 10.1016/S0140-6736(16)30950-3; Vassar R, 2016, DEVELOPING THERAPEUTICS FOR ALZHEIMER'S DISEASE: PROGRESS AND CHALLENGES, P39, DOI 10.1016/B978-0-12-802173-6.00003-4; Wilkinson D, 2014, LANCET NEUROL, V13, P1092, DOI 10.1016/S1474-4422(14)70198-X	12	13	14	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					4	5		10.1016/S1474-4422(16)30356-8	http://dx.doi.org/10.1016/S1474-4422(16)30356-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979354				2022-12-18	WOS:000389869200003
J	Devinsky, O; Marsh, E; Friedman, D				Devinsky, Orrin; Marsh, Eric; Friedman, Daniel			Cannabidiol in patients with treatment-resistant epilepsy Reply	LANCET NEUROLOGY			English	Letter									[Devinsky, Orrin; Friedman, Daniel] NYU, Langone Med Ctr, Comprehens Epilepsy Ctr, New York, NY USA; [Marsh, Eric] Univ Penn, Childrens Hosp Philadelphia, Dept Neurol, Div Child Neurol, Philadelphia, PA 19104 USA; [Marsh, Eric] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Child Neurol, Philadelphia, PA 19104 USA; [Marsh, Eric] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	New York University; NYU Langone Medical Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Devinsky, O (corresponding author), NYU, Langone Med Ctr, Comprehens Epilepsy Ctr, New York, NY USA.	od4@nyu.edu		Devinsky, Orrin/0000-0003-0044-4632				Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8	1	13	15	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2016	15	6					545	546		10.1016/S1474-4422(16)00120-4	http://dx.doi.org/10.1016/S1474-4422(16)00120-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI9PW	27302119	Bronze			2022-12-18	WOS:000373835900012
J	Kochanek, PM; Clark, RSB				Kochanek, Patrick M.; Clark, Robert S. B.			Traumatic brain injury research highlights in 2015	LANCET NEUROLOGY			English	Editorial Material							COMMON DATA ELEMENTS; BIOMARKERS		[Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kochanek, PM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu						Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Nichol A, 2015, LANCET; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Titus DJ, 2015, EXP NEUROL, V263, P254, DOI 10.1016/j.expneurol.2014.10.020; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	13	13	14	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					13	15		10.1016/S1474-4422(15)00339-7	http://dx.doi.org/10.1016/S1474-4422(15)00339-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700899				2022-12-18	WOS:000366313900008
J	Muir, KW				Muir, Keith W.			Stroke in 2015: the year of endovascular treatment	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; TRIAL; THROMBECTOMY; EFFICACY; SAFETY; ONSET		[Muir, Keith W.] Univ Glasgow, Queen Elizabeth Univ Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland	Queen Elizabeth University Hospital (QEUH); University of Glasgow	Muir, KW (corresponding author), Univ Glasgow, Queen Elizabeth Univ Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland.	keith.muir@glasgow.ac.uk	Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X	National Institute for Health Research [14/08/47] Funding Source: researchfish; Stroke Association [TSA2011/06] Funding Source: researchfish; Department of Health [HTA/14/08/47] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Stroke Association; Department of Health		Albers GW, 2015, LANCET NEUROL, V14, P575, DOI 10.1016/S1474-4422(15)00047-2; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Morris S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4757; Saver JL, 2015, INT J STROKE, V10, P439, DOI 10.1111/ijs.12459; The AVERT Trial Collaboration Group, 2015, LANCET, V386, P46	9	13	14	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					2	3		10.1016/S1474-4422(15)00337-3	http://dx.doi.org/10.1016/S1474-4422(15)00337-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700893				2022-12-18	WOS:000366313900002
J	Otte, WM; van Diessen, E; van Eijsden, P; van der Maas, F; Patsalos, PN; Newton, PN; Alvarenga, IC; Braun, KP; Sander, JW				Otte, Willem M.; van Diessen, Eric; van Eijsden, Pieter; van der Maas, Frank; Patsalos, Philip N.; Newton, Paul N.; Alvarenga, Incio C.; Braun, Kees P.; Sander, Josemir W.			Counterfeit antiepileptic drugs threaten community services in Guinea-Bissau and Nigeria	LANCET NEUROLOGY			English	Letter							EPILEPSY		[Otte, Willem M.; van Diessen, Eric; Braun, Kees P.] Univ Med Ctr Utrecht, Dept Pediat Neurol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [van Eijsden, Pieter] Univ Med Ctr Utrecht, Dept Neurosurg, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Otte, Willem M.] Univ Med Ctr Utrecht, Biomed MR Imaging & Spect Grp, Ctr Image Sci, Utrecht, Netherlands; [Patsalos, Philip N.] Reabil Base Comunitaria Effata, Bissau, Guinea Bissau; [Patsalos, Philip N.] Epilepsy Soc, Therapeut Drug Monitoring Unit, Gerrards Cross, England; [Newton, Paul N.] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Viangchan, Laos; [Newton, Paul N.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [Alvarenga, Incio C.] WHO, Bissau, Guinea Bissau; [Sander, Josemir W.] NIHR Univ, UCL Inst Neurol, Coll London Hosp Biomed Res Ctr, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; [Sander, Josemir W.] SEIN, Heemstede, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Oxford; World Health Organization; University of London; University College London	Otte, WM (corresponding author), Univ Med Ctr Utrecht, Dept Pediat Neurol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.	l.sander@ucl.ac.uk	Otte, Willem M/I-1228-2013; Sander, Josemir/C-1576-2008; Otte, Willem M./J-6140-2019	Otte, Willem M/0000-0003-1511-6834; Sander, Josemir/0000-0001-6041-9661; Otte, Willem M./0000-0003-1511-6834; Newton, Paul/0000-0002-4608-6431	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Degardin K, 2014, J PHARMACEUT BIOMED, V87, P167, DOI 10.1016/j.jpba.2013.01.009; Khasnabis C., 2010, COMMUNITY BASED REHA; Meinardi H, 2001, EPILEPSIA, V42, P136, DOI 10.1046/j.1528-1157.2001.32800.x; Wang WZ, 2006, LANCET NEUROL, V5, P46, DOI 10.1016/S1474-4422(05)70254-4	4	13	13	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1075	1076		10.1016/S1474-4422(15)00255-0	http://dx.doi.org/10.1016/S1474-4422(15)00255-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	26466777	Bronze			2022-12-18	WOS:000362975200011
J	Kwakkel, G; Meskers, CGM				Kwakkel, Gert; Meskers, Carel G. M.			Botulinum toxin A for upper limb spasticity	LANCET NEUROLOGY			English	Editorial Material							STROKE; MUSCLE; ASHWORTH		[Kwakkel, Gert; Meskers, Carel G. M.] Vrije Univ Amsterdam, MOVE Res Inst Amsterdam, Dept Rehabil Med, Med Ctr, NL-1007 MB Amsterdam, Netherlands; [Kwakkel, Gert] Amsterdam Rehabil Res Ctr Reade Amsterdam, Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Kwakkel, G (corresponding author), Vrije Univ Amsterdam, MOVE Res Inst Amsterdam, Dept Rehabil Med, Med Ctr, NL-1007 MB Amsterdam, Netherlands.	g.kwakkel@vumc.nl		Meskers, Carel/0000-0002-5056-5611; Kwakkel, Gert/0000-0002-4041-4043				Baguley IJ, 2011, J REHABIL MED, V43, P1032, DOI 10.2340/16501977-0885; de Vlugt E, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-35; Demetrios M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009689.pub2; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Fleuren JFM, 2010, J NEUROL NEUROSUR PS, V81, P46, DOI 10.1136/jnnp.2009.177071; Foley N, 2013, ARCH PHYS MED REHAB, V94, P977, DOI 10.1016/j.apmr.2012.12.006; Gaverth J, 2014, J REHABIL MED, V46, P629, DOI 10.2340/16501977-1824; Gracies JM, 2015, LANCET NEUROL, V14, P992, DOI 10.1016/S1474-4422(15)00216-1; Grigoriu AI, 2015, ARCH PHYS MED REHAB, V96, P2067, DOI 10.1016/j.apmr.2015.05.002; Lieber RL, 2004, MUSCLE NERVE, V29, P615, DOI 10.1002/mus.20059; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Shaw L, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14260	12	13	13	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					969	+		10.1016/S1474-4422(15)00222-7	http://dx.doi.org/10.1016/S1474-4422(15)00222-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2VI	26318835				2022-12-18	WOS:000361188400003
J	Jimenez-Shahed, J				Jimenez-Shahed, Joohi			Design challenges for stimulation trials of Tourette's syndrome	LANCET NEUROLOGY			English	Editorial Material							DEEP BRAIN-STIMULATION		[Jimenez-Shahed, Joohi] Baylor Coll Med, Parkinsons Dis Ctr, Deep Brain Stimulat Program, Houston, TX 77030 USA; [Jimenez-Shahed, Joohi] Baylor Coll Med, Movement Disorders Clin, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Jimenez-Shahed, J (corresponding author), Baylor Coll Med, Parkinsons Dis Ctr, Deep Brain Stimulat Program, Houston, TX 77030 USA.	jshahed@bcm.edu	jimenez-shahed, joohi/ABD-3632-2020	jimenez-shahed, joohi/0000-0002-9772-7569				Ackermans L, 2011, BRAIN, V134, P832, DOI 10.1093/brain/awq380; DeLong M, 2010, CLIN EEG NEUROSCI, V41, P61, DOI 10.1177/155005941004100204; Kefalopoulou Z, 2015, LANCET NEUROL; Maciunas RJ, 2007, J NEUROSURG, V107, P1004, DOI 10.3171/JNS-07/11/1004; Maling N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044215; Schrock LE, 2015, MOVEMENT DISORD, V30, P448, DOI 10.1002/mds.26094; Viswanathan A, 2012, STEREOT FUNCT NEUROS, V90, P213, DOI 10.1159/000337776; Wichmann T, 2011, BASAL GANGLIA, V1, P65, DOI 10.1016/j.baga.2011.05.001	8	13	13	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2015	14	6					563	565		10.1016/S1474-4422(15)00043-5	http://dx.doi.org/10.1016/S1474-4422(15)00043-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CI5WG	25882028				2022-12-18	WOS:000354829900004
J	Coetzee, T; Zaratin, P; Gleason, TL				Coetzee, Timothy; Zaratin, Paola; Gleason, Trevis L.			Overcoming barriers in progressive multiple sclerosis research	LANCET NEUROLOGY			English	Editorial Material									[Coetzee, Timothy] Natl Multiple Sclerosis Soc, New York, NY 10017 USA; [Zaratin, Paola] Italian Multiple Sclerosis Fdn, Genoa, Italy		Coetzee, T (corresponding author), Natl Multiple Sclerosis Soc, New York, NY 10017 USA.	timothy.coetzee@nmss.org	Coetzee, Timothy/GQQ-3000-2022					Borreani C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109679; Feinstein A, 2015, LANCET NEUROL, V14, P194, DOI 10.1016/S1474-4422(14)70231-5; Fox RJ, 2012, MULT SCLER J, V18, P1534, DOI 10.1177/1352458512458169; Jackson K, MY SILVER LINING; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Ontaneda D, 2015, LANCET NEUROL, V14, P208, DOI 10.1016/S1474-4422(14)70264-9; Zeller D, 2014, NEUROSCIENCE, V283, P222, DOI 10.1016/j.neuroscience.2014.05.043	7	13	13	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2015	14	2					132	133		10.1016/S1474-4422(14)70323-0	http://dx.doi.org/10.1016/S1474-4422(14)70323-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY9KS	25772884				2022-12-18	WOS:000347869400006
J	Schneider, LS				Schneider, Lon S.			Idalopirdine for Alzheimer's disease: written in the stars	LANCET NEUROLOGY			English	Editorial Material							5-HT6 RECEPTOR ANTAGONISTS; OBJECT RECOGNITION; FRONTAL-CORTEX; SB-742457		Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Arnt J, 2010, INT J NEUROPSYCHOPH, V13, P1021, DOI 10.1017/S1461145710000659; Becker RE, 2008, J ALZHEIMERS DIS, V15, P303; Dawson LA, 2000, BRIT J PHARMACOL, V130, P23, DOI 10.1038/sj.bjp.0703288; Dawson LA, 2001, NEUROPSYCHOPHARMACOL, V25, P662, DOI 10.1016/S0893-133X(01)00265-2; de Bruin NMWJ, 2011, NEUROBIOL LEARN MEM, V96, P392, DOI 10.1016/j.nlm.2011.06.015; Jones RW, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt49; Maher-Edwards G, 2010, CURR ALZHEIMER RES, V7, P374, DOI 10.2174/156720510791383831; Maher-Edwards G, 2011, INT J GERIATR PSYCH, V26, P536, DOI 10.1002/gps.2562; Schaffhauser H, 2009, BIOCHEM PHARMACOL, V78, P1035, DOI 10.1016/j.bcp.2009.06.021; Schneider LS, 2011, ARCH NEUROL-CHICAGO, V68, P58, DOI 10.1001/archneurol.2010.343; Upton N, 2008, NEUROTHERAPEUTICS, V5, P458, DOI 10.1016/j.nurt.2008.05.008; Wilkinson D, 2014, LANCET NEUROL	12	13	13	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1063	1065		10.1016/S1474-4422(14)70232-7	http://dx.doi.org/10.1016/S1474-4422(14)70232-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25297011				2022-12-18	WOS:000343783900003
J	Biessels, GJ				Biessels, Geert Jan			Capitalising on modifiable risk factors for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA; PREVALENCE		Univ Med Ctr, Dept Neurol, Brain Ctr Rudolf Magnus, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Biessels, GJ (corresponding author), Univ Med Ctr, Dept Neurol, Brain Ctr Rudolf Magnus, POB 85500, NL-3508 GA Utrecht, Netherlands.	g.j.biessels@umcutrecht.nl						Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Nyberg J, 2014, BRAIN, V137, P1514, DOI 10.1093/brain/awu041; Plassman BL, 2010, ANN INTERN MED, V153, P182, DOI 10.7326/0003-4819-153-3-201008030-00258; Schrijvers EMC, 2012, NEUROLOGY, V78, P1456, DOI 10.1212/WNL.0b013e3182553be6	6	13	13	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2014	13	8					752	753		10.1016/S1474-4422(14)70154-1	http://dx.doi.org/10.1016/S1474-4422(14)70154-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AL9JB	25030506				2022-12-18	WOS:000339456300004
J	Brayne, C				Brayne, Carol			A population perspective on the IWG-2 research diagnostic criteria for Alzheimer's disease Comment	LANCET NEUROLOGY			English	Editorial Material							COGNITIVE IMPAIRMENT; DEMENTIA		Univ Cambridge, Sch Clin Med, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England	University of Cambridge	Brayne, C (corresponding author), Univ Cambridge, Sch Clin Med, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Forvie Site,Cambridge Biomed Campus, Cambridge CB2 0SR, England.	carol.brayne@medschl.cam.ac.uk	Brayne, Carol/AAA-4285-2020	Brayne, Carol/0000-0001-5307-663X	National Institute for Health Research [NF-SI-0611-10084] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		BRAYNE C, 1993, BRIT J PSYCHIAT, V162, P439, DOI 10.1192/bjp.162.4.439; Brayne C, 2007, NAT REV NEUROSCI, V8, P233, DOI 10.1038/nrn2091; Brayne C, 2012, LANCET, V380, P1441, DOI 10.1016/S0140-6736(12)61803-0; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Erkinjuntti T, 1997, NEW ENGL J MED, V337, P1667, DOI 10.1056/NEJM199712043372306; Hachinski V, 2006, STROKE, V37, P2220, DOI 10.1161/01.STR.0000237236.88823.47; Lock M., 2013, ALZHEIMER CONUNDRUM; Matthews FE, 2008, J AM GERIATR SOC, V56, P1424, DOI 10.1111/j.1532-5415.2008.01820.x; Morris JC, 2014, J INTERN MED, V275, P204, DOI 10.1111/joim.12199; Richards M, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4670	10	13	13	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					532	534		10.1016/S1474-4422(14)70098-5	http://dx.doi.org/10.1016/S1474-4422(14)70098-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK	24849852				2022-12-18	WOS:000337212700006
J	Paul, F				Paul, Friedemann			Hope for a rare disease: eculizumab in neuromyelitis optica	LANCET NEUROLOGY			English	Editorial Material							MULTIPLE-SCLEROSIS; SPECTRUM; LESIONS		[Paul, Friedemann] Charite, NeuroCure Clin Res Ctr, D-10117 Berlin, Germany; [Paul, Friedemann] Charite, Clin & Expt Multiple Sclerosis Res Ctr, Dept Neurol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Paul, F (corresponding author), Charite, NeuroCure Clin Res Ctr, D-10117 Berlin, Germany.	friedemann.paul@charite.de	Paul, Friedemann/ABF-9415-2020	paul, friedemann/0000-0002-6378-0070				Hinson SR, 2007, NEUROLOGY, V69, P2221, DOI 10.1212/01.WNL.0000289761.64862.ce; Jarius S, 2011, J NEUROL SCI, V306, P82, DOI 10.1016/j.jns.2011.03.038; Jarius S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-14; Jarius S, 2010, NAT REV NEUROL, V6, P383, DOI 10.1038/nrneurol.2010.72; Kim SH, 2012, MULT SCLER J, V18, P1480, DOI 10.1177/1352458512439439; Kim W, 2012, MULT SCLER INT, V2012, DOI 10.1155/2012/735486; Kimbrough DJ, 2012, MULT SCLER RELAT DIS, V1, P180, DOI 10.1016/j.msard.2012.06.002; Kleiter I, 2012, ARCH NEUROL-CHICAGO, V69, P239, DOI 10.1001/archneurol.2011.216; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Min JH, 2012, MULT SCLER J, V18, P113, DOI 10.1177/1352458511431973; Pittock SJ, 2013, LANCET NEUROL, V12, P554, DOI 10.1016/S1474-4422(13)70076-0; Popescu BFG, 2011, NEUROLOGY, V76, P1229, DOI 10.1212/WNL.0b013e318214332c; Qian PQ, 2012, ARCH NEUROL-CHICAGO, V69, P1482, DOI 10.1001/archneurol.2012.768; Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344; Saadoun S, 2010, BRAIN, V133, P349, DOI 10.1093/brain/awp309; Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8	17	13	13	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2013	12	6					529	531		10.1016/S1474-4422(13)70089-9	http://dx.doi.org/10.1016/S1474-4422(13)70089-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161SL	23623398				2022-12-18	WOS:000320213500004
J	Krack, P; Hariz, MI				Krack, Paul; Hariz, Marwan I.			Deep brain stimulation in Parkinson's disease: reconciliation of evidence-based medicine with clinical practice	LANCET NEUROLOGY			English	Editorial Material							SUBTHALAMIC NUCLEUS STIMULATION; PALLIDAL STIMULATION; RANDOMIZED-TRIAL; PD		[Krack, Paul] Univ Hosp Grenoble, Dept Psychiat & Neurol, F-38043 Grenoble, France; [Krack, Paul] INSERM, Grenoble Inst Neurosci, U836, Grenoble, France; [Hariz, Marwan I.] UCL Inst Neurol, London, England	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of London; University College London	Krack, P (corresponding author), Univ Hosp Grenoble, Dept Psychiat & Neurol, F-38043 Grenoble, France.	paul.krack@ujf-grenoble.fr		Krack, Paul/0000-0002-3508-7295				Anderson VC, 2005, ARCH NEUROL-CHICAGO, V62, P554, DOI 10.1001/archneur.62.4.554; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Esselink RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3; Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083; Houeto JL, 2000, NEUROLOGY, V55, P728, DOI 10.1212/WNL.55.5.728; Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Krack P, 1998, BRAIN, V121, P451, DOI 10.1093/brain/121.3.451; Krack P, 2010, NAT REV NEUROL, V6, P535, DOI 10.1038/nrneurol.2010.141; Odekerken VJ, 2012, LANCET NEUROL; Okun MS, 2005, ARCH NEUROL-CHICAGO, V62, P533, DOI 10.1001/archneur.62.4.533; Schwab J., 1968, 3 S PARK DIS, P152; Smeding HMM, 2006, NEUROLOGY, V66, P1830, DOI 10.1212/01.wnl.0000234881.77830.66; Volkmann J, 2004, ANN NEUROL, V55, P871, DOI 10.1002/ana.20091; Volkmann J, 2001, NEUROLOGY, V56, P548, DOI 10.1212/WNL.56.4.548; Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4	16	13	13	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					25	26		10.1016/S1474-4422(12)70270-3	http://dx.doi.org/10.1016/S1474-4422(12)70270-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23168020	Green Published			2022-12-18	WOS:000312429400014
J	Freedman, MS; Uccelli, A				Freedman, Mark S.; Uccelli, Antonio			Neurorepair with mesenchymal stem cells: hope or hype?	LANCET NEUROLOGY			English	Editorial Material							MULTIPLE-SCLEROSIS		[Freedman, Mark S.] Univ Ottawa, Neurol Program, Ottawa, ON, Canada; [Uccelli, Antonio] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16126 Genoa, Italy	University of Ottawa; University of Genoa	Freedman, MS (corresponding author), Univ Ottawa, Neurol Program, Ottawa, ON, Canada.	mfreedman@ottawahospital.on.ca	UCCELLI, Antonio/E-7343-2012	UCCELLI, Antonio/0000-0002-2008-6038				Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Chen JT, 2007, NEUROIMAGE, V36, P1152, DOI 10.1016/j.neuroimage.2007.03.073; Connick P, 2012, LANCET NEUROL, V11, P150, DOI 10.1016/S1474-4422(11)70305-2; Freedman MS, 2010, MULT SCLER J, V16, P503, DOI 10.1177/1352458509359727; Uccelli A, 2007, REGEN MED, V2, P7, DOI 10.2217/17460751.2.1.7; Uccelli A, 2011, LANCET NEUROL, V10, P649, DOI 10.1016/S1474-4422(11)70121-1	6	13	13	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2012	11	2					123	125		10.1016/S1474-4422(12)70001-7	http://dx.doi.org/10.1016/S1474-4422(12)70001-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	885EF	22236383				2022-12-18	WOS:000299760600004
J	Gilden, D				Gilden, Don			Treatment of Bell's palsy-the pendulum has swung back to steroids alone	LANCET NEUROLOGY			English	Editorial Material							PREDNISOLONE; ROCHESTER; ACYCLOVIR; PROGNOSIS		Univ Colorado, Denver Sch Med, Dept Neurol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gilden, D (corresponding author), Univ Colorado, Denver Sch Med, Dept Neurol, Denver, CO 80262 USA.	don.gilden@uchsc.edu						CAWTHORNE T, 1951, P ROY SOC MED, V44, P565, DOI 10.1177/003591575104400711; Engstrom M, 2008, LANCET NEUROL, V7, P993, DOI 10.1016/S1474-4422(08)70221-7; Gilden DH, 2004, NEW ENGL J MED, V351, P1323, DOI 10.1056/NEJMcp041120; Gilden DH, 2007, NEW ENGL J MED, V357, P1653, DOI 10.1056/NEJMe078188; Hato N, 2003, OTOL NEUROTOL, V24, P948, DOI 10.1097/00129492-200311000-00022; Hato N, 2008, LANCET, V372, P1220, DOI 10.1016/S0140-6736(08)61516-0; HAUSER WA, 1971, MAYO CLIN PROC, V46, P258; KATUSIC SK, 1986, ANN NEUROL, V20, P622, DOI 10.1002/ana.410200511; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694; Sullivan FM, 2007, NEW ENGL J MED, V357, P1598, DOI 10.1056/NEJMoa072006; Yetiser S, 2003, CLIN IMAG, V27, P77, DOI 10.1016/S0899-7071(02)00485-0	13	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					976	977		10.1016/S1474-4422(08)70222-9	http://dx.doi.org/10.1016/S1474-4422(08)70222-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP	18849194				2022-12-18	WOS:000260745800002
J	Whyte, J				Whyte, John			Clinical implications of the integrity of the pain matrix	LANCET NEUROLOGY			English	Editorial Material							MINIMALLY CONSCIOUS STATE		Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474				Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5	5	13	13	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					979	980		10.1016/S1474-4422(08)70220-5	http://dx.doi.org/10.1016/S1474-4422(08)70220-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP	18835750				2022-12-18	WOS:000260745800004
J	Dawson, TM				Dawson, Ted M.			Non-autonomous cell death in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									[Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Dept Neurol, Inst Cell Engn, Baltimore, MD 21205 USA; [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Dawson, TM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Inst Cell Engn, 733 N Broadway,BRB 731, Baltimore, MD 21205 USA.	tdawson@jhmi.edu			NINDS NIH HHS [P50 NS038377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; KORDOWER JH, 2008, NAT MED         0406; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; LI JY, 2008, NAT MED         0406, DOI DOI 10.1038/NM1746; Liberatore GT, 1999, NAT MED, V5, P1403; MENDEZ I, 2008, NAT MED         0406, DOI DOI 10.1038/NM1752; Tabar V, 2008, NAT MED, V14, P379, DOI 10.1038/nm1732	7	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2008	7	6					474	475		10.1016/S1474-4422(08)70099-1	http://dx.doi.org/10.1016/S1474-4422(08)70099-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	305WF	18485311	Green Accepted			2022-12-18	WOS:000256207800006
J	Carri, MT				Carri, Maria Teresa			Minocycline for patients with ALS	LANCET NEUROLOGY			English	Editorial Material							TRIALS		[Carri, Maria Teresa] Univ Roma Tor Vergata, Santa Lucia Fdn, IRCCS, Dept Biol, I-00173 Rome, Italy	IRCCS Santa Lucia; University of Rome Tor Vergata	Carri, MT (corresponding author), Univ Roma Tor Vergata, Santa Lucia Fdn, IRCCS, Dept Biol, I-00173 Rome, Italy.	carri@Bio.uniroma2.it	Carri, Maria Teresa/K-5480-2016	Carri, Maria Teresa/0000-0002-1789-1546	Telethon [GGP07018] Funding Source: Medline	Telethon(Fondazione Telethon)		Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Kriz J, 2003, ANN NEUROL, V53, P429, DOI 10.1002/ana.10500; Swash M, 2007, LANCET NEUROL, V6, P1034, DOI 10.1016/S1474-4422(07)70271-5	5	13	13	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2008	7	2					118	119		10.1016/S1474-4422(08)70005-X	http://dx.doi.org/10.1016/S1474-4422(08)70005-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261PY	18207105				2022-12-18	WOS:000253093700005
J	Swash, M				Swash, Michael			Learning from failed trials an ALS	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; CLINICAL-TRIALS		Royal London Hosp, Dept Neurol, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital	Swash, M (corresponding author), Royal London Hosp, Dept Neurol, London E1 1BB, England.	mswash@btinternet.com		Swash, Michael/0000-0002-8717-8914				Aggarwal A, 2002, J NEUROL NEUROSUR PS, V73, P199, DOI 10.1136/jnnp.73.2.199; De Carvalho M, 2005, AMYOTROPH LATERAL SC, V6, P202, DOI 10.1080/14660820510011997; de Carvalho M, 2005, AMYOTROPH LATERAL SC, V6, P17, DOI 10.1080/14660820410020600; DiBernardo AB, 2006, BBA-MOL BASIS DIS, V1762, P1139, DOI 10.1016/j.bbadis.2006.03.007; GORDON PH, 2007, LANCET NEUROL; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Miller R, 2007, NEUROLOGY, V69, P776, DOI 10.1212/01.wnl.0000269676.07319.09; RANGANATHAN S, 2007, AMYOTROPH LATERAL SC; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155	9	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2007	6	12					1034	1035		10.1016/S1474-4422(07)70271-5	http://dx.doi.org/10.1016/S1474-4422(07)70271-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239UI	17980666				2022-12-18	WOS:000251543100002
J	Forsting, M				Forsting, Michael			Shortcomings and promises of recent carotid-stenting trials	LANCET NEUROLOGY			English	Editorial Material							ENDARTERECTOMY		Univ Duisburg Essen, Univ Hosp Essen, Essen, Germany	University of Duisburg Essen	Forsting, M (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Essen, Germany.	michael.forsting@uni-due.de	Forsting, Michael/C-6925-2013					Baldwin PJ, 1999, BRIT J SURG, V86, P1078, DOI 10.1046/j.1365-2168.1999.01169.x; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Slattery J, 1996, LANCET, V347, P1591; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	6	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					101	102		10.1016/S1474-4422(07)70010-8	http://dx.doi.org/10.1016/S1474-4422(07)70010-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG	17239792				2022-12-18	WOS:000243795300005
J	Postuma, RB; Montplaisir, J				Postuma, RB; Montplaisir, J			Potential early markers of Parkinson's disease in idiopathic rapid-eye-movement sleep behaviour disorder	LANCET NEUROLOGY			English	Editorial Material									McGill Univ, Montreal Gen Hosp, Dept Neurol, Montreal, PQ H3G 1A4, Canada; Hop Sacre Coeur, Ctr Etud Sommeil, Montreal, PQ H4J 1C5, Canada	McGill University; Universite de Montreal	Postuma, RB (corresponding author), McGill Univ, Montreal Gen Hosp, Dept Neurol, Montreal, PQ H3G 1A4, Canada.	ron.postuma@muhc.mcgill.ca	Postuma, Ronald/ABE-7465-2020					Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Gagnon JF, 2006, LANCET NEUROL, V5, P424, DOI 10.1016/S1474-4422(06)70441-0; Iranzo A, 2006, LANCET NEUROL, V5, P572, DOI 10.1016/S1474-4422(06)70476-8; Olson EJ, 2000, BRAIN, V123, P331, DOI 10.1093/brain/123.2.331; Postuma RB, 2006, NEUROLOGY, V66, P845, DOI 10.1212/01.wnl.0000203648.80727.5b; Schenck CH, 1996, NEUROLOGY, V46, P388, DOI 10.1212/WNL.46.2.388; Schenck CH, 2002, SLEEP, V25, P120, DOI 10.1093/sleep/25.2.120; Stiasny-Kolster K, 2005, BRAIN, V128, P126, DOI 10.1093/brain/awh322	8	13	13	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2006	5	7					552	553		10.1016/S1474-4422(06)70478-1	http://dx.doi.org/10.1016/S1474-4422(06)70478-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	058PE	16781982				2022-12-18	WOS:000238676100002
J	Cipolotti, L; Moscovitch, M				Cipolotti, L; Moscovitch, M			The hippocampus and remote autobiographical memory	LANCET NEUROLOGY			English	Letter							RETROGRADE-AMNESIA; NEUROANATOMY		UCL Natl Hosp Neurol & Neurosurg, Dept Neuropsychol, London, England; Univ Palermo, Dipartimento Psicol, Palermo, Italy; Univ Toronto, Dept Psychol, Toronto, ON, Canada	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Palermo; University of Toronto	Cipolotti, L (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neuropsychol, Queen Sq, London, England.	l.cipolotti@ion.ucl.ac.uk		cipolotti, lisa/0000-0001-5838-3647				Bayley PJ, 2005, NEURON, V46, P799, DOI 10.1016/j.neuron.2005.04.034; Chan D, 2002, NEUROSCI LETT, V329, P61, DOI 10.1016/j.neulet.2002.05.001; Cipolotti L, 2001, NEUROPSYCHOLOGIA, V39, P151, DOI 10.1016/S0028-3932(00)00103-2; CIPOLOTTI L, 2005, NEUROPSYCHOLOGI 0713, DOI DOI 10.1016/J.NEUROPSYCHOLOGIA.2005.05.014; Moscovitch M, 2005, J ANAT, V207, P35, DOI 10.1111/j.1469-7580.2005.00421.x; Thomas L, 2005, LANCET NEUROL, V4, P460, DOI 10.1016/S1474-4422(05)70132-0	6	13	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2005	4	12					792	793		10.1016/S1474-4422(05)70232-5	http://dx.doi.org/10.1016/S1474-4422(05)70232-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989SG	16297835				2022-12-18	WOS:000233693500005
J	Mitha, AP				Mitha, AP			ISAT: coiling or clipping for ruptured intracranial aneurysms?	LANCET NEUROLOGY			English	Letter							ENDOVASCULAR COILING; SUBARACHNOID HEMORRHAGE; TRIAL ISAT; OCCLUSION; OUTCOMES		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Mitha, AP (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	cogilvy@partners.org						Britz GW, 2005, LANCET, V366, P783, DOI 10.1016/S0140-6736(05)67190-5; Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656; Harbaugh RE, 2003, SURG NEUROL, V59, P165; Henkes H, 2004, NEUROSURGERY, V54, P268, DOI 10.1227/01.NEU.0000103221.16671.F0; Hoh BL, 2004, NEUROSURGERY, V55, P779, DOI 10.1227/01.NEU.0000137628.51839.D5; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Ogilvy CS, 2003, STROKE, V34, P2540, DOI 10.1161/01.STR.0000092894.71909.FF; Qureshi AI, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163081.55025.CD; Raymond J, 1997, NEUROSURGERY, V41, P1235, DOI 10.1097/00006123-199712000-00002	12	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2005	4	12					791	792		10.1016/S1474-4422(05)70231-3	http://dx.doi.org/10.1016/S1474-4422(05)70231-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989SG	16297834				2022-12-18	WOS:000233693500004
J	Lindley, RI; Wardlaw, JM; Sandercock, PAG				Lindley, RI; Wardlaw, JM; Sandercock, PAG			Alteplase and ischaemic stroke: have new reviews of old data helped?	LANCET NEUROLOGY			English	Review							TISSUE-PLASMINOGEN ACTIVATOR; THROMBOLYTIC THERAPY; CONTROLLED-TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; MORTALITY; ASSOCIATION; GUIDELINES; MANAGEMENT; STATEMENT	Background Thrombolysis for stroke is still not widely used as current recommendations restrict treatment to selected patients. In general, these are patients who can be assessed quickly by specialised stroke teams, have intracranial haemorrhage excluded by appropriate brain imaging, and are treated with alteplase (recombinant tissue plasminogen activator; rt-PA) within 3 h of symptom onset. There is, however, still much debate regarding the scope of treatment and the reorganisation of services required to support an effective service. Recent developments Two recent publications have helped clarify some issues. The first was an individual-patient data meta-analysis of the alteplase trials. These analyses suggest treatment effects beyond the usual 3 h time window, but other than time to treatment no other factors influenced the effects of treatment. The second publication was a reanalysis of the original National Institute of Neurological Disorders and Stroke (NINDS) alteplase trial, done after criticism of the original study. The reanalysis confirmed that there was significant baseline imbalance of stroke severity between treatment and control groups in the NINDS trial, but established that this did not materially affect the positive results of the trial. However, the recording of blood pressure in the study was found to be inconsistent and therefore unsuitable for reanalysis. The previously published data on recommendations for blood-pressure control, arising from the NINDS trial, needs to be reconsidered in this light. Both studies included too few patients to provide reliable data on which clinical and radiological features influence the response to alteplase. Where next? The individual-patient data meta-analysis and reanalysis of the NINDS trial have probably exhausted the potential of previous trials to answer questions on the effects of thrombolysis. Further randomised trials comparing thrombolysis with control will be required to determine whether elderly people benefit from treatment or whether there are worthwhile benefits from alteplase beyond 3 h (and in such patients, whether advanced magnetic resonance imaging is an effective way to select those most likely to benefit). Various new approaches to reperfusion. also require assessment in large-scale trials: new thrombolytic drugs, the combination of intravenous and intraarterial thrombolytic drugs, combinations of thrombolytics with new antiplatelet agents, and augmentation of thrombolysis either with mechanical devices or with transcranial ultrasound.	Univ Sydney, Westmead Hosp, Moran Fdn Older Australians, Sydney, NSW 2006, Australia; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland	University of Sydney; University of Edinburgh	Lindley, RI (corresponding author), Univ Sydney, Westmead Hosp, Moran Fdn Older Australians, C24, Sydney, NSW 2006, Australia.	richardl@westgate.wh.usyd.edu.au	Hernandez, María/GYU-3543-2022; Lindley, Richard/B-8148-2013; Wardlaw, Joanna M/Y-3456-2019	Lindley, Richard/0000-0002-0104-5679; Wardlaw, Joanna M/0000-0002-9812-6642				Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Chopp M, 1996, STROKE, V27, P711; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Grotta JC, 2003, CIRCULATION, V107, P2769, DOI 10.1161/01.CIR.0000069565.43766.ED; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2004, LANCET, V363, P768; Heuschmann PU, 2003, STROKE, V34, P1106, DOI 10.1161/01.STR.0000065198.80347.C5; Hoffman JR, 2003, MED J AUSTRALIA, V179, P333, DOI 10.5694/j.1326-5377.2003.tb05584.x; Hoffman JR, 2000, WESTERN J MED, V173, P149, DOI 10.1136/ewjm.173.3.149; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Katzan IL, 2001, STROKE, V32, P861, DOI 10.1161/01.STR.32.4.861; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; MANN J, 2002, W J MED, V17, P192; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Norris JW, 1998, CAN J NEUROL SCI, V25, P257, DOI 10.1017/S0317167100034120; Parsons MW, 2002, ANN NEUROL, V51, P28, DOI 10.1002/ana.10067; Pendlebury ST, 2004, STROKE, V35, P2368, DOI 10.1161/01.STR.0000140632.83868.a2; Reed SD, 2001, STROKE, V32, P1832, DOI 10.1161/01.STR.32.8.1832; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213	25	13	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2005	4	4					249	253		10.1016/S1474-4422(05)70044-2	http://dx.doi.org/10.1016/S1474-4422(05)70044-2			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910ID	15778104				2022-12-18	WOS:000227923600016
J	Burton, A				Burton, A			Olig1 needed for remyelination	LANCET NEUROLOGY			English	News Item													Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763					0	13	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					80	80		10.1016/S1474-4422(05)00978-6	http://dx.doi.org/10.1016/S1474-4422(05)00978-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15709220				2022-12-18	WOS:000226712300009
J	Reynolds, EH				Reynolds, EH			Todd, Faraday, and the electrical basis of brain activity	LANCET NEUROLOGY			English	Review								Robert Bentley Todd (1809-60) was the UK's first eminent neurologist and neuroscientist. An anatomist, physiologist, and clinical scientist with an interest in the nervous system, he was the first to confirm the electrical basis of brain activity in the 1840s. He was influenced by his contemporary, Michael Faraday at the Royal Institution, and by two colleagues at King's College, John Daniell and Charles Wheatstone, who were also working at the cutting edge of electrical science. Todd conceived of nervous polarity (force) generated in nervous centres and compared this with the polar force of voltaic electricity developed in the galvanic battery. He brilliantly foresaw each nerve vesicle (cell) and its related fibres (ie, neuron) as a distinct apparatus for the development and transmission of nervous polarity. Epilepsy was the result of periodic unnatural development of nervous force leading to the "disruptive discharge" described by Faraday. Faraday, who studied animal electricity in the Gymnotus (electric eel), and Todd saw nervous polarity as a higher form of interchangeable energy.	Kings Coll London, Inst Epileptol, Weston Educ Ctr, London SE5 9PJ, England	University of London; King's College London	Reynolds, EH (corresponding author), Kings Coll London, Inst Epileptol, Weston Educ Ctr, Denmark Hill Campus Cutcombe Rd, London SE5 9PJ, England.	reynolds@buckles.u-net.com						Brazier M. A. B., 1988, HIST NEUROPHYSIOLOGY; Caton R., 1877, BMJ-BRIT MED J, V1, P62; Clarke Edwin, 1987, 19 CENTURY ORIGINS N; du Bois-Reymond EH, 1848, UNTERSUCHUNGEN THIER, DOI [10.3931/e-rara-62271, DOI 10.3931/E-RARA-62271]; Faraday M, 1839, PHILOS T R SOC, V129, P1; FARADAY M, 1933, FARADAYS DIARY, V3, P352; Faraday M. IV., 1833, BOL SOC MAT MEX, V123, P23; Ferrier D, 1873, Br Med J, V1, P457; Fritsch G, 1870, ARCH ANAT PHYSL WISS, V37, P300, DOI 10.1007/bf01759916; Galvani L., 1791, BONOIENSI SCI ARTIUM, V7, P363; Gowers WR, 1892, MANUAL DIS NERVOUS S, VI; HELMSTADTER C, 1993, B HIST MED, V67, P282; Jackson J. H., 1890, LANCET, V1, P685; JACKSON JH, 1890, LANCET, V1, P735; JACKSON JH, 1890, LANCET, V1, P785; Lyons JB, 1982, HIST ASPECTS NEUROSC, P137; MATTEUCCI C, 1846, PHIL T R SOC, V136, P483; PROCHASKA J, 1784, FUNCIONIBUS NERVOSI; Reynolds EH, 2001, LANCET, V358, P575, DOI 10.1016/S0140-6736(01)05710-5; REYNOLDS EH, 2003, GUYS KINGS ST THOMAS, V116, P826; Schwann T., 1839, MIKROSKOPISCHE UNTER; Temkin O., 1971, THE FALLING SICKNESS; Thompson Silvanus P., 1898, M FARADAY HIS LIFE W; Todd RB, 1854, CLIN LECT PARALYSIS; Todd RB, 1849, LONDON MED GAZ, V8; TODD RB, 1845, PHYSL DESCRIPTIVE AN; Todd RB, 1849, LONDON MED GAZ, V8, P815; Todd RB, 1849, LONDON MED GAZ, V8, P724; TODD RB, 1856, PHYSL ANATOMY PHYSL; TODD RB, 1847, CYCLOPAEDIA ANATOMY, V3, P585; Todd RB, 1849, LONDON MED GAZ, V8, p[661, 724, 766, 815, 837]; TODD RB, 1996, CORERSPONDENCE M FAR, V3, P348; Volta A., 1793, PHILOS T R SOC LOND, V83, P10	33	13	13	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2004	3	9					557	563		10.1016/S1474-4422(04)00842-7	http://dx.doi.org/10.1016/S1474-4422(04)00842-7			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	849VD	15324724				2022-12-18	WOS:000223568300020
J	Hawkes, C				Hawkes, C			Olfactory testing in parkinsonism	LANCET NEUROLOGY			English	Editorial Material							DISEASE; DYSFUNCTION; RELATIVES		Oldchurch Hosp, Essex Neurosci Ctr, Romford RM7 0BE, Essex, England		Hawkes, C (corresponding author), Oldchurch Hosp, Essex Neurosci Ctr, Romford RM7 0BE, Essex, England.	chrishawkes@msn.com						ANSARI KA, 1975, J CHRON DIS, V28, P493, DOI 10.1016/0021-9681(75)90058-2; Berendse HW, 2001, ANN NEUROL, V50, P34, DOI 10.1002/ana.1049; Braak H., 2002, J NEUROL S3, V249, P1, DOI [1007/s00415-002-1301-4, 10.1007/s00415-002-1301-4, DOI 10.1007/S00415-002-1301-4]; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; Hawkes C, 2003, MOVEMENT DISORD, V18, P364, DOI 10.1002/mds.10379; Katzenschlager R., 2002, EUR J NEUROL S2, V9, p[SC, 27]; Khan NL, 2004, NEUROLOGY, V62, P1224, DOI 10.1212/01.WNL.0000118281.66802.81; Markopoulou K, 1997, NEUROLOGY, V49, P1262, DOI 10.1212/WNL.49.5.1262; Montgomery EB, 1999, NEUROLOGY, V52, P757, DOI 10.1212/WNL.52.4.757; SCHERFLER C, 2004, BRAIN	10	13	14	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2004	3	7					393	394		10.1016/S1474-4422(04)00801-4	http://dx.doi.org/10.1016/S1474-4422(04)00801-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832ZQ	15207792				2022-12-18	WOS:000222306600011
J	Olanow, CW				Olanow, CW			Dietary vitamin E and Parkinson's disease: something to chew on	LANCET NEUROLOGY			English	Letter									CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Olanow, CW (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurol, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	warren.olanow@MSSM.edu						Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1990, NEUROLOGY, V40, P32; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Zhang SM, 2002, NEUROLOGY, V59, P1161, DOI 10.1212/01.WNL.0000028688.75881.12	5	13	13	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2003	2	2					74	74		10.1016/S1474-4422(03)00300-4	http://dx.doi.org/10.1016/S1474-4422(03)00300-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	638BY	12849259				2022-12-18	WOS:000180550600011
J	Piccini, P				Piccini, P			Dyskinesias after transplantation in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							PATIENT		Univ London Imperial Coll Sci Technol & Med, PET Neurol Grp, MRC, Ctr Clin Sci, London W12 ONN, England; Univ London Imperial Coll Sci Technol & Med, Div Neurosci, London W12 ONN, England	Imperial College London; Imperial College London	Piccini, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, PET Neurol Grp, MRC, Ctr Clin Sci, Du Cane Rd, London W12 ONN, England.	paola.piccini@csc.mrc.ac.uk		Piccini, Paola/0000-0003-4162-6141	MRC [MC_U120036861] Funding Source: UKRI; Medical Research Council [MC_U120036861] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Dunnett SB, 2001, NAT REV NEUROSCI, V2, P365, DOI 10.1038/35072572; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Lindvall O, 2001, LANCET, pS47; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Piccini P, 2000, ANN NEUROL, V48, P689, DOI 10.1002/1531-8249(200011)48:5<689::AID-ANA1>3.0.CO;2-N; YLONG M, 2002, ANN NEUROL, V52, P628	8	13	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2002	1	8					472	472		10.1016/S1474-4422(02)00235-1	http://dx.doi.org/10.1016/S1474-4422(02)00235-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618PP	12849327				2022-12-18	WOS:000179426700018
J	Nadeau, SE				Nadeau, SE			A paradigm shift in neurorehabilitation	LANCET NEUROLOGY			English	Editorial Material							PRIMARY SOMATOSENSORY CORTEX; REPETITIVE STRAIN INJURY; INDUCED MOVEMENT THERAPY; FOCAL HAND DYSTONIA; FUNCTIONAL REORGANIZATION; CORTICAL REORGANIZATION; ADULT MONKEYS; PLASTICITY; STROKE; REPRESENTATIONS	The practice of neurorehabilitation in the clinic has undergone a paradigm shift as a result of influences from basic and clinical research. I have identified six areas of knowledge that by advancing so rapidly have brought about this paradigm shift: first, the increased understanding of how the CNS is reorganised after training or injury; second, the knowledge of how declarative and procedural memory operates and how this can influence rehabilitation therapy; third, a greater appreciation of the chemical factors that promote learning and neural remodelling; fourth, the fact that computational neuroscience can teach us how complex behaviour can emerge from the interaction of thousands of neurons; fifth, the influence of evidence-based medicine on neurorehabilitation; and sixth, the importance of reliable outcome measures for both injury and treatment. These are young scientific disciplines that offer great opportunities for further research. The complexity of neurorehabilitation will also require greater attention to a substantially neglected problem, the incorporation of techniques that have been proven effective in clinical trials into routine and effective clinical practice.	GRECC 182, Malcom Randall DVA Med Ctr, Gainesville, FL 32608 USA; Malcom Randall Dept Vet AffairsMed Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA; Malcom Randall Dept Vet AffairsMed Ctr, Rehabil Outcomes Res Ctr, Gainesville, FL USA; Univ Florida, Coll Med, Dept Neurol, Gainesville, FL USA	Geriatric Research Education & Clinical Center; State University System of Florida; University of Florida	Nadeau, SE (corresponding author), GRECC 182, Malcom Randall DVA Med Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA.	snadeau@ufl.edu						Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Buck D, 2000, STROKE, V31, P2004, DOI 10.1161/01.STR.31.8.2004; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Byl NN, 1997, PHYS THER, V77, P269, DOI 10.1093/ptj/77.3.269; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; Conway TW, 1998, J INT NEUROPSYCH SOC, V4, P608, DOI 10.1017/S1355617798466104; Duncan MM, 1999, WOMEN HEALTH, V30, P1; Edgerton VR, 2001, J PHYSIOL-LONDON, V533, P15, DOI 10.1111/j.1469-7793.2001.0015b.x; Elbert T, 1998, NEUROREPORT, V9, P3571, DOI 10.1097/00001756-199811160-00006; ELBERT T, 2001, IMPENDING PARADIGM S; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; Finger S., 1994, ORIGINS NEUROSCIENCE; Florence SL, 1995, J NEUROSCI, V15, P8083; GATES MA, 2000, PROG BRAIN RES, V127, P125; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KEW JJM, 1994, J NEUROPHYSIOL, V72, P2517, DOI 10.1152/jn.1994.72.5.2517; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; McClelland JL, 1986, PDP RES GROUP PARALL; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Nadeau SE, 2001, BRAIN LANG, V79, P511, DOI 10.1006/brln.2001.2566; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; O'Reilly RC, 1998, TRENDS COGN SCI, V2, P455, DOI 10.1016/S1364-6613(98)01241-8; Plaut DC, 1996, PSYCHOL REV, V103, P56, DOI 10.1037/0033-295X.103.1.56; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Sampaio E, 2001, BRAIN RES, V908, P204, DOI 10.1016/S0006-8993(01)02667-1; Scheffler B, 1999, TRENDS NEUROSCI, V22, P348, DOI 10.1016/S0166-2236(99)01416-2; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; Taub E, 1999, J REHABIL RES DEV, V36, P237; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; WEILLER C, 1993, ANN NEUROL, V33, P181; Wernig A, 1999, J NEUROTRAUM, V16, P719, DOI 10.1089/neu.1999.16.719; Xerri C, 1999, CEREB CORTEX, V9, P264, DOI 10.1093/cercor/9.3.264	40	13	14	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2002	1	2					126	130		10.1016/S1474-4422(02)00044-3	http://dx.doi.org/10.1016/S1474-4422(02)00044-3			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	588HA	12849517				2022-12-18	WOS:000177695000021
J	Al-Hassany, L; Goadsby, PJ; Danser, AHJ; MaassenVanDenBrink, A				Al-Hassany, Linda; Goadsby, Peter J.; Danser, A. H. Jan; MaassenVanDenBrink, Antoinette			Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions	LANCET NEUROLOGY			English	Article							DOUBLE-BLIND; RECEPTOR ANTAGONISTS; SEX-DIFFERENCES; CGRP RECEPTOR; PLACEBO; UBROGEPANT; HEADACHE; ERENUMAB; SAFETY; PHARMACOKINETICS	Migraine is the second most disabling disorder across all age groups worldwide. Since 2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP), which is implicated in migraine pathophysiology, have become available: gepants (CGRP receptor antagonists) and monoclonal antibodies directed against CGRP or its receptor. Despite phase 3 clinical trials and some real world evidence, knowledge of the pharmacology and related clinical effects of these drugs is low, and trial data are not necessarily generalisable to all populations. Additionally, several pharmacodynamic processes affected by both gepants and monoclonal antibodies to CGRP and its receptor are not fully understood. Sex, body-mass index, age, ethnic background, and other characteristics, which are subject to considerable variation, might affect the pharmacokinetics of these therapies, especially gepants. If studies confirm this possibility, these characteristics could assist clinicians in choosing the optimal treatment for patients with migraine. The choice between a gepant or monoclonal antibody should be made carefully, taking into consideration a patient's comorbidities and preferences. As more becomes known about CGRP-targeted therapies, management based on the characteristics of patients could have a more prominent role in the treatment of migraine.	[Al-Hassany, Linda; Danser, A. H. Jan; MaassenVanDenBrink, Antoinette] Univ Med Ctr Rotterdam, Dept Internal Med, Div Vasc Med & Pharmacol, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Goadsby, Peter J.] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, SLaM Biomed Res Ctr, London, England; [Goadsby, Peter J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA	Erasmus University Rotterdam; Erasmus MC; University of London; King's College London; University of California System; University of California Los Angeles	MaassenVanDenBrink, A (corresponding author), Univ Med Ctr Rotterdam, Dept Internal Med, Div Vasc Med & Pharmacol, Erasmus MC, NL-3000 CA Rotterdam, Netherlands.	a.vanharen-maassenvandenbrink@erasmusmc.nl	Danser, Jan/GLR-1479-2022	Goadsby, Peter/0000-0003-3260-5904				Adeney KL, 2006, HEADACHE, V46, P794, DOI 10.1111/j.1526-4610.2006.00432.x; Ailani J, 2020, HEADACHE, V60, P141, DOI 10.1111/head.13682; Allergan USA. Inc, 2019, UBR UBR US PRESCR IN; Amgen Inc, 2018, ER AIM US PRESCR INF; Ankrom W, 2020, J CLIN PHARMACOL, V60, P1157, DOI 10.1002/jcph.1610; Ashina M, 2021, EUR J NEUROL, V28, P1716, DOI 10.1111/ene.14715; Baker B, 2015, 17 C INT HEAD SOC VA; Barbanti P, 2021, HEADACHE, V61, P363, DOI 10.1111/head.14032; Benet LZ, 2016, ADV DRUG DELIVER REV, V101, P89, DOI 10.1016/j.addr.2016.05.007; Benet LZ, 2013, J PHARM SCI-US, V102, P34, DOI 10.1002/jps.23359; Bhakta M, 2021, CEPHALALGIA, V41, P499, DOI 10.1177/0333102420983282; Biohaven Pharmaceuticals, 2021, ZAV; Biohaven Pharmaceuticals Inc, 2020, RIM NURT ODT US PRES; Blumenfeld AM, 2021, HEADACHE, V61, P422, DOI 10.1111/head.14089; Blumenfeld AM, 2020, HEADACHE, V60, P2431, DOI 10.1111/head.13994; Boinpally R, 2020, HEADACHE, V60, P45; Boinpally R, 2021, CLIN PHARM DRUG DEV, V10, P726, DOI 10.1002/cpdd.916; Bussiere JL, 2019, REGUL TOXICOL PHARM, V106, P224, DOI 10.1016/j.yrtph.2019.05.013; Center For Drug Evaluation And Research. Office of Clinical Pharmacology Review, 2019, CLIN PHARM REV S; Charles A, 2019, LANCET, V394, P1765, DOI 10.1016/S0140-6736(19)32504-8; Cheng LS, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070672; Cohen JM, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-020-01211-5; Conway CM, 2019, 61 ANN SCI M AM HEAD; Corcoran C, 2019, SCI PROGRESS-UK, V102, P171, DOI 10.1177/0036850419854290; Cotreau MM, 2005, CLIN PHARMACOKINET, V44, P33, DOI 10.2165/00003088-200544010-00002; Croop R, 2021, LANCET, V397, P51, DOI 10.1016/S0140-6736(20)32544-7; D'Andrea G, 2009, NEUROL SCI, V30, pS55, DOI 10.1007/s10072-009-0070-6; de Hoon J, 2018, CLIN PHARMACOL THER, V103, P815, DOI 10.1002/cpt.799; Deen M, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0807-1; di Cola FS, 2020, NEUROL SCI, V41, P489, DOI 10.1007/s10072-020-04670-5; Diener HC, 2021, HEADACHE, V61, P125, DOI 10.1111/head.14036; Dodick D, 2004, HEADACHE, V44, P414, DOI 10.1111/j.1526-4610.2004.04078.x; Dodick DW, 2021, CEPHALALGIA, V41, P340, DOI 10.1177/0333102420966658; Dodick DW, 2019, NEW ENGL J MED, V381, P2230, DOI 10.1056/NEJMoa1813049; Dorne JLCM, 2003, FOOD CHEM TOXICOL, V41, P201, DOI 10.1016/S0278-6915(02)00209-0; DrugBank, 2021, VAZ; DrugBank, 2021, AT; DrugBank, 2021, UBR; Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582-018-0003-1; Eli Lilly and Company, 2019, LASM REYVOWT US PRES; Eli Lilly and Company, 2018, GALC EMGALITYTM US P; Fan JH, 2014, BIOCHEM PHARMACOL, V87, P93, DOI 10.1016/j.bcp.2013.09.007; Favoni V, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-0979-y; Fiedler-Kelly J, 2020, HEADACHE, V60, P1376, DOI 10.1111/head.13845; Fiedler-Kelly JB, 2019, BRIT J CLIN PHARMACO, V85, P2721, DOI 10.1111/bcp.14096; Frattale I, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-020-01213-3; Ghanizada H, 2021, ANN NEUROL, V89, P1157, DOI 10.1002/ana.26072; Gingell JJ, 2020, ACS PHARMACOL TRANSL, V3, P296, DOI 10.1021/acsptsci.9b00089; Goadsby PJ, 2019, NEUROLOGY, V92; Goadsby PJ, 2019, CEPHALALGIA, V39, P817, DOI 10.1177/0333102419835459; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; Guttman Y, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00224; Hanley MJ, 2010, CLIN PHARMACOKINET, V49, P71, DOI 10.2165/11318100-000000000-00000; Hargreaves R, 2019, HEADACHE, V59, P951, DOI 10.1111/head.13510; Holle-Lee D, 2020, EUR J NEUROL, V27, P162; Huang HY, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.235125; Hutchinson S, 2021, CEPHALALGIA, V41, P979, DOI 10.1177/03331024211000311; Ieiri I, 2012, DRUG METAB PHARMACOK, V27, P85, DOI 10.2133/dmpk.DMPK-11-RV-098; Ivans A, 2020, NEUROLOGY, V94; Jakate A, 2019, HEADACHE, V59, P86; Jakate A., 2020, CEPHALALGIA REP, V3, P1, DOI [10.1177/2515816320921186, DOI 10.1177/2515816320921186]; Jakate A, 2021, HEADACHE, V61, P642, DOI 10.1111/head.14095; Jakate A, 2020, CLIN PHARMACOL THER, V107, P1014, DOI 10.1002/cpt.1696; Jensen C, 2021, NEUROLOGY, V96; Juhasz G, 2005, CEPHALALGIA, V25, P179, DOI 10.1111/j.1468-2982.2005.00836.x; Kee Z, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01249; Kielbasa W, 2020, J CLIN PHARMACOL, V60, P229, DOI 10.1002/jcph.1511; Labastida-Ramirez A, 2019, CEPHALALGIA, V39, P435, DOI 10.1177/0333102417739584; Ledford H, 2020, NATURE, V586, P488, DOI 10.1038/d41586-020-02946-6; Lentsch SD, 2021, MATURITAS, V145, P73, DOI 10.1016/j.maturitas.2020.12.012; Li CC, 2019, NEUROLOGY, V92; Lionetto L, 2016, EXPERT OPIN DRUG MET, V12, P399, DOI 10.1517/17425255.2016.1154042; Lipton RB, 2019, JAMA-J AM MED ASSOC, V322, P1887, DOI 10.1001/jama.2019.16711; Lundbeck Seattle BioPharmaceuticals, 2020, EPT VYEPTITM US PRES; MaassenVanDenBrink A, 2016, TRENDS PHARMACOL SCI, V37, P779, DOI 10.1016/j.tips.2016.06.002; Manoukian R, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-0992-1; Mansoor A, 2019, VOLUME DISTRIBUTION; Marcus R, 2014, CEPHALALGIA, V34, P114, DOI 10.1177/0333102413500727; MedChemExpress, 2021, VAZ HYDR; Moore E, 2020, J PHARMACOL EXP THER; Moreno-Ajona D, 2020, CURR OPIN NEUROL, V33, P309, DOI 10.1097/WCO.0000000000000806; Mullin K, 2020, NEUROLOGY, V94, pE2121, DOI 10.1212/WNL.0000000000008944; Noseda R, 2021, CEPHALALGIA, V41, P789, DOI 10.1177/0333102420983292; Ogu C C, 2000, Proc (Bayl Univ Med Cent), V13, P421; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; Pan KS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01240; Pensato U, 2020, NEUROL SCI, V41, P457, DOI 10.1007/s10072-020-04658-1; Pham A, 2020, HEADACHE, V60, P4; Reuter U, 2020, EUR J NEUROL, V27, P1298; Robbins L, 2020, HEADACHE, V60, P8; Robblee J, 2020, HEADACHE, V60, P2014, DOI 10.1111/head.13951; Roberto G, 2015, CEPHALALGIA, V35, P118, DOI 10.1177/0333102414550416; Rubio-Beltran E, 2020, CEPHALALGIA, V40, P357, DOI 10.1177/0333102419884943; Sakai F., 2020, CEPHALALGIA REP, V3, P1, DOI [10.1177/2515816320932573, DOI 10.1177/2515816320932573]; Schim J, 2020, NEUROLOGY, V94; Schjerning AM, 2020, NAT REV CARDIOL, V17, P574, DOI 10.1038/s41569-020-0366-z; Silberstein SD, 2020, HEADACHE, V60, P113; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01173-8; Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088-200948030-00001; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Szkutnik-Fiedler D, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121180; Taylor FR, 2019, HEADACHE, V59, P131, DOI 10.1111/head.13432; Tepper Stewart J, 2003, Expert Opin Drug Saf, V2, P123, DOI 10.1517/eods.2.2.123.21388; Teva Pharmaceuticals USA, 2018, FREM AJOVYTM US PRES; Vu T, 2017, PHARM RES-DORDR, V34, P1784, DOI 10.1007/s11095-017-2183-6; Toutain PL, 2004, J VET PHARMACOL THER, V27, P441, DOI 10.1111/j.1365-2885.2004.00602.x; Trobec K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079603; UpToDate, 2021, CYT P450 3A INCL 3A4; US. Food and Drug Administration, 2016, DRUG DEV DRUG INT TA; van Casteren DS, 2021, NEUROLOGY, V96, P162, DOI 10.1212/WNL.0000000000011216; Vernieri Fabrizio, 2021, J Headache Pain, V22, P35, DOI 10.1186/s10194-021-01247-1; Vgontzas A, 2020, LANCET, V396, P95, DOI 10.1016/S0140-6736(19)32952-6; Walker CS, 2015, ANN CLIN TRANSL NEUR, V2, P595, DOI 10.1002/acn3.197; Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393; Wu CY, 2005, PHARM RES-DORDR, V22, P11, DOI 10.1007/s11095-004-9004-4	116	12	12	6	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					284	294		10.1016/S1474-4422(21)00409-9	http://dx.doi.org/10.1016/S1474-4422(21)00409-9			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35093196				2022-12-18	WOS:000759721800024
J	Ibanez, K; Polke, J; Hagelstrom, RT; Dolzhenko, E; Pasko, D; Thomas, ERA; Daugherty, LC; Kasperaviciute, D; Smith, KR; Deans, ZC; Hill, S; Fowler, T; Scott, RH; Hardy, J; Chinnery, PF; Houlden, H; Rendon, A; Caulfield, MJ; Eberle, MA; Taft, RJ; Tucci, A				Ibanez, Kristina; Polke, James; Hagelstrom, R. Tanner; Dolzhenko, Egor; Pasko, Dorota; Thomas, Ellen Rachel Amy; Daugherty, Louise C.; Kasperaviciute, Dalia; Smith, Katherine R.; Deans, Zandra C.; Hill, Sue; Fowler, Tom; Scott, Richard H.; Hardy, John; Chinnery, Patrick F.; Houlden, Henry; Rendon, Augusto; Caulfield, Mark J.; Eberle, Michael A.; Taft, Ryan J.; Tucci, Arianna		Genomics England Res Consortium	Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	LANCET NEUROLOGY			English	Article							ONSET	Background Repeat expansion disorders affect about 1 in 3000 individuals and are clinically heterogeneous diseases caused by expansions of short tandem DNA repeats. Genetic testing is often locus-specific, resulting in underdiagnosis of people who have atypical clinical presentations, especially in paediatric patients without a previous positive family history. Whole genome sequencing is increasingly used as a first-line test for other rare genetic disorders, and we aimed to assess its performance in the diagnosis of patients with neurological repeat expansion disorders. Methods We retrospectively assessed the diagnostic accuracy of whole genome sequencing to detect the most common repeat expansion loci associated with neurological outcomes (AR, ATN1, ATXN1, ATXN2, ATXN3, ATXN7, C9orf72, CACNA1A, DMPK, FMR1, FXN, HTT, and TBP) using samples obtained within the National Health Service in England from patients who were suspected of having neurological disorders; previous PCR test results were used as the reference standard. The clinical accuracy of whole genome sequencing to detect repeat expansions was prospectively examined in previously genetically tested and undiagnosed patients recruited in 2013-17 to the 100 000 Genomes Project in the UK, who were suspected of having a genetic neurological disorder (familial or early-onset forms of ataxia, neuropathy, spastic paraplegia, dementia, motor neuron disease, parkinsonian movement disorders, intellectual disability, or neuromuscular disorders). If a repeat expansion call was made using whole genome sequencing, PCR was used to confirm the result. Findings The diagnostic accuracy of whole genome sequencing to detect repeat expansions was evaluated against 793 PCR tests previously performed within the NHS from 404 patients. Whole genome sequencing correctly classified 215 of 221 expanded alleles and 1316 of 1321 non-expanded alleles, showing 97.3% sensitivity (95% CI 94.2-99.0) and 99.6% specificity (99.1-99.9) across the 13 disease-associated loci when compared with PCR test results. In samples from 11 631 patients in the 100 000 Genomes Project, whole genome sequencing identified 81 repeat expansions, which were also tested by PCR: 68 were confirmed as repeat expansions in the full pathogenic range, 11 were non-pathogenic intermediate expansions or premutations, and two were non-expanded repeats (16% false discovery rate). Interpretation In our study, whole genome sequencing for the detection of repeat expansions showed high sensitivity and specificity, and it led to identification of neurological repeat expansion disorders in previously undiagnosed patients. These findings support implementation of whole genome sequencing in clinical laboratories for diagnosis of patients who have a neurological presentation consistent with a repeat expansion disorder. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.	[Ibanez, Kristina; Pasko, Dorota; Thomas, Ellen Rachel Amy; Daugherty, Louise C.; Kasperaviciute, Dalia; Smith, Katherine R.; Fowler, Tom; Scott, Richard H.; Rendon, Augusto; Caulfield, Mark J.; Tucci, Arianna] Queen Mary Univ London, Genom England, London, England; [Ibanez, Kristina; Kasperaviciute, Dalia; Smith, Katherine R.; Caulfield, Mark J.; Tucci, Arianna] Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England; [Polke, James; Houlden, Henry] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London, England; [Hagelstrom, R. Tanner; Dolzhenko, Egor; Eberle, Michael A.; Taft, Ryan J.] Illumina, San Diego, CA 92122 USA; [Daugherty, Louise C.] Healx, Cambridge, England; [Deans, Zandra C.] Royal Infirm Edinburgh NHS Trust, Dept Lab Med, Genom Qual Assessment, Edinburgh, Midlothian, Scotland; [Deans, Zandra C.] NHS England & NHS Improvement, London, England; [Scott, Richard H.] UCL Great Ormond St Inst Child Hlth, Dept Genet & Genom Med, London, England; [Hardy, John] UCL, Inst Neurol, Dept Neurodegenerat Disorders, London, England; [Houlden, Henry] UCL, Inst Neurol, Dept Neuromuscular Dis, London, England; [Chinnery, Patrick F.] Univ Cambridge, MRC Mitochondrial Biol Unit, Cambridge, England; [Chinnery, Patrick F.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Illumina; Royal Infirmary of Edinburgh; University of Edinburgh; University of London; University College London; University of London; University College London; University of London; University College London; University of Cambridge; University of Cambridge	Tucci, A (corresponding author), Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England.; Taft, RJ (corresponding author), Illumina, San Diego, CA 92122 USA.	rtaft@illumina.com; a.tucci@qmul.ac.uk	Houlden, Henry J/C-1532-2008; Hardy, John/C-2451-2009; Fowler, Tom/AGT-1933-2022; Schrag, Anette/B-4181-2011; Polychronopoulos, Dimitris/G-8214-2014	Houlden, Henry J/0000-0002-2866-7777; Hardy, John/0000-0002-3122-0423; Fowler, Tom/0000-0002-7258-2279; Schrag, Anette/0000-0002-9872-6680; Patch, Christine/0000-0002-4191-0663; Daugherty, Louise/0000-0003-4546-6667; Naresh, Kikkeri N/0000-0003-3807-3638; Menzies, Lara/0000-0003-3710-501X; McDonagh, Ellen M/0000-0001-5806-6174; Tucci, Arianna/0000-0001-5644-0070; Polychronopoulos, Dimitris/0000-0001-9427-3082	Medical Research Council; Department of Health and Social Care; National Health Service England; National Institute for Health Research; Illumina	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health and Social Care; National Health Service England; National Institute for Health Research(National Institute for Health Research (NIHR)); Illumina	Medical Research Council, Department of Health and Social Care, National Health Service England, National Institute for Health Research, and Illumina.	Ansorge O, 2004, ANN NEUROL, V56, P448, DOI 10.1002/ana.20230; Ashley EA, 2016, NAT REV GENET, V17, P507, DOI 10.1038/nrg.2016.86; Aydin G, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-017-1009-9; Bahlo Melanie, 2018, F1000Res, V7, DOI 10.12688/f1000research.13980.1; Bird TD., 2019, GENEREVIEWS; Cortese A, 2019, NAT GENET, V51, P649, DOI 10.1038/s41588-019-0372-4; Dolzhenko E, 2019, BIOINFORMATICS, V35, P4754, DOI 10.1093/bioinformatics/btz431; Dolzhenko E, 2017, GENOME RES, V27, P1895, DOI 10.1101/gr.225672.117; Ellerby LM, 2019, NEUROTHERAPEUTICS, V16, P924, DOI 10.1007/s13311-019-00823-3; Genomics England, 2018, RAR DIS COND CLIN DA; Gossye, 2015, C9ORF72 FRONTOTEMPOR; Gousse G, 2018, ARCH PEDIATRIE, V25, P42, DOI 10.1016/j.arcped.2017.09.029; Graziola F, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01026; Gross AM, 2019, GENET MED, V21, P1121, DOI 10.1038/s41436-018-0295-y; Ishiura H, 2019, NAT GENET, V51, P1222, DOI 10.1038/s41588-019-0458-z; Ishiura H, 2018, NAT GENET, V50, P581, DOI 10.1038/s41588-018-0067-2; Klockgether T, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0074-3; La Spada A, 1999, GENEREVIEWS; Liu HY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55832-1; Lynch DS, 2016, EUR J HUM GENET, V24, P857, DOI 10.1038/ejhg.2015.200; Mantere T, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00426; MITCHELL N, 2019, TREMOR OTHER HYPERKI, DOI DOI 10.5334/TOHM.484; Mousavi N, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz501; National Health System, 2021, NAT GEN TEST DIR TES; Ngo KJ, 2020, HUM MUTAT, V41, P487, DOI 10.1002/humu.23946; Paulson Henry, 2018, Handb Clin Neurol, V147, P105, DOI 10.1016/B978-0-444-63233-3.00009-9; Rafehi H, 2020, MOVEMENT DISORD, V35, P1675, DOI 10.1002/mds.28105; Rafehi H, 2019, AM J HUM GENET, V105, P151, DOI 10.1016/j.ajhg.2019.05.016; Ramocki MB, 2008, J CHILD NEUROL, V23, P999, DOI 10.1177/0883073808315622; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Robinson PN, 2008, AM J HUM GENET, V83, P610, DOI 10.1016/j.ajhg.2008.09.017; Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003; Schneider SA, 2006, NEUROLOGY, V67, P1701, DOI 10.1212/01.wnl.0000242740.01273.00; Schneider SA, 2016, MOV DISORD CLIN PRAC, V3, P342, DOI 10.1002/mdc3.12312; Shakkottai VG, 2013, NEUROL CLIN, V31, P987, DOI 10.1016/j.ncl.2013.04.006; Tankard RM, 2018, AM J HUM GENET, V103, P858, DOI 10.1016/j.ajhg.2018.10.015; Trost B, 2020, NATURE, V586, P80, DOI 10.1038/s41586-020-2579-z; Turro E, 2020, NATURE, V583, P96, DOI 10.1038/s41586-020-2434-2	38	12	12	5	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					234	245		10.1016/S1474-4422(21)00462-2	http://dx.doi.org/10.1016/S1474-4422(21)00462-2			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182509	Green Accepted, Green Published			2022-12-18	WOS:000759721800020
J	Chhatwal, JP; Schultz, SA; McDade, E; Schultz, AP; Liu, L; Hanseeuw, BJ; Joseph-Mathurin, N; Feldman, R; Fitzpatrick, CD; Sparks, KP; Levin, J; Berman, SB; Renton, AE; Esposito, BT; Fernandez, MV; Sung, YJ; Lee, JH; Klunk, WE; Hofmann, A; Noble, JM; Graff-Radford, N; Mori, H; Salloway, SM; Masters, CL; Martins, R; Karch, CM; Xiong, CJ; Cruchaga, C; Perrin, RJ; Gordon, BA; Benzinger, TLS; Fox, NC; Schofield, PR; Fagan, AM; Goate, AM; Morris, JC; Bateman, RJ; Johnson, KA; Sperling, RA; Investigators, DIAN				Chhatwal, Jasmeer P.; Schultz, Stephanie A.; McDade, Eric; Schultz, Aaron P.; Liu, Lei; Hanseeuw, Bernard J.; Joseph-Mathurin, Nelly; Feldman, Rebecca; Fitzpatrick, Colleen; Sparks, Kathryn P.; Levin, Johannes; Berman, Sarah B.; Renton, Alan E.; Esposito, Bianca; Fernandez, Maria Vitoria; Sung, Yun Ju; Lee, Jae Hong; Klunk, William E.; Hofmann, Anna; Noble, James M.; Graff-Radford, Neill; Mori, Hiroshi; Salloway, Steven M.; Masters, Colin L.; Martins, Ralph; Karch, Celeste M.; Xiong, Chengjie; Cruchaga, Carlos; Perrin, Richard J.; Gordon, Brian A.; Benzinger, Tammie L. S.; Fox, Nick C.; Schofield, Peter R.; Fagan, Anne M.; Goate, Alison M.; Morris, John C.; Bateman, Randall J.; Johnson, Keith A.; Sperling, Reisa A.; Investigators, Dominantly Inherited Alzheimer's Network			Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	LANCET NEUROLOGY			English	Article							IN-VITRO; PRESENILIN-1; MUTATIONS; DEPOSITION; MECHANISM	Background Insights gained from studying individuals with autosomal dominant Alzheimer's disease have broadly influenced mechanistic hypotheses, biomarker development, and clinical trials in both sporadic and dominantly inherited Alzheimer's disease. Although pathogenic variants causing autosomal dominant Alzheimer's disease are highly penetrant, there is substantial heterogeneity in levels of amyloid 13 (A13) between individuals. We aimed to examine whether this heterogeneity is related to disease progression and to investigate the association with mutation location within PSEN1, PSEN2, or APP. Methods We did cross-sectional and longitudinal analyses of data from the Dominantly Inherited Alzheimer's Network (DIAN) observational study, which enrols individuals from families affected by autosomal dominant Alzheimer's disease. 340 participants in the DIAN study who were aged 18 years or older, had a history of autosomal dominant Alzheimer's disease in their family, and who were enrolled between September, 2008, and June, 2019, were included in our analysis. 206 participants were carriers of pathogenic mutations in PSEN1, PSEN2, or APP, and 134 were non-carriers. 62 unique pathogenic variants were identified in the cohort and were grouped in two ways. First, we sorted variants in PSEN1, PSEN2, or APP by the affected protein domain. Second, we divided PSEN1 variants according to position before or after codon 200. We examined variant-dependent variability in A13 biomarkers, specifically Pittsburgh-Compound-B PET (PiB-PET) signal, levels of CSF A131-42 (A1342), and levels of A131-40 (A1340). Findings Cortical and striatal PiB-PET signal showed striking variant-dependent variability using both grouping approaches (p<0.0001), despite similar progression on the clinical dementia rating (p>0.7), and CSF A1342 levels (codon-based grouping: p=0.49; domain-based grouping: p=0.095). Longitudinal PiB-PET signal also varied across codon-based groups, mirroring cross-sectional analyses. Interpretation Autosomal dominant Alzheimer's disease pathogenic variants showed highly differential temporal and regional patterns of PiB-PET signal, despite similar functional progression. These findings suggest that although increased PiB-PET signal is generally seen in autosomal dominant Alzheimer's disease, higher levels of PiB-PET signal at an individual level might not reflect more severe or more advanced disease. Our results have high relevance for ongoing clinical trials in autosomal dominant Alzheimer's disease, including those using A13 PET as a surrogate marker of disease progression. Additionally, and pertinent to both sporadic and autosomal dominant Alzheimer's disease, our results suggest that CSF and PET measures of A13 levels are not interchangeable and might reflect different A13-driven pathobiological processes. Funding National Institute on Aging, Doris Duke Charitable Foundation, German Center for Neurodegenerative Diseases, Japanese Agency for Medical Research and Development. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Chhatwal, Jasmeer P.; Schultz, Stephanie A.; Schultz, Aaron P.; Johnson, Keith A.; Sperling, Reisa A.] Harvard Med Sch, Dept Neurol, Boston, MA 02114 USA; [Chhatwal, Jasmeer P.; Schultz, Stephanie A.; Schultz, Aaron P.; Hanseeuw, Bernard J.; Fitzpatrick, Colleen; Sparks, Kathryn P.; Johnson, Keith A.; Sperling, Reisa A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Chhatwal, Jasmeer P.; Liu, Lei; Fitzpatrick, Colleen; Johnson, Keith A.; Sperling, Reisa A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [McDade, Eric; Karch, Celeste M.; Fagan, Anne M.; Morris, John C.; Bateman, Randall J.] Washington Univ, Dept Neurol, St Louis, MO USA; [Joseph-Mathurin, Nelly; Feldman, Rebecca; Gordon, Brian A.; Benzinger, Tammie L. S.] Washington Univ St Louis, Mallinckrodt Inst Radiol, St Louis, MO USA; [Fernandez, Maria Vitoria; Sung, Yun Ju; Cruchaga, Carlos] Washington Univ St Louis, Dept Psychiat, St Louis, MO USA; [Xiong, Chengjie] Washington Univ St Louis, Div Biostat, St Louis, MO USA; [Perrin, Richard J.] Washington Univ St Louis, Dept Pathol, St Louis, MO USA; [Hanseeuw, Bernard J.] Catholic Univ Louvain, Brussels, Belgium; [Levin, Johannes] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany; [Levin, Johannes] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Berman, Sarah B.; Klunk, William E.] Univ Pittsburg, Dept Neurol, Pittsburgh, PA USA; [Klunk, William E.] Univ Pittsburg, Dept Psychiat, Pittsburgh, PA USA; [Levin, Johannes] German Ctr Neurodegenerat Dis, Munich, Germany; [Hofmann, Anna] German Ctr Neurodegenerat Dis, Tubingen, Germany; [Lee, Jae Hong] Univ Ulsan, Dept Neurol, Asan Med Ctr, Coll Med, Seoul, South Korea; [Noble, James M.] Columbia Univ, Irving Med Ctr, Dept Neurol, New York, NY USA; [Graff-Radford, Neill] Mayo Clin, Dept Neurol, Jacksonville, FL USA; [Mori, Hiroshi] Osaka City Univ, Sumiyoshi Ward, Osaka, Japan; [Fox, Nick C.] UCL, Queen Sq Inst Neurol, Dementia Res Ctr, London, England; [Salloway, Steven M.] Brown Univ, Butler Hosp, Memory & Aging Program, Sch Med, Providence, RI USA; [Masters, Colin L.] Univ Melbourne, Melbourne, Vic, Australia; [Masters, Colin L.] Florey Inst, Melbourne, Vic, Australia; [Martins, Ralph] Macquarie Univ, Dept Biomed Sci, Sydney, NSW, Australia; [Schofield, Peter R.] Neurosci Res Australia, Sydney, NSW, Australia; [Schofield, Peter R.] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia; [Renton, Alan E.; Esposito, Bianca; Goate, Alison M.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Universite Catholique Louvain; University of Munich; University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Ulsan; Asan Medical Center; Columbia University; NewYork-Presbyterian Hospital; Mayo Clinic; Osaka Metropolitan University; University of London; University College London; Brown University; Butler Hospital Rhode Island; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Macquarie University; Neuroscience Research Australia; University of New South Wales Sydney; Icahn School of Medicine at Mount Sinai	Chhatwal, JP (corresponding author), Harvard Med Sch, Dept Neurol, Boston, MA 02114 USA.	chhatwal.jasmeer@mgh.harvard.edu	Noble, James McCallum/AAA-4218-2020; Fox, Nick C/B-1319-2009; Cruchaga, Carlos/ABF-4065-2020; Gordon, Brian/U-7794-2019; Levin, Johannes/E-4052-2010; Berman, Sarah/I-2792-2014; Liu, Lei/R-7673-2017	Noble, James McCallum/0000-0003-0648-6702; Fox, Nick C/0000-0002-6660-657X; Cruchaga, Carlos/0000-0002-0276-2899; Gordon, Brian/0000-0003-2109-2955; Levin, Johannes/0000-0001-5092-4306; Berman, Sarah/0000-0002-5096-4962; Liu, Lei/0000-0002-4604-4629				Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bentahir M, 2006, J NEUROCHEM, V96, P732, DOI 10.1111/j.1471-4159.2005.03578.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Chavez-Gutierrez L, 2012, EMBO J, V31, P2261, DOI 10.1038/emboj.2012.79; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Maarouf CL, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-20; Mann DMA, 2001, NEUROPATH APPL NEURO, V27, P189, DOI 10.1046/j.1365-2990.2001.00316.x; Mann DMA, 2001, AM J PATHOL, V158, P2165, DOI 10.1016/S0002-9440(10)64688-3; Miravalle L, 2005, BIOCHEMISTRY-US, V44, P10810, DOI 10.1021/bi0508237; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Connor A, 2021, BRAIN, V144, P2964, DOI 10.1093/brain/awab166; Paterson RW, 2019, NAT REV NEUROL, V15, P419, DOI 10.1038/s41582-019-0222-0; Potter R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005615; Reiman EM, 2012, LANCET NEUROL, V11, P1048, DOI 10.1016/S1474-4422(12)70228-4; Ringman JM, 2016, J NEUROPATH EXP NEUR, V75, P284, DOI 10.1093/jnen/nlv028; Ryman Davis C, 2014, Neurology, V83, P253, DOI 10.1212/WNL.0000000000000596; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Scholl M, 2012, NEUROLOGY, V79, P229, DOI 10.1212/WNL.0b013e31825fdf18; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Su Y, 2015, NEUROIMAGE, V107, P55, DOI 10.1016/j.neuroimage.2014.11.058; Sun LF, 2017, P NATL ACAD SCI USA, V114, pE476, DOI 10.1073/pnas.1618657114; Swanson CJ, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00813-8; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; Wolfe MS, 2019, NEUROCHEM RES, V44, P5, DOI 10.1007/s11064-018-2511-1; Xia D, 2015, NEURON, V85, P967, DOI 10.1016/j.neuron.2015.02.010	26	12	12	7	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					140	152		10.1016/S1474-4422(21)00375-6	http://dx.doi.org/10.1016/S1474-4422(21)00375-6			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065037	Green Published			2022-12-18	WOS:000769111800015
J	Verschuuren, JJ; Palace, J; Murai, H; Tannemaat, MR; Kaminski, HJ; Bril, V				Verschuuren, Jan J. G. M.; Palace, Jacqueline; Murai, Hiroyuki; Tannemaat, Martijn R.; Kaminski, Henry J.; Bril, Vera			Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	LANCET NEUROLOGY			English	Article							GENERALIZED MYASTHENIA-GRAVIS; INTERNATIONAL CONSENSUS GUIDANCE; QUALITY-OF-LIFE; PLASMA-EXCHANGE; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; SAFETY; EFFICACY; TRIAL; MULTICENTER	Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-mediated autoimmune diseases of the neuromuscular junction that usually present with weakness in ocular muscles and in proximal muscles of the limb and trunk. Prognosis regarding muscle strength, functional abilities, quality of life, and survival is generally good. However, some patients do not respond to treatment. Symptomatic drugs, corticosteroids, and steroid-sparing immunosuppressive drugs remain the cornerstone of treatment. In the past few years, new biological agents against complement, the FcRn receptor, or B-cell antigens have been tested in clinical trials. These new therapies extend the possibilities for targeted immunotherapies and promise exciting new options with a relatively rapid mode of action. Challenges in their use might occur, with barriers due to an increase in cost of care and additional considerations in the choice of drugs, and potential consequences of infection and vaccination due to the COVID-19 pandemic.	[Verschuuren, Jan J. G. M.; Tannemaat, Martijn R.] Leiden Univ, Dept Neurol, Med Ctr, NL-2333 ZA Leiden, Netherlands; [Palace, Jacqueline] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Murai, Hiroyuki] Int Univ Hlth & Welf, Dept Neurol, Narita, Japan; [Kaminski, Henry J.] George Washington Univ & Hlth Sci, Dept Neurol & Rehabil Med, Sch Med, Washington, DC USA; [Bril, Vera] Univ Toronto, Dept Med, Toronto, ON, Canada	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Oxford; International University of Health & Welfare; George Washington University; University of Toronto	Verschuuren, JJ (corresponding author), Leiden Univ, Dept Neurol, Med Ctr, NL-2333 ZA Leiden, Netherlands.	j.j.g.m.verschuuren@lumc.nl	Tannemaat, Martijn/S-3445-2016	Tannemaat, Martijn/0000-0003-2929-0390				Akaishi T, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.06.65; Alabbad S, 2020, BIODRUGS, V34, P557, DOI 10.1007/s40259-020-00443-w; Alcantara M, 2021, EUR J NEUROL, V28, P639, DOI 10.1111/ene.14547; Alharbi M, 2021, CAN J NEUROL SCI, V48, P767, DOI 10.1017/cjn.2021.2; Alipour-Faz A, 2017, ACTA NEUROL BELG, V117, P245, DOI 10.1007/s13760-016-0689-z; Alshaikh JT, 2016, MUSCLE NERVE, V53, P370, DOI 10.1002/mus.24904; Anand P, 2020, MUSCLE NERVE, V62, P254, DOI 10.1002/mus.26918; Assini A, 2021, EUR J NEUROL, V28, P3537, DOI 10.1111/ene.14721; Barnett C, 2020, NAT REV NEUROL, V16, P299, DOI 10.1038/s41582-020-0345-3; Barnett C, 2019, EXPERT OPIN PHARMACO, V20, P2295, DOI 10.1080/14656566.2019.1682548; Barnett C, 2013, J NEUROL NEUROSUR PS, V84, P94, DOI 10.1136/jnnp-2011-301449; Barth D, 2011, NEUROLOGY, V76, P2017, DOI 10.1212/WNL.0b013e31821e5505; Benatar M, 2016, MUSCLE NERVE, V53, P363, DOI 10.1002/mus.24769; Boldingh MI, 2016, NEUROLOGY, V87, P2139, DOI 10.1212/WNL.0000000000003339; Bril V, 2021, NEUROLOGY, V96, pE853, DOI [10.1212/WNL.0000000000011108, 10.1212/WNL.0000000000011350]; Bril V, 2012, ANN NY ACAD SCI, V1275, P1, DOI 10.1111/j.1749-6632.2012.06767.x; Bryant A, 2016, JAMA NEUROL, V73, P652, DOI 10.1001/jamaneurol.2016.0113; Businaro P, 2021, MUSCLE NERVE, V64, P206, DOI 10.1002/mus.27324; Canadian Agency for Drugs and Technologies in Health, 2020, PHARMACOECONOMIC REP; Chen D, 2016, J CLIN MED, V5, DOI 10.3390/jcm5120107; Dalakas MC, 2020, CURR OPIN NEUROL, V33, P545, DOI 10.1097/WCO.0000000000000858; Diaz-Maroto I, 2020, NEUROLOGIA ENGL ED, P30300; Ebadi H, 2013, MUSCLE NERVE, V47, P510, DOI 10.1002/mus.23626; Ellebrecht CT, 2014, JAMA DERMATOL, V150, P1331, DOI 10.1001/jamadermatol.2014.1939; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Evoli A, 2016, NEUROLOGY, V86, P1070, DOI 10.1212/WNL.0000000000002466; Fedyk ER, 2020, BRIT J CLIN PHARMACO, V86, P1314, DOI 10.1111/bcp.14241; Gamez J, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419864497; Gilhus NE, 2018, EUR J NEUROL, V25, P1402, DOI 10.1111/ene.13788; Gilhus NE, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0079-y; Grob D, 2008, MUSCLE NERVE, V37, P141, DOI 10.1002/mus.20950; Guptill JT, 2016, AUTOIMMUNITY, V49, P472, DOI 10.1080/08916934.2016.1214823; Habib AA, 2020, MUSCLE NERVE, V62, P579, DOI 10.1002/mus.26919; Hakansson I, 2017, NEUROMUSCULAR DISORD, V27, P90, DOI 10.1016/j.nmd.2016.09.020; Hauser SL, 2017, NEW ENGL J MED, V376, P1694, DOI 10.1056/NEJMc1702076; Heckmann JM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-97; Hehir MK, 2017, NEUROLOGY, V89, P1069, DOI 10.1212/WNL.0000000000004341; Hewett K, 2018, NEUROLOGY, V90, pE1425, DOI 10.1212/WNL.0000000000005323; Howard JF, 2021, EXPERT OPIN INV DRUG, V30, P483, DOI 10.1080/13543784.2021.1897567; Howard JF, 2020, JAMA NEUROL, V77, P582, DOI 10.1001/jamaneurol.2019.5125; Howard JF, 2019, NEUROLOGY, V92, pE2661, DOI 10.1212/WNL.0000000000007600; Howard JF, 2018, ANN NY ACAD SCI, V1412, P113, DOI 10.1111/nyas.13522; Howard JF, 2017, LANCET NEUROL, V16, P976, DOI 10.1016/S1474-4422(17)30369-1; Howard JF, 2021, LANCET NEUROL, V20, P526, DOI 10.1016/S1474-4422(21)00159-9; Hubers A, 2020, J NEUROL NEUROSUR PS, V91, P1124, DOI 10.1136/jnnp-2020-323565; Huijbers MG, 2022, LANCET NEUROL, V21, P163, DOI 10.1016/S1474-4422(21)00357-4; Im SH, 2001, J IMMUNOL, V166, P6893, DOI 10.4049/jimmunol.166.11.6893; Imai T, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00868; Jacob S, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420911784; Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803; Jakubikova M, 2021, EUR J NEUROL, V28, P3418, DOI 10.1111/ene.14951; Jaretzki A 3rd, 2000, Ann Thorac Surg, V70, P327; Jensen Paul, 2008, J Clin Neuromuscul Dis, V9, P352, DOI 10.1097/CND.0b013e3181660807; Jonsson DI, 2017, NEUROMUSCULAR DISORD, V27, P565, DOI 10.1016/j.nmd.2017.03.007; Karelis G, 2019, EUR NEUROL, V81, P223, DOI 10.1159/000502818; Kohler S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024523; Kulasekararaj AG, 2019, BLOOD, V133, P540, DOI 10.1182/blood-2018-09-876805; Kushlaf H, 2020, MUSCLE NERVE, V62, pE65, DOI 10.1002/mus.27020; Lai CC, 2021, EXPERT REV VACCINES, V20, P1013, DOI 10.1080/14760584.2021.1949293; Lee M, 2018, ANN NY ACAD SCI, V1412, P129, DOI 10.1111/nyas.13538; Lee MK, 2018, J CLIN NEUROSCI, V50, P194, DOI 10.1016/j.jocn.2018.01.024; Levy RA, 2016, AUTOIMMUN REV, V15, P955, DOI 10.1016/j.autrev.2016.07.014; Li F, 2018, J NEUROL, V265, P2773, DOI 10.1007/s00415-018-9056-8; Ling LE, 2019, CLIN PHARMACOL THER, V105, P1031, DOI 10.1002/cpt.1276; Lipka AF, 2020, NEUROLOGY, V94, pE511, DOI 10.1212/WNL.0000000000008747; Lipka AF, 2017, NEUROMUSCULAR DISORD, V27, P259, DOI 10.1016/j.nmd.2016.11.009; Luo J, 2018, ANN NY ACAD SCI, V1413, P76, DOI 10.1111/nyas.13550; Maddison P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67571-9; MAHER ER, 1986, BRIT MED J, V292, P306, DOI 10.1136/bmj.292.6516.306; Mantegazza R, 2021, NEUROLOGY, V96, pE610, DOI 10.1212/WNL.0000000000011207; Mantegazza R, 2018, THER ADV NEUROL DISO, V11, P1, DOI 10.1177/1756285617749134; McKeage K, 2019, DRUGS, V79, P347, DOI 10.1007/s40265-019-01068-2; Melzer N, 2016, J NEUROL, V263, P1473, DOI 10.1007/s00415-016-8045-z; Menon D, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00538; Morandi F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121527; Munot P, 2020, NEUROMUSCULAR DISORD, V30, P254, DOI 10.1016/j.nmd.2020.02.001; Muppidi S, 2019, MUSCLE NERVE, V60, P14, DOI 10.1002/mus.26447; Murai H., 2015, CLIN EXP NEUROIMMUNO, V6, P21, DOI [10.1111/cen3.12180, DOI 10.1111/CEN3.12180]; Narayanaswami P, 2021, NEUROLOGY, V96, P114, DOI 10.1212/WNL.0000000000011124; Huong NTC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2415-8; Nishimura J, 2014, NEW ENGL J MED, V370, P632, DOI 10.1056/NEJMoa1311084; Norwood F, 2014, J NEUROL NEUROSUR PS, V85, P538, DOI 10.1136/jnnp-2013-305572; O'Connell K, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00743; Ortiz-Salas Paola, 2016, J Clin Neuromuscul Dis, V18, P1, DOI 10.1097/CND.0000000000000119; Oyama M, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420904207; Pasnoor M, 2016, NEUROLOGY, V87, P57, DOI 10.1212/WNL.0000000000002795; Pasnoor M, 2012, ANN NY ACAD SCI, V1275, P23, DOI 10.1111/j.1749-6632.2012.06804.x; Patel DD, 2020, J ALLERGY CLIN IMMUN, V146, P467, DOI 10.1016/j.jaci.2020.07.015; Ponticelli C, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120552; Punga AR, 2022, LANCET NEUROL, V21, P176, DOI 10.1016/S1474-4422(21)00297-0; Rahbek MA, 2017, MUSCLE NERVE, V56, P700, DOI 10.1002/mus.25552; Rein N, 2020, J NEUROL SCI, V417, DOI 10.1016/j.jns.2020.117053; Restivo DA, 2020, ANN INTERN MED, V173, P1027, DOI 10.7326/L20-0845; Ristov J, 2018, AM J TRANSPLANT, V18, P2895, DOI 10.1111/ajt.14872; Sanders DB, 2016, NEUROLOGY, V87, P419, DOI 10.1212/WNL.0000000000002790; Sesarman A, 2010, CELL MOL LIFE SCI, V67, P2533, DOI 10.1007/s00018-010-0318-6; Sheridan D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195909; Sorensen PS, 2014, NEUROLOGY, V82, P573, DOI 10.1212/WNL.0000000000000125; Melo CLS, 2019, NEUROMUSCULAR DISORD, V29, P142, DOI 10.1016/j.nmd.2018.11.008; Strijbos E, 2019, VACCINE, V37, P919, DOI 10.1016/j.vaccine.2019.01.007; Titulaer MJ, 2011, J CLIN ONCOL, V29, P902, DOI 10.1200/JCO.2010.32.0440; TSUJIHATA M, 1989, NEUROLOGY, V39, P1359, DOI 10.1212/WNL.39.10.1359; Utsugisawa K, 2017, MUSCLE NERVE, V55, P794, DOI 10.1002/mus.25397; Vecchio D, 2020, NEUROMUSCULAR DISORD, V30, P120, DOI 10.1016/j.nmd.2019.11.008; Voet NBM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003907.pub5; Wang SH, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1482-4; Westerberg E, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011510; Westerberg E, 2017, MUSCLE NERVE, V56, P207, DOI 10.1002/mus.25493; Wolfe GI, 2016, NEW ENGL J MED, V375, P511, DOI 10.1056/NEJMoa1602489; Yamamoto S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020888; Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747; Zhao C, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.736190; Zhou Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.733418; Zinman L, 2007, NEUROLOGY, V68, P837, DOI 10.1212/01.wnl.0000256698.69121.45; Zuercher AW, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102366	115	12	12	15	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					189	202		10.1016/S1474-4422(21)00463-4	http://dx.doi.org/10.1016/S1474-4422(21)00463-4			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065041				2022-12-18	WOS:000769111800019
J	Blumcke, I; Budday, S; Poduri, A; Lal, D; Kobow, K; Baulac, S				Blumcke, Ingmar; Budday, Silvia; Poduri, Annapurna; Lal, Dennis; Kobow, Katja; Baulac, Stephanie			Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours	LANCET NEUROLOGY			English	Review							METHYLATION-BASED CLASSIFICATION; PATHWAY MUTATIONS CAUSE; SOMATIC MUTATIONS; MAMMALIAN TARGET; MTOR PATHWAY; MALFORMATIONS; COMPLEX; SPECTRUM; SYSTEM; GENES	During the past decade, there have been considerable advances in understanding of the genetic and morphogenic processes underlying cortical malformations and developmental brain tumours. Focal malformations are caused by somatic (postzygotic) variants in genes related to cell growth (ie, in the mTOR pathway in focal cortical dysplasia type 2), which are acquired in neuronal progenitors during neurodevelopment. In comparison, developmental brain tumours result from somatic variants in genes related to cell proliferation (eg, in the MAP-kinase pathway in ganglioglioma), which affect proliferating glioneuronal precursors. The timing of the genetic event and the specific gene involved during neurodevelopment will drive the nature and size of the lesion, whether it is a developmental malformation or a brain tumour. There is also emerging evidence that epigenetic processes underlie a molecular memory in epileptogenesis. This knowledge will together facilitate understanding of why and how patients with these lesions have epilepsy, and could form a basis for a move towards precision medicine for this challenging cohort of patients.	[Blumcke, Ingmar; Kobow, Katja] Univ Hosp Erlangen, Inst Neuropathol, D-91054 Erlangen, Germany; [Budday, Silvia] Friedrich Alexander Univ Erlangen Nuremberg, Inst Appl Mech, Dept Mech Engn, Erlangen, Germany; [Poduri, Annapurna] Boston Childrens Hosp, Dept Neurol, Epilepsy Genet Program, Boston, MA USA; [Poduri, Annapurna] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA; [Lal, Dennis] Cleveland Clin, Epilepsy Ctr, Cleveland, OH 44106 USA; [Lal, Dennis] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA; [Baulac, Stephanie] Sorbonne Univ, Inst Cerveau, Paris Brain Inst ICM, INSERM,CNRS, Paris, France	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Blumcke, I (corresponding author), Univ Hosp Erlangen, Inst Neuropathol, D-91054 Erlangen, Germany.	bluemcke@uk-erlangen.de	Baulac, Stephanie/O-2099-2016	Baulac, Stephanie/0000-0001-6430-4693; Kobow, Katja/0000-0002-0074-2480				Bae T, 2018, SCIENCE, V359, P550, DOI 10.1126/science.aan8690; Baek ST, 2015, NAT MED, V21, P1445, DOI 10.1038/nm.3982; Bagnall RD, 2016, ANN NEUROL, V79, P522, DOI 10.1002/ana.24596; Baldassari S, 2019, ACTA NEUROPATHOL, V138, P885, DOI 10.1007/s00401-019-02061-5; Baldassari S, 2019, GENET MED, V21, P398, DOI 10.1038/s41436-018-0060-2; Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044; Baulac S, 2015, ANN NEUROL, V77, P675, DOI 10.1002/ana.24368; Benova B, 2021, EUR J PAEDIATR NEURO, V30, P88, DOI 10.1016/j.ejpn.2020.12.001; Bershteyn M, 2017, CELL STEM CELL, V20, P435, DOI 10.1016/j.stem.2016.12.007; Blair JD, 2018, NAT MED, V24, P1568, DOI 10.1038/s41591-018-0139-y; Blumcke I, 2019, NEUROPATH APPL NEURO, V45, P95, DOI 10.1111/nan.12522; Blumcke I, 2017, NEW ENGL J MED, V377, P1648, DOI 10.1056/NEJMoa1703784; Blumcke I, 2021, BRAIN PATHOL, V31, DOI 10.1111/bpa.12956; Bonduelle T, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-020-01085-3; Budday S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00257; Budday S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05644; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Carminati E, 2020, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00580; D'Gama AM, 2017, CELL REP, V21, P3754, DOI 10.1016/j.celrep.2017.11.106; D'Gama AM, 2015, ANN NEUROL, V77, P720, DOI 10.1002/ana.24357; de Rooij R, 2018, J MECH PHYS SOLIDS, V112, P563, DOI 10.1016/j.jmps.2017.12.011; Debski KJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25668; Esk C, 2020, SCIENCE, V370, P935, DOI 10.1126/science.abb5390; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Perez MF, 2019, NAT CELL BIOL, V21, P143, DOI 10.1038/s41556-018-0242-9; Garcia KE, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0321; Garnier L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00177; Greiner A, 2021, SOFT MATTER, V17, P1210, DOI 10.1039/d0sm02209h; Guerrini R, 2021, NEUROL-GENET, V7, DOI 10.1212/NXG.0000000000000540; Guo JJU, 2011, NAT NEUROSCI, V14, P1345, DOI 10.1038/nn.2900; Hartlieb T, 2019, EPILEPSY BEHAV, V91, P68, DOI 10.1016/j.yebeh.2018.07.009; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hsieh LS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11753; Hu ST, 2018, ANN NEUROL, V84, P140, DOI 10.1002/ana.25272; Huang J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00506; Jansen LA, 2015, BRAIN, V138, P1613, DOI 10.1093/brain/awv045; Khan TA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1043-9; Kiese K, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0485-x; Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1; Kim S, 2021, ANN NEUROL, V89, P1248, DOI 10.1002/ana.26080; Klaus J, 2019, NAT MED, V25, P561, DOI 10.1038/s41591-019-0371-0; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Koboldt DC, 2021, BRAIN, V144, P2971, DOI 10.1093/brain/awab173; Kobow K, 2020, ACTA NEUROPATHOL, V140, P881, DOI 10.1007/s00401-020-02228-5; Kobow K, 2020, EPILEPTIC DISORD, V22, P127, DOI 10.1684/epd.2020.1143; Kobow K, 2019, EPILEPSIA, V60, P1091, DOI 10.1111/epi.14934; Koh HY, 2018, NAT MED, V24, P1662, DOI 10.1038/s41591-018-0172-x; Krueger DA, 2013, ANN NEUROL, V74, P679, DOI 10.1002/ana.23960; Kubach J, 2020, EPILEPSIA, V61, P421, DOI 10.1111/epi.16447; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Lee JH, 2012, NAT GENET, V44, P941, DOI 10.1038/ng.2329; Lee WS, 2021, ANN CLIN TRANSL NEUR, V8, P485, DOI 10.1002/acn3.51286; Lee WS, 2020, NEUROLOGY, V95, pE2542, DOI 10.1212/WNL.0000000000010670; Lee WS, 2019, ANN CLIN TRANSL NEUR, V6, P1338, DOI 10.1002/acn3.50815; Leoni C, 2019, AM J MED GENET A, V179, P1319, DOI 10.1002/ajmg.a.61160; Leventer RJ, 2015, NEUROLOGY, V84, P2029, DOI 10.1212/WNL.0000000000001594; Lim JS, 2017, AM J HUM GENET, V100, P454, DOI 10.1016/j.ajhg.2017.01.030; Lim JS, 2015, NAT MED, V21, P395, DOI 10.1038/nm.3824; Lodato MA, 2018, SCIENCE, V359, P555, DOI 10.1126/science.aao4426; Marks AM, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26969; Marsan E, 2018, NEUROPATH APPL NEURO, V44, P6, DOI 10.1111/nan.12463; McConnell MJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal1641; Mirzaa GM, 2016, JAMA NEUROL, V73, P836, DOI 10.1001/jamaneurol.2016.0363; Moller RS, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000118; Nakashima M, 2015, ANN NEUROL, V78, P375, DOI 10.1002/ana.24444; Nascimento FA, 2015, NEUROL-GENET, V1, DOI 10.1212/NXG.0000000000000028; Ng BG, 2013, AM J HUM GENET, V92, P632, DOI 10.1016/j.ajhg.2013.03.012; Nguyen LH, 2019, J NEUROSCI, V39, P2762, DOI 10.1523/JNEUROSCI.2260-18.2019; Nieto-Estevez V, 2020, EPILEPSY CURR, V20, P282, DOI 10.1177/1535759720949254; Orozco JIJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06715-y; Overwater IE, 2016, NEUROLOGY, V87, P1011, DOI 10.1212/WNL.0000000000003077; Park SM, 2018, NEURON, V99, P83, DOI 10.1016/j.neuron.2018.05.039; Pelorosso C, 2019, HUM MOL GENET, V28, P3755, DOI 10.1093/hmg/ddz194; Philippe L, 2019, J NEURO-ONCOL, V145, P135, DOI 10.1007/s11060-019-03280-2; Poduri A, 2013, SCIENCE, V341, P43, DOI 10.1126/science.1237758; Poduri A, 2012, NEURON, V74, P41, DOI 10.1016/j.neuron.2012.03.010; Ribierre T, 2018, J CLIN INVEST, V128, P2452, DOI 10.1172/JCI99384; Ricos MG, 2016, ANN NEUROL, V79, P120, DOI 10.1002/ana.24547; Riviere JB, 2012, NAT GENET, V44, P934, DOI 10.1038/ng.2331; Rushing EJ, 2021, MEMO-MAG EUR MED ONC, V14, P188, DOI 10.1007/s12254-021-00680-x; Ryall S, 2020, CANCER CELL, V37, P569, DOI 10.1016/j.ccell.2020.03.011; Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9; Sanders MWCB, 2019, EPILEPSIA OPEN, V4, P609, DOI 10.1002/epi4.12366; Sarnat HB, 2014, PROG BRAIN RES, V213, P181, DOI 10.1016/B978-0-444-63326-2.00010-7; Schurr J, 2017, BRAIN PATHOL, V27, P26, DOI 10.1111/bpa.12347; Shi XY, 2020, ANN NEUROL, V88, P1077, DOI 10.1002/ana.25890; Sim NS, 2019, ACTA NEUROPATHOL, V138, P901, DOI 10.1007/s00401-019-02052-6; Slegers RJ, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00904-x; Stricker SH, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00005; Tallinen T, 2016, NAT PHYS, V12, P588, DOI [10.1038/NPHYS3632, 10.1038/nphys3632]; Velasco S, 2020, ANNU REV NEUROSCI, V43, P375, DOI 10.1146/annurev-neuro-070918-050154; Venot Q, 2018, NATURE, V558, P540, DOI 10.1038/s41586-018-0217-9; Weckhuysen S, 2016, EPILEPSIA, V57, P994, DOI 10.1111/epi.13391; Witt H, 2018, NEURO-ONCOLOGY, V20, P1616, DOI 10.1093/neuonc/noy118; Witters P, 2020, GENET MED, V22, P1102, DOI 10.1038/s41436-020-0767-8; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Ye ZM, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcaa235; Zarzor MS., 2021, BRAIN MULTIPHYS, V2, DOI [DOI 10.1016/J.BRAIN.2021.100025, 10.1016/j.brain.2021.100025]; Zocher S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23993-1	99	12	12	5	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					943	955		10.1016/S1474-4422(21)00265-9	http://dx.doi.org/10.1016/S1474-4422(21)00265-9			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL5PY	34687638				2022-12-18	WOS:000710458300017
J	Budinger, D; Barral, S; Soo, AKS; Kurian, MA				Budinger, Dimitri; Barral, Serena; Soo, Audrey K. S.; Kurian, Manju A.			The role of manganese dysregulation in neurological disease: emerging evidence	LANCET NEUROLOGY			English	Review							INDUCED PARKINSONISM; SLC39A8 DEFICIENCY; THALAMIC GABA; IN-VITRO; EXPOSURE; TRANSPORTER; SLC30A10; CELL; HYPERMANGANESEMIA; POLYCYTHEMIA	Manganese is an essential trace metal. The dysregulation of manganese seen in a broad spectrum of neurological disorders reflects its importance in brain development and key neurophysiological processes. Historically, the observation of acquired manganism in miners and people who misuse drugs provided early evidence of brain toxicity related to manganese exposure. The identification of inherited manganese transportopathies, which cause neurodevelopmental and neurodegenerative syndromes, further corroborates the neurotoxic potential of this element. Moreover, manganese dyshomoeostasis is also implicated in Parkinson's disease and other neurodegenerative conditions, such as Alzheimer's disease and Huntington's disease. Ongoing and future research will facilitate the development of better targeted therapeutical strategies than are currently available for manganese-associated neurological disorders.	[Budinger, Dimitri; Barral, Serena; Soo, Audrey K. S.; Kurian, Manju A.] UCL, Zayed Ctr Res Rare Dis Children, Dev Neurosci, London, England; [Soo, Audrey K. S.; Kurian, Manju A.] Great Ormond St Hosp Sick Children, Dept Neurol, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Kurian, MA (corresponding author), Ctr Res Rare Dis Children, London WC1N 1DZ, England.	manju.kurian@ucl.ac.uk		Soo, Audrey Ker Shin/0000-0003-2124-6731; barral, serena/0000-0002-1430-3614	NIHR Professorship; Jules Thorn Award for Biomedical Research; Rosetrees Trust; Sir Jules Thorn Trust; Great Ormond Street Hospital Children's Charity; NIHR Great Ormond Street Hospital Biomedical Research Centre PhD fellowship	NIHR Professorship; Jules Thorn Award for Biomedical Research; Rosetrees Trust(Rosetrees Trust); Sir Jules Thorn Trust; Great Ormond Street Hospital Children's Charity; NIHR Great Ormond Street Hospital Biomedical Research Centre PhD fellowship	MAK is funded by an NIHR Professorship, the Jules Thorn Award for Biomedical Research, and Rosetrees Trust. DB is funded by the Sir Jules Thorn Trust and SB is funded by the Great Ormond Street Hospital Children's Charity. AKSS is funded by an NIHR Great Ormond Street Hospital Biomedical Research Centre PhD fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We would like to thank Ulrike Dydak, Susan Hayflick, Katrina Wakeman, and Shanti Balasubramaniam for kindly providing anonymised MRI images to illustrate the neuroimaging findings in manganese-related neurological disorders. We would also like to thank Maya Thomas and Sangeetha Yoganathan for providing up-to-date details of the case illustrated in the panel. We also thank Robert Spaull for proofreading the manuscript.	Andruska Kristin M, 2015, Curr Epidemiol Rep, V2, P143; Aschner JL, 2015, AM J CLIN NUTR, V102, P1482, DOI 10.3945/ajcn.115.116285; Avelino MA, 2014, J NEUROL SCI, V341, P150, DOI 10.1016/j.jns.2014.03.057; Aydemir TB, 2017, J NEUROSCI, V37, P5996, DOI 10.1523/JNEUROSCI.0285-17.2017; Balachandran RC, 2020, J BIOL CHEM, V295, P6312, DOI 10.1074/jbc.REV119.009453; Barral S, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00078; Bichell TJV, 2017, BBA-MOL BASIS DIS, V1863, P1596, DOI 10.1016/j.bbadis.2017.02.013; Bjorklund G, 2018, CURR MED CHEM, V25, P2198, DOI 10.2174/0929867325666171129124616; Boycott KM, 2015, AM J HUM GENET, V97, P886, DOI 10.1016/j.ajhg.2015.11.002; Brna P, 2011, J CHILD NEUROL, V26, P891, DOI 10.1177/0883073810393962; Bryan MR, 2020, MOL NEUROBIOL, V57, P1570, DOI 10.1007/s12035-019-01824-1; Bryan MR, 2019, HUM MOL GENET, V28, P3825, DOI 10.1093/hmg/ddz209; Carmona A, 2019, ACS CHEM NEUROSCI, V10, P599, DOI 10.1021/acschemneuro.8b00451; Casjen S, 2018, NEUROTOXICOLOGY, V64, P60, DOI 10.1016/j.neuro.2017.08.004; Chen JY, 2018, BIOCHEM BIOPH RES CO, V498, P171, DOI 10.1016/j.bbrc.2018.02.007; Chen P, 2018, FRONT BIOSCI-LANDMRK, V23, P1655, DOI 10.2741/4665; Chen P, 2015, J NEUROCHEM, V134, P601, DOI 10.1111/jnc.13170; Cherry JD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0411-8; Choi EK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21464-0; Criswell SR, 2019, J OCCUP ENVIRON MED, V61, P641, DOI 10.1097/JOM.0000000000001634; Criswell SR, 2018, NEUROLOGY, V91, pE1022, DOI 10.1212/WNL.0000000000006163; Criswell SR, 2018, NEUROTOXICOLOGY, V64, P43, DOI 10.1016/j.neuro.2017.07.004; Damase TR, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.628137; Deverman BE, 2018, NAT REV DRUG DISCOV, V17, P641, DOI 10.1038/nrd.2018.110; Faridani OR, 2016, NAT BIOTECHNOL, V34, P1264, DOI 10.1038/nbt.3701; Fernandes J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00676; Fernandes J, 2019, TOXICOL SCI, V169, P84, DOI 10.1093/toxsci/kfz028; Fernandes J, 2017, TOXICOL SCI, V155, P213, DOI 10.1093/toxsci/kfw196; Figueroa-Romero C, 2020, ANN CLIN TRANSL NEUR, V7, P872, DOI 10.1002/acn3.51006; Fujimori K, 2018, NAT MED, V24, P1579, DOI 10.1038/s41591-018-0140-5; Ghosh R, 2020, TREMOR OTHER HYPERK, V10, DOI 10.5334/tohm.537; Guilarte TR, 2015, TOXICOL SCI, V146, P204, DOI 10.1093/toxsci/kfv099; Gulab S, 2018, NEUROPEDIATRICS, V49, P72, DOI 10.1055/s-0037-1608778; Gyorgy B, 2018, MOL THER-NUCL ACIDS, V11, P429, DOI 10.1016/j.omtn.2018.03.007; Hanna J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00478; Harischandra DS, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00654; Harischandra DS, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau4543; Harischandra DS, 2018, NEUROTOXICOLOGY, V64, P267, DOI 10.1016/j.neuro.2017.04.007; Harischandra DS, 2015, TOXICOL SCI, V143, P454, DOI 10.1093/toxsci/kfu247; He R, 2017, BIOCHEM BIOPH RES CO, V486, P342, DOI 10.1016/j.bbrc.2017.03.041; Horning KJ, 2015, ANNU REV NUTR, V35, P71, DOI 10.1146/annurev-nutr-071714-034419; Iyare PU, 2019, NEUROTOXICOLOGY, V73, P1, DOI 10.1016/j.neuro.2019.02.013; Josephs KA, 2005, NEUROLOGY, V64, P2033, DOI 10.1212/01.WNL.0000167411.93483.A1; Joshi P, 2019, NEUROTOXICOLOGY, V75, P148, DOI 10.1016/j.neuro.2019.09.007; Juneja M, 2018, J GENE MED, V20, DOI 10.1002/jgm.3012; Kirkley KS, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0871-0; Kondo T, 2017, CELL REP, V21, P2304, DOI 10.1016/j.celrep.2017.10.109; Koscielak J, 2005, HANDBOOK OF CARBOHYDRATE ENGINEERING, P99, DOI 10.1201/9781420027631.ch4; Kwakye GF, 2015, INT J ENV RES PUB HE, V12, P7519, DOI 10.3390/ijerph120707519; Lambrianides S, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117101; Lee EY, 2021, PARKINSONISM RELAT D, V85, P37, DOI 10.1016/j.parkreldis.2021.02.020; Lee E, 2017, ADV NEUROBIOL, V16, P1, DOI 10.1007/978-3-319-55769-4_1; Lewerenz J, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00469; Li LM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7580707; Lin M, 2020, J NEUROSCI, V40, P5871, DOI 10.1523/JNEUROSCI.2830-19.2020; Lin W, 2017, J CLIN INVEST, V127, P2407, DOI 10.1172/JCI90896; Little D, 2019, NEUROBIOL AGING, V78, P130, DOI 10.1016/j.neurobiolaging.2019.02.008; Lucchini Roberto, 2017, Adv Neurobiol, V18, P13, DOI 10.1007/978-3-319-60189-2_2; Ma RE, 2018, NEUROTOXICOLOGY, V64, P30, DOI 10.1016/j.neuro.2017.08.013; Maret W, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010066; Marreilha Dos Santos A P, 2017, Clin Pharmacol Transl Med, V1, P54; Marti-Sanchez L, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0758-x; Martins AC, 2020, EXPERT REV NEUROTHER, V20, P1109, DOI 10.1080/14737175.2020.1807330; Martins AC, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16193546; Mealer RG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70108-9; Mercadante CJ, 2019, J CLIN INVEST, V129, P5442, DOI 10.1172/JCI129710; Monteys AM, 2017, MOL THER, V25, P12, DOI 10.1016/j.ymthe.2016.11.010; Mukhtiar K, 2016, BRAIN DEV-JPN, V38, P862, DOI 10.1016/j.braindev.2016.04.005; Nakata T, 2020, P NATL ACAD SCI USA, V117, P28930, DOI 10.1073/pnas.2014742117; Namnah M, 2020, MOV DISORD CLIN PRAC, V7, P569, DOI 10.1002/mdc3.12947; Nebert DW, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0233-3; Neely MD, 2017, TOXICOL SCI, V159, P366, DOI 10.1093/toxsci/kfx145; O'Neal Stefanie L, 2015, Curr Environ Health Rep, V2, P315, DOI 10.1007/s40572-015-0056-x; Ofengeim D, 2017, TRENDS MOL MED, V23, P563, DOI 10.1016/j.molmed.2017.04.006; Park JH, 2020, J INHERIT METAB DIS, V43, P1370, DOI 10.1002/jimd.12306; Park JH, 2018, GENET MED, V20, P259, DOI 10.1038/gim.2017.106; Park JH, 2015, AM J HUM GENET, V97, P894, DOI 10.1016/j.ajhg.2015.11.003; Partridge B, 2020, J NEUROSCI METH, V331, DOI 10.1016/j.jneumeth.2019.108484; Pearson TS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24524-8; Peres TV, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0099-0; Pfalzer AC, 2020, METALLOMICS, V12, P1118, DOI 10.1039/d0mt00081g; Popichak KA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1349-4; Quadri M, 2015, MOVEMENT DISORD, V30, P996, DOI 10.1002/mds.26202; Quadri M, 2012, AM J HUM GENET, V90, P467, DOI 10.1016/j.ajhg.2012.01.017; Riley LG, 2017, J INHERIT METAB DIS, V40, P261, DOI 10.1007/s10545-016-0010-6; Rodan LH, 2018, MOL GENET METAB, V124, P161, DOI 10.1016/j.ymgme.2018.04.002; Roth JA, 2014, NEUROTOXICOLOGY, V44, P314, DOI 10.1016/j.neuro.2014.08.006; Schweitzer JS, 2020, NEW ENGL J MED, V382, P1926, DOI 10.1056/NEJMoa1915872; Shin HW, 2017, TREMOR OTHER HYPERK, V7, DOI 10.7916/D8TB1K44; Sikk K, 2015, INT REV NEUROBIOL, V120, P257, DOI 10.1016/bs.irn.2015.02.002; Smith MR, 2017, BIOCHEM BIOPH RES CO, V482, P388, DOI 10.1016/j.bbrc.2016.10.126; Sunuwar L, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140978; Tarale P, 2018, TOXICOL IN VITRO, V46, P94, DOI 10.1016/j.tiv.2017.10.003; Taylor CA, 2019, J BIOL CHEM, V294, P1860, DOI 10.1074/jbc.RA118.005628; Thompson KJ, 2019, BIOMETALS, V32, P829, DOI 10.1007/s10534-019-00216-1; Tidball AM, 2015, HUM MOL GENET, V24, P1929, DOI 10.1093/hmg/ddu609; Tjalkens Ronald B, 2017, Adv Neurobiol, V18, P159, DOI 10.1007/978-3-319-60189-2_8; Trujillo CA, 2019, CELL STEM CELL, V25, P558, DOI 10.1016/j.stem.2019.08.002; Tuschl K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11601; Tuschl K, 2012, AM J HUM GENET, V90, P457, DOI 10.1016/j.ajhg.2012.01.018; Wallace DR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040901; Wang LX, 2017, PROTEIN CELL, V8, P365, DOI 10.1007/s13238-017-0397-3; Ward EJ, 2018, ANN WORK EXPOS HEAL, V62, P101, DOI 10.1093/annweh/wxx091; Warren EB, 2020, TOXICOL SCI, V176, P446, DOI 10.1093/toxsci/kfaa079; Watts ME, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00216; Williams M, 2012, TOXICOLOGICAL PROFIL; Yan DY, 2019, NEUROTOX RES, V36, P66, DOI 10.1007/s12640-019-00016-y; Yang HJ, 2018, NEUROTOXICOLOGY, V64, P78, DOI 10.1016/j.neuro.2017.02.014; Ye Q, 2017, METALLOMICS, V9, P1028, DOI 10.1039/c7mt00079k; Zaki MS, 2018, CLIN GENET, V93, P905, DOI 10.1111/cge.13184; Zeglam A, 2019, ACTA NEUROL BELG, V119, P379, DOI 10.1007/s13760-018-1024-7; Zhang ZY, 2016, NEUROCHEM RES, V41, P409, DOI 10.1007/s11064-016-1844-x; Zhu GL, 2019, TOXICOL LETT, V309, P10, DOI 10.1016/j.toxlet.2019.04.004; Zhu XX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30436-3	114	12	12	6	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					956	968		10.1016/S1474-4422(21)00238-6	http://dx.doi.org/10.1016/S1474-4422(21)00238-6			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL5PY	34687639	Green Submitted			2022-12-18	WOS:000710458300018
J	Carmona-Iragui, M; Alcolea, D; Barroeta, I; Videla, L; Munoz, L; Van Pelt, KL; Schmitt, FA; Lightner, DD; Koehl, LM; Jicha, G; Sacco, S; Mircher, C; Pape, SE; Hithersay, R; Clare, ICH; Holland, AJ; Nubling, G; Levin, J; Zaman, SH; Strydom, A; Rebillat, AS; Head, E; Blesa, R; Lleo, A; Fortea, J				Carmona-Iragui, Maria; Alcolea, Daniel; Barroeta, Isabel; Videla, Laura; Munoz, Laia; Van Pelt, Kathyrn L.; Schmitt, Frederick A.; Lightner, Donita D.; Koehl, Lisa M.; Jicha, Gregory; Sacco, Silvia; Mircher, Clotilde; Pape, Sarah E.; Hithersay, Rosalyn; Clare, Isabel C. H.; Holland, Anthony J.; Nubling, Georg; Levin, Johannes; Zaman, Shahid H.; Strydom, Andre; Rebillat, Anne-Sophie; Head, Elizabeth; Blesa, Rafael; Lleo, Alberto; Fortea, Juan			Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study	LANCET NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; DEMENTIA; ATROPHY	Background Adults with Down syndrome are at an ultra-high risk of Alzheimer's disease, but diagnosis of Alzheimer's disease in this population is challenging. We aimed to validate the clinical utility of plasma neurofilament light chain (NfL) for the diagnosis of symptomatic Alzheimer's disease in Down syndrome, assess its prognostic value, and establish longitudinal changes in adults with Down syndrome. Methods We did a multicentre cohort study, including adults with Down syndrome (>= 18 years), recruited from six hospitals and university medical centres in France, Germany, Spain, the UK, and the USA, who had been assessed, followed up, and provided at least two plasma samples. Participants were classified by local clinicians, who were masked to biomarker data, as asymptomatic (ie, no clinical suspicion of Alzheimer's disease), prodromal Alzheimer's disease, or Alzheimer's disease dementia. We classified individuals who progressed along the Alzheimer's disease continuum during follow-up as progressors. Plasma samples were analysed retrospectively; NfL concentrations were measured centrally using commercial kits for biomarker detection. We used ANOVA to evaluate differences in baseline NfL concentrations, Cox regression to study their prognostic value, and linear mixed models to estimate longitudinal changes. To account for potential confounders, we included age, sex, and intellectual disability as covariates in the analyses. Findings Between Aug 2, 2010, and July 16, 2019, we analysed 608 samples from 236 people with Down syndrome: 165 (70%) were asymptomatic, 32 (14%) had prodromal Alzheimer's disease, and 29 (12%) had Alzheimer's disease dementia; ten [4%] participants were excluded because their classification was uncertain. Mean follow-up was 3.6 years (SD 1.6, range 0.6-9.2). Baseline plasma NfL concentrations showed an area under the receiver operating characteristic curve of 0.83 (95% CI 0.76-0.91) in the prodromal group and 0.94 (0.90-0.97) in the dementia group for differentiating from participants who were asymptomatic. An increase of 1 pg/mL in baseline NfL concentrations was associated with a 1.04-fold risk of clinical progression (95% CI 1.01-1.07; p=0.0034). Plasma NfL concentrations showed an annual increase of 3.0% (95% CI 0.4-5.8) per year in the asymptomatic non-progressors group, 11.5% (4.9-18.5) per year in the asymptomatic progressors group, and 16.0% (8.4-24.0) per year in the prodromal Alzheimer's disease progressors group. In participants with Alzheimer's disease dementia, NfL concentrations increased by a mean of 24.3% (15.3-34.1). Interpretation Plasma NfL concentrations have excellent diagnostic and prognostic performance for symptomatic Alzheimer's disease in Down syndrome. The longitudinal trajectory of plasma NfL supports its use as a theragnostic marker in clinical trials. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Carmona-Iragui, Maria; Alcolea, Daniel; Barroeta, Isabel; Videla, Laura; Munoz, Laia; Blesa, Rafael; Lleo, Alberto; Fortea, Juan] Univ Autonoma Barcelona, Biomed Res Inst St Pau, Hosp Santa Creu & St Pau, St Pau Memory Unit,Neurol Dept, Barcelona, Spain; [Carmona-Iragui, Maria; Alcolea, Daniel; Barroeta, Isabel; Videla, Laura; Munoz, Laia; Blesa, Rafael; Lleo, Alberto; Fortea, Juan] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Carmona-Iragui, Maria; Videla, Laura; Fortea, Juan] Fundacio Catalana Sindrome, Barcelona Med Ctr, Barcelona, Spain; [Carmona-Iragui, Maria; Videla, Laura; Sacco, Silvia; Pape, Sarah E.; Levin, Johannes; Zaman, Shahid H.; Strydom, Andre; Rebillat, Anne-Sophie; Fortea, Juan] Horizon 21 Consortium, Paris, France; [Schmitt, Frederick A.; Lightner, Donita D.; Koehl, Lisa M.; Jicha, Gregory] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; [Van Pelt, Kathyrn L.; Schmitt, Frederick A.; Jicha, Gregory] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Sacco, Silvia; Mircher, Clotilde; Rebillat, Anne-Sophie] Inst Jerome Lejeune, Paris, France; [Pape, Sarah E.; Hithersay, Rosalyn; Strydom, Andre] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England; [Pape, Sarah E.; Strydom, Andre] South London & Maudsley Fdn NHS Trust, London, England; [Pape, Sarah E.; Hithersay, Rosalyn; Strydom, Andre] LonDownS Consortium, London, England; [Clare, Isabel C. H.; Holland, Anthony J.; Zaman, Shahid H.] Univ Cambridge, Dept Psychiat, Cambridge, England; [Clare, Isabel C. H.; Zaman, Shahid H.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England; [Clare, Isabel C. H.] East England, Natl Inst Hlth Res, Appl Res Collaborat, Cambridge, England; [Nubling, Georg; Levin, Johannes] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany; [Levin, Johannes] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Levin, Johannes] German Ctr Neurodegenerat Dis, Munich, Germany; [Head, Elizabeth] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA	Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; CIBERNED; University of Kentucky; University of Kentucky; University of London; King's College London; University of Cambridge; University of Cambridge; University of Munich; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of California System; University of California Irvine	Carmona-Iragui, M (corresponding author), Hosp Santa Creu & Sant Pau, Dept Neurol, Memory Unit, Barcelona 08025 167, Spain.	mcarmonai@santpau.cat; jfortea@santpau.cat	Levin, Johannes/W-8686-2019; Fortea, Juan/AFU-3179-2022	Levin, Johannes/0000-0001-5092-4306; Fortea, Juan/0000-0002-1340-638X; Carmona Iragui, Maria/0000-0001-6914-2339; Strydom, Andre/0000-0002-2502-6704; Hithersay, Rosalyn/0000-0001-9689-347X; Alcolea, Daniel/0000-0002-3819-3245	AC Immune; La Caixa Foundation; Instituto de Salud Carlos III; National Institute on Aging; Wellcome Trust; Jerome Lejeune Foundation; Medical Research Council; National Institute for Health Research; EU Joint Programme-Neurodegenerative Disease Research; Alzheimer's society; Deutsche Forschungsgemeinschaft; Stiftung fur die Erforschung von Verhaltens und Umwelteinflussen auf die menschliche Gesundheit; NHS National Institute of Health Research Applied Research Collaborations East of England, UK	AC Immune; La Caixa Foundation(La Caixa Foundation); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome Trust); Jerome Lejeune Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); EU Joint Programme-Neurodegenerative Disease Research; Alzheimer's society; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Stiftung fur die Erforschung von Verhaltens und Umwelteinflussen auf die menschliche Gesundheit; NHS National Institute of Health Research Applied Research Collaborations East of England, UK	AC Immune, La Caixa Foundation, Instituto de Salud Carlos III, National Institute on Aging, Wellcome Trust, Jerome Lejeune Foundation, Medical Research Council, National Institute for Health Research, EU Joint Programme-Neurodegenerative Disease Research, Alzheimer's society, Deutsche Forschungsgemeinschaft, Stiftung fur die Erforschung von Verhaltens und Umwelteinflussen auf die menschliche Gesundheit, and NHS National Institute of Health Research Applied Research Collaborations East of England, UK.	Alcolea D, 2017, NEUROLOGY, V89, P178, DOI 10.1212/WNL.0000000000004088; Alcolea D, 2014, J ALZHEIMERS DIS, V39, P719, DOI 10.3233/JAD-131334; Ballard C, 2016, LANCET NEUROL, V15, P622, DOI 10.1016/S1474-4422(16)00063-6; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Fortea J, 2020, LANCET, V395, P1988, DOI 10.1016/S0140-6736(20)30689-9; Fortea J, 2018, LANCET NEUROL, V17, P860, DOI 10.1016/S1474-4422(18)30285-0; Handen BL, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12065; Hua X, 2016, NEUROBIOL AGING, V37, P26, DOI 10.1016/j.neurobiolaging.2015.09.018; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Kuhle J, 2019, NEUROLOGY, V92, pE1007, DOI 10.1212/WNL.0000000000007032; Lewczuk P, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0404-9; Lleo A, 2019, ALZHEIMERS DEMENT, V15, P742, DOI 10.1016/j.jalz.2019.01.015; Lleo A, 2015, NAT REV NEUROL, V11, P41, DOI 10.1038/nrneurol.2014.232; Mattsson N, 2019, JAMA NEUROL, V76, P791, DOI 10.1001/jamaneurol.2019.0765; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; McDade E, 2018, NEUROLOGY, V91, pE1295, DOI 10.1212/WNL.0000000000006277; Moran JA, 2013, MAYO CLIN PROC, V88, P831, DOI 10.1016/j.mayocp.2013.04.024; Olsson B, 2019, J NEUROL, V266, P2129, DOI 10.1007/s00415-019-09389-8; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Quiroz YT, 2020, LANCET NEUROL, V19, P513, DOI 10.1016/S1474-4422(20)30137-X; Raffi MS, 2019, J ALZHEIMERS DIS, V70, P131, DOI 10.3233/JAD-190322; Sabuncu MR, 2011, ARCH NEUROL-CHICAGO, V68, P1040, DOI 10.1001/archneurol.2011.167; Sanchez-Valle R, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0439-y; Shinomoto M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211575; Startin CM, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0477-0; Strydom Andre, 2018, Alzheimers Dement (N Y), V4, P703, DOI 10.1016/j.trci.2018.10.006; Strydom A, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0367-x; Sugarman MA, 2020, NEUROBIOL AGING, V94, P60, DOI 10.1016/j.neurobiolaging.2020.05.011; Sutphen CL, 2018, ALZHEIMERS DEMENT, V14, P869, DOI 10.1016/j.jalz.2018.01.012; Weston PSJ, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0472-5; Whitwell JL, 2010, NEUROTOX RES, V18, P339, DOI 10.1007/s12640-010-9175-1; Wiseman FK, 2015, NAT REV NEUROSCI, V16, P564, DOI 10.1038/nrn3983; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310	34	12	12	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					605	614		10.1016/S1474-4422(21)00129-0	http://dx.doi.org/10.1016/S1474-4422(21)00129-0			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34302785	Green Submitted, Green Accepted			2022-12-18	WOS:000677684700014
J	English, C; MacDonald-Wicks, L; Patterson, A; Attia, J; Hankey, GJ				English, Coralie; MacDonald-Wicks, Lesley; Patterson, Amanda; Attia, John; Hankey, Graeme J.			The role of diet in secondary stroke prevention	LANCET NEUROLOGY			English	Review							TRANSIENT ISCHEMIC ATTACK; RISK-FACTORS; MYOCARDIAL-INFARCTION; FOLIC-ACID; METAANALYSIS; DISEASE; INTERVENTION; MORTALITY; COUNTRIES; NUTRITION	Poor quality diet and nutrition is strongly associated with risk of first stroke, and adherence to a Mediterranean-style diet has been reported to reduce the risk of first stroke. The association between diet quality and the risk of recurrent stroke is less certain and there is no reliable evidence that improving diet quality or dietary supplementation reduces recurrent stroke risk. Current evidence is largely based on epidemiological studies of diverse dietary approaches, ranging from nutritional supplements to specific foods, food groups, and dietary patterns, and is difficult to interpret. In the absence of reliable evidence from randomised clinical trials, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach can be used to assess the potential causal role of diet quality and interventions in reducing recurrent stroke, and to provide guidance for clinical practice and directions for future research. Further work is needed to identify and develop the most promising dietary interventions for evaluation by large randomised clinical trials.	[English, Coralie] Univ Newcastle, Sch Hlth Sci, Newcastle, NSW 2308, Australia; [English, Coralie] Univ Newcastle, Prior Res Ctr Stroke & Brain Injury, Sch Hlth Sci, Newcastle, NSW, Australia; [MacDonald-Wicks, Lesley; Patterson, Amanda] Univ Newcastle, Prior Res Ctr Phys Act & Nutr, Newcastle, NSW, Australia; [Attia, John] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [English, Coralie] Florey Inst Neurosci & Mental Hlth, Ctr Res Excellence Stroke Recovery & Rehabil, Melbourne, Vic, Australia; [English, Coralie] Hunter Med Res Inst, Melbourne, Vic, Australia; [Hankey, Graeme J.] Univ Western Australia, Fac Hlth & Med Sci, Med Sch, Nedlands, WA, Australia	University of Newcastle; University of Newcastle; University of Newcastle; University of Newcastle; Florey Institute of Neuroscience & Mental Health; Hunter Medical Research Institute; University of Western Australia	English, C (corresponding author), Univ Newcastle, Sch Hlth Sci, Newcastle, NSW 2308, Australia.; English, C (corresponding author), Univ Newcastle, Prior Res Ctr Stroke & Brain Injury, Newscastle, NSW 2308, Australia.	coralie.english@newcastle.edu.au	MACDONALD-WICKS, LESLEY/G-7086-2013; English, Coralie/D-4591-2009; Hankey, Graeme J/H-4968-2014	MACDONALD-WICKS, LESLEY/0000-0003-4668-7752; English, Coralie/0000-0001-5910-7927; Hankey, Graeme J/0000-0002-6044-7328				Abdelhamid AS, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003177.pub5; Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1326; Ahmadi M, 2020, LANCET NEUROL, V19, P49, DOI 10.1016/S1474-4422(19)30369-2; Amarenco P, 2016, NEW ENGL J MED, V374, P1533, DOI 10.1056/NEJMoa1412981; Amarenco P, 2009, LANCET NEUROL, V8, P453, DOI 10.1016/S1474-4422(09)70058-4; Barbarawi M, 2019, JAMA CARDIOL, V4, P765, DOI 10.1001/jamacardio.2019.1870; Becerra-Tomas N, 2020, CRIT REV FOOD SCI, V60, P1207, DOI 10.1080/10408398.2019.1565281; Bechthold A, 2019, CRIT REV FOOD SCI, V59, P1071, DOI 10.1080/10408398.2017.1392288; Bergstrom L, 2017, STROKE, V48, P2046, DOI 10.1161/STROKEAHA.117.016815; Bernhardt J, 2019, NEUROREHAB NEURAL RE, V33, P959, DOI 10.1177/1545968319888642; Bonaccio M, 2018, BRIT J NUTR, V120, P841, DOI 10.1017/S0007114518002179; Chareonrungrueangchai K, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041088; Chen GC, 2019, EUR J EPIDEMIOL, V34, P337, DOI 10.1007/s10654-019-00504-7; D'Andrea E, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2224; de Graaf MNS, 2019, APL BIOENG, V3, DOI 10.1063/1.5090986; Deng A, 2018, NUTR METAB CARDIOVAS, V28, P1012, DOI 10.1016/j.numecd.2018.05.011; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4; Filippou CD, 2020, ADV NUTR, V11, P1150, DOI 10.1093/advances/nmaa041; Fretts AM, 2014, BRIT J NUTR, V112, P1206, DOI 10.1017/S0007114514001925; Glenn AJ, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00080; Graudal N, 2014, AM J HYPERTENS, V27, P1129, DOI 10.1093/ajh/hpu028; Gu KJ, 2020, J CANCER PREV, V25, P127, DOI 10.15430/JCP.2020.25.3.127; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hankey GJ, 2010, LANCET NEUROL, V9, P855, DOI 10.1016/S1474-4422(10)70187-3; Hankey GJ, 2017, STROKE, V48, P3168, DOI 10.1161/STROKEAHA.117.016993; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hooper L, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011583.pub2, 10.1002/14651858.CD011737]; Horikawa C, 2019, EUR J NUTR, V58, P281, DOI 10.1007/s00394-017-1592-y; Hsu CY, 2018, J STROKE, V20, P99, DOI 10.5853/jos.2017.01522; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Huang LP, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m315; Huang LP, 2020, AM HEART J, V221, P136, DOI 10.1016/j.ahj.2019.12.020; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V320, P969, DOI 10.1001/jama.2018.11025; Lagstrom H, 2020, AM J CLIN NUTR, V111, P787, DOI 10.1093/ajcn/nqz329; Liu G, 2019, CIRC RES, V124, P920, DOI 10.1161/CIRCRESAHA.118.314316; Mehta T, 2019, J STROKE CEREBROVASC, V28, P2124, DOI 10.1016/j.jstrokecerebrovasdis.2019.04.009; Mena MP, 2009, AM J CLIN NUTR, V89, P248, DOI 10.3945/ajcn.2008.26094; Moller G, 2017, AM J CLIN NUTR, V106, P1394, DOI 10.3945/ajcn.116.139626; Neal B, 2017, AM HEART J, V188, P109, DOI 10.1016/j.ahj.2017.02.033; O'Donnell MJ, 2016, LANCET, V388, P761, DOI 10.1016/S0140-6736(16)30506-2; Olaiya MT, 2017, STROKE, V48, P2504, DOI 10.1161/STROKEAHA.117.017499; Toi PL, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092722; Prentice RL, 2017, AM J CLIN NUTR, V106, P35, DOI 10.3945/ajcn.117.153270; Raman G, 2019, AM J CLIN NUTR, V110, P1067, DOI 10.1093/ajcn/nqz178; Rees K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub3; Rees K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002128.pub4; Rosato V, 2019, EUR J NUTR, V58, P173, DOI 10.1007/s00394-017-1582-0; Schunemann HJ, 2020, J CLIN EPIDEMIOL, V122, P129, DOI 10.1016/j.jclinepi.2019.12.020; Schwingshackl L, 2019, CRIT REV FOOD SCI, V59, P2674, DOI 10.1080/10408398.2018.1463967; Solfrizzi V, 2018, J ALZHEIMERS DIS, V64, pS229, DOI 10.3233/JAD-179940; Tan Y, 2017, NEUROL RES, V39, P484, DOI 10.1080/01616412.2017.1322804; Aung T, 2018, JAMA CARDIOL, V3, P225, DOI 10.1001/jamacardio.2017.5205; Toledo E, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-207; Tong TYN, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4897; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Wallin A, 2018, CLIN NUTR, V37, P590, DOI 10.1016/j.clnu.2017.01.012; Wang Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017095; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; Wu LY, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0505-z; Zeraatkar D, 2019, ANN INTERN MED, V171, P721, DOI 10.7326/M19-0622; Zhao M, 2017, NEUROLOGY, V88, P1830, DOI [10.1212/WNL.0000000000003909, 10.1212/wnl.0000000000003909]	63	12	12	2	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					150	160		10.1016/S1474-4422(20)30433-6	http://dx.doi.org/10.1016/S1474-4422(20)30433-6		JAN 2021	11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33347806				2022-12-18	WOS:000610201500022
J	Roman, GC; Reis, J; Spencer, PS; Buguet, A; Ozturk, S; Wasay, M				Roman, Gustavo C.; Reis, Jacques; Spencer, Peter S.; Buguet, Alain; Ozturk, Serefnur; Wasay, Mohammad		World Federation Neurology Environ	COVID-19 international neurological registries	LANCET NEUROLOGY			English	Letter									[Roman, Gustavo C.] Houston Methodist Hosp, Dept Neurol, Methodist Neurol Inst, Houston, TX 77030 USA; [Roman, Gustavo C.] Weill Cornell Med Coll, New York, NY 10065 USA; [Roman, Gustavo C.] World Federat Neurol, Environm Neurol Specialty Grp, London, England; [Reis, Jacques] Univ Strasbourg, Fac Med, Strasbourg, France; [Reis, Jacques] RISE Assoc, Oberhausbergen, France; [Spencer, Peter S.] Oregon Hlth & Sci Univ, Dept Neurol, Oregon Inst Occupat Hlth Sci, Sch Med, Portland, OR 97201 USA; [Buguet, Alain] Claude Bernard Lyon 1 Univ, Malaria Res Unit, Villeurbanne, France; [Buguet, Alain] French Army Hlth Serv, Paris, France; [Ozturk, Serefnur] Selcuk Univ, Fac Med, Dept Neurol, Konya, Turkey; [Ozturk, Serefnur] Soc Turkish Neurol, Ankara, Turkey; [Wasay, Mohammad] Aga Khan Univ, Neurol Sect, Dept Med, Karachi, Pakistan; [Wasay, Mohammad] Pakistan Int Neurosci Soc, Karachi, Pakistan	The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Oregon Health & Science University; Selcuk University; Aga Khan University	Roman, GC (corresponding author), Houston Methodist Hosp, Dept Neurol, Methodist Neurol Inst, Houston, TX 77030 USA.; Roman, GC (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.; Roman, GC (corresponding author), World Federat Neurol, Environm Neurol Specialty Grp, London, England.	gcroman@houstonmethodist.org		Medina, Marco Tulio/0000-0003-0469-054X				Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062; Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187; Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031	5	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					484	485		10.1016/S1474-4422(20)30148-4	http://dx.doi.org/10.1016/S1474-4422(20)30148-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK		Bronze, Green Published			2022-12-18	WOS:000544059200021
J	Fasano, A; Mancini, M				Fasano, Alfonso; Mancini, Martina			Wearable-based mobility monitoring: the long road ahead	LANCET NEUROLOGY			English	Editorial Material									[Fasano, Alfonso] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada; [Fasano, Alfonso] Toronto Western Hosp, Krembil Brain Inst, Toronto, ON M5T 2S8, Canada; [Fasano, Alfonso] Univ Toronto, Div Neurol, Toronto, ON, Canada; [Fasano, Alfonso] Ctr Adv Neurotechnol Innovat Applicat, Toronto, ON, Canada; [Mancini, Martina] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, Portland, OR 97201 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Oregon Health & Science University	Fasano, A (corresponding author), Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada.; Fasano, A (corresponding author), Toronto Western Hosp, Krembil Brain Inst, Toronto, ON M5T 2S8, Canada.; Fasano, A (corresponding author), Univ Toronto, Div Neurol, Toronto, ON, Canada.; Fasano, A (corresponding author), Ctr Adv Neurotechnol Innovat Applicat, Toronto, ON, Canada.	alfonso.fasano@uhn.ca		Mancini, Martina/0000-0002-4532-3984				Artusi CA, 2018, PARKINSONISM RELAT D, V46, pS53, DOI 10.1016/j.parkreldis.2017.07.022; Buckingham Bruce, 2005, Diabetes Technol Ther, V7, P440, DOI 10.1089/dia.2005.7.440; Eadicicco L., 2016, 4 THINGS KNOW FITBIT; Framingham M, IDC 2019; Noah B, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-017-0002-4; Osterloh R., GOOGLE; Piwek L, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001953; de Lima ALS, 2017, J NEUROL, V264, P1642, DOI 10.1007/s00415-017-8424-0; Vienne A, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00817; Warmerdam E, 2020, LANCET NEUROL, V19, P462, DOI 10.1016/S1474-4422(19)30397-7	10	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					378	379		10.1016/S1474-4422(20)30033-8	http://dx.doi.org/10.1016/S1474-4422(20)30033-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32059810				2022-12-18	WOS:000573045100008
J	Shi, CH; Luo, HY; Fan, Y; Li, YS; Xu, YM				Shi, Chang-He; Luo, Hai-Yang; Fan, Yu; Li, Yu-Sheng; Xu, Yu-Ming			LRP10 in alpha-synucleinopathies	LANCET NEUROLOGY			English	Letter									[Shi, Chang-He; Luo, Hai-Yang; Fan, Yu; Li, Yu-Sheng; Xu, Yu-Ming] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China	Zhengzhou University	Xu, YM (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China.	xuyuming@zzu.edu.cn	Hoenicka, Janet/B-2908-2014	Hoenicka, Janet/0000-0002-6790-6988				HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Quadri M, 2018, LANCET NEUROL, V17, P597, DOI 10.1016/S1474-4422(18)30179-0	2	12	12	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1034	1035		10.1016/S1474-4422(18)30402-2	http://dx.doi.org/10.1016/S1474-4422(18)30402-2			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30507387	Bronze			2022-12-18	WOS:000450119300012
J	Schwab, JM; Maas, AIR; Hsieh, JTC; Curt, A				Schwab, Jan M.; Maas, Andrew I. R.; Hsieh, Jane T. C.; Curt, Armin			Raising awareness for spinal cord injury research	LANCET NEUROLOGY			English	Letter							RECOVERY		[Schwab, Jan M.] Ohio State Univ, Spinal Cord Injury Div Paraplegiol, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA; [Schwab, Jan M.; Maas, Andrew I. R.; Hsieh, Jane T. C.; Curt, Armin] Wings Life Spinal Cord Res Fdn, Salzburg, Austria; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Curt, Armin] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland	University System of Ohio; Ohio State University; University of Antwerp; University of Antwerp; University of Zurich	Schwab, JM (corresponding author), Ohio State Univ, Spinal Cord Injury Div Paraplegiol, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA.; Schwab, JM (corresponding author), Wings Life Spinal Cord Res Fdn, Salzburg, Austria.	jan.schwab@osumc.edu	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264; Schwab, Jan/0000-0001-6784-4919				Curt A, 2012, SPINAL CORD, V50, P352, DOI 10.1038/sc.2011.113; Curt A, 2017, JAMA NEUROL, V74, P635, DOI 10.1001/jamaneurol.2017.0318; Geoffroy CG, 2014, CURR OPIN NEUROBIOL, V27, P31, DOI 10.1016/j.conb.2014.02.012; Kucher K., 2018, NEUROREHABIL NEURAL; Schwab ME, 2014, CURR OPIN NEUROBIOL, V27, P53, DOI 10.1016/j.conb.2014.02.011; Spinal Cord Injury (SCI), 2016, J SPINAL CORD MED, V39, P493, DOI [10.1080/10790268.2016.1210925, DOI 10.1080/10790268.2016.1210925]; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Wang XX, 2006, ANN NEUROL, V60, P540, DOI 10.1002/ana.20953	8	12	13	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2018	17	7					581	582		10.1016/S1474-4422(18)30206-0	http://dx.doi.org/10.1016/S1474-4422(18)30206-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK8RP	29914704	Bronze			2022-12-18	WOS:000436495200012
J	Schwenkenbecher, P; Wurster, U; Suhs, KW; Stangel, M; Skripuletz, T				Schwenkenbecher, Philipp; Wurster, Ulrich; Suehs, Kurt-Wolfram; Stangel, Martin; Skripuletz, Thomas			Applying the 2017 McDonald diagnostic criteria for multiple sclerosis	LANCET NEUROLOGY			English	Letter									[Schwenkenbecher, Philipp; Wurster, Ulrich; Suehs, Kurt-Wolfram; Stangel, Martin; Skripuletz, Thomas] Hannover Med Sch, Clin Neuroimmunol & Neurochem, Dept Neurol, D-30625 Hannover, Germany	Hannover Medical School	Skripuletz, T (corresponding author), Hannover Med Sch, Clin Neuroimmunol & Neurochem, Dept Neurol, D-30625 Hannover, Germany.	Skripuletz.Thomas@MH-Hannover.de	Stangel, Martin/AAH-5345-2020		Bayer Healthcare; Merck-Serono; Baxter/Baxalta; CSL Behring; Sanofi-Genzyme; Grifols; Merck; Roche; Novartis; Teva; Med-Day; Biogen Idec	Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Merck-Serono(Merck & Company); Baxter/Baxalta; CSL Behring; Sanofi-Genzyme(Sanofi-AventisGenzyme Corporation); Grifols; Merck(Merck & Company); Roche(Roche Holding); Novartis(Novartis); Teva(Teva Pharmaceutical Industries); Med-Day; Biogen Idec(Biogen)	PS reports grants from Bayer Healthcare and Merck-Serono. K-WS reports grants from Merck-Serono. MS reports personal fees from Bayer Healthcare, Baxter/Baxalta, CSL Behring, Sanofi-Genzyme, Grifols, Merck, Roche, Novartis, Teva, and Med-Day. TS reports grants from Bayer Healthcare, Merck-Serono, Novartis, and Genzyme, and personal fees from Bayer Healthcare and Biogen Idec. UW declares no competing interests. The investigation was approved by the local ethics committee of the Hannover Medical School. This is a retrospective study and only data were included that were evaluated for patients' treatment.	Schwenkenbecher P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091592; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2	2	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					498	498		10.1016/S1474-4422(18)30160-1	http://dx.doi.org/10.1016/S1474-4422(18)30160-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778358	Bronze			2022-12-18	WOS:000432463400017
J	Abbott, SM; Knutson, KL; Zee, PC				Abbott, Sabra M.; Knutson, Kristen L.; Zee, Phyllis C.			Health implications of sleep and circadian rhythm research in 2017	LANCET NEUROLOGY			English	Editorial Material									[Abbott, Sabra M.; Knutson, Kristen L.; Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Zee, PC (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.	p-zee@northwestern.edu	Zee, Phyllis C/GPF-3704-2022	Knutson, Kristen/0000-0002-2751-6168				Facco FL, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.05.066; Fifel K, 2017, MOVEMENT DISORD, V32, P682, DOI 10.1002/mds.26865; Ju YE, 2017, BRAIN, V140, P2104, DOI 10.1093/brain/awx148; Sprecher KE, 2017, NEUROLOGY, V89, P445, DOI 10.1212/WNL.0000000000004171; St-Onge MP, 2016, CIRCULATION, V134, pE367, DOI 10.1161/CIR.0000000000000444; Videnovic A, 2017, JAMA NEUROL, V74, P411, DOI 10.1001/jamaneurol.2016.5192	6	12	13	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					17	18		10.1016/S1474-4422(17)30410-6	http://dx.doi.org/10.1016/S1474-4422(17)30410-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29262995				2022-12-18	WOS:000418570500011
J	Xydakis, MS; Belluscio, L				Xydakis, Michael S.; Belluscio, Leonardo			Detection of neurodegenerative disease using olfaction	LANCET NEUROLOGY			English	Editorial Material							ODOR IDENTIFICATION; PARKINSONS-DISEASE; DYSFUNCTION; ASSOCIATION; IMPAIRMENT; DEMENTIA		[Xydakis, Michael S.] Uniformed Serv Univ Hlth Sci, Otorhinolaryngol Head & Neck Surg, Bethesda, MD 20814 USA; [Xydakis, Michael S.] Walter Reed Natl Mil Med Ctr, Smell & Taste Disorders Ctr, Bethesda, MD 20892 USA; [Belluscio, Leonardo] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Xydakis, Michael S.] Air Force Res Lab, Wright Patterson AFB, OH USA	Uniformed Services University of the Health Sciences - USA; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Defense; United States Air Force; US Air Force Research Laboratory	Xydakis, MS (corresponding author), Uniformed Serv Univ Hlth Sci, Otorhinolaryngol Head & Neck Surg, Bethesda, MD 20814 USA.; Xydakis, MS (corresponding author), Walter Reed Natl Mil Med Ctr, Smell & Taste Disorders Ctr, Bethesda, MD 20892 USA.; Xydakis, MS (corresponding author), Air Force Res Lab, Wright Patterson AFB, OH USA.	michael.xydakis@usuhs.edu						Albers AD, 2016, ANN NEUROL, V80, P846, DOI 10.1002/ana.24792; Devanand DP, 2015, NEUROLOGY, V84, P182, DOI 10.1212/WNL.0000000000001132; Doty RL, 2007, AM J RHINOL, V21, P460, DOI 10.2500/ajr.2007.21.3043; Doty RL, 2017, LANCET NEUROL, V16, P478, DOI 10.1016/S1474-4422(17)30123-0; Hummel T, 2007, EUR ARCH OTO-RHINO-L, V264, P237, DOI 10.1007/s00405-006-0173-0; Krismer F, 2017, PARKINSONISM RELAT D, V35, P36, DOI 10.1016/j.parkreldis.2016.11.010; Mahlknecht P, 2016, MOVEMENT DISORD, V31, P1408, DOI 10.1002/mds.26637; Mahlknecht P, 2015, NEUROLOGY, V84, P654, DOI 10.1212/WNL.0000000000001265; Roberts RO, 2016, JAMA NEUROL, V73, P93, DOI 10.1001/jamaneurol.2015.2952; Ross GW, 2008, ANN NEUROL, V63, P167, DOI 10.1002/ana.21291; Stamps JJ, 2013, J NEUROL SCI, V333, P19, DOI 10.1016/j.jns.2013.06.033; Xydakis MS, 2015, NEUROLOGY, V84, P1559, DOI 10.1212/WNL.0000000000001475	12	12	12	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					415	416		10.1016/S1474-4422(17)30125-4	http://dx.doi.org/10.1016/S1474-4422(17)30125-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU1WD	28504103				2022-12-18	WOS:000400815800005
J	Charidimou, A; Soo, Y; Heo, JH; Srikanth, V				Charidimou, Andreas; Soo, Yannie; Heo, Ji Hoe; Srikanth, Velandai		META-MICROBLEEDS Consortium	A call for researchers to join the META-MICROBLEEDS Consortium	LANCET NEUROLOGY			English	Letter							CEREBRAL MICROBLEEDS		[Charidimou, Andreas] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Dept Neurol, Boston, MA 02114 USA; [Charidimou, Andreas] Harvard Med Sch, Boston, MA 02215 USA; [Soo, Yannie] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Heo, Ji Hoe] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea; [Srikanth, Velandai] Monash Univ, Sch Clin Sci, Stroke & Ageing Res Ctr, Dept Med,Monash Hlth, Melbourne, Vic, Australia; [Srikanth, Velandai] Monash Hlth, Neurosci, Stroke Unit, Melbourne, Vic, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Chinese University of Hong Kong; Yonsei University; Yonsei University Health System; Monash University	Charidimou, A (corresponding author), Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Dept Neurol, Boston, MA 02114 USA.; Charidimou, A (corresponding author), Harvard Med Sch, Boston, MA 02215 USA.	acharidimou@mgh.harvard.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Heo, Ji Hoe/0000-0001-9898-3321; Srikanth, Velandai/0000-0002-8442-8981				Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1; Charidimou A, 2013, STROKE, V44, P995, DOI 10.1161/STROKEAHA.111.000038; Elliott JH, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001603; Fisher M, 2014, NEUROLOGY, V83, P1304, DOI 10.1212/WNL.0000000000000871; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; The Lancet Neurology, 2015, LANCET NEUROL, V14, P235; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8	7	12	12	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2016	15	9					900	900		10.1016/S1474-4422(16)30124-7	http://dx.doi.org/10.1016/S1474-4422(16)30124-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1YY	27478945	Bronze			2022-12-18	WOS:000381279200007
J	Antoine, JC				Antoine, Jean-Christophe			Autoimmune encephalitis: paving the way for early diagnosis	LANCET NEUROLOGY			English	Editorial Material									[Antoine, Jean-Christophe] Univ Hosp, Dept Neurol, F-42055 St Etienne, France	CHU de St Etienne	Antoine, JC (corresponding author), Univ Hosp, Dept Neurol, F-42055 St Etienne, France.	j.christophe.antoine@chu-st-etienne.fr	Antoine, Jean-Christophe/R-2224-2017	Antoine, Jean-Christophe/0000-0003-4944-9362				Armangue T, 2015, NEUROLOGY, V85, P1736, DOI 10.1212/WNL.0000000000002125; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Didelot A, 2009, CURR OPIN ONCOL, V21, P566, DOI 10.1097/CCO.0b013e3283306647; Graus F, 2016, LANCET NEUROL; Irani SR, 2011, NEUROLOGY, V77, P2140; Linnoila JJ, 2014, SEMIN NEUROL, V34, P458, DOI 10.1055/s-0034-1390394; Malter MP, 2014, J NEUROL, V261, P1695, DOI 10.1007/s00415-014-7408-6; Zekeridou A, 2015, J NEUROL, V262, P1859, DOI 10.1007/s00415-015-7781-9	8	12	13	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					349	350		10.1016/S1474-4422(16)00025-9	http://dx.doi.org/10.1016/S1474-4422(16)00025-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26906965				2022-12-18	WOS:000371974000005
J	Detyniecki, K; Hirsch, LJ				Detyniecki, Kamil; Hirsch, Lawrence J.			Cannabidiol for epilepsy: trying to see through the haze	LANCET NEUROLOGY			English	Editorial Material							PHARMACOLOGY; MARIJUANA		[Detyniecki, Kamil; Hirsch, Lawrence J.] Yale Univ, Comprehens Epilepsy Ctr, New Haven, CT 06520 USA	Yale University	Hirsch, LJ (corresponding author), Yale Univ, Comprehens Epilepsy Ctr, New Haven, CT 06520 USA.	lawrence.hirsch@yale.edu		Hirsch, Lawrence/0000-0002-6333-832X				American Epilepsy Society, 2014, AES POS MED MAR; Detyniecki K, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0586-5; Devinsky O, 2015, LANCET NEUROL; Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631; Geffrey AL, 2015, EPILEPSIA, V56, P1246, DOI 10.1111/epi.13060; Koppel BS, 2014, NEUROLOGY, V82, P1556, DOI 10.1212/WNL.0000000000000363; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Press CA, 2015, EPILEPSY BEHAV, V45, P49, DOI 10.1016/j.yebeh.2015.02.043; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Zalesky A, 2012, BRAIN, V135, P2245, DOI 10.1093/brain/aws136	10	12	12	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2016	15	3					235	237		10.1016/S1474-4422(16)00002-8	http://dx.doi.org/10.1016/S1474-4422(16)00002-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE1ON	26776916				2022-12-18	WOS:000370396400004
J	Kasner, SE				Kasner, Scott E.			CADISS: a feasibility trial that answered its question	LANCET NEUROLOGY			English	Editorial Material							CERVICAL ARTERY DISSECTION; STROKE; ANTICOAGULATION		Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kasner, SE (corresponding author), Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.	kasner@mail.med.upenn.edu						Dogliotti A, 2013, CLIN CARDIOL, V36, P61, DOI 10.1002/clc.22081; Georgiadis D, 2009, NEUROLOGY, V72, P1810, DOI 10.1212/WNL.0b013e3181a2a50a; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Lyrer P, 2010, COCHRANE DB SYST REV; Markus HS, 2015, LANCET NEUROL, V14, P361, DOI 10.1016/S1474-4422(15)70018-9; Sandercock PAG, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000248.pub2; Sandercock PAG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000029.pub2; Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206; Touze E, 2003, NEUROLOGY, V61, P1347, DOI 10.1212/01.WNL.0000094325.95097.86; Weimar C, 2010, J NEUROL NEUROSUR PS, V81, P869, DOI 10.1136/jnnp.2009.192153	11	12	13	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					342	+		10.1016/S1474-4422(14)70271-6	http://dx.doi.org/10.1016/S1474-4422(14)70271-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE5RD	25684165	hybrid			2022-12-18	WOS:000351892400002
J	Luhder, F; Gold, R				Luehder, Fred; Gold, Ralf			Trial and error in clinical studies: lessons from ATAMS	LANCET NEUROLOGY			English	Editorial Material							REMITTING MULTIPLE-SCLEROSIS; REGULATORY B-CELLS; AUTOIMMUNITY; MULTICENTER; ATACICEPT; BAFF		[Luehder, Fred] Hertie Fdn, Inst Multiple Sclerosis Res, Dept Neuroimmunol, Gottingen, Germany; [Luehder, Fred] Univ Gottingen, Sch Med, Max Planck Inst Expt Med, Gottingen, Germany; [Gold, Ralf] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany	Max Planck Society; University of Gottingen; Ruhr University Bochum	Luhder, F (corresponding author), Hertie Fdn, Inst Multiple Sclerosis Res, Dept Neuroimmunol, Gottingen, Germany.	ralf.gold@ruhr-uni-bochum.de						Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; Berer K, 2011, MOL IMMUNOL, V48, P1332, DOI 10.1016/j.molimm.2010.10.025; Dall'Era M, 2007, ARTHRITIS RHEUM, V56, P4142, DOI 10.1002/art.23047; Genovese MC, 2011, ARTHRITIS RHEUM-US, V63, P1793, DOI 10.1002/art.30373; Harp CT, 2010, EUR J IMMUNOL, V40, P2942, DOI 10.1002/eji.201040516; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Kappos L, 2014, LANCET NEUROL; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Krumbholz M, 2008, BRAIN, V131, P1455, DOI 10.1093/brain/awn077; Lund FE, 2010, NAT REV IMMUNOL, V10, P236, DOI 10.1038/nri2729; Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844; Pillai S, 2011, CURR OPIN IMMUNOL, V23, P721, DOI 10.1016/j.coi.2011.10.007; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Yang M, 2010, J IMMUNOL, V184, P3321, DOI 10.4049/jimmunol.0902551	14	12	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2014	13	4					340	341		10.1016/S1474-4422(14)70050-X	http://dx.doi.org/10.1016/S1474-4422(14)70050-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB6NN	24613348				2022-12-18	WOS:000349743800002
J	Wardlaw, J; Smith, C; Dichgans, M				Wardlaw, Joanna; Smith, Colin; Dichgans, Martin			Microbleeds in cerebral small vessel disease reply	LANCET NEUROLOGY			English	Letter									[Wardlaw, Joanna] Univ Edinburgh, Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [Smith, Colin] Univ Edinburgh, Edinburgh EH4 2XU, Midlothian, Scotland; [Wardlaw, Joanna] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH4 2XU, Midlothian, Scotland; [Wardlaw, Joanna] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH4 2XU, Midlothian, Scotland; [Dichgans, Martin] Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany; [Dichgans, Martin] German Ctr Neurodegenerat Dis, Munich, Germany; [Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Munich	Wardlaw, J (corresponding author), Univ Edinburgh, Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.	joanna.wardlaw@ed.ac.uk	Dichgans, Martin/HCH-3247-2022; Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022	Dichgans, Martin/0000-0002-0654-387X; Wardlaw, Joanna M/0000-0002-9812-6642; Smith, Colin/0000-0002-4507-5132				Bailey EL, 2011, NEUROPATH APPL NEURO, V37, P711, DOI 10.1111/j.1365-2990.2011.01170.x; Bailey EL, 2009, STROKE; Bailey EL, 2011, INT J STROKE, V6, P434, DOI 10.1111/j.1747-4949.2011.00659.x; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Viswanathan A, 2011, ANN NEUROL, V70, P871, DOI 10.1002/ana.22516; Wardlaw JM, 2013, LANCET NEUROL, V12, P483, DOI 10.1016/S1474-4422(13)70060-7	6	12	13	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2013	12	8					736	737		10.1016/S1474-4422(13)70152-2	http://dx.doi.org/10.1016/S1474-4422(13)70152-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195GP	23867195				2022-12-18	WOS:000322690600010
J	Wildemann, B; Jarius, S				Wildemann, Brigitte; Jarius, Sven			The expanding range of autoimmune disorders of the nervous system	LANCET NEUROLOGY			English	Editorial Material							MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS-OPTICA; MULTIPLE-SCLEROSIS; MULTICENTER; ANTIBODIES		[Wildemann, Brigitte; Jarius, Sven] Heidelberg Univ, Dept Neurol, Div Mol Neuroimmunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Wildemann, B (corresponding author), Heidelberg Univ, Dept Neurol, Div Mol Neuroimmunol, D-69120 Heidelberg, Germany.	sven.jarius@med.uni-heidelberg.de						Boronat A, ANN NEUROL IN PRESS; de Graaff E, 2012, ANN NEUROL, V71, P815, DOI 10.1002/ana.23550; Jarius S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-14; Kitley J, 2012, NEUROLOGY, V79, P1273, DOI 10.1212/WNL.0b013e31826aac4e; Kitley J, 2012, BRAIN, V135, P1834, DOI 10.1093/brain/aws109; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Mader S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-184; Pevzner A, 2012, J NEUROL, V259, P427, DOI 10.1007/s00415-011-6194-7; Pittock SJ, 2012, 2012 ANN M AM NEUR A; Pruss H, 2012, NEUROLOGY, V78, P1743, DOI 10.1212/WNL.0b013e318258300d; Pruss H, ANN NEUROL IN PRESS; Rostasy K, MULT SCLER IN PRESS; Srivastava R, 2012, NEW ENGL J MED, V367, P115, DOI 10.1056/NEJMoa1110740; Varrin-Doyer M, 2012, ANN NEUROL, V72, P53, DOI 10.1002/ana.23651; Waters PJ, 2012, NEUROLOGY, V78, P665, DOI 10.1212/WNL.0b013e318248dec1; Zhang B, 2012, ARCH NEUROL-CHICAGO, V69, P445, DOI 10.1001/archneurol.2011.2393	16	12	12	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					22	24		10.1016/S1474-4422(12)70301-0	http://dx.doi.org/10.1016/S1474-4422(12)70301-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237898				2022-12-18	WOS:000312429400013
J	Cohen, PD; Isaacs, T; Willocks, P; Herman, L; Stamford, J; Riggare, S; Wittekind, P				Cohen, Perry D.; Isaacs, Tom; Willocks, Peggy; Herman, Linda; Stamford, Jon; Riggare, Sara; Wittekind, Paula			Sham neurosurgical procedures: the patients' perspective	LANCET NEUROLOGY			English	Letter									[Cohen, Perry D.; Isaacs, Tom; Willocks, Peggy; Herman, Linda; Stamford, Jon; Riggare, Sara; Wittekind, Paula] Parkinsons Movement, London, England; [Isaacs, Tom; Stamford, Jon] Cure Parkinsons Trust, London, England		Cohen, PD (corresponding author), Parkinsons Movement, Aldgate High St, London, England.	jon.stamford@parkinsonsmovement.com		Riggare, Sara/0000-0002-2256-7310				Cohen PD, 2007, NEUROTHERAPEUTICS, V4, P537, DOI 10.1016/j.nurt.2007.04.008; Galpern WR, LANCET NEUROL, V11, P643; Havemann J., 2010, NEUROL NOW, V6, P35; National Institutes of Health Office of Biotechnology Activities, DESCR C SHAM NEUR PR; The Cure Parkinson's Trust, 2010, RESP SHAM SURG SURV	5	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2012	11	12					1022	1022		10.1016/S1474-4422(12)70277-6	http://dx.doi.org/10.1016/S1474-4422(12)70277-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044CX	23153402				2022-12-18	WOS:000311598100010
J	Monchi, O; Stoessl, AJ				Monchi, Oury; Stoessl, A. Jon			Imaging neural correlates of mild cognitive impairment in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							DOPAMINE RELEASE; PERFORMANCE		[Monchi, Oury] Ctr Rech Inst Univ Geriatrie Montreal, Montreal, PQ, Canada; [Monchi, Oury] Univ Montreal, Dept Radiol Radiooncol & Nucl Med, Montreal, PQ, Canada; [Stoessl, A. Jon] Pacific Parkinsons Res Ctr, Vancouver Coastal Hlth, Vancouver, BC, Canada; [Stoessl, A. Jon] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Stoessl, A. Jon] Natl Parkinson Fdn Ctr Excellence, Vancouver, BC, Canada	Universite de Montreal; Universite de Montreal; Vancouver Coastal Health Research Institute; University of British Columbia	Monchi, O (corresponding author), Ctr Rech Inst Univ Geriatrie Montreal, Montreal, PQ, Canada.	jstoessl@interchange.ubc.ca	Monchi, Oury/N-8417-2019; Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246				Dagher A, 2001, BRAIN, V124, P1020, DOI 10.1093/brain/124.5.1020; Ekman U, 2012, LANCET NEUROL, V11, P679, DOI 10.1016/S1474-4422(12)70138-2; Foltynie T, 2004, BRAIN, V127, P550, DOI 10.1093/brain/awh067; Huang C, 2008, NEUROLOGY, V70, P1470, DOI 10.1212/01.wnl.0000304050.05332.9c; Janvin CC, 2006, MOVEMENT DISORD, V21, P1343, DOI 10.1002/mds.20974; Ko JH, 2009, NEUROIMAGE, V46, P516, DOI 10.1016/j.neuroimage.2009.02.031; Lewis SJG, 2003, J NEUROSCI, V23, P6351, DOI 10.1523/jneurosci.23-15-06351.2003; Litvan I, 2011, MOVEMENT DISORD, V26, P1814, DOI 10.1002/mds.23823; Lyoo CH, 2010, EUR NEUROL, V64, P65, DOI 10.1159/000315036; Monchi O, 2007, BRAIN, V130, P233, DOI 10.1093/brain/awl326; Monchi O, 2006, NEUROIMAGE, V33, P907, DOI 10.1016/j.neuroimage.2006.06.058; Monchi Oury, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS77, DOI 10.1016/S1353-8020(11)70025-6; Polito C, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.004; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; Weintraub D, 2011, ARCH NEUROL-CHICAGO, V68, P1562, DOI 10.1001/archneurol.2011.725	15	12	11	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2012	11	8					653	655		10.1016/S1474-4422(12)70162-X	http://dx.doi.org/10.1016/S1474-4422(12)70162-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983AX	22814534				2022-12-18	WOS:000307089700003
J	Wardlaw, JM				Wardlaw, Joanna M.			Prediction of haematoma expansion with the CTA spot sign: a useful biomarker?	LANCET NEUROLOGY			English	Editorial Material							INTRACEREBRAL HEMORRHAGE		Univ Edinburgh, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Wardlaw, JM (corresponding author), Univ Edinburgh, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.	joanna.wardlaw@ed.ac.uk	Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022	Wardlaw, Joanna M/0000-0002-9812-6642; 				Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Palumbo V, 2007, NEUROLOGY, V68, P1020, DOI 10.1212/01.wnl.0000257817.29883.48; Viswanathan A, 2011, ANN NEUROL, V70, P871, DOI 10.1002/ana.22516; Yudkin J, 2012, BRIT MED J, V344, P22	6	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2012	11	4					294	295		10.1016/S1474-4422(12)70045-5	http://dx.doi.org/10.1016/S1474-4422(12)70045-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	915CD	22405629				2022-12-18	WOS:000301999600002
J	Maas, A; Stocchetti, N				Maas, Andrew; Stocchetti, Nino			Hypothermia and the complexity of trials in patients with traumatic brain injury	LANCET NEUROLOGY			English	Editorial Material							MILD HYPOTHERMIA; HEAD-INJURY		[Maas, Andrew] Univ Antwerp Hosp, Edegem, Belgium; Univ Milan, Neurosci Intens Care Unit, Fdn IRCCS, Cagranda Osped,Maggiore Policlin, Milan, Italy	University of Antwerp; University of Milan	Maas, A (corresponding author), Univ Antwerp Hosp, Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013; Stocchetti, Nino/O-7444-2017	Maas, Andrew IR/0000-0003-1612-1264; Stocchetti, Nino/0000-0003-3250-6834	NINDS NIH HHS [NS 042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042691] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews PJD, 2010, INTENS CARE MED, V36, P1990, DOI 10.1007/s00134-010-2031-1; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; *MON U, POLAR RCT STUD; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013	10	12	13	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2011	10	2					111	113		10.1016/S1474-4422(10)70312-4	http://dx.doi.org/10.1016/S1474-4422(10)70312-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	721IT	21169064				2022-12-18	WOS:000287347500003
J	Boeve, BF				Boeve, Bradley F.			Predicting the future in idiopathic rapid-eye movement sleep behaviour disorder	LANCET NEUROLOGY			English	Editorial Material							REM-SLEEP; NEURODEGENERATIVE DISORDER		Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Boeve, BF (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	bboeve@mayo.edu			NATIONAL INSTITUTE ON AGING [P50AG016574, R01AG015866, U01AG006786, U24AG026395] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boeve BF, 2007, BRAIN, V130, P2770, DOI 10.1093/brain/awm056; Boeve BF, 2010, ANN NY ACAD SCI, V1184, P15, DOI 10.1111/j.1749-6632.2009.05115.x; Claassen DO, 2010, NEUROLOGY, V75, P494, DOI 10.1212/WNL.0b013e3181ec7fac; IRANZO A, 2010, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(10)70216-7; Iranzo A, 2006, LANCET NEUROL, V5, P572, DOI 10.1016/S1474-4422(06)70476-8; Miyamoto T, 2008, SLEEP, V31, P717, DOI 10.1093/sleep/31.5.717; Postuma RB, 2009, NEUROLOGY, V72, pA106; Schenck CH, 1996, NEUROLOGY, V46, P388, DOI 10.1212/WNL.46.2.388; SCHENCK CH, 1986, SLEEP, V9, P293, DOI 10.1093/sleep/9.2.293; Stiasny-Kolster K, 2005, BRAIN, V128, P126, DOI 10.1093/brain/awh322	10	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2010	9	11					1040	1042		10.1016/S1474-4422(10)70221-0	http://dx.doi.org/10.1016/S1474-4422(10)70221-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680PL	20869916				2022-12-18	WOS:000284246800004
J	McIntyre, P				McIntyre, Peter			Adjunctive dexamethasone in meningitis: does value depend on clinical setting?	LANCET NEUROLOGY			English	Editorial Material							CHILDHOOD BACTERIAL-MENINGITIS		[McIntyre, Peter] Royal Alexandra Hosp Children, Sydney, NSW, Australia; [McIntyre, Peter] Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney	McIntyre, P (corresponding author), Royal Alexandra Hosp Children, Sydney, NSW, Australia.	peterm@chw.edu.au	McIntyre, Peter/GNM-5277-2022	McIntyre, Peter/0000-0001-5808-7450				Gordon SB, 2000, CLIN INFECT DIS, V31, P53, DOI 10.1086/313910; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Korshin A, 2007, SCAND J INFECT DIS, V39, P963, DOI 10.1080/00365540701449393; Mai NTH, 2007, NEW ENGL J MED, V357, P2431, DOI 10.1056/NEJMoa070852; Molyneux E, 1998, TROP MED INT HEALTH, V3, P610, DOI 10.1046/j.1365-3156.1998.00278.x; Murray CJL, 2001, GLOBAL BURDEN DIS 20; Peltola H, 2007, CLIN INFECT DIS, V45, P1277, DOI 10.1086/522534; Thwaites GE, 2002, LANCET, V360, P1287, DOI 10.1016/S0140-6736(02)11318-3; van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2; van de Beek D, 2010, LANCET NEUROL, V9, P254, DOI 10.1016/S1474-4422(10)70023-5	11	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2010	9	3					229	231		10.1016/S1474-4422(10)70022-3	http://dx.doi.org/10.1016/S1474-4422(10)70022-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	565BL	20138010				2022-12-18	WOS:000275263400003
J	Volta, U; De Giorgio, R				Volta, Umberto; De Giorgio, Roberto			Gluten sensitivity: an emerging issue behind neurological impairment?	LANCET NEUROLOGY			English	Editorial Material							CELIAC-DISEASE; ANTIBODIES; ATAXIA		[Volta, Umberto] Univ Bologna, Dept Clin Med, Ctr Unificato Ric BioMed Applicata, Bologna, Italy; Univ Bologna, Dept Digest Dis, Ctr Unificato Ric BioMed Applicata, Bologna, Italy; Univ Bologna, Dept Internal Med, Ctr Unificato Ric BioMed Applicata, Bologna, Italy; St Orsola Malpighi Hosp, I-40138 Bologna, Italy	University of Bologna; University of Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Volta, U (corresponding author), Univ Bologna, Dept Clin Med, Ctr Unificato Ric BioMed Applicata, Bologna, Italy.	umberto.volta@aosp.bo.it		Volta, Umberto/0000-0003-3405-3808; De Giorgio, Roberto/0000-0003-0867-5873				Cervio E, 2007, GASTROENTEROLOGY, V133, P195, DOI 10.1053/j.gastro.2007.04.070; Di Sabatino A, 2009, LANCET, V373, P1480, DOI 10.1016/S0140-6736(09)60254-3; GOBBI G, 1992, LANCET, V340, P439; Hadjivassiliou M, 2006, NEUROLOGY, V66, P373, DOI 10.1212/01.wnl.0000196480.55601.3a; Hadjivassiliou M, 2004, TRENDS IMMUNOL, V25, P578, DOI 10.1016/j.it.2004.08.011; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Hadjivassiliou M, 2008, ANN NEUROL, V64, P332, DOI 10.1002/ana.21450; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; Karell K, 2003, HUM IMMUNOL, V64, P469, DOI 10.1016/S0198-8859(03)00027-2; Koskinen O, 2010, J CLIN GASTROENTEROL, V44, P483, DOI 10.1097/MCG.0b013e3181b64557; Lock RJ, 2005, J NEUROL NEUROSUR PS, V76, P1601, DOI 10.1136/jnnp.2004.058487; Volta U, 2006, DIGEST LIVER DIS, V38, P183, DOI 10.1016/j.dld.2005.11.013; Volta U, 2002, SCAND J GASTROENTERO, V37, P1276, DOI 10.1080/003655202761020542; Volta U, 2010, J CLIN GASTROENTEROL, V44, P186, DOI 10.1097/MCG.0b013e3181c378f6	14	12	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2010	9	3					233	235		10.1016/S1474-4422(09)70357-6	http://dx.doi.org/10.1016/S1474-4422(09)70357-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	565BL	20170835				2022-12-18	WOS:000275263400005
J	Burton, A				Burton, Adrian			Oscar Gershanik: putting Argentina on the world neurology map	LANCET NEUROLOGY			English	Biographical-Item												burtona@wanadoo.es							0	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					138	138		10.1016/S1474-4422(09)70009-2	http://dx.doi.org/10.1016/S1474-4422(09)70009-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO	19679272				2022-12-18	WOS:000262752000011
J	Aisen, PS				Aisen, Paul S.			Tarenflurbil: a shot on goal	LANCET NEUROLOGY			English	Editorial Material							GAMMA-SECRETASE; ALZHEIMERS-DISEASE; NSAIDS		Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	University of California System; University of California San Diego	Aisen, PS (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr,M-C 0949, San Diego, CA 92093 USA.	paisen@ucsd.edu						Aisen PS, 2005, CNS DRUGS, V19, P989, DOI 10.2165/00023210-200519120-00002; Randall JB, 2006, NAT MED, V12, P856, DOI 10.1038/nm1438; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Siemers ER, 2007, CLIN NEUROPHARMACOL, V30, P317, DOI 10.1097/WNF.0b013e31805b7660; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wilcock GK, 2008, LANCET NEUROL, V7, P483, DOI 10.1016/S1474-4422(08)70090-5; Wolfe MS, 2008, CURR TOP MED CHEM, V8, P2, DOI 10.2174/156802608783334024	7	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2008	7	6					468	469		10.1016/S1474-4422(08)70091-7	http://dx.doi.org/10.1016/S1474-4422(08)70091-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	305WF	18450518				2022-12-18	WOS:000256207800002
J	Petersen, RC				Petersen, Ronald C.			MCl treatment trials: failure or not?	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE		Mayo Clin, Coll Med, Alzheimers Dis Res Ctr, Rochester, MN 55905 USA	Mayo Clinic	Petersen, RC (corresponding author), Mayo Clin, Coll Med, Alzheimers Dis Res Ctr, Rochester, MN 55905 USA.	peter8@mayo.edu						Aggarwal NT, 2005, NEUROCASE, V11, P3, DOI 10.1080/13554790490903038; Bennett DA, 2002, NEUROLOGY, V59, P198, DOI 10.1212/WNL.59.2.198; Feldman HH, 2007, LANCET NEUROL, V6, P501, DOI 10.1016/S1474-4422(07)70109-6; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x	8	12	12	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					473	475		10.1016/S1474-4422(07)70113-8	http://dx.doi.org/10.1016/S1474-4422(07)70113-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509475				2022-12-18	WOS:000247044900004
J	Ramagopalan, SV; Dyment, DA; Herrera, BM; Criscuoli, M; Yee, IM; Sadovnick, AD; Ebers, GC				Ramagopalan, Sreeram V.; Dyment, David A.; Herrera, Blanca M.; Criscuoli, Maria; Yee, Irene M.; Sadovnick, A. Dessa; Ebers, George C.			Clustering of autoimmune disease in families at high risk for multiple sclerosis?	LANCET NEUROLOGY			English	Editorial Material									Wellcome Trust Ctr Human Genet, Oxford, England; Univ Oxford, Dept Clin Neurol, Oxford, England; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC, Canada	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of British Columbia; University of British Columbia	Ramagopalan, SV (corresponding author), Wellcome Trust Ctr Human Genet, Oxford, England.	george.ebers@clneuro.oxford.ac.uk		Ebers, George/0000-0003-4771-4177; Sadovnick, Dessa/0000-0003-2987-2008				Barcellos LF, 2006, LANCET NEUROL, V5, P924, DOI 10.1016/S1474-4422(06)70552-X; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Karsh J, 2005, EUR J EPIDEMIOL, V20, P783, DOI 10.1007/s10654-005-0704-9; RAMAGOPALAN SV, 2006, ASHG ANN M NEW ORL L; Sadovnick AD, 1998, CAN J NEUROL SCI, V25, P216, DOI 10.1017/S0317167100034041	5	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2007	6	3					206	207		10.1016/S1474-4422(07)70043-1	http://dx.doi.org/10.1016/S1474-4422(07)70043-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138BU	17303524				2022-12-18	WOS:000244338400006
J	Beran, RG				Beran, RG			SUDEP - to discuss or not discuss: that is the question	LANCET NEUROLOGY			English	Editorial Material							SUDDEN UNEXPECTED DEATH; EPILEPSY SUDEP; MORTALITY; COHORT		Liverpool Hosp, Liverpool, Merseyside, England		Beran, RG (corresponding author), Liverpool Hosp, Liverpool, Merseyside, England.	roy.beran@unsw.edu.au		Beran, Roy/0000-0002-5884-0606				Beran RG, 2004, SEIZURE-EUR J EPILEP, V13, P523, DOI 10.1016/j.seizure.2003.12.008; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; Langan Y, 2005, NEUROLOGY, V64, P1131, DOI 10.1212/01.WNL.0000156352.61328.CB; MOHANRA R, 2006, LANCET NEUROLOG 0503; Morton B, 2006, J NEUROL NEUROSUR PS, V77, P199, DOI 10.1136/jnnp.2005.066852; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Rugg-Gunn FJ, 2004, LANCET, V364, P2212, DOI 10.1016/S0140-6736(04)17594-6; Sander JW, 2004, J NEUROL NEUROSUR PS, V75, P349, DOI 10.1136/jnnp.2003.029223; Shackleton DP, 1999, J NEUROL NEUROSUR PS, V66, P636, DOI 10.1136/jnnp.66.5.636; Tellez-Zenteno JF, 2005, EPILEPSY RES, V65, P101, DOI 10.1016/j.eplepsyres.2005.05.004	10	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					464	465		10.1016/S1474-4422(06)70449-5	http://dx.doi.org/10.1016/S1474-4422(06)70449-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16713912				2022-12-18	WOS:000237906000002
J	Hansson, O; Zetterberg, H; Buchlave, P; Londos, E; Blennow, K; Minthon, L				Hansson, O; Zetterberg, H; Buchlave, P; Londos, E; Blennow, K; Minthon, L			Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. (vol 5, pg 228, 2006)	LANCET NEUROLOGY			English	Correction													Hansson, Oskar/A-7134-2013	Hansson, Oskar/0000-0001-8467-7286				Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6	1	12	12	2	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					293	293		10.1016/S1474-4422(06)70393-3	http://dx.doi.org/10.1016/S1474-4422(06)70393-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI		Bronze			2022-12-18	WOS:000236535200010
J	Dubowitz, V				Dubowitz, V			Prednisone for Duchenne muscular dystrophy	LANCET NEUROLOGY			English	Editorial Material							LOW-DOSAGE; SCHEDULE		Univ London Imperial Coll Sci Technol & Med, Dubowitz Neuromuscular Ctr, London W12 0NN, England	Imperial College London; University of London; University College London	Dubowitz, V (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dubowitz Neuromuscular Ctr, Hammersmith Campus, London W12 0NN, England.	v.dubowitz@ic.ac.uk						BEENAKKER EAC, 2002, ARCH NEUROL-CHICAGO, V62, P128; Frosk P, 2004, NEUROMUSCULAR DISORD, V14, P579; Kinali M, 2002, NEUROMUSCULAR DISORD, V12, pS169, DOI 10.1016/S0960-8966(02)00097-4; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Moxley RT, 2005, NEUROLOGY, V64, P13, DOI 10.1212/01.WNL.0000148485.00049.B7; QUINLIVAN RM, 1992, NEUROMUSCULAR DISORD, V2, P165, DOI 10.1016/0960-8966(92)90002-N; SEWRY CA, 1993, NEUROMUSCULAR DISORD, V3, P141, DOI 10.1016/0960-8966(93)90006-6	7	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2005	4	5					264	264		10.1016/S1474-4422(05)70050-8	http://dx.doi.org/10.1016/S1474-4422(05)70050-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	919AE	15847833				2022-12-18	WOS:000228589900002
J	Berger, JR				Berger, JR			AIDS and stroke risk	LANCET NEUROLOGY			English	Letter							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CENTRAL-NERVOUS-SYSTEM; DEFICIENCY SYNDROME AIDS; CEREBROVASCULAR-DISEASE; HIV-INFECTION; AUTOPSY; VIRUS; NEUROPATHOLOGY; VASCULITIS; ANGIITIS		Univ Kentucky, Coll Med, Dept Neurol, Lexington, KY 40536 USA	University of Kentucky	Berger, JR (corresponding author), Univ Kentucky, Coll Med, Dept Neurol, Lexington, KY 40536 USA.	jrbneuro@uky.edu						ANDERS KH, 1986, AM J PATHOL, V124, P537; BERGER JR, 1990, AIDS, V4, P239, DOI 10.1097/00002030-199003000-00010; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; Chetty R, 2001, J CLIN PATHOL, V54, P275, DOI 10.1136/jcp.54.4.275; Cole JW, 2004, STROKE, V35, P51, DOI 10.1161/01.STR.0000105393.57853.11; Evers S, 2003, CEREBROVASC DIS, V15, P199, DOI 10.1159/000068828; Gillams AR, 1997, AM J NEURORADIOL, V18, P1581; Hoffmann M, 2000, J NEUROVIROL, V6, P229, DOI 10.3109/13550280009015825; KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X; LANG W, 1989, ACTA NEUROPATHOL, V77, P379, DOI 10.1007/BF00687372; Mallon P W, 2001, HIV Med, V2, P166, DOI 10.1046/j.1468-1293.2001.00071.x; MIZUSAWA H, 1988, ACTA NEUROPATHOL, V76, P451, DOI 10.1007/BF00686383; Nogueras C, 2002, ARCH NEUROL-CHICAGO, V59, P468, DOI 10.1001/archneur.59.3.468; PETITO CK, 1986, J NEUROPATH EXP NEUR, V45, P635, DOI 10.1097/00005072-198611000-00003; RHODES RH, 1987, HUM PATHOL, V18, P636, DOI 10.1016/S0046-8177(87)80365-9; Saif MW, 2001, AIDS PATIENT CARE ST, V15, P15, DOI 10.1089/108729101460065; SCARAVILLI F, 1989, ARCH PATHOL LAB MED, V113, P192; VINTERS HV, 1988, NEUROPATH APPL NEURO, V14, P417, DOI 10.1111/j.1365-2990.1988.tb01142.x; YANKNER BA, 1986, ANN NEUROL, V20, P362, DOI 10.1002/ana.410200316; 1987, MMWR MORB MORTAL WKL, V36, pS1	20	12	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2004	3	4					206	207		10.1016/S1474-4422(04)00704-5	http://dx.doi.org/10.1016/S1474-4422(04)00704-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	814QU	15039031				2022-12-18	WOS:000220990000013
J	Bosch, X				Bosch, X			Post-polio syndrome recognised by European parliament	LANCET NEUROLOGY			English	News Item																			0	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					4	4		10.1016/S1474-4422(03)00633-1	http://dx.doi.org/10.1016/S1474-4422(03)00633-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14700053				2022-12-18	WOS:000187447100003
J	Skoog, I				Skoog, I			Highs and lows of blood pressure: a cause of Alzheimer's disease?	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA		Sahlgrens Univ Hosp, Dept Psychiat, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Skoog, I (corresponding author), Sahlgrens Univ Hosp, Dept Psychiat, S-41345 Gothenburg, Sweden.							Launer LJ, 2000, NEUROBIOL AGING, V21, P49, DOI 10.1016/S0197-4580(00)00096-8; Qiu CX, 2003, ARCH NEUROL-CHICAGO, V60, P223, DOI 10.1001/archneur.60.2.223; Ruitenberg A, 2001, DEMENT GERIATR COGN, V12, P33, DOI 10.1159/000051233; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; SPARKS DL, 1995, J NEUROL SCI, V131, P162, DOI 10.1016/0022-510X(95)00105-B	5	12	13	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					334	334		10.1016/S1474-4422(03)00405-8	http://dx.doi.org/10.1016/S1474-4422(03)00405-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH	12849147				2022-12-18	WOS:000183115000014
J	Garzon, T; Mellibovsky, L; Roquer, J; Perich, X; Diez-Perez, A				Garzon, T; Mellibovsky, L; Roquer, J; Perich, X; Diez-Perez, A			Ataxic form of central pontine myelinolysis	LANCET NEUROLOGY			English	Editorial Material									Univ Autonoma Barcelona, Hosp Mar, Dept Internal Med, E-08003 Barcelona, Spain; Univ Autonoma Barcelona, Hosp Mar, Dept Neurol, E-08003 Barcelona, Spain; Univ Autonoma Barcelona, Hosp Mar, Dept Radiol, E-08003 Barcelona, Spain	Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Garzon, T (corresponding author), ABS Nova Lloreda, Avda Cataluna S-N, Barcelona, Spain.		Roquer, Jaume/G-8919-2017; Roquer, Jaume/D-9483-2011	Roquer, Jaume/0000-0001-5992-2606; Diez-Perez, Adolfo/0000-0001-8162-0209				ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154, DOI 10.1001/archneurpsyc.1959.02340140020004; DEFEBVRE L, 1995, J NEUROL, V242, P450, DOI 10.1007/BF00873548; GILLE M, 1993, REV NEUROL, V149, P344; Rajbhandari SM, 1998, DIABETIC MED, V15, P259, DOI 10.1002/(SICI)1096-9136(199803)15:3<259::AID-DIA548>3.3.CO;2-A; STELLER U, 1988, J NEUROL, V235, P379, DOI 10.1007/BF00314240	5	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2002	1	8					517	518		10.1016/S1474-4422(02)00224-7	http://dx.doi.org/10.1016/S1474-4422(02)00224-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618PP	12849338				2022-12-18	WOS:000179426700028
J	Schreuder, FHBM; van Nieuwenhuizen, KM; Hofmeijer, J; Vermeer, SE; Kerkhoff, H; Zock, E; Luijckx, GJ; Messchendorp, GP; van Tuijl, J; Bienfait, HP; Booij, SJ; van den Wijngaard, IR; Remmers, MJM; Schreuder, AHCML; Dippel, DW; Staals, J; Brouwers, PJAM; Wermer, MJH; Coutinho, JM; Kwa, VIH; van Gelder, IC; Schutgens, REG; Zweedijk, B; Algra, A; van Dalen, JW; Kappelle, LJ; Rinkel, GJE; van Der Worp, HB; Klijn, CJM				Schreuder, Floris H. B. M.; van Nieuwenhuizen, Koen M.; Hofmeijer, Jeannette; Vermeer, Sarah E.; Kerkhoff, Henk; Zock, Elles; Luijckx, Gert-Jan; Messchendorp, Gert P.; van Tuijl, Julia; Bienfait, H. Paul; Booij, Suzanne J.; van den Wijngaard, Ido R.; Remmers, Michel J. M.; Schreuder, Antonia H. C. M. L.; Dippel, Diederik W.; Staals, Julie; Brouwers, Paul J. A. M.; Wermer, Marieke J. H.; Coutinho, Jonathan M.; Kwa, Vincent I. H.; van Gelder, Isabelle C.; Schutgens, Roger E. G.; Zweedijk, Berber; Algra, Ale; van Dalen, Jan Willem; Kappelle, L. Jaap; Rinkel, Gabriel J. E.; van Der Worp, H. Bart; Klijn, Catharina J. M.		APACHE-AF Trial Investigator	Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial	LANCET NEUROLOGY			English	Article							ANTITHROMBOTIC TREATMENT; INTRACRANIAL HEMORRHAGE; SECONDARY PREVENTION; ORAL ANTICOAGULANTS; VASCULAR EVENTS; STROKE	Background In patients with atrial fibrillation who survive an anticoagulation-associated intracerebral haemorrhage, a decision must be made as to whether restarting or permanently avoiding anticoagulation is the best long-term strategy to prevent recurrent stroke and other vascular events. In APACHE-AF, we aimed to estimate the rates of non-fatal stroke or vascular death in such patients when treated with apixaban compared with when anticoagulation was avoided, to inform the design of a larger trial. Methods APACHE-AF was a prospective, randomised, open-label, phase 2 trial with masked endpoint assessment, done at 16 hospitals in the Netherlands. Patients who survived intracerebral haemorrhage while treated with anticoagulation for atrial fibrillation were eligible for inclusion 7-90 days after the haemorrhage. Participants also had a CHA2DS2-VASc score of at least 2 and a score on the modified Rankin scale (mRS) of 4 or less. Participants were randomly assigned (1:1) to receive oral apixaban (5 mg twice daily or a reduced dose of 2.5 mg twice daily) or to avoid anticoagulation (oral antiplatelet agents could be prescribed at the discretion of the treating physician) by a central computerised randomisation system, stratified by the intention to start or withhold antiplatelet therapy in participants randomised to avoiding anticoagulation, and minimised for age and intracerebral haemorrhage location. The primary outcome was a composite of non-fatal stroke or vascular death, whichever came first, during a minimum follow-up of 6 months, analysed using Cox proportional hazards modelling in the intention-to-treat population. APACHE-AF is registered with ClinicalTrials.gov (NCT02565693) and the Netherlands Trial Register (NL4395), and the trial is closed to enrolment at all participating sites. Findings Between Jan 15, 2015, and July 6, 2020, we recruited 101 patients (median age 78 years [IQR 73-83]; 55 [54%] were men and 46 [46%] were women; 100 [99%] were White and one [1%] was Black) a median of 46 days (IQR 21-74) after intracerebral haemorrhage. 50 were assigned to apixaban and 51 to avoid anticoagulation (of whom 26 [51%] started antiplatelet therapy). None were lost to follow-up. Over a median follow-up of 1.9 years (IQR 1.0-3.1; 222 person-years), non-fatal stroke or vascular death occurred in 13 (26%) participants allocated to apixaban (annual event rate 12.6% [95% CI 6.7-21.5]) and in 12 (24%) allocated to avoid anticoagulation (11.9% [95% CI 6.2-20.8]; adjusted hazard ratio 1.05 [95% CI 0.48-2.31]; p=0.90). Serious adverse events that were not outcome events occurred in 29 (58%) of 50 participants assigned to apixaban and 29 (57%) of 51 assigned to avoid anticoagulation. Interpretation Patients with atrial fibrillation who had an intracerebral haemorrhage while taking anticoagulants have a high subsequent annual risk of non-fatal stroke or vascular death, whether allocated to apixaban or to avoid anticoagulation. Our data underline the need for randomised controlled trials large enough to allow identification of subgroups in whom restarting anticoagulation might be either beneficial or hazardous. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Schreuder, Floris H. B. M.; van Dalen, Jan Willem; Klijn, Catharina J. M.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [van Nieuwenhuizen, Koen M.; Zweedijk, Berber; Algra, Ale; Kappelle, L. Jaap; Rinkel, Gabriel J. E.; van Der Worp, H. Bart; Klijn, Catharina J. M.] Univ Med Ctr Utrecht, Brain Ctr, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Schutgens, Roger E. G.] Univ Med Ctr Utrecht, Van Creveldklin, Utrecht, Netherlands; [Algra, Ale] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Hofmeijer, Jeannette; Vermeer, Sarah E.] Rijnstate Hosp, Dept Neurol, Arnhem, Netherlands; [Kerkhoff, Henk; Zock, Elles] Albert Schweitzer Hosp, Dept Neurol, Dordrecht, Netherlands; [Luijckx, Gert-Jan; Messchendorp, Gert P.] Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [van Gelder, Isabelle C.] Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [van Tuijl, Julia] Elisabeth TweeSteden Hosp, Dept Neurol, Tilburg, Netherlands; [Bienfait, H. Paul] Gelre Hosp, Dept Neurol, Apeldoorn, Netherlands; [Booij, Suzanne J.] Canisius Wilhelmina Hosp, Dept Neurol, Nijmegen, Netherlands; [van den Wijngaard, Ido R.] Haaglanden MC, Dept Neurol, The Hague, Netherlands; [van den Wijngaard, Ido R.; Wermer, Marieke J. H.] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands; [Remmers, Michel J. M.] Amphia, Dept Neurol, Breda, Netherlands; [Schreuder, Antonia H. C. M. L.] Zuyderland, Dept Neurol, Heerlen, Netherlands; [Dippel, Diederik W.] Erasmus MC Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands; [Staals, Julie] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands; [Brouwers, Paul J. A. M.] Med Spectrum Twente, Dept Neurol, Enschede, Netherlands; [Coutinho, Jonathan M.] Amsterdam UMC Locat AMC, Dept Neurol, Amsterdam, Netherlands; [Kwa, Vincent I. H.] OLVG, Dept Neurol, Amsterdam, Netherlands	Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Rijnstate Hospital; Albert Schweitzer Ziekenhuis; University of Groningen; University of Groningen; Elisabeth-TweeSteden Ziekenhuis (ETZ); Gelre Hospitals; Canisius-Wilhelmina Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Amphia Hospital; Erasmus University Rotterdam; Erasmus MC; Maastricht University; Medical Spectrum Twente	Klijn, CJM (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, NL-6500 HB Nijmegen, Netherlands.	karin.klijn@radboudumc.nl	Schreuder, Floris HBM/B-8036-2018	Schreuder, Floris HBM/0000-0002-7815-0207; van Nieuwenhuizen, Koen/0000-0002-4815-002X	Dutch Heart Foundation [2012T077]	Dutch Heart Foundation(Netherlands Heart Foundation)	We thank all participants, their relatives, and caregivers; outcome event adjudicators; and data monitoring committee members. We thank the Dutch Heart Foundation for funding the trial as part of a Clinical Established Investigator grant to CJMK (grant 2012T077) . We thank the data safety monitoring board members H Boersma (chair) , S A J Chamuleau, and P J Koudstaal; and H M Nathoe for his role in the outcome adjudication committee.	Arba F, 2017, J STROKE CEREBROVASC, V26, P1506, DOI 10.1016/j.jstrokecerebrovasdis.2017.03.002; Biffi A, 2017, ANN NEUROL, V82, P755, DOI 10.1002/ana.25079; Casolla B, 2019, STROKE, V50, P1100, DOI 10.1161/STROKEAHA.118.024449; Chao TF, 2016, CIRCULATION, V133, P1540, DOI 10.1161/CIRCULATIONAHA.115.019794; Chen Yiping, 2020, Lancet Glob Health, V8, pe580, DOI 10.1016/S2214-109X(20)30069-3; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Hindricks G, 2021, EUR HEART J, V42, P546, DOI 10.1093/eurheartj/ehaa945; Hofmeijer J, 2015, Pract Neurol, V15, P250, DOI 10.1136/practneurol-2015-001104; Jakel L, 2022, ALZHEIMERS DEMENT, V18, P10, DOI 10.1002/alz.12366; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Klijn CJM, 2019, EUR STROKE J, V4, P198, DOI 10.1177/2396987319841187; Korompoki E, 2017, NEUROLOGY, V89, P687, DOI 10.1212/WNL.0000000000004235; Kuramatsu JB, 2015, JAMA-J AM MED ASSOC, V313, P824, DOI 10.1001/jama.2015.0846; Larsen KT, 2020, EUR STROKE J, V5, P414, DOI 10.1177/2396987320954671; Lee TWR, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005599.pub5, 10.1002/14651858.CD012144.pub2]; Lega JC, 2013, J THROMB HAEMOST, V11, P1240, DOI 10.1111/jth.12294; Li LX, 2021, LANCET NEUROL, V20, P437, DOI 10.1016/S1474-4422(21)00075-2; Murthy SB, 2020, STROKE, V51, P137, DOI 10.1161/STROKEAHA.119.026207; Murthy SB, 2017, STROKE, V48, P1594, DOI 10.1161/STROKEAHA.116.016327; Pasquini M, 2014, STROKE, V45, P2643, DOI 10.1161/STROKEAHA.114.006202; Patel A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54491-6; Rodrigues MA, 2018, LANCET NEUROL, V17, P232, DOI 10.1016/S1474-4422(18)30006-1; Shoamanesh A, 2021, INT J STROKE, V16, P321, DOI 10.1177/1747493020968424; SoSTART Collaboration, 2021, Lancet Neurol, V20, P842, DOI 10.1016/S1474-4422(21)00264-7; van Nieuwenhuizen KM, 2020, EUR STROKE J, V5, P336, DOI 10.1177/2396987320953394; van Nieuwenhuizen KM, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0898-4; Xu Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191137; Zhu WG, 2021, STROKE, V52, P1225, DOI 10.1161/STROKEAHA.120.031007	29	11	11	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					907	916		10.1016/S1474-4422(21)00298-2	http://dx.doi.org/10.1016/S1474-4422(21)00298-2			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL5PY	34687635	Green Published			2022-12-18	WOS:000710458300014
J	Hachinski, V; Avan, A; Gilliland, J; Oveisgharan, S				Hachinski, Vladimir; Avan, Abolfazl; Gilliland, Jason; Oveisgharan, Shahram			A new definition of brain health	LANCET NEUROLOGY			English	Letter							DEMENTIA; STROKE; PREVENTION		[Hachinski, Vladimir] Western Univ, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada; [Gilliland, Jason] Western Univ, Dept Geog, Sch Hlth Studies, London, ON N6A 5A5, Canada; [Avan, Abolfazl] Mashhad Univ Med Sci, Dept Publ Hlth, Mashhad, Razavi Khorasan, Iran; [Oveisgharan, Shahram] Rush Univ, Med Ctr, Dept Neurol Sci, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Mashhad University Medical Science; Rush University	Hachinski, V (corresponding author), Western Univ, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada.	vladimir.hachinski@lhsc.on.ca	Gilliland, Jason A/E-3393-2019	Gilliland, Jason A/0000-0002-2909-2178				HACHINSKI VC, 1993, NEUROLOGY, V43, P2159, DOI 10.1212/WNL.43.10.2159-a; Hachinski V, 2006, STROKE, V37, P2220, DOI 10.1161/01.STR.0000237236.88823.47; Hachinski V, 2019, ALZHEIMERS DEMENT, V15, P961, DOI 10.1016/j.jalz.2019.06.001; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Sposato LA, 2015, JAMA NEUROL, V72, P1529, DOI 10.1001/jamaneurol.2015.2816	5	11	11	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					335	336		10.1016/S1474-4422(21)00102-2	http://dx.doi.org/10.1016/S1474-4422(21)00102-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33894188	Bronze, Green Submitted			2022-12-18	WOS:000717465200010
J	Roberts, DR; Stahn, AC; Seidler, RD; Wuyts, FL				Roberts, Donna R.; Stahn, Alexander C.; Seidler, Rachael D.; Wuyts, Floris L.			Towards understanding the effects of spaceflight on the brain	LANCET NEUROLOGY			English	Letter									[Roberts, Donna R.] Med Univ South Carolina, Dept Neuroradiol, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA; [Stahn, Alexander C.] Univ Penn, Dept Psychiat, Perelman Sch Med, Unit Expt Psychiat, Philadelphia, PA 19104 USA; [Stahn, Alexander C.] Charite Univ Med Berlin, Berlin, Germany; [Stahn, Alexander C.] Free Univ Berlin, Berlin, Germany; [Stahn, Alexander C.] Humboldt Univ, Berlin, Germany; [Stahn, Alexander C.] Berlin Inst Hlth, Inst Physiol, Berlin, Germany; [Seidler, Rachael D.] Univ Florida, Norman Fixel Inst Neurol Dis, Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [Wuyts, Floris L.] Univ Antwerp, Lab Equilibrium Invest & Aerosp, Antwerp, Belgium	Medical University of South Carolina; University of Pennsylvania; Pennsylvania Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; State University System of Florida; University of Florida; University of Antwerp	Roberts, DR (corresponding author), Med Univ South Carolina, Dept Neuroradiol, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA.	robertdr@musc.edu						Koppelmans V, 2016, NPJ MICROGRAVITY, V2, DOI 10.1038/s41526-016-0001-9; Mader TH, 2011, OPHTHALMOLOGY, V118, P2058, DOI 10.1016/j.ophtha.2011.06.021; Roberts DR, 2017, NEW ENGL J MED, V377, P1746, DOI 10.1056/NEJMoa1705129; Stahn AC, 2019, NEW ENGL J MED, V381, P2273, DOI 10.1056/NEJMc1904905; Van Ombergen A, 2018, NEW ENGL J MED, V379, P1678, DOI 10.1056/NEJMc1809011	5	11	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					808	808		10.1016/S1474-4422(20)30304-5	http://dx.doi.org/10.1016/S1474-4422(20)30304-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949538	Bronze			2022-12-18	WOS:000581119100012
J	Giordano, A; Schwarz, G; Cacciaguerra, L; Esposito, F; Filippi, M				Giordano, Antonino; Schwarz, Ghil; Cacciaguerra, Laura; Esposito, Federica; Filippi, Massimo			COVID-19: can we learn from encephalitis lethargica?	LANCET NEUROLOGY			English	Editorial Material													Cacciaguerra, Laura/AAA-2318-2022; Filippi, Massimo/K-1755-2018; Esposito, Federica/K-6537-2016	Cacciaguerra, Laura/0000-0001-9342-2410; Filippi, Massimo/0000-0002-5485-0479; Esposito, Federica/0000-0003-2550-0805				Braak H, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a023630; Dube M, 2018, J VIROL, V92, DOI 10.1128/JVI.00404-18; Durrant DM, 2016, ACS CHEM NEUROSCI, V7, P464, DOI 10.1021/acschemneuro.6b00043; Hoffman LA, 2017, BRAIN, V140, P2246, DOI 10.1093/brain/awx177; Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1	5	11	12	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2020	19	7					570	570		10.1016/S1474-4422(20)30189-7	http://dx.doi.org/10.1016/S1474-4422(20)30189-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MF5BW	32562680	Bronze, Green Published			2022-12-18	WOS:000545358600025
J	Foltynie, T				Foltynie, Thomas			Glycolysis as a therapeutic target for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							RISK		[Foltynie, Thomas] UCL, Univ Coll London Inst Neurol, Dept Clin & Movement Neurosci, London WC1N 3BG, England	University of London; University College London	Foltynie, T (corresponding author), UCL, Univ Coll London Inst Neurol, Dept Clin & Movement Neurosci, London WC1N 3BG, England.	t.foltynie@ucl.ac.uk						Athauda D, 2015, NAT REV NEUROL, V11, P25, DOI 10.1038/nrneurol.2014.226; Brundin P, 2019, EUR J NEUROSCI, V49, P307, DOI 10.1111/ejn.14175; Cai R, 2019, J CLIN INVEST, V129, P4539, DOI 10.1172/JCI129987; Chen XP, 2015, NAT CHEM BIOL, V11, P19, DOI 10.1038/nchembio.1657; Dong ZL, 2009, SYST BIOL REPROD MED, V55, P129, DOI 10.1080/19396360902833235; Gronich N, 2018, MOVEMENT DISORD, V33, P1465, DOI 10.1002/mds.108; Mittal S, 2017, SCIENCE, V357, P891, DOI 10.1126/science.aaf3934; Nielsen SS, 2018, ANN NEUROL, V84, P683, DOI 10.1002/ana.25341	8	11	13	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1072	1074		10.1016/S1474-4422(19)30404-1	http://dx.doi.org/10.1016/S1474-4422(19)30404-1			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31628009	Green Submitted			2022-12-18	WOS:000495892200007
J	Selkoe, D				Selkoe, Dennis			beta-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED-TRIAL; VERUBECESTAT		[Selkoe, Dennis] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA; [Selkoe, Dennis] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Selkoe, D (corresponding author), Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA.; Selkoe, D (corresponding author), Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA.	dselkoe@bwh.harvard.edu						Egan MF, 2019, NEW ENGL J MED, V380, P1408, DOI 10.1056/NEJMoa1812840; Egan MF, 2018, NEW ENGL J MED, V378, P1691, DOI 10.1056/NEJMoa1706441; Henley D, 2019, NEW ENGL J MED, V380, P1483, DOI 10.1056/NEJMc1813435; Hitt B, 2012, J BIOL CHEM, V287, P38408, DOI 10.1074/jbc.M112.415505; Li S, NEW ENGL J MED; Ou-Yang MH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5620; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323	7	11	11	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2019	18	7					624	626		10.1016/S1474-4422(19)30202-9	http://dx.doi.org/10.1016/S1474-4422(19)30202-9			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IC7SE	31202466				2022-12-18	WOS:000471176500009
J	Dichgans, M				Dichgans, Martin			Dementia risk after transient ischaemic attack and stroke	LANCET NEUROLOGY			English	Editorial Material									[Dichgans, Martin] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany; [Dichgans, Martin] German Ctr Neurodegenerat Dis, Munich, Germany; [Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany	University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Munich	Dichgans, M (corresponding author), Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.; Dichgans, M (corresponding author), German Ctr Neurodegenerat Dis, Munich, Germany.; Dichgans, M (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.	martin.dichgans@med.uni-muenchen.de	Dichgans, Martin/HCH-3247-2022	Dichgans, Martin/0000-0002-0654-387X	EU [666881]; Fondation Leducq; German Research Foundation [DI 722/13-1]; Vascular Dementia Research Foundation	EU(European Commission); Fondation Leducq(Leducq Foundation); German Research Foundation(German Research Foundation (DFG)); Vascular Dementia Research Foundation	I have received grants from the EU's Horizon 2020 research and innovation programme (SVDs@ target; grant no 666881), the Fondation Leducq (Transatlantic Networks of Excellence on the Pathogenesis of Small Vessel Disease of the Brain), the German Research Foundation (DI 722/13-1), and the Vascular Dementia Research Foundation, and speaker's honoraria from Boehringer Ingelheim, Bayer Vital, and Pfizer.	Biessels GJ, 2018, NAT REV ENDOCRINOL, V14, P591, DOI 10.1038/s41574-018-0048-7; de Bruijn RFAG, 2015, JAMA NEUROL, V72, P1288, DOI 10.1001/jamaneurol.2015.2161; Georgakis M, NEUROLOGY; Levine DA, 2018, STROKE, V49, P987, DOI 10.1161/STROKEAHA.117.018529; Lopez-Cancio E, 2017, NEUROLOGY, V88, P245, DOI 10.1212/WNL.0000000000003517; Mok VCT, 2016, ALZHEIMERS DEMENT, V12, P1167, DOI 10.1016/j.jalz.2016.05.007; Moulin S, 2016, LANCET NEUROL, V15, P820, DOI 10.1016/S1474-4422(16)00130-7; Pendlebury ST, 2019, LANCET NEUROL, V18, P248, DOI 10.1016/S1474-4422(18)30442-3; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Zietemann V, 2018, NEUROLOGY, V91, pE1838, DOI 10.1212/WNL.0000000000006506	10	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					223	225		10.1016/S1474-4422(18)30497-6	http://dx.doi.org/10.1016/S1474-4422(18)30497-6			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	30784546	Green Published, hybrid			2022-12-18	WOS:000458509100007
J	McDonald, CM; Mercuri, E				McDonald, Craig M.; Mercuri, Eugenio			Evidence-based care in Duchenne muscular dystrophy	LANCET NEUROLOGY			English	Editorial Material							MANAGEMENT; DIAGNOSIS; LIFE		[McDonald, Craig M.] Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Sacramento, CA 95817 USA; [Mercuri, Eugenio] Catholic Univ, Policlin Gemelli, Pediat Neurol Unit, Rome, Italy; [Mercuri, Eugenio] Catholic Univ, Policlin Gemelli, Nemo Ctr, Rome, Italy	University of California System; University of California Davis; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	McDonald, CM (corresponding author), Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Sacramento, CA 95817 USA.	cmmcdonald@ucdavis.edu	Mercuri, Eugenio/G-1351-2015	Mercuri, Eugenio/0000-0002-9851-5365	Sarepta Therapeutics; PTC Therapeutics; Pfizer; Santhera Pharmaceuticals; Italfarmaco; Reveragen; Eli Lilly; Capricor Therapeutics; Biogen	Sarepta Therapeutics; PTC Therapeutics; Pfizer(Pfizer); Santhera Pharmaceuticals; Italfarmaco; Reveragen; Eli Lilly(Eli Lilly); Capricor Therapeutics; Biogen(Biogen)	CMM has received research support from Sarepta Therapeutics, PTC Therapeutics, Pfizer, Santhera Pharmaceuticals, Italfarmaco, Reveragen, Eli Lilly, and Capricor Therapeutics, and has served on advisory boards for PTC Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals, Eli Lilly, Catabasis, and Astellas/Mitobridge. EM received research support from Biogen, and has served on the advisory boards for Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Roche, Biogen, and AveXis.	Birnkrant DJ, 2018, LANCET NEUROL, V17, P347, DOI 10.1016/S1474-4422(18)30025-5; Birnkrant DJ, 2018, LANCET NEUROL, V17, P445, DOI 10.1016/S1474-4422(18)30026-7; Birnkrant DJ, 2018, LANCET NEUROL, V17, P251, DOI 10.1016/S1474-4422(18)30024-3; Bushby K, 2010, LANCET NEUROL, V9, P177, DOI 10.1016/S1474-4422(09)70272-8; Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6; McDonald CM, 2018, LANCET, V391, P451, DOI 10.1016/S0140-6736(17)32160-8; Moat SJ, 2013, EUR J HUM GENET, V21, P1049, DOI 10.1038/ejhg.2012.301; Romitti P., 2009, Morbidity and Mortality Weekly Report, V58, P1119; Romitti PA, 2015, PEDIATRICS, V135, P513, DOI 10.1542/peds.2014-2044	9	11	11	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					389	391		10.1016/S1474-4422(18)30115-7	http://dx.doi.org/10.1016/S1474-4422(18)30115-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29656735				2022-12-18	WOS:000429968100006
J	Ploughman, M				Ploughman, Michelle			A new era of multiple sclerosis rehabilitation: lessons from stroke	LANCET NEUROLOGY			English	Editorial Material							RECOVERY		[Ploughman, Michelle] Mem Univ Newfoundland, Fac Med, St John, NF A1A 1E5, Canada	Memorial University Newfoundland	Ploughman, M (corresponding author), Mem Univ Newfoundland, Fac Med, St John, NF A1A 1E5, Canada.	michelle.ploughman@med.mun.ca	Ploughman, Michelle/AAO-8768-2020					Austin MW, 2014, NEUROSCI RES, V87, P8, DOI 10.1016/j.neures.2014.06.007; Cree BAC, 2016, ANN NEUROL, V80, P499, DOI 10.1002/ana.24747; Motl RW, 2017, LANCET NEUROL, V16, P848, DOI 10.1016/S1474-4422(17)30281-8; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Rossi S, 2009, NEUROBIOL DIS, V36, P51, DOI 10.1016/j.nbd.2009.06.013; Salbach NM, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0631-7; Yong H, 2018, J NEUROSCI RES, V96, P927, DOI 10.1002/jnr.24090	8	11	13	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					768	769		10.1016/S1474-4422(17)30301-0	http://dx.doi.org/10.1016/S1474-4422(17)30301-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28920876				2022-12-18	WOS:000410379900006
J	Jha, RM; Kochanek, PM				Jha, Ruchira M.; Kochanek, Patrick M.			Adding insight to injury: a new era in neurotrauma	LANCET NEUROLOGY			English	Editorial Material							CARE		[Jha, Ruchira M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Crit Care Med,Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kochanek, PM (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Crit Care Med,Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA.	kochanekpm@ccm.upmc.edu			US National Institutes of Health [KL2-TR001856]; US Department of Defense [WH81XWH-14-2-0018]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS101036] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	RMJ is supported by grant KL2-TR001856 from the US National Institutes of Health. PMK is supported by grant WH81XWH-14-2-0018 from the US Department of Defense. We declare no competing interests.	Chabner BA, 2011, NEW ENGL J MED, V364, P1087, DOI 10.1056/NEJMp1100548; Hatfield I, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1273-9; HELGASON CM, 1987, CAN J NEUROL SCI, V14, P560; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Jha RM, 2017, NEUROCRIT CARE, V26, P213, DOI 10.1007/s12028-016-0309-z; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Nielson JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169490; RMJ is supported by grant KL2-TR001856 from the US National Institutes of Health, KL2TR001856 US NAT I; Srinivasan VM, 2014, J NEUROSURG, V120, P228, DOI 10.3171/2013.6.JNS121577; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7	12	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2017	16	8					578	580		10.1016/S1474-4422(17)30225-9	http://dx.doi.org/10.1016/S1474-4422(17)30225-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA1LP	28721915	Green Accepted			2022-12-18	WOS:000405201300006
J	Volkmar, FR; McPartland, JC				Volkmar, Fred R.; McPartland, James C.			Moving beyond a categorical diagnosis of autism	LANCET NEUROLOGY			English	Editorial Material									[Volkmar, Fred R.; McPartland, James C.] Yale Univ, Ctr Child Study, POB 207900,230 South Frontage Rd, New Haven, CT 06520 USA	Yale University	Volkmar, FR (corresponding author), Yale Univ, Ctr Child Study, POB 207900,230 South Frontage Rd, New Haven, CT 06520 USA.	fred.volkmar@yale.edu	Volkmar, Fred/AEB-0666-2022		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH107426] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI 10.1176/appi.books.9780890425596; Bernier R, 2014, CELL, V158, P263, DOI 10.1016/j.cell.2014.06.017; Constantino JN, 2015, LANCET NEUROLOGY; Dawson G, 2012, J AM ACAD CHILD PSY, V51, P1150, DOI 10.1016/j.jaac.2012.08.018; Ingersoll B., 2014, HDB AUTISM PERVASIVE, V4, P28; McPartland J, 2004, J CHILD PSYCHOL PSYC, V45, P1235, DOI 10.1111/j.1469-7610.2004.00318.x; McPartland J., 2014, HDB AUTISM PERVASIVE, V4, P482; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Smith IC, 2015, J AUTISM DEV DISORD, V45, P2541, DOI 10.1007/s10803-015-2423-8; Volkmar FR, 2014, J AUTISM DEV DISORD, V44, P2979, DOI 10.1007/s10803-014-2265-9; World Health Organization, 2018, INT STAT CLASS DIS R	11	11	11	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2016	15	3					237	238		10.1016/S1474-4422(15)00299-9	http://dx.doi.org/10.1016/S1474-4422(15)00299-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DE1ON	26497770				2022-12-18	WOS:000370396400005
J	Calabresi, P; Di Filippo, M				Calabresi, Paolo; Di Filippo, Massimiliano			Multitarget disease-modifying therapy in Parkinson's disease?	LANCET NEUROLOGY			English	Editorial Material									[Calabresi, Paolo; Di Filippo, Massimiliano] Univ Perugia, Osped Santa Maria Misericordia, Neurol Clin, Dept Med, I-06156 Perugia, Italy; [Calabresi, Paolo] IRCCS Fdn Santa Lucia, Rome, Italy	Hospital Santa Maria della Misericordia; University of Perugia; IRCCS Santa Lucia	Calabresi, P (corresponding author), Univ Perugia, Osped Santa Maria Misericordia, Neurol Clin, Dept Med, I-06156 Perugia, Italy.	paolo.calabresi@unipg.it	Calabresi, Paolo/G-8496-2011	Calabresi, Paolo/0000-0003-0326-5509				Calabresi P, 2014, NAT NEUROSCI, V17, P1022, DOI 10.1038/nn.3743; Cirnaru MD, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00049; Collier TJ, 2011, NAT REV NEUROSCI, V12, P359, DOI 10.1038/nrn3039; Goldman JG, 2014, CURR OPIN NEUROL, V27, P434, DOI 10.1097/WCO.0000000000000112; Henry AG, 2015, HUM MOL GENET, V24, P6013, DOI 10.1093/hmg/ddv314; Kalia LV, 2015, MOVEMENT DISORD, V30, P1442, DOI 10.1002/mds.26354; Lindstrom V, 2014, IMMUNOTHERAPY-UK, V6, P141, DOI [10.2217/imt.13.162, 10.2217/IMT.13.162]; Schapira AHV, 2013, CURR OPIN NEUROL, V26, P395, DOI 10.1097/WCO.0b013e3283633741; Volta M, 2015, LANCET NEUROL, V14, P1054, DOI 10.1016/S1474-4422(15)00186-6; Yue M, 2015, NEUROBIOL DIS, V78, P172, DOI 10.1016/j.nbd.2015.02.031	10	11	11	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					975	976		10.1016/S1474-4422(15)00227-6	http://dx.doi.org/10.1016/S1474-4422(15)00227-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2VI	26376965				2022-12-18	WOS:000361188400006
J	Liu, GY; Li, KS				Liu, Guiyou; Li, Keshen			CHCHD2 and Parkinson's disease	LANCET NEUROLOGY			English	Letter							GENOME-WIDE ASSOCIATION; LOCI; METAANALYSIS		[Liu, Guiyou] Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Genome Anal Lab, Tianjin Airport Econ Area, Tianjin 300308, Peoples R China; [Li, Keshen] Guangdong Med Coll, Inst Neurol, Zhanjiang, Peoples R China	Chinese Academy of Sciences; Tianjin Institute of Industrial Biotechnology, CAS; Guangdong Medical University	Liu, GY (corresponding author), Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Genome Anal Lab, Tianjin Airport Econ Area, Xiqi Dao 32, Tianjin 300308, Peoples R China.	liuguiyou1981@163.com		Liu, Guiyou/0000-0002-1126-2888				Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; Borovecki F, 2011, PROG NEURO-PSYCHOPH, V35, P340, DOI 10.1016/j.pnpbp.2010.12.019; Chung SJ, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2013.05.022; Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; Gao JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024211; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Lill CM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002548; Liu GY, 2015, MOL NEUROBIOL, V52, P1629, DOI 10.1007/s12035-014-8946-8; Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485	10	11	11	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					679	680		10.1016/S1474-4422(15)00131-3	http://dx.doi.org/10.1016/S1474-4422(15)00131-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067112	Green Published, Bronze			2022-12-18	WOS:000356195900010
J	Golzari, SE; Mahmoodpoor, A				Golzari, Samad Ej; Mahmoodpoor, Ata			Sepsis-associated encephalopathy versus sepsis-induced encephalopathy	LANCET NEUROLOGY			English	Letter									[Golzari, Samad Ej] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz 5157698616, Iran; [Mahmoodpoor, Ata] Tabriz Univ Med Sci, Cardiovasc Res Ctr, Tabriz 5157698616, Iran	Tabriz University of Medical Science; Tabriz University of Medical Science	Golzari, SE (corresponding author), Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz 5157698616, Iran.	amahmoodpoor@yahoo.com	mahmoodpoor, ata/AAR-9972-2021; mahmoodpoor, Ata/AAD-6597-2021; Golzari, Samad EJ/L-5785-2017	mahmoodpoor, Ata/0000-0002-4361-6230; Golzari, Samad EJ/0000-0003-3815-8770				Hotchkiss RS, 2010, NEW ENGL J MED, V363, P87, DOI 10.1056/NEJMcibr1004371; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Lamar CD, 2011, J NEUROPSYCH CLIN N, V23, P236, DOI 10.1176/appi.neuropsych.23.3.237; Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1; Zampieri FG, 2011, CLINICS, V66, P1825, DOI 10.1590/S1807-59322011001000024	5	11	13	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					967	968		10.1016/S1474-4422(14)70205-4	http://dx.doi.org/10.1016/S1474-4422(14)70205-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25231515				2022-12-18	WOS:000341959700007
J	Hart, RG; Diener, HC; Connolly, SJ				Hart, Robert G.; Diener, Hans-Christoph; Connolly, Stuart J.			Embolic strokes of undetermined source: support for a new clinical construct Reply	LANCET NEUROLOGY			English	Letter									[Hart, Robert G.; Connolly, Stuart J.] McMaster Univ, Hamilton, ON L8L 2X2, Canada; [Hart, Robert G.; Connolly, Stuart J.] Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Diener, Hans-Christoph] Univ Duisburg Essen, Essen, Germany	McMaster University; Population Health Research Institute; University of Duisburg Essen	Hart, RG (corresponding author), McMaster Univ, Hamilton, ON L8L 2X2, Canada.	robert.hart@phri.ca	Diener, Hans-Christoph/AAF-7275-2019						0	11	12	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					967	967		10.1016/S1474-4422(14)70197-8	http://dx.doi.org/10.1016/S1474-4422(14)70197-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25231516				2022-12-18	WOS:000341959700006
J	Charidimou, A; Jager, HRJ				Charidimou, Andreas; Jaeger, Hans Rolf J.			Developing biomarkers for cerebral amyloid angiopathy trials: do potential disease phenotypes hold promise?	LANCET NEUROLOGY			English	Letter							CLINICAL SPECTRUM		[Charidimou, Andreas] UCL Inst Neurol, Stroke Res Grp, Dept Brain Repair & Rehabil, London WC1N 3BG, England; [Charidimou, Andreas; Jaeger, Hans Rolf J.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Jaeger, Hans Rolf J.] UCL Inst Neurol, Lysholm Dept Neuroradiol, London, England; [Jaeger, Hans Rolf J.] UCL Inst Neurol, Dept Brain Repair & Rehabil, London, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Charidimou, A (corresponding author), UCL Inst Neurol, Stroke Res Grp, Dept Brain Repair & Rehabil, London WC1N 3BG, England.	andreas.charidimou.09@ucl.ac.uk	Demchuk, Andrew M/E-1103-2012; Jager, Hans Rolf/K-1868-2013	Demchuk, Andrew M/0000-0002-4930-7789; Jager, Hans Rolf/0000-0002-6403-4184				Charidimou A, 2013, NEUROLOGY, V81, P626, DOI 10.1212/WNL.0b013e3182a08f2c; Charidimou A, 2012, J NEUROL NEUROSUR PS, V83, P124, DOI 10.1136/jnnp-2011-301308; GREENBERG SM, 1993, NEUROLOGY, V43, P2073, DOI 10.1212/WNL.43.10.2073; Greenberg SM, 2014, LANCET NEUROL, V13, P419, DOI 10.1016/S1474-4422(14)70003-1; Greenberg SM, 2009, STROKE, V40, P2382, DOI 10.1161/STROKEAHA.109.548974; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311	6	11	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					538	540		10.1016/S1474-4422(14)70096-1	http://dx.doi.org/10.1016/S1474-4422(14)70096-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK	24849855				2022-12-18	WOS:000337212700012
J	Chio, A; Mora, G				Chio, Adriano; Mora, Gabriele			The final chapter of the ALS lithium saga	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; TRIAL; CARBONATE		[Chio, Adriano] Univ Turin, Dept Neurosci, ALS Ctr, I-10124 Turin, Italy; [Mora, Gabriele] Sci Inst Milan, IRCCS, Fdn Salvatore Maugeri, ALS Ctr, Milan, Italy	University of Turin; Istituti Clinici Scientifici Maugeri IRCCS	Chio, A (corresponding author), Univ Turin, Dept Neurosci, ALS Ctr, I-10124 Turin, Italy.	achio@usa.net	Chio, Adriano/K-3425-2016; Mora, Gabriele/Z-2346-2019	Chio, Adriano/0000-0001-9579-5341; Mora, Gabriele/0000-0002-8388-2373; Morrison, Karen Elaine/0000-0003-0216-5717				Aggarwal SP, 2010, LANCET NEUROL, V9, P481, DOI 10.1016/S1474-4422(10)70068-5; Beghi E, 2011, AMYOTROPH LATERAL SC, V12, P1, DOI 10.3109/17482968.2010.502940; Chio A, 2010, NEUROLOGY, V75, P619, DOI 10.1212/WNL.0b013e3181ed9e7c; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105; Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334; Miller RG, 2011, NEUROLOGY, V77, P973, DOI 10.1212/WNL.0b013e31822dc7a5; UKMND-LiCALS Study Group, 2013, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(13)70037-1; Verstraete E, 2012, J NEUROL NEUROSUR PS, V83, P557, DOI 10.1136/jnnp-2011-302021; Wicks P, 2011, NAT BIOTECHNOL, V29, P411, DOI 10.1038/nbt.1837	10	11	12	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2013	12	4					324	325		10.1016/S1474-4422(13)70040-1	http://dx.doi.org/10.1016/S1474-4422(13)70040-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SZ	23453346				2022-12-18	WOS:000318531600002
J	McKeon, A				McKeon, Andrew			The importance of early and sustained treatment of a common autoimmune encephalitis	LANCET NEUROLOGY			English	Editorial Material							NMDA-RECEPTOR		[McKeon, Andrew] Mayo Clin, Dept Neurol, Coll Med, Rochester, MN 55905 USA; [McKeon, Andrew] Mayo Clin, Dept Lab Med & Pathol, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McKeon, A (corresponding author), Mayo Clin, Dept Neurol, Coll Med, Rochester, MN 55905 USA.	mckeon.andrew@mayo.edu	McKeon, Andrew/AAY-9214-2021	McKeon, Andrew/0000-0001-6856-8143				Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Dhamija R, 2011, PEDIATR NEUROL, V44, P275, DOI 10.1016/j.pediatrneurol.2010.10.015; Flanagan EP, 2010, MAYO CLIN PROC, V85, P881, DOI 10.4065/mcp.2010.0326; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Irani SR, 2010, BRAIN, V133, P1655, DOI 10.1093/brain/awq113; Masdeu JC, 2012, AM J PSYCHIAT, V169, P1120, DOI 10.1176/appi.ajp.2012.12050646; McKeon Andrew, 2010, Continuum (Minneap Minn), V16, P80, DOI 10.1212/01.CON.0000368213.63964.34; Quek AML, 2012, ARCH NEUROL-CHICAGO, V69, P582, DOI 10.1001/archneurol.2011.2985; Titulaer M, 2012, LANCET NEUROL	10	11	16	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					123	125		10.1016/S1474-4422(12)70319-8	http://dx.doi.org/10.1016/S1474-4422(12)70319-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23290629				2022-12-18	WOS:000314330200004
J	Sormani, MP; Bruzzi, P				Sormani, Maria Pia; Bruzzi, Paolo			Reporting of subgroup analyses from clinical trials	LANCET NEUROLOGY			English	Letter							MULTIPLE-SCLEROSIS; FINGOLIMOD		[Sormani, Maria Pia] Univ Genoa, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy; [Bruzzi, Paolo] Ist Nazl Ric Canc, IRCCS AUO San Martino IST, Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST	Sormani, MP (corresponding author), Univ Genoa, Dept Hlth Sci DISSAL, Via Pastore 1, I-16132 Genoa, Italy.	mariapia.sormani@unige.it	Sormani, Maria Pia/ABH-8756-2020; Bruzzi, Paolo/AAU-3363-2021	Bruzzi, Paolo/0000-0002-7874-2077; SORMANI, MARIA PIA/0000-0001-6892-104X				Comi G, 2009, LANCET, V374, P1503, DOI 10.1016/S0140-6736(09)61259-9; Devonshire V, 2012, LANCET NEUROL, V11, P420, DOI 10.1016/S1474-4422(12)70056-X; GIOVANNONI G, 2011, OPTN SRTR ANN REP, V10, P329, DOI DOI 10.1016/S1474-4422(11)70023-0; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003	6	11	11	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2012	11	9					747	747		10.1016/S1474-4422(12)70181-3	http://dx.doi.org/10.1016/S1474-4422(12)70181-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	994DS	22898729				2022-12-18	WOS:000307911700007
J	Wong, GKC; Poon, WS				Wong, George Kwok Chu; Poon, Wai Sang			Clazosentan for patients with subarachnoid haemorrhage: lessons learned	LANCET NEUROLOGY			English	Letter							DOUBLE-BLIND; TRIAL; VASOSPASM		[Wong, George Kwok Chu; Poon, Wai Sang] Chinese Univ Hong Kong, Prince Wales Hosp, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Wong, GKC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China.	georgewong@surgery.cuhk.edu.hk	Wong, George KC/A-6378-2011; Poon, Wai Sang/F-1558-2011; Wong, George Kwok Chu/L-4344-2016; Poon, Wai S/HGD-3084-2022	Wong, George KC/0000-0002-6078-2548; 				Alaraj A, 2010, WORLD NEUROSURG, V74, P138, DOI 10.1016/j.wneu.2010.05.006; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Sabri M, 2011, STROKE, V42, P1454, DOI 10.1161/STROKEAHA.110.604728; Wong GKC, 2011, NEUROSURGERY, V68, P1556, DOI 10.1227/NEU.0b013e31820cd40d; Wong GKC, 2010, STROKE, V41, P921, DOI 10.1161/STROKEAHA.109.571125	6	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2011	10	10					871	871		10.1016/S1474-4422(11)70189-2	http://dx.doi.org/10.1016/S1474-4422(11)70189-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832OP	21939894	Bronze			2022-12-18	WOS:000295814600006
J	Polderman, KH; Andrews, PJD				Polderman, Kees H.; Andrews, Peter J. D.			Hypothermia in patients with brain injury: the way forward?	LANCET NEUROLOGY			English	Letter							THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE		[Polderman, Kees H.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Andrews, Peter J. D.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Edinburgh	Polderman, KH (corresponding author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA.	k.polderman@tip.nl	Polderman, Kees H/K-3623-2012					Andrews PJD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3	6	11	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					404	405		10.1016/S1474-4422(11)70084-9	http://dx.doi.org/10.1016/S1474-4422(11)70084-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV	21511190	Bronze			2022-12-18	WOS:000290424800007
J	Iranzo, A; Lomeria, F; Stockner, H				Iranzo, A.; Lomeria, F.; Stockner, H.		Sleep Innsbruck Barcelona SINBAR	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder a prospective study (vol 9, pg 1070, 2010)	LANCET NEUROLOGY			English	Correction																		Iranzo A, 2010, LANCET NEUROL, V9, P1070, DOI 10.1016/S1474-4422(10)70216-7	1	11	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2010	9	11					1045	1045		10.1016/S1474-4422(10)70216-7	http://dx.doi.org/10.1016/S1474-4422(10)70216-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680PL					2022-12-18	WOS:000284246800007
J	Gandy, S				Gandy, Sam			Testing the amyloid hypothesis of Alzheimer's disease in vivo	LANCET NEUROLOGY			English	Editorial Material							LATREPIRDINE; PATHOGENESIS; VITRO		[Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Gandy, S (corresponding author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.	samuel.gandy@mssm.edu			NIA NIH HHS [P01 AG010491-14, P01 AG010491] Funding Source: Medline; NINDS NIH HHS [R01 NS075685] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aslund A, 2009, ACS CHEM BIOL, V4, P673, DOI 10.1021/cb900112v; Bachurin SO, 2009, DOKL BIOCHEM BIOPHYS, V428, P235, DOI 10.1134/S1607672909050032; Bertram L, 2005, J CLIN INVEST, V115, P1449, DOI 10.1172/JCI24761; Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Lemere CA, 2010, NAT REV NEUROL, V6, P108, DOI 10.1038/nrneurol.2009.219; Lublin AL, 2010, MT SINAI J MED, V77, P43, DOI 10.1002/msj.20160; Nicoll JAR, 2006, J NEUROPATH EXP NEUR, V65, P1040, DOI 10.1097/01.jnen.0000240466.10758.ce; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Sabbagh MN, 2010, CURR OPIN INVEST DR, V11, P80; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Sleegers K, 2010, TRENDS GENET, V26, P84, DOI 10.1016/j.tig.2009.12.004; Small SA, 2006, NEURON, V52, P15, DOI 10.1016/j.neuron.2006.09.001; Steele JW, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-51; Swanoski MT, 2009, AM J HEALTH-SYST PH, V66, P1950, DOI 10.2146/ajhp080576; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Zhu XW, 2004, LANCET NEUROL, V3, P219, DOI 10.1016/S1474-4422(04)00707-0	19	11	11	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					333	335		10.1016/S1474-4422(10)70055-7	http://dx.doi.org/10.1016/S1474-4422(10)70055-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA	20189880	Green Accepted			2022-12-18	WOS:000276142000003
J	Berger, JR; Houff, SA				Berger, Joseph R.; Houff, Sidney A.			Neurological infections: the year of PML and influenza	LANCET NEUROLOGY			English	Editorial Material							GUILLAIN-BARRE-SYNDROME; JC VIRUS; CHILDREN		[Berger, Joseph R.; Houff, Sidney A.] Univ Kentucky, Dept Neurol, Coll Med, Kentucky Clin L 445, Louisville, KY USA	University of Kentucky	Berger, JR (corresponding author), Univ Kentucky, Dept Neurol, Coll Med, Kentucky Clin L 445, Louisville, KY USA.	jrbneuro@uky.edu						Brickelmaier M, 2009, ANTIMICROB AGENTS CH, V53, P1840, DOI 10.1128/AAC.01614-08; Chen YP, 2009, NEW ENGL J MED, V361, P1067, DOI 10.1056/NEJMoa0904267; Churchill MJ, 2009, ANN NEUROL, V66, P253, DOI 10.1002/ana.21697; Evans D, 2009, J INFECT DIS, V200, P321, DOI 10.1086/603560; Haber P, 2009, DRUG SAFETY, V32, P309, DOI 10.2165/00002018-200932040-00005; Huang YC, 2009, PEDIATR INFECT DIS J, V28, P647, DOI 10.1097/INF.0b013e3181986bf9; Marraa CM, 2009, AIDS, V23, P1359, DOI 10.1097/QAD.0b013e32832c4152; Takanashi J, 2009, BRAIN DEV-JPN, V31, P521, DOI 10.1016/j.braindev.2009.02.012; 2009, MMWR MORB MORTAL WKL, V58, P773	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					14	17		10.1016/S1474-4422(09)70337-0	http://dx.doi.org/10.1016/S1474-4422(09)70337-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	20083028				2022-12-18	WOS:000273199700009
J	Honnorat, J				Honnorat, Jerome			Autoimmune limbic encephalitis: an expanding concept	LANCET NEUROLOGY			English	Editorial Material							ANTIBODIES		Univ Lyon 1, INSERM, U842, Hop Neurol, F-69677 Bron, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Honnorat, J (corresponding author), Univ Lyon 1, INSERM, U842, Hop Neurol, 59 Blvd Pinel, F-69677 Bron, France.	jerome.honnorat@chu-lyon.fr	Honnorat, jerome/G-6394-2017	Honnorat, jerome/0000-0002-4721-5952				BRIERLEY JB, 1960, BRAIN, V83, P357, DOI 10.1093/brain/83.3.357; CORSELLIS JA, 1968, BRAIN, V91, P481, DOI 10.1093/brain/91.3.481; Dalmau J, 2004, BRAIN, V127, P1831, DOI 10.1093/brain/awh203; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Gambardella A, 2003, NEUROLOGY, V60, P560, DOI 10.1212/01.WNL.0000046520.79877.D8; Graus F, 2008, NEUROLOGY, V71, P930, DOI 10.1212/01.wnl.0000325917.48466.55; Honnorat J, 2009, J NEUROL NEUROSUR PS, V80, P412, DOI 10.1136/jnnp.2007.138016; Lai MZ, 2009, ANN NEUROL, V65, P424, DOI 10.1002/ana.21589; Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2; Manto MU, 2007, ANN NEUROL, V61, P544, DOI 10.1002/ana.21123; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077	11	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					24	25		10.1016/S1474-4422(09)70333-3	http://dx.doi.org/10.1016/S1474-4422(09)70333-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	19962349				2022-12-18	WOS:000273199700014
J	Ross, E				Ross, Emma			Unapproved drug use: compassionate or cause for concern?	LANCET NEUROLOGY			English	Editorial Material												emmalross@mac.com							0	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					136	137		10.1016/S1474-4422(09)70008-0	http://dx.doi.org/10.1016/S1474-4422(09)70008-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO	19161905				2022-12-18	WOS:000262752000010
J	MacLean, HJ; Freedman, MS				MacLean, Heather J.; Freedman, Mark S.			Multiple sclerosis: following clues from cause to cure	LANCET NEUROLOGY			English	Editorial Material							RELAPSING MS; PLACEBO		[MacLean, Heather J.; Freedman, Mark S.] Ottawa Hosp Gen Campus, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute	MacLean, HJ (corresponding author), Ottawa Hosp Gen Campus, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	mfreedman@ottawahospital.on.ca						[Anonymous], 2008, ARCH NEUROL-CHICAGO, V65, P1044, DOI 10.1001/archneurol.65.8.noc80042; Chang A, 2008, BRAIN, V131, P2366, DOI 10.1093/brain/awn157; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Dwyer T, 2008, NEUROLOGY, V71, P583, DOI 10.1212/01.wnl.0000323928.57408.93; Fagius J, 2009, MULT SCLER, V15, P229, DOI 10.1177/1352458508096875; Kragt JJ, 2009, MULT SCLER J, V15, P9, DOI 10.1177/1352458508095920; Mikol DD, 2008, LANCET NEUROL, V7, P903, DOI 10.1016/S1474-4422(08)70200-X; OCONNOR P, INTERFERON BETA 1B 5; Oger J, 2005, J NEUROL SCI, V237, P45, DOI 10.1016/j.jns.2005.05.014; Polman Chris H, 2006, N Engl J Med, V354, P899	10	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					6	8		10.1016/S1474-4422(08)70272-2	http://dx.doi.org/10.1016/S1474-4422(08)70272-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081501				2022-12-18	WOS:000261860700004
J	Burton, A				Burton, Adrian			YouTube-ing your way to neurological knowledge	LANCET NEUROLOGY			English	Editorial Material												burtona@wanadoo.es							0	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1086	1087		10.1016/S1474-4422(08)70252-7	http://dx.doi.org/10.1016/S1474-4422(08)70252-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	19007734				2022-12-18	WOS:000261396000011
J	Martin, R				Martin, Roland			Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							AUTOIMMUNE INFLAMMATION; ANTIBODY; IL-23; CELLS		Univ Med Ctr Eppendorf, Ctr Mol Neurobiol, Inst Neuroimmunol & Clin Multiple Sclerosis Res, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Martin, R (corresponding author), Univ Med Ctr Eppendorf, Ctr Mol Neurobiol, Inst Neuroimmunol & Clin Multiple Sclerosis Res, Hamburg, Germany.	roland.martin@zmnh.uni-hamburg.de		Martin, Roland/0000-0002-0982-1329				Bailey SL, 2007, NAT IMMUNOL, V8, P172, DOI 10.1038/ni1430; Becher B, 2003, J CLIN INVEST, V112, P1186, DOI 10.1172/JCI200319079; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648; Kikly K, 2006, CURR OPIN IMMUNOL, V18, P670, DOI 10.1016/j.coi.2006.09.008; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507; Segal BM, 2008, LANCET NEUROL, V7, P796, DOI 10.1016/S1474-4422(08)70173-X; t'Hart BA, 2005, J IMMUNOL, V175, P4761	9	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					765	766		10.1016/S1474-4422(08)70174-1	http://dx.doi.org/10.1016/S1474-4422(08)70174-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ	18702995				2022-12-18	WOS:000258988400004
J	Hankey, GJ				Hankey, Graeme J.			Is hornocysteine a causal and treatable risk factor for stroke?	LANCET NEUROLOGY			English	Editorial Material							FOLIC-ACID SUPPLEMENTATION; PREVENTION; PROSTATE; CANCER		Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia	Royal Perth Hospital; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, 197 Wellington St, Perth, WA 6001, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720; Clarke R, 2006, AM HEART J, V151, P282, DOI 10.1016/j.ahj.2005.04.025; Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351; Lawson KA, 2007, J NATL CANCER I, V99, P754, DOI 10.1093/jnci/djk177; Spence JD, 2007, LANCET NEUROL, V6, P830, DOI 10.1016/S1474-4422(07)70219-3; Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895; Wald DS, 2006, BMJ-BRIT MED J, V333, P1114, DOI 10.1136/bmj.39000.486701.68; Wang XB, 2007, LANCET, V369, P1876, DOI 10.1016/S0140-6736(07)60854-X	8	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					751	752		10.1016/S1474-4422(07)70200-4	http://dx.doi.org/10.1016/S1474-4422(07)70200-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706554				2022-12-18	WOS:000249065200004
J	Qiu, J				Qiu, Jane			Ticking time bomb faced by China's ageing population	LANCET NEUROLOGY			English	Editorial Material								China has 6 million patients with dementia and, with a rapidly ageing population, is estimated to have 1 million new cases every year. Faced with this ticking time bomb, it is crucial for the government to plan policy and allocate health and welfare resources for the future. Jane Qiu reports.				jane@janeqiu.com							0	11	18	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					582	583		10.1016/S1474-4422(07)70162-X	http://dx.doi.org/10.1016/S1474-4422(07)70162-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ	17632847				2022-12-18	WOS:000247673000009
J	Butcher, J				Butcher, James			Alzheimer's researchers open the doors to data sharing	LANCET NEUROLOGY			English	Editorial Material												james@two-cultures.com							0	11	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					480	481		10.1016/S1474-4422(07)70118-7	http://dx.doi.org/10.1016/S1474-4422(07)70118-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509479				2022-12-18	WOS:000247044900009
